DDI-MedLine.d141.s0	Toxicity	0	7	O
DDI-MedLine.d141.s0	of	9	10	O
DDI-MedLine.d141.s0	cadmium	12	18	O
DDI-MedLine.d141.s0	and	20	22	O
DDI-MedLine.d141.s0	zinc	24	27	B-drug
DDI-MedLine.d141.s0	to	29	30	O
DDI-MedLine.d141.s0	encystment	32	41	O
DDI-MedLine.d141.s0	and	43	45	O
DDI-MedLine.d141.s0	in	47	48	O
DDI-MedLine.d141.s0	vitro	50	54	O
DDI-MedLine.d141.s0	excystment	56	65	O
DDI-MedLine.d141.s0	of	67	68	O
DDI-MedLine.d141.s0	Parorchis	70	78	O
DDI-MedLine.d141.s0	acanthus	80	87	O
DDI-MedLine.d141.s0	(	89	89	O
DDI-MedLine.d141.s0	Digenea	90	96	O
DDI-MedLine.d141.s0	:	97	97	O
DDI-MedLine.d141.s0	Philophthalmidae	99	114	O
DDI-MedLine.d141.s0	)	115	115	O
DDI-MedLine.d141.s0	.	116	116	O
DDI-MedLine.d141.s1	The	0	2	O
DDI-MedLine.d141.s1	toxicity	4	11	O
DDI-MedLine.d141.s1	of	13	14	O
DDI-MedLine.d141.s1	cadmium	16	22	O
DDI-MedLine.d141.s1	,	23	23	O
DDI-MedLine.d141.s1	zinc	25	28	B-drug
DDI-MedLine.d141.s1	and	30	32	O
DDI-MedLine.d141.s1	cadmium/zinc	34	45	O
DDI-MedLine.d141.s1	mixtures	47	54	O
DDI-MedLine.d141.s1	at	56	57	O
DDI-MedLine.d141.s1	concentrations	59	72	O
DDI-MedLine.d141.s1	ranging	74	80	O
DDI-MedLine.d141.s1	from	82	85	O
DDI-MedLine.d141.s1	1000	87	90	O
DDI-MedLine.d141.s1	to	92	93	O
DDI-MedLine.d141.s1	50000	95	99	O
DDI-MedLine.d141.s1	microg/l	101	108	O
DDI-MedLine.d141.s1	were	110	113	O
DDI-MedLine.d141.s1	investigated	115	126	O
DDI-MedLine.d141.s1	against	128	134	O
DDI-MedLine.d141.s1	cercariae	136	144	O
DDI-MedLine.d141.s1	and	146	148	O
DDI-MedLine.d141.s1	metacercariae	150	162	O
DDI-MedLine.d141.s1	of	164	165	O
DDI-MedLine.d141.s1	Parorchis	167	175	O
DDI-MedLine.d141.s1	acanthus	177	184	O
DDI-MedLine.d141.s1	obtained	186	193	O
DDI-MedLine.d141.s1	from	195	198	O
DDI-MedLine.d141.s1	the	200	202	O
DDI-MedLine.d141.s1	dog	204	206	O
DDI-MedLine.d141.s1	whelk	208	212	O
DDI-MedLine.d141.s1	Nucella	214	220	O
DDI-MedLine.d141.s1	lapillus	222	229	O
DDI-MedLine.d141.s1	.	230	230	O
DDI-MedLine.d141.s2	Cercarial	0	8	O
DDI-MedLine.d141.s2	encystment	10	19	O
DDI-MedLine.d141.s2	at	21	22	O
DDI-MedLine.d141.s2	concentrations	24	37	O
DDI-MedLine.d141.s2	of	39	40	O
DDI-MedLine.d141.s2	25000	42	46	O
DDI-MedLine.d141.s2	microg/l	48	55	O
DDI-MedLine.d141.s2	or	57	58	O
DDI-MedLine.d141.s2	higher	60	65	O
DDI-MedLine.d141.s2	was	67	69	O
DDI-MedLine.d141.s2	significantly	71	83	O
DDI-MedLine.d141.s2	impaired	85	92	O
DDI-MedLine.d141.s2	by	94	95	O
DDI-MedLine.d141.s2	all	97	99	O
DDI-MedLine.d141.s2	test	101	104	O
DDI-MedLine.d141.s2	metals	106	111	O
DDI-MedLine.d141.s2	;	112	112	O
DDI-MedLine.d141.s3	however	0	6	O
DDI-MedLine.d141.s3	,	7	7	O
DDI-MedLine.d141.s3	at	9	10	O
DDI-MedLine.d141.s3	lower	12	16	O
DDI-MedLine.d141.s3	concentrations	18	31	O
DDI-MedLine.d141.s3	only	33	36	O
DDI-MedLine.d141.s3	zinc	38	41	B-drug
DDI-MedLine.d141.s3	demonstrated	43	54	O
DDI-MedLine.d141.s3	toxicity	56	63	O
DDI-MedLine.d141.s3	.	64	64	O
DDI-MedLine.d141.s4	Mixtures	0	7	O
DDI-MedLine.d141.s4	of	9	10	O
DDI-MedLine.d141.s4	cadmium	12	18	O
DDI-MedLine.d141.s4	and	20	22	O
DDI-MedLine.d141.s4	zinc	24	27	B-drug
DDI-MedLine.d141.s4	had	29	31	O
DDI-MedLine.d141.s4	a	30	30	O
DDI-MedLine.d141.s4	synergistic	35	45	O
DDI-MedLine.d141.s4	effect	47	52	O
DDI-MedLine.d141.s4	compared	54	61	O
DDI-MedLine.d141.s4	with	63	66	O
DDI-MedLine.d141.s4	single	68	73	O
DDI-MedLine.d141.s4	metal	75	79	O
DDI-MedLine.d141.s4	toxicity	81	88	O
DDI-MedLine.d141.s4	but	90	92	O
DDI-MedLine.d141.s4	only	94	97	O
DDI-MedLine.d141.s4	at	99	100	O
DDI-MedLine.d141.s4	50000	102	106	O
DDI-MedLine.d141.s4	microg/l	108	115	O
DDI-MedLine.d141.s4	.	116	116	O
DDI-MedLine.d141.s5	Excystment	0	9	O
DDI-MedLine.d141.s5	in	11	12	O
DDI-MedLine.d141.s5	vitro	14	18	O
DDI-MedLine.d141.s5	was	20	22	O
DDI-MedLine.d141.s5	only	24	27	O
DDI-MedLine.d141.s5	significantly	29	41	O
DDI-MedLine.d141.s5	affected	43	50	O
DDI-MedLine.d141.s5	by	52	53	O
DDI-MedLine.d141.s5	cercariae	55	63	O
DDI-MedLine.d141.s5	exposed	65	71	O
DDI-MedLine.d141.s5	to	73	74	O
DDI-MedLine.d141.s5	cadmium/zinc	76	87	O
DDI-MedLine.d141.s5	mixtures	89	96	O
DDI-MedLine.d141.s5	whilst	98	103	O
DDI-MedLine.d141.s5	encysting	105	113	O
DDI-MedLine.d141.s5	.	114	114	O
DDI-MedLine.d141.s6	Twenty-four	0	10	O
DDI-MedLine.d141.s6	h	12	12	O
DDI-MedLine.d141.s6	exposures	14	22	O
DDI-MedLine.d141.s6	of	24	25	O
DDI-MedLine.d141.s6	fully	27	31	O
DDI-MedLine.d141.s6	formed	33	38	O
DDI-MedLine.d141.s6	cysts	40	44	O
DDI-MedLine.d141.s6	had	46	48	O
DDI-MedLine.d141.s6	no	50	51	O
DDI-MedLine.d141.s6	effect	53	58	O
DDI-MedLine.d141.s6	on	60	61	O
DDI-MedLine.d141.s6	excystment	63	72	O
DDI-MedLine.d141.s6	in	74	75	O
DDI-MedLine.d141.s6	vitro	77	81	O
DDI-MedLine.d141.s6	.	82	82	O
DDI-MedLine.d141.s7	Effects	0	6	O
DDI-MedLine.d141.s7	on	8	9	O
DDI-MedLine.d141.s7	in	11	12	O
DDI-MedLine.d141.s7	vitro	14	18	O
DDI-MedLine.d141.s7	excystment	20	29	O
DDI-MedLine.d141.s7	rates	31	35	O
DDI-MedLine.d141.s7	over	37	40	O
DDI-MedLine.d141.s7	a	42	42	O
DDI-MedLine.d141.s7	2	44	44	O
DDI-MedLine.d141.s7	h	46	46	O
DDI-MedLine.d141.s7	period	48	53	O
DDI-MedLine.d141.s7	demonstrated	55	66	O
DDI-MedLine.d141.s7	widespread	68	77	O
DDI-MedLine.d141.s7	effects	79	85	O
DDI-MedLine.d141.s7	for	87	89	O
DDI-MedLine.d141.s7	cercariae-exposed	91	107	O
DDI-MedLine.d141.s7	P	109	109	O
DDI-MedLine.d141.s7	.	110	110	O
DDI-MedLine.d141.s8	acanthus	0	7	O
DDI-MedLine.d141.s8	.	8	8	O
DDI-MedLine.d141.s9	No	0	1	O
DDI-MedLine.d141.s9	effects	3	9	O
DDI-MedLine.d141.s9	were	11	14	O
DDI-MedLine.d141.s9	evident	16	22	O
DDI-MedLine.d141.s9	on	24	25	O
DDI-MedLine.d141.s9	excystment	27	36	O
DDI-MedLine.d141.s9	rates	38	42	O
DDI-MedLine.d141.s9	of	44	45	O
DDI-MedLine.d141.s9	cyst-exposed	47	58	O
DDI-MedLine.d141.s9	parasites	60	68	O
DDI-MedLine.d141.s9	.	69	69	O
DDI-DrugBank.d149.s0	Possible	0	7	O
DDI-DrugBank.d149.s0	drug	9	12	O
DDI-DrugBank.d149.s0	interactions	14	25	O
DDI-DrugBank.d149.s0	of	27	28	O
DDI-DrugBank.d149.s0	HUMORSOL	30	37	B-brand
DDI-DrugBank.d149.s0	with	39	42	O
DDI-DrugBank.d149.s0	succinylcholine	44	58	B-drug
DDI-DrugBank.d149.s0	or	60	61	O
DDI-DrugBank.d149.s0	with	63	66	O
DDI-DrugBank.d149.s0	other	68	72	O
DDI-DrugBank.d149.s0	anticholinesterase	74	91	B-group
DDI-DrugBank.d149.s0	agents	93	98	I-group
DDI-DrugBank.d149.s0	.	99	99	O
DDI-DrugBank.d526.s0	When	0	3	O
DDI-DrugBank.d526.s0	administered	5	16	O
DDI-DrugBank.d526.s0	concurrently	18	29	O
DDI-DrugBank.d526.s0	,	30	30	O
DDI-DrugBank.d526.s0	the	32	34	O
DDI-DrugBank.d526.s0	following	36	44	O
DDI-DrugBank.d526.s0	drugs	46	50	O
DDI-DrugBank.d526.s0	may	52	54	O
DDI-DrugBank.d526.s0	interact	56	63	O
DDI-DrugBank.d526.s0	with	65	68	O
DDI-DrugBank.d526.s0	adrenal	70	76	B-group
DDI-DrugBank.d526.s0	corticosteroids	78	92	I-group
DDI-DrugBank.d526.s0	.	93	93	O
DDI-DrugBank.d526.s1	Amphotericin	0	11	B-drug
DDI-DrugBank.d526.s1	B	13	13	O
DDI-DrugBank.d526.s1	or	15	16	O
DDI-DrugBank.d526.s1	potassium-depleting	18	36	B-group
DDI-DrugBank.d526.s1	diuretics	38	46	I-group
DDI-DrugBank.d526.s1	(	48	48	O
DDI-DrugBank.d526.s1	benzothiadiazines	49	65	B-group
DDI-DrugBank.d526.s1	and	67	69	O
DDI-DrugBank.d526.s1	related	71	77	O
DDI-DrugBank.d526.s1	drugs	79	83	O
DDI-DrugBank.d526.s1	,	84	84	O
DDI-DrugBank.d526.s1	ethacrynic	86	95	B-drug
DDI-DrugBank.d526.s1	acid	97	100	I-drug
DDI-DrugBank.d526.s1	and	102	104	O
DDI-DrugBank.d526.s1	furosemide	106	115	B-drug
DDI-DrugBank.d526.s1	)	116	116	O
DDI-DrugBank.d526.s1	enhanced	118	125	O
DDI-DrugBank.d526.s1	hypokalemia	127	137	O
DDI-DrugBank.d526.s1	.	138	138	O
DDI-DrugBank.d526.s2	Check	0	4	O
DDI-DrugBank.d526.s2	serum	6	10	O
DDI-DrugBank.d526.s2	potassium	12	20	O
DDI-DrugBank.d526.s2	levels	22	27	O
DDI-DrugBank.d526.s2	at	29	30	O
DDI-DrugBank.d526.s2	frequent	32	39	O
DDI-DrugBank.d526.s2	intervals	41	49	O
DDI-DrugBank.d526.s2	;	50	50	O
DDI-DrugBank.d526.s3	use	0	2	O
DDI-DrugBank.d526.s3	potassium	4	12	B-drug
DDI-DrugBank.d526.s3	supplements	14	24	O
DDI-DrugBank.d526.s3	if	26	27	O
DDI-DrugBank.d526.s3	necessary	29	37	O
DDI-DrugBank.d526.s3	.	39	39	O
DDI-DrugBank.d526.s4	Digitalis	0	8	B-group
DDI-DrugBank.d526.s4	glycosides	10	19	I-group
DDI-DrugBank.d526.s4	enhanced	21	28	O
DDI-DrugBank.d526.s4	possibility	30	40	O
DDI-DrugBank.d526.s4	of	42	43	O
DDI-DrugBank.d526.s4	arrhythmias	45	55	O
DDI-DrugBank.d526.s4	or	57	58	O
DDI-DrugBank.d526.s4	digitalis	60	68	B-group
DDI-DrugBank.d526.s4	toxicity	70	77	O
DDI-DrugBank.d526.s4	associated	79	88	O
DDI-DrugBank.d526.s4	with	90	93	O
DDI-DrugBank.d526.s4	hypokalemia	95	105	O
DDI-DrugBank.d526.s4	.	106	106	O
DDI-DrugBank.d526.s5	Monitor	0	6	O
DDI-DrugBank.d526.s5	serum	8	12	O
DDI-DrugBank.d526.s5	potassium	14	22	O
DDI-DrugBank.d526.s5	levels	24	29	O
DDI-DrugBank.d526.s5	;	30	30	O
DDI-DrugBank.d526.s6	use	0	2	O
DDI-DrugBank.d526.s6	potassium	4	12	B-drug
DDI-DrugBank.d526.s6	supplements	14	24	O
DDI-DrugBank.d526.s6	if	26	27	O
DDI-DrugBank.d526.s6	necessary	29	37	O
DDI-DrugBank.d526.s6	.	38	38	O
DDI-DrugBank.d526.s7	Oral	0	3	O
DDI-DrugBank.d526.s7	anticoagulants	5	18	B-group
DDI-DrugBank.d526.s7	decreased	20	28	O
DDI-DrugBank.d526.s7	prothrombin	30	40	O
DDI-DrugBank.d526.s7	time	42	45	O
DDI-DrugBank.d526.s7	response	47	54	O
DDI-DrugBank.d526.s7	.	55	55	O
DDI-DrugBank.d526.s8	Monitor	0	6	O
DDI-DrugBank.d526.s8	prothrombin	8	18	O
DDI-DrugBank.d526.s8	levels	20	25	O
DDI-DrugBank.d526.s8	and	27	29	O
DDI-DrugBank.d526.s8	adjust	31	36	O
DDI-DrugBank.d526.s8	anticoagulant	38	50	B-group
DDI-DrugBank.d526.s8	dosage	52	57	O
DDI-DrugBank.d526.s8	accordingly	59	69	O
DDI-DrugBank.d526.s8	.	70	70	O
DDI-DrugBank.d526.s9	Antidiabetic	0	11	B-group
DDI-DrugBank.d526.s9	drugs	13	17	I-group
DDI-DrugBank.d526.s9	(	19	19	O
DDI-DrugBank.d526.s9	oral	20	23	O
DDI-DrugBank.d526.s9	agents	25	30	O
DDI-DrugBank.d526.s9	and	32	34	O
DDI-DrugBank.d526.s9	insulin	36	42	B-drug
DDI-DrugBank.d526.s9	)	43	43	O
DDI-DrugBank.d526.s9	diminished	45	54	O
DDI-DrugBank.d526.s9	antidiabetic	56	67	O
DDI-DrugBank.d526.s9	effect	69	74	O
DDI-DrugBank.d526.s9	.	75	75	O
DDI-DrugBank.d526.s10	Monitor	0	6	O
DDI-DrugBank.d526.s10	for	8	10	O
DDI-DrugBank.d526.s10	symptoms	12	19	O
DDI-DrugBank.d526.s10	of	21	22	O
DDI-DrugBank.d526.s10	hyperglycemia	24	36	O
DDI-DrugBank.d526.s10	;	37	37	O
DDI-DrugBank.d526.s11	adjust	0	5	O
DDI-DrugBank.d526.s11	dosage	7	12	O
DDI-DrugBank.d526.s11	of	14	15	O
DDI-DrugBank.d526.s11	antidiabetic	17	28	B-group
DDI-DrugBank.d526.s11	drug	30	33	I-group
DDI-DrugBank.d526.s11	upward	35	40	O
DDI-DrugBank.d526.s11	if	42	43	O
DDI-DrugBank.d526.s11	necessary	45	53	O
DDI-DrugBank.d526.s11	.	54	54	O
DDI-DrugBank.d526.s12	Aspirin	0	6	B-brand
DDI-DrugBank.d526.s12	increased	8	16	O
DDI-DrugBank.d526.s12	ulcerogenic	18	28	O
DDI-DrugBank.d526.s12	effect	30	35	O
DDI-DrugBank.d526.s12	;	36	36	O
DDI-DrugBank.d526.s13	decreased	0	8	O
DDI-DrugBank.d526.s13	pharmacologic	10	22	O
DDI-DrugBank.d526.s13	effect	24	29	O
DDI-DrugBank.d526.s13	of	31	32	O
DDI-DrugBank.d526.s13	aspirin	34	40	B-brand
DDI-DrugBank.d526.s13	.	41	41	O
DDI-DrugBank.d526.s14	Rarely	0	5	O
DDI-DrugBank.d526.s14	salicylate	7	16	B-group
DDI-DrugBank.d526.s14	toxicity	18	25	O
DDI-DrugBank.d526.s14	may	27	29	O
DDI-DrugBank.d526.s14	occur	31	35	O
DDI-DrugBank.d526.s14	in	37	38	O
DDI-DrugBank.d526.s14	patients	40	47	O
DDI-DrugBank.d526.s14	who	49	51	O
DDI-DrugBank.d526.s14	discontinue	53	63	O
DDI-DrugBank.d526.s14	steroids	65	72	B-group
DDI-DrugBank.d526.s14	after	74	78	O
DDI-DrugBank.d526.s14	concurrent	80	89	O
DDI-DrugBank.d526.s14	high-dose	91	99	O
DDI-DrugBank.d526.s14	aspirin	101	107	B-brand
DDI-DrugBank.d526.s14	therapy	109	115	O
DDI-DrugBank.d526.s14	.	116	116	O
DDI-DrugBank.d526.s15	Monitor	0	6	O
DDI-DrugBank.d526.s15	salicylate	8	17	B-group
DDI-DrugBank.d526.s15	levels	19	24	O
DDI-DrugBank.d526.s15	or	26	27	O
DDI-DrugBank.d526.s15	the	29	31	O
DDI-DrugBank.d526.s15	therapeutic	33	43	O
DDI-DrugBank.d526.s15	effect	45	50	O
DDI-DrugBank.d526.s15	for	52	54	O
DDI-DrugBank.d526.s15	which	56	60	O
DDI-DrugBank.d526.s15	aspirin	62	68	B-brand
DDI-DrugBank.d526.s15	is	70	71	O
DDI-DrugBank.d526.s15	given	73	77	O
DDI-DrugBank.d526.s15	;	78	78	O
DDI-DrugBank.d526.s16	adjust	0	5	O
DDI-DrugBank.d526.s16	salicylate	7	16	B-group
DDI-DrugBank.d526.s16	dosage	18	23	O
DDI-DrugBank.d526.s16	accordingly	25	35	O
DDI-DrugBank.d526.s16	if	37	38	O
DDI-DrugBank.d526.s16	effect	40	45	O
DDI-DrugBank.d526.s16	is	47	48	O
DDI-DrugBank.d526.s16	altered	50	56	O
DDI-DrugBank.d526.s16	.	57	57	O
DDI-DrugBank.d526.s17	Barbiturates	0	11	B-group
DDI-DrugBank.d526.s17	,	12	12	O
DDI-DrugBank.d526.s17	phenytoin	14	22	B-drug
DDI-DrugBank.d526.s17	,	23	23	O
DDI-DrugBank.d526.s17	or	25	26	O
DDI-DrugBank.d526.s17	rifampin	28	35	B-drug
DDI-DrugBank.d526.s17	increased	37	45	O
DDI-DrugBank.d526.s17	metabolic	47	55	O
DDI-DrugBank.d526.s17	clearance	57	65	O
DDI-DrugBank.d526.s17	of	67	68	O
DDI-DrugBank.d526.s17	fludrocortisone	70	84	B-drug
DDI-DrugBank.d526.s17	acetate	86	92	I-drug
DDI-DrugBank.d526.s17	because	94	100	O
DDI-DrugBank.d526.s17	of	102	103	O
DDI-DrugBank.d526.s17	the	105	107	O
DDI-DrugBank.d526.s17	induction	109	117	O
DDI-DrugBank.d526.s17	of	119	120	O
DDI-DrugBank.d526.s17	hepatic	122	128	O
DDI-DrugBank.d526.s17	enzymes	130	136	O
DDI-DrugBank.d526.s17	.	137	137	O
DDI-DrugBank.d526.s18	Observe	0	6	O
DDI-DrugBank.d526.s18	the	8	10	O
DDI-DrugBank.d526.s18	patient	12	18	O
DDI-DrugBank.d526.s18	for	20	22	O
DDI-DrugBank.d526.s18	possible	24	31	O
DDI-DrugBank.d526.s18	diminished	33	42	O
DDI-DrugBank.d526.s18	effect	44	49	O
DDI-DrugBank.d526.s18	of	51	52	O
DDI-DrugBank.d526.s18	steroid	54	60	B-group
DDI-DrugBank.d526.s18	and	62	64	O
DDI-DrugBank.d526.s18	increase	66	73	O
DDI-DrugBank.d526.s18	the	75	77	O
DDI-DrugBank.d526.s18	steroid	79	85	B-group
DDI-DrugBank.d526.s18	dosage	87	92	O
DDI-DrugBank.d526.s18	accordingly	94	104	O
DDI-DrugBank.d526.s18	.	105	105	O
DDI-DrugBank.d526.s19	Anabolic	0	7	B-group
DDI-DrugBank.d526.s19	steroids	9	16	I-group
DDI-DrugBank.d526.s19	(	18	18	O
DDI-DrugBank.d526.s19	particularly	19	30	O
DDI-DrugBank.d526.s19	C-17	32	35	O
DDI-DrugBank.d526.s19	alkylated	37	45	O
DDI-DrugBank.d526.s19	androgens	47	55	B-group
DDI-DrugBank.d526.s19	such	57	60	O
DDI-DrugBank.d526.s19	as	62	63	O
DDI-DrugBank.d526.s19	oxymetholone	65	76	B-drug
DDI-DrugBank.d526.s19	,	77	77	O
DDI-DrugBank.d526.s19	methandrostenolone	79	96	B-drug
DDI-DrugBank.d526.s19	,	97	97	O
DDI-DrugBank.d526.s19	norethandrolone	99	113	B-drug
DDI-DrugBank.d526.s19	,	114	114	O
DDI-DrugBank.d526.s19	and	105	107	I-drug
DDI-DrugBank.d526.s19	similar	120	126	O
DDI-DrugBank.d526.s19	compounds	128	136	O
DDI-DrugBank.d526.s19	)	137	137	O
DDI-DrugBank.d526.s19	enhanced	139	146	O
DDI-DrugBank.d526.s19	tendency	148	155	O
DDI-DrugBank.d526.s19	toward	157	162	O
DDI-DrugBank.d526.s19	edema	164	168	O
DDI-DrugBank.d526.s19	.	169	169	O
DDI-DrugBank.d526.s20	Use	0	2	O
DDI-DrugBank.d526.s20	caution	4	10	O
DDI-DrugBank.d526.s20	when	12	15	O
DDI-DrugBank.d526.s20	giving	17	22	O
DDI-DrugBank.d526.s20	these	24	28	O
DDI-DrugBank.d526.s20	drugs	30	34	O
DDI-DrugBank.d526.s20	together	36	43	O
DDI-DrugBank.d526.s20	,	44	44	O
DDI-DrugBank.d526.s20	especially	46	55	O
DDI-DrugBank.d526.s20	in	57	58	O
DDI-DrugBank.d526.s20	patients	60	67	O
DDI-DrugBank.d526.s20	with	69	72	O
DDI-DrugBank.d526.s20	hepatic	74	80	O
DDI-DrugBank.d526.s20	or	82	83	O
DDI-DrugBank.d526.s20	cardiac	85	91	O
DDI-DrugBank.d526.s20	disease	93	99	O
DDI-DrugBank.d526.s20	.	100	100	O
DDI-DrugBank.d526.s21	Vaccines	0	7	B-group
DDI-DrugBank.d526.s21	neurological	9	20	O
DDI-DrugBank.d526.s21	complications	22	34	O
DDI-DrugBank.d526.s21	and	36	38	O
DDI-DrugBank.d526.s21	lack	40	43	O
DDI-DrugBank.d526.s21	of	45	46	O
DDI-DrugBank.d526.s21	antibody	48	55	O
DDI-DrugBank.d526.s21	response	57	64	O
DDI-DrugBank.d526.s21	.	66	66	O
DDI-DrugBank.d526.s22	Estrogen	0	7	B-group
DDI-DrugBank.d526.s22	increased	9	17	O
DDI-DrugBank.d526.s22	levels	19	24	O
DDI-DrugBank.d526.s22	of	26	27	O
DDI-DrugBank.d526.s22	corticosteroid-binding	29	50	O
DDI-DrugBank.d526.s22	globulin	52	59	O
DDI-DrugBank.d526.s22	,	60	60	O
DDI-DrugBank.d526.s22	thereby	62	68	O
DDI-DrugBank.d526.s22	increasing	70	79	O
DDI-DrugBank.d526.s22	the	81	83	O
DDI-DrugBank.d526.s22	bound	85	89	O
DDI-DrugBank.d526.s22	(	91	91	O
DDI-DrugBank.d526.s22	inactive	92	99	O
DDI-DrugBank.d526.s22	)	100	100	O
DDI-DrugBank.d526.s22	fraction	102	109	O
DDI-DrugBank.d526.s22	;	110	110	O
DDI-DrugBank.d526.s23	this	0	3	O
DDI-DrugBank.d526.s23	effect	5	10	O
DDI-DrugBank.d526.s23	is	12	13	O
DDI-DrugBank.d526.s23	at	15	16	O
DDI-DrugBank.d526.s23	least	18	22	O
DDI-DrugBank.d526.s23	balanced	24	31	O
DDI-DrugBank.d526.s23	by	33	34	O
DDI-DrugBank.d526.s23	decreased	36	44	O
DDI-DrugBank.d526.s23	metabolism	46	55	O
DDI-DrugBank.d526.s23	of	57	58	O
DDI-DrugBank.d526.s23	corticosteroids	60	74	B-group
DDI-DrugBank.d526.s23	.	75	75	O
DDI-DrugBank.d526.s24	When	0	3	O
DDI-DrugBank.d526.s24	estrogen	5	12	B-group
DDI-DrugBank.d526.s24	therapy	14	20	O
DDI-DrugBank.d526.s24	is	22	23	O
DDI-DrugBank.d526.s24	initiated	25	33	O
DDI-DrugBank.d526.s24	,	34	34	O
DDI-DrugBank.d526.s24	a	36	36	O
DDI-DrugBank.d526.s24	reduction	38	46	O
DDI-DrugBank.d526.s24	in	48	49	O
DDI-DrugBank.d526.s24	corticosteroid	51	64	B-group
DDI-DrugBank.d526.s24	dosage	66	71	O
DDI-DrugBank.d526.s24	may	73	75	O
DDI-DrugBank.d526.s24	be	77	78	O
DDI-DrugBank.d526.s24	required	80	87	O
DDI-DrugBank.d526.s24	,	88	88	O
DDI-DrugBank.d526.s24	and	90	92	O
DDI-DrugBank.d526.s24	increased	94	102	O
DDI-DrugBank.d526.s24	amounts	104	110	O
DDI-DrugBank.d526.s24	may	112	114	O
DDI-DrugBank.d526.s24	be	116	117	O
DDI-DrugBank.d526.s24	required	119	126	O
DDI-DrugBank.d526.s24	when	128	131	O
DDI-DrugBank.d526.s24	estrogen	133	140	B-group
DDI-DrugBank.d526.s24	is	142	143	O
DDI-DrugBank.d526.s24	terminated	145	154	O
DDI-DrugBank.d526.s24	.	155	155	O
DDI-DrugBank.d526.s25	Drug/Laboratory	0	14	O
DDI-DrugBank.d526.s25	Test	16	19	O
DDI-DrugBank.d526.s25	Interactions	21	32	O
DDI-DrugBank.d526.s25	Corticosteroids	34	48	B-group
DDI-DrugBank.d526.s25	may	50	52	O
DDI-DrugBank.d526.s25	affect	54	59	O
DDI-DrugBank.d526.s25	the	61	63	O
DDI-DrugBank.d526.s25	nitrobluetetrazolium	65	84	O
DDI-DrugBank.d526.s25	test	86	89	O
DDI-DrugBank.d526.s25	for	91	93	O
DDI-DrugBank.d526.s25	bacterial	95	103	O
DDI-DrugBank.d526.s25	infection	105	113	O
DDI-DrugBank.d526.s25	and	115	117	O
DDI-DrugBank.d526.s25	produce	119	125	O
DDI-DrugBank.d526.s25	false-negative	127	140	O
DDI-DrugBank.d526.s25	results	142	148	O
DDI-DrugBank.d526.s26	.	0	0	O
DDI-DrugBank.d488.s0	Drug	0	3	O
DDI-DrugBank.d488.s0	Interactions	5	16	O
DDI-DrugBank.d488.s0	:	17	17	O
DDI-DrugBank.d488.s0	a	19	19	O
DDI-DrugBank.d488.s0	.	20	20	O
DDI-DrugBank.d488.s0	Drugs	22	26	O
DDI-DrugBank.d488.s0	Enhancing	28	36	O
DDI-DrugBank.d488.s0	Heparin	38	44	B-drug
DDI-DrugBank.d488.s0	Effect	46	51	O
DDI-DrugBank.d488.s0	:	52	52	O
DDI-DrugBank.d488.s0	Oral	54	57	O
DDI-DrugBank.d488.s0	anticoagulants	59	72	B-group
DDI-DrugBank.d488.s0	:	73	73	O
DDI-DrugBank.d488.s0	Heparin	75	81	B-drug
DDI-DrugBank.d488.s0	sodium	83	88	I-drug
DDI-DrugBank.d488.s0	may	90	92	O
DDI-DrugBank.d488.s0	prolong	94	100	O
DDI-DrugBank.d488.s0	the	102	104	O
DDI-DrugBank.d488.s0	one-stage	106	114	O
DDI-DrugBank.d488.s0	prothrombin	116	126	O
DDI-DrugBank.d488.s0	time	128	131	O
DDI-DrugBank.d488.s0	.	132	132	O
DDI-DrugBank.d488.s1	Therefore	0	8	O
DDI-DrugBank.d488.s1	,	9	9	O
DDI-DrugBank.d488.s1	when	11	14	O
DDI-DrugBank.d488.s1	heparin	16	22	B-drug
DDI-DrugBank.d488.s1	sodium	24	29	I-drug
DDI-DrugBank.d488.s1	is	31	32	O
DDI-DrugBank.d488.s1	given	34	38	O
DDI-DrugBank.d488.s1	with	40	43	O
DDI-DrugBank.d488.s1	dicumarol	45	53	B-drug
DDI-DrugBank.d488.s1	or	55	56	O
DDI-DrugBank.d488.s1	warfarin	58	65	B-drug
DDI-DrugBank.d488.s1	sodium	67	72	I-drug
DDI-DrugBank.d488.s1	,	73	73	O
DDI-DrugBank.d488.s1	a	75	75	O
DDI-DrugBank.d488.s1	period	77	82	O
DDI-DrugBank.d488.s1	of	84	85	O
DDI-DrugBank.d488.s1	at	87	88	O
DDI-DrugBank.d488.s1	least	90	94	O
DDI-DrugBank.d488.s1	5	96	96	O
DDI-DrugBank.d488.s1	hours	98	102	O
DDI-DrugBank.d488.s1	after	104	108	O
DDI-DrugBank.d488.s1	the	110	112	O
DDI-DrugBank.d488.s1	last	114	117	O
DDI-DrugBank.d488.s1	intravenous	119	129	O
DDI-DrugBank.d488.s1	dose	131	134	O
DDI-DrugBank.d488.s1	or	136	137	O
DDI-DrugBank.d488.s1	24	139	140	O
DDI-DrugBank.d488.s1	hours	142	146	O
DDI-DrugBank.d488.s1	after	148	152	O
DDI-DrugBank.d488.s1	the	154	156	O
DDI-DrugBank.d488.s1	last	158	161	O
DDI-DrugBank.d488.s1	subcutaneous	163	174	O
DDI-DrugBank.d488.s1	dose	176	179	O
DDI-DrugBank.d488.s1	should	181	186	O
DDI-DrugBank.d488.s1	elapse	188	193	O
DDI-DrugBank.d488.s1	before	195	200	O
DDI-DrugBank.d488.s1	blood	202	206	O
DDI-DrugBank.d488.s1	is	208	209	O
DDI-DrugBank.d488.s1	drawn	211	215	O
DDI-DrugBank.d488.s1	if	217	218	O
DDI-DrugBank.d488.s1	a	190	190	O
DDI-DrugBank.d488.s1	valid	222	226	O
DDI-DrugBank.d488.s1	prothrombin	228	238	O
DDI-DrugBank.d488.s1	time	240	243	O
DDI-DrugBank.d488.s1	is	208	209	O
DDI-DrugBank.d488.s1	to	248	249	O
DDI-DrugBank.d488.s1	be	251	252	O
DDI-DrugBank.d488.s1	obtained	254	261	O
DDI-DrugBank.d488.s1	.	262	262	O
DDI-DrugBank.d488.s2	Platelet	0	7	B-group
DDI-DrugBank.d488.s2	inhibitors	9	18	I-group
DDI-DrugBank.d488.s2	:	19	19	O
DDI-DrugBank.d488.s2	Drugs	21	25	O
DDI-DrugBank.d488.s2	such	27	30	O
DDI-DrugBank.d488.s2	as	32	33	O
DDI-DrugBank.d488.s2	acetylsalicylic	35	49	B-drug
DDI-DrugBank.d488.s2	acid	51	54	I-drug
DDI-DrugBank.d488.s2	,	55	55	O
DDI-DrugBank.d488.s2	dextran	57	63	B-drug
DDI-DrugBank.d488.s2	,	64	64	O
DDI-DrugBank.d488.s2	phenylbutazone	66	79	B-drug
DDI-DrugBank.d488.s2	,	80	80	O
DDI-DrugBank.d488.s2	ibuprofen	82	90	B-drug
DDI-DrugBank.d488.s2	,	91	91	O
DDI-DrugBank.d488.s2	indomethacin	93	104	B-drug
DDI-DrugBank.d488.s2	,	105	105	O
DDI-DrugBank.d488.s2	dipyridamole	107	118	B-drug
DDI-DrugBank.d488.s2	,	119	119	O
DDI-DrugBank.d488.s2	hydroxychloroquine	121	138	B-drug
DDI-DrugBank.d488.s2	and	140	142	O
DDI-DrugBank.d488.s2	others	144	149	O
DDI-DrugBank.d488.s2	that	151	154	O
DDI-DrugBank.d488.s2	interfere	156	164	O
DDI-DrugBank.d488.s2	with	166	169	O
DDI-DrugBank.d488.s2	platelet-aggregation	171	190	O
DDI-DrugBank.d488.s2	reactions	192	200	O
DDI-DrugBank.d488.s2	(	202	202	O
DDI-DrugBank.d488.s2	the	203	205	O
DDI-DrugBank.d488.s2	main	207	210	O
DDI-DrugBank.d488.s2	hemostatic	212	221	O
DDI-DrugBank.d488.s2	defense	223	229	O
DDI-DrugBank.d488.s2	of	231	232	O
DDI-DrugBank.d488.s2	heparinized	234	244	O
DDI-DrugBank.d488.s2	patients	246	253	O
DDI-DrugBank.d488.s2	)	254	254	O
DDI-DrugBank.d488.s2	may	256	258	O
DDI-DrugBank.d488.s2	induce	260	265	O
DDI-DrugBank.d488.s2	bleeding	267	274	O
DDI-DrugBank.d488.s2	and	276	278	O
DDI-DrugBank.d488.s2	should	280	285	O
DDI-DrugBank.d488.s2	be	287	288	O
DDI-DrugBank.d488.s2	used	290	293	O
DDI-DrugBank.d488.s2	with	295	298	O
DDI-DrugBank.d488.s2	caution	300	306	O
DDI-DrugBank.d488.s2	in	272	273	O
DDI-DrugBank.d488.s2	patients	311	318	O
DDI-DrugBank.d488.s2	receiving	320	328	O
DDI-DrugBank.d488.s2	heparin	330	336	B-drug
DDI-DrugBank.d488.s2	sodium	338	343	I-drug
DDI-DrugBank.d488.s2	.	344	344	O
DDI-DrugBank.d488.s3	The	0	2	O
DDI-DrugBank.d488.s3	anticoagulant	4	16	O
DDI-DrugBank.d488.s3	effect	18	23	O
DDI-DrugBank.d488.s3	of	25	26	O
DDI-DrugBank.d488.s3	heparin	28	34	B-drug
DDI-DrugBank.d488.s3	is	36	37	O
DDI-DrugBank.d488.s3	enhanced	39	46	O
DDI-DrugBank.d488.s3	by	48	49	O
DDI-DrugBank.d488.s3	concurrent	51	60	O
DDI-DrugBank.d488.s3	treatment	62	70	O
DDI-DrugBank.d488.s3	with	72	75	O
DDI-DrugBank.d488.s3	antithrombin	77	88	B-drug
DDI-DrugBank.d488.s3	III	90	92	I-drug
DDI-DrugBank.d488.s3	(	94	94	O
DDI-DrugBank.d488.s3	human	95	99	O
DDI-DrugBank.d488.s3	)	100	100	O
DDI-DrugBank.d488.s3	in	102	103	O
DDI-DrugBank.d488.s3	patients	105	112	O
DDI-DrugBank.d488.s3	with	114	117	O
DDI-DrugBank.d488.s3	hereditary	119	128	O
DDI-DrugBank.d488.s3	antithrombin	130	141	O
DDI-DrugBank.d488.s3	III	143	145	O
DDI-DrugBank.d488.s3	deficiency	147	156	O
DDI-DrugBank.d488.s3	.	157	157	O
DDI-DrugBank.d488.s4	Thus	0	3	O
DDI-DrugBank.d488.s4	in	5	6	O
DDI-DrugBank.d488.s4	order	8	12	O
DDI-DrugBank.d488.s4	to	14	15	O
DDI-DrugBank.d488.s4	avoid	17	21	O
DDI-DrugBank.d488.s4	bleeding	23	30	O
DDI-DrugBank.d488.s4	,	31	31	O
DDI-DrugBank.d488.s4	reduced	33	39	O
DDI-DrugBank.d488.s4	dosage	41	46	O
DDI-DrugBank.d488.s4	of	48	49	O
DDI-DrugBank.d488.s4	heparin	51	57	B-drug
DDI-DrugBank.d488.s4	is	59	60	O
DDI-DrugBank.d488.s4	recommended	62	72	O
DDI-DrugBank.d488.s4	during	74	79	O
DDI-DrugBank.d488.s4	treatment	81	89	O
DDI-DrugBank.d488.s4	with	91	94	O
DDI-DrugBank.d488.s4	antithrombin	96	107	B-drug
DDI-DrugBank.d488.s4	III	109	111	I-drug
DDI-DrugBank.d488.s4	(	113	113	O
DDI-DrugBank.d488.s4	human	114	118	O
DDI-DrugBank.d488.s4	)	119	119	O
DDI-DrugBank.d488.s4	.	120	120	O
DDI-DrugBank.d488.s5	b	0	0	O
DDI-DrugBank.d488.s5	.	1	1	O
DDI-DrugBank.d488.s6	Drugs	0	4	O
DDI-DrugBank.d488.s6	Decreasing	6	15	O
DDI-DrugBank.d488.s6	Heparin	17	23	B-drug
DDI-DrugBank.d488.s6	Effect	25	30	O
DDI-DrugBank.d488.s6	:	31	31	O
DDI-DrugBank.d488.s6	Digitalis	33	41	B-group
DDI-DrugBank.d488.s6	,	42	42	O
DDI-DrugBank.d488.s6	tetracyclines	44	56	B-group
DDI-DrugBank.d488.s6	,	57	57	O
DDI-DrugBank.d488.s6	nicotine	59	66	B-drug
DDI-DrugBank.d488.s6	,	67	67	O
DDI-DrugBank.d488.s6	or	69	70	O
DDI-DrugBank.d488.s6	antihistamines	72	85	B-group
DDI-DrugBank.d488.s6	may	87	89	O
DDI-DrugBank.d488.s6	partially	91	99	O
DDI-DrugBank.d488.s6	counteract	101	110	O
DDI-DrugBank.d488.s6	the	112	114	O
DDI-DrugBank.d488.s6	anticoagulant	116	128	O
DDI-DrugBank.d488.s6	action	130	135	O
DDI-DrugBank.d488.s6	of	137	138	O
DDI-DrugBank.d488.s6	heparin	140	146	B-drug
DDI-DrugBank.d488.s6	sodium	148	153	I-drug
DDI-DrugBank.d488.s6	.	154	154	O
DDI-DrugBank.d488.s7	Heparin	0	6	B-drug
DDI-DrugBank.d488.s7	Sodium	8	13	I-drug
DDI-DrugBank.d488.s7	Injection	15	23	O
DDI-DrugBank.d488.s7	should	25	30	O
DDI-DrugBank.d488.s7	not	32	34	O
DDI-DrugBank.d488.s7	be	36	37	O
DDI-DrugBank.d488.s7	mixed	39	43	O
DDI-DrugBank.d488.s7	with	45	48	O
DDI-DrugBank.d488.s7	doxorubicin	50	60	B-drug
DDI-DrugBank.d488.s7	,	61	61	O
DDI-DrugBank.d488.s7	droperidol	63	72	B-drug
DDI-DrugBank.d488.s7	,	73	73	O
DDI-DrugBank.d488.s7	ciprofloxacin	75	87	B-drug
DDI-DrugBank.d488.s7	,	88	88	O
DDI-DrugBank.d488.s7	or	90	91	O
DDI-DrugBank.d488.s7	mitoxantrone	93	104	B-drug
DDI-DrugBank.d488.s7	,	105	105	O
DDI-DrugBank.d488.s7	since	107	111	O
DDI-DrugBank.d488.s7	it	113	114	O
DDI-DrugBank.d488.s7	has	116	118	O
DDI-DrugBank.d488.s7	been	120	123	O
DDI-DrugBank.d488.s7	reported	125	132	O
DDI-DrugBank.d488.s7	that	134	137	O
DDI-DrugBank.d488.s7	these	139	143	O
DDI-DrugBank.d488.s7	drugs	145	149	O
DDI-DrugBank.d488.s7	are	151	153	O
DDI-DrugBank.d488.s7	incompatible	155	166	O
DDI-DrugBank.d488.s7	with	168	171	O
DDI-DrugBank.d488.s7	heparin	173	179	B-drug
DDI-DrugBank.d488.s7	and	181	183	O
DDI-DrugBank.d488.s7	a	161	161	O
DDI-DrugBank.d488.s7	precipitate	187	197	O
DDI-DrugBank.d488.s7	may	199	201	O
DDI-DrugBank.d488.s7	form	203	206	O
DDI-DrugBank.d488.s7	.	207	207	O
DDI-DrugBank.d488.s8	Drug/	0	4	O
DDI-DrugBank.d488.s8	Laboratory	6	15	O
DDI-DrugBank.d488.s8	Tests	17	21	O
DDI-DrugBank.d488.s8	Interactions	23	34	O
DDI-DrugBank.d488.s8	Hyperaminotransferasemia	36	59	O
DDI-DrugBank.d488.s8	:	60	60	O
DDI-DrugBank.d488.s8	Significant	62	72	O
DDI-DrugBank.d488.s8	elevations	74	83	O
DDI-DrugBank.d488.s8	of	85	86	O
DDI-DrugBank.d488.s8	aminotransferase	88	103	O
DDI-DrugBank.d488.s8	(	105	105	O
DDI-DrugBank.d488.s8	SGOT	106	109	O
DDI-DrugBank.d488.s8	[	111	111	O
DDI-DrugBank.d488.s8	S-AST	112	116	O
DDI-DrugBank.d488.s8	]	117	117	O
DDI-DrugBank.d488.s8	and	119	121	O
DDI-DrugBank.d488.s8	SGPT	123	126	O
DDI-DrugBank.d488.s8	[	128	128	O
DDI-DrugBank.d488.s8	S-ALT	129	133	O
DDI-DrugBank.d488.s8	]	134	134	O
DDI-DrugBank.d488.s8	)	135	135	O
DDI-DrugBank.d488.s8	levels	137	142	O
DDI-DrugBank.d488.s8	have	144	147	O
DDI-DrugBank.d488.s8	occurred	149	156	O
DDI-DrugBank.d488.s8	in	158	159	O
DDI-DrugBank.d488.s8	a	145	145	O
DDI-DrugBank.d488.s8	high	163	166	O
DDI-DrugBank.d488.s8	percentage	168	177	O
DDI-DrugBank.d488.s8	of	179	180	O
DDI-DrugBank.d488.s8	patients	182	189	O
DDI-DrugBank.d488.s8	(	191	191	O
DDI-DrugBank.d488.s8	and	192	194	O
DDI-DrugBank.d488.s8	healthy	196	202	O
DDI-DrugBank.d488.s8	subjects	204	211	O
DDI-DrugBank.d488.s8	)	212	212	O
DDI-DrugBank.d488.s8	who	214	216	O
DDI-DrugBank.d488.s8	have	218	221	O
DDI-DrugBank.d488.s8	received	223	230	O
DDI-DrugBank.d488.s8	heparin	232	238	B-drug
DDI-DrugBank.d488.s8	sodium	240	245	I-drug
DDI-DrugBank.d488.s8	.	246	246	O
DDI-DrugBank.d488.s9	Since	0	4	O
DDI-DrugBank.d488.s9	aminotransferase	6	21	O
DDI-DrugBank.d488.s9	determinations	23	36	O
DDI-DrugBank.d488.s9	are	38	40	O
DDI-DrugBank.d488.s9	important	42	50	O
DDI-DrugBank.d488.s9	in	52	53	O
DDI-DrugBank.d488.s9	the	55	57	O
DDI-DrugBank.d488.s9	differential	59	70	O
DDI-DrugBank.d488.s9	diagnosis	72	80	O
DDI-DrugBank.d488.s9	of	82	83	O
DDI-DrugBank.d488.s9	myocardial	85	94	O
DDI-DrugBank.d488.s9	infarction	96	105	O
DDI-DrugBank.d488.s9	,	106	106	O
DDI-DrugBank.d488.s9	liver	108	112	O
DDI-DrugBank.d488.s9	disease	114	120	O
DDI-DrugBank.d488.s9	and	122	124	O
DDI-DrugBank.d488.s9	pulmonary	126	134	O
DDI-DrugBank.d488.s9	emboli	136	141	O
DDI-DrugBank.d488.s9	,	142	142	O
DDI-DrugBank.d488.s9	rises	144	148	O
DDI-DrugBank.d488.s9	that	150	153	O
DDI-DrugBank.d488.s9	might	155	159	O
DDI-DrugBank.d488.s9	be	161	162	O
DDI-DrugBank.d488.s9	caused	164	169	O
DDI-DrugBank.d488.s9	by	171	172	O
DDI-DrugBank.d488.s9	drugs	174	178	O
DDI-DrugBank.d488.s9	(	180	180	O
DDI-DrugBank.d488.s9	heparin	181	187	B-drug
DDI-DrugBank.d488.s9	sodium	189	194	I-drug
DDI-DrugBank.d488.s9	)	195	195	O
DDI-DrugBank.d488.s9	should	197	202	O
DDI-DrugBank.d488.s9	be	204	205	O
DDI-DrugBank.d488.s9	interpreted	207	217	O
DDI-DrugBank.d488.s9	with	219	222	O
DDI-DrugBank.d488.s9	caution	224	230	O
DDI-DrugBank.d488.s9	.	231	231	O
DDI-DrugBank.d138.s0	Although	0	7	O
DDI-DrugBank.d138.s0	specific	9	16	O
DDI-DrugBank.d138.s0	drug	18	21	O
DDI-DrugBank.d138.s0	interaction	23	33	O
DDI-DrugBank.d138.s0	studies	35	41	O
DDI-DrugBank.d138.s0	have	43	46	O
DDI-DrugBank.d138.s0	not	48	50	O
DDI-DrugBank.d138.s0	been	52	55	O
DDI-DrugBank.d138.s0	conducted	57	65	O
DDI-DrugBank.d138.s0	with	67	70	O
DDI-DrugBank.d138.s0	ALPHAGAN	72	79	B-brand
DDI-DrugBank.d138.s0	P	74	74	O
DDI-DrugBank.d138.s0	,	82	82	O
DDI-DrugBank.d138.s0	the	84	86	O
DDI-DrugBank.d138.s0	possibility	88	98	O
DDI-DrugBank.d138.s0	of	100	101	O
DDI-DrugBank.d138.s0	an	103	104	O
DDI-DrugBank.d138.s0	additive	106	113	O
DDI-DrugBank.d138.s0	or	115	116	O
DDI-DrugBank.d138.s0	potentiating	118	129	O
DDI-DrugBank.d138.s0	effect	131	136	O
DDI-DrugBank.d138.s0	with	138	141	O
DDI-DrugBank.d138.s0	CNS	143	145	B-group
DDI-DrugBank.d138.s0	depressants	147	157	I-group
DDI-DrugBank.d138.s0	(	159	159	O
DDI-DrugBank.d138.s0	alcohol	160	166	B-drug
DDI-DrugBank.d138.s0	,	167	167	O
DDI-DrugBank.d138.s0	barbiturates	169	180	B-group
DDI-DrugBank.d138.s0	,	167	167	O
DDI-DrugBank.d138.s0	opiates	183	189	B-group
DDI-DrugBank.d138.s0	,	167	167	O
DDI-DrugBank.d138.s0	sedatives	192	200	B-group
DDI-DrugBank.d138.s0	,	181	181	O
DDI-DrugBank.d138.s0	or	203	204	O
DDI-DrugBank.d138.s0	anesthetics	206	216	B-group
DDI-DrugBank.d138.s0	)	217	217	O
DDI-DrugBank.d138.s0	should	219	224	O
DDI-DrugBank.d138.s0	be	226	227	O
DDI-DrugBank.d138.s0	considered	229	238	O
DDI-DrugBank.d138.s0	.	239	239	O
DDI-DrugBank.d138.s1	Alpha-agonists	0	13	B-group
DDI-DrugBank.d138.s1	,	14	14	O
DDI-DrugBank.d138.s1	as	16	17	O
DDI-DrugBank.d138.s1	a	19	19	O
DDI-DrugBank.d138.s1	class	21	25	O
DDI-DrugBank.d138.s1	,	26	26	O
DDI-DrugBank.d138.s1	may	28	30	O
DDI-DrugBank.d138.s1	reduce	32	37	O
DDI-DrugBank.d138.s1	pulse	39	43	O
DDI-DrugBank.d138.s1	and	45	47	O
DDI-DrugBank.d138.s1	blood	49	53	O
DDI-DrugBank.d138.s1	pressure	55	62	O
DDI-DrugBank.d138.s1	.	63	63	O
DDI-DrugBank.d138.s2	Caution	0	6	O
DDI-DrugBank.d138.s2	in	8	9	O
DDI-DrugBank.d138.s2	using	11	15	O
DDI-DrugBank.d138.s2	concomitant	17	27	O
DDI-DrugBank.d138.s2	drugs	29	33	O
DDI-DrugBank.d138.s2	such	35	38	O
DDI-DrugBank.d138.s2	as	40	41	O
DDI-DrugBank.d138.s2	beta-blockers	43	55	B-group
DDI-DrugBank.d138.s2	(	57	57	O
DDI-DrugBank.d138.s2	ophthalmic	58	67	O
DDI-DrugBank.d138.s2	and	69	71	O
DDI-DrugBank.d138.s2	systemic	73	80	O
DDI-DrugBank.d138.s2	)	81	81	O
DDI-DrugBank.d138.s2	,	82	82	O
DDI-DrugBank.d138.s2	anti-hypertensives	84	101	B-group
DDI-DrugBank.d138.s2	and/or	103	108	O
DDI-DrugBank.d138.s2	cardiac	110	116	B-group
DDI-DrugBank.d138.s2	glycosides	118	127	I-group
DDI-DrugBank.d138.s2	is	129	130	O
DDI-DrugBank.d138.s2	advised	132	138	O
DDI-DrugBank.d138.s2	.	139	139	O
DDI-DrugBank.d138.s3	Tricyclic	0	8	B-group
DDI-DrugBank.d138.s3	antidepressants	10	24	I-group
DDI-DrugBank.d138.s3	have	26	29	O
DDI-DrugBank.d138.s3	been	31	34	O
DDI-DrugBank.d138.s3	reported	36	43	O
DDI-DrugBank.d138.s3	to	45	46	O
DDI-DrugBank.d138.s3	blunt	48	52	O
DDI-DrugBank.d138.s3	the	54	56	O
DDI-DrugBank.d138.s3	hypotensive	58	68	O
DDI-DrugBank.d138.s3	effect	70	75	O
DDI-DrugBank.d138.s3	of	77	78	O
DDI-DrugBank.d138.s3	systemic	80	87	O
DDI-DrugBank.d138.s3	clonidine.It	89	100	O
DDI-DrugBank.d138.s3	is	102	103	O
DDI-DrugBank.d138.s3	not	105	107	O
DDI-DrugBank.d138.s3	known	109	113	O
DDI-DrugBank.d138.s3	whether	115	121	O
DDI-DrugBank.d138.s3	the	118	120	O
DDI-DrugBank.d138.s3	concurrent	127	136	O
DDI-DrugBank.d138.s3	use	138	140	O
DDI-DrugBank.d138.s3	of	142	143	O
DDI-DrugBank.d138.s3	these	145	149	O
DDI-DrugBank.d138.s3	agents	151	156	O
DDI-DrugBank.d138.s3	with	158	161	O
DDI-DrugBank.d138.s3	ALPHAGAN	163	170	B-brand
DDI-DrugBank.d138.s3	P	165	165	O
DDI-DrugBank.d138.s3	in	174	175	O
DDI-DrugBank.d138.s3	humans	177	182	O
DDI-DrugBank.d138.s3	can	184	186	O
DDI-DrugBank.d138.s3	lead	188	191	O
DDI-DrugBank.d138.s3	to	193	194	O
DDI-DrugBank.d138.s3	resulting	196	204	O
DDI-DrugBank.d138.s3	interference	206	217	O
DDI-DrugBank.d138.s3	with	219	222	O
DDI-DrugBank.d138.s3	the	224	226	O
DDI-DrugBank.d138.s3	IOP	228	230	O
DDI-DrugBank.d138.s3	lowering	232	239	O
DDI-DrugBank.d138.s3	effect	241	246	O
DDI-DrugBank.d138.s3	.	247	247	O
DDI-DrugBank.d138.s4	No	0	1	O
DDI-DrugBank.d138.s4	data	3	6	O
DDI-DrugBank.d138.s4	on	8	9	O
DDI-DrugBank.d138.s4	the	11	13	O
DDI-DrugBank.d138.s4	level	15	19	O
DDI-DrugBank.d138.s4	of	21	22	O
DDI-DrugBank.d138.s4	circulating	24	34	O
DDI-DrugBank.d138.s4	catecholamines	36	49	O
DDI-DrugBank.d138.s4	after	51	55	O
DDI-DrugBank.d138.s4	ALPHAGAN	57	64	B-brand
DDI-DrugBank.d138.s4	P	59	59	O
DDI-DrugBank.d138.s4	administration	68	81	O
DDI-DrugBank.d138.s4	are	83	85	O
DDI-DrugBank.d138.s4	available	87	95	O
DDI-DrugBank.d138.s4	.	96	96	O
DDI-DrugBank.d138.s5	Caution	0	6	O
DDI-DrugBank.d138.s5	,	7	7	O
DDI-DrugBank.d138.s5	however	9	15	O
DDI-DrugBank.d138.s5	,	16	16	O
DDI-DrugBank.d138.s5	is	18	19	O
DDI-DrugBank.d138.s5	advised	21	27	O
DDI-DrugBank.d138.s5	in	29	30	O
DDI-DrugBank.d138.s5	patients	32	39	O
DDI-DrugBank.d138.s5	taking	41	46	O
DDI-DrugBank.d138.s5	tricyclic	48	56	B-group
DDI-DrugBank.d138.s5	antidepressants	58	72	I-group
DDI-DrugBank.d138.s5	which	74	78	O
DDI-DrugBank.d138.s5	can	80	82	O
DDI-DrugBank.d138.s5	affect	84	89	O
DDI-DrugBank.d138.s5	the	91	93	O
DDI-DrugBank.d138.s5	metabolism	95	104	O
DDI-DrugBank.d138.s5	and	106	108	O
DDI-DrugBank.d138.s5	uptake	110	115	O
DDI-DrugBank.d138.s5	of	117	118	O
DDI-DrugBank.d138.s5	circulating	120	130	O
DDI-DrugBank.d138.s5	amines	132	137	O
DDI-DrugBank.d138.s5	.	138	138	O
DDI-MedLine.d34.s0	Interactions	0	11	O
DDI-MedLine.d34.s0	of	13	14	O
DDI-MedLine.d34.s0	cobalt	16	21	B-drug
DDI-MedLine.d34.s0	and	23	25	O
DDI-MedLine.d34.s0	iron	27	30	B-drug
DDI-MedLine.d34.s0	in	32	33	O
DDI-MedLine.d34.s0	absorption	35	44	O
DDI-MedLine.d34.s0	and	46	48	O
DDI-MedLine.d34.s0	retention	50	58	O
DDI-MedLine.d34.s0	.	59	59	O
DDI-MedLine.d34.s1	The	0	2	O
DDI-MedLine.d34.s1	effects	4	10	O
DDI-MedLine.d34.s1	of	12	13	O
DDI-MedLine.d34.s1	supplementary	15	27	O
DDI-MedLine.d34.s1	oral	29	32	O
DDI-MedLine.d34.s1	cobalt	34	39	B-drug
DDI-MedLine.d34.s1	and	41	43	O
DDI-MedLine.d34.s1	iron	45	48	B-drug
DDI-MedLine.d34.s1	,	49	49	O
DDI-MedLine.d34.s1	as	51	52	O
DDI-MedLine.d34.s1	well	54	57	O
DDI-MedLine.d34.s1	as	51	52	O
DDI-MedLine.d34.s1	the	62	64	O
DDI-MedLine.d34.s1	interaction	66	76	O
DDI-MedLine.d34.s1	between	78	84	O
DDI-MedLine.d34.s1	both	86	89	O
DDI-MedLine.d34.s1	at	91	92	O
DDI-MedLine.d34.s1	the	94	96	O
DDI-MedLine.d34.s1	absorption	98	107	O
DDI-MedLine.d34.s1	site	109	112	O
DDI-MedLine.d34.s1	,	113	113	O
DDI-MedLine.d34.s1	fecal	115	119	O
DDI-MedLine.d34.s1	and	121	123	O
DDI-MedLine.d34.s1	urinary	125	131	O
DDI-MedLine.d34.s1	excretion	133	141	O
DDI-MedLine.d34.s1	as	143	144	O
DDI-MedLine.d34.s1	well	146	149	O
DDI-MedLine.d34.s1	as	143	144	O
DDI-MedLine.d34.s1	the	154	156	O
DDI-MedLine.d34.s1	retention	158	166	O
DDI-MedLine.d34.s1	of	168	169	O
DDI-MedLine.d34.s1	these	171	175	O
DDI-MedLine.d34.s1	trace	177	181	O
DDI-MedLine.d34.s1	elements	183	190	O
DDI-MedLine.d34.s1	were	192	195	O
DDI-MedLine.d34.s1	determined	197	206	O
DDI-MedLine.d34.s1	by	208	209	O
DDI-MedLine.d34.s1	using	211	215	O
DDI-MedLine.d34.s1	four	217	220	O
DDI-MedLine.d34.s1	diets	222	226	O
DDI-MedLine.d34.s1	containing	228	237	O
DDI-MedLine.d34.s1	either	239	244	O
DDI-MedLine.d34.s1	9	246	246	O
DDI-MedLine.d34.s1	or	248	249	O
DDI-MedLine.d34.s1	63	251	252	O
DDI-MedLine.d34.s1	micrograms/kg	254	266	O
DDI-MedLine.d34.s1	of	268	269	O
DDI-MedLine.d34.s1	Co	271	272	B-drug
DDI-MedLine.d34.s1	and	274	276	O
DDI-MedLine.d34.s1	48	278	279	O
DDI-MedLine.d34.s1	or	248	249	O
DDI-MedLine.d34.s1	446	284	286	O
DDI-MedLine.d34.s1	mg/kg	288	292	O
DDI-MedLine.d34.s1	of	268	269	O
DDI-MedLine.d34.s1	Fe	297	298	B-drug
DDI-MedLine.d34.s1	over	300	303	O
DDI-MedLine.d34.s1	a	261	261	O
DDI-MedLine.d34.s1	period	307	312	O
DDI-MedLine.d34.s1	of	268	269	O
DDI-MedLine.d34.s1	19	317	318	O
DDI-MedLine.d34.s1	days	320	323	O
DDI-MedLine.d34.s1	in	325	326	O
DDI-MedLine.d34.s1	a	274	274	O
DDI-MedLine.d34.s1	total	330	334	O
DDI-MedLine.d34.s1	of	294	295	O
DDI-MedLine.d34.s1	24	339	340	O
DDI-MedLine.d34.s1	rats	342	345	O
DDI-MedLine.d34.s1	.	346	346	O
DDI-MedLine.d34.s2	Retention	0	8	O
DDI-MedLine.d34.s2	was	10	12	O
DDI-MedLine.d34.s2	calculated	14	23	O
DDI-MedLine.d34.s2	by	25	26	O
DDI-MedLine.d34.s2	the	28	30	O
DDI-MedLine.d34.s2	balance	32	38	O
DDI-MedLine.d34.s2	technique	40	48	O
DDI-MedLine.d34.s2	and	50	52	O
DDI-MedLine.d34.s2	by	54	55	O
DDI-MedLine.d34.s2	the	57	59	O
DDI-MedLine.d34.s2	comparative	61	71	O
DDI-MedLine.d34.s2	slaughter	73	81	O
DDI-MedLine.d34.s2	technique	83	91	O
DDI-MedLine.d34.s2	.	92	92	O
DDI-MedLine.d34.s3	After	0	4	O
DDI-MedLine.d34.s3	one	6	8	O
DDI-MedLine.d34.s3	day	10	12	O
DDI-MedLine.d34.s3	,	13	13	O
DDI-MedLine.d34.s3	fecal	15	19	O
DDI-MedLine.d34.s3	as	21	22	O
DDI-MedLine.d34.s3	well	24	27	O
DDI-MedLine.d34.s3	as	29	30	O
DDI-MedLine.d34.s3	urinary	32	38	O
DDI-MedLine.d34.s3	excretion	40	48	O
DDI-MedLine.d34.s3	of	50	51	O
DDI-MedLine.d34.s3	both	53	56	O
DDI-MedLine.d34.s3	elements	58	65	O
DDI-MedLine.d34.s3	had	67	69	O
DDI-MedLine.d34.s3	already	71	77	O
DDI-MedLine.d34.s3	responded	79	87	O
DDI-MedLine.d34.s3	to	89	90	O
DDI-MedLine.d34.s3	the	92	94	O
DDI-MedLine.d34.s3	dietary	96	102	O
DDI-MedLine.d34.s3	treatments	104	113	O
DDI-MedLine.d34.s3	,	114	114	O
DDI-MedLine.d34.s3	with	116	119	O
DDI-MedLine.d34.s3	constant	121	128	O
DDI-MedLine.d34.s3	values	130	135	O
DDI-MedLine.d34.s3	being	137	141	O
DDI-MedLine.d34.s3	reached	143	149	O
DDI-MedLine.d34.s3	after	151	155	O
DDI-MedLine.d34.s3	approximately	157	169	O
DDI-MedLine.d34.s3	three	171	175	O
DDI-MedLine.d34.s3	days	177	180	O
DDI-MedLine.d34.s3	.	181	181	O
DDI-MedLine.d34.s4	Cobalt	0	5	B-drug
DDI-MedLine.d34.s4	excretion	7	15	O
DDI-MedLine.d34.s4	was	17	19	O
DDI-MedLine.d34.s4	enhanced	21	28	O
DDI-MedLine.d34.s4	by	30	31	O
DDI-MedLine.d34.s4	supplementary	33	45	O
DDI-MedLine.d34.s4	cobalt	47	52	B-drug
DDI-MedLine.d34.s4	;	53	53	O
DDI-MedLine.d34.s5	fecal	0	4	O
DDI-MedLine.d34.s5	excretion	6	14	O
DDI-MedLine.d34.s5	,	15	15	O
DDI-MedLine.d34.s5	too	17	19	O
DDI-MedLine.d34.s5	,	20	20	O
DDI-MedLine.d34.s5	was	22	24	O
DDI-MedLine.d34.s5	increased	26	34	O
DDI-MedLine.d34.s5	by	36	37	O
DDI-MedLine.d34.s5	supplementary	39	51	O
DDI-MedLine.d34.s5	iron	53	56	B-drug
DDI-MedLine.d34.s5	;	57	57	O
DDI-MedLine.d34.s6	whereas	0	6	O
DDI-MedLine.d34.s6	urinary	8	14	O
DDI-MedLine.d34.s6	excretion	16	24	O
DDI-MedLine.d34.s6	was	26	28	O
DDI-MedLine.d34.s6	decreased	30	38	O
DDI-MedLine.d34.s6	in	40	41	O
DDI-MedLine.d34.s6	both	43	46	O
DDI-MedLine.d34.s6	cases	48	52	O
DDI-MedLine.d34.s6	.	53	53	O
DDI-MedLine.d34.s7	Additional	0	9	O
DDI-MedLine.d34.s7	iron	11	14	B-drug
DDI-MedLine.d34.s7	significantly	16	28	O
DDI-MedLine.d34.s7	inhibited	30	38	O
DDI-MedLine.d34.s7	the	40	42	O
DDI-MedLine.d34.s7	absorption	44	53	O
DDI-MedLine.d34.s7	of	55	56	O
DDI-MedLine.d34.s7	cobalt	58	63	B-drug
DDI-MedLine.d34.s7	in	65	66	O
DDI-MedLine.d34.s7	both	68	71	O
DDI-MedLine.d34.s7	dietary	73	79	O
DDI-MedLine.d34.s7	cobalt	81	86	B-drug
DDI-MedLine.d34.s7	treatments	88	97	O
DDI-MedLine.d34.s7	.	98	98	O
DDI-MedLine.d34.s8	The	0	2	O
DDI-MedLine.d34.s8	lower	4	8	O
DDI-MedLine.d34.s8	rate	10	13	O
DDI-MedLine.d34.s8	of	15	16	O
DDI-MedLine.d34.s8	absorption	18	27	O
DDI-MedLine.d34.s8	in	29	30	O
DDI-MedLine.d34.s8	the	32	34	O
DDI-MedLine.d34.s8	groups	36	41	O
DDI-MedLine.d34.s8	receiving	43	51	O
DDI-MedLine.d34.s8	446	53	55	O
DDI-MedLine.d34.s8	mg	57	58	O
DDI-MedLine.d34.s8	Fe	60	61	B-drug
DDI-MedLine.d34.s8	instead	63	69	O
DDI-MedLine.d34.s8	of	71	72	O
DDI-MedLine.d34.s8	48	74	75	O
DDI-MedLine.d34.s8	mg	77	78	O
DDI-MedLine.d34.s8	of	71	72	O
DDI-MedLine.d34.s8	Fe	83	84	B-drug
DDI-MedLine.d34.s8	per	86	88	O
DDI-MedLine.d34.s8	kg	90	91	O
DDI-MedLine.d34.s8	diet	93	96	O
DDI-MedLine.d34.s8	resulted	98	105	O
DDI-MedLine.d34.s8	in	107	108	O
DDI-MedLine.d34.s8	a	110	110	O
DDI-MedLine.d34.s8	decreased	112	120	O
DDI-MedLine.d34.s8	renal	122	126	O
DDI-MedLine.d34.s8	excretion	128	136	O
DDI-MedLine.d34.s8	of	138	139	O
DDI-MedLine.d34.s8	cobalt	141	146	B-drug
DDI-MedLine.d34.s8	.	147	147	O
DDI-MedLine.d34.s9	Consequently	0	11	O
DDI-MedLine.d34.s9	,	12	12	O
DDI-MedLine.d34.s9	the	14	16	O
DDI-MedLine.d34.s9	effect	18	23	O
DDI-MedLine.d34.s9	of	25	26	O
DDI-MedLine.d34.s9	iron	28	31	B-drug
DDI-MedLine.d34.s9	on	30	31	I-drug
DDI-MedLine.d34.s9	the	36	38	O
DDI-MedLine.d34.s9	retention	40	48	O
DDI-MedLine.d34.s9	of	50	51	O
DDI-MedLine.d34.s9	cobalt	53	58	B-drug
DDI-MedLine.d34.s9	was	60	62	O
DDI-MedLine.d34.s9	lower	64	68	O
DDI-MedLine.d34.s9	than	70	73	O
DDI-MedLine.d34.s9	on	75	76	O
DDI-MedLine.d34.s9	absorption	78	87	O
DDI-MedLine.d34.s9	.	88	88	O
DDI-MedLine.d34.s10	This	0	3	O
DDI-MedLine.d34.s10	suggests	5	12	O
DDI-MedLine.d34.s10	that	14	17	O
DDI-MedLine.d34.s10	interactions	19	30	O
DDI-MedLine.d34.s10	between	32	38	O
DDI-MedLine.d34.s10	the	40	42	O
DDI-MedLine.d34.s10	two	44	46	O
DDI-MedLine.d34.s10	elements	48	55	O
DDI-MedLine.d34.s10	only	57	60	O
DDI-MedLine.d34.s10	take	62	65	O
DDI-MedLine.d34.s10	place	67	71	O
DDI-MedLine.d34.s10	at	73	74	O
DDI-MedLine.d34.s10	the	76	78	O
DDI-MedLine.d34.s10	site	80	83	O
DDI-MedLine.d34.s10	of	85	86	O
DDI-MedLine.d34.s10	absorption	88	97	O
DDI-MedLine.d34.s10	.	98	98	O
DDI-MedLine.d34.s11	Because	0	6	O
DDI-MedLine.d34.s11	of	8	9	O
DDI-MedLine.d34.s11	the	11	13	O
DDI-MedLine.d34.s11	low	15	17	O
DDI-MedLine.d34.s11	dietary	19	25	O
DDI-MedLine.d34.s11	cobalt	27	32	B-drug
DDI-MedLine.d34.s11	concentration	34	46	O
DDI-MedLine.d34.s11	as	48	49	O
DDI-MedLine.d34.s11	compared	51	58	O
DDI-MedLine.d34.s11	to	60	61	O
DDI-MedLine.d34.s11	the	63	65	O
DDI-MedLine.d34.s11	iron	67	70	B-drug
DDI-MedLine.d34.s11	contents	72	79	O
DDI-MedLine.d34.s11	of	81	82	O
DDI-MedLine.d34.s11	the	84	86	O
DDI-MedLine.d34.s11	diets	88	92	O
DDI-MedLine.d34.s11	,	93	93	O
DDI-MedLine.d34.s11	no	95	96	O
DDI-MedLine.d34.s11	effect	98	103	O
DDI-MedLine.d34.s11	of	105	106	O
DDI-MedLine.d34.s11	cobalt	108	113	B-drug
DDI-MedLine.d34.s11	on	115	116	O
DDI-MedLine.d34.s11	iron	118	121	B-drug
DDI-MedLine.d34.s11	absorption	123	132	O
DDI-MedLine.d34.s11	and	134	136	O
DDI-MedLine.d34.s11	excretion	138	146	O
DDI-MedLine.d34.s11	occurred	148	155	O
DDI-MedLine.d34.s11	.	156	156	O
DDI-MedLine.d34.s12	Differences	0	10	O
DDI-MedLine.d34.s12	in	12	13	O
DDI-MedLine.d34.s12	iron	15	18	B-drug
DDI-MedLine.d34.s12	balance	20	26	O
DDI-MedLine.d34.s12	were	28	31	O
DDI-MedLine.d34.s12	only	33	36	O
DDI-MedLine.d34.s12	observed	38	45	O
DDI-MedLine.d34.s12	between	47	53	O
DDI-MedLine.d34.s12	both	55	58	O
DDI-MedLine.d34.s12	dietary	60	66	O
DDI-MedLine.d34.s12	concentrations	68	81	O
DDI-MedLine.d34.s12	,	82	82	O
DDI-MedLine.d34.s12	showing	84	90	O
DDI-MedLine.d34.s12	a	92	92	O
DDI-MedLine.d34.s12	higher	94	99	O
DDI-MedLine.d34.s12	absolute	101	108	O
DDI-MedLine.d34.s12	but	110	112	O
DDI-MedLine.d34.s12	a	101	101	O
DDI-MedLine.d34.s12	lower	116	120	O
DDI-MedLine.d34.s12	relative	122	129	O
DDI-MedLine.d34.s12	absorption	131	140	O
DDI-MedLine.d34.s12	as	142	143	O
DDI-MedLine.d34.s12	well	145	148	O
DDI-MedLine.d34.s12	as	142	143	O
DDI-MedLine.d34.s12	retention	153	161	O
DDI-MedLine.d34.s12	in	163	164	O
DDI-MedLine.d34.s12	the	166	168	O
DDI-MedLine.d34.s12	groups	170	175	O
DDI-MedLine.d34.s12	fed	177	179	O
DDI-MedLine.d34.s12	further	181	187	O
DDI-MedLine.d34.s12	Fe	189	190	B-drug
DDI-MedLine.d34.s12	.	191	191	O
DDI-MedLine.d34.s12	(	192	192	O
DDI-MedLine.d34.s12	ABSTRACT	193	200	O
DDI-MedLine.d34.s12	TRUNCATED	202	210	O
DDI-MedLine.d34.s12	AT	207	208	O
DDI-MedLine.d34.s12	250	215	217	O
DDI-MedLine.d34.s12	WORDS	219	223	O
DDI-MedLine.d34.s12	)	224	224	O
DDI-DrugBank.d204.s0	When	0	3	O
DDI-DrugBank.d204.s0	administered	5	16	O
DDI-DrugBank.d204.s0	concurrently	18	29	O
DDI-DrugBank.d204.s0	,	30	30	O
DDI-DrugBank.d204.s0	the	32	34	O
DDI-DrugBank.d204.s0	following	36	44	O
DDI-DrugBank.d204.s0	drugs	46	50	O
DDI-DrugBank.d204.s0	may	52	54	O
DDI-DrugBank.d204.s0	interact	56	63	O
DDI-DrugBank.d204.s0	with	65	68	O
DDI-DrugBank.d204.s0	beta-adrenergic	70	84	B-group
DDI-DrugBank.d204.s0	receptor	86	93	I-group
DDI-DrugBank.d204.s0	blocking	95	102	I-group
DDI-DrugBank.d204.s0	agents	104	109	I-group
DDI-DrugBank.d204.s0	:	110	110	O
DDI-DrugBank.d204.s0	Anesthetics	112	122	B-group
DDI-DrugBank.d204.s0	,	123	123	O
DDI-DrugBank.d204.s0	general	125	131	O
DDI-DrugBank.d204.s0	:	132	132	O
DDI-DrugBank.d204.s0	exaggeration	134	145	O
DDI-DrugBank.d204.s0	of	147	148	O
DDI-DrugBank.d204.s0	the	150	152	O
DDI-DrugBank.d204.s0	hypotension	154	164	O
DDI-DrugBank.d204.s0	induced	166	172	O
DDI-DrugBank.d204.s0	by	174	175	O
DDI-DrugBank.d204.s0	general	177	183	O
DDI-DrugBank.d204.s0	anesthetics	185	195	B-group
DDI-DrugBank.d204.s0	.	196	196	O
DDI-DrugBank.d204.s1	Antidiabetic	0	11	B-group
DDI-DrugBank.d204.s1	drugs	13	17	I-group
DDI-DrugBank.d204.s1	(	19	19	O
DDI-DrugBank.d204.s1	oral	20	23	O
DDI-DrugBank.d204.s1	agents	25	30	O
DDI-DrugBank.d204.s1	and	32	34	O
DDI-DrugBank.d204.s1	insulin	36	42	B-drug
DDI-DrugBank.d204.s1	)	43	43	O
DDI-DrugBank.d204.s1	:	44	44	O
DDI-DrugBank.d204.s1	hypoglycemia	46	57	O
DDI-DrugBank.d204.s1	or	59	60	O
DDI-DrugBank.d204.s1	hyperglycemia	62	74	O
DDI-DrugBank.d204.s1	;	75	75	O
DDI-DrugBank.d204.s2	adjust	0	5	O
DDI-DrugBank.d204.s2	dosage	7	12	O
DDI-DrugBank.d204.s2	of	14	15	O
DDI-DrugBank.d204.s2	antidiabetic	17	28	B-group
DDI-DrugBank.d204.s2	drug	30	33	I-group
DDI-DrugBank.d204.s2	accordingly	35	45	O
DDI-DrugBank.d204.s2	.	46	46	O
DDI-DrugBank.d204.s3	Catecholamine-depleting	0	22	O
DDI-DrugBank.d204.s3	drugs	24	28	O
DDI-DrugBank.d204.s3	(	30	30	O
DDI-DrugBank.d204.s3	e.g.	31	34	O
DDI-DrugBank.d204.s3	,	35	35	O
DDI-DrugBank.d204.s3	reserpine	37	45	B-drug
DDI-DrugBank.d204.s3	)	46	46	O
DDI-DrugBank.d204.s3	:	47	47	O
DDI-DrugBank.d204.s3	additive	49	56	O
DDI-DrugBank.d204.s3	effect	58	63	O
DDI-DrugBank.d204.s3	;	64	64	O
DDI-DrugBank.d204.s4	monitor	0	6	O
DDI-DrugBank.d204.s4	closely	8	14	O
DDI-DrugBank.d204.s4	for	16	18	O
DDI-DrugBank.d204.s4	evidence	20	27	O
DDI-DrugBank.d204.s4	of	29	30	O
DDI-DrugBank.d204.s4	hypotension	32	42	O
DDI-DrugBank.d204.s4	and/or	44	49	O
DDI-DrugBank.d204.s4	excessive	51	59	O
DDI-DrugBank.d204.s4	bradycardia	61	71	O
DDI-DrugBank.d204.s4	(	73	73	O
DDI-DrugBank.d204.s4	e.g.	74	77	O
DDI-DrugBank.d204.s4	,	78	78	O
DDI-DrugBank.d204.s4	vertigo	80	86	O
DDI-DrugBank.d204.s4	,	78	78	O
DDI-DrugBank.d204.s4	syncope	89	95	O
DDI-DrugBank.d204.s4	,	87	87	O
DDI-DrugBank.d204.s4	postural	98	105	O
DDI-DrugBank.d204.s4	hypotension	107	117	O
DDI-DrugBank.d204.s4	)	118	118	O
DDI-DrugBank.d204.s4	.	119	119	O
DDI-DrugBank.d204.s5	Response	0	7	O
DDI-DrugBank.d204.s5	to	9	10	O
DDI-DrugBank.d204.s5	Treatment	12	20	O
DDI-DrugBank.d204.s5	for	22	24	O
DDI-DrugBank.d204.s5	Anaphylactic	26	37	O
DDI-DrugBank.d204.s5	Reaction	39	46	O
DDI-DrugBank.d204.s5	:	47	47	O
DDI-DrugBank.d204.s5	While	49	53	O
DDI-DrugBank.d204.s5	taking	55	60	O
DDI-DrugBank.d204.s5	beta-blockers	62	74	B-group
DDI-DrugBank.d204.s5	,	75	75	O
DDI-DrugBank.d204.s5	patients	77	84	O
DDI-DrugBank.d204.s5	with	86	89	O
DDI-DrugBank.d204.s5	a	91	91	O
DDI-DrugBank.d204.s5	history	93	99	O
DDI-DrugBank.d204.s5	of	101	102	O
DDI-DrugBank.d204.s5	severe	104	109	O
DDI-DrugBank.d204.s5	anaphylactic	111	122	O
DDI-DrugBank.d204.s5	reaction	124	131	O
DDI-DrugBank.d204.s5	to	133	134	O
DDI-DrugBank.d204.s5	a	118	118	O
DDI-DrugBank.d204.s5	variety	138	144	O
DDI-DrugBank.d204.s5	of	146	147	O
DDI-DrugBank.d204.s5	allergens	149	157	O
DDI-DrugBank.d204.s5	may	159	161	O
DDI-DrugBank.d204.s5	be	163	164	O
DDI-DrugBank.d204.s5	more	166	169	O
DDI-DrugBank.d204.s5	reactive	171	178	O
DDI-DrugBank.d204.s5	to	180	181	O
DDI-DrugBank.d204.s5	repeated	183	190	O
DDI-DrugBank.d204.s5	challenge	192	200	O
DDI-DrugBank.d204.s5	,	201	201	O
DDI-DrugBank.d204.s5	either	203	208	O
DDI-DrugBank.d204.s5	accidental	210	219	O
DDI-DrugBank.d204.s5	,	201	201	O
DDI-DrugBank.d204.s5	diagnostic	222	231	O
DDI-DrugBank.d204.s5	,	201	201	O
DDI-DrugBank.d204.s5	or	234	235	O
DDI-DrugBank.d204.s5	therapeutic	237	247	O
DDI-DrugBank.d204.s5	.	248	248	O
DDI-DrugBank.d204.s6	Such	0	3	O
DDI-DrugBank.d204.s6	patients	5	12	O
DDI-DrugBank.d204.s6	may	14	16	O
DDI-DrugBank.d204.s6	be	18	19	O
DDI-DrugBank.d204.s6	unresponsive	21	32	O
DDI-DrugBank.d204.s6	to	34	35	O
DDI-DrugBank.d204.s6	the	37	39	O
DDI-DrugBank.d204.s6	usual	41	45	O
DDI-DrugBank.d204.s6	doses	47	51	O
DDI-DrugBank.d204.s6	of	53	54	O
DDI-DrugBank.d204.s6	epinephrine	56	66	B-drug
DDI-DrugBank.d204.s6	used	68	71	O
DDI-DrugBank.d204.s6	to	73	74	O
DDI-DrugBank.d204.s6	treat	76	80	O
DDI-DrugBank.d204.s6	allergic	82	89	O
DDI-DrugBank.d204.s6	reaction	91	98	O
DDI-DrugBank.d204.s6	.	99	99	O
DDI-DrugBank.d194.s0	Caution	0	6	O
DDI-DrugBank.d194.s0	should	8	13	O
DDI-DrugBank.d194.s0	be	15	16	O
DDI-DrugBank.d194.s0	exercised	18	26	O
DDI-DrugBank.d194.s0	when	28	31	O
DDI-DrugBank.d194.s0	administering	33	45	O
DDI-DrugBank.d194.s0	ETOPOPHOS	47	55	B-brand
DDI-DrugBank.d194.s0	with	57	60	O
DDI-DrugBank.d194.s0	drugs	62	66	O
DDI-DrugBank.d194.s0	that	68	71	O
DDI-DrugBank.d194.s0	are	73	75	O
DDI-DrugBank.d194.s0	known	77	81	O
DDI-DrugBank.d194.s0	to	83	84	O
DDI-DrugBank.d194.s0	inhibit	86	92	O
DDI-DrugBank.d194.s0	phosphatase	94	104	O
DDI-DrugBank.d194.s0	activities	106	115	O
DDI-DrugBank.d194.s0	(	117	117	O
DDI-DrugBank.d194.s0	e.g.	118	121	O
DDI-DrugBank.d194.s0	,	122	122	O
DDI-DrugBank.d194.s0	levamisole	124	133	B-drug
DDI-DrugBank.d194.s0	hydrochloride	135	147	I-drug
DDI-DrugBank.d194.s0	)	148	148	O
DDI-DrugBank.d194.s0	.	149	149	O
DDI-DrugBank.d194.s1	High-dose	0	8	O
DDI-DrugBank.d194.s1	cyclosporin	10	20	B-drug
DDI-DrugBank.d194.s1	A	22	22	O
DDI-DrugBank.d194.s1	resulting	24	32	O
DDI-DrugBank.d194.s1	in	30	31	O
DDI-DrugBank.d194.s1	concentrations	37	50	O
DDI-DrugBank.d194.s1	above	52	56	O
DDI-DrugBank.d194.s1	2000	58	61	O
DDI-DrugBank.d194.s1	ng/mL	63	67	O
DDI-DrugBank.d194.s1	administered	69	80	O
DDI-DrugBank.d194.s1	with	82	85	O
DDI-DrugBank.d194.s1	oral	87	90	O
DDI-DrugBank.d194.s1	etoposide	92	100	B-drug
DDI-DrugBank.d194.s1	has	102	104	O
DDI-DrugBank.d194.s1	led	106	108	O
DDI-DrugBank.d194.s1	to	110	111	O
DDI-DrugBank.d194.s1	an	113	114	O
DDI-DrugBank.d194.s1	80	116	117	O
DDI-DrugBank.d194.s1	%	118	118	O
DDI-DrugBank.d194.s1	increase	120	127	O
DDI-DrugBank.d194.s1	in	120	121	O
DDI-DrugBank.d194.s1	etoposide	132	140	B-drug
DDI-DrugBank.d194.s1	exposure	142	149	O
DDI-DrugBank.d194.s1	with	151	154	O
DDI-DrugBank.d194.s1	a	156	156	O
DDI-DrugBank.d194.s1	38	158	159	O
DDI-DrugBank.d194.s1	%	160	160	O
DDI-DrugBank.d194.s1	decrease	162	169	O
DDI-DrugBank.d194.s1	in	171	172	O
DDI-DrugBank.d194.s1	total	174	178	O
DDI-DrugBank.d194.s1	body	180	183	O
DDI-DrugBank.d194.s1	clearance	185	193	O
DDI-DrugBank.d194.s1	of	195	196	O
DDI-DrugBank.d194.s1	etoposide	198	206	B-drug
DDI-DrugBank.d194.s1	compared	208	215	O
DDI-DrugBank.d194.s1	to	199	200	I-drug
DDI-DrugBank.d194.s1	etoposide	198	206	B-drug
DDI-DrugBank.d194.s1	alone	230	234	O
DDI-DrugBank.d194.s1	.	235	235	O
DDI-MedLine.d113.s0	Acid-catalyzed	0	13	O
DDI-MedLine.d113.s0	ethanolysis	15	25	O
DDI-MedLine.d113.s0	of	27	28	O
DDI-MedLine.d113.s0	temazepam	30	38	B-drug
DDI-MedLine.d113.s0	in	40	41	O
DDI-MedLine.d113.s0	anhydrous	43	51	O
DDI-MedLine.d113.s0	and	53	55	O
DDI-MedLine.d113.s0	aqueous	57	63	O
DDI-MedLine.d113.s0	ethanol	65	71	B-drug
DDI-MedLine.d113.s0	solutions	73	81	O
DDI-MedLine.d113.s0	.	82	82	O
DDI-MedLine.d113.s1	The	0	2	O
DDI-MedLine.d113.s1	benzodiazepines	4	18	B-group
DDI-MedLine.d113.s1	are	20	22	O
DDI-MedLine.d113.s1	a	24	24	O
DDI-MedLine.d113.s1	family	26	31	O
DDI-MedLine.d113.s1	of	33	34	O
DDI-MedLine.d113.s1	anxiolytic	36	45	B-group
DDI-MedLine.d113.s1	and	47	49	O
DDI-MedLine.d113.s1	hypnotic	51	58	B-group
DDI-MedLine.d113.s1	drugs	60	64	I-group
DDI-MedLine.d113.s1	.	65	65	O
DDI-MedLine.d113.s2	When	0	3	O
DDI-MedLine.d113.s2	taken	5	9	O
DDI-MedLine.d113.s2	concurrently	11	22	O
DDI-MedLine.d113.s2	with	24	27	O
DDI-MedLine.d113.s2	ethanol	29	35	B-drug
DDI-MedLine.d113.s2	,	36	36	O
DDI-MedLine.d113.s2	a	38	38	O
DDI-MedLine.d113.s2	pharmacological	40	54	O
DDI-MedLine.d113.s2	interaction	56	66	O
DDI-MedLine.d113.s2	may	68	70	O
DDI-MedLine.d113.s2	occur	72	76	O
DDI-MedLine.d113.s2	,	77	77	O
DDI-MedLine.d113.s2	potentiating	79	90	O
DDI-MedLine.d113.s2	the	92	94	O
DDI-MedLine.d113.s2	central	96	102	O
DDI-MedLine.d113.s2	nervous	104	110	O
DDI-MedLine.d113.s2	system	112	117	O
DDI-MedLine.d113.s2	depression	119	128	O
DDI-MedLine.d113.s2	produced	130	137	O
DDI-MedLine.d113.s2	by	139	140	O
DDI-MedLine.d113.s2	either	142	147	O
DDI-MedLine.d113.s2	drug	149	152	O
DDI-MedLine.d113.s2	.	153	153	O
DDI-MedLine.d113.s3	In	0	1	O
DDI-MedLine.d113.s3	addition	3	10	O
DDI-MedLine.d113.s3	to	12	13	O
DDI-MedLine.d113.s3	this	15	18	O
DDI-MedLine.d113.s3	pharmacological	20	34	O
DDI-MedLine.d113.s3	interaction	36	46	O
DDI-MedLine.d113.s3	,	47	47	O
DDI-MedLine.d113.s3	this	49	52	O
DDI-MedLine.d113.s3	report	54	59	O
DDI-MedLine.d113.s3	describes	61	69	O
DDI-MedLine.d113.s3	a	71	71	O
DDI-MedLine.d113.s3	novel	73	77	O
DDI-MedLine.d113.s3	chemical	79	86	O
DDI-MedLine.d113.s3	reaction	88	95	O
DDI-MedLine.d113.s3	between	97	103	O
DDI-MedLine.d113.s3	temazepam	105	113	B-drug
DDI-MedLine.d113.s3	(	115	115	O
DDI-MedLine.d113.s3	a	108	108	O
DDI-MedLine.d113.s3	benzodiazepine	118	131	B-group
DDI-MedLine.d113.s3	)	132	132	O
DDI-MedLine.d113.s3	and	134	136	O
DDI-MedLine.d113.s3	ethanol	138	144	B-drug
DDI-MedLine.d113.s3	under	146	150	O
DDI-MedLine.d113.s3	acidic	152	157	O
DDI-MedLine.d113.s3	conditions	159	168	O
DDI-MedLine.d113.s3	similar	170	176	O
DDI-MedLine.d113.s3	to	178	179	O
DDI-MedLine.d113.s3	those	181	185	O
DDI-MedLine.d113.s3	found	187	191	O
DDI-MedLine.d113.s3	in	193	194	O
DDI-MedLine.d113.s3	vivo	196	199	O
DDI-MedLine.d113.s3	,	200	200	O
DDI-MedLine.d113.s3	resulting	202	210	O
DDI-MedLine.d113.s3	in	193	194	O
DDI-MedLine.d113.s3	a	215	215	O
DDI-MedLine.d113.s3	3-ethoxylated	217	229	O
DDI-MedLine.d113.s3	product	231	237	O
DDI-MedLine.d113.s3	.	238	238	O
DDI-MedLine.d113.s4	Optimal	0	6	O
DDI-MedLine.d113.s4	conditions	8	17	O
DDI-MedLine.d113.s4	,	18	18	O
DDI-MedLine.d113.s4	kinetics	20	27	O
DDI-MedLine.d113.s4	,	28	28	O
DDI-MedLine.d113.s4	equilibrium	30	40	O
DDI-MedLine.d113.s4	,	41	41	O
DDI-MedLine.d113.s4	and	43	45	O
DDI-MedLine.d113.s4	the	47	49	O
DDI-MedLine.d113.s4	mechanism	51	59	O
DDI-MedLine.d113.s4	of	61	62	O
DDI-MedLine.d113.s4	this	64	67	O
DDI-MedLine.d113.s4	acid-catalyzed	69	82	O
DDI-MedLine.d113.s4	ethanolysis	84	94	O
DDI-MedLine.d113.s4	are	96	98	O
DDI-MedLine.d113.s4	reported	100	107	O
DDI-MedLine.d113.s4	.	108	108	O
DDI-MedLine.d113.s5	The	0	2	O
DDI-MedLine.d113.s5	results	4	10	O
DDI-MedLine.d113.s5	raise	12	16	O
DDI-MedLine.d113.s5	the	18	20	O
DDI-MedLine.d113.s5	possibility	22	32	O
DDI-MedLine.d113.s5	that	34	37	O
DDI-MedLine.d113.s5	the	39	41	O
DDI-MedLine.d113.s5	ethanolysis	43	53	O
DDI-MedLine.d113.s5	reaction	55	62	O
DDI-MedLine.d113.s5	may	64	66	O
DDI-MedLine.d113.s5	occur	68	72	O
DDI-MedLine.d113.s5	in	74	75	O
DDI-MedLine.d113.s5	the	77	79	O
DDI-MedLine.d113.s5	stomach	81	87	O
DDI-MedLine.d113.s5	of	89	90	O
DDI-MedLine.d113.s5	people	92	97	O
DDI-MedLine.d113.s5	who	99	101	O
DDI-MedLine.d113.s5	consume	103	109	O
DDI-MedLine.d113.s5	alcohol	111	117	B-drug
DDI-MedLine.d113.s5	and	119	121	O
DDI-MedLine.d113.s5	3-hydroxy-1,4-benzodiazepine	123	150	B-group
DDI-MedLine.d113.s5	on	152	153	O
DDI-MedLine.d113.s5	a	144	144	O
DDI-MedLine.d113.s5	regular	157	163	O
DDI-MedLine.d113.s5	basis	165	169	O
DDI-MedLine.d113.s5	.	170	170	O
DDI-MedLine.d113.s6	The	0	2	O
DDI-MedLine.d113.s6	acid-catalyzed	4	17	O
DDI-MedLine.d113.s6	ethanol-drug	19	30	O
DDI-MedLine.d113.s6	reaction	32	39	O
DDI-MedLine.d113.s6	is	41	42	O
DDI-MedLine.d113.s6	a	44	44	O
DDI-MedLine.d113.s6	relatively	46	55	O
DDI-MedLine.d113.s6	unexplored	57	66	O
DDI-MedLine.d113.s6	area	68	71	O
DDI-MedLine.d113.s6	and	73	75	O
DDI-MedLine.d113.s6	may	77	79	O
DDI-MedLine.d113.s6	alter	81	85	O
DDI-MedLine.d113.s6	the	87	89	O
DDI-MedLine.d113.s6	pharmacological	91	105	O
DDI-MedLine.d113.s6	action	107	112	O
DDI-MedLine.d113.s6	of	114	115	O
DDI-MedLine.d113.s6	some	117	120	O
DDI-MedLine.d113.s6	drugs	122	126	O
DDI-MedLine.d113.s6	.	127	127	O
DDI-DrugBank.d453.s0	Cytosine	0	7	B-drug
DDI-DrugBank.d453.s0	arabinoside	9	19	I-drug
DDI-DrugBank.d453.s0	,	20	20	O
DDI-DrugBank.d453.s0	a	22	22	O
DDI-DrugBank.d453.s0	cytostatic	24	33	B-group
DDI-DrugBank.d453.s0	agent	35	39	I-group
DDI-DrugBank.d453.s0	,	40	40	O
DDI-DrugBank.d453.s0	has	42	44	O
DDI-DrugBank.d453.s0	been	46	49	O
DDI-DrugBank.d453.s0	reported	51	58	O
DDI-DrugBank.d453.s0	to	60	61	O
DDI-DrugBank.d453.s0	inactivate	63	72	O
DDI-DrugBank.d453.s0	the	74	76	O
DDI-DrugBank.d453.s0	antifungal	78	87	O
DDI-DrugBank.d453.s0	activity	89	96	O
DDI-DrugBank.d453.s0	of	98	99	O
DDI-DrugBank.d453.s0	flucytosine	101	111	B-drug
DDI-DrugBank.d453.s0	by	113	114	O
DDI-DrugBank.d453.s0	competitive	116	126	O
DDI-DrugBank.d453.s0	inhibition	128	137	O
DDI-DrugBank.d453.s0	.	138	138	O
DDI-DrugBank.d453.s1	Drugs	0	4	O
DDI-DrugBank.d453.s1	which	6	10	O
DDI-DrugBank.d453.s1	impair	12	17	O
DDI-DrugBank.d453.s1	glomerular	19	28	O
DDI-DrugBank.d453.s1	filtration	30	39	O
DDI-DrugBank.d453.s1	may	41	43	O
DDI-DrugBank.d453.s1	prolong	45	51	O
DDI-DrugBank.d453.s1	the	53	55	O
DDI-DrugBank.d453.s1	biological	57	66	O
DDI-DrugBank.d453.s1	half-life	68	76	O
DDI-DrugBank.d453.s1	of	78	79	O
DDI-DrugBank.d453.s1	flucytosine	81	91	B-drug
DDI-DrugBank.d453.s1	.	92	92	O
DDI-DrugBank.d453.s2	Drug/Laboratory	0	14	O
DDI-DrugBank.d453.s2	Test	16	19	O
DDI-DrugBank.d453.s2	Interactions	21	32	O
DDI-DrugBank.d453.s2	:	33	33	O
DDI-DrugBank.d453.s2	Measurement	35	45	O
DDI-DrugBank.d453.s2	of	47	48	O
DDI-DrugBank.d453.s2	serum	50	54	O
DDI-DrugBank.d453.s2	creatinine	56	65	O
DDI-DrugBank.d453.s2	levels	67	72	O
DDI-DrugBank.d453.s2	should	74	79	O
DDI-DrugBank.d453.s2	be	81	82	O
DDI-DrugBank.d453.s2	determined	84	93	O
DDI-DrugBank.d453.s2	by	95	96	O
DDI-DrugBank.d453.s2	the	98	100	O
DDI-DrugBank.d453.s2	Jaffe	102	106	O
DDI-DrugBank.d453.s2	reaction	108	115	O
DDI-DrugBank.d453.s2	,	116	116	O
DDI-DrugBank.d453.s2	since	118	122	O
DDI-DrugBank.d453.s2	Ancobon	124	130	B-brand
DDI-DrugBank.d453.s2	does	132	135	O
DDI-DrugBank.d453.s2	not	137	139	O
DDI-DrugBank.d453.s2	interfere	141	149	O
DDI-DrugBank.d453.s2	with	151	154	O
DDI-DrugBank.d453.s2	the	156	158	O
DDI-DrugBank.d453.s2	determination	160	172	O
DDI-DrugBank.d453.s2	of	174	175	O
DDI-DrugBank.d453.s2	creatinine	177	186	O
DDI-DrugBank.d453.s2	values	188	193	O
DDI-DrugBank.d453.s2	by	195	196	O
DDI-DrugBank.d453.s2	this	198	201	O
DDI-DrugBank.d453.s2	method	203	208	O
DDI-DrugBank.d453.s2	.	209	209	O
DDI-DrugBank.d453.s3	Most	0	3	O
DDI-DrugBank.d453.s3	automated	5	13	O
DDI-DrugBank.d453.s3	equipment	15	23	O
DDI-DrugBank.d453.s3	for	25	27	O
DDI-DrugBank.d453.s3	measurement	29	39	O
DDI-DrugBank.d453.s3	of	41	42	O
DDI-DrugBank.d453.s3	creatinine	44	53	O
DDI-DrugBank.d453.s3	makes	55	59	O
DDI-DrugBank.d453.s3	use	61	63	O
DDI-DrugBank.d453.s3	of	65	66	O
DDI-DrugBank.d453.s3	the	68	70	O
DDI-DrugBank.d453.s3	Jaffe	72	76	O
DDI-DrugBank.d453.s3	reaction	78	85	O
DDI-DrugBank.d453.s3	.	86	86	O
DDI-DrugBank.d322.s0	Amantadine	0	9	B-drug
DDI-DrugBank.d322.s0	,	10	10	O
DDI-DrugBank.d322.s0	tricyclic	12	20	B-group
DDI-DrugBank.d322.s0	antidepressants	22	36	I-group
DDI-DrugBank.d322.s0	,	37	37	O
DDI-DrugBank.d322.s0	and	39	41	O
DDI-DrugBank.d322.s0	MAOIs	43	47	B-group
DDI-DrugBank.d322.s0	may	49	51	O
DDI-DrugBank.d322.s0	increase	53	60	O
DDI-DrugBank.d322.s0	anticholinergic	62	76	O
DDI-DrugBank.d322.s0	effect	78	83	O
DDI-DrugBank.d322.s0	of	85	86	O
DDI-DrugBank.d322.s0	clidinium	88	96	B-drug
DDI-DrugBank.d322.s0	.	97	97	O
DDI-DrugBank.d322.s1	Clidinium	0	8	B-drug
DDI-DrugBank.d322.s1	may	10	12	O
DDI-DrugBank.d322.s1	decrease	14	21	O
DDI-DrugBank.d322.s1	the	23	25	O
DDI-DrugBank.d322.s1	effect	27	32	O
DDI-DrugBank.d322.s1	of	34	35	O
DDI-DrugBank.d322.s1	phenothiazines	37	50	B-group
DDI-DrugBank.d322.s1	,	51	51	O
DDI-DrugBank.d322.s1	levodopa	53	60	B-drug
DDI-DrugBank.d322.s1	,	61	61	O
DDI-DrugBank.d322.s1	and	63	65	O
DDI-DrugBank.d322.s1	ketoconazole	67	78	B-drug
DDI-DrugBank.d322.s1	.	79	79	O
DDI-DrugBank.d130.s0	Lincomycin	0	9	B-drug
DDI-DrugBank.d130.s0	has	11	13	O
DDI-DrugBank.d130.s0	been	15	18	O
DDI-DrugBank.d130.s0	shown	20	24	O
DDI-DrugBank.d130.s0	to	26	27	O
DDI-DrugBank.d130.s0	have	29	32	O
DDI-DrugBank.d130.s0	neuromuscular	34	46	O
DDI-DrugBank.d130.s0	blocking	48	55	O
DDI-DrugBank.d130.s0	properties	57	66	O
DDI-DrugBank.d130.s0	that	68	71	O
DDI-DrugBank.d130.s0	may	73	75	O
DDI-DrugBank.d130.s0	enhance	77	83	O
DDI-DrugBank.d130.s0	the	85	87	O
DDI-DrugBank.d130.s0	action	89	94	O
DDI-DrugBank.d130.s0	of	96	97	O
DDI-DrugBank.d130.s0	other	99	103	O
DDI-DrugBank.d130.s0	neuromuscular	105	117	B-group
DDI-DrugBank.d130.s0	blocking	119	126	I-group
DDI-DrugBank.d130.s0	agents	128	133	I-group
DDI-DrugBank.d130.s0	.	134	134	O
DDI-DrugBank.d130.s1	Therefore	0	8	O
DDI-DrugBank.d130.s1	,	9	9	O
DDI-DrugBank.d130.s1	it	11	12	O
DDI-DrugBank.d130.s1	should	14	19	O
DDI-DrugBank.d130.s1	be	21	22	O
DDI-DrugBank.d130.s1	used	24	27	O
DDI-DrugBank.d130.s1	in	29	30	O
DDI-DrugBank.d130.s1	caution	32	38	O
DDI-DrugBank.d130.s1	in	40	41	O
DDI-DrugBank.d130.s1	patients	43	50	O
DDI-DrugBank.d130.s1	receiving	52	60	O
DDI-DrugBank.d130.s1	such	62	65	O
DDI-DrugBank.d130.s1	agents	67	72	O
DDI-DrugBank.d130.s1	.	73	73	O
DDI-DrugBank.d130.s2	Antagonism	0	9	O
DDI-DrugBank.d130.s2	between	11	17	O
DDI-DrugBank.d130.s2	lincomycin	19	28	B-drug
DDI-DrugBank.d130.s2	and	30	32	O
DDI-DrugBank.d130.s2	erythromycin	34	45	B-drug
DDI-DrugBank.d130.s2	in	44	45	I-drug
DDI-DrugBank.d130.s2	vitro	50	54	O
DDI-DrugBank.d130.s2	has	56	58	O
DDI-DrugBank.d130.s2	been	60	63	O
DDI-DrugBank.d130.s2	demonstrated	65	76	O
DDI-DrugBank.d130.s2	.	77	77	O
DDI-DrugBank.d130.s3	Because	0	6	O
DDI-DrugBank.d130.s3	of	8	9	O
DDI-DrugBank.d130.s3	possible	11	18	O
DDI-DrugBank.d130.s3	clinical	20	27	O
DDI-DrugBank.d130.s3	significance	29	40	O
DDI-DrugBank.d130.s3	,	41	41	O
DDI-DrugBank.d130.s3	the	43	45	O
DDI-DrugBank.d130.s3	two	47	49	O
DDI-DrugBank.d130.s3	drugs	51	55	O
DDI-DrugBank.d130.s3	should	57	62	O
DDI-DrugBank.d130.s3	not	64	66	O
DDI-DrugBank.d130.s3	be	68	69	O
DDI-DrugBank.d130.s3	administered	71	82	O
DDI-DrugBank.d130.s3	concurrently	84	95	O
DDI-DrugBank.d130.s3	.	96	96	O
DDI-DrugBank.d751.s0	AGGRASTAT	0	8	B-brand
DDI-DrugBank.d751.s0	has	10	12	O
DDI-DrugBank.d751.s0	been	14	17	O
DDI-DrugBank.d751.s0	studied	19	25	O
DDI-DrugBank.d751.s0	on	27	28	O
DDI-DrugBank.d751.s0	a	30	30	O
DDI-DrugBank.d751.s0	background	32	41	O
DDI-DrugBank.d751.s0	of	43	44	O
DDI-DrugBank.d751.s0	aspirin	46	52	B-brand
DDI-DrugBank.d751.s0	and	54	56	O
DDI-DrugBank.d751.s0	heparin	58	64	B-drug
DDI-DrugBank.d751.s0	.	65	65	O
DDI-DrugBank.d751.s1	The	0	2	O
DDI-DrugBank.d751.s1	use	4	6	O
DDI-DrugBank.d751.s1	of	8	9	O
DDI-DrugBank.d751.s1	AGGRASTAT	11	19	B-brand
DDI-DrugBank.d751.s1	,	20	20	O
DDI-DrugBank.d751.s1	in	22	23	O
DDI-DrugBank.d751.s1	combination	25	35	O
DDI-DrugBank.d751.s1	with	37	40	O
DDI-DrugBank.d751.s1	heparin	42	48	B-drug
DDI-DrugBank.d751.s1	and	50	52	O
DDI-DrugBank.d751.s1	aspirin	54	60	B-brand
DDI-DrugBank.d751.s1	,	61	61	O
DDI-DrugBank.d751.s1	has	63	65	O
DDI-DrugBank.d751.s1	been	67	70	O
DDI-DrugBank.d751.s1	associated	72	81	O
DDI-DrugBank.d751.s1	with	83	86	O
DDI-DrugBank.d751.s1	an	88	89	O
DDI-DrugBank.d751.s1	increase	91	98	O
DDI-DrugBank.d751.s1	in	91	92	O
DDI-DrugBank.d751.s1	bleeding	103	110	O
DDI-DrugBank.d751.s1	compared	112	119	O
DDI-DrugBank.d751.s1	to	121	122	O
DDI-DrugBank.d751.s1	heparin	124	130	B-drug
DDI-DrugBank.d751.s1	and	132	134	O
DDI-DrugBank.d751.s1	aspirin	136	142	B-drug
DDI-DrugBank.d751.s1	alone	144	148	O
DDI-DrugBank.d751.s1	(	150	150	O
DDI-DrugBank.d751.s1	see	151	153	O
DDI-DrugBank.d321.s0	Dexamethasone	0	12	B-drug
DDI-DrugBank.d321.s0	:	13	13	O
DDI-DrugBank.d321.s0	Steady-state	15	26	O
DDI-DrugBank.d321.s0	trough	28	33	O
DDI-DrugBank.d321.s0	concentrations	35	48	O
DDI-DrugBank.d321.s0	of	50	51	O
DDI-DrugBank.d321.s0	albendazole	53	63	B-drug
DDI-DrugBank.d321.s0	sulfoxide	65	73	I-drug
DDI-DrugBank.d321.s0	were	75	78	O
DDI-DrugBank.d321.s0	about	80	84	O
DDI-DrugBank.d321.s0	56	86	87	O
DDI-DrugBank.d321.s0	%	88	88	O
DDI-DrugBank.d321.s0	higher	90	95	O
DDI-DrugBank.d321.s0	when	97	100	O
DDI-DrugBank.d321.s0	8	102	102	O
DDI-DrugBank.d321.s0	mg	104	105	O
DDI-DrugBank.d321.s0	dexamethasone	107	119	B-drug
DDI-DrugBank.d321.s0	was	121	123	O
DDI-DrugBank.d321.s0	coadministered	125	138	O
DDI-DrugBank.d321.s0	with	140	143	O
DDI-DrugBank.d321.s0	each	145	148	O
DDI-DrugBank.d321.s0	dose	150	153	O
DDI-DrugBank.d321.s0	of	155	156	O
DDI-DrugBank.d321.s0	albendazole	158	168	B-drug
DDI-DrugBank.d321.s0	(	170	170	O
DDI-DrugBank.d321.s0	15	171	172	O
DDI-DrugBank.d321.s0	mg/kg/day	174	182	O
DDI-DrugBank.d321.s0	)	183	183	O
DDI-DrugBank.d321.s0	in	185	186	O
DDI-DrugBank.d321.s0	eight	188	192	O
DDI-DrugBank.d321.s0	neurocysticercosis	194	211	O
DDI-DrugBank.d321.s0	patients	213	220	O
DDI-DrugBank.d321.s0	.	221	221	O
DDI-DrugBank.d321.s1	Praziquantel	0	11	B-drug
DDI-DrugBank.d321.s1	:	12	12	O
DDI-DrugBank.d321.s1	In	14	15	O
DDI-DrugBank.d321.s1	the	17	19	O
DDI-DrugBank.d321.s1	fed	21	23	O
DDI-DrugBank.d321.s1	state	25	29	O
DDI-DrugBank.d321.s1	,	30	30	O
DDI-DrugBank.d321.s1	praziquantel	32	43	B-drug
DDI-DrugBank.d321.s1	(	45	45	O
DDI-DrugBank.d321.s1	40	46	47	O
DDI-DrugBank.d321.s1	mg/kg	49	53	O
DDI-DrugBank.d321.s1	)	54	54	O
DDI-DrugBank.d321.s1	increased	56	64	O
DDI-DrugBank.d321.s1	mean	66	69	O
DDI-DrugBank.d321.s1	maximum	71	77	O
DDI-DrugBank.d321.s1	plasma	79	84	O
DDI-DrugBank.d321.s1	concentration	86	98	O
DDI-DrugBank.d321.s1	and	100	102	O
DDI-DrugBank.d321.s1	area	104	107	O
DDI-DrugBank.d321.s1	under	109	113	O
DDI-DrugBank.d321.s1	the	115	117	O
DDI-DrugBank.d321.s1	curve	119	123	O
DDI-DrugBank.d321.s1	of	125	126	O
DDI-DrugBank.d321.s1	albendazole	128	138	B-drug
DDI-DrugBank.d321.s1	sulfoxide	140	148	I-drug
DDI-DrugBank.d321.s1	by	150	151	O
DDI-DrugBank.d321.s1	about	153	157	O
DDI-DrugBank.d321.s1	50	159	160	O
DDI-DrugBank.d321.s1	%	161	161	O
DDI-DrugBank.d321.s1	in	163	164	O
DDI-DrugBank.d321.s1	healthy	166	172	O
DDI-DrugBank.d321.s1	subjects	174	181	O
DDI-DrugBank.d321.s1	(	183	183	O
DDI-DrugBank.d321.s1	n=10	184	187	O
DDI-DrugBank.d321.s1	)	188	188	O
DDI-DrugBank.d321.s1	compared	190	197	O
DDI-DrugBank.d321.s1	with	199	202	O
DDI-DrugBank.d321.s1	a	194	194	O
DDI-DrugBank.d321.s1	separate	206	213	O
DDI-DrugBank.d321.s1	group	215	219	O
DDI-DrugBank.d321.s1	of	221	222	O
DDI-DrugBank.d321.s1	subjects	224	231	O
DDI-DrugBank.d321.s1	(	233	233	O
DDI-DrugBank.d321.s1	n=6	234	236	O
DDI-DrugBank.d321.s1	)	237	237	O
DDI-DrugBank.d321.s1	given	239	243	O
DDI-DrugBank.d321.s1	albendazole	245	255	B-drug
DDI-DrugBank.d321.s1	alone	257	261	O
DDI-DrugBank.d321.s1	.	262	262	O
DDI-DrugBank.d321.s2	Mean	0	3	O
DDI-DrugBank.d321.s2	T	5	5	O
DDI-DrugBank.d321.s2	max	7	9	O
DDI-DrugBank.d321.s2	and	11	13	O
DDI-DrugBank.d321.s2	mean	15	18	O
DDI-DrugBank.d321.s2	plasma	20	25	O
DDI-DrugBank.d321.s2	elimination	27	37	O
DDI-DrugBank.d321.s2	half-life	39	47	O
DDI-DrugBank.d321.s2	of	49	50	O
DDI-DrugBank.d321.s2	albendazole	52	62	B-drug
DDI-DrugBank.d321.s2	sulfoxide	64	72	I-drug
DDI-DrugBank.d321.s2	were	74	77	O
DDI-DrugBank.d321.s2	unchanged	79	87	O
DDI-DrugBank.d321.s2	.	88	88	O
DDI-DrugBank.d321.s3	The	0	2	O
DDI-DrugBank.d321.s3	pharmacokinetics	4	19	O
DDI-DrugBank.d321.s3	of	21	22	O
DDI-DrugBank.d321.s3	praziquantel	24	35	B-drug
DDI-DrugBank.d321.s3	were	37	40	O
DDI-DrugBank.d321.s3	unchanged	42	50	O
DDI-DrugBank.d321.s3	following	52	60	O
DDI-DrugBank.d321.s3	coadministration	62	77	O
DDI-DrugBank.d321.s3	with	79	82	O
DDI-DrugBank.d321.s3	albendazole	84	94	B-drug
DDI-DrugBank.d321.s3	(	96	96	O
DDI-DrugBank.d321.s3	400	97	99	O
DDI-DrugBank.d321.s3	mg	101	102	O
DDI-DrugBank.d321.s3	)	103	103	O
DDI-DrugBank.d321.s3	.	104	104	O
DDI-DrugBank.d321.s4	Cimetidine	0	9	B-drug
DDI-DrugBank.d321.s4	:	10	10	O
DDI-DrugBank.d321.s4	Albendazole	12	22	B-drug
DDI-DrugBank.d321.s4	sulfoxide	24	32	I-drug
DDI-DrugBank.d321.s4	concentrations	34	47	O
DDI-DrugBank.d321.s4	in	49	50	O
DDI-DrugBank.d321.s4	bile	52	55	O
DDI-DrugBank.d321.s4	and	57	59	O
DDI-DrugBank.d321.s4	cystic	61	66	O
DDI-DrugBank.d321.s4	fluid	68	72	O
DDI-DrugBank.d321.s4	were	74	77	O
DDI-DrugBank.d321.s4	increased	79	87	O
DDI-DrugBank.d321.s4	(	89	89	O
DDI-DrugBank.d321.s4	about	90	94	O
DDI-DrugBank.d321.s4	2-fold	96	101	O
DDI-DrugBank.d321.s4	)	102	102	O
DDI-DrugBank.d321.s4	in	104	105	O
DDI-DrugBank.d321.s4	hydatid	107	113	O
DDI-DrugBank.d321.s4	cyst	115	118	O
DDI-DrugBank.d321.s4	patients	120	127	O
DDI-DrugBank.d321.s4	treated	129	135	O
DDI-DrugBank.d321.s4	with	137	140	O
DDI-DrugBank.d321.s4	cimetidine	142	151	B-drug
DDI-DrugBank.d321.s4	(	153	153	O
DDI-DrugBank.d321.s4	10	154	155	O
DDI-DrugBank.d321.s4	mg/kg/day	157	165	O
DDI-DrugBank.d321.s4	)	166	166	O
DDI-DrugBank.d321.s4	(	153	153	O
DDI-DrugBank.d321.s4	n=7	169	171	O
DDI-DrugBank.d321.s4	)	166	166	O
DDI-DrugBank.d321.s4	compared	174	181	O
DDI-DrugBank.d321.s4	with	183	186	O
DDI-DrugBank.d321.s4	albendazole	188	198	B-drug
DDI-DrugBank.d321.s4	(	200	200	O
DDI-DrugBank.d321.s4	20	201	202	O
DDI-DrugBank.d321.s4	mg/kg/day	204	212	O
DDI-DrugBank.d321.s4	)	213	213	O
DDI-DrugBank.d321.s4	alone	215	219	O
DDI-DrugBank.d321.s4	(	200	200	O
DDI-DrugBank.d321.s4	n=12	222	225	O
DDI-DrugBank.d321.s4	)	213	213	O
DDI-DrugBank.d321.s4	.	227	227	O
DDI-DrugBank.d321.s5	Albendazole	0	10	B-drug
DDI-DrugBank.d321.s5	sulfoxide	12	20	I-drug
DDI-DrugBank.d321.s5	plasma	22	27	O
DDI-DrugBank.d321.s5	concentrations	29	42	O
DDI-DrugBank.d321.s5	were	44	47	O
DDI-DrugBank.d321.s5	unchanged	49	57	O
DDI-DrugBank.d321.s5	4	59	59	O
DDI-DrugBank.d321.s5	hours	61	65	O
DDI-DrugBank.d321.s5	after	67	71	O
DDI-DrugBank.d321.s5	dosing	73	78	O
DDI-DrugBank.d321.s5	.	79	79	O
DDI-DrugBank.d321.s6	Theophylline	0	11	B-drug
DDI-DrugBank.d321.s6	:	12	12	O
DDI-DrugBank.d321.s6	The	14	16	O
DDI-DrugBank.d321.s6	pharmacokinetics	18	33	O
DDI-DrugBank.d321.s6	of	35	36	O
DDI-DrugBank.d321.s6	theophylline	38	49	B-drug
DDI-DrugBank.d321.s6	(	51	51	O
DDI-DrugBank.d321.s6	aminophylline	52	64	B-drug
DDI-DrugBank.d321.s6	5.8	66	68	O
DDI-DrugBank.d321.s6	mg/kg	70	74	O
DDI-DrugBank.d321.s6	infused	76	82	O
DDI-DrugBank.d321.s6	over	84	87	O
DDI-DrugBank.d321.s6	20	89	90	O
DDI-DrugBank.d321.s6	minutes	92	98	O
DDI-DrugBank.d321.s6	)	99	99	O
DDI-DrugBank.d321.s6	were	101	104	O
DDI-DrugBank.d321.s6	unchanged	106	114	O
DDI-DrugBank.d321.s6	following	116	124	O
DDI-DrugBank.d321.s6	a	126	126	O
DDI-DrugBank.d321.s6	single	128	133	O
DDI-DrugBank.d321.s6	oral	135	138	O
DDI-DrugBank.d321.s6	dose	140	143	O
DDI-DrugBank.d321.s6	of	145	146	O
DDI-DrugBank.d321.s6	albendazole	148	158	B-drug
DDI-DrugBank.d321.s6	(	160	160	O
DDI-DrugBank.d321.s6	400	161	163	O
DDI-DrugBank.d321.s6	mg	165	166	O
DDI-DrugBank.d321.s6	)	167	167	O
DDI-DrugBank.d321.s6	in	169	170	O
DDI-DrugBank.d321.s6	6	172	172	O
DDI-DrugBank.d321.s6	healthy	174	180	O
DDI-DrugBank.d321.s6	subjects	182	189	O
DDI-DrugBank.d321.s6	.	190	190	O
DDI-DrugBank.d263.s0	Zidovudine	0	9	B-drug
DDI-DrugBank.d263.s0	:	10	10	O
DDI-DrugBank.d263.s0	There	12	16	O
DDI-DrugBank.d263.s0	is	18	19	O
DDI-DrugBank.d263.s0	no	21	22	O
DDI-DrugBank.d263.s0	significant	24	34	O
DDI-DrugBank.d263.s0	pharmacokinetic	36	50	O
DDI-DrugBank.d263.s0	interaction	52	62	O
DDI-DrugBank.d263.s0	between	64	70	O
DDI-DrugBank.d263.s0	ZDV	72	74	B-drug
DDI-DrugBank.d263.s0	and	76	78	O
DDI-DrugBank.d263.s0	zalcitabine	80	90	B-drug
DDI-DrugBank.d263.s0	which	92	96	O
DDI-DrugBank.d263.s0	has	98	100	O
DDI-DrugBank.d263.s0	been	102	105	O
DDI-DrugBank.d263.s0	confirmed	107	115	O
DDI-DrugBank.d263.s0	clinically	117	126	O
DDI-DrugBank.d263.s0	.	127	127	O
DDI-DrugBank.d263.s1	Zalcitabine	0	10	B-drug
DDI-DrugBank.d263.s1	also	12	15	O
DDI-DrugBank.d263.s1	has	17	19	O
DDI-DrugBank.d263.s1	no	21	22	O
DDI-DrugBank.d263.s1	significant	24	34	O
DDI-DrugBank.d263.s1	effect	36	41	O
DDI-DrugBank.d263.s1	on	43	44	O
DDI-DrugBank.d263.s1	the	46	48	O
DDI-DrugBank.d263.s1	intracellular	50	62	O
DDI-DrugBank.d263.s1	phosphorylation	64	78	O
DDI-DrugBank.d263.s1	of	80	81	O
DDI-DrugBank.d263.s1	ZDV	83	85	B-drug
DDI-DrugBank.d263.s1	,	86	86	O
DDI-DrugBank.d263.s1	as	88	89	O
DDI-DrugBank.d263.s1	shown	91	95	O
DDI-DrugBank.d263.s1	in	97	98	O
DDI-DrugBank.d263.s1	vitro	100	104	O
DDI-DrugBank.d263.s1	in	97	98	O
DDI-DrugBank.d263.s1	peripheral	109	118	O
DDI-DrugBank.d263.s1	blood	120	124	O
DDI-DrugBank.d263.s1	mononuclear	126	136	O
DDI-DrugBank.d263.s1	cells	138	142	O
DDI-DrugBank.d263.s1	or	144	145	O
DDI-DrugBank.d263.s1	in	147	148	O
DDI-DrugBank.d263.s1	two	150	152	O
DDI-DrugBank.d263.s1	other	154	158	O
DDI-DrugBank.d263.s1	cell	138	141	O
DDI-DrugBank.d263.s1	lines	165	169	O
DDI-DrugBank.d263.s1	(	171	171	O
DDI-DrugBank.d263.s1	U937	172	175	O
DDI-DrugBank.d263.s1	and	177	179	O
DDI-DrugBank.d263.s1	Molt-4	181	186	O
DDI-DrugBank.d263.s1	)	187	187	O
DDI-DrugBank.d263.s1	.	188	188	O
DDI-DrugBank.d263.s2	In	0	1	O
DDI-DrugBank.d263.s2	the	3	5	O
DDI-DrugBank.d263.s2	same	7	10	O
DDI-DrugBank.d263.s2	study	12	16	O
DDI-DrugBank.d263.s2	it	18	19	O
DDI-DrugBank.d263.s2	was	21	23	O
DDI-DrugBank.d263.s2	shown	25	29	O
DDI-DrugBank.d263.s2	that	31	34	O
DDI-DrugBank.d263.s2	didanosine	36	45	B-drug
DDI-DrugBank.d263.s2	and	47	49	O
DDI-DrugBank.d263.s2	stavudine	51	59	B-drug
DDI-DrugBank.d263.s2	had	61	63	O
DDI-DrugBank.d263.s2	no	65	66	O
DDI-DrugBank.d263.s2	significant	68	78	O
DDI-DrugBank.d263.s2	effect	80	85	O
DDI-DrugBank.d263.s2	on	87	88	O
DDI-DrugBank.d263.s2	the	90	92	O
DDI-DrugBank.d263.s2	intracellular	94	106	O
DDI-DrugBank.d263.s2	phosphorylation	108	122	O
DDI-DrugBank.d263.s2	of	124	125	O
DDI-DrugBank.d263.s2	zalcitabine	127	137	B-drug
DDI-DrugBank.d263.s2	in	135	136	I-drug
DDI-DrugBank.d263.s2	peripheral	142	151	O
DDI-DrugBank.d263.s2	blood	153	157	O
DDI-DrugBank.d263.s2	mononuclear	159	169	O
DDI-DrugBank.d263.s2	cells	171	175	O
DDI-DrugBank.d263.s2	.	176	176	O
DDI-DrugBank.d263.s3	Lamivudine	0	9	B-drug
DDI-DrugBank.d263.s3	:	10	10	O
DDI-DrugBank.d263.s3	In	12	13	O
DDI-DrugBank.d263.s3	vitro	15	19	O
DDI-DrugBank.d263.s3	studies	21	27	O
DDI-DrugBank.d263.s3	in	29	30	O
DDI-DrugBank.d263.s3	peripheral	32	41	O
DDI-DrugBank.d263.s3	blood	43	47	O
DDI-DrugBank.d263.s3	mononuclear	49	59	O
DDI-DrugBank.d263.s3	cells	61	65	O
DDI-DrugBank.d263.s3	,	66	66	O
DDI-DrugBank.d263.s3	U937	68	71	O
DDI-DrugBank.d263.s3	and	73	75	O
DDI-DrugBank.d263.s3	Molt-4	77	82	O
DDI-DrugBank.d263.s3	cells	84	88	O
DDI-DrugBank.d263.s3	revealed	90	97	O
DDI-DrugBank.d263.s3	that	99	102	O
DDI-DrugBank.d263.s3	lamivudine	104	113	B-drug
DDI-DrugBank.d263.s3	significantly	115	127	O
DDI-DrugBank.d263.s3	inhibited	129	137	O
DDI-DrugBank.d263.s3	zalcitabine	139	149	B-drug
DDI-DrugBank.d263.s3	phosphorylation	151	165	O
DDI-DrugBank.d263.s3	in	147	148	I-drug
DDI-DrugBank.d263.s3	a	161	161	O
DDI-DrugBank.d263.s3	dose	172	175	O
DDI-DrugBank.d263.s3	dependent	177	185	O
DDI-DrugBank.d263.s3	manner	187	192	O
DDI-DrugBank.d263.s3	.	193	193	O
DDI-DrugBank.d263.s4	Effects	0	6	O
DDI-DrugBank.d263.s4	were	8	11	O
DDI-DrugBank.d263.s4	already	13	19	O
DDI-DrugBank.d263.s4	seen	21	24	O
DDI-DrugBank.d263.s4	with	26	29	O
DDI-DrugBank.d263.s4	doses	31	35	O
DDI-DrugBank.d263.s4	corresponding	37	49	O
DDI-DrugBank.d263.s4	to	51	52	O
DDI-DrugBank.d263.s4	relevant	54	61	O
DDI-DrugBank.d263.s4	plasma	63	68	O
DDI-DrugBank.d263.s4	levels	70	75	O
DDI-DrugBank.d263.s4	in	77	78	O
DDI-DrugBank.d263.s4	humans	80	85	O
DDI-DrugBank.d263.s4	,	86	86	O
DDI-DrugBank.d263.s4	and	88	90	O
DDI-DrugBank.d263.s4	the	92	94	O
DDI-DrugBank.d263.s4	intracellular	96	108	O
DDI-DrugBank.d263.s4	phosphorylation	110	124	O
DDI-DrugBank.d263.s4	of	126	127	O
DDI-DrugBank.d263.s4	zalcitabine	129	139	B-drug
DDI-DrugBank.d263.s4	to	141	142	O
DDI-DrugBank.d263.s4	its	144	146	O
DDI-DrugBank.d263.s4	three	148	152	O
DDI-DrugBank.d263.s4	metabolites	154	164	O
DDI-DrugBank.d263.s4	(	166	166	O
DDI-DrugBank.d263.s4	including	167	175	O
DDI-DrugBank.d263.s4	the	177	179	O
DDI-DrugBank.d263.s4	active	181	186	O
DDI-DrugBank.d263.s4	zalcitabine	188	198	O
DDI-DrugBank.d263.s4	triphosphate	200	211	O
DDI-DrugBank.d263.s4	metabolite	213	222	O
DDI-DrugBank.d263.s4	)	223	223	O
DDI-DrugBank.d263.s4	was	225	227	O
DDI-DrugBank.d263.s4	significantly	229	241	O
DDI-DrugBank.d263.s4	inhibited	243	251	O
DDI-DrugBank.d263.s4	.	252	252	O
DDI-DrugBank.d263.s5	Zalcitabine	0	10	B-drug
DDI-DrugBank.d263.s5	inhibited	12	20	O
DDI-DrugBank.d263.s5	lamivudine	22	31	B-drug
DDI-DrugBank.d263.s5	phosphorylation	33	47	O
DDI-DrugBank.d263.s5	at	49	50	O
DDI-DrugBank.d263.s5	high	52	55	O
DDI-DrugBank.d263.s5	concentration	57	69	O
DDI-DrugBank.d263.s5	ratios	71	76	O
DDI-DrugBank.d263.s5	(	78	78	O
DDI-DrugBank.d263.s5	10	79	80	O
DDI-DrugBank.d263.s5	and	82	84	O
DDI-DrugBank.d263.s5	100	86	88	O
DDI-DrugBank.d263.s5	)	89	89	O
DDI-DrugBank.d263.s5	;	90	90	O
DDI-DrugBank.d263.s6	however	0	6	O
DDI-DrugBank.d263.s6	,	7	7	O
DDI-DrugBank.d263.s6	it	9	10	O
DDI-DrugBank.d263.s6	is	12	13	O
DDI-DrugBank.d263.s6	considered	15	24	O
DDI-DrugBank.d263.s6	to	26	27	O
DDI-DrugBank.d263.s6	be	29	30	O
DDI-DrugBank.d263.s6	unlikely	32	39	O
DDI-DrugBank.d263.s6	that	41	44	O
DDI-DrugBank.d263.s6	this	46	49	O
DDI-DrugBank.d263.s6	decrease	51	58	O
DDI-DrugBank.d263.s6	of	60	61	O
DDI-DrugBank.d263.s6	phosphorylated	63	76	O
DDI-DrugBank.d263.s6	lamivudine	78	87	B-drug
DDI-DrugBank.d263.s6	concentration	89	101	O
DDI-DrugBank.d263.s6	is	103	104	O
DDI-DrugBank.d263.s6	of	106	107	O
DDI-DrugBank.d263.s6	clinical	109	116	O
DDI-DrugBank.d263.s6	significance	118	129	O
DDI-DrugBank.d263.s6	,	130	130	O
DDI-DrugBank.d263.s6	as	132	133	O
DDI-DrugBank.d263.s6	lamivudine	135	144	B-drug
DDI-DrugBank.d263.s6	is	146	147	O
DDI-DrugBank.d263.s6	a	132	132	O
DDI-DrugBank.d263.s6	more	151	154	O
DDI-DrugBank.d263.s6	efficient	156	164	O
DDI-DrugBank.d263.s6	substrate	166	174	O
DDI-DrugBank.d263.s6	for	176	178	O
DDI-DrugBank.d263.s6	deoxycytidine	180	192	O
DDI-DrugBank.d263.s6	kinase	194	199	O
DDI-DrugBank.d263.s6	than	201	204	O
DDI-DrugBank.d263.s6	zalcitabine	206	216	B-drug
DDI-DrugBank.d263.s6	.	217	217	O
DDI-DrugBank.d263.s7	These	0	4	O
DDI-DrugBank.d263.s7	in	6	7	O
DDI-DrugBank.d263.s7	vitro	9	13	O
DDI-DrugBank.d263.s7	studies	15	21	O
DDI-DrugBank.d263.s7	suggest	23	29	O
DDI-DrugBank.d263.s7	that	31	34	O
DDI-DrugBank.d263.s7	concomitant	36	46	O
DDI-DrugBank.d263.s7	administration	48	61	O
DDI-DrugBank.d263.s7	of	63	64	O
DDI-DrugBank.d263.s7	zalcitabine	66	76	B-drug
DDI-DrugBank.d263.s7	and	78	80	O
DDI-DrugBank.d263.s7	lamivudine	82	91	B-drug
DDI-DrugBank.d263.s7	in	89	90	I-drug
DDI-DrugBank.d263.s7	humans	96	101	O
DDI-DrugBank.d263.s7	may	103	105	O
DDI-DrugBank.d263.s7	result	107	112	O
DDI-DrugBank.d263.s7	in	114	115	O
DDI-DrugBank.d263.s7	sub-therapeutic	117	131	O
DDI-DrugBank.d263.s7	concentrations	133	146	O
DDI-DrugBank.d263.s7	of	148	149	O
DDI-DrugBank.d263.s7	active	151	156	O
DDI-DrugBank.d263.s7	phosphorylated	158	171	O
DDI-DrugBank.d263.s7	zalcitabine	173	183	B-drug
DDI-DrugBank.d263.s7	,	184	184	O
DDI-DrugBank.d263.s7	which	186	190	O
DDI-DrugBank.d263.s7	may	192	194	O
DDI-DrugBank.d263.s7	lead	196	199	O
DDI-DrugBank.d263.s7	to	201	202	O
DDI-DrugBank.d263.s7	a	179	179	O
DDI-DrugBank.d263.s7	decreased	206	214	O
DDI-DrugBank.d263.s7	antiretroviral	216	229	B-group
DDI-DrugBank.d263.s7	effect	231	236	O
DDI-DrugBank.d263.s7	of	238	239	O
DDI-DrugBank.d263.s7	zalcitabine	241	251	B-drug
DDI-DrugBank.d263.s7	.	252	252	O
DDI-DrugBank.d263.s8	It	0	1	O
DDI-DrugBank.d263.s8	is	3	4	O
DDI-DrugBank.d263.s8	unknown	6	12	O
DDI-DrugBank.d263.s8	how	14	16	O
DDI-DrugBank.d263.s8	the	18	20	O
DDI-DrugBank.d263.s8	effect	22	27	O
DDI-DrugBank.d263.s8	seen	29	32	O
DDI-DrugBank.d263.s8	in	34	35	O
DDI-DrugBank.d263.s8	these	37	41	O
DDI-DrugBank.d263.s8	in	34	35	O
DDI-DrugBank.d263.s8	vitro	46	50	O
DDI-DrugBank.d263.s8	studies	52	58	O
DDI-DrugBank.d263.s8	translates	60	69	O
DDI-DrugBank.d263.s8	into	71	74	O
DDI-DrugBank.d263.s8	clinical	76	83	O
DDI-DrugBank.d263.s8	consequences	85	96	O
DDI-DrugBank.d263.s8	.	97	97	O
DDI-DrugBank.d263.s9	Concomitant	0	10	O
DDI-DrugBank.d263.s9	use	12	14	O
DDI-DrugBank.d263.s9	of	16	17	O
DDI-DrugBank.d263.s9	zalcitabine	19	29	B-drug
DDI-DrugBank.d263.s9	and	31	33	O
DDI-DrugBank.d263.s9	lamivudine	35	44	B-drug
DDI-DrugBank.d263.s9	is	46	47	O
DDI-DrugBank.d263.s9	not	49	51	O
DDI-DrugBank.d263.s9	recommended	53	63	O
DDI-DrugBank.d263.s9	.	64	64	O
DDI-DrugBank.d263.s10	Saquinavir	0	9	B-drug
DDI-DrugBank.d263.s10	:	10	10	O
DDI-DrugBank.d263.s10	The	12	14	O
DDI-DrugBank.d263.s10	combination	16	26	O
DDI-DrugBank.d263.s10	of	28	29	O
DDI-DrugBank.d263.s10	HIVID	31	35	B-drug
DDI-DrugBank.d263.s10	,	36	36	O
DDI-DrugBank.d263.s10	saquinavir	38	47	B-drug
DDI-DrugBank.d263.s10	,	48	48	O
DDI-DrugBank.d263.s10	and	50	52	O
DDI-DrugBank.d263.s10	ZDV	54	56	B-drug
DDI-DrugBank.d263.s10	has	58	60	O
DDI-DrugBank.d263.s10	been	62	65	O
DDI-DrugBank.d263.s10	studied	67	73	O
DDI-DrugBank.d263.s10	(	75	75	O
DDI-DrugBank.d263.s10	as	76	77	O
DDI-DrugBank.d263.s10	triple	79	84	O
DDI-DrugBank.d263.s10	combination	86	96	O
DDI-DrugBank.d263.s10	)	97	97	O
DDI-DrugBank.d263.s10	in	90	91	O
DDI-DrugBank.d263.s10	adults	102	107	O
DDI-DrugBank.d263.s10	.	108	108	O
DDI-DrugBank.d263.s11	Pharmacokinetic	0	14	O
DDI-DrugBank.d263.s11	data	16	19	O
DDI-DrugBank.d263.s11	suggest	21	27	O
DDI-DrugBank.d263.s11	that	29	32	O
DDI-DrugBank.d263.s11	absorption	34	43	O
DDI-DrugBank.d263.s11	,	44	44	O
DDI-DrugBank.d263.s11	metabolism	46	55	O
DDI-DrugBank.d263.s11	,	56	56	O
DDI-DrugBank.d263.s11	and	58	60	O
DDI-DrugBank.d263.s11	elimination	62	72	O
DDI-DrugBank.d263.s11	of	74	75	O
DDI-DrugBank.d263.s11	each	77	80	O
DDI-DrugBank.d263.s11	of	74	75	O
DDI-DrugBank.d263.s11	these	85	89	O
DDI-DrugBank.d263.s11	drugs	91	95	O
DDI-DrugBank.d263.s11	are	97	99	O
DDI-DrugBank.d263.s11	unchanged	101	109	O
DDI-DrugBank.d263.s11	when	111	114	O
DDI-DrugBank.d263.s11	they	116	119	O
DDI-DrugBank.d263.s11	are	121	123	O
DDI-DrugBank.d263.s11	used	125	128	O
DDI-DrugBank.d263.s11	together	130	137	O
DDI-DrugBank.d263.s11	.	138	138	O
DDI-DrugBank.d263.s12	Drugs	0	4	O
DDI-DrugBank.d263.s12	Associated	6	15	O
DDI-DrugBank.d263.s12	With	17	20	O
DDI-DrugBank.d263.s12	Peripheral	22	31	O
DDI-DrugBank.d263.s12	Neuropathy	33	42	O
DDI-DrugBank.d263.s12	:	43	43	O
DDI-DrugBank.d263.s12	The	45	47	O
DDI-DrugBank.d263.s12	concomitant	49	59	O
DDI-DrugBank.d263.s12	use	61	63	O
DDI-DrugBank.d263.s12	of	65	66	O
DDI-DrugBank.d263.s12	HIVID	68	72	B-drug
DDI-DrugBank.d263.s12	with	74	77	O
DDI-DrugBank.d263.s12	drugs	79	83	O
DDI-DrugBank.d263.s12	that	85	88	O
DDI-DrugBank.d263.s12	have	90	93	O
DDI-DrugBank.d263.s12	the	95	97	O
DDI-DrugBank.d263.s12	potential	99	107	O
DDI-DrugBank.d263.s12	to	109	110	O
DDI-DrugBank.d263.s12	cause	112	116	O
DDI-DrugBank.d263.s12	peripheral	118	127	O
DDI-DrugBank.d263.s12	neuropathy	129	138	O
DDI-DrugBank.d263.s12	should	140	145	O
DDI-DrugBank.d263.s12	be	147	148	O
DDI-DrugBank.d263.s12	avoided	150	156	O
DDI-DrugBank.d263.s12	where	158	162	O
DDI-DrugBank.d263.s12	possible	164	171	O
DDI-DrugBank.d263.s12	.	172	172	O
DDI-DrugBank.d263.s13	Drugs	0	4	O
DDI-DrugBank.d263.s13	that	6	9	O
DDI-DrugBank.d263.s13	have	11	14	O
DDI-DrugBank.d263.s13	been	16	19	O
DDI-DrugBank.d263.s13	associated	21	30	O
DDI-DrugBank.d263.s13	with	32	35	O
DDI-DrugBank.d263.s13	peripheral	37	46	O
DDI-DrugBank.d263.s13	neuropathy	48	57	O
DDI-DrugBank.d263.s13	include	59	65	O
DDI-DrugBank.d263.s13	antiretroviral	67	80	B-drug
DDI-DrugBank.d263.s13	nucleoside	82	91	I-drug
DDI-DrugBank.d263.s13	analogues	93	101	I-drug
DDI-DrugBank.d263.s13	,	102	102	O
DDI-DrugBank.d263.s13	chloramphenicol	104	118	B-drug
DDI-DrugBank.d263.s13	,	119	119	O
DDI-DrugBank.d263.s13	cisplatin	121	129	B-drug
DDI-DrugBank.d263.s13	,	119	119	O
DDI-DrugBank.d263.s13	dapsone	132	138	B-drug
DDI-DrugBank.d263.s13	,	130	130	O
DDI-DrugBank.d263.s13	disulfiram	141	150	B-drug
DDI-DrugBank.d263.s13	,	139	139	O
DDI-DrugBank.d263.s13	ethionamide	153	163	B-drug
DDI-DrugBank.d263.s13	,	151	151	O
DDI-DrugBank.d263.s13	glutethimide	166	177	B-drug
DDI-DrugBank.d263.s13	,	164	164	O
DDI-DrugBank.d263.s13	gold	180	183	B-drug
DDI-DrugBank.d263.s13	,	178	178	O
DDI-DrugBank.d263.s13	hydralazine	186	196	B-drug
DDI-DrugBank.d263.s13	,	178	178	O
DDI-DrugBank.d263.s13	iodoquinol	199	208	B-drug
DDI-DrugBank.d263.s13	,	197	197	O
DDI-DrugBank.d263.s13	isoniazid	211	219	B-drug
DDI-DrugBank.d263.s13	,	209	209	O
DDI-DrugBank.d263.s13	metronidazole	222	234	B-drug
DDI-DrugBank.d263.s13	,	220	220	O
DDI-DrugBank.d263.s13	nitrofurantoin	237	250	B-drug
DDI-DrugBank.d263.s13	,	235	235	O
DDI-DrugBank.d263.s13	phenytoin	253	261	B-drug
DDI-DrugBank.d263.s13	,	251	251	O
DDI-DrugBank.d263.s13	ribavirin	264	272	B-drug
DDI-DrugBank.d263.s13	,	251	251	O
DDI-DrugBank.d263.s13	and	275	277	O
DDI-DrugBank.d263.s13	vincristine	279	289	B-drug
DDI-DrugBank.d263.s13	.	290	290	O
DDI-DrugBank.d263.s14	Concomitant	0	10	O
DDI-DrugBank.d263.s14	use	12	14	O
DDI-DrugBank.d263.s14	of	16	17	O
DDI-DrugBank.d263.s14	HIVID	19	23	B-drug
DDI-DrugBank.d263.s14	with	25	28	O
DDI-DrugBank.d263.s14	didanosine	30	39	B-drug
DDI-DrugBank.d263.s14	is	41	42	O
DDI-DrugBank.d263.s14	not	44	46	O
DDI-DrugBank.d263.s14	recommended	48	58	O
DDI-DrugBank.d263.s14	.	59	59	O
DDI-DrugBank.d263.s15	Intravenous	0	10	O
DDI-DrugBank.d263.s15	Pentamidine	12	22	B-drug
DDI-DrugBank.d263.s15	:	23	23	O
DDI-DrugBank.d263.s15	Treatment	25	33	O
DDI-DrugBank.d263.s15	with	35	38	O
DDI-DrugBank.d263.s15	HIVID	40	44	B-drug
DDI-DrugBank.d263.s15	should	46	51	O
DDI-DrugBank.d263.s15	be	53	54	O
DDI-DrugBank.d263.s15	interrupted	56	66	O
DDI-DrugBank.d263.s15	when	68	71	O
DDI-DrugBank.d263.s15	the	73	75	O
DDI-DrugBank.d263.s15	use	77	79	O
DDI-DrugBank.d263.s15	of	81	82	O
DDI-DrugBank.d263.s15	a	84	84	O
DDI-DrugBank.d263.s15	drug	86	89	O
DDI-DrugBank.d263.s15	that	91	94	O
DDI-DrugBank.d263.s15	has	96	98	O
DDI-DrugBank.d263.s15	the	100	102	O
DDI-DrugBank.d263.s15	potential	104	112	O
DDI-DrugBank.d263.s15	to	114	115	O
DDI-DrugBank.d263.s15	cause	117	121	O
DDI-DrugBank.d263.s15	pancreatitis	123	134	O
DDI-DrugBank.d263.s15	is	133	134	O
DDI-DrugBank.d263.s15	required	139	146	O
DDI-DrugBank.d263.s15	.	147	147	O
DDI-DrugBank.d263.s16	Death	0	4	O
DDI-DrugBank.d263.s16	due	6	8	O
DDI-DrugBank.d263.s16	to	10	11	O
DDI-DrugBank.d263.s16	fulminant	13	21	O
DDI-DrugBank.d263.s16	pancreatitis	23	34	O
DDI-DrugBank.d263.s16	possibly	36	43	O
DDI-DrugBank.d263.s16	related	45	51	O
DDI-DrugBank.d263.s16	to	53	54	O
DDI-DrugBank.d263.s16	intravenous	56	66	O
DDI-DrugBank.d263.s16	pentamidine	68	78	B-drug
DDI-DrugBank.d263.s16	and	80	82	O
DDI-DrugBank.d263.s16	HIVID	84	88	B-drug
DDI-DrugBank.d263.s16	has	90	92	O
DDI-DrugBank.d263.s16	been	94	97	O
DDI-DrugBank.d263.s16	reported	99	106	O
DDI-DrugBank.d263.s16	.	107	107	O
DDI-DrugBank.d263.s17	If	0	1	O
DDI-DrugBank.d263.s17	intravenous	3	13	O
DDI-DrugBank.d263.s17	pentamidine	15	25	B-drug
DDI-DrugBank.d263.s17	is	27	28	O
DDI-DrugBank.d263.s17	required	30	37	O
DDI-DrugBank.d263.s17	to	39	40	O
DDI-DrugBank.d263.s17	treat	42	46	O
DDI-DrugBank.d263.s17	Pneumocystis	48	59	O
DDI-DrugBank.d263.s17	carinii	61	67	O
DDI-DrugBank.d263.s17	pneumonia	69	77	O
DDI-DrugBank.d263.s17	,	78	78	O
DDI-DrugBank.d263.s17	treatment	80	88	O
DDI-DrugBank.d263.s17	with	90	93	O
DDI-DrugBank.d263.s17	HIVID	95	99	B-drug
DDI-DrugBank.d263.s17	should	101	106	O
DDI-DrugBank.d263.s17	be	108	109	O
DDI-DrugBank.d263.s17	interrupted	111	121	O
DDI-DrugBank.d263.s17	.	122	122	O
DDI-DrugBank.d263.s18	Amphotericin	0	11	B-drug
DDI-DrugBank.d263.s18	,	12	12	O
DDI-DrugBank.d263.s18	Foscarnet	14	22	B-drug
DDI-DrugBank.d263.s18	,	23	23	O
DDI-DrugBank.d263.s18	and	25	27	O
DDI-DrugBank.d263.s18	Aminoglycosides	29	43	B-group
DDI-DrugBank.d263.s18	:	44	44	O
DDI-DrugBank.d263.s18	Drugs	46	50	O
DDI-DrugBank.d263.s18	such	52	55	O
DDI-DrugBank.d263.s18	as	57	58	O
DDI-DrugBank.d263.s18	amphotericin	60	71	B-drug
DDI-DrugBank.d263.s18	,	72	72	O
DDI-DrugBank.d263.s18	foscarnet	74	82	B-drug
DDI-DrugBank.d263.s18	,	83	83	O
DDI-DrugBank.d263.s18	and	85	87	O
DDI-DrugBank.d263.s18	aminoglycosides	89	103	B-group
DDI-DrugBank.d263.s18	may	105	107	O
DDI-DrugBank.d263.s18	increase	109	116	O
DDI-DrugBank.d263.s18	the	118	120	O
DDI-DrugBank.d263.s18	risk	122	125	O
DDI-DrugBank.d263.s18	of	127	128	O
DDI-DrugBank.d263.s18	developing	130	139	O
DDI-DrugBank.d263.s18	peripheral	141	150	O
DDI-DrugBank.d263.s18	neuropathy	152	161	O
DDI-DrugBank.d263.s18	or	163	164	O
DDI-DrugBank.d263.s18	other	166	170	O
DDI-DrugBank.d263.s18	HIVID-associated	172	187	O
DDI-DrugBank.d263.s18	adverse	189	195	O
DDI-DrugBank.d263.s18	events	197	202	O
DDI-DrugBank.d263.s18	by	204	205	O
DDI-DrugBank.d263.s18	interfering	207	217	O
DDI-DrugBank.d263.s18	with	219	222	O
DDI-DrugBank.d263.s18	the	224	226	O
DDI-DrugBank.d263.s18	renal	228	232	O
DDI-DrugBank.d263.s18	clearance	234	242	O
DDI-DrugBank.d263.s18	of	244	245	O
DDI-DrugBank.d263.s18	zalcitabine	247	257	B-drug
DDI-DrugBank.d263.s18	(	259	259	O
DDI-DrugBank.d263.s18	thereby	260	266	O
DDI-DrugBank.d263.s18	raising	268	274	O
DDI-DrugBank.d263.s18	systemic	276	283	O
DDI-DrugBank.d263.s18	exposure	285	292	O
DDI-DrugBank.d263.s18	)	293	293	O
DDI-DrugBank.d263.s18	.	294	294	O
DDI-DrugBank.d263.s19	Patients	0	7	O
DDI-DrugBank.d263.s19	who	9	11	O
DDI-DrugBank.d263.s19	require	13	19	O
DDI-DrugBank.d263.s19	the	21	23	O
DDI-DrugBank.d263.s19	use	25	27	O
DDI-DrugBank.d263.s19	of	29	30	O
DDI-DrugBank.d263.s19	one	32	34	O
DDI-DrugBank.d263.s19	of	29	30	O
DDI-DrugBank.d263.s19	these	39	43	O
DDI-DrugBank.d263.s19	drugs	45	49	O
DDI-DrugBank.d263.s19	with	51	54	O
DDI-DrugBank.d263.s19	HIVID	56	60	B-drug
DDI-DrugBank.d263.s19	should	62	67	O
DDI-DrugBank.d263.s19	have	69	72	O
DDI-DrugBank.d263.s19	frequent	74	81	O
DDI-DrugBank.d263.s19	clinical	83	90	O
DDI-DrugBank.d263.s19	and	92	94	O
DDI-DrugBank.d263.s19	laboratory	96	105	O
DDI-DrugBank.d263.s19	monitoring	107	116	O
DDI-DrugBank.d263.s19	with	118	121	O
DDI-DrugBank.d263.s19	dosage	123	128	O
DDI-DrugBank.d263.s19	adjustment	130	139	O
DDI-DrugBank.d263.s19	for	141	143	O
DDI-DrugBank.d263.s19	any	145	147	O
DDI-DrugBank.d263.s19	significant	149	159	O
DDI-DrugBank.d263.s19	change	161	166	O
DDI-DrugBank.d263.s19	in	168	169	O
DDI-DrugBank.d263.s19	renal	171	175	O
DDI-DrugBank.d263.s19	function	177	184	O
DDI-DrugBank.d263.s19	.	185	185	O
DDI-DrugBank.d263.s20	Probenecid	0	9	B-drug
DDI-DrugBank.d263.s20	or	11	12	O
DDI-DrugBank.d263.s20	Cimetidine	14	23	B-drug
DDI-DrugBank.d263.s20	:	24	24	O
DDI-DrugBank.d263.s20	Concomitant	26	36	O
DDI-DrugBank.d263.s20	administration	38	51	O
DDI-DrugBank.d263.s20	of	53	54	O
DDI-DrugBank.d263.s20	probenecid	56	65	B-drug
DDI-DrugBank.d263.s20	or	67	68	O
DDI-DrugBank.d263.s20	cimetidine	70	79	B-drug
DDI-DrugBank.d263.s20	decreases	81	89	O
DDI-DrugBank.d263.s20	the	91	93	O
DDI-DrugBank.d263.s20	elimination	95	105	O
DDI-DrugBank.d263.s20	of	107	108	O
DDI-DrugBank.d263.s20	zalcitabine	110	120	B-drug
DDI-DrugBank.d263.s20	,	121	121	O
DDI-DrugBank.d263.s20	most	123	126	O
DDI-DrugBank.d263.s20	likely	128	133	O
DDI-DrugBank.d263.s20	by	135	136	O
DDI-DrugBank.d263.s20	inhibition	138	147	O
DDI-DrugBank.d263.s20	of	149	150	O
DDI-DrugBank.d263.s20	renal	152	156	O
DDI-DrugBank.d263.s20	tubular	158	164	O
DDI-DrugBank.d263.s20	secretion	166	174	O
DDI-DrugBank.d263.s20	of	176	177	O
DDI-DrugBank.d263.s20	zalcitabine	179	189	B-drug
DDI-DrugBank.d263.s20	.	190	190	O
DDI-DrugBank.d263.s21	Patients	0	7	O
DDI-DrugBank.d263.s21	receiving	9	17	O
DDI-DrugBank.d263.s21	these	19	23	O
DDI-DrugBank.d263.s21	drugs	25	29	O
DDI-DrugBank.d263.s21	in	31	32	O
DDI-DrugBank.d263.s21	combination	34	44	O
DDI-DrugBank.d263.s21	with	46	49	O
DDI-DrugBank.d263.s21	zalcitabine	51	61	B-drug
DDI-DrugBank.d263.s21	should	63	68	O
DDI-DrugBank.d263.s21	be	70	71	O
DDI-DrugBank.d263.s21	monitored	73	81	O
DDI-DrugBank.d263.s21	for	83	85	O
DDI-DrugBank.d263.s21	signs	87	91	O
DDI-DrugBank.d263.s21	of	93	94	O
DDI-DrugBank.d263.s21	toxicity	96	103	O
DDI-DrugBank.d263.s21	and	105	107	O
DDI-DrugBank.d263.s21	the	109	111	O
DDI-DrugBank.d263.s21	dose	113	116	O
DDI-DrugBank.d263.s21	of	118	119	O
DDI-DrugBank.d263.s21	zalcitabine	121	131	B-drug
DDI-DrugBank.d263.s21	reduced	133	139	O
DDI-DrugBank.d263.s21	if	141	142	O
DDI-DrugBank.d263.s21	warranted	144	152	O
DDI-DrugBank.d263.s21	.	153	153	O
DDI-DrugBank.d263.s22	Magnesium/Aluminum-containing	0	28	O
DDI-DrugBank.d263.s22	Antacid	30	36	B-group
DDI-DrugBank.d263.s22	Products	38	45	I-group
DDI-DrugBank.d263.s22	:	46	46	O
DDI-DrugBank.d263.s22	Absorption	48	57	O
DDI-DrugBank.d263.s22	of	59	60	O
DDI-DrugBank.d263.s22	zalcitabine	62	72	B-drug
DDI-DrugBank.d263.s22	is	74	75	O
DDI-DrugBank.d263.s22	moderately	77	86	O
DDI-DrugBank.d263.s22	reduced	88	94	O
DDI-DrugBank.d263.s22	(	96	96	O
DDI-DrugBank.d263.s22	approximately	97	109	O
DDI-DrugBank.d263.s22	25	111	112	O
DDI-DrugBank.d263.s22	%	113	113	O
DDI-DrugBank.d263.s22	)	114	114	O
DDI-DrugBank.d263.s22	when	116	119	O
DDI-DrugBank.d263.s22	coadministered	121	134	O
DDI-DrugBank.d263.s22	with	136	139	O
DDI-DrugBank.d263.s22	magnesium/aluminum-containing	141	169	O
DDI-DrugBank.d263.s22	antacid	171	177	B-group
DDI-DrugBank.d263.s22	products	179	186	I-group
DDI-DrugBank.d263.s22	.	187	187	O
DDI-DrugBank.d263.s23	The	0	2	O
DDI-DrugBank.d263.s23	clinical	4	11	O
DDI-DrugBank.d263.s23	significance	13	24	O
DDI-DrugBank.d263.s23	of	26	27	O
DDI-DrugBank.d263.s23	this	29	32	O
DDI-DrugBank.d263.s23	reduction	34	42	O
DDI-DrugBank.d263.s23	is	44	45	O
DDI-DrugBank.d263.s23	not	47	49	O
DDI-DrugBank.d263.s23	known	51	55	O
DDI-DrugBank.d263.s23	,	56	56	O
DDI-DrugBank.d263.s23	hence	58	62	O
DDI-DrugBank.d263.s23	zalcitabine	64	74	B-drug
DDI-DrugBank.d263.s23	is	76	77	O
DDI-DrugBank.d263.s23	not	79	81	O
DDI-DrugBank.d263.s23	recommended	83	93	O
DDI-DrugBank.d263.s23	to	95	96	O
DDI-DrugBank.d263.s23	be	98	99	O
DDI-DrugBank.d263.s23	ingested	101	108	O
DDI-DrugBank.d263.s23	simultaneously	110	123	O
DDI-DrugBank.d263.s23	with	125	128	O
DDI-DrugBank.d263.s23	magnesium/aluminum-containing	130	158	O
DDI-DrugBank.d263.s23	antacids	160	167	B-group
DDI-DrugBank.d263.s23	.	168	168	O
DDI-DrugBank.d263.s24	Metoclopramide	0	13	B-drug
DDI-DrugBank.d263.s24	:	14	14	O
DDI-DrugBank.d263.s24	Bioavailability	16	30	O
DDI-DrugBank.d263.s24	is	32	33	O
DDI-DrugBank.d263.s24	mildly	35	40	O
DDI-DrugBank.d263.s24	reduced	42	48	O
DDI-DrugBank.d263.s24	(	50	50	O
DDI-DrugBank.d263.s24	approximately	51	63	O
DDI-DrugBank.d263.s24	10	65	66	O
DDI-DrugBank.d263.s24	%	67	67	O
DDI-DrugBank.d263.s24	)	68	68	O
DDI-DrugBank.d263.s24	when	70	73	O
DDI-DrugBank.d263.s24	zalcitabine	75	85	B-drug
DDI-DrugBank.d263.s24	and	87	89	O
DDI-DrugBank.d263.s24	metoclopramide	91	104	B-drug
DDI-DrugBank.d263.s24	are	106	108	O
DDI-DrugBank.d263.s24	coadministered	110	123	O
DDI-DrugBank.d263.s24	.	124	124	O
DDI-DrugBank.d263.s25	Doxorubicin	0	10	B-drug
DDI-DrugBank.d263.s25	:	11	11	O
DDI-DrugBank.d263.s25	Doxorubicin	13	23	B-drug
DDI-DrugBank.d263.s25	caused	25	30	O
DDI-DrugBank.d263.s25	a	32	32	O
DDI-DrugBank.d263.s25	decrease	34	41	O
DDI-DrugBank.d263.s25	in	43	44	O
DDI-DrugBank.d263.s25	zalcitabine	46	56	B-drug
DDI-DrugBank.d263.s25	phosphorylation	58	72	O
DDI-DrugBank.d263.s25	(	74	74	O
DDI-DrugBank.d263.s25	50	76	77	O
DDI-DrugBank.d263.s25	%	78	78	O
DDI-DrugBank.d263.s25	inhibition	80	89	O
DDI-DrugBank.d263.s25	of	91	92	O
DDI-DrugBank.d263.s25	total	94	98	O
DDI-DrugBank.d263.s25	phosphate	100	108	O
DDI-DrugBank.d263.s25	formation	110	118	O
DDI-DrugBank.d263.s25	)	119	119	O
DDI-DrugBank.d263.s25	in	121	122	O
DDI-DrugBank.d263.s25	U937/Molt	124	132	O
DDI-DrugBank.d263.s25	4	134	134	O
DDI-DrugBank.d263.s25	cells	136	140	O
DDI-DrugBank.d263.s25	.	141	141	O
DDI-DrugBank.d263.s26	Although	0	7	O
DDI-DrugBank.d263.s26	there	9	13	O
DDI-DrugBank.d263.s26	may	15	17	O
DDI-DrugBank.d263.s26	be	19	20	O
DDI-DrugBank.d263.s26	decreased	22	30	O
DDI-DrugBank.d263.s26	zalcitabine	32	42	B-drug
DDI-DrugBank.d263.s26	activity	44	51	O
DDI-DrugBank.d263.s26	because	53	59	O
DDI-DrugBank.d263.s26	of	61	62	O
DDI-DrugBank.d263.s26	lessened	64	71	O
DDI-DrugBank.d263.s26	active	73	78	O
DDI-DrugBank.d263.s26	metabolite	80	89	O
DDI-DrugBank.d263.s26	formation	91	99	O
DDI-DrugBank.d263.s26	,	100	100	O
DDI-DrugBank.d263.s26	the	102	104	O
DDI-DrugBank.d263.s26	clinical	106	113	O
DDI-DrugBank.d263.s26	relevance	115	123	O
DDI-DrugBank.d263.s26	of	125	126	O
DDI-DrugBank.d263.s26	these	128	132	O
DDI-DrugBank.d263.s26	in	134	135	O
DDI-DrugBank.d263.s26	vitro	137	141	O
DDI-DrugBank.d263.s26	results	143	149	O
DDI-DrugBank.d263.s26	are	151	153	O
DDI-DrugBank.d263.s26	not	155	157	O
DDI-DrugBank.d263.s26	known	159	163	O
DDI-DrugBank.d263.s26	.	164	164	O
DDI-DrugBank.d258.s0	Loratadine	0	9	B-drug
DDI-DrugBank.d258.s0	(	11	11	O
DDI-DrugBank.d258.s0	10	12	13	O
DDI-DrugBank.d258.s0	mg	15	16	O
DDI-DrugBank.d258.s0	once	18	21	O
DDI-DrugBank.d258.s0	daily	23	27	O
DDI-DrugBank.d258.s0	)	28	28	O
DDI-DrugBank.d258.s0	has	30	32	O
DDI-DrugBank.d258.s0	been	34	37	O
DDI-DrugBank.d258.s0	coadministered	39	52	O
DDI-DrugBank.d258.s0	with	54	57	O
DDI-DrugBank.d258.s0	therapeutic	59	69	O
DDI-DrugBank.d258.s0	doses	71	75	O
DDI-DrugBank.d258.s0	of	77	78	O
DDI-DrugBank.d258.s0	erythromycin	80	91	B-drug
DDI-DrugBank.d258.s0	,	92	92	O
DDI-DrugBank.d258.s0	cimetidine	94	103	B-drug
DDI-DrugBank.d258.s0	,	92	92	O
DDI-DrugBank.d258.s0	and	106	108	O
DDI-DrugBank.d258.s0	ketoconazole	110	121	B-drug
DDI-DrugBank.d258.s0	in	123	124	O
DDI-DrugBank.d258.s0	controlled	126	135	O
DDI-DrugBank.d258.s0	clinical	137	144	O
DDI-DrugBank.d258.s0	pharmacology	146	157	O
DDI-DrugBank.d258.s0	studies	159	165	O
DDI-DrugBank.d258.s0	in	167	168	O
DDI-DrugBank.d258.s0	adult	170	174	O
DDI-DrugBank.d258.s0	volunteers	176	185	O
DDI-DrugBank.d258.s0	.	186	186	O
DDI-DrugBank.d258.s1	Although	0	7	O
DDI-DrugBank.d258.s1	increased	9	17	O
DDI-DrugBank.d258.s1	plasma	19	24	O
DDI-DrugBank.d258.s1	concentrations	26	39	O
DDI-DrugBank.d258.s1	(	41	41	O
DDI-DrugBank.d258.s1	AUC	42	44	O
DDI-DrugBank.d258.s1	0-24	46	49	O
DDI-DrugBank.d258.s1	hrs	51	53	O
DDI-DrugBank.d258.s1	)	54	54	O
DDI-DrugBank.d258.s1	of	56	57	O
DDI-DrugBank.d258.s1	loratadine	59	68	B-drug
DDI-DrugBank.d258.s1	and/or	70	75	O
DDI-DrugBank.d258.s1	descarboethoxyloratadine	77	100	B-drug
DDI-DrugBank.d258.s1	were	102	105	O
DDI-DrugBank.d258.s1	observed	107	114	O
DDI-DrugBank.d258.s1	following	116	124	O
DDI-DrugBank.d258.s1	coadministration	126	141	O
DDI-DrugBank.d258.s1	of	143	144	O
DDI-DrugBank.d258.s1	loratadine	146	155	B-drug
DDI-DrugBank.d258.s1	with	157	160	O
DDI-DrugBank.d258.s1	each	162	165	O
DDI-DrugBank.d258.s1	of	167	168	O
DDI-DrugBank.d258.s1	these	170	174	O
DDI-DrugBank.d258.s1	drugs	176	180	O
DDI-DrugBank.d258.s1	in	182	183	O
DDI-DrugBank.d258.s1	normal	185	190	O
DDI-DrugBank.d258.s1	volunteers	192	201	O
DDI-DrugBank.d258.s1	(	203	203	O
DDI-DrugBank.d258.s1	n	183	183	O
DDI-DrugBank.d258.s1	=	206	206	O
DDI-DrugBank.d258.s1	24	208	209	O
DDI-DrugBank.d258.s1	in	211	212	O
DDI-DrugBank.d258.s1	each	214	217	O
DDI-DrugBank.d258.s1	study	219	223	O
DDI-DrugBank.d258.s1	)	224	224	O
DDI-DrugBank.d258.s1	,	225	225	O
DDI-DrugBank.d258.s1	there	227	231	O
DDI-DrugBank.d258.s1	were	233	236	O
DDI-DrugBank.d258.s1	no	238	239	O
DDI-DrugBank.d258.s1	clinically	241	250	O
DDI-DrugBank.d258.s1	relevant	252	259	O
DDI-DrugBank.d258.s1	changes	261	267	O
DDI-DrugBank.d258.s1	in	243	244	O
DDI-DrugBank.d258.s1	the	272	274	O
DDI-DrugBank.d258.s1	safety	276	281	O
DDI-DrugBank.d258.s1	profile	283	289	O
DDI-DrugBank.d258.s1	of	285	286	O
DDI-DrugBank.d258.s1	loratadine	294	303	B-drug
DDI-DrugBank.d258.s1	,	304	304	O
DDI-DrugBank.d258.s1	as	306	307	O
DDI-DrugBank.d258.s1	assessed	309	316	O
DDI-DrugBank.d258.s1	by	318	319	O
DDI-DrugBank.d258.s1	electrocardiographic	321	340	O
DDI-DrugBank.d258.s1	parameters	342	351	O
DDI-DrugBank.d258.s1	,	352	352	O
DDI-DrugBank.d258.s1	clinical	354	361	O
DDI-DrugBank.d258.s1	laboratory	363	372	O
DDI-DrugBank.d258.s1	tests	374	378	O
DDI-DrugBank.d258.s1	,	352	352	O
DDI-DrugBank.d258.s1	vital	381	385	O
DDI-DrugBank.d258.s1	signs	387	391	O
DDI-DrugBank.d258.s1	,	352	352	O
DDI-DrugBank.d258.s1	and	394	396	O
DDI-DrugBank.d258.s1	adverse	398	404	O
DDI-DrugBank.d258.s1	events	406	411	O
DDI-DrugBank.d258.s1	.	412	412	O
DDI-DrugBank.d258.s2	There	0	4	O
DDI-DrugBank.d258.s2	were	6	9	O
DDI-DrugBank.d258.s2	no	11	12	O
DDI-DrugBank.d258.s2	significant	14	24	O
DDI-DrugBank.d258.s2	effects	26	32	O
DDI-DrugBank.d258.s2	on	34	35	O
DDI-DrugBank.d258.s2	QTc	37	39	O
DDI-DrugBank.d258.s2	intervals	41	49	O
DDI-DrugBank.d258.s2	,	50	50	O
DDI-DrugBank.d258.s2	and	52	54	O
DDI-DrugBank.d258.s2	no	56	57	O
DDI-DrugBank.d258.s2	reports	59	65	O
DDI-DrugBank.d258.s2	of	67	68	O
DDI-DrugBank.d258.s2	sedation	70	77	O
DDI-DrugBank.d258.s2	or	79	80	O
DDI-DrugBank.d258.s2	syncope	82	88	O
DDI-DrugBank.d258.s2	.	89	89	O
DDI-DrugBank.d258.s3	No	0	1	O
DDI-DrugBank.d258.s3	effects	3	9	O
DDI-DrugBank.d258.s3	on	11	12	O
DDI-DrugBank.d258.s3	plasma	14	19	O
DDI-DrugBank.d258.s3	concentrations	21	34	O
DDI-DrugBank.d258.s3	of	36	37	O
DDI-DrugBank.d258.s3	cimetidine	39	48	B-drug
DDI-DrugBank.d258.s3	or	50	51	O
DDI-DrugBank.d258.s3	ketoconazole	53	64	B-drug
DDI-DrugBank.d258.s3	were	66	69	O
DDI-DrugBank.d258.s3	observed	71	78	O
DDI-DrugBank.d258.s3	.	79	79	O
DDI-DrugBank.d258.s4	Plasma	0	5	O
DDI-DrugBank.d258.s4	concentrations	7	20	O
DDI-DrugBank.d258.s4	(	22	22	O
DDI-DrugBank.d258.s4	AUC	23	25	O
DDI-DrugBank.d258.s4	0-24	27	30	O
DDI-DrugBank.d258.s4	hrs	32	34	O
DDI-DrugBank.d258.s4	)	35	35	O
DDI-DrugBank.d258.s4	of	37	38	O
DDI-DrugBank.d258.s4	erythromycin	40	51	B-drug
DDI-DrugBank.d258.s4	decreased	53	61	O
DDI-DrugBank.d258.s4	15	63	64	O
DDI-DrugBank.d258.s4	%	65	65	O
DDI-DrugBank.d258.s4	with	67	70	O
DDI-DrugBank.d258.s4	coadministration	72	87	O
DDI-DrugBank.d258.s4	of	89	90	O
DDI-DrugBank.d258.s4	loratadine	92	101	B-drug
DDI-DrugBank.d258.s4	relative	103	110	O
DDI-DrugBank.d258.s4	to	112	113	O
DDI-DrugBank.d258.s4	that	115	118	O
DDI-DrugBank.d258.s4	observed	120	127	O
DDI-DrugBank.d258.s4	with	129	132	O
DDI-DrugBank.d258.s4	erythromycin	134	145	B-drug
DDI-DrugBank.d258.s4	alone	147	151	O
DDI-DrugBank.d258.s4	.	152	152	O
DDI-DrugBank.d258.s5	The	0	2	O
DDI-DrugBank.d258.s5	clinical	4	11	O
DDI-DrugBank.d258.s5	relevance	13	21	O
DDI-DrugBank.d258.s5	of	23	24	O
DDI-DrugBank.d258.s5	this	26	29	O
DDI-DrugBank.d258.s5	difference	31	40	O
DDI-DrugBank.d258.s5	is	42	43	O
DDI-DrugBank.d258.s5	unknown	45	51	O
DDI-DrugBank.d258.s5	.	52	52	O
DDI-DrugBank.d258.s6	These	0	4	O
DDI-DrugBank.d258.s6	above	6	10	O
DDI-DrugBank.d258.s6	findings	12	19	O
DDI-DrugBank.d258.s6	are	21	23	O
DDI-DrugBank.d258.s6	summarized	25	34	O
DDI-DrugBank.d258.s6	in	36	37	O
DDI-DrugBank.d258.s6	TABLE	39	43	O
DDI-DrugBank.d258.s6	1	45	45	O
DDI-DrugBank.d258.s6	.	46	46	O
DDI-DrugBank.d258.s7	TABLE	0	4	O
DDI-DrugBank.d258.s7	1	6	6	O
DDI-DrugBank.d258.s7	Effects	8	14	O
DDI-DrugBank.d258.s7	on	16	17	O
DDI-DrugBank.d258.s7	Plasma	19	24	O
DDI-DrugBank.d258.s7	Concentrations	26	39	O
DDI-DrugBank.d258.s7	(	41	41	O
DDI-DrugBank.d258.s7	AUC	42	44	O
DDI-DrugBank.d258.s7	0-24	46	49	O
DDI-DrugBank.d258.s7	hrs	51	53	O
DDI-DrugBank.d258.s7	)	54	54	O
DDI-DrugBank.d258.s7	of	56	57	O
DDI-DrugBank.d258.s7	Loratadine	59	68	B-drug
DDI-DrugBank.d258.s7	and	70	72	O
DDI-DrugBank.d258.s7	Descarboethoxyloratadine	74	97	B-drug
DDI-DrugBank.d258.s7	After	99	103	O
DDI-DrugBank.d258.s7	10	105	106	O
DDI-DrugBank.d258.s7	Days	108	111	O
DDI-DrugBank.d258.s7	of	113	114	O
DDI-DrugBank.d258.s7	Coadministration	116	131	O
DDI-DrugBank.d258.s7	(	133	133	O
DDI-DrugBank.d258.s7	Loratadine	134	143	B-drug
DDI-DrugBank.d258.s7	10	145	146	O
DDI-DrugBank.d258.s7	mg	148	149	O
DDI-DrugBank.d258.s7	)	150	150	O
DDI-DrugBank.d258.s7	in	141	142	I-drug
DDI-DrugBank.d258.s7	Normal	155	160	O
DDI-DrugBank.d258.s7	Volunteers	162	171	O
DDI-DrugBank.d258.s8	Loratadine	0	9	B-drug
DDI-DrugBank.d258.s8	Descarboethoxyloratadine	11	34	B-drug
DDI-DrugBank.d258.s9	Erythromycin	0	11	B-drug
DDI-DrugBank.d258.s9	(	13	13	O
DDI-DrugBank.d258.s9	500	14	16	O
DDI-DrugBank.d258.s9	mg	18	19	O
DDI-DrugBank.d258.s9	q8h	21	23	O
DDI-DrugBank.d258.s9	)	24	24	O
DDI-DrugBank.d258.s9	+	26	26	O
DDI-DrugBank.d258.s9	40	28	29	O
DDI-DrugBank.d258.s9	%	30	30	O
DDI-DrugBank.d258.s9	+46	32	34	O
DDI-DrugBank.d258.s9	%	30	30	O
DDI-DrugBank.d258.s10	Cimetidine	0	9	B-drug
DDI-DrugBank.d258.s10	(	11	11	O
DDI-DrugBank.d258.s10	300	12	14	O
DDI-DrugBank.d258.s10	mg	16	17	O
DDI-DrugBank.d258.s10	qid	19	21	O
DDI-DrugBank.d258.s10	)	22	22	O
DDI-DrugBank.d258.s10	+103	24	27	O
DDI-DrugBank.d258.s10	%	28	28	O
DDI-DrugBank.d258.s10	+	30	30	O
DDI-DrugBank.d258.s10	6	32	32	O
DDI-DrugBank.d258.s10	%	28	28	O
DDI-DrugBank.d258.s11	Ketoconazole	0	11	B-drug
DDI-DrugBank.d258.s11	(	13	13	O
DDI-DrugBank.d258.s11	200	14	16	O
DDI-DrugBank.d258.s11	mg	18	19	O
DDI-DrugBank.d258.s11	q12h	21	24	O
DDI-DrugBank.d258.s11	)	25	25	O
DDI-DrugBank.d258.s11	+307	27	30	O
DDI-DrugBank.d258.s11	%	31	31	O
DDI-DrugBank.d258.s11	+73	33	35	O
DDI-DrugBank.d258.s11	%	31	31	O
DDI-DrugBank.d258.s12	There	0	4	O
DDI-DrugBank.d258.s12	does	6	9	O
DDI-DrugBank.d258.s12	not	11	13	O
DDI-DrugBank.d258.s12	appear	15	20	O
DDI-DrugBank.d258.s12	to	22	23	O
DDI-DrugBank.d258.s12	be	25	26	O
DDI-DrugBank.d258.s12	an	28	29	O
DDI-DrugBank.d258.s12	increase	31	38	O
DDI-DrugBank.d258.s12	in	40	41	O
DDI-DrugBank.d258.s12	adverse	43	49	O
DDI-DrugBank.d258.s12	events	51	56	O
DDI-DrugBank.d258.s12	in	58	59	O
DDI-DrugBank.d258.s12	subjects	61	68	O
DDI-DrugBank.d258.s12	who	70	72	O
DDI-DrugBank.d258.s12	received	74	81	O
DDI-DrugBank.d258.s12	oral	83	86	O
DDI-DrugBank.d258.s12	contraceptives	88	101	B-group
DDI-DrugBank.d258.s12	and	103	105	O
DDI-DrugBank.d258.s12	loratadine	107	116	B-drug
DDI-DrugBank.d258.s12	.	117	117	O
DDI-DrugBank.d495.s0	Tablet	0	5	O
DDI-DrugBank.d495.s0	If	7	8	O
DDI-DrugBank.d495.s0	a	10	10	O
DDI-DrugBank.d495.s0	patient	12	18	O
DDI-DrugBank.d495.s0	receiving	20	28	O
DDI-DrugBank.d495.s0	clonidine	30	38	B-drug
DDI-DrugBank.d495.s0	hydrochloride	40	52	I-drug
DDI-DrugBank.d495.s0	is	54	55	O
DDI-DrugBank.d495.s0	also	57	60	O
DDI-DrugBank.d495.s0	taking	62	67	O
DDI-DrugBank.d495.s0	tricyclic	69	77	B-group
DDI-DrugBank.d495.s0	antidepressants	79	93	I-group
DDI-DrugBank.d495.s0	,	94	94	O
DDI-DrugBank.d495.s0	the	96	98	O
DDI-DrugBank.d495.s0	effect	100	105	O
DDI-DrugBank.d495.s0	of	107	108	O
DDI-DrugBank.d495.s0	clonidine	110	118	B-drug
DDI-DrugBank.d495.s0	may	120	122	O
DDI-DrugBank.d495.s0	be	124	125	O
DDI-DrugBank.d495.s0	reduced	127	133	O
DDI-DrugBank.d495.s0	,	134	134	O
DDI-DrugBank.d495.s0	thus	136	139	O
DDI-DrugBank.d495.s0	necessitating	141	153	O
DDI-DrugBank.d495.s0	an	155	156	O
DDI-DrugBank.d495.s0	increase	158	165	O
DDI-DrugBank.d495.s0	in	151	152	O
DDI-DrugBank.d495.s0	dosage	170	175	O
DDI-DrugBank.d495.s0	.	176	176	O
DDI-DrugBank.d495.s1	Clonidine	0	8	B-drug
DDI-DrugBank.d495.s1	hydrochloride	10	22	I-drug
DDI-DrugBank.d495.s1	may	24	26	O
DDI-DrugBank.d495.s1	enhance	28	34	O
DDI-DrugBank.d495.s1	the	36	38	O
DDI-DrugBank.d495.s1	CNS-depressive	40	53	O
DDI-DrugBank.d495.s1	effects	55	61	O
DDI-DrugBank.d495.s1	of	63	64	O
DDI-DrugBank.d495.s1	alcohol	66	72	B-drug
DDI-DrugBank.d495.s1	,	73	73	O
DDI-DrugBank.d495.s1	barbiturates	75	86	B-group
DDI-DrugBank.d495.s1	or	88	89	O
DDI-DrugBank.d495.s1	other	91	95	O
DDI-DrugBank.d495.s1	sedatives	97	105	B-group
DDI-DrugBank.d495.s1	.	106	106	O
DDI-DrugBank.d495.s2	Amitriptyline	0	12	B-drug
DDI-DrugBank.d495.s2	in	14	15	O
DDI-DrugBank.d495.s2	combination	17	27	O
DDI-DrugBank.d495.s2	with	29	32	O
DDI-DrugBank.d495.s2	clonidine	34	42	B-drug
DDI-DrugBank.d495.s2	enhances	44	51	O
DDI-DrugBank.d495.s2	the	53	55	O
DDI-DrugBank.d495.s2	manifestation	57	69	O
DDI-DrugBank.d495.s2	of	71	72	O
DDI-DrugBank.d495.s2	corneal	74	80	O
DDI-DrugBank.d495.s2	lesions	82	88	O
DDI-DrugBank.d495.s2	in	90	91	O
DDI-DrugBank.d495.s2	rats	93	96	O
DDI-DrugBank.d495.s2	Epidural	98	105	O
DDI-DrugBank.d495.s2	Injection	107	115	O
DDI-DrugBank.d495.s2	Clonidine	117	125	B-drug
DDI-DrugBank.d495.s2	may	127	129	O
DDI-DrugBank.d495.s2	potentiate	131	140	O
DDI-DrugBank.d495.s2	the	142	144	O
DDI-DrugBank.d495.s2	CNS-depressive	146	159	O
DDI-DrugBank.d495.s2	effect	161	166	O
DDI-DrugBank.d495.s2	of	168	169	O
DDI-DrugBank.d495.s2	alcohol	171	177	B-drug
DDI-DrugBank.d495.s2	,	178	178	O
DDI-DrugBank.d495.s2	barbiturates	180	191	B-group
DDI-DrugBank.d495.s2	or	193	194	O
DDI-DrugBank.d495.s2	other	196	200	O
DDI-DrugBank.d495.s2	sedating	202	209	B-group
DDI-DrugBank.d495.s2	drugs	211	215	I-group
DDI-DrugBank.d495.s2	.	216	216	O
DDI-DrugBank.d495.s3	Narcotic	0	7	B-group
DDI-DrugBank.d495.s3	analgesics	9	18	I-group
DDI-DrugBank.d495.s3	may	20	22	O
DDI-DrugBank.d495.s3	potentiate	24	33	O
DDI-DrugBank.d495.s3	the	35	37	O
DDI-DrugBank.d495.s3	hypotensive	39	49	O
DDI-DrugBank.d495.s3	effects	51	57	O
DDI-DrugBank.d495.s3	of	59	60	O
DDI-DrugBank.d495.s3	clonidine	62	70	B-drug
DDI-DrugBank.d495.s3	.	71	71	O
DDI-DrugBank.d495.s4	Tricyclic	0	8	B-group
DDI-DrugBank.d495.s4	antidepressants	10	24	I-group
DDI-DrugBank.d495.s4	may	26	28	O
DDI-DrugBank.d495.s4	antagonize	30	39	O
DDI-DrugBank.d495.s4	the	41	43	O
DDI-DrugBank.d495.s4	hypotensive	45	55	O
DDI-DrugBank.d495.s4	effects	57	63	O
DDI-DrugBank.d495.s4	of	65	66	O
DDI-DrugBank.d495.s4	clonidine	68	76	B-drug
DDI-DrugBank.d495.s4	.	77	77	O
DDI-DrugBank.d495.s5	The	0	2	O
DDI-DrugBank.d495.s5	effects	4	10	O
DDI-DrugBank.d495.s5	of	12	13	O
DDI-DrugBank.d495.s5	tricyclic	15	23	B-group
DDI-DrugBank.d495.s5	antidepressants	25	39	I-group
DDI-DrugBank.d495.s5	on	41	42	O
DDI-DrugBank.d495.s5	clonidines	44	53	O
DDI-DrugBank.d495.s5	analgesic	55	63	O
DDI-DrugBank.d495.s5	actions	65	71	O
DDI-DrugBank.d495.s5	are	73	75	O
DDI-DrugBank.d495.s5	not	77	79	O
DDI-DrugBank.d495.s5	known	81	85	O
DDI-DrugBank.d495.s5	.	86	86	O
DDI-DrugBank.d495.s6	Beta	0	3	B-group
DDI-DrugBank.d495.s6	blockers	5	12	I-group
DDI-DrugBank.d495.s6	may	14	16	O
DDI-DrugBank.d495.s6	exacerbate	18	27	O
DDI-DrugBank.d495.s6	the	29	31	O
DDI-DrugBank.d495.s6	hypertensive	33	44	O
DDI-DrugBank.d495.s6	response	46	53	O
DDI-DrugBank.d495.s6	seen	55	58	O
DDI-DrugBank.d495.s6	with	60	63	O
DDI-DrugBank.d495.s6	clonidine	65	73	B-drug
DDI-DrugBank.d495.s6	withdrawl	75	83	O
DDI-DrugBank.d495.s6	.	84	84	O
DDI-DrugBank.d495.s7	Also	0	3	O
DDI-DrugBank.d495.s7	,	4	4	O
DDI-DrugBank.d495.s7	due	6	8	O
DDI-DrugBank.d495.s7	to	10	11	O
DDI-DrugBank.d495.s7	the	13	15	O
DDI-DrugBank.d495.s7	potential	17	25	O
DDI-DrugBank.d495.s7	for	27	29	O
DDI-DrugBank.d495.s7	additive	31	38	O
DDI-DrugBank.d495.s7	effects	40	46	O
DDI-DrugBank.d495.s7	such	48	51	O
DDI-DrugBank.d495.s7	as	53	54	O
DDI-DrugBank.d495.s7	bradycardia	56	66	O
DDI-DrugBank.d495.s7	and	68	70	O
DDI-DrugBank.d495.s7	AV	72	73	O
DDI-DrugBank.d495.s7	block	75	79	O
DDI-DrugBank.d495.s7	,	80	80	O
DDI-DrugBank.d495.s7	caution	82	88	O
DDI-DrugBank.d495.s7	is	90	91	O
DDI-DrugBank.d495.s7	warranted	93	101	O
DDI-DrugBank.d495.s7	in	103	104	O
DDI-DrugBank.d495.s7	patients	106	113	O
DDI-DrugBank.d495.s7	receiving	115	123	O
DDI-DrugBank.d495.s7	clonidine	125	133	B-drug
DDI-DrugBank.d495.s7	with	135	138	O
DDI-DrugBank.d495.s7	agents	140	145	O
DDI-DrugBank.d495.s7	known	147	151	O
DDI-DrugBank.d495.s7	to	153	154	O
DDI-DrugBank.d495.s7	affect	156	161	O
DDI-DrugBank.d495.s7	sinus	163	167	O
DDI-DrugBank.d495.s7	node	169	172	O
DDI-DrugBank.d495.s7	function	174	181	O
DDI-DrugBank.d495.s7	or	183	184	O
DDI-DrugBank.d495.s7	AV	186	187	O
DDI-DrugBank.d495.s7	nodal	189	193	O
DDI-DrugBank.d495.s7	conduction	195	204	O
DDI-DrugBank.d495.s7	(	206	206	O
DDI-DrugBank.d495.s7	e.g.	207	210	O
DDI-DrugBank.d495.s7	,	211	211	O
DDI-DrugBank.d495.s7	digitalis	213	221	B-group
DDI-DrugBank.d495.s7	,	211	211	O
DDI-DrugBank.d495.s7	calcium	224	230	B-group
DDI-DrugBank.d495.s7	channel	232	238	I-group
DDI-DrugBank.d495.s7	blockers	240	247	I-group
DDI-DrugBank.d495.s7	,	211	211	O
DDI-DrugBank.d495.s7	and	250	252	O
DDI-DrugBank.d495.s7	beta-blockers	254	266	B-group
DDI-DrugBank.d495.s7	.	267	267	O
DDI-DrugBank.d495.s7	)	268	268	O
DDI-DrugBank.d495.s8	There	0	4	O
DDI-DrugBank.d495.s8	is	6	7	O
DDI-DrugBank.d495.s8	one	9	11	O
DDI-DrugBank.d495.s8	reported	13	20	O
DDI-DrugBank.d495.s8	case	22	25	O
DDI-DrugBank.d495.s8	of	27	28	O
DDI-DrugBank.d495.s8	a	30	30	O
DDI-DrugBank.d495.s8	patient	32	38	O
DDI-DrugBank.d495.s8	with	40	43	O
DDI-DrugBank.d495.s8	acute	45	49	O
DDI-DrugBank.d495.s8	delirium	51	58	O
DDI-DrugBank.d495.s8	associated	60	69	O
DDI-DrugBank.d495.s8	with	71	74	O
DDI-DrugBank.d495.s8	the	76	78	O
DDI-DrugBank.d495.s8	simultaneous	80	91	O
DDI-DrugBank.d495.s8	use	93	95	O
DDI-DrugBank.d495.s8	of	97	98	O
DDI-DrugBank.d495.s8	fluphenazine	100	111	B-drug
DDI-DrugBank.d495.s8	and	113	115	O
DDI-DrugBank.d495.s8	oral	117	120	O
DDI-DrugBank.d495.s8	clonidine	122	130	B-drug
DDI-DrugBank.d495.s8	.	131	131	O
DDI-DrugBank.d495.s9	Symptoms	0	7	O
DDI-DrugBank.d495.s9	resolved	9	16	O
DDI-DrugBank.d495.s9	when	18	21	O
DDI-DrugBank.d495.s9	clonidine	23	31	B-drug
DDI-DrugBank.d495.s9	was	33	35	O
DDI-DrugBank.d495.s9	withdrawn	37	45	O
DDI-DrugBank.d495.s9	and	47	49	O
DDI-DrugBank.d495.s9	recurred	51	58	O
DDI-DrugBank.d495.s9	when	60	63	O
DDI-DrugBank.d495.s9	the	65	67	O
DDI-DrugBank.d495.s9	patient	69	75	O
DDI-DrugBank.d495.s9	was	77	79	O
DDI-DrugBank.d495.s9	rechallenged	81	92	O
DDI-DrugBank.d495.s9	with	94	97	O
DDI-DrugBank.d495.s9	clonidine	99	107	B-drug
DDI-DrugBank.d495.s9	.	108	108	O
DDI-DrugBank.d495.s10	Epidural	0	7	O
DDI-DrugBank.d495.s10	clonidine	9	17	B-drug
DDI-DrugBank.d495.s10	may	19	21	O
DDI-DrugBank.d495.s10	prolong	23	29	O
DDI-DrugBank.d495.s10	the	31	33	O
DDI-DrugBank.d495.s10	duration	35	42	O
DDI-DrugBank.d495.s10	of	44	45	O
DDI-DrugBank.d495.s10	pharmacologic	47	59	O
DDI-DrugBank.d495.s10	effects	61	67	O
DDI-DrugBank.d495.s10	of	69	70	O
DDI-DrugBank.d495.s10	epidural	72	79	O
DDI-DrugBank.d495.s10	local	81	85	O
DDI-DrugBank.d495.s10	anesthetics	87	97	B-group
DDI-DrugBank.d495.s10	,	98	98	O
DDI-DrugBank.d495.s10	including	100	108	O
DDI-DrugBank.d495.s10	both	110	113	O
DDI-DrugBank.d495.s10	sensory	115	121	O
DDI-DrugBank.d495.s10	and	123	125	O
DDI-DrugBank.d495.s10	motor	127	131	O
DDI-DrugBank.d495.s10	blockade	133	140	O
DDI-DrugBank.d495.s10	.	141	141	O
DDI-DrugBank.d57.s0	In	0	1	O
DDI-DrugBank.d57.s0	vitro	3	7	O
DDI-DrugBank.d57.s0	mixing	9	14	O
DDI-DrugBank.d57.s0	of	16	17	O
DDI-DrugBank.d57.s0	an	19	20	O
DDI-DrugBank.d57.s0	aminoglycoside	22	35	B-group
DDI-DrugBank.d57.s0	with	37	40	O
DDI-DrugBank.d57.s0	beta-lactamtype	42	56	O
DDI-DrugBank.d57.s0	antibiotics	58	68	B-group
DDI-DrugBank.d57.s0	(	70	70	O
DDI-DrugBank.d57.s0	penicillins	71	81	B-group
DDI-DrugBank.d57.s0	or	83	84	O
DDI-DrugBank.d57.s0	cephalosporins	86	99	B-group
DDI-DrugBank.d57.s0	)	100	100	O
DDI-DrugBank.d57.s0	may	102	104	O
DDI-DrugBank.d57.s0	result	106	111	O
DDI-DrugBank.d57.s0	in	113	114	O
DDI-DrugBank.d57.s0	a	103	103	O
DDI-DrugBank.d57.s0	significant	118	128	O
DDI-DrugBank.d57.s0	mutual	130	135	O
DDI-DrugBank.d57.s0	inactivation	137	148	O
DDI-DrugBank.d57.s0	.	149	149	O
DDI-DrugBank.d57.s1	Even	0	3	O
DDI-DrugBank.d57.s1	when	5	8	O
DDI-DrugBank.d57.s1	an	10	11	O
DDI-DrugBank.d57.s1	aminoglycoside	13	26	B-group
DDI-DrugBank.d57.s1	and	28	30	O
DDI-DrugBank.d57.s1	a	28	28	O
DDI-DrugBank.d57.s1	penicillin-type	34	48	O
DDI-DrugBank.d57.s1	drug	50	53	O
DDI-DrugBank.d57.s1	are	55	57	O
DDI-DrugBank.d57.s1	administered	59	70	O
DDI-DrugBank.d57.s1	separately	72	81	O
DDI-DrugBank.d57.s1	by	83	84	O
DDI-DrugBank.d57.s1	different	86	94	O
DDI-DrugBank.d57.s1	routes	96	101	O
DDI-DrugBank.d57.s1	,	102	102	O
DDI-DrugBank.d57.s1	a	104	104	O
DDI-DrugBank.d57.s1	reduction	106	114	O
DDI-DrugBank.d57.s1	in	116	117	O
DDI-DrugBank.d57.s1	aminoglycoside	119	132	B-group
DDI-DrugBank.d57.s1	serum	134	138	O
DDI-DrugBank.d57.s1	half-life	140	148	O
DDI-DrugBank.d57.s1	or	150	151	O
DDI-DrugBank.d57.s1	serum	134	138	O
DDI-DrugBank.d57.s1	levels	159	164	O
DDI-DrugBank.d57.s1	has	166	168	O
DDI-DrugBank.d57.s1	been	170	173	O
DDI-DrugBank.d57.s1	reported	175	182	O
DDI-DrugBank.d57.s1	in	184	185	O
DDI-DrugBank.d57.s1	patients	187	194	O
DDI-DrugBank.d57.s1	with	196	199	O
DDI-DrugBank.d57.s1	impaired	201	208	O
DDI-DrugBank.d57.s1	renal	210	214	O
DDI-DrugBank.d57.s1	function	216	223	O
DDI-DrugBank.d57.s1	and	225	227	O
DDI-DrugBank.d57.s1	in	229	230	O
DDI-DrugBank.d57.s1	some	232	235	O
DDI-DrugBank.d57.s1	patients	237	244	O
DDI-DrugBank.d57.s1	with	246	249	O
DDI-DrugBank.d57.s1	normal	251	256	O
DDI-DrugBank.d57.s1	renal	258	262	O
DDI-DrugBank.d57.s1	function	264	271	O
DDI-DrugBank.d57.s1	.	272	272	O
DDI-DrugBank.d57.s2	Usually	0	6	O
DDI-DrugBank.d57.s2	,	7	7	O
DDI-DrugBank.d57.s2	such	9	12	O
DDI-DrugBank.d57.s2	inactivation	14	25	O
DDI-DrugBank.d57.s2	of	27	28	O
DDI-DrugBank.d57.s2	the	30	32	O
DDI-DrugBank.d57.s2	aminoglycoside	34	47	B-group
DDI-DrugBank.d57.s2	is	49	50	O
DDI-DrugBank.d57.s2	clinically	52	61	O
DDI-DrugBank.d57.s2	significant	63	73	O
DDI-DrugBank.d57.s2	only	75	78	O
DDI-DrugBank.d57.s2	in	80	81	O
DDI-DrugBank.d57.s2	patients	83	90	O
DDI-DrugBank.d57.s2	with	92	95	O
DDI-DrugBank.d57.s2	severely	97	104	O
DDI-DrugBank.d57.s2	impaired	106	113	O
DDI-DrugBank.d57.s2	renal	115	119	O
DDI-DrugBank.d57.s2	function	121	128	O
DDI-DrugBank.d57.s2	..	129	130	O
DDI-DrugBank.d57.s3	See	0	2	O
DDI-DrugBank.d573.s0	Interaction	0	10	O
DDI-DrugBank.d573.s0	with	12	15	O
DDI-DrugBank.d573.s0	Guanethidine	17	28	B-drug
DDI-DrugBank.d573.s0	:	29	29	O
DDI-DrugBank.d573.s0	Although	31	38	O
DDI-DrugBank.d573.s0	minoxidil	40	48	B-drug
DDI-DrugBank.d573.s0	does	50	53	O
DDI-DrugBank.d573.s0	not	55	57	O
DDI-DrugBank.d573.s0	itself	59	64	O
DDI-DrugBank.d573.s0	cause	66	70	O
DDI-DrugBank.d573.s0	orthostatic	72	82	O
DDI-DrugBank.d573.s0	hypotension	84	94	O
DDI-DrugBank.d573.s0	,	95	95	O
DDI-DrugBank.d573.s0	its	97	99	O
DDI-DrugBank.d573.s0	administration	101	114	O
DDI-DrugBank.d573.s0	to	116	117	O
DDI-DrugBank.d573.s0	patients	119	126	O
DDI-DrugBank.d573.s0	already	128	134	O
DDI-DrugBank.d573.s0	receiving	136	144	O
DDI-DrugBank.d573.s0	guanethidine	146	157	B-drug
DDI-DrugBank.d573.s0	can	159	161	O
DDI-DrugBank.d573.s0	result	163	168	O
DDI-DrugBank.d573.s0	in	155	156	I-drug
DDI-DrugBank.d573.s0	profound	173	180	O
DDI-DrugBank.d573.s0	orthostatic	182	192	O
DDI-DrugBank.d573.s0	effects	194	200	O
DDI-DrugBank.d573.s0	.	201	201	O
DDI-DrugBank.d573.s1	If	0	1	O
DDI-DrugBank.d573.s1	at	3	4	O
DDI-DrugBank.d573.s1	all	6	8	O
DDI-DrugBank.d573.s1	possible	10	17	O
DDI-DrugBank.d573.s1	guanethidine	19	30	B-drug
DDI-DrugBank.d573.s1	should	32	37	O
DDI-DrugBank.d573.s1	be	39	40	O
DDI-DrugBank.d573.s1	discontinued	42	53	O
DDI-DrugBank.d573.s1	well	55	58	O
DDI-DrugBank.d573.s1	before	60	65	O
DDI-DrugBank.d573.s1	minoxidil	67	75	B-drug
DDI-DrugBank.d573.s1	is	77	78	O
DDI-DrugBank.d573.s1	begun	80	84	O
DDI-DrugBank.d573.s1	.	85	85	O
DDI-DrugBank.d573.s2	Where	0	4	O
DDI-DrugBank.d573.s2	this	6	9	O
DDI-DrugBank.d573.s2	is	11	12	O
DDI-DrugBank.d573.s2	not	14	16	O
DDI-DrugBank.d573.s2	possible	18	25	O
DDI-DrugBank.d573.s2	,	26	26	O
DDI-DrugBank.d573.s2	minoxidil	28	36	B-drug
DDI-DrugBank.d573.s2	therapy	38	44	O
DDI-DrugBank.d573.s2	should	46	51	O
DDI-DrugBank.d573.s2	be	53	54	O
DDI-DrugBank.d573.s2	started	56	62	O
DDI-DrugBank.d573.s2	in	64	65	O
DDI-DrugBank.d573.s2	the	67	69	O
DDI-DrugBank.d573.s2	hospital	71	78	O
DDI-DrugBank.d573.s2	and	80	82	O
DDI-DrugBank.d573.s2	the	84	86	O
DDI-DrugBank.d573.s2	patient	88	94	O
DDI-DrugBank.d573.s2	should	96	101	O
DDI-DrugBank.d573.s2	remain	103	108	O
DDI-DrugBank.d573.s2	institutionalized	110	126	O
DDI-DrugBank.d573.s2	until	128	132	O
DDI-DrugBank.d573.s2	severe	134	139	O
DDI-DrugBank.d573.s2	orthostatic	141	151	O
DDI-DrugBank.d573.s2	effects	153	159	O
DDI-DrugBank.d573.s2	are	161	163	O
DDI-DrugBank.d573.s2	no	165	166	O
DDI-DrugBank.d573.s2	longer	168	173	O
DDI-DrugBank.d573.s2	present	175	181	O
DDI-DrugBank.d573.s2	or	183	184	O
DDI-DrugBank.d573.s2	the	186	188	O
DDI-DrugBank.d573.s2	patient	190	196	O
DDI-DrugBank.d573.s2	has	198	200	O
DDI-DrugBank.d573.s2	learned	202	208	O
DDI-DrugBank.d573.s2	to	210	211	O
DDI-DrugBank.d573.s2	avoid	213	217	O
DDI-DrugBank.d573.s2	activities	219	228	O
DDI-DrugBank.d573.s2	that	230	233	O
DDI-DrugBank.d573.s2	provoke	235	241	O
DDI-DrugBank.d573.s2	them	243	246	O
DDI-DrugBank.d573.s2	.	247	247	O
DDI-DrugBank.d285.s0	Reduced	0	6	O
DDI-DrugBank.d285.s0	efficacy	8	15	O
DDI-DrugBank.d285.s0	and	17	19	O
DDI-DrugBank.d285.s0	increased	21	29	O
DDI-DrugBank.d285.s0	incidence	31	39	O
DDI-DrugBank.d285.s0	of	41	42	O
DDI-DrugBank.d285.s0	breakthrough	44	55	O
DDI-DrugBank.d285.s0	bleeding	57	64	O
DDI-DrugBank.d285.s0	and	66	68	O
DDI-DrugBank.d285.s0	menstrual	70	78	O
DDI-DrugBank.d285.s0	irregularities	80	93	O
DDI-DrugBank.d285.s0	have	95	98	O
DDI-DrugBank.d285.s0	been	100	103	O
DDI-DrugBank.d285.s0	associated	105	114	O
DDI-DrugBank.d285.s0	with	116	119	O
DDI-DrugBank.d285.s0	concomitant	121	131	O
DDI-DrugBank.d285.s0	use	133	135	O
DDI-DrugBank.d285.s0	of	137	138	O
DDI-DrugBank.d285.s0	rifampin	140	147	B-drug
DDI-DrugBank.d285.s0	.	148	148	O
DDI-DrugBank.d285.s1	A	0	0	O
DDI-DrugBank.d285.s1	similar	2	8	O
DDI-DrugBank.d285.s1	association	10	20	O
DDI-DrugBank.d285.s1	,	21	21	O
DDI-DrugBank.d285.s1	though	23	28	O
DDI-DrugBank.d285.s1	less	30	33	O
DDI-DrugBank.d285.s1	marked	35	40	O
DDI-DrugBank.d285.s1	,	41	41	O
DDI-DrugBank.d285.s1	has	43	45	O
DDI-DrugBank.d285.s1	been	47	50	O
DDI-DrugBank.d285.s1	suggested	52	60	O
DDI-DrugBank.d285.s1	with	62	65	O
DDI-DrugBank.d285.s1	barbiturates	67	78	B-group
DDI-DrugBank.d285.s1	,	79	79	O
DDI-DrugBank.d285.s1	phenyl-butazone	81	95	O
DDI-DrugBank.d285.s1	,	96	96	O
DDI-DrugBank.d285.s1	phenytoin	98	106	B-drug
DDI-DrugBank.d285.s1	sodium	108	113	I-drug
DDI-DrugBank.d285.s1	,	114	114	O
DDI-DrugBank.d285.s1	carbamazepine	116	128	B-drug
DDI-DrugBank.d285.s1	and	130	132	O
DDI-DrugBank.d285.s1	possibly	134	141	O
DDI-DrugBank.d285.s1	with	143	146	O
DDI-DrugBank.d285.s1	griseofulvin	148	159	B-drug
DDI-DrugBank.d285.s1	,	160	160	O
DDI-DrugBank.d285.s1	ampicillin	162	171	B-drug
DDI-DrugBank.d285.s1	,	160	160	O
DDI-DrugBank.d285.s1	and	174	176	O
DDI-DrugBank.d285.s1	tetracyclines	178	190	B-group
DDI-DrugBank.d285.s1	(	192	192	O
DDI-DrugBank.d285.s1	72	193	194	O
DDI-DrugBank.d285.s1	)	195	195	O
DDI-DrugBank.d285.s2	.	0	0	O
DDI-DrugBank.d623.s0	No	0	1	O
DDI-DrugBank.d623.s0	drug-drug	3	11	O
DDI-DrugBank.d623.s0	interaction	13	23	O
DDI-DrugBank.d623.s0	studies	25	31	O
DDI-DrugBank.d623.s0	have	33	36	O
DDI-DrugBank.d623.s0	been	38	41	O
DDI-DrugBank.d623.s0	conducted	43	51	O
DDI-DrugBank.d623.s0	with	53	56	O
DDI-DrugBank.d623.s0	depo-subQ	58	66	B-brand
DDI-DrugBank.d623.s0	provera	68	74	I-brand
DDI-DrugBank.d623.s0	104	76	78	I-brand
DDI-DrugBank.d623.s0	.	79	79	O
DDI-DrugBank.d623.s1	Aminoglutethimide	0	16	B-drug
DDI-DrugBank.d623.s1	administered	18	29	O
DDI-DrugBank.d623.s1	concomitantly	31	43	O
DDI-DrugBank.d623.s1	with	45	48	O
DDI-DrugBank.d623.s1	depo-subQ	50	58	B-brand
DDI-DrugBank.d623.s1	provera	60	66	I-brand
DDI-DrugBank.d623.s1	104	68	70	I-brand
DDI-DrugBank.d623.s1	may	72	74	O
DDI-DrugBank.d623.s1	significantly	76	88	O
DDI-DrugBank.d623.s1	decrease	90	97	O
DDI-DrugBank.d623.s1	the	99	101	O
DDI-DrugBank.d623.s1	serum	103	107	O
DDI-DrugBank.d623.s1	concentrations	109	122	O
DDI-DrugBank.d623.s1	of	124	125	O
DDI-DrugBank.d623.s1	MPA	127	129	B-drug
DDI-DrugBank.d623.s1	.	130	130	O
DDI-DrugBank.d623.s2	Laboratory	0	9	O
DDI-DrugBank.d623.s2	Tests	11	15	O
DDI-DrugBank.d623.s2	The	17	19	O
DDI-DrugBank.d623.s2	pathologist	21	31	O
DDI-DrugBank.d623.s2	should	33	38	O
DDI-DrugBank.d623.s2	be	40	41	O
DDI-DrugBank.d623.s2	advised	43	49	O
DDI-DrugBank.d623.s2	of	51	52	O
DDI-DrugBank.d623.s2	progestin	54	62	O
DDI-DrugBank.d623.s2	therapy	64	70	O
DDI-DrugBank.d623.s2	when	72	75	O
DDI-DrugBank.d623.s2	relevant	77	84	O
DDI-DrugBank.d623.s2	specimens	86	94	O
DDI-DrugBank.d623.s2	are	96	98	O
DDI-DrugBank.d623.s2	submitted	100	108	O
DDI-DrugBank.d623.s2	.	109	109	O
DDI-DrugBank.d623.s3	The	0	2	O
DDI-DrugBank.d623.s3	physician	4	12	O
DDI-DrugBank.d623.s3	should	14	19	O
DDI-DrugBank.d623.s3	be	21	22	O
DDI-DrugBank.d623.s3	informed	24	31	O
DDI-DrugBank.d623.s3	that	33	36	O
DDI-DrugBank.d623.s3	certain	38	44	O
DDI-DrugBank.d623.s3	endocrine	46	54	O
DDI-DrugBank.d623.s3	and	56	58	O
DDI-DrugBank.d623.s3	liver	60	64	O
DDI-DrugBank.d623.s3	function	66	73	O
DDI-DrugBank.d623.s3	tests	75	79	O
DDI-DrugBank.d623.s3	,	80	80	O
DDI-DrugBank.d623.s3	and	82	84	O
DDI-DrugBank.d623.s3	blood	86	90	O
DDI-DrugBank.d623.s3	components	92	101	O
DDI-DrugBank.d623.s3	may	103	105	O
DDI-DrugBank.d623.s3	be	107	108	O
DDI-DrugBank.d623.s3	affected	110	117	O
DDI-DrugBank.d623.s3	by	119	120	O
DDI-DrugBank.d623.s3	progestin	122	130	O
DDI-DrugBank.d623.s3	therapy	132	138	O
DDI-DrugBank.d623.s3	:	139	139	O
DDI-DrugBank.d623.s3	(	141	141	O
DDI-DrugBank.d623.s3	a	136	136	O
DDI-DrugBank.d623.s3	)	143	143	O
DDI-DrugBank.d623.s3	Plasma	145	150	O
DDI-DrugBank.d623.s3	and	152	154	O
DDI-DrugBank.d623.s3	urinary	156	162	O
DDI-DrugBank.d623.s3	steroid	164	170	O
DDI-DrugBank.d623.s3	levels	172	177	O
DDI-DrugBank.d623.s3	are	179	181	O
DDI-DrugBank.d623.s3	decreased	183	191	O
DDI-DrugBank.d623.s3	(	193	193	O
DDI-DrugBank.d623.s3	e.g.	194	197	O
DDI-DrugBank.d623.s3	,	198	198	O
DDI-DrugBank.d623.s3	progesterone	200	211	O
DDI-DrugBank.d623.s3	,	198	198	O
DDI-DrugBank.d623.s3	estradiol	214	222	O
DDI-DrugBank.d623.s3	,	198	198	O
DDI-DrugBank.d623.s3	pregnanediol	225	236	O
DDI-DrugBank.d623.s3	,	212	212	O
DDI-DrugBank.d623.s3	testosterone	239	250	O
DDI-DrugBank.d623.s3	,	223	223	O
DDI-DrugBank.d623.s3	cortisol	253	260	O
DDI-DrugBank.d623.s3	)	261	261	O
DDI-DrugBank.d623.s3	.	262	262	O
DDI-DrugBank.d623.s4	(	0	0	O
DDI-DrugBank.d623.s4	b	1	1	O
DDI-DrugBank.d623.s4	)	2	2	O
DDI-DrugBank.d623.s4	Plasma	4	9	O
DDI-DrugBank.d623.s4	and	11	13	O
DDI-DrugBank.d623.s4	urinary	15	21	O
DDI-DrugBank.d623.s4	gonadotropin	23	34	O
DDI-DrugBank.d623.s4	levels	36	41	O
DDI-DrugBank.d623.s4	are	43	45	O
DDI-DrugBank.d623.s4	decreased	47	55	O
DDI-DrugBank.d623.s4	(	57	57	O
DDI-DrugBank.d623.s4	e.g.	58	61	O
DDI-DrugBank.d623.s4	,	62	62	O
DDI-DrugBank.d623.s4	LH	64	65	O
DDI-DrugBank.d623.s4	,	62	62	O
DDI-DrugBank.d623.s4	FSH	68	70	O
DDI-DrugBank.d623.s4	)	71	71	O
DDI-DrugBank.d623.s4	.	72	72	O
DDI-DrugBank.d623.s5	(	0	0	O
DDI-DrugBank.d623.s5	c	1	1	O
DDI-DrugBank.d623.s5	)	2	2	O
DDI-DrugBank.d623.s5	SHBG	4	7	O
DDI-DrugBank.d623.s5	concentrations	9	22	O
DDI-DrugBank.d623.s5	are	24	26	O
DDI-DrugBank.d623.s5	decreased	28	36	O
DDI-DrugBank.d623.s5	.	37	37	O
DDI-DrugBank.d623.s6	(	0	0	O
DDI-DrugBank.d623.s6	d	1	1	O
DDI-DrugBank.d623.s6	)	2	2	O
DDI-DrugBank.d623.s6	T3-uptake	4	12	O
DDI-DrugBank.d623.s6	values	14	19	O
DDI-DrugBank.d623.s6	may	21	23	O
DDI-DrugBank.d623.s6	decrease	25	32	O
DDI-DrugBank.d623.s6	.	33	33	O
DDI-DrugBank.d623.s7	(	0	0	O
DDI-DrugBank.d623.s7	e	1	1	O
DDI-DrugBank.d623.s7	)	2	2	O
DDI-DrugBank.d623.s7	There	4	8	O
DDI-DrugBank.d623.s7	may	10	12	O
DDI-DrugBank.d623.s7	be	14	15	O
DDI-DrugBank.d623.s7	small	17	21	O
DDI-DrugBank.d623.s7	changes	23	29	O
DDI-DrugBank.d623.s7	in	31	32	O
DDI-DrugBank.d623.s7	coagulation	34	44	O
DDI-DrugBank.d623.s7	factors	46	52	O
DDI-DrugBank.d623.s7	.	53	53	O
DDI-DrugBank.d623.s8	(	0	0	O
DDI-DrugBank.d623.s8	f	1	1	O
DDI-DrugBank.d623.s8	)	2	2	O
DDI-DrugBank.d623.s8	Sulfobromophthalein	4	22	O
DDI-DrugBank.d623.s8	and	24	26	O
DDI-DrugBank.d623.s8	other	28	32	O
DDI-DrugBank.d623.s8	liver	34	38	O
DDI-DrugBank.d623.s8	function	40	47	O
DDI-DrugBank.d623.s8	test	49	52	O
DDI-DrugBank.d623.s8	values	54	59	O
DDI-DrugBank.d623.s8	may	61	63	O
DDI-DrugBank.d623.s8	be	65	66	O
DDI-DrugBank.d623.s8	increased	68	76	O
DDI-DrugBank.d623.s8	slightly	78	85	O
DDI-DrugBank.d623.s8	.	86	86	O
DDI-DrugBank.d623.s9	(	0	0	O
DDI-DrugBank.d623.s9	g	1	1	O
DDI-DrugBank.d623.s9	)	2	2	O
DDI-DrugBank.d623.s9	There	4	8	O
DDI-DrugBank.d623.s9	may	10	12	O
DDI-DrugBank.d623.s9	be	14	15	O
DDI-DrugBank.d623.s9	small	17	21	O
DDI-DrugBank.d623.s9	changes	23	29	O
DDI-DrugBank.d623.s9	in	31	32	O
DDI-DrugBank.d623.s9	lipid	34	38	O
DDI-DrugBank.d623.s9	profiles	40	47	O
DDI-DrugBank.d623.s9	.	48	48	O
DDI-DrugBank.d363.s0	No	0	1	O
DDI-DrugBank.d363.s0	clinically	3	12	O
DDI-DrugBank.d363.s0	significant	14	24	O
DDI-DrugBank.d363.s0	adverse	26	32	O
DDI-DrugBank.d363.s0	interactions	34	45	O
DDI-DrugBank.d363.s0	with	47	50	O
DDI-DrugBank.d363.s0	commonly	52	59	O
DDI-DrugBank.d363.s0	used	61	64	O
DDI-DrugBank.d363.s0	preanesthetic	66	78	O
DDI-DrugBank.d363.s0	drugs	80	84	O
DDI-DrugBank.d363.s0	,	85	85	O
DDI-DrugBank.d363.s0	or	87	88	O
DDI-DrugBank.d363.s0	drugs	80	84	O
DDI-DrugBank.d363.s0	used	96	99	O
DDI-DrugBank.d363.s0	during	101	106	O
DDI-DrugBank.d363.s0	anesthesia	108	117	O
DDI-DrugBank.d363.s0	(	119	119	O
DDI-DrugBank.d363.s0	muscle	120	125	B-group
DDI-DrugBank.d363.s0	relaxants	127	135	I-group
DDI-DrugBank.d363.s0	,	136	136	O
DDI-DrugBank.d363.s0	intravenous	138	148	O
DDI-DrugBank.d363.s0	agents	150	155	O
DDI-DrugBank.d363.s0	,	156	156	O
DDI-DrugBank.d363.s0	and	158	160	O
DDI-DrugBank.d363.s0	local	162	166	O
DDI-DrugBank.d363.s0	anesthetic	168	177	B-group
DDI-DrugBank.d363.s0	agents	179	184	I-group
DDI-DrugBank.d363.s0	)	185	185	O
DDI-DrugBank.d363.s0	were	187	190	O
DDI-DrugBank.d363.s0	reported	192	199	O
DDI-DrugBank.d363.s0	in	201	202	O
DDI-DrugBank.d363.s0	clinical	204	211	O
DDI-DrugBank.d363.s0	trials	213	218	O
DDI-DrugBank.d363.s0	.	219	219	O
DDI-DrugBank.d363.s1	The	0	2	O
DDI-DrugBank.d363.s1	effect	4	9	O
DDI-DrugBank.d363.s1	of	11	12	O
DDI-DrugBank.d363.s1	desflurane	14	23	B-drug
DDI-DrugBank.d363.s1	on	25	26	O
DDI-DrugBank.d363.s1	the	28	30	O
DDI-DrugBank.d363.s1	disposition	32	42	O
DDI-DrugBank.d363.s1	of	44	45	O
DDI-DrugBank.d363.s1	other	47	51	O
DDI-DrugBank.d363.s1	drugs	53	57	O
DDI-DrugBank.d363.s1	has	59	61	O
DDI-DrugBank.d363.s1	not	63	65	O
DDI-DrugBank.d363.s1	been	67	70	O
DDI-DrugBank.d363.s1	determined	72	81	O
DDI-DrugBank.d363.s1	.	82	82	O
DDI-DrugBank.d363.s2	Like	0	3	O
DDI-DrugBank.d363.s2	isoflurane	5	14	B-drug
DDI-DrugBank.d363.s2	,	15	15	O
DDI-DrugBank.d363.s2	desflurane	17	26	B-drug
DDI-DrugBank.d363.s2	does	28	31	O
DDI-DrugBank.d363.s2	not	33	35	O
DDI-DrugBank.d363.s2	predispose	37	46	O
DDI-DrugBank.d363.s2	to	48	49	O
DDI-DrugBank.d363.s2	premature	51	59	O
DDI-DrugBank.d363.s2	ventricular	61	71	O
DDI-DrugBank.d363.s2	arrhythmias	73	83	O
DDI-DrugBank.d363.s2	in	85	86	O
DDI-DrugBank.d363.s2	the	88	90	O
DDI-DrugBank.d363.s2	presence	92	99	O
DDI-DrugBank.d363.s2	of	101	102	O
DDI-DrugBank.d363.s2	exogenously	104	114	O
DDI-DrugBank.d363.s2	infused	116	122	O
DDI-DrugBank.d363.s2	epinephrine	124	134	B-drug
DDI-DrugBank.d363.s2	in	126	127	I-drug
DDI-DrugBank.d363.s2	swine	139	143	O
DDI-DrugBank.d363.s2	.	144	144	O
DDI-DrugBank.d406.s0	May	0	2	O
DDI-DrugBank.d406.s0	interact	4	11	O
DDI-DrugBank.d406.s0	with	13	16	O
DDI-DrugBank.d406.s0	cefamandole	18	28	B-drug
DDI-DrugBank.d406.s0	naftate	30	36	I-drug
DDI-DrugBank.d406.s0	,	37	37	O
DDI-DrugBank.d406.s0	cephalothin	39	49	B-drug
DDI-DrugBank.d406.s0	sodium	51	56	I-drug
DDI-DrugBank.d406.s0	,	57	57	O
DDI-DrugBank.d406.s0	magnesium	59	67	B-drug
DDI-DrugBank.d406.s0	sulfate	69	75	I-drug
DDI-DrugBank.d406.s0	,	76	76	O
DDI-DrugBank.d406.s0	prednisolone	78	89	B-drug
DDI-DrugBank.d406.s0	sodium	91	96	I-drug
DDI-DrugBank.d406.s0	succinate	98	106	I-drug
DDI-DrugBank.d406.s0	,	107	107	O
DDI-DrugBank.d406.s0	and	109	111	O
DDI-DrugBank.d406.s0	prochlorperazine	113	128	B-drug
DDI-DrugBank.d406.s0	edisylate	130	138	I-drug
DDI-DrugBank.d406.s0	.	139	139	O
DDI-DrugBank.d161.s0	No	0	1	O
DDI-DrugBank.d161.s0	specific	3	10	O
DDI-DrugBank.d161.s0	drug	12	15	O
DDI-DrugBank.d161.s0	interaction	17	27	O
DDI-DrugBank.d161.s0	studies	29	35	O
DDI-DrugBank.d161.s0	have	37	40	O
DDI-DrugBank.d161.s0	been	42	45	O
DDI-DrugBank.d161.s0	conducted	47	55	O
DDI-DrugBank.d161.s0	.	56	56	O
DDI-DrugBank.d161.s1	For	0	2	O
DDI-DrugBank.d161.s1	information	4	14	O
DDI-DrugBank.d161.s1	on	16	17	O
DDI-DrugBank.d161.s1	the	19	21	O
DDI-DrugBank.d161.s1	pharmacokinetics	23	38	O
DDI-DrugBank.d161.s1	of	40	41	O
DDI-DrugBank.d161.s1	Gemzar	43	48	B-brand
DDI-DrugBank.d161.s1	and	50	52	O
DDI-DrugBank.d161.s1	cisplatin	54	62	B-drug
DDI-DrugBank.d161.s1	in	61	62	I-drug
DDI-DrugBank.d161.s1	combination	67	77	O
DDI-DrugBank.d161.s1	,	78	78	O
DDI-DrugBank.d161.s1	see	80	82	O
DDI-DrugBank.d161.s1	Drug	84	87	O
DDI-DrugBank.d161.s1	Interactions	89	100	O
DDI-DrugBank.d161.s1	under	102	106	O
DDI-DrugBank.d161.s1	CLINICAL	108	115	O
DDI-DrugBank.d161.s1	PHARMACOLOGY	117	128	O
DDI-DrugBank.d161.s1	section	130	136	O
DDI-DrugBank.d161.s1	.	137	137	O
DDI-DrugBank.d189.s0	No	0	1	O
DDI-DrugBank.d189.s0	Important	3	11	O
DDI-DrugBank.d189.s0	Interactions	13	24	O
DDI-DrugBank.d189.s0	To	26	27	O
DDI-DrugBank.d189.s0	Date	29	32	O
DDI-DrugBank.d189.s0	Levosimendan	34	45	B-drug
DDI-DrugBank.d189.s0	does	47	50	O
DDI-DrugBank.d189.s0	not	52	54	O
DDI-DrugBank.d189.s0	have	56	59	O
DDI-DrugBank.d189.s0	clinically	61	70	O
DDI-DrugBank.d189.s0	important	72	80	O
DDI-DrugBank.d189.s0	pharmacokinetic	82	96	O
DDI-DrugBank.d189.s0	interactions	98	109	O
DDI-DrugBank.d189.s0	with	111	114	O
DDI-DrugBank.d189.s0	captopril	116	124	B-drug
DDI-DrugBank.d189.s0	,	125	125	O
DDI-DrugBank.d189.s0	beta-blockers	127	139	B-group
DDI-DrugBank.d189.s0	,	125	125	O
DDI-DrugBank.d189.s0	felodipine	142	151	B-drug
DDI-DrugBank.d189.s0	,	140	140	O
DDI-DrugBank.d189.s0	digoxin	154	160	B-drug
DDI-DrugBank.d189.s0	,	152	152	O
DDI-DrugBank.d189.s0	warfarin	163	170	B-drug
DDI-DrugBank.d189.s0	,	161	161	O
DDI-DrugBank.d189.s0	isosorbide	173	182	B-drug
DDI-DrugBank.d189.s0	mononitrate	184	194	I-drug
DDI-DrugBank.d189.s0	,	195	195	O
DDI-DrugBank.d189.s0	carvedilol	197	206	B-drug
DDI-DrugBank.d189.s0	,	195	195	O
DDI-DrugBank.d189.s0	ethanol	209	215	B-drug
DDI-DrugBank.d189.s0	or	217	218	O
DDI-DrugBank.d189.s0	itraconazole	220	231	B-drug
DDI-DrugBank.d189.s0	.	232	232	O
DDI-DrugBank.d634.s0	Anticoagulants	0	13	B-group
DDI-DrugBank.d634.s0	(	15	15	O
DDI-DrugBank.d634.s0	oral	16	19	O
DDI-DrugBank.d634.s0	)	20	20	O
DDI-DrugBank.d634.s0	:	21	21	O
DDI-DrugBank.d634.s0	The	23	25	O
DDI-DrugBank.d634.s0	activity	27	34	O
DDI-DrugBank.d634.s0	of	36	37	O
DDI-DrugBank.d634.s0	oral	39	42	O
DDI-DrugBank.d634.s0	anticoagulants	44	57	B-group
DDI-DrugBank.d634.s0	may	59	61	O
DDI-DrugBank.d634.s0	be	63	64	O
DDI-DrugBank.d634.s0	potentiated	66	76	O
DDI-DrugBank.d634.s0	by	78	79	O
DDI-DrugBank.d634.s0	anti-vitamin-K	81	94	O
DDI-DrugBank.d634.s0	activity	96	103	O
DDI-DrugBank.d634.s0	attributed	105	114	O
DDI-DrugBank.d634.s0	to	116	117	O
DDI-DrugBank.d634.s0	methimazole	119	129	B-drug
DDI-DrugBank.d634.s0	.	130	130	O
DDI-DrugBank.d634.s1	-adrenergic	0	10	O
DDI-DrugBank.d634.s1	blocking	12	19	I-group
DDI-DrugBank.d634.s1	agents	21	26	I-group
DDI-DrugBank.d634.s1	:	27	27	O
DDI-DrugBank.d634.s1	Hyperthyroidism	29	43	O
DDI-DrugBank.d634.s1	may	45	47	O
DDI-DrugBank.d634.s1	cause	49	53	O
DDI-DrugBank.d634.s1	an	55	56	O
DDI-DrugBank.d634.s1	increased	58	66	O
DDI-DrugBank.d634.s1	clearance	68	76	O
DDI-DrugBank.d634.s1	of	78	79	O
DDI-DrugBank.d634.s1	beta	81	84	O
DDI-DrugBank.d634.s1	ratio	86	90	O
DDI-DrugBank.d634.s1	.	91	91	O
DDI-DrugBank.d634.s2	A	0	0	O
DDI-DrugBank.d634.s2	dose	2	5	O
DDI-DrugBank.d634.s2	reduction	7	15	O
DDI-DrugBank.d634.s2	of	17	18	O
DDI-DrugBank.d634.s2	beta-adrenergic	20	34	B-group
DDI-DrugBank.d634.s2	blockers	36	43	I-group
DDI-DrugBank.d634.s2	may	45	47	O
DDI-DrugBank.d634.s2	be	49	50	O
DDI-DrugBank.d634.s2	needed	52	57	O
DDI-DrugBank.d634.s2	when	59	62	O
DDI-DrugBank.d634.s2	a	64	64	O
DDI-DrugBank.d634.s2	hyperthyroid	66	77	O
DDI-DrugBank.d634.s2	patient	79	85	O
DDI-DrugBank.d634.s2	becomes	87	93	O
DDI-DrugBank.d634.s2	euthyroid	95	103	O
DDI-DrugBank.d634.s2	.	104	104	O
DDI-DrugBank.d634.s3	Digitalis	0	8	B-group
DDI-DrugBank.d634.s3	glycosides	10	19	I-group
DDI-DrugBank.d634.s3	:	20	20	O
DDI-DrugBank.d634.s3	Serum	22	26	O
DDI-DrugBank.d634.s3	digitalis	28	36	O
DDI-DrugBank.d634.s3	levels	38	43	O
DDI-DrugBank.d634.s3	may	45	47	O
DDI-DrugBank.d634.s3	be	49	50	O
DDI-DrugBank.d634.s3	increased	52	60	O
DDI-DrugBank.d634.s3	when	62	65	O
DDI-DrugBank.d634.s3	hyperthyroid	67	78	O
DDI-DrugBank.d634.s3	patients	80	87	O
DDI-DrugBank.d634.s3	on	89	90	O
DDI-DrugBank.d634.s3	a	81	81	O
DDI-DrugBank.d634.s3	stable	94	99	O
DDI-DrugBank.d634.s3	digitalis	101	109	B-group
DDI-DrugBank.d634.s3	glycoside	111	119	I-group
DDI-DrugBank.d634.s3	regimen	121	127	O
DDI-DrugBank.d634.s3	become	129	134	O
DDI-DrugBank.d634.s3	euthyroid	136	144	O
DDI-DrugBank.d634.s3	;	145	145	O
DDI-DrugBank.d634.s4	reduced	0	6	O
DDI-DrugBank.d634.s4	dosage	8	13	O
DDI-DrugBank.d634.s4	of	15	16	O
DDI-DrugBank.d634.s4	digitalis	18	26	B-group
DDI-DrugBank.d634.s4	glycosides	28	37	I-group
DDI-DrugBank.d634.s4	may	39	41	O
DDI-DrugBank.d634.s4	be	43	44	O
DDI-DrugBank.d634.s4	required	46	53	O
DDI-DrugBank.d634.s4	.	54	54	O
DDI-DrugBank.d634.s5	Theophylline	0	11	B-drug
DDI-DrugBank.d634.s5	:	12	12	O
DDI-DrugBank.d634.s5	Theophylline	14	25	B-drug
DDI-DrugBank.d634.s5	clearance	27	35	O
DDI-DrugBank.d634.s5	may	37	39	O
DDI-DrugBank.d634.s5	decrease	41	48	O
DDI-DrugBank.d634.s5	when	50	53	O
DDI-DrugBank.d634.s5	hyperthyroid	55	66	O
DDI-DrugBank.d634.s5	patients	68	75	O
DDI-DrugBank.d634.s5	on	77	78	O
DDI-DrugBank.d634.s5	a	80	80	O
DDI-DrugBank.d634.s5	stable	82	87	O
DDI-DrugBank.d634.s5	theophylline	89	100	B-drug
DDI-DrugBank.d634.s5	regimen	102	108	O
DDI-DrugBank.d634.s5	become	110	115	O
DDI-DrugBank.d634.s5	euthyroid	117	125	O
DDI-DrugBank.d634.s5	;	126	126	O
DDI-DrugBank.d634.s6	a	0	0	O
DDI-DrugBank.d634.s6	reduced	2	8	O
DDI-DrugBank.d634.s6	dose	10	13	O
DDI-DrugBank.d634.s6	of	15	16	O
DDI-DrugBank.d634.s6	theophylline	18	29	B-drug
DDI-DrugBank.d634.s6	may	31	33	O
DDI-DrugBank.d634.s6	be	35	36	O
DDI-DrugBank.d634.s6	needed	38	43	O
DDI-DrugBank.d634.s6	.	44	44	O
DDI-DrugBank.d103.s0	Short-Acting	0	11	B-group
DDI-DrugBank.d103.s0	beta2-agonists	13	26	I-group
DDI-DrugBank.d103.s0	:	27	27	O
DDI-DrugBank.d103.s0	Aerosol	29	35	O
DDI-DrugBank.d103.s0	bronchodilators	37	51	B-group
DDI-DrugBank.d103.s0	of	53	54	O
DDI-DrugBank.d103.s0	the	56	58	O
DDI-DrugBank.d103.s0	short-acting	60	71	O
DDI-DrugBank.d103.s0	adrenergic	73	82	O
DDI-DrugBank.d103.s0	stimulant	84	92	O
DDI-DrugBank.d103.s0	type	94	97	O
DDI-DrugBank.d103.s0	may	99	101	O
DDI-DrugBank.d103.s0	be	103	104	O
DDI-DrugBank.d103.s0	used	106	109	O
DDI-DrugBank.d103.s0	for	111	113	O
DDI-DrugBank.d103.s0	relief	115	120	O
DDI-DrugBank.d103.s0	of	122	123	O
DDI-DrugBank.d103.s0	breakthrough	125	136	O
DDI-DrugBank.d103.s0	symptoms	138	145	O
DDI-DrugBank.d103.s0	while	147	151	O
DDI-DrugBank.d103.s0	using	153	157	O
DDI-DrugBank.d103.s0	formoterol	159	168	B-drug
DDI-DrugBank.d103.s0	.	169	169	O
DDI-DrugBank.d103.s1	However	0	6	O
DDI-DrugBank.d103.s1	,	7	7	O
DDI-DrugBank.d103.s1	increasing	9	18	O
DDI-DrugBank.d103.s1	use	20	22	O
DDI-DrugBank.d103.s1	of	24	25	O
DDI-DrugBank.d103.s1	such	27	30	O
DDI-DrugBank.d103.s1	preparations	32	43	O
DDI-DrugBank.d103.s1	to	45	46	O
DDI-DrugBank.d103.s1	control	48	54	O
DDI-DrugBank.d103.s1	symptoms	56	63	O
DDI-DrugBank.d103.s1	indicates	65	73	O
DDI-DrugBank.d103.s1	deterioration	75	87	O
DDI-DrugBank.d103.s1	of	89	90	O
DDI-DrugBank.d103.s1	asthma	92	97	O
DDI-DrugBank.d103.s1	control	99	105	O
DDI-DrugBank.d103.s1	and	107	109	O
DDI-DrugBank.d103.s1	the	111	113	O
DDI-DrugBank.d103.s1	need	115	118	O
DDI-DrugBank.d103.s1	to	120	121	O
DDI-DrugBank.d103.s1	reassess	123	130	O
DDI-DrugBank.d103.s1	the	132	134	O
DDI-DrugBank.d103.s1	patient	136	142	O
DDI-DrugBank.d103.s1	s	126	126	O
DDI-DrugBank.d103.s1	therapy	146	152	O
DDI-DrugBank.d103.s1	.	153	153	O
DDI-DrugBank.d103.s2	Concomitant	0	10	O
DDI-DrugBank.d103.s2	administration	12	25	O
DDI-DrugBank.d103.s2	of	27	28	O
DDI-DrugBank.d103.s2	other	30	34	O
DDI-DrugBank.d103.s2	sympathomimetic	36	50	B-group
DDI-DrugBank.d103.s2	agents	52	57	I-group
DDI-DrugBank.d103.s2	may	59	61	O
DDI-DrugBank.d103.s2	potentiate	63	72	O
DDI-DrugBank.d103.s2	the	74	76	O
DDI-DrugBank.d103.s2	undesirable	78	88	O
DDI-DrugBank.d103.s2	effects	90	96	O
DDI-DrugBank.d103.s2	of	98	99	O
DDI-DrugBank.d103.s2	FORADIL	101	107	B-brand
DDI-DrugBank.d103.s2	.	108	108	O
DDI-DrugBank.d103.s3	Monoamine	0	8	B-group
DDI-DrugBank.d103.s3	Oxidase	10	16	I-group
DDI-DrugBank.d103.s3	Inhibitors	18	27	I-group
DDI-DrugBank.d103.s3	and	29	31	O
DDI-DrugBank.d103.s3	Tricyclic	33	41	B-group
DDI-DrugBank.d103.s3	Antidepressants	43	57	I-group
DDI-DrugBank.d103.s3	:	58	58	O
DDI-DrugBank.d103.s3	FORADIL	60	66	B-brand
DDI-DrugBank.d103.s3	should	68	73	O
DDI-DrugBank.d103.s3	be	75	76	O
DDI-DrugBank.d103.s3	administered	78	89	O
DDI-DrugBank.d103.s3	with	91	94	O
DDI-DrugBank.d103.s3	extreme	96	102	O
DDI-DrugBank.d103.s3	caution	104	110	O
DDI-DrugBank.d103.s3	in	112	113	O
DDI-DrugBank.d103.s3	patients	115	122	O
DDI-DrugBank.d103.s3	being	124	128	O
DDI-DrugBank.d103.s3	treated	130	136	O
DDI-DrugBank.d103.s3	with	138	141	O
DDI-DrugBank.d103.s3	monoamine	143	151	B-group
DDI-DrugBank.d103.s3	oxidase	153	159	I-group
DDI-DrugBank.d103.s3	inhibitors	161	170	I-group
DDI-DrugBank.d103.s3	or	168	169	I-group
DDI-DrugBank.d103.s3	tricyclic	175	183	B-group
DDI-DrugBank.d103.s3	antidepressants	185	199	I-group
DDI-DrugBank.d103.s3	because	201	207	O
DDI-DrugBank.d103.s3	the	209	211	O
DDI-DrugBank.d103.s3	action	213	218	O
DDI-DrugBank.d103.s3	of	220	221	O
DDI-DrugBank.d103.s3	formoterol	223	232	B-drug
DDI-DrugBank.d103.s3	on	217	218	O
DDI-DrugBank.d103.s3	the	209	211	O
DDI-DrugBank.d103.s3	cardiovascular	241	254	O
DDI-DrugBank.d103.s3	system	256	261	O
DDI-DrugBank.d103.s3	may	263	265	O
DDI-DrugBank.d103.s3	be	267	268	O
DDI-DrugBank.d103.s3	potentiated	270	280	O
DDI-DrugBank.d103.s3	by	282	283	O
DDI-DrugBank.d103.s3	these	285	289	O
DDI-DrugBank.d103.s3	agents	291	296	O
DDI-DrugBank.d103.s3	.	297	297	O
DDI-DrugBank.d103.s4	Corticosteroids	0	14	B-group
DDI-DrugBank.d103.s4	,	15	15	O
DDI-DrugBank.d103.s4	Methylxanthines	17	31	B-group
DDI-DrugBank.d103.s4	and	33	35	O
DDI-DrugBank.d103.s4	Diuretics	37	45	B-group
DDI-DrugBank.d103.s4	:	46	46	O
DDI-DrugBank.d103.s4	Concomitant	48	58	O
DDI-DrugBank.d103.s4	treatment	60	68	O
DDI-DrugBank.d103.s4	with	70	73	O
DDI-DrugBank.d103.s4	xanthine	75	82	B-group
DDI-DrugBank.d103.s4	derivatives	84	94	I-group
DDI-DrugBank.d103.s4	,	95	95	O
DDI-DrugBank.d103.s4	steroids	97	104	B-group
DDI-DrugBank.d103.s4	,	105	105	O
DDI-DrugBank.d103.s4	or	107	108	O
DDI-DrugBank.d103.s4	diuretics	110	118	B-group
DDI-DrugBank.d103.s4	may	120	122	O
DDI-DrugBank.d103.s4	potentiate	124	133	O
DDI-DrugBank.d103.s4	a	121	121	O
DDI-DrugBank.d103.s4	possible	137	144	O
DDI-DrugBank.d103.s4	hypokalemic	146	156	O
DDI-DrugBank.d103.s4	effect	158	163	O
DDI-DrugBank.d103.s4	of	165	166	O
DDI-DrugBank.d103.s4	beta2-agonists	169	182	B-group
DDI-DrugBank.d103.s4	.	183	183	O
DDI-DrugBank.d103.s5	Hypokalemia	0	10	O
DDI-DrugBank.d103.s5	may	12	14	O
DDI-DrugBank.d103.s5	increase	16	23	O
DDI-DrugBank.d103.s5	susceptibility	25	38	O
DDI-DrugBank.d103.s5	to	40	41	O
DDI-DrugBank.d103.s5	cardiac	43	49	O
DDI-DrugBank.d103.s5	arrhythmias	51	61	O
DDI-DrugBank.d103.s5	in	63	64	O
DDI-DrugBank.d103.s5	patients	66	73	O
DDI-DrugBank.d103.s5	treated	75	81	O
DDI-DrugBank.d103.s5	with	83	86	O
DDI-DrugBank.d103.s5	digitalis	88	96	B-group
DDI-DrugBank.d103.s5	.	97	97	O
DDI-DrugBank.d103.s6	-adrenergic	0	10	O
DDI-DrugBank.d103.s6	Blockers	12	19	O
DDI-DrugBank.d103.s6	:	20	20	O
DDI-DrugBank.d103.s6	-adrenergic	23	33	O
DDI-DrugBank.d103.s6	blockers	35	42	O
DDI-DrugBank.d103.s6	may	44	46	O
DDI-DrugBank.d103.s6	weaken	48	53	O
DDI-DrugBank.d103.s6	or	55	56	O
DDI-DrugBank.d103.s6	antagonise	58	67	O
DDI-DrugBank.d103.s6	the	69	71	O
DDI-DrugBank.d103.s6	effect	73	78	O
DDI-DrugBank.d103.s6	of	80	81	O
DDI-DrugBank.d103.s6	FORADIL	83	89	B-brand
DDI-DrugBank.d103.s6	.	90	90	O
DDI-DrugBank.d103.s7	Therefore	0	8	O
DDI-DrugBank.d103.s7	FORADIL	10	16	B-brand
DDI-DrugBank.d103.s7	should	18	23	O
DDI-DrugBank.d103.s7	not	25	27	O
DDI-DrugBank.d103.s7	be	29	30	O
DDI-DrugBank.d103.s7	given	32	36	O
DDI-DrugBank.d103.s7	together	38	45	O
DDI-DrugBank.d103.s7	with	47	50	O
DDI-DrugBank.d103.s7	-adrenergic	53	63	O
DDI-DrugBank.d103.s7	blockers	65	72	O
DDI-DrugBank.d103.s7	(	74	74	O
DDI-DrugBank.d103.s7	including	75	83	O
DDI-DrugBank.d103.s7	eye	85	87	O
DDI-DrugBank.d103.s7	drops	89	93	O
DDI-DrugBank.d103.s7	)	94	94	O
DDI-DrugBank.d103.s7	unless	96	101	O
DDI-DrugBank.d103.s7	there	103	107	O
DDI-DrugBank.d103.s7	are	109	111	O
DDI-DrugBank.d103.s7	compelling	113	122	O
DDI-DrugBank.d103.s7	reasons	124	130	O
DDI-DrugBank.d103.s7	for	132	134	O
DDI-DrugBank.d103.s7	their	136	140	O
DDI-DrugBank.d103.s7	use	142	144	O
DDI-DrugBank.d103.s7	.	145	145	O
DDI-DrugBank.d103.s8	Other	0	4	O
DDI-DrugBank.d103.s8	Drugs	6	10	O
DDI-DrugBank.d103.s8	:	11	11	O
DDI-DrugBank.d103.s8	Drugs	12	16	O
DDI-DrugBank.d103.s8	such	18	21	O
DDI-DrugBank.d103.s8	as	23	24	O
DDI-DrugBank.d103.s8	quinidine	26	34	B-drug
DDI-DrugBank.d103.s8	,	35	35	O
DDI-DrugBank.d103.s8	disopyramide	37	48	B-drug
DDI-DrugBank.d103.s8	,	49	49	O
DDI-DrugBank.d103.s8	procainamide	51	62	B-drug
DDI-DrugBank.d103.s8	,	63	63	O
DDI-DrugBank.d103.s8	phenothiazines	65	78	B-group
DDI-DrugBank.d103.s8	,	79	79	O
DDI-DrugBank.d103.s8	antihistamines	81	94	B-group
DDI-DrugBank.d103.s8	,	95	95	O
DDI-DrugBank.d103.s8	and	97	99	O
DDI-DrugBank.d103.s8	tricyclic	101	109	B-group
DDI-DrugBank.d103.s8	antidepressants	111	125	I-group
DDI-DrugBank.d103.s8	may	127	129	O
DDI-DrugBank.d103.s8	be	131	132	O
DDI-DrugBank.d103.s8	associated	134	143	O
DDI-DrugBank.d103.s8	with	145	148	O
DDI-DrugBank.d103.s8	QT-interval	150	160	O
DDI-DrugBank.d103.s8	prolongation	162	173	O
DDI-DrugBank.d103.s8	and	175	177	O
DDI-DrugBank.d103.s8	an	175	176	O
DDI-DrugBank.d103.s8	increased	182	190	O
DDI-DrugBank.d103.s8	risk	192	195	O
DDI-DrugBank.d103.s8	of	197	198	O
DDI-DrugBank.d103.s8	ventricular	200	210	O
DDI-DrugBank.d103.s8	arrhythmia	212	221	O
DDI-DrugBank.d103.s8	.	222	222	O
DDI-DrugBank.d103.s9	INFORMATION	0	10	O
DDI-DrugBank.d103.s9	TO	12	13	O
DDI-DrugBank.d103.s9	BE	15	16	O
DDI-DrugBank.d103.s9	PROVIDED	18	25	O
DDI-DrugBank.d103.s9	TO	27	28	O
DDI-DrugBank.d103.s9	THE	30	32	O
DDI-DrugBank.d103.s9	PATIENT	34	40	O
DDI-DrugBank.d103.s9	OR	42	43	O
DDI-DrugBank.d103.s9	GUARDIAN	45	52	O
DDI-DrugBank.d103.s9	See	54	56	O
DDI-DrugBank.d103.s9	illustrated	58	68	O
DDI-DrugBank.d103.s9	Information	70	80	O
DDI-DrugBank.d103.s9	For	82	84	O
DDI-DrugBank.d103.s9	The	86	88	O
DDI-DrugBank.d103.s9	Patient	90	96	O
DDI-DrugBank.d103.s9	or	83	84	O
DDI-DrugBank.d103.s9	Guardian	101	108	O
DDI-DrugBank.d103.s9	section	110	116	O
DDI-DrugBank.d103.s9	.	117	117	O
DDI-DrugBank.d103.s10	It	0	1	O
DDI-DrugBank.d103.s10	is	3	4	O
DDI-DrugBank.d103.s10	important	6	14	O
DDI-DrugBank.d103.s10	that	16	19	O
DDI-DrugBank.d103.s10	patients	21	28	O
DDI-DrugBank.d103.s10	understand	30	39	O
DDI-DrugBank.d103.s10	how	41	43	O
DDI-DrugBank.d103.s10	to	45	46	O
DDI-DrugBank.d103.s10	use	48	50	O
DDI-DrugBank.d103.s10	FORADIL	52	58	B-brand
DDI-DrugBank.d103.s10	(	61	61	O
DDI-DrugBank.d103.s10	formoterol	62	71	B-drug
DDI-DrugBank.d103.s10	fumarate	73	80	I-drug
DDI-DrugBank.d103.s10	)	81	81	O
DDI-DrugBank.d103.s10	capsules	83	90	O
DDI-DrugBank.d103.s10	with	92	95	O
DDI-DrugBank.d103.s10	the	97	99	O
DDI-DrugBank.d103.s10	supplied	101	108	O
DDI-DrugBank.d103.s10	AerolizerTM	110	120	O
DDI-DrugBank.d103.s10	inhalation	122	131	O
DDI-DrugBank.d103.s10	device	133	138	O
DDI-DrugBank.d103.s10	and	140	142	O
DDI-DrugBank.d103.s10	how	144	146	O
DDI-DrugBank.d103.s10	it	148	149	O
DDI-DrugBank.d103.s10	should	151	156	O
DDI-DrugBank.d103.s10	be	158	159	O
DDI-DrugBank.d103.s10	used	161	164	O
DDI-DrugBank.d103.s10	in	166	167	O
DDI-DrugBank.d103.s10	relation	169	176	O
DDI-DrugBank.d103.s10	to	178	179	O
DDI-DrugBank.d103.s10	other	181	185	O
DDI-DrugBank.d103.s10	asthma	187	192	O
DDI-DrugBank.d103.s10	or	194	195	O
DDI-DrugBank.d103.s10	COPD	197	200	O
DDI-DrugBank.d103.s10	medications	202	212	O
DDI-DrugBank.d103.s10	they	214	217	O
DDI-DrugBank.d103.s10	are	219	221	O
DDI-DrugBank.d103.s10	taking	223	228	O
DDI-DrugBank.d103.s10	.	229	229	O
DDI-DrugBank.d103.s11	Patients/Guardians	0	17	O
DDI-DrugBank.d103.s11	should	19	24	O
DDI-DrugBank.d103.s11	be	26	27	O
DDI-DrugBank.d103.s11	given	29	33	O
DDI-DrugBank.d103.s11	the	35	37	O
DDI-DrugBank.d103.s11	following	39	47	O
DDI-DrugBank.d103.s11	information	49	59	O
DDI-DrugBank.d103.s11	:	60	60	O
DDI-DrugBank.d103.s11	i	57	57	O
DDI-DrugBank.d103.s11	.	63	63	O
DDI-DrugBank.d103.s12	The	0	2	O
DDI-DrugBank.d103.s12	recommended	4	14	O
DDI-DrugBank.d103.s12	dosage	16	21	O
DDI-DrugBank.d103.s12	(	23	23	O
DDI-DrugBank.d103.s12	one	24	26	O
DDI-DrugBank.d103.s12	or	28	29	O
DDI-DrugBank.d103.s12	two	31	33	O
DDI-DrugBank.d103.s12	capsules	35	42	O
DDI-DrugBank.d103.s12	twice	44	48	O
DDI-DrugBank.d103.s12	daily	50	54	O
DDI-DrugBank.d103.s12	,	55	55	O
DDI-DrugBank.d103.s12	morning	57	63	O
DDI-DrugBank.d103.s12	and	65	67	O
DDI-DrugBank.d103.s12	evening	69	75	O
DDI-DrugBank.d103.s12	)	76	76	O
DDI-DrugBank.d103.s12	should	78	83	O
DDI-DrugBank.d103.s12	not	85	87	O
DDI-DrugBank.d103.s12	be	89	90	O
DDI-DrugBank.d103.s12	exceeded	92	99	O
DDI-DrugBank.d103.s12	.	100	100	O
DDI-DrugBank.d103.s13	ii	0	1	O
DDI-DrugBank.d103.s13	.	2	2	O
DDI-DrugBank.d103.s14	FORADIL	0	6	B-brand
DDI-DrugBank.d103.s14	is	8	9	O
DDI-DrugBank.d103.s14	not	11	13	O
DDI-DrugBank.d103.s14	meant	15	19	O
DDI-DrugBank.d103.s14	to	21	22	O
DDI-DrugBank.d103.s14	relieve	24	30	O
DDI-DrugBank.d103.s14	acute	32	36	O
DDI-DrugBank.d103.s14	asthma	38	43	O
DDI-DrugBank.d103.s14	or	45	46	O
DDI-DrugBank.d103.s14	COPD	48	51	O
DDI-DrugBank.d103.s14	symptoms	53	60	O
DDI-DrugBank.d103.s14	and	62	64	O
DDI-DrugBank.d103.s14	extra	66	70	O
DDI-DrugBank.d103.s14	doses	72	76	O
DDI-DrugBank.d103.s14	should	78	83	O
DDI-DrugBank.d103.s14	not	85	87	O
DDI-DrugBank.d103.s14	be	89	90	O
DDI-DrugBank.d103.s14	used	92	95	O
DDI-DrugBank.d103.s14	for	97	99	O
DDI-DrugBank.d103.s14	that	101	104	O
DDI-DrugBank.d103.s14	purpose	106	112	O
DDI-DrugBank.d103.s14	.	113	113	O
DDI-DrugBank.d103.s15	Acute	0	4	O
DDI-DrugBank.d103.s15	symptoms	6	13	O
DDI-DrugBank.d103.s15	should	15	20	O
DDI-DrugBank.d103.s15	be	22	23	O
DDI-DrugBank.d103.s15	treated	25	31	O
DDI-DrugBank.d103.s15	with	33	36	O
DDI-DrugBank.d103.s15	a	38	38	O
DDI-DrugBank.d103.s15	short-acting	40	51	O
DDI-DrugBank.d103.s15	,	52	52	O
DDI-DrugBank.d103.s15	inhaled	54	60	O
DDI-DrugBank.d103.s15	beta2-agonist	63	75	B-group
DDI-DrugBank.d103.s15	such	77	80	O
DDI-DrugBank.d103.s15	as	82	83	O
DDI-DrugBank.d103.s15	salbutamol	85	94	B-drug
DDI-DrugBank.d103.s15	(	96	96	O
DDI-DrugBank.d103.s15	the	97	99	O
DDI-DrugBank.d103.s15	physician	101	109	O
DDI-DrugBank.d103.s15	should	111	116	O
DDI-DrugBank.d103.s15	provide	118	124	O
DDI-DrugBank.d103.s15	the	126	128	O
DDI-DrugBank.d103.s15	patient	130	136	O
DDI-DrugBank.d103.s15	with	138	141	O
DDI-DrugBank.d103.s15	such	143	146	O
DDI-DrugBank.d103.s15	medication	148	157	O
DDI-DrugBank.d103.s15	and	159	161	O
DDI-DrugBank.d103.s15	instruct	163	170	O
DDI-DrugBank.d103.s15	the	172	174	O
DDI-DrugBank.d103.s15	patient	176	182	O
DDI-DrugBank.d103.s15	in	163	164	O
DDI-DrugBank.d103.s15	how	187	189	O
DDI-DrugBank.d103.s15	it	191	192	O
DDI-DrugBank.d103.s15	should	194	199	O
DDI-DrugBank.d103.s15	be	201	202	O
DDI-DrugBank.d103.s15	used	204	207	O
DDI-DrugBank.d103.s15	)	208	208	O
DDI-DrugBank.d103.s15	.	209	209	O
DDI-DrugBank.d103.s16	iii	0	2	O
DDI-DrugBank.d103.s16	.	3	3	O
DDI-DrugBank.d103.s17	The	0	2	O
DDI-DrugBank.d103.s17	physician	4	12	O
DDI-DrugBank.d103.s17	should	14	19	O
DDI-DrugBank.d103.s17	be	21	22	O
DDI-DrugBank.d103.s17	notified	24	31	O
DDI-DrugBank.d103.s17	immediately	33	43	O
DDI-DrugBank.d103.s17	if	45	46	O
DDI-DrugBank.d103.s17	any	48	50	O
DDI-DrugBank.d103.s17	of	52	53	O
DDI-DrugBank.d103.s17	the	55	57	O
DDI-DrugBank.d103.s17	following	59	67	O
DDI-DrugBank.d103.s17	situations	69	78	O
DDI-DrugBank.d103.s17	occur	80	84	O
DDI-DrugBank.d103.s17	,	85	85	O
DDI-DrugBank.d103.s17	which	87	91	O
DDI-DrugBank.d103.s17	may	93	95	O
DDI-DrugBank.d103.s17	be	97	98	O
DDI-DrugBank.d103.s17	a	94	94	O
DDI-DrugBank.d103.s17	sign	102	105	O
DDI-DrugBank.d103.s17	of	107	108	O
DDI-DrugBank.d103.s17	seriously	110	118	O
DDI-DrugBank.d103.s17	worsening	120	128	O
DDI-DrugBank.d103.s17	asthma	130	135	O
DDI-DrugBank.d103.s17	:	136	136	O
DDI-DrugBank.d103.s17	Decreased	140	148	O
DDI-DrugBank.d103.s17	effectiveness	150	162	O
DDI-DrugBank.d103.s17	of	164	165	O
DDI-DrugBank.d103.s17	short-acting	167	178	B-group
DDI-DrugBank.d103.s17	,	179	179	O
DDI-DrugBank.d103.s17	inhaled	181	187	I-group
DDI-DrugBank.d103.s17	beta2-agonists	189	202	I-group
DDI-DrugBank.d103.s17	;	203	203	O
DDI-DrugBank.d103.s18	Need	0	3	O
DDI-DrugBank.d103.s18	for	5	7	O
DDI-DrugBank.d103.s18	more	9	12	O
DDI-DrugBank.d103.s18	inhalations	14	24	O
DDI-DrugBank.d103.s18	than	26	29	O
DDI-DrugBank.d103.s18	usual	31	35	O
DDI-DrugBank.d103.s18	of	37	38	O
DDI-DrugBank.d103.s18	short-acting	40	51	B-group
DDI-DrugBank.d103.s18	,	52	52	O
DDI-DrugBank.d103.s18	inhaled	54	60	I-group
DDI-DrugBank.d103.s18	beta2-agonists	62	75	I-group
DDI-DrugBank.d103.s18	.	76	76	O
DDI-DrugBank.d103.s19	iv	0	1	O
DDI-DrugBank.d103.s19	.	2	2	O
DDI-DrugBank.d103.s20	FORADIL	0	6	B-brand
DDI-DrugBank.d103.s20	should	8	13	O
DDI-DrugBank.d103.s20	not	15	17	O
DDI-DrugBank.d103.s20	be	19	20	O
DDI-DrugBank.d103.s20	used	22	25	O
DDI-DrugBank.d103.s20	as	27	28	O
DDI-DrugBank.d103.s20	a	27	27	O
DDI-DrugBank.d103.s20	substitute	32	41	O
DDI-DrugBank.d103.s20	for	43	45	O
DDI-DrugBank.d103.s20	oral	47	50	O
DDI-DrugBank.d103.s20	or	44	45	O
DDI-DrugBank.d103.s20	inhaled	55	61	O
DDI-DrugBank.d103.s20	corticosteroids	63	77	B-group
DDI-DrugBank.d103.s20	.	78	78	O
DDI-DrugBank.d103.s21	The	0	2	O
DDI-DrugBank.d103.s21	dosage	4	9	O
DDI-DrugBank.d103.s21	of	11	12	O
DDI-DrugBank.d103.s21	these	14	18	O
DDI-DrugBank.d103.s21	medications	20	30	O
DDI-DrugBank.d103.s21	should	32	37	O
DDI-DrugBank.d103.s21	not	39	41	O
DDI-DrugBank.d103.s21	be	43	44	O
DDI-DrugBank.d103.s21	changed	46	52	O
DDI-DrugBank.d103.s21	and	54	56	O
DDI-DrugBank.d103.s21	they	58	61	O
DDI-DrugBank.d103.s21	should	63	68	O
DDI-DrugBank.d103.s21	not	70	72	O
DDI-DrugBank.d103.s21	be	74	75	O
DDI-DrugBank.d103.s21	stopped	77	83	O
DDI-DrugBank.d103.s21	without	85	91	O
DDI-DrugBank.d103.s21	consulting	93	102	O
DDI-DrugBank.d103.s21	the	104	106	O
DDI-DrugBank.d103.s21	physician	108	116	O
DDI-DrugBank.d103.s21	,	117	117	O
DDI-DrugBank.d103.s21	even	119	122	O
DDI-DrugBank.d103.s21	if	124	125	O
DDI-DrugBank.d103.s21	the	127	129	O
DDI-DrugBank.d103.s21	patient	131	137	O
DDI-DrugBank.d103.s21	feels	139	143	O
DDI-DrugBank.d103.s21	better	145	150	O
DDI-DrugBank.d103.s21	after	152	156	O
DDI-DrugBank.d103.s21	initiating	158	167	O
DDI-DrugBank.d103.s21	treatment	169	177	O
DDI-DrugBank.d103.s21	with	179	182	O
DDI-DrugBank.d103.s21	FORADIL	184	190	B-brand
DDI-DrugBank.d103.s21	.	191	191	O
DDI-DrugBank.d103.s22	v.	0	1	O
DDI-DrugBank.d103.s22	Patients	3	10	O
DDI-DrugBank.d103.s22	should	12	17	O
DDI-DrugBank.d103.s22	be	19	20	O
DDI-DrugBank.d103.s22	cautioned	22	30	O
DDI-DrugBank.d103.s22	regarding	32	40	O
DDI-DrugBank.d103.s22	potential	42	50	O
DDI-DrugBank.d103.s22	adverse	52	58	O
DDI-DrugBank.d103.s22	cardiovascular	60	73	O
DDI-DrugBank.d103.s22	effects	75	81	O
DDI-DrugBank.d103.s22	,	82	82	O
DDI-DrugBank.d103.s22	such	84	87	O
DDI-DrugBank.d103.s22	as	89	90	O
DDI-DrugBank.d103.s22	palpitations	92	103	O
DDI-DrugBank.d103.s22	or	105	106	O
DDI-DrugBank.d103.s22	chest	108	112	O
DDI-DrugBank.d103.s22	pain	114	117	O
DDI-DrugBank.d103.s22	.	118	118	O
DDI-DrugBank.d103.s23	vi	0	1	O
DDI-DrugBank.d103.s23	.	2	2	O
DDI-DrugBank.d103.s24	In	0	1	O
DDI-DrugBank.d103.s24	patients	3	10	O
DDI-DrugBank.d103.s24	receiving	12	20	O
DDI-DrugBank.d103.s24	FORADIL	22	28	B-brand
DDI-DrugBank.d103.s24	,	29	29	O
DDI-DrugBank.d103.s24	other	31	35	O
DDI-DrugBank.d103.s24	inhaled	37	43	O
DDI-DrugBank.d103.s24	medications	45	55	O
DDI-DrugBank.d103.s24	should	57	62	O
DDI-DrugBank.d103.s24	be	64	65	O
DDI-DrugBank.d103.s24	used	67	70	O
DDI-DrugBank.d103.s24	only	72	75	O
DDI-DrugBank.d103.s24	as	77	78	O
DDI-DrugBank.d103.s24	directed	80	87	O
DDI-DrugBank.d103.s24	by	89	90	O
DDI-DrugBank.d103.s24	the	92	94	O
DDI-DrugBank.d103.s24	physician	96	104	O
DDI-DrugBank.d103.s24	.	105	105	O
DDI-DrugBank.d103.s25	vii	0	2	O
DDI-DrugBank.d103.s25	.	3	3	O
DDI-DrugBank.d103.s26	Guardians	0	8	O
DDI-DrugBank.d103.s26	of	10	11	O
DDI-DrugBank.d103.s26	children	13	20	O
DDI-DrugBank.d103.s26	who	22	24	O
DDI-DrugBank.d103.s26	have	26	29	O
DDI-DrugBank.d103.s26	been	31	34	O
DDI-DrugBank.d103.s26	prescribed	36	45	O
DDI-DrugBank.d103.s26	FORADIL	47	53	B-brand
DDI-DrugBank.d103.s26	should	55	60	O
DDI-DrugBank.d103.s26	be	62	63	O
DDI-DrugBank.d103.s26	alerted	65	71	O
DDI-DrugBank.d103.s26	to	73	74	O
DDI-DrugBank.d103.s26	the	76	78	O
DDI-DrugBank.d103.s26	general	80	86	O
DDI-DrugBank.d103.s26	concern	88	94	O
DDI-DrugBank.d103.s26	regarding	96	104	O
DDI-DrugBank.d103.s26	asthma	106	111	O
DDI-DrugBank.d103.s26	therapy	113	119	O
DDI-DrugBank.d103.s26	compliance	121	130	O
DDI-DrugBank.d103.s26	,	131	131	O
DDI-DrugBank.d103.s26	especially	133	142	O
DDI-DrugBank.d103.s26	neglect	144	150	O
DDI-DrugBank.d103.s26	of	152	153	O
DDI-DrugBank.d103.s26	anti-inflammatory	155	171	O
DDI-DrugBank.d103.s26	therapy	173	179	O
DDI-DrugBank.d103.s26	and	181	183	O
DDI-DrugBank.d103.s26	overuse	185	191	O
DDI-DrugBank.d103.s26	of	193	194	O
DDI-DrugBank.d103.s26	short-acting	196	207	B-group
DDI-DrugBank.d103.s26	beta2-agonists	210	223	I-group
DDI-DrugBank.d103.s26	.	224	224	O
DDI-MedLine.d11.s0	Immunosuppressive	0	16	B-group
DDI-MedLine.d11.s0	drugs	18	22	I-group
DDI-MedLine.d11.s0	and	24	26	O
DDI-MedLine.d11.s0	their	28	32	O
DDI-MedLine.d11.s0	complications	34	46	O
DDI-MedLine.d11.s0	.	47	47	O
DDI-MedLine.d11.s1	Drugs	0	4	O
DDI-MedLine.d11.s1	that	6	9	O
DDI-MedLine.d11.s1	suppress	11	18	O
DDI-MedLine.d11.s1	the	20	22	O
DDI-MedLine.d11.s1	immune	24	29	O
DDI-MedLine.d11.s1	system	31	36	O
DDI-MedLine.d11.s1	are	38	40	O
DDI-MedLine.d11.s1	widely	42	47	O
DDI-MedLine.d11.s1	used	49	52	O
DDI-MedLine.d11.s1	.	53	53	O
DDI-MedLine.d11.s2	They	0	3	O
DDI-MedLine.d11.s2	are	5	7	O
DDI-MedLine.d11.s2	part	9	12	O
DDI-MedLine.d11.s2	of	14	15	O
DDI-MedLine.d11.s2	the	17	19	O
DDI-MedLine.d11.s2	treatment	21	29	O
DDI-MedLine.d11.s2	of	31	32	O
DDI-MedLine.d11.s2	patients	34	41	O
DDI-MedLine.d11.s2	with	43	46	O
DDI-MedLine.d11.s2	organ	48	52	O
DDI-MedLine.d11.s2	transplants	54	64	O
DDI-MedLine.d11.s2	,	65	65	O
DDI-MedLine.d11.s2	malignancy	67	76	O
DDI-MedLine.d11.s2	,	77	77	O
DDI-MedLine.d11.s2	and	79	81	O
DDI-MedLine.d11.s2	increasingly	83	94	O
DDI-MedLine.d11.s2	those	96	100	O
DDI-MedLine.d11.s2	with	102	105	O
DDI-MedLine.d11.s2	conditions	107	116	O
DDI-MedLine.d11.s2	such	118	121	O
DDI-MedLine.d11.s2	as	123	124	O
DDI-MedLine.d11.s2	psoriasis	126	134	O
DDI-MedLine.d11.s2	,	135	135	O
DDI-MedLine.d11.s2	rheumatoid	137	146	O
DDI-MedLine.d11.s2	arthritis	148	156	O
DDI-MedLine.d11.s2	,	157	157	O
DDI-MedLine.d11.s2	and	159	161	O
DDI-MedLine.d11.s2	liver	163	167	O
DDI-MedLine.d11.s2	and	159	161	O
DDI-MedLine.d11.s2	bowel	173	177	O
DDI-MedLine.d11.s2	disease	179	185	O
DDI-MedLine.d11.s2	in	187	188	O
DDI-MedLine.d11.s2	which	190	194	O
DDI-MedLine.d11.s2	inflammation	196	207	O
DDI-MedLine.d11.s2	is	180	181	O
DDI-MedLine.d11.s2	an	212	213	O
DDI-MedLine.d11.s2	aetiological	215	226	O
DDI-MedLine.d11.s2	factor	228	233	O
DDI-MedLine.d11.s2	.	234	234	O
DDI-MedLine.d11.s3	Because	0	6	O
DDI-MedLine.d11.s3	of	8	9	O
DDI-MedLine.d11.s3	the	11	13	O
DDI-MedLine.d11.s3	broadening	15	24	O
DDI-MedLine.d11.s3	indications	26	36	O
DDI-MedLine.d11.s3	for	38	40	O
DDI-MedLine.d11.s3	immunosuppressive	42	58	B-group
DDI-MedLine.d11.s3	drugs	60	64	I-group
DDI-MedLine.d11.s3	,	65	65	O
DDI-MedLine.d11.s3	and	67	69	O
DDI-MedLine.d11.s3	the	71	73	O
DDI-MedLine.d11.s3	prolonged	75	83	O
DDI-MedLine.d11.s3	survival	85	92	O
DDI-MedLine.d11.s3	in	94	95	O
DDI-MedLine.d11.s3	conditions	97	106	O
DDI-MedLine.d11.s3	for	108	110	O
DDI-MedLine.d11.s3	which	112	116	O
DDI-MedLine.d11.s3	they	118	121	O
DDI-MedLine.d11.s3	are	123	125	O
DDI-MedLine.d11.s3	being	127	131	O
DDI-MedLine.d11.s3	used	133	136	O
DDI-MedLine.d11.s3	,	137	137	O
DDI-MedLine.d11.s3	many	139	142	O
DDI-MedLine.d11.s3	patients	144	151	O
DDI-MedLine.d11.s3	on	153	154	O
DDI-MedLine.d11.s3	immunosuppression	156	172	O
DDI-MedLine.d11.s3	are	174	176	O
DDI-MedLine.d11.s3	now	178	180	O
DDI-MedLine.d11.s3	cared	182	186	O
DDI-MedLine.d11.s3	for	188	190	O
DDI-MedLine.d11.s3	in	192	193	O
DDI-MedLine.d11.s3	the	195	197	O
DDI-MedLine.d11.s3	community	199	207	O
DDI-MedLine.d11.s3	or	189	190	O
DDI-MedLine.d11.s3	seen	212	215	O
DDI-MedLine.d11.s3	in	192	193	O
DDI-MedLine.d11.s3	non-specialist	220	233	O
DDI-MedLine.d11.s3	hospitals	235	243	O
DDI-MedLine.d11.s3	,	244	244	O
DDI-MedLine.d11.s3	usually	246	252	O
DDI-MedLine.d11.s3	in	217	218	O
DDI-MedLine.d11.s3	close	257	261	O
DDI-MedLine.d11.s3	collaboration	263	275	O
DDI-MedLine.d11.s3	with	277	280	O
DDI-MedLine.d11.s3	a	241	241	O
DDI-MedLine.d11.s3	specialist	284	293	O
DDI-MedLine.d11.s3	.	294	294	O
DDI-MedLine.d11.s4	This	0	3	O
DDI-MedLine.d11.s4	article	5	11	O
DDI-MedLine.d11.s4	looks	13	17	O
DDI-MedLine.d11.s4	at	19	20	O
DDI-MedLine.d11.s4	five	22	25	O
DDI-MedLine.d11.s4	commonly	27	34	O
DDI-MedLine.d11.s4	used	36	39	O
DDI-MedLine.d11.s4	immunosuppressive	41	57	B-group
DDI-MedLine.d11.s4	drugs	59	63	I-group
DDI-MedLine.d11.s4	in	65	66	O
DDI-MedLine.d11.s4	turn	68	71	O
DDI-MedLine.d11.s4	(	73	73	O
DDI-MedLine.d11.s4	corticosteroids	74	88	B-group
DDI-MedLine.d11.s4	,	89	89	O
DDI-MedLine.d11.s4	cyclosporin	91	101	B-drug
DDI-MedLine.d11.s4	,	102	102	O
DDI-MedLine.d11.s4	azathioprine	104	115	B-drug
DDI-MedLine.d11.s4	,	116	116	O
DDI-MedLine.d11.s4	methotrexate	118	129	B-drug
DDI-MedLine.d11.s4	,	116	116	O
DDI-MedLine.d11.s4	cyclophosphamide	132	147	B-drug
DDI-MedLine.d11.s4	)	148	148	O
DDI-MedLine.d11.s4	,	149	149	O
DDI-MedLine.d11.s4	discussing	151	160	O
DDI-MedLine.d11.s4	the	162	164	O
DDI-MedLine.d11.s4	main	166	169	O
DDI-MedLine.d11.s4	,	170	170	O
DDI-MedLine.d11.s4	non-infection	172	184	O
DDI-MedLine.d11.s4	,	170	170	O
DDI-MedLine.d11.s4	unwanted	187	194	O
DDI-MedLine.d11.s4	effects	196	202	O
DDI-MedLine.d11.s4	,	185	185	O
DDI-MedLine.d11.s4	ways	205	208	O
DDI-MedLine.d11.s4	to	210	211	O
DDI-MedLine.d11.s4	avoid	213	217	O
DDI-MedLine.d11.s4	them	219	222	O
DDI-MedLine.d11.s4	and	224	226	O
DDI-MedLine.d11.s4	what	228	231	O
DDI-MedLine.d11.s4	to	210	211	O
DDI-MedLine.d11.s4	do	236	237	O
DDI-MedLine.d11.s4	if	239	240	O
DDI-MedLine.d11.s4	problems	242	249	O
DDI-MedLine.d11.s4	arise	251	255	O
DDI-MedLine.d11.s4	.	256	256	O
DDI-MedLine.d11.s5	The	0	2	O
DDI-MedLine.d11.s5	management	4	13	O
DDI-MedLine.d11.s5	of	15	16	O
DDI-MedLine.d11.s5	infection	18	26	O
DDI-MedLine.d11.s5	is	28	29	O
DDI-MedLine.d11.s5	dealt	31	35	O
DDI-MedLine.d11.s5	with	37	40	O
DDI-MedLine.d11.s5	as	42	43	O
DDI-MedLine.d11.s5	a	42	42	O
DDI-MedLine.d11.s5	separate	47	54	O
DDI-MedLine.d11.s5	section	56	62	O
DDI-MedLine.d11.s5	.	63	63	O
DDI-DrugBank.d102.s0	No	0	1	O
DDI-DrugBank.d102.s0	information	3	13	O
DDI-DrugBank.d102.s0	provided	15	22	O
DDI-DrugBank.d585.s0	The	0	2	O
DDI-DrugBank.d585.s0	following	4	12	O
DDI-DrugBank.d585.s0	agents	14	19	O
DDI-DrugBank.d585.s0	may	21	23	O
DDI-DrugBank.d585.s0	increase	25	32	O
DDI-DrugBank.d585.s0	certain	34	40	O
DDI-DrugBank.d585.s0	actions	42	48	O
DDI-DrugBank.d585.s0	or	50	51	O
DDI-DrugBank.d585.s0	side	53	56	O
DDI-DrugBank.d585.s0	effects	58	64	O
DDI-DrugBank.d585.s0	of	66	67	O
DDI-DrugBank.d585.s0	anticholinergic	69	83	B-group
DDI-DrugBank.d585.s0	drugs	85	89	I-group
DDI-DrugBank.d585.s0	:	90	90	O
DDI-DrugBank.d585.s0	amantadine	92	101	B-drug
DDI-DrugBank.d585.s0	,	102	102	O
DDI-DrugBank.d585.s0	antiarrhythmic	104	117	B-group
DDI-DrugBank.d585.s0	agents	119	124	I-group
DDI-DrugBank.d585.s0	of	126	127	I-group
DDI-DrugBank.d585.s0	class	129	133	I-group
DDI-DrugBank.d585.s0	I	135	135	O
DDI-DrugBank.d585.s0	(	137	137	O
DDI-DrugBank.d585.s0	e.g.	138	141	O
DDI-DrugBank.d585.s0	,	142	142	O
DDI-DrugBank.d585.s0	quinidine	144	152	B-drug
DDI-DrugBank.d585.s0	)	153	153	O
DDI-DrugBank.d585.s0	,	142	142	O
DDI-DrugBank.d585.s0	antihistamines	156	169	B-group
DDI-DrugBank.d585.s0	,	154	154	O
DDI-DrugBank.d585.s0	antipsychotic	172	184	B-group
DDI-DrugBank.d585.s0	agents	186	191	I-group
DDI-DrugBank.d585.s0	(	193	193	O
DDI-DrugBank.d585.s0	e.g.	194	197	O
DDI-DrugBank.d585.s0	,	198	198	O
DDI-DrugBank.d585.s0	phenothiazines	200	213	B-group
DDI-DrugBank.d585.s0	)	214	214	O
DDI-DrugBank.d585.s0	,	198	198	O
DDI-DrugBank.d585.s0	benzodiazepines	217	231	B-group
DDI-DrugBank.d585.s0	,	215	215	O
DDI-DrugBank.d585.s0	MAO	234	236	B-group
DDI-DrugBank.d585.s0	inhibitors	238	247	I-group
DDI-DrugBank.d585.s0	,	232	232	O
DDI-DrugBank.d585.s0	narcotic	250	257	B-group
DDI-DrugBank.d585.s0	analgesics	259	268	I-group
DDI-DrugBank.d585.s0	(	270	270	O
DDI-DrugBank.d585.s0	e.g.	271	274	O
DDI-DrugBank.d585.s0	,	248	248	O
DDI-DrugBank.d585.s0	meperidine	277	286	B-drug
DDI-DrugBank.d585.s0	)	287	287	O
DDI-DrugBank.d585.s0	,	275	275	O
DDI-DrugBank.d585.s0	nitrates	290	297	B-group
DDI-DrugBank.d585.s0	and	299	301	O
DDI-DrugBank.d585.s0	nitrites	303	310	B-group
DDI-DrugBank.d585.s0	,	288	288	O
DDI-DrugBank.d585.s0	sympathomimetic	313	327	B-group
DDI-DrugBank.d585.s0	agents	329	334	I-group
DDI-DrugBank.d585.s0	,	311	311	O
DDI-DrugBank.d585.s0	tricyclic	337	345	B-group
DDI-DrugBank.d585.s0	antidepressants	347	361	I-group
DDI-DrugBank.d585.s0	,	335	335	O
DDI-DrugBank.d585.s0	and	364	366	O
DDI-DrugBank.d585.s0	other	368	372	O
DDI-DrugBank.d585.s0	drugs	374	378	O
DDI-DrugBank.d585.s0	having	380	385	O
DDI-DrugBank.d585.s0	anticholinergic	387	401	O
DDI-DrugBank.d585.s0	activity	403	410	O
DDI-DrugBank.d585.s0	.	411	411	O
DDI-DrugBank.d585.s1	Anticholinergics	0	15	B-group
DDI-DrugBank.d585.s1	antagonize	17	26	O
DDI-DrugBank.d585.s1	the	28	30	O
DDI-DrugBank.d585.s1	effects	32	38	O
DDI-DrugBank.d585.s1	of	40	41	O
DDI-DrugBank.d585.s1	antiglaucoma	43	54	B-group
DDI-DrugBank.d585.s1	agents	56	61	I-group
DDI-DrugBank.d585.s1	.	62	62	O
DDI-DrugBank.d585.s2	Anticholinergic	0	14	B-group
DDI-DrugBank.d585.s2	drugs	16	20	I-group
DDI-DrugBank.d585.s2	in	22	23	O
DDI-DrugBank.d585.s2	the	25	27	O
DDI-DrugBank.d585.s2	presence	29	36	O
DDI-DrugBank.d585.s2	of	38	39	O
DDI-DrugBank.d585.s2	increased	41	49	O
DDI-DrugBank.d585.s2	intraocular	51	61	O
DDI-DrugBank.d585.s2	pressure	63	70	O
DDI-DrugBank.d585.s2	may	72	74	O
DDI-DrugBank.d585.s2	be	76	77	O
DDI-DrugBank.d585.s2	hazardous	79	87	O
DDI-DrugBank.d585.s2	when	89	92	O
DDI-DrugBank.d585.s2	taken	94	98	O
DDI-DrugBank.d585.s2	concurrently	100	111	O
DDI-DrugBank.d585.s2	with	113	116	O
DDI-DrugBank.d585.s2	agents	118	123	O
DDI-DrugBank.d585.s2	such	125	128	O
DDI-DrugBank.d585.s2	as	130	131	O
DDI-DrugBank.d585.s2	corticosteroids	133	147	B-group
DDI-DrugBank.d585.s2	.	148	148	O
DDI-DrugBank.d585.s3	Anticholinergic	0	14	B-group
DDI-DrugBank.d585.s3	agents	16	21	I-group
DDI-DrugBank.d585.s3	may	23	25	O
DDI-DrugBank.d585.s3	affect	27	32	O
DDI-DrugBank.d585.s3	gastrointestinal	34	49	O
DDI-DrugBank.d585.s3	absorption	51	60	O
DDI-DrugBank.d585.s3	of	62	63	O
DDI-DrugBank.d585.s3	various	65	71	O
DDI-DrugBank.d585.s3	drugs	73	77	O
DDI-DrugBank.d585.s3	,	78	78	O
DDI-DrugBank.d585.s3	such	80	83	O
DDI-DrugBank.d585.s3	as	85	86	O
DDI-DrugBank.d585.s3	slowly	88	93	O
DDI-DrugBank.d585.s3	dissolving	95	104	O
DDI-DrugBank.d585.s3	dosage	106	111	O
DDI-DrugBank.d585.s3	forms	113	117	O
DDI-DrugBank.d585.s3	of	119	120	O
DDI-DrugBank.d585.s3	digoxin	122	128	B-drug
DDI-DrugBank.d585.s3	;	129	129	O
DDI-DrugBank.d585.s4	increased	0	8	O
DDI-DrugBank.d585.s4	serum	10	14	O
DDI-DrugBank.d585.s4	digoxin	16	22	B-drug
DDI-DrugBank.d585.s4	concentrations	24	37	O
DDI-DrugBank.d585.s4	may	39	41	O
DDI-DrugBank.d585.s4	result	43	48	O
DDI-DrugBank.d585.s4	.	49	49	O
DDI-DrugBank.d585.s5	Anticholinergic	0	14	B-group
DDI-DrugBank.d585.s5	drugs	16	20	I-group
DDI-DrugBank.d585.s5	may	22	24	O
DDI-DrugBank.d585.s5	antagonize	26	35	O
DDI-DrugBank.d585.s5	the	37	39	O
DDI-DrugBank.d585.s5	effects	41	47	O
DDI-DrugBank.d585.s5	of	49	50	O
DDI-DrugBank.d585.s5	drugs	52	56	O
DDI-DrugBank.d585.s5	that	58	61	O
DDI-DrugBank.d585.s5	alter	63	67	O
DDI-DrugBank.d585.s5	gastrointestinal	69	84	O
DDI-DrugBank.d585.s5	motility	86	93	O
DDI-DrugBank.d585.s5	,	94	94	O
DDI-DrugBank.d585.s5	such	96	99	O
DDI-DrugBank.d585.s5	as	101	102	O
DDI-DrugBank.d585.s5	metoclopramide	104	117	B-drug
DDI-DrugBank.d585.s5	.	118	118	O
DDI-DrugBank.d585.s6	Because	0	6	O
DDI-DrugBank.d585.s6	antacids	8	15	B-group
DDI-DrugBank.d585.s6	may	17	19	O
DDI-DrugBank.d585.s6	interfere	21	29	O
DDI-DrugBank.d585.s6	with	31	34	O
DDI-DrugBank.d585.s6	the	36	38	O
DDI-DrugBank.d585.s6	absorption	40	49	O
DDI-DrugBank.d585.s6	of	51	52	O
DDI-DrugBank.d585.s6	anticholinergic	54	68	B-group
DDI-DrugBank.d585.s6	agents	70	75	I-group
DDI-DrugBank.d585.s6	,	76	76	O
DDI-DrugBank.d585.s6	simultaneous	78	89	O
DDI-DrugBank.d585.s6	use	91	93	O
DDI-DrugBank.d585.s6	of	95	96	O
DDI-DrugBank.d585.s6	these	98	102	O
DDI-DrugBank.d585.s6	drugs	104	108	O
DDI-DrugBank.d585.s6	should	110	115	O
DDI-DrugBank.d585.s6	be	117	118	O
DDI-DrugBank.d585.s6	avoided	120	126	O
DDI-DrugBank.d585.s6	.	127	127	O
DDI-DrugBank.d585.s7	The	0	2	O
DDI-DrugBank.d585.s7	inhibiting	4	13	O
DDI-DrugBank.d585.s7	effects	15	21	O
DDI-DrugBank.d585.s7	of	23	24	O
DDI-DrugBank.d585.s7	anticholinergic	26	40	B-group
DDI-DrugBank.d585.s7	drugs	42	46	I-group
DDI-DrugBank.d585.s7	on	48	49	O
DDI-DrugBank.d585.s7	gastric	51	57	O
DDI-DrugBank.d585.s7	hydrochloric	59	70	O
DDI-DrugBank.d585.s7	acid	72	75	O
DDI-DrugBank.d585.s7	secretion	77	85	O
DDI-DrugBank.d585.s7	are	87	89	O
DDI-DrugBank.d585.s7	antagonized	91	101	O
DDI-DrugBank.d585.s7	by	103	104	O
DDI-DrugBank.d585.s7	agents	106	111	O
DDI-DrugBank.d585.s7	used	113	116	O
DDI-DrugBank.d585.s7	to	118	119	O
DDI-DrugBank.d585.s7	treat	121	125	O
DDI-DrugBank.d585.s7	achlorhydria	127	138	O
DDI-DrugBank.d585.s7	and	140	142	O
DDI-DrugBank.d585.s7	those	144	148	O
DDI-DrugBank.d585.s7	used	150	153	O
DDI-DrugBank.d585.s7	to	155	156	O
DDI-DrugBank.d585.s7	test	158	161	O
DDI-DrugBank.d585.s7	gastric	163	169	O
DDI-DrugBank.d585.s7	secretion	171	179	O
DDI-DrugBank.d585.s7	.	180	180	O
DDI-DrugBank.d591.s0	Ropivacaine	0	10	B-drug
DDI-DrugBank.d591.s0	should	12	17	O
DDI-DrugBank.d591.s0	be	19	20	O
DDI-DrugBank.d591.s0	used	22	25	O
DDI-DrugBank.d591.s0	with	27	30	O
DDI-DrugBank.d591.s0	caution	32	38	O
DDI-DrugBank.d591.s0	in	40	41	O
DDI-DrugBank.d591.s0	patients	43	50	O
DDI-DrugBank.d591.s0	receiving	52	60	O
DDI-DrugBank.d591.s0	other	62	66	O
DDI-DrugBank.d591.s0	local	68	72	O
DDI-DrugBank.d591.s0	anesthetics	74	84	B-group
DDI-DrugBank.d591.s0	or	86	87	O
DDI-DrugBank.d591.s0	agents	89	94	O
DDI-DrugBank.d591.s0	structurally	96	107	O
DDI-DrugBank.d591.s0	related	109	115	O
DDI-DrugBank.d591.s0	to	117	118	O
DDI-DrugBank.d591.s0	amide-type	120	129	B-group
DDI-DrugBank.d591.s0	local	131	135	I-group
DDI-DrugBank.d591.s0	anesthetics	137	147	I-group
DDI-DrugBank.d591.s0	,	148	148	O
DDI-DrugBank.d591.s0	since	150	154	O
DDI-DrugBank.d591.s0	the	141	143	I-group
DDI-DrugBank.d591.s0	toxic	160	164	O
DDI-DrugBank.d591.s0	effects	166	172	O
DDI-DrugBank.d591.s0	of	174	175	O
DDI-DrugBank.d591.s0	these	177	181	O
DDI-DrugBank.d591.s0	drugs	183	187	O
DDI-DrugBank.d591.s0	are	189	191	O
DDI-DrugBank.d591.s0	additive	193	200	O
DDI-DrugBank.d591.s0	.	201	201	O
DDI-DrugBank.d591.s1	Cytochrome	0	9	O
DDI-DrugBank.d591.s1	P4501A2	11	17	O
DDI-DrugBank.d591.s1	is	19	20	O
DDI-DrugBank.d591.s1	involved	22	29	O
DDI-DrugBank.d591.s1	in	31	32	O
DDI-DrugBank.d591.s1	the	34	36	O
DDI-DrugBank.d591.s1	formation	38	46	O
DDI-DrugBank.d591.s1	of	48	49	O
DDI-DrugBank.d591.s1	3-hydroxy	51	59	B-drug_n
DDI-DrugBank.d591.s1	ropivacaine	61	71	I-drug_n
DDI-DrugBank.d591.s1	,	72	72	O
DDI-DrugBank.d591.s1	the	74	76	O
DDI-DrugBank.d591.s1	major	78	82	O
DDI-DrugBank.d591.s1	metabolite	84	93	O
DDI-DrugBank.d591.s1	.	94	94	O
DDI-DrugBank.d591.s2	In	0	1	O
DDI-DrugBank.d591.s2	vivo	3	6	O
DDI-DrugBank.d591.s2	,	7	7	O
DDI-DrugBank.d591.s2	the	9	11	O
DDI-DrugBank.d591.s2	plasma	13	18	O
DDI-DrugBank.d591.s2	clearance	20	28	O
DDI-DrugBank.d591.s2	of	30	31	O
DDI-DrugBank.d591.s2	ropivacaine	33	43	B-drug
DDI-DrugBank.d591.s2	was	45	47	O
DDI-DrugBank.d591.s2	reduced	49	55	O
DDI-DrugBank.d591.s2	by	57	58	O
DDI-DrugBank.d591.s2	70	60	61	O
DDI-DrugBank.d591.s2	%	62	62	O
DDI-DrugBank.d591.s2	during	64	69	O
DDI-DrugBank.d591.s2	coadministration	71	86	O
DDI-DrugBank.d591.s2	of	88	89	O
DDI-DrugBank.d591.s2	fluvoxamine	91	101	B-drug
DDI-DrugBank.d591.s2	(	103	103	O
DDI-DrugBank.d591.s2	25	104	105	O
DDI-DrugBank.d591.s2	mg	107	108	O
DDI-DrugBank.d591.s2	bid	110	112	O
DDI-DrugBank.d591.s2	for	114	116	O
DDI-DrugBank.d591.s2	2	104	104	O
DDI-DrugBank.d591.s2	days	120	123	O
DDI-DrugBank.d591.s2	)	124	124	O
DDI-DrugBank.d591.s2	,	125	125	O
DDI-DrugBank.d591.s2	a	121	121	O
DDI-DrugBank.d591.s2	selective	129	137	O
DDI-DrugBank.d591.s2	and	139	141	O
DDI-DrugBank.d591.s2	potent	143	148	O
DDI-DrugBank.d591.s2	CYP1A2	150	155	O
DDI-DrugBank.d591.s2	inhibitor	157	165	O
DDI-DrugBank.d591.s2	.	166	166	O
DDI-DrugBank.d591.s3	Thus	0	3	O
DDI-DrugBank.d591.s3	strong	5	10	O
DDI-DrugBank.d591.s3	inhibitors	12	21	O
DDI-DrugBank.d591.s3	of	23	24	O
DDI-DrugBank.d591.s3	cytochrome	26	35	O
DDI-DrugBank.d591.s3	P4501A2	37	43	O
DDI-DrugBank.d591.s3	,	44	44	O
DDI-DrugBank.d591.s3	such	46	49	O
DDI-DrugBank.d591.s3	as	51	52	O
DDI-DrugBank.d591.s3	fluvoxamine	54	64	B-drug
DDI-DrugBank.d591.s3	,	65	65	O
DDI-DrugBank.d591.s3	given	67	71	O
DDI-DrugBank.d591.s3	concomitantly	73	85	O
DDI-DrugBank.d591.s3	during	87	92	O
DDI-DrugBank.d591.s3	administration	94	107	O
DDI-DrugBank.d591.s3	of	109	110	O
DDI-DrugBank.d591.s3	Ropivacaine	112	122	B-drug
DDI-DrugBank.d591.s3	,	123	123	O
DDI-DrugBank.d591.s3	can	125	127	O
DDI-DrugBank.d591.s3	interact	129	136	O
DDI-DrugBank.d591.s3	with	138	141	O
DDI-DrugBank.d591.s3	Ropivacaine	143	153	B-drug
DDI-DrugBank.d591.s3	leading	155	161	O
DDI-DrugBank.d591.s3	to	163	164	O
DDI-DrugBank.d591.s3	increased	166	174	O
DDI-DrugBank.d591.s3	ropivacaine	176	186	B-drug
DDI-DrugBank.d591.s3	plasma	188	193	O
DDI-DrugBank.d591.s3	levels	195	200	O
DDI-DrugBank.d591.s3	.	201	201	O
DDI-DrugBank.d591.s4	Caution	0	6	O
DDI-DrugBank.d591.s4	should	8	13	O
DDI-DrugBank.d591.s4	be	15	16	O
DDI-DrugBank.d591.s4	exercised	18	26	O
DDI-DrugBank.d591.s4	when	28	31	O
DDI-DrugBank.d591.s4	CYP1A2	33	38	O
DDI-DrugBank.d591.s4	inhibitors	40	49	O
DDI-DrugBank.d591.s4	are	51	53	O
DDI-DrugBank.d591.s4	coadministered	55	68	O
DDI-DrugBank.d591.s4	.	69	69	O
DDI-DrugBank.d591.s5	Possible	0	7	O
DDI-DrugBank.d591.s5	interactions	9	20	O
DDI-DrugBank.d591.s5	with	22	25	O
DDI-DrugBank.d591.s5	drugs	27	31	O
DDI-DrugBank.d591.s5	known	33	37	O
DDI-DrugBank.d591.s5	to	39	40	O
DDI-DrugBank.d591.s5	be	42	43	O
DDI-DrugBank.d591.s5	metabolized	45	55	O
DDI-DrugBank.d591.s5	by	57	58	O
DDI-DrugBank.d591.s5	CYP1A2	60	65	O
DDI-DrugBank.d591.s5	via	67	69	O
DDI-DrugBank.d591.s5	competitive	71	81	O
DDI-DrugBank.d591.s5	inhibition	83	92	O
DDI-DrugBank.d591.s5	such	94	97	O
DDI-DrugBank.d591.s5	as	99	100	O
DDI-DrugBank.d591.s5	theophylline	102	113	B-drug
DDI-DrugBank.d591.s5	and	115	117	O
DDI-DrugBank.d591.s5	imipramine	119	128	B-drug
DDI-DrugBank.d591.s5	may	130	132	O
DDI-DrugBank.d591.s5	also	134	137	O
DDI-DrugBank.d591.s5	occur	139	143	O
DDI-DrugBank.d591.s5	.	144	144	O
DDI-DrugBank.d591.s6	Coadministration	0	15	O
DDI-DrugBank.d591.s6	of	17	18	O
DDI-DrugBank.d591.s6	a	20	20	O
DDI-DrugBank.d591.s6	selective	22	30	O
DDI-DrugBank.d591.s6	and	32	34	O
DDI-DrugBank.d591.s6	potent	36	41	O
DDI-DrugBank.d591.s6	inhibitor	43	51	O
DDI-DrugBank.d591.s6	of	53	54	O
DDI-DrugBank.d591.s6	CYP3A4	56	61	O
DDI-DrugBank.d591.s6	,	62	62	O
DDI-DrugBank.d591.s6	ketoconazole	64	75	B-drug
DDI-DrugBank.d591.s6	(	77	77	O
DDI-DrugBank.d591.s6	100	78	80	O
DDI-DrugBank.d591.s6	mg	82	83	O
DDI-DrugBank.d591.s6	bid	85	87	O
DDI-DrugBank.d591.s6	for	89	91	O
DDI-DrugBank.d591.s6	2	93	93	O
DDI-DrugBank.d591.s6	days	95	98	O
DDI-DrugBank.d591.s6	with	100	103	O
DDI-DrugBank.d591.s6	ropivacaine	105	115	B-drug
DDI-DrugBank.d591.s6	infusion	117	124	O
DDI-DrugBank.d591.s6	administered	126	137	O
DDI-DrugBank.d591.s6	1	139	139	O
DDI-DrugBank.d591.s6	hour	141	144	O
DDI-DrugBank.d591.s6	after	146	150	O
DDI-DrugBank.d591.s6	ketoconazole	152	163	B-drug
DDI-DrugBank.d591.s6	)	164	164	O
DDI-DrugBank.d591.s6	caused	166	171	O
DDI-DrugBank.d591.s6	a	159	159	O
DDI-DrugBank.d591.s6	15	175	176	O
DDI-DrugBank.d591.s6	%	177	177	O
DDI-DrugBank.d591.s6	reduction	179	187	O
DDI-DrugBank.d591.s6	in	189	190	O
DDI-DrugBank.d591.s6	in-vivo	192	198	O
DDI-DrugBank.d591.s6	plasma	200	205	O
DDI-DrugBank.d591.s6	clearance	207	215	O
DDI-DrugBank.d591.s6	of	217	218	O
DDI-DrugBank.d591.s6	ropivacaine	220	230	B-drug
DDI-DrugBank.d591.s6	.	231	231	O
DDI-DrugBank.d340.s0	Nelfinavir	0	9	B-drug
DDI-DrugBank.d340.s0	is	11	12	O
DDI-DrugBank.d340.s0	an	14	15	O
DDI-DrugBank.d340.s0	inhibitor	17	25	O
DDI-DrugBank.d340.s0	of	27	28	O
DDI-DrugBank.d340.s0	CYP3A	30	34	O
DDI-DrugBank.d340.s0	(	36	36	O
DDI-DrugBank.d340.s0	cytochrome	37	46	O
DDI-DrugBank.d340.s0	P450	48	51	O
DDI-DrugBank.d340.s0	3A	53	54	O
DDI-DrugBank.d340.s0	)	55	55	O
DDI-DrugBank.d340.s0	.	56	56	O
DDI-DrugBank.d340.s1	Coadministration	0	15	O
DDI-DrugBank.d340.s1	of	17	18	O
DDI-DrugBank.d340.s1	VIRACEPT	20	27	B-brand
DDI-DrugBank.d340.s1	and	29	31	O
DDI-DrugBank.d340.s1	drugs	33	37	O
DDI-DrugBank.d340.s1	primarily	39	47	O
DDI-DrugBank.d340.s1	metabolized	49	59	O
DDI-DrugBank.d340.s1	by	61	62	O
DDI-DrugBank.d340.s1	CYP3A	64	68	O
DDI-DrugBank.d340.s1	(	70	70	O
DDI-DrugBank.d340.s1	e.g.	71	74	O
DDI-DrugBank.d340.s1	,	75	75	O
DDI-DrugBank.d340.s1	dihydropyridine	77	91	B-group
DDI-DrugBank.d340.s1	calcium	93	99	I-group
DDI-DrugBank.d340.s1	channel	101	107	I-group
DDI-DrugBank.d340.s1	blockers	109	116	I-group
DDI-DrugBank.d340.s1	)	117	117	O
DDI-DrugBank.d340.s1	may	119	121	O
DDI-DrugBank.d340.s1	result	123	128	O
DDI-DrugBank.d340.s1	in	130	131	O
DDI-DrugBank.d340.s1	increased	133	141	O
DDI-DrugBank.d340.s1	plasma	143	148	O
DDI-DrugBank.d340.s1	concentrations	150	163	O
DDI-DrugBank.d340.s1	of	165	166	O
DDI-DrugBank.d340.s1	the	168	170	O
DDI-DrugBank.d340.s1	other	172	176	O
DDI-DrugBank.d340.s1	drug	178	181	O
DDI-DrugBank.d340.s1	that	183	186	O
DDI-DrugBank.d340.s1	could	188	192	O
DDI-DrugBank.d340.s1	increase	194	201	O
DDI-DrugBank.d340.s1	or	203	204	O
DDI-DrugBank.d340.s1	prolong	206	212	O
DDI-DrugBank.d340.s1	both	214	217	O
DDI-DrugBank.d340.s1	its	219	221	O
DDI-DrugBank.d340.s1	therapeutic	223	233	O
DDI-DrugBank.d340.s1	and	235	237	O
DDI-DrugBank.d340.s1	adverse	239	245	O
DDI-DrugBank.d340.s1	effects	247	253	O
DDI-DrugBank.d340.s1	.	254	254	O
DDI-DrugBank.d340.s2	Nelfinavir	0	9	B-drug
DDI-DrugBank.d340.s2	is	11	12	O
DDI-DrugBank.d340.s2	metabolized	14	24	O
DDI-DrugBank.d340.s2	in	26	27	O
DDI-DrugBank.d340.s2	proof	29	33	O
DDI-DrugBank.d340.s2	by	35	36	O
DDI-DrugBank.d340.s2	C.P.A	38	42	O
DDI-DrugBank.d340.s2	.	39	39	O
DDI-DrugBank.d340.s3	Coadministration	0	15	O
DDI-DrugBank.d340.s3	of	17	18	O
DDI-DrugBank.d340.s3	VIRACEPT	20	27	B-brand
DDI-DrugBank.d340.s3	and	29	31	O
DDI-DrugBank.d340.s3	drugs	33	37	O
DDI-DrugBank.d340.s3	that	39	42	O
DDI-DrugBank.d340.s3	induce	44	49	O
DDI-DrugBank.d340.s3	CYP3A	51	55	O
DDI-DrugBank.d340.s3	may	57	59	O
DDI-DrugBank.d340.s3	decrease	61	68	O
DDI-DrugBank.d340.s3	nelfinavir	70	79	B-drug
DDI-DrugBank.d340.s3	plasma	81	86	O
DDI-DrugBank.d340.s3	concentrations	88	101	O
DDI-DrugBank.d340.s3	and	103	105	O
DDI-DrugBank.d340.s3	reduce	107	112	O
DDI-DrugBank.d340.s3	its	114	116	O
DDI-DrugBank.d340.s3	therapeutic	118	128	O
DDI-DrugBank.d340.s3	effect	130	135	O
DDI-DrugBank.d340.s3	.	136	136	O
DDI-DrugBank.d340.s4	Coadministration	0	15	O
DDI-DrugBank.d340.s4	of	17	18	O
DDI-DrugBank.d340.s4	VIRACEPT	20	27	B-brand
DDI-DrugBank.d340.s4	and	29	31	O
DDI-DrugBank.d340.s4	drugs	33	37	O
DDI-DrugBank.d340.s4	that	39	42	O
DDI-DrugBank.d340.s4	inhibit	44	50	O
DDI-DrugBank.d340.s4	CYP3A	52	56	O
DDI-DrugBank.d340.s4	may	58	60	O
DDI-DrugBank.d340.s4	increase	62	69	O
DDI-DrugBank.d340.s4	nelfinavir	71	80	B-drug
DDI-DrugBank.d340.s4	plasma	82	87	O
DDI-DrugBank.d340.s4	concentrations	89	102	O
DDI-DrugBank.d340.s4	.	103	103	O
DDI-DrugBank.d340.s5	Based	0	4	O
DDI-DrugBank.d340.s5	on	6	7	O
DDI-DrugBank.d340.s5	known	9	13	O
DDI-DrugBank.d340.s5	metabolic	15	23	O
DDI-DrugBank.d340.s5	profiles	25	32	O
DDI-DrugBank.d340.s5	,	33	33	O
DDI-DrugBank.d340.s5	clinically	35	44	O
DDI-DrugBank.d340.s5	significant	46	56	O
DDI-DrugBank.d340.s5	drug	58	61	O
DDI-DrugBank.d340.s5	interactions	63	74	O
DDI-DrugBank.d340.s5	are	76	78	O
DDI-DrugBank.d340.s5	not	80	82	O
DDI-DrugBank.d340.s5	expected	84	91	O
DDI-DrugBank.d340.s5	between	93	99	O
DDI-DrugBank.d340.s5	VIRACEPT	101	108	B-brand
DDI-DrugBank.d340.s5	and	110	112	O
DDI-DrugBank.d340.s5	dapsone	114	120	B-drug
DDI-DrugBank.d340.s5	,	121	121	O
DDI-DrugBank.d340.s5	trimethoprim/sulfamethoxazole	123	151	O
DDI-DrugBank.d340.s5	,	152	152	O
DDI-DrugBank.d340.s5	clarithromycin	154	167	B-drug
DDI-DrugBank.d340.s5	,	152	152	O
DDI-DrugBank.d340.s5	erythromycin	170	181	B-drug
DDI-DrugBank.d340.s5	,	168	168	O
DDI-DrugBank.d340.s5	itraconazole	184	195	B-drug
DDI-DrugBank.d340.s5	or	197	198	O
DDI-DrugBank.d340.s5	fluconazole	200	210	B-drug
DDI-DrugBank.d340.s5	.	211	211	O
DDI-DrugBank.d340.s6	Drugs	0	4	O
DDI-DrugBank.d340.s6	That	6	9	O
DDI-DrugBank.d340.s6	Should	11	16	O
DDI-DrugBank.d340.s6	Not	18	20	O
DDI-DrugBank.d340.s6	Be	22	23	O
DDI-DrugBank.d340.s6	Coadministered	25	38	O
DDI-DrugBank.d340.s6	With	40	43	O
DDI-DrugBank.d340.s6	VIRACEPT	45	52	B-brand
DDI-DrugBank.d340.s6	Antiarrhythmics	54	68	B-group
DDI-DrugBank.d340.s6	:	69	69	O
DDI-DrugBank.d340.s6	amiodarone	71	80	B-drug
DDI-DrugBank.d340.s6	,	81	81	O
DDI-DrugBank.d340.s6	quinidine	83	91	B-drug
DDI-DrugBank.d340.s6	Antihistamines	93	106	B-group
DDI-DrugBank.d340.s6	:	107	107	O
DDI-DrugBank.d340.s6	astemizole	109	118	B-drug
DDI-DrugBank.d340.s6	,	119	119	O
DDI-DrugBank.d340.s6	terfenadine	121	131	B-drug
DDI-DrugBank.d340.s6	Antimigraine	133	144	O
DDI-DrugBank.d340.s6	:	145	145	O
DDI-DrugBank.d340.s6	ergot	147	151	B-group
DDI-DrugBank.d340.s6	derivatives	153	163	I-group
DDI-DrugBank.d340.s6	Antimycobacterial	165	181	B-group
DDI-DrugBank.d340.s6	agents	183	188	I-group
DDI-DrugBank.d340.s6	:	189	189	O
DDI-DrugBank.d340.s6	rifampin	191	198	B-drug
DDI-DrugBank.d340.s6	Benzodiazepines	200	214	B-group
DDI-DrugBank.d340.s6	midazolam	216	224	B-drug
DDI-DrugBank.d340.s6	,	225	225	O
DDI-DrugBank.d340.s6	triazolam	227	235	B-drug
DDI-DrugBank.d340.s6	GI	237	238	O
DDI-DrugBank.d340.s6	motility	240	247	O
DDI-DrugBank.d340.s6	agents	249	254	O
DDI-DrugBank.d340.s6	:	255	255	O
DDI-DrugBank.d340.s6	cisapride	257	265	B-drug
DDI-DrugBank.d340.s7	Drugs	0	4	O
DDI-DrugBank.d340.s7	Which	6	10	O
DDI-DrugBank.d340.s7	Require	12	18	O
DDI-DrugBank.d340.s7	a	20	20	O
DDI-DrugBank.d340.s7	Dose	22	25	O
DDI-DrugBank.d340.s7	Reduction	27	35	O
DDI-DrugBank.d340.s7	When	37	40	O
DDI-DrugBank.d340.s7	Coadminstered	42	54	O
DDI-DrugBank.d340.s7	With	56	59	O
DDI-DrugBank.d340.s7	VIRACEPT	61	68	B-brand
DDI-DrugBank.d340.s7	Antimycobacterial	70	86	B-group
DDI-DrugBank.d340.s7	agents	88	93	I-group
DDI-DrugBank.d340.s7	:	94	94	O
DDI-DrugBank.d340.s7	rifabutin	96	104	B-drug
DDI-DrugBank.d340.s8	*	0	0	O
DDI-DrugBank.d340.s8	This	2	5	O
DDI-DrugBank.d340.s8	table	7	11	O
DDI-DrugBank.d340.s8	is	13	14	O
DDI-DrugBank.d340.s8	not	16	18	O
DDI-DrugBank.d340.s8	all	20	22	O
DDI-DrugBank.d340.s8	inclusive	24	32	O
DDI-DrugBank.d340.s8	*	34	34	O
DDI-DrugBank.d340.s8	*	34	34	O
DDI-DrugBank.d340.s8	VIRACEPT	37	44	B-brand
DDI-DrugBank.d340.s8	may	46	48	O
DDI-DrugBank.d340.s8	not	50	52	O
DDI-DrugBank.d340.s8	be	54	55	O
DDI-DrugBank.d340.s8	effective	57	65	O
DDI-DrugBank.d340.s8	due	67	69	O
DDI-DrugBank.d340.s8	to	71	72	O
DDI-DrugBank.d340.s8	decreased	74	82	O
DDI-DrugBank.d340.s8	nelfinavir	84	93	B-drug
DDI-DrugBank.d340.s8	plasma	95	100	O
DDI-DrugBank.d340.s8	concentrations	102	115	O
DDI-DrugBank.d340.s8	in	117	118	O
DDI-DrugBank.d340.s8	patients	120	127	O
DDI-DrugBank.d340.s8	taking	129	134	O
DDI-DrugBank.d340.s8	these	136	140	O
DDI-DrugBank.d340.s8	agents	142	147	O
DDI-DrugBank.d340.s8	concomitantly	149	161	O
DDI-DrugBank.d340.s9	Antihistamines	0	13	B-group
DDI-DrugBank.d340.s10	Terfenadine	0	10	B-drug
DDI-DrugBank.d340.s10	:	11	11	O
DDI-DrugBank.d340.s10	Administration	13	26	O
DDI-DrugBank.d340.s10	of	28	29	O
DDI-DrugBank.d340.s10	terfenadine	31	41	B-drug
DDI-DrugBank.d340.s10	with	43	46	O
DDI-DrugBank.d340.s10	VIRACEPT	48	55	B-brand
DDI-DrugBank.d340.s10	resulted	57	64	O
DDI-DrugBank.d340.s10	in	66	67	O
DDI-DrugBank.d340.s10	the	69	71	O
DDI-DrugBank.d340.s10	appearance	73	82	O
DDI-DrugBank.d340.s10	of	84	85	O
DDI-DrugBank.d340.s10	unchanged	87	95	O
DDI-DrugBank.d340.s10	terfenadine	97	107	B-drug
DDI-DrugBank.d340.s10	in	105	106	I-drug
DDI-DrugBank.d340.s10	plasma	112	117	O
DDI-DrugBank.d340.s10	;	118	118	O
DDI-DrugBank.d340.s11	therefore	0	8	O
DDI-DrugBank.d340.s11	,	9	9	O
DDI-DrugBank.d340.s11	VIRACEPT	11	18	B-brand
DDI-DrugBank.d340.s11	should	20	25	O
DDI-DrugBank.d340.s11	not	27	29	O
DDI-DrugBank.d340.s11	be	31	32	O
DDI-DrugBank.d340.s11	administered	34	45	O
DDI-DrugBank.d340.s11	concurrently	47	58	O
DDI-DrugBank.d340.s11	with	60	63	O
DDI-DrugBank.d340.s11	terfenadine	65	75	B-drug
DDI-DrugBank.d340.s11	because	77	83	O
DDI-DrugBank.d340.s11	of	85	86	O
DDI-DrugBank.d340.s11	the	88	90	O
DDI-DrugBank.d340.s11	potential	92	100	O
DDI-DrugBank.d340.s11	for	102	104	O
DDI-DrugBank.d340.s11	serious	106	112	O
DDI-DrugBank.d340.s11	and/or	114	119	O
DDI-DrugBank.d340.s11	life-threatening	121	136	O
DDI-DrugBank.d340.s11	cardiac	138	144	O
DDI-DrugBank.d340.s11	arrhythmias	146	156	O
DDI-DrugBank.d340.s11	.	157	157	O
DDI-DrugBank.d340.s12	Because	0	6	O
DDI-DrugBank.d340.s12	a	8	8	O
DDI-DrugBank.d340.s12	similar	10	16	O
DDI-DrugBank.d340.s12	interaction	18	28	O
DDI-DrugBank.d340.s12	is	30	31	O
DDI-DrugBank.d340.s12	likely	33	38	O
DDI-DrugBank.d340.s12	,	39	39	O
DDI-DrugBank.d340.s12	VIRACEPT	41	48	B-brand
DDI-DrugBank.d340.s12	should	50	55	O
DDI-DrugBank.d340.s12	also	57	60	O
DDI-DrugBank.d340.s12	not	62	64	O
DDI-DrugBank.d340.s12	be	66	67	O
DDI-DrugBank.d340.s12	administered	69	80	O
DDI-DrugBank.d340.s12	concurrently	82	93	O
DDI-DrugBank.d340.s12	with	95	98	O
DDI-DrugBank.d340.s12	astemizole	100	109	B-drug
DDI-DrugBank.d340.s12	.	110	110	O
DDI-DrugBank.d340.s13	Anti-HIV	0	7	B-group
DDI-DrugBank.d340.s13	Protease	9	16	I-group
DDI-DrugBank.d340.s13	Inhibitors	18	27	I-group
DDI-DrugBank.d340.s14	Indinavir	0	8	B-drug
DDI-DrugBank.d340.s14	:	9	9	O
DDI-DrugBank.d340.s14	Coadministration	11	26	O
DDI-DrugBank.d340.s14	of	28	29	O
DDI-DrugBank.d340.s14	indinavir	31	39	B-drug
DDI-DrugBank.d340.s14	with	41	44	O
DDI-DrugBank.d340.s14	VIRACEPT	46	53	B-brand
DDI-DrugBank.d340.s14	resulted	55	62	O
DDI-DrugBank.d340.s14	in	64	65	O
DDI-DrugBank.d340.s14	an	67	68	O
DDI-DrugBank.d340.s14	83	70	71	O
DDI-DrugBank.d340.s14	%	72	72	O
DDI-DrugBank.d340.s14	increase	74	81	O
DDI-DrugBank.d340.s14	in	74	75	O
DDI-DrugBank.d340.s14	nelfinavir	86	95	B-drug
DDI-DrugBank.d340.s14	plasma	97	102	O
DDI-DrugBank.d340.s14	AUC	104	106	O
DDI-DrugBank.d340.s14	and	108	110	O
DDI-DrugBank.d340.s14	a	99	99	O
DDI-DrugBank.d340.s14	51	114	115	O
DDI-DrugBank.d340.s14	%	116	116	O
DDI-DrugBank.d340.s14	increase	118	125	O
DDI-DrugBank.d340.s14	in	118	119	O
DDI-DrugBank.d340.s14	indinavir	130	138	B-drug
DDI-DrugBank.d340.s14	plasma	140	145	O
DDI-DrugBank.d340.s14	A.C	147	149	O
DDI-DrugBank.d340.s14	.	148	148	O
DDI-DrugBank.d340.s15	Currently	0	8	O
DDI-DrugBank.d340.s15	,	9	9	O
DDI-DrugBank.d340.s15	there	11	15	O
DDI-DrugBank.d340.s15	are	17	19	O
DDI-DrugBank.d340.s15	no	21	22	O
DDI-DrugBank.d340.s15	safety	24	29	O
DDI-DrugBank.d340.s15	and	31	33	O
DDI-DrugBank.d340.s15	efficacy	35	42	O
DDI-DrugBank.d340.s15	data	44	47	O
DDI-DrugBank.d340.s15	available	49	57	O
DDI-DrugBank.d340.s15	from	59	62	O
DDI-DrugBank.d340.s15	the	64	66	O
DDI-DrugBank.d340.s15	use	68	70	O
DDI-DrugBank.d340.s15	of	72	73	O
DDI-DrugBank.d340.s15	this	75	78	O
DDI-DrugBank.d340.s15	combination	80	90	O
DDI-DrugBank.d340.s15	.	91	91	O
DDI-DrugBank.d340.s16	Ritonavir	0	8	B-drug
DDI-DrugBank.d340.s16	:	9	9	O
DDI-DrugBank.d340.s16	Coadministration	11	26	O
DDI-DrugBank.d340.s16	of	28	29	O
DDI-DrugBank.d340.s16	ritonavir	31	39	B-drug
DDI-DrugBank.d340.s16	with	41	44	O
DDI-DrugBank.d340.s16	VIRACEPT	46	53	B-brand
DDI-DrugBank.d340.s16	resulted	55	62	O
DDI-DrugBank.d340.s16	in	64	65	O
DDI-DrugBank.d340.s16	a	67	67	O
DDI-DrugBank.d340.s16	152	69	71	O
DDI-DrugBank.d340.s16	%	72	72	O
DDI-DrugBank.d340.s16	increase	74	81	O
DDI-DrugBank.d340.s16	in	74	75	O
DDI-DrugBank.d340.s16	nelfinavir	86	95	B-drug
DDI-DrugBank.d340.s16	plasma	97	102	O
DDI-DrugBank.d340.s16	AUC	104	106	O
DDI-DrugBank.d340.s16	and	108	110	O
DDI-DrugBank.d340.s16	very	112	115	O
DDI-DrugBank.d340.s16	little	117	122	O
DDI-DrugBank.d340.s16	change	124	129	O
DDI-DrugBank.d340.s16	in	131	132	O
DDI-DrugBank.d340.s16	ritonavir	134	142	B-drug
DDI-DrugBank.d340.s16	plasma	144	149	O
DDI-DrugBank.d340.s16	A.C	151	153	O
DDI-DrugBank.d340.s16	.	152	152	O
DDI-DrugBank.d340.s17	Currently	0	8	O
DDI-DrugBank.d340.s17	,	9	9	O
DDI-DrugBank.d340.s17	there	11	15	O
DDI-DrugBank.d340.s17	are	17	19	O
DDI-DrugBank.d340.s17	no	21	22	O
DDI-DrugBank.d340.s17	safety	24	29	O
DDI-DrugBank.d340.s17	and	31	33	O
DDI-DrugBank.d340.s17	efficacy	35	42	O
DDI-DrugBank.d340.s17	data	44	47	O
DDI-DrugBank.d340.s17	available	49	57	O
DDI-DrugBank.d340.s17	from	59	62	O
DDI-DrugBank.d340.s17	the	64	66	O
DDI-DrugBank.d340.s17	use	68	70	O
DDI-DrugBank.d340.s17	of	72	73	O
DDI-DrugBank.d340.s17	this	75	78	O
DDI-DrugBank.d340.s17	combination	80	90	O
DDI-DrugBank.d340.s17	.	91	91	O
DDI-DrugBank.d340.s18	Saquinavir	0	9	B-drug
DDI-DrugBank.d340.s18	:	10	10	O
DDI-DrugBank.d340.s18	Coadministration	12	27	O
DDI-DrugBank.d340.s18	of	29	30	O
DDI-DrugBank.d340.s18	saquinavir	32	41	B-drug
DDI-DrugBank.d340.s18	(	43	43	O
DDI-DrugBank.d340.s18	using	44	48	O
DDI-DrugBank.d340.s18	an	50	51	O
DDI-DrugBank.d340.s18	experimental	53	64	O
DDI-DrugBank.d340.s18	soft-gelatin	66	77	O
DDI-DrugBank.d340.s18	capsule	79	85	O
DDI-DrugBank.d340.s18	formulation	87	97	O
DDI-DrugBank.d340.s18	of	99	100	O
DDI-DrugBank.d340.s18	saquinavir	102	111	B-drug
DDI-DrugBank.d340.s18	1200mg	113	118	O
DDI-DrugBank.d340.s18	)	119	119	O
DDI-DrugBank.d340.s18	with	121	124	O
DDI-DrugBank.d340.s18	VIRACEPT	126	133	B-brand
DDI-DrugBank.d340.s18	resulted	135	142	O
DDI-DrugBank.d340.s18	in	144	145	O
DDI-DrugBank.d340.s18	an	147	148	O
DDI-DrugBank.d340.s18	18	150	151	O
DDI-DrugBank.d340.s18	%	152	152	O
DDI-DrugBank.d340.s18	increase	154	161	O
DDI-DrugBank.d340.s18	in	144	145	O
DDI-DrugBank.d340.s18	nelfinavir	166	175	B-drug
DDI-DrugBank.d340.s18	plasma	177	182	O
DDI-DrugBank.d340.s18	AUC	184	186	O
DDI-DrugBank.d340.s18	and	188	190	O
DDI-DrugBank.d340.s18	a	172	172	O
DDI-DrugBank.d340.s18	4-fold	194	199	O
DDI-DrugBank.d340.s18	increase	201	208	O
DDI-DrugBank.d340.s18	in	201	202	O
DDI-DrugBank.d340.s18	saquinavir	213	222	B-drug
DDI-DrugBank.d340.s18	plasma	224	229	O
DDI-DrugBank.d340.s18	A.C	231	233	O
DDI-DrugBank.d340.s18	.	232	232	O
DDI-DrugBank.d340.s19	If	0	1	O
DDI-DrugBank.d340.s19	used	3	6	O
DDI-DrugBank.d340.s19	in	8	9	O
DDI-DrugBank.d340.s19	combination	11	21	O
DDI-DrugBank.d340.s19	with	23	26	O
DDI-DrugBank.d340.s19	saquinavir	28	37	B-drug
DDI-DrugBank.d340.s19	hard	39	42	O
DDI-DrugBank.d340.s19	gelatin	44	50	O
DDI-DrugBank.d340.s19	capsules	52	59	O
DDI-DrugBank.d340.s19	at	61	62	O
DDI-DrugBank.d340.s19	the	64	66	O
DDI-DrugBank.d340.s19	recommended	68	78	O
DDI-DrugBank.d340.s19	dose	80	83	O
DDI-DrugBank.d340.s19	of	85	86	O
DDI-DrugBank.d340.s19	600	88	90	O
DDI-DrugBank.d340.s19	mg	92	93	O
DDI-DrugBank.d340.s19	tid	95	97	O
DDI-DrugBank.d340.s19	,	98	98	O
DDI-DrugBank.d340.s19	no	100	101	O
DDI-DrugBank.d340.s19	dose	103	106	O
DDI-DrugBank.d340.s19	adjustments	108	118	O
DDI-DrugBank.d340.s19	are	120	122	O
DDI-DrugBank.d340.s19	needed	124	129	O
DDI-DrugBank.d340.s19	.	130	130	O
DDI-DrugBank.d340.s20	Currently	0	8	O
DDI-DrugBank.d340.s20	,	9	9	O
DDI-DrugBank.d340.s20	there	11	15	O
DDI-DrugBank.d340.s20	are	17	19	O
DDI-DrugBank.d340.s20	no	21	22	O
DDI-DrugBank.d340.s20	safety	24	29	O
DDI-DrugBank.d340.s20	and	31	33	O
DDI-DrugBank.d340.s20	efficacy	35	42	O
DDI-DrugBank.d340.s20	data	44	47	O
DDI-DrugBank.d340.s20	available	49	57	O
DDI-DrugBank.d340.s20	from	59	62	O
DDI-DrugBank.d340.s20	the	64	66	O
DDI-DrugBank.d340.s20	use	68	70	O
DDI-DrugBank.d340.s20	of	72	73	O
DDI-DrugBank.d340.s20	this	75	78	O
DDI-DrugBank.d340.s20	combination	80	90	O
DDI-DrugBank.d340.s20	.	91	91	O
DDI-DrugBank.d340.s21	Antifungal	0	9	B-group
DDI-DrugBank.d340.s21	Agents	11	16	I-group
DDI-DrugBank.d340.s22	Ketoconazole	0	11	B-drug
DDI-DrugBank.d340.s22	:	12	12	O
DDI-DrugBank.d340.s22	Coadministration	14	29	O
DDI-DrugBank.d340.s22	of	31	32	O
DDI-DrugBank.d340.s22	ketoconazole	34	45	B-drug
DDI-DrugBank.d340.s22	with	47	50	O
DDI-DrugBank.d340.s22	VIRACEPT	52	59	B-brand
DDI-DrugBank.d340.s22	resulted	61	68	O
DDI-DrugBank.d340.s22	in	70	71	O
DDI-DrugBank.d340.s22	a	73	73	O
DDI-DrugBank.d340.s22	35	75	76	O
DDI-DrugBank.d340.s22	%	77	77	O
DDI-DrugBank.d340.s22	increase	79	86	O
DDI-DrugBank.d340.s22	in	79	80	O
DDI-DrugBank.d340.s22	nelfinavir	91	100	B-drug
DDI-DrugBank.d340.s22	plasma	102	107	O
DDI-DrugBank.d340.s22	A.C	109	111	O
DDI-DrugBank.d340.s22	.	110	110	O
DDI-DrugBank.d340.s23	This	0	3	O
DDI-DrugBank.d340.s23	change	5	10	O
DDI-DrugBank.d340.s23	was	12	14	O
DDI-DrugBank.d340.s23	not	16	18	O
DDI-DrugBank.d340.s23	considered	20	29	O
DDI-DrugBank.d340.s23	clinically	31	40	O
DDI-DrugBank.d340.s23	significant	42	52	O
DDI-DrugBank.d340.s23	and	54	56	O
DDI-DrugBank.d340.s23	no	58	59	O
DDI-DrugBank.d340.s23	dose	61	64	O
DDI-DrugBank.d340.s23	adjustment	66	75	O
DDI-DrugBank.d340.s23	is	77	78	O
DDI-DrugBank.d340.s23	needed	80	85	O
DDI-DrugBank.d340.s23	when	87	90	O
DDI-DrugBank.d340.s23	ketoconazole	92	103	B-drug
DDI-DrugBank.d340.s23	and	105	107	O
DDI-DrugBank.d340.s23	VIRACEPT	109	116	B-brand
DDI-DrugBank.d340.s23	are	118	120	O
DDI-DrugBank.d340.s23	coadministered	122	135	O
DDI-DrugBank.d340.s23	.	136	136	O
DDI-DrugBank.d340.s24	Anti-HIV	0	7	B-group
DDI-DrugBank.d340.s24	Reverse	9	15	I-group
DDI-DrugBank.d340.s24	Transcriptase	17	29	I-group
DDI-DrugBank.d340.s24	Inhibitors	31	40	I-group
DDI-DrugBank.d340.s25	Didanosine	0	9	B-drug
DDI-DrugBank.d340.s25	:	10	10	O
DDI-DrugBank.d340.s25	It	12	13	O
DDI-DrugBank.d340.s25	is	15	16	O
DDI-DrugBank.d340.s25	recommended	18	28	O
DDI-DrugBank.d340.s25	that	30	33	O
DDI-DrugBank.d340.s25	didanosine	35	44	B-drug
DDI-DrugBank.d340.s25	be	46	47	O
DDI-DrugBank.d340.s25	administered	49	60	O
DDI-DrugBank.d340.s25	on	62	63	O
DDI-DrugBank.d340.s25	an	65	66	O
DDI-DrugBank.d340.s25	empty	68	72	O
DDI-DrugBank.d340.s25	stomach	74	80	O
DDI-DrugBank.d340.s25	;	81	81	O
DDI-DrugBank.d340.s26	therefore	0	8	O
DDI-DrugBank.d340.s26	,	9	9	O
DDI-DrugBank.d340.s26	nelfinavir	11	20	B-drug
DDI-DrugBank.d340.s26	should	22	27	O
DDI-DrugBank.d340.s26	be	29	30	O
DDI-DrugBank.d340.s26	administered	32	43	O
DDI-DrugBank.d340.s26	(	45	45	O
DDI-DrugBank.d340.s26	with	46	49	O
DDI-DrugBank.d340.s26	food	51	54	O
DDI-DrugBank.d340.s26	)	55	55	O
DDI-DrugBank.d340.s26	one	57	59	O
DDI-DrugBank.d340.s26	hour	61	64	O
DDI-DrugBank.d340.s26	after	66	70	O
DDI-DrugBank.d340.s26	or	72	73	O
DDI-DrugBank.d340.s26	more	75	78	O
DDI-DrugBank.d340.s26	than	80	83	O
DDI-DrugBank.d340.s26	two	85	87	O
DDI-DrugBank.d340.s26	hours	89	93	O
DDI-DrugBank.d340.s26	before	95	100	O
DDI-DrugBank.d340.s26	didanosine	102	111	B-drug
DDI-DrugBank.d340.s26	.	112	112	O
DDI-DrugBank.d340.s27	A	0	0	O
DDI-DrugBank.d340.s27	dose	2	5	O
DDI-DrugBank.d340.s27	adjustment	7	16	O
DDI-DrugBank.d340.s27	is	18	19	O
DDI-DrugBank.d340.s27	not	21	23	O
DDI-DrugBank.d340.s27	needed	25	30	O
DDI-DrugBank.d340.s27	when	32	35	O
DDI-DrugBank.d340.s27	zidovudine	37	46	B-drug
DDI-DrugBank.d340.s27	is	48	49	O
DDI-DrugBank.d340.s27	administered	51	62	O
DDI-DrugBank.d340.s27	with	64	67	O
DDI-DrugBank.d340.s27	VIRACEPT	69	76	B-brand
DDI-DrugBank.d340.s27	.	77	77	O
DDI-DrugBank.d340.s28	Little	0	5	O
DDI-DrugBank.d340.s28	or	7	8	O
DDI-DrugBank.d340.s28	no	10	11	O
DDI-DrugBank.d340.s28	change	13	18	O
DDI-DrugBank.d340.s28	in	20	21	O
DDI-DrugBank.d340.s28	the	23	25	O
DDI-DrugBank.d340.s28	pharmacokinetics	27	42	O
DDI-DrugBank.d340.s28	of	44	45	O
DDI-DrugBank.d340.s28	either	47	52	O
DDI-DrugBank.d340.s28	drug	54	57	O
DDI-DrugBank.d340.s28	was	59	61	O
DDI-DrugBank.d340.s28	observed	63	70	O
DDI-DrugBank.d340.s28	when	72	75	O
DDI-DrugBank.d340.s28	VIRACEPT	77	84	B-brand
DDI-DrugBank.d340.s28	was	86	88	O
DDI-DrugBank.d340.s28	coadministered	90	103	O
DDI-DrugBank.d340.s28	with	105	108	O
DDI-DrugBank.d340.s28	lamivudine	110	119	B-drug
DDI-DrugBank.d340.s28	or	121	122	O
DDI-DrugBank.d340.s28	stavudine	124	132	B-drug
DDI-DrugBank.d340.s28	.	133	133	O
DDI-DrugBank.d340.s29	Antimycobacterial	0	16	B-group
DDI-DrugBank.d340.s29	Agents	18	23	I-group
DDI-DrugBank.d340.s30	Rifabutin	0	8	B-drug
DDI-DrugBank.d340.s30	:	9	9	O
DDI-DrugBank.d340.s30	Coadministration	11	26	O
DDI-DrugBank.d340.s30	of	28	29	O
DDI-DrugBank.d340.s30	rifabutin	31	39	B-drug
DDI-DrugBank.d340.s30	and	41	43	O
DDI-DrugBank.d340.s30	VIRACEPT	45	52	B-brand
DDI-DrugBank.d340.s30	resulted	54	61	O
DDI-DrugBank.d340.s30	in	63	64	O
DDI-DrugBank.d340.s30	a	66	66	O
DDI-DrugBank.d340.s30	32	68	69	O
DDI-DrugBank.d340.s30	%	70	70	O
DDI-DrugBank.d340.s30	decrease	72	79	O
DDI-DrugBank.d340.s30	in	81	82	O
DDI-DrugBank.d340.s30	nelfinavir	84	93	B-drug
DDI-DrugBank.d340.s30	plasma	95	100	O
DDI-DrugBank.d340.s30	AUC	102	104	O
DDI-DrugBank.d340.s30	and	106	108	O
DDI-DrugBank.d340.s30	a	97	97	O
DDI-DrugBank.d340.s30	207	112	114	O
DDI-DrugBank.d340.s30	%	115	115	O
DDI-DrugBank.d340.s30	increase	117	124	O
DDI-DrugBank.d340.s30	in	117	118	O
DDI-DrugBank.d340.s30	rifabutin	129	137	B-drug
DDI-DrugBank.d340.s30	plasma	139	144	O
DDI-DrugBank.d340.s30	A.C	146	148	O
DDI-DrugBank.d340.s30	.	147	147	O
DDI-DrugBank.d340.s31	It	0	1	O
DDI-DrugBank.d340.s31	is	3	4	O
DDI-DrugBank.d340.s31	recommended	6	16	O
DDI-DrugBank.d340.s31	that	18	21	O
DDI-DrugBank.d340.s31	the	23	25	O
DDI-DrugBank.d340.s31	dose	27	30	O
DDI-DrugBank.d340.s31	of	32	33	O
DDI-DrugBank.d340.s31	rifabutin	35	43	B-drug
DDI-DrugBank.d340.s31	be	45	46	O
DDI-DrugBank.d340.s31	reduced	48	54	O
DDI-DrugBank.d340.s31	to	56	57	O
DDI-DrugBank.d340.s31	one-half	59	66	O
DDI-DrugBank.d340.s31	the	68	70	O
DDI-DrugBank.d340.s31	usual	72	76	O
DDI-DrugBank.d340.s31	dose	78	81	O
DDI-DrugBank.d340.s31	when	83	86	O
DDI-DrugBank.d340.s31	administered	88	99	O
DDI-DrugBank.d340.s31	with	101	104	O
DDI-DrugBank.d340.s31	VIRACEPT	106	113	B-brand
DDI-DrugBank.d340.s31	.	114	114	O
DDI-DrugBank.d340.s32	Rifampin	0	7	B-drug
DDI-DrugBank.d340.s32	:	8	8	O
DDI-DrugBank.d340.s32	Coadministration	10	25	O
DDI-DrugBank.d340.s32	of	27	28	O
DDI-DrugBank.d340.s32	rifampin	30	37	B-drug
DDI-DrugBank.d340.s32	and	39	41	O
DDI-DrugBank.d340.s32	VIRACEPT	43	50	B-brand
DDI-DrugBank.d340.s32	resulted	52	59	O
DDI-DrugBank.d340.s32	in	61	62	O
DDI-DrugBank.d340.s32	an	64	65	O
DDI-DrugBank.d340.s32	82	67	68	O
DDI-DrugBank.d340.s32	%	69	69	O
DDI-DrugBank.d340.s32	decrease	71	78	O
DDI-DrugBank.d340.s32	in	80	81	O
DDI-DrugBank.d340.s32	nelfinavir	83	92	B-drug
DDI-DrugBank.d340.s32	plasma	94	99	O
DDI-DrugBank.d340.s32	A.C	101	103	O
DDI-DrugBank.d340.s32	.	102	102	O
DDI-DrugBank.d340.s33	VIRACEPT	0	7	B-brand
DDI-DrugBank.d340.s33	and	9	11	O
DDI-DrugBank.d340.s33	rifampin	13	20	B-drug
DDI-DrugBank.d340.s33	should	22	27	O
DDI-DrugBank.d340.s33	not	29	31	O
DDI-DrugBank.d340.s33	be	33	34	O
DDI-DrugBank.d340.s33	coadministered	36	49	O
DDI-DrugBank.d340.s33	.	50	50	O
DDI-DrugBank.d340.s34	Oral	0	3	O
DDI-DrugBank.d340.s34	Contraceptives	5	18	B-group
DDI-DrugBank.d340.s35	Ethinyl	0	6	B-drug
DDI-DrugBank.d340.s35	Estradiol	8	16	I-drug
DDI-DrugBank.d340.s35	and	18	20	O
DDI-DrugBank.d340.s35	Norethindrone	22	34	B-drug
DDI-DrugBank.d340.s35	:	35	35	O
DDI-DrugBank.d340.s35	Coadministration	37	52	O
DDI-DrugBank.d340.s35	of	54	55	O
DDI-DrugBank.d340.s35	VIRACEPT	57	64	B-brand
DDI-DrugBank.d340.s35	with	66	69	O
DDI-DrugBank.d340.s35	OVCON-35	71	78	B-brand
DDI-DrugBank.d340.s35	resulted	80	87	O
DDI-DrugBank.d340.s35	in	89	90	O
DDI-DrugBank.d340.s35	a	92	92	O
DDI-DrugBank.d340.s35	47	94	95	O
DDI-DrugBank.d340.s35	%	96	96	O
DDI-DrugBank.d340.s35	decrease	98	105	O
DDI-DrugBank.d340.s35	in	107	108	O
DDI-DrugBank.d340.s35	ethinyl	110	116	B-drug
DDI-DrugBank.d340.s35	estradiol	118	126	I-drug
DDI-DrugBank.d340.s35	and	128	130	O
DDI-DrugBank.d340.s35	an	128	129	O
DDI-DrugBank.d340.s35	18	135	136	O
DDI-DrugBank.d340.s35	%	137	137	O
DDI-DrugBank.d340.s35	decrease	139	146	O
DDI-DrugBank.d340.s35	in	148	149	O
DDI-DrugBank.d340.s35	norethindrone	151	163	B-drug
DDI-DrugBank.d340.s35	plasma	165	170	O
DDI-DrugBank.d340.s35	concentrations	172	185	O
DDI-DrugBank.d340.s35	.	186	186	O
DDI-DrugBank.d340.s36	Alternate	0	8	O
DDI-DrugBank.d340.s36	or	10	11	O
DDI-DrugBank.d340.s36	additional	13	22	O
DDI-DrugBank.d340.s36	contraceptive	24	36	O
DDI-DrugBank.d340.s36	measures	38	45	O
DDI-DrugBank.d340.s36	should	47	52	O
DDI-DrugBank.d340.s36	be	54	55	O
DDI-DrugBank.d340.s36	used	57	60	O
DDI-DrugBank.d340.s36	during	62	67	O
DDI-DrugBank.d340.s36	therapy	69	75	O
DDI-DrugBank.d340.s36	with	77	80	O
DDI-DrugBank.d340.s36	VIRACEPT	82	89	B-brand
DDI-DrugBank.d119.s0	The	0	2	O
DDI-DrugBank.d119.s0	following	4	12	O
DDI-DrugBank.d119.s0	drug	14	17	O
DDI-DrugBank.d119.s0	interactions	19	30	O
DDI-DrugBank.d119.s0	have	32	35	O
DDI-DrugBank.d119.s0	been	37	40	O
DDI-DrugBank.d119.s0	reported	42	49	O
DDI-DrugBank.d119.s0	with	51	54	O
DDI-DrugBank.d119.s0	etomidate	56	64	B-drug
DDI-DrugBank.d119.s0	.	65	65	O
DDI-DrugBank.d119.s1	Drug	0	3	O
DDI-DrugBank.d119.s1	Effect	5	10	O
DDI-DrugBank.d119.s2	Probenecid	0	9	B-drug
DDI-DrugBank.d119.s2	Prolonged	14	22	O
DDI-DrugBank.d119.s2	action	24	29	O
DDI-DrugBank.d119.s2	of	31	32	O
DDI-DrugBank.d119.s2	etomidate	34	42	B-drug
DDI-DrugBank.d119.s3	Diazoxide	0	8	B-drug
DDI-DrugBank.d119.s3	Hypotension	13	23	O
DDI-DrugBank.d119.s4	Zimelidine	0	9	B-drug_n
DDI-DrugBank.d119.s4	etomidate	14	22	B-drug
DDI-DrugBank.d119.s4	antagonism	24	33	O
DDI-DrugBank.d119.s5	Opioid	0	5	B-group
DDI-DrugBank.d119.s5	analgesics	7	16	I-group
DDI-DrugBank.d119.s5	Decreased	21	29	O
DDI-DrugBank.d119.s5	antinociceptive	31	45	O
DDI-DrugBank.d119.s5	action	47	52	O
DDI-DrugBank.d119.s6	Aminophylline	0	12	B-drug
DDI-DrugBank.d119.s6	Etomidate	18	26	B-drug
DDI-DrugBank.d119.s6	antagonism	28	37	O
DDI-DrugBank.d119.s7	Midazolam	0	8	B-drug
DDI-DrugBank.d119.s7	Synergism	13	21	O
DDI-DrugBank.d66.s0	Human	0	4	B-drug
DDI-DrugBank.d66.s0	growth	6	11	I-drug
DDI-DrugBank.d66.s0	hormone	13	19	I-drug
DDI-DrugBank.d66.s0	-	21	21	O
DDI-DrugBank.d66.s0	Concomitant	23	33	O
DDI-DrugBank.d66.s0	use	35	37	O
DDI-DrugBank.d66.s0	of	39	40	O
DDI-DrugBank.d66.s0	L-glutamine	42	52	B-drug
DDI-DrugBank.d66.s0	and	54	56	O
DDI-DrugBank.d66.s0	human	58	62	B-drug
DDI-DrugBank.d66.s0	growth	64	69	I-drug
DDI-DrugBank.d66.s0	hormone	71	77	I-drug
DDI-DrugBank.d66.s0	may	79	81	O
DDI-DrugBank.d66.s0	enhance	83	89	O
DDI-DrugBank.d66.s0	nutrient	91	98	O
DDI-DrugBank.d66.s0	absorption	100	109	O
DDI-DrugBank.d66.s0	in	111	112	O
DDI-DrugBank.d66.s0	those	114	118	O
DDI-DrugBank.d66.s0	with	120	123	O
DDI-DrugBank.d66.s0	severe	125	130	O
DDI-DrugBank.d66.s0	short	132	136	O
DDI-DrugBank.d66.s0	bowel	138	142	O
DDI-DrugBank.d66.s0	syndrome	144	151	O
DDI-DrugBank.d66.s0	.	152	152	O
DDI-DrugBank.d66.s1	L-glutamine	0	10	B-drug
DDI-DrugBank.d66.s1	has	12	14	O
DDI-DrugBank.d66.s1	orphan	16	21	O
DDI-DrugBank.d66.s1	drug	23	26	O
DDI-DrugBank.d66.s1	status	28	33	O
DDI-DrugBank.d66.s1	for	35	37	O
DDI-DrugBank.d66.s1	this	39	42	O
DDI-DrugBank.d66.s1	indication	44	53	O
DDI-DrugBank.d66.s1	.	54	54	O
DDI-DrugBank.d66.s2	Indomethacin	0	11	B-drug
DDI-DrugBank.d66.s2	-	13	13	O
DDI-DrugBank.d66.s2	Concomitant	15	25	O
DDI-DrugBank.d66.s2	use	27	29	O
DDI-DrugBank.d66.s2	of	31	32	O
DDI-DrugBank.d66.s2	L-glutamine	34	44	B-drug
DDI-DrugBank.d66.s2	and	46	48	O
DDI-DrugBank.d66.s2	indomethacin	50	61	B-drug
DDI-DrugBank.d66.s2	may	63	65	O
DDI-DrugBank.d66.s2	ameliorate	67	76	O
DDI-DrugBank.d66.s2	increased	78	86	O
DDI-DrugBank.d66.s2	intestinal	88	97	O
DDI-DrugBank.d66.s2	permeability	99	110	O
DDI-DrugBank.d66.s2	caused	112	117	O
DDI-DrugBank.d66.s2	by	119	120	O
DDI-DrugBank.d66.s2	indomethacin	122	133	B-drug
DDI-DrugBank.d66.s2	.	134	134	O
DDI-DrugBank.d66.s3	The	0	2	O
DDI-DrugBank.d66.s3	reported	4	11	O
DDI-DrugBank.d66.s3	dose	13	16	O
DDI-DrugBank.d66.s3	used	18	21	O
DDI-DrugBank.d66.s3	for	23	25	O
DDI-DrugBank.d66.s3	L-glutamine	27	37	B-drug
DDI-DrugBank.d66.s3	was	39	41	O
DDI-DrugBank.d66.s3	21	43	44	O
DDI-DrugBank.d66.s3	grams	46	50	O
DDI-DrugBank.d66.s3	daily	52	56	O
DDI-DrugBank.d66.s3	taken	58	62	O
DDI-DrugBank.d66.s3	in	64	65	O
DDI-DrugBank.d66.s3	divided	67	73	O
DDI-DrugBank.d66.s3	doses	75	79	O
DDI-DrugBank.d66.s3	three	81	85	O
DDI-DrugBank.d66.s3	times	87	91	O
DDI-DrugBank.d66.s3	a	93	93	O
DDI-DrugBank.d66.s3	day	95	97	O
DDI-DrugBank.d66.s3	.	98	98	O
DDI-DrugBank.d66.s4	Further	0	6	O
DDI-DrugBank.d66.s4	,	7	7	O
DDI-DrugBank.d66.s4	misoprostol	9	19	B-drug
DDI-DrugBank.d66.s4	is	21	22	O
DDI-DrugBank.d66.s4	reported	24	31	O
DDI-DrugBank.d66.s4	to	33	34	O
DDI-DrugBank.d66.s4	have	36	39	O
DDI-DrugBank.d66.s4	a	37	37	O
DDI-DrugBank.d66.s4	synergistic	43	53	O
DDI-DrugBank.d66.s4	effect	55	60	O
DDI-DrugBank.d66.s4	with	62	65	O
DDI-DrugBank.d66.s4	this	67	70	O
DDI-DrugBank.d66.s4	combination	72	82	O
DDI-DrugBank.d66.s4	in	76	77	O
DDI-DrugBank.d66.s4	ameliorating	87	98	O
DDI-DrugBank.d66.s4	intestinal	100	109	O
DDI-DrugBank.d66.s4	permeability	111	122	O
DDI-DrugBank.d66.s4	.	123	123	O
DDI-DrugBank.d66.s5	Methotrexate	0	11	B-drug
DDI-DrugBank.d66.s5	-	13	13	O
DDI-DrugBank.d66.s5	There	15	19	O
DDI-DrugBank.d66.s5	is	21	22	O
DDI-DrugBank.d66.s5	one	24	26	O
DDI-DrugBank.d66.s5	report	28	33	O
DDI-DrugBank.d66.s5	that	35	38	O
DDI-DrugBank.d66.s5	methotrexate	40	51	B-drug
DDI-DrugBank.d66.s5	may	53	55	O
DDI-DrugBank.d66.s5	decrease	57	64	O
DDI-DrugBank.d66.s5	the	66	68	O
DDI-DrugBank.d66.s5	possible	70	77	O
DDI-DrugBank.d66.s5	effectiveness	79	91	O
DDI-DrugBank.d66.s5	of	93	94	O
DDI-DrugBank.d66.s5	supplemental	96	107	O
DDI-DrugBank.d66.s5	L-glutamine	109	119	B-drug
DDI-DrugBank.d66.s5	for	121	123	O
DDI-DrugBank.d66.s5	chemotherapy-induced	125	144	O
DDI-DrugBank.d66.s5	mucositis	146	154	O
DDI-DrugBank.d66.s5	.	155	155	O
DDI-DrugBank.d66.s6	In	0	1	O
DDI-DrugBank.d66.s6	another	3	9	O
DDI-DrugBank.d66.s6	report	11	16	O
DDI-DrugBank.d66.s6	,	17	17	O
DDI-DrugBank.d66.s6	nine	19	22	O
DDI-DrugBank.d66.s6	patients	24	31	O
DDI-DrugBank.d66.s6	with	33	36	O
DDI-DrugBank.d66.s6	breast	38	43	O
DDI-DrugBank.d66.s6	cancer	45	50	O
DDI-DrugBank.d66.s6	were	52	55	O
DDI-DrugBank.d66.s6	reported	57	64	O
DDI-DrugBank.d66.s6	to	66	67	O
DDI-DrugBank.d66.s6	have	69	72	O
DDI-DrugBank.d66.s6	decreased	74	82	O
DDI-DrugBank.d66.s6	symptoms	84	91	O
DDI-DrugBank.d66.s6	of	93	94	O
DDI-DrugBank.d66.s6	methotrexate-related	96	115	O
DDI-DrugBank.d66.s6	toxicity	117	124	O
DDI-DrugBank.d66.s6	when	126	129	O
DDI-DrugBank.d66.s6	given	131	135	O
DDI-DrugBank.d66.s6	supplemental	137	148	O
DDI-DrugBank.d66.s6	L-glutamine	150	160	B-drug
DDI-DrugBank.d66.s6	at	162	163	O
DDI-DrugBank.d66.s6	a	147	147	O
DDI-DrugBank.d66.s6	dose	167	170	O
DDI-DrugBank.d66.s6	of	172	173	O
DDI-DrugBank.d66.s6	0.5	175	177	O
DDI-DrugBank.d66.s6	gram/kilogram/day	179	195	O
DDI-DrugBank.d66.s6	.	176	176	O
DDI-DrugBank.d66.s7	Paclitaxel	0	9	B-drug
DDI-DrugBank.d66.s7	-	11	11	O
DDI-DrugBank.d66.s7	In	13	14	O
DDI-DrugBank.d66.s7	one	16	18	O
DDI-DrugBank.d66.s7	report	20	25	O
DDI-DrugBank.d66.s7	,	26	26	O
DDI-DrugBank.d66.s7	L-glutamine	28	38	B-drug
DDI-DrugBank.d66.s7	at	40	41	O
DDI-DrugBank.d66.s7	a	40	40	O
DDI-DrugBank.d66.s7	dose	45	48	O
DDI-DrugBank.d66.s7	of	50	51	O
DDI-DrugBank.d66.s7	10	53	54	O
DDI-DrugBank.d66.s7	grams	56	60	O
DDI-DrugBank.d66.s7	three	62	66	O
DDI-DrugBank.d66.s7	times	68	72	O
DDI-DrugBank.d66.s7	daily	74	78	O
DDI-DrugBank.d66.s7	,	79	79	O
DDI-DrugBank.d66.s7	given	81	85	O
DDI-DrugBank.d66.s7	24	87	88	O
DDI-DrugBank.d66.s7	hours	90	94	O
DDI-DrugBank.d66.s7	after	96	100	O
DDI-DrugBank.d66.s7	receiving	102	110	O
DDI-DrugBank.d66.s7	paclitaxel	112	121	B-drug
DDI-DrugBank.d66.s7	,	122	122	O
DDI-DrugBank.d66.s7	appeared	124	131	O
DDI-DrugBank.d66.s7	to	133	134	O
DDI-DrugBank.d66.s7	prevent	136	142	O
DDI-DrugBank.d66.s7	the	144	146	O
DDI-DrugBank.d66.s7	development	148	158	O
DDI-DrugBank.d66.s7	of	160	161	O
DDI-DrugBank.d66.s7	myalgia	163	169	O
DDI-DrugBank.d66.s7	and	171	173	O
DDI-DrugBank.d66.s7	arthralgia	175	184	O
DDI-DrugBank.d66.s7	,	185	185	O
DDI-DrugBank.d66.s7	adverse	187	193	O
DDI-DrugBank.d66.s7	reactions	195	203	O
DDI-DrugBank.d66.s7	of	205	206	O
DDI-DrugBank.d66.s7	paclitaxel	208	217	B-drug
DDI-DrugBank.d66.s7	.	218	218	O
DDI-DrugBank.d231.s0	Furosemide	0	9	B-drug
DDI-DrugBank.d231.s0	may	11	13	O
DDI-DrugBank.d231.s0	increase	15	22	O
DDI-DrugBank.d231.s0	the	24	26	O
DDI-DrugBank.d231.s0	ototoxic	28	35	O
DDI-DrugBank.d231.s0	potential	37	45	O
DDI-DrugBank.d231.s0	of	47	48	O
DDI-DrugBank.d231.s0	aminoglycoside	50	63	B-group
DDI-DrugBank.d231.s0	antibiotics	65	75	I-group
DDI-DrugBank.d231.s0	,	76	76	O
DDI-DrugBank.d231.s0	especially	78	87	O
DDI-DrugBank.d231.s0	in	89	90	O
DDI-DrugBank.d231.s0	the	92	94	O
DDI-DrugBank.d231.s0	presence	96	103	O
DDI-DrugBank.d231.s0	of	105	106	O
DDI-DrugBank.d231.s0	impaired	108	115	O
DDI-DrugBank.d231.s0	renal	117	121	O
DDI-DrugBank.d231.s0	function	123	130	O
DDI-DrugBank.d231.s0	.	131	131	O
DDI-DrugBank.d231.s1	Except	0	5	O
DDI-DrugBank.d231.s1	in	7	8	O
DDI-DrugBank.d231.s1	life-threatening	10	25	O
DDI-DrugBank.d231.s1	situations	27	36	O
DDI-DrugBank.d231.s1	,	37	37	O
DDI-DrugBank.d231.s1	avoid	39	43	O
DDI-DrugBank.d231.s1	this	45	48	O
DDI-DrugBank.d231.s1	combination	50	60	O
DDI-DrugBank.d231.s1	.	61	61	O
DDI-DrugBank.d231.s2	Furosemide	0	9	B-drug
DDI-DrugBank.d231.s2	should	11	16	O
DDI-DrugBank.d231.s2	not	18	20	O
DDI-DrugBank.d231.s2	be	22	23	O
DDI-DrugBank.d231.s2	used	25	28	O
DDI-DrugBank.d231.s2	concomitantly	30	42	O
DDI-DrugBank.d231.s2	with	44	47	O
DDI-DrugBank.d231.s2	ethacrynic	49	58	B-drug
DDI-DrugBank.d231.s2	acid	60	63	I-drug
DDI-DrugBank.d231.s2	because	65	71	O
DDI-DrugBank.d231.s2	of	73	74	O
DDI-DrugBank.d231.s2	the	76	78	O
DDI-DrugBank.d231.s2	possibility	80	90	O
DDI-DrugBank.d231.s2	of	92	93	O
DDI-DrugBank.d231.s2	ototoxicity	95	105	O
DDI-DrugBank.d231.s2	.	106	106	O
DDI-DrugBank.d231.s3	Patients	0	7	O
DDI-DrugBank.d231.s3	receiving	9	17	O
DDI-DrugBank.d231.s3	high	19	22	O
DDI-DrugBank.d231.s3	doses	24	28	O
DDI-DrugBank.d231.s3	of	30	31	O
DDI-DrugBank.d231.s3	salicylates	33	43	B-group
DDI-DrugBank.d231.s3	concomitantly	45	57	O
DDI-DrugBank.d231.s3	with	59	62	O
DDI-DrugBank.d231.s3	furosemide	64	73	B-drug
DDI-DrugBank.d231.s3	,	74	74	O
DDI-DrugBank.d231.s3	as	76	77	O
DDI-DrugBank.d231.s3	in	79	80	O
DDI-DrugBank.d231.s3	rheumatic	82	90	O
DDI-DrugBank.d231.s3	disease	92	98	O
DDI-DrugBank.d231.s3	,	99	99	O
DDI-DrugBank.d231.s3	may	101	103	O
DDI-DrugBank.d231.s3	experience	105	114	O
DDI-DrugBank.d231.s3	salicylate	116	125	B-group
DDI-DrugBank.d231.s3	toxicity	127	134	O
DDI-DrugBank.d231.s3	at	123	124	I-group
DDI-DrugBank.d231.s3	lower	139	143	O
DDI-DrugBank.d231.s3	doses	145	149	O
DDI-DrugBank.d231.s3	because	151	157	O
DDI-DrugBank.d231.s3	of	159	160	O
DDI-DrugBank.d231.s3	competitive	162	172	O
DDI-DrugBank.d231.s3	renal	174	178	O
DDI-DrugBank.d231.s3	excretory	180	188	O
DDI-DrugBank.d231.s3	sites	190	194	O
DDI-DrugBank.d231.s3	.	195	195	O
DDI-DrugBank.d231.s4	Furosemide	0	9	B-drug
DDI-DrugBank.d231.s4	has	11	13	O
DDI-DrugBank.d231.s4	a	15	15	O
DDI-DrugBank.d231.s4	tendency	17	24	O
DDI-DrugBank.d231.s4	to	26	27	O
DDI-DrugBank.d231.s4	antagonize	29	38	O
DDI-DrugBank.d231.s4	the	40	42	O
DDI-DrugBank.d231.s4	skeletal	44	51	O
DDI-DrugBank.d231.s4	muscle	53	58	O
DDI-DrugBank.d231.s4	relaxing	60	67	O
DDI-DrugBank.d231.s4	effect	69	74	O
DDI-DrugBank.d231.s4	of	76	77	O
DDI-DrugBank.d231.s4	tubocurarine	79	90	B-drug
DDI-DrugBank.d231.s4	and	92	94	O
DDI-DrugBank.d231.s4	may	96	98	O
DDI-DrugBank.d231.s4	potentiate	100	109	O
DDI-DrugBank.d231.s4	the	111	113	O
DDI-DrugBank.d231.s4	action	115	120	O
DDI-DrugBank.d231.s4	of	122	123	O
DDI-DrugBank.d231.s4	succinylcholine	125	139	B-drug
DDI-DrugBank.d231.s4	.	140	140	O
DDI-DrugBank.d231.s5	Lithium	0	6	B-drug
DDI-DrugBank.d231.s5	generally	8	16	O
DDI-DrugBank.d231.s5	should	18	23	O
DDI-DrugBank.d231.s5	not	25	27	O
DDI-DrugBank.d231.s5	be	29	30	O
DDI-DrugBank.d231.s5	given	32	36	O
DDI-DrugBank.d231.s5	with	38	41	O
DDI-DrugBank.d231.s5	diuretics	43	51	B-group
DDI-DrugBank.d231.s5	because	53	59	O
DDI-DrugBank.d231.s5	they	61	64	O
DDI-DrugBank.d231.s5	reduce	66	71	O
DDI-DrugBank.d231.s5	lithiums	73	80	O
DDI-DrugBank.d231.s5	renal	82	86	O
DDI-DrugBank.d231.s5	clearance	88	96	O
DDI-DrugBank.d231.s5	and	98	100	O
DDI-DrugBank.d231.s5	add	102	104	O
DDI-DrugBank.d231.s5	a	91	91	O
DDI-DrugBank.d231.s5	high	108	111	O
DDI-DrugBank.d231.s5	risk	113	116	O
DDI-DrugBank.d231.s5	of	118	119	O
DDI-DrugBank.d231.s5	lithium	121	127	B-drug
DDI-DrugBank.d231.s5	toxicity	129	136	O
DDI-DrugBank.d231.s5	.	137	137	O
DDI-DrugBank.d231.s6	Furosemide	0	9	B-drug
DDI-DrugBank.d231.s6	may	11	13	O
DDI-DrugBank.d231.s6	add	15	17	O
DDI-DrugBank.d231.s6	to	19	20	O
DDI-DrugBank.d231.s6	or	22	23	O
DDI-DrugBank.d231.s6	potentiate	25	34	O
DDI-DrugBank.d231.s6	the	36	38	O
DDI-DrugBank.d231.s6	therapeutic	40	50	O
DDI-DrugBank.d231.s6	effect	52	57	O
DDI-DrugBank.d231.s6	of	59	60	O
DDI-DrugBank.d231.s6	other	62	66	O
DDI-DrugBank.d231.s6	antihypertensive	68	83	B-group
DDI-DrugBank.d231.s6	drugs	85	89	I-group
DDI-DrugBank.d231.s6	.	90	90	O
DDI-DrugBank.d231.s7	Potentiation	0	11	O
DDI-DrugBank.d231.s7	occurs	13	18	O
DDI-DrugBank.d231.s7	with	20	23	O
DDI-DrugBank.d231.s7	ganglionic	25	34	B-group
DDI-DrugBank.d231.s7	or	36	37	O
DDI-DrugBank.d231.s7	peripheral	39	48	B-group
DDI-DrugBank.d231.s7	adrenergic	50	59	I-group
DDI-DrugBank.d231.s7	blocking	61	68	I-group
DDI-DrugBank.d231.s7	drugs	70	74	I-group
DDI-DrugBank.d231.s7	.	75	75	O
DDI-DrugBank.d231.s8	Furosemide	0	9	B-drug
DDI-DrugBank.d231.s8	may	11	13	O
DDI-DrugBank.d231.s8	decrease	15	22	O
DDI-DrugBank.d231.s8	arterial	24	31	O
DDI-DrugBank.d231.s8	responsiveness	33	46	O
DDI-DrugBank.d231.s8	to	48	49	O
DDI-DrugBank.d231.s8	norepinephrine	51	64	B-drug
DDI-DrugBank.d231.s8	.	65	65	O
DDI-DrugBank.d231.s9	However	0	6	O
DDI-DrugBank.d231.s9	,	7	7	O
DDI-DrugBank.d231.s9	norepinephrine	9	22	B-drug
DDI-DrugBank.d231.s9	may	24	26	O
DDI-DrugBank.d231.s9	still	28	32	O
DDI-DrugBank.d231.s9	be	34	35	O
DDI-DrugBank.d231.s9	used	37	40	O
DDI-DrugBank.d231.s9	effectively	42	52	O
DDI-DrugBank.d231.s9	.	53	53	O
DDI-DrugBank.d231.s10	Tablets	0	6	O
DDI-DrugBank.d231.s10	Simultaneous	8	19	O
DDI-DrugBank.d231.s10	administration	21	34	O
DDI-DrugBank.d231.s10	of	36	37	O
DDI-DrugBank.d231.s10	sucralfate	39	48	B-drug
DDI-DrugBank.d231.s10	and	50	52	O
DDI-DrugBank.d231.s10	furosemide	54	63	B-drug
DDI-DrugBank.d231.s10	tablets	65	71	O
DDI-DrugBank.d231.s10	may	73	75	O
DDI-DrugBank.d231.s10	reduce	77	82	O
DDI-DrugBank.d231.s10	the	84	86	O
DDI-DrugBank.d231.s10	natriuretic	88	98	O
DDI-DrugBank.d231.s10	and	100	102	O
DDI-DrugBank.d231.s10	antihypertensive	104	119	O
DDI-DrugBank.d231.s10	effects	121	127	O
DDI-DrugBank.d231.s10	of	129	130	O
DDI-DrugBank.d231.s10	furosemide	132	141	B-drug
DDI-DrugBank.d231.s10	.	142	142	O
DDI-DrugBank.d231.s11	Patients	0	7	O
DDI-DrugBank.d231.s11	receiving	9	17	O
DDI-DrugBank.d231.s11	both	19	22	O
DDI-DrugBank.d231.s11	drugs	24	28	O
DDI-DrugBank.d231.s11	should	30	35	O
DDI-DrugBank.d231.s11	be	37	38	O
DDI-DrugBank.d231.s11	observed	40	47	O
DDI-DrugBank.d231.s11	closely	49	55	O
DDI-DrugBank.d231.s11	to	57	58	O
DDI-DrugBank.d231.s11	determine	60	68	O
DDI-DrugBank.d231.s11	if	70	71	O
DDI-DrugBank.d231.s11	the	73	75	O
DDI-DrugBank.d231.s11	desired	77	83	O
DDI-DrugBank.d231.s11	diuretic	85	92	O
DDI-DrugBank.d231.s11	and/or	94	99	O
DDI-DrugBank.d231.s11	antihypertensive	101	116	O
DDI-DrugBank.d231.s11	effect	118	123	O
DDI-DrugBank.d231.s11	of	125	126	O
DDI-DrugBank.d231.s11	furosemide	128	137	B-drug
DDI-DrugBank.d231.s11	is	139	140	O
DDI-DrugBank.d231.s11	achieved	142	149	O
DDI-DrugBank.d231.s11	.	150	150	O
DDI-DrugBank.d231.s12	The	0	2	O
DDI-DrugBank.d231.s12	intake	4	9	O
DDI-DrugBank.d231.s12	of	11	12	O
DDI-DrugBank.d231.s12	furosemide	14	23	B-drug
DDI-DrugBank.d231.s12	and	25	27	O
DDI-DrugBank.d231.s12	sucralfate	29	38	B-drug
DDI-DrugBank.d231.s12	should	40	45	O
DDI-DrugBank.d231.s12	be	47	48	O
DDI-DrugBank.d231.s12	separated	50	58	O
DDI-DrugBank.d231.s12	by	60	61	O
DDI-DrugBank.d231.s12	at	55	56	O
DDI-DrugBank.d231.s12	least	66	70	O
DDI-DrugBank.d231.s12	two	72	74	O
DDI-DrugBank.d231.s12	hours	76	80	O
DDI-DrugBank.d231.s12	.	81	81	O
DDI-DrugBank.d231.s13	Tablets	0	6	O
DDI-DrugBank.d231.s13	,	7	7	O
DDI-DrugBank.d231.s13	Injection	9	17	O
DDI-DrugBank.d231.s13	,	18	18	O
DDI-DrugBank.d231.s13	and	20	22	O
DDI-DrugBank.d231.s13	Oral	24	27	O
DDI-DrugBank.d231.s13	Solution	29	36	O
DDI-DrugBank.d231.s13	One	38	40	O
DDI-DrugBank.d231.s13	study	42	46	O
DDI-DrugBank.d231.s13	in	48	49	O
DDI-DrugBank.d231.s13	six	51	53	O
DDI-DrugBank.d231.s13	subjects	55	62	O
DDI-DrugBank.d231.s13	demonstrated	64	75	O
DDI-DrugBank.d231.s13	that	77	80	O
DDI-DrugBank.d231.s13	the	82	84	O
DDI-DrugBank.d231.s13	combination	86	96	O
DDI-DrugBank.d231.s13	of	98	99	O
DDI-DrugBank.d231.s13	furosemide	101	110	B-drug
DDI-DrugBank.d231.s13	and	112	114	O
DDI-DrugBank.d231.s13	acetylsalicylic	116	130	B-drug
DDI-DrugBank.d231.s13	acid	132	135	I-drug
DDI-DrugBank.d231.s13	temporarily	137	147	O
DDI-DrugBank.d231.s13	reduced	149	155	O
DDI-DrugBank.d231.s13	creatinine	157	166	O
DDI-DrugBank.d231.s13	clearance	168	176	O
DDI-DrugBank.d231.s13	in	162	163	O
DDI-DrugBank.d231.s13	patients	181	188	O
DDI-DrugBank.d231.s13	with	190	193	O
DDI-DrugBank.d231.s13	chronic	195	201	O
DDI-DrugBank.d231.s13	renal	203	207	O
DDI-DrugBank.d231.s13	insufficiency	209	221	O
DDI-DrugBank.d231.s13	.	222	222	O
DDI-DrugBank.d231.s14	There	0	4	O
DDI-DrugBank.d231.s14	are	6	8	O
DDI-DrugBank.d231.s14	case	10	13	O
DDI-DrugBank.d231.s14	reports	15	21	O
DDI-DrugBank.d231.s14	of	23	24	O
DDI-DrugBank.d231.s14	patients	26	33	O
DDI-DrugBank.d231.s14	who	35	37	O
DDI-DrugBank.d231.s14	developed	39	47	O
DDI-DrugBank.d231.s14	increased	49	57	O
DDI-DrugBank.d231.s14	BUN	59	61	O
DDI-DrugBank.d231.s14	,	62	62	O
DDI-DrugBank.d231.s14	serum	64	68	O
DDI-DrugBank.d231.s14	creatinine	70	79	O
DDI-DrugBank.d231.s14	and	81	83	O
DDI-DrugBank.d231.s14	serum	85	89	O
DDI-DrugBank.d231.s14	potassium	91	99	O
DDI-DrugBank.d231.s14	levels	101	106	O
DDI-DrugBank.d231.s14	,	107	107	O
DDI-DrugBank.d231.s14	and	109	111	O
DDI-DrugBank.d231.s14	weight	113	118	O
DDI-DrugBank.d231.s14	gain	120	123	O
DDI-DrugBank.d231.s14	when	125	128	O
DDI-DrugBank.d231.s14	furosemide	130	139	B-drug
DDI-DrugBank.d231.s14	was	141	143	O
DDI-DrugBank.d231.s14	used	145	148	O
DDI-DrugBank.d231.s14	in	150	151	O
DDI-DrugBank.d231.s14	conjunction	153	163	O
DDI-DrugBank.d231.s14	with	165	168	O
DDI-DrugBank.d231.s14	NSAIDs	170	175	B-group
DDI-DrugBank.d231.s14	.	176	176	O
DDI-DrugBank.d231.s15	Literature	0	9	O
DDI-DrugBank.d231.s15	reports	11	17	O
DDI-DrugBank.d231.s15	indicate	19	26	O
DDI-DrugBank.d231.s15	that	28	31	O
DDI-DrugBank.d231.s15	coadministration	33	48	O
DDI-DrugBank.d231.s15	of	50	51	O
DDI-DrugBank.d231.s15	indomethacin	53	64	B-drug
DDI-DrugBank.d231.s15	may	66	68	O
DDI-DrugBank.d231.s15	reduce	70	75	O
DDI-DrugBank.d231.s15	the	77	79	O
DDI-DrugBank.d231.s15	natriuretic	81	91	O
DDI-DrugBank.d231.s15	and	93	95	O
DDI-DrugBank.d231.s15	antihypertensive	97	112	O
DDI-DrugBank.d231.s15	effects	114	120	O
DDI-DrugBank.d231.s15	of	122	123	O
DDI-DrugBank.d231.s15	furosemide	125	134	B-drug
DDI-DrugBank.d231.s15	in	136	137	O
DDI-DrugBank.d231.s15	some	139	142	O
DDI-DrugBank.d231.s15	patients	144	151	O
DDI-DrugBank.d231.s15	by	153	154	O
DDI-DrugBank.d231.s15	inhibiting	156	165	O
DDI-DrugBank.d231.s15	prostaglandin	167	179	O
DDI-DrugBank.d231.s15	synthesis	181	189	O
DDI-DrugBank.d231.s15	.	190	190	O
DDI-DrugBank.d231.s16	Indomethacin	0	11	B-drug
DDI-DrugBank.d231.s16	may	13	15	O
DDI-DrugBank.d231.s16	also	17	20	O
DDI-DrugBank.d231.s16	affect	22	27	O
DDI-DrugBank.d231.s16	plasma	29	34	O
DDI-DrugBank.d231.s16	renin	36	40	O
DDI-DrugBank.d231.s16	levels	42	47	O
DDI-DrugBank.d231.s16	,	48	48	O
DDI-DrugBank.d231.s16	aldosterone	50	60	O
DDI-DrugBank.d231.s16	excretion	62	70	O
DDI-DrugBank.d231.s16	,	71	71	O
DDI-DrugBank.d231.s16	and	73	75	O
DDI-DrugBank.d231.s16	renin	77	81	O
DDI-DrugBank.d231.s16	profile	83	89	O
DDI-DrugBank.d231.s16	evaluation	91	100	O
DDI-DrugBank.d231.s16	.	101	101	O
DDI-DrugBank.d231.s17	Patients	0	7	O
DDI-DrugBank.d231.s17	receiving	9	17	O
DDI-DrugBank.d231.s17	both	19	22	O
DDI-DrugBank.d231.s17	indomethacin	24	35	B-drug
DDI-DrugBank.d231.s17	and	37	39	O
DDI-DrugBank.d231.s17	furosemide	41	50	B-drug
DDI-DrugBank.d231.s17	should	52	57	O
DDI-DrugBank.d231.s17	be	59	60	O
DDI-DrugBank.d231.s17	observed	62	69	O
DDI-DrugBank.d231.s17	closely	71	77	O
DDI-DrugBank.d231.s17	to	79	80	O
DDI-DrugBank.d231.s17	determine	82	90	O
DDI-DrugBank.d231.s17	if	92	93	O
DDI-DrugBank.d231.s17	the	95	97	O
DDI-DrugBank.d231.s17	desired	99	105	O
DDI-DrugBank.d231.s17	diuretic	107	114	O
DDI-DrugBank.d231.s17	and/or	116	121	O
DDI-DrugBank.d231.s17	antihypertensive	123	138	O
DDI-DrugBank.d231.s17	effect	140	145	O
DDI-DrugBank.d231.s17	of	147	148	O
DDI-DrugBank.d231.s17	furosemide	150	159	B-drug
DDI-DrugBank.d231.s17	is	161	162	O
DDI-DrugBank.d231.s17	achieved	164	171	O
DDI-DrugBank.d231.s17	.	172	172	O
DDI-DrugBank.d716.s0	You	0	2	O
DDI-DrugBank.d716.s0	can	4	6	O
DDI-DrugBank.d716.s0	not	7	9	O
DDI-DrugBank.d716.s0	take	11	14	O
DDI-DrugBank.d716.s0	mazindol	16	23	B-drug
DDI-DrugBank.d716.s0	if	25	26	O
DDI-DrugBank.d716.s0	you	28	30	O
DDI-DrugBank.d716.s0	have	32	35	O
DDI-DrugBank.d716.s0	taken	37	41	O
DDI-DrugBank.d716.s0	a	38	38	O
DDI-DrugBank.d716.s0	monoamine	45	53	B-group
DDI-DrugBank.d716.s0	oxidase	55	61	I-group
DDI-DrugBank.d716.s0	inhibitor	63	71	I-group
DDI-DrugBank.d716.s0	(	73	73	O
DDI-DrugBank.d716.s0	MAOI	74	77	B-group
DDI-DrugBank.d716.s0	)	78	78	O
DDI-DrugBank.d716.s0	such	80	83	O
DDI-DrugBank.d716.s0	as	85	86	O
DDI-DrugBank.d716.s0	isocarboxazid	88	100	B-drug
DDI-DrugBank.d716.s0	(	102	102	O
DDI-DrugBank.d716.s0	Marplan	103	109	B-brand
DDI-DrugBank.d716.s0	)	110	110	O
DDI-DrugBank.d716.s0	,	111	111	O
DDI-DrugBank.d716.s0	tranylcypromine	113	127	B-drug
DDI-DrugBank.d716.s0	(	129	129	O
DDI-DrugBank.d716.s0	Parnate	130	136	B-brand
DDI-DrugBank.d716.s0	)	137	137	O
DDI-DrugBank.d716.s0	,	138	138	O
DDI-DrugBank.d716.s0	or	140	141	O
DDI-DrugBank.d716.s0	phenelzine	143	152	B-drug
DDI-DrugBank.d716.s0	(	154	154	O
DDI-DrugBank.d716.s0	Nardil	155	160	B-brand
DDI-DrugBank.d716.s0	)	161	161	O
DDI-DrugBank.d716.s0	in	150	151	I-drug
DDI-DrugBank.d716.s0	the	166	168	O
DDI-DrugBank.d716.s0	last	170	173	O
DDI-DrugBank.d716.s0	14	175	176	O
DDI-DrugBank.d716.s0	days	178	181	O
DDI-DrugBank.d716.s0	.	182	182	O
DDI-DrugBank.d716.s1	Changes	0	6	O
DDI-DrugBank.d716.s1	in	8	9	O
DDI-DrugBank.d716.s1	insulin	11	17	B-drug
DDI-DrugBank.d716.s1	and	19	21	O
DDI-DrugBank.d716.s1	other	23	27	O
DDI-DrugBank.d716.s1	diabetes	29	36	O
DDI-DrugBank.d716.s1	drug	38	41	O
DDI-DrugBank.d716.s1	therapies	43	51	O
DDI-DrugBank.d716.s1	may	53	55	O
DDI-DrugBank.d716.s1	be	57	58	O
DDI-DrugBank.d716.s1	necessary	60	68	O
DDI-DrugBank.d716.s1	during	70	75	O
DDI-DrugBank.d716.s1	treatment	77	85	O
DDI-DrugBank.d716.s1	with	87	90	O
DDI-DrugBank.d716.s1	mazindol	92	99	B-drug
DDI-DrugBank.d716.s1	.	100	100	O
DDI-DrugBank.d716.s2	Mazindol	0	7	B-drug
DDI-DrugBank.d716.s2	may	9	11	O
DDI-DrugBank.d716.s2	reduce	13	18	O
DDI-DrugBank.d716.s2	the	20	22	O
DDI-DrugBank.d716.s2	effects	24	30	O
DDI-DrugBank.d716.s2	of	32	33	O
DDI-DrugBank.d716.s2	guanethidine	35	46	B-drug
DDI-DrugBank.d716.s2	(	48	48	O
DDI-DrugBank.d716.s2	Ismelin	49	55	B-brand
DDI-DrugBank.d716.s2	)	56	56	O
DDI-DrugBank.d716.s2	.	57	57	O
DDI-DrugBank.d716.s3	This	0	3	O
DDI-DrugBank.d716.s3	could	5	9	O
DDI-DrugBank.d716.s3	lead	11	14	O
DDI-DrugBank.d716.s3	to	16	17	O
DDI-DrugBank.d716.s3	an	19	20	O
DDI-DrugBank.d716.s3	increase	22	29	O
DDI-DrugBank.d716.s3	in	31	32	O
DDI-DrugBank.d716.s3	blood	34	38	O
DDI-DrugBank.d716.s3	pressure	40	47	O
DDI-DrugBank.d716.s3	.	48	48	O
DDI-DrugBank.d716.s4	Tell	0	3	O
DDI-DrugBank.d716.s4	your	5	8	O
DDI-DrugBank.d716.s4	doctor	10	15	O
DDI-DrugBank.d716.s4	if	17	18	O
DDI-DrugBank.d716.s4	you	20	22	O
DDI-DrugBank.d716.s4	are	24	26	O
DDI-DrugBank.d716.s4	taking	28	33	O
DDI-DrugBank.d716.s4	guanethidine	35	46	B-drug
DDI-DrugBank.d716.s4	.	47	47	O
DDI-DrugBank.d716.s5	Before	0	5	O
DDI-DrugBank.d716.s5	taking	7	12	O
DDI-DrugBank.d716.s5	this	14	17	O
DDI-DrugBank.d716.s5	medication	19	28	O
DDI-DrugBank.d716.s5	,	29	29	O
DDI-DrugBank.d716.s5	tell	31	34	O
DDI-DrugBank.d716.s5	your	36	39	O
DDI-DrugBank.d716.s5	doctor	41	46	O
DDI-DrugBank.d716.s5	if	48	49	O
DDI-DrugBank.d716.s5	you	51	53	O
DDI-DrugBank.d716.s5	are	55	57	O
DDI-DrugBank.d716.s5	taking	59	64	O
DDI-DrugBank.d716.s5	a	55	55	O
DDI-DrugBank.d716.s5	tricyclic	68	76	B-group
DDI-DrugBank.d716.s5	antidepressant	78	91	I-group
DDI-DrugBank.d716.s5	such	93	96	O
DDI-DrugBank.d716.s5	as	98	99	O
DDI-DrugBank.d716.s5	amitriptyline	101	113	B-drug
DDI-DrugBank.d716.s5	(	115	115	O
DDI-DrugBank.d716.s5	Elavil	116	121	B-brand
DDI-DrugBank.d716.s5	)	122	122	O
DDI-DrugBank.d716.s5	,	123	123	O
DDI-DrugBank.d716.s5	amoxapine	125	133	B-drug
DDI-DrugBank.d716.s5	(	135	135	O
DDI-DrugBank.d716.s5	Asendin	136	142	B-brand
DDI-DrugBank.d716.s5	)	143	143	O
DDI-DrugBank.d716.s5	,	144	144	O
DDI-DrugBank.d716.s5	doxepin	146	152	B-drug
DDI-DrugBank.d716.s5	(	135	135	O
DDI-DrugBank.d716.s5	Sinequan	155	162	B-brand
DDI-DrugBank.d716.s5	)	143	143	O
DDI-DrugBank.d716.s5	,	144	144	O
DDI-DrugBank.d716.s5	nortriptyline	166	178	B-drug
DDI-DrugBank.d716.s5	(	180	180	O
DDI-DrugBank.d716.s5	Pamelor	181	187	B-brand
DDI-DrugBank.d716.s5	)	188	188	O
DDI-DrugBank.d716.s5	,	189	189	O
DDI-DrugBank.d716.s5	imipramine	191	200	B-drug
DDI-DrugBank.d716.s5	(	180	180	O
DDI-DrugBank.d716.s5	Tofranil	203	210	B-brand
DDI-DrugBank.d716.s5	)	188	188	O
DDI-DrugBank.d716.s5	,	189	189	O
DDI-DrugBank.d716.s5	clomipramine	214	225	B-drug
DDI-DrugBank.d716.s5	(	202	202	O
DDI-DrugBank.d716.s5	Anafranil	228	236	B-brand
DDI-DrugBank.d716.s5	)	211	211	O
DDI-DrugBank.d716.s5	,	212	212	O
DDI-DrugBank.d716.s5	protriptyline	240	252	B-drug
DDI-DrugBank.d716.s5	(	227	227	O
DDI-DrugBank.d716.s5	Vivactil	255	262	B-brand
DDI-DrugBank.d716.s5	)	237	237	O
DDI-DrugBank.d716.s5	,	238	238	O
DDI-DrugBank.d716.s5	or	266	267	O
DDI-DrugBank.d716.s5	desipramine	269	279	B-drug
DDI-DrugBank.d716.s5	(	254	254	O
DDI-DrugBank.d716.s5	Norpramin	282	290	B-brand
DDI-DrugBank.d716.s5	)	263	263	O
DDI-DrugBank.d716.s5	.	292	292	O
DDI-DrugBank.d716.s6	These	0	4	O
DDI-DrugBank.d716.s6	drugs	6	10	O
DDI-DrugBank.d716.s6	may	12	14	O
DDI-DrugBank.d716.s6	decrease	16	23	O
DDI-DrugBank.d716.s6	the	25	27	O
DDI-DrugBank.d716.s6	effects	29	35	O
DDI-DrugBank.d716.s6	of	37	38	O
DDI-DrugBank.d716.s6	mazindol	40	47	B-drug
DDI-DrugBank.d716.s6	.	48	48	O
DDI-DrugBank.d16.s0	Prospective	0	10	O
DDI-DrugBank.d16.s0	studies	12	18	O
DDI-DrugBank.d16.s0	on	20	21	O
DDI-DrugBank.d16.s0	the	23	25	O
DDI-DrugBank.d16.s0	potential	27	35	O
DDI-DrugBank.d16.s0	for	37	39	O
DDI-DrugBank.d16.s0	hydroxyurea	41	51	B-drug
DDI-DrugBank.d16.s0	to	53	54	O
DDI-DrugBank.d16.s0	interact	56	63	O
DDI-DrugBank.d16.s0	with	65	68	O
DDI-DrugBank.d16.s0	other	70	74	O
DDI-DrugBank.d16.s0	drugs	76	80	O
DDI-DrugBank.d16.s0	have	82	85	O
DDI-DrugBank.d16.s0	not	87	89	O
DDI-DrugBank.d16.s0	been	91	94	O
DDI-DrugBank.d16.s0	performed	96	104	O
DDI-DrugBank.d16.s0	.	105	105	O
DDI-DrugBank.d16.s1	Concurrent	0	9	O
DDI-DrugBank.d16.s1	use	11	13	O
DDI-DrugBank.d16.s1	of	15	16	O
DDI-DrugBank.d16.s1	hydroxyurea	18	28	B-drug
DDI-DrugBank.d16.s1	and	30	32	O
DDI-DrugBank.d16.s1	other	34	38	O
DDI-DrugBank.d16.s1	myelosuppressive	40	55	O
DDI-DrugBank.d16.s1	agents	57	62	O
DDI-DrugBank.d16.s1	or	64	65	O
DDI-DrugBank.d16.s1	radiation	67	75	O
DDI-DrugBank.d16.s1	therapy	77	83	O
DDI-DrugBank.d16.s1	may	85	87	O
DDI-DrugBank.d16.s1	increase	89	96	O
DDI-DrugBank.d16.s1	the	98	100	O
DDI-DrugBank.d16.s1	likelihood	102	111	O
DDI-DrugBank.d16.s1	of	113	114	O
DDI-DrugBank.d16.s1	bone	116	119	O
DDI-DrugBank.d16.s1	marrow	121	126	O
DDI-DrugBank.d16.s1	depression	128	137	O
DDI-DrugBank.d16.s1	or	139	140	O
DDI-DrugBank.d16.s1	other	142	146	O
DDI-DrugBank.d16.s1	adverse	148	154	O
DDI-DrugBank.d16.s1	events	156	161	O
DDI-DrugBank.d16.s1	.	162	162	O
DDI-DrugBank.d16.s2	Since	0	4	O
DDI-DrugBank.d16.s2	hydroxyurea	6	16	B-drug
DDI-DrugBank.d16.s2	may	18	20	O
DDI-DrugBank.d16.s2	raise	22	26	O
DDI-DrugBank.d16.s2	the	28	30	O
DDI-DrugBank.d16.s2	serum	32	36	O
DDI-DrugBank.d16.s2	uric	38	41	O
DDI-DrugBank.d16.s2	acid	43	46	O
DDI-DrugBank.d16.s2	level	48	52	O
DDI-DrugBank.d16.s2	,	53	53	O
DDI-DrugBank.d16.s2	dosage	55	60	O
DDI-DrugBank.d16.s2	adjustment	62	71	O
DDI-DrugBank.d16.s2	of	73	74	O
DDI-DrugBank.d16.s2	uricosuric	76	85	B-group
DDI-DrugBank.d16.s2	medication	87	96	I-group
DDI-DrugBank.d16.s2	may	98	100	O
DDI-DrugBank.d16.s2	be	102	103	O
DDI-DrugBank.d16.s2	necessary	105	113	O
DDI-DrugBank.d16.s3	.	0	0	O
DDI-DrugBank.d121.s0	Nephrotoxicity	0	13	O
DDI-DrugBank.d121.s0	has	15	17	O
DDI-DrugBank.d121.s0	been	19	22	O
DDI-DrugBank.d121.s0	reported	24	31	O
DDI-DrugBank.d121.s0	following	33	41	O
DDI-DrugBank.d121.s0	concomitant	43	53	O
DDI-DrugBank.d121.s0	administration	55	68	O
DDI-DrugBank.d121.s0	of	70	71	O
DDI-DrugBank.d121.s0	aminoglycoside	73	86	B-group
DDI-DrugBank.d121.s0	antibiotics	88	98	I-group
DDI-DrugBank.d121.s0	and	100	102	O
DDI-DrugBank.d121.s0	cephalosporin	104	116	B-group
DDI-DrugBank.d121.s0	antibiotics	118	128	I-group
DDI-DrugBank.d121.s0	.	129	129	O
DDI-DrugBank.d121.s1	Concomitant	0	10	O
DDI-DrugBank.d121.s1	administration	12	25	O
DDI-DrugBank.d121.s1	of	27	28	O
DDI-DrugBank.d121.s1	probenecid	30	39	B-drug
DDI-DrugBank.d121.s1	doubled	41	47	O
DDI-DrugBank.d121.s1	the	49	51	O
DDI-DrugBank.d121.s1	AUC	53	55	O
DDI-DrugBank.d121.s1	for	57	59	O
DDI-DrugBank.d121.s1	cefprozil	61	69	B-drug
DDI-DrugBank.d121.s1	.	70	70	O
DDI-DrugBank.d121.s2	The	0	2	O
DDI-DrugBank.d121.s2	bioavailability	4	18	O
DDI-DrugBank.d121.s2	of	20	21	O
DDI-DrugBank.d121.s2	the	23	25	O
DDI-DrugBank.d121.s2	capsule	27	33	O
DDI-DrugBank.d121.s2	formulation	35	45	O
DDI-DrugBank.d121.s2	of	47	48	O
DDI-DrugBank.d121.s2	cefprozil	50	58	B-drug
DDI-DrugBank.d121.s2	was	60	62	O
DDI-DrugBank.d121.s2	not	64	66	O
DDI-DrugBank.d121.s2	affected	68	75	O
DDI-DrugBank.d121.s2	when	77	80	O
DDI-DrugBank.d121.s2	administered	82	93	O
DDI-DrugBank.d121.s2	5	95	95	O
DDI-DrugBank.d121.s2	minutes	97	103	O
DDI-DrugBank.d121.s2	following	105	113	O
DDI-DrugBank.d121.s2	an	115	116	O
DDI-DrugBank.d121.s2	antacid	118	124	B-group
DDI-DrugBank.d121.s2	.	125	125	O
DDI-DrugBank.d84.s0	The	0	2	O
DDI-DrugBank.d84.s0	concomitant	4	14	O
DDI-DrugBank.d84.s0	administration	16	29	O
DDI-DrugBank.d84.s0	of	31	32	O
DDI-DrugBank.d84.s0	Exjade	34	39	B-brand
DDI-DrugBank.d84.s0	and	41	43	O
DDI-DrugBank.d84.s0	aluminum-containing	45	63	O
DDI-DrugBank.d84.s0	antacid	65	71	B-group
DDI-DrugBank.d84.s0	preparations	73	84	I-group
DDI-DrugBank.d84.s0	has	86	88	O
DDI-DrugBank.d84.s0	not	90	92	O
DDI-DrugBank.d84.s0	been	94	97	O
DDI-DrugBank.d84.s0	formally	99	106	O
DDI-DrugBank.d84.s0	studied	108	114	O
DDI-DrugBank.d84.s0	.	115	115	O
DDI-DrugBank.d84.s1	Although	0	7	O
DDI-DrugBank.d84.s1	deferasirox	9	19	B-drug
DDI-DrugBank.d84.s1	has	21	23	O
DDI-DrugBank.d84.s1	a	22	22	O
DDI-DrugBank.d84.s1	lower	27	31	O
DDI-DrugBank.d84.s1	affinity	33	40	O
DDI-DrugBank.d84.s1	for	42	44	O
DDI-DrugBank.d84.s1	aluminum	46	53	B-drug
DDI-DrugBank.d84.s1	than	55	58	O
DDI-DrugBank.d84.s1	for	60	62	O
DDI-DrugBank.d84.s1	iron	64	67	B-drug
DDI-DrugBank.d84.s1	,	68	68	O
DDI-DrugBank.d84.s1	Exjade	70	75	B-brand
DDI-DrugBank.d84.s1	should	77	82	O
DDI-DrugBank.d84.s1	not	84	86	O
DDI-DrugBank.d84.s1	be	88	89	O
DDI-DrugBank.d84.s1	taken	91	95	O
DDI-DrugBank.d84.s1	with	97	100	O
DDI-DrugBank.d84.s1	aluminum-containing	102	120	O
DDI-DrugBank.d84.s1	antacid	122	128	B-group
DDI-DrugBank.d84.s1	preparations	130	141	I-group
DDI-DrugBank.d84.s1	.	142	142	O
DDI-DrugBank.d84.s2	In	0	1	O
DDI-DrugBank.d84.s2	healthy	3	9	O
DDI-DrugBank.d84.s2	volunteers	11	20	O
DDI-DrugBank.d84.s2	,	21	21	O
DDI-DrugBank.d84.s2	Exjade	23	28	B-brand
DDI-DrugBank.d84.s2	had	30	32	O
DDI-DrugBank.d84.s2	no	34	35	O
DDI-DrugBank.d84.s2	effect	37	42	O
DDI-DrugBank.d84.s2	on	44	45	O
DDI-DrugBank.d84.s2	the	47	49	O
DDI-DrugBank.d84.s2	pharmacokinetics	51	66	O
DDI-DrugBank.d84.s2	of	68	69	O
DDI-DrugBank.d84.s2	digoxin	71	77	B-drug
DDI-DrugBank.d84.s2	.	78	78	O
DDI-DrugBank.d84.s3	The	0	2	O
DDI-DrugBank.d84.s3	effect	4	9	O
DDI-DrugBank.d84.s3	of	11	12	O
DDI-DrugBank.d84.s3	digoxin	14	20	B-drug
DDI-DrugBank.d84.s3	on	22	23	O
DDI-DrugBank.d84.s3	Exjade	25	30	B-brand
DDI-DrugBank.d84.s3	pharmacokinetics	32	47	O
DDI-DrugBank.d84.s3	has	49	51	O
DDI-DrugBank.d84.s3	not	53	55	O
DDI-DrugBank.d84.s3	been	57	60	O
DDI-DrugBank.d84.s3	studied	62	68	O
DDI-DrugBank.d84.s3	.	69	69	O
DDI-DrugBank.d84.s4	The	0	2	O
DDI-DrugBank.d84.s4	concomitant	4	14	O
DDI-DrugBank.d84.s4	administration	16	29	O
DDI-DrugBank.d84.s4	of	31	32	O
DDI-DrugBank.d84.s4	Exjade	34	39	B-brand
DDI-DrugBank.d84.s4	and	41	43	O
DDI-DrugBank.d84.s4	vitamin	45	51	B-drug
DDI-DrugBank.d84.s4	C	53	53	O
DDI-DrugBank.d84.s4	has	55	57	O
DDI-DrugBank.d84.s4	not	59	61	O
DDI-DrugBank.d84.s4	been	63	66	O
DDI-DrugBank.d84.s4	formally	68	75	O
DDI-DrugBank.d84.s4	studied	77	83	O
DDI-DrugBank.d84.s4	.	84	84	O
DDI-DrugBank.d84.s5	Doses	0	4	O
DDI-DrugBank.d84.s5	of	6	7	O
DDI-DrugBank.d84.s5	vitamin	9	15	B-drug
DDI-DrugBank.d84.s5	C	17	17	O
DDI-DrugBank.d84.s5	up	19	20	O
DDI-DrugBank.d84.s5	to	22	23	O
DDI-DrugBank.d84.s5	200	25	27	O
DDI-DrugBank.d84.s5	mg	29	30	O
DDI-DrugBank.d84.s5	were	32	35	O
DDI-DrugBank.d84.s5	allowed	37	43	O
DDI-DrugBank.d84.s5	in	45	46	O
DDI-DrugBank.d84.s5	clinical	48	55	O
DDI-DrugBank.d84.s5	studies	57	63	O
DDI-DrugBank.d84.s5	without	65	71	O
DDI-DrugBank.d84.s5	negative	73	80	O
DDI-DrugBank.d84.s5	consequences	82	93	O
DDI-DrugBank.d84.s5	.	94	94	O
DDI-DrugBank.d84.s6	The	0	2	O
DDI-DrugBank.d84.s6	interaction	4	14	O
DDI-DrugBank.d84.s6	of	16	17	O
DDI-DrugBank.d84.s6	Exjade	19	24	B-brand
DDI-DrugBank.d84.s6	with	26	29	O
DDI-DrugBank.d84.s6	hydroxyurea	31	41	B-drug
DDI-DrugBank.d84.s6	has	43	45	O
DDI-DrugBank.d84.s6	not	47	49	O
DDI-DrugBank.d84.s6	been	51	54	O
DDI-DrugBank.d84.s6	formally	56	63	O
DDI-DrugBank.d84.s6	studied	65	71	O
DDI-DrugBank.d84.s6	.	72	72	O
DDI-DrugBank.d84.s7	No	0	1	O
DDI-DrugBank.d84.s7	inhibition	3	12	O
DDI-DrugBank.d84.s7	of	14	15	O
DDI-DrugBank.d84.s7	deferasirox	17	27	B-drug
DDI-DrugBank.d84.s7	metabolism	29	38	O
DDI-DrugBank.d84.s7	by	40	41	O
DDI-DrugBank.d84.s7	hydroxyurea	43	53	B-drug
DDI-DrugBank.d84.s7	is	55	56	O
DDI-DrugBank.d84.s7	expected	58	65	O
DDI-DrugBank.d84.s7	based	67	71	O
DDI-DrugBank.d84.s7	on	73	74	O
DDI-DrugBank.d84.s7	the	76	78	O
DDI-DrugBank.d84.s7	results	80	86	O
DDI-DrugBank.d84.s7	of	88	89	O
DDI-DrugBank.d84.s7	an	91	92	O
DDI-DrugBank.d84.s7	in	94	95	O
DDI-DrugBank.d84.s7	vitro	97	101	O
DDI-DrugBank.d84.s7	study	103	107	O
DDI-DrugBank.d84.s7	.	108	108	O
DDI-DrugBank.d84.s8	Exjade	0	5	B-brand
DDI-DrugBank.d84.s8	should	7	12	O
DDI-DrugBank.d84.s8	not	14	16	O
DDI-DrugBank.d84.s8	be	18	19	O
DDI-DrugBank.d84.s8	combined	21	28	O
DDI-DrugBank.d84.s8	with	30	33	O
DDI-DrugBank.d84.s8	other	35	39	O
DDI-DrugBank.d84.s8	iron	41	44	O
DDI-DrugBank.d84.s8	chelator	46	53	O
DDI-DrugBank.d84.s8	therapies	55	63	O
DDI-DrugBank.d84.s8	,	64	64	O
DDI-DrugBank.d84.s8	as	66	67	O
DDI-DrugBank.d84.s8	safety	69	74	O
DDI-DrugBank.d84.s8	of	76	77	O
DDI-DrugBank.d84.s8	such	79	82	O
DDI-DrugBank.d84.s8	combinations	84	95	O
DDI-DrugBank.d84.s8	has	97	99	O
DDI-DrugBank.d84.s8	not	101	103	O
DDI-DrugBank.d84.s8	been	105	108	O
DDI-DrugBank.d84.s8	established	110	120	O
DDI-DrugBank.d84.s8	.	121	121	O
DDI-DrugBank.d84.s9	Drug/Food	0	8	O
DDI-DrugBank.d84.s9	Interactions	10	21	O
DDI-DrugBank.d84.s9	The	23	25	O
DDI-DrugBank.d84.s9	bioavailability	27	41	O
DDI-DrugBank.d84.s9	(	43	43	O
DDI-DrugBank.d84.s9	AUC	44	46	O
DDI-DrugBank.d84.s9	)	47	47	O
DDI-DrugBank.d84.s9	of	49	50	O
DDI-DrugBank.d84.s9	deferasirox	52	62	B-drug
DDI-DrugBank.d84.s9	was	64	66	O
DDI-DrugBank.d84.s9	variably	68	75	O
DDI-DrugBank.d84.s9	increased	77	85	O
DDI-DrugBank.d84.s9	when	87	90	O
DDI-DrugBank.d84.s9	taken	92	96	O
DDI-DrugBank.d84.s9	with	98	101	O
DDI-DrugBank.d84.s9	a	93	93	O
DDI-DrugBank.d84.s9	meal	105	108	O
DDI-DrugBank.d84.s9	.	109	109	O
DDI-DrugBank.d84.s10	Deferasirox	0	10	B-drug
DDI-DrugBank.d84.s10	should	12	17	O
DDI-DrugBank.d84.s10	be	19	20	O
DDI-DrugBank.d84.s10	taken	22	26	O
DDI-DrugBank.d84.s10	on	28	29	O
DDI-DrugBank.d84.s10	an	31	32	O
DDI-DrugBank.d84.s10	empty	34	38	O
DDI-DrugBank.d84.s10	stomach	40	46	O
DDI-DrugBank.d84.s10	30	48	49	O
DDI-DrugBank.d84.s10	minutes	51	57	O
DDI-DrugBank.d84.s10	before	59	64	O
DDI-DrugBank.d84.s10	eating	66	71	O
DDI-DrugBank.d84.s10	.	72	72	O
DDI-DrugBank.d84.s11	Exjade	0	5	B-brand
DDI-DrugBank.d84.s11	tablets	7	13	O
DDI-DrugBank.d84.s11	for	15	17	O
DDI-DrugBank.d84.s11	oral	19	22	O
DDI-DrugBank.d84.s11	suspension	24	33	O
DDI-DrugBank.d84.s11	can	35	37	O
DDI-DrugBank.d84.s11	be	39	40	O
DDI-DrugBank.d84.s11	dispersed	42	50	O
DDI-DrugBank.d84.s11	in	52	53	O
DDI-DrugBank.d84.s11	water	55	59	O
DDI-DrugBank.d84.s11	,	60	60	O
DDI-DrugBank.d84.s11	orange	62	67	O
DDI-DrugBank.d84.s11	juice	69	73	O
DDI-DrugBank.d84.s11	,	74	74	O
DDI-DrugBank.d84.s11	or	76	77	O
DDI-DrugBank.d84.s11	apple	79	83	O
DDI-DrugBank.d84.s11	juice	85	89	O
DDI-DrugBank.d84.s11	.	90	90	O
DDI-MedLine.d108.s0	Administration	0	13	O
DDI-MedLine.d108.s0	of	15	16	O
DDI-MedLine.d108.s0	lithium	18	24	B-drug
DDI-MedLine.d108.s0	prophylaxis	26	36	O
DDI-MedLine.d108.s0	.	37	37	O
DDI-MedLine.d108.s1	Successful	0	9	O
DDI-MedLine.d108.s1	prophylaxis	11	21	O
DDI-MedLine.d108.s1	of	23	24	O
DDI-MedLine.d108.s1	manic-depressive	26	41	O
DDI-MedLine.d108.s1	disorder	43	50	O
DDI-MedLine.d108.s1	requires	52	59	O
DDI-MedLine.d108.s1	more	61	64	O
DDI-MedLine.d108.s1	than	66	69	O
DDI-MedLine.d108.s1	the	71	73	O
DDI-MedLine.d108.s1	prescription	75	86	O
DDI-MedLine.d108.s1	of	88	89	O
DDI-MedLine.d108.s1	lithium	91	97	B-drug
DDI-MedLine.d108.s1	carbonate	99	107	I-drug
DDI-MedLine.d108.s1	.	108	108	O
DDI-MedLine.d108.s2	The	0	2	O
DDI-MedLine.d108.s2	administrative	4	17	O
DDI-MedLine.d108.s2	arrangements	19	30	O
DDI-MedLine.d108.s2	in	32	33	O
DDI-MedLine.d108.s2	an	35	36	O
DDI-MedLine.d108.s2	area	38	41	O
DDI-MedLine.d108.s2	of	43	44	O
DDI-MedLine.d108.s2	Scotland	46	53	O
DDI-MedLine.d108.s2	were	55	58	O
DDI-MedLine.d108.s2	accompanied	60	70	O
DDI-MedLine.d108.s2	by	72	73	O
DDI-MedLine.d108.s2	a	66	66	O
DDI-MedLine.d108.s2	300	77	79	O
DDI-MedLine.d108.s2	%	80	80	O
DDI-MedLine.d108.s2	increase	82	89	O
DDI-MedLine.d108.s2	in	82	83	O
DDI-MedLine.d108.s2	the	94	96	O
DDI-MedLine.d108.s2	frequency	98	106	O
DDI-MedLine.d108.s2	of	108	109	O
DDI-MedLine.d108.s2	admissions	111	120	O
DDI-MedLine.d108.s2	for	122	124	O
DDI-MedLine.d108.s2	mania	126	130	O
DDI-MedLine.d108.s2	,	131	131	O
DDI-MedLine.d108.s2	whereas	133	139	O
DDI-MedLine.d108.s2	in	141	142	O
DDI-MedLine.d108.s2	an	127	128	O
DDI-MedLine.d108.s2	area	147	150	O
DDI-MedLine.d108.s2	of	152	153	O
DDI-MedLine.d108.s2	the	155	157	O
DDI-MedLine.d108.s2	West	159	162	O
DDI-MedLine.d108.s2	Midlands	164	171	O
DDI-MedLine.d108.s2	,	172	172	O
DDI-MedLine.d108.s2	a	147	147	O
DDI-MedLine.d108.s2	large	176	180	O
DDI-MedLine.d108.s2	decrease	182	189	O
DDI-MedLine.d108.s2	was	191	193	O
DDI-MedLine.d108.s2	achieved	195	202	O
DDI-MedLine.d108.s2	.	203	203	O
DDI-DrugBank.d527.s0	A	0	0	O
DDI-DrugBank.d527.s0	number	2	7	O
DDI-DrugBank.d527.s0	of	9	10	O
DDI-DrugBank.d527.s0	substances	12	21	O
DDI-DrugBank.d527.s0	affect	23	28	O
DDI-DrugBank.d527.s0	glucose	30	36	O
DDI-DrugBank.d527.s0	metabolism	38	47	O
DDI-DrugBank.d527.s0	and	49	51	O
DDI-DrugBank.d527.s0	may	53	55	O
DDI-DrugBank.d527.s0	require	57	63	O
DDI-DrugBank.d527.s0	insulin	65	71	B-drug
DDI-DrugBank.d527.s0	dose	73	76	O
DDI-DrugBank.d527.s0	adjustment	78	87	O
DDI-DrugBank.d527.s0	and	89	91	O
DDI-DrugBank.d527.s0	particularly	93	104	O
DDI-DrugBank.d527.s0	close	106	110	O
DDI-DrugBank.d527.s0	monitoring	112	121	O
DDI-DrugBank.d527.s0	.	122	122	O
DDI-DrugBank.d527.s1	The	0	2	O
DDI-DrugBank.d527.s1	following	4	12	O
DDI-DrugBank.d527.s1	are	14	16	O
DDI-DrugBank.d527.s1	examples	18	25	O
DDI-DrugBank.d527.s1	of	27	28	O
DDI-DrugBank.d527.s1	substances	30	39	O
DDI-DrugBank.d527.s1	that	41	44	O
DDI-DrugBank.d527.s1	may	46	48	O
DDI-DrugBank.d527.s1	increase	50	57	O
DDI-DrugBank.d527.s1	the	59	61	O
DDI-DrugBank.d527.s1	blood-glucose-lowering	63	84	O
DDI-DrugBank.d527.s1	effect	86	91	O
DDI-DrugBank.d527.s1	and	93	95	O
DDI-DrugBank.d527.s1	susceptibility	97	110	O
DDI-DrugBank.d527.s1	to	112	113	O
DDI-DrugBank.d527.s1	hypoglycemia	115	126	O
DDI-DrugBank.d527.s1	:	127	127	O
DDI-DrugBank.d527.s1	oral	129	132	O
DDI-DrugBank.d527.s1	antidiabetes	134	145	O
DDI-DrugBank.d527.s1	products	147	154	O
DDI-DrugBank.d527.s1	,	155	155	O
DDI-DrugBank.d527.s1	ACE	157	159	B-group
DDI-DrugBank.d527.s1	inhibitors	161	170	I-group
DDI-DrugBank.d527.s1	,	155	155	O
DDI-DrugBank.d527.s1	disopyramide	173	184	B-drug
DDI-DrugBank.d527.s1	,	171	171	O
DDI-DrugBank.d527.s1	fibrates	187	194	B-group
DDI-DrugBank.d527.s1	,	185	185	O
DDI-DrugBank.d527.s1	fluoxetine	197	206	B-drug
DDI-DrugBank.d527.s1	,	185	185	O
DDI-DrugBank.d527.s1	MAO	209	211	B-group
DDI-DrugBank.d527.s1	inhibitors	213	222	I-group
DDI-DrugBank.d527.s1	,	207	207	O
DDI-DrugBank.d527.s1	propoxyphene	225	236	B-drug
DDI-DrugBank.d527.s1	,	223	223	O
DDI-DrugBank.d527.s1	salicylates	239	249	B-group
DDI-DrugBank.d527.s1	,	223	223	O
DDI-DrugBank.d527.s1	somatostatin	252	263	B-group
DDI-DrugBank.d527.s1	analog	265	270	I-group
DDI-DrugBank.d527.s1	(	272	272	O
DDI-DrugBank.d527.s1	e.g.	273	276	O
DDI-DrugBank.d527.s1	,	250	250	O
DDI-DrugBank.d527.s1	octreotide	279	288	B-drug
DDI-DrugBank.d527.s1	)	289	289	O
DDI-DrugBank.d527.s1	,	277	277	O
DDI-DrugBank.d527.s1	sulfonamide	292	302	B-group
DDI-DrugBank.d527.s1	antibiotics	304	314	I-group
DDI-DrugBank.d527.s1	.	315	315	O
DDI-DrugBank.d527.s2	The	0	2	O
DDI-DrugBank.d527.s2	following	4	12	O
DDI-DrugBank.d527.s2	are	14	16	O
DDI-DrugBank.d527.s2	examples	18	25	O
DDI-DrugBank.d527.s2	of	27	28	O
DDI-DrugBank.d527.s2	substances	30	39	O
DDI-DrugBank.d527.s2	that	41	44	O
DDI-DrugBank.d527.s2	may	46	48	O
DDI-DrugBank.d527.s2	reduce	50	55	O
DDI-DrugBank.d527.s2	the	57	59	O
DDI-DrugBank.d527.s2	blood-glucose-lowering	61	82	O
DDI-DrugBank.d527.s2	effect	84	89	O
DDI-DrugBank.d527.s2	of	91	92	O
DDI-DrugBank.d527.s2	insulin	94	100	B-drug
DDI-DrugBank.d527.s2	:	101	101	O
DDI-DrugBank.d527.s2	corticosteroids	103	117	B-group
DDI-DrugBank.d527.s2	,	118	118	O
DDI-DrugBank.d527.s2	danazol	120	126	B-drug
DDI-DrugBank.d527.s2	,	118	118	O
DDI-DrugBank.d527.s2	diuretics	129	137	B-group
DDI-DrugBank.d527.s2	,	127	127	O
DDI-DrugBank.d527.s2	sympathomimetic	140	154	B-group
DDI-DrugBank.d527.s2	agents	156	161	I-group
DDI-DrugBank.d527.s2	(	163	163	O
DDI-DrugBank.d527.s2	e.g.	164	167	O
DDI-DrugBank.d527.s2	,	168	168	O
DDI-DrugBank.d527.s2	epinephrine	170	180	B-drug
DDI-DrugBank.d527.s2	,	168	168	O
DDI-DrugBank.d527.s2	albuterol	183	191	B-drug
DDI-DrugBank.d527.s2	,	181	181	O
DDI-DrugBank.d527.s2	terbutaline	194	204	B-drug
DDI-DrugBank.d527.s2	)	205	205	O
DDI-DrugBank.d527.s2	,	192	192	O
DDI-DrugBank.d527.s2	isoniazid	208	216	B-drug
DDI-DrugBank.d527.s2	,	206	206	O
DDI-DrugBank.d527.s2	phenothiazine	219	231	B-group
DDI-DrugBank.d527.s2	derivatives	233	243	I-group
DDI-DrugBank.d527.s2	,	244	244	O
DDI-DrugBank.d527.s2	somatropin	246	255	B-drug
DDI-DrugBank.d527.s2	,	244	244	O
DDI-DrugBank.d527.s2	thyroid	258	264	B-group
DDI-DrugBank.d527.s2	hormones	266	273	I-group
DDI-DrugBank.d527.s2	,	256	256	O
DDI-DrugBank.d527.s2	estrogens	276	284	B-group
DDI-DrugBank.d527.s2	,	256	256	O
DDI-DrugBank.d527.s2	progestogens	287	298	B-group
DDI-DrugBank.d527.s2	(	300	300	O
DDI-DrugBank.d527.s2	e.g.	301	304	O
DDI-DrugBank.d527.s2	,	274	274	O
DDI-DrugBank.d527.s2	in	307	308	O
DDI-DrugBank.d527.s2	oral	310	313	O
DDI-DrugBank.d527.s2	contraceptives	315	328	B-group
DDI-DrugBank.d527.s2	)	329	329	O
DDI-DrugBank.d527.s2	.	302	302	O
DDI-DrugBank.d527.s3	Beta-blockers	0	12	B-group
DDI-DrugBank.d527.s3	,	13	13	O
DDI-DrugBank.d527.s3	clonidine	15	23	B-drug
DDI-DrugBank.d527.s3	,	24	24	O
DDI-DrugBank.d527.s3	lithium	26	32	B-drug
DDI-DrugBank.d527.s3	salts	34	38	O
DDI-DrugBank.d527.s3	,	39	39	O
DDI-DrugBank.d527.s3	and	41	43	O
DDI-DrugBank.d527.s3	alcohol	45	51	B-drug
DDI-DrugBank.d527.s3	may	53	55	O
DDI-DrugBank.d527.s3	either	57	62	O
DDI-DrugBank.d527.s3	potentiate	64	73	O
DDI-DrugBank.d527.s3	or	75	76	O
DDI-DrugBank.d527.s3	weaken	78	83	O
DDI-DrugBank.d527.s3	the	85	87	O
DDI-DrugBank.d527.s3	blood-glucose-lowering	89	110	O
DDI-DrugBank.d527.s3	effect	112	117	O
DDI-DrugBank.d527.s3	of	119	120	O
DDI-DrugBank.d527.s3	insulin	122	128	B-drug
DDI-DrugBank.d527.s3	.	129	129	O
DDI-DrugBank.d527.s4	Pentamidine	0	10	B-drug
DDI-DrugBank.d527.s4	may	12	14	O
DDI-DrugBank.d527.s4	cause	16	20	O
DDI-DrugBank.d527.s4	hypoglycemia	22	33	O
DDI-DrugBank.d527.s4	,	34	34	O
DDI-DrugBank.d527.s4	which	36	40	O
DDI-DrugBank.d527.s4	may	42	44	O
DDI-DrugBank.d527.s4	sometimes	46	54	O
DDI-DrugBank.d527.s4	be	56	57	O
DDI-DrugBank.d527.s4	followed	59	66	O
DDI-DrugBank.d527.s4	by	68	69	O
DDI-DrugBank.d527.s4	hyperglycemia	71	83	O
DDI-DrugBank.d527.s4	.	84	84	O
DDI-DrugBank.d527.s5	In	0	1	O
DDI-DrugBank.d527.s5	addition	3	10	O
DDI-DrugBank.d527.s5	,	11	11	O
DDI-DrugBank.d527.s5	under	13	17	O
DDI-DrugBank.d527.s5	the	19	21	O
DDI-DrugBank.d527.s5	influence	23	31	O
DDI-DrugBank.d527.s5	of	33	34	O
DDI-DrugBank.d527.s5	sympatholytic	36	48	O
DDI-DrugBank.d527.s5	medicinal	50	58	O
DDI-DrugBank.d527.s5	products	60	67	O
DDI-DrugBank.d527.s5	such	69	72	O
DDI-DrugBank.d527.s5	as	74	75	O
DDI-DrugBank.d527.s5	beta-blockers	77	89	B-group
DDI-DrugBank.d527.s5	,	90	90	O
DDI-DrugBank.d527.s5	clonidine	92	100	B-drug
DDI-DrugBank.d527.s5	,	90	90	O
DDI-DrugBank.d527.s5	guanethidine	103	114	B-drug
DDI-DrugBank.d527.s5	,	115	115	O
DDI-DrugBank.d527.s5	and	117	119	O
DDI-DrugBank.d527.s5	reserpine	121	129	B-drug
DDI-DrugBank.d527.s5	,	115	115	O
DDI-DrugBank.d527.s5	the	132	134	O
DDI-DrugBank.d527.s5	signs	136	140	O
DDI-DrugBank.d527.s5	of	142	143	O
DDI-DrugBank.d527.s5	hypoglycemia	145	156	O
DDI-DrugBank.d527.s5	may	158	160	O
DDI-DrugBank.d527.s5	be	162	163	O
DDI-DrugBank.d527.s5	reduced	165	171	O
DDI-DrugBank.d527.s5	or	173	174	O
DDI-DrugBank.d527.s5	absent	176	181	O
DDI-DrugBank.d527.s5	.	182	182	O
DDI-MedLine.d61.s0	Pharmacokinetic	0	14	O
DDI-MedLine.d61.s0	evaluation	16	25	O
DDI-MedLine.d61.s0	of	27	28	O
DDI-MedLine.d61.s0	the	30	32	O
DDI-MedLine.d61.s0	digoxin-amiodarone	34	51	O
DDI-MedLine.d61.s0	interaction	53	63	O
DDI-MedLine.d61.s0	.	64	64	O
DDI-MedLine.d61.s1	Amiodarone	0	9	B-drug
DDI-MedLine.d61.s1	is	11	12	O
DDI-MedLine.d61.s1	known	14	18	O
DDI-MedLine.d61.s1	to	20	21	O
DDI-MedLine.d61.s1	raise	23	27	O
DDI-MedLine.d61.s1	serum	29	33	O
DDI-MedLine.d61.s1	digoxin	35	41	B-drug
DDI-MedLine.d61.s1	levels	43	48	O
DDI-MedLine.d61.s1	.	49	49	O
DDI-MedLine.d61.s2	This	0	3	O
DDI-MedLine.d61.s2	study	5	9	O
DDI-MedLine.d61.s2	was	11	13	O
DDI-MedLine.d61.s2	designed	15	22	O
DDI-MedLine.d61.s2	to	24	25	O
DDI-MedLine.d61.s2	evaluate	27	34	O
DDI-MedLine.d61.s2	the	36	38	O
DDI-MedLine.d61.s2	pharmacokinetic	40	54	O
DDI-MedLine.d61.s2	basis	56	60	O
DDI-MedLine.d61.s2	of	62	63	O
DDI-MedLine.d61.s2	this	65	68	O
DDI-MedLine.d61.s2	interaction	70	80	O
DDI-MedLine.d61.s2	in	70	71	O
DDI-MedLine.d61.s2	10	85	86	O
DDI-MedLine.d61.s2	normal	88	93	O
DDI-MedLine.d61.s2	subjects	95	102	O
DDI-MedLine.d61.s2	.	103	103	O
DDI-MedLine.d61.s3	The	0	2	O
DDI-MedLine.d61.s3	pharmacokinetic	4	18	O
DDI-MedLine.d61.s3	variables	20	28	O
DDI-MedLine.d61.s3	for	30	32	O
DDI-MedLine.d61.s3	digoxin	34	40	B-drug
DDI-MedLine.d61.s3	were	42	45	O
DDI-MedLine.d61.s3	determined	47	56	O
DDI-MedLine.d61.s3	after	58	62	O
DDI-MedLine.d61.s3	a	58	58	O
DDI-MedLine.d61.s3	1.0	66	68	O
DDI-MedLine.d61.s3	mg	70	71	O
DDI-MedLine.d61.s3	intravenous	73	83	O
DDI-MedLine.d61.s3	dose	85	88	O
DDI-MedLine.d61.s3	of	90	91	O
DDI-MedLine.d61.s3	digoxin	93	99	B-drug
DDI-MedLine.d61.s3	in	98	99	I-drug
DDI-MedLine.d61.s3	each	104	107	O
DDI-MedLine.d61.s3	subject	109	115	O
DDI-MedLine.d61.s3	,	116	116	O
DDI-MedLine.d61.s3	before	118	123	O
DDI-MedLine.d61.s3	and	125	127	O
DDI-MedLine.d61.s3	after	129	133	O
DDI-MedLine.d61.s3	oral	135	138	O
DDI-MedLine.d61.s3	amiodarone	140	149	B-drug
DDI-MedLine.d61.s3	,	150	150	O
DDI-MedLine.d61.s3	400	152	154	O
DDI-MedLine.d61.s3	mg	156	157	O
DDI-MedLine.d61.s3	daily	159	163	O
DDI-MedLine.d61.s3	for	165	167	O
DDI-MedLine.d61.s3	3	169	169	O
DDI-MedLine.d61.s3	weeks	171	175	O
DDI-MedLine.d61.s3	.	176	176	O
DDI-MedLine.d61.s4	During	0	5	O
DDI-MedLine.d61.s4	amiodarone	7	16	B-drug
DDI-MedLine.d61.s4	administration	18	31	O
DDI-MedLine.d61.s4	,	32	32	O
DDI-MedLine.d61.s4	systemic	34	41	O
DDI-MedLine.d61.s4	clearance	43	51	O
DDI-MedLine.d61.s4	of	53	54	O
DDI-MedLine.d61.s4	digoxin	56	62	B-drug
DDI-MedLine.d61.s4	was	64	66	O
DDI-MedLine.d61.s4	reduced	68	74	O
DDI-MedLine.d61.s4	from	76	79	O
DDI-MedLine.d61.s4	234	81	83	O
DDI-MedLine.d61.s4	+/-	85	87	O
DDI-MedLine.d61.s4	72	89	90	O
DDI-MedLine.d61.s4	ml/min	92	97	O
DDI-MedLine.d61.s4	(	99	99	O
DDI-MedLine.d61.s4	mean	100	103	O
DDI-MedLine.d61.s4	+/-	105	107	O
DDI-MedLine.d61.s4	standard	109	116	O
DDI-MedLine.d61.s4	deviation	118	126	O
DDI-MedLine.d61.s4	)	127	127	O
DDI-MedLine.d61.s4	to	129	130	O
DDI-MedLine.d61.s4	172	132	134	O
DDI-MedLine.d61.s4	+/-	136	138	O
DDI-MedLine.d61.s4	33	140	141	O
DDI-MedLine.d61.s4	ml/min	143	148	O
DDI-MedLine.d61.s4	(	150	150	O
DDI-MedLine.d61.s4	p	151	151	O
DDI-MedLine.d61.s4	less	153	156	O
DDI-MedLine.d61.s4	than	158	161	O
DDI-MedLine.d61.s4	0.01	163	166	O
DDI-MedLine.d61.s4	)	167	167	O
DDI-MedLine.d61.s4	.	164	164	O
DDI-MedLine.d61.s5	This	0	3	O
DDI-MedLine.d61.s5	was	5	7	O
DDI-MedLine.d61.s5	due	9	11	O
DDI-MedLine.d61.s5	to	13	14	O
DDI-MedLine.d61.s5	reductions	16	25	O
DDI-MedLine.d61.s5	in	27	28	O
DDI-MedLine.d61.s5	both	30	33	O
DDI-MedLine.d61.s5	renal	35	39	O
DDI-MedLine.d61.s5	clearance	41	49	O
DDI-MedLine.d61.s5	(	51	51	O
DDI-MedLine.d61.s5	from	52	55	O
DDI-MedLine.d61.s5	105	57	59	O
DDI-MedLine.d61.s5	+/-	61	63	O
DDI-MedLine.d61.s5	39	65	66	O
DDI-MedLine.d61.s5	to	68	69	O
DDI-MedLine.d61.s5	84	71	72	O
DDI-MedLine.d61.s5	+/-	61	63	O
DDI-MedLine.d61.s5	15	78	79	O
DDI-MedLine.d61.s5	ml/min	81	86	O
DDI-MedLine.d61.s5	)	87	87	O
DDI-MedLine.d61.s5	(	89	89	O
DDI-MedLine.d61.s5	p	90	90	O
DDI-MedLine.d61.s5	less	92	95	O
DDI-MedLine.d61.s5	than	97	100	O
DDI-MedLine.d61.s5	0.05	102	105	O
DDI-MedLine.d61.s5	)	87	87	O
DDI-MedLine.d61.s5	and	108	110	O
DDI-MedLine.d61.s5	nonrenal	112	119	O
DDI-MedLine.d61.s5	clearance	121	129	O
DDI-MedLine.d61.s5	(	131	131	O
DDI-MedLine.d61.s5	from	132	135	O
DDI-MedLine.d61.s5	130	137	139	O
DDI-MedLine.d61.s5	+/-	141	143	O
DDI-MedLine.d61.s5	38	145	146	O
DDI-MedLine.d61.s5	to	148	149	O
DDI-MedLine.d61.s5	88	151	152	O
DDI-MedLine.d61.s5	+/-	141	143	O
DDI-MedLine.d61.s5	20	158	159	O
DDI-MedLine.d61.s5	ml/min	161	166	O
DDI-MedLine.d61.s5	)	167	167	O
DDI-MedLine.d61.s5	(	169	169	O
DDI-MedLine.d61.s5	p	170	170	O
DDI-MedLine.d61.s5	less	172	175	O
DDI-MedLine.d61.s5	than	177	180	O
DDI-MedLine.d61.s5	0.01	182	185	O
DDI-MedLine.d61.s5	)	167	167	O
DDI-MedLine.d61.s5	.	183	183	O
DDI-MedLine.d61.s6	Digoxin	0	6	B-drug
DDI-MedLine.d61.s6	half-life	8	16	O
DDI-MedLine.d61.s6	of	18	19	O
DDI-MedLine.d61.s6	elimination	21	31	O
DDI-MedLine.d61.s6	was	33	35	O
DDI-MedLine.d61.s6	prolonged	37	45	O
DDI-MedLine.d61.s6	from	47	50	O
DDI-MedLine.d61.s6	34	52	53	O
DDI-MedLine.d61.s6	+/-	55	57	O
DDI-MedLine.d61.s6	13	59	60	O
DDI-MedLine.d61.s6	to	62	63	O
DDI-MedLine.d61.s6	40	65	66	O
DDI-MedLine.d61.s6	+/-	68	70	O
DDI-MedLine.d61.s6	16	72	73	O
DDI-MedLine.d61.s6	hours	75	79	O
DDI-MedLine.d61.s6	(	81	81	O
DDI-MedLine.d61.s6	p	82	82	O
DDI-MedLine.d61.s6	less	84	87	O
DDI-MedLine.d61.s6	than	89	92	O
DDI-MedLine.d61.s6	0.05	94	97	O
DDI-MedLine.d61.s6	)	98	98	O
DDI-MedLine.d61.s6	.	95	95	O
DDI-MedLine.d61.s7	Digoxin	0	6	B-drug
DDI-MedLine.d61.s7	volume	8	13	O
DDI-MedLine.d61.s7	of	15	16	O
DDI-MedLine.d61.s7	distribution	18	29	O
DDI-MedLine.d61.s7	was	31	33	O
DDI-MedLine.d61.s7	not	35	37	O
DDI-MedLine.d61.s7	significantly	39	51	O
DDI-MedLine.d61.s7	changed	53	59	O
DDI-MedLine.d61.s7	.	60	60	O
DDI-MedLine.d61.s8	Amiodarone	0	9	B-drug
DDI-MedLine.d61.s8	caused	11	16	O
DDI-MedLine.d61.s8	a	18	18	O
DDI-MedLine.d61.s8	three-	20	25	O
DDI-MedLine.d61.s8	to	27	28	O
DDI-MedLine.d61.s8	fivefold	30	37	O
DDI-MedLine.d61.s8	increase	39	46	O
DDI-MedLine.d61.s8	in	48	49	O
DDI-MedLine.d61.s8	serum	51	55	O
DDI-MedLine.d61.s8	reverse	57	63	O
DDI-MedLine.d61.s8	triiodothyronine	65	80	O
DDI-MedLine.d61.s8	levels	82	87	O
DDI-MedLine.d61.s8	,	88	88	O
DDI-MedLine.d61.s8	but	90	92	O
DDI-MedLine.d61.s8	changes	94	100	O
DDI-MedLine.d61.s8	in	102	103	O
DDI-MedLine.d61.s8	thyroid	105	111	O
DDI-MedLine.d61.s8	function	113	120	O
DDI-MedLine.d61.s8	were	122	125	O
DDI-MedLine.d61.s8	not	127	129	O
DDI-MedLine.d61.s8	quantitatively	131	144	O
DDI-MedLine.d61.s8	related	146	152	O
DDI-MedLine.d61.s8	to	154	155	O
DDI-MedLine.d61.s8	the	157	159	O
DDI-MedLine.d61.s8	changes	161	167	O
DDI-MedLine.d61.s8	in	169	170	O
DDI-MedLine.d61.s8	digoxin	172	178	B-drug
DDI-MedLine.d61.s8	pharmacokinetics	180	195	O
DDI-MedLine.d61.s8	.	196	196	O
DDI-MedLine.d61.s9	These	0	4	O
DDI-MedLine.d61.s9	alterations	6	16	O
DDI-MedLine.d61.s9	in	18	19	O
DDI-MedLine.d61.s9	digoxin	21	27	B-drug
DDI-MedLine.d61.s9	pharmacokinetics	29	44	O
DDI-MedLine.d61.s9	produced	46	53	O
DDI-MedLine.d61.s9	by	55	56	O
DDI-MedLine.d61.s9	amiodarone	58	67	B-drug
DDI-MedLine.d61.s9	explain	69	75	O
DDI-MedLine.d61.s9	the	77	79	O
DDI-MedLine.d61.s9	increase	81	88	O
DDI-MedLine.d61.s9	in	81	82	O
DDI-MedLine.d61.s9	serum	93	97	O
DDI-MedLine.d61.s9	digoxin	99	105	B-drug
DDI-MedLine.d61.s9	level	107	111	O
DDI-MedLine.d61.s9	that	113	116	O
DDI-MedLine.d61.s9	has	118	120	O
DDI-MedLine.d61.s9	been	122	125	O
DDI-MedLine.d61.s9	observed	127	134	O
DDI-MedLine.d61.s9	when	136	139	O
DDI-MedLine.d61.s9	this	141	144	O
DDI-MedLine.d61.s9	drug	146	149	O
DDI-MedLine.d61.s9	combination	151	161	O
DDI-MedLine.d61.s9	has	163	165	O
DDI-MedLine.d61.s9	been	167	170	O
DDI-MedLine.d61.s9	used	172	175	O
DDI-MedLine.d61.s9	clinically	177	186	O
DDI-MedLine.d61.s9	.	187	187	O
DDI-DrugBank.d71.s0	Lamivudine	0	9	B-drug
DDI-DrugBank.d71.s0	is	11	12	O
DDI-DrugBank.d71.s0	predominantly	14	26	O
DDI-DrugBank.d71.s0	eliminated	28	37	O
DDI-DrugBank.d71.s0	in	39	40	O
DDI-DrugBank.d71.s0	the	42	44	O
DDI-DrugBank.d71.s0	urine	46	50	O
DDI-DrugBank.d71.s0	by	52	53	O
DDI-DrugBank.d71.s0	active	55	60	O
DDI-DrugBank.d71.s0	organic	62	68	O
DDI-DrugBank.d71.s0	cationic	70	77	O
DDI-DrugBank.d71.s0	secretion	79	87	O
DDI-DrugBank.d71.s0	.	88	88	O
DDI-DrugBank.d71.s1	The	0	2	O
DDI-DrugBank.d71.s1	possibility	4	14	O
DDI-DrugBank.d71.s1	of	16	17	O
DDI-DrugBank.d71.s1	interactions	19	30	O
DDI-DrugBank.d71.s1	with	32	35	O
DDI-DrugBank.d71.s1	other	37	41	O
DDI-DrugBank.d71.s1	drugs	43	47	O
DDI-DrugBank.d71.s1	administered	49	60	O
DDI-DrugBank.d71.s1	concurrently	62	73	O
DDI-DrugBank.d71.s1	should	75	80	O
DDI-DrugBank.d71.s1	be	82	83	O
DDI-DrugBank.d71.s1	considered	85	94	O
DDI-DrugBank.d71.s1	,	95	95	O
DDI-DrugBank.d71.s1	particularly	97	108	O
DDI-DrugBank.d71.s1	when	110	113	O
DDI-DrugBank.d71.s1	their	115	119	O
DDI-DrugBank.d71.s1	main	121	124	O
DDI-DrugBank.d71.s1	route	126	130	O
DDI-DrugBank.d71.s1	of	132	133	O
DDI-DrugBank.d71.s1	elimination	135	145	O
DDI-DrugBank.d71.s1	is	147	148	O
DDI-DrugBank.d71.s1	active	150	155	O
DDI-DrugBank.d71.s1	renal	157	161	O
DDI-DrugBank.d71.s1	secretion	163	171	O
DDI-DrugBank.d71.s1	via	173	175	O
DDI-DrugBank.d71.s1	the	177	179	O
DDI-DrugBank.d71.s1	organic	181	187	O
DDI-DrugBank.d71.s1	cationic	189	196	O
DDI-DrugBank.d71.s1	transport	198	206	O
DDI-DrugBank.d71.s1	system	208	213	O
DDI-DrugBank.d71.s1	(	215	215	O
DDI-DrugBank.d71.s1	e.g.	216	219	O
DDI-DrugBank.d71.s1	,	220	220	O
DDI-DrugBank.d71.s1	trimethoprim	222	233	B-drug
DDI-DrugBank.d71.s1	)	234	234	O
DDI-DrugBank.d71.s1	.	217	217	O
DDI-DrugBank.d71.s2	No	0	1	O
DDI-DrugBank.d71.s2	change	3	8	O
DDI-DrugBank.d71.s2	in	10	11	O
DDI-DrugBank.d71.s2	dose	13	16	O
DDI-DrugBank.d71.s2	of	18	19	O
DDI-DrugBank.d71.s2	either	21	26	O
DDI-DrugBank.d71.s2	drug	28	31	O
DDI-DrugBank.d71.s2	is	33	34	O
DDI-DrugBank.d71.s2	recommended	36	46	O
DDI-DrugBank.d71.s2	.	47	47	O
DDI-DrugBank.d71.s3	There	0	4	O
DDI-DrugBank.d71.s3	is	6	7	O
DDI-DrugBank.d71.s3	no	9	10	O
DDI-DrugBank.d71.s3	information	12	22	O
DDI-DrugBank.d71.s3	regarding	24	32	O
DDI-DrugBank.d71.s3	the	34	36	O
DDI-DrugBank.d71.s3	effect	38	43	O
DDI-DrugBank.d71.s3	on	45	46	O
DDI-DrugBank.d71.s3	lamivudine	48	57	B-drug
DDI-DrugBank.d71.s3	pharmacokinetics	59	74	O
DDI-DrugBank.d71.s3	of	76	77	O
DDI-DrugBank.d71.s3	higher	79	84	O
DDI-DrugBank.d71.s3	doses	86	90	O
DDI-DrugBank.d71.s3	of	92	93	O
DDI-DrugBank.d71.s3	TMP/SMX	95	101	O
DDI-DrugBank.d71.s3	such	103	106	O
DDI-DrugBank.d71.s3	as	108	109	O
DDI-DrugBank.d71.s3	those	111	115	O
DDI-DrugBank.d71.s3	used	117	120	O
DDI-DrugBank.d71.s3	to	122	123	O
DDI-DrugBank.d71.s3	treat	125	129	O
DDI-DrugBank.d71.s3	Pneumocystis	131	142	O
DDI-DrugBank.d71.s3	carinii	144	150	O
DDI-DrugBank.d71.s3	pneumonia	152	160	O
DDI-DrugBank.d71.s3	.	161	161	O
DDI-DrugBank.d71.s4	No	0	1	O
DDI-DrugBank.d71.s4	data	3	6	O
DDI-DrugBank.d71.s4	are	8	10	O
DDI-DrugBank.d71.s4	available	12	20	O
DDI-DrugBank.d71.s4	regarding	22	30	O
DDI-DrugBank.d71.s4	interactions	32	43	O
DDI-DrugBank.d71.s4	with	45	48	O
DDI-DrugBank.d71.s4	other	50	54	O
DDI-DrugBank.d71.s4	drugs	56	60	O
DDI-DrugBank.d71.s4	that	62	65	O
DDI-DrugBank.d71.s4	have	67	70	O
DDI-DrugBank.d71.s4	renal	72	76	O
DDI-DrugBank.d71.s4	clearance	78	86	O
DDI-DrugBank.d71.s4	mechanisms	88	97	O
DDI-DrugBank.d71.s4	similar	99	105	O
DDI-DrugBank.d71.s4	to	107	108	O
DDI-DrugBank.d71.s4	that	110	113	O
DDI-DrugBank.d71.s4	of	115	116	O
DDI-DrugBank.d71.s4	lamivudine	118	127	B-drug
DDI-DrugBank.d71.s4	.	128	128	O
DDI-DrugBank.d71.s5	Lamivudine	0	9	B-drug
DDI-DrugBank.d71.s5	and	11	13	O
DDI-DrugBank.d71.s5	zalcitabine	15	25	B-drug
DDI-DrugBank.d71.s5	may	27	29	O
DDI-DrugBank.d71.s5	inhibit	31	37	O
DDI-DrugBank.d71.s5	the	39	41	O
DDI-DrugBank.d71.s5	intracellular	43	55	O
DDI-DrugBank.d71.s5	phosphorylation	57	71	O
DDI-DrugBank.d71.s5	of	73	74	O
DDI-DrugBank.d71.s5	one	76	78	O
DDI-DrugBank.d71.s5	another	80	86	O
DDI-DrugBank.d71.s5	.	87	87	O
DDI-DrugBank.d71.s6	Therefore	0	8	O
DDI-DrugBank.d71.s6	,	9	9	O
DDI-DrugBank.d71.s6	use	11	13	O
DDI-DrugBank.d71.s6	of	15	16	O
DDI-DrugBank.d71.s6	lamivudine	18	27	B-drug
DDI-DrugBank.d71.s6	in	25	26	I-drug
DDI-DrugBank.d71.s6	combination	32	42	O
DDI-DrugBank.d71.s6	with	44	47	O
DDI-DrugBank.d71.s6	zalcitabine	49	59	B-drug
DDI-DrugBank.d71.s6	is	61	62	O
DDI-DrugBank.d71.s6	not	64	66	O
DDI-DrugBank.d71.s6	recommended	68	78	O
DDI-DrugBank.d71.s7	.	0	0	O
DDI-DrugBank.d710.s0	Cimetidine	0	9	B-drug
DDI-DrugBank.d710.s0	:	10	10	O
DDI-DrugBank.d710.s0	The	12	14	O
DDI-DrugBank.d710.s0	effects	16	22	O
DDI-DrugBank.d710.s0	of	24	25	O
DDI-DrugBank.d710.s0	chronic	27	33	O
DDI-DrugBank.d710.s0	cimetidine	35	44	B-drug
DDI-DrugBank.d710.s0	use	46	48	O
DDI-DrugBank.d710.s0	on	50	51	O
DDI-DrugBank.d710.s0	the	53	55	O
DDI-DrugBank.d710.s0	metabolism	57	66	O
DDI-DrugBank.d710.s0	of	68	69	O
DDI-DrugBank.d710.s0	rimantadine	71	81	B-drug
DDI-DrugBank.d710.s0	are	83	85	O
DDI-DrugBank.d710.s0	not	87	89	O
DDI-DrugBank.d710.s0	known	91	95	O
DDI-DrugBank.d710.s0	.	96	96	O
DDI-DrugBank.d710.s1	When	0	3	O
DDI-DrugBank.d710.s1	a	5	5	O
DDI-DrugBank.d710.s1	single	7	12	O
DDI-DrugBank.d710.s1	100	14	16	O
DDI-DrugBank.d710.s1	mg	18	19	O
DDI-DrugBank.d710.s1	dose	21	24	O
DDI-DrugBank.d710.s1	of	26	27	O
DDI-DrugBank.d710.s1	rimantadine	29	39	B-drug
DDI-DrugBank.d710.s1	HCl	41	43	I-drug
DDI-DrugBank.d710.s1	was	45	47	O
DDI-DrugBank.d710.s1	administered	49	60	O
DDI-DrugBank.d710.s1	one	62	64	O
DDI-DrugBank.d710.s1	hour	66	69	O
DDI-DrugBank.d710.s1	after	71	75	O
DDI-DrugBank.d710.s1	the	77	79	O
DDI-DrugBank.d710.s1	initiation	81	90	O
DDI-DrugBank.d710.s1	of	92	93	O
DDI-DrugBank.d710.s1	Cimetidine	95	104	B-drug
DDI-DrugBank.d710.s1	(	106	106	O
DDI-DrugBank.d710.s1	300	107	109	O
DDI-DrugBank.d710.s1	mg	111	112	O
DDI-DrugBank.d710.s1	four	114	117	O
DDI-DrugBank.d710.s1	times	119	123	O
DDI-DrugBank.d710.s1	a	125	125	O
DDI-DrugBank.d710.s1	day	127	129	O
DDI-DrugBank.d710.s1	)	130	130	O
DDI-DrugBank.d710.s1	,	131	131	O
DDI-DrugBank.d710.s1	the	133	135	O
DDI-DrugBank.d710.s1	apparent	137	144	O
DDI-DrugBank.d710.s1	total	146	150	O
DDI-DrugBank.d710.s1	rimantadine	152	162	B-drug
DDI-DrugBank.d710.s1	clearance	164	172	O
DDI-DrugBank.d710.s1	of	174	175	O
DDI-DrugBank.d710.s1	this	177	180	O
DDI-DrugBank.d710.s1	single	182	187	O
DDI-DrugBank.d710.s1	dose	189	192	O
DDI-DrugBank.d710.s1	in	183	184	O
DDI-DrugBank.d710.s1	normal	197	202	O
DDI-DrugBank.d710.s1	healthy	204	210	O
DDI-DrugBank.d710.s1	adults	212	217	O
DDI-DrugBank.d710.s1	was	219	221	O
DDI-DrugBank.d710.s1	reduced	223	229	O
DDI-DrugBank.d710.s1	by	231	232	O
DDI-DrugBank.d710.s1	18	234	235	O
DDI-DrugBank.d710.s1	%	236	236	O
DDI-DrugBank.d710.s1	(	238	238	O
DDI-DrugBank.d710.s1	compared	239	246	O
DDI-DrugBank.d710.s1	to	248	249	O
DDI-DrugBank.d710.s1	the	251	253	O
DDI-DrugBank.d710.s1	apparent	255	262	O
DDI-DrugBank.d710.s1	total	264	268	O
DDI-DrugBank.d710.s1	rimantadine	270	280	B-drug
DDI-DrugBank.d710.s1	clearance	282	290	O
DDI-DrugBank.d710.s1	in	278	279	I-drug
DDI-DrugBank.d710.s1	the	251	253	O
DDI-DrugBank.d710.s1	same	299	302	O
DDI-DrugBank.d710.s1	subjects	304	311	O
DDI-DrugBank.d710.s1	in	278	279	I-drug
DDI-DrugBank.d710.s1	the	295	297	O
DDI-DrugBank.d710.s1	absence	320	326	O
DDI-DrugBank.d710.s1	of	328	329	O
DDI-DrugBank.d710.s1	cimetidine	331	340	B-drug
DDI-DrugBank.d710.s1	)	341	341	O
DDI-DrugBank.d710.s1	.	342	342	O
DDI-DrugBank.d710.s2	Acetaminophen	0	12	B-drug
DDI-DrugBank.d710.s2	:	13	13	O
DDI-DrugBank.d710.s2	Rimantadine	15	25	B-drug
DDI-DrugBank.d710.s2	HCl	27	29	I-drug
DDI-DrugBank.d710.s2	,	30	30	O
DDI-DrugBank.d710.s2	100	32	34	O
DDI-DrugBank.d710.s2	mg	36	37	O
DDI-DrugBank.d710.s2	,	38	38	O
DDI-DrugBank.d710.s2	was	40	42	O
DDI-DrugBank.d710.s2	given	44	48	O
DDI-DrugBank.d710.s2	twice	50	54	O
DDI-DrugBank.d710.s2	daily	56	60	O
DDI-DrugBank.d710.s2	for	62	64	O
DDI-DrugBank.d710.s2	13	66	67	O
DDI-DrugBank.d710.s2	days	69	72	O
DDI-DrugBank.d710.s2	to	74	75	O
DDI-DrugBank.d710.s2	12	77	78	O
DDI-DrugBank.d710.s2	healthy	80	86	O
DDI-DrugBank.d710.s2	volunteers	88	97	O
DDI-DrugBank.d710.s2	.	98	98	O
DDI-DrugBank.d710.s3	On	0	1	O
DDI-DrugBank.d710.s3	day	3	5	O
DDI-DrugBank.d710.s3	11	7	8	O
DDI-DrugBank.d710.s3	,	9	9	O
DDI-DrugBank.d710.s3	acetaminophen	11	23	B-drug
DDI-DrugBank.d710.s3	(	25	25	O
DDI-DrugBank.d710.s3	650	26	28	O
DDI-DrugBank.d710.s3	mg	30	31	O
DDI-DrugBank.d710.s3	four	33	36	O
DDI-DrugBank.d710.s3	times	38	42	O
DDI-DrugBank.d710.s3	daily	44	48	O
DDI-DrugBank.d710.s3	)	49	49	O
DDI-DrugBank.d710.s3	was	51	53	O
DDI-DrugBank.d710.s3	started	55	61	O
DDI-DrugBank.d710.s3	and	63	65	O
DDI-DrugBank.d710.s3	continued	67	75	O
DDI-DrugBank.d710.s3	for	77	79	O
DDI-DrugBank.d710.s3	8	81	81	O
DDI-DrugBank.d710.s3	days	83	86	O
DDI-DrugBank.d710.s3	.	87	87	O
DDI-DrugBank.d710.s4	The	0	2	O
DDI-DrugBank.d710.s4	pharmacokinetics	4	19	O
DDI-DrugBank.d710.s4	of	21	22	O
DDI-DrugBank.d710.s4	rimantadine	24	34	B-drug
DDI-DrugBank.d710.s4	were	36	39	O
DDI-DrugBank.d710.s4	assessed	41	48	O
DDI-DrugBank.d710.s4	on	50	51	O
DDI-DrugBank.d710.s4	days	53	56	O
DDI-DrugBank.d710.s4	11	58	59	O
DDI-DrugBank.d710.s4	and	61	63	O
DDI-DrugBank.d710.s4	13	65	66	O
DDI-DrugBank.d710.s4	.	67	67	O
DDI-DrugBank.d710.s5	Coadministration	0	15	O
DDI-DrugBank.d710.s5	with	17	20	O
DDI-DrugBank.d710.s5	acetaminophen	22	34	B-drug
DDI-DrugBank.d710.s5	reduced	36	42	O
DDI-DrugBank.d710.s5	the	44	46	O
DDI-DrugBank.d710.s5	peak	48	51	O
DDI-DrugBank.d710.s5	concentration	53	65	O
DDI-DrugBank.d710.s5	and	67	69	O
DDI-DrugBank.d710.s5	AUC	71	73	O
DDI-DrugBank.d710.s5	values	75	80	O
DDI-DrugBank.d710.s5	for	82	84	O
DDI-DrugBank.d710.s5	rimantadine	86	96	B-drug
DDI-DrugBank.d710.s5	by	98	99	O
DDI-DrugBank.d710.s5	approximately	101	113	O
DDI-DrugBank.d710.s5	11	115	116	O
DDI-DrugBank.d710.s5	%	117	117	O
DDI-DrugBank.d710.s5	.	118	118	O
DDI-DrugBank.d710.s6	Aspirin	0	6	B-brand
DDI-DrugBank.d710.s6	:	7	7	O
DDI-DrugBank.d710.s6	Rimantadine	9	19	B-drug
DDI-DrugBank.d710.s6	HCl	21	23	I-drug
DDI-DrugBank.d710.s6	,	24	24	O
DDI-DrugBank.d710.s6	100	26	28	O
DDI-DrugBank.d710.s6	mg	30	31	O
DDI-DrugBank.d710.s6	,	32	32	O
DDI-DrugBank.d710.s6	was	34	36	O
DDI-DrugBank.d710.s6	given	38	42	O
DDI-DrugBank.d710.s6	twice	44	48	O
DDI-DrugBank.d710.s6	daily	50	54	O
DDI-DrugBank.d710.s6	fro	56	58	O
DDI-DrugBank.d710.s6	13	60	61	O
DDI-DrugBank.d710.s6	days	63	66	O
DDI-DrugBank.d710.s6	to	68	69	O
DDI-DrugBank.d710.s6	12	71	72	O
DDI-DrugBank.d710.s6	healthy	74	80	O
DDI-DrugBank.d710.s6	volunteers	82	91	O
DDI-DrugBank.d710.s6	.	92	92	O
DDI-DrugBank.d710.s7	On	0	1	O
DDI-DrugBank.d710.s7	day	3	5	O
DDI-DrugBank.d710.s7	11	7	8	O
DDI-DrugBank.d710.s7	,	9	9	O
DDI-DrugBank.d710.s7	aspirin	11	17	B-brand
DDI-DrugBank.d710.s7	(	19	19	O
DDI-DrugBank.d710.s7	650	20	22	O
DDI-DrugBank.d710.s7	mg	24	25	O
DDI-DrugBank.d710.s7	,	26	26	O
DDI-DrugBank.d710.s7	four	28	31	O
DDI-DrugBank.d710.s7	times	33	37	O
DDI-DrugBank.d710.s7	daily	39	43	O
DDI-DrugBank.d710.s7	)	44	44	O
DDI-DrugBank.d710.s7	was	46	48	O
DDI-DrugBank.d710.s7	started	50	56	O
DDI-DrugBank.d710.s7	and	58	60	O
DDI-DrugBank.d710.s7	continued	62	70	O
DDI-DrugBank.d710.s7	for	72	74	O
DDI-DrugBank.d710.s7	8	76	76	O
DDI-DrugBank.d710.s7	days	78	81	O
DDI-DrugBank.d710.s7	.	82	82	O
DDI-DrugBank.d710.s8	The	0	2	O
DDI-DrugBank.d710.s8	pharmacokinetics	4	19	O
DDI-DrugBank.d710.s8	of	21	22	O
DDI-DrugBank.d710.s8	rimantadine	24	34	B-drug
DDI-DrugBank.d710.s8	were	36	39	O
DDI-DrugBank.d710.s8	assessed	41	48	O
DDI-DrugBank.d710.s8	on	50	51	O
DDI-DrugBank.d710.s8	days	53	56	O
DDI-DrugBank.d710.s8	11	58	59	O
DDI-DrugBank.d710.s8	and	61	63	O
DDI-DrugBank.d710.s8	13	65	66	O
DDI-DrugBank.d710.s8	.	67	67	O
DDI-DrugBank.d710.s9	Peak	0	3	O
DDI-DrugBank.d710.s9	plasma	5	10	O
DDI-DrugBank.d710.s9	concentrations	12	25	O
DDI-DrugBank.d710.s9	and	27	29	O
DDI-DrugBank.d710.s9	AUC	31	33	O
DDI-DrugBank.d710.s9	of	35	36	O
DDI-DrugBank.d710.s9	rimantadine	38	48	B-drug
DDI-DrugBank.d710.s9	were	50	53	O
DDI-DrugBank.d710.s9	reduced	55	61	O
DDI-DrugBank.d710.s9	approximately	63	75	O
DDI-DrugBank.d710.s9	10	77	78	O
DDI-DrugBank.d710.s9	%	79	79	O
DDI-DrugBank.d710.s9	in	81	82	O
DDI-DrugBank.d710.s9	the	84	86	O
DDI-DrugBank.d710.s9	presence	88	95	O
DDI-DrugBank.d710.s9	of	97	98	O
DDI-DrugBank.d710.s9	aspirin	100	106	B-brand
DDI-DrugBank.d710.s9	.	107	107	O
DDI-DrugBank.d51.s0	ATROVENT	0	7	B-brand
DDI-DrugBank.d51.s0	Inhalation	9	18	O
DDI-DrugBank.d51.s0	Aerosol	20	26	O
DDI-DrugBank.d51.s0	has	28	30	O
DDI-DrugBank.d51.s0	been	32	35	O
DDI-DrugBank.d51.s0	used	37	40	O
DDI-DrugBank.d51.s0	concomitantly	42	54	O
DDI-DrugBank.d51.s0	with	56	59	O
DDI-DrugBank.d51.s0	other	61	65	O
DDI-DrugBank.d51.s0	drugs	67	71	O
DDI-DrugBank.d51.s0	,	72	72	O
DDI-DrugBank.d51.s0	including	74	82	O
DDI-DrugBank.d51.s0	sympathomimetic	84	98	B-group
DDI-DrugBank.d51.s0	bronchodilators	100	114	I-group
DDI-DrugBank.d51.s0	,	115	115	O
DDI-DrugBank.d51.s0	methylxanthines	117	131	B-group
DDI-DrugBank.d51.s0	,	132	132	O
DDI-DrugBank.d51.s0	and	134	136	O
DDI-DrugBank.d51.s0	steroids	138	145	B-group
DDI-DrugBank.d51.s0	,	132	132	O
DDI-DrugBank.d51.s0	commonly	148	155	O
DDI-DrugBank.d51.s0	used	157	160	O
DDI-DrugBank.d51.s0	in	162	163	O
DDI-DrugBank.d51.s0	the	165	167	O
DDI-DrugBank.d51.s0	treatment	169	177	O
DDI-DrugBank.d51.s0	of	179	180	O
DDI-DrugBank.d51.s0	chronic	182	188	O
DDI-DrugBank.d51.s0	obstructive	190	200	O
DDI-DrugBank.d51.s0	pulmonary	202	210	O
DDI-DrugBank.d51.s0	disease	212	218	O
DDI-DrugBank.d51.s0	.	219	219	O
DDI-DrugBank.d51.s1	With	0	3	O
DDI-DrugBank.d51.s1	the	5	7	O
DDI-DrugBank.d51.s1	exception	9	17	O
DDI-DrugBank.d51.s1	of	19	20	O
DDI-DrugBank.d51.s1	albuterol	22	30	B-drug
DDI-DrugBank.d51.s1	,	31	31	O
DDI-DrugBank.d51.s1	there	33	37	O
DDI-DrugBank.d51.s1	are	39	41	O
DDI-DrugBank.d51.s1	no	43	44	O
DDI-DrugBank.d51.s1	formal	46	51	O
DDI-DrugBank.d51.s1	studies	53	59	O
DDI-DrugBank.d51.s1	fully	61	65	O
DDI-DrugBank.d51.s1	evaluating	67	76	O
DDI-DrugBank.d51.s1	the	78	80	O
DDI-DrugBank.d51.s1	interaction	82	92	O
DDI-DrugBank.d51.s1	effects	94	100	O
DDI-DrugBank.d51.s1	of	102	103	O
DDI-DrugBank.d51.s1	ATROVENT	105	112	B-brand
DDI-DrugBank.d51.s1	Inhalation	114	123	O
DDI-DrugBank.d51.s1	Aerosol	125	131	O
DDI-DrugBank.d51.s1	and	133	135	O
DDI-DrugBank.d51.s1	these	137	141	O
DDI-DrugBank.d51.s1	drugs	143	147	O
DDI-DrugBank.d51.s1	with	149	152	O
DDI-DrugBank.d51.s1	respect	154	160	O
DDI-DrugBank.d51.s1	to	162	163	O
DDI-DrugBank.d51.s1	effectiveness	165	177	O
DDI-DrugBank.d51.s1	.	178	178	O
DDI-DrugBank.d51.s2	Anticholinergic	0	14	B-group
DDI-DrugBank.d51.s2	agents	16	21	I-group
DDI-DrugBank.d51.s2	:	22	22	O
DDI-DrugBank.d51.s2	Although	24	31	O
DDI-DrugBank.d51.s2	ipratropium	33	43	B-drug
DDI-DrugBank.d51.s2	bromide	45	51	I-drug
DDI-DrugBank.d51.s2	is	53	54	O
DDI-DrugBank.d51.s2	minimally	56	64	O
DDI-DrugBank.d51.s2	absorbed	66	73	O
DDI-DrugBank.d51.s2	into	75	78	O
DDI-DrugBank.d51.s2	the	80	82	O
DDI-DrugBank.d51.s2	systemic	84	91	O
DDI-DrugBank.d51.s2	circulation	93	103	O
DDI-DrugBank.d51.s2	,	104	104	O
DDI-DrugBank.d51.s2	there	106	110	O
DDI-DrugBank.d51.s2	is	112	113	O
DDI-DrugBank.d51.s2	some	115	118	O
DDI-DrugBank.d51.s2	potential	120	128	O
DDI-DrugBank.d51.s2	for	130	132	O
DDI-DrugBank.d51.s2	an	134	135	O
DDI-DrugBank.d51.s2	additive	137	144	O
DDI-DrugBank.d51.s2	interaction	146	156	O
DDI-DrugBank.d51.s2	with	158	161	O
DDI-DrugBank.d51.s2	concomitantly	163	175	O
DDI-DrugBank.d51.s2	used	177	180	O
DDI-DrugBank.d51.s2	anticholinergic	182	196	B-group
DDI-DrugBank.d51.s2	medications	198	208	I-group
DDI-DrugBank.d51.s2	.	209	209	O
DDI-DrugBank.d51.s3	Caution	0	6	O
DDI-DrugBank.d51.s3	is	8	9	O
DDI-DrugBank.d51.s3	therefore	11	19	O
DDI-DrugBank.d51.s3	advised	21	27	O
DDI-DrugBank.d51.s3	in	29	30	O
DDI-DrugBank.d51.s3	the	32	34	O
DDI-DrugBank.d51.s3	coadministration	36	51	O
DDI-DrugBank.d51.s3	of	53	54	O
DDI-DrugBank.d51.s3	ATROVENT	56	63	B-brand
DDI-DrugBank.d51.s3	Inhalation	65	74	O
DDI-DrugBank.d51.s3	Aerosol	76	82	O
DDI-DrugBank.d51.s3	with	84	87	O
DDI-DrugBank.d51.s3	other	89	93	O
DDI-DrugBank.d51.s3	anticholinergic-containing	95	120	O
DDI-DrugBank.d51.s3	drugs	122	126	O
DDI-DrugBank.d51.s3	.	127	127	O
DDI-MedLine.d85.s0	Misonidazole	0	11	B-drug_n
DDI-MedLine.d85.s0	protects	13	20	O
DDI-MedLine.d85.s0	mouse	22	26	O
DDI-MedLine.d85.s0	tumour	28	33	O
DDI-MedLine.d85.s0	and	35	37	O
DDI-MedLine.d85.s0	normal	39	44	O
DDI-MedLine.d85.s0	tissues	46	52	O
DDI-MedLine.d85.s0	from	54	57	O
DDI-MedLine.d85.s0	the	59	61	O
DDI-MedLine.d85.s0	toxicity	63	70	O
DDI-MedLine.d85.s0	of	72	73	O
DDI-MedLine.d85.s0	oral	75	78	O
DDI-MedLine.d85.s0	CCNU	80	83	B-drug
DDI-MedLine.d85.s0	.	84	84	O
DDI-MedLine.d85.s1	Because	0	6	O
DDI-MedLine.d85.s1	the	8	10	O
DDI-MedLine.d85.s1	nitrosourea	12	22	B-group
DDI-MedLine.d85.s1	CCNU	24	27	B-drug
DDI-MedLine.d85.s1	is	29	30	O
DDI-MedLine.d85.s1	given	32	36	O
DDI-MedLine.d85.s1	exclusively	38	48	O
DDI-MedLine.d85.s1	by	50	51	O
DDI-MedLine.d85.s1	the	53	55	O
DDI-MedLine.d85.s1	oral	57	60	O
DDI-MedLine.d85.s1	route	62	66	O
DDI-MedLine.d85.s1	in	68	69	O
DDI-MedLine.d85.s1	man	71	73	O
DDI-MedLine.d85.s1	,	74	74	O
DDI-MedLine.d85.s1	we	76	77	O
DDI-MedLine.d85.s1	have	79	82	O
DDI-MedLine.d85.s1	carried	84	90	O
DDI-MedLine.d85.s1	out	92	94	O
DDI-MedLine.d85.s1	studies	96	102	O
DDI-MedLine.d85.s1	in	104	105	O
DDI-MedLine.d85.s1	mice	107	110	O
DDI-MedLine.d85.s1	on	112	113	O
DDI-MedLine.d85.s1	the	115	117	O
DDI-MedLine.d85.s1	antitumour	119	128	O
DDI-MedLine.d85.s1	activity	130	137	O
DDI-MedLine.d85.s1	,	138	138	O
DDI-MedLine.d85.s1	acute	140	144	O
DDI-MedLine.d85.s1	toxicity	146	153	O
DDI-MedLine.d85.s1	and	155	157	O
DDI-MedLine.d85.s1	pharmacokinetics	159	174	O
DDI-MedLine.d85.s1	of	176	177	O
DDI-MedLine.d85.s1	oral	179	182	O
DDI-MedLine.d85.s1	CCNU	184	187	B-drug
DDI-MedLine.d85.s1	,	188	188	O
DDI-MedLine.d85.s1	either	190	195	O
DDI-MedLine.d85.s1	alone	197	201	O
DDI-MedLine.d85.s1	or	179	180	O
DDI-MedLine.d85.s1	in	206	207	O
DDI-MedLine.d85.s1	combination	209	219	O
DDI-MedLine.d85.s1	with	221	224	O
DDI-MedLine.d85.s1	the	192	194	O
DDI-MedLine.d85.s1	chemosensitizer	230	244	O
DDI-MedLine.d85.s1	misonidazole	246	257	B-drug_n
DDI-MedLine.d85.s1	.	258	258	O
DDI-MedLine.d85.s2	In	0	1	O
DDI-MedLine.d85.s2	both	3	6	O
DDI-MedLine.d85.s2	plasma	8	13	O
DDI-MedLine.d85.s2	and	15	17	O
DDI-MedLine.d85.s2	KHT	19	21	O
DDI-MedLine.d85.s2	tumour	23	28	O
DDI-MedLine.d85.s2	the	30	32	O
DDI-MedLine.d85.s2	peak	34	37	O
DDI-MedLine.d85.s2	concentration	39	51	O
DDI-MedLine.d85.s2	and	53	55	O
DDI-MedLine.d85.s2	``	-1	0	O
DDI-MedLine.d85.s2	early	58	62	O
DDI-MedLine.d85.s2	''	-1	0	O
DDI-MedLine.d85.s3	AUC	0	2	O
DDI-MedLine.d85.s3	for	4	6	O
DDI-MedLine.d85.s3	total	8	12	O
DDI-MedLine.d85.s3	nitrosoureas	14	25	B-group
DDI-MedLine.d85.s3	were	27	30	O
DDI-MedLine.d85.s3	about	32	36	O
DDI-MedLine.d85.s3	1.4-1.5	38	44	O
DDI-MedLine.d85.s3	fold	46	49	O
DDI-MedLine.d85.s3	greater	51	57	O
DDI-MedLine.d85.s3	for	59	61	O
DDI-MedLine.d85.s3	the	63	65	O
DDI-MedLine.d85.s3	oral	67	70	O
DDI-MedLine.d85.s3	compared	72	79	O
DDI-MedLine.d85.s3	to	81	82	O
DDI-MedLine.d85.s3	the	84	86	O
DDI-MedLine.d85.s3	i.p	88	90	O
DDI-MedLine.d85.s3	.	89	89	O
DDI-MedLine.d85.s4	route	0	4	O
DDI-MedLine.d85.s4	.	5	5	O
DDI-MedLine.d85.s5	These	0	4	O
DDI-MedLine.d85.s5	differences	6	16	O
DDI-MedLine.d85.s5	were	18	21	O
DDI-MedLine.d85.s5	reflected	23	31	O
DDI-MedLine.d85.s5	in	33	34	O
DDI-MedLine.d85.s5	the	36	38	O
DDI-MedLine.d85.s5	roughly	40	46	O
DDI-MedLine.d85.s5	twofold	48	54	O
DDI-MedLine.d85.s5	greater	56	62	O
DDI-MedLine.d85.s5	antitumour	64	73	O
DDI-MedLine.d85.s5	activity	75	82	O
DDI-MedLine.d85.s5	for	84	86	O
DDI-MedLine.d85.s5	the	88	90	O
DDI-MedLine.d85.s5	oral	92	95	O
DDI-MedLine.d85.s5	route	97	101	O
DDI-MedLine.d85.s5	.	102	102	O
DDI-MedLine.d85.s6	In	0	1	O
DDI-MedLine.d85.s6	contrast	3	10	O
DDI-MedLine.d85.s6	,	11	11	O
DDI-MedLine.d85.s6	acute	13	17	O
DDI-MedLine.d85.s6	toxicity	19	26	O
DDI-MedLine.d85.s6	tests	28	32	O
DDI-MedLine.d85.s6	showed	34	39	O
DDI-MedLine.d85.s6	that	41	44	O
DDI-MedLine.d85.s6	oral	46	49	O
DDI-MedLine.d85.s6	CCNU	51	54	B-drug
DDI-MedLine.d85.s6	was	56	58	O
DDI-MedLine.d85.s6	1.45	60	63	O
DDI-MedLine.d85.s6	times	65	69	O
DDI-MedLine.d85.s6	less	71	74	O
DDI-MedLine.d85.s6	toxic	76	80	O
DDI-MedLine.d85.s6	to	76	77	O
DDI-MedLine.d85.s6	normal	85	90	O
DDI-MedLine.d85.s6	tissue	92	97	O
DDI-MedLine.d85.s6	,	98	98	O
DDI-MedLine.d85.s6	although	100	107	O
DDI-MedLine.d85.s6	the	109	111	O
DDI-MedLine.d85.s6	dose-limiting	113	125	O
DDI-MedLine.d85.s6	organ	127	131	O
DDI-MedLine.d85.s6	may	133	135	O
DDI-MedLine.d85.s6	be	137	138	O
DDI-MedLine.d85.s6	different	140	148	O
DDI-MedLine.d85.s6	for	150	152	O
DDI-MedLine.d85.s6	the	154	156	O
DDI-MedLine.d85.s6	two	158	160	O
DDI-MedLine.d85.s6	routes	162	167	O
DDI-MedLine.d85.s6	.	168	168	O
DDI-MedLine.d85.s7	Misonidazole	0	11	B-drug_n
DDI-MedLine.d85.s7	reduced	13	19	O
DDI-MedLine.d85.s7	the	21	23	O
DDI-MedLine.d85.s7	antitumour	25	34	O
DDI-MedLine.d85.s7	activity	36	43	O
DDI-MedLine.d85.s7	of	45	46	O
DDI-MedLine.d85.s7	oral	48	51	O
DDI-MedLine.d85.s7	CCNU	53	56	B-drug
DDI-MedLine.d85.s7	by	58	59	O
DDI-MedLine.d85.s7	dose	61	64	O
DDI-MedLine.d85.s7	modifying	66	74	O
DDI-MedLine.d85.s7	factors	76	82	O
DDI-MedLine.d85.s7	(	84	84	O
DDI-MedLine.d85.s7	DMF	85	87	O
DDI-MedLine.d85.s7	)	88	88	O
DDI-MedLine.d85.s7	of	90	91	O
DDI-MedLine.d85.s7	0.58-0.71	93	101	O
DDI-MedLine.d85.s7	.	94	94	O
DDI-MedLine.d85.s8	Similarly	0	8	O
DDI-MedLine.d85.s8	,	9	9	O
DDI-MedLine.d85.s8	the	11	13	O
DDI-MedLine.d85.s8	acute	15	19	O
DDI-MedLine.d85.s8	toxicity	21	28	O
DDI-MedLine.d85.s8	was	30	32	O
DDI-MedLine.d85.s8	also	34	37	O
DDI-MedLine.d85.s8	diminished	39	48	O
DDI-MedLine.d85.s8	by	50	51	O
DDI-MedLine.d85.s8	a	53	53	O
DDI-MedLine.d85.s8	DMF	55	57	O
DDI-MedLine.d85.s8	of	59	60	O
DDI-MedLine.d85.s8	0.74	62	65	O
DDI-MedLine.d85.s8	.	63	63	O
DDI-MedLine.d85.s9	Misonidazole	0	11	B-drug_n
DDI-MedLine.d85.s9	has	13	15	O
DDI-MedLine.d85.s9	a	17	17	O
DDI-MedLine.d85.s9	complex	19	25	O
DDI-MedLine.d85.s9	effect	27	32	O
DDI-MedLine.d85.s9	on	34	35	O
DDI-MedLine.d85.s9	oral	37	40	O
DDI-MedLine.d85.s9	CCNU	42	45	B-drug
DDI-MedLine.d85.s9	pharmacokinetics	47	62	O
DDI-MedLine.d85.s9	.	63	63	O
DDI-MedLine.d85.s10	The	0	2	O
DDI-MedLine.d85.s10	plasma	4	9	O
DDI-MedLine.d85.s10	and	11	13	O
DDI-MedLine.d85.s10	tumour	15	20	O
DDI-MedLine.d85.s10	total	22	26	O
DDI-MedLine.d85.s10	nitrosourea	28	38	B-group
DDI-MedLine.d85.s10	peak	40	43	O
DDI-MedLine.d85.s10	concentrations	45	58	O
DDI-MedLine.d85.s10	were	60	63	O
DDI-MedLine.d85.s10	reduced	65	71	O
DDI-MedLine.d85.s10	by	73	74	O
DDI-MedLine.d85.s10	1.5	76	78	O
DDI-MedLine.d85.s10	and	80	82	O
DDI-MedLine.d85.s10	1.7	84	86	O
DDI-MedLine.d85.s10	fold	88	91	O
DDI-MedLine.d85.s10	respectively	93	104	O
DDI-MedLine.d85.s10	.	105	105	O
DDI-MedLine.d85.s11	Misonidazole	0	11	B-drug_n
DDI-MedLine.d85.s11	also	13	16	O
DDI-MedLine.d85.s11	reduced	18	24	O
DDI-MedLine.d85.s11	the	26	28	O
DDI-MedLine.d85.s11	``	-1	0	O
DDI-MedLine.d85.s11	early	31	35	O
DDI-MedLine.d85.s11	''	-1	0	O
DDI-MedLine.d85.s12	nitrosourea	0	10	B-group
DDI-MedLine.d85.s12	AUC	12	14	O
DDI-MedLine.d85.s12	,	15	15	O
DDI-MedLine.d85.s12	with	17	20	O
DDI-MedLine.d85.s12	the	22	24	O
DDI-MedLine.d85.s12	extent	26	31	O
DDI-MedLine.d85.s12	of	33	34	O
DDI-MedLine.d85.s12	the	36	38	O
DDI-MedLine.d85.s12	reduction	40	48	O
DDI-MedLine.d85.s12	depending	50	58	O
DDI-MedLine.d85.s12	on	60	61	O
DDI-MedLine.d85.s12	the	63	65	O
DDI-MedLine.d85.s12	minimum	67	73	O
DDI-MedLine.d85.s12	effective	75	83	O
DDI-MedLine.d85.s12	concentration	85	97	O
DDI-MedLine.d85.s12	(	99	99	O
DDI-MedLine.d85.s12	MEC	100	102	O
DDI-MedLine.d85.s12	)	103	103	O
DDI-MedLine.d85.s12	chosen	105	110	O
DDI-MedLine.d85.s12	.	111	111	O
DDI-MedLine.d85.s13	For	0	2	O
DDI-MedLine.d85.s13	example	4	10	O
DDI-MedLine.d85.s13	,	11	11	O
DDI-MedLine.d85.s13	the	13	15	O
DDI-MedLine.d85.s13	plasma	17	22	O
DDI-MedLine.d85.s13	nitrosourea	24	34	B-group
DDI-MedLine.d85.s13	AUC	36	38	O
DDI-MedLine.d85.s13	was	40	42	O
DDI-MedLine.d85.s13	reduced	44	50	O
DDI-MedLine.d85.s13	by	52	53	O
DDI-MedLine.d85.s13	factors	55	61	O
DDI-MedLine.d85.s13	of	63	64	O
DDI-MedLine.d85.s13	1.05	66	69	O
DDI-MedLine.d85.s13	and	71	73	O
DDI-MedLine.d85.s13	9.6	75	77	O
DDI-MedLine.d85.s13	for	79	81	O
DDI-MedLine.d85.s13	MEC	83	85	O
DDI-MedLine.d85.s13	values	87	92	O
DDI-MedLine.d85.s13	of	94	95	O
DDI-MedLine.d85.s13	1	97	97	O
DDI-MedLine.d85.s13	and	99	101	O
DDI-MedLine.d85.s13	2	103	103	O
DDI-MedLine.d85.s13	micrograms	105	114	O
DDI-MedLine.d85.s13	ml-1	116	119	O
DDI-MedLine.d85.s13	respectively	121	132	O
DDI-MedLine.d85.s13	.	133	133	O
DDI-MedLine.d85.s14	We	0	1	O
DDI-MedLine.d85.s14	propose	3	9	O
DDI-MedLine.d85.s14	these	11	15	O
DDI-MedLine.d85.s14	pharmacokinetic	17	31	O
DDI-MedLine.d85.s14	changes	33	39	O
DDI-MedLine.d85.s14	to	41	42	O
DDI-MedLine.d85.s14	be	44	45	O
DDI-MedLine.d85.s14	the	47	49	O
DDI-MedLine.d85.s14	underlying	51	60	O
DDI-MedLine.d85.s14	mechanism	62	70	O
DDI-MedLine.d85.s14	for	72	74	O
DDI-MedLine.d85.s14	the	76	78	O
DDI-MedLine.d85.s14	reduction	80	88	O
DDI-MedLine.d85.s14	of	90	91	O
DDI-MedLine.d85.s14	oral	93	96	O
DDI-MedLine.d85.s14	CCNU	98	101	B-drug
DDI-MedLine.d85.s14	cytotoxicity	103	114	O
DDI-MedLine.d85.s14	by	116	117	O
DDI-MedLine.d85.s14	misonidazole	119	130	B-drug_n
DDI-MedLine.d85.s14	.	131	131	O
DDI-MedLine.d85.s15	Clinical	0	7	O
DDI-MedLine.d85.s15	trials	9	14	O
DDI-MedLine.d85.s15	of	16	17	O
DDI-MedLine.d85.s15	such	19	22	O
DDI-MedLine.d85.s15	combinations	24	35	O
DDI-MedLine.d85.s15	should	37	42	O
DDI-MedLine.d85.s15	be	44	45	O
DDI-MedLine.d85.s15	accompanied	47	57	O
DDI-MedLine.d85.s15	by	59	60	O
DDI-MedLine.d85.s15	detailed	62	69	O
DDI-MedLine.d85.s15	pharmacokinetic	71	85	O
DDI-MedLine.d85.s15	evaluation	87	96	O
DDI-MedLine.d85.s15	.	97	97	O
DDI-DrugBank.d578.s0	The	0	2	O
DDI-DrugBank.d578.s0	pharmacokinetic	4	18	O
DDI-DrugBank.d578.s0	interactions	20	31	O
DDI-DrugBank.d578.s0	listed	33	38	O
DDI-DrugBank.d578.s0	below	40	44	O
DDI-DrugBank.d578.s0	are	46	48	O
DDI-DrugBank.d578.s0	potentially	50	60	O
DDI-DrugBank.d578.s0	clinically	62	71	O
DDI-DrugBank.d578.s0	important	73	81	O
DDI-DrugBank.d578.s0	.	82	82	O
DDI-DrugBank.d578.s1	Mutual	0	5	O
DDI-DrugBank.d578.s1	inhibition	7	16	O
DDI-DrugBank.d578.s1	of	18	19	O
DDI-DrugBank.d578.s1	metabolism	21	30	O
DDI-DrugBank.d578.s1	occurs	32	37	O
DDI-DrugBank.d578.s1	with	39	42	O
DDI-DrugBank.d578.s1	concurrent	44	53	O
DDI-DrugBank.d578.s1	use	55	57	O
DDI-DrugBank.d578.s1	of	59	60	O
DDI-DrugBank.d578.s1	cyclosporin	62	72	B-drug
DDI-DrugBank.d578.s1	and	74	76	O
DDI-DrugBank.d578.s1	methylprednisolone	78	95	B-drug
DDI-DrugBank.d578.s1	;	96	96	O
DDI-DrugBank.d578.s2	therefore	0	8	O
DDI-DrugBank.d578.s2	,	9	9	O
DDI-DrugBank.d578.s2	it	11	12	O
DDI-DrugBank.d578.s2	is	14	15	O
DDI-DrugBank.d578.s2	possible	17	24	O
DDI-DrugBank.d578.s2	that	26	29	O
DDI-DrugBank.d578.s2	adverse	31	37	O
DDI-DrugBank.d578.s2	events	39	44	O
DDI-DrugBank.d578.s2	associated	46	55	O
DDI-DrugBank.d578.s2	with	57	60	O
DDI-DrugBank.d578.s2	the	62	64	O
DDI-DrugBank.d578.s2	individual	66	75	O
DDI-DrugBank.d578.s2	use	77	79	O
DDI-DrugBank.d578.s2	of	81	82	O
DDI-DrugBank.d578.s2	either	84	89	O
DDI-DrugBank.d578.s2	drug	91	94	O
DDI-DrugBank.d578.s2	may	96	98	O
DDI-DrugBank.d578.s2	be	100	101	O
DDI-DrugBank.d578.s2	more	103	106	O
DDI-DrugBank.d578.s2	apt	108	110	O
DDI-DrugBank.d578.s2	to	112	113	O
DDI-DrugBank.d578.s2	occur	115	119	O
DDI-DrugBank.d578.s2	.	120	120	O
DDI-DrugBank.d578.s3	convulsions	0	10	O
DDI-DrugBank.d578.s3	have	12	15	O
DDI-DrugBank.d578.s3	been	17	20	O
DDI-DrugBank.d578.s3	reported	22	29	O
DDI-DrugBank.d578.s3	with	31	34	O
DDI-DrugBank.d578.s3	concurrent	36	45	O
DDI-DrugBank.d578.s3	use	47	49	O
DDI-DrugBank.d578.s3	of	51	52	O
DDI-DrugBank.d578.s3	methylprednisolone	54	71	B-drug
DDI-DrugBank.d578.s3	and	73	75	O
DDI-DrugBank.d578.s3	cyclosporin	77	87	B-drug
DDI-DrugBank.d578.s3	.	88	88	O
DDI-DrugBank.d578.s4	Drugs	0	4	O
DDI-DrugBank.d578.s4	that	6	9	O
DDI-DrugBank.d578.s4	induce	11	16	O
DDI-DrugBank.d578.s4	hepatic	18	24	O
DDI-DrugBank.d578.s4	enzymes	26	32	O
DDI-DrugBank.d578.s4	such	34	37	O
DDI-DrugBank.d578.s4	as	39	40	O
DDI-DrugBank.d578.s4	phenobarbital	42	54	B-drug
DDI-DrugBank.d578.s4	,	55	55	O
DDI-DrugBank.d578.s4	phenytoin	57	65	B-drug
DDI-DrugBank.d578.s4	,	66	66	O
DDI-DrugBank.d578.s4	and	68	70	O
DDI-DrugBank.d578.s4	rifampin	72	79	B-drug
DDI-DrugBank.d578.s4	may	81	83	O
DDI-DrugBank.d578.s4	increase	85	92	O
DDI-DrugBank.d578.s4	the	94	96	O
DDI-DrugBank.d578.s4	clearance	98	106	O
DDI-DrugBank.d578.s4	of	108	109	O
DDI-DrugBank.d578.s4	methylprednisolone	111	128	B-drug
DDI-DrugBank.d578.s4	and	130	132	O
DDI-DrugBank.d578.s4	may	134	136	O
DDI-DrugBank.d578.s4	require	138	144	O
DDI-DrugBank.d578.s4	increased	146	154	O
DDI-DrugBank.d578.s4	in	146	147	O
DDI-DrugBank.d578.s4	methylprednisolone	159	176	B-drug
DDI-DrugBank.d578.s4	dose	178	181	O
DDI-DrugBank.d578.s4	to	183	184	O
DDI-DrugBank.d578.s4	achieve	186	192	O
DDI-DrugBank.d578.s4	the	194	196	O
DDI-DrugBank.d578.s4	desired	198	204	O
DDI-DrugBank.d578.s4	response	206	213	O
DDI-DrugBank.d578.s4	.	214	214	O
DDI-DrugBank.d578.s5	Drugs	0	4	O
DDI-DrugBank.d578.s5	such	6	9	O
DDI-DrugBank.d578.s5	as	11	12	O
DDI-DrugBank.d578.s5	troleandomycin	14	27	B-drug
DDI-DrugBank.d578.s5	and	29	31	O
DDI-DrugBank.d578.s5	ketoconazole	33	44	B-drug
DDI-DrugBank.d578.s5	may	46	48	O
DDI-DrugBank.d578.s5	inhibit	50	56	O
DDI-DrugBank.d578.s5	the	58	60	O
DDI-DrugBank.d578.s5	metabolism	62	71	O
DDI-DrugBank.d578.s5	of	73	74	O
DDI-DrugBank.d578.s5	methylprednisolone	76	93	B-drug
DDI-DrugBank.d578.s5	and	95	97	O
DDI-DrugBank.d578.s5	thus	99	102	O
DDI-DrugBank.d578.s5	decrease	104	111	O
DDI-DrugBank.d578.s5	its	113	115	O
DDI-DrugBank.d578.s5	clearance	117	125	O
DDI-DrugBank.d578.s5	.	126	126	O
DDI-DrugBank.d578.s6	Therefore	0	8	O
DDI-DrugBank.d578.s6	,	9	9	O
DDI-DrugBank.d578.s6	the	11	13	O
DDI-DrugBank.d578.s6	dose	15	18	O
DDI-DrugBank.d578.s6	of	20	21	O
DDI-DrugBank.d578.s6	methylprednisolone	23	40	B-drug
DDI-DrugBank.d578.s6	should	42	47	O
DDI-DrugBank.d578.s6	be	49	50	O
DDI-DrugBank.d578.s6	titrated	52	59	O
DDI-DrugBank.d578.s6	to	61	62	O
DDI-DrugBank.d578.s6	avoid	64	68	O
DDI-DrugBank.d578.s6	steroid	70	76	O
DDI-DrugBank.d578.s6	toxicity	78	85	O
DDI-DrugBank.d578.s6	.	86	86	O
DDI-DrugBank.d578.s7	Methylprednisolone	0	17	B-drug
DDI-DrugBank.d578.s7	may	19	21	O
DDI-DrugBank.d578.s7	increase	23	30	O
DDI-DrugBank.d578.s7	the	32	34	O
DDI-DrugBank.d578.s7	clearance	36	44	O
DDI-DrugBank.d578.s7	of	46	47	O
DDI-DrugBank.d578.s7	chronic	49	55	O
DDI-DrugBank.d578.s7	high	57	60	O
DDI-DrugBank.d578.s7	dose	62	65	O
DDI-DrugBank.d578.s7	aspirin	67	73	B-brand
DDI-DrugBank.d578.s7	.	74	74	O
DDI-DrugBank.d578.s8	This	0	3	O
DDI-DrugBank.d578.s8	could	5	9	O
DDI-DrugBank.d578.s8	lead	11	14	O
DDI-DrugBank.d578.s8	to	16	17	O
DDI-DrugBank.d578.s8	decreased	19	27	O
DDI-DrugBank.d578.s8	salicylate	29	38	B-group
DDI-DrugBank.d578.s8	serum	40	44	O
DDI-DrugBank.d578.s8	levels	46	51	O
DDI-DrugBank.d578.s8	or	53	54	O
DDI-DrugBank.d578.s8	increase	56	63	O
DDI-DrugBank.d578.s8	the	65	67	O
DDI-DrugBank.d578.s8	risk	69	72	O
DDI-DrugBank.d578.s8	of	74	75	O
DDI-DrugBank.d578.s8	salicylate	77	86	B-group
DDI-DrugBank.d578.s8	toxicity	88	95	O
DDI-DrugBank.d578.s8	when	97	100	O
DDI-DrugBank.d578.s8	methylprednisolone	102	119	B-drug
DDI-DrugBank.d578.s8	is	113	114	I-drug
DDI-DrugBank.d578.s8	withdrawn	124	132	O
DDI-DrugBank.d578.s8	.	133	133	O
DDI-DrugBank.d578.s9	Aspirin	0	6	B-brand
DDI-DrugBank.d578.s9	should	8	13	O
DDI-DrugBank.d578.s9	be	15	16	O
DDI-DrugBank.d578.s9	used	18	21	O
DDI-DrugBank.d578.s9	cautiously	23	32	O
DDI-DrugBank.d578.s9	in	34	35	O
DDI-DrugBank.d578.s9	conjunction	37	47	O
DDI-DrugBank.d578.s9	with	49	52	O
DDI-DrugBank.d578.s9	corticosteroids	54	68	B-group
DDI-DrugBank.d578.s9	in	70	71	O
DDI-DrugBank.d578.s9	patients	73	80	O
DDI-DrugBank.d578.s9	suffering	82	90	O
DDI-DrugBank.d578.s9	from	92	95	O
DDI-DrugBank.d578.s9	hypoprothrombinemia	97	115	O
DDI-DrugBank.d578.s9	.	116	116	O
DDI-DrugBank.d578.s10	The	0	2	O
DDI-DrugBank.d578.s10	effect	4	9	O
DDI-DrugBank.d578.s10	of	11	12	O
DDI-DrugBank.d578.s10	methylprednisolone	14	31	B-drug
DDI-DrugBank.d578.s10	on	29	30	I-drug
DDI-DrugBank.d578.s10	oral	36	39	O
DDI-DrugBank.d578.s10	anticoagulants	41	54	B-group
DDI-DrugBank.d578.s10	is	56	57	O
DDI-DrugBank.d578.s10	variable	59	66	O
DDI-DrugBank.d578.s10	.	67	67	O
DDI-DrugBank.d578.s11	There	0	4	O
DDI-DrugBank.d578.s11	are	6	8	O
DDI-DrugBank.d578.s11	reports	10	16	O
DDI-DrugBank.d578.s11	of	18	19	O
DDI-DrugBank.d578.s11	enhanced	21	28	O
DDI-DrugBank.d578.s11	as	30	31	O
DDI-DrugBank.d578.s11	well	33	36	O
DDI-DrugBank.d578.s11	as	38	39	O
DDI-DrugBank.d578.s11	diminished	41	50	O
DDI-DrugBank.d578.s11	effects	52	58	O
DDI-DrugBank.d578.s11	of	60	61	O
DDI-DrugBank.d578.s11	anticoagulant	63	75	B-group
DDI-DrugBank.d578.s11	when	77	80	O
DDI-DrugBank.d578.s11	given	82	86	O
DDI-DrugBank.d578.s11	concurrently	88	99	O
DDI-DrugBank.d578.s11	with	101	104	O
DDI-DrugBank.d578.s11	corticosteroids	106	120	B-group
DDI-DrugBank.d578.s11	.	121	121	O
DDI-DrugBank.d578.s12	Therefore	0	8	O
DDI-DrugBank.d578.s12	,	9	9	O
DDI-DrugBank.d578.s12	coagulation	11	21	O
DDI-DrugBank.d578.s12	indices	23	29	O
DDI-DrugBank.d578.s12	should	31	36	O
DDI-DrugBank.d578.s12	be	38	39	O
DDI-DrugBank.d578.s12	monitored	41	49	O
DDI-DrugBank.d578.s12	to	45	46	O
DDI-DrugBank.d578.s12	maintain	54	61	O
DDI-DrugBank.d578.s12	the	63	65	O
DDI-DrugBank.d578.s12	desired	67	73	O
DDI-DrugBank.d578.s12	anticoagulant	75	87	O
DDI-DrugBank.d578.s12	effect	89	94	O
DDI-DrugBank.d578.s12	.	95	95	O
DDI-DrugBank.d229.s0	Drug	0	3	O
DDI-DrugBank.d229.s0	Interaction	5	15	O
DDI-DrugBank.d229.s0	During	17	22	O
DDI-DrugBank.d229.s0	Pregnancy	24	32	O
DDI-DrugBank.d229.s0	:	33	33	O
DDI-DrugBank.d229.s0	Cromolyn	35	42	B-drug
DDI-DrugBank.d229.s0	sodium	44	49	I-drug
DDI-DrugBank.d229.s0	and	51	53	O
DDI-DrugBank.d229.s0	isoproterenol	55	67	B-drug
DDI-DrugBank.d229.s0	were	69	72	O
DDI-DrugBank.d229.s0	studied	74	80	O
DDI-DrugBank.d229.s0	following	82	90	O
DDI-DrugBank.d229.s0	subcutaneous	92	103	O
DDI-DrugBank.d229.s0	injections	105	114	O
DDI-DrugBank.d229.s0	in	105	106	O
DDI-DrugBank.d229.s0	pregnant	119	126	O
DDI-DrugBank.d229.s0	mice	128	131	O
DDI-DrugBank.d229.s0	.	132	132	O
DDI-DrugBank.d229.s1	Cromolyn	0	7	B-drug
DDI-DrugBank.d229.s1	sodium	9	14	I-drug
DDI-DrugBank.d229.s1	alone	16	20	O
DDI-DrugBank.d229.s1	in	22	23	O
DDI-DrugBank.d229.s1	doses	25	29	O
DDI-DrugBank.d229.s1	up	31	32	O
DDI-DrugBank.d229.s1	to	34	35	O
DDI-DrugBank.d229.s1	540	37	39	O
DDI-DrugBank.d229.s1	mg/kg/day	41	49	O
DDI-DrugBank.d229.s1	(	51	51	O
DDI-DrugBank.d229.s1	approximately	52	64	O
DDI-DrugBank.d229.s1	340	66	68	O
DDI-DrugBank.d229.s1	times	70	74	O
DDI-DrugBank.d229.s1	the	76	78	O
DDI-DrugBank.d229.s1	maximum	80	86	O
DDI-DrugBank.d229.s1	recommended	88	98	O
DDI-DrugBank.d229.s1	daily	100	104	O
DDI-DrugBank.d229.s1	inhalation	106	115	O
DDI-DrugBank.d229.s1	dose	117	120	O
DDI-DrugBank.d229.s1	in	106	107	O
DDI-DrugBank.d229.s1	adults	125	130	O
DDI-DrugBank.d229.s1	on	114	115	O
DDI-DrugBank.d229.s1	a	125	125	O
DDI-DrugBank.d229.s1	mg/m2	137	141	O
DDI-DrugBank.d229.s1	basis	143	147	O
DDI-DrugBank.d229.s1	)	148	148	O
DDI-DrugBank.d229.s1	did	150	152	O
DDI-DrugBank.d229.s1	not	154	156	O
DDI-DrugBank.d229.s1	cause	158	162	O
DDI-DrugBank.d229.s1	significant	164	174	O
DDI-DrugBank.d229.s1	increases	176	184	O
DDI-DrugBank.d229.s1	in	176	177	O
DDI-DrugBank.d229.s1	resorptions	189	199	O
DDI-DrugBank.d229.s1	or	192	193	O
DDI-DrugBank.d229.s1	major	204	208	O
DDI-DrugBank.d229.s1	malformations	210	222	O
DDI-DrugBank.d229.s1	.	223	223	O
DDI-DrugBank.d229.s2	Isoproterenol	0	12	B-drug
DDI-DrugBank.d229.s2	alone	14	18	O
DDI-DrugBank.d229.s2	at	20	21	O
DDI-DrugBank.d229.s2	a	20	20	O
DDI-DrugBank.d229.s2	dose	25	28	O
DDI-DrugBank.d229.s2	of	30	31	O
DDI-DrugBank.d229.s2	2.7	33	35	O
DDI-DrugBank.d229.s2	mg/kg/day	37	45	O
DDI-DrugBank.d229.s2	(	47	47	O
DDI-DrugBank.d229.s2	approximately	48	60	O
DDI-DrugBank.d229.s2	7	62	62	O
DDI-DrugBank.d229.s2	times	64	68	O
DDI-DrugBank.d229.s2	the	70	72	O
DDI-DrugBank.d229.s2	maximum	74	80	O
DDI-DrugBank.d229.s2	recommended	82	92	O
DDI-DrugBank.d229.s2	daily	94	98	O
DDI-DrugBank.d229.s2	inhalation	100	109	O
DDI-DrugBank.d229.s2	dose	111	114	O
DDI-DrugBank.d229.s2	in	100	101	O
DDI-DrugBank.d229.s2	adults	119	124	O
DDI-DrugBank.d229.s2	on	108	109	O
DDI-DrugBank.d229.s2	a	119	119	O
DDI-DrugBank.d229.s2	mg/m2	131	135	O
DDI-DrugBank.d229.s2	basis	137	141	O
DDI-DrugBank.d229.s2	)	142	142	O
DDI-DrugBank.d229.s2	increased	144	152	O
DDI-DrugBank.d229.s2	both	154	157	O
DDI-DrugBank.d229.s2	resorptions	159	169	O
DDI-DrugBank.d229.s2	and	171	173	O
DDI-DrugBank.d229.s2	malformations	175	187	O
DDI-DrugBank.d229.s2	.	188	188	O
DDI-DrugBank.d229.s3	The	0	2	O
DDI-DrugBank.d229.s3	addition	4	11	O
DDI-DrugBank.d229.s3	of	13	14	O
DDI-DrugBank.d229.s3	540	16	18	O
DDI-DrugBank.d229.s3	mg/kg/day	20	28	O
DDI-DrugBank.d229.s3	of	30	31	O
DDI-DrugBank.d229.s3	cromolyn	33	40	B-drug
DDI-DrugBank.d229.s3	sodium	42	47	I-drug
DDI-DrugBank.d229.s3	(	49	49	O
DDI-DrugBank.d229.s3	approximately	50	62	O
DDI-DrugBank.d229.s3	340	64	66	O
DDI-DrugBank.d229.s3	times	68	72	O
DDI-DrugBank.d229.s3	the	74	76	O
DDI-DrugBank.d229.s3	maximum	78	84	O
DDI-DrugBank.d229.s3	recommended	86	96	O
DDI-DrugBank.d229.s3	daily	98	102	O
DDI-DrugBank.d229.s3	inhalation	104	113	O
DDI-DrugBank.d229.s3	dose	115	118	O
DDI-DrugBank.d229.s3	in	104	105	O
DDI-DrugBank.d229.s3	adults	123	128	O
DDI-DrugBank.d229.s3	on	112	113	O
DDI-DrugBank.d229.s3	a	123	123	O
DDI-DrugBank.d229.s3	mg/m2	135	139	O
DDI-DrugBank.d229.s3	basis	141	145	O
DDI-DrugBank.d229.s3	)	146	146	O
DDI-DrugBank.d229.s3	to	148	149	O
DDI-DrugBank.d229.s3	2.7	151	153	O
DDI-DrugBank.d229.s3	mg/kg/day	155	163	O
DDI-DrugBank.d229.s3	of	165	166	O
DDI-DrugBank.d229.s3	isoproterenol	168	180	B-drug
DDI-DrugBank.d229.s3	(	182	182	O
DDI-DrugBank.d229.s3	approximately	183	195	O
DDI-DrugBank.d229.s3	7	197	197	O
DDI-DrugBank.d229.s3	times	199	203	O
DDI-DrugBank.d229.s3	the	205	207	O
DDI-DrugBank.d229.s3	maximum	209	215	O
DDI-DrugBank.d229.s3	recommended	217	227	O
DDI-DrugBank.d229.s3	daily	229	233	O
DDI-DrugBank.d229.s3	inhalation	235	244	O
DDI-DrugBank.d229.s3	dose	246	249	O
DDI-DrugBank.d229.s3	in	235	236	O
DDI-DrugBank.d229.s3	adults	254	259	O
DDI-DrugBank.d229.s3	on	243	244	O
DDI-DrugBank.d229.s3	a	230	230	O
DDI-DrugBank.d229.s3	mg/m2	266	270	O
DDI-DrugBank.d229.s3	basis	272	276	O
DDI-DrugBank.d229.s3	)	277	277	O
DDI-DrugBank.d229.s3	appears	279	285	O
DDI-DrugBank.d229.s3	to	287	288	O
DDI-DrugBank.d229.s3	have	290	293	O
DDI-DrugBank.d229.s3	increased	295	303	O
DDI-DrugBank.d229.s3	the	305	307	O
DDI-DrugBank.d229.s3	incidence	309	317	O
DDI-DrugBank.d229.s3	of	319	320	O
DDI-DrugBank.d229.s3	both	322	325	O
DDI-DrugBank.d229.s3	resorptions	327	337	O
DDI-DrugBank.d229.s3	and	339	341	O
DDI-DrugBank.d229.s3	malformations	343	355	O
DDI-DrugBank.d229.s3	.	356	356	O
DDI-MedLine.d143.s0	[	0	0	O
DDI-MedLine.d143.s0	Interaction	1	11	O
DDI-MedLine.d143.s0	between	13	19	O
DDI-MedLine.d143.s0	clopidogrel	21	31	B-drug
DDI-MedLine.d143.s0	and	33	35	O
DDI-MedLine.d143.s0	proton	37	42	B-group
DDI-MedLine.d143.s0	pump	44	47	I-group
DDI-MedLine.d143.s0	inhibitors	49	58	I-group
DDI-MedLine.d143.s0	]	59	59	O
DDI-MedLine.d143.s0	.	60	60	O
DDI-MedLine.d143.s1	The	0	2	O
DDI-MedLine.d143.s1	drug	4	7	O
DDI-MedLine.d143.s1	interaction	9	19	O
DDI-MedLine.d143.s1	between	21	27	O
DDI-MedLine.d143.s1	proton	29	34	B-group
DDI-MedLine.d143.s1	pump	36	39	I-group
DDI-MedLine.d143.s1	inhibitors	41	50	I-group
DDI-MedLine.d143.s1	and	52	54	O
DDI-MedLine.d143.s1	clopidogrel	56	66	B-drug
DDI-MedLine.d143.s1	has	68	70	O
DDI-MedLine.d143.s1	been	72	75	O
DDI-MedLine.d143.s1	the	77	79	O
DDI-MedLine.d143.s1	subject	81	87	O
DDI-MedLine.d143.s1	of	89	90	O
DDI-MedLine.d143.s1	much	92	95	O
DDI-MedLine.d143.s1	study	97	101	O
DDI-MedLine.d143.s1	in	103	104	O
DDI-MedLine.d143.s1	recent	106	111	O
DDI-MedLine.d143.s1	years	113	117	O
DDI-MedLine.d143.s1	.	118	118	O
DDI-MedLine.d143.s2	Contradictory	0	12	O
DDI-MedLine.d143.s2	results	14	20	O
DDI-MedLine.d143.s2	regarding	22	30	O
DDI-MedLine.d143.s2	the	32	34	O
DDI-MedLine.d143.s2	effect	36	41	O
DDI-MedLine.d143.s2	of	43	44	O
DDI-MedLine.d143.s2	proton	46	51	B-group
DDI-MedLine.d143.s2	pump	53	56	I-group
DDI-MedLine.d143.s2	inhibitors	58	67	I-group
DDI-MedLine.d143.s2	on	69	70	O
DDI-MedLine.d143.s2	platelet	72	79	O
DDI-MedLine.d143.s2	reactivity	81	90	O
DDI-MedLine.d143.s2	and	92	94	O
DDI-MedLine.d143.s2	on	96	97	O
DDI-MedLine.d143.s2	clinical	99	106	O
DDI-MedLine.d143.s2	outcome	108	114	O
DDI-MedLine.d143.s2	in	101	102	O
DDI-MedLine.d143.s2	clopidogrel-treated	119	137	O
DDI-MedLine.d143.s2	patients	139	146	O
DDI-MedLine.d143.s2	have	148	151	O
DDI-MedLine.d143.s2	been	153	156	O
DDI-MedLine.d143.s2	reported	158	165	O
DDI-MedLine.d143.s2	in	167	168	O
DDI-MedLine.d143.s2	literature	170	179	O
DDI-MedLine.d143.s2	.	180	180	O
DDI-MedLine.d143.s3	Concomitant	0	10	O
DDI-MedLine.d143.s3	use	12	14	O
DDI-MedLine.d143.s3	of	16	17	O
DDI-MedLine.d143.s3	omeprazole	19	28	B-drug
DDI-MedLine.d143.s3	and	30	32	O
DDI-MedLine.d143.s3	clopidogrel	34	44	B-drug
DDI-MedLine.d143.s3	was	46	48	O
DDI-MedLine.d143.s3	found	50	54	O
DDI-MedLine.d143.s3	to	56	57	O
DDI-MedLine.d143.s3	decrease	59	66	O
DDI-MedLine.d143.s3	the	68	70	O
DDI-MedLine.d143.s3	exposure	72	79	O
DDI-MedLine.d143.s3	(	81	81	O
DDI-MedLine.d143.s3	AUC	82	84	O
DDI-MedLine.d143.s3	)	85	85	O
DDI-MedLine.d143.s3	to	87	88	O
DDI-MedLine.d143.s3	clopidogrel	90	100	O
DDI-MedLine.d143.s3	's	101	102	O
DDI-MedLine.d143.s3	active	104	109	O
DDI-MedLine.d143.s3	metabolite	111	120	O
DDI-MedLine.d143.s3	by	122	123	O
DDI-MedLine.d143.s3	50	125	126	O
DDI-MedLine.d143.s3	%	127	127	O
DDI-MedLine.d143.s3	and	129	131	O
DDI-MedLine.d143.s3	to	133	134	O
DDI-MedLine.d143.s3	sharply	136	142	O
DDI-MedLine.d143.s3	increase	144	151	O
DDI-MedLine.d143.s3	platelet	153	160	O
DDI-MedLine.d143.s3	reactivity	162	171	O
DDI-MedLine.d143.s3	,	172	172	O
DDI-MedLine.d143.s3	as	149	150	O
DDI-MedLine.d143.s3	a	155	155	O
DDI-MedLine.d143.s3	result	179	184	O
DDI-MedLine.d143.s3	of	186	187	O
DDI-MedLine.d143.s3	inhibition	189	198	O
DDI-MedLine.d143.s3	by	200	201	O
DDI-MedLine.d143.s3	omeprazole	203	212	B-drug
DDI-MedLine.d143.s3	of	186	187	O
DDI-MedLine.d143.s3	CYP2C19	217	223	O
DDI-MedLine.d143.s3	,	224	224	O
DDI-MedLine.d143.s3	a	208	208	O
DDI-MedLine.d143.s3	cytochrome	228	237	O
DDI-MedLine.d143.s3	P450	239	242	O
DDI-MedLine.d143.s3	(	244	244	O
DDI-MedLine.d143.s3	CYP	217	219	O
DDI-MedLine.d143.s3	)	248	248	O
DDI-MedLine.d143.s3	enzyme	250	255	O
DDI-MedLine.d143.s3	.	256	256	O
DDI-MedLine.d143.s4	Pantoprazole	0	11	B-drug
DDI-MedLine.d143.s4	has	13	15	O
DDI-MedLine.d143.s4	a	17	17	O
DDI-MedLine.d143.s4	much	19	22	O
DDI-MedLine.d143.s4	weaker	24	29	O
DDI-MedLine.d143.s4	effect	31	36	O
DDI-MedLine.d143.s4	on	38	39	O
DDI-MedLine.d143.s4	clopidogrel	41	51	B-drug
DDI-MedLine.d143.s4	's	52	53	O
DDI-MedLine.d143.s4	pharmacokinetics	55	70	O
DDI-MedLine.d143.s4	and	72	74	O
DDI-MedLine.d143.s4	on	76	77	O
DDI-MedLine.d143.s4	platelet	79	86	O
DDI-MedLine.d143.s4	reactivity	88	97	O
DDI-MedLine.d143.s4	during	99	104	O
DDI-MedLine.d143.s4	concomitant	106	116	O
DDI-MedLine.d143.s4	use	118	120	O
DDI-MedLine.d143.s4	.	121	121	O
DDI-MedLine.d143.s5	The	0	2	O
DDI-MedLine.d143.s5	influence	4	12	O
DDI-MedLine.d143.s5	of	14	15	O
DDI-MedLine.d143.s5	the	17	19	O
DDI-MedLine.d143.s5	other	21	25	O
DDI-MedLine.d143.s5	proton	27	32	B-group
DDI-MedLine.d143.s5	pump	34	37	I-group
DDI-MedLine.d143.s5	inhibitors	39	48	I-group
DDI-MedLine.d143.s5	when	50	53	O
DDI-MedLine.d143.s5	used	55	58	O
DDI-MedLine.d143.s5	simultaneously	60	73	O
DDI-MedLine.d143.s5	with	75	78	O
DDI-MedLine.d143.s5	clopidogrel	80	90	B-drug
DDI-MedLine.d143.s5	has	92	94	O
DDI-MedLine.d143.s5	not	96	98	O
DDI-MedLine.d143.s5	yet	100	102	O
DDI-MedLine.d143.s5	been	104	107	O
DDI-MedLine.d143.s5	investigated	109	120	O
DDI-MedLine.d143.s5	in	109	110	O
DDI-MedLine.d143.s5	adequately	125	134	O
DDI-MedLine.d143.s5	randomized	136	145	O
DDI-MedLine.d143.s5	studies	147	153	O
DDI-MedLine.d143.s5	.	154	154	O
DDI-MedLine.d143.s6	Regulatory	0	9	O
DDI-MedLine.d143.s6	agencies	11	18	O
DDI-MedLine.d143.s6	state	20	24	O
DDI-MedLine.d143.s6	that	26	29	O
DDI-MedLine.d143.s6	the	31	33	O
DDI-MedLine.d143.s6	combination	35	45	O
DDI-MedLine.d143.s6	of	47	48	O
DDI-MedLine.d143.s6	clopidogrel	50	60	B-drug
DDI-MedLine.d143.s6	and	62	64	O
DDI-MedLine.d143.s6	the	66	68	O
DDI-MedLine.d143.s6	CYP2C19	70	76	O
DDI-MedLine.d143.s6	inhibitors	78	87	O
DDI-MedLine.d143.s6	omeprazole	89	98	B-drug
DDI-MedLine.d143.s6	and	100	102	O
DDI-MedLine.d143.s6	esomeprazole	104	115	B-drug
DDI-MedLine.d143.s6	should	117	122	O
DDI-MedLine.d143.s6	be	124	125	O
DDI-MedLine.d143.s6	avoided	127	133	O
DDI-MedLine.d143.s6	.	134	134	O
DDI-MedLine.d143.s7	To	0	1	O
DDI-MedLine.d143.s7	date	3	6	O
DDI-MedLine.d143.s7	,	7	7	O
DDI-MedLine.d143.s7	there	9	13	O
DDI-MedLine.d143.s7	is	15	16	O
DDI-MedLine.d143.s7	no	18	19	O
DDI-MedLine.d143.s7	conclusive	21	30	O
DDI-MedLine.d143.s7	evidence	32	39	O
DDI-MedLine.d143.s7	of	41	42	O
DDI-MedLine.d143.s7	a	44	44	O
DDI-MedLine.d143.s7	clinically-relevant	46	64	O
DDI-MedLine.d143.s7	interaction	66	76	O
DDI-MedLine.d143.s7	between	78	84	O
DDI-MedLine.d143.s7	any	86	88	O
DDI-MedLine.d143.s7	of	90	91	O
DDI-MedLine.d143.s7	the	93	95	O
DDI-MedLine.d143.s7	proton	97	102	B-group
DDI-MedLine.d143.s7	pump	104	107	I-group
DDI-MedLine.d143.s7	inhibitors	109	118	I-group
DDI-MedLine.d143.s7	and	120	122	O
DDI-MedLine.d143.s7	clopidogrel	124	134	B-drug
DDI-MedLine.d143.s7	.	135	135	O
DDI-DrugBank.d524.s0	Albuterol	0	8	B-drug
DDI-DrugBank.d524.s0	,	9	9	O
DDI-DrugBank.d524.s0	Antihistamines	11	24	B-group
DDI-DrugBank.d524.s0	,	25	25	O
DDI-DrugBank.d524.s0	antidiabetic	27	38	B-group
DDI-DrugBank.d524.s0	drugs	40	44	I-group
DDI-DrugBank.d524.s0	,	45	45	O
DDI-DrugBank.d524.s0	diuretics	47	55	B-group
DDI-DrugBank.d524.s0	,	56	56	O
DDI-DrugBank.d524.s0	digitalis	58	66	B-group
DDI-DrugBank.d524.s0	.	67	67	O
DDI-MedLine.d9.s0	Pharmacokinetics	0	15	O
DDI-MedLine.d9.s0	of	17	18	O
DDI-MedLine.d9.s0	calcium-entry	20	32	B-group
DDI-MedLine.d9.s0	blockers	34	41	I-group
DDI-MedLine.d9.s0	.	42	42	O
DDI-MedLine.d9.s1	Effective	0	8	O
DDI-MedLine.d9.s1	use	10	12	O
DDI-MedLine.d9.s1	of	14	15	O
DDI-MedLine.d9.s1	drugs	17	21	O
DDI-MedLine.d9.s1	in	23	24	O
DDI-MedLine.d9.s1	therapy	26	32	O
DDI-MedLine.d9.s1	depends	34	40	O
DDI-MedLine.d9.s1	not	42	44	O
DDI-MedLine.d9.s1	only	46	49	O
DDI-MedLine.d9.s1	on	46	47	O
DDI-MedLine.d9.s1	clinical	54	61	O
DDI-MedLine.d9.s1	acumen	63	68	O
DDI-MedLine.d9.s1	but	70	72	O
DDI-MedLine.d9.s1	also	74	77	O
DDI-MedLine.d9.s1	on	79	80	O
DDI-MedLine.d9.s1	the	82	84	O
DDI-MedLine.d9.s1	availability	86	97	O
DDI-MedLine.d9.s1	of	99	100	O
DDI-MedLine.d9.s1	relevant	102	109	O
DDI-MedLine.d9.s1	pharmacokinetic	111	125	O
DDI-MedLine.d9.s1	and	127	129	O
DDI-MedLine.d9.s1	pharmacodynamic	131	145	O
DDI-MedLine.d9.s1	data	147	150	O
DDI-MedLine.d9.s1	.	151	151	O
DDI-MedLine.d9.s2	Such	0	3	O
DDI-MedLine.d9.s2	information	5	15	O
DDI-MedLine.d9.s2	assists	17	23	O
DDI-MedLine.d9.s2	in	25	26	O
DDI-MedLine.d9.s2	development	28	38	O
DDI-MedLine.d9.s2	of	40	41	O
DDI-MedLine.d9.s2	safe	43	46	O
DDI-MedLine.d9.s2	dosing	48	53	O
DDI-MedLine.d9.s2	regimens	55	62	O
DDI-MedLine.d9.s2	,	63	63	O
DDI-MedLine.d9.s2	prediction	65	74	O
DDI-MedLine.d9.s2	of	76	77	O
DDI-MedLine.d9.s2	abnormal	79	86	O
DDI-MedLine.d9.s2	handling	88	95	O
DDI-MedLine.d9.s2	of	97	98	O
DDI-MedLine.d9.s2	drugs	100	104	O
DDI-MedLine.d9.s2	in	93	94	O
DDI-MedLine.d9.s2	states	109	114	O
DDI-MedLine.d9.s2	of	116	117	O
DDI-MedLine.d9.s2	disease	119	125	O
DDI-MedLine.d9.s2	and	127	129	O
DDI-MedLine.d9.s2	disorder	131	138	O
DDI-MedLine.d9.s2	and	127	129	O
DDI-MedLine.d9.s2	anticipation	144	155	O
DDI-MedLine.d9.s2	of	157	158	O
DDI-MedLine.d9.s2	drug	160	163	O
DDI-MedLine.d9.s2	interactions	165	176	O
DDI-MedLine.d9.s2	.	177	177	O
DDI-MedLine.d9.s3	For	0	2	O
DDI-MedLine.d9.s3	the	4	6	O
DDI-MedLine.d9.s3	calcium-entry	8	20	B-group
DDI-MedLine.d9.s3	blocking	22	29	I-group
DDI-MedLine.d9.s3	agents	31	36	I-group
DDI-MedLine.d9.s3	now	38	40	O
DDI-MedLine.d9.s3	available	42	50	O
DDI-MedLine.d9.s3	in	52	53	O
DDI-MedLine.d9.s3	the	55	57	O
DDI-MedLine.d9.s3	United	59	64	O
DDI-MedLine.d9.s3	States	66	71	O
DDI-MedLine.d9.s3	(	73	73	O
DDI-MedLine.d9.s3	verapamil	74	82	B-drug
DDI-MedLine.d9.s3	,	83	83	O
DDI-MedLine.d9.s3	nifedipine	85	94	B-drug
DDI-MedLine.d9.s3	and	96	98	O
DDI-MedLine.d9.s3	diltiazem	100	108	B-drug
DDI-MedLine.d9.s3	)	109	109	O
DDI-MedLine.d9.s3	,	110	110	O
DDI-MedLine.d9.s3	these	112	116	O
DDI-MedLine.d9.s3	data	118	121	O
DDI-MedLine.d9.s3	appeared	123	130	O
DDI-MedLine.d9.s3	well	132	135	O
DDI-MedLine.d9.s3	after	137	141	O
DDI-MedLine.d9.s3	clinical	143	150	O
DDI-MedLine.d9.s3	patterns	152	159	O
DDI-MedLine.d9.s3	of	161	162	O
DDI-MedLine.d9.s3	use	164	166	O
DDI-MedLine.d9.s3	evolved	168	174	O
DDI-MedLine.d9.s3	.	175	175	O
DDI-MedLine.d9.s4	Nonetheless	0	10	O
DDI-MedLine.d9.s4	,	11	11	O
DDI-MedLine.d9.s4	their	13	17	O
DDI-MedLine.d9.s4	relevance	19	27	O
DDI-MedLine.d9.s4	continues	29	37	O
DDI-MedLine.d9.s4	to	39	40	O
DDI-MedLine.d9.s4	be	42	43	O
DDI-MedLine.d9.s4	demonstrated	45	56	O
DDI-MedLine.d9.s4	by	58	59	O
DDI-MedLine.d9.s4	the	61	63	O
DDI-MedLine.d9.s4	dependence	65	74	O
DDI-MedLine.d9.s4	of	76	77	O
DDI-MedLine.d9.s4	each	79	82	O
DDI-MedLine.d9.s4	agent	84	88	O
DDI-MedLine.d9.s4	on	90	91	O
DDI-MedLine.d9.s4	intact	93	98	O
DDI-MedLine.d9.s4	liver	100	104	O
DDI-MedLine.d9.s4	blood	106	110	O
DDI-MedLine.d9.s4	flow	112	115	O
DDI-MedLine.d9.s4	and	117	119	O
DDI-MedLine.d9.s4	function	121	128	O
DDI-MedLine.d9.s4	for	130	132	O
DDI-MedLine.d9.s4	normal	134	139	O
DDI-MedLine.d9.s4	rates	141	145	O
DDI-MedLine.d9.s4	of	147	148	O
DDI-MedLine.d9.s4	elimination	150	160	O
DDI-MedLine.d9.s4	;	161	161	O
DDI-MedLine.d9.s5	by	0	1	O
DDI-MedLine.d9.s5	the	3	5	O
DDI-MedLine.d9.s5	nonlinear	7	15	O
DDI-MedLine.d9.s5	kinetic	17	23	O
DDI-MedLine.d9.s5	characteristics	25	39	O
DDI-MedLine.d9.s5	for	41	43	O
DDI-MedLine.d9.s5	verapamil	45	53	B-drug
DDI-MedLine.d9.s5	and	55	57	O
DDI-MedLine.d9.s5	diltiazem	59	67	B-drug
DDI-MedLine.d9.s5	(	69	69	O
DDI-MedLine.d9.s5	and	70	72	O
DDI-MedLine.d9.s5	probably	74	81	O
DDI-MedLine.d9.s5	for	83	85	O
DDI-MedLine.d9.s5	nifedipine	87	96	B-drug
DDI-MedLine.d9.s5	,	97	97	O
DDI-MedLine.d9.s5	as	99	100	O
DDI-MedLine.d9.s5	well	102	105	O
DDI-MedLine.d9.s5	)	106	106	O
DDI-MedLine.d9.s5	and	108	110	O
DDI-MedLine.d9.s5	the	112	114	O
DDI-MedLine.d9.s5	derivative	116	125	O
DDI-MedLine.d9.s5	implications	127	138	O
DDI-MedLine.d9.s5	for	140	142	O
DDI-MedLine.d9.s5	decreased	144	152	O
DDI-MedLine.d9.s5	dosing	154	159	O
DDI-MedLine.d9.s5	frequency	161	169	O
DDI-MedLine.d9.s5	requirements	171	182	O
DDI-MedLine.d9.s5	;	183	183	O
DDI-MedLine.d9.s6	and	0	2	O
DDI-MedLine.d9.s6	by	4	5	O
DDI-MedLine.d9.s6	observations	7	18	O
DDI-MedLine.d9.s6	now	20	22	O
DDI-MedLine.d9.s6	appearing	24	32	O
DDI-MedLine.d9.s6	on	34	35	O
DDI-MedLine.d9.s6	the	37	39	O
DDI-MedLine.d9.s6	relation	41	48	O
DDI-MedLine.d9.s6	between	50	56	O
DDI-MedLine.d9.s6	plasma	58	63	O
DDI-MedLine.d9.s6	drug	65	68	O
DDI-MedLine.d9.s6	levels	70	75	O
DDI-MedLine.d9.s6	and	77	79	O
DDI-MedLine.d9.s6	drug	81	84	O
DDI-MedLine.d9.s6	effects	86	92	O
DDI-MedLine.d9.s6	,	93	93	O
DDI-MedLine.d9.s6	both	95	98	O
DDI-MedLine.d9.s6	therapeutic	100	110	O
DDI-MedLine.d9.s6	and	112	114	O
DDI-MedLine.d9.s6	toxic	116	120	O
DDI-MedLine.d9.s6	.	121	121	O
DDI-MedLine.d9.s7	Such	0	3	O
DDI-MedLine.d9.s7	data	5	8	O
DDI-MedLine.d9.s7	are	10	12	O
DDI-MedLine.d9.s7	discussed	14	22	O
DDI-MedLine.d9.s7	herein	24	29	O
DDI-MedLine.d9.s7	,	30	30	O
DDI-MedLine.d9.s7	with	32	35	O
DDI-MedLine.d9.s7	emphasis	37	44	O
DDI-MedLine.d9.s7	on	46	47	O
DDI-MedLine.d9.s7	those	49	53	O
DDI-MedLine.d9.s7	aspects	55	61	O
DDI-MedLine.d9.s7	that	63	66	O
DDI-MedLine.d9.s7	impact	68	73	O
DDI-MedLine.d9.s7	on	75	76	O
DDI-MedLine.d9.s7	the	78	80	O
DDI-MedLine.d9.s7	clinical	82	89	O
DDI-MedLine.d9.s7	use	91	93	O
DDI-MedLine.d9.s7	of	95	96	O
DDI-MedLine.d9.s7	the	98	100	O
DDI-MedLine.d9.s7	calcium-entry	102	114	B-group
DDI-MedLine.d9.s7	antagonists	116	126	I-group
DDI-MedLine.d9.s7	.	127	127	O
DDI-MedLine.d216.s0	Exposure	0	7	O
DDI-MedLine.d216.s0	to	9	10	O
DDI-MedLine.d216.s0	oral	12	15	O
DDI-MedLine.d216.s0	S-ketamine	17	26	B-drug
DDI-MedLine.d216.s0	is	28	29	O
DDI-MedLine.d216.s0	unaffected	31	40	O
DDI-MedLine.d216.s0	by	42	43	O
DDI-MedLine.d216.s0	itraconazole	45	56	B-drug
DDI-MedLine.d216.s0	but	58	60	O
DDI-MedLine.d216.s0	greatly	62	68	O
DDI-MedLine.d216.s0	increased	70	78	O
DDI-MedLine.d216.s0	by	80	81	O
DDI-MedLine.d216.s0	ticlopidine	83	93	B-drug
DDI-MedLine.d216.s0	.	94	94	O
DDI-MedLine.d216.s1	This	0	3	O
DDI-MedLine.d216.s1	study	5	9	O
DDI-MedLine.d216.s1	examined	11	18	O
DDI-MedLine.d216.s1	drug-drug	20	28	O
DDI-MedLine.d216.s1	interactions	30	41	O
DDI-MedLine.d216.s1	of	43	44	O
DDI-MedLine.d216.s1	oral	46	49	O
DDI-MedLine.d216.s1	S-ketamine	51	60	B-drug
DDI-MedLine.d216.s1	with	62	65	O
DDI-MedLine.d216.s1	the	67	69	O
DDI-MedLine.d216.s1	cytochrome	71	80	O
DDI-MedLine.d216.s1	P450	82	85	O
DDI-MedLine.d216.s1	(	87	87	O
DDI-MedLine.d216.s1	CYP	88	90	O
DDI-MedLine.d216.s1	)	91	91	O
DDI-MedLine.d216.s1	2B6	93	95	O
DDI-MedLine.d216.s1	inhibitor	97	105	O
DDI-MedLine.d216.s1	ticlopidine	107	117	B-drug
DDI-MedLine.d216.s1	and	119	121	O
DDI-MedLine.d216.s1	the	123	125	O
DDI-MedLine.d216.s1	CYP3A	127	131	O
DDI-MedLine.d216.s1	inhibitor	133	141	O
DDI-MedLine.d216.s1	itraconazole	143	154	B-drug
DDI-MedLine.d216.s1	.	155	155	O
DDI-MedLine.d216.s2	In	0	1	O
DDI-MedLine.d216.s2	this	3	6	O
DDI-MedLine.d216.s2	randomized	8	17	O
DDI-MedLine.d216.s2	,	18	18	O
DDI-MedLine.d216.s2	blinded	20	26	O
DDI-MedLine.d216.s2	,	27	27	O
DDI-MedLine.d216.s2	crossover	29	37	O
DDI-MedLine.d216.s2	study	39	43	O
DDI-MedLine.d216.s2	,	44	44	O
DDI-MedLine.d216.s2	11	46	47	O
DDI-MedLine.d216.s2	healthy	49	55	O
DDI-MedLine.d216.s2	volunteers	57	66	O
DDI-MedLine.d216.s2	ingested	68	75	O
DDI-MedLine.d216.s2	0.2	77	79	O
DDI-MedLine.d216.s2	mg/kg	81	85	O
DDI-MedLine.d216.s2	S-ketamine	87	96	B-drug
DDI-MedLine.d216.s2	after	98	102	O
DDI-MedLine.d216.s2	pretreatments	104	116	O
DDI-MedLine.d216.s2	with	118	121	O
DDI-MedLine.d216.s2	oral	123	126	O
DDI-MedLine.d216.s2	ticlopidine	128	138	B-drug
DDI-MedLine.d216.s2	(	140	140	O
DDI-MedLine.d216.s2	250	141	143	O
DDI-MedLine.d216.s2	mg	145	146	O
DDI-MedLine.d216.s2	twice	148	152	O
DDI-MedLine.d216.s2	daily	154	158	O
DDI-MedLine.d216.s2	)	159	159	O
DDI-MedLine.d216.s2	,	160	160	O
DDI-MedLine.d216.s2	itraconazole	162	173	B-drug
DDI-MedLine.d216.s2	(	175	175	O
DDI-MedLine.d216.s2	200	176	178	O
DDI-MedLine.d216.s2	mg	180	181	O
DDI-MedLine.d216.s2	once	183	186	O
DDI-MedLine.d216.s2	daily	188	192	O
DDI-MedLine.d216.s2	)	193	193	O
DDI-MedLine.d216.s2	,	194	194	O
DDI-MedLine.d216.s2	or	196	197	O
DDI-MedLine.d216.s2	placebo	199	205	O
DDI-MedLine.d216.s2	in	207	208	O
DDI-MedLine.d216.s2	6-day	210	214	O
DDI-MedLine.d216.s2	treatment	216	224	O
DDI-MedLine.d216.s2	periods	226	232	O
DDI-MedLine.d216.s2	at	219	220	O
DDI-MedLine.d216.s2	intervals	237	245	O
DDI-MedLine.d216.s2	of	247	248	O
DDI-MedLine.d216.s2	4	250	250	O
DDI-MedLine.d216.s2	weeks	252	256	O
DDI-MedLine.d216.s2	.	257	257	O
DDI-MedLine.d216.s3	Ticlopidine	0	10	B-drug
DDI-MedLine.d216.s3	treatment	12	20	O
DDI-MedLine.d216.s3	increased	22	30	O
DDI-MedLine.d216.s3	the	32	34	O
DDI-MedLine.d216.s3	mean	36	39	O
DDI-MedLine.d216.s3	area	41	44	O
DDI-MedLine.d216.s3	under	46	50	O
DDI-MedLine.d216.s3	the	52	54	O
DDI-MedLine.d216.s3	plasma	56	61	O
DDI-MedLine.d216.s3	concentration-time	63	80	O
DDI-MedLine.d216.s3	curve	82	86	O
DDI-MedLine.d216.s3	extrapolated	88	99	O
DDI-MedLine.d216.s3	to	101	102	O
DDI-MedLine.d216.s3	infinity	104	111	O
DDI-MedLine.d216.s3	(	113	113	O
DDI-MedLine.d216.s3	AUC	114	116	O
DDI-MedLine.d216.s3	(	113	113	O
DDI-MedLine.d216.s3	0-	118	119	O
DDI-MedLine.d216.s3	)	123	123	O
DDI-MedLine.d216.s3	)	123	123	O
DDI-MedLine.d216.s3	of	126	127	O
DDI-MedLine.d216.s3	oral	129	132	O
DDI-MedLine.d216.s3	ketamine	134	141	B-drug
DDI-MedLine.d216.s3	by	143	144	O
DDI-MedLine.d216.s3	2.4-fold	146	153	O
DDI-MedLine.d216.s3	,	154	154	O
DDI-MedLine.d216.s3	whereas	156	162	O
DDI-MedLine.d216.s3	itraconazole	164	175	B-drug
DDI-MedLine.d216.s3	treatment	177	185	O
DDI-MedLine.d216.s3	did	187	189	O
DDI-MedLine.d216.s3	not	191	193	O
DDI-MedLine.d216.s3	increase	195	202	O
DDI-MedLine.d216.s3	the	204	206	O
DDI-MedLine.d216.s3	exposure	208	215	O
DDI-MedLine.d216.s3	to	217	218	O
DDI-MedLine.d216.s3	S-ketamine	220	229	B-drug
DDI-MedLine.d216.s3	.	230	230	O
DDI-MedLine.d216.s4	The	0	2	O
DDI-MedLine.d216.s4	ratio	4	8	O
DDI-MedLine.d216.s4	of	10	11	O
DDI-MedLine.d216.s4	norketamine	13	23	B-drug_n
DDI-MedLine.d216.s4	AUC	25	27	O
DDI-MedLine.d216.s4	(	28	28	O
DDI-MedLine.d216.s4	0-	29	30	O
DDI-MedLine.d216.s4	)	34	34	O
DDI-MedLine.d216.s4	to	36	37	O
DDI-MedLine.d216.s4	ketamine	39	46	B-drug
DDI-MedLine.d216.s4	AUC	48	50	O
DDI-MedLine.d216.s4	(	51	51	O
DDI-MedLine.d216.s4	0-	52	53	O
DDI-MedLine.d216.s4	)	57	57	O
DDI-MedLine.d216.s4	was	59	61	O
DDI-MedLine.d216.s4	significantly	63	75	O
DDI-MedLine.d216.s4	decreased	77	85	O
DDI-MedLine.d216.s4	in	87	88	O
DDI-MedLine.d216.s4	the	90	92	O
DDI-MedLine.d216.s4	ticlopidine	94	104	B-drug
DDI-MedLine.d216.s4	(	106	106	O
DDI-MedLine.d216.s4	P	107	107	O
DDI-MedLine.d216.s4	&	109	109	O
DDI-MedLine.d216.s4	lt	110	111	O
DDI-MedLine.d216.s4	;	112	112	O
DDI-MedLine.d216.s4	0.001	114	118	O
DDI-MedLine.d216.s4	)	119	119	O
DDI-MedLine.d216.s4	and	121	123	O
DDI-MedLine.d216.s4	itraconazole	125	136	B-drug
DDI-MedLine.d216.s4	phases	138	143	O
DDI-MedLine.d216.s4	(	145	145	O
DDI-MedLine.d216.s4	P	146	146	O
DDI-MedLine.d216.s4	=	148	148	O
DDI-MedLine.d216.s4	0.006	150	154	O
DDI-MedLine.d216.s4	)	155	155	O
DDI-MedLine.d216.s4	as	140	141	O
DDI-MedLine.d216.s4	compared	160	167	O
DDI-MedLine.d216.s4	to	169	170	O
DDI-MedLine.d216.s4	placebo	172	178	O
DDI-MedLine.d216.s4	.	151	151	O
DDI-MedLine.d216.s5	In	0	1	O
DDI-MedLine.d216.s5	the	3	5	O
DDI-MedLine.d216.s5	ticlopidine	7	17	B-drug
DDI-MedLine.d216.s5	and	19	21	O
DDI-MedLine.d216.s5	itraconazole	23	34	B-drug
DDI-MedLine.d216.s5	phases	36	41	O
DDI-MedLine.d216.s5	,	42	42	O
DDI-MedLine.d216.s5	the	44	46	O
DDI-MedLine.d216.s5	areas	48	52	O
DDI-MedLine.d216.s5	under	54	58	O
DDI-MedLine.d216.s5	the	60	62	O
DDI-MedLine.d216.s5	effect-time	64	74	O
DDI-MedLine.d216.s5	curves	76	81	O
DDI-MedLine.d216.s5	(	83	83	O
DDI-MedLine.d216.s5	self-reported	84	96	O
DDI-MedLine.d216.s5	drowsiness	98	107	O
DDI-MedLine.d216.s5	and	109	111	O
DDI-MedLine.d216.s5	performance	113	123	O
DDI-MedLine.d216.s5	)	124	124	O
DDI-MedLine.d216.s5	were	126	129	O
DDI-MedLine.d216.s5	significantly	131	143	O
DDI-MedLine.d216.s5	higher	145	150	O
DDI-MedLine.d216.s5	than	152	155	O
DDI-MedLine.d216.s5	those	157	161	O
DDI-MedLine.d216.s5	in	163	164	O
DDI-MedLine.d216.s5	the	166	168	O
DDI-MedLine.d216.s5	placebo	170	176	O
DDI-MedLine.d216.s5	phase	178	182	O
DDI-MedLine.d216.s5	(	184	184	O
DDI-MedLine.d216.s5	P	185	185	O
DDI-MedLine.d216.s5	<	187	187	O
DDI-MedLine.d216.s5	0.05	189	192	O
DDI-MedLine.d216.s5	)	193	193	O
DDI-MedLine.d216.s5	.	190	190	O
DDI-MedLine.d216.s6	The	0	2	O
DDI-MedLine.d216.s6	findings	4	11	O
DDI-MedLine.d216.s6	suggest	13	19	O
DDI-MedLine.d216.s6	that	21	24	O
DDI-MedLine.d216.s6	the	26	28	O
DDI-MedLine.d216.s6	dosage	30	35	O
DDI-MedLine.d216.s6	of	37	38	O
DDI-MedLine.d216.s6	S-ketamine	40	49	B-drug
DDI-MedLine.d216.s6	should	51	56	O
DDI-MedLine.d216.s6	be	58	59	O
DDI-MedLine.d216.s6	reduced	61	67	O
DDI-MedLine.d216.s6	in	69	70	O
DDI-MedLine.d216.s6	patients	72	79	O
DDI-MedLine.d216.s6	receiving	81	89	O
DDI-MedLine.d216.s6	ticlopidine	91	101	B-drug
DDI-MedLine.d216.s6	.	102	102	O
DDI-DrugBank.d404.s0	Interactions	0	11	O
DDI-DrugBank.d404.s0	for	13	15	O
DDI-DrugBank.d404.s0	vitamin	17	23	B-group
DDI-DrugBank.d404.s0	D	25	25	O
DDI-DrugBank.d404.s0	analogues	27	35	O
DDI-DrugBank.d404.s0	(	37	37	O
DDI-DrugBank.d404.s0	Vitamin	38	44	B-drug
DDI-DrugBank.d404.s0	D2	46	47	I-drug
DDI-DrugBank.d404.s0	,	48	48	O
DDI-DrugBank.d404.s0	Vitamin	50	56	B-drug
DDI-DrugBank.d404.s0	D3	58	59	I-drug
DDI-DrugBank.d404.s0	,	60	60	O
DDI-DrugBank.d404.s0	Calcitriol	62	71	B-drug
DDI-DrugBank.d404.s0	,	72	72	O
DDI-DrugBank.d404.s0	and	74	76	O
DDI-DrugBank.d404.s0	Calcidiol	78	86	B-drug
DDI-DrugBank.d404.s0	)	87	87	O
DDI-DrugBank.d404.s0	:	88	88	O
DDI-DrugBank.d404.s0	Cholestyramine	90	103	B-drug
DDI-DrugBank.d404.s0	:	104	104	O
DDI-DrugBank.d404.s0	Cholestyramine	106	119	B-drug
DDI-DrugBank.d404.s0	has	121	123	O
DDI-DrugBank.d404.s0	been	125	128	O
DDI-DrugBank.d404.s0	reported	130	137	O
DDI-DrugBank.d404.s0	to	139	140	O
DDI-DrugBank.d404.s0	reduce	142	147	O
DDI-DrugBank.d404.s0	intestinal	149	158	O
DDI-DrugBank.d404.s0	absorption	160	169	O
DDI-DrugBank.d404.s0	of	171	172	O
DDI-DrugBank.d404.s0	fat	174	176	B-group
DDI-DrugBank.d404.s0	soluble	178	184	I-group
DDI-DrugBank.d404.s0	vitamins	186	193	I-group
DDI-DrugBank.d404.s0	;	194	194	O
DDI-DrugBank.d404.s1	as	0	1	O
DDI-DrugBank.d404.s1	such	3	6	O
DDI-DrugBank.d404.s1	it	8	9	O
DDI-DrugBank.d404.s1	may	11	13	O
DDI-DrugBank.d404.s1	impair	15	20	O
DDI-DrugBank.d404.s1	intestinal	22	31	O
DDI-DrugBank.d404.s1	absorption	33	42	O
DDI-DrugBank.d404.s1	of	44	45	O
DDI-DrugBank.d404.s1	any	47	49	O
DDI-DrugBank.d404.s1	of	44	45	O
DDI-DrugBank.d404.s1	vitamin	54	60	B-group
DDI-DrugBank.d404.s1	D	62	62	O
DDI-DrugBank.d404.s1	.	63	63	O
DDI-DrugBank.d404.s2	Phenytoin/Phenobarbital	0	22	O
DDI-DrugBank.d404.s2	:	23	23	O
DDI-DrugBank.d404.s2	The	25	27	O
DDI-DrugBank.d404.s2	coadministration	29	44	O
DDI-DrugBank.d404.s2	of	46	47	O
DDI-DrugBank.d404.s2	phenytoin	49	57	B-drug
DDI-DrugBank.d404.s2	or	59	60	O
DDI-DrugBank.d404.s2	phenobarbital	62	74	B-drug
DDI-DrugBank.d404.s2	will	76	79	O
DDI-DrugBank.d404.s2	not	81	83	O
DDI-DrugBank.d404.s2	affect	85	90	O
DDI-DrugBank.d404.s2	plasma	92	97	O
DDI-DrugBank.d404.s2	concentrations	99	112	O
DDI-DrugBank.d404.s2	of	114	115	O
DDI-DrugBank.d404.s2	vitamin	117	123	B-group
DDI-DrugBank.d404.s2	D	125	125	O
DDI-DrugBank.d404.s2	,	126	126	O
DDI-DrugBank.d404.s2	but	128	130	O
DDI-DrugBank.d404.s2	may	132	134	O
DDI-DrugBank.d404.s2	reduce	136	141	O
DDI-DrugBank.d404.s2	endogenous	143	152	O
DDI-DrugBank.d404.s2	plasma	154	159	O
DDI-DrugBank.d404.s2	levels	161	166	O
DDI-DrugBank.d404.s2	of	168	169	O
DDI-DrugBank.d404.s2	calcitriol/ergocalcitriol	171	195	O
DDI-DrugBank.d404.s2	by	197	198	O
DDI-DrugBank.d404.s2	accelerating	200	211	O
DDI-DrugBank.d404.s2	metabolism	213	222	O
DDI-DrugBank.d404.s2	.	223	223	O
DDI-DrugBank.d404.s3	Since	0	4	O
DDI-DrugBank.d404.s3	blood	6	10	O
DDI-DrugBank.d404.s3	level	12	16	O
DDI-DrugBank.d404.s3	of	18	19	O
DDI-DrugBank.d404.s3	calcitriol/ergocalcitriol	21	45	O
DDI-DrugBank.d404.s3	will	47	50	O
DDI-DrugBank.d404.s3	be	52	53	O
DDI-DrugBank.d404.s3	reduced	55	61	O
DDI-DrugBank.d404.s3	,	62	62	O
DDI-DrugBank.d404.s3	higher	64	69	O
DDI-DrugBank.d404.s3	doses	71	75	O
DDI-DrugBank.d404.s3	of	77	78	O
DDI-DrugBank.d404.s3	Rocaltrol	80	88	B-brand
DDI-DrugBank.d404.s3	may	90	92	O
DDI-DrugBank.d404.s3	be	94	95	O
DDI-DrugBank.d404.s3	necessary	97	105	O
DDI-DrugBank.d404.s3	if	107	108	O
DDI-DrugBank.d404.s3	these	110	114	O
DDI-DrugBank.d404.s3	drugs	116	120	O
DDI-DrugBank.d404.s3	are	122	124	O
DDI-DrugBank.d404.s3	administered	126	137	O
DDI-DrugBank.d404.s3	simultaneously	139	152	O
DDI-DrugBank.d404.s3	.	153	153	O
DDI-DrugBank.d404.s4	Thiazides	0	8	B-group
DDI-DrugBank.d404.s4	:	9	9	O
DDI-DrugBank.d404.s4	Thiazides	11	19	B-group
DDI-DrugBank.d404.s4	are	21	23	O
DDI-DrugBank.d404.s4	known	25	29	O
DDI-DrugBank.d404.s4	to	31	32	O
DDI-DrugBank.d404.s4	induce	34	39	O
DDI-DrugBank.d404.s4	hypercalcemia	41	53	O
DDI-DrugBank.d404.s4	by	55	56	O
DDI-DrugBank.d404.s4	the	58	60	O
DDI-DrugBank.d404.s4	reduction	62	70	O
DDI-DrugBank.d404.s4	of	72	73	O
DDI-DrugBank.d404.s4	calcium	75	81	O
DDI-DrugBank.d404.s4	excretion	83	91	O
DDI-DrugBank.d404.s4	in	93	94	O
DDI-DrugBank.d404.s4	urine	96	100	O
DDI-DrugBank.d404.s4	.	101	101	O
DDI-DrugBank.d404.s5	Some	0	3	O
DDI-DrugBank.d404.s5	reports	5	11	O
DDI-DrugBank.d404.s5	have	13	16	O
DDI-DrugBank.d404.s5	shown	18	22	O
DDI-DrugBank.d404.s5	that	24	27	O
DDI-DrugBank.d404.s5	the	29	31	O
DDI-DrugBank.d404.s5	concomitant	33	43	O
DDI-DrugBank.d404.s5	administration	45	58	O
DDI-DrugBank.d404.s5	of	60	61	O
DDI-DrugBank.d404.s5	thiazides	63	71	B-group
DDI-DrugBank.d404.s5	with	73	76	O
DDI-DrugBank.d404.s5	vitamin	78	84	B-group
DDI-DrugBank.d404.s5	D	86	86	O
DDI-DrugBank.d404.s5	causes	88	93	O
DDI-DrugBank.d404.s5	hypercalcemia	95	107	O
DDI-DrugBank.d404.s5	.	108	108	O
DDI-DrugBank.d404.s6	Therefore	0	8	O
DDI-DrugBank.d404.s6	,	9	9	O
DDI-DrugBank.d404.s6	precaution	11	20	O
DDI-DrugBank.d404.s6	should	22	27	O
DDI-DrugBank.d404.s6	be	29	30	O
DDI-DrugBank.d404.s6	taken	32	36	O
DDI-DrugBank.d404.s6	when	38	41	O
DDI-DrugBank.d404.s6	coadministration	43	58	O
DDI-DrugBank.d404.s6	is	60	61	O
DDI-DrugBank.d404.s6	necessary	63	71	O
DDI-DrugBank.d404.s6	.	72	72	O
DDI-DrugBank.d404.s7	Digitalis	0	8	B-group
DDI-DrugBank.d404.s7	:	9	9	O
DDI-DrugBank.d404.s7	Vitamin	11	17	B-group
DDI-DrugBank.d404.s7	D	19	19	O
DDI-DrugBank.d404.s7	dosage	21	26	O
DDI-DrugBank.d404.s7	must	28	31	O
DDI-DrugBank.d404.s7	be	33	34	O
DDI-DrugBank.d404.s7	determined	36	45	O
DDI-DrugBank.d404.s7	with	47	50	O
DDI-DrugBank.d404.s7	care	52	55	O
DDI-DrugBank.d404.s7	in	57	58	O
DDI-DrugBank.d404.s7	patients	60	67	O
DDI-DrugBank.d404.s7	undergoing	69	78	O
DDI-DrugBank.d404.s7	treatment	80	88	O
DDI-DrugBank.d404.s7	with	90	93	O
DDI-DrugBank.d404.s7	digitalis	95	103	B-group
DDI-DrugBank.d404.s7	,	104	104	O
DDI-DrugBank.d404.s7	as	106	107	O
DDI-DrugBank.d404.s7	hypercalcemia	109	121	O
DDI-DrugBank.d404.s7	in	123	124	O
DDI-DrugBank.d404.s7	such	126	129	O
DDI-DrugBank.d404.s7	patients	131	138	O
DDI-DrugBank.d404.s7	may	140	142	O
DDI-DrugBank.d404.s7	precipitate	144	154	O
DDI-DrugBank.d404.s7	cardiac	156	162	O
DDI-DrugBank.d404.s7	arrhythmias	164	174	O
DDI-DrugBank.d404.s7	.	175	175	O
DDI-DrugBank.d404.s8	Ketoconazole	0	11	B-drug
DDI-DrugBank.d404.s8	:	12	12	O
DDI-DrugBank.d404.s8	Ketoconazole	14	25	B-drug
DDI-DrugBank.d404.s8	may	27	29	O
DDI-DrugBank.d404.s8	inhibit	31	37	O
DDI-DrugBank.d404.s8	both	39	42	O
DDI-DrugBank.d404.s8	synthetic	44	52	O
DDI-DrugBank.d404.s8	and	54	56	O
DDI-DrugBank.d404.s8	catabolic	58	66	O
DDI-DrugBank.d404.s8	enzymes	68	74	O
DDI-DrugBank.d404.s8	of	76	77	O
DDI-DrugBank.d404.s8	vitamin	79	85	B-group
DDI-DrugBank.d404.s8	D	87	87	O
DDI-DrugBank.d404.s8	.	88	88	O
DDI-DrugBank.d404.s9	Reductions	0	9	O
DDI-DrugBank.d404.s9	in	11	12	O
DDI-DrugBank.d404.s9	serum	14	18	O
DDI-DrugBank.d404.s9	endogenous	20	29	O
DDI-DrugBank.d404.s9	vitamin	31	37	O
DDI-DrugBank.d404.s9	D	39	39	O
DDI-DrugBank.d404.s9	concentrations	41	54	O
DDI-DrugBank.d404.s9	have	56	59	O
DDI-DrugBank.d404.s9	been	61	64	O
DDI-DrugBank.d404.s9	observed	66	73	O
DDI-DrugBank.d404.s9	following	75	83	O
DDI-DrugBank.d404.s9	the	85	87	O
DDI-DrugBank.d404.s9	administration	89	102	O
DDI-DrugBank.d404.s9	of	104	105	O
DDI-DrugBank.d404.s9	300	107	109	O
DDI-DrugBank.d404.s9	mg/day	111	116	O
DDI-DrugBank.d404.s9	to	118	119	O
DDI-DrugBank.d404.s9	1200	121	124	O
DDI-DrugBank.d404.s9	mg/day	111	116	O
DDI-DrugBank.d404.s9	ketoconazole	133	144	B-drug
DDI-DrugBank.d404.s9	for	146	148	O
DDI-DrugBank.d404.s9	a	130	130	O
DDI-DrugBank.d404.s9	week	152	155	O
DDI-DrugBank.d404.s9	to	135	136	I-drug
DDI-DrugBank.d404.s9	healthy	160	166	O
DDI-DrugBank.d404.s9	men	168	170	O
DDI-DrugBank.d404.s9	.	171	171	O
DDI-DrugBank.d404.s10	However	0	6	O
DDI-DrugBank.d404.s10	,	7	7	O
DDI-DrugBank.d404.s10	in	9	10	O
DDI-DrugBank.d404.s10	vivo	12	15	O
DDI-DrugBank.d404.s10	drug	17	20	O
DDI-DrugBank.d404.s10	interaction	22	32	O
DDI-DrugBank.d404.s10	studies	34	40	O
DDI-DrugBank.d404.s10	of	42	43	O
DDI-DrugBank.d404.s10	ketoconazole	45	56	B-drug
DDI-DrugBank.d404.s10	with	58	61	O
DDI-DrugBank.d404.s10	vitamin	63	69	B-group
DDI-DrugBank.d404.s10	D	71	71	O
DDI-DrugBank.d404.s10	have	73	76	O
DDI-DrugBank.d404.s10	not	78	80	O
DDI-DrugBank.d404.s10	been	82	85	O
DDI-DrugBank.d404.s10	investigated	87	98	O
DDI-DrugBank.d404.s10	.	99	99	O
DDI-DrugBank.d404.s11	Corticosteroids	0	14	B-group
DDI-DrugBank.d404.s11	:	15	15	O
DDI-DrugBank.d404.s11	A	17	17	O
DDI-DrugBank.d404.s11	relationship	19	30	O
DDI-DrugBank.d404.s11	of	32	33	O
DDI-DrugBank.d404.s11	functional	35	44	O
DDI-DrugBank.d404.s11	antagonism	46	55	O
DDI-DrugBank.d404.s11	exists	57	62	O
DDI-DrugBank.d404.s11	between	64	70	O
DDI-DrugBank.d404.s11	vitamin	72	78	B-group
DDI-DrugBank.d404.s11	D	80	80	O
DDI-DrugBank.d404.s11	analogues	82	90	O
DDI-DrugBank.d404.s11	,	91	91	O
DDI-DrugBank.d404.s11	which	93	97	O
DDI-DrugBank.d404.s11	promote	99	105	O
DDI-DrugBank.d404.s11	calcium	107	113	O
DDI-DrugBank.d404.s11	absorption	115	124	O
DDI-DrugBank.d404.s11	,	125	125	O
DDI-DrugBank.d404.s11	and	127	129	O
DDI-DrugBank.d404.s11	corticosteroids	131	145	B-group
DDI-DrugBank.d404.s11	,	146	146	O
DDI-DrugBank.d404.s11	which	148	152	O
DDI-DrugBank.d404.s11	inhibit	154	160	O
DDI-DrugBank.d404.s11	calcium	162	168	O
DDI-DrugBank.d404.s11	absorption	170	179	O
DDI-DrugBank.d404.s11	.	180	180	O
DDI-DrugBank.d404.s12	Phosphate-Binding	0	16	O
DDI-DrugBank.d404.s12	Agents	18	23	O
DDI-DrugBank.d404.s12	:	24	24	O
DDI-DrugBank.d404.s12	Since	26	30	O
DDI-DrugBank.d404.s12	vitamin	32	38	B-group
DDI-DrugBank.d404.s12	D	40	40	O
DDI-DrugBank.d404.s12	also	42	45	O
DDI-DrugBank.d404.s12	has	47	49	O
DDI-DrugBank.d404.s12	an	51	52	O
DDI-DrugBank.d404.s12	effect	54	59	O
DDI-DrugBank.d404.s12	on	61	62	O
DDI-DrugBank.d404.s12	phosphate	64	72	O
DDI-DrugBank.d404.s12	transport	74	82	O
DDI-DrugBank.d404.s12	in	84	85	O
DDI-DrugBank.d404.s12	the	87	89	O
DDI-DrugBank.d404.s12	intestine	91	99	O
DDI-DrugBank.d404.s12	,	100	100	O
DDI-DrugBank.d404.s12	kidneys	102	108	O
DDI-DrugBank.d404.s12	and	110	112	O
DDI-DrugBank.d404.s12	bones	114	118	O
DDI-DrugBank.d404.s12	,	119	119	O
DDI-DrugBank.d404.s12	the	121	123	O
DDI-DrugBank.d404.s12	dosage	125	130	O
DDI-DrugBank.d404.s12	of	132	133	O
DDI-DrugBank.d404.s12	phosphate-binding	135	151	O
DDI-DrugBank.d404.s12	agents	153	158	O
DDI-DrugBank.d404.s12	must	160	163	O
DDI-DrugBank.d404.s12	be	165	166	O
DDI-DrugBank.d404.s12	adjusted	168	175	O
DDI-DrugBank.d404.s12	in	177	178	O
DDI-DrugBank.d404.s12	accordance	180	189	O
DDI-DrugBank.d404.s12	with	191	194	O
DDI-DrugBank.d404.s12	the	196	198	O
DDI-DrugBank.d404.s12	serum	200	204	O
DDI-DrugBank.d404.s12	phosphate	206	214	O
DDI-DrugBank.d404.s12	concentration	216	228	O
DDI-DrugBank.d404.s12	.	229	229	O
DDI-DrugBank.d404.s13	Vitamin	0	6	B-group
DDI-DrugBank.d404.s13	D	8	8	O
DDI-DrugBank.d404.s13	:	9	9	O
DDI-DrugBank.d404.s13	The	11	13	O
DDI-DrugBank.d404.s13	coadministration	15	30	O
DDI-DrugBank.d404.s13	of	32	33	O
DDI-DrugBank.d404.s13	any	35	37	O
DDI-DrugBank.d404.s13	of	39	40	O
DDI-DrugBank.d404.s13	the	42	44	O
DDI-DrugBank.d404.s13	vitamin	46	52	B-group
DDI-DrugBank.d404.s13	D	54	54	O
DDI-DrugBank.d404.s13	analogues	56	64	O
DDI-DrugBank.d404.s13	should	66	71	O
DDI-DrugBank.d404.s13	be	73	74	O
DDI-DrugBank.d404.s13	avoided	76	82	O
DDI-DrugBank.d404.s13	as	84	85	O
DDI-DrugBank.d404.s13	this	87	90	O
DDI-DrugBank.d404.s13	could	92	96	O
DDI-DrugBank.d404.s13	create	98	103	O
DDI-DrugBank.d404.s13	possible	105	112	O
DDI-DrugBank.d404.s13	additive	114	121	O
DDI-DrugBank.d404.s13	effects	123	129	O
DDI-DrugBank.d404.s13	and	131	133	O
DDI-DrugBank.d404.s13	hypercalcemia	135	147	O
DDI-DrugBank.d404.s13	.	148	148	O
DDI-DrugBank.d404.s14	Calcium	0	6	B-drug
DDI-DrugBank.d404.s14	Supplements	8	18	O
DDI-DrugBank.d404.s14	:	19	19	O
DDI-DrugBank.d404.s14	Uncontrolled	21	32	O
DDI-DrugBank.d404.s14	intake	34	39	O
DDI-DrugBank.d404.s14	of	41	42	O
DDI-DrugBank.d404.s14	additional	44	53	O
DDI-DrugBank.d404.s14	calcium-containing	55	72	O
DDI-DrugBank.d404.s14	preparations	74	85	O
DDI-DrugBank.d404.s14	should	87	92	O
DDI-DrugBank.d404.s14	be	94	95	O
DDI-DrugBank.d404.s14	avoided	97	103	O
DDI-DrugBank.d404.s14	.	104	104	O
DDI-DrugBank.d404.s15	Magnesium	0	8	B-drug
DDI-DrugBank.d404.s15	:	9	9	O
DDI-DrugBank.d404.s15	Magnesium-containing	11	30	O
DDI-DrugBank.d404.s15	preparations	32	43	O
DDI-DrugBank.d404.s15	(	45	45	O
DDI-DrugBank.d404.s15	eg	46	47	O
DDI-DrugBank.d404.s15	,	48	48	O
DDI-DrugBank.d404.s15	antacids	50	57	B-group
DDI-DrugBank.d404.s15	)	58	58	O
DDI-DrugBank.d404.s15	may	60	62	O
DDI-DrugBank.d404.s15	cause	64	68	O
DDI-DrugBank.d404.s15	hypermagnesemia	70	84	O
DDI-DrugBank.d404.s15	and	86	88	O
DDI-DrugBank.d404.s15	should	90	95	O
DDI-DrugBank.d404.s15	therefore	97	105	O
DDI-DrugBank.d404.s15	not	107	109	O
DDI-DrugBank.d404.s15	be	111	112	O
DDI-DrugBank.d404.s15	taken	114	118	O
DDI-DrugBank.d404.s15	during	120	125	O
DDI-DrugBank.d404.s15	therapy	127	133	O
DDI-DrugBank.d404.s15	with	135	138	O
DDI-DrugBank.d404.s15	vitamin	140	146	B-group
DDI-DrugBank.d404.s15	D	148	148	O
DDI-DrugBank.d404.s15	by	150	151	O
DDI-DrugBank.d404.s15	patients	153	160	O
DDI-DrugBank.d404.s15	on	162	163	O
DDI-DrugBank.d404.s15	chronic	165	171	O
DDI-DrugBank.d404.s15	renal	173	177	O
DDI-DrugBank.d404.s15	dialysis	179	186	O
DDI-DrugBank.d404.s15	.	187	187	O
DDI-MedLine.d115.s0	Concomitant	0	10	O
DDI-MedLine.d115.s0	cyclophosphamide	12	27	B-drug
DDI-MedLine.d115.s0	,	28	28	O
DDI-MedLine.d115.s0	doxorubicin	30	40	B-drug
DDI-MedLine.d115.s0	,	41	41	O
DDI-MedLine.d115.s0	vincristine	43	53	B-drug
DDI-MedLine.d115.s0	,	54	54	O
DDI-MedLine.d115.s0	and	56	58	O
DDI-MedLine.d115.s0	prednisone	60	69	B-drug
DDI-MedLine.d115.s0	chemotherapy	71	82	O
DDI-MedLine.d115.s0	plus	84	87	O
DDI-MedLine.d115.s0	highly	89	94	B-group
DDI-MedLine.d115.s0	active	96	101	I-group
DDI-MedLine.d115.s0	antiretroviral	103	116	I-group
DDI-MedLine.d115.s0	therapy	118	124	O
DDI-MedLine.d115.s0	in	126	127	O
DDI-MedLine.d115.s0	patients	129	136	O
DDI-MedLine.d115.s0	with	138	141	O
DDI-MedLine.d115.s0	human	143	147	O
DDI-MedLine.d115.s0	immunodeficiency	149	164	O
DDI-MedLine.d115.s0	virus-related	166	178	O
DDI-MedLine.d115.s0	,	179	179	O
DDI-MedLine.d115.s0	non-Hodgkin	181	191	O
DDI-MedLine.d115.s0	lymphoma	193	200	O
DDI-MedLine.d115.s0	.	201	201	O
DDI-MedLine.d115.s1	BACKGROUND	0	9	O
DDI-MedLine.d115.s1	:	10	10	O
DDI-MedLine.d115.s1	The	12	14	O
DDI-MedLine.d115.s1	feasibility	16	26	O
DDI-MedLine.d115.s1	and	28	30	O
DDI-MedLine.d115.s1	efficacy	32	39	O
DDI-MedLine.d115.s1	of	41	42	O
DDI-MedLine.d115.s1	concomitant	44	54	O
DDI-MedLine.d115.s1	chemotherapy	56	67	O
DDI-MedLine.d115.s1	and	69	71	O
DDI-MedLine.d115.s1	highly	73	78	B-group
DDI-MedLine.d115.s1	active	80	85	I-group
DDI-MedLine.d115.s1	antiretroviral	87	100	I-group
DDI-MedLine.d115.s1	therapy	102	108	O
DDI-MedLine.d115.s1	(	110	110	O
DDI-MedLine.d115.s1	HAART	111	115	O
DDI-MedLine.d115.s1	)	116	116	O
DDI-MedLine.d115.s1	is	118	119	O
DDI-MedLine.d115.s1	still	121	125	O
DDI-MedLine.d115.s1	unknown	127	133	O
DDI-MedLine.d115.s1	in	135	136	O
DDI-MedLine.d115.s1	patients	138	145	O
DDI-MedLine.d115.s1	with	147	150	O
DDI-MedLine.d115.s1	human	152	156	O
DDI-MedLine.d115.s1	immunodeficiency	158	173	O
DDI-MedLine.d115.s1	virus	175	179	O
DDI-MedLine.d115.s1	(	181	181	O
DDI-MedLine.d115.s1	HIV	182	184	O
DDI-MedLine.d115.s1	)	185	185	O
DDI-MedLine.d115.s1	-related	186	193	O
DDI-MedLine.d115.s1	malignancies	195	206	O
DDI-MedLine.d115.s1	.	207	207	O
DDI-MedLine.d115.s2	To	0	1	O
DDI-MedLine.d115.s2	evaluate	3	10	O
DDI-MedLine.d115.s2	the	12	14	O
DDI-MedLine.d115.s2	impact	16	21	O
DDI-MedLine.d115.s2	of	23	24	O
DDI-MedLine.d115.s2	chemotherapy	26	37	O
DDI-MedLine.d115.s2	plus	39	42	O
DDI-MedLine.d115.s2	HAART	44	48	O
DDI-MedLine.d115.s2	on	50	51	O
DDI-MedLine.d115.s2	the	53	55	O
DDI-MedLine.d115.s2	clinical	57	64	O
DDI-MedLine.d115.s2	course	66	71	O
DDI-MedLine.d115.s2	of	73	74	O
DDI-MedLine.d115.s2	patients	76	83	O
DDI-MedLine.d115.s2	with	85	88	O
DDI-MedLine.d115.s2	HIV-related	90	100	O
DDI-MedLine.d115.s2	,	101	101	O
DDI-MedLine.d115.s2	systemic	103	110	O
DDI-MedLine.d115.s2	,	101	101	O
DDI-MedLine.d115.s2	non-Hodgkin	113	123	O
DDI-MedLine.d115.s2	lymphoma	125	132	O
DDI-MedLine.d115.s2	(	134	134	O
DDI-MedLine.d115.s2	HIV-NHL	135	141	O
DDI-MedLine.d115.s2	)	142	142	O
DDI-MedLine.d115.s2	,	143	143	O
DDI-MedLine.d115.s2	the	145	147	O
DDI-MedLine.d115.s2	authors	149	155	O
DDI-MedLine.d115.s2	compared	157	164	O
DDI-MedLine.d115.s2	retrospectively	166	180	O
DDI-MedLine.d115.s2	a	161	161	O
DDI-MedLine.d115.s2	group	184	188	O
DDI-MedLine.d115.s2	of	190	191	O
DDI-MedLine.d115.s2	24	193	194	O
DDI-MedLine.d115.s2	patients	196	203	O
DDI-MedLine.d115.s2	with	205	208	O
DDI-MedLine.d115.s2	HIV-NHL	210	216	O
DDI-MedLine.d115.s2	who	218	220	O
DDI-MedLine.d115.s2	were	222	225	O
DDI-MedLine.d115.s2	treated	227	233	O
DDI-MedLine.d115.s2	with	205	208	O
DDI-MedLine.d115.s2	the	240	242	O
DDI-MedLine.d115.s2	cyclophosphamide	244	259	B-drug
DDI-MedLine.d115.s2	,	260	260	O
DDI-MedLine.d115.s2	doxorubicin	262	272	B-drug
DDI-MedLine.d115.s2	,	260	260	O
DDI-MedLine.d115.s2	vincristine	275	285	B-drug
DDI-MedLine.d115.s2	,	260	260	O
DDI-MedLine.d115.s2	and	288	290	O
DDI-MedLine.d115.s2	prednisone	292	301	B-drug
DDI-MedLine.d115.s2	(	303	303	O
DDI-MedLine.d115.s2	CHOP	304	307	O
DDI-MedLine.d115.s2	)	308	308	O
DDI-MedLine.d115.s2	chemotherapy	310	321	O
DDI-MedLine.d115.s2	regimen	323	329	O
DDI-MedLine.d115.s2	plus	331	334	O
DDI-MedLine.d115.s2	HAART	336	340	O
DDI-MedLine.d115.s2	with	342	345	O
DDI-MedLine.d115.s2	a	319	319	O
DDI-MedLine.d115.s2	group	349	353	O
DDI-MedLine.d115.s2	of	355	356	O
DDI-MedLine.d115.s2	80	358	359	O
DDI-MedLine.d115.s2	patients	361	368	O
DDI-MedLine.d115.s2	who	370	372	O
DDI-MedLine.d115.s2	were	374	377	O
DDI-MedLine.d115.s2	treated	379	385	O
DDI-MedLine.d115.s2	with	342	345	O
DDI-MedLine.d115.s2	CHOP	392	395	O
DDI-MedLine.d115.s2	chemotherapy	397	408	O
DDI-MedLine.d115.s2	or	410	411	O
DDI-MedLine.d115.s2	a	362	362	O
DDI-MedLine.d115.s2	CHOP-like	415	423	O
DDI-MedLine.d115.s2	regimen	425	431	O
DDI-MedLine.d115.s2	(	433	433	O
DDI-MedLine.d115.s2	i.e.	434	437	O
DDI-MedLine.d115.s2	,	438	438	O
DDI-MedLine.d115.s2	cyclophosphamide	440	455	B-drug
DDI-MedLine.d115.s2	,	438	438	O
DDI-MedLine.d115.s2	doxorubicin	458	468	B-drug
DDI-MedLine.d115.s2	,	438	438	O
DDI-MedLine.d115.s2	teniposide	471	480	B-drug
DDI-MedLine.d115.s2	,	438	438	O
DDI-MedLine.d115.s2	and	483	485	O
DDI-MedLine.d115.s2	prednisone	487	496	B-drug
DDI-MedLine.d115.s2	with	498	501	O
DDI-MedLine.d115.s2	vincristine	503	513	B-drug
DDI-MedLine.d115.s2	plus	515	518	O
DDI-MedLine.d115.s2	bleomycin	520	528	B-drug
DDI-MedLine.d115.s2	)	529	529	O
DDI-MedLine.d115.s2	without	531	537	O
DDI-MedLine.d115.s2	receiving	539	547	O
DDI-MedLine.d115.s2	antiretroviral	549	562	B-group
DDI-MedLine.d115.s2	therapy	564	570	O
DDI-MedLine.d115.s2	.	571	571	O
DDI-MedLine.d115.s3	METHODS	0	6	O
DDI-MedLine.d115.s3	:	7	7	O
DDI-MedLine.d115.s3	All	9	11	O
DDI-MedLine.d115.s3	patients	13	20	O
DDI-MedLine.d115.s3	were	22	25	O
DDI-MedLine.d115.s3	enrolled	27	34	O
DDI-MedLine.d115.s3	in	36	37	O
DDI-MedLine.d115.s3	two	39	41	O
DDI-MedLine.d115.s3	sequential	43	52	O
DDI-MedLine.d115.s3	trials	54	59	O
DDI-MedLine.d115.s3	performed	61	69	O
DDI-MedLine.d115.s3	at	71	72	O
DDI-MedLine.d115.s3	the	74	76	O
DDI-MedLine.d115.s3	Aviano	78	83	O
DDI-MedLine.d115.s3	Cancer	85	90	O
DDI-MedLine.d115.s3	Center	92	97	O
DDI-MedLine.d115.s3	,	98	98	O
DDI-MedLine.d115.s3	Italy	100	104	O
DDI-MedLine.d115.s3	,	98	98	O
DDI-MedLine.d115.s3	from	107	110	O
DDI-MedLine.d115.s3	April	112	116	O
DDI-MedLine.d115.s3	1988	118	121	O
DDI-MedLine.d115.s3	to	123	124	O
DDI-MedLine.d115.s3	December	126	133	O
DDI-MedLine.d115.s3	1998	135	138	O
DDI-MedLine.d115.s3	.	139	139	O
DDI-MedLine.d115.s4	HAART	0	4	O
DDI-MedLine.d115.s4	was	6	8	O
DDI-MedLine.d115.s4	included	10	17	O
DDI-MedLine.d115.s4	with	19	22	O
DDI-MedLine.d115.s4	combination	24	34	O
DDI-MedLine.d115.s4	therapy	36	42	O
DDI-MedLine.d115.s4	from	44	47	O
DDI-MedLine.d115.s4	January	49	55	O
DDI-MedLine.d115.s4	1997	57	60	O
DDI-MedLine.d115.s4	.	61	61	O
DDI-MedLine.d115.s5	Antiretroviral	0	13	B-group
DDI-MedLine.d115.s5	regimens	15	22	O
DDI-MedLine.d115.s5	consisted	24	32	O
DDI-MedLine.d115.s5	of	34	35	O
DDI-MedLine.d115.s5	two	37	39	O
DDI-MedLine.d115.s5	reverse	41	47	B-group
DDI-MedLine.d115.s5	transcriptase	49	61	I-group
DDI-MedLine.d115.s5	inhibitors	63	72	I-group
DDI-MedLine.d115.s5	and	74	76	O
DDI-MedLine.d115.s5	one	78	80	O
DDI-MedLine.d115.s5	protease	82	89	B-group
DDI-MedLine.d115.s5	inhibitor	91	99	I-group
DDI-MedLine.d115.s5	.	100	100	O
DDI-MedLine.d115.s6	RESULTS	0	6	O
DDI-MedLine.d115.s6	:	7	7	O
DDI-MedLine.d115.s6	The	9	11	O
DDI-MedLine.d115.s6	two	13	15	O
DDI-MedLine.d115.s6	treatment	17	25	O
DDI-MedLine.d115.s6	groups	27	32	O
DDI-MedLine.d115.s6	were	34	37	O
DDI-MedLine.d115.s6	well	39	42	O
DDI-MedLine.d115.s6	matched	44	50	O
DDI-MedLine.d115.s6	with	52	55	O
DDI-MedLine.d115.s6	regard	57	62	O
DDI-MedLine.d115.s6	to	64	65	O
DDI-MedLine.d115.s6	patient	67	73	O
DDI-MedLine.d115.s6	demographics	75	86	O
DDI-MedLine.d115.s6	,	87	87	O
DDI-MedLine.d115.s6	NHL	89	91	O
DDI-MedLine.d115.s6	characteristics	93	107	O
DDI-MedLine.d115.s6	,	108	108	O
DDI-MedLine.d115.s6	HIV	110	112	O
DDI-MedLine.d115.s6	status	114	119	O
DDI-MedLine.d115.s6	,	108	108	O
DDI-MedLine.d115.s6	and	122	124	O
DDI-MedLine.d115.s6	treatment	126	134	O
DDI-MedLine.d115.s6	,	120	120	O
DDI-MedLine.d115.s6	i.e.	137	140	O
DDI-MedLine.d115.s6	,	135	135	O
DDI-MedLine.d115.s6	the	143	145	O
DDI-MedLine.d115.s6	number	147	152	O
DDI-MedLine.d115.s6	of	154	155	O
DDI-MedLine.d115.s6	cycles	157	162	O
DDI-MedLine.d115.s6	and	164	166	O
DDI-MedLine.d115.s6	chemotherapy	168	179	O
DDI-MedLine.d115.s6	dose	181	184	O
DDI-MedLine.d115.s6	.	185	185	O
DDI-MedLine.d115.s7	The	0	2	O
DDI-MedLine.d115.s7	response	4	11	O
DDI-MedLine.d115.s7	rates	13	17	O
DDI-MedLine.d115.s7	were	19	22	O
DDI-MedLine.d115.s7	similar	24	30	O
DDI-MedLine.d115.s7	between	32	38	O
DDI-MedLine.d115.s7	the	40	42	O
DDI-MedLine.d115.s7	two	44	46	O
DDI-MedLine.d115.s7	groups	48	53	O
DDI-MedLine.d115.s7	.	54	54	O
DDI-MedLine.d115.s8	Severe	0	5	O
DDI-MedLine.d115.s8	anemia	7	12	O
DDI-MedLine.d115.s8	(	14	14	O
DDI-MedLine.d115.s8	Grade	15	19	O
DDI-MedLine.d115.s8	3-4	21	23	O
DDI-MedLine.d115.s8	according	25	33	O
DDI-MedLine.d115.s8	to	35	36	O
DDI-MedLine.d115.s8	the	38	40	O
DDI-MedLine.d115.s8	World	42	46	O
DDI-MedLine.d115.s8	Health	48	53	O
DDI-MedLine.d115.s8	Organization	55	66	O
DDI-MedLine.d115.s8	criteria	68	75	O
DDI-MedLine.d115.s8	)	76	76	O
DDI-MedLine.d115.s8	was	78	80	O
DDI-MedLine.d115.s8	significantly	82	94	O
DDI-MedLine.d115.s8	greater	96	102	O
DDI-MedLine.d115.s8	in	104	105	O
DDI-MedLine.d115.s8	the	107	109	O
DDI-MedLine.d115.s8	patients	111	118	O
DDI-MedLine.d115.s8	who	120	122	O
DDI-MedLine.d115.s8	received	124	131	O
DDI-MedLine.d115.s8	CHOP-HAART	133	142	O
DDI-MedLine.d115.s8	compared	144	151	O
DDI-MedLine.d115.s8	with	153	156	O
DDI-MedLine.d115.s8	the	158	160	O
DDI-MedLine.d115.s8	patients	162	169	O
DDI-MedLine.d115.s8	who	171	173	O
DDI-MedLine.d115.s8	received	175	182	O
DDI-MedLine.d115.s8	CHOP	184	187	O
DDI-MedLine.d115.s8	alone	189	193	O
DDI-MedLine.d115.s8	(	195	195	O
DDI-MedLine.d115.s8	33	196	197	O
DDI-MedLine.d115.s8	%	198	198	O
DDI-MedLine.d115.s8	vs.	200	202	O
DDI-MedLine.d115.s8	7	204	204	O
DDI-MedLine.d115.s8	%	198	198	O
DDI-MedLine.d115.s8	,	206	206	O
DDI-MedLine.d115.s8	respectively	208	219	O
DDI-MedLine.d115.s8	;	220	220	O
DDI-MedLine.d115.s8	P	222	222	O
DDI-MedLine.d115.s8	=	224	224	O
DDI-MedLine.d115.s8	0.001	226	230	O
DDI-MedLine.d115.s8	)	231	231	O
DDI-MedLine.d115.s8	.	202	202	O
DDI-MedLine.d115.s9	Leukopenia	0	9	O
DDI-MedLine.d115.s9	was	11	13	O
DDI-MedLine.d115.s9	similar	15	21	O
DDI-MedLine.d115.s9	between	23	29	O
DDI-MedLine.d115.s9	the	31	33	O
DDI-MedLine.d115.s9	two	35	37	O
DDI-MedLine.d115.s9	groups	39	44	O
DDI-MedLine.d115.s9	,	45	45	O
DDI-MedLine.d115.s9	but	47	49	O
DDI-MedLine.d115.s9	colony	51	56	O
DDI-MedLine.d115.s9	stimulating	58	68	O
DDI-MedLine.d115.s9	factor	70	75	O
DDI-MedLine.d115.s9	support	77	83	O
DDI-MedLine.d115.s9	was	85	87	O
DDI-MedLine.d115.s9	significantly	89	101	O
DDI-MedLine.d115.s9	greater	103	109	O
DDI-MedLine.d115.s9	in	111	112	O
DDI-MedLine.d115.s9	the	114	116	O
DDI-MedLine.d115.s9	CHOP-HAART	118	127	O
DDI-MedLine.d115.s9	group	129	133	O
DDI-MedLine.d115.s9	than	135	138	O
DDI-MedLine.d115.s9	in	140	141	O
DDI-MedLine.d115.s9	the	143	145	O
DDI-MedLine.d115.s9	control	147	153	O
DDI-MedLine.d115.s9	group	155	159	O
DDI-MedLine.d115.s9	(	161	161	O
DDI-MedLine.d115.s9	92	162	163	O
DDI-MedLine.d115.s9	%	164	164	O
DDI-MedLine.d115.s9	vs.	166	168	O
DDI-MedLine.d115.s9	66	170	171	O
DDI-MedLine.d115.s9	%	164	164	O
DDI-MedLine.d115.s9	,	173	173	O
DDI-MedLine.d115.s9	respectively	175	186	O
DDI-MedLine.d115.s9	;	187	187	O
DDI-MedLine.d115.s9	P	189	189	O
DDI-MedLine.d115.s9	=	191	191	O
DDI-MedLine.d115.s9	0.03	193	196	O
DDI-MedLine.d115.s9	)	197	197	O
DDI-MedLine.d115.s9	.	168	168	O
DDI-MedLine.d115.s10	Seventeen	0	8	O
DDI-MedLine.d115.s10	percent	10	16	O
DDI-MedLine.d115.s10	of	18	19	O
DDI-MedLine.d115.s10	CHOP-HAART	21	30	O
DDI-MedLine.d115.s10	patients	32	39	O
DDI-MedLine.d115.s10	developed	41	49	O
DDI-MedLine.d115.s10	severe	51	56	O
DDI-MedLine.d115.s10	autonomic	58	66	O
DDI-MedLine.d115.s10	neurotoxicity	68	80	O
DDI-MedLine.d115.s10	,	81	81	O
DDI-MedLine.d115.s10	whereas	83	89	O
DDI-MedLine.d115.s10	none	91	94	O
DDI-MedLine.d115.s10	of	96	97	O
DDI-MedLine.d115.s10	the	99	101	O
DDI-MedLine.d115.s10	CHOP	103	106	O
DDI-MedLine.d115.s10	patients	108	115	O
DDI-MedLine.d115.s10	developed	117	125	O
DDI-MedLine.d115.s10	neurotoxicity	127	139	O
DDI-MedLine.d115.s10	(	141	141	O
DDI-MedLine.d115.s10	P	142	142	O
DDI-MedLine.d115.s10	=	144	144	O
DDI-MedLine.d115.s10	0.002	146	150	O
DDI-MedLine.d115.s10	)	151	151	O
DDI-MedLine.d115.s10	.	147	147	O
DDI-MedLine.d115.s11	At	0	1	O
DDI-MedLine.d115.s11	similar	3	9	O
DDI-MedLine.d115.s11	median	11	16	O
DDI-MedLine.d115.s11	follow-up	18	26	O
DDI-MedLine.d115.s11	,	27	27	O
DDI-MedLine.d115.s11	opportunistic	29	41	O
DDI-MedLine.d115.s11	infection	43	51	O
DDI-MedLine.d115.s11	(	53	53	O
DDI-MedLine.d115.s11	OI	54	55	O
DDI-MedLine.d115.s11	)	56	56	O
DDI-MedLine.d115.s11	rates	58	62	O
DDI-MedLine.d115.s11	and	64	66	O
DDI-MedLine.d115.s11	mortality	68	76	O
DDI-MedLine.d115.s11	were	78	81	O
DDI-MedLine.d115.s11	significantly	83	95	O
DDI-MedLine.d115.s11	lower	97	101	O
DDI-MedLine.d115.s11	in	103	104	O
DDI-MedLine.d115.s11	the	106	108	O
DDI-MedLine.d115.s11	CHOP-HAART	110	119	O
DDI-MedLine.d115.s11	patients	121	128	O
DDI-MedLine.d115.s11	than	130	133	O
DDI-MedLine.d115.s11	in	135	136	O
DDI-MedLine.d115.s11	the	138	140	O
DDI-MedLine.d115.s11	CHOP	142	145	O
DDI-MedLine.d115.s11	patients	147	154	O
DDI-MedLine.d115.s11	(	156	156	O
DDI-MedLine.d115.s11	18	157	158	O
DDI-MedLine.d115.s11	%	159	159	O
DDI-MedLine.d115.s11	vs.	161	163	O
DDI-MedLine.d115.s11	52	165	166	O
DDI-MedLine.d115.s11	%	159	159	O
DDI-MedLine.d115.s11	,	168	168	O
DDI-MedLine.d115.s11	respectively	170	181	O
DDI-MedLine.d115.s11	;	182	182	O
DDI-MedLine.d115.s11	P	184	184	O
DDI-MedLine.d115.s11	=	186	186	O
DDI-MedLine.d115.s11	0.05	188	191	O
DDI-MedLine.d115.s11	;	182	182	O
DDI-MedLine.d115.s11	and	194	196	O
DDI-MedLine.d115.s11	38	198	199	O
DDI-MedLine.d115.s11	%	200	200	O
DDI-MedLine.d115.s11	vs.	202	204	O
DDI-MedLine.d115.s11	85	206	207	O
DDI-MedLine.d115.s11	%	200	200	O
DDI-MedLine.d115.s11	,	209	209	O
DDI-MedLine.d115.s11	respectively	211	222	O
DDI-MedLine.d115.s11	;	192	192	O
DDI-MedLine.d115.s11	P	225	225	O
DDI-MedLine.d115.s11	=	227	227	O
DDI-MedLine.d115.s11	0.001	229	233	O
DDI-MedLine.d115.s11	)	234	234	O
DDI-MedLine.d115.s11	.	204	204	O
DDI-MedLine.d115.s12	The	0	2	O
DDI-MedLine.d115.s12	median	4	9	O
DDI-MedLine.d115.s12	survival	11	18	O
DDI-MedLine.d115.s12	for	20	22	O
DDI-MedLine.d115.s12	CHOP-HAART	24	33	O
DDI-MedLine.d115.s12	patients	35	42	O
DDI-MedLine.d115.s12	was	44	46	O
DDI-MedLine.d115.s12	not	48	50	O
DDI-MedLine.d115.s12	reached	52	58	O
DDI-MedLine.d115.s12	,	59	59	O
DDI-MedLine.d115.s12	whereas	61	67	O
DDI-MedLine.d115.s12	the	69	71	O
DDI-MedLine.d115.s12	medial	73	78	O
DDI-MedLine.d115.s12	survival	80	87	O
DDI-MedLine.d115.s12	of	89	90	O
DDI-MedLine.d115.s12	CHOP	92	95	O
DDI-MedLine.d115.s12	patients	97	104	O
DDI-MedLine.d115.s12	was	106	108	O
DDI-MedLine.d115.s12	7	110	110	O
DDI-MedLine.d115.s12	months	112	117	O
DDI-MedLine.d115.s12	(	119	119	O
DDI-MedLine.d115.s12	P	120	120	O
DDI-MedLine.d115.s12	=	122	122	O
DDI-MedLine.d115.s12	0.03	124	127	O
DDI-MedLine.d115.s12	)	128	128	O
DDI-MedLine.d115.s12	.	125	125	O
DDI-MedLine.d115.s13	CONCLUSIONS	0	10	O
DDI-MedLine.d115.s13	:	11	11	O
DDI-MedLine.d115.s13	The	13	15	O
DDI-MedLine.d115.s13	combination	17	27	O
DDI-MedLine.d115.s13	of	29	30	O
DDI-MedLine.d115.s13	CHOP	32	35	O
DDI-MedLine.d115.s13	plus	37	40	O
DDI-MedLine.d115.s13	HAART	42	46	O
DDI-MedLine.d115.s13	is	48	49	O
DDI-MedLine.d115.s13	feasible	51	58	O
DDI-MedLine.d115.s13	and	60	62	O
DDI-MedLine.d115.s13	may	64	66	O
DDI-MedLine.d115.s13	reduce	68	73	O
DDI-MedLine.d115.s13	the	75	77	O
DDI-MedLine.d115.s13	morbidity	79	87	O
DDI-MedLine.d115.s13	from	89	92	O
DDI-MedLine.d115.s13	OIs	94	96	O
DDI-MedLine.d115.s13	in	98	99	O
DDI-MedLine.d115.s13	HIV-NHL	101	107	O
DDI-MedLine.d115.s13	patients	109	116	O
DDI-MedLine.d115.s13	.	117	117	O
DDI-MedLine.d115.s14	However	0	6	O
DDI-MedLine.d115.s14	,	7	7	O
DDI-MedLine.d115.s14	careful	9	15	O
DDI-MedLine.d115.s14	attention	17	25	O
DDI-MedLine.d115.s14	must	27	30	O
DDI-MedLine.d115.s14	be	32	33	O
DDI-MedLine.d115.s14	directed	35	42	O
DDI-MedLine.d115.s14	to	44	45	O
DDI-MedLine.d115.s14	cross	47	51	O
DDI-MedLine.d115.s14	toxicity	53	60	O
DDI-MedLine.d115.s14	and	62	64	O
DDI-MedLine.d115.s14	possible	66	73	O
DDI-MedLine.d115.s14	pharmacokinetic	75	89	O
DDI-MedLine.d115.s14	interactions	91	102	O
DDI-MedLine.d115.s14	between	104	110	O
DDI-MedLine.d115.s14	antiretroviral	112	125	B-group
DDI-MedLine.d115.s14	and	127	129	O
DDI-MedLine.d115.s14	antineoplastic	131	144	B-group
DDI-MedLine.d115.s14	drugs	146	150	I-group
DDI-MedLine.d115.s14	.	151	151	O
DDI-MedLine.d115.s15	The	0	2	O
DDI-MedLine.d115.s15	impact	4	9	O
DDI-MedLine.d115.s15	of	11	12	O
DDI-MedLine.d115.s15	the	14	16	O
DDI-MedLine.d115.s15	combined	18	25	O
DDI-MedLine.d115.s15	chemotherapy	27	38	O
DDI-MedLine.d115.s15	plus	40	43	O
DDI-MedLine.d115.s15	HAART	45	49	O
DDI-MedLine.d115.s15	treatment	51	59	O
DDI-MedLine.d115.s15	on	61	62	O
DDI-MedLine.d115.s15	patient	64	70	O
DDI-MedLine.d115.s15	survival	72	79	O
DDI-MedLine.d115.s15	needs	81	85	O
DDI-MedLine.d115.s15	urgently	87	94	O
DDI-MedLine.d115.s15	to	96	97	O
DDI-MedLine.d115.s15	be	99	100	O
DDI-MedLine.d115.s15	evaluated	102	110	O
DDI-MedLine.d115.s15	in	112	113	O
DDI-MedLine.d115.s15	prospective	115	125	O
DDI-MedLine.d115.s15	studies	127	133	O
DDI-MedLine.d115.s15	.	134	134	O
DDI-DrugBank.d195.s0	Anastrozole	0	10	B-drug
DDI-DrugBank.d195.s0	inhibited	12	20	O
DDI-DrugBank.d195.s0	in	22	23	O
DDI-DrugBank.d195.s0	vitro	25	29	O
DDI-DrugBank.d195.s0	metabolic	31	39	O
DDI-DrugBank.d195.s0	reactions	41	49	O
DDI-DrugBank.d195.s0	catalyzed	51	59	O
DDI-DrugBank.d195.s0	by	61	62	O
DDI-DrugBank.d195.s0	cytochromes	64	74	O
DDI-DrugBank.d195.s0	P450	76	79	O
DDI-DrugBank.d195.s0	1A2	81	83	O
DDI-DrugBank.d195.s0	,	84	84	O
DDI-DrugBank.d195.s0	2C8/9	86	90	O
DDI-DrugBank.d195.s0	,	84	84	O
DDI-DrugBank.d195.s0	and	93	95	O
DDI-DrugBank.d195.s0	3A4	97	99	O
DDI-DrugBank.d195.s0	but	101	103	O
DDI-DrugBank.d195.s0	only	105	108	O
DDI-DrugBank.d195.s0	at	110	111	O
DDI-DrugBank.d195.s0	relatively	113	122	O
DDI-DrugBank.d195.s0	high	124	127	O
DDI-DrugBank.d195.s0	concentrations	129	142	O
DDI-DrugBank.d195.s0	.	143	143	O
DDI-DrugBank.d195.s1	Anastrozole	0	10	B-drug
DDI-DrugBank.d195.s1	did	12	14	O
DDI-DrugBank.d195.s1	not	16	18	O
DDI-DrugBank.d195.s1	inhibit	20	26	O
DDI-DrugBank.d195.s1	P450	28	31	O
DDI-DrugBank.d195.s1	2A6	33	35	O
DDI-DrugBank.d195.s1	or	37	38	O
DDI-DrugBank.d195.s1	the	40	42	O
DDI-DrugBank.d195.s1	polymorphic	44	54	O
DDI-DrugBank.d195.s1	P450	56	59	O
DDI-DrugBank.d195.s1	2D6	61	63	O
DDI-DrugBank.d195.s1	in	65	66	O
DDI-DrugBank.d195.s1	human	68	72	O
DDI-DrugBank.d195.s1	liver	74	78	O
DDI-DrugBank.d195.s1	microsomes	80	89	O
DDI-DrugBank.d195.s1	.	90	90	O
DDI-DrugBank.d195.s2	Anastrozole	0	10	B-drug
DDI-DrugBank.d195.s2	did	12	14	O
DDI-DrugBank.d195.s2	not	16	18	O
DDI-DrugBank.d195.s2	alter	20	24	O
DDI-DrugBank.d195.s2	the	26	28	O
DDI-DrugBank.d195.s2	pharmacokinetics	30	45	O
DDI-DrugBank.d195.s2	of	47	48	O
DDI-DrugBank.d195.s2	antipyrine	50	59	B-drug
DDI-DrugBank.d195.s2	.	60	60	O
DDI-DrugBank.d195.s3	Although	0	7	O
DDI-DrugBank.d195.s3	there	9	13	O
DDI-DrugBank.d195.s3	have	15	18	O
DDI-DrugBank.d195.s3	been	20	23	O
DDI-DrugBank.d195.s3	no	25	26	O
DDI-DrugBank.d195.s3	formal	28	33	O
DDI-DrugBank.d195.s3	interaction	35	45	O
DDI-DrugBank.d195.s3	studies	47	53	O
DDI-DrugBank.d195.s3	other	55	59	O
DDI-DrugBank.d195.s3	than	61	64	O
DDI-DrugBank.d195.s3	with	66	69	O
DDI-DrugBank.d195.s3	antipyrine	71	80	B-drug
DDI-DrugBank.d195.s3	,	81	81	O
DDI-DrugBank.d195.s3	based	83	87	O
DDI-DrugBank.d195.s3	on	89	90	O
DDI-DrugBank.d195.s3	these	92	96	O
DDI-DrugBank.d195.s3	in	98	99	O
DDI-DrugBank.d195.s3	vivo	101	104	O
DDI-DrugBank.d195.s3	and	106	108	O
DDI-DrugBank.d195.s3	in	98	99	O
DDI-DrugBank.d195.s3	vitro	113	117	O
DDI-DrugBank.d195.s3	studies	119	125	O
DDI-DrugBank.d195.s3	,	126	126	O
DDI-DrugBank.d195.s3	it	114	115	O
DDI-DrugBank.d195.s3	is	131	132	O
DDI-DrugBank.d195.s3	unlikely	134	141	O
DDI-DrugBank.d195.s3	that	143	146	O
DDI-DrugBank.d195.s3	co-administration	148	164	O
DDI-DrugBank.d195.s3	of	166	167	O
DDI-DrugBank.d195.s3	a	145	145	O
DDI-DrugBank.d195.s3	1	171	171	O
DDI-DrugBank.d195.s3	mg	173	174	O
DDI-DrugBank.d195.s3	dose	176	179	O
DDI-DrugBank.d195.s3	of	166	167	O
DDI-DrugBank.d195.s3	ARIMIDEX	184	191	B-brand
DDI-DrugBank.d195.s3	with	193	196	O
DDI-DrugBank.d195.s3	other	198	202	O
DDI-DrugBank.d195.s3	drugs	204	208	O
DDI-DrugBank.d195.s3	will	210	213	O
DDI-DrugBank.d195.s3	result	215	220	O
DDI-DrugBank.d195.s3	in	222	223	O
DDI-DrugBank.d195.s3	clinically	225	234	O
DDI-DrugBank.d195.s3	significant	236	246	O
DDI-DrugBank.d195.s3	drug	248	251	O
DDI-DrugBank.d195.s3	inhibition	253	262	O
DDI-DrugBank.d195.s3	of	264	265	O
DDI-DrugBank.d195.s3	cytochrome	267	276	O
DDI-DrugBank.d195.s3	P450-mediated	278	290	O
DDI-DrugBank.d195.s3	metabolism	292	301	O
DDI-DrugBank.d195.s3	of	264	265	O
DDI-DrugBank.d195.s3	the	306	308	O
DDI-DrugBank.d195.s3	other	310	314	O
DDI-DrugBank.d195.s3	drugs	316	320	O
DDI-DrugBank.d195.s3	.	321	321	O
DDI-DrugBank.d195.s4	An	0	1	O
DDI-DrugBank.d195.s4	interaction	3	13	O
DDI-DrugBank.d195.s4	study	15	19	O
DDI-DrugBank.d195.s4	with	21	24	O
DDI-DrugBank.d195.s4	warfarin	26	33	B-drug
DDI-DrugBank.d195.s4	showed	35	40	O
DDI-DrugBank.d195.s4	no	42	43	O
DDI-DrugBank.d195.s4	clinically	45	54	O
DDI-DrugBank.d195.s4	significant	56	66	O
DDI-DrugBank.d195.s4	effect	68	73	O
DDI-DrugBank.d195.s4	of	75	76	O
DDI-DrugBank.d195.s4	anastrozole	78	88	B-drug
DDI-DrugBank.d195.s4	on	90	91	O
DDI-DrugBank.d195.s4	warfarin	93	100	B-drug
DDI-DrugBank.d195.s4	pharmacokinetics	102	117	O
DDI-DrugBank.d195.s4	or	119	120	O
DDI-DrugBank.d195.s4	anticoagulant	122	134	O
DDI-DrugBank.d195.s4	activity	136	143	O
DDI-DrugBank.d195.s4	.	144	144	O
DDI-DrugBank.d195.s5	At	0	1	O
DDI-DrugBank.d195.s5	a	3	3	O
DDI-DrugBank.d195.s5	median	5	10	O
DDI-DrugBank.d195.s5	follow-up	12	20	O
DDI-DrugBank.d195.s5	of	22	23	O
DDI-DrugBank.d195.s5	33	25	26	O
DDI-DrugBank.d195.s5	months	28	33	O
DDI-DrugBank.d195.s5	,	34	34	O
DDI-DrugBank.d195.s5	the	36	38	O
DDI-DrugBank.d195.s5	combination	40	50	O
DDI-DrugBank.d195.s5	of	52	53	O
DDI-DrugBank.d195.s5	ARIMIDEX	55	62	B-brand
DDI-DrugBank.d195.s5	and	64	66	O
DDI-DrugBank.d195.s5	tamoxifen	68	76	B-drug
DDI-DrugBank.d195.s5	did	78	80	O
DDI-DrugBank.d195.s5	not	82	84	O
DDI-DrugBank.d195.s5	demonstrate	86	96	O
DDI-DrugBank.d195.s5	any	98	100	O
DDI-DrugBank.d195.s5	efficacy	102	109	O
DDI-DrugBank.d195.s5	benefit	111	117	O
DDI-DrugBank.d195.s5	when	119	122	O
DDI-DrugBank.d195.s5	compared	124	131	O
DDI-DrugBank.d195.s5	with	133	136	O
DDI-DrugBank.d195.s5	tamoxifen	138	146	B-drug
DDI-DrugBank.d195.s5	in	148	149	O
DDI-DrugBank.d195.s5	all	151	153	O
DDI-DrugBank.d195.s5	patients	155	162	O
DDI-DrugBank.d195.s5	as	164	165	O
DDI-DrugBank.d195.s5	well	167	170	O
DDI-DrugBank.d195.s5	as	164	165	O
DDI-DrugBank.d195.s5	in	148	149	O
DDI-DrugBank.d195.s5	the	178	180	O
DDI-DrugBank.d195.s5	hormone	182	188	O
DDI-DrugBank.d195.s5	receptor-positive	190	206	O
DDI-DrugBank.d195.s5	subpopulation	208	220	O
DDI-DrugBank.d195.s5	.	221	221	O
DDI-DrugBank.d195.s6	This	0	3	O
DDI-DrugBank.d195.s6	treatment	5	13	O
DDI-DrugBank.d195.s6	arm	15	17	O
DDI-DrugBank.d195.s6	was	19	21	O
DDI-DrugBank.d195.s6	discontinued	23	34	O
DDI-DrugBank.d195.s6	from	36	39	O
DDI-DrugBank.d195.s6	the	41	43	O
DDI-DrugBank.d195.s6	trial	45	49	O
DDI-DrugBank.d195.s6	.	50	50	O
DDI-DrugBank.d195.s7	Based	0	4	O
DDI-DrugBank.d195.s7	on	6	7	O
DDI-DrugBank.d195.s7	clinical	9	16	O
DDI-DrugBank.d195.s7	and	18	20	O
DDI-DrugBank.d195.s7	pharmacokinetic	22	36	O
DDI-DrugBank.d195.s7	results	38	44	O
DDI-DrugBank.d195.s7	from	46	49	O
DDI-DrugBank.d195.s7	the	51	53	O
DDI-DrugBank.d195.s7	ATAC	55	58	O
DDI-DrugBank.d195.s7	trial	60	64	O
DDI-DrugBank.d195.s7	,	65	65	O
DDI-DrugBank.d195.s7	tamoxifen	67	75	B-drug
DDI-DrugBank.d195.s7	should	77	82	O
DDI-DrugBank.d195.s7	not	84	86	O
DDI-DrugBank.d195.s7	be	88	89	O
DDI-DrugBank.d195.s7	administered	91	102	O
DDI-DrugBank.d195.s7	with	104	107	O
DDI-DrugBank.d195.s7	anastrozole	109	119	B-drug
DDI-DrugBank.d195.s7	(	121	121	O
DDI-DrugBank.d195.s7	see	122	124	O
DDI-DrugBank.d195.s7	CLINICAL	126	133	O
DDI-DrugBank.d195.s7	PHARMACOLOGY	135	146	O
DDI-DrugBank.d195.s7	Drug	150	153	O
DDI-DrugBank.d195.s7	Interactions	155	166	O
DDI-DrugBank.d195.s7	and	168	170	O
DDI-DrugBank.d195.s7	CLINICAL	172	179	O
DDI-DrugBank.d195.s7	PHARMACOLOGY	181	192	O
DDI-DrugBank.d195.s7	-	194	194	O
DDI-DrugBank.d195.s7	Clinical	196	203	O
DDI-DrugBank.d195.s7	Studies	205	211	O
DDI-DrugBank.d195.s7	-	194	194	O
DDI-DrugBank.d195.s7	Adjuvant	215	222	O
DDI-DrugBank.d195.s7	Treatment	224	232	O
DDI-DrugBank.d195.s7	of	234	235	O
DDI-DrugBank.d195.s7	Breast	237	242	O
DDI-DrugBank.d195.s7	Cancer	244	249	O
DDI-DrugBank.d195.s7	in	251	252	O
DDI-DrugBank.d195.s7	Postmenopausal	254	267	O
DDI-DrugBank.d195.s7	Women	269	273	O
DDI-DrugBank.d195.s7	subsections	275	285	O
DDI-DrugBank.d195.s7	)	286	286	O
DDI-DrugBank.d195.s7	.	287	287	O
DDI-DrugBank.d195.s8	Co-administration	0	16	O
DDI-DrugBank.d195.s8	of	18	19	O
DDI-DrugBank.d195.s8	anastrozole	21	31	B-drug
DDI-DrugBank.d195.s8	and	33	35	O
DDI-DrugBank.d195.s8	tamoxifen	37	45	B-drug
DDI-DrugBank.d195.s8	resulted	47	54	O
DDI-DrugBank.d195.s8	in	56	57	O
DDI-DrugBank.d195.s8	a	59	59	O
DDI-DrugBank.d195.s8	reduction	61	69	O
DDI-DrugBank.d195.s8	of	71	72	O
DDI-DrugBank.d195.s8	anastrozole	74	84	B-drug
DDI-DrugBank.d195.s8	plasma	86	91	O
DDI-DrugBank.d195.s8	levels	93	98	O
DDI-DrugBank.d195.s8	by	100	101	O
DDI-DrugBank.d195.s8	27	103	104	O
DDI-DrugBank.d195.s8	%	105	105	O
DDI-DrugBank.d195.s8	compared	107	114	O
DDI-DrugBank.d195.s8	with	116	119	O
DDI-DrugBank.d195.s8	those	121	125	O
DDI-DrugBank.d195.s8	achieved	127	134	O
DDI-DrugBank.d195.s8	with	136	139	O
DDI-DrugBank.d195.s8	anastrozole	141	151	B-drug
DDI-DrugBank.d195.s8	alone	153	157	O
DDI-DrugBank.d195.s8	.	158	158	O
DDI-DrugBank.d195.s9	Estrogen-containing	0	18	O
DDI-DrugBank.d195.s9	therapies	20	28	O
DDI-DrugBank.d195.s9	should	30	35	O
DDI-DrugBank.d195.s9	not	37	39	O
DDI-DrugBank.d195.s9	be	41	42	O
DDI-DrugBank.d195.s9	used	44	47	O
DDI-DrugBank.d195.s9	with	49	52	O
DDI-DrugBank.d195.s9	ARIMIDEX	54	61	B-brand
DDI-DrugBank.d195.s9	as	63	64	O
DDI-DrugBank.d195.s9	they	66	69	O
DDI-DrugBank.d195.s9	may	71	73	O
DDI-DrugBank.d195.s9	diminish	75	82	O
DDI-DrugBank.d195.s9	its	84	86	O
DDI-DrugBank.d195.s9	pharmacologic	88	100	O
DDI-DrugBank.d195.s9	action	102	107	O
DDI-DrugBank.d195.s9	.	108	108	O
DDI-DrugBank.d195.s10	Drug/Laboratory	0	14	O
DDI-DrugBank.d195.s10	Test	16	19	O
DDI-DrugBank.d195.s10	Interactions	21	32	O
DDI-DrugBank.d195.s10	No	34	35	O
DDI-DrugBank.d195.s10	clinically	37	46	O
DDI-DrugBank.d195.s10	significant	48	58	O
DDI-DrugBank.d195.s10	changes	60	66	O
DDI-DrugBank.d195.s10	in	68	69	O
DDI-DrugBank.d195.s10	the	71	73	O
DDI-DrugBank.d195.s10	results	75	81	O
DDI-DrugBank.d195.s10	of	83	84	O
DDI-DrugBank.d195.s10	clinical	86	93	O
DDI-DrugBank.d195.s10	laboratory	95	104	O
DDI-DrugBank.d195.s10	tests	106	110	O
DDI-DrugBank.d195.s10	have	112	115	O
DDI-DrugBank.d195.s10	been	117	120	O
DDI-DrugBank.d195.s10	observed	122	129	O
DDI-DrugBank.d195.s11	.	0	0	O
DDI-DrugBank.d469.s0	Drugs	0	4	O
DDI-DrugBank.d469.s0	which	6	10	O
DDI-DrugBank.d469.s0	may	12	14	O
DDI-DrugBank.d469.s0	enhance	16	22	O
DDI-DrugBank.d469.s0	the	24	26	O
DDI-DrugBank.d469.s0	neuromuscular	28	40	O
DDI-DrugBank.d469.s0	blocking	42	49	O
DDI-DrugBank.d469.s0	action	51	56	O
DDI-DrugBank.d469.s0	of	58	59	O
DDI-DrugBank.d469.s0	TRACRIUM	61	68	B-brand
DDI-DrugBank.d469.s0	include	70	76	O
DDI-DrugBank.d469.s0	:	77	77	O
DDI-DrugBank.d469.s0	enflurane	79	87	B-drug
DDI-DrugBank.d469.s0	;	88	88	O
DDI-DrugBank.d469.s1	isoflurane	0	9	B-drug
DDI-DrugBank.d469.s1	;	10	10	O
DDI-DrugBank.d469.s2	halothane	0	8	B-drug
DDI-DrugBank.d469.s2	;	9	9	O
DDI-DrugBank.d469.s3	certain	0	6	O
DDI-DrugBank.d469.s3	antibiotics	8	18	B-group
DDI-DrugBank.d469.s3	,	19	19	O
DDI-DrugBank.d469.s3	especially	21	30	O
DDI-DrugBank.d469.s3	the	32	34	O
DDI-DrugBank.d469.s3	aminoglycosides	36	50	B-group
DDI-DrugBank.d469.s3	and	52	54	O
DDI-DrugBank.d469.s3	polymyxins	56	65	B-group
DDI-DrugBank.d469.s3	;	66	66	O
DDI-DrugBank.d469.s4	lithium	0	6	B-drug
DDI-DrugBank.d469.s4	;	7	7	O
DDI-DrugBank.d469.s5	magnesium	0	8	B-drug
DDI-DrugBank.d469.s5	salts	10	14	O
DDI-DrugBank.d469.s5	;	15	15	O
DDI-DrugBank.d469.s6	procainamide	0	11	B-drug
DDI-DrugBank.d469.s6	;	12	12	O
DDI-DrugBank.d469.s7	Drugs	0	4	O
DDI-DrugBank.d469.s7	which	6	10	O
DDI-DrugBank.d469.s7	may	12	14	O
DDI-DrugBank.d469.s7	enhance	16	22	O
DDI-DrugBank.d469.s7	the	24	26	O
DDI-DrugBank.d469.s7	neuromuscular	28	40	O
DDI-DrugBank.d469.s7	blocking	42	49	O
DDI-DrugBank.d469.s7	action	51	56	O
DDI-DrugBank.d469.s7	of	58	59	O
DDI-DrugBank.d469.s7	TRACRIUM	61	68	B-brand
DDI-DrugBank.d469.s7	include	70	76	O
DDI-DrugBank.d469.s7	:	77	77	O
DDI-DrugBank.d469.s7	enflurane	79	87	B-drug
DDI-DrugBank.d469.s7	;	88	88	O
DDI-DrugBank.d469.s7	isoflurane	89	98	B-drug
DDI-DrugBank.d469.s7	;	88	88	O
DDI-DrugBank.d469.s7	halothane	100	108	B-drug
DDI-DrugBank.d469.s7	;	99	99	O
DDI-DrugBank.d469.s7	certain	110	116	O
DDI-DrugBank.d469.s7	antibiotics	118	128	B-group
DDI-DrugBank.d469.s7	,	129	129	O
DDI-DrugBank.d469.s7	especially	131	140	O
DDI-DrugBank.d469.s7	the	142	144	O
DDI-DrugBank.d469.s7	aminoglycosides	146	160	B-group
DDI-DrugBank.d469.s7	and	162	164	O
DDI-DrugBank.d469.s7	polymyxins	166	175	B-group
DDI-DrugBank.d469.s7	;	176	176	O
DDI-DrugBank.d469.s7	lithium	177	183	B-drug
DDI-DrugBank.d469.s7	;	176	176	O
DDI-DrugBank.d469.s7	magnesium	185	193	B-drug
DDI-DrugBank.d469.s7	salts	195	199	O
DDI-DrugBank.d469.s7	;	184	184	O
DDI-DrugBank.d469.s7	procainamide	201	212	B-drug
DDI-DrugBank.d469.s7	;	200	200	O
DDI-DrugBank.d469.s7	and	214	216	O
DDI-DrugBank.d469.s7	quinidine	218	226	B-drug
DDI-DrugBank.d469.s7	.	227	227	O
DDI-DrugBank.d469.s8	If	0	1	O
DDI-DrugBank.d469.s8	other	3	7	O
DDI-DrugBank.d469.s8	muscle	9	14	B-group
DDI-DrugBank.d469.s8	relaxants	16	24	I-group
DDI-DrugBank.d469.s8	are	26	28	O
DDI-DrugBank.d469.s8	used	30	33	O
DDI-DrugBank.d469.s8	during	35	40	O
DDI-DrugBank.d469.s8	the	42	44	O
DDI-DrugBank.d469.s8	same	46	49	O
DDI-DrugBank.d469.s8	procedure	51	59	O
DDI-DrugBank.d469.s8	,	60	60	O
DDI-DrugBank.d469.s8	the	62	64	O
DDI-DrugBank.d469.s8	possibility	66	76	O
DDI-DrugBank.d469.s8	of	78	79	O
DDI-DrugBank.d469.s8	a	81	81	O
DDI-DrugBank.d469.s8	synergistic	83	93	O
DDI-DrugBank.d469.s8	or	95	96	O
DDI-DrugBank.d469.s8	antagonist	98	107	O
DDI-DrugBank.d469.s8	effect	109	114	O
DDI-DrugBank.d469.s8	should	116	121	O
DDI-DrugBank.d469.s8	be	123	124	O
DDI-DrugBank.d469.s8	considered	126	135	O
DDI-DrugBank.d469.s8	.	136	136	O
DDI-DrugBank.d469.s9	The	0	2	O
DDI-DrugBank.d469.s9	prior	4	8	O
DDI-DrugBank.d469.s9	administration	10	23	O
DDI-DrugBank.d469.s9	of	25	26	O
DDI-DrugBank.d469.s9	succinylcholine	28	42	B-drug
DDI-DrugBank.d469.s9	does	44	47	O
DDI-DrugBank.d469.s9	not	49	51	O
DDI-DrugBank.d469.s9	enhance	53	59	O
DDI-DrugBank.d469.s9	the	61	63	O
DDI-DrugBank.d469.s9	duration	65	72	O
DDI-DrugBank.d469.s9	,	73	73	O
DDI-DrugBank.d469.s9	but	75	77	O
DDI-DrugBank.d469.s9	quickens	79	86	O
DDI-DrugBank.d469.s9	the	88	90	O
DDI-DrugBank.d469.s9	onset	92	96	O
DDI-DrugBank.d469.s9	and	98	100	O
DDI-DrugBank.d469.s9	may	102	104	O
DDI-DrugBank.d469.s9	increase	106	113	O
DDI-DrugBank.d469.s9	the	115	117	O
DDI-DrugBank.d469.s9	depth	119	123	O
DDI-DrugBank.d469.s9	,	124	124	O
DDI-DrugBank.d469.s9	of	126	127	O
DDI-DrugBank.d469.s9	neuromuscular	129	141	O
DDI-DrugBank.d469.s9	block	143	147	O
DDI-DrugBank.d469.s9	induced	149	155	O
DDI-DrugBank.d469.s9	by	157	158	O
DDI-DrugBank.d469.s9	TRACRIUM	160	167	B-brand
DDI-DrugBank.d469.s9	.	168	168	O
DDI-DrugBank.d469.s10	TRACRIUM	0	7	B-brand
DDI-DrugBank.d469.s10	should	9	14	O
DDI-DrugBank.d469.s10	not	16	18	O
DDI-DrugBank.d469.s10	be	20	21	O
DDI-DrugBank.d469.s10	administered	23	34	O
DDI-DrugBank.d469.s10	until	36	40	O
DDI-DrugBank.d469.s10	a	42	42	O
DDI-DrugBank.d469.s10	patient	44	50	O
DDI-DrugBank.d469.s10	has	52	54	O
DDI-DrugBank.d469.s10	recovered	56	64	O
DDI-DrugBank.d469.s10	from	66	69	O
DDI-DrugBank.d469.s10	succinylcholine-induced	71	93	O
DDI-DrugBank.d469.s10	neuromuscular	95	107	O
DDI-DrugBank.d469.s10	block	109	113	O
DDI-DrugBank.d469.s10	.	114	114	O
DDI-DrugBank.d146.s0	Colchicine	0	9	B-drug
DDI-DrugBank.d146.s0	is	11	12	O
DDI-DrugBank.d146.s0	inhibited	14	22	O
DDI-DrugBank.d146.s0	by	24	25	O
DDI-DrugBank.d146.s0	acidifying	27	36	B-group
DDI-DrugBank.d146.s0	agents	38	43	I-group
DDI-DrugBank.d146.s0	.	44	44	O
DDI-DrugBank.d146.s1	The	0	2	O
DDI-DrugBank.d146.s1	action	4	9	O
DDI-DrugBank.d146.s1	of	11	12	O
DDI-DrugBank.d146.s1	colchicine	14	23	B-drug
DDI-DrugBank.d146.s1	is	25	26	O
DDI-DrugBank.d146.s1	potentiated	28	38	O
DDI-DrugBank.d146.s1	by	40	41	O
DDI-DrugBank.d146.s1	alkalinizing	43	54	B-group
DDI-DrugBank.d146.s1	agents	56	61	I-group
DDI-DrugBank.d146.s1	.	62	62	O
DDI-DrugBank.d146.s2	Colchicine	0	9	B-drug
DDI-DrugBank.d146.s2	may	11	13	O
DDI-DrugBank.d146.s2	increase	15	22	O
DDI-DrugBank.d146.s2	sensitivity	24	34	O
DDI-DrugBank.d146.s2	to	36	37	O
DDI-DrugBank.d146.s2	the	39	41	O
DDI-DrugBank.d146.s2	CNS	43	45	B-group
DDI-DrugBank.d146.s2	depressants	47	57	I-group
DDI-DrugBank.d146.s2	.	58	58	O
DDI-DrugBank.d146.s3	Response	0	7	O
DDI-DrugBank.d146.s3	to	9	10	O
DDI-DrugBank.d146.s3	sympathomimetic	12	26	B-group
DDI-DrugBank.d146.s3	agents	28	33	I-group
DDI-DrugBank.d146.s3	may	35	37	O
DDI-DrugBank.d146.s3	be	39	40	O
DDI-DrugBank.d146.s3	enhanced	42	49	O
DDI-DrugBank.d146.s3	by	51	52	O
DDI-DrugBank.d146.s3	colchicine	54	63	B-drug
DDI-DrugBank.d146.s3	.	64	64	O
DDI-MedLine.d27.s0	[	0	0	O
DDI-MedLine.d27.s0	The	1	3	O
DDI-MedLine.d27.s0	GABA-ergic	5	14	O
DDI-MedLine.d27.s0	system	16	21	O
DDI-MedLine.d27.s0	and	23	25	O
DDI-MedLine.d27.s0	brain	27	31	O
DDI-MedLine.d27.s0	edema	33	37	O
DDI-MedLine.d27.s0	]	38	38	O
DDI-MedLine.d27.s0	It	41	42	O
DDI-MedLine.d27.s0	has	44	46	O
DDI-MedLine.d27.s0	been	48	51	O
DDI-MedLine.d27.s0	shown	53	57	O
DDI-MedLine.d27.s0	in	59	60	O
DDI-MedLine.d27.s0	rats	62	65	O
DDI-MedLine.d27.s0	with	67	70	O
DDI-MedLine.d27.s0	experimental	72	83	O
DDI-MedLine.d27.s0	toxic	85	89	O
DDI-MedLine.d27.s0	and	91	93	O
DDI-MedLine.d27.s0	traumatic	95	103	O
DDI-MedLine.d27.s0	edemas	105	110	O
DDI-MedLine.d27.s0	that	112	115	O
DDI-MedLine.d27.s0	picrotoxin	117	126	B-drug_n
DDI-MedLine.d27.s0	(	128	128	O
DDI-MedLine.d27.s0	1	129	129	O
DDI-MedLine.d27.s0	mg/kg	131	135	O
DDI-MedLine.d27.s0	)	136	136	O
DDI-MedLine.d27.s0	removes	138	144	O
DDI-MedLine.d27.s0	the	146	148	O
DDI-MedLine.d27.s0	antiedematous	150	162	O
DDI-MedLine.d27.s0	action	164	169	O
DDI-MedLine.d27.s0	of	171	172	O
DDI-MedLine.d27.s0	diazepam	174	181	B-drug
DDI-MedLine.d27.s0	,	182	182	O
DDI-MedLine.d27.s0	phenazepam	184	193	B-drug_n
DDI-MedLine.d27.s0	,	182	182	O
DDI-MedLine.d27.s0	phenibut	196	203	B-drug_n
DDI-MedLine.d27.s0	and	205	207	O
DDI-MedLine.d27.s0	amizyl	209	214	B-drug_n
DDI-MedLine.d27.s0	and	205	207	O
DDI-MedLine.d27.s0	reduces	220	226	O
DDI-MedLine.d27.s0	the	228	230	O
DDI-MedLine.d27.s0	action	232	237	O
DDI-MedLine.d27.s0	of	239	240	O
DDI-MedLine.d27.s0	phentolamine	242	253	B-drug
DDI-MedLine.d27.s0	.	254	254	O
DDI-MedLine.d27.s1	When	0	3	O
DDI-MedLine.d27.s1	the	5	7	O
DDI-MedLine.d27.s1	dose	9	12	O
DDI-MedLine.d27.s1	of	14	15	O
DDI-MedLine.d27.s1	picrotoxin	17	26	B-drug_n
DDI-MedLine.d27.s1	is	28	29	O
DDI-MedLine.d27.s1	minimized	31	39	O
DDI-MedLine.d27.s1	to	41	42	O
DDI-MedLine.d27.s1	0.5	44	46	O
DDI-MedLine.d27.s1	mg/kg	48	52	O
DDI-MedLine.d27.s1	such	54	57	O
DDI-MedLine.d27.s1	an	59	60	O
DDI-MedLine.d27.s1	effect	62	67	O
DDI-MedLine.d27.s1	is	69	70	O
DDI-MedLine.d27.s1	not	72	74	O
DDI-MedLine.d27.s1	observed	76	83	O
DDI-MedLine.d27.s1	.	84	84	O
DDI-MedLine.d27.s2	Prolonged	0	8	O
DDI-MedLine.d27.s2	daily	10	14	O
DDI-MedLine.d27.s2	administration	16	29	O
DDI-MedLine.d27.s2	of	31	32	O
DDI-MedLine.d27.s2	picrotoxin	34	43	B-drug_n
DDI-MedLine.d27.s2	in	42	43	I-drug_n
DDI-MedLine.d27.s2	a	48	48	O
DDI-MedLine.d27.s2	dose	50	53	O
DDI-MedLine.d27.s2	of	55	56	O
DDI-MedLine.d27.s2	1	58	58	O
DDI-MedLine.d27.s2	mg/kg	60	64	O
DDI-MedLine.d27.s2	results	66	72	O
DDI-MedLine.d27.s2	in	74	75	O
DDI-MedLine.d27.s2	the	77	79	O
DDI-MedLine.d27.s2	development	81	91	O
DDI-MedLine.d27.s2	of	93	94	O
DDI-MedLine.d27.s2	brain	96	100	O
DDI-MedLine.d27.s2	edema	102	106	O
DDI-MedLine.d27.s2	.	107	107	O
DDI-MedLine.d27.s3	It	0	1	O
DDI-MedLine.d27.s3	is	3	4	O
DDI-MedLine.d27.s3	recommended	6	16	O
DDI-MedLine.d27.s3	that	18	21	O
DDI-MedLine.d27.s3	GABA-positive	23	35	O
DDI-MedLine.d27.s3	drugs	37	41	O
DDI-MedLine.d27.s3	be	43	44	O
DDI-MedLine.d27.s3	included	46	53	O
DDI-MedLine.d27.s3	into	55	58	O
DDI-MedLine.d27.s3	a	60	60	O
DDI-MedLine.d27.s3	complex	62	68	O
DDI-MedLine.d27.s3	of	70	71	O
DDI-MedLine.d27.s3	treatment	73	81	O
DDI-MedLine.d27.s3	measures	83	90	O
DDI-MedLine.d27.s3	for	92	94	O
DDI-MedLine.d27.s3	edema	96	100	O
DDI-MedLine.d27.s3	.	101	101	O
DDI-DrugBank.d92.s0	No	0	1	O
DDI-DrugBank.d92.s0	well-known	3	12	O
DDI-DrugBank.d92.s0	drug	14	17	O
DDI-DrugBank.d92.s0	interactions	19	30	O
DDI-DrugBank.d92.s0	with	32	35	O
DDI-DrugBank.d92.s0	glutamic	37	44	B-drug
DDI-DrugBank.d92.s0	acid	46	49	I-drug
DDI-DrugBank.d743.s0	Ketoconazole	0	11	B-drug
DDI-DrugBank.d743.s0	:	12	12	O
DDI-DrugBank.d743.s0	Spontaneous	14	24	O
DDI-DrugBank.d743.s0	adverse	26	32	O
DDI-DrugBank.d743.s0	reaction	34	41	O
DDI-DrugBank.d743.s0	reports	43	49	O
DDI-DrugBank.d743.s0	of	51	52	O
DDI-DrugBank.d743.s0	patients	54	61	O
DDI-DrugBank.d743.s0	taking	63	68	O
DDI-DrugBank.d743.s0	concomitant	70	80	O
DDI-DrugBank.d743.s0	ketoconazole	82	93	B-drug
DDI-DrugBank.d743.s0	with	95	98	O
DDI-DrugBank.d743.s0	recommended	100	110	O
DDI-DrugBank.d743.s0	doses	112	116	O
DDI-DrugBank.d743.s0	of	118	119	O
DDI-DrugBank.d743.s0	terfenadine	121	131	B-drug
DDI-DrugBank.d743.s0	demonstrate	133	143	O
DDI-DrugBank.d743.s0	QT	145	146	O
DDI-DrugBank.d743.s0	interval	148	155	O
DDI-DrugBank.d743.s0	prolongation	157	168	O
DDI-DrugBank.d743.s0	and	170	172	O
DDI-DrugBank.d743.s0	rare	174	177	O
DDI-DrugBank.d743.s0	serious	179	185	O
DDI-DrugBank.d743.s0	cardiac	187	193	O
DDI-DrugBank.d743.s0	events	195	200	O
DDI-DrugBank.d743.s0	,	201	201	O
DDI-DrugBank.d743.s0	e.g	203	205	O
DDI-DrugBank.d743.s0	.	204	204	O
DDI-DrugBank.d743.s1	death	0	4	O
DDI-DrugBank.d743.s1	,	5	5	O
DDI-DrugBank.d743.s1	cardiac	7	13	O
DDI-DrugBank.d743.s1	arrest	15	20	O
DDI-DrugBank.d743.s1	,	21	21	O
DDI-DrugBank.d743.s1	and	23	25	O
DDI-DrugBank.d743.s1	ventricular	27	37	O
DDI-DrugBank.d743.s1	arrhythmia	39	48	O
DDI-DrugBank.d743.s1	including	50	58	O
DDI-DrugBank.d743.s1	torsades	60	67	O
DDI-DrugBank.d743.s1	de	65	66	O
DDI-DrugBank.d743.s1	pointes	72	78	O
DDI-DrugBank.d743.s1	.	79	79	O
DDI-DrugBank.d743.s2	Pharmacokinetic	0	14	O
DDI-DrugBank.d743.s2	data	16	19	O
DDI-DrugBank.d743.s2	indicate	21	28	O
DDI-DrugBank.d743.s2	that	30	33	O
DDI-DrugBank.d743.s2	ketoconazole	35	46	B-drug
DDI-DrugBank.d743.s2	markedly	48	55	O
DDI-DrugBank.d743.s2	inhibits	57	64	O
DDI-DrugBank.d743.s2	the	66	68	O
DDI-DrugBank.d743.s2	metabolism	70	79	O
DDI-DrugBank.d743.s2	of	81	82	O
DDI-DrugBank.d743.s2	terfenadine	84	94	B-drug
DDI-DrugBank.d743.s2	,	95	95	O
DDI-DrugBank.d743.s2	resulting	97	105	O
DDI-DrugBank.d743.s2	in	103	104	O
DDI-DrugBank.d743.s2	elevated	110	117	O
DDI-DrugBank.d743.s2	plasma	119	124	O
DDI-DrugBank.d743.s2	terfenadine	126	136	B-drug
DDI-DrugBank.d743.s2	levels	138	143	O
DDI-DrugBank.d743.s2	.	144	144	O
DDI-DrugBank.d743.s3	Presence	0	7	O
DDI-DrugBank.d743.s3	of	9	10	O
DDI-DrugBank.d743.s3	unchanged	12	20	O
DDI-DrugBank.d743.s3	terfenadine	22	32	B-drug
DDI-DrugBank.d743.s3	is	34	35	O
DDI-DrugBank.d743.s3	associated	37	46	O
DDI-DrugBank.d743.s3	with	48	51	O
DDI-DrugBank.d743.s3	statistically	53	65	O
DDI-DrugBank.d743.s3	significant	67	77	O
DDI-DrugBank.d743.s3	prolongation	79	90	O
DDI-DrugBank.d743.s3	of	92	93	O
DDI-DrugBank.d743.s3	the	95	97	O
DDI-DrugBank.d743.s3	QT	99	100	O
DDI-DrugBank.d743.s3	and	102	104	O
DDI-DrugBank.d743.s3	QTc	106	108	O
DDI-DrugBank.d743.s3	intervals	110	118	O
DDI-DrugBank.d743.s3	.	119	119	O
DDI-DrugBank.d743.s4	Concomitant	0	10	O
DDI-DrugBank.d743.s4	administration	12	25	O
DDI-DrugBank.d743.s4	of	27	28	O
DDI-DrugBank.d743.s4	ketoconazole	30	41	B-drug
DDI-DrugBank.d743.s4	and	43	45	O
DDI-DrugBank.d743.s4	terfenadine	47	57	B-drug
DDI-DrugBank.d743.s4	is	59	60	O
DDI-DrugBank.d743.s4	contraindicated	62	76	O
DDI-DrugBank.d743.s4	.	77	77	O
DDI-DrugBank.d743.s5	Itraconazole	0	11	B-drug
DDI-DrugBank.d743.s5	:	12	12	O
DDI-DrugBank.d743.s5	Torsades	14	21	O
DDI-DrugBank.d743.s5	de	23	24	O
DDI-DrugBank.d743.s5	pointes	26	32	O
DDI-DrugBank.d743.s5	and	34	36	O
DDI-DrugBank.d743.s5	elevated	38	45	O
DDI-DrugBank.d743.s5	parent	47	52	O
DDI-DrugBank.d743.s5	terfenadine	54	64	B-drug
DDI-DrugBank.d743.s5	levels	66	71	O
DDI-DrugBank.d743.s5	have	73	76	O
DDI-DrugBank.d743.s5	been	78	81	O
DDI-DrugBank.d743.s5	reported	83	90	O
DDI-DrugBank.d743.s5	during	92	97	O
DDI-DrugBank.d743.s5	concomitant	99	109	O
DDI-DrugBank.d743.s5	use	111	113	O
DDI-DrugBank.d743.s5	of	115	116	O
DDI-DrugBank.d743.s5	terfenadine	118	128	B-drug
DDI-DrugBank.d743.s5	and	130	132	O
DDI-DrugBank.d743.s5	itraconazole	134	145	B-drug
DDI-DrugBank.d743.s5	in	147	148	O
DDI-DrugBank.d743.s5	clinical	150	157	O
DDI-DrugBank.d743.s5	trials	159	164	O
DDI-DrugBank.d743.s5	of	166	167	O
DDI-DrugBank.d743.s5	itraconazole	169	180	B-drug
DDI-DrugBank.d743.s5	and	182	184	O
DDI-DrugBank.d743.s5	from	186	189	O
DDI-DrugBank.d743.s5	foreign	191	197	O
DDI-DrugBank.d743.s5	post-marketing	199	212	O
DDI-DrugBank.d743.s5	sources	214	220	O
DDI-DrugBank.d743.s5	.	221	221	O
DDI-DrugBank.d743.s6	One	0	2	O
DDI-DrugBank.d743.s6	death	4	8	O
DDI-DrugBank.d743.s6	has	10	12	O
DDI-DrugBank.d743.s6	also	14	17	O
DDI-DrugBank.d743.s6	been	19	22	O
DDI-DrugBank.d743.s6	reported	24	31	O
DDI-DrugBank.d743.s6	from	33	36	O
DDI-DrugBank.d743.s6	foreign	38	44	O
DDI-DrugBank.d743.s6	post-	46	50	O
DDI-DrugBank.d743.s6	marketing	52	60	O
DDI-DrugBank.d743.s6	sources	62	68	O
DDI-DrugBank.d743.s6	.	69	69	O
DDI-DrugBank.d743.s7	Concomitant	0	10	O
DDI-DrugBank.d743.s7	administration	12	25	O
DDI-DrugBank.d743.s7	of	27	28	O
DDI-DrugBank.d743.s7	itraconazole	30	41	B-drug
DDI-DrugBank.d743.s7	and	43	45	O
DDI-DrugBank.d743.s7	terfenadine	47	57	B-drug
DDI-DrugBank.d743.s7	is	59	60	O
DDI-DrugBank.d743.s7	contraindicated	62	76	O
DDI-DrugBank.d743.s7	.	77	77	O
DDI-DrugBank.d743.s8	Due	0	2	O
DDI-DrugBank.d743.s8	to	4	5	O
DDI-DrugBank.d743.s8	the	7	9	O
DDI-DrugBank.d743.s8	chemical	11	18	O
DDI-DrugBank.d743.s8	similarity	20	29	O
DDI-DrugBank.d743.s8	of	31	32	O
DDI-DrugBank.d743.s8	other	34	38	O
DDI-DrugBank.d743.s8	azole-type	40	49	B-group
DDI-DrugBank.d743.s8	antifungal	51	60	I-group
DDI-DrugBank.d743.s8	agents	62	67	I-group
DDI-DrugBank.d743.s8	(	69	69	O
DDI-DrugBank.d743.s8	including	70	78	O
DDI-DrugBank.d743.s8	fluconazole	80	90	B-drug
DDI-DrugBank.d743.s8	,	91	91	O
DDI-DrugBank.d743.s8	metronidazole	93	105	B-drug
DDI-DrugBank.d743.s8	,	106	106	O
DDI-DrugBank.d743.s8	and	108	110	O
DDI-DrugBank.d743.s8	miconazole	112	121	B-drug
DDI-DrugBank.d743.s8	)	122	122	O
DDI-DrugBank.d743.s8	to	124	125	O
DDI-DrugBank.d743.s8	ketoconazole	127	138	B-drug
DDI-DrugBank.d743.s8	,	139	139	O
DDI-DrugBank.d743.s8	and	141	143	O
DDI-DrugBank.d743.s8	itraconazole	145	156	B-drug
DDI-DrugBank.d743.s8	,	139	139	O
DDI-DrugBank.d743.s8	concomitant	159	169	O
DDI-DrugBank.d743.s8	use	171	173	O
DDI-DrugBank.d743.s8	of	175	176	O
DDI-DrugBank.d743.s8	these	178	182	O
DDI-DrugBank.d743.s8	products	184	191	O
DDI-DrugBank.d743.s8	with	193	196	O
DDI-DrugBank.d743.s8	terfenadine	198	208	B-drug
DDI-DrugBank.d743.s8	is	210	211	O
DDI-DrugBank.d743.s8	not	213	215	O
DDI-DrugBank.d743.s8	recommended	217	227	O
DDI-DrugBank.d743.s8	pending	229	235	O
DDI-DrugBank.d743.s8	full	237	240	O
DDI-DrugBank.d743.s8	examination	242	252	O
DDI-DrugBank.d743.s8	of	254	255	O
DDI-DrugBank.d743.s8	potential	257	265	O
DDI-DrugBank.d743.s8	interactions	267	278	O
DDI-DrugBank.d743.s8	.	279	279	O
DDI-DrugBank.d743.s9	Macrolides	0	9	B-group
DDI-DrugBank.d743.s9	:	10	10	O
DDI-DrugBank.d743.s9	Clinical	12	19	O
DDI-DrugBank.d743.s9	drug	21	24	O
DDI-DrugBank.d743.s9	interaction	26	36	O
DDI-DrugBank.d743.s9	studies	38	44	O
DDI-DrugBank.d743.s9	indicate	46	53	O
DDI-DrugBank.d743.s9	that	55	58	O
DDI-DrugBank.d743.s9	erythromycin	60	71	B-drug
DDI-DrugBank.d743.s9	and	73	75	O
DDI-DrugBank.d743.s9	clarithromycin	77	90	B-drug
DDI-DrugBank.d743.s9	can	92	94	O
DDI-DrugBank.d743.s9	exert	96	100	O
DDI-DrugBank.d743.s9	an	93	94	O
DDI-DrugBank.d743.s9	effect	105	110	O
DDI-DrugBank.d743.s9	on	112	113	O
DDI-DrugBank.d743.s9	terfenadine	115	125	B-drug
DDI-DrugBank.d743.s9	metabolism	127	136	O
DDI-DrugBank.d743.s9	by	138	139	O
DDI-DrugBank.d743.s9	a	130	130	O
DDI-DrugBank.d743.s9	mechanism	143	151	O
DDI-DrugBank.d743.s9	which	153	157	O
DDI-DrugBank.d743.s9	may	159	161	O
DDI-DrugBank.d743.s9	be	163	164	O
DDI-DrugBank.d743.s9	similar	166	172	O
DDI-DrugBank.d743.s9	to	174	175	O
DDI-DrugBank.d743.s9	that	177	180	O
DDI-DrugBank.d743.s9	of	182	183	O
DDI-DrugBank.d743.s9	ketoconazole	185	196	B-drug
DDI-DrugBank.d743.s9	,	197	197	O
DDI-DrugBank.d743.s9	but	199	201	O
DDI-DrugBank.d743.s9	to	174	175	O
DDI-DrugBank.d743.s9	a	179	179	O
DDI-DrugBank.d743.s9	lesser	208	213	O
DDI-DrugBank.d743.s9	extent	215	220	O
DDI-DrugBank.d743.s9	.	221	221	O
DDI-DrugBank.d743.s10	Although	0	7	O
DDI-DrugBank.d743.s10	erythromycin	9	20	O
DDI-DrugBank.d743.s10	measurably	22	31	O
DDI-DrugBank.d743.s10	decreases	33	41	O
DDI-DrugBank.d743.s10	the	43	45	O
DDI-DrugBank.d743.s10	clearance	47	55	O
DDI-DrugBank.d743.s10	of	57	58	O
DDI-DrugBank.d743.s10	the	60	62	O
DDI-DrugBank.d743.s10	terfenadine	64	74	B-drug
DDI-DrugBank.d743.s10	acid	76	79	O
DDI-DrugBank.d743.s10	metabolite	81	90	O
DDI-DrugBank.d743.s10	,	91	91	O
DDI-DrugBank.d743.s10	its	93	95	O
DDI-DrugBank.d743.s10	influence	97	105	O
DDI-DrugBank.d743.s10	on	107	108	O
DDI-DrugBank.d743.s10	terfenadine	110	120	O
DDI-DrugBank.d743.s10	plasma	122	127	O
DDI-DrugBank.d743.s10	levels	129	134	O
DDI-DrugBank.d743.s10	is	136	137	O
DDI-DrugBank.d743.s10	still	139	143	O
DDI-DrugBank.d743.s10	under	145	149	O
DDI-DrugBank.d743.s10	investigation	151	163	O
DDI-DrugBank.d743.s10	.	164	164	O
DDI-DrugBank.d743.s11	A	0	0	O
DDI-DrugBank.d743.s11	few	2	4	O
DDI-DrugBank.d743.s11	spontaneous	6	16	O
DDI-DrugBank.d743.s11	accounts	18	25	O
DDI-DrugBank.d743.s11	of	27	28	O
DDI-DrugBank.d743.s11	QT	30	31	O
DDI-DrugBank.d743.s11	interval	33	40	O
DDI-DrugBank.d743.s11	prolongation	42	53	O
DDI-DrugBank.d743.s11	with	55	58	O
DDI-DrugBank.d743.s11	ventricular	60	70	O
DDI-DrugBank.d743.s11	arrhythmia	72	81	O
DDI-DrugBank.d743.s11	including	83	91	O
DDI-DrugBank.d743.s11	torsades	93	100	O
DDI-DrugBank.d743.s11	de	98	99	O
DDI-DrugBank.d743.s11	pointes	105	111	O
DDI-DrugBank.d743.s11	,	112	112	O
DDI-DrugBank.d743.s11	have	114	117	O
DDI-DrugBank.d743.s11	been	119	122	O
DDI-DrugBank.d743.s11	reported	124	131	O
DDI-DrugBank.d743.s11	in	133	134	O
DDI-DrugBank.d743.s11	patients	136	143	O
DDI-DrugBank.d743.s11	receiving	145	153	O
DDI-DrugBank.d743.s11	erythromycin	155	166	B-drug
DDI-DrugBank.d743.s11	or	168	169	O
DDI-DrugBank.d743.s11	troleandomycin	171	184	B-drug
DDI-DrugBank.d743.s11	.	185	185	O
DDI-DrugBank.d743.s12	Concomitant	0	10	O
DDI-DrugBank.d743.s12	administration	12	25	O
DDI-DrugBank.d743.s12	of	27	28	O
DDI-DrugBank.d743.s12	terfenadine	30	40	B-drug
DDI-DrugBank.d743.s12	with	42	45	O
DDI-DrugBank.d743.s12	clarithromycin	47	60	B-drug
DDI-DrugBank.d743.s12	,	61	61	O
DDI-DrugBank.d743.s12	erythromycin	63	74	B-drug
DDI-DrugBank.d743.s12	,	75	75	O
DDI-DrugBank.d743.s12	or	77	78	O
DDI-DrugBank.d743.s12	troleandomycin	80	93	B-drug
DDI-DrugBank.d743.s12	is	95	96	O
DDI-DrugBank.d743.s12	contraindicated	98	112	O
DDI-DrugBank.d743.s12	:	113	113	O
DDI-DrugBank.d743.s12	Pending	115	121	O
DDI-DrugBank.d743.s12	full	123	126	O
DDI-DrugBank.d743.s12	characterization	128	143	O
DDI-DrugBank.d743.s12	of	145	146	O
DDI-DrugBank.d743.s12	potential	148	156	O
DDI-DrugBank.d743.s12	interactions	158	169	O
DDI-DrugBank.d743.s12	,	170	170	O
DDI-DrugBank.d743.s12	concomitant	172	182	O
DDI-DrugBank.d743.s12	administration	184	197	O
DDI-DrugBank.d743.s12	of	199	200	O
DDI-DrugBank.d743.s12	terfenadine	202	212	B-drug
DDI-DrugBank.d743.s12	with	214	217	O
DDI-DrugBank.d743.s12	other	219	223	O
DDI-DrugBank.d743.s12	macrolide	225	233	B-group
DDI-DrugBank.d743.s12	antibiotics	235	245	I-group
DDI-DrugBank.d743.s12	,	246	246	O
DDI-DrugBank.d743.s12	including	248	256	O
DDI-DrugBank.d743.s12	azithromycin	258	269	B-drug
DDI-DrugBank.d743.s12	,	246	246	O
DDI-DrugBank.d743.s12	is	272	273	O
DDI-DrugBank.d743.s12	not	275	277	O
DDI-DrugBank.d743.s12	recommended	279	289	O
DDI-DrugBank.d743.s12	.	290	290	O
DDI-DrugBank.d743.s13	Studies	0	6	O
DDI-DrugBank.d743.s13	to	8	9	O
DDI-DrugBank.d743.s13	evaluate	11	18	O
DDI-DrugBank.d743.s13	potential	20	28	O
DDI-DrugBank.d743.s13	interactions	30	41	O
DDI-DrugBank.d743.s13	of	43	44	O
DDI-DrugBank.d743.s13	terfenadine	46	56	B-drug
DDI-DrugBank.d743.s13	with	58	61	O
DDI-DrugBank.d743.s13	azithromycin	63	74	B-drug
DDI-DrugBank.d743.s13	are	76	78	O
DDI-DrugBank.d743.s13	in	73	74	I-drug
DDI-DrugBank.d743.s13	progress	83	90	O
DDI-DrugBank.d743.s13	.	91	91	O
DDI-DrugBank.d602.s0	Caution	0	6	O
DDI-DrugBank.d602.s0	is	8	9	O
DDI-DrugBank.d602.s0	recommended	11	21	O
DDI-DrugBank.d602.s0	when	23	26	O
DDI-DrugBank.d602.s0	administering	28	40	O
DDI-DrugBank.d602.s0	NEXAVAR	42	48	B-brand
DDI-DrugBank.d602.s0	with	50	53	O
DDI-DrugBank.d602.s0	compounds	55	63	O
DDI-DrugBank.d602.s0	that	65	68	O
DDI-DrugBank.d602.s0	are	70	72	O
DDI-DrugBank.d602.s0	metabolized/eliminated	74	95	O
DDI-DrugBank.d602.s0	predominantly	97	109	O
DDI-DrugBank.d602.s0	by	111	112	O
DDI-DrugBank.d602.s0	the	114	116	O
DDI-DrugBank.d602.s0	UGT1A1	118	123	O
DDI-DrugBank.d602.s0	pathway	125	131	O
DDI-DrugBank.d602.s0	(	133	133	O
DDI-DrugBank.d602.s0	e.g	134	136	O
DDI-DrugBank.d602.s0	.	135	135	O
DDI-DrugBank.d602.s0	irinotecan	139	148	B-drug
DDI-DrugBank.d602.s0	)	149	149	O
DDI-DrugBank.d602.s0	.	135	135	O
DDI-DrugBank.d602.s1	Concomitant	0	10	O
DDI-DrugBank.d602.s1	treatment	12	20	O
DDI-DrugBank.d602.s1	with	22	25	O
DDI-DrugBank.d602.s1	NEXAVAR	27	33	B-brand
DDI-DrugBank.d602.s1	resulted	35	42	O
DDI-DrugBank.d602.s1	in	44	45	O
DDI-DrugBank.d602.s1	a	47	47	O
DDI-DrugBank.d602.s1	21	49	50	O
DDI-DrugBank.d602.s1	%	51	51	O
DDI-DrugBank.d602.s1	increase	53	60	O
DDI-DrugBank.d602.s1	in	53	54	O
DDI-DrugBank.d602.s1	the	65	67	O
DDI-DrugBank.d602.s1	AUC	69	71	O
DDI-DrugBank.d602.s1	of	73	74	O
DDI-DrugBank.d602.s1	doxorubicin	76	86	B-drug
DDI-DrugBank.d602.s1	.	87	87	O
DDI-DrugBank.d602.s2	Caution	0	6	O
DDI-DrugBank.d602.s2	is	8	9	O
DDI-DrugBank.d602.s2	recommended	11	21	O
DDI-DrugBank.d602.s2	when	23	26	O
DDI-DrugBank.d602.s2	administering	28	40	O
DDI-DrugBank.d602.s2	doxorubicin	42	52	B-drug
DDI-DrugBank.d602.s2	with	54	57	O
DDI-DrugBank.d602.s2	NEXAVAR	59	65	B-brand
DDI-DrugBank.d602.s2	.	66	66	O
DDI-DrugBank.d602.s3	Sorafenib	0	8	B-drug
DDI-DrugBank.d602.s3	inhibits	10	17	O
DDI-DrugBank.d602.s3	CYP2B6	19	24	O
DDI-DrugBank.d602.s3	and	26	28	O
DDI-DrugBank.d602.s3	CYP2C8	30	35	O
DDI-DrugBank.d602.s3	in	37	38	O
DDI-DrugBank.d602.s3	vitro	40	44	O
DDI-DrugBank.d602.s3	with	46	49	O
DDI-DrugBank.d602.s3	Ki	51	52	O
DDI-DrugBank.d602.s3	values	54	59	O
DDI-DrugBank.d602.s3	of	61	62	O
DDI-DrugBank.d602.s3	6	64	64	O
DDI-DrugBank.d602.s3	and	66	68	O
DDI-DrugBank.d602.s3	1-2	70	72	O
DDI-DrugBank.d602.s3	?	74	74	O
DDI-DrugBank.d602.s3	M	75	75	O
DDI-DrugBank.d602.s3	,	76	76	O
DDI-DrugBank.d602.s3	respectively	78	89	O
DDI-DrugBank.d602.s3	.	90	90	O
DDI-DrugBank.d602.s4	Systemic	0	7	O
DDI-DrugBank.d602.s4	exposure	9	16	O
DDI-DrugBank.d602.s4	to	18	19	O
DDI-DrugBank.d602.s4	substrates	21	30	O
DDI-DrugBank.d602.s4	of	32	33	O
DDI-DrugBank.d602.s4	CYP2B6	35	40	O
DDI-DrugBank.d602.s4	and	42	44	O
DDI-DrugBank.d602.s4	CYP2C8	46	51	O
DDI-DrugBank.d602.s4	is	53	54	O
DDI-DrugBank.d602.s4	expected	56	63	O
DDI-DrugBank.d602.s4	to	65	66	O
DDI-DrugBank.d602.s4	increase	68	75	O
DDI-DrugBank.d602.s4	when	77	80	O
DDI-DrugBank.d602.s4	co-administered	82	96	O
DDI-DrugBank.d602.s4	with	98	101	O
DDI-DrugBank.d602.s4	NEXAVAR	103	109	B-brand
DDI-DrugBank.d602.s4	.	110	110	O
DDI-DrugBank.d602.s5	Caution	0	6	O
DDI-DrugBank.d602.s5	is	8	9	O
DDI-DrugBank.d602.s5	recommended	11	21	O
DDI-DrugBank.d602.s5	when	23	26	O
DDI-DrugBank.d602.s5	administering	28	40	O
DDI-DrugBank.d602.s5	substrates	42	51	O
DDI-DrugBank.d602.s5	of	53	54	O
DDI-DrugBank.d602.s5	CYP2B6	56	61	O
DDI-DrugBank.d602.s5	and	63	65	O
DDI-DrugBank.d602.s5	CYP2C8	67	72	O
DDI-DrugBank.d602.s5	with	74	77	O
DDI-DrugBank.d602.s5	NEXAVAR	79	85	B-brand
DDI-DrugBank.d602.s5	.	86	86	O
DDI-DrugBank.d158.s0	Urinary	0	6	O
DDI-DrugBank.d158.s0	acidifying	8	17	O
DDI-DrugBank.d158.s0	agents	19	24	O
DDI-DrugBank.d158.s0	These	26	30	O
DDI-DrugBank.d158.s0	agents	32	37	O
DDI-DrugBank.d158.s0	(	39	39	O
DDI-DrugBank.d158.s0	ammonium	40	47	B-drug
DDI-DrugBank.d158.s0	chloride	49	56	I-drug
DDI-DrugBank.d158.s0	,	57	57	O
DDI-DrugBank.d158.s0	sodium	59	64	B-drug
DDI-DrugBank.d158.s0	acid	66	69	I-drug
DDI-DrugBank.d158.s0	phosphate	71	79	I-drug
DDI-DrugBank.d158.s0	,	80	80	O
DDI-DrugBank.d158.s0	etc	82	84	O
DDI-DrugBank.d158.s0	.	85	85	O
DDI-DrugBank.d158.s0	)	86	86	O
DDI-DrugBank.d158.s0	increase	88	95	O
DDI-DrugBank.d158.s0	the	97	99	O
DDI-DrugBank.d158.s0	concentration	101	113	O
DDI-DrugBank.d158.s0	of	115	116	O
DDI-DrugBank.d158.s0	the	118	120	O
DDI-DrugBank.d158.s0	ionized	122	128	O
DDI-DrugBank.d158.s0	species	130	136	O
DDI-DrugBank.d158.s0	of	138	139	O
DDI-DrugBank.d158.s0	the	141	143	O
DDI-DrugBank.d158.s0	amphetamine	145	155	B-drug
DDI-DrugBank.d158.s0	molecule	157	164	O
DDI-DrugBank.d158.s0	,	165	165	O
DDI-DrugBank.d158.s0	thereby	167	173	O
DDI-DrugBank.d158.s0	increasing	175	184	O
DDI-DrugBank.d158.s0	urinary	186	192	O
DDI-DrugBank.d158.s0	excretion	194	202	O
DDI-DrugBank.d158.s0	.	203	203	O
DDI-DrugBank.d158.s1	Both	0	3	O
DDI-DrugBank.d158.s1	groups	5	10	O
DDI-DrugBank.d158.s1	of	12	13	O
DDI-DrugBank.d158.s1	agents	15	20	O
DDI-DrugBank.d158.s1	lower	22	26	O
DDI-DrugBank.d158.s1	blood	28	32	O
DDI-DrugBank.d158.s1	levels	34	39	O
DDI-DrugBank.d158.s1	and	41	43	O
DDI-DrugBank.d158.s1	efficacy	45	52	O
DDI-DrugBank.d158.s1	of	54	55	O
DDI-DrugBank.d158.s1	amphetamines	57	68	B-group
DDI-DrugBank.d158.s1	.	69	69	O
DDI-DrugBank.d158.s2	Adrenergic	0	9	B-group
DDI-DrugBank.d158.s2	blockers	11	18	I-group
DDI-DrugBank.d158.s2	Adrenergic	20	29	B-group
DDI-DrugBank.d158.s2	blockers	31	38	I-group
DDI-DrugBank.d158.s2	are	40	42	O
DDI-DrugBank.d158.s2	inhibited	44	52	O
DDI-DrugBank.d158.s2	by	54	55	O
DDI-DrugBank.d158.s2	amphetamines	57	68	B-group
DDI-DrugBank.d158.s2	.	69	69	O
DDI-DrugBank.d158.s3	Antidepressants	0	14	B-group
DDI-DrugBank.d158.s3	,	15	15	O
DDI-DrugBank.d158.s3	tricyclic	17	25	B-group
DDI-DrugBank.d158.s3	Amphetamines	27	38	B-group
DDI-DrugBank.d158.s3	may	40	42	O
DDI-DrugBank.d158.s3	enhance	44	50	O
DDI-DrugBank.d158.s3	the	52	54	O
DDI-DrugBank.d158.s3	activity	56	63	O
DDI-DrugBank.d158.s3	of	65	66	O
DDI-DrugBank.d158.s3	tricyclic	68	76	B-drug
DDI-DrugBank.d158.s3	antidepressants	78	92	I-drug
DDI-DrugBank.d158.s3	or	94	95	O
DDI-DrugBank.d158.s3	sympathomimetic	97	111	B-group
DDI-DrugBank.d158.s3	agents	113	118	I-group
DDI-DrugBank.d158.s3	;	119	119	O
DDI-DrugBank.d158.s4	d-amphetamine	0	12	B-drug
DDI-DrugBank.d158.s4	with	14	17	O
DDI-DrugBank.d158.s4	desipramine	19	29	B-drug
DDI-DrugBank.d158.s4	or	31	32	O
DDI-DrugBank.d158.s4	protriptyline	34	46	B-drug
DDI-DrugBank.d158.s4	and	48	50	O
DDI-DrugBank.d158.s4	possibly	52	59	O
DDI-DrugBank.d158.s4	other	61	65	O
DDI-DrugBank.d158.s4	tricyclics	67	76	B-group
DDI-DrugBank.d158.s4	cause	78	82	O
DDI-DrugBank.d158.s4	striking	84	91	O
DDI-DrugBank.d158.s4	and	93	95	O
DDI-DrugBank.d158.s4	sustained	97	105	O
DDI-DrugBank.d158.s4	increases	107	115	O
DDI-DrugBank.d158.s4	in	107	108	O
DDI-DrugBank.d158.s4	the	120	122	O
DDI-DrugBank.d158.s4	concentration	124	136	O
DDI-DrugBank.d158.s4	of	138	139	O
DDI-DrugBank.d158.s4	d-amphetamine	141	153	B-drug
DDI-DrugBank.d158.s4	in	151	152	I-drug
DDI-DrugBank.d158.s4	the	158	160	O
DDI-DrugBank.d158.s4	brain	162	166	O
DDI-DrugBank.d158.s4	;	167	167	O
DDI-DrugBank.d158.s5	cardiovascular	0	13	O
DDI-DrugBank.d158.s5	effects	15	21	O
DDI-DrugBank.d158.s5	can	23	25	O
DDI-DrugBank.d158.s5	be	27	28	O
DDI-DrugBank.d158.s5	potentiated	30	40	O
DDI-DrugBank.d158.s5	.	41	41	O
DDI-DrugBank.d158.s6	MAO	0	2	B-group
DDI-DrugBank.d158.s6	inhibitors	4	13	I-group
DDI-DrugBank.d158.s6	MAOI	15	18	B-group
DDI-DrugBank.d158.s6	antidepressants	20	34	I-group
DDI-DrugBank.d158.s6	,	35	35	O
DDI-DrugBank.d158.s6	as	37	38	O
DDI-DrugBank.d158.s6	well	40	43	O
DDI-DrugBank.d158.s6	as	45	46	O
DDI-DrugBank.d158.s6	a	45	45	O
DDI-DrugBank.d158.s6	metabolite	50	59	O
DDI-DrugBank.d158.s6	of	61	62	O
DDI-DrugBank.d158.s6	furazolidone	64	75	B-drug
DDI-DrugBank.d158.s6	,	76	76	O
DDI-DrugBank.d158.s6	slow	78	81	O
DDI-DrugBank.d158.s6	amphetamine	83	93	B-drug
DDI-DrugBank.d158.s6	metabolism	95	104	O
DDI-DrugBank.d158.s6	.	105	105	O
DDI-DrugBank.d158.s7	This	0	3	O
DDI-DrugBank.d158.s7	slowing	5	11	O
DDI-DrugBank.d158.s7	potentiates	13	23	O
DDI-DrugBank.d158.s7	amphetamines	25	36	B-group
DDI-DrugBank.d158.s7	,	37	37	O
DDI-DrugBank.d158.s7	increasing	39	48	O
DDI-DrugBank.d158.s7	their	50	54	O
DDI-DrugBank.d158.s7	effect	56	61	O
DDI-DrugBank.d158.s7	on	63	64	O
DDI-DrugBank.d158.s7	the	66	68	O
DDI-DrugBank.d158.s7	release	70	76	O
DDI-DrugBank.d158.s7	of	78	79	O
DDI-DrugBank.d158.s7	norepinephrine	81	94	O
DDI-DrugBank.d158.s7	and	96	98	O
DDI-DrugBank.d158.s7	other	100	104	O
DDI-DrugBank.d158.s7	monoamines	106	115	O
DDI-DrugBank.d158.s7	from	117	120	O
DDI-DrugBank.d158.s7	adrenergic	122	131	O
DDI-DrugBank.d158.s7	nerve	133	137	O
DDI-DrugBank.d158.s7	endings	139	145	O
DDI-DrugBank.d158.s7	;	146	146	O
DDI-DrugBank.d158.s8	this	0	3	O
DDI-DrugBank.d158.s8	can	5	7	O
DDI-DrugBank.d158.s8	cause	9	13	O
DDI-DrugBank.d158.s8	headaches	15	23	O
DDI-DrugBank.d158.s8	and	25	27	O
DDI-DrugBank.d158.s8	other	29	33	O
DDI-DrugBank.d158.s8	signs	35	39	O
DDI-DrugBank.d158.s8	of	41	42	O
DDI-DrugBank.d158.s8	hypertensive	44	55	O
DDI-DrugBank.d158.s8	crisis	57	62	O
DDI-DrugBank.d158.s8	.	63	63	O
DDI-DrugBank.d158.s9	A	0	0	O
DDI-DrugBank.d158.s9	variety	2	8	O
DDI-DrugBank.d158.s9	of	10	11	O
DDI-DrugBank.d158.s9	toxic	13	17	O
DDI-DrugBank.d158.s9	neurological	19	30	O
DDI-DrugBank.d158.s9	effects	32	38	O
DDI-DrugBank.d158.s9	and	40	42	O
DDI-DrugBank.d158.s9	malignant	44	52	O
DDI-DrugBank.d158.s9	hyperpyrexia	54	65	O
DDI-DrugBank.d158.s9	can	67	69	O
DDI-DrugBank.d158.s9	occur	71	75	O
DDI-DrugBank.d158.s9	,	76	76	O
DDI-DrugBank.d158.s9	sometimes	78	86	O
DDI-DrugBank.d158.s9	with	88	91	O
DDI-DrugBank.d158.s9	fatal	93	97	O
DDI-DrugBank.d158.s9	results	99	105	O
DDI-DrugBank.d158.s9	.	106	106	O
DDI-DrugBank.d158.s10	Antihistamines	0	13	B-group
DDI-DrugBank.d158.s10	:	14	14	O
DDI-DrugBank.d158.s10	Amphetamines	16	27	B-group
DDI-DrugBank.d158.s10	may	29	31	O
DDI-DrugBank.d158.s10	counteract	33	42	O
DDI-DrugBank.d158.s10	the	44	46	O
DDI-DrugBank.d158.s10	sedative	48	55	O
DDI-DrugBank.d158.s10	effect	57	62	O
DDI-DrugBank.d158.s10	of	64	65	O
DDI-DrugBank.d158.s10	antihistamines	67	80	B-group
DDI-DrugBank.d158.s10	.	81	81	O
DDI-DrugBank.d158.s11	Antihypertensives	0	16	B-group
DDI-DrugBank.d158.s11	:	17	17	O
DDI-DrugBank.d158.s11	Amphetamines	19	30	B-group
DDI-DrugBank.d158.s11	may	32	34	O
DDI-DrugBank.d158.s11	antagonize	36	45	O
DDI-DrugBank.d158.s11	the	47	49	O
DDI-DrugBank.d158.s11	hypotensive	51	61	O
DDI-DrugBank.d158.s11	effects	63	69	O
DDI-DrugBank.d158.s11	of	71	72	O
DDI-DrugBank.d158.s11	antihypertensives	74	90	B-drug
DDI-DrugBank.d158.s11	.	91	91	O
DDI-DrugBank.d158.s12	Chlorpromazine	0	13	B-drug
DDI-DrugBank.d158.s12	:	14	14	O
DDI-DrugBank.d158.s12	Chlorpromazine	16	29	B-drug
DDI-DrugBank.d158.s12	blocks	31	36	O
DDI-DrugBank.d158.s12	dopamine	38	45	O
DDI-DrugBank.d158.s12	and	47	49	O
DDI-DrugBank.d158.s12	norepinephrine	51	64	O
DDI-DrugBank.d158.s12	receptors	66	74	O
DDI-DrugBank.d158.s12	,	75	75	O
DDI-DrugBank.d158.s12	thus	77	80	O
DDI-DrugBank.d158.s12	inhibiting	82	91	O
DDI-DrugBank.d158.s12	the	93	95	O
DDI-DrugBank.d158.s12	central	97	103	O
DDI-DrugBank.d158.s12	stimulant	105	113	O
DDI-DrugBank.d158.s12	effects	115	121	O
DDI-DrugBank.d158.s12	of	123	124	O
DDI-DrugBank.d158.s12	amphetamines	126	137	B-group
DDI-DrugBank.d158.s12	and	139	141	O
DDI-DrugBank.d158.s12	can	143	145	O
DDI-DrugBank.d158.s12	be	147	148	O
DDI-DrugBank.d158.s12	used	150	153	O
DDI-DrugBank.d158.s12	to	155	156	O
DDI-DrugBank.d158.s12	treat	158	162	O
DDI-DrugBank.d158.s12	amphetamine	164	174	B-group
DDI-DrugBank.d158.s12	poisoning	176	184	O
DDI-DrugBank.d158.s12	.	185	185	O
DDI-DrugBank.d158.s13	Ethosuximide	0	11	B-drug
DDI-DrugBank.d158.s13	:	12	12	O
DDI-DrugBank.d158.s13	Amphetamines	14	25	B-group
DDI-DrugBank.d158.s13	may	27	29	O
DDI-DrugBank.d158.s13	delay	31	35	O
DDI-DrugBank.d158.s13	intestinal	37	46	O
DDI-DrugBank.d158.s13	absorption	48	57	O
DDI-DrugBank.d158.s13	of	59	60	O
DDI-DrugBank.d158.s13	ethosuximide	62	73	B-drug
DDI-DrugBank.d158.s13	.	74	74	O
DDI-DrugBank.d158.s14	Haloperidol	0	10	B-drug
DDI-DrugBank.d158.s14	:	11	11	O
DDI-DrugBank.d158.s14	Haloperidol	13	23	B-drug
DDI-DrugBank.d158.s14	blocks	25	30	O
DDI-DrugBank.d158.s14	dopamine	32	39	O
DDI-DrugBank.d158.s14	receptors	41	49	O
DDI-DrugBank.d158.s14	,	50	50	O
DDI-DrugBank.d158.s14	thus	52	55	O
DDI-DrugBank.d158.s14	inhibiting	57	66	O
DDI-DrugBank.d158.s14	the	68	70	O
DDI-DrugBank.d158.s14	central	72	78	O
DDI-DrugBank.d158.s14	stimulant	80	88	O
DDI-DrugBank.d158.s14	effects	90	96	O
DDI-DrugBank.d158.s14	of	98	99	O
DDI-DrugBank.d158.s14	amphetamines	101	112	B-group
DDI-DrugBank.d158.s14	.	113	113	O
DDI-DrugBank.d158.s15	Lithium	0	6	B-drug
DDI-DrugBank.d158.s15	carbonate	8	16	I-drug
DDI-DrugBank.d158.s15	:	17	17	O
DDI-DrugBank.d158.s15	The	19	21	O
DDI-DrugBank.d158.s15	anorectic	23	31	O
DDI-DrugBank.d158.s15	and	33	35	O
DDI-DrugBank.d158.s15	stimulatory	37	47	O
DDI-DrugBank.d158.s15	effects	49	55	O
DDI-DrugBank.d158.s15	of	57	58	O
DDI-DrugBank.d158.s15	amphetamines	60	71	B-group
DDI-DrugBank.d158.s15	may	73	75	O
DDI-DrugBank.d158.s15	be	77	78	O
DDI-DrugBank.d158.s15	inhibited	80	88	O
DDI-DrugBank.d158.s15	by	90	91	O
DDI-DrugBank.d158.s15	lithium	93	99	B-drug
DDI-DrugBank.d158.s15	carbonate	101	109	I-drug
DDI-DrugBank.d158.s15	.	110	110	O
DDI-DrugBank.d158.s16	Meperidine	0	9	B-drug
DDI-DrugBank.d158.s16	:	10	10	O
DDI-DrugBank.d158.s16	Amphetamines	12	23	B-group
DDI-DrugBank.d158.s16	potentiate	25	34	O
DDI-DrugBank.d158.s16	the	36	38	O
DDI-DrugBank.d158.s16	analgesic	40	48	O
DDI-DrugBank.d158.s16	effect	50	55	O
DDI-DrugBank.d158.s16	of	57	58	O
DDI-DrugBank.d158.s16	meperidine	60	69	B-drug
DDI-DrugBank.d158.s16	.	70	70	O
DDI-DrugBank.d158.s17	Methenamine	0	10	B-drug
DDI-DrugBank.d158.s17	therapy	12	18	O
DDI-DrugBank.d158.s17	Urinary	20	26	O
DDI-DrugBank.d158.s17	excretion	28	36	O
DDI-DrugBank.d158.s17	of	38	39	O
DDI-DrugBank.d158.s17	amphetamines	41	52	B-group
DDI-DrugBank.d158.s17	is	54	55	O
DDI-DrugBank.d158.s17	increased	57	65	O
DDI-DrugBank.d158.s17	,	66	66	O
DDI-DrugBank.d158.s17	and	68	70	O
DDI-DrugBank.d158.s17	efficacy	72	79	O
DDI-DrugBank.d158.s17	is	81	82	O
DDI-DrugBank.d158.s17	reduced	84	90	O
DDI-DrugBank.d158.s17	by	92	93	O
DDI-DrugBank.d158.s17	acidifying	95	104	O
DDI-DrugBank.d158.s17	agents	106	111	O
DDI-DrugBank.d158.s17	used	113	116	O
DDI-DrugBank.d158.s17	in	102	103	O
DDI-DrugBank.d158.s17	methenamine	121	131	B-drug
DDI-DrugBank.d158.s17	therapy	133	139	O
DDI-DrugBank.d158.s17	.	140	140	O
DDI-DrugBank.d158.s18	Norepinephrine	0	13	B-drug
DDI-DrugBank.d158.s18	:	14	14	O
DDI-DrugBank.d158.s18	Amphetamines	16	27	B-group
DDI-DrugBank.d158.s18	enhance	29	35	O
DDI-DrugBank.d158.s18	the	37	39	O
DDI-DrugBank.d158.s18	adrenergic	41	50	O
DDI-DrugBank.d158.s18	effect	52	57	O
DDI-DrugBank.d158.s18	of	59	60	O
DDI-DrugBank.d158.s18	norepinephrine	62	75	B-drug
DDI-DrugBank.d158.s18	.	76	76	O
DDI-DrugBank.d158.s19	Phenobarbital	0	12	B-drug
DDI-DrugBank.d158.s19	:	13	13	O
DDI-DrugBank.d158.s19	Amphetamines	15	26	B-group
DDI-DrugBank.d158.s19	may	28	30	O
DDI-DrugBank.d158.s19	delay	32	36	O
DDI-DrugBank.d158.s19	intestinal	38	47	O
DDI-DrugBank.d158.s19	absorption	49	58	O
DDI-DrugBank.d158.s19	of	60	61	O
DDI-DrugBank.d158.s19	phenobarbital	63	75	B-drug
DDI-DrugBank.d158.s19	;	76	76	O
DDI-DrugBank.d158.s20	co-administration	0	16	O
DDI-DrugBank.d158.s20	of	18	19	O
DDI-DrugBank.d158.s20	phenobarbital	21	33	B-drug
DDI-DrugBank.d158.s20	may	35	37	O
DDI-DrugBank.d158.s20	produce	39	45	O
DDI-DrugBank.d158.s20	a	47	47	O
DDI-DrugBank.d158.s20	synergistic	49	59	O
DDI-DrugBank.d158.s20	anticonvulsant	61	74	O
DDI-DrugBank.d158.s20	action	76	81	O
DDI-DrugBank.d158.s20	.	82	82	O
DDI-DrugBank.d158.s21	Phenytoin	0	8	B-drug
DDI-DrugBank.d158.s21	:	9	9	O
DDI-DrugBank.d158.s21	Amphetamines	11	22	B-group
DDI-DrugBank.d158.s21	may	24	26	O
DDI-DrugBank.d158.s21	delay	28	32	O
DDI-DrugBank.d158.s21	intestinal	34	43	O
DDI-DrugBank.d158.s21	absorption	45	54	O
DDI-DrugBank.d158.s21	of	56	57	O
DDI-DrugBank.d158.s21	phenytoin	59	67	B-drug
DDI-DrugBank.d158.s21	;	68	68	O
DDI-DrugBank.d158.s22	co-administration	0	16	O
DDI-DrugBank.d158.s22	of	18	19	O
DDI-DrugBank.d158.s22	phenytoin	21	29	B-drug
DDI-DrugBank.d158.s22	may	31	33	O
DDI-DrugBank.d158.s22	produce	35	41	O
DDI-DrugBank.d158.s22	a	43	43	O
DDI-DrugBank.d158.s22	synergistic	45	55	O
DDI-DrugBank.d158.s22	anticonvulsant	57	70	O
DDI-DrugBank.d158.s22	action	72	77	O
DDI-DrugBank.d158.s22	.	78	78	O
DDI-DrugBank.d158.s23	Propoxyphene	0	11	B-drug
DDI-DrugBank.d158.s23	:	12	12	O
DDI-DrugBank.d158.s23	In	14	15	O
DDI-DrugBank.d158.s23	cases	17	21	O
DDI-DrugBank.d158.s23	of	23	24	O
DDI-DrugBank.d158.s23	propoxyphene	26	37	B-drug
DDI-DrugBank.d158.s23	overdosage	39	48	O
DDI-DrugBank.d158.s23	,	49	49	O
DDI-DrugBank.d158.s23	amphetamine	51	61	B-drug
DDI-DrugBank.d158.s23	CNS	63	65	O
DDI-DrugBank.d158.s23	stimulation	67	77	O
DDI-DrugBank.d158.s23	is	79	80	O
DDI-DrugBank.d158.s23	potentiated	82	92	O
DDI-DrugBank.d158.s23	and	94	96	O
DDI-DrugBank.d158.s23	fatal	98	102	O
DDI-DrugBank.d158.s23	convulsions	104	114	O
DDI-DrugBank.d158.s23	can	116	118	O
DDI-DrugBank.d158.s23	occur	120	124	O
DDI-DrugBank.d158.s23	.	125	125	O
DDI-DrugBank.d158.s24	Veratrum	0	7	B-group
DDI-DrugBank.d158.s24	alkaloids	9	17	I-group
DDI-DrugBank.d158.s24	:	18	18	O
DDI-DrugBank.d158.s24	Amphetamines	20	31	B-group
DDI-DrugBank.d158.s24	inhibit	33	39	O
DDI-DrugBank.d158.s24	the	41	43	O
DDI-DrugBank.d158.s24	hypotensive	45	55	O
DDI-DrugBank.d158.s24	effect	57	62	O
DDI-DrugBank.d158.s24	of	64	65	O
DDI-DrugBank.d158.s24	veratrum	67	74	B-group
DDI-DrugBank.d158.s24	alkaloids	76	84	I-group
DDI-DrugBank.d158.s24	.	85	85	O
DDI-DrugBank.d158.s25	Drug/Laboratory	0	14	O
DDI-DrugBank.d158.s25	Test	16	19	O
DDI-DrugBank.d158.s25	Interactions	21	32	O
DDI-DrugBank.d158.s25	:	33	33	O
DDI-DrugBank.d158.s25	Amphetamines	35	46	B-group
DDI-DrugBank.d158.s25	can	48	50	O
DDI-DrugBank.d158.s25	cause	52	56	O
DDI-DrugBank.d158.s25	a	53	53	O
DDI-DrugBank.d158.s25	significant	60	70	O
DDI-DrugBank.d158.s25	elevation	72	80	O
DDI-DrugBank.d158.s25	in	82	83	O
DDI-DrugBank.d158.s25	plasma	85	90	O
DDI-DrugBank.d158.s25	corticosteroid	92	105	O
DDI-DrugBank.d158.s25	levels	107	112	O
DDI-DrugBank.d158.s25	.	113	113	O
DDI-DrugBank.d158.s26	This	0	3	O
DDI-DrugBank.d158.s26	increase	5	12	O
DDI-DrugBank.d158.s26	is	14	15	O
DDI-DrugBank.d158.s26	greatest	17	24	O
DDI-DrugBank.d158.s26	in	26	27	O
DDI-DrugBank.d158.s26	the	29	31	O
DDI-DrugBank.d158.s26	evening	33	39	O
DDI-DrugBank.d158.s26	.	40	40	O
DDI-DrugBank.d158.s27	Amphetamines	0	11	B-group
DDI-DrugBank.d158.s27	may	13	15	O
DDI-DrugBank.d158.s27	interfere	17	25	O
DDI-DrugBank.d158.s27	with	27	30	O
DDI-DrugBank.d158.s27	urinary	32	38	O
DDI-DrugBank.d158.s27	steroid	40	46	O
DDI-DrugBank.d158.s27	determinations	48	61	O
DDI-DrugBank.d158.s27	.	62	62	O
DDI-DrugBank.d143.s0	Amiodarone	0	9	B-drug
DDI-DrugBank.d143.s0	is	11	12	O
DDI-DrugBank.d143.s0	metabolized	14	24	O
DDI-DrugBank.d143.s0	to	26	27	O
DDI-DrugBank.d143.s0	desethylamiodarone	29	46	B-drug
DDI-DrugBank.d143.s0	by	48	49	O
DDI-DrugBank.d143.s0	the	51	53	O
DDI-DrugBank.d143.s0	cytochrome	55	64	O
DDI-DrugBank.d143.s0	P450	66	69	O
DDI-DrugBank.d143.s0	(	71	71	O
DDI-DrugBank.d143.s0	CYP450	72	77	O
DDI-DrugBank.d143.s0	)	78	78	O
DDI-DrugBank.d143.s0	enzyme	80	85	O
DDI-DrugBank.d143.s0	group	87	91	O
DDI-DrugBank.d143.s0	,	92	92	O
DDI-DrugBank.d143.s0	specifically	94	105	O
DDI-DrugBank.d143.s0	cytochromes	107	117	O
DDI-DrugBank.d143.s0	P450	119	122	O
DDI-DrugBank.d143.s0	3A4	124	126	O
DDI-DrugBank.d143.s0	(	128	128	O
DDI-DrugBank.d143.s0	CYP3A4	129	134	O
DDI-DrugBank.d143.s0	)	135	135	O
DDI-DrugBank.d143.s0	and	137	139	O
DDI-DrugBank.d143.s0	CYP2C8	141	146	O
DDI-DrugBank.d143.s0	.	147	147	O
DDI-DrugBank.d143.s1	The	0	2	O
DDI-DrugBank.d143.s1	CYP3A4	4	9	O
DDI-DrugBank.d143.s1	isoenzyme	11	19	O
DDI-DrugBank.d143.s1	is	21	22	O
DDI-DrugBank.d143.s1	present	24	30	O
DDI-DrugBank.d143.s1	in	32	33	O
DDI-DrugBank.d143.s1	both	35	38	O
DDI-DrugBank.d143.s1	the	40	42	O
DDI-DrugBank.d143.s1	liver	44	48	O
DDI-DrugBank.d143.s1	and	50	52	O
DDI-DrugBank.d143.s1	intestines	54	63	O
DDI-DrugBank.d143.s1	.	64	64	O
DDI-DrugBank.d143.s2	Amiodarone	0	9	B-drug
DDI-DrugBank.d143.s2	is	11	12	O
DDI-DrugBank.d143.s2	also	14	17	O
DDI-DrugBank.d143.s2	known	19	23	O
DDI-DrugBank.d143.s2	to	25	26	O
DDI-DrugBank.d143.s2	be	28	29	O
DDI-DrugBank.d143.s2	an	31	32	O
DDI-DrugBank.d143.s2	inhibitor	34	42	O
DDI-DrugBank.d143.s2	of	44	45	O
DDI-DrugBank.d143.s2	CYP3A4	47	52	O
DDI-DrugBank.d143.s2	.	53	53	O
DDI-DrugBank.d143.s3	Therefore	0	8	O
DDI-DrugBank.d143.s3	,	9	9	O
DDI-DrugBank.d143.s3	amiodarone	11	20	B-drug
DDI-DrugBank.d143.s3	has	22	24	O
DDI-DrugBank.d143.s3	the	26	28	O
DDI-DrugBank.d143.s3	potential	30	38	O
DDI-DrugBank.d143.s3	for	40	42	O
DDI-DrugBank.d143.s3	interactions	44	55	O
DDI-DrugBank.d143.s3	with	57	60	O
DDI-DrugBank.d143.s3	drugs	62	66	O
DDI-DrugBank.d143.s3	or	68	69	O
DDI-DrugBank.d143.s3	substances	71	80	O
DDI-DrugBank.d143.s3	that	82	85	O
DDI-DrugBank.d143.s3	may	87	89	O
DDI-DrugBank.d143.s3	be	91	92	O
DDI-DrugBank.d143.s3	substrates	94	103	O
DDI-DrugBank.d143.s3	,	104	104	O
DDI-DrugBank.d143.s3	inhibitors	106	115	O
DDI-DrugBank.d143.s3	or	113	114	O
DDI-DrugBank.d143.s3	inducers	120	127	O
DDI-DrugBank.d143.s3	of	129	130	O
DDI-DrugBank.d143.s3	CYP3A4	132	137	O
DDI-DrugBank.d143.s3	.	138	138	O
DDI-DrugBank.d143.s4	While	0	4	O
DDI-DrugBank.d143.s4	only	6	9	O
DDI-DrugBank.d143.s4	a	11	11	O
DDI-DrugBank.d143.s4	limited	13	19	O
DDI-DrugBank.d143.s4	number	21	26	O
DDI-DrugBank.d143.s4	of	28	29	O
DDI-DrugBank.d143.s4	in	31	32	O
DDI-DrugBank.d143.s4	vivo	34	37	O
DDI-DrugBank.d143.s4	drug-drug	39	47	O
DDI-DrugBank.d143.s4	interactions	49	60	O
DDI-DrugBank.d143.s4	with	62	65	O
DDI-DrugBank.d143.s4	amiodarone	67	76	B-drug
DDI-DrugBank.d143.s4	have	78	81	O
DDI-DrugBank.d143.s4	been	83	86	O
DDI-DrugBank.d143.s4	reported	88	95	O
DDI-DrugBank.d143.s4	,	96	96	O
DDI-DrugBank.d143.s4	chiefly	98	104	O
DDI-DrugBank.d143.s4	with	106	109	O
DDI-DrugBank.d143.s4	the	111	113	O
DDI-DrugBank.d143.s4	oral	115	118	O
DDI-DrugBank.d143.s4	formulation	120	130	O
DDI-DrugBank.d143.s4	,	131	131	O
DDI-DrugBank.d143.s4	the	133	135	O
DDI-DrugBank.d143.s4	potential	137	145	O
DDI-DrugBank.d143.s4	for	147	149	O
DDI-DrugBank.d143.s4	other	151	155	O
DDI-DrugBank.d143.s4	interactions	157	168	O
DDI-DrugBank.d143.s4	should	170	175	O
DDI-DrugBank.d143.s4	be	177	178	O
DDI-DrugBank.d143.s4	anticipated	180	190	O
DDI-DrugBank.d143.s4	.	191	191	O
DDI-DrugBank.d143.s5	This	0	3	O
DDI-DrugBank.d143.s5	is	5	6	O
DDI-DrugBank.d143.s5	especially	8	17	O
DDI-DrugBank.d143.s5	important	19	27	O
DDI-DrugBank.d143.s5	for	29	31	O
DDI-DrugBank.d143.s5	drugs	33	37	O
DDI-DrugBank.d143.s5	associated	39	48	O
DDI-DrugBank.d143.s5	with	50	53	O
DDI-DrugBank.d143.s5	serious	55	61	O
DDI-DrugBank.d143.s5	toxicity	63	70	O
DDI-DrugBank.d143.s5	,	71	71	O
DDI-DrugBank.d143.s5	such	73	76	O
DDI-DrugBank.d143.s5	as	78	79	O
DDI-DrugBank.d143.s5	other	81	85	O
DDI-DrugBank.d143.s5	antiarrhythmics	87	101	B-group
DDI-DrugBank.d143.s5	.	102	102	O
DDI-DrugBank.d143.s6	If	0	1	O
DDI-DrugBank.d143.s6	such	3	6	O
DDI-DrugBank.d143.s6	drugs	8	12	O
DDI-DrugBank.d143.s6	are	14	16	O
DDI-DrugBank.d143.s6	needed	18	23	O
DDI-DrugBank.d143.s6	,	24	24	O
DDI-DrugBank.d143.s6	their	26	30	O
DDI-DrugBank.d143.s6	dose	32	35	O
DDI-DrugBank.d143.s6	should	37	42	O
DDI-DrugBank.d143.s6	be	44	45	O
DDI-DrugBank.d143.s6	reassessed	47	56	O
DDI-DrugBank.d143.s6	and	58	60	O
DDI-DrugBank.d143.s6	,	61	61	O
DDI-DrugBank.d143.s6	where	63	67	O
DDI-DrugBank.d143.s6	appropriate	69	79	O
DDI-DrugBank.d143.s6	,	80	80	O
DDI-DrugBank.d143.s6	plasma	82	87	O
DDI-DrugBank.d143.s6	concentration	89	101	O
DDI-DrugBank.d143.s6	measured	103	110	O
DDI-DrugBank.d143.s6	.	111	111	O
DDI-DrugBank.d143.s7	In	0	1	O
DDI-DrugBank.d143.s7	view	3	6	O
DDI-DrugBank.d143.s7	of	8	9	O
DDI-DrugBank.d143.s7	the	11	13	O
DDI-DrugBank.d143.s7	long	15	18	O
DDI-DrugBank.d143.s7	and	20	22	O
DDI-DrugBank.d143.s7	variable	24	31	O
DDI-DrugBank.d143.s7	half-life	33	41	O
DDI-DrugBank.d143.s7	of	43	44	O
DDI-DrugBank.d143.s7	amiodarone	46	55	B-drug
DDI-DrugBank.d143.s7	,	56	56	O
DDI-DrugBank.d143.s7	potential	58	66	O
DDI-DrugBank.d143.s7	for	68	70	O
DDI-DrugBank.d143.s7	drug	72	75	O
DDI-DrugBank.d143.s7	interactions	77	88	O
DDI-DrugBank.d143.s7	exists	90	95	O
DDI-DrugBank.d143.s7	not	97	99	O
DDI-DrugBank.d143.s7	only	101	104	O
DDI-DrugBank.d143.s7	with	106	109	O
DDI-DrugBank.d143.s7	concomitant	111	121	O
DDI-DrugBank.d143.s7	medication	123	132	O
DDI-DrugBank.d143.s7	but	134	136	O
DDI-DrugBank.d143.s7	also	138	141	O
DDI-DrugBank.d143.s7	with	143	146	O
DDI-DrugBank.d143.s7	drugs	148	152	O
DDI-DrugBank.d143.s7	administered	154	165	O
DDI-DrugBank.d143.s7	after	167	171	O
DDI-DrugBank.d143.s7	discontinuation	173	187	O
DDI-DrugBank.d143.s7	of	189	190	O
DDI-DrugBank.d143.s7	amiodarone	192	201	B-drug
DDI-DrugBank.d143.s7	.	202	202	O
DDI-DrugBank.d143.s8	Since	0	4	O
DDI-DrugBank.d143.s8	amiodarone	6	15	B-drug
DDI-DrugBank.d143.s8	is	17	18	O
DDI-DrugBank.d143.s8	a	20	20	O
DDI-DrugBank.d143.s8	substrate	22	30	O
DDI-DrugBank.d143.s8	for	32	34	O
DDI-DrugBank.d143.s8	CYP3A4	36	41	O
DDI-DrugBank.d143.s8	and	43	45	O
DDI-DrugBank.d143.s8	CYP2C8	47	52	O
DDI-DrugBank.d143.s8	,	53	53	O
DDI-DrugBank.d143.s8	drugs/substances	55	70	O
DDI-DrugBank.d143.s8	that	72	75	O
DDI-DrugBank.d143.s8	inhibit	77	83	O
DDI-DrugBank.d143.s8	these	85	89	O
DDI-DrugBank.d143.s8	isoenzymes	91	100	O
DDI-DrugBank.d143.s8	may	102	104	O
DDI-DrugBank.d143.s8	decrease	106	113	O
DDI-DrugBank.d143.s8	the	115	117	O
DDI-DrugBank.d143.s8	metabolism	119	128	O
DDI-DrugBank.d143.s8	and	130	132	O
DDI-DrugBank.d143.s8	increase	134	141	O
DDI-DrugBank.d143.s8	serum	143	147	O
DDI-DrugBank.d143.s8	concentration	149	161	O
DDI-DrugBank.d143.s8	of	163	164	O
DDI-DrugBank.d143.s8	amiodarone	166	175	B-drug
DDI-DrugBank.d143.s8	.	176	176	O
DDI-DrugBank.d143.s9	Reported	0	7	O
DDI-DrugBank.d143.s9	examples	9	16	O
DDI-DrugBank.d143.s9	include	18	24	O
DDI-DrugBank.d143.s9	the	26	28	O
DDI-DrugBank.d143.s9	following	30	38	O
DDI-DrugBank.d143.s9	:	39	39	O
DDI-DrugBank.d143.s9	Protease	41	48	B-group
DDI-DrugBank.d143.s9	Inhibitors	50	59	I-group
DDI-DrugBank.d143.s9	:	60	60	O
DDI-DrugBank.d143.s9	Protease	62	69	B-group
DDI-DrugBank.d143.s9	inhibitors	71	80	I-group
DDI-DrugBank.d143.s9	are	82	84	O
DDI-DrugBank.d143.s9	known	86	90	O
DDI-DrugBank.d143.s9	to	92	93	O
DDI-DrugBank.d143.s9	inhibit	95	101	O
DDI-DrugBank.d143.s9	CYP3A4	103	108	O
DDI-DrugBank.d143.s9	to	110	111	O
DDI-DrugBank.d143.s9	varying	113	119	O
DDI-DrugBank.d143.s9	degrees	121	127	O
DDI-DrugBank.d143.s9	.	128	128	O
DDI-DrugBank.d143.s10	A	0	0	O
DDI-DrugBank.d143.s10	case	2	5	O
DDI-DrugBank.d143.s10	report	7	12	O
DDI-DrugBank.d143.s10	of	14	15	O
DDI-DrugBank.d143.s10	one	17	19	O
DDI-DrugBank.d143.s10	patient	21	27	O
DDI-DrugBank.d143.s10	taking	29	34	O
DDI-DrugBank.d143.s10	amiodarone	36	45	B-drug
DDI-DrugBank.d143.s10	200	47	49	O
DDI-DrugBank.d143.s10	mg	51	52	O
DDI-DrugBank.d143.s10	and	54	56	O
DDI-DrugBank.d143.s10	indinavir	58	66	B-drug
DDI-DrugBank.d143.s10	800	68	70	O
DDI-DrugBank.d143.s10	mg	72	73	O
DDI-DrugBank.d143.s10	three	75	79	O
DDI-DrugBank.d143.s10	times	81	85	O
DDI-DrugBank.d143.s10	a	87	87	O
DDI-DrugBank.d143.s10	day	89	91	O
DDI-DrugBank.d143.s10	resulted	93	100	O
DDI-DrugBank.d143.s10	in	102	103	O
DDI-DrugBank.d143.s10	increases	105	113	O
DDI-DrugBank.d143.s10	in	102	103	O
DDI-DrugBank.d143.s10	amiodarone	118	127	B-drug
DDI-DrugBank.d143.s10	concentrations	129	142	O
DDI-DrugBank.d143.s10	from	144	147	O
DDI-DrugBank.d143.s10	0.9	149	151	O
DDI-DrugBank.d143.s10	mg/L	153	156	O
DDI-DrugBank.d143.s10	to	158	159	O
DDI-DrugBank.d143.s10	1.3	161	163	O
DDI-DrugBank.d143.s10	mg/L	153	156	O
DDI-DrugBank.d143.s10	.	150	150	O
DDI-DrugBank.d143.s11	DEA	0	2	O
DDI-DrugBank.d143.s11	concentrations	4	17	O
DDI-DrugBank.d143.s11	were	19	22	O
DDI-DrugBank.d143.s11	not	24	26	O
DDI-DrugBank.d143.s11	affected	28	35	O
DDI-DrugBank.d143.s11	.	36	36	O
DDI-DrugBank.d143.s12	There	0	4	O
DDI-DrugBank.d143.s12	was	6	8	O
DDI-DrugBank.d143.s12	no	10	11	O
DDI-DrugBank.d143.s12	evidence	13	20	O
DDI-DrugBank.d143.s12	of	22	23	O
DDI-DrugBank.d143.s12	toxicity	25	32	O
DDI-DrugBank.d143.s12	.	33	33	O
DDI-DrugBank.d143.s13	Monitoring	0	9	O
DDI-DrugBank.d143.s13	for	11	13	O
DDI-DrugBank.d143.s13	amiodarone	15	24	B-drug
DDI-DrugBank.d143.s13	toxicity	26	33	O
DDI-DrugBank.d143.s13	and	35	37	O
DDI-DrugBank.d143.s13	serial	39	44	O
DDI-DrugBank.d143.s13	measurement	46	56	O
DDI-DrugBank.d143.s13	of	58	59	O
DDI-DrugBank.d143.s13	amiodarone	61	70	B-drug
DDI-DrugBank.d143.s13	serum	72	76	O
DDI-DrugBank.d143.s13	concentration	78	90	O
DDI-DrugBank.d143.s13	during	92	97	O
DDI-DrugBank.d143.s13	concomitant	99	109	O
DDI-DrugBank.d143.s13	protease	111	118	B-group
DDI-DrugBank.d143.s13	inhibitor	120	128	I-group
DDI-DrugBank.d143.s13	therapy	130	136	O
DDI-DrugBank.d143.s13	should	138	143	O
DDI-DrugBank.d143.s13	be	145	146	O
DDI-DrugBank.d143.s13	considered	148	157	O
DDI-DrugBank.d143.s13	.	158	158	O
DDI-DrugBank.d143.s14	Histamine	0	8	B-group
DDI-DrugBank.d143.s14	H2	10	11	I-group
DDI-DrugBank.d143.s14	antagonists	13	23	I-group
DDI-DrugBank.d143.s14	:	24	24	O
DDI-DrugBank.d143.s14	Cimetidine	26	35	B-drug
DDI-DrugBank.d143.s14	inhibits	37	44	O
DDI-DrugBank.d143.s14	CYP3A4	46	51	O
DDI-DrugBank.d143.s14	and	53	55	O
DDI-DrugBank.d143.s14	can	57	59	O
DDI-DrugBank.d143.s14	increase	61	68	O
DDI-DrugBank.d143.s14	serum	70	74	O
DDI-DrugBank.d143.s14	amiodarone	76	85	B-drug
DDI-DrugBank.d143.s14	levels	87	92	O
DDI-DrugBank.d143.s14	.	93	93	O
DDI-DrugBank.d143.s15	Other	0	4	O
DDI-DrugBank.d143.s15	substances	6	15	O
DDI-DrugBank.d143.s15	:	16	16	O
DDI-DrugBank.d143.s15	Grapefruit	18	27	O
DDI-DrugBank.d143.s15	juice	29	33	O
DDI-DrugBank.d143.s15	given	35	39	O
DDI-DrugBank.d143.s15	to	41	42	O
DDI-DrugBank.d143.s15	healthy	44	50	O
DDI-DrugBank.d143.s15	volunteers	52	61	O
DDI-DrugBank.d143.s15	increased	63	71	O
DDI-DrugBank.d143.s15	amiodarone	73	82	B-drug
DDI-DrugBank.d143.s15	AUC	84	86	O
DDI-DrugBank.d143.s15	by	88	89	O
DDI-DrugBank.d143.s15	50	91	92	O
DDI-DrugBank.d143.s15	%	93	93	O
DDI-DrugBank.d143.s15	and	95	97	O
DDI-DrugBank.d143.s15	Cmax	99	102	O
DDI-DrugBank.d143.s15	by	104	105	O
DDI-DrugBank.d143.s15	84	107	108	O
DDI-DrugBank.d143.s15	%	93	93	O
DDI-DrugBank.d143.s15	,	110	110	O
DDI-DrugBank.d143.s15	resulting	112	120	O
DDI-DrugBank.d143.s15	in	118	119	O
DDI-DrugBank.d143.s15	increased	125	133	O
DDI-DrugBank.d143.s15	plasma	135	140	O
DDI-DrugBank.d143.s15	levels	142	147	O
DDI-DrugBank.d143.s15	of	149	150	O
DDI-DrugBank.d143.s15	amiodarone	152	161	B-drug
DDI-DrugBank.d143.s15	.	162	162	O
DDI-DrugBank.d143.s16	Grapefruit	0	9	O
DDI-DrugBank.d143.s16	juice	11	15	O
DDI-DrugBank.d143.s16	should	17	22	O
DDI-DrugBank.d143.s16	not	24	26	O
DDI-DrugBank.d143.s16	be	28	29	O
DDI-DrugBank.d143.s16	taken	31	35	O
DDI-DrugBank.d143.s16	during	37	42	O
DDI-DrugBank.d143.s16	treatment	44	52	O
DDI-DrugBank.d143.s16	with	54	57	O
DDI-DrugBank.d143.s16	oral	59	62	O
DDI-DrugBank.d143.s16	amiodarone	64	73	O
DDI-DrugBank.d143.s16	.	74	74	O
DDI-DrugBank.d143.s17	This	0	3	O
DDI-DrugBank.d143.s17	information	5	15	O
DDI-DrugBank.d143.s17	should	17	22	O
DDI-DrugBank.d143.s17	be	24	25	O
DDI-DrugBank.d143.s17	considered	27	36	O
DDI-DrugBank.d143.s17	when	38	41	O
DDI-DrugBank.d143.s17	changing	43	50	O
DDI-DrugBank.d143.s17	from	52	55	O
DDI-DrugBank.d143.s17	intravenous	57	67	O
DDI-DrugBank.d143.s17	amiodarone	69	78	B-drug
DDI-DrugBank.d143.s17	to	80	81	O
DDI-DrugBank.d143.s17	oral	83	86	O
DDI-DrugBank.d143.s17	amiodarone	88	97	B-drug
DDI-DrugBank.d143.s17	.	99	99	O
DDI-DrugBank.d143.s18	Amiodarone	0	9	B-drug
DDI-DrugBank.d143.s18	may	11	13	O
DDI-DrugBank.d143.s18	suppress	15	22	O
DDI-DrugBank.d143.s18	certain	24	30	O
DDI-DrugBank.d143.s18	CYP450	32	37	O
DDI-DrugBank.d143.s18	enzymes	39	45	O
DDI-DrugBank.d143.s18	,	46	46	O
DDI-DrugBank.d143.s18	including	48	56	O
DDI-DrugBank.d143.s18	CYP1A2	58	63	B-drug
DDI-DrugBank.d143.s18	,	64	64	O
DDI-DrugBank.d143.s18	CYP2C9	66	71	B-drug
DDI-DrugBank.d143.s18	,	64	64	O
DDI-DrugBank.d143.s18	CYP2D6	74	79	B-drug
DDI-DrugBank.d143.s18	,	72	72	O
DDI-DrugBank.d143.s18	and	82	84	O
DDI-DrugBank.d143.s18	CYP3A4	86	91	B-drug
DDI-DrugBank.d143.s18	.	92	92	O
DDI-DrugBank.d143.s19	This	0	3	O
DDI-DrugBank.d143.s19	inhibition	5	14	O
DDI-DrugBank.d143.s19	can	16	18	O
DDI-DrugBank.d143.s19	result	20	25	O
DDI-DrugBank.d143.s19	in	27	28	O
DDI-DrugBank.d143.s19	unexpectedly	30	41	O
DDI-DrugBank.d143.s19	high	43	46	O
DDI-DrugBank.d143.s19	plasma	48	53	O
DDI-DrugBank.d143.s19	levels	55	60	O
DDI-DrugBank.d143.s19	of	62	63	O
DDI-DrugBank.d143.s19	other	65	69	O
DDI-DrugBank.d143.s19	drugs	71	75	B-drug
DDI-DrugBank.d143.s19	which	77	81	O
DDI-DrugBank.d143.s19	are	83	85	O
DDI-DrugBank.d143.s19	metabolized	87	97	O
DDI-DrugBank.d143.s19	by	99	100	O
DDI-DrugBank.d143.s19	those	102	106	O
DDI-DrugBank.d143.s19	CYP450	108	113	O
DDI-DrugBank.d143.s19	enzymes	115	121	O
DDI-DrugBank.d143.s19	.	122	122	O
DDI-DrugBank.d143.s20	Reported	0	7	O
DDI-DrugBank.d143.s20	examples	9	16	O
DDI-DrugBank.d143.s20	of	18	19	O
DDI-DrugBank.d143.s20	this	21	24	O
DDI-DrugBank.d143.s20	interaction	26	36	O
DDI-DrugBank.d143.s20	include	38	44	O
DDI-DrugBank.d143.s20	the	46	48	O
DDI-DrugBank.d143.s20	following	50	58	O
DDI-DrugBank.d143.s20	:	59	59	O
DDI-DrugBank.d143.s20	Immunosuppressives	61	78	O
DDI-DrugBank.d143.s20	:	79	79	O
DDI-DrugBank.d143.s20	Cyclosporine	81	92	B-drug
DDI-DrugBank.d143.s20	(	94	94	O
DDI-DrugBank.d143.s20	CYP3A4	95	100	B-drug
DDI-DrugBank.d143.s20	substrate	102	110	O
DDI-DrugBank.d143.s20	)	111	111	O
DDI-DrugBank.d143.s20	administered	113	124	O
DDI-DrugBank.d143.s20	in	116	117	O
DDI-DrugBank.d143.s20	combination	129	139	O
DDI-DrugBank.d143.s20	with	141	144	O
DDI-DrugBank.d143.s20	oral	146	149	O
DDI-DrugBank.d143.s20	amiodarone	151	160	B-drug
DDI-DrugBank.d143.s20	has	162	164	O
DDI-DrugBank.d143.s20	been	166	169	O
DDI-DrugBank.d143.s20	reported	171	178	O
DDI-DrugBank.d143.s20	to	180	181	O
DDI-DrugBank.d143.s20	produce	183	189	O
DDI-DrugBank.d143.s20	persistently	191	202	O
DDI-DrugBank.d143.s20	elevated	204	211	O
DDI-DrugBank.d143.s20	plasma	213	218	O
DDI-DrugBank.d143.s20	concentrations	220	233	O
DDI-DrugBank.d143.s20	of	235	236	O
DDI-DrugBank.d143.s20	cyclosporine	238	249	B-drug
DDI-DrugBank.d143.s20	resulting	251	259	O
DDI-DrugBank.d143.s20	in	247	248	I-drug
DDI-DrugBank.d143.s20	elevated	264	271	O
DDI-DrugBank.d143.s20	creatinine	273	282	O
DDI-DrugBank.d143.s20	,	283	283	O
DDI-DrugBank.d143.s20	despite	285	291	O
DDI-DrugBank.d143.s20	reduction	293	301	O
DDI-DrugBank.d143.s20	in	278	279	O
DDI-DrugBank.d143.s20	dose	306	309	O
DDI-DrugBank.d143.s20	of	311	312	O
DDI-DrugBank.d143.s20	cyclosporine	314	325	B-drug
DDI-DrugBank.d143.s20	.	326	326	O
DDI-DrugBank.d143.s21	HMG-CoA	0	6	B-drug
DDI-DrugBank.d143.s21	Reductase	8	16	I-drug
DDI-DrugBank.d143.s21	Inhibitors	18	27	I-drug
DDI-DrugBank.d143.s21	:	28	28	O
DDI-DrugBank.d143.s21	Simvastatin	30	40	B-drug
DDI-DrugBank.d143.s21	(	42	42	O
DDI-DrugBank.d143.s21	CYP3A4	43	48	B-drug
DDI-DrugBank.d143.s21	substrate	50	58	O
DDI-DrugBank.d143.s21	)	59	59	O
DDI-DrugBank.d143.s21	in	61	62	O
DDI-DrugBank.d143.s21	combination	64	74	O
DDI-DrugBank.d143.s21	with	76	79	O
DDI-DrugBank.d143.s21	amiodarone	81	90	B-drug
DDI-DrugBank.d143.s21	has	92	94	O
DDI-DrugBank.d143.s21	been	96	99	O
DDI-DrugBank.d143.s21	associated	101	110	O
DDI-DrugBank.d143.s21	with	112	115	O
DDI-DrugBank.d143.s21	reports	117	123	O
DDI-DrugBank.d143.s21	of	125	126	O
DDI-DrugBank.d143.s21	myopathy/rhabdomyolysis	128	150	O
DDI-DrugBank.d143.s21	.	151	151	O
DDI-DrugBank.d143.s22	Cardiovasculars	0	14	O
DDI-DrugBank.d143.s22	:	15	15	O
DDI-DrugBank.d143.s22	Cardiac	17	23	B-drug
DDI-DrugBank.d143.s22	glycosides	25	34	I-drug
DDI-DrugBank.d143.s22	:	35	35	O
DDI-DrugBank.d143.s22	In	37	38	O
DDI-DrugBank.d143.s22	patients	40	47	O
DDI-DrugBank.d143.s22	receiving	49	57	O
DDI-DrugBank.d143.s22	digoxin	59	65	B-drug
DDI-DrugBank.d143.s22	therapy	67	73	O
DDI-DrugBank.d143.s22	,	74	74	O
DDI-DrugBank.d143.s22	administration	76	89	O
DDI-DrugBank.d143.s22	of	91	92	O
DDI-DrugBank.d143.s22	oral	94	97	O
DDI-DrugBank.d143.s22	amiodarone	99	108	B-drug
DDI-DrugBank.d143.s22	regularly	110	118	O
DDI-DrugBank.d143.s22	results	120	126	O
DDI-DrugBank.d143.s22	in	128	129	O
DDI-DrugBank.d143.s22	an	131	132	O
DDI-DrugBank.d143.s22	increase	134	141	O
DDI-DrugBank.d143.s22	in	128	129	O
DDI-DrugBank.d143.s22	serum	146	150	O
DDI-DrugBank.d143.s22	digoxin	152	158	B-drug
DDI-DrugBank.d143.s22	concentration	160	172	O
DDI-DrugBank.d143.s22	that	174	177	O
DDI-DrugBank.d143.s22	may	179	181	O
DDI-DrugBank.d143.s22	reach	183	187	O
DDI-DrugBank.d143.s22	toxic	189	193	O
DDI-DrugBank.d143.s22	levels	195	200	O
DDI-DrugBank.d143.s22	with	202	205	O
DDI-DrugBank.d143.s22	resultant	207	215	O
DDI-DrugBank.d143.s22	clinical	217	224	O
DDI-DrugBank.d143.s22	toxicity	226	233	O
DDI-DrugBank.d143.s22	.	234	234	O
DDI-DrugBank.d143.s23	Amiodarone	0	9	B-drug
DDI-DrugBank.d143.s23	taken	11	15	O
DDI-DrugBank.d143.s23	concomitantly	17	29	O
DDI-DrugBank.d143.s23	with	31	34	O
DDI-DrugBank.d143.s23	digoxin	36	42	B-drug
DDI-DrugBank.d143.s23	increases	44	52	O
DDI-DrugBank.d143.s23	the	54	56	O
DDI-DrugBank.d143.s23	serum	58	62	O
DDI-DrugBank.d143.s23	digoxin	64	70	B-drug
DDI-DrugBank.d143.s23	concentration	72	84	O
DDI-DrugBank.d143.s23	by	86	87	O
DDI-DrugBank.d143.s23	70	89	90	O
DDI-DrugBank.d143.s23	%	91	91	O
DDI-DrugBank.d143.s23	after	93	97	O
DDI-DrugBank.d143.s23	one	99	101	O
DDI-DrugBank.d143.s23	day	103	105	O
DDI-DrugBank.d143.s23	.	106	106	O
DDI-DrugBank.d143.s24	On	0	1	O
DDI-DrugBank.d143.s24	administration	3	16	O
DDI-DrugBank.d143.s24	of	18	19	O
DDI-DrugBank.d143.s24	oral	21	24	O
DDI-DrugBank.d143.s24	amiodarone	26	35	B-drug
DDI-DrugBank.d143.s24	,	36	36	O
DDI-DrugBank.d143.s24	the	38	40	O
DDI-DrugBank.d143.s24	need	42	45	O
DDI-DrugBank.d143.s24	for	47	49	O
DDI-DrugBank.d143.s24	digitalis	51	59	B-group
DDI-DrugBank.d143.s24	therapy	61	67	O
DDI-DrugBank.d143.s24	should	69	74	O
DDI-DrugBank.d143.s24	be	76	77	O
DDI-DrugBank.d143.s24	reviewed	79	86	O
DDI-DrugBank.d143.s24	and	88	90	O
DDI-DrugBank.d143.s24	the	92	94	O
DDI-DrugBank.d143.s24	dose	96	99	O
DDI-DrugBank.d143.s24	reduced	101	107	O
DDI-DrugBank.d143.s24	by	109	110	O
DDI-DrugBank.d143.s24	approximately	112	124	O
DDI-DrugBank.d143.s24	50	126	127	O
DDI-DrugBank.d143.s24	%	128	128	O
DDI-DrugBank.d143.s24	or	130	131	O
DDI-DrugBank.d143.s24	discontinued	133	144	O
DDI-DrugBank.d143.s24	.	145	145	O
DDI-DrugBank.d143.s25	If	0	1	O
DDI-DrugBank.d143.s25	digitalis	3	11	B-drug
DDI-DrugBank.d143.s25	treatment	13	21	O
DDI-DrugBank.d143.s25	is	23	24	O
DDI-DrugBank.d143.s25	continued	26	34	O
DDI-DrugBank.d143.s25	,	35	35	O
DDI-DrugBank.d143.s25	serum	37	41	O
DDI-DrugBank.d143.s25	levels	43	48	O
DDI-DrugBank.d143.s25	should	50	55	O
DDI-DrugBank.d143.s25	be	57	58	O
DDI-DrugBank.d143.s25	closely	60	66	O
DDI-DrugBank.d143.s25	monitored	68	76	O
DDI-DrugBank.d143.s25	and	78	80	O
DDI-DrugBank.d143.s25	patients	82	89	O
DDI-DrugBank.d143.s25	observed	91	98	O
DDI-DrugBank.d143.s25	for	100	102	O
DDI-DrugBank.d143.s25	clinical	104	111	O
DDI-DrugBank.d143.s25	evidence	113	120	O
DDI-DrugBank.d143.s25	of	122	123	O
DDI-DrugBank.d143.s25	toxicity	125	132	O
DDI-DrugBank.d143.s25	.	133	133	O
DDI-DrugBank.d143.s26	These	0	4	O
DDI-DrugBank.d143.s26	precautions	6	16	O
DDI-DrugBank.d143.s26	probably	18	25	O
DDI-DrugBank.d143.s26	should	27	32	O
DDI-DrugBank.d143.s26	apply	34	38	O
DDI-DrugBank.d143.s26	to	40	41	O
DDI-DrugBank.d143.s26	digitoxin	43	51	B-drug
DDI-DrugBank.d143.s26	administration	53	66	O
DDI-DrugBank.d143.s26	as	68	69	O
DDI-DrugBank.d143.s26	well	71	74	O
DDI-DrugBank.d143.s26	.	75	75	O
DDI-DrugBank.d143.s27	Antiarrhythmics	0	14	B-drug
DDI-DrugBank.d143.s27	:	15	15	O
DDI-DrugBank.d143.s27	Other	17	21	O
DDI-DrugBank.d143.s27	antiarrhythmic	23	36	B-drug
DDI-DrugBank.d143.s27	drugs	38	42	O
DDI-DrugBank.d143.s27	,	43	43	O
DDI-DrugBank.d143.s27	such	45	48	O
DDI-DrugBank.d143.s27	as	50	51	O
DDI-DrugBank.d143.s27	quinidine	53	61	B-drug
DDI-DrugBank.d143.s27	,	62	62	O
DDI-DrugBank.d143.s27	procainamide	64	75	B-drug
DDI-DrugBank.d143.s27	,	76	76	O
DDI-DrugBank.d143.s27	disopyramide	78	89	B-drug
DDI-DrugBank.d143.s27	,	90	90	O
DDI-DrugBank.d143.s27	and	92	94	O
DDI-DrugBank.d143.s27	phenytoin	96	104	B-drug
DDI-DrugBank.d143.s27	,	105	105	O
DDI-DrugBank.d143.s27	have	107	110	O
DDI-DrugBank.d143.s27	been	112	115	O
DDI-DrugBank.d143.s27	used	117	120	O
DDI-DrugBank.d143.s27	concurrently	122	133	O
DDI-DrugBank.d143.s27	with	135	138	O
DDI-DrugBank.d143.s27	amiodarone	140	149	B-drug
DDI-DrugBank.d143.s27	.	150	150	O
DDI-DrugBank.d143.s28	There	0	4	O
DDI-DrugBank.d143.s28	have	6	9	O
DDI-DrugBank.d143.s28	been	11	14	O
DDI-DrugBank.d143.s28	case	16	19	O
DDI-DrugBank.d143.s28	reports	21	27	O
DDI-DrugBank.d143.s28	of	29	30	O
DDI-DrugBank.d143.s28	increased	32	40	O
DDI-DrugBank.d143.s28	steady-state	42	53	O
DDI-DrugBank.d143.s28	levels	55	60	O
DDI-DrugBank.d143.s28	of	62	63	O
DDI-DrugBank.d143.s28	quinidine	65	73	B-drug
DDI-DrugBank.d143.s28	,	74	74	O
DDI-DrugBank.d143.s28	procainamide	76	87	B-drug
DDI-DrugBank.d143.s28	,	88	88	O
DDI-DrugBank.d143.s28	and	90	92	O
DDI-DrugBank.d143.s28	phenytoin	94	102	B-drug
DDI-DrugBank.d143.s28	during	104	109	O
DDI-DrugBank.d143.s28	concomitant	111	121	O
DDI-DrugBank.d143.s28	therapy	123	129	O
DDI-DrugBank.d143.s28	with	131	134	O
DDI-DrugBank.d143.s28	amiodarone	136	145	B-drug
DDI-DrugBank.d143.s28	.	146	146	O
DDI-DrugBank.d143.s29	Phenytoin	0	8	B-drug
DDI-DrugBank.d143.s29	decreases	10	18	O
DDI-DrugBank.d143.s29	serum	20	24	O
DDI-DrugBank.d143.s29	amiodarone	26	35	O
DDI-DrugBank.d143.s29	levels	37	42	O
DDI-DrugBank.d143.s29	.	43	43	O
DDI-DrugBank.d143.s30	Amiodarone	0	9	B-drug
DDI-DrugBank.d143.s30	taken	11	15	O
DDI-DrugBank.d143.s30	concomitantly	17	29	O
DDI-DrugBank.d143.s30	with	31	34	O
DDI-DrugBank.d143.s30	quinidine	36	44	B-drug
DDI-DrugBank.d143.s30	increases	46	54	O
DDI-DrugBank.d143.s30	quinidine	56	64	B-drug
DDI-DrugBank.d143.s30	serum	66	70	O
DDI-DrugBank.d143.s30	concentration	72	84	O
DDI-DrugBank.d143.s30	by	86	87	O
DDI-DrugBank.d143.s30	33	89	90	O
DDI-DrugBank.d143.s30	%	91	91	O
DDI-DrugBank.d143.s30	after	93	97	O
DDI-DrugBank.d143.s30	two	99	101	O
DDI-DrugBank.d143.s30	days	103	106	O
DDI-DrugBank.d143.s30	.	107	107	O
DDI-DrugBank.d143.s31	Amiodarone	0	9	B-drug
DDI-DrugBank.d143.s31	taken	11	15	O
DDI-DrugBank.d143.s31	concomitantly	17	29	O
DDI-DrugBank.d143.s31	with	31	34	O
DDI-DrugBank.d143.s31	procainamide	36	47	B-drug
DDI-DrugBank.d143.s31	for	49	51	O
DDI-DrugBank.d143.s31	less	53	56	O
DDI-DrugBank.d143.s31	than	58	61	O
DDI-DrugBank.d143.s31	seven	63	67	O
DDI-DrugBank.d143.s31	days	69	72	O
DDI-DrugBank.d143.s31	increases	74	82	O
DDI-DrugBank.d143.s31	plasma	84	89	O
DDI-DrugBank.d143.s31	concentrations	91	104	O
DDI-DrugBank.d143.s31	of	106	107	O
DDI-DrugBank.d143.s31	procainamide	109	120	B-drug
DDI-DrugBank.d143.s31	and	122	124	O
DDI-DrugBank.d143.s31	n-acetyl	126	133	O
DDI-DrugBank.d143.s31	procainamide	135	146	B-drug
DDI-DrugBank.d143.s31	by	148	149	O
DDI-DrugBank.d143.s31	55	151	152	O
DDI-DrugBank.d143.s31	%	153	153	O
DDI-DrugBank.d143.s31	and	155	157	O
DDI-DrugBank.d143.s31	33	159	160	O
DDI-DrugBank.d143.s31	%	153	153	O
DDI-DrugBank.d143.s31	,	162	162	O
DDI-DrugBank.d143.s31	respectively	164	175	O
DDI-DrugBank.d143.s31	.	176	176	O
DDI-DrugBank.d143.s32	Quinidine	0	8	B-drug
DDI-DrugBank.d143.s32	and	10	12	O
DDI-DrugBank.d143.s32	procainamide	14	25	O
DDI-DrugBank.d143.s32	doses	27	31	O
DDI-DrugBank.d143.s32	should	33	38	O
DDI-DrugBank.d143.s32	be	40	41	O
DDI-DrugBank.d143.s32	reduced	43	49	O
DDI-DrugBank.d143.s32	by	51	52	O
DDI-DrugBank.d143.s32	one-third	54	62	O
DDI-DrugBank.d143.s32	when	64	67	O
DDI-DrugBank.d143.s32	either	69	74	O
DDI-DrugBank.d143.s32	is	76	77	O
DDI-DrugBank.d143.s32	administered	79	90	O
DDI-DrugBank.d143.s32	with	92	95	O
DDI-DrugBank.d143.s32	amiodarone	97	106	B-drug
DDI-DrugBank.d143.s32	.	107	107	O
DDI-DrugBank.d143.s33	Plasma	0	5	O
DDI-DrugBank.d143.s33	levels	7	12	O
DDI-DrugBank.d143.s33	of	14	15	O
DDI-DrugBank.d143.s33	flecainide	17	26	B-drug
DDI-DrugBank.d143.s33	have	28	31	O
DDI-DrugBank.d143.s33	been	33	36	O
DDI-DrugBank.d143.s33	reported	38	45	O
DDI-DrugBank.d143.s33	to	47	48	O
DDI-DrugBank.d143.s33	increase	50	57	O
DDI-DrugBank.d143.s33	in	50	51	O
DDI-DrugBank.d143.s33	the	62	64	O
DDI-DrugBank.d143.s33	presence	66	73	O
DDI-DrugBank.d143.s33	of	75	76	O
DDI-DrugBank.d143.s33	oral	78	81	O
DDI-DrugBank.d143.s33	amiodarone	83	92	B-drug
DDI-DrugBank.d143.s33	;	93	93	O
DDI-DrugBank.d143.s34	because	0	6	O
DDI-DrugBank.d143.s34	of	8	9	O
DDI-DrugBank.d143.s34	this	11	14	O
DDI-DrugBank.d143.s34	,	15	15	O
DDI-DrugBank.d143.s34	the	17	19	O
DDI-DrugBank.d143.s34	dosage	21	26	O
DDI-DrugBank.d143.s34	of	28	29	O
DDI-DrugBank.d143.s34	flecainide	31	40	B-drug
DDI-DrugBank.d143.s34	should	42	47	O
DDI-DrugBank.d143.s34	be	49	50	O
DDI-DrugBank.d143.s34	adjusted	52	59	O
DDI-DrugBank.d143.s34	when	61	64	O
DDI-DrugBank.d143.s34	these	66	70	O
DDI-DrugBank.d143.s34	drugs	72	76	B-drug
DDI-DrugBank.d143.s34	are	78	80	O
DDI-DrugBank.d143.s34	administered	82	93	O
DDI-DrugBank.d143.s34	concomitantly	95	107	O
DDI-DrugBank.d143.s34	.	108	108	O
DDI-DrugBank.d143.s35	In	0	1	O
DDI-DrugBank.d143.s35	general	3	9	O
DDI-DrugBank.d143.s35	,	10	10	O
DDI-DrugBank.d143.s35	any	12	14	O
DDI-DrugBank.d143.s35	added	16	20	O
DDI-DrugBank.d143.s35	antiarrhythmic	22	35	B-drug
DDI-DrugBank.d143.s35	drug	37	40	I-drug
DDI-DrugBank.d143.s35	should	42	47	O
DDI-DrugBank.d143.s35	be	49	50	O
DDI-DrugBank.d143.s35	initiated	52	60	O
DDI-DrugBank.d143.s35	at	57	58	O
DDI-DrugBank.d143.s35	a	57	57	O
DDI-DrugBank.d143.s35	lower	67	71	O
DDI-DrugBank.d143.s35	than	73	76	O
DDI-DrugBank.d143.s35	usual	78	82	O
DDI-DrugBank.d143.s35	dose	84	87	O
DDI-DrugBank.d143.s35	with	89	92	O
DDI-DrugBank.d143.s35	careful	94	100	O
DDI-DrugBank.d143.s35	monitoring	102	111	O
DDI-DrugBank.d143.s35	.	112	112	O
DDI-DrugBank.d143.s36	Combination	0	10	O
DDI-DrugBank.d143.s36	of	12	13	O
DDI-DrugBank.d143.s36	amiodarone	15	24	B-drug
DDI-DrugBank.d143.s36	with	26	29	O
DDI-DrugBank.d143.s36	other	31	35	O
DDI-DrugBank.d143.s36	antiarrhythmic	37	50	B-drug
DDI-DrugBank.d143.s36	therapy	52	58	O
DDI-DrugBank.d143.s36	should	60	65	O
DDI-DrugBank.d143.s36	be	67	68	O
DDI-DrugBank.d143.s36	reserved	70	77	O
DDI-DrugBank.d143.s36	for	79	81	O
DDI-DrugBank.d143.s36	patients	83	90	O
DDI-DrugBank.d143.s36	with	92	95	O
DDI-DrugBank.d143.s36	life-threatening	97	112	O
DDI-DrugBank.d143.s36	ventricular	114	124	O
DDI-DrugBank.d143.s36	arrhythmias	126	136	O
DDI-DrugBank.d143.s36	who	138	140	O
DDI-DrugBank.d143.s36	are	142	144	O
DDI-DrugBank.d143.s36	incompletely	146	157	O
DDI-DrugBank.d143.s36	responsive	159	168	O
DDI-DrugBank.d143.s36	to	170	171	O
DDI-DrugBank.d143.s36	a	173	173	O
DDI-DrugBank.d143.s36	single	175	180	O
DDI-DrugBank.d143.s36	agent	182	186	O
DDI-DrugBank.d143.s36	or	188	189	O
DDI-DrugBank.d143.s36	incompletely	191	202	O
DDI-DrugBank.d143.s36	responsive	204	213	O
DDI-DrugBank.d143.s36	to	215	216	O
DDI-DrugBank.d143.s36	amiodarone	218	227	B-drug
DDI-DrugBank.d143.s36	.	228	228	O
DDI-DrugBank.d143.s37	During	0	5	O
DDI-DrugBank.d143.s37	transfer	7	14	O
DDI-DrugBank.d143.s37	to	16	17	O
DDI-DrugBank.d143.s37	oral	19	22	O
DDI-DrugBank.d143.s37	amiodarone	24	33	B-drug
DDI-DrugBank.d143.s37	,	34	34	O
DDI-DrugBank.d143.s37	the	36	38	O
DDI-DrugBank.d143.s37	dose	40	43	O
DDI-DrugBank.d143.s37	levels	45	50	O
DDI-DrugBank.d143.s37	of	52	53	O
DDI-DrugBank.d143.s37	previously	55	64	O
DDI-DrugBank.d143.s37	administered	66	77	O
DDI-DrugBank.d143.s37	agents	79	84	O
DDI-DrugBank.d143.s37	should	86	91	O
DDI-DrugBank.d143.s37	be	93	94	O
DDI-DrugBank.d143.s37	reduced	96	102	O
DDI-DrugBank.d143.s37	by	104	105	O
DDI-DrugBank.d143.s37	30	107	108	O
DDI-DrugBank.d143.s37	to	110	111	O
DDI-DrugBank.d143.s37	50	113	114	O
DDI-DrugBank.d143.s37	%	115	115	O
DDI-DrugBank.d143.s37	several	117	123	O
DDI-DrugBank.d143.s37	days	125	128	O
DDI-DrugBank.d143.s37	after	130	134	O
DDI-DrugBank.d143.s37	the	136	138	O
DDI-DrugBank.d143.s37	addition	140	147	O
DDI-DrugBank.d143.s37	of	149	150	O
DDI-DrugBank.d143.s37	oral	152	155	O
DDI-DrugBank.d143.s37	amiodarone	157	166	B-drug
DDI-DrugBank.d143.s37	.	167	167	O
DDI-DrugBank.d143.s38	The	0	2	O
DDI-DrugBank.d143.s38	continued	4	12	O
DDI-DrugBank.d143.s38	need	14	17	O
DDI-DrugBank.d143.s38	for	19	21	O
DDI-DrugBank.d143.s38	the	23	25	O
DDI-DrugBank.d143.s38	other	27	31	O
DDI-DrugBank.d143.s38	antiarrhythmic	33	46	B-drug
DDI-DrugBank.d143.s38	agent	48	52	O
DDI-DrugBank.d143.s38	should	54	59	O
DDI-DrugBank.d143.s38	be	61	62	O
DDI-DrugBank.d143.s38	reviewed	64	71	O
DDI-DrugBank.d143.s38	after	73	77	O
DDI-DrugBank.d143.s38	the	79	81	O
DDI-DrugBank.d143.s38	effects	83	89	O
DDI-DrugBank.d143.s38	of	91	92	O
DDI-DrugBank.d143.s38	amiodarone	94	103	B-drug
DDI-DrugBank.d143.s38	have	105	108	O
DDI-DrugBank.d143.s38	been	110	113	O
DDI-DrugBank.d143.s38	established	115	125	O
DDI-DrugBank.d143.s38	,	126	126	O
DDI-DrugBank.d143.s38	and	128	130	O
DDI-DrugBank.d143.s38	discontinuation	132	146	O
DDI-DrugBank.d143.s38	ordinarily	148	157	O
DDI-DrugBank.d143.s38	should	159	164	O
DDI-DrugBank.d143.s38	be	166	167	O
DDI-DrugBank.d143.s38	attempted	169	177	O
DDI-DrugBank.d143.s38	.	178	178	O
DDI-DrugBank.d143.s39	If	0	1	O
DDI-DrugBank.d143.s39	the	3	5	O
DDI-DrugBank.d143.s39	treatment	7	15	O
DDI-DrugBank.d143.s39	is	17	18	O
DDI-DrugBank.d143.s39	continued	20	28	O
DDI-DrugBank.d143.s39	,	29	29	O
DDI-DrugBank.d143.s39	these	31	35	O
DDI-DrugBank.d143.s39	patients	37	44	O
DDI-DrugBank.d143.s39	should	46	51	O
DDI-DrugBank.d143.s39	be	53	54	O
DDI-DrugBank.d143.s39	particularly	56	67	O
DDI-DrugBank.d143.s39	carefully	69	77	O
DDI-DrugBank.d143.s39	monitored	79	87	O
DDI-DrugBank.d143.s39	for	89	91	O
DDI-DrugBank.d143.s39	adverse	93	99	O
DDI-DrugBank.d143.s39	effects	101	107	O
DDI-DrugBank.d143.s39	,	108	108	O
DDI-DrugBank.d143.s39	especially	110	119	O
DDI-DrugBank.d143.s39	conduction	121	130	O
DDI-DrugBank.d143.s39	disturbances	132	143	O
DDI-DrugBank.d143.s39	and	145	147	O
DDI-DrugBank.d143.s39	exacerbation	149	160	O
DDI-DrugBank.d143.s39	of	162	163	O
DDI-DrugBank.d143.s39	tachyarrhythmias	165	180	O
DDI-DrugBank.d143.s39	,	181	181	O
DDI-DrugBank.d143.s39	as	179	180	O
DDI-DrugBank.d143.s39	amiodarone	186	195	B-drug
DDI-DrugBank.d143.s39	is	197	198	O
DDI-DrugBank.d143.s39	continued	200	208	O
DDI-DrugBank.d143.s39	.	209	209	O
DDI-DrugBank.d143.s40	In	0	1	O
DDI-DrugBank.d143.s40	amiodarone-treated	3	20	O
DDI-DrugBank.d143.s40	patients	22	29	O
DDI-DrugBank.d143.s40	who	31	33	O
DDI-DrugBank.d143.s40	require	35	41	O
DDI-DrugBank.d143.s40	additional	43	52	O
DDI-DrugBank.d143.s40	antiarrhythmic	54	67	B-drug
DDI-DrugBank.d143.s40	therapy	69	75	O
DDI-DrugBank.d143.s40	,	76	76	O
DDI-DrugBank.d143.s40	the	78	80	O
DDI-DrugBank.d143.s40	initial	82	88	O
DDI-DrugBank.d143.s40	dose	90	93	O
DDI-DrugBank.d143.s40	of	95	96	O
DDI-DrugBank.d143.s40	such	98	101	O
DDI-DrugBank.d143.s40	agents	103	108	O
DDI-DrugBank.d143.s40	should	110	115	O
DDI-DrugBank.d143.s40	be	117	118	O
DDI-DrugBank.d143.s40	approximately	120	132	O
DDI-DrugBank.d143.s40	half	134	137	O
DDI-DrugBank.d143.s40	of	139	140	O
DDI-DrugBank.d143.s40	the	142	144	O
DDI-DrugBank.d143.s40	usual	146	150	O
DDI-DrugBank.d143.s40	recommended	152	162	O
DDI-DrugBank.d143.s40	dose	164	167	O
DDI-DrugBank.d143.s40	.	168	168	O
DDI-DrugBank.d143.s41	Antihypertensives	0	16	B-drug
DDI-DrugBank.d143.s41	:	17	17	O
DDI-DrugBank.d143.s41	Amiodarone	19	28	B-drug
DDI-DrugBank.d143.s41	should	30	35	O
DDI-DrugBank.d143.s41	be	37	38	O
DDI-DrugBank.d143.s41	used	40	43	O
DDI-DrugBank.d143.s41	with	45	48	O
DDI-DrugBank.d143.s41	caution	50	56	O
DDI-DrugBank.d143.s41	in	58	59	O
DDI-DrugBank.d143.s41	patients	61	68	O
DDI-DrugBank.d143.s41	receiving	70	78	O
DDI-DrugBank.d143.s41	-receptor	81	89	O
DDI-DrugBank.d143.s41	blocking	91	98	O
DDI-DrugBank.d143.s41	agents	100	105	O
DDI-DrugBank.d143.s41	(	107	107	O
DDI-DrugBank.d143.s41	e.g.	108	111	O
DDI-DrugBank.d143.s41	,	112	112	O
DDI-DrugBank.d143.s41	propranolol	114	124	B-drug
DDI-DrugBank.d143.s41	,	112	112	O
DDI-DrugBank.d143.s41	a	119	119	O
DDI-DrugBank.d143.s41	CYP3A4	129	134	B-drug
DDI-DrugBank.d143.s41	inhibitor	136	144	O
DDI-DrugBank.d143.s41	)	145	145	O
DDI-DrugBank.d143.s41	or	143	144	O
DDI-DrugBank.d143.s41	calcium	150	156	B-drug
DDI-DrugBank.d143.s41	channel	158	164	I-drug
DDI-DrugBank.d143.s41	antagonists	166	176	O
DDI-DrugBank.d143.s41	(	178	178	O
DDI-DrugBank.d143.s41	e.g.	179	182	O
DDI-DrugBank.d143.s41	,	183	183	O
DDI-DrugBank.d143.s41	verapamil	185	193	B-drug
DDI-DrugBank.d143.s41	,	183	183	O
DDI-DrugBank.d143.s41	a	188	188	O
DDI-DrugBank.d143.s41	CYP3A4	198	203	B-drug
DDI-DrugBank.d143.s41	substrate	205	213	O
DDI-DrugBank.d143.s41	,	194	194	O
DDI-DrugBank.d143.s41	and	216	218	O
DDI-DrugBank.d143.s41	diltiazem	220	228	B-drug
DDI-DrugBank.d143.s41	,	214	214	O
DDI-DrugBank.d143.s41	a	211	211	O
DDI-DrugBank.d143.s41	CYP3A4	233	238	B-drug
DDI-DrugBank.d143.s41	inhibitor	240	248	O
DDI-DrugBank.d143.s41	)	249	249	O
DDI-DrugBank.d143.s41	because	251	257	O
DDI-DrugBank.d143.s41	of	259	260	O
DDI-DrugBank.d143.s41	the	262	264	O
DDI-DrugBank.d143.s41	possible	266	273	O
DDI-DrugBank.d143.s41	potentiation	275	286	O
DDI-DrugBank.d143.s41	of	259	260	O
DDI-DrugBank.d143.s41	bradycardia	291	301	O
DDI-DrugBank.d143.s41	,	302	302	O
DDI-DrugBank.d143.s41	sinus	304	308	O
DDI-DrugBank.d143.s41	arrest	310	315	O
DDI-DrugBank.d143.s41	,	302	302	O
DDI-DrugBank.d143.s41	and	318	320	O
DDI-DrugBank.d143.s41	AV	322	323	O
DDI-DrugBank.d143.s41	block	325	329	O
DDI-DrugBank.d143.s41	;	330	330	O
DDI-DrugBank.d143.s42	if	0	1	O
DDI-DrugBank.d143.s42	necessary	3	11	O
DDI-DrugBank.d143.s42	,	12	12	O
DDI-DrugBank.d143.s42	amiodarone	14	23	B-drug
DDI-DrugBank.d143.s42	can	25	27	O
DDI-DrugBank.d143.s42	continue	29	36	O
DDI-DrugBank.d143.s42	to	38	39	O
DDI-DrugBank.d143.s42	be	41	42	O
DDI-DrugBank.d143.s42	used	44	47	O
DDI-DrugBank.d143.s42	after	49	53	O
DDI-DrugBank.d143.s42	insertion	55	63	O
DDI-DrugBank.d143.s42	of	65	66	O
DDI-DrugBank.d143.s42	a	68	68	O
DDI-DrugBank.d143.s42	pacemaker	70	78	O
DDI-DrugBank.d143.s42	in	80	81	O
DDI-DrugBank.d143.s42	patients	83	90	O
DDI-DrugBank.d143.s42	with	92	95	O
DDI-DrugBank.d143.s42	severe	97	102	O
DDI-DrugBank.d143.s42	bradycardia	104	114	O
DDI-DrugBank.d143.s42	or	116	117	O
DDI-DrugBank.d143.s42	sinus	119	123	O
DDI-DrugBank.d143.s42	arrest	125	130	O
DDI-DrugBank.d143.s42	.	131	131	O
DDI-DrugBank.d143.s43	Anticoagulants	0	13	B-drug
DDI-DrugBank.d143.s43	:	14	14	O
DDI-DrugBank.d143.s43	Potentiation	16	27	O
DDI-DrugBank.d143.s43	of	29	30	O
DDI-DrugBank.d143.s43	warfarin-type	32	44	O
DDI-DrugBank.d143.s43	(	46	46	O
DDI-DrugBank.d143.s43	CYP2C9	47	52	B-drug
DDI-DrugBank.d143.s43	and	54	56	O
DDI-DrugBank.d143.s43	CYP3A4	58	63	B-drug
DDI-DrugBank.d143.s43	substrate	65	73	O
DDI-DrugBank.d143.s43	)	74	74	O
DDI-DrugBank.d143.s43	anticoagulant	76	88	B-drug
DDI-DrugBank.d143.s43	response	90	97	O
DDI-DrugBank.d143.s43	is	99	100	O
DDI-DrugBank.d143.s43	almost	102	107	O
DDI-DrugBank.d143.s43	always	109	114	O
DDI-DrugBank.d143.s43	seen	116	119	O
DDI-DrugBank.d143.s43	in	121	122	O
DDI-DrugBank.d143.s43	patients	124	131	O
DDI-DrugBank.d143.s43	receiving	133	141	O
DDI-DrugBank.d143.s43	amiodarone	143	152	B-drug
DDI-DrugBank.d143.s43	and	154	156	O
DDI-DrugBank.d143.s43	can	158	160	O
DDI-DrugBank.d143.s43	result	162	167	O
DDI-DrugBank.d143.s43	in	169	170	O
DDI-DrugBank.d143.s43	serious	172	178	O
DDI-DrugBank.d143.s43	or	180	181	O
DDI-DrugBank.d143.s43	fatal	183	187	O
DDI-DrugBank.d143.s43	bleeding	189	196	O
DDI-DrugBank.d143.s43	.	197	197	O
DDI-DrugBank.d143.s44	Since	0	4	O
DDI-DrugBank.d143.s44	the	6	8	O
DDI-DrugBank.d143.s44	concomitant	10	20	O
DDI-DrugBank.d143.s44	administration	22	35	O
DDI-DrugBank.d143.s44	of	37	38	O
DDI-DrugBank.d143.s44	warfarin	40	47	B-drug
DDI-DrugBank.d143.s44	with	49	52	O
DDI-DrugBank.d143.s44	amiodarone	54	63	B-drug
DDI-DrugBank.d143.s44	increases	65	73	O
DDI-DrugBank.d143.s44	the	75	77	O
DDI-DrugBank.d143.s44	prothrombin	79	89	O
DDI-DrugBank.d143.s44	time	91	94	O
DDI-DrugBank.d143.s44	by	96	97	O
DDI-DrugBank.d143.s44	100	99	101	O
DDI-DrugBank.d143.s44	%	102	102	O
DDI-DrugBank.d143.s44	after	104	108	O
DDI-DrugBank.d143.s44	3	110	110	O
DDI-DrugBank.d143.s44	to	112	113	O
DDI-DrugBank.d143.s44	4	115	115	O
DDI-DrugBank.d143.s44	days	117	120	O
DDI-DrugBank.d143.s44	,	121	121	O
DDI-DrugBank.d143.s44	the	123	125	O
DDI-DrugBank.d143.s44	dose	127	130	O
DDI-DrugBank.d143.s44	of	132	133	O
DDI-DrugBank.d143.s44	the	123	125	O
DDI-DrugBank.d143.s44	anticoagulant	139	151	B-drug
DDI-DrugBank.d143.s44	should	153	158	O
DDI-DrugBank.d143.s44	be	160	161	O
DDI-DrugBank.d143.s44	reduced	163	169	O
DDI-DrugBank.d143.s44	by	171	172	O
DDI-DrugBank.d143.s44	one-third	174	182	O
DDI-DrugBank.d143.s44	to	184	185	O
DDI-DrugBank.d143.s44	one-half	187	194	O
DDI-DrugBank.d143.s44	,	195	195	O
DDI-DrugBank.d143.s44	and	197	199	O
DDI-DrugBank.d143.s44	prothrombin	201	211	O
DDI-DrugBank.d143.s44	times	213	217	O
DDI-DrugBank.d143.s44	should	219	224	O
DDI-DrugBank.d143.s44	be	226	227	O
DDI-DrugBank.d143.s44	monitored	229	237	O
DDI-DrugBank.d143.s44	closely	239	245	O
DDI-DrugBank.d143.s44	.	246	246	O
DDI-DrugBank.d143.s45	Some	0	3	O
DDI-DrugBank.d143.s45	drugs/substances	5	20	O
DDI-DrugBank.d143.s45	are	22	24	O
DDI-DrugBank.d143.s45	known	26	30	O
DDI-DrugBank.d143.s45	to	32	33	O
DDI-DrugBank.d143.s45	accelerate	35	44	O
DDI-DrugBank.d143.s45	the	46	48	O
DDI-DrugBank.d143.s45	metabolism	50	59	O
DDI-DrugBank.d143.s45	of	61	62	O
DDI-DrugBank.d143.s45	amiodarone	64	73	B-drug
DDI-DrugBank.d143.s45	by	75	76	O
DDI-DrugBank.d143.s45	stimulating	78	88	O
DDI-DrugBank.d143.s45	the	90	92	O
DDI-DrugBank.d143.s45	synthesis	94	102	O
DDI-DrugBank.d143.s45	of	104	105	O
DDI-DrugBank.d143.s45	CYP3A4	107	112	B-drug
DDI-DrugBank.d143.s45	(	114	114	O
DDI-DrugBank.d143.s45	enzyme	115	120	O
DDI-DrugBank.d143.s45	induction	122	130	O
DDI-DrugBank.d143.s45	)	131	131	O
DDI-DrugBank.d143.s45	.	132	132	O
DDI-DrugBank.d143.s46	This	0	3	O
DDI-DrugBank.d143.s46	may	5	7	O
DDI-DrugBank.d143.s46	lead	9	12	O
DDI-DrugBank.d143.s46	to	14	15	O
DDI-DrugBank.d143.s46	low	17	19	O
DDI-DrugBank.d143.s46	amiodarone	21	30	B-drug
DDI-DrugBank.d143.s46	serum	32	36	O
DDI-DrugBank.d143.s46	levels	38	43	O
DDI-DrugBank.d143.s46	and	45	47	O
DDI-DrugBank.d143.s46	potential	49	57	O
DDI-DrugBank.d143.s46	decrease	59	66	O
DDI-DrugBank.d143.s46	in	68	69	O
DDI-DrugBank.d143.s46	efficacy	71	78	O
DDI-DrugBank.d143.s46	.	79	79	O
DDI-DrugBank.d143.s47	Reported	0	7	O
DDI-DrugBank.d143.s47	examples	9	16	O
DDI-DrugBank.d143.s47	of	18	19	O
DDI-DrugBank.d143.s47	this	21	24	O
DDI-DrugBank.d143.s47	interaction	26	36	O
DDI-DrugBank.d143.s47	include	38	44	O
DDI-DrugBank.d143.s47	the	46	48	O
DDI-DrugBank.d143.s47	following	50	58	O
DDI-DrugBank.d143.s47	:	59	59	O
DDI-DrugBank.d143.s47	Antibiotics	61	71	B-drug
DDI-DrugBank.d143.s47	:	72	72	O
DDI-DrugBank.d143.s47	Rifampin	74	81	B-drug
DDI-DrugBank.d143.s47	is	83	84	O
DDI-DrugBank.d143.s47	a	77	77	O
DDI-DrugBank.d143.s47	potent	88	93	O
DDI-DrugBank.d143.s47	inducer	95	101	O
DDI-DrugBank.d143.s47	of	103	104	O
DDI-DrugBank.d143.s47	CYP3A4	106	111	B-drug
DDI-DrugBank.d143.s47	.	112	112	O
DDI-DrugBank.d143.s48	Administration	0	13	O
DDI-DrugBank.d143.s48	of	15	16	O
DDI-DrugBank.d143.s48	rifampin	18	25	B-drug
DDI-DrugBank.d143.s48	concomitantly	27	39	O
DDI-DrugBank.d143.s48	with	41	44	O
DDI-DrugBank.d143.s48	oral	46	49	O
DDI-DrugBank.d143.s48	amiodarone	51	60	B-drug
DDI-DrugBank.d143.s48	has	62	64	O
DDI-DrugBank.d143.s48	been	66	69	O
DDI-DrugBank.d143.s48	shown	71	75	O
DDI-DrugBank.d143.s48	to	77	78	O
DDI-DrugBank.d143.s48	result	80	85	O
DDI-DrugBank.d143.s48	in	87	88	O
DDI-DrugBank.d143.s48	decreases	90	98	O
DDI-DrugBank.d143.s48	in	87	88	O
DDI-DrugBank.d143.s48	serum	103	107	O
DDI-DrugBank.d143.s48	concentrations	109	122	O
DDI-DrugBank.d143.s48	of	124	125	O
DDI-DrugBank.d143.s48	amiodarone	127	136	B-drug
DDI-DrugBank.d143.s48	and	138	140	O
DDI-DrugBank.d143.s48	desethylamiodarone	142	159	B-drug
DDI-DrugBank.d143.s48	.	160	160	O
DDI-DrugBank.d143.s49	Other	0	4	O
DDI-DrugBank.d143.s49	substances	6	15	O
DDI-DrugBank.d143.s49	,	16	16	O
DDI-DrugBank.d143.s49	including	18	26	O
DDI-DrugBank.d143.s49	herbal	28	33	O
DDI-DrugBank.d143.s49	preparations	35	46	O
DDI-DrugBank.d143.s49	:	47	47	O
DDI-DrugBank.d143.s49	St.	49	51	O
DDI-DrugBank.d143.s49	John	53	56	O
DDI-DrugBank.d143.s49	s	58	58	O
DDI-DrugBank.d143.s49	Wort	60	63	O
DDI-DrugBank.d143.s49	(	65	65	O
DDI-DrugBank.d143.s49	Hypericum	66	74	O
DDI-DrugBank.d143.s49	perforatum	76	85	O
DDI-DrugBank.d143.s49	)	86	86	O
DDI-DrugBank.d143.s49	induces	88	94	O
DDI-DrugBank.d143.s49	CYP3A4	96	101	O
DDI-DrugBank.d143.s49	.	102	102	O
DDI-DrugBank.d143.s50	Since	0	4	O
DDI-DrugBank.d143.s50	amiodarone	6	15	B-drug
DDI-DrugBank.d143.s50	is	17	18	O
DDI-DrugBank.d143.s50	a	20	20	O
DDI-DrugBank.d143.s50	substrate	22	30	O
DDI-DrugBank.d143.s50	for	32	34	O
DDI-DrugBank.d143.s50	CYP3A4	36	41	B-drug
DDI-DrugBank.d143.s50	,	42	42	O
DDI-DrugBank.d143.s50	there	44	48	O
DDI-DrugBank.d143.s50	is	50	51	O
DDI-DrugBank.d143.s50	the	44	46	O
DDI-DrugBank.d143.s50	potential	57	65	O
DDI-DrugBank.d143.s50	that	67	70	O
DDI-DrugBank.d143.s50	the	72	74	O
DDI-DrugBank.d143.s50	use	76	78	O
DDI-DrugBank.d143.s50	of	80	81	O
DDI-DrugBank.d143.s50	St.	83	85	O
DDI-DrugBank.d143.s50	John	87	90	O
DDI-DrugBank.d143.s50	s	77	77	O
DDI-DrugBank.d143.s50	Wort	94	97	O
DDI-DrugBank.d143.s50	in	99	100	O
DDI-DrugBank.d143.s50	patients	102	109	O
DDI-DrugBank.d143.s50	receiving	111	119	O
DDI-DrugBank.d143.s50	amiodarone	121	130	B-drug
DDI-DrugBank.d143.s50	could	132	136	O
DDI-DrugBank.d143.s50	result	138	143	O
DDI-DrugBank.d143.s50	in	145	146	O
DDI-DrugBank.d143.s50	reduced	148	154	O
DDI-DrugBank.d143.s50	amiodarone	156	165	B-drug
DDI-DrugBank.d143.s50	levels	167	172	O
DDI-DrugBank.d143.s50	.	173	173	O
DDI-DrugBank.d143.s51	Other	0	4	O
DDI-DrugBank.d143.s51	reported	6	13	O
DDI-DrugBank.d143.s51	interactions	15	26	O
DDI-DrugBank.d143.s51	with	28	31	O
DDI-DrugBank.d143.s51	amiodarone	33	42	B-drug
DDI-DrugBank.d143.s51	:	43	43	O
DDI-DrugBank.d143.s51	Fentanyl	45	52	B-drug
DDI-DrugBank.d143.s51	(	54	54	O
DDI-DrugBank.d143.s51	CYP3A4	55	60	B-drug
DDI-DrugBank.d143.s51	substrate	62	70	O
DDI-DrugBank.d143.s51	)	71	71	O
DDI-DrugBank.d143.s51	in	73	74	O
DDI-DrugBank.d143.s51	combination	76	86	O
DDI-DrugBank.d143.s51	with	88	91	O
DDI-DrugBank.d143.s51	amiodarone	93	102	B-drug
DDI-DrugBank.d143.s51	may	104	106	O
DDI-DrugBank.d143.s51	cause	108	112	O
DDI-DrugBank.d143.s51	hypotension	114	124	O
DDI-DrugBank.d143.s51	,	125	125	O
DDI-DrugBank.d143.s51	bradycardia	127	137	O
DDI-DrugBank.d143.s51	,	125	125	O
DDI-DrugBank.d143.s51	and	140	142	O
DDI-DrugBank.d143.s51	decreased	144	152	O
DDI-DrugBank.d143.s51	cardiac	154	160	O
DDI-DrugBank.d143.s51	output	162	167	O
DDI-DrugBank.d143.s51	.	168	168	O
DDI-DrugBank.d143.s52	Sinus	0	4	O
DDI-DrugBank.d143.s52	bradycardia	6	16	O
DDI-DrugBank.d143.s52	has	18	20	O
DDI-DrugBank.d143.s52	been	22	25	O
DDI-DrugBank.d143.s52	reported	27	34	O
DDI-DrugBank.d143.s52	with	36	39	O
DDI-DrugBank.d143.s52	oral	41	44	O
DDI-DrugBank.d143.s52	amiodarone	46	55	B-drug
DDI-DrugBank.d143.s52	in	57	58	O
DDI-DrugBank.d143.s52	combination	60	70	O
DDI-DrugBank.d143.s52	with	72	75	O
DDI-DrugBank.d143.s52	lidocaine	77	85	B-drug
DDI-DrugBank.d143.s52	(	87	87	O
DDI-DrugBank.d143.s52	CYP3A4	88	93	B-drug
DDI-DrugBank.d143.s52	substrate	95	103	O
DDI-DrugBank.d143.s52	)	104	104	O
DDI-DrugBank.d143.s52	given	106	110	O
DDI-DrugBank.d143.s52	for	112	114	O
DDI-DrugBank.d143.s52	local	116	120	O
DDI-DrugBank.d143.s52	anesthesia	122	131	B-drug
DDI-DrugBank.d143.s52	.	132	132	O
DDI-DrugBank.d143.s53	Seizure	0	6	O
DDI-DrugBank.d143.s53	,	7	7	O
DDI-DrugBank.d143.s53	associated	9	18	O
DDI-DrugBank.d143.s53	with	20	23	O
DDI-DrugBank.d143.s53	increased	25	33	O
DDI-DrugBank.d143.s53	lidocaine	35	43	B-drug
DDI-DrugBank.d143.s53	concentrations	45	58	O
DDI-DrugBank.d143.s53	,	59	59	O
DDI-DrugBank.d143.s53	has	61	63	O
DDI-DrugBank.d143.s53	been	65	68	O
DDI-DrugBank.d143.s53	reported	70	77	O
DDI-DrugBank.d143.s53	with	79	82	O
DDI-DrugBank.d143.s53	concomitant	84	94	O
DDI-DrugBank.d143.s53	administration	96	109	O
DDI-DrugBank.d143.s53	of	111	112	O
DDI-DrugBank.d143.s53	intravenous	114	124	O
DDI-DrugBank.d143.s53	amiodarone	126	135	B-drug
DDI-DrugBank.d143.s53	.	136	136	O
DDI-DrugBank.d143.s54	Dextromethorphan	0	15	B-drug
DDI-DrugBank.d143.s54	is	17	18	O
DDI-DrugBank.d143.s54	a	20	20	O
DDI-DrugBank.d143.s54	substrate	22	30	O
DDI-DrugBank.d143.s54	for	32	34	O
DDI-DrugBank.d143.s54	both	36	39	O
DDI-DrugBank.d143.s54	CYP2D6	41	46	B-drug
DDI-DrugBank.d143.s54	and	48	50	O
DDI-DrugBank.d143.s54	CYP3A4	52	57	B-drug
DDI-DrugBank.d143.s54	.	58	58	O
DDI-DrugBank.d143.s55	Amiodarone	0	9	B-drug
DDI-DrugBank.d143.s55	inhibits	11	18	O
DDI-DrugBank.d143.s55	CYP2D6	20	25	B-drug
DDI-DrugBank.d143.s55	.	26	26	O
DDI-DrugBank.d143.s56	Cholestyramine	0	13	B-drug
DDI-DrugBank.d143.s56	increases	15	23	O
DDI-DrugBank.d143.s56	enterohepatic	25	37	O
DDI-DrugBank.d143.s56	elimination	39	49	O
DDI-DrugBank.d143.s56	of	51	52	O
DDI-DrugBank.d143.s56	amiodarone	54	63	B-drug
DDI-DrugBank.d143.s56	and	65	67	O
DDI-DrugBank.d143.s56	may	69	71	O
DDI-DrugBank.d143.s56	reduce	73	78	O
DDI-DrugBank.d143.s56	its	80	82	O
DDI-DrugBank.d143.s56	serum	84	88	O
DDI-DrugBank.d143.s56	levels	90	95	O
DDI-DrugBank.d143.s56	and	97	99	O
DDI-DrugBank.d143.s56	t1/2	101	104	O
DDI-DrugBank.d143.s56	.	105	105	O
DDI-DrugBank.d143.s57	Disopyramide	0	11	B-drug
DDI-DrugBank.d143.s57	increases	13	21	O
DDI-DrugBank.d143.s57	QT	23	24	O
DDI-DrugBank.d143.s57	prolongation	26	37	O
DDI-DrugBank.d143.s57	which	39	43	O
DDI-DrugBank.d143.s57	could	45	49	O
DDI-DrugBank.d143.s57	cause	51	55	O
DDI-DrugBank.d143.s57	arrhythmia	57	66	O
DDI-DrugBank.d143.s57	.	67	67	O
DDI-DrugBank.d143.s58	Fluoroquinolones	0	15	B-drug
DDI-DrugBank.d143.s58	,	16	16	O
DDI-DrugBank.d143.s58	macrolide	18	26	B-drug
DDI-DrugBank.d143.s58	antibiotics	28	38	I-drug
DDI-DrugBank.d143.s58	,	39	39	O
DDI-DrugBank.d143.s58	and	41	43	O
DDI-DrugBank.d143.s58	azoles	45	50	O
DDI-DrugBank.d143.s58	are	52	54	O
DDI-DrugBank.d143.s58	known	56	60	O
DDI-DrugBank.d143.s58	to	62	63	O
DDI-DrugBank.d143.s58	cause	65	69	O
DDI-DrugBank.d143.s58	QTc	71	73	O
DDI-DrugBank.d143.s58	prolongation	75	86	O
DDI-DrugBank.d143.s58	.	87	87	O
DDI-DrugBank.d143.s59	There	0	4	O
DDI-DrugBank.d143.s59	have	6	9	O
DDI-DrugBank.d143.s59	been	11	14	O
DDI-DrugBank.d143.s59	reports	16	22	O
DDI-DrugBank.d143.s59	of	24	25	O
DDI-DrugBank.d143.s59	QTc	27	29	O
DDI-DrugBank.d143.s59	prolongation	31	42	O
DDI-DrugBank.d143.s59	,	43	43	O
DDI-DrugBank.d143.s59	with	45	48	O
DDI-DrugBank.d143.s59	or	50	51	O
DDI-DrugBank.d143.s59	without	53	59	O
DDI-DrugBank.d143.s59	TdP	61	63	O
DDI-DrugBank.d143.s59	,	64	64	O
DDI-DrugBank.d143.s59	in	66	67	O
DDI-DrugBank.d143.s59	patients	69	76	O
DDI-DrugBank.d143.s59	taking	78	83	O
DDI-DrugBank.d143.s59	amiodarone	85	94	B-drug
DDI-DrugBank.d143.s59	when	96	99	O
DDI-DrugBank.d143.s59	fluoroquinolones	101	116	B-drug
DDI-DrugBank.d143.s59	,	117	117	O
DDI-DrugBank.d143.s59	macrolide	119	127	B-drug
DDI-DrugBank.d143.s59	antibiotics	129	139	I-drug
DDI-DrugBank.d143.s59	,	140	140	O
DDI-DrugBank.d143.s59	or	142	143	O
DDI-DrugBank.d143.s59	azoles	145	150	O
DDI-DrugBank.d143.s59	were	152	155	O
DDI-DrugBank.d143.s59	administered	157	168	O
DDI-DrugBank.d143.s59	concomitantly	170	182	O
DDI-DrugBank.d143.s59	.	183	183	O
DDI-DrugBank.d143.s60	Hemodynamic	0	10	O
DDI-DrugBank.d143.s60	and	12	14	O
DDI-DrugBank.d143.s60	electrophysiologic	16	33	O
DDI-DrugBank.d143.s60	interactions	35	46	O
DDI-DrugBank.d143.s60	have	48	51	O
DDI-DrugBank.d143.s60	also	53	56	O
DDI-DrugBank.d143.s60	been	58	61	O
DDI-DrugBank.d143.s60	observed	63	70	O
DDI-DrugBank.d143.s60	after	72	76	O
DDI-DrugBank.d143.s60	concomitant	78	88	O
DDI-DrugBank.d143.s60	administration	90	103	O
DDI-DrugBank.d143.s60	with	105	108	O
DDI-DrugBank.d143.s60	propranolol	110	120	B-drug
DDI-DrugBank.d143.s60	,	121	121	O
DDI-DrugBank.d143.s60	diltiazem	123	131	B-drug
DDI-DrugBank.d143.s60	,	121	121	O
DDI-DrugBank.d143.s60	and	134	136	O
DDI-DrugBank.d143.s60	verapamil	138	146	B-drug
DDI-DrugBank.d143.s60	.	147	147	O
DDI-DrugBank.d143.s61	Volatile	0	7	O
DDI-DrugBank.d143.s61	Anesthetic	9	18	B-drug
DDI-DrugBank.d143.s61	Agents	20	25	O
DDI-DrugBank.d143.s61	:	26	26	O
DDI-DrugBank.d143.s61	.	27	27	O
DDI-DrugBank.d143.s62	In	0	1	O
DDI-DrugBank.d143.s62	addition	3	10	O
DDI-DrugBank.d143.s62	to	12	13	O
DDI-DrugBank.d143.s62	the	15	17	O
DDI-DrugBank.d143.s62	interactions	19	30	O
DDI-DrugBank.d143.s62	noted	32	36	O
DDI-DrugBank.d143.s62	above	38	42	O
DDI-DrugBank.d143.s62	,	43	43	O
DDI-DrugBank.d143.s62	chronic	45	51	O
DDI-DrugBank.d143.s62	(	53	53	O
DDI-DrugBank.d143.s62	2	56	56	O
DDI-DrugBank.d143.s62	weeks	58	62	O
DDI-DrugBank.d143.s62	)	63	63	O
DDI-DrugBank.d143.s62	oral	65	68	O
DDI-DrugBank.d143.s62	Cordarone	70	78	B-drug
DDI-DrugBank.d143.s62	administration	80	93	O
DDI-DrugBank.d143.s62	impairs	95	101	O
DDI-DrugBank.d143.s62	metabolism	103	112	O
DDI-DrugBank.d143.s62	of	114	115	O
DDI-DrugBank.d143.s62	phenytoin	117	125	B-drug
DDI-DrugBank.d143.s62	,	126	126	O
DDI-DrugBank.d143.s62	dextromethorphan	128	143	B-drug
DDI-DrugBank.d143.s62	,	126	126	O
DDI-DrugBank.d143.s62	and	146	148	O
DDI-DrugBank.d143.s62	methotrexate	150	161	B-drug
DDI-DrugBank.d143.s62	.	162	162	O
DDI-DrugBank.d143.s63	Electrolyte	0	10	O
DDI-DrugBank.d143.s63	Disturbances	12	23	O
DDI-DrugBank.d143.s63	Patients	25	32	O
DDI-DrugBank.d143.s63	with	34	37	O
DDI-DrugBank.d143.s63	hypokalemia	39	49	O
DDI-DrugBank.d143.s63	or	51	52	O
DDI-DrugBank.d143.s63	hypomagnesemia	54	67	O
DDI-DrugBank.d143.s63	should	69	74	O
DDI-DrugBank.d143.s63	have	76	79	O
DDI-DrugBank.d143.s63	the	81	83	O
DDI-DrugBank.d143.s63	condition	85	93	O
DDI-DrugBank.d143.s63	corrected	95	103	O
DDI-DrugBank.d143.s63	whenever	105	112	O
DDI-DrugBank.d143.s63	possible	114	121	O
DDI-DrugBank.d143.s63	before	123	128	O
DDI-DrugBank.d143.s63	being	130	134	O
DDI-DrugBank.d143.s63	treated	136	142	O
DDI-DrugBank.d143.s63	with	144	147	O
DDI-DrugBank.d143.s63	Cordarone	149	157	B-drug
DDI-DrugBank.d143.s63	I.V.	159	162	I-drug
DDI-DrugBank.d143.s63	,	163	163	O
DDI-DrugBank.d143.s63	as	165	166	O
DDI-DrugBank.d143.s63	these	168	172	O
DDI-DrugBank.d143.s63	disorders	174	182	O
DDI-DrugBank.d143.s63	can	184	186	O
DDI-DrugBank.d143.s63	exaggerate	188	197	O
DDI-DrugBank.d143.s63	the	199	201	O
DDI-DrugBank.d143.s63	degree	203	208	O
DDI-DrugBank.d143.s63	of	210	211	O
DDI-DrugBank.d143.s63	QTc	213	215	O
DDI-DrugBank.d143.s63	prolongation	217	228	O
DDI-DrugBank.d143.s63	and	230	232	O
DDI-DrugBank.d143.s63	increase	234	241	O
DDI-DrugBank.d143.s63	the	243	245	O
DDI-DrugBank.d143.s63	potential	247	255	O
DDI-DrugBank.d143.s63	for	257	259	O
DDI-DrugBank.d143.s63	TdP	261	263	O
DDI-DrugBank.d143.s63	.	264	264	O
DDI-DrugBank.d143.s64	Special	0	6	O
DDI-DrugBank.d143.s64	attention	8	16	O
DDI-DrugBank.d143.s64	should	18	23	O
DDI-DrugBank.d143.s64	be	25	26	O
DDI-DrugBank.d143.s64	given	28	32	O
DDI-DrugBank.d143.s64	to	34	35	O
DDI-DrugBank.d143.s64	electrolyte	37	47	O
DDI-DrugBank.d143.s64	and	49	51	O
DDI-DrugBank.d143.s64	acid-base	53	61	O
DDI-DrugBank.d143.s64	balance	63	69	O
DDI-DrugBank.d143.s64	in	71	72	O
DDI-DrugBank.d143.s64	patients	74	81	O
DDI-DrugBank.d143.s64	experiencing	83	94	O
DDI-DrugBank.d143.s64	severe	96	101	O
DDI-DrugBank.d143.s64	or	103	104	O
DDI-DrugBank.d143.s64	prolonged	106	114	O
DDI-DrugBank.d143.s64	diarrhea	116	123	O
DDI-DrugBank.d143.s64	or	125	126	O
DDI-DrugBank.d143.s64	in	128	129	O
DDI-DrugBank.d143.s64	patients	131	138	O
DDI-DrugBank.d143.s64	receiving	140	148	O
DDI-DrugBank.d143.s64	concomitant	150	160	O
DDI-DrugBank.d143.s64	diuretics	162	170	B-drug
DDI-DrugBank.d143.s64	.	171	171	O
DDI-DrugBank.d412.s0	In	0	1	O
DDI-DrugBank.d412.s0	one	3	5	O
DDI-DrugBank.d412.s0	survey	7	12	O
DDI-DrugBank.d412.s0	,	13	13	O
DDI-DrugBank.d412.s0	2.3	15	17	O
DDI-DrugBank.d412.s0	%	18	18	O
DDI-DrugBank.d412.s0	of	20	21	O
DDI-DrugBank.d412.s0	patients	23	30	O
DDI-DrugBank.d412.s0	taking	32	37	O
DDI-DrugBank.d412.s0	labetalol	39	47	B-drug
DDI-DrugBank.d412.s0	HCl	49	51	I-drug
DDI-DrugBank.d412.s0	in	53	54	O
DDI-DrugBank.d412.s0	combination	56	66	O
DDI-DrugBank.d412.s0	with	68	71	O
DDI-DrugBank.d412.s0	tricyclic	73	81	B-group
DDI-DrugBank.d412.s0	antidepressants	83	97	I-group
DDI-DrugBank.d412.s0	experienced	99	109	O
DDI-DrugBank.d412.s0	tremor	111	116	O
DDI-DrugBank.d412.s0	,	117	117	O
DDI-DrugBank.d412.s0	as	119	120	O
DDI-DrugBank.d412.s0	compared	122	129	O
DDI-DrugBank.d412.s0	to	131	132	O
DDI-DrugBank.d412.s0	0.7	134	136	O
DDI-DrugBank.d412.s0	%	137	137	O
DDI-DrugBank.d412.s0	reported	139	146	O
DDI-DrugBank.d412.s0	to	131	132	O
DDI-DrugBank.d412.s0	occur	151	155	O
DDI-DrugBank.d412.s0	with	157	160	O
DDI-DrugBank.d412.s0	labetalol	162	170	B-drug
DDI-DrugBank.d412.s0	HCl	172	174	I-drug
DDI-DrugBank.d412.s0	alone	176	180	O
DDI-DrugBank.d412.s0	.	181	181	O
DDI-DrugBank.d412.s1	The	0	2	O
DDI-DrugBank.d412.s1	contribution	4	15	O
DDI-DrugBank.d412.s1	of	17	18	O
DDI-DrugBank.d412.s1	each	20	23	O
DDI-DrugBank.d412.s1	of	25	26	O
DDI-DrugBank.d412.s1	the	28	30	O
DDI-DrugBank.d412.s1	treatments	32	41	O
DDI-DrugBank.d412.s1	to	43	44	O
DDI-DrugBank.d412.s1	this	46	49	O
DDI-DrugBank.d412.s1	adverse	51	57	O
DDI-DrugBank.d412.s1	reaction	59	66	O
DDI-DrugBank.d412.s1	is	68	69	O
DDI-DrugBank.d412.s1	unknown	71	77	O
DDI-DrugBank.d412.s1	but	79	81	O
DDI-DrugBank.d412.s1	the	83	85	O
DDI-DrugBank.d412.s1	possibility	87	97	O
DDI-DrugBank.d412.s1	of	99	100	O
DDI-DrugBank.d412.s1	a	102	102	O
DDI-DrugBank.d412.s1	drug	104	107	O
DDI-DrugBank.d412.s1	interaction	109	119	O
DDI-DrugBank.d412.s1	can	121	123	O
DDI-DrugBank.d412.s1	not	124	126	O
DDI-DrugBank.d412.s1	be	128	129	O
DDI-DrugBank.d412.s1	excluded	131	138	O
DDI-DrugBank.d412.s1	.	139	139	O
DDI-DrugBank.d412.s2	Drugs	0	4	O
DDI-DrugBank.d412.s2	possessing	6	15	O
DDI-DrugBank.d412.s2	beta-blocking	17	29	O
DDI-DrugBank.d412.s2	properties	31	40	O
DDI-DrugBank.d412.s2	can	42	44	O
DDI-DrugBank.d412.s2	blunt	46	50	O
DDI-DrugBank.d412.s2	the	52	54	O
DDI-DrugBank.d412.s2	bronchodilator	56	69	O
DDI-DrugBank.d412.s2	effect	71	76	O
DDI-DrugBank.d412.s2	of	78	79	O
DDI-DrugBank.d412.s2	beta-receptor	81	93	B-group
DDI-DrugBank.d412.s2	agonist	95	101	I-group
DDI-DrugBank.d412.s2	drugs	103	107	I-group
DDI-DrugBank.d412.s2	in	109	110	O
DDI-DrugBank.d412.s2	patients	112	119	O
DDI-DrugBank.d412.s2	with	121	124	O
DDI-DrugBank.d412.s2	bronchospasm	126	137	O
DDI-DrugBank.d412.s2	;	138	138	O
DDI-DrugBank.d412.s3	therefore	0	8	O
DDI-DrugBank.d412.s3	,	9	9	O
DDI-DrugBank.d412.s3	doses	11	15	O
DDI-DrugBank.d412.s3	greater	17	23	O
DDI-DrugBank.d412.s3	than	25	28	O
DDI-DrugBank.d412.s3	the	30	32	O
DDI-DrugBank.d412.s3	normal	34	39	O
DDI-DrugBank.d412.s3	antiasthmatic	41	53	O
DDI-DrugBank.d412.s3	dose	55	58	O
DDI-DrugBank.d412.s3	of	60	61	O
DDI-DrugBank.d412.s3	beta-agonist	63	74	B-group
DDI-DrugBank.d412.s3	bronchodilator	76	89	I-group
DDI-DrugBank.d412.s3	drugs	91	95	I-group
DDI-DrugBank.d412.s3	may	97	99	O
DDI-DrugBank.d412.s3	be	101	102	O
DDI-DrugBank.d412.s3	required	104	111	O
DDI-DrugBank.d412.s3	.	112	112	O
DDI-DrugBank.d412.s4	Cimetidine	0	9	B-drug
DDI-DrugBank.d412.s4	has	11	13	O
DDI-DrugBank.d412.s4	been	15	18	O
DDI-DrugBank.d412.s4	shown	20	24	O
DDI-DrugBank.d412.s4	to	26	27	O
DDI-DrugBank.d412.s4	increase	29	36	O
DDI-DrugBank.d412.s4	the	38	40	O
DDI-DrugBank.d412.s4	bioavailability	42	56	O
DDI-DrugBank.d412.s4	of	58	59	O
DDI-DrugBank.d412.s4	labetalol	61	69	B-drug
DDI-DrugBank.d412.s4	HCl	71	73	I-drug
DDI-DrugBank.d412.s4	.	74	74	O
DDI-DrugBank.d412.s5	Since	0	4	O
DDI-DrugBank.d412.s5	this	6	9	O
DDI-DrugBank.d412.s5	could	11	15	O
DDI-DrugBank.d412.s5	be	17	18	O
DDI-DrugBank.d412.s5	explained	20	28	O
DDI-DrugBank.d412.s5	either	30	35	O
DDI-DrugBank.d412.s5	by	37	38	O
DDI-DrugBank.d412.s5	enhanced	40	47	O
DDI-DrugBank.d412.s5	absorption	49	58	O
DDI-DrugBank.d412.s5	or	52	53	O
DDI-DrugBank.d412.s5	by	63	64	O
DDI-DrugBank.d412.s5	an	66	67	O
DDI-DrugBank.d412.s5	alteration	69	78	O
DDI-DrugBank.d412.s5	of	80	81	O
DDI-DrugBank.d412.s5	hepatic	83	89	O
DDI-DrugBank.d412.s5	metabolism	91	100	O
DDI-DrugBank.d412.s5	of	102	103	O
DDI-DrugBank.d412.s5	labetalol	105	113	B-drug
DDI-DrugBank.d412.s5	HCl	115	117	I-drug
DDI-DrugBank.d412.s5	,	118	118	O
DDI-DrugBank.d412.s5	special	120	126	O
DDI-DrugBank.d412.s5	care	128	131	O
DDI-DrugBank.d412.s5	should	133	138	O
DDI-DrugBank.d412.s5	be	140	141	O
DDI-DrugBank.d412.s5	used	143	146	O
DDI-DrugBank.d412.s5	in	148	149	O
DDI-DrugBank.d412.s5	establishing	151	162	O
DDI-DrugBank.d412.s5	the	164	166	O
DDI-DrugBank.d412.s5	dose	168	171	O
DDI-DrugBank.d412.s5	required	173	180	O
DDI-DrugBank.d412.s5	for	182	184	O
DDI-DrugBank.d412.s5	blood	186	190	O
DDI-DrugBank.d412.s5	pressure	192	199	O
DDI-DrugBank.d412.s5	control	201	207	O
DDI-DrugBank.d412.s5	in	209	210	O
DDI-DrugBank.d412.s5	such	212	215	O
DDI-DrugBank.d412.s5	patients	217	224	O
DDI-DrugBank.d412.s5	.	225	225	O
DDI-DrugBank.d412.s6	Synergism	0	8	O
DDI-DrugBank.d412.s6	has	10	12	O
DDI-DrugBank.d412.s6	been	14	17	O
DDI-DrugBank.d412.s6	shown	19	23	O
DDI-DrugBank.d412.s6	between	25	31	O
DDI-DrugBank.d412.s6	halothane	33	41	B-drug
DDI-DrugBank.d412.s6	anesthesia	43	52	O
DDI-DrugBank.d412.s6	and	54	56	O
DDI-DrugBank.d412.s6	intravenously	58	70	O
DDI-DrugBank.d412.s6	administered	72	83	O
DDI-DrugBank.d412.s6	labetalol	85	93	B-drug
DDI-DrugBank.d412.s6	HCl	95	97	I-drug
DDI-DrugBank.d412.s6	.	98	98	O
DDI-DrugBank.d412.s7	During	0	5	O
DDI-DrugBank.d412.s7	controlled	7	16	O
DDI-DrugBank.d412.s7	hypotensive	18	28	O
DDI-DrugBank.d412.s7	anesthesia	30	39	O
DDI-DrugBank.d412.s7	using	41	45	O
DDI-DrugBank.d412.s7	labetalol	47	55	B-drug
DDI-DrugBank.d412.s7	HCl	57	59	I-drug
DDI-DrugBank.d412.s7	in	61	62	O
DDI-DrugBank.d412.s7	association	64	74	O
DDI-DrugBank.d412.s7	with	76	79	O
DDI-DrugBank.d412.s7	halothane	81	89	B-drug
DDI-DrugBank.d412.s7	,	90	90	O
DDI-DrugBank.d412.s7	high	92	95	O
DDI-DrugBank.d412.s7	concentrations	97	110	O
DDI-DrugBank.d412.s7	(	112	112	O
DDI-DrugBank.d412.s7	3	113	113	O
DDI-DrugBank.d412.s7	%	114	114	O
DDI-DrugBank.d412.s7	or	116	117	O
DDI-DrugBank.d412.s7	above	119	123	O
DDI-DrugBank.d412.s7	)	124	124	O
DDI-DrugBank.d412.s7	of	126	127	O
DDI-DrugBank.d412.s7	halothane	129	137	B-drug
DDI-DrugBank.d412.s7	should	139	144	O
DDI-DrugBank.d412.s7	not	146	148	O
DDI-DrugBank.d412.s7	be	150	151	O
DDI-DrugBank.d412.s7	used	153	156	O
DDI-DrugBank.d412.s7	because	158	164	O
DDI-DrugBank.d412.s7	the	166	168	O
DDI-DrugBank.d412.s7	degree	170	175	O
DDI-DrugBank.d412.s7	of	177	178	O
DDI-DrugBank.d412.s7	hypotension	180	190	O
DDI-DrugBank.d412.s7	will	192	195	O
DDI-DrugBank.d412.s7	be	197	198	O
DDI-DrugBank.d412.s7	increased	200	208	O
DDI-DrugBank.d412.s7	and	210	212	O
DDI-DrugBank.d412.s7	because	214	220	O
DDI-DrugBank.d412.s7	of	222	223	O
DDI-DrugBank.d412.s7	the	225	227	O
DDI-DrugBank.d412.s7	possibility	229	239	O
DDI-DrugBank.d412.s7	of	222	223	O
DDI-DrugBank.d412.s7	a	210	210	O
DDI-DrugBank.d412.s7	large	246	250	O
DDI-DrugBank.d412.s7	reduction	252	260	O
DDI-DrugBank.d412.s7	in	262	263	O
DDI-DrugBank.d412.s7	cardiac	265	271	O
DDI-DrugBank.d412.s7	output	273	278	O
DDI-DrugBank.d412.s7	and	280	282	O
DDI-DrugBank.d412.s7	an	280	281	O
DDI-DrugBank.d412.s7	increase	287	294	O
DDI-DrugBank.d412.s7	in	262	263	O
DDI-DrugBank.d412.s7	central	299	305	O
DDI-DrugBank.d412.s7	venous	307	312	O
DDI-DrugBank.d412.s7	pressure	314	321	O
DDI-DrugBank.d412.s7	.	322	322	O
DDI-DrugBank.d412.s8	The	0	2	O
DDI-DrugBank.d412.s8	anesthesiologist	4	19	O
DDI-DrugBank.d412.s8	should	21	26	O
DDI-DrugBank.d412.s8	be	28	29	O
DDI-DrugBank.d412.s8	informed	31	38	O
DDI-DrugBank.d412.s8	when	40	43	O
DDI-DrugBank.d412.s8	a	45	45	O
DDI-DrugBank.d412.s8	patient	47	53	O
DDI-DrugBank.d412.s8	is	55	56	O
DDI-DrugBank.d412.s8	receiving	58	66	O
DDI-DrugBank.d412.s8	labetalol	68	76	B-drug
DDI-DrugBank.d412.s8	HCl	78	80	I-drug
DDI-DrugBank.d412.s8	.	81	81	O
DDI-DrugBank.d412.s9	Labetalol	0	8	B-drug
DDI-DrugBank.d412.s9	HCl	10	12	I-drug
DDI-DrugBank.d412.s9	blunts	14	19	O
DDI-DrugBank.d412.s9	the	21	23	O
DDI-DrugBank.d412.s9	reflex	25	30	O
DDI-DrugBank.d412.s9	tachycardia	32	42	O
DDI-DrugBank.d412.s9	produced	44	51	O
DDI-DrugBank.d412.s9	by	53	54	O
DDI-DrugBank.d412.s9	nitroglycerin	56	68	B-drug
DDI-DrugBank.d412.s9	without	70	76	O
DDI-DrugBank.d412.s9	preventing	78	87	O
DDI-DrugBank.d412.s9	its	89	91	O
DDI-DrugBank.d412.s9	hypotensive	93	103	O
DDI-DrugBank.d412.s9	effect	105	110	O
DDI-DrugBank.d412.s9	.	111	111	O
DDI-DrugBank.d412.s10	If	0	1	O
DDI-DrugBank.d412.s10	labetalol	3	11	B-drug
DDI-DrugBank.d412.s10	HCl	13	15	I-drug
DDI-DrugBank.d412.s10	is	17	18	O
DDI-DrugBank.d412.s10	used	20	23	O
DDI-DrugBank.d412.s10	with	25	28	O
DDI-DrugBank.d412.s10	nitroglycerin	30	42	B-drug
DDI-DrugBank.d412.s10	in	41	42	I-drug
DDI-DrugBank.d412.s10	patients	47	54	O
DDI-DrugBank.d412.s10	with	56	59	O
DDI-DrugBank.d412.s10	angina	61	66	O
DDI-DrugBank.d412.s10	pectoris	68	75	O
DDI-DrugBank.d412.s10	,	76	76	O
DDI-DrugBank.d412.s10	additional	78	87	O
DDI-DrugBank.d412.s10	antihypertensive	89	104	O
DDI-DrugBank.d412.s10	effects	106	112	O
DDI-DrugBank.d412.s10	may	114	116	O
DDI-DrugBank.d412.s10	occur	118	122	O
DDI-DrugBank.d412.s10	.	123	123	O
DDI-DrugBank.d412.s11	Care	0	3	O
DDI-DrugBank.d412.s11	should	5	10	O
DDI-DrugBank.d412.s11	be	12	13	O
DDI-DrugBank.d412.s11	taken	15	19	O
DDI-DrugBank.d412.s11	if	21	22	O
DDI-DrugBank.d412.s11	labetalol	24	32	B-drug
DDI-DrugBank.d412.s11	is	34	35	O
DDI-DrugBank.d412.s11	used	37	40	O
DDI-DrugBank.d412.s11	concomitantly	42	54	O
DDI-DrugBank.d412.s11	with	56	59	O
DDI-DrugBank.d412.s11	calcium	61	67	B-group
DDI-DrugBank.d412.s11	antagonists	69	79	O
DDI-DrugBank.d412.s11	of	81	82	O
DDI-DrugBank.d412.s11	the	84	86	O
DDI-DrugBank.d412.s11	verapamil	88	96	B-drug
DDI-DrugBank.d412.s11	type	98	101	O
DDI-DrugBank.d412.s11	.	102	102	O
DDI-DrugBank.d412.s12	Risk	0	3	O
DDI-DrugBank.d412.s12	of	5	6	O
DDI-DrugBank.d412.s12	Anaphylactic	8	19	O
DDI-DrugBank.d412.s12	Reaction	21	28	O
DDI-DrugBank.d412.s12	While	30	34	O
DDI-DrugBank.d412.s12	taking	36	41	O
DDI-DrugBank.d412.s12	beta-blockers	43	55	B-group
DDI-DrugBank.d412.s12	,	56	56	O
DDI-DrugBank.d412.s12	patients	58	65	O
DDI-DrugBank.d412.s12	with	67	70	O
DDI-DrugBank.d412.s12	a	72	72	O
DDI-DrugBank.d412.s12	history	74	80	O
DDI-DrugBank.d412.s12	of	82	83	O
DDI-DrugBank.d412.s12	severe	85	90	O
DDI-DrugBank.d412.s12	anaphylactic	92	103	O
DDI-DrugBank.d412.s12	reaction	105	112	O
DDI-DrugBank.d412.s12	to	114	115	O
DDI-DrugBank.d412.s12	a	107	107	O
DDI-DrugBank.d412.s12	variety	119	125	O
DDI-DrugBank.d412.s12	of	127	128	O
DDI-DrugBank.d412.s12	allergens	130	138	O
DDI-DrugBank.d412.s12	may	140	142	O
DDI-DrugBank.d412.s12	be	144	145	O
DDI-DrugBank.d412.s12	more	147	150	O
DDI-DrugBank.d412.s12	reactive	152	159	O
DDI-DrugBank.d412.s12	to	161	162	O
DDI-DrugBank.d412.s12	repeated	164	171	O
DDI-DrugBank.d412.s12	challenge	173	181	O
DDI-DrugBank.d412.s12	,	182	182	O
DDI-DrugBank.d412.s12	either	184	189	O
DDI-DrugBank.d412.s12	accidental	191	200	O
DDI-DrugBank.d412.s12	,	182	182	O
DDI-DrugBank.d412.s12	diagnostic	203	212	O
DDI-DrugBank.d412.s12	,	201	201	O
DDI-DrugBank.d412.s12	or	215	216	O
DDI-DrugBank.d412.s12	therapeutic	218	228	O
DDI-DrugBank.d412.s12	.	229	229	O
DDI-DrugBank.d412.s13	Such	0	3	O
DDI-DrugBank.d412.s13	patients	5	12	O
DDI-DrugBank.d412.s13	may	14	16	O
DDI-DrugBank.d412.s13	be	18	19	O
DDI-DrugBank.d412.s13	unresponsive	21	32	O
DDI-DrugBank.d412.s13	to	34	35	O
DDI-DrugBank.d412.s13	the	37	39	O
DDI-DrugBank.d412.s13	usual	41	45	O
DDI-DrugBank.d412.s13	doses	47	51	O
DDI-DrugBank.d412.s13	of	53	54	O
DDI-DrugBank.d412.s13	epinephrine	56	66	B-drug
DDI-DrugBank.d412.s13	used	68	71	O
DDI-DrugBank.d412.s13	to	73	74	O
DDI-DrugBank.d412.s13	treat	76	80	O
DDI-DrugBank.d412.s13	allergic	82	89	O
DDI-DrugBank.d412.s13	reaction	91	98	O
DDI-DrugBank.d412.s13	.	99	99	O
DDI-DrugBank.d412.s14	Drug/Laboratory	0	14	O
DDI-DrugBank.d412.s14	Test	16	19	O
DDI-DrugBank.d412.s14	Interactions	21	32	O
DDI-DrugBank.d412.s14	The	34	36	O
DDI-DrugBank.d412.s14	presence	38	45	O
DDI-DrugBank.d412.s14	of	47	48	O
DDI-DrugBank.d412.s14	labetalol	50	58	O
DDI-DrugBank.d412.s14	metabolites	60	70	O
DDI-DrugBank.d412.s14	in	72	73	O
DDI-DrugBank.d412.s14	the	75	77	O
DDI-DrugBank.d412.s14	urine	79	83	O
DDI-DrugBank.d412.s14	may	85	87	O
DDI-DrugBank.d412.s14	result	89	94	O
DDI-DrugBank.d412.s14	in	96	97	O
DDI-DrugBank.d412.s14	falsely	99	105	O
DDI-DrugBank.d412.s14	elevated	107	114	O
DDI-DrugBank.d412.s14	levels	116	121	O
DDI-DrugBank.d412.s14	of	123	124	O
DDI-DrugBank.d412.s14	urinary	126	132	O
DDI-DrugBank.d412.s14	catecholamines	134	147	O
DDI-DrugBank.d412.s14	,	148	148	O
DDI-DrugBank.d412.s14	metanephrine	150	161	O
DDI-DrugBank.d412.s14	,	148	148	O
DDI-DrugBank.d412.s14	normetanephrine	164	178	O
DDI-DrugBank.d412.s14	and	180	182	O
DDI-DrugBank.d412.s14	vanillylmandelic	184	199	O
DDI-DrugBank.d412.s14	acid	201	204	O
DDI-DrugBank.d412.s14	when	206	209	O
DDI-DrugBank.d412.s14	measured	211	218	O
DDI-DrugBank.d412.s14	by	220	221	O
DDI-DrugBank.d412.s14	fluorimetric	223	234	O
DDI-DrugBank.d412.s14	or	226	227	O
DDI-DrugBank.d412.s14	photometric	239	249	O
DDI-DrugBank.d412.s14	methods	251	257	O
DDI-DrugBank.d412.s14	.	258	258	O
DDI-DrugBank.d412.s15	In	0	1	O
DDI-DrugBank.d412.s15	screening	3	11	O
DDI-DrugBank.d412.s15	patients	13	20	O
DDI-DrugBank.d412.s15	suspected	22	30	O
DDI-DrugBank.d412.s15	of	32	33	O
DDI-DrugBank.d412.s15	having	35	40	O
DDI-DrugBank.d412.s15	a	36	36	O
DDI-DrugBank.d412.s15	pheochromocytoma	44	59	O
DDI-DrugBank.d412.s15	and	61	63	O
DDI-DrugBank.d412.s15	being	65	69	O
DDI-DrugBank.d412.s15	treated	71	77	O
DDI-DrugBank.d412.s15	with	79	82	O
DDI-DrugBank.d412.s15	labetalol	84	92	B-drug
DDI-DrugBank.d412.s15	HCl	94	96	I-drug
DDI-DrugBank.d412.s15	,	97	97	O
DDI-DrugBank.d412.s15	a	85	85	O
DDI-DrugBank.d412.s15	specific	101	108	O
DDI-DrugBank.d412.s15	method	110	115	O
DDI-DrugBank.d412.s15	,	116	116	O
DDI-DrugBank.d412.s15	such	118	121	O
DDI-DrugBank.d412.s15	as	123	124	O
DDI-DrugBank.d412.s15	a	123	123	O
DDI-DrugBank.d412.s15	high	128	131	O
DDI-DrugBank.d412.s15	performance	133	143	O
DDI-DrugBank.d412.s15	liquid	145	150	O
DDI-DrugBank.d412.s15	chromatographic	152	166	O
DDI-DrugBank.d412.s15	assay	168	172	O
DDI-DrugBank.d412.s15	with	174	177	O
DDI-DrugBank.d412.s15	solid	179	183	O
DDI-DrugBank.d412.s15	phase	185	189	O
DDI-DrugBank.d412.s15	extraction	191	200	O
DDI-DrugBank.d412.s15	(	202	202	O
DDI-DrugBank.d412.s15	e.g.	203	206	O
DDI-DrugBank.d412.s15	,	207	207	O
DDI-DrugBank.d412.s15	J	209	209	O
DDI-DrugBank.d412.s15	Chromatogr	211	220	O
DDI-DrugBank.d412.s15	385:241,1987	222	233	O
DDI-DrugBank.d412.s15	)	234	234	O
DDI-DrugBank.d412.s15	should	236	241	O
DDI-DrugBank.d412.s15	be	243	244	O
DDI-DrugBank.d412.s15	employed	246	253	O
DDI-DrugBank.d412.s15	in	255	256	O
DDI-DrugBank.d412.s15	determining	258	268	O
DDI-DrugBank.d412.s15	levels	270	275	O
DDI-DrugBank.d412.s15	of	277	278	O
DDI-DrugBank.d412.s15	catecholamines	280	293	O
DDI-DrugBank.d412.s15	.	294	294	O
DDI-DrugBank.d412.s16	Labetalol	0	8	B-drug
DDI-DrugBank.d412.s16	HCl	10	12	I-drug
DDI-DrugBank.d412.s16	has	14	16	O
DDI-DrugBank.d412.s16	also	18	21	O
DDI-DrugBank.d412.s16	been	23	26	O
DDI-DrugBank.d412.s16	reported	28	35	O
DDI-DrugBank.d412.s16	to	37	38	O
DDI-DrugBank.d412.s16	produce	40	46	O
DDI-DrugBank.d412.s16	a	48	48	O
DDI-DrugBank.d412.s16	false	50	54	O
DDI-DrugBank.d412.s16	positive	56	63	O
DDI-DrugBank.d412.s16	test	65	68	O
DDI-DrugBank.d412.s16	for	70	72	O
DDI-DrugBank.d412.s16	amphetamine	74	84	B-drug
DDI-DrugBank.d412.s16	when	86	89	O
DDI-DrugBank.d412.s16	screening	91	99	O
DDI-DrugBank.d412.s16	urine	101	105	O
DDI-DrugBank.d412.s16	for	107	109	O
DDI-DrugBank.d412.s16	the	111	113	O
DDI-DrugBank.d412.s16	presence	115	122	O
DDI-DrugBank.d412.s16	of	124	125	O
DDI-DrugBank.d412.s16	drugs	127	131	O
DDI-DrugBank.d412.s16	using	133	137	O
DDI-DrugBank.d412.s16	the	139	141	O
DDI-DrugBank.d412.s16	commercially	143	154	O
DDI-DrugBank.d412.s16	available	156	164	O
DDI-DrugBank.d412.s16	assay	166	170	O
DDI-DrugBank.d412.s16	methods	172	178	O
DDI-DrugBank.d412.s16	Toxi-Lab	180	187	O
DDI-DrugBank.d412.s16	A	189	189	O
DDI-DrugBank.d412.s16	(	192	192	O
DDI-DrugBank.d412.s16	thin-layer	193	202	O
DDI-DrugBank.d412.s16	chromatographic	204	218	O
DDI-DrugBank.d412.s16	assay	220	224	O
DDI-DrugBank.d412.s16	)	225	225	O
DDI-DrugBank.d412.s16	and	227	229	O
DDI-DrugBank.d412.s16	Emit-d.a.u	231	240	O
DDI-DrugBank.d412.s16	.	237	237	O
DDI-DrugBank.d412.s16	(	244	244	O
DDI-DrugBank.d412.s16	radioenzymatic	245	258	O
DDI-DrugBank.d412.s16	assay	260	264	O
DDI-DrugBank.d412.s16	)	265	265	O
DDI-DrugBank.d412.s16	.	237	237	O
DDI-DrugBank.d412.s17	When	0	3	O
DDI-DrugBank.d412.s17	patients	5	12	O
DDI-DrugBank.d412.s17	being	14	18	O
DDI-DrugBank.d412.s17	treated	20	26	O
DDI-DrugBank.d412.s17	with	28	31	O
DDI-DrugBank.d412.s17	labetalol	33	41	B-drug
DDI-DrugBank.d412.s17	have	43	46	O
DDI-DrugBank.d412.s17	a	44	44	O
DDI-DrugBank.d412.s17	positive	50	57	O
DDI-DrugBank.d412.s17	urine	59	63	O
DDI-DrugBank.d412.s17	test	65	68	O
DDI-DrugBank.d412.s17	for	70	72	O
DDI-DrugBank.d412.s17	amphetamine	74	84	B-drug
DDI-DrugBank.d412.s17	using	86	90	O
DDI-DrugBank.d412.s17	these	92	96	O
DDI-DrugBank.d412.s17	techniques	98	107	O
DDI-DrugBank.d412.s17	confirmation	109	120	O
DDI-DrugBank.d412.s17	should	122	127	O
DDI-DrugBank.d412.s17	be	129	130	O
DDI-DrugBank.d412.s17	made	132	135	O
DDI-DrugBank.d412.s17	by	137	138	O
DDI-DrugBank.d412.s17	using	140	144	O
DDI-DrugBank.d412.s17	more	146	149	O
DDI-DrugBank.d412.s17	specific	151	158	O
DDI-DrugBank.d412.s17	methods	160	166	O
DDI-DrugBank.d412.s17	such	168	171	O
DDI-DrugBank.d412.s17	as	173	174	O
DDI-DrugBank.d412.s17	a	173	173	O
DDI-DrugBank.d412.s17	gas	178	180	O
DDI-DrugBank.d412.s17	chromatographic-mass	182	201	O
DDI-DrugBank.d412.s17	spectrometer	203	214	O
DDI-DrugBank.d412.s17	technique	216	224	O
DDI-DrugBank.d412.s17	.	225	225	O
DDI-DrugBank.d599.s0	Excessive	0	8	O
DDI-DrugBank.d599.s0	glucocorticoid	10	23	O
DDI-DrugBank.d599.s0	therapy	25	31	O
DDI-DrugBank.d599.s0	will	33	36	O
DDI-DrugBank.d599.s0	inhibit	38	44	O
DDI-DrugBank.d599.s0	the	46	48	O
DDI-DrugBank.d599.s0	growth-promoting	50	65	O
DDI-DrugBank.d599.s0	effect	67	72	O
DDI-DrugBank.d599.s0	of	74	75	O
DDI-DrugBank.d599.s0	human	77	81	B-drug
DDI-DrugBank.d599.s0	GH	83	84	I-drug
DDI-DrugBank.d599.s0	.	85	85	O
DDI-DrugBank.d599.s1	Patients	0	7	O
DDI-DrugBank.d599.s1	with	9	12	O
DDI-DrugBank.d599.s1	ACTH	14	17	O
DDI-DrugBank.d599.s1	deficiency	19	28	O
DDI-DrugBank.d599.s1	should	30	35	O
DDI-DrugBank.d599.s1	have	37	40	O
DDI-DrugBank.d599.s1	their	42	46	O
DDI-DrugBank.d599.s1	glucocorticoid-replacement	48	73	O
DDI-DrugBank.d599.s1	dose	75	78	O
DDI-DrugBank.d599.s1	carefully	80	88	O
DDI-DrugBank.d599.s1	adjusted	90	97	O
DDI-DrugBank.d599.s1	to	99	100	O
DDI-DrugBank.d599.s1	avoid	102	106	O
DDI-DrugBank.d599.s1	an	108	109	O
DDI-DrugBank.d599.s1	inhibitory	111	120	O
DDI-DrugBank.d599.s1	effect	122	127	O
DDI-DrugBank.d599.s1	on	129	130	O
DDI-DrugBank.d599.s1	growth	132	137	O
DDI-DrugBank.d599.s1	.	138	138	O
DDI-DrugBank.d599.s2	The	0	2	O
DDI-DrugBank.d599.s2	use	4	6	O
DDI-DrugBank.d599.s2	of	8	9	O
DDI-DrugBank.d599.s2	Nutropin	11	18	B-brand
DDI-DrugBank.d599.s2	in	17	18	I-brand
DDI-DrugBank.d599.s2	patients	23	30	O
DDI-DrugBank.d599.s2	with	32	35	O
DDI-DrugBank.d599.s2	chronic	37	43	O
DDI-DrugBank.d599.s2	renal	45	49	O
DDI-DrugBank.d599.s2	insufficiency	51	63	O
DDI-DrugBank.d599.s2	receiving	65	73	O
DDI-DrugBank.d599.s2	glucocorticoid	75	88	O
DDI-DrugBank.d599.s2	therapy	90	96	O
DDI-DrugBank.d599.s2	has	98	100	O
DDI-DrugBank.d599.s2	not	102	104	O
DDI-DrugBank.d599.s2	been	106	109	O
DDI-DrugBank.d599.s2	evaluated	111	119	O
DDI-DrugBank.d599.s2	.	120	120	O
DDI-DrugBank.d599.s3	Concomitant	0	10	O
DDI-DrugBank.d599.s3	glucocorticoid	12	25	O
DDI-DrugBank.d599.s3	therapy	27	33	O
DDI-DrugBank.d599.s3	may	35	37	O
DDI-DrugBank.d599.s3	inhibit	39	45	O
DDI-DrugBank.d599.s3	the	47	49	O
DDI-DrugBank.d599.s3	growth-promoting	51	66	O
DDI-DrugBank.d599.s3	effect	68	73	O
DDI-DrugBank.d599.s3	of	75	76	O
DDI-DrugBank.d599.s3	Nutropin	78	85	B-brand
DDI-DrugBank.d599.s3	.	86	86	O
DDI-DrugBank.d599.s4	If	0	1	O
DDI-DrugBank.d599.s4	glucocorticoid	3	16	B-group
DDI-DrugBank.d599.s4	replacement	18	28	O
DDI-DrugBank.d599.s4	is	30	31	O
DDI-DrugBank.d599.s4	required	33	40	O
DDI-DrugBank.d599.s4	,	41	41	O
DDI-DrugBank.d599.s4	the	43	45	O
DDI-DrugBank.d599.s4	glucocorticoid	47	60	B-group
DDI-DrugBank.d599.s4	dose	62	65	O
DDI-DrugBank.d599.s4	should	67	72	O
DDI-DrugBank.d599.s4	be	74	75	O
DDI-DrugBank.d599.s4	carefully	77	85	O
DDI-DrugBank.d599.s4	adjusted	87	94	O
DDI-DrugBank.d599.s4	.	95	95	O
DDI-DrugBank.d599.s5	There	0	4	O
DDI-DrugBank.d599.s5	was	6	8	O
DDI-DrugBank.d599.s5	no	10	11	O
DDI-DrugBank.d599.s5	evidence	13	20	O
DDI-DrugBank.d599.s5	in	22	23	O
DDI-DrugBank.d599.s5	the	25	27	O
DDI-DrugBank.d599.s5	controlled	29	38	O
DDI-DrugBank.d599.s5	studies	40	46	O
DDI-DrugBank.d599.s5	of	48	49	O
DDI-DrugBank.d599.s5	Nutropin	51	58	B-brand
DDI-DrugBank.d599.s5	s	62	62	O
DDI-DrugBank.d599.s5	interaction	64	74	O
DDI-DrugBank.d599.s5	with	76	79	O
DDI-DrugBank.d599.s5	drugs	81	85	O
DDI-DrugBank.d599.s5	commonly	87	94	O
DDI-DrugBank.d599.s5	used	96	99	O
DDI-DrugBank.d599.s5	in	101	102	O
DDI-DrugBank.d599.s5	chronic	104	110	O
DDI-DrugBank.d599.s5	renal	112	116	O
DDI-DrugBank.d599.s5	insufficiency	118	130	O
DDI-DrugBank.d599.s5	patients	132	139	O
DDI-DrugBank.d599.s5	.	140	140	O
DDI-DrugBank.d599.s6	Limited	0	6	O
DDI-DrugBank.d599.s6	published	8	16	O
DDI-DrugBank.d599.s6	data	18	21	O
DDI-DrugBank.d599.s6	indicate	23	30	O
DDI-DrugBank.d599.s6	that	32	35	O
DDI-DrugBank.d599.s6	GH	37	38	B-drug
DDI-DrugBank.d599.s6	treatment	40	48	O
DDI-DrugBank.d599.s6	increases	50	58	O
DDI-DrugBank.d599.s6	cytochrome	60	69	O
DDI-DrugBank.d599.s6	P450	71	74	O
DDI-DrugBank.d599.s6	(	76	76	O
DDI-DrugBank.d599.s6	CP450	77	81	O
DDI-DrugBank.d599.s6	)	82	82	O
DDI-DrugBank.d599.s6	mediated	84	91	O
DDI-DrugBank.d599.s6	antipyrine	93	102	B-drug
DDI-DrugBank.d599.s6	clearance	104	112	O
DDI-DrugBank.d599.s6	in	100	101	I-drug
DDI-DrugBank.d599.s6	man	117	119	O
DDI-DrugBank.d599.s6	.	120	120	O
DDI-DrugBank.d599.s7	These	0	4	O
DDI-DrugBank.d599.s7	data	6	9	O
DDI-DrugBank.d599.s7	suggest	11	17	O
DDI-DrugBank.d599.s7	that	19	22	O
DDI-DrugBank.d599.s7	GH	24	25	B-drug
DDI-DrugBank.d599.s7	administration	27	40	O
DDI-DrugBank.d599.s7	may	42	44	O
DDI-DrugBank.d599.s7	alter	46	50	O
DDI-DrugBank.d599.s7	the	52	54	O
DDI-DrugBank.d599.s7	clearance	56	64	O
DDI-DrugBank.d599.s7	of	66	67	O
DDI-DrugBank.d599.s7	compounds	69	77	O
DDI-DrugBank.d599.s7	known	79	83	O
DDI-DrugBank.d599.s7	to	85	86	O
DDI-DrugBank.d599.s7	be	88	89	O
DDI-DrugBank.d599.s7	metabolized	91	101	O
DDI-DrugBank.d599.s7	by	103	104	O
DDI-DrugBank.d599.s7	CP450	106	110	O
DDI-DrugBank.d599.s7	liver	112	116	O
DDI-DrugBank.d599.s7	enzymes	118	124	O
DDI-DrugBank.d599.s7	(	126	126	O
DDI-DrugBank.d599.s7	e.g.	127	130	O
DDI-DrugBank.d599.s7	,	131	131	O
DDI-DrugBank.d599.s7	corticosteroids	133	147	B-group
DDI-DrugBank.d599.s7	,	131	131	O
DDI-DrugBank.d599.s7	sex	150	152	B-group
DDI-DrugBank.d599.s7	steroids	140	147	I-group
DDI-DrugBank.d599.s7	,	148	148	O
DDI-DrugBank.d599.s7	anticonvulsants	164	178	B-group
DDI-DrugBank.d599.s7	,	162	162	O
DDI-DrugBank.d599.s7	cyclosporin	181	191	B-drug
DDI-DrugBank.d599.s7	)	192	192	O
DDI-DrugBank.d599.s7	.	193	193	O
DDI-DrugBank.d599.s8	Careful	0	6	O
DDI-DrugBank.d599.s8	monitoring	8	17	O
DDI-DrugBank.d599.s8	is	19	20	O
DDI-DrugBank.d599.s8	advisable	22	30	O
DDI-DrugBank.d599.s8	when	32	35	O
DDI-DrugBank.d599.s8	GH	37	38	B-drug
DDI-DrugBank.d599.s8	is	40	41	O
DDI-DrugBank.d599.s8	administered	43	54	O
DDI-DrugBank.d599.s8	in	56	57	O
DDI-DrugBank.d599.s8	combination	59	69	O
DDI-DrugBank.d599.s8	with	71	74	O
DDI-DrugBank.d599.s8	other	76	80	O
DDI-DrugBank.d599.s8	drugs	82	86	O
DDI-DrugBank.d599.s8	known	88	92	O
DDI-DrugBank.d599.s8	to	94	95	O
DDI-DrugBank.d599.s8	be	97	98	O
DDI-DrugBank.d599.s8	metabolized	100	110	O
DDI-DrugBank.d599.s8	by	112	113	O
DDI-DrugBank.d599.s8	CP450	115	119	O
DDI-DrugBank.d599.s8	liver	121	125	O
DDI-DrugBank.d599.s8	enzymes	127	133	O
DDI-DrugBank.d599.s8	.	134	134	O
DDI-DrugBank.d366.s0	May	0	2	O
DDI-DrugBank.d366.s0	interact	4	11	O
DDI-DrugBank.d366.s0	with	13	16	O
DDI-DrugBank.d366.s0	skin	18	21	O
DDI-DrugBank.d366.s0	products	23	30	O
DDI-DrugBank.d366.s0	or	32	33	O
DDI-DrugBank.d366.s0	shampoos	35	42	O
DDI-DrugBank.d366.s0	for	44	46	O
DDI-DrugBank.d366.s0	dandruff	48	55	O
DDI-DrugBank.d366.s0	or	57	58	O
DDI-DrugBank.d366.s0	psoriasis	60	68	O
DDI-DrugBank.d366.s0	.	69	69	O
DDI-DrugBank.d774.s0	Trilostane	0	9	B-drug
DDI-DrugBank.d774.s0	may	11	13	O
DDI-DrugBank.d774.s0	interact	15	22	O
DDI-DrugBank.d774.s0	with	24	27	O
DDI-DrugBank.d774.s0	aminoglutethimide	29	45	B-drug
DDI-DrugBank.d774.s0	or	47	48	O
DDI-DrugBank.d774.s0	mitotane	50	57	B-drug
DDI-DrugBank.d774.s0	(	59	59	O
DDI-DrugBank.d774.s0	causing	60	66	O
DDI-DrugBank.d774.s0	too	68	70	O
DDI-DrugBank.d774.s0	great	72	76	O
DDI-DrugBank.d774.s0	a	75	75	O
DDI-DrugBank.d774.s0	decrease	80	87	O
DDI-DrugBank.d774.s0	in	89	90	O
DDI-DrugBank.d774.s0	adrenal	92	98	O
DDI-DrugBank.d774.s0	function	100	107	O
DDI-DrugBank.d774.s0	)	108	108	O
DDI-DrugBank.d774.s0	.	109	109	O
DDI-DrugBank.d728.s0	No	0	1	O
DDI-DrugBank.d728.s0	specific	3	10	O
DDI-DrugBank.d728.s0	cytochrome	12	21	O
DDI-DrugBank.d728.s0	P450-based	23	32	O
DDI-DrugBank.d728.s0	drug	34	37	O
DDI-DrugBank.d728.s0	interaction	39	49	O
DDI-DrugBank.d728.s0	studies	51	57	O
DDI-DrugBank.d728.s0	have	59	62	O
DDI-DrugBank.d728.s0	been	64	67	O
DDI-DrugBank.d728.s0	conducted	69	77	O
DDI-DrugBank.d728.s0	.	78	78	O
DDI-DrugBank.d728.s1	No	0	1	O
DDI-DrugBank.d728.s1	pharmacokinetic	3	17	O
DDI-DrugBank.d728.s1	interaction	19	29	O
DDI-DrugBank.d728.s1	between	31	37	O
DDI-DrugBank.d728.s1	85	39	40	O
DDI-DrugBank.d728.s1	mg/m2	42	46	O
DDI-DrugBank.d728.s1	ELOXATIN	48	55	B-brand
DDI-DrugBank.d728.s1	and	57	59	O
DDI-DrugBank.d728.s1	infusional	61	70	O
DDI-DrugBank.d728.s1	5-FU	72	75	B-drug
DDI-DrugBank.d728.s1	has	77	79	O
DDI-DrugBank.d728.s1	been	81	84	O
DDI-DrugBank.d728.s1	observed	86	93	O
DDI-DrugBank.d728.s1	in	95	96	O
DDI-DrugBank.d728.s1	patients	98	105	O
DDI-DrugBank.d728.s1	treated	107	113	O
DDI-DrugBank.d728.s1	every	115	119	O
DDI-DrugBank.d728.s1	2	121	121	O
DDI-DrugBank.d728.s1	weeks	123	127	O
DDI-DrugBank.d728.s1	.	128	128	O
DDI-DrugBank.d728.s2	Increases	0	8	O
DDI-DrugBank.d728.s2	of	10	11	O
DDI-DrugBank.d728.s2	5-FU	13	16	B-drug
DDI-DrugBank.d728.s2	plasma	18	23	O
DDI-DrugBank.d728.s2	concentrations	25	38	O
DDI-DrugBank.d728.s2	by	40	41	O
DDI-DrugBank.d728.s2	approximately	43	55	O
DDI-DrugBank.d728.s2	20	57	58	O
DDI-DrugBank.d728.s2	%	59	59	O
DDI-DrugBank.d728.s2	have	61	64	O
DDI-DrugBank.d728.s2	been	66	69	O
DDI-DrugBank.d728.s2	observed	71	78	O
DDI-DrugBank.d728.s2	with	80	83	O
DDI-DrugBank.d728.s2	doses	85	89	O
DDI-DrugBank.d728.s2	of	91	92	O
DDI-DrugBank.d728.s2	130	94	96	O
DDI-DrugBank.d728.s2	mg/m2	98	102	O
DDI-DrugBank.d728.s2	ELOXATIN	104	111	B-brand
DDI-DrugBank.d728.s2	dosed	113	117	O
DDI-DrugBank.d728.s2	every	119	123	O
DDI-DrugBank.d728.s2	3	125	125	O
DDI-DrugBank.d728.s2	weeks	127	131	O
DDI-DrugBank.d728.s2	.	132	132	O
DDI-DrugBank.d728.s3	Since	0	4	O
DDI-DrugBank.d728.s3	platinum	6	13	O
DDI-DrugBank.d728.s3	containing	15	24	O
DDI-DrugBank.d728.s3	species	26	32	O
DDI-DrugBank.d728.s3	are	34	36	O
DDI-DrugBank.d728.s3	eliminated	38	47	O
DDI-DrugBank.d728.s3	primarily	49	57	O
DDI-DrugBank.d728.s3	through	59	65	O
DDI-DrugBank.d728.s3	the	67	69	O
DDI-DrugBank.d728.s3	kidney	71	76	O
DDI-DrugBank.d728.s3	,	77	77	O
DDI-DrugBank.d728.s3	clearance	79	87	O
DDI-DrugBank.d728.s3	of	89	90	O
DDI-DrugBank.d728.s3	these	92	96	O
DDI-DrugBank.d728.s3	products	98	105	O
DDI-DrugBank.d728.s3	may	107	109	O
DDI-DrugBank.d728.s3	be	111	112	O
DDI-DrugBank.d728.s3	decreased	114	122	O
DDI-DrugBank.d728.s3	by	124	125	O
DDI-DrugBank.d728.s3	coadministration	127	142	O
DDI-DrugBank.d728.s3	of	144	145	O
DDI-DrugBank.d728.s3	potentially	147	157	O
DDI-DrugBank.d728.s3	nephrotoxic	159	169	O
DDI-DrugBank.d728.s3	compounds	171	179	O
DDI-DrugBank.d728.s3	;	180	180	O
DDI-DrugBank.d728.s4	although	0	7	O
DDI-DrugBank.d728.s4	,	8	8	O
DDI-DrugBank.d728.s4	this	10	13	O
DDI-DrugBank.d728.s4	has	15	17	O
DDI-DrugBank.d728.s4	not	19	21	O
DDI-DrugBank.d728.s4	been	23	26	O
DDI-DrugBank.d728.s4	specifically	28	39	O
DDI-DrugBank.d728.s4	studied	41	47	O
DDI-DrugBank.d728.s4	.	48	48	O
DDI-MedLine.d81.s0	Hypothermia	0	10	O
DDI-MedLine.d81.s0	as	12	13	O
DDI-MedLine.d81.s0	an	15	16	O
DDI-MedLine.d81.s0	index	18	22	O
DDI-MedLine.d81.s0	of	24	25	O
DDI-MedLine.d81.s0	the	27	29	O
DDI-MedLine.d81.s0	disulfiram-ethanol	31	48	O
DDI-MedLine.d81.s0	reaction	50	57	O
DDI-MedLine.d81.s0	in	59	60	O
DDI-MedLine.d81.s0	the	62	64	O
DDI-MedLine.d81.s0	rat	66	68	O
DDI-MedLine.d81.s0	.	69	69	O
DDI-MedLine.d81.s1	Decreased	0	8	O
DDI-MedLine.d81.s1	core	10	13	O
DDI-MedLine.d81.s1	temperature	15	25	O
DDI-MedLine.d81.s1	in	27	28	O
DDI-MedLine.d81.s1	female	30	35	O
DDI-MedLine.d81.s1	rats	37	40	O
DDI-MedLine.d81.s1	was	42	44	O
DDI-MedLine.d81.s1	investigated	46	57	O
DDI-MedLine.d81.s1	as	59	60	O
DDI-MedLine.d81.s1	one	62	64	O
DDI-MedLine.d81.s1	possible	66	73	O
DDI-MedLine.d81.s1	index	75	79	O
DDI-MedLine.d81.s1	of	81	82	O
DDI-MedLine.d81.s1	the	84	86	O
DDI-MedLine.d81.s1	disulfiram-ethanol	88	105	O
DDI-MedLine.d81.s1	reaction	107	114	O
DDI-MedLine.d81.s1	(	116	116	O
DDI-MedLine.d81.s1	DER	117	119	O
DDI-MedLine.d81.s1	)	120	120	O
DDI-MedLine.d81.s1	.	121	121	O
DDI-MedLine.d81.s2	Core	0	3	O
DDI-MedLine.d81.s2	temperature	5	15	O
DDI-MedLine.d81.s2	was	17	19	O
DDI-MedLine.d81.s2	decreased	21	29	O
DDI-MedLine.d81.s2	in	31	32	O
DDI-MedLine.d81.s2	rats	34	37	O
DDI-MedLine.d81.s2	in	39	40	O
DDI-MedLine.d81.s2	a	35	35	O
DDI-MedLine.d81.s2	dose-dependent	44	57	O
DDI-MedLine.d81.s2	manner	59	64	O
DDI-MedLine.d81.s2	when	66	69	O
DDI-MedLine.d81.s2	ethanol	71	77	B-drug
DDI-MedLine.d81.s2	was	79	81	O
DDI-MedLine.d81.s2	administered	83	94	O
DDI-MedLine.d81.s2	to	96	97	O
DDI-MedLine.d81.s2	rats	99	102	O
DDI-MedLine.d81.s2	treated	104	110	O
DDI-MedLine.d81.s2	with	112	115	O
DDI-MedLine.d81.s2	disulfiram	117	126	B-drug
DDI-MedLine.d81.s2	8	128	128	O
DDI-MedLine.d81.s2	hours	130	134	O
DDI-MedLine.d81.s2	before	136	141	O
DDI-MedLine.d81.s2	the	143	145	O
DDI-MedLine.d81.s2	ethanol	147	153	B-drug
DDI-MedLine.d81.s2	challenge	155	163	O
DDI-MedLine.d81.s2	.	164	164	O
DDI-MedLine.d81.s3	The	0	2	O
DDI-MedLine.d81.s3	decrease	4	11	O
DDI-MedLine.d81.s3	in	13	14	O
DDI-MedLine.d81.s3	temperature	16	26	O
DDI-MedLine.d81.s3	began	28	32	O
DDI-MedLine.d81.s3	within	34	39	O
DDI-MedLine.d81.s3	20	41	42	O
DDI-MedLine.d81.s3	minutes	44	50	O
DDI-MedLine.d81.s3	after	52	56	O
DDI-MedLine.d81.s3	ethanol	58	64	B-drug
DDI-MedLine.d81.s3	administration	66	79	O
DDI-MedLine.d81.s3	,	80	80	O
DDI-MedLine.d81.s3	reaching	82	89	O
DDI-MedLine.d81.s3	a	84	84	O
DDI-MedLine.d81.s3	maximal	93	99	O
DDI-MedLine.d81.s3	decrease	101	108	O
DDI-MedLine.d81.s3	between	110	116	O
DDI-MedLine.d81.s3	60	118	119	O
DDI-MedLine.d81.s3	and	121	123	O
DDI-MedLine.d81.s3	120	125	127	O
DDI-MedLine.d81.s3	minutes	129	135	O
DDI-MedLine.d81.s3	post	137	140	O
DDI-MedLine.d81.s3	ethanol	142	148	B-drug
DDI-MedLine.d81.s3	.	149	149	O
DDI-MedLine.d81.s4	The	0	2	O
DDI-MedLine.d81.s4	core	4	7	O
DDI-MedLine.d81.s4	temperature	9	19	O
DDI-MedLine.d81.s4	returned	21	28	O
DDI-MedLine.d81.s4	to	30	31	O
DDI-MedLine.d81.s4	normal	33	38	O
DDI-MedLine.d81.s4	300	40	42	O
DDI-MedLine.d81.s4	minutes	44	50	O
DDI-MedLine.d81.s4	after	52	56	O
DDI-MedLine.d81.s4	ethanol	58	64	B-drug
DDI-MedLine.d81.s4	.	65	65	O
DDI-MedLine.d81.s5	The	0	2	O
DDI-MedLine.d81.s5	blood	4	8	O
DDI-MedLine.d81.s5	pressure	10	17	O
DDI-MedLine.d81.s5	(	19	19	O
DDI-MedLine.d81.s5	carotid	20	26	O
DDI-MedLine.d81.s5	cannulation	28	38	O
DDI-MedLine.d81.s5	)	39	39	O
DDI-MedLine.d81.s5	decreased	41	49	O
DDI-MedLine.d81.s5	along	51	55	O
DDI-MedLine.d81.s5	with	57	60	O
DDI-MedLine.d81.s5	the	62	64	O
DDI-MedLine.d81.s5	core	66	69	O
DDI-MedLine.d81.s5	temperature	71	81	O
DDI-MedLine.d81.s5	.	82	82	O
DDI-MedLine.d81.s6	Maximal	0	6	O
DDI-MedLine.d81.s6	hypotension	8	18	O
DDI-MedLine.d81.s6	was	20	22	O
DDI-MedLine.d81.s6	found	24	28	O
DDI-MedLine.d81.s6	120	30	32	O
DDI-MedLine.d81.s6	minutes	34	40	O
DDI-MedLine.d81.s6	post	42	45	O
DDI-MedLine.d81.s6	ethanol	47	53	B-drug
DDI-MedLine.d81.s6	,	54	54	O
DDI-MedLine.d81.s6	and	56	58	O
DDI-MedLine.d81.s6	returned	60	67	O
DDI-MedLine.d81.s6	to	69	70	O
DDI-MedLine.d81.s6	normal	72	77	O
DDI-MedLine.d81.s6	300	79	81	O
DDI-MedLine.d81.s6	minutes	83	89	O
DDI-MedLine.d81.s6	after	91	95	O
DDI-MedLine.d81.s6	ethanol	97	103	B-drug
DDI-MedLine.d81.s6	.	104	104	O
DDI-MedLine.d81.s7	Heart	0	4	O
DDI-MedLine.d81.s7	rate	6	9	O
DDI-MedLine.d81.s7	increased	11	19	O
DDI-MedLine.d81.s7	initially	21	29	O
DDI-MedLine.d81.s7	and	31	33	O
DDI-MedLine.d81.s7	returned	35	42	O
DDI-MedLine.d81.s7	to	44	45	O
DDI-MedLine.d81.s7	normal	47	52	O
DDI-MedLine.d81.s7	40	54	55	O
DDI-MedLine.d81.s7	minutes	57	63	O
DDI-MedLine.d81.s7	after	65	69	O
DDI-MedLine.d81.s7	ethanol	71	77	B-drug
DDI-MedLine.d81.s7	challenge	79	87	O
DDI-MedLine.d81.s7	.	88	88	O
DDI-MedLine.d111.s0	Effect	0	5	O
DDI-MedLine.d111.s0	of	7	8	O
DDI-MedLine.d111.s0	coadministered	10	23	O
DDI-MedLine.d111.s0	drugs	25	29	O
DDI-MedLine.d111.s0	and	31	33	O
DDI-MedLine.d111.s0	ethanol	35	41	B-drug
DDI-MedLine.d111.s0	on	43	44	O
DDI-MedLine.d111.s0	the	46	48	O
DDI-MedLine.d111.s0	binding	50	56	O
DDI-MedLine.d111.s0	of	58	59	O
DDI-MedLine.d111.s0	therapeutic	61	71	O
DDI-MedLine.d111.s0	drugs	73	77	O
DDI-MedLine.d111.s0	to	79	80	O
DDI-MedLine.d111.s0	human	82	86	O
DDI-MedLine.d111.s0	serum	88	92	O
DDI-MedLine.d111.s0	in	94	95	O
DDI-MedLine.d111.s0	vitro	97	101	O
DDI-MedLine.d111.s0	.	102	102	O
DDI-MedLine.d111.s1	The	0	2	O
DDI-MedLine.d111.s1	effects	4	10	O
DDI-MedLine.d111.s1	of	12	13	O
DDI-MedLine.d111.s1	coadministered	15	28	O
DDI-MedLine.d111.s1	drugs	30	34	O
DDI-MedLine.d111.s1	and	36	38	O
DDI-MedLine.d111.s1	ethanol	40	46	B-drug
DDI-MedLine.d111.s1	on	48	49	O
DDI-MedLine.d111.s1	the	51	53	O
DDI-MedLine.d111.s1	binding	55	61	O
DDI-MedLine.d111.s1	of	63	64	O
DDI-MedLine.d111.s1	therapeutic	66	76	O
DDI-MedLine.d111.s1	drugs	78	82	O
DDI-MedLine.d111.s1	to	84	85	O
DDI-MedLine.d111.s1	human	87	91	O
DDI-MedLine.d111.s1	serum	93	97	O
DDI-MedLine.d111.s1	in	99	100	O
DDI-MedLine.d111.s1	vitro	102	106	O
DDI-MedLine.d111.s1	was	108	110	O
DDI-MedLine.d111.s1	investigated	112	123	O
DDI-MedLine.d111.s1	.	124	124	O
DDI-MedLine.d111.s2	Acetaminophen	0	12	B-drug
DDI-MedLine.d111.s2	,	13	13	O
DDI-MedLine.d111.s2	lidocaine	15	23	B-drug
DDI-MedLine.d111.s2	,	24	24	O
DDI-MedLine.d111.s2	phenobarbital	26	38	B-drug
DDI-MedLine.d111.s2	,	39	39	O
DDI-MedLine.d111.s2	quinidine	41	49	B-drug
DDI-MedLine.d111.s2	,	50	50	O
DDI-MedLine.d111.s2	theophylline	52	63	B-drug
DDI-MedLine.d111.s2	,	64	64	O
DDI-MedLine.d111.s2	and	66	68	O
DDI-MedLine.d111.s2	valproic	70	77	B-drug
DDI-MedLine.d111.s2	acid	79	82	I-drug
DDI-MedLine.d111.s2	were	84	87	O
DDI-MedLine.d111.s2	added	89	93	O
DDI-MedLine.d111.s2	to	95	96	O
DDI-MedLine.d111.s2	pooled	98	103	O
DDI-MedLine.d111.s2	human	105	109	O
DDI-MedLine.d111.s2	serum	111	115	O
DDI-MedLine.d111.s2	at	117	118	O
DDI-MedLine.d111.s2	therapeutic	120	130	O
DDI-MedLine.d111.s2	concentrations	132	145	O
DDI-MedLine.d111.s2	.	146	146	O
DDI-MedLine.d111.s3	To	0	1	O
DDI-MedLine.d111.s3	each	3	6	O
DDI-MedLine.d111.s3	preparation	8	18	O
DDI-MedLine.d111.s3	was	20	22	O
DDI-MedLine.d111.s3	added	24	28	O
DDI-MedLine.d111.s3	one	30	32	O
DDI-MedLine.d111.s3	additional	34	43	O
DDI-MedLine.d111.s3	drug	45	48	O
DDI-MedLine.d111.s3	at	50	51	O
DDI-MedLine.d111.s3	three	53	57	O
DDI-MedLine.d111.s3	concentrations	59	72	O
DDI-MedLine.d111.s3	ranging	74	80	O
DDI-MedLine.d111.s3	from	82	85	O
DDI-MedLine.d111.s3	therapeutic	87	97	O
DDI-MedLine.d111.s3	to	99	100	O
DDI-MedLine.d111.s3	toxic	102	106	O
DDI-MedLine.d111.s3	.	107	107	O
DDI-MedLine.d111.s4	The	0	2	O
DDI-MedLine.d111.s4	following	4	12	O
DDI-MedLine.d111.s4	eight	14	18	O
DDI-MedLine.d111.s4	target	20	25	O
DDI-MedLine.d111.s4	drug/added	27	36	O
DDI-MedLine.d111.s4	drug	38	41	O
DDI-MedLine.d111.s4	combinations	43	54	O
DDI-MedLine.d111.s4	were	56	59	O
DDI-MedLine.d111.s4	studied	61	67	O
DDI-MedLine.d111.s4	:	68	68	O
DDI-MedLine.d111.s4	acetaminophen/phenobarbital	70	96	O
DDI-MedLine.d111.s4	.	97	97	O
DDI-MedLine.d111.s5	acetaminophen/theophylline	0	25	O
DDI-MedLine.d111.s5	,	26	26	O
DDI-MedLine.d111.s5	lidocaine/quinidine	28	46	O
DDI-MedLine.d111.s5	,	47	47	O
DDI-MedLine.d111.s5	phenobarbital/acetaminophen	49	75	O
DDI-MedLine.d111.s5	,	76	76	O
DDI-MedLine.d111.s5	phenobarbital/valproic	78	99	O
DDI-MedLine.d111.s5	acid	101	104	I-drug
DDI-MedLine.d111.s5	,	105	105	O
DDI-MedLine.d111.s5	quinidine/lidocaine	107	125	O
DDI-MedLine.d111.s5	,	126	126	O
DDI-MedLine.d111.s5	theophylline/acetaminophen	128	153	O
DDI-MedLine.d111.s5	,	154	154	O
DDI-MedLine.d111.s5	and	156	158	O
DDI-MedLine.d111.s5	valproic	160	167	B-drug
DDI-MedLine.d111.s5	acid/phenobarbital	169	186	O
DDI-MedLine.d111.s5	.	187	187	O
DDI-MedLine.d111.s6	Each	0	3	O
DDI-MedLine.d111.s6	serum	5	9	O
DDI-MedLine.d111.s6	without	11	17	O
DDI-MedLine.d111.s6	the	19	21	O
DDI-MedLine.d111.s6	other	23	27	O
DDI-MedLine.d111.s6	added	29	33	O
DDI-MedLine.d111.s6	drug	35	38	O
DDI-MedLine.d111.s6	as	40	41	O
DDI-MedLine.d111.s6	well	43	46	O
DDI-MedLine.d111.s6	as	40	41	O
DDI-MedLine.d111.s6	the	51	53	O
DDI-MedLine.d111.s6	serum	55	59	O
DDI-MedLine.d111.s6	supplemented	61	72	O
DDI-MedLine.d111.s6	with	74	77	O
DDI-MedLine.d111.s6	the	79	81	O
DDI-MedLine.d111.s6	other	83	87	O
DDI-MedLine.d111.s6	drug	89	92	O
DDI-MedLine.d111.s6	at	94	95	O
DDI-MedLine.d111.s6	the	79	81	O
DDI-MedLine.d111.s6	three	101	105	O
DDI-MedLine.d111.s6	concentrations	107	120	O
DDI-MedLine.d111.s6	was	122	124	O
DDI-MedLine.d111.s6	dialyzed	126	133	O
DDI-MedLine.d111.s6	against	135	141	O
DDI-MedLine.d111.s6	phosphate	143	151	O
DDI-MedLine.d111.s6	buffer	153	158	O
DDI-MedLine.d111.s6	.	159	159	O
DDI-MedLine.d111.s7	Similarly	0	8	O
DDI-MedLine.d111.s7	dialyzed	10	17	O
DDI-MedLine.d111.s7	were	19	22	O
DDI-MedLine.d111.s7	phenobarbital	24	36	B-drug
DDI-MedLine.d111.s7	,	37	37	O
DDI-MedLine.d111.s7	quinidine	39	47	B-drug
DDI-MedLine.d111.s7	,	48	48	O
DDI-MedLine.d111.s7	and	50	52	O
DDI-MedLine.d111.s7	theophylline	54	65	B-drug
DDI-MedLine.d111.s7	,	66	66	O
DDI-MedLine.d111.s7	both	68	71	O
DDI-MedLine.d111.s7	alone	73	77	O
DDI-MedLine.d111.s7	at	79	80	O
DDI-MedLine.d111.s7	therapeutic	82	92	O
DDI-MedLine.d111.s7	concentrations	94	107	O
DDI-MedLine.d111.s7	in	109	110	O
DDI-MedLine.d111.s7	serum	112	116	O
DDI-MedLine.d111.s7	and	118	120	O
DDI-MedLine.d111.s7	with	122	125	O
DDI-MedLine.d111.s7	ethanol	127	133	B-drug
DDI-MedLine.d111.s7	at	135	136	O
DDI-MedLine.d111.s7	three	138	142	O
DDI-MedLine.d111.s7	different	144	152	O
DDI-MedLine.d111.s7	concentrations	154	167	O
DDI-MedLine.d111.s7	in	169	170	O
DDI-MedLine.d111.s7	serum	172	176	O
DDI-MedLine.d111.s7	.	177	177	O
DDI-MedLine.d111.s8	The	0	2	O
DDI-MedLine.d111.s8	percentage	4	13	O
DDI-MedLine.d111.s8	of	15	16	O
DDI-MedLine.d111.s8	drug	18	21	O
DDI-MedLine.d111.s8	binding	23	29	O
DDI-MedLine.d111.s8	in	27	28	O
DDI-MedLine.d111.s8	each	34	37	O
DDI-MedLine.d111.s8	preparation	39	49	O
DDI-MedLine.d111.s8	was	51	53	O
DDI-MedLine.d111.s8	calculated	55	64	O
DDI-MedLine.d111.s8	.	65	65	O
DDI-MedLine.d111.s9	Acetaminophen	0	12	B-drug
DDI-MedLine.d111.s9	diminished	14	23	O
DDI-MedLine.d111.s9	the	25	27	O
DDI-MedLine.d111.s9	binding	29	35	O
DDI-MedLine.d111.s9	of	37	38	O
DDI-MedLine.d111.s9	theophylline	40	51	B-drug
DDI-MedLine.d111.s9	to	53	54	O
DDI-MedLine.d111.s9	human	56	60	O
DDI-MedLine.d111.s9	serum	62	66	O
DDI-MedLine.d111.s9	by	68	69	O
DDI-MedLine.d111.s9	a	71	71	O
DDI-MedLine.d111.s9	net	73	75	O
DDI-MedLine.d111.s9	change	77	82	O
DDI-MedLine.d111.s9	of	84	85	O
DDI-MedLine.d111.s9	5.7	87	89	O
DDI-MedLine.d111.s9	%	90	90	O
DDI-MedLine.d111.s9	(	92	92	O
DDI-MedLine.d111.s9	percentage	93	102	O
DDI-MedLine.d111.s9	increase	104	111	O
DDI-MedLine.d111.s9	in	104	105	O
DDI-MedLine.d111.s9	free	116	119	O
DDI-MedLine.d111.s9	drug	121	124	O
DDI-MedLine.d111.s9	fraction	126	133	O
DDI-MedLine.d111.s9	[	135	135	O
DDI-MedLine.d111.s9	FDF	136	138	O
DDI-MedLine.d111.s9	]	139	139	O
DDI-MedLine.d111.s9	,	140	140	O
DDI-MedLine.d111.s9	11.0	142	145	O
DDI-MedLine.d111.s9	%	146	146	O
DDI-MedLine.d111.s9	)	147	147	O
DDI-MedLine.d111.s9	at	149	150	O
DDI-MedLine.d111.s9	662	152	154	O
DDI-MedLine.d111.s9	micromol/L	156	165	O
DDI-MedLine.d111.s9	and	167	169	O
DDI-MedLine.d111.s9	by	171	172	O
DDI-MedLine.d111.s9	a	149	149	O
DDI-MedLine.d111.s9	net	176	178	O
DDI-MedLine.d111.s9	change	180	185	O
DDI-MedLine.d111.s9	of	187	188	O
DDI-MedLine.d111.s9	7.1	190	192	O
DDI-MedLine.d111.s9	%	193	193	O
DDI-MedLine.d111.s9	(	195	195	O
DDI-MedLine.d111.s9	percentage	196	205	O
DDI-MedLine.d111.s9	increase	207	214	O
DDI-MedLine.d111.s9	in	207	208	O
DDI-MedLine.d111.s9	FDF	219	221	O
DDI-MedLine.d111.s9	,	222	222	O
DDI-MedLine.d111.s9	13.7	224	227	O
DDI-MedLine.d111.s9	%	193	193	O
DDI-MedLine.d111.s9	)	229	229	O
DDI-MedLine.d111.s9	at	231	232	O
DDI-MedLine.d111.s9	1324	234	237	O
DDI-MedLine.d111.s9	micromol/L	239	248	O
DDI-MedLine.d111.s9	.	226	226	O
DDI-MedLine.d111.s10	Theophylline	0	11	B-drug
DDI-MedLine.d111.s10	decreased	13	21	O
DDI-MedLine.d111.s10	the	23	25	O
DDI-MedLine.d111.s10	binding	27	33	O
DDI-MedLine.d111.s10	of	35	36	O
DDI-MedLine.d111.s10	acetaminophen	38	50	B-drug
DDI-MedLine.d111.s10	by	52	53	O
DDI-MedLine.d111.s10	a	55	55	O
DDI-MedLine.d111.s10	net	57	59	O
DDI-MedLine.d111.s10	change	61	66	O
DDI-MedLine.d111.s10	of	68	69	O
DDI-MedLine.d111.s10	6.8	71	73	O
DDI-MedLine.d111.s10	%	74	74	O
DDI-MedLine.d111.s10	(	76	76	O
DDI-MedLine.d111.s10	percentage	77	86	O
DDI-MedLine.d111.s10	increase	88	95	O
DDI-MedLine.d111.s10	in	88	89	O
DDI-MedLine.d111.s10	FDF	100	102	O
DDI-MedLine.d111.s10	,	103	103	O
DDI-MedLine.d111.s10	8.8	105	107	O
DDI-MedLine.d111.s10	%	108	108	O
DDI-MedLine.d111.s10	)	109	109	O
DDI-MedLine.d111.s10	at	111	112	O
DDI-MedLine.d111.s10	277.5	114	118	O
DDI-MedLine.d111.s10	micromol/L	120	129	O
DDI-MedLine.d111.s10	;	130	130	O
DDI-MedLine.d111.s11	phenobarbital	0	12	B-drug
DDI-MedLine.d111.s11	reduced	14	20	O
DDI-MedLine.d111.s11	it	22	23	O
DDI-MedLine.d111.s11	by	25	26	O
DDI-MedLine.d111.s11	a	28	28	O
DDI-MedLine.d111.s11	net	30	32	O
DDI-MedLine.d111.s11	change	34	39	O
DDI-MedLine.d111.s11	of	41	42	O
DDI-MedLine.d111.s11	6.6	44	46	O
DDI-MedLine.d111.s11	%	47	47	O
DDI-MedLine.d111.s11	(	49	49	O
DDI-MedLine.d111.s11	percentage	50	59	O
DDI-MedLine.d111.s11	increase	61	68	O
DDI-MedLine.d111.s11	in	61	62	O
DDI-MedLine.d111.s11	FDF	73	75	O
DDI-MedLine.d111.s11	,	76	76	O
DDI-MedLine.d111.s11	8.5	78	80	O
DDI-MedLine.d111.s11	%	81	81	O
DDI-MedLine.d111.s11	)	82	82	O
DDI-MedLine.d111.s11	at	84	85	O
DDI-MedLine.d111.s11	431	87	89	O
DDI-MedLine.d111.s11	micromol/L	91	100	O
DDI-MedLine.d111.s11	.	101	101	O
DDI-MedLine.d111.s12	Valproic	0	7	B-drug
DDI-MedLine.d111.s12	acid	9	12	I-drug
DDI-MedLine.d111.s12	diminished	14	23	O
DDI-MedLine.d111.s12	binding	25	31	O
DDI-MedLine.d111.s12	of	33	34	O
DDI-MedLine.d111.s12	phenobarbital	36	48	B-drug
DDI-MedLine.d111.s12	by	50	51	O
DDI-MedLine.d111.s12	a	47	47	O
DDI-MedLine.d111.s12	net	55	57	O
DDI-MedLine.d111.s12	change	59	64	O
DDI-MedLine.d111.s12	of	66	67	O
DDI-MedLine.d111.s12	9.9	69	71	O
DDI-MedLine.d111.s12	%	72	72	O
DDI-MedLine.d111.s12	(	74	74	O
DDI-MedLine.d111.s12	percentage	75	84	O
DDI-MedLine.d111.s12	increase	86	93	O
DDI-MedLine.d111.s12	in	86	87	O
DDI-MedLine.d111.s12	FDF	98	100	O
DDI-MedLine.d111.s12	,	101	101	O
DDI-MedLine.d111.s12	21.2	103	106	O
DDI-MedLine.d111.s12	%	107	107	O
DDI-MedLine.d111.s12	)	108	108	O
DDI-MedLine.d111.s12	at	110	111	O
DDI-MedLine.d111.s12	1732	113	116	O
DDI-MedLine.d111.s12	micromol/L	118	127	O
DDI-MedLine.d111.s12	.	128	128	O
DDI-MedLine.d111.s13	No	0	1	O
DDI-MedLine.d111.s13	significant	3	13	O
DDI-MedLine.d111.s13	effects	15	21	O
DDI-MedLine.d111.s13	were	23	26	O
DDI-MedLine.d111.s13	noted	28	32	O
DDI-MedLine.d111.s13	with	34	37	O
DDI-MedLine.d111.s13	other	39	43	O
DDI-MedLine.d111.s13	drug	45	48	O
DDI-MedLine.d111.s13	combinations	50	61	O
DDI-MedLine.d111.s13	or	63	64	O
DDI-MedLine.d111.s13	with	66	69	O
DDI-MedLine.d111.s13	the	71	73	O
DDI-MedLine.d111.s13	addition	75	82	O
DDI-MedLine.d111.s13	of	84	85	O
DDI-MedLine.d111.s13	ethanol	87	93	B-drug
DDI-MedLine.d111.s13	.	94	94	O
DDI-MedLine.d111.s14	Coingestion	0	10	O
DDI-MedLine.d111.s14	of	12	13	O
DDI-MedLine.d111.s14	acetaminophen	15	27	B-drug
DDI-MedLine.d111.s14	with	29	32	O
DDI-MedLine.d111.s14	theophylline	34	45	B-drug
DDI-MedLine.d111.s14	,	46	46	O
DDI-MedLine.d111.s14	phenobarbital	48	60	B-drug
DDI-MedLine.d111.s14	with	62	65	O
DDI-MedLine.d111.s14	acetaminophen	67	79	B-drug
DDI-MedLine.d111.s14	,	80	80	O
DDI-MedLine.d111.s14	and	82	84	O
DDI-MedLine.d111.s14	valproic	86	93	B-drug
DDI-MedLine.d111.s14	acid	95	98	I-drug
DDI-MedLine.d111.s14	with	100	103	O
DDI-MedLine.d111.s14	phenobarbital	105	117	B-drug
DDI-MedLine.d111.s14	at	119	120	O
DDI-MedLine.d111.s14	high	122	125	O
DDI-MedLine.d111.s14	to	127	128	O
DDI-MedLine.d111.s14	toxic	130	134	O
DDI-MedLine.d111.s14	concentrations	136	149	O
DDI-MedLine.d111.s14	decreases	151	159	O
DDI-MedLine.d111.s14	the	161	163	O
DDI-MedLine.d111.s14	binding	165	171	O
DDI-MedLine.d111.s14	of	173	174	O
DDI-MedLine.d111.s14	the	161	163	O
DDI-MedLine.d111.s14	target	180	185	O
DDI-MedLine.d111.s14	drug	187	190	O
DDI-MedLine.d111.s14	.	191	191	O
DDI-MedLine.d111.s15	The	0	2	O
DDI-MedLine.d111.s15	resulting	4	12	O
DDI-MedLine.d111.s15	increase	14	21	O
DDI-MedLine.d111.s15	in	23	24	O
DDI-MedLine.d111.s15	free	26	29	O
DDI-MedLine.d111.s15	drug	31	34	O
DDI-MedLine.d111.s15	concentration	36	48	O
DDI-MedLine.d111.s15	may	50	52	O
DDI-MedLine.d111.s15	lead	54	57	O
DDI-MedLine.d111.s15	to	59	60	O
DDI-MedLine.d111.s15	enhanced	62	69	O
DDI-MedLine.d111.s15	drug	71	74	O
DDI-MedLine.d111.s15	effect	76	81	O
DDI-MedLine.d111.s15	in	83	84	O
DDI-MedLine.d111.s15	vivo	86	89	O
DDI-MedLine.d111.s15	.	90	90	O
DDI-DrugBank.d576.s0	Salicylates	0	10	B-group
DDI-DrugBank.d576.s0	antagonize	12	21	O
DDI-DrugBank.d576.s0	the	23	25	O
DDI-DrugBank.d576.s0	uricosuric	27	36	O
DDI-DrugBank.d576.s0	action	38	43	O
DDI-DrugBank.d576.s0	of	45	46	O
DDI-DrugBank.d576.s0	.	48	48	O
DDI-DrugBank.d576.s0	drugs	50	54	O
DDI-DrugBank.d576.s0	used	56	59	O
DDI-DrugBank.d576.s0	to	61	62	O
DDI-DrugBank.d576.s0	treat	64	68	O
DDI-DrugBank.d576.s0	gout	70	73	O
DDI-DrugBank.d576.s0	.	74	74	O
DDI-DrugBank.d576.s1	ASPIRIN	0	6	B-brand
DDI-DrugBank.d576.s1	AND	8	10	O
DDI-DrugBank.d576.s1	OTHER	12	16	O
DDI-DrugBank.d576.s1	SALICYLATE	18	27	B-group
DDI-DrugBank.d576.s1	DRUGS	29	33	I-group
DDI-DrugBank.d576.s1	WILL	35	38	O
DDI-DrugBank.d576.s1	BE	40	41	O
DDI-DrugBank.d576.s1	ADDITIVE	43	50	O
DDI-DrugBank.d576.s1	TO	52	53	O
DDI-DrugBank.d576.s1	DISALCID	55	62	B-brand
DDI-DrugBank.d576.s1	AND	64	66	O
DDI-DrugBank.d576.s1	MAY	68	70	O
DDI-DrugBank.d576.s1	INCREASE	72	79	O
DDI-DrugBank.d576.s1	PLASMA	81	86	O
DDI-DrugBank.d576.s1	CONCENTRATIONS	88	101	O
DDI-DrugBank.d576.s1	OF	103	104	O
DDI-DrugBank.d576.s1	SALICYLIC	106	114	B-drug
DDI-DrugBank.d576.s1	ACID	116	119	I-drug
DDI-DrugBank.d576.s1	TO	121	122	O
DDI-DrugBank.d576.s1	TOXIC	124	128	O
DDI-DrugBank.d576.s1	LEVELS	130	135	O
DDI-DrugBank.d576.s1	.	136	136	O
DDI-DrugBank.d576.s2	Drugs	0	4	O
DDI-DrugBank.d576.s2	and	6	8	O
DDI-DrugBank.d576.s2	foods	10	14	O
DDI-DrugBank.d576.s2	that	16	19	O
DDI-DrugBank.d576.s2	raise	21	25	O
DDI-DrugBank.d576.s2	urine	27	31	O
DDI-DrugBank.d576.s2	pH	33	34	O
DDI-DrugBank.d576.s2	will	36	39	O
DDI-DrugBank.d576.s2	increase	41	48	O
DDI-DrugBank.d576.s2	renal	50	54	O
DDI-DrugBank.d576.s2	clearance	56	64	O
DDI-DrugBank.d576.s2	and	66	68	O
DDI-DrugBank.d576.s2	urinary	70	76	O
DDI-DrugBank.d576.s2	excretion	78	86	O
DDI-DrugBank.d576.s2	of	88	89	O
DDI-DrugBank.d576.s2	salicylic	91	99	B-drug
DDI-DrugBank.d576.s2	acid	101	104	I-drug
DDI-DrugBank.d576.s2	,	105	105	O
DDI-DrugBank.d576.s2	thus	107	110	O
DDI-DrugBank.d576.s2	lowering	112	119	O
DDI-DrugBank.d576.s2	plasma	121	126	O
DDI-DrugBank.d576.s2	levels	128	133	O
DDI-DrugBank.d576.s2	;	134	134	O
DDI-DrugBank.d576.s3	acidifying	0	9	O
DDI-DrugBank.d576.s3	drugs	11	15	O
DDI-DrugBank.d576.s3	or	17	18	O
DDI-DrugBank.d576.s3	foods	20	24	O
DDI-DrugBank.d576.s3	will	26	29	O
DDI-DrugBank.d576.s3	decrease	31	38	O
DDI-DrugBank.d576.s3	urinary	40	46	O
DDI-DrugBank.d576.s3	excretion	48	56	O
DDI-DrugBank.d576.s3	and	58	60	O
DDI-DrugBank.d576.s3	increase	62	69	O
DDI-DrugBank.d576.s3	plasma	71	76	O
DDI-DrugBank.d576.s3	levels	78	83	O
DDI-DrugBank.d576.s3	.	84	84	O
DDI-DrugBank.d576.s4	Salicylates	0	10	B-group
DDI-DrugBank.d576.s4	given	12	16	O
DDI-DrugBank.d576.s4	concomitantly	18	30	O
DDI-DrugBank.d576.s4	with	32	35	O
DDI-DrugBank.d576.s4	anticoagulant	37	49	B-group
DDI-DrugBank.d576.s4	drugs	51	55	I-group
DDI-DrugBank.d576.s4	may	57	59	O
DDI-DrugBank.d576.s4	predispose	61	70	O
DDI-DrugBank.d576.s4	to	72	73	O
DDI-DrugBank.d576.s4	systemic	75	82	O
DDI-DrugBank.d576.s4	bleeding	84	91	O
DDI-DrugBank.d576.s4	.	92	92	O
DDI-DrugBank.d576.s5	Salicylates	0	10	B-group
DDI-DrugBank.d576.s5	may	12	14	O
DDI-DrugBank.d576.s5	enhance	16	22	O
DDI-DrugBank.d576.s5	the	24	26	O
DDI-DrugBank.d576.s5	hypoglycemic	28	39	O
DDI-DrugBank.d576.s5	effect	41	46	O
DDI-DrugBank.d576.s5	of	48	49	O
DDI-DrugBank.d576.s5	oral	51	54	O
DDI-DrugBank.d576.s5	antidiabetic	56	67	B-group
DDI-DrugBank.d576.s5	drugs	69	73	I-group
DDI-DrugBank.d576.s5	of	75	76	O
DDI-DrugBank.d576.s5	the	78	80	O
DDI-DrugBank.d576.s5	sulfonylurea	82	93	O
DDI-DrugBank.d576.s5	class	95	99	O
DDI-DrugBank.d576.s5	.	100	100	O
DDI-DrugBank.d576.s6	Salicylate	0	9	B-group
DDI-DrugBank.d576.s6	competes	11	18	O
DDI-DrugBank.d576.s6	with	20	23	O
DDI-DrugBank.d576.s6	a	25	25	O
DDI-DrugBank.d576.s6	number	27	32	O
DDI-DrugBank.d576.s6	of	34	35	O
DDI-DrugBank.d576.s6	drugs	37	41	O
DDI-DrugBank.d576.s6	for	43	45	O
DDI-DrugBank.d576.s6	protein	47	53	O
DDI-DrugBank.d576.s6	binding	55	61	O
DDI-DrugBank.d576.s6	sites	63	67	O
DDI-DrugBank.d576.s6	,	68	68	O
DDI-DrugBank.d576.s6	notably	70	76	O
DDI-DrugBank.d576.s6	penicillin	78	87	B-drug
DDI-DrugBank.d576.s6	,	88	88	O
DDI-DrugBank.d576.s6	thiopental	90	99	B-drug
DDI-DrugBank.d576.s6	,	88	88	O
DDI-DrugBank.d576.s6	thyroxine	102	110	B-drug
DDI-DrugBank.d576.s6	,	100	100	O
DDI-DrugBank.d576.s6	triiodothyronine	113	128	B-drug
DDI-DrugBank.d576.s6	,	129	129	O
DDI-DrugBank.d576.s6	phenytoin	131	139	B-drug
DDI-DrugBank.d576.s6	,	129	129	O
DDI-DrugBank.d576.s6	sulfinpyrazone	142	155	B-drug
DDI-DrugBank.d576.s6	,	140	140	O
DDI-DrugBank.d576.s6	naproxen	158	165	B-drug
DDI-DrugBank.d576.s6	,	156	156	O
DDI-DrugBank.d576.s6	warfarin	168	175	B-drug
DDI-DrugBank.d576.s6	,	166	166	O
DDI-DrugBank.d576.s6	methotrexate	178	189	B-drug
DDI-DrugBank.d576.s6	,	176	176	O
DDI-DrugBank.d576.s6	and	192	194	O
DDI-DrugBank.d576.s6	possibly	196	203	O
DDI-DrugBank.d576.s6	corticosteroids	205	219	B-group
DDI-DrugBank.d576.s6	.	220	220	O
DDI-DrugBank.d576.s7	Drug/	0	4	O
DDI-DrugBank.d576.s7	Laboratory	6	15	O
DDI-DrugBank.d576.s7	Test	17	20	O
DDI-DrugBank.d576.s7	Interactions	22	33	O
DDI-DrugBank.d576.s7	Salicylate	35	44	B-group
DDI-DrugBank.d576.s7	competes	46	53	O
DDI-DrugBank.d576.s7	with	55	58	O
DDI-DrugBank.d576.s7	thyroid	60	66	O
DDI-DrugBank.d576.s7	hormone	68	74	O
DDI-DrugBank.d576.s7	for	76	78	O
DDI-DrugBank.d576.s7	binding	80	86	O
DDI-DrugBank.d576.s7	to	88	89	O
DDI-DrugBank.d576.s7	plasma	91	96	O
DDI-DrugBank.d576.s7	proteins	98	105	O
DDI-DrugBank.d576.s7	,	106	106	O
DDI-DrugBank.d576.s7	which	108	112	O
DDI-DrugBank.d576.s7	may	114	116	O
DDI-DrugBank.d576.s7	be	118	119	O
DDI-DrugBank.d576.s7	reflected	121	129	O
DDI-DrugBank.d576.s7	in	131	132	O
DDI-DrugBank.d576.s7	a	115	115	O
DDI-DrugBank.d576.s7	depressed	136	144	O
DDI-DrugBank.d576.s7	plasma	146	151	O
DDI-DrugBank.d576.s7	T4	153	154	O
DDI-DrugBank.d576.s7	value	156	160	O
DDI-DrugBank.d576.s7	in	162	163	O
DDI-DrugBank.d576.s7	some	165	168	O
DDI-DrugBank.d576.s7	patients	170	177	O
DDI-DrugBank.d576.s7	;	178	178	O
DDI-DrugBank.d576.s8	thyroid	0	6	O
DDI-DrugBank.d576.s8	function	8	15	O
DDI-DrugBank.d576.s8	and	17	19	O
DDI-DrugBank.d576.s8	basal	21	25	O
DDI-DrugBank.d576.s8	metabolism	27	36	O
DDI-DrugBank.d576.s8	are	38	40	O
DDI-DrugBank.d576.s8	unaffected	42	51	O
DDI-DrugBank.d576.s8	.	52	52	O
DDI-DrugBank.d506.s0	If	0	1	O
DDI-DrugBank.d506.s0	phenytoin	3	11	B-drug
DDI-DrugBank.d506.s0	or	13	14	O
DDI-DrugBank.d506.s0	other	16	20	O
DDI-DrugBank.d506.s0	hepatic	22	28	O
DDI-DrugBank.d506.s0	enzyme	30	35	O
DDI-DrugBank.d506.s0	inducers	37	44	O
DDI-DrugBank.d506.s0	are	46	48	O
DDI-DrugBank.d506.s0	taken	50	54	O
DDI-DrugBank.d506.s0	concurrently	56	67	O
DDI-DrugBank.d506.s0	with	69	72	O
DDI-DrugBank.d506.s0	Norpace	74	80	B-brand
DDI-DrugBank.d506.s0	or	75	76	I-brand
DDI-DrugBank.d506.s0	Norpace	74	80	B-brand
DDI-DrugBank.d506.s0	CR	93	94	I-brand
DDI-DrugBank.d506.s0	,	95	95	O
DDI-DrugBank.d506.s0	lower	97	101	O
DDI-DrugBank.d506.s0	plasma	103	108	O
DDI-DrugBank.d506.s0	levels	110	115	O
DDI-DrugBank.d506.s0	of	117	118	O
DDI-DrugBank.d506.s0	disopyramide	120	131	B-drug
DDI-DrugBank.d506.s0	may	133	135	O
DDI-DrugBank.d506.s0	occur	137	141	O
DDI-DrugBank.d506.s0	.	142	142	O
DDI-DrugBank.d506.s1	Monitoring	0	9	O
DDI-DrugBank.d506.s1	of	11	12	O
DDI-DrugBank.d506.s1	disopyramide	14	25	B-drug
DDI-DrugBank.d506.s1	plasma	27	32	O
DDI-DrugBank.d506.s1	levels	34	39	O
DDI-DrugBank.d506.s1	is	41	42	O
DDI-DrugBank.d506.s1	recommended	44	54	O
DDI-DrugBank.d506.s1	in	56	57	O
DDI-DrugBank.d506.s1	such	59	62	O
DDI-DrugBank.d506.s1	concurrent	64	73	O
DDI-DrugBank.d506.s1	use	75	77	O
DDI-DrugBank.d506.s1	to	79	80	O
DDI-DrugBank.d506.s1	avoid	82	86	O
DDI-DrugBank.d506.s1	ineffective	88	98	O
DDI-DrugBank.d506.s1	therapy	100	106	O
DDI-DrugBank.d506.s1	.	107	107	O
DDI-DrugBank.d506.s2	Other	0	4	O
DDI-DrugBank.d506.s2	antiarrhythmic	6	19	B-group
DDI-DrugBank.d506.s2	drugs	21	25	I-group
DDI-DrugBank.d506.s2	(	27	27	O
DDI-DrugBank.d506.s2	eg	28	29	O
DDI-DrugBank.d506.s2	,	30	30	O
DDI-DrugBank.d506.s2	quinidine	32	40	B-drug
DDI-DrugBank.d506.s2	,	41	41	O
DDI-DrugBank.d506.s2	procainamide	43	54	B-drug
DDI-DrugBank.d506.s2	,	55	55	O
DDI-DrugBank.d506.s2	lidocaine	57	65	B-drug
DDI-DrugBank.d506.s2	,	66	66	O
DDI-DrugBank.d506.s2	propranolol	68	78	B-drug
DDI-DrugBank.d506.s2	)	79	79	O
DDI-DrugBank.d506.s2	have	81	84	O
DDI-DrugBank.d506.s2	occasionally	86	97	O
DDI-DrugBank.d506.s2	been	99	102	O
DDI-DrugBank.d506.s2	used	104	107	O
DDI-DrugBank.d506.s2	concurrently	109	120	O
DDI-DrugBank.d506.s2	with	122	125	O
DDI-DrugBank.d506.s2	Norpace	127	133	B-brand
DDI-DrugBank.d506.s2	.	134	134	O
DDI-DrugBank.d506.s3	Excessive	0	8	O
DDI-DrugBank.d506.s3	widening	10	17	O
DDI-DrugBank.d506.s3	of	19	20	O
DDI-DrugBank.d506.s3	the	22	24	O
DDI-DrugBank.d506.s3	QRS	26	28	O
DDI-DrugBank.d506.s3	complex	30	36	O
DDI-DrugBank.d506.s3	and/or	38	43	O
DDI-DrugBank.d506.s3	prolongation	45	56	O
DDI-DrugBank.d506.s3	of	58	59	O
DDI-DrugBank.d506.s3	the	61	63	O
DDI-DrugBank.d506.s3	Q-T	65	67	O
DDI-DrugBank.d506.s3	interval	69	76	O
DDI-DrugBank.d506.s3	may	78	80	O
DDI-DrugBank.d506.s3	occur	82	86	O
DDI-DrugBank.d506.s3	in	88	89	O
DDI-DrugBank.d506.s3	these	91	95	O
DDI-DrugBank.d506.s3	situations	97	106	O
DDI-DrugBank.d506.s3	.	107	107	O
DDI-DrugBank.d506.s4	In	0	1	O
DDI-DrugBank.d506.s4	healthy	3	9	O
DDI-DrugBank.d506.s4	subjects	11	18	O
DDI-DrugBank.d506.s4	,	19	19	O
DDI-DrugBank.d506.s4	no	21	22	O
DDI-DrugBank.d506.s4	significant	24	34	O
DDI-DrugBank.d506.s4	drug-drug	36	44	O
DDI-DrugBank.d506.s4	interaction	46	56	O
DDI-DrugBank.d506.s4	was	58	60	O
DDI-DrugBank.d506.s4	observed	62	69	O
DDI-DrugBank.d506.s4	when	71	74	O
DDI-DrugBank.d506.s4	Norpace	76	82	B-brand
DDI-DrugBank.d506.s4	was	84	86	O
DDI-DrugBank.d506.s4	coadministered	88	101	O
DDI-DrugBank.d506.s4	with	103	106	O
DDI-DrugBank.d506.s4	either	108	113	O
DDI-DrugBank.d506.s4	propranolol	115	125	B-drug
DDI-DrugBank.d506.s4	or	127	128	O
DDI-DrugBank.d506.s4	diazepam	130	137	B-drug
DDI-DrugBank.d506.s4	.	138	138	O
DDI-DrugBank.d506.s5	Concomitant	0	10	O
DDI-DrugBank.d506.s5	administration	12	25	O
DDI-DrugBank.d506.s5	of	27	28	O
DDI-DrugBank.d506.s5	Norpace	30	36	B-brand
DDI-DrugBank.d506.s5	and	38	40	O
DDI-DrugBank.d506.s5	quinidine	42	50	B-drug
DDI-DrugBank.d506.s5	resulted	52	59	O
DDI-DrugBank.d506.s5	in	61	62	O
DDI-DrugBank.d506.s5	slight	64	69	O
DDI-DrugBank.d506.s5	increases	71	79	O
DDI-DrugBank.d506.s5	in	71	72	O
DDI-DrugBank.d506.s5	plasma	84	89	O
DDI-DrugBank.d506.s5	disopyramide	91	102	B-drug
DDI-DrugBank.d506.s5	levels	104	109	O
DDI-DrugBank.d506.s5	and	111	113	O
DDI-DrugBank.d506.s5	slight	115	120	O
DDI-DrugBank.d506.s5	decreases	122	130	O
DDI-DrugBank.d506.s5	in	132	133	O
DDI-DrugBank.d506.s5	plasma	135	140	O
DDI-DrugBank.d506.s5	quinidine	142	150	B-drug
DDI-DrugBank.d506.s5	levels	152	157	O
DDI-DrugBank.d506.s5	.	158	158	O
DDI-DrugBank.d506.s6	Norpace	0	6	B-brand
DDI-DrugBank.d506.s6	does	8	11	O
DDI-DrugBank.d506.s6	not	13	15	O
DDI-DrugBank.d506.s6	increase	17	24	O
DDI-DrugBank.d506.s6	serum	26	30	O
DDI-DrugBank.d506.s6	digoxin	32	38	B-drug
DDI-DrugBank.d506.s6	levels	40	45	O
DDI-DrugBank.d506.s6	.	46	46	O
DDI-DrugBank.d506.s7	Patients	0	7	O
DDI-DrugBank.d506.s7	taking	9	14	O
DDI-DrugBank.d506.s7	disopyramide	16	27	B-drug
DDI-DrugBank.d506.s7	phosphate	29	37	I-drug
DDI-DrugBank.d506.s7	and	39	41	O
DDI-DrugBank.d506.s7	erythromycin	43	54	B-drug
DDI-DrugBank.d506.s7	concomitantly	56	68	O
DDI-DrugBank.d506.s7	may	70	72	O
DDI-DrugBank.d506.s7	develop	74	80	O
DDI-DrugBank.d506.s7	increased	82	90	O
DDI-DrugBank.d506.s7	serum	92	96	O
DDI-DrugBank.d506.s7	concentrations	98	111	O
DDI-DrugBank.d506.s7	of	113	114	O
DDI-DrugBank.d506.s7	disopyramide	116	127	B-drug
DDI-DrugBank.d506.s7	resulting	129	137	O
DDI-DrugBank.d506.s7	in	135	136	O
DDI-DrugBank.d506.s7	excessive	142	150	O
DDI-DrugBank.d506.s7	widening	152	159	O
DDI-DrugBank.d506.s7	of	161	162	O
DDI-DrugBank.d506.s7	the	164	166	O
DDI-DrugBank.d506.s7	QRS	168	170	O
DDI-DrugBank.d506.s7	complex	172	178	O
DDI-DrugBank.d506.s7	and/or	180	185	O
DDI-DrugBank.d506.s7	prolongation	187	198	O
DDI-DrugBank.d506.s7	of	200	201	O
DDI-DrugBank.d506.s7	the	203	205	O
DDI-DrugBank.d506.s7	Q-T	207	209	O
DDI-DrugBank.d506.s7	interval	211	218	O
DDI-DrugBank.d506.s7	.	219	219	O
DDI-DrugBank.d506.s8	Patients	0	7	O
DDI-DrugBank.d506.s8	taking	9	14	O
DDI-DrugBank.d506.s8	disopyramide	16	27	B-drug
DDI-DrugBank.d506.s8	phosphate	29	37	I-drug
DDI-DrugBank.d506.s8	and	39	41	O
DDI-DrugBank.d506.s8	hepatic	43	49	O
DDI-DrugBank.d506.s8	enzyme	51	56	O
DDI-DrugBank.d506.s8	inhibitors	58	67	O
DDI-DrugBank.d506.s8	concomitantly	69	81	O
DDI-DrugBank.d506.s8	should	83	88	O
DDI-DrugBank.d506.s8	be	90	91	O
DDI-DrugBank.d506.s8	closely	93	99	O
DDI-DrugBank.d506.s8	monitored	101	109	O
DDI-DrugBank.d506.s8	.	110	110	O
DDI-DrugBank.d506.s9	Until	0	4	O
DDI-DrugBank.d506.s9	data	6	9	O
DDI-DrugBank.d506.s9	on	11	12	O
DDI-DrugBank.d506.s9	possible	14	21	O
DDI-DrugBank.d506.s9	interactions	23	34	O
DDI-DrugBank.d506.s9	between	36	42	O
DDI-DrugBank.d506.s9	verapamil	44	52	B-drug
DDI-DrugBank.d506.s9	and	54	56	O
DDI-DrugBank.d506.s9	disopyramide	58	69	B-drug
DDI-DrugBank.d506.s9	phosphate	71	79	I-drug
DDI-DrugBank.d506.s9	are	81	83	O
DDI-DrugBank.d506.s9	obtained	85	92	O
DDI-DrugBank.d506.s9	,	93	93	O
DDI-DrugBank.d506.s9	disopyramide	95	106	B-drug
DDI-DrugBank.d506.s9	should	108	113	O
DDI-DrugBank.d506.s9	not	115	117	O
DDI-DrugBank.d506.s9	be	119	120	O
DDI-DrugBank.d506.s9	administered	122	133	O
DDI-DrugBank.d506.s9	within	135	140	O
DDI-DrugBank.d506.s9	48	142	143	O
DDI-DrugBank.d506.s9	hours	145	149	O
DDI-DrugBank.d506.s9	before	151	156	O
DDI-DrugBank.d506.s9	or	154	155	O
DDI-DrugBank.d506.s9	24	161	162	O
DDI-DrugBank.d506.s9	hours	145	149	O
DDI-DrugBank.d506.s9	after	170	174	O
DDI-DrugBank.d506.s9	verapamil	176	184	B-drug
DDI-DrugBank.d506.s9	administration	186	199	O
DDI-DrugBank.d506.s9	.	200	200	O
DDI-DrugBank.d529.s0	Antacids	0	7	B-group
DDI-DrugBank.d529.s0	:	8	8	O
DDI-DrugBank.d529.s0	Administration	10	23	O
DDI-DrugBank.d529.s0	of	25	26	O
DDI-DrugBank.d529.s0	flurbiprofen	28	39	B-drug
DDI-DrugBank.d529.s0	to	41	42	O
DDI-DrugBank.d529.s0	volunteers	44	53	O
DDI-DrugBank.d529.s0	under	55	59	O
DDI-DrugBank.d529.s0	fasting	61	67	O
DDI-DrugBank.d529.s0	conditions	69	78	O
DDI-DrugBank.d529.s0	,	79	79	O
DDI-DrugBank.d529.s0	or	81	82	O
DDI-DrugBank.d529.s0	with	84	87	O
DDI-DrugBank.d529.s0	antacid	89	95	B-group
DDI-DrugBank.d529.s0	suspension	97	106	O
DDI-DrugBank.d529.s0	yielded	108	114	O
DDI-DrugBank.d529.s0	similar	116	122	O
DDI-DrugBank.d529.s0	serum	124	128	O
DDI-DrugBank.d529.s0	flurbiprofen	130	141	B-drug
DDI-DrugBank.d529.s0	time	143	146	O
DDI-DrugBank.d529.s0	profiles	148	155	O
DDI-DrugBank.d529.s0	in	157	158	O
DDI-DrugBank.d529.s0	young	160	164	O
DDI-DrugBank.d529.s0	subjects	166	173	O
DDI-DrugBank.d529.s0	(	175	175	O
DDI-DrugBank.d529.s0	n=12	176	179	O
DDI-DrugBank.d529.s0	)	180	180	O
DDI-DrugBank.d529.s0	.	181	181	O
DDI-DrugBank.d529.s1	In	0	1	O
DDI-DrugBank.d529.s1	geriatric	3	11	O
DDI-DrugBank.d529.s1	subjects	13	20	O
DDI-DrugBank.d529.s1	(	22	22	O
DDI-DrugBank.d529.s1	n=7	23	25	O
DDI-DrugBank.d529.s1	)	26	26	O
DDI-DrugBank.d529.s1	there	28	32	O
DDI-DrugBank.d529.s1	was	34	36	O
DDI-DrugBank.d529.s1	a	35	35	O
DDI-DrugBank.d529.s1	reduction	40	48	O
DDI-DrugBank.d529.s1	in	50	51	O
DDI-DrugBank.d529.s1	the	53	55	O
DDI-DrugBank.d529.s1	rate	57	60	O
DDI-DrugBank.d529.s1	but	62	64	O
DDI-DrugBank.d529.s1	not	66	68	O
DDI-DrugBank.d529.s1	the	70	72	O
DDI-DrugBank.d529.s1	extent	74	79	O
DDI-DrugBank.d529.s1	of	81	82	O
DDI-DrugBank.d529.s1	flurbiprofen	84	95	B-drug
DDI-DrugBank.d529.s1	absorption	97	106	O
DDI-DrugBank.d529.s1	.	107	107	O
DDI-DrugBank.d529.s2	Anticoagulants	0	13	B-group
DDI-DrugBank.d529.s2	:	14	14	O
DDI-DrugBank.d529.s2	Flurbiprofen	16	27	B-drug
DDI-DrugBank.d529.s2	like	29	32	O
DDI-DrugBank.d529.s2	other	34	38	O
DDI-DrugBank.d529.s2	nonsteroidal	40	51	B-group
DDI-DrugBank.d529.s2	anti-inflammatory	53	69	I-group
DDI-DrugBank.d529.s2	drugs	71	75	I-group
DDI-DrugBank.d529.s2	,	76	76	O
DDI-DrugBank.d529.s2	has	78	80	O
DDI-DrugBank.d529.s2	been	82	85	O
DDI-DrugBank.d529.s2	shown	87	91	O
DDI-DrugBank.d529.s2	to	93	94	O
DDI-DrugBank.d529.s2	affect	96	101	O
DDI-DrugBank.d529.s2	bleeding	103	110	O
DDI-DrugBank.d529.s2	parameters	112	121	O
DDI-DrugBank.d529.s2	in	123	124	O
DDI-DrugBank.d529.s2	patients	126	133	O
DDI-DrugBank.d529.s2	receiving	135	143	O
DDI-DrugBank.d529.s2	anti-coagulants	145	159	B-group
DDI-DrugBank.d529.s2	,	160	160	O
DDI-DrugBank.d529.s2	and	162	164	O
DDI-DrugBank.d529.s2	serious	166	172	O
DDI-DrugBank.d529.s2	clinical	174	181	O
DDI-DrugBank.d529.s2	bleeding	183	190	O
DDI-DrugBank.d529.s2	has	192	194	O
DDI-DrugBank.d529.s2	been	196	199	O
DDI-DrugBank.d529.s2	reported	201	208	O
DDI-DrugBank.d529.s2	.	209	209	O
DDI-DrugBank.d529.s3	The	0	2	O
DDI-DrugBank.d529.s3	physician	4	12	O
DDI-DrugBank.d529.s3	should	14	19	O
DDI-DrugBank.d529.s3	be	21	22	O
DDI-DrugBank.d529.s3	cautious	24	31	O
DDI-DrugBank.d529.s3	when	33	36	O
DDI-DrugBank.d529.s3	administering	38	50	O
DDI-DrugBank.d529.s3	flurbiprofen	52	63	B-drug
DDI-DrugBank.d529.s3	to	65	66	O
DDI-DrugBank.d529.s3	patients	68	75	O
DDI-DrugBank.d529.s3	taking	77	82	O
DDI-DrugBank.d529.s3	anticoagulants	84	97	B-group
DDI-DrugBank.d529.s3	.	98	98	O
DDI-DrugBank.d529.s4	Aspirin	0	6	B-brand
DDI-DrugBank.d529.s4	:	7	7	O
DDI-DrugBank.d529.s4	Concurrent	9	18	O
DDI-DrugBank.d529.s4	administration	20	33	O
DDI-DrugBank.d529.s4	of	35	36	O
DDI-DrugBank.d529.s4	aspirin	38	44	B-brand
DDI-DrugBank.d529.s4	and	46	48	O
DDI-DrugBank.d529.s4	flurbiprofen	50	61	B-drug
DDI-DrugBank.d529.s4	resulted	63	70	O
DDI-DrugBank.d529.s4	in	72	73	O
DDI-DrugBank.d529.s4	50	75	76	O
DDI-DrugBank.d529.s4	%	77	77	O
DDI-DrugBank.d529.s4	lower	79	83	O
DDI-DrugBank.d529.s4	serum	85	89	O
DDI-DrugBank.d529.s4	flurbiprofen	91	102	B-drug
DDI-DrugBank.d529.s4	concentrations	104	117	O
DDI-DrugBank.d529.s4	.	118	118	O
DDI-DrugBank.d529.s5	This	0	3	O
DDI-DrugBank.d529.s5	effect	5	10	O
DDI-DrugBank.d529.s5	of	12	13	O
DDI-DrugBank.d529.s5	aspirin	15	21	B-brand
DDI-DrugBank.d529.s5	(	23	23	O
DDI-DrugBank.d529.s5	which	24	28	O
DDI-DrugBank.d529.s5	also	30	33	O
DDI-DrugBank.d529.s5	lowers	35	40	O
DDI-DrugBank.d529.s5	serum	42	46	O
DDI-DrugBank.d529.s5	concentrations	48	61	O
DDI-DrugBank.d529.s5	of	63	64	O
DDI-DrugBank.d529.s5	other	66	70	O
DDI-DrugBank.d529.s5	nonsteroidal	72	83	B-group
DDI-DrugBank.d529.s5	anti-inflammatory	85	101	I-group
DDI-DrugBank.d529.s5	drugs	103	107	I-group
DDI-DrugBank.d529.s5	given	109	113	O
DDI-DrugBank.d529.s5	with	115	118	O
DDI-DrugBank.d529.s5	it	116	117	O
DDI-DrugBank.d529.s5	)	122	122	O
DDI-DrugBank.d529.s5	has	124	126	O
DDI-DrugBank.d529.s5	been	128	131	O
DDI-DrugBank.d529.s5	demonstrated	133	144	O
DDI-DrugBank.d529.s5	in	146	147	O
DDI-DrugBank.d529.s5	patients	149	156	O
DDI-DrugBank.d529.s5	with	158	161	O
DDI-DrugBank.d529.s5	rheumatoid	163	172	O
DDI-DrugBank.d529.s5	arthritis	174	182	O
DDI-DrugBank.d529.s5	(	184	184	O
DDI-DrugBank.d529.s5	n=	185	186	O
DDI-DrugBank.d529.s5	15	188	189	O
DDI-DrugBank.d529.s5	)	190	190	O
DDI-DrugBank.d529.s5	as	192	193	O
DDI-DrugBank.d529.s5	well	195	198	O
DDI-DrugBank.d529.s5	as	192	193	O
DDI-DrugBank.d529.s5	normal	203	208	O
DDI-DrugBank.d529.s5	volunteers	210	219	O
DDI-DrugBank.d529.s5	(	221	221	O
DDI-DrugBank.d529.s5	n=	222	223	O
DDI-DrugBank.d529.s5	16	225	226	O
DDI-DrugBank.d529.s5	)	227	227	O
DDI-DrugBank.d529.s5	.	228	228	O
DDI-DrugBank.d529.s6	Concurrent	0	9	O
DDI-DrugBank.d529.s6	use	11	13	O
DDI-DrugBank.d529.s6	of	15	16	O
DDI-DrugBank.d529.s6	flurbiprofen	18	29	B-drug
DDI-DrugBank.d529.s6	and	31	33	O
DDI-DrugBank.d529.s6	aspirin	35	41	B-brand
DDI-DrugBank.d529.s6	is	43	44	O
DDI-DrugBank.d529.s6	therefore	46	54	O
DDI-DrugBank.d529.s6	not	56	58	O
DDI-DrugBank.d529.s6	recommended	60	70	O
DDI-DrugBank.d529.s6	.	71	71	O
DDI-DrugBank.d529.s7	Beta-adrenergic	0	14	B-group
DDI-DrugBank.d529.s7	Blocking	16	23	I-group
DDI-DrugBank.d529.s7	Agents	25	30	I-group
DDI-DrugBank.d529.s7	:	31	31	O
DDI-DrugBank.d529.s7	The	33	35	O
DDI-DrugBank.d529.s7	effect	37	42	O
DDI-DrugBank.d529.s7	of	44	45	O
DDI-DrugBank.d529.s7	flurbiprofen	47	58	B-drug
DDI-DrugBank.d529.s7	on	60	61	O
DDI-DrugBank.d529.s7	blood	63	67	O
DDI-DrugBank.d529.s7	pressure	69	76	O
DDI-DrugBank.d529.s7	response	78	85	O
DDI-DrugBank.d529.s7	to	87	88	O
DDI-DrugBank.d529.s7	propranolol	90	100	B-drug
DDI-DrugBank.d529.s7	and	102	104	O
DDI-DrugBank.d529.s7	atenolol	106	113	B-drug
DDI-DrugBank.d529.s7	was	115	117	O
DDI-DrugBank.d529.s7	evaluated	119	127	O
DDI-DrugBank.d529.s7	in	129	130	O
DDI-DrugBank.d529.s7	men	132	134	O
DDI-DrugBank.d529.s7	with	136	139	O
DDI-DrugBank.d529.s7	mild	141	144	O
DDI-DrugBank.d529.s7	uncomplicated	146	158	O
DDI-DrugBank.d529.s7	hypertension	160	171	O
DDI-DrugBank.d529.s7	(	173	173	O
DDI-DrugBank.d529.s7	n	167	167	O
DDI-DrugBank.d529.s7	=	176	176	O
DDI-DrugBank.d529.s7	10	178	179	O
DDI-DrugBank.d529.s7	)	180	180	O
DDI-DrugBank.d529.s7	.	181	181	O
DDI-DrugBank.d529.s8	Flurbiprofen	0	11	B-drug
DDI-DrugBank.d529.s8	pretreatment	13	24	O
DDI-DrugBank.d529.s8	attenuated	26	35	O
DDI-DrugBank.d529.s8	the	37	39	O
DDI-DrugBank.d529.s8	hypotensive	41	51	O
DDI-DrugBank.d529.s8	effect	53	58	O
DDI-DrugBank.d529.s8	of	60	61	O
DDI-DrugBank.d529.s8	a	63	63	O
DDI-DrugBank.d529.s8	single	65	70	O
DDI-DrugBank.d529.s8	dose	72	75	O
DDI-DrugBank.d529.s8	of	77	78	O
DDI-DrugBank.d529.s8	propranolol	80	90	B-drug
DDI-DrugBank.d529.s8	but	92	94	O
DDI-DrugBank.d529.s8	not	96	98	O
DDI-DrugBank.d529.s8	atenolol	100	107	B-drug
DDI-DrugBank.d529.s8	.	108	108	O
DDI-DrugBank.d529.s9	Flurbiprofen	0	11	B-drug
DDI-DrugBank.d529.s9	did	13	15	O
DDI-DrugBank.d529.s9	not	17	19	O
DDI-DrugBank.d529.s9	appear	21	26	O
DDI-DrugBank.d529.s9	to	28	29	O
DDI-DrugBank.d529.s9	affect	31	36	O
DDI-DrugBank.d529.s9	the	38	40	O
DDI-DrugBank.d529.s9	beta-blocker-mediated	42	62	O
DDI-DrugBank.d529.s9	reduction	64	72	O
DDI-DrugBank.d529.s9	in	74	75	O
DDI-DrugBank.d529.s9	heart	77	81	O
DDI-DrugBank.d529.s9	rate	83	86	O
DDI-DrugBank.d529.s9	.	87	87	O
DDI-DrugBank.d529.s10	Flurbiprofen	0	11	B-drug
DDI-DrugBank.d529.s10	did	13	15	O
DDI-DrugBank.d529.s10	not	17	19	O
DDI-DrugBank.d529.s10	affect	21	26	O
DDI-DrugBank.d529.s10	the	28	30	O
DDI-DrugBank.d529.s10	pharmacokinetic	32	46	O
DDI-DrugBank.d529.s10	profile	48	54	O
DDI-DrugBank.d529.s10	of	50	51	O
DDI-DrugBank.d529.s10	either	59	64	O
DDI-DrugBank.d529.s10	drug	66	69	O
DDI-DrugBank.d529.s10	,	70	70	O
DDI-DrugBank.d529.s10	and	72	74	O
DDI-DrugBank.d529.s10	the	76	78	O
DDI-DrugBank.d529.s10	mechanism	80	88	O
DDI-DrugBank.d529.s10	under	90	94	O
DDI-DrugBank.d529.s10	lying	96	100	O
DDI-DrugBank.d529.s10	the	102	104	O
DDI-DrugBank.d529.s10	interference	106	117	O
DDI-DrugBank.d529.s10	with	119	122	O
DDI-DrugBank.d529.s10	propranolols	124	135	O
DDI-DrugBank.d529.s10	hypotensive	137	147	O
DDI-DrugBank.d529.s10	effect	149	154	O
DDI-DrugBank.d529.s10	is	156	157	O
DDI-DrugBank.d529.s10	unknown	159	165	O
DDI-DrugBank.d529.s10	.	166	166	O
DDI-DrugBank.d529.s11	Patients	0	7	O
DDI-DrugBank.d529.s11	taking	9	14	O
DDI-DrugBank.d529.s11	both	16	19	O
DDI-DrugBank.d529.s11	flurbiprofen	21	32	B-drug
DDI-DrugBank.d529.s11	and	34	36	O
DDI-DrugBank.d529.s11	a	34	34	O
DDI-DrugBank.d529.s11	beta-blocker	40	51	B-group
DDI-DrugBank.d529.s11	should	53	58	O
DDI-DrugBank.d529.s11	be	60	61	O
DDI-DrugBank.d529.s11	monitored	63	71	O
DDI-DrugBank.d529.s11	to	67	68	O
DDI-DrugBank.d529.s11	ensure	76	81	O
DDI-DrugBank.d529.s11	that	83	86	O
DDI-DrugBank.d529.s11	a	85	85	O
DDI-DrugBank.d529.s11	satisfactory	90	101	O
DDI-DrugBank.d529.s11	hypotensive	103	113	O
DDI-DrugBank.d529.s11	effect	115	120	O
DDI-DrugBank.d529.s11	is	122	123	O
DDI-DrugBank.d529.s11	achieved	125	132	O
DDI-DrugBank.d529.s11	.	133	133	O
DDI-DrugBank.d529.s12	Cimetidine	0	9	B-drug
DDI-DrugBank.d529.s12	,	10	10	O
DDI-DrugBank.d529.s12	Ranitidine	12	21	B-drug
DDI-DrugBank.d529.s12	:	22	22	O
DDI-DrugBank.d529.s12	In	24	25	O
DDI-DrugBank.d529.s12	normal	27	32	O
DDI-DrugBank.d529.s12	volunteers	34	43	O
DDI-DrugBank.d529.s12	(	45	45	O
DDI-DrugBank.d529.s12	n=9	46	48	O
DDI-DrugBank.d529.s12	)	49	49	O
DDI-DrugBank.d529.s12	,	50	50	O
DDI-DrugBank.d529.s12	pretreatment	52	63	O
DDI-DrugBank.d529.s12	with	65	68	O
DDI-DrugBank.d529.s12	cimetidine	70	79	B-drug
DDI-DrugBank.d529.s12	or	81	82	O
DDI-DrugBank.d529.s12	ranitidine	84	93	B-drug
DDI-DrugBank.d529.s12	did	95	97	O
DDI-DrugBank.d529.s12	not	99	101	O
DDI-DrugBank.d529.s12	affect	103	108	O
DDI-DrugBank.d529.s12	flurbiprofen	110	121	B-drug
DDI-DrugBank.d529.s12	pharmacokinetics	123	138	O
DDI-DrugBank.d529.s12	except	140	145	O
DDI-DrugBank.d529.s12	that	147	150	O
DDI-DrugBank.d529.s12	a	149	149	O
DDI-DrugBank.d529.s12	small	154	158	O
DDI-DrugBank.d529.s12	(	160	160	O
DDI-DrugBank.d529.s12	13	161	162	O
DDI-DrugBank.d529.s12	%	164	164	O
DDI-DrugBank.d529.s12	)	165	165	O
DDI-DrugBank.d529.s12	but	167	169	O
DDI-DrugBank.d529.s12	statistically	171	183	O
DDI-DrugBank.d529.s12	significant	185	195	O
DDI-DrugBank.d529.s12	increase	197	204	O
DDI-DrugBank.d529.s12	in	197	198	O
DDI-DrugBank.d529.s12	the	209	211	O
DDI-DrugBank.d529.s12	area	213	216	O
DDI-DrugBank.d529.s12	under	218	222	O
DDI-DrugBank.d529.s12	the	209	211	O
DDI-DrugBank.d529.s12	serum	228	232	O
DDI-DrugBank.d529.s12	concentration	234	246	O
DDI-DrugBank.d529.s12	curve	248	252	O
DDI-DrugBank.d529.s12	of	254	255	O
DDI-DrugBank.d529.s12	flurbiprofen	257	268	B-drug
DDI-DrugBank.d529.s12	resulted	270	277	O
DDI-DrugBank.d529.s12	with	279	282	O
DDI-DrugBank.d529.s12	cimetidine	284	293	B-drug
DDI-DrugBank.d529.s12	.	294	294	O
DDI-DrugBank.d529.s13	Digoxin	0	6	B-drug
DDI-DrugBank.d529.s13	:	7	7	O
DDI-DrugBank.d529.s13	Studies	9	15	O
DDI-DrugBank.d529.s13	of	17	18	O
DDI-DrugBank.d529.s13	concomitant	20	30	O
DDI-DrugBank.d529.s13	administration	32	45	O
DDI-DrugBank.d529.s13	of	47	48	O
DDI-DrugBank.d529.s13	flurbiprofen	50	61	B-drug
DDI-DrugBank.d529.s13	and	63	65	O
DDI-DrugBank.d529.s13	digoxin	67	73	B-drug
DDI-DrugBank.d529.s13	to	75	76	O
DDI-DrugBank.d529.s13	healthy	78	84	O
DDI-DrugBank.d529.s13	men	86	88	O
DDI-DrugBank.d529.s13	(	90	90	O
DDI-DrugBank.d529.s13	n=	91	92	O
DDI-DrugBank.d529.s13	14	94	95	O
DDI-DrugBank.d529.s13	)	96	96	O
DDI-DrugBank.d529.s13	did	98	100	O
DDI-DrugBank.d529.s13	not	102	104	O
DDI-DrugBank.d529.s13	show	106	109	O
DDI-DrugBank.d529.s13	a	111	111	O
DDI-DrugBank.d529.s13	change	113	118	O
DDI-DrugBank.d529.s13	in	120	121	O
DDI-DrugBank.d529.s13	the	123	125	O
DDI-DrugBank.d529.s13	steady	127	132	O
DDI-DrugBank.d529.s13	state	134	138	O
DDI-DrugBank.d529.s13	serum	140	144	O
DDI-DrugBank.d529.s13	levels	146	151	O
DDI-DrugBank.d529.s13	of	153	154	O
DDI-DrugBank.d529.s13	either	156	161	O
DDI-DrugBank.d529.s13	drug	163	166	O
DDI-DrugBank.d529.s13	.	167	167	O
DDI-DrugBank.d529.s14	Diuretics	0	8	B-group
DDI-DrugBank.d529.s14	:	9	9	O
DDI-DrugBank.d529.s14	Studies	11	17	O
DDI-DrugBank.d529.s14	in	19	20	O
DDI-DrugBank.d529.s14	normal	22	27	O
DDI-DrugBank.d529.s14	volunteers	29	38	O
DDI-DrugBank.d529.s14	have	40	43	O
DDI-DrugBank.d529.s14	shown	45	49	O
DDI-DrugBank.d529.s14	that	51	54	O
DDI-DrugBank.d529.s14	flurbiprofen	56	67	B-drug
DDI-DrugBank.d529.s14	like	69	72	O
DDI-DrugBank.d529.s14	other	74	78	O
DDI-DrugBank.d529.s14	nonsteroidal	80	91	B-group
DDI-DrugBank.d529.s14	anti-inflammatory	93	109	I-group
DDI-DrugBank.d529.s14	drugs	111	115	I-group
DDI-DrugBank.d529.s14	,	116	116	O
DDI-DrugBank.d529.s14	can	118	120	O
DDI-DrugBank.d529.s14	interfere	122	130	O
DDI-DrugBank.d529.s14	with	132	135	O
DDI-DrugBank.d529.s14	the	137	139	O
DDI-DrugBank.d529.s14	effects	141	147	O
DDI-DrugBank.d529.s14	of	149	150	O
DDI-DrugBank.d529.s14	furosemide	152	161	B-drug
DDI-DrugBank.d529.s14	.	162	162	O
DDI-DrugBank.d529.s15	Although	0	7	O
DDI-DrugBank.d529.s15	results	9	15	O
DDI-DrugBank.d529.s15	have	17	20	O
DDI-DrugBank.d529.s15	varied	22	27	O
DDI-DrugBank.d529.s15	from	29	32	O
DDI-DrugBank.d529.s15	study	34	38	O
DDI-DrugBank.d529.s15	to	40	41	O
DDI-DrugBank.d529.s15	study	43	47	O
DDI-DrugBank.d529.s15	,	48	48	O
DDI-DrugBank.d529.s15	effects	50	56	O
DDI-DrugBank.d529.s15	have	58	61	O
DDI-DrugBank.d529.s15	been	63	66	O
DDI-DrugBank.d529.s15	shown	68	72	O
DDI-DrugBank.d529.s15	on	74	75	O
DDI-DrugBank.d529.s15	furosemide-stimulated	77	97	O
DDI-DrugBank.d529.s15	diuresis	99	106	O
DDI-DrugBank.d529.s15	,	107	107	O
DDI-DrugBank.d529.s15	natriuresis	109	119	O
DDI-DrugBank.d529.s15	,	107	107	O
DDI-DrugBank.d529.s15	and	122	124	O
DDI-DrugBank.d529.s15	kaliuresis	126	135	O
DDI-DrugBank.d529.s15	.	136	136	O
DDI-DrugBank.d529.s16	Other	0	4	O
DDI-DrugBank.d529.s16	nonsteroidal	6	17	B-group
DDI-DrugBank.d529.s16	anti-inflammatory	19	35	I-group
DDI-DrugBank.d529.s16	drugs	37	41	I-group
DDI-DrugBank.d529.s16	that	43	46	O
DDI-DrugBank.d529.s16	inhibit	48	54	O
DDI-DrugBank.d529.s16	prostaglandin	56	68	O
DDI-DrugBank.d529.s16	synthesis	70	78	O
DDI-DrugBank.d529.s16	have	80	83	O
DDI-DrugBank.d529.s16	been	85	88	O
DDI-DrugBank.d529.s16	shown	90	94	O
DDI-DrugBank.d529.s16	to	96	97	O
DDI-DrugBank.d529.s16	interfere	99	107	O
DDI-DrugBank.d529.s16	with	109	112	O
DDI-DrugBank.d529.s16	thiazide	114	121	B-group
DDI-DrugBank.d529.s16	diuretics	123	131	I-group
DDI-DrugBank.d529.s16	in	133	134	O
DDI-DrugBank.d529.s16	some	136	139	O
DDI-DrugBank.d529.s16	studies	141	147	O
DDI-DrugBank.d529.s16	and	149	151	O
DDI-DrugBank.d529.s16	with	153	156	O
DDI-DrugBank.d529.s16	potassium-sparing	158	174	B-group
DDI-DrugBank.d529.s16	diuretics	176	184	I-group
DDI-DrugBank.d529.s16	.	185	185	O
DDI-DrugBank.d529.s17	Patients	0	7	O
DDI-DrugBank.d529.s17	receiving	9	17	O
DDI-DrugBank.d529.s17	flurbiprofen	19	30	B-drug
DDI-DrugBank.d529.s17	and	32	34	O
DDI-DrugBank.d529.s17	furosemide	36	45	B-drug
DDI-DrugBank.d529.s17	or	47	48	O
DDI-DrugBank.d529.s17	other	50	54	O
DDI-DrugBank.d529.s17	diuretics	56	64	B-group
DDI-DrugBank.d529.s17	should	66	71	O
DDI-DrugBank.d529.s17	be	73	74	O
DDI-DrugBank.d529.s17	observed	76	83	O
DDI-DrugBank.d529.s17	closely	85	91	O
DDI-DrugBank.d529.s17	to	93	94	O
DDI-DrugBank.d529.s17	determine	96	104	O
DDI-DrugBank.d529.s17	if	106	107	O
DDI-DrugBank.d529.s17	the	109	111	O
DDI-DrugBank.d529.s17	desired	113	119	O
DDI-DrugBank.d529.s17	effect	121	126	O
DDI-DrugBank.d529.s17	is	128	129	O
DDI-DrugBank.d529.s17	obtained	131	138	O
DDI-DrugBank.d529.s17	.	139	139	O
DDI-DrugBank.d529.s18	Oral	0	3	O
DDI-DrugBank.d529.s18	Hypoglycemic	5	16	B-group
DDI-DrugBank.d529.s18	Agents	18	23	I-group
DDI-DrugBank.d529.s18	:	24	24	O
DDI-DrugBank.d529.s18	In	26	27	O
DDI-DrugBank.d529.s18	one	29	31	O
DDI-DrugBank.d529.s18	study	33	37	O
DDI-DrugBank.d529.s18	,	38	38	O
DDI-DrugBank.d529.s18	flurbiprofen	40	51	B-drug
DDI-DrugBank.d529.s18	was	53	55	O
DDI-DrugBank.d529.s18	given	57	61	O
DDI-DrugBank.d529.s18	to	63	64	O
DDI-DrugBank.d529.s18	adult	66	70	O
DDI-DrugBank.d529.s18	diabetics	72	80	O
DDI-DrugBank.d529.s18	who	82	84	O
DDI-DrugBank.d529.s18	were	86	89	O
DDI-DrugBank.d529.s18	already	91	97	O
DDI-DrugBank.d529.s18	receiving	99	107	O
DDI-DrugBank.d529.s18	glyburide	109	117	B-drug
DDI-DrugBank.d529.s18	(	119	119	O
DDI-DrugBank.d529.s18	n=4	120	122	O
DDI-DrugBank.d529.s18	)	123	123	O
DDI-DrugBank.d529.s18	,	124	124	O
DDI-DrugBank.d529.s18	metformin	126	134	B-drug
DDI-DrugBank.d529.s18	(	119	119	O
DDI-DrugBank.d529.s18	n=2	137	139	O
DDI-DrugBank.d529.s18	)	123	123	O
DDI-DrugBank.d529.s18	chlorpropamide	142	155	B-drug
DDI-DrugBank.d529.s18	with	157	160	O
DDI-DrugBank.d529.s18	phenformin	162	171	B-drug
DDI-DrugBank.d529.s18	(	173	173	O
DDI-DrugBank.d529.s18	n=	174	175	O
DDI-DrugBank.d529.s18	3	177	177	O
DDI-DrugBank.d529.s18	)	178	178	O
DDI-DrugBank.d529.s18	or	167	168	I-drug
DDI-DrugBank.d529.s18	glyburide	183	191	B-drug
DDI-DrugBank.d529.s18	with	193	196	O
DDI-DrugBank.d529.s18	phenformin	198	207	B-drug
DDI-DrugBank.d529.s18	(	209	209	O
DDI-DrugBank.d529.s18	n=6	210	212	O
DDI-DrugBank.d529.s18	)	213	213	O
DDI-DrugBank.d529.s18	.	214	214	O
DDI-DrugBank.d529.s19	Although	0	7	O
DDI-DrugBank.d529.s19	there	9	13	O
DDI-DrugBank.d529.s19	was	15	17	O
DDI-DrugBank.d529.s19	a	16	16	O
DDI-DrugBank.d529.s19	slight	21	26	O
DDI-DrugBank.d529.s19	reduction	28	36	O
DDI-DrugBank.d529.s19	in	38	39	O
DDI-DrugBank.d529.s19	blood	41	45	O
DDI-DrugBank.d529.s19	sugar	47	51	O
DDI-DrugBank.d529.s19	concentrations	53	66	O
DDI-DrugBank.d529.s19	during	68	73	O
DDI-DrugBank.d529.s19	concomitant	75	85	O
DDI-DrugBank.d529.s19	administration	87	100	O
DDI-DrugBank.d529.s19	of	102	103	O
DDI-DrugBank.d529.s19	flurbiprofen	105	116	B-drug
DDI-DrugBank.d529.s19	and	118	120	O
DDI-DrugBank.d529.s19	hypoglycemic	122	133	B-group
DDI-DrugBank.d529.s19	agents	135	140	I-group
DDI-DrugBank.d529.s19	,	141	141	O
DDI-DrugBank.d529.s19	there	143	147	O
DDI-DrugBank.d529.s19	were	149	152	O
DDI-DrugBank.d529.s19	no	154	155	O
DDI-DrugBank.d529.s19	signs	157	161	O
DDI-DrugBank.d529.s19	or	163	164	O
DDI-DrugBank.d529.s19	symptoms	166	173	O
DDI-DrugBank.d529.s19	of	175	176	O
DDI-DrugBank.d529.s19	hypoglycemia	178	189	O
DDI-DrugBank.d529.s19	.	190	190	O
DDI-DrugBank.d552.s0	Nabilone	0	7	B-drug
DDI-DrugBank.d552.s0	should	9	14	O
DDI-DrugBank.d552.s0	be	16	17	O
DDI-DrugBank.d552.s0	administered	19	30	O
DDI-DrugBank.d552.s0	with	32	35	O
DDI-DrugBank.d552.s0	caution	37	43	O
DDI-DrugBank.d552.s0	to	45	46	O
DDI-DrugBank.d552.s0	patients	48	55	O
DDI-DrugBank.d552.s0	who	57	59	O
DDI-DrugBank.d552.s0	are	61	63	O
DDI-DrugBank.d552.s0	taking	65	70	O
DDI-DrugBank.d552.s0	other	72	76	O
DDI-DrugBank.d552.s0	psychoactive	78	89	B-group
DDI-DrugBank.d552.s0	drugs	91	95	I-group
DDI-DrugBank.d552.s0	or	97	98	O
DDI-DrugBank.d552.s0	CNS	100	102	B-group
DDI-DrugBank.d552.s0	depressants	104	114	I-group
DDI-DrugBank.d552.s0	,	115	115	O
DDI-DrugBank.d552.s0	including	117	125	O
DDI-DrugBank.d552.s0	alcohol	127	133	B-drug
DDI-DrugBank.d552.s0	,	134	134	O
DDI-DrugBank.d552.s0	barbiturates	136	147	B-group
DDI-DrugBank.d552.s0	and	149	151	O
DDI-DrugBank.d552.s0	narcotic	153	160	B-group
DDI-DrugBank.d552.s0	analgesics	162	171	I-group
DDI-DrugBank.d552.s0	,	172	172	O
DDI-DrugBank.d552.s0	or	174	175	O
DDI-DrugBank.d552.s0	to	177	178	O
DDI-DrugBank.d552.s0	those	180	184	O
DDI-DrugBank.d552.s0	with	186	189	O
DDI-DrugBank.d552.s0	a	164	164	O
DDI-DrugBank.d552.s0	history	193	199	O
DDI-DrugBank.d552.s0	of	201	202	O
DDI-DrugBank.d552.s0	psychiatric	204	214	O
DDI-DrugBank.d552.s0	disorder	216	223	O
DDI-DrugBank.d552.s0	(	225	225	O
DDI-DrugBank.d552.s0	including	226	234	O
DDI-DrugBank.d552.s0	manic-depressive	236	251	O
DDI-DrugBank.d552.s0	illness	253	259	O
DDI-DrugBank.d552.s0	and	261	263	O
DDI-DrugBank.d552.s0	schizophrenia	265	277	O
DDI-DrugBank.d552.s0	)	278	278	O
DDI-DrugBank.d552.s0	.	279	279	O
DDI-DrugBank.d552.s1	Nabilone	0	7	B-drug
DDI-DrugBank.d552.s1	has	9	11	O
DDI-DrugBank.d552.s1	been	13	16	O
DDI-DrugBank.d552.s1	shown	18	22	O
DDI-DrugBank.d552.s1	to	24	25	O
DDI-DrugBank.d552.s1	have	27	30	O
DDI-DrugBank.d552.s1	an	32	33	O
DDI-DrugBank.d552.s1	additive	35	42	O
DDI-DrugBank.d552.s1	CNS	44	46	O
DDI-DrugBank.d552.s1	depressant	48	57	O
DDI-DrugBank.d552.s1	effect	59	64	O
DDI-DrugBank.d552.s1	when	66	69	O
DDI-DrugBank.d552.s1	given	71	75	O
DDI-DrugBank.d552.s1	with	77	80	O
DDI-DrugBank.d552.s1	either	82	87	O
DDI-DrugBank.d552.s1	diazepam	89	96	B-drug
DDI-DrugBank.d552.s1	,	97	97	O
DDI-DrugBank.d552.s1	secobarbitone	99	111	B-brand
DDI-DrugBank.d552.s1	sodium	113	118	I-brand
DDI-DrugBank.d552.s1	,	119	119	O
DDI-DrugBank.d552.s1	alcohol	121	127	B-drug
DDI-DrugBank.d552.s1	or	129	130	O
DDI-DrugBank.d552.s1	codeine	132	138	B-drug
DDI-DrugBank.d552.s1	.	139	139	O
DDI-DrugBank.d345.s0	Since	0	4	O
DDI-DrugBank.d345.s0	colestipol	6	15	B-drug
DDI-DrugBank.d345.s0	hydrochloride	17	29	I-drug
DDI-DrugBank.d345.s0	is	31	32	O
DDI-DrugBank.d345.s0	an	34	35	O
DDI-DrugBank.d345.s0	anion	37	41	B-group
DDI-DrugBank.d345.s0	exchange	43	50	I-group
DDI-DrugBank.d345.s0	resin	52	56	I-group
DDI-DrugBank.d345.s0	,	57	57	O
DDI-DrugBank.d345.s0	it	59	60	O
DDI-DrugBank.d345.s0	may	62	64	O
DDI-DrugBank.d345.s0	have	66	69	O
DDI-DrugBank.d345.s0	a	63	63	O
DDI-DrugBank.d345.s0	strong	73	78	O
DDI-DrugBank.d345.s0	affinity	80	87	O
DDI-DrugBank.d345.s0	for	89	91	O
DDI-DrugBank.d345.s0	anions	93	98	O
DDI-DrugBank.d345.s0	other	100	104	O
DDI-DrugBank.d345.s0	than	106	109	O
DDI-DrugBank.d345.s0	the	101	103	O
DDI-DrugBank.d345.s0	bile	115	118	O
DDI-DrugBank.d345.s0	acids	120	124	O
DDI-DrugBank.d345.s0	.	125	125	O
DDI-DrugBank.d345.s1	In	0	1	O
DDI-DrugBank.d345.s1	vitro	3	7	O
DDI-DrugBank.d345.s1	studies	9	15	O
DDI-DrugBank.d345.s1	have	17	20	O
DDI-DrugBank.d345.s1	indicated	22	30	O
DDI-DrugBank.d345.s1	that	32	35	O
DDI-DrugBank.d345.s1	colestipol	37	46	B-drug
DDI-DrugBank.d345.s1	hydrochloride	48	60	I-drug
DDI-DrugBank.d345.s1	binds	62	66	O
DDI-DrugBank.d345.s1	a	68	68	O
DDI-DrugBank.d345.s1	number	70	75	O
DDI-DrugBank.d345.s1	of	77	78	O
DDI-DrugBank.d345.s1	drugs	80	84	O
DDI-DrugBank.d345.s1	.	85	85	O
DDI-DrugBank.d345.s2	Therefore	0	8	O
DDI-DrugBank.d345.s2	,	9	9	O
DDI-DrugBank.d345.s2	COLESTlD	11	18	B-brand
DDI-DrugBank.d345.s2	Tablets	20	26	O
DDI-DrugBank.d345.s2	may	28	30	O
DDI-DrugBank.d345.s2	delay	32	36	O
DDI-DrugBank.d345.s2	or	38	39	O
DDI-DrugBank.d345.s2	reduce	41	46	O
DDI-DrugBank.d345.s2	the	48	50	O
DDI-DrugBank.d345.s2	absorption	52	61	O
DDI-DrugBank.d345.s2	of	63	64	O
DDI-DrugBank.d345.s2	concomitant	66	76	O
DDI-DrugBank.d345.s2	oral	78	81	O
DDI-DrugBank.d345.s2	medication	83	92	O
DDI-DrugBank.d345.s2	.	93	93	O
DDI-DrugBank.d345.s3	The	0	2	O
DDI-DrugBank.d345.s3	interval	4	11	O
DDI-DrugBank.d345.s3	between	13	19	O
DDI-DrugBank.d345.s3	the	21	23	O
DDI-DrugBank.d345.s3	administration	25	38	O
DDI-DrugBank.d345.s3	of	40	41	O
DDI-DrugBank.d345.s3	COLESTID	43	50	B-brand
DDI-DrugBank.d345.s3	Tablets	52	58	O
DDI-DrugBank.d345.s3	and	60	62	O
DDI-DrugBank.d345.s3	any	64	66	O
DDI-DrugBank.d345.s3	other	68	72	O
DDI-DrugBank.d345.s3	medication	74	83	O
DDI-DrugBank.d345.s3	should	85	90	O
DDI-DrugBank.d345.s3	be	92	93	O
DDI-DrugBank.d345.s3	as	95	96	O
DDI-DrugBank.d345.s3	long	98	101	O
DDI-DrugBank.d345.s3	as	95	96	O
DDI-DrugBank.d345.s3	possible	106	113	O
DDI-DrugBank.d345.s3	.	114	114	O
DDI-DrugBank.d345.s4	Patients	0	7	O
DDI-DrugBank.d345.s4	should	9	14	O
DDI-DrugBank.d345.s4	take	16	19	O
DDI-DrugBank.d345.s4	other	21	25	O
DDI-DrugBank.d345.s4	drugs	27	31	O
DDI-DrugBank.d345.s4	at	33	34	O
DDI-DrugBank.d345.s4	least	36	40	O
DDI-DrugBank.d345.s4	one	42	44	O
DDI-DrugBank.d345.s4	hour	46	49	O
DDI-DrugBank.d345.s4	before	51	56	O
DDI-DrugBank.d345.s4	or	54	55	O
DDI-DrugBank.d345.s4	four	61	64	O
DDI-DrugBank.d345.s4	hours	66	70	O
DDI-DrugBank.d345.s4	after	72	76	O
DDI-DrugBank.d345.s4	COLESTID	78	85	B-brand
DDI-DrugBank.d345.s4	Tablets	87	93	O
DDI-DrugBank.d345.s4	to	95	96	O
DDI-DrugBank.d345.s4	avoid	98	102	O
DDI-DrugBank.d345.s4	impeding	104	111	O
DDI-DrugBank.d345.s4	their	113	117	O
DDI-DrugBank.d345.s4	absorption	119	128	O
DDI-DrugBank.d345.s4	.	129	129	O
DDI-DrugBank.d345.s5	Repeated	0	7	O
DDI-DrugBank.d345.s5	doses	9	13	O
DDI-DrugBank.d345.s5	of	15	16	O
DDI-DrugBank.d345.s5	colestipol	18	27	B-drug
DDI-DrugBank.d345.s5	hydrochloride	29	41	I-drug
DDI-DrugBank.d345.s5	given	43	47	O
DDI-DrugBank.d345.s5	prior	49	53	O
DDI-DrugBank.d345.s5	to	55	56	O
DDI-DrugBank.d345.s5	a	58	58	O
DDI-DrugBank.d345.s5	single	60	65	O
DDI-DrugBank.d345.s5	dose	67	70	O
DDI-DrugBank.d345.s5	of	72	73	O
DDI-DrugBank.d345.s5	propranolol	75	85	B-drug
DDI-DrugBank.d345.s5	in	87	88	O
DDI-DrugBank.d345.s5	human	90	94	O
DDI-DrugBank.d345.s5	trials	96	101	O
DDI-DrugBank.d345.s5	have	103	106	O
DDI-DrugBank.d345.s5	been	108	111	O
DDI-DrugBank.d345.s5	reported	113	120	O
DDI-DrugBank.d345.s5	to	122	123	O
DDI-DrugBank.d345.s5	decrease	125	132	O
DDI-DrugBank.d345.s5	propranolol	134	144	B-drug
DDI-DrugBank.d345.s5	absorption	146	155	O
DDI-DrugBank.d345.s5	.	156	156	O
DDI-DrugBank.d345.s6	However	0	6	O
DDI-DrugBank.d345.s6	,	7	7	O
DDI-DrugBank.d345.s6	in	9	10	O
DDI-DrugBank.d345.s6	a	12	12	O
DDI-DrugBank.d345.s6	follow-up	14	22	O
DDI-DrugBank.d345.s6	study	24	28	O
DDI-DrugBank.d345.s6	in	30	31	O
DDI-DrugBank.d345.s6	normal	33	38	O
DDI-DrugBank.d345.s6	subjects	40	47	O
DDI-DrugBank.d345.s6	,	48	48	O
DDI-DrugBank.d345.s6	single-dose	50	60	O
DDI-DrugBank.d345.s6	administration	62	75	O
DDI-DrugBank.d345.s6	of	77	78	O
DDI-DrugBank.d345.s6	colestipol	80	89	B-drug
DDI-DrugBank.d345.s6	hydrochloride	91	103	I-drug
DDI-DrugBank.d345.s6	and	105	107	O
DDI-DrugBank.d345.s6	propranolol	109	119	B-drug
DDI-DrugBank.d345.s6	and	121	123	O
DDI-DrugBank.d345.s6	twice-a-day	125	135	O
DDI-DrugBank.d345.s6	administration	137	150	O
DDI-DrugBank.d345.s6	for	152	154	O
DDI-DrugBank.d345.s6	5	156	156	O
DDI-DrugBank.d345.s6	days	158	161	O
DDI-DrugBank.d345.s6	of	163	164	O
DDI-DrugBank.d345.s6	both	166	169	O
DDI-DrugBank.d345.s6	agents	171	176	O
DDI-DrugBank.d345.s6	did	178	180	O
DDI-DrugBank.d345.s6	not	182	184	O
DDI-DrugBank.d345.s6	affect	186	191	O
DDI-DrugBank.d345.s6	the	193	195	O
DDI-DrugBank.d345.s6	extent	197	202	O
DDI-DrugBank.d345.s6	of	204	205	O
DDI-DrugBank.d345.s6	propranolol	207	217	B-drug
DDI-DrugBank.d345.s6	absorption	219	228	O
DDI-DrugBank.d345.s6	,	229	229	O
DDI-DrugBank.d345.s6	but	231	233	O
DDI-DrugBank.d345.s6	had	235	237	O
DDI-DrugBank.d345.s6	a	212	212	O
DDI-DrugBank.d345.s6	small	241	245	O
DDI-DrugBank.d345.s6	yet	247	249	O
DDI-DrugBank.d345.s6	statistically	251	263	O
DDI-DrugBank.d345.s6	significant	265	275	O
DDI-DrugBank.d345.s6	effect	277	282	O
DDI-DrugBank.d345.s6	on	284	285	O
DDI-DrugBank.d345.s6	its	287	289	O
DDI-DrugBank.d345.s6	rate	291	294	O
DDI-DrugBank.d345.s6	of	296	297	O
DDI-DrugBank.d345.s6	absorption	299	308	O
DDI-DrugBank.d345.s6	;	309	309	O
DDI-DrugBank.d345.s7	the	0	2	O
DDI-DrugBank.d345.s7	time	4	7	O
DDI-DrugBank.d345.s7	to	9	10	O
DDI-DrugBank.d345.s7	reach	12	16	O
DDI-DrugBank.d345.s7	maximum	18	24	O
DDI-DrugBank.d345.s7	concentration	26	38	O
DDI-DrugBank.d345.s7	was	40	42	O
DDI-DrugBank.d345.s7	delayed	44	50	O
DDI-DrugBank.d345.s7	approximately	52	64	O
DDI-DrugBank.d345.s7	30	66	67	O
DDI-DrugBank.d345.s7	minutes	69	75	O
DDI-DrugBank.d345.s7	.	76	76	O
DDI-DrugBank.d345.s8	Effects	0	6	O
DDI-DrugBank.d345.s8	on	8	9	O
DDI-DrugBank.d345.s8	the	11	13	O
DDI-DrugBank.d345.s8	absorption	15	24	O
DDI-DrugBank.d345.s8	of	26	27	O
DDI-DrugBank.d345.s8	other	29	33	O
DDI-DrugBank.d345.s8	beta-blockers	35	47	B-group
DDI-DrugBank.d345.s8	have	49	52	O
DDI-DrugBank.d345.s8	not	54	56	O
DDI-DrugBank.d345.s8	been	58	61	O
DDI-DrugBank.d345.s8	determined	63	72	O
DDI-DrugBank.d345.s8	.	73	73	O
DDI-DrugBank.d345.s9	Therefore	0	8	O
DDI-DrugBank.d345.s9	,	9	9	O
DDI-DrugBank.d345.s9	patients	11	18	O
DDI-DrugBank.d345.s9	on	20	21	O
DDI-DrugBank.d345.s9	propranolol	23	33	B-drug
DDI-DrugBank.d345.s9	should	35	40	O
DDI-DrugBank.d345.s9	be	42	43	O
DDI-DrugBank.d345.s9	observed	45	52	O
DDI-DrugBank.d345.s9	when	54	57	O
DDI-DrugBank.d345.s9	COLESTID	59	66	B-brand
DDI-DrugBank.d345.s9	Tablets	68	74	O
DDI-DrugBank.d345.s9	are	76	78	O
DDI-DrugBank.d345.s9	either	80	85	O
DDI-DrugBank.d345.s9	added	87	91	O
DDI-DrugBank.d345.s9	or	93	94	O
DDI-DrugBank.d345.s9	deleted	96	102	O
DDI-DrugBank.d345.s9	from	104	107	O
DDI-DrugBank.d345.s9	a	109	109	O
DDI-DrugBank.d345.s9	therapeutic	111	121	O
DDI-DrugBank.d345.s9	regimen	123	129	O
DDI-DrugBank.d345.s9	.	130	130	O
DDI-DrugBank.d345.s10	Studies	0	6	O
DDI-DrugBank.d345.s10	in	8	9	O
DDI-DrugBank.d345.s10	humans	11	16	O
DDI-DrugBank.d345.s10	show	18	21	O
DDI-DrugBank.d345.s10	that	23	26	O
DDI-DrugBank.d345.s10	the	28	30	O
DDI-DrugBank.d345.s10	absorption	32	41	O
DDI-DrugBank.d345.s10	of	43	44	O
DDI-DrugBank.d345.s10	chlorothiazide	46	59	B-drug
DDI-DrugBank.d345.s10	as	61	62	O
DDI-DrugBank.d345.s10	reflected	64	72	O
DDI-DrugBank.d345.s10	in	74	75	O
DDI-DrugBank.d345.s10	urinary	77	83	O
DDI-DrugBank.d345.s10	excretion	85	93	O
DDI-DrugBank.d345.s10	is	95	96	O
DDI-DrugBank.d345.s10	markedly	98	105	O
DDI-DrugBank.d345.s10	decreased	107	115	O
DDI-DrugBank.d345.s10	even	117	120	O
DDI-DrugBank.d345.s10	when	122	125	O
DDI-DrugBank.d345.s10	administered	127	138	O
DDI-DrugBank.d345.s10	one	140	142	O
DDI-DrugBank.d345.s10	hour	144	147	O
DDI-DrugBank.d345.s10	before	149	154	O
DDI-DrugBank.d345.s10	colestipol	156	165	B-drug
DDI-DrugBank.d345.s10	hydrochloride	167	179	I-drug
DDI-DrugBank.d345.s10	.	180	180	O
DDI-DrugBank.d345.s11	The	0	2	O
DDI-DrugBank.d345.s11	absorption	4	13	O
DDI-DrugBank.d345.s11	of	15	16	O
DDI-DrugBank.d345.s11	tetracycline	18	29	B-drug
DDI-DrugBank.d345.s11	,	30	30	O
DDI-DrugBank.d345.s11	furosemide	32	41	B-drug
DDI-DrugBank.d345.s11	,	42	42	O
DDI-DrugBank.d345.s11	penicillin	44	53	B-drug
DDI-DrugBank.d345.s11	G	55	55	O
DDI-DrugBank.d345.s11	,	56	56	O
DDI-DrugBank.d345.s11	hydrochlorothiazide	58	76	B-drug
DDI-DrugBank.d345.s11	,	77	77	O
DDI-DrugBank.d345.s11	and	79	81	O
DDI-DrugBank.d345.s11	gemfibrozil	83	93	B-drug
DDI-DrugBank.d345.s11	was	95	97	O
DDI-DrugBank.d345.s11	significantly	99	111	O
DDI-DrugBank.d345.s11	decreased	113	121	O
DDI-DrugBank.d345.s11	when	123	126	O
DDI-DrugBank.d345.s11	given	128	132	O
DDI-DrugBank.d345.s11	simultaneously	134	147	O
DDI-DrugBank.d345.s11	with	149	152	O
DDI-DrugBank.d345.s11	colestipol	154	163	B-drug
DDI-DrugBank.d345.s11	hydrochloride	165	177	I-drug
DDI-DrugBank.d345.s11	;	178	178	O
DDI-DrugBank.d345.s12	these	0	4	O
DDI-DrugBank.d345.s12	drugs	6	10	O
DDI-DrugBank.d345.s12	were	12	15	O
DDI-DrugBank.d345.s12	not	17	19	O
DDI-DrugBank.d345.s12	tested	21	26	O
DDI-DrugBank.d345.s12	to	28	29	O
DDI-DrugBank.d345.s12	determine	31	39	O
DDI-DrugBank.d345.s12	the	41	43	O
DDI-DrugBank.d345.s12	effect	45	50	O
DDI-DrugBank.d345.s12	of	52	53	O
DDI-DrugBank.d345.s12	administration	55	68	O
DDI-DrugBank.d345.s12	one	70	72	O
DDI-DrugBank.d345.s12	hour	74	77	O
DDI-DrugBank.d345.s12	before	79	84	O
DDI-DrugBank.d345.s12	colestipol	86	95	B-drug
DDI-DrugBank.d345.s12	hydrochloride	97	109	I-drug
DDI-DrugBank.d345.s12	.	110	110	O
DDI-DrugBank.d345.s13	No	0	1	O
DDI-DrugBank.d345.s13	depressant	3	12	O
DDI-DrugBank.d345.s13	effect	14	19	O
DDI-DrugBank.d345.s13	on	21	22	O
DDI-DrugBank.d345.s13	blood	24	28	O
DDI-DrugBank.d345.s13	levels	30	35	O
DDI-DrugBank.d345.s13	in	37	38	O
DDI-DrugBank.d345.s13	humans	40	45	O
DDI-DrugBank.d345.s13	was	47	49	O
DDI-DrugBank.d345.s13	noted	51	55	O
DDI-DrugBank.d345.s13	when	57	60	O
DDI-DrugBank.d345.s13	colestipol	62	71	B-drug
DDI-DrugBank.d345.s13	hydrochloride	73	85	I-drug
DDI-DrugBank.d345.s13	was	87	89	O
DDI-DrugBank.d345.s13	administered	91	102	O
DDI-DrugBank.d345.s13	with	104	107	O
DDI-DrugBank.d345.s13	any	109	111	O
DDI-DrugBank.d345.s13	of	113	114	O
DDI-DrugBank.d345.s13	the	116	118	O
DDI-DrugBank.d345.s13	following	120	128	O
DDI-DrugBank.d345.s13	drugs	130	134	O
DDI-DrugBank.d345.s13	:	135	135	O
DDI-DrugBank.d345.s13	aspirin	137	143	B-brand
DDI-DrugBank.d345.s13	,	144	144	O
DDI-DrugBank.d345.s13	clindamycin	146	156	B-brand
DDI-DrugBank.d345.s13	,	144	144	O
DDI-DrugBank.d345.s13	clofibrate	159	168	B-drug
DDI-DrugBank.d345.s13	,	157	157	O
DDI-DrugBank.d345.s13	methyldopa	171	180	B-drug
DDI-DrugBank.d345.s13	,	157	157	O
DDI-DrugBank.d345.s13	nicotinic	183	191	B-drug
DDI-DrugBank.d345.s13	acid	193	196	I-drug
DDI-DrugBank.d345.s13	(	198	198	O
DDI-DrugBank.d345.s13	niacin	199	204	B-drug
DDI-DrugBank.d345.s13	)	205	205	O
DDI-DrugBank.d345.s13	,	181	181	O
DDI-DrugBank.d345.s13	tolbutamide	208	218	B-drug
DDI-DrugBank.d345.s13	,	206	206	O
DDI-DrugBank.d345.s13	phenytoin	221	229	B-drug
DDI-DrugBank.d345.s13	or	231	232	O
DDI-DrugBank.d345.s13	warfarin	234	241	B-drug
DDI-DrugBank.d345.s13	.	242	242	O
DDI-DrugBank.d345.s14	Particular	0	9	O
DDI-DrugBank.d345.s14	caution	11	17	O
DDI-DrugBank.d345.s14	should	19	24	O
DDI-DrugBank.d345.s14	be	26	27	O
DDI-DrugBank.d345.s14	observed	29	36	O
DDI-DrugBank.d345.s14	with	38	41	O
DDI-DrugBank.d345.s14	digitalis	43	51	B-group
DDI-DrugBank.d345.s14	preparations	53	64	I-group
DDI-DrugBank.d345.s14	since	66	70	O
DDI-DrugBank.d345.s14	there	72	76	O
DDI-DrugBank.d345.s14	are	78	80	O
DDI-DrugBank.d345.s14	conflicting	82	92	O
DDI-DrugBank.d345.s14	results	94	100	O
DDI-DrugBank.d345.s14	for	102	104	O
DDI-DrugBank.d345.s14	the	106	108	O
DDI-DrugBank.d345.s14	effect	110	115	O
DDI-DrugBank.d345.s14	of	117	118	O
DDI-DrugBank.d345.s14	colestipol	120	129	B-drug
DDI-DrugBank.d345.s14	hydrochloride	131	143	I-drug
DDI-DrugBank.d345.s14	on	145	146	O
DDI-DrugBank.d345.s14	the	148	150	O
DDI-DrugBank.d345.s14	availability	152	163	O
DDI-DrugBank.d345.s14	of	165	166	O
DDI-DrugBank.d345.s14	digoxin	168	174	B-drug
DDI-DrugBank.d345.s14	and	176	178	O
DDI-DrugBank.d345.s14	digitoxin	180	188	B-drug
DDI-DrugBank.d345.s14	.	189	189	O
DDI-DrugBank.d345.s15	The	0	2	O
DDI-DrugBank.d345.s15	potential	4	12	O
DDI-DrugBank.d345.s15	for	14	16	O
DDI-DrugBank.d345.s15	binding	18	24	O
DDI-DrugBank.d345.s15	of	26	27	O
DDI-DrugBank.d345.s15	these	29	33	O
DDI-DrugBank.d345.s15	drugs	35	39	O
DDI-DrugBank.d345.s15	if	41	42	O
DDI-DrugBank.d345.s15	given	44	48	O
DDI-DrugBank.d345.s15	concomitantly	50	62	O
DDI-DrugBank.d345.s15	is	64	65	O
DDI-DrugBank.d345.s15	present	67	73	O
DDI-DrugBank.d345.s15	.	74	74	O
DDI-DrugBank.d345.s16	Discontinuing	0	12	O
DDI-DrugBank.d345.s16	colestipol	14	23	B-drug
DDI-DrugBank.d345.s16	hydrochloride	25	37	I-drug
DDI-DrugBank.d345.s16	could	39	43	O
DDI-DrugBank.d345.s16	pose	45	48	O
DDI-DrugBank.d345.s16	a	50	50	O
DDI-DrugBank.d345.s16	hazard	52	57	O
DDI-DrugBank.d345.s16	to	59	60	O
DDI-DrugBank.d345.s16	health	62	67	O
DDI-DrugBank.d345.s16	if	69	70	O
DDI-DrugBank.d345.s16	a	64	64	O
DDI-DrugBank.d345.s16	potentially	74	84	O
DDI-DrugBank.d345.s16	toxic	86	90	O
DDI-DrugBank.d345.s16	drug	92	95	O
DDI-DrugBank.d345.s16	that	97	100	O
DDI-DrugBank.d345.s16	is	102	103	O
DDI-DrugBank.d345.s16	significantly	105	117	O
DDI-DrugBank.d345.s16	bound	119	123	O
DDI-DrugBank.d345.s16	to	125	126	O
DDI-DrugBank.d345.s16	the	128	130	O
DDI-DrugBank.d345.s16	resin	132	136	B-group
DDI-DrugBank.d345.s16	has	138	140	O
DDI-DrugBank.d345.s16	been	142	145	O
DDI-DrugBank.d345.s16	titrated	147	154	O
DDI-DrugBank.d345.s16	to	156	157	O
DDI-DrugBank.d345.s16	a	139	139	O
DDI-DrugBank.d345.s16	maintenance	161	171	O
DDI-DrugBank.d345.s16	level	173	177	O
DDI-DrugBank.d345.s16	while	179	183	O
DDI-DrugBank.d345.s16	the	185	187	O
DDI-DrugBank.d345.s16	patient	189	195	O
DDI-DrugBank.d345.s16	was	197	199	O
DDI-DrugBank.d345.s16	taking	201	206	O
DDI-DrugBank.d345.s16	colestipol	208	217	B-drug
DDI-DrugBank.d345.s16	hydrochloride	219	231	I-drug
DDI-DrugBank.d345.s16	.	232	232	O
DDI-DrugBank.d345.s17	Bile	0	3	B-group
DDI-DrugBank.d345.s17	acid	5	8	I-group
DDI-DrugBank.d345.s17	binding	10	16	I-group
DDI-DrugBank.d345.s17	resins	18	23	I-group
DDI-DrugBank.d345.s17	may	25	27	O
DDI-DrugBank.d345.s17	also	29	32	O
DDI-DrugBank.d345.s17	interfere	34	42	O
DDI-DrugBank.d345.s17	with	44	47	O
DDI-DrugBank.d345.s17	the	49	51	O
DDI-DrugBank.d345.s17	absorption	53	62	O
DDI-DrugBank.d345.s17	of	64	65	O
DDI-DrugBank.d345.s17	oral	67	70	O
DDI-DrugBank.d345.s17	phosphate	72	80	B-drug
DDI-DrugBank.d345.s17	supplements	82	92	O
DDI-DrugBank.d345.s17	and	94	96	O
DDI-DrugBank.d345.s17	hydrocortisone	98	111	B-drug
DDI-DrugBank.d345.s17	.	112	112	O
DDI-MedLine.d184.s0	Amphetamine	0	10	B-drug
DDI-MedLine.d184.s0	locomotor	12	20	O
DDI-MedLine.d184.s0	sensitization	22	34	O
DDI-MedLine.d184.s0	and	36	38	O
DDI-MedLine.d184.s0	conditioned	40	50	O
DDI-MedLine.d184.s0	place	52	56	O
DDI-MedLine.d184.s0	preference	58	67	O
DDI-MedLine.d184.s0	in	69	70	O
DDI-MedLine.d184.s0	adolescent	72	81	O
DDI-MedLine.d184.s0	male	83	86	O
DDI-MedLine.d184.s0	and	88	90	O
DDI-MedLine.d184.s0	female	92	97	O
DDI-MedLine.d184.s0	rats	99	102	O
DDI-MedLine.d184.s0	neonatally	104	113	O
DDI-MedLine.d184.s0	treated	115	121	O
DDI-MedLine.d184.s0	with	123	126	O
DDI-MedLine.d184.s0	quinpirole	128	137	B-drug_n
DDI-MedLine.d184.s0	.	138	138	O
DDI-MedLine.d184.s1	Neonatal	0	7	O
DDI-MedLine.d184.s1	quinpirole	9	18	B-drug_n
DDI-MedLine.d184.s1	treatment	20	28	O
DDI-MedLine.d184.s1	has	30	32	O
DDI-MedLine.d184.s1	been	34	37	O
DDI-MedLine.d184.s1	shown	39	43	O
DDI-MedLine.d184.s1	to	45	46	O
DDI-MedLine.d184.s1	produce	48	54	O
DDI-MedLine.d184.s1	an	56	57	O
DDI-MedLine.d184.s1	increase	59	66	O
DDI-MedLine.d184.s1	in	59	60	O
DDI-MedLine.d184.s1	dopamine	71	78	O
DDI-MedLine.d184.s1	D2-like	80	86	O
DDI-MedLine.d184.s1	receptor	88	95	O
DDI-MedLine.d184.s1	sensitivity	97	107	O
DDI-MedLine.d184.s1	that	109	112	O
DDI-MedLine.d184.s1	persists	114	121	O
DDI-MedLine.d184.s1	throughout	123	132	O
DDI-MedLine.d184.s1	the	134	136	O
DDI-MedLine.d184.s1	subject	138	144	O
DDI-MedLine.d184.s1	's	145	146	O
DDI-MedLine.d184.s1	lifetime	148	155	O
DDI-MedLine.d184.s1	.	156	156	O
DDI-MedLine.d184.s2	The	0	2	O
DDI-MedLine.d184.s2	objective	4	12	O
DDI-MedLine.d184.s2	was	14	16	O
DDI-MedLine.d184.s2	to	18	19	O
DDI-MedLine.d184.s2	analyze	21	27	O
DDI-MedLine.d184.s2	the	29	31	O
DDI-MedLine.d184.s2	effects	33	39	O
DDI-MedLine.d184.s2	of	41	42	O
DDI-MedLine.d184.s2	neonatal	44	51	O
DDI-MedLine.d184.s2	quinpirole	53	62	B-drug_n
DDI-MedLine.d184.s2	treatment	64	72	O
DDI-MedLine.d184.s2	on	74	75	O
DDI-MedLine.d184.s2	effects	77	83	O
DDI-MedLine.d184.s2	of	85	86	O
DDI-MedLine.d184.s2	amphetamine	88	98	B-drug
DDI-MedLine.d184.s2	in	96	97	I-drug
DDI-MedLine.d184.s2	adolescent	103	112	O
DDI-MedLine.d184.s2	rats	114	117	O
DDI-MedLine.d184.s2	using	119	123	O
DDI-MedLine.d184.s2	locomotor	125	133	O
DDI-MedLine.d184.s2	sensitization	135	147	O
DDI-MedLine.d184.s2	and	149	151	O
DDI-MedLine.d184.s2	conditioned	153	163	O
DDI-MedLine.d184.s2	place	165	169	O
DDI-MedLine.d184.s2	preference	171	180	O
DDI-MedLine.d184.s2	procedures	182	191	O
DDI-MedLine.d184.s2	.	192	192	O
DDI-MedLine.d184.s3	Sprague-Dawley	0	13	O
DDI-MedLine.d184.s3	rats	15	18	O
DDI-MedLine.d184.s3	were	20	23	O
DDI-MedLine.d184.s3	treated	25	31	O
DDI-MedLine.d184.s3	with	33	36	O
DDI-MedLine.d184.s3	quinpirole	38	47	B-drug_n
DDI-MedLine.d184.s3	(	49	49	O
DDI-MedLine.d184.s3	1	50	50	O
DDI-MedLine.d184.s3	mg/kg	52	56	O
DDI-MedLine.d184.s3	)	57	57	O
DDI-MedLine.d184.s3	or	59	60	O
DDI-MedLine.d184.s3	saline	62	67	O
DDI-MedLine.d184.s3	from	69	72	O
DDI-MedLine.d184.s3	postnatal	74	82	O
DDI-MedLine.d184.s3	days	84	87	O
DDI-MedLine.d184.s3	(	89	89	O
DDI-MedLine.d184.s3	P	90	90	O
DDI-MedLine.d184.s3	)	91	91	O
DDI-MedLine.d184.s3	1	92	92	O
DDI-MedLine.d184.s3	to	94	95	O
DDI-MedLine.d184.s3	P11	97	99	O
DDI-MedLine.d184.s3	and	101	103	O
DDI-MedLine.d184.s3	raised	105	110	O
DDI-MedLine.d184.s3	to	94	95	O
DDI-MedLine.d184.s3	adolescence	115	125	O
DDI-MedLine.d184.s3	.	126	126	O
DDI-MedLine.d184.s4	For	0	2	O
DDI-MedLine.d184.s4	locomotor	4	12	O
DDI-MedLine.d184.s4	sensitization	14	26	O
DDI-MedLine.d184.s4	,	27	27	O
DDI-MedLine.d184.s4	subjects	29	36	O
DDI-MedLine.d184.s4	were	38	41	O
DDI-MedLine.d184.s4	given	43	47	O
DDI-MedLine.d184.s4	amphetamine	49	59	B-drug
DDI-MedLine.d184.s4	(	61	61	O
DDI-MedLine.d184.s4	1	62	62	O
DDI-MedLine.d184.s4	mg/kg	64	68	O
DDI-MedLine.d184.s4	)	69	69	O
DDI-MedLine.d184.s4	or	71	72	O
DDI-MedLine.d184.s4	saline	74	79	O
DDI-MedLine.d184.s4	every	81	85	O
DDI-MedLine.d184.s4	second	87	92	O
DDI-MedLine.d184.s4	day	94	96	O
DDI-MedLine.d184.s4	from	98	101	O
DDI-MedLine.d184.s4	P35	103	105	O
DDI-MedLine.d184.s4	to	107	108	O
DDI-MedLine.d184.s4	P47	110	112	O
DDI-MedLine.d184.s4	and	114	116	O
DDI-MedLine.d184.s4	were	118	121	O
DDI-MedLine.d184.s4	placed	123	128	O
DDI-MedLine.d184.s4	into	130	133	O
DDI-MedLine.d184.s4	a	114	114	O
DDI-MedLine.d184.s4	locomotor	137	145	O
DDI-MedLine.d184.s4	arena	147	151	O
DDI-MedLine.d184.s4	.	152	152	O
DDI-MedLine.d184.s5	In	0	1	O
DDI-MedLine.d184.s5	female	3	8	O
DDI-MedLine.d184.s5	rats	10	13	O
DDI-MedLine.d184.s5	,	14	14	O
DDI-MedLine.d184.s5	neonatal	16	23	O
DDI-MedLine.d184.s5	quinpirole	25	34	B-drug_n
DDI-MedLine.d184.s5	treatment	36	44	O
DDI-MedLine.d184.s5	enhanced	46	53	O
DDI-MedLine.d184.s5	amphetamine	55	65	B-drug
DDI-MedLine.d184.s5	locomotor	67	75	O
DDI-MedLine.d184.s5	sensitization	77	89	O
DDI-MedLine.d184.s5	compared	91	98	O
DDI-MedLine.d184.s5	with	100	103	O
DDI-MedLine.d184.s5	quinpirole-free	105	119	O
DDI-MedLine.d184.s5	controls	121	128	O
DDI-MedLine.d184.s5	sensitized	130	139	O
DDI-MedLine.d184.s5	to	141	142	O
DDI-MedLine.d184.s5	amphetamine	144	154	B-drug
DDI-MedLine.d184.s5	.	155	155	O
DDI-MedLine.d184.s6	Male	0	3	O
DDI-MedLine.d184.s6	rats	5	8	O
DDI-MedLine.d184.s6	demonstrated	10	21	O
DDI-MedLine.d184.s6	sensitization	23	35	O
DDI-MedLine.d184.s6	to	37	38	O
DDI-MedLine.d184.s6	amphetamine	40	50	B-drug
DDI-MedLine.d184.s6	,	51	51	O
DDI-MedLine.d184.s6	although	53	60	O
DDI-MedLine.d184.s6	this	62	65	O
DDI-MedLine.d184.s6	was	67	69	O
DDI-MedLine.d184.s6	muted	71	75	O
DDI-MedLine.d184.s6	compared	77	84	O
DDI-MedLine.d184.s6	with	86	89	O
DDI-MedLine.d184.s6	female	91	96	O
DDI-MedLine.d184.s6	rats	98	101	O
DDI-MedLine.d184.s6	,	102	102	O
DDI-MedLine.d184.s6	and	104	106	O
DDI-MedLine.d184.s6	were	108	111	O
DDI-MedLine.d184.s6	unaffected	113	122	O
DDI-MedLine.d184.s6	by	124	125	O
DDI-MedLine.d184.s6	neonatal	127	134	O
DDI-MedLine.d184.s6	quinpirole	136	145	B-drug_n
DDI-MedLine.d184.s6	.	146	146	O
DDI-MedLine.d184.s7	For	0	2	O
DDI-MedLine.d184.s7	conditioned	4	14	O
DDI-MedLine.d184.s7	place	16	20	O
DDI-MedLine.d184.s7	preference	22	31	O
DDI-MedLine.d184.s7	,	32	32	O
DDI-MedLine.d184.s7	subjects	34	41	O
DDI-MedLine.d184.s7	were	43	46	O
DDI-MedLine.d184.s7	conditioned	48	58	O
DDI-MedLine.d184.s7	for	60	62	O
DDI-MedLine.d184.s7	8	64	64	O
DDI-MedLine.d184.s7	consecutive	66	76	O
DDI-MedLine.d184.s7	days	78	81	O
DDI-MedLine.d184.s7	(	83	83	O
DDI-MedLine.d184.s7	P32-39	84	89	O
DDI-MedLine.d184.s7	)	90	90	O
DDI-MedLine.d184.s7	with	92	95	O
DDI-MedLine.d184.s7	amphetamine	97	107	B-drug
DDI-MedLine.d184.s7	(	109	109	O
DDI-MedLine.d184.s7	1	110	110	O
DDI-MedLine.d184.s7	mg/kg	112	116	O
DDI-MedLine.d184.s7	)	117	117	O
DDI-MedLine.d184.s7	or	119	120	O
DDI-MedLine.d184.s7	saline	122	127	O
DDI-MedLine.d184.s7	and	129	131	O
DDI-MedLine.d184.s7	a	123	123	O
DDI-MedLine.d184.s7	drug-free	135	143	O
DDI-MedLine.d184.s7	preference	145	154	O
DDI-MedLine.d184.s7	test	156	159	O
DDI-MedLine.d184.s7	was	161	163	O
DDI-MedLine.d184.s7	conducted	165	173	O
DDI-MedLine.d184.s7	at	175	176	O
DDI-MedLine.d184.s7	P40	178	180	O
DDI-MedLine.d184.s7	.	181	181	O
DDI-MedLine.d184.s8	Rats	0	3	O
DDI-MedLine.d184.s8	treated	5	11	O
DDI-MedLine.d184.s8	with	13	16	O
DDI-MedLine.d184.s8	neonatal	18	25	O
DDI-MedLine.d184.s8	quinpirole	27	36	B-drug_n
DDI-MedLine.d184.s8	enhanced	38	45	O
DDI-MedLine.d184.s8	time	47	50	O
DDI-MedLine.d184.s8	spent	52	56	O
DDI-MedLine.d184.s8	in	58	59	O
DDI-MedLine.d184.s8	the	61	63	O
DDI-MedLine.d184.s8	amphetamine-paired	65	82	O
DDI-MedLine.d184.s8	context	84	90	O
DDI-MedLine.d184.s8	compared	92	99	O
DDI-MedLine.d184.s8	with	101	104	O
DDI-MedLine.d184.s8	quinpirole-free	106	120	O
DDI-MedLine.d184.s8	controls	122	129	O
DDI-MedLine.d184.s8	conditioned	131	141	O
DDI-MedLine.d184.s8	with	143	146	O
DDI-MedLine.d184.s8	amphetamine	148	158	B-drug
DDI-MedLine.d184.s8	,	159	159	O
DDI-MedLine.d184.s8	but	161	163	O
DDI-MedLine.d184.s8	only	165	168	O
DDI-MedLine.d184.s8	female	170	175	O
DDI-MedLine.d184.s8	controls	177	184	O
DDI-MedLine.d184.s8	conditioned	186	196	O
DDI-MedLine.d184.s8	with	198	201	O
DDI-MedLine.d184.s8	amphetamine	203	213	B-drug
DDI-MedLine.d184.s8	spent	215	219	O
DDI-MedLine.d184.s8	more	221	224	O
DDI-MedLine.d184.s8	time	226	229	O
DDI-MedLine.d184.s8	in	211	212	I-drug
DDI-MedLine.d184.s8	the	234	236	O
DDI-MedLine.d184.s8	drug-paired	238	248	O
DDI-MedLine.d184.s8	context	250	256	O
DDI-MedLine.d184.s8	compared	258	265	O
DDI-MedLine.d184.s8	with	267	270	O
DDI-MedLine.d184.s8	saline-treated	272	285	O
DDI-MedLine.d184.s8	controls	287	294	O
DDI-MedLine.d184.s8	.	295	295	O
DDI-MedLine.d184.s9	Increased	0	8	O
DDI-MedLine.d184.s9	D	10	10	O
DDI-MedLine.d184.s9	-like	14	18	O
DDI-MedLine.d184.s9	receptor	20	27	O
DDI-MedLine.d184.s9	sensitivity	29	39	O
DDI-MedLine.d184.s9	appears	41	47	O
DDI-MedLine.d184.s9	to	49	50	O
DDI-MedLine.d184.s9	have	52	55	O
DDI-MedLine.d184.s9	enhanced	57	64	O
DDI-MedLine.d184.s9	the	66	68	O
DDI-MedLine.d184.s9	behavioral	70	79	O
DDI-MedLine.d184.s9	effects	81	87	O
DDI-MedLine.d184.s9	of	89	90	O
DDI-MedLine.d184.s9	amphetamine	92	102	B-drug
DDI-MedLine.d184.s9	,	103	103	O
DDI-MedLine.d184.s9	but	105	107	O
DDI-MedLine.d184.s9	these	109	113	O
DDI-MedLine.d184.s9	effects	115	121	O
DDI-MedLine.d184.s9	were	123	126	O
DDI-MedLine.d184.s9	more	128	131	O
DDI-MedLine.d184.s9	prevalent	133	141	O
DDI-MedLine.d184.s9	in	143	144	O
DDI-MedLine.d184.s9	adolescent	146	155	O
DDI-MedLine.d184.s9	female	157	162	O
DDI-MedLine.d184.s9	rats	164	167	O
DDI-MedLine.d184.s9	compared	169	176	O
DDI-MedLine.d184.s9	with	178	181	O
DDI-MedLine.d184.s9	male	159	162	O
DDI-MedLine.d184.s9	rats	164	167	O
DDI-MedLine.d184.s9	.	192	192	O
DDI-DrugBank.d434.s0	The	0	2	O
DDI-DrugBank.d434.s0	drug	4	7	O
DDI-DrugBank.d434.s0	interaction	9	19	O
DDI-DrugBank.d434.s0	data	21	24	O
DDI-DrugBank.d434.s0	described	26	34	O
DDI-DrugBank.d434.s0	in	36	37	O
DDI-DrugBank.d434.s0	this	39	42	O
DDI-DrugBank.d434.s0	section	44	50	O
DDI-DrugBank.d434.s0	were	52	55	O
DDI-DrugBank.d434.s0	obtained	57	64	O
DDI-DrugBank.d434.s0	from	66	69	O
DDI-DrugBank.d434.s0	controlled	71	80	O
DDI-DrugBank.d434.s0	clinical	82	89	O
DDI-DrugBank.d434.s0	trials	91	96	O
DDI-DrugBank.d434.s0	and	98	100	O
DDI-DrugBank.d434.s0	studies	102	108	O
DDI-DrugBank.d434.s0	involving	110	118	O
DDI-DrugBank.d434.s0	otherwise	120	128	O
DDI-DrugBank.d434.s0	healthy	130	136	O
DDI-DrugBank.d434.s0	adults	138	143	O
DDI-DrugBank.d434.s0	with	145	148	O
DDI-DrugBank.d434.s0	epilepsy	150	157	O
DDI-DrugBank.d434.s0	.	158	158	O
DDI-DrugBank.d434.s1	Use	0	2	O
DDI-DrugBank.d434.s1	in	4	5	O
DDI-DrugBank.d434.s1	Conjunction	7	17	O
DDI-DrugBank.d434.s1	with	19	22	O
DDI-DrugBank.d434.s1	Other	24	28	O
DDI-DrugBank.d434.s1	Antiepileptic	30	42	B-group
DDI-DrugBank.d434.s1	Drugs	44	48	I-group
DDI-DrugBank.d434.s1	:	49	49	O
DDI-DrugBank.d434.s1	The	51	53	O
DDI-DrugBank.d434.s1	addition	55	62	O
DDI-DrugBank.d434.s1	of	64	65	O
DDI-DrugBank.d434.s1	Felbatol	67	74	B-brand
DDI-DrugBank.d434.s1	to	72	73	I-brand
DDI-DrugBank.d434.s1	antiepileptic	80	92	B-group
DDI-DrugBank.d434.s1	drugs	94	98	I-group
DDI-DrugBank.d434.s1	(	100	100	O
DDI-DrugBank.d434.s1	AEDs	101	104	B-group
DDI-DrugBank.d434.s1	)	105	105	O
DDI-DrugBank.d434.s1	affects	107	113	O
DDI-DrugBank.d434.s1	the	115	117	O
DDI-DrugBank.d434.s1	steady-state	119	130	O
DDI-DrugBank.d434.s1	plasma	132	137	O
DDI-DrugBank.d434.s1	concentrations	139	152	O
DDI-DrugBank.d434.s1	of	154	155	O
DDI-DrugBank.d434.s1	AEDs	157	160	B-group
DDI-DrugBank.d434.s1	.	161	161	O
DDI-DrugBank.d434.s2	The	0	2	O
DDI-DrugBank.d434.s2	net	4	6	O
DDI-DrugBank.d434.s2	effect	8	13	O
DDI-DrugBank.d434.s2	of	15	16	O
DDI-DrugBank.d434.s2	these	18	22	O
DDI-DrugBank.d434.s2	interactions	24	35	O
DDI-DrugBank.d434.s2	is	37	38	O
DDI-DrugBank.d434.s2	summarized	40	49	O
DDI-DrugBank.d434.s2	in	51	52	O
DDI-DrugBank.d434.s2	the	54	56	O
DDI-DrugBank.d434.s2	following	58	66	O
DDI-DrugBank.d434.s2	table	68	72	O
DDI-DrugBank.d434.s2	:	73	73	O
DDI-DrugBank.d434.s2	AED	75	77	B-group
DDI-DrugBank.d434.s2	AED	75	77	B-group
DDI-DrugBank.d434.s2	Felbatol	83	90	B-brand
DDI-DrugBank.d434.s3	Coadministered	0	13	O
DDI-DrugBank.d434.s3	Concentration	15	27	O
DDI-DrugBank.d434.s3	Concentration	29	41	O
DDI-DrugBank.d434.s4	Phenytoin	0	8	B-drug
DDI-DrugBank.d434.s5	Valproate	0	8	B-drug
DDI-DrugBank.d434.s5	*	13	13	O
DDI-DrugBank.d434.s5	*	13	13	O
DDI-DrugBank.d434.s6	Carbamazepine	0	12	B-drug
DDI-DrugBank.d434.s6	(	14	14	O
DDI-DrugBank.d434.s6	CBZ	15	17	B-drug
DDI-DrugBank.d434.s6	)	18	18	O
DDI-DrugBank.d434.s7	*	0	0	O
DDI-DrugBank.d434.s7	CBZ	1	3	O
DDI-DrugBank.d434.s7	epoxide	5	11	O
DDI-DrugBank.d434.s8	Phenobarbital	0	12	B-drug
DDI-DrugBank.d434.s9	*	0	0	O
DDI-DrugBank.d434.s9	Not	1	3	O
DDI-DrugBank.d434.s9	administered	5	16	O
DDI-DrugBank.d434.s9	,	17	17	O
DDI-DrugBank.d434.s9	but	19	21	O
DDI-DrugBank.d434.s9	an	23	24	O
DDI-DrugBank.d434.s9	active	26	31	O
DDI-DrugBank.d434.s9	metabolite	33	42	O
DDI-DrugBank.d434.s9	of	44	45	O
DDI-DrugBank.d434.s9	carbamazepine	47	59	B-drug
DDI-DrugBank.d434.s9	.	60	60	O
DDI-DrugBank.d434.s10	*	0	0	O
DDI-DrugBank.d434.s10	*	1	1	O
DDI-DrugBank.d434.s10	No	2	3	O
DDI-DrugBank.d434.s10	significant	5	15	O
DDI-DrugBank.d434.s10	effect	17	22	O
DDI-DrugBank.d434.s10	.	23	23	O
DDI-DrugBank.d434.s11	Specific	0	7	O
DDI-DrugBank.d434.s11	Effects	9	15	O
DDI-DrugBank.d434.s11	of	17	18	O
DDI-DrugBank.d434.s11	Felbatol	20	27	B-brand
DDI-DrugBank.d434.s11	on	30	31	O
DDI-DrugBank.d434.s11	Other	33	37	O
DDI-DrugBank.d434.s11	Antiepileptic	39	51	B-group
DDI-DrugBank.d434.s11	Drugs	53	57	I-group
DDI-DrugBank.d434.s11	Phenytoin	59	67	B-drug
DDI-DrugBank.d434.s11	:	68	68	O
DDI-DrugBank.d434.s11	Felbatol	70	77	B-brand
DDI-DrugBank.d434.s11	causes	80	85	O
DDI-DrugBank.d434.s11	an	87	88	O
DDI-DrugBank.d434.s11	increase	90	97	O
DDI-DrugBank.d434.s11	in	90	91	O
DDI-DrugBank.d434.s11	steady-state	102	113	O
DDI-DrugBank.d434.s11	phenytoin	115	123	B-drug
DDI-DrugBank.d434.s11	plasma	125	130	O
DDI-DrugBank.d434.s11	concentrations	132	145	O
DDI-DrugBank.d434.s11	.	146	146	O
DDI-DrugBank.d434.s12	In	0	1	O
DDI-DrugBank.d434.s12	10	3	4	O
DDI-DrugBank.d434.s12	otherwise	6	14	O
DDI-DrugBank.d434.s12	healthy	16	22	O
DDI-DrugBank.d434.s12	subjects	24	31	O
DDI-DrugBank.d434.s12	with	33	36	O
DDI-DrugBank.d434.s12	epilepsy	38	45	O
DDI-DrugBank.d434.s12	ingesting	47	55	O
DDI-DrugBank.d434.s12	phenytoin	57	65	B-drug
DDI-DrugBank.d434.s12	,	66	66	O
DDI-DrugBank.d434.s12	the	68	70	O
DDI-DrugBank.d434.s12	steadystate	72	82	O
DDI-DrugBank.d434.s12	trough	84	89	O
DDI-DrugBank.d434.s12	(	91	91	O
DDI-DrugBank.d434.s12	Cmin	92	95	O
DDI-DrugBank.d434.s12	)	96	96	O
DDI-DrugBank.d434.s12	phenytoin	98	106	B-drug
DDI-DrugBank.d434.s12	plasma	108	113	O
DDI-DrugBank.d434.s12	concentration	115	127	O
DDI-DrugBank.d434.s12	was	129	131	O
DDI-DrugBank.d434.s12	17	133	134	O
DDI-DrugBank.d434.s12	5	136	136	O
DDI-DrugBank.d434.s12	micrograms/mL	138	150	O
DDI-DrugBank.d434.s12	.	151	151	O
DDI-DrugBank.d434.s13	The	0	2	O
DDI-DrugBank.d434.s13	steady-state	4	15	O
DDI-DrugBank.d434.s13	Cmin	17	20	O
DDI-DrugBank.d434.s13	increased	22	30	O
DDI-DrugBank.d434.s13	to	32	33	O
DDI-DrugBank.d434.s13	21	35	36	O
DDI-DrugBank.d434.s13	5	38	38	O
DDI-DrugBank.d434.s13	micrograms/mL	40	52	O
DDI-DrugBank.d434.s13	when	54	57	O
DDI-DrugBank.d434.s13	1200	59	62	O
DDI-DrugBank.d434.s13	mg/day	64	69	O
DDI-DrugBank.d434.s13	of	71	72	O
DDI-DrugBank.d434.s13	felbamate	74	82	B-drug
DDI-DrugBank.d434.s13	was	84	86	O
DDI-DrugBank.d434.s13	coadministered	88	101	O
DDI-DrugBank.d434.s13	.	102	102	O
DDI-DrugBank.d434.s14	Increasing	0	9	O
DDI-DrugBank.d434.s14	the	11	13	O
DDI-DrugBank.d434.s14	felbamate	15	23	B-drug
DDI-DrugBank.d434.s14	dose	25	28	O
DDI-DrugBank.d434.s14	to	30	31	O
DDI-DrugBank.d434.s14	1800	33	36	O
DDI-DrugBank.d434.s14	mg/day	38	43	O
DDI-DrugBank.d434.s14	in	45	46	O
DDI-DrugBank.d434.s14	six	48	50	O
DDI-DrugBank.d434.s14	of	52	53	O
DDI-DrugBank.d434.s14	these	55	59	O
DDI-DrugBank.d434.s14	subjects	61	68	O
DDI-DrugBank.d434.s14	increased	70	78	O
DDI-DrugBank.d434.s14	the	80	82	O
DDI-DrugBank.d434.s14	steady-state	84	95	O
DDI-DrugBank.d434.s14	phenytoin	97	105	B-drug
DDI-DrugBank.d434.s14	Cmin	107	110	O
DDI-DrugBank.d434.s14	to	102	103	I-drug
DDI-DrugBank.d434.s14	25	115	116	O
DDI-DrugBank.d434.s14	7	118	118	O
DDI-DrugBank.d434.s14	micrograms/mL	120	132	O
DDI-DrugBank.d434.s14	.	133	133	O
DDI-DrugBank.d434.s15	In	0	1	O
DDI-DrugBank.d434.s15	order	3	7	O
DDI-DrugBank.d434.s15	to	9	10	O
DDI-DrugBank.d434.s15	maintain	12	19	O
DDI-DrugBank.d434.s15	phenytoin	21	29	B-drug
DDI-DrugBank.d434.s15	levels	31	36	O
DDI-DrugBank.d434.s15	,	37	37	O
DDI-DrugBank.d434.s15	limit	39	43	O
DDI-DrugBank.d434.s15	adverse	45	51	O
DDI-DrugBank.d434.s15	experiences	53	63	O
DDI-DrugBank.d434.s15	,	64	64	O
DDI-DrugBank.d434.s15	and	66	68	O
DDI-DrugBank.d434.s15	achieve	70	76	O
DDI-DrugBank.d434.s15	the	78	80	O
DDI-DrugBank.d434.s15	felbamate	82	90	B-drug
DDI-DrugBank.d434.s15	dose	92	95	O
DDI-DrugBank.d434.s15	of	97	98	O
DDI-DrugBank.d434.s15	3600	100	103	O
DDI-DrugBank.d434.s15	mg/day	105	110	O
DDI-DrugBank.d434.s15	,	111	111	O
DDI-DrugBank.d434.s15	a	109	109	O
DDI-DrugBank.d434.s15	phenytoin	115	123	B-drug
DDI-DrugBank.d434.s15	dose	125	128	O
DDI-DrugBank.d434.s15	reduction	130	138	O
DDI-DrugBank.d434.s15	of	140	141	O
DDI-DrugBank.d434.s15	approximately	143	155	O
DDI-DrugBank.d434.s15	40	157	158	O
DDI-DrugBank.d434.s15	%	159	159	O
DDI-DrugBank.d434.s15	was	161	163	O
DDI-DrugBank.d434.s15	necessary	165	173	O
DDI-DrugBank.d434.s15	for	175	177	O
DDI-DrugBank.d434.s15	eight	179	183	O
DDI-DrugBank.d434.s15	of	185	186	O
DDI-DrugBank.d434.s15	these	188	192	O
DDI-DrugBank.d434.s15	10	194	195	O
DDI-DrugBank.d434.s15	subjects	197	204	O
DDI-DrugBank.d434.s15	.	205	205	O
DDI-DrugBank.d434.s16	In	0	1	O
DDI-DrugBank.d434.s16	a	3	3	O
DDI-DrugBank.d434.s16	controlled	5	14	O
DDI-DrugBank.d434.s16	clinical	16	23	O
DDI-DrugBank.d434.s16	trial	25	29	O
DDI-DrugBank.d434.s16	,	30	30	O
DDI-DrugBank.d434.s16	a	28	28	O
DDI-DrugBank.d434.s16	20	34	35	O
DDI-DrugBank.d434.s16	%	36	36	O
DDI-DrugBank.d434.s16	reduction	38	46	O
DDI-DrugBank.d434.s16	of	48	49	O
DDI-DrugBank.d434.s16	the	51	53	O
DDI-DrugBank.d434.s16	phenytoin	55	63	B-drug
DDI-DrugBank.d434.s16	dose	65	68	O
DDI-DrugBank.d434.s16	at	70	71	O
DDI-DrugBank.d434.s16	the	73	75	O
DDI-DrugBank.d434.s16	initiation	77	86	O
DDI-DrugBank.d434.s16	of	88	89	O
DDI-DrugBank.d434.s16	Felbatol	91	98	B-brand
DDI-DrugBank.d434.s16	therapy	101	107	O
DDI-DrugBank.d434.s16	resulted	109	116	O
DDI-DrugBank.d434.s16	in	118	119	O
DDI-DrugBank.d434.s16	phenytoin	121	129	B-drug
DDI-DrugBank.d434.s16	levels	131	136	O
DDI-DrugBank.d434.s16	comparable	138	147	O
DDI-DrugBank.d434.s16	to	126	127	I-drug
DDI-DrugBank.d434.s16	those	152	156	O
DDI-DrugBank.d434.s16	prior	158	162	O
DDI-DrugBank.d434.s16	to	149	150	O
DDI-DrugBank.d434.s16	Felbatol	167	174	B-brand
DDI-DrugBank.d434.s16	administration	177	190	O
DDI-DrugBank.d434.s16	.	191	191	O
DDI-DrugBank.d434.s17	Carbamazepine	0	12	B-drug
DDI-DrugBank.d434.s17	:	13	13	O
DDI-DrugBank.d434.s17	Felbatol	15	22	B-brand
DDI-DrugBank.d434.s17	causes	25	30	O
DDI-DrugBank.d434.s17	a	32	32	O
DDI-DrugBank.d434.s17	decrease	34	41	O
DDI-DrugBank.d434.s17	in	43	44	O
DDI-DrugBank.d434.s17	the	46	48	O
DDI-DrugBank.d434.s17	steady-state	50	61	O
DDI-DrugBank.d434.s17	carbamazepine	63	75	B-drug
DDI-DrugBank.d434.s17	plasma	77	82	O
DDI-DrugBank.d434.s17	concentrations	84	97	O
DDI-DrugBank.d434.s17	and	99	101	O
DDI-DrugBank.d434.s17	an	99	100	O
DDI-DrugBank.d434.s17	increase	106	113	O
DDI-DrugBank.d434.s17	in	106	107	O
DDI-DrugBank.d434.s17	the	118	120	O
DDI-DrugBank.d434.s17	steady-state	122	133	O
DDI-DrugBank.d434.s17	carbamazepine	135	147	B-drug_n
DDI-DrugBank.d434.s17	epoxide	149	155	I-drug_n
DDI-DrugBank.d434.s17	plasma	157	162	O
DDI-DrugBank.d434.s17	concentration	164	176	O
DDI-DrugBank.d434.s17	.	177	177	O
DDI-DrugBank.d434.s18	In	0	1	O
DDI-DrugBank.d434.s18	nine	3	6	O
DDI-DrugBank.d434.s18	otherwise	8	16	O
DDI-DrugBank.d434.s18	healthy	18	24	O
DDI-DrugBank.d434.s18	subjects	26	33	O
DDI-DrugBank.d434.s18	with	35	38	O
DDI-DrugBank.d434.s18	epilepsy	40	47	O
DDI-DrugBank.d434.s18	ingesting	49	57	O
DDI-DrugBank.d434.s18	carbamazepine	59	71	B-drug
DDI-DrugBank.d434.s18	,	72	72	O
DDI-DrugBank.d434.s18	the	74	76	O
DDI-DrugBank.d434.s18	steady-state	78	89	O
DDI-DrugBank.d434.s18	trough	91	96	O
DDI-DrugBank.d434.s18	(	98	98	O
DDI-DrugBank.d434.s18	Cmin	99	102	O
DDI-DrugBank.d434.s18	)	103	103	O
DDI-DrugBank.d434.s18	carbamazepine	105	117	B-drug
DDI-DrugBank.d434.s18	concentration	119	131	O
DDI-DrugBank.d434.s18	was	133	135	O
DDI-DrugBank.d434.s18	8	137	137	O
DDI-DrugBank.d434.s18	2	139	139	O
DDI-DrugBank.d434.s18	micrograms/mL	141	153	O
DDI-DrugBank.d434.s18	.	154	154	O
DDI-DrugBank.d434.s19	The	0	2	O
DDI-DrugBank.d434.s19	carbamazepine	4	16	B-drug
DDI-DrugBank.d434.s19	steady-state	18	29	O
DDI-DrugBank.d434.s19	Cmin	31	34	O
DDI-DrugBank.d434.s19	decreased	36	44	O
DDI-DrugBank.d434.s19	31	46	47	O
DDI-DrugBank.d434.s19	%	48	48	O
DDI-DrugBank.d434.s19	to	50	51	O
DDI-DrugBank.d434.s19	5	53	53	O
DDI-DrugBank.d434.s19	1	47	47	O
DDI-DrugBank.d434.s19	micrograms/mL	57	69	O
DDI-DrugBank.d434.s19	when	71	74	O
DDI-DrugBank.d434.s19	felbamate	76	84	B-drug
DDI-DrugBank.d434.s19	(	86	86	O
DDI-DrugBank.d434.s19	3000	87	90	O
DDI-DrugBank.d434.s19	mg/day	92	97	O
DDI-DrugBank.d434.s19	,	98	98	O
DDI-DrugBank.d434.s19	divided	100	106	O
DDI-DrugBank.d434.s19	into	108	111	O
DDI-DrugBank.d434.s19	three	113	117	O
DDI-DrugBank.d434.s19	doses	119	123	O
DDI-DrugBank.d434.s19	)	124	124	O
DDI-DrugBank.d434.s19	was	126	128	O
DDI-DrugBank.d434.s19	coadministered	130	143	O
DDI-DrugBank.d434.s19	.	144	144	O
DDI-DrugBank.d434.s20	Carbamazepine	0	12	B-drug_n
DDI-DrugBank.d434.s20	epoxide	14	20	I-drug_n
DDI-DrugBank.d434.s20	steady-state	22	33	O
DDI-DrugBank.d434.s20	Cmin	35	38	O
DDI-DrugBank.d434.s20	concentrations	40	53	O
DDI-DrugBank.d434.s20	increased	55	63	O
DDI-DrugBank.d434.s20	57	65	66	O
DDI-DrugBank.d434.s20	%	67	67	O
DDI-DrugBank.d434.s20	from	69	72	O
DDI-DrugBank.d434.s20	1.0	74	76	O
DDI-DrugBank.d434.s20	0.3	78	80	O
DDI-DrugBank.d434.s20	to	82	83	O
DDI-DrugBank.d434.s20	1.6	85	87	O
DDI-DrugBank.d434.s20	0.4	89	91	O
DDI-DrugBank.d434.s20	micrograms/mL	93	105	O
DDI-DrugBank.d434.s20	with	107	110	O
DDI-DrugBank.d434.s20	the	112	114	O
DDI-DrugBank.d434.s20	addition	116	123	O
DDI-DrugBank.d434.s20	of	125	126	O
DDI-DrugBank.d434.s20	felbamate	128	136	B-drug
DDI-DrugBank.d434.s20	.	137	137	O
DDI-DrugBank.d434.s21	In	0	1	O
DDI-DrugBank.d434.s21	clinical	3	10	O
DDI-DrugBank.d434.s21	trials	12	17	O
DDI-DrugBank.d434.s21	,	18	18	O
DDI-DrugBank.d434.s21	similar	20	26	O
DDI-DrugBank.d434.s21	changes	28	34	O
DDI-DrugBank.d434.s21	in	36	37	O
DDI-DrugBank.d434.s21	carbamazepine	39	51	B-drug
DDI-DrugBank.d434.s21	and	53	55	O
DDI-DrugBank.d434.s21	carbamazepine	57	69	B-drug_n
DDI-DrugBank.d434.s21	epoxide	71	77	I-drug_n
DDI-DrugBank.d434.s21	were	79	82	O
DDI-DrugBank.d434.s21	seen	84	87	O
DDI-DrugBank.d434.s21	.	88	88	O
DDI-DrugBank.d434.s22	Valproate	0	8	B-drug
DDI-DrugBank.d434.s22	:	9	9	O
DDI-DrugBank.d434.s22	Felbatol	11	18	B-brand
DDI-DrugBank.d434.s22	causes	21	26	O
DDI-DrugBank.d434.s22	an	28	29	O
DDI-DrugBank.d434.s22	increase	31	38	O
DDI-DrugBank.d434.s22	in	40	41	O
DDI-DrugBank.d434.s22	steady-state	43	54	O
DDI-DrugBank.d434.s22	valproate	56	64	B-drug
DDI-DrugBank.d434.s22	concentrations	66	79	O
DDI-DrugBank.d434.s22	.	80	80	O
DDI-DrugBank.d434.s23	In	0	1	O
DDI-DrugBank.d434.s23	four	3	6	O
DDI-DrugBank.d434.s23	subjects	8	15	O
DDI-DrugBank.d434.s23	with	17	20	O
DDI-DrugBank.d434.s23	epilepsy	22	29	O
DDI-DrugBank.d434.s23	ingesting	31	39	O
DDI-DrugBank.d434.s23	valproate	41	49	B-drug
DDI-DrugBank.d434.s23	,	50	50	O
DDI-DrugBank.d434.s23	the	52	54	O
DDI-DrugBank.d434.s23	steady-state	56	67	O
DDI-DrugBank.d434.s23	trough	69	74	O
DDI-DrugBank.d434.s23	(	76	76	O
DDI-DrugBank.d434.s23	Cmin	77	80	O
DDI-DrugBank.d434.s23	)	81	81	O
DDI-DrugBank.d434.s23	valproate	83	91	B-drug
DDI-DrugBank.d434.s23	plasma	93	98	O
DDI-DrugBank.d434.s23	concentration	100	112	O
DDI-DrugBank.d434.s23	was	114	116	O
DDI-DrugBank.d434.s23	63	118	119	O
DDI-DrugBank.d434.s23	16	121	122	O
DDI-DrugBank.d434.s23	micrograms/mL	124	136	O
DDI-DrugBank.d434.s23	.	137	137	O
DDI-DrugBank.d434.s24	The	0	2	O
DDI-DrugBank.d434.s24	steady-state	4	15	O
DDI-DrugBank.d434.s24	Cmin	17	20	O
DDI-DrugBank.d434.s24	increased	22	30	O
DDI-DrugBank.d434.s24	to	32	33	O
DDI-DrugBank.d434.s24	78	35	36	O
DDI-DrugBank.d434.s24	14	38	39	O
DDI-DrugBank.d434.s24	micrograms/mL	41	53	O
DDI-DrugBank.d434.s24	when	55	58	O
DDI-DrugBank.d434.s24	1200	60	63	O
DDI-DrugBank.d434.s24	mg/day	65	70	O
DDI-DrugBank.d434.s24	of	72	73	O
DDI-DrugBank.d434.s24	felbamate	75	83	B-drug
DDI-DrugBank.d434.s24	was	85	87	O
DDI-DrugBank.d434.s24	coadministered	89	102	O
DDI-DrugBank.d434.s24	.	103	103	O
DDI-DrugBank.d434.s25	Increasing	0	9	O
DDI-DrugBank.d434.s25	the	11	13	O
DDI-DrugBank.d434.s25	felbamate	15	23	B-drug
DDI-DrugBank.d434.s25	dose	25	28	O
DDI-DrugBank.d434.s25	to	30	31	O
DDI-DrugBank.d434.s25	2400	33	36	O
DDI-DrugBank.d434.s25	mg/day	38	43	O
DDI-DrugBank.d434.s25	increased	45	53	O
DDI-DrugBank.d434.s25	the	55	57	O
DDI-DrugBank.d434.s25	steadystate	59	69	O
DDI-DrugBank.d434.s25	valproate	71	79	B-drug
DDI-DrugBank.d434.s25	Cmin	81	84	O
DDI-DrugBank.d434.s25	to	86	87	O
DDI-DrugBank.d434.s25	96	89	90	O
DDI-DrugBank.d434.s25	25	92	93	O
DDI-DrugBank.d434.s25	micrograms/mL	95	107	O
DDI-DrugBank.d434.s25	.	108	108	O
DDI-DrugBank.d434.s26	Corresponding	0	12	O
DDI-DrugBank.d434.s26	values	14	19	O
DDI-DrugBank.d434.s26	for	21	23	O
DDI-DrugBank.d434.s26	free	25	28	O
DDI-DrugBank.d434.s26	valproate	30	38	B-drug
DDI-DrugBank.d434.s26	Cmin	40	43	O
DDI-DrugBank.d434.s26	concentrations	45	58	O
DDI-DrugBank.d434.s26	were	60	63	O
DDI-DrugBank.d434.s26	7	65	65	O
DDI-DrugBank.d434.s26	3	67	67	O
DDI-DrugBank.d434.s26	,	68	68	O
DDI-DrugBank.d434.s26	9	70	70	O
DDI-DrugBank.d434.s26	4	72	72	O
DDI-DrugBank.d434.s26	,	68	68	O
DDI-DrugBank.d434.s26	and	75	77	O
DDI-DrugBank.d434.s26	11	79	80	O
DDI-DrugBank.d434.s26	6	82	82	O
DDI-DrugBank.d434.s26	micrograms/mL	84	96	O
DDI-DrugBank.d434.s26	for	98	100	O
DDI-DrugBank.d434.s26	0	102	102	O
DDI-DrugBank.d434.s26	,	103	103	O
DDI-DrugBank.d434.s26	1200	105	108	O
DDI-DrugBank.d434.s26	,	103	103	O
DDI-DrugBank.d434.s26	and	111	113	O
DDI-DrugBank.d434.s26	2400	115	118	O
DDI-DrugBank.d434.s26	mg/day	120	125	O
DDI-DrugBank.d434.s26	Felbatol	127	134	B-brand
DDI-DrugBank.d434.s26	,	136	136	O
DDI-DrugBank.d434.s26	respectively	138	149	O
DDI-DrugBank.d434.s26	.	150	150	O
DDI-DrugBank.d434.s27	The	0	2	O
DDI-DrugBank.d434.s27	ratios	4	9	O
DDI-DrugBank.d434.s27	of	11	12	O
DDI-DrugBank.d434.s27	the	14	16	O
DDI-DrugBank.d434.s27	AUCs	18	21	O
DDI-DrugBank.d434.s27	of	23	24	O
DDI-DrugBank.d434.s27	unbound	26	32	O
DDI-DrugBank.d434.s27	valproate	34	42	B-drug
DDI-DrugBank.d434.s27	to	44	45	O
DDI-DrugBank.d434.s27	the	47	49	O
DDI-DrugBank.d434.s27	AUCs	51	54	O
DDI-DrugBank.d434.s27	of	56	57	O
DDI-DrugBank.d434.s27	the	47	49	O
DDI-DrugBank.d434.s27	total	63	67	O
DDI-DrugBank.d434.s27	valproate	69	77	B-drug
DDI-DrugBank.d434.s27	were	79	82	O
DDI-DrugBank.d434.s27	11.1	84	87	O
DDI-DrugBank.d434.s27	%	89	89	O
DDI-DrugBank.d434.s27	,	90	90	O
DDI-DrugBank.d434.s27	13.0	92	95	O
DDI-DrugBank.d434.s27	%	89	89	O
DDI-DrugBank.d434.s27	,	90	90	O
DDI-DrugBank.d434.s27	and	99	101	O
DDI-DrugBank.d434.s27	11.5	103	106	O
DDI-DrugBank.d434.s27	%	89	89	O
DDI-DrugBank.d434.s27	,	90	90	O
DDI-DrugBank.d434.s27	with	110	113	O
DDI-DrugBank.d434.s27	coadministration	115	130	O
DDI-DrugBank.d434.s27	of	132	133	O
DDI-DrugBank.d434.s27	0	135	135	O
DDI-DrugBank.d434.s27	,	136	136	O
DDI-DrugBank.d434.s27	1200	138	141	O
DDI-DrugBank.d434.s27	,	136	136	O
DDI-DrugBank.d434.s27	and	144	146	O
DDI-DrugBank.d434.s27	2400	148	151	O
DDI-DrugBank.d434.s27	mg/day	153	158	O
DDI-DrugBank.d434.s27	of	132	133	O
DDI-DrugBank.d434.s27	Felbatol	163	170	B-brand
DDI-DrugBank.d434.s27	,	142	142	O
DDI-DrugBank.d434.s27	respectively	174	185	O
DDI-DrugBank.d434.s27	.	186	186	O
DDI-DrugBank.d434.s28	Phenobarbital	0	12	B-drug
DDI-DrugBank.d434.s28	:	13	13	O
DDI-DrugBank.d434.s28	Coadministration	15	30	O
DDI-DrugBank.d434.s28	of	32	33	O
DDI-DrugBank.d434.s28	felbamate	35	43	B-drug
DDI-DrugBank.d434.s28	with	45	48	O
DDI-DrugBank.d434.s28	phenobarbital	50	62	B-drug
DDI-DrugBank.d434.s28	causes	64	69	O
DDI-DrugBank.d434.s28	an	71	72	O
DDI-DrugBank.d434.s28	increase	74	81	O
DDI-DrugBank.d434.s28	in	74	75	O
DDI-DrugBank.d434.s28	phenobarbital	86	98	B-drug
DDI-DrugBank.d434.s28	plasma	100	105	O
DDI-DrugBank.d434.s28	concentrations	107	120	O
DDI-DrugBank.d434.s28	,	121	121	O
DDI-DrugBank.d434.s28	In	123	124	O
DDI-DrugBank.d434.s28	12	126	127	O
DDI-DrugBank.d434.s28	otherwise	129	137	O
DDI-DrugBank.d434.s28	healthy	139	145	O
DDI-DrugBank.d434.s28	male	147	150	O
DDI-DrugBank.d434.s28	volunteers	152	161	O
DDI-DrugBank.d434.s28	ingesting	163	171	O
DDI-DrugBank.d434.s28	phenobarbital	173	185	B-drug
DDI-DrugBank.d434.s28	,	186	186	O
DDI-DrugBank.d434.s28	the	188	190	O
DDI-DrugBank.d434.s28	steady-state	192	203	O
DDI-DrugBank.d434.s28	trough	205	210	O
DDI-DrugBank.d434.s28	(	212	212	O
DDI-DrugBank.d434.s28	Cmin	213	216	O
DDI-DrugBank.d434.s28	)	217	217	O
DDI-DrugBank.d434.s28	phenobarbital	219	231	B-drug
DDI-DrugBank.d434.s28	concentration	233	245	O
DDI-DrugBank.d434.s28	was	247	249	O
DDI-DrugBank.d434.s28	14.2	251	254	O
DDI-DrugBank.d434.s28	micrograms/mL	256	268	O
DDI-DrugBank.d434.s28	.	253	253	O
DDI-DrugBank.d434.s29	The	0	2	O
DDI-DrugBank.d434.s29	steady-state	4	15	O
DDI-DrugBank.d434.s29	Cmin	17	20	O
DDI-DrugBank.d434.s29	concentration	22	34	O
DDI-DrugBank.d434.s29	increased	36	44	O
DDI-DrugBank.d434.s29	to	46	47	O
DDI-DrugBank.d434.s29	17.8	49	52	O
DDI-DrugBank.d434.s29	micrograms/mL	54	66	O
DDI-DrugBank.d434.s29	when	68	71	O
DDI-DrugBank.d434.s29	2400	73	76	O
DDI-DrugBank.d434.s29	mg/day	78	83	O
DDI-DrugBank.d434.s29	of	85	86	O
DDI-DrugBank.d434.s29	felbamate	88	96	B-drug
DDI-DrugBank.d434.s29	was	98	100	O
DDI-DrugBank.d434.s29	coadministered	102	115	O
DDI-DrugBank.d434.s29	for	117	119	O
DDI-DrugBank.d434.s29	one	121	123	O
DDI-DrugBank.d434.s29	week	125	128	O
DDI-DrugBank.d434.s29	.	129	129	O
DDI-DrugBank.d434.s30	Effects	0	6	O
DDI-DrugBank.d434.s30	of	8	9	O
DDI-DrugBank.d434.s30	Other	11	15	O
DDI-DrugBank.d434.s30	Antiepileptic	17	29	B-group
DDI-DrugBank.d434.s30	Drugs	31	35	I-group
DDI-DrugBank.d434.s30	on	37	38	O
DDI-DrugBank.d434.s30	Felbatol	40	47	B-brand
DDI-DrugBank.d434.s30	Phenytoin	50	58	B-drug
DDI-DrugBank.d434.s30	:	59	59	O
DDI-DrugBank.d434.s30	Phenytoin	61	69	B-drug
DDI-DrugBank.d434.s30	causes	71	76	O
DDI-DrugBank.d434.s30	an	78	79	O
DDI-DrugBank.d434.s30	approximate	81	91	O
DDI-DrugBank.d434.s30	doubling	93	100	O
DDI-DrugBank.d434.s30	of	102	103	O
DDI-DrugBank.d434.s30	the	105	107	O
DDI-DrugBank.d434.s30	clearance	109	117	O
DDI-DrugBank.d434.s30	of	102	103	O
DDI-DrugBank.d434.s30	Felbatol	122	129	B-brand
DDI-DrugBank.d434.s30	(	132	132	O
DDI-DrugBank.d434.s30	felbamate	133	141	B-drug
DDI-DrugBank.d434.s30	)	142	142	O
DDI-DrugBank.d434.s30	at	126	127	I-brand
DDI-DrugBank.d434.s30	steady	147	152	O
DDI-DrugBank.d434.s30	state	154	158	O
DDI-DrugBank.d434.s30	and	160	162	O
DDI-DrugBank.d434.s30	,	163	163	O
DDI-DrugBank.d434.s30	therefore	165	173	O
DDI-DrugBank.d434.s30	,	163	163	O
DDI-DrugBank.d434.s30	the	165	167	O
DDI-DrugBank.d434.s30	addition	180	187	O
DDI-DrugBank.d434.s30	of	189	190	O
DDI-DrugBank.d434.s30	phenytoin	192	200	B-drug
DDI-DrugBank.d434.s30	causes	202	207	O
DDI-DrugBank.d434.s30	an	209	210	O
DDI-DrugBank.d434.s30	approximate	212	222	O
DDI-DrugBank.d434.s30	45	224	225	O
DDI-DrugBank.d434.s30	%	226	226	O
DDI-DrugBank.d434.s30	decrease	228	235	O
DDI-DrugBank.d434.s30	in	237	238	O
DDI-DrugBank.d434.s30	the	240	242	O
DDI-DrugBank.d434.s30	steady-state	244	255	O
DDI-DrugBank.d434.s30	trough	257	262	O
DDI-DrugBank.d434.s30	concentrations	264	277	O
DDI-DrugBank.d434.s30	of	279	280	O
DDI-DrugBank.d434.s30	Felbatol	282	289	B-brand
DDI-DrugBank.d434.s30	as	292	293	O
DDI-DrugBank.d434.s30	compared	295	302	O
DDI-DrugBank.d434.s30	to	287	288	I-brand
DDI-DrugBank.d434.s30	the	307	309	O
DDI-DrugBank.d434.s30	same	311	314	O
DDI-DrugBank.d434.s30	dose	316	319	O
DDI-DrugBank.d434.s30	of	279	280	O
DDI-DrugBank.d434.s30	Felbatol	282	289	B-brand
DDI-DrugBank.d434.s30	given	334	338	O
DDI-DrugBank.d434.s30	as	292	293	O
DDI-DrugBank.d434.s30	monotherapy	343	353	O
DDI-DrugBank.d434.s30	.	354	354	O
DDI-DrugBank.d434.s31	Carbamazepine	0	12	B-drug
DDI-DrugBank.d434.s31	:	13	13	O
DDI-DrugBank.d434.s31	Carbamazepine	15	27	B-drug
DDI-DrugBank.d434.s31	causes	29	34	O
DDI-DrugBank.d434.s31	an	36	37	O
DDI-DrugBank.d434.s31	approximate	39	49	O
DDI-DrugBank.d434.s31	50	51	52	O
DDI-DrugBank.d434.s31	%	53	53	O
DDI-DrugBank.d434.s31	increase	55	62	O
DDI-DrugBank.d434.s31	in	64	65	O
DDI-DrugBank.d434.s31	the	67	69	O
DDI-DrugBank.d434.s31	clearance	71	79	O
DDI-DrugBank.d434.s31	of	81	82	O
DDI-DrugBank.d434.s31	Felbatol	84	91	B-brand
DDI-DrugBank.d434.s31	at	88	89	I-brand
DDI-DrugBank.d434.s31	steady	97	102	O
DDI-DrugBank.d434.s31	state	104	108	O
DDI-DrugBank.d434.s31	and	110	112	O
DDI-DrugBank.d434.s31	,	113	113	O
DDI-DrugBank.d434.s31	therefore	115	123	O
DDI-DrugBank.d434.s31	,	113	113	O
DDI-DrugBank.d434.s31	the	115	117	O
DDI-DrugBank.d434.s31	addition	130	137	O
DDI-DrugBank.d434.s31	of	139	140	O
DDI-DrugBank.d434.s31	carbamazepine	142	154	B-drug
DDI-DrugBank.d434.s31	results	156	162	O
DDI-DrugBank.d434.s31	in	152	153	I-drug
DDI-DrugBank.d434.s31	an	167	168	O
DDI-DrugBank.d434.s31	approximate	170	180	O
DDI-DrugBank.d434.s31	40	182	183	O
DDI-DrugBank.d434.s31	%	184	184	O
DDI-DrugBank.d434.s31	decrease	186	193	O
DDI-DrugBank.d434.s31	in	195	196	O
DDI-DrugBank.d434.s31	the	198	200	O
DDI-DrugBank.d434.s31	steady-state	202	213	O
DDI-DrugBank.d434.s31	trough	215	220	O
DDI-DrugBank.d434.s31	concentrations	222	235	O
DDI-DrugBank.d434.s31	of	237	238	O
DDI-DrugBank.d434.s31	Felbatol	240	247	B-brand
DDI-DrugBank.d434.s31	as	250	251	O
DDI-DrugBank.d434.s31	compared	253	260	O
DDI-DrugBank.d434.s31	to	245	246	I-brand
DDI-DrugBank.d434.s31	the	265	267	O
DDI-DrugBank.d434.s31	same	269	272	O
DDI-DrugBank.d434.s31	dose	274	277	O
DDI-DrugBank.d434.s31	of	237	238	O
DDI-DrugBank.d434.s31	Felbatol	240	247	B-brand
DDI-DrugBank.d434.s31	given	292	296	O
DDI-DrugBank.d434.s31	as	298	299	O
DDI-DrugBank.d434.s31	monotherapy	301	311	O
DDI-DrugBank.d434.s31	.	312	312	O
DDI-DrugBank.d434.s32	Valproate	0	8	B-drug
DDI-DrugBank.d434.s32	:	9	9	O
DDI-DrugBank.d434.s32	Available	11	19	O
DDI-DrugBank.d434.s32	data	21	24	O
DDI-DrugBank.d434.s32	suggest	26	32	O
DDI-DrugBank.d434.s32	that	34	37	O
DDI-DrugBank.d434.s32	there	39	43	O
DDI-DrugBank.d434.s32	is	45	46	O
DDI-DrugBank.d434.s32	no	48	49	O
DDI-DrugBank.d434.s32	significant	51	61	O
DDI-DrugBank.d434.s32	effect	63	68	O
DDI-DrugBank.d434.s32	of	70	71	O
DDI-DrugBank.d434.s32	valproate	73	81	B-drug
DDI-DrugBank.d434.s32	on	83	84	O
DDI-DrugBank.d434.s32	the	86	88	O
DDI-DrugBank.d434.s32	clearance	90	98	O
DDI-DrugBank.d434.s32	of	100	101	O
DDI-DrugBank.d434.s32	Felbatol	103	110	B-brand
DDI-DrugBank.d434.s32	at	107	108	I-brand
DDI-DrugBank.d434.s32	steady	116	121	O
DDI-DrugBank.d434.s32	state	123	127	O
DDI-DrugBank.d434.s32	,	128	128	O
DDI-DrugBank.d434.s32	Therefore	130	138	O
DDI-DrugBank.d434.s32	,	128	128	O
DDI-DrugBank.d434.s32	the	141	143	O
DDI-DrugBank.d434.s32	addition	145	152	O
DDI-DrugBank.d434.s32	of	154	155	O
DDI-DrugBank.d434.s32	valproate	157	165	B-drug
DDI-DrugBank.d434.s32	is	167	168	O
DDI-DrugBank.d434.s32	not	170	172	O
DDI-DrugBank.d434.s32	expected	174	181	O
DDI-DrugBank.d434.s32	to	183	184	O
DDI-DrugBank.d434.s32	cause	186	190	O
DDI-DrugBank.d434.s32	a	163	163	O
DDI-DrugBank.d434.s32	clinically	194	203	O
DDI-DrugBank.d434.s32	important	205	213	O
DDI-DrugBank.d434.s32	effect	215	220	O
DDI-DrugBank.d434.s32	on	222	223	O
DDI-DrugBank.d434.s32	Felbatol	225	232	B-brand
DDI-DrugBank.d434.s32	(	235	235	O
DDI-DrugBank.d434.s32	felbamate	236	244	B-drug
DDI-DrugBank.d434.s32	)	245	245	O
DDI-DrugBank.d434.s32	plasma	247	252	O
DDI-DrugBank.d434.s32	concentrations	254	267	O
DDI-DrugBank.d434.s32	.	268	268	O
DDI-DrugBank.d434.s33	Phenobarbital	0	12	B-drug
DDI-DrugBank.d434.s33	:	13	13	O
DDI-DrugBank.d434.s33	It	15	16	O
DDI-DrugBank.d434.s33	appears	18	24	O
DDI-DrugBank.d434.s33	that	26	29	O
DDI-DrugBank.d434.s33	phenobarbital	31	43	B-drug
DDI-DrugBank.d434.s33	may	45	47	O
DDI-DrugBank.d434.s33	reduce	49	54	O
DDI-DrugBank.d434.s33	plasma	56	61	O
DDI-DrugBank.d434.s33	felbamate	63	71	B-drug
DDI-DrugBank.d434.s33	concentrations	73	86	O
DDI-DrugBank.d434.s33	.	87	87	O
DDI-DrugBank.d434.s34	Steady-state	0	11	O
DDI-DrugBank.d434.s34	plasma	13	18	O
DDI-DrugBank.d434.s34	felbamate	20	28	B-drug
DDI-DrugBank.d434.s34	concentrations	30	43	O
DDI-DrugBank.d434.s34	were	45	48	O
DDI-DrugBank.d434.s34	found	50	54	O
DDI-DrugBank.d434.s34	to	56	57	O
DDI-DrugBank.d434.s34	be	59	60	O
DDI-DrugBank.d434.s34	29	62	63	O
DDI-DrugBank.d434.s34	%	64	64	O
DDI-DrugBank.d434.s34	lower	66	70	O
DDI-DrugBank.d434.s34	than	72	75	O
DDI-DrugBank.d434.s34	the	77	79	O
DDI-DrugBank.d434.s34	mean	81	84	O
DDI-DrugBank.d434.s34	concentrations	86	99	O
DDI-DrugBank.d434.s34	of	101	102	O
DDI-DrugBank.d434.s34	a	94	94	O
DDI-DrugBank.d434.s34	group	106	110	O
DDI-DrugBank.d434.s34	of	101	102	O
DDI-DrugBank.d434.s34	newly	115	119	O
DDI-DrugBank.d434.s34	diagnosed	121	129	O
DDI-DrugBank.d434.s34	subjects	131	138	O
DDI-DrugBank.d434.s34	with	140	143	O
DDI-DrugBank.d434.s34	epilepsy	145	152	O
DDI-DrugBank.d434.s34	also	154	157	O
DDI-DrugBank.d434.s34	receiving	159	167	O
DDI-DrugBank.d434.s34	2400	169	172	O
DDI-DrugBank.d434.s34	mg	174	175	O
DDI-DrugBank.d434.s34	of	177	178	O
DDI-DrugBank.d434.s34	felbamate	180	188	B-drug
DDI-DrugBank.d434.s34	a	184	184	O
DDI-DrugBank.d434.s34	day	192	194	O
DDI-DrugBank.d434.s34	.	195	195	O
DDI-DrugBank.d434.s35	Effects	0	6	O
DDI-DrugBank.d434.s35	of	8	9	O
DDI-DrugBank.d434.s35	Antacids	11	18	B-group
DDI-DrugBank.d434.s35	on	20	21	O
DDI-DrugBank.d434.s35	Felbatol	23	30	B-brand
DDI-DrugBank.d434.s35	The	33	35	O
DDI-DrugBank.d434.s35	rate	37	40	O
DDI-DrugBank.d434.s35	and	42	44	O
DDI-DrugBank.d434.s35	extent	46	51	O
DDI-DrugBank.d434.s35	of	53	54	O
DDI-DrugBank.d434.s35	absorption	56	65	O
DDI-DrugBank.d434.s35	of	67	68	O
DDI-DrugBank.d434.s35	a	70	70	O
DDI-DrugBank.d434.s35	2400	72	75	O
DDI-DrugBank.d434.s35	mg	77	78	O
DDI-DrugBank.d434.s35	dose	80	83	O
DDI-DrugBank.d434.s35	of	85	86	O
DDI-DrugBank.d434.s35	Felbatol	88	95	B-brand
DDI-DrugBank.d434.s35	as	98	99	O
DDI-DrugBank.d434.s35	monotherapy	101	111	O
DDI-DrugBank.d434.s35	given	113	117	O
DDI-DrugBank.d434.s35	as	98	99	O
DDI-DrugBank.d434.s35	tablets	122	128	O
DDI-DrugBank.d434.s35	was	130	132	O
DDI-DrugBank.d434.s35	not	134	136	O
DDI-DrugBank.d434.s35	affected	138	145	O
DDI-DrugBank.d434.s35	when	147	150	O
DDI-DrugBank.d434.s35	coadministered	152	165	O
DDI-DrugBank.d434.s35	with	167	170	O
DDI-DrugBank.d434.s35	antacids	172	179	B-group
DDI-DrugBank.d434.s35	.	180	180	O
DDI-DrugBank.d434.s36	Effects	0	6	O
DDI-DrugBank.d434.s36	of	8	9	O
DDI-DrugBank.d434.s36	Erythromycin	11	22	B-drug
DDI-DrugBank.d434.s36	on	24	25	O
DDI-DrugBank.d434.s36	Felbatol	27	34	B-brand
DDI-DrugBank.d434.s36	The	37	39	O
DDI-DrugBank.d434.s36	coadministration	41	56	O
DDI-DrugBank.d434.s36	of	58	59	O
DDI-DrugBank.d434.s36	erythromycin	61	72	B-drug
DDI-DrugBank.d434.s36	(	74	74	O
DDI-DrugBank.d434.s36	1000	75	78	O
DDI-DrugBank.d434.s36	mg/day	80	85	O
DDI-DrugBank.d434.s36	)	86	86	O
DDI-DrugBank.d434.s36	for	88	90	O
DDI-DrugBank.d434.s36	10	92	93	O
DDI-DrugBank.d434.s36	days	95	98	O
DDI-DrugBank.d434.s36	did	100	102	O
DDI-DrugBank.d434.s36	not	104	106	O
DDI-DrugBank.d434.s36	alter	108	112	O
DDI-DrugBank.d434.s36	the	114	116	O
DDI-DrugBank.d434.s36	pharmacokinetic	118	132	O
DDI-DrugBank.d434.s36	parameters	134	143	O
DDI-DrugBank.d434.s36	of	145	146	O
DDI-DrugBank.d434.s36	Cmax	148	151	O
DDI-DrugBank.d434.s36	,	152	152	O
DDI-DrugBank.d434.s36	Cmin	154	157	O
DDI-DrugBank.d434.s36	,	152	152	O
DDI-DrugBank.d434.s36	AUC	160	162	O
DDI-DrugBank.d434.s36	,	152	152	O
DDI-DrugBank.d434.s36	CI/kg	165	169	O
DDI-DrugBank.d434.s36	or	171	172	O
DDI-DrugBank.d434.s36	tmax	174	177	O
DDI-DrugBank.d434.s36	at	179	180	O
DDI-DrugBank.d434.s36	felbamate	182	190	B-drug
DDI-DrugBank.d434.s36	daily	192	196	O
DDI-DrugBank.d434.s36	doses	198	202	O
DDI-DrugBank.d434.s36	of	204	205	O
DDI-DrugBank.d434.s36	3000	207	210	O
DDI-DrugBank.d434.s36	or	212	213	O
DDI-DrugBank.d434.s36	3600	215	218	O
DDI-DrugBank.d434.s36	mg/day	220	225	O
DDI-DrugBank.d434.s36	in	227	228	O
DDI-DrugBank.d434.s36	10	230	231	O
DDI-DrugBank.d434.s36	otherwise	233	241	O
DDI-DrugBank.d434.s36	healthy	243	249	O
DDI-DrugBank.d434.s36	subjects	251	258	O
DDI-DrugBank.d434.s36	with	260	263	O
DDI-DrugBank.d434.s36	epilepsy	265	272	O
DDI-DrugBank.d434.s36	.	273	273	O
DDI-DrugBank.d434.s37	Effects	0	6	O
DDI-DrugBank.d434.s37	of	8	9	O
DDI-DrugBank.d434.s37	Felbatol	11	18	B-brand
DDI-DrugBank.d434.s37	on	21	22	O
DDI-DrugBank.d434.s37	Low-Dose	24	31	O
DDI-DrugBank.d434.s37	Combination	33	43	B-group
DDI-DrugBank.d434.s37	Oral	45	48	I-group
DDI-DrugBank.d434.s37	Contraceptives	50	63	I-group
DDI-DrugBank.d434.s37	A	65	65	O
DDI-DrugBank.d434.s37	group	67	71	O
DDI-DrugBank.d434.s37	of	73	74	O
DDI-DrugBank.d434.s37	24	76	77	O
DDI-DrugBank.d434.s37	nonsmoking	79	88	O
DDI-DrugBank.d434.s37	,	89	89	O
DDI-DrugBank.d434.s37	healthy	91	97	O
DDI-DrugBank.d434.s37	white	99	103	O
DDI-DrugBank.d434.s37	female	105	110	O
DDI-DrugBank.d434.s37	volunteers	112	121	O
DDI-DrugBank.d434.s37	established	123	133	O
DDI-DrugBank.d434.s37	on	135	136	O
DDI-DrugBank.d434.s37	an	138	139	O
DDI-DrugBank.d434.s37	oral	141	144	O
DDI-DrugBank.d434.s37	contraceptive	146	158	B-group
DDI-DrugBank.d434.s37	regimen	160	166	O
DDI-DrugBank.d434.s37	containing	168	177	O
DDI-DrugBank.d434.s37	30	179	180	O
DDI-DrugBank.d434.s37	mg	182	183	O
DDI-DrugBank.d434.s37	ethinyl	185	191	B-drug
DDI-DrugBank.d434.s37	estradiol	193	201	I-drug
DDI-DrugBank.d434.s37	and	203	205	O
DDI-DrugBank.d434.s37	75	207	208	O
DDI-DrugBank.d434.s37	mg	182	183	O
DDI-DrugBank.d434.s37	gestodene	213	221	B-drug
DDI-DrugBank.d434.s37	for	223	225	O
DDI-DrugBank.d434.s37	at	227	228	O
DDI-DrugBank.d434.s37	least	230	234	O
DDI-DrugBank.d434.s37	3	236	236	O
DDI-DrugBank.d434.s37	months	238	243	O
DDI-DrugBank.d434.s37	received	245	252	O
DDI-DrugBank.d434.s37	2400	254	257	O
DDI-DrugBank.d434.s37	mg/day	259	264	O
DDI-DrugBank.d434.s37	of	266	267	O
DDI-DrugBank.d434.s37	felbamate	269	277	B-drug
DDI-DrugBank.d434.s37	from	279	282	O
DDI-DrugBank.d434.s37	midcycle	284	291	O
DDI-DrugBank.d434.s37	(	293	293	O
DDI-DrugBank.d434.s37	day	262	264	O
DDI-DrugBank.d434.s37	15	298	299	O
DDI-DrugBank.d434.s37	)	300	300	O
DDI-DrugBank.d434.s37	to	302	303	O
DDI-DrugBank.d434.s37	midcycle	284	291	O
DDI-DrugBank.d434.s37	(	293	293	O
DDI-DrugBank.d434.s37	day	294	296	O
DDI-DrugBank.d434.s37	14	319	320	O
DDI-DrugBank.d434.s37	)	300	300	O
DDI-DrugBank.d434.s37	of	323	324	O
DDI-DrugBank.d434.s37	two	326	328	O
DDI-DrugBank.d434.s37	consecutive	330	340	O
DDI-DrugBank.d434.s37	oral	342	345	O
DDI-DrugBank.d434.s37	contraceptive	347	359	B-group
DDI-DrugBank.d434.s37	cycles	361	366	O
DDI-DrugBank.d434.s37	.	367	367	O
DDI-DrugBank.d434.s38	Felbamate	0	8	B-drug
DDI-DrugBank.d434.s38	treatment	10	18	O
DDI-DrugBank.d434.s38	resulted	20	27	O
DDI-DrugBank.d434.s38	in	29	30	O
DDI-DrugBank.d434.s38	a	32	32	O
DDI-DrugBank.d434.s38	42	34	35	O
DDI-DrugBank.d434.s38	%	36	36	O
DDI-DrugBank.d434.s38	decrease	38	45	O
DDI-DrugBank.d434.s38	in	47	48	O
DDI-DrugBank.d434.s38	the	50	52	O
DDI-DrugBank.d434.s38	gestodene	54	62	B-drug
DDI-DrugBank.d434.s38	AUC	64	66	O
DDI-DrugBank.d434.s38	0-24	68	71	O
DDI-DrugBank.d434.s38	,	72	72	O
DDI-DrugBank.d434.s38	but	74	76	O
DDI-DrugBank.d434.s38	no	78	79	O
DDI-DrugBank.d434.s38	clinically	81	90	O
DDI-DrugBank.d434.s38	relevant	92	99	O
DDI-DrugBank.d434.s38	effect	101	106	O
DDI-DrugBank.d434.s38	was	108	110	O
DDI-DrugBank.d434.s38	observed	112	119	O
DDI-DrugBank.d434.s38	on	121	122	O
DDI-DrugBank.d434.s38	the	124	126	O
DDI-DrugBank.d434.s38	pharmacokinetic	128	142	O
DDI-DrugBank.d434.s38	parameters	144	153	O
DDI-DrugBank.d434.s38	of	155	156	O
DDI-DrugBank.d434.s38	ethinyl	158	164	B-drug
DDI-DrugBank.d434.s38	estradiol	166	174	I-drug
DDI-DrugBank.d434.s38	.	175	175	O
DDI-DrugBank.d434.s39	No	0	1	O
DDI-DrugBank.d434.s39	volunteer	3	11	O
DDI-DrugBank.d434.s39	showed	13	18	O
DDI-DrugBank.d434.s39	hormonal	20	27	O
DDI-DrugBank.d434.s39	evidence	29	36	O
DDI-DrugBank.d434.s39	of	38	39	O
DDI-DrugBank.d434.s39	ovulation	41	49	O
DDI-DrugBank.d434.s39	,	50	50	O
DDI-DrugBank.d434.s39	but	52	54	O
DDI-DrugBank.d434.s39	one	56	58	O
DDI-DrugBank.d434.s39	volunteer	60	68	O
DDI-DrugBank.d434.s39	reported	70	77	O
DDI-DrugBank.d434.s39	intermenstrual	79	92	O
DDI-DrugBank.d434.s39	bleeding	94	101	O
DDI-DrugBank.d434.s39	during	103	108	O
DDI-DrugBank.d434.s39	felbamate	110	118	B-drug
DDI-DrugBank.d434.s39	treatment	120	128	O
DDI-DrugBank.d434.s39	.	129	129	O
DDI-DrugBank.d499.s0	The	0	2	O
DDI-DrugBank.d499.s0	following	4	12	O
DDI-DrugBank.d499.s0	drug	14	17	O
DDI-DrugBank.d499.s0	interactions	19	30	O
DDI-DrugBank.d499.s0	were	32	35	O
DDI-DrugBank.d499.s0	studied	37	43	O
DDI-DrugBank.d499.s0	with	45	48	O
DDI-DrugBank.d499.s0	ketoprofen	50	59	B-drug
DDI-DrugBank.d499.s0	doses	61	65	O
DDI-DrugBank.d499.s0	of	67	68	O
DDI-DrugBank.d499.s0	200	70	72	O
DDI-DrugBank.d499.s0	mg/day	74	79	O
DDI-DrugBank.d499.s0	.	80	80	O
DDI-DrugBank.d499.s1	The	0	2	O
DDI-DrugBank.d499.s1	possibility	4	14	O
DDI-DrugBank.d499.s1	of	16	17	O
DDI-DrugBank.d499.s1	increased	19	27	O
DDI-DrugBank.d499.s1	interaction	29	39	O
DDI-DrugBank.d499.s1	should	41	46	O
DDI-DrugBank.d499.s1	be	48	49	O
DDI-DrugBank.d499.s1	kept	51	54	O
DDI-DrugBank.d499.s1	in	56	57	O
DDI-DrugBank.d499.s1	mind	59	62	O
DDI-DrugBank.d499.s1	when	64	67	O
DDI-DrugBank.d499.s1	Orudis	69	74	B-brand
DDI-DrugBank.d499.s1	doses	76	80	O
DDI-DrugBank.d499.s1	greater	82	88	O
DDI-DrugBank.d499.s1	than	90	93	O
DDI-DrugBank.d499.s1	50	95	96	O
DDI-DrugBank.d499.s1	mg	98	99	O
DDI-DrugBank.d499.s1	as	101	102	O
DDI-DrugBank.d499.s1	a	92	92	O
DDI-DrugBank.d499.s1	single	106	111	O
DDI-DrugBank.d499.s1	dose	113	116	O
DDI-DrugBank.d499.s1	or	118	119	O
DDI-DrugBank.d499.s1	200	121	123	O
DDI-DrugBank.d499.s1	mg	125	126	O
DDI-DrugBank.d499.s1	of	128	129	O
DDI-DrugBank.d499.s1	ketoprofen	131	140	B-drug
DDI-DrugBank.d499.s1	per	142	144	O
DDI-DrugBank.d499.s1	day	146	148	O
DDI-DrugBank.d499.s1	are	150	152	O
DDI-DrugBank.d499.s1	used	154	157	O
DDI-DrugBank.d499.s1	concomitantly	159	171	O
DDI-DrugBank.d499.s1	with	173	176	O
DDI-DrugBank.d499.s1	highly	178	183	O
DDI-DrugBank.d499.s1	bound	185	189	O
DDI-DrugBank.d499.s1	drugs	191	195	O
DDI-DrugBank.d499.s1	.	196	196	O
DDI-DrugBank.d499.s2	1	0	0	O
DDI-DrugBank.d499.s2	.	1	1	O
DDI-DrugBank.d499.s3	Antacids	0	7	B-group
DDI-DrugBank.d499.s3	:	8	8	O
DDI-DrugBank.d499.s3	Concomitant	10	20	O
DDI-DrugBank.d499.s3	administration	22	35	O
DDI-DrugBank.d499.s3	of	37	38	O
DDI-DrugBank.d499.s3	magnesium	40	48	B-drug
DDI-DrugBank.d499.s3	hydroxide	50	58	I-drug
DDI-DrugBank.d499.s3	and	60	62	O
DDI-DrugBank.d499.s3	aluminum	64	71	B-drug
DDI-DrugBank.d499.s3	hydroxide	73	81	I-drug
DDI-DrugBank.d499.s3	does	83	86	O
DDI-DrugBank.d499.s3	not	88	90	O
DDI-DrugBank.d499.s3	interfere	92	100	O
DDI-DrugBank.d499.s3	with	102	105	O
DDI-DrugBank.d499.s3	the	107	109	O
DDI-DrugBank.d499.s3	rate	111	114	O
DDI-DrugBank.d499.s3	or	116	117	O
DDI-DrugBank.d499.s3	extent	119	124	O
DDI-DrugBank.d499.s3	of	126	127	O
DDI-DrugBank.d499.s3	the	129	131	O
DDI-DrugBank.d499.s3	absorption	133	142	O
DDI-DrugBank.d499.s3	of	126	127	O
DDI-DrugBank.d499.s3	ketoprofen	147	156	B-drug
DDI-DrugBank.d499.s3	administered	158	169	O
DDI-DrugBank.d499.s3	as	171	172	O
DDI-DrugBank.d499.s3	Orudis	174	179	B-brand
DDI-DrugBank.d499.s3	.	180	180	O
DDI-DrugBank.d499.s4	2	0	0	O
DDI-DrugBank.d499.s4	.	1	1	O
DDI-DrugBank.d499.s5	Aspirin	0	6	B-brand
DDI-DrugBank.d499.s5	:	7	7	O
DDI-DrugBank.d499.s5	Ketoprofen	9	18	B-drug
DDI-DrugBank.d499.s5	does	20	23	O
DDI-DrugBank.d499.s5	not	25	27	O
DDI-DrugBank.d499.s5	alter	29	33	O
DDI-DrugBank.d499.s5	aspirin	35	41	B-brand
DDI-DrugBank.d499.s5	absorption	43	52	O
DDI-DrugBank.d499.s5	;	53	53	O
DDI-DrugBank.d499.s6	however	0	6	O
DDI-DrugBank.d499.s6	,	7	7	O
DDI-DrugBank.d499.s6	in	9	10	O
DDI-DrugBank.d499.s6	a	12	12	O
DDI-DrugBank.d499.s6	study	14	18	O
DDI-DrugBank.d499.s6	of	20	21	O
DDI-DrugBank.d499.s6	12	23	24	O
DDI-DrugBank.d499.s6	normal	26	31	O
DDI-DrugBank.d499.s6	subjects	33	40	O
DDI-DrugBank.d499.s6	,	41	41	O
DDI-DrugBank.d499.s6	concurrent	43	52	O
DDI-DrugBank.d499.s6	administration	54	67	O
DDI-DrugBank.d499.s6	of	69	70	O
DDI-DrugBank.d499.s6	aspirin	72	78	B-brand
DDI-DrugBank.d499.s6	decreased	80	88	O
DDI-DrugBank.d499.s6	ketoprofen	90	99	B-drug
DDI-DrugBank.d499.s6	protein	101	107	O
DDI-DrugBank.d499.s6	binding	109	115	O
DDI-DrugBank.d499.s6	and	117	119	O
DDI-DrugBank.d499.s6	increased	121	129	O
DDI-DrugBank.d499.s6	ketoprofen	131	140	B-drug
DDI-DrugBank.d499.s6	plasma	142	147	O
DDI-DrugBank.d499.s6	clearance	149	157	O
DDI-DrugBank.d499.s6	from	159	162	O
DDI-DrugBank.d499.s6	0.07	164	167	O
DDI-DrugBank.d499.s6	L/kg/h	169	174	O
DDI-DrugBank.d499.s6	without	176	182	O
DDI-DrugBank.d499.s6	aspirin	184	190	B-brand
DDI-DrugBank.d499.s6	to	192	193	O
DDI-DrugBank.d499.s6	0.11	195	198	O
DDI-DrugBank.d499.s6	L/kg/h	200	205	O
DDI-DrugBank.d499.s6	with	207	210	O
DDI-DrugBank.d499.s6	aspirin	184	190	B-brand
DDI-DrugBank.d499.s6	.	196	196	O
DDI-DrugBank.d499.s7	The	0	2	O
DDI-DrugBank.d499.s7	clinical	4	11	O
DDI-DrugBank.d499.s7	significance	13	24	O
DDI-DrugBank.d499.s7	of	26	27	O
DDI-DrugBank.d499.s7	these	29	33	O
DDI-DrugBank.d499.s7	changes	35	41	O
DDI-DrugBank.d499.s7	has	43	45	O
DDI-DrugBank.d499.s7	not	47	49	O
DDI-DrugBank.d499.s7	been	51	54	O
DDI-DrugBank.d499.s7	adequately	56	65	O
DDI-DrugBank.d499.s7	studied	67	73	O
DDI-DrugBank.d499.s7	.	74	74	O
DDI-DrugBank.d499.s8	Therefore	0	8	O
DDI-DrugBank.d499.s8	,	9	9	O
DDI-DrugBank.d499.s8	concurrent	11	20	O
DDI-DrugBank.d499.s8	use	22	24	O
DDI-DrugBank.d499.s8	of	26	27	O
DDI-DrugBank.d499.s8	aspirin	29	35	B-brand
DDI-DrugBank.d499.s8	and	37	39	O
DDI-DrugBank.d499.s8	ketoprofen	41	50	B-drug
DDI-DrugBank.d499.s8	is	52	53	O
DDI-DrugBank.d499.s8	not	55	57	O
DDI-DrugBank.d499.s8	recommended	59	69	O
DDI-DrugBank.d499.s8	.	70	70	O
DDI-DrugBank.d499.s9	3	0	0	O
DDI-DrugBank.d499.s9	.	1	1	O
DDI-DrugBank.d499.s10	Diuretic	0	7	B-group
DDI-DrugBank.d499.s10	:	8	8	O
DDI-DrugBank.d499.s10	Hydrochlorothiazide	10	28	B-drug
DDI-DrugBank.d499.s10	,	29	29	O
DDI-DrugBank.d499.s10	given	31	35	O
DDI-DrugBank.d499.s10	concomitantly	37	49	O
DDI-DrugBank.d499.s10	with	51	54	O
DDI-DrugBank.d499.s10	ketoprofen	56	65	B-drug
DDI-DrugBank.d499.s10	,	66	66	O
DDI-DrugBank.d499.s10	produces	68	75	O
DDI-DrugBank.d499.s10	a	77	77	O
DDI-DrugBank.d499.s10	reduction	79	87	O
DDI-DrugBank.d499.s10	in	89	90	O
DDI-DrugBank.d499.s10	urinary	92	98	O
DDI-DrugBank.d499.s10	potassium	100	108	O
DDI-DrugBank.d499.s10	and	110	112	O
DDI-DrugBank.d499.s10	chloride	114	121	O
DDI-DrugBank.d499.s10	excretion	123	131	O
DDI-DrugBank.d499.s10	compared	133	140	O
DDI-DrugBank.d499.s10	to	142	143	O
DDI-DrugBank.d499.s10	hydrochlorothiazide	145	163	B-drug
DDI-DrugBank.d499.s10	alone	165	169	O
DDI-DrugBank.d499.s10	.	170	170	O
DDI-DrugBank.d499.s11	Patients	0	7	O
DDI-DrugBank.d499.s11	taking	9	14	O
DDI-DrugBank.d499.s11	diuretics	16	24	B-group
DDI-DrugBank.d499.s11	are	26	28	O
DDI-DrugBank.d499.s11	at	30	31	O
DDI-DrugBank.d499.s11	a	30	30	O
DDI-DrugBank.d499.s11	greater	35	41	O
DDI-DrugBank.d499.s11	risk	43	46	O
DDI-DrugBank.d499.s11	of	48	49	O
DDI-DrugBank.d499.s11	developing	51	60	O
DDI-DrugBank.d499.s11	renal	62	66	O
DDI-DrugBank.d499.s11	failure	68	74	O
DDI-DrugBank.d499.s11	secondary	76	84	O
DDI-DrugBank.d499.s11	to	86	87	O
DDI-DrugBank.d499.s11	a	82	82	O
DDI-DrugBank.d499.s11	decrease	91	98	O
DDI-DrugBank.d499.s11	in	100	101	O
DDI-DrugBank.d499.s11	renal	103	107	O
DDI-DrugBank.d499.s11	blood	109	113	O
DDI-DrugBank.d499.s11	flow	115	118	O
DDI-DrugBank.d499.s11	caused	120	125	O
DDI-DrugBank.d499.s11	by	127	128	O
DDI-DrugBank.d499.s11	prostaglandin	130	142	O
DDI-DrugBank.d499.s11	inhibition	144	153	O
DDI-DrugBank.d499.s11	.	154	154	O
DDI-DrugBank.d499.s12	4	0	0	O
DDI-DrugBank.d499.s12	.	1	1	O
DDI-DrugBank.d499.s13	Digoxin	0	6	B-drug
DDI-DrugBank.d499.s13	:	7	7	O
DDI-DrugBank.d499.s13	In	9	10	O
DDI-DrugBank.d499.s13	a	12	12	O
DDI-DrugBank.d499.s13	study	14	18	O
DDI-DrugBank.d499.s13	in	20	21	O
DDI-DrugBank.d499.s13	12	23	24	O
DDI-DrugBank.d499.s13	patients	26	33	O
DDI-DrugBank.d499.s13	with	35	38	O
DDI-DrugBank.d499.s13	congestive	40	49	O
DDI-DrugBank.d499.s13	heart	51	55	O
DDI-DrugBank.d499.s13	failure	57	63	O
DDI-DrugBank.d499.s13	where	65	69	O
DDI-DrugBank.d499.s13	ketoprofen	71	80	B-drug
DDI-DrugBank.d499.s13	and	82	84	O
DDI-DrugBank.d499.s13	digoxin	86	92	B-drug
DDI-DrugBank.d499.s13	were	94	97	O
DDI-DrugBank.d499.s13	concomitantly	99	111	O
DDI-DrugBank.d499.s13	administered	113	124	O
DDI-DrugBank.d499.s13	,	125	125	O
DDI-DrugBank.d499.s13	ketoprofen	127	136	B-drug
DDI-DrugBank.d499.s13	did	138	140	O
DDI-DrugBank.d499.s13	not	142	144	O
DDI-DrugBank.d499.s13	alter	146	150	O
DDI-DrugBank.d499.s13	the	152	154	O
DDI-DrugBank.d499.s13	serum	156	160	O
DDI-DrugBank.d499.s13	levels	162	167	O
DDI-DrugBank.d499.s13	of	169	170	O
DDI-DrugBank.d499.s13	digoxin	172	178	B-drug
DDI-DrugBank.d499.s13	.	179	179	O
DDI-DrugBank.d499.s14	5	0	0	O
DDI-DrugBank.d499.s14	.	1	1	O
DDI-DrugBank.d499.s15	Warfarin	0	7	B-drug
DDI-DrugBank.d499.s15	:	8	8	O
DDI-DrugBank.d499.s15	In	10	11	O
DDI-DrugBank.d499.s15	a	13	13	O
DDI-DrugBank.d499.s15	short-term	15	24	O
DDI-DrugBank.d499.s15	controlled	26	35	O
DDI-DrugBank.d499.s15	study	37	41	O
DDI-DrugBank.d499.s15	in	43	44	O
DDI-DrugBank.d499.s15	14	46	47	O
DDI-DrugBank.d499.s15	normal	49	54	O
DDI-DrugBank.d499.s15	volunteers	56	65	O
DDI-DrugBank.d499.s15	,	66	66	O
DDI-DrugBank.d499.s15	ketoprofen	68	77	B-drug
DDI-DrugBank.d499.s15	did	79	81	O
DDI-DrugBank.d499.s15	not	83	85	O
DDI-DrugBank.d499.s15	significantly	87	99	O
DDI-DrugBank.d499.s15	interfere	101	109	O
DDI-DrugBank.d499.s15	with	111	114	O
DDI-DrugBank.d499.s15	the	116	118	O
DDI-DrugBank.d499.s15	effect	120	125	O
DDI-DrugBank.d499.s15	of	127	128	O
DDI-DrugBank.d499.s15	warfarin	130	137	B-drug
DDI-DrugBank.d499.s15	on	139	140	O
DDI-DrugBank.d499.s15	prothrombin	142	152	O
DDI-DrugBank.d499.s15	time	154	157	O
DDI-DrugBank.d499.s15	.	158	158	O
DDI-DrugBank.d499.s16	Bleeding	0	7	O
DDI-DrugBank.d499.s16	from	9	12	O
DDI-DrugBank.d499.s16	a	14	14	O
DDI-DrugBank.d499.s16	number	16	21	O
DDI-DrugBank.d499.s16	of	23	24	O
DDI-DrugBank.d499.s16	sites	26	30	O
DDI-DrugBank.d499.s16	may	32	34	O
DDI-DrugBank.d499.s16	be	36	37	O
DDI-DrugBank.d499.s16	a	33	33	O
DDI-DrugBank.d499.s16	complication	41	52	O
DDI-DrugBank.d499.s16	of	54	55	O
DDI-DrugBank.d499.s16	warfarin	57	64	B-drug
DDI-DrugBank.d499.s16	treatment	66	74	O
DDI-DrugBank.d499.s16	and	76	78	O
DDI-DrugBank.d499.s16	GI	80	81	O
DDI-DrugBank.d499.s16	bleeding	83	90	O
DDI-DrugBank.d499.s16	a	76	76	O
DDI-DrugBank.d499.s16	complication	94	105	O
DDI-DrugBank.d499.s16	of	107	108	O
DDI-DrugBank.d499.s16	ketoprofen	110	119	B-drug
DDI-DrugBank.d499.s16	treatment	121	129	O
DDI-DrugBank.d499.s16	.	130	130	O
DDI-DrugBank.d499.s17	Because	0	6	O
DDI-DrugBank.d499.s17	prostaglandina	8	21	O
DDI-DrugBank.d499.s17	play	23	26	O
DDI-DrugBank.d499.s17	an	28	29	O
DDI-DrugBank.d499.s17	important	31	39	O
DDI-DrugBank.d499.s17	role	41	44	O
DDI-DrugBank.d499.s17	in	46	47	O
DDI-DrugBank.d499.s17	hemostasis	49	58	O
DDI-DrugBank.d499.s17	and	60	62	O
DDI-DrugBank.d499.s17	ketoprofen	64	73	B-drug
DDI-DrugBank.d499.s17	has	75	77	O
DDI-DrugBank.d499.s17	an	79	80	O
DDI-DrugBank.d499.s17	effect	82	87	O
DDI-DrugBank.d499.s17	on	89	90	O
DDI-DrugBank.d499.s17	platelet	92	99	O
DDI-DrugBank.d499.s17	function	101	108	O
DDI-DrugBank.d499.s17	as	110	111	O
DDI-DrugBank.d499.s17	well	113	116	O
DDI-DrugBank.d499.s17	,	117	117	O
DDI-DrugBank.d499.s17	concurent	119	127	O
DDI-DrugBank.d499.s17	therapy	129	135	O
DDI-DrugBank.d499.s17	with	137	140	O
DDI-DrugBank.d499.s17	ketoprofen	142	151	B-drug
DDI-DrugBank.d499.s17	and	153	155	O
DDI-DrugBank.d499.s17	warfarin	157	164	B-drug
DDI-DrugBank.d499.s17	requires	166	173	O
DDI-DrugBank.d499.s17	close	175	179	O
DDI-DrugBank.d499.s17	monitoring	181	190	O
DDI-DrugBank.d499.s17	of	192	193	O
DDI-DrugBank.d499.s17	patients	195	202	O
DDI-DrugBank.d499.s17	on	182	183	O
DDI-DrugBank.d499.s17	both	207	210	O
DDI-DrugBank.d499.s17	drugs	212	216	O
DDI-DrugBank.d499.s17	.	217	217	O
DDI-DrugBank.d499.s18	6	0	0	O
DDI-DrugBank.d499.s18	.	1	1	O
DDI-DrugBank.d499.s19	Probenecid	0	9	B-drug
DDI-DrugBank.d499.s19	:	10	10	O
DDI-DrugBank.d499.s19	Probenecid	12	21	B-drug
DDI-DrugBank.d499.s19	increases	23	31	O
DDI-DrugBank.d499.s19	both	33	36	O
DDI-DrugBank.d499.s19	free	38	41	O
DDI-DrugBank.d499.s19	and	43	45	O
DDI-DrugBank.d499.s19	bound	47	51	O
DDI-DrugBank.d499.s19	ketoprofen	53	62	B-drug
DDI-DrugBank.d499.s19	by	64	65	O
DDI-DrugBank.d499.s19	reducing	67	74	O
DDI-DrugBank.d499.s19	the	76	78	O
DDI-DrugBank.d499.s19	plasma	80	85	O
DDI-DrugBank.d499.s19	clearance	87	95	O
DDI-DrugBank.d499.s19	of	97	98	O
DDI-DrugBank.d499.s19	ketoprofen	100	109	B-drug
DDI-DrugBank.d499.s19	to	102	103	I-drug
DDI-DrugBank.d499.s19	about	114	118	O
DDI-DrugBank.d499.s19	one-third	120	128	O
DDI-DrugBank.d499.s19	,	129	129	O
DDI-DrugBank.d499.s19	as	131	132	O
DDI-DrugBank.d499.s19	well	134	137	O
DDI-DrugBank.d499.s19	as	131	132	O
DDI-DrugBank.d499.s19	decreasing	142	151	O
DDI-DrugBank.d499.s19	its	153	155	O
DDI-DrugBank.d499.s19	protein	157	163	O
DDI-DrugBank.d499.s19	binding	165	171	O
DDI-DrugBank.d499.s19	.	172	172	O
DDI-DrugBank.d499.s20	Therefore	0	8	O
DDI-DrugBank.d499.s20	,	9	9	O
DDI-DrugBank.d499.s20	the	11	13	O
DDI-DrugBank.d499.s20	combination	15	25	O
DDI-DrugBank.d499.s20	of	27	28	O
DDI-DrugBank.d499.s20	ketoprofen	30	39	B-drug
DDI-DrugBank.d499.s20	and	41	43	O
DDI-DrugBank.d499.s20	probenecid	45	54	B-drug
DDI-DrugBank.d499.s20	is	56	57	O
DDI-DrugBank.d499.s20	not	59	61	O
DDI-DrugBank.d499.s20	recommended	63	73	O
DDI-DrugBank.d499.s20	.	74	74	O
DDI-DrugBank.d499.s21	7	0	0	O
DDI-DrugBank.d499.s21	.	1	1	O
DDI-DrugBank.d499.s22	Methotrexate	0	11	B-drug
DDI-DrugBank.d499.s22	:	12	12	O
DDI-DrugBank.d499.s22	Ketoprofen	14	23	B-drug
DDI-DrugBank.d499.s22	,	24	24	O
DDI-DrugBank.d499.s22	like	26	29	O
DDI-DrugBank.d499.s22	other	31	35	O
DDI-DrugBank.d499.s22	NSAIDs	37	42	B-group
DDI-DrugBank.d499.s22	,	43	43	O
DDI-DrugBank.d499.s22	may	45	47	O
DDI-DrugBank.d499.s22	cause	49	53	O
DDI-DrugBank.d499.s22	changes	55	61	O
DDI-DrugBank.d499.s22	in	63	64	O
DDI-DrugBank.d499.s22	the	66	68	O
DDI-DrugBank.d499.s22	elimination	70	80	O
DDI-DrugBank.d499.s22	of	82	83	O
DDI-DrugBank.d499.s22	methotrexate	85	96	B-drug
DDI-DrugBank.d499.s22	leading	98	104	O
DDI-DrugBank.d499.s22	to	106	107	O
DDI-DrugBank.d499.s22	elevated	109	116	O
DDI-DrugBank.d499.s22	serum	118	122	O
DDI-DrugBank.d499.s22	levels	124	129	O
DDI-DrugBank.d499.s22	of	131	132	O
DDI-DrugBank.d499.s22	the	134	136	O
DDI-DrugBank.d499.s22	drug	138	141	O
DDI-DrugBank.d499.s22	and	143	145	O
DDI-DrugBank.d499.s22	increased	147	155	O
DDI-DrugBank.d499.s22	toxicity	157	164	O
DDI-DrugBank.d499.s22	.	165	165	O
DDI-DrugBank.d499.s23	8	0	0	O
DDI-DrugBank.d499.s23	.	1	1	O
DDI-DrugBank.d499.s24	Lithium	0	6	B-drug
DDI-DrugBank.d499.s24	:	7	7	O
DDI-DrugBank.d499.s24	Nonsteroidal	9	20	B-group
DDI-DrugBank.d499.s24	anti-inflammatory	22	38	I-group
DDI-DrugBank.d499.s24	agents	40	45	I-group
DDI-DrugBank.d499.s24	have	47	50	O
DDI-DrugBank.d499.s24	been	52	55	O
DDI-DrugBank.d499.s24	reported	57	64	O
DDI-DrugBank.d499.s24	to	66	67	O
DDI-DrugBank.d499.s24	increase	69	76	O
DDI-DrugBank.d499.s24	steadystate	78	88	O
DDI-DrugBank.d499.s24	plasma	90	95	O
DDI-DrugBank.d499.s24	lithium	97	103	B-drug
DDI-DrugBank.d499.s24	levels	105	110	O
DDI-DrugBank.d499.s24	.	111	111	O
DDI-DrugBank.d499.s25	It	0	1	O
DDI-DrugBank.d499.s25	is	3	4	O
DDI-DrugBank.d499.s25	recommended	6	16	O
DDI-DrugBank.d499.s25	that	18	21	O
DDI-DrugBank.d499.s25	plasma	23	28	O
DDI-DrugBank.d499.s25	lithium	30	36	B-drug
DDI-DrugBank.d499.s25	levels	38	43	O
DDI-DrugBank.d499.s25	be	45	46	O
DDI-DrugBank.d499.s25	monitored	48	56	O
DDI-DrugBank.d499.s25	when	58	61	O
DDI-DrugBank.d499.s25	ketoprofen	63	72	B-drug
DDI-DrugBank.d499.s25	is	74	75	O
DDI-DrugBank.d499.s25	coadministered	77	90	O
DDI-DrugBank.d499.s25	with	92	95	O
DDI-DrugBank.d499.s25	lithium	97	103	B-drug
DDI-DrugBank.d499.s25	.	104	104	O
DDI-DrugBank.d499.s26	DRUG/LABORATORY	0	14	O
DDI-DrugBank.d499.s26	TEST	16	19	O
DDI-DrugBank.d499.s26	INTERACTIONS	21	32	O
DDI-DrugBank.d499.s26	:	33	33	O
DDI-DrugBank.d499.s26	EFFECT	35	40	O
DDI-DrugBank.d499.s26	ON	42	43	O
DDI-DrugBank.d499.s26	BLOOD	45	49	O
DDI-DrugBank.d499.s26	COAGULATION	51	61	O
DDI-DrugBank.d499.s26	Ketoprofen	63	72	B-drug
DDI-DrugBank.d499.s26	decreases	74	82	O
DDI-DrugBank.d499.s26	platelet	84	91	O
DDI-DrugBank.d499.s26	adhesion	93	100	O
DDI-DrugBank.d499.s26	and	102	104	O
DDI-DrugBank.d499.s26	aggregation	106	116	O
DDI-DrugBank.d499.s26	.	117	117	O
DDI-DrugBank.d499.s27	Therefore	0	8	O
DDI-DrugBank.d499.s27	,	9	9	O
DDI-DrugBank.d499.s27	it	11	12	O
DDI-DrugBank.d499.s27	can	14	16	O
DDI-DrugBank.d499.s27	prolong	18	24	O
DDI-DrugBank.d499.s27	bleeding	26	33	O
DDI-DrugBank.d499.s27	time	35	38	O
DDI-DrugBank.d499.s27	by	40	41	O
DDI-DrugBank.d499.s27	approximately	43	55	O
DDI-DrugBank.d499.s27	3	57	57	O
DDI-DrugBank.d499.s27	to	59	60	O
DDI-DrugBank.d499.s27	4	62	62	O
DDI-DrugBank.d499.s27	minutes	64	70	O
DDI-DrugBank.d499.s27	from	72	75	O
DDI-DrugBank.d499.s27	baseline	77	84	O
DDI-DrugBank.d499.s27	values	86	91	O
DDI-DrugBank.d499.s27	.	92	92	O
DDI-DrugBank.d499.s28	There	0	4	O
DDI-DrugBank.d499.s28	is	6	7	O
DDI-DrugBank.d499.s28	no	9	10	O
DDI-DrugBank.d499.s28	significant	12	22	O
DDI-DrugBank.d499.s28	change	24	29	O
DDI-DrugBank.d499.s28	in	31	32	O
DDI-DrugBank.d499.s28	platelet	34	41	O
DDI-DrugBank.d499.s28	count	43	47	O
DDI-DrugBank.d499.s28	,	48	48	O
DDI-DrugBank.d499.s28	prothrombin	50	60	O
DDI-DrugBank.d499.s28	time	62	65	O
DDI-DrugBank.d499.s28	,	66	66	O
DDI-DrugBank.d499.s28	partial	68	74	O
DDI-DrugBank.d499.s28	thromboplastin	76	89	O
DDI-DrugBank.d499.s28	time	91	94	O
DDI-DrugBank.d499.s28	,	95	95	O
DDI-DrugBank.d499.s28	or	97	98	O
DDI-DrugBank.d499.s28	thrombin	100	107	O
DDI-DrugBank.d499.s28	time	109	112	O
DDI-DrugBank.d499.s28	.	113	113	O
DDI-DrugBank.d678.s0	Drugs	0	4	O
DDI-DrugBank.d678.s0	affecting	6	14	O
DDI-DrugBank.d678.s0	pituitary	16	24	O
DDI-DrugBank.d678.s0	or	26	27	O
DDI-DrugBank.d678.s0	adrenocortical	29	42	O
DDI-DrugBank.d678.s0	function	44	51	O
DDI-DrugBank.d678.s0	,	52	52	O
DDI-DrugBank.d678.s0	including	54	62	O
DDI-DrugBank.d678.s0	all	64	66	O
DDI-DrugBank.d678.s0	corticosteroid	68	81	O
DDI-DrugBank.d678.s0	therapy	83	89	O
DDI-DrugBank.d678.s0	,	90	90	O
DDI-DrugBank.d678.s0	must	92	95	O
DDI-DrugBank.d678.s0	be	97	98	O
DDI-DrugBank.d678.s0	discontinued	100	111	O
DDI-DrugBank.d678.s0	prior	113	117	O
DDI-DrugBank.d678.s0	to	119	120	O
DDI-DrugBank.d678.s0	and	122	124	O
DDI-DrugBank.d678.s0	during	126	131	O
DDI-DrugBank.d678.s0	testing	133	139	O
DDI-DrugBank.d678.s0	with	141	144	O
DDI-DrugBank.d678.s0	Metopirone	146	155	B-brand
DDI-DrugBank.d678.s0	.	156	156	O
DDI-DrugBank.d678.s1	The	0	2	O
DDI-DrugBank.d678.s1	metabolism	4	13	O
DDI-DrugBank.d678.s1	of	15	16	O
DDI-DrugBank.d678.s1	Metopirone	18	27	B-brand
DDI-DrugBank.d678.s1	is	29	30	O
DDI-DrugBank.d678.s1	accelerated	32	42	O
DDI-DrugBank.d678.s1	by	44	45	O
DDI-DrugBank.d678.s1	phenytoin	47	55	B-drug
DDI-DrugBank.d678.s1	;	56	56	O
DDI-DrugBank.d678.s2	therefore	0	8	O
DDI-DrugBank.d678.s2	,	9	9	O
DDI-DrugBank.d678.s2	results	11	17	O
DDI-DrugBank.d678.s2	of	19	20	O
DDI-DrugBank.d678.s2	the	22	24	O
DDI-DrugBank.d678.s2	test	26	29	O
DDI-DrugBank.d678.s2	may	31	33	O
DDI-DrugBank.d678.s2	be	35	36	O
DDI-DrugBank.d678.s2	inaccurate	38	47	O
DDI-DrugBank.d678.s2	in	49	50	O
DDI-DrugBank.d678.s2	patients	52	59	O
DDI-DrugBank.d678.s2	taking	61	66	O
DDI-DrugBank.d678.s2	phenytoin	68	76	B-drug
DDI-DrugBank.d678.s2	within	78	83	O
DDI-DrugBank.d678.s2	two	85	87	O
DDI-DrugBank.d678.s2	weeks	89	93	O
DDI-DrugBank.d678.s2	before	95	100	O
DDI-DrugBank.d678.s2	.	101	101	O
DDI-DrugBank.d678.s3	Asubnormal	0	9	O
DDI-DrugBank.d678.s3	response	11	18	O
DDI-DrugBank.d678.s3	may	20	22	O
DDI-DrugBank.d678.s3	occur	24	28	O
DDI-DrugBank.d678.s3	in	30	31	O
DDI-DrugBank.d678.s3	patients	33	40	O
DDI-DrugBank.d678.s3	on	42	43	O
DDI-DrugBank.d678.s3	estrogen	45	52	O
DDI-DrugBank.d678.s3	therapy	54	60	O
DDI-DrugBank.d678.s3	.	61	61	O
DDI-DrugBank.d678.s4	Metopirone	0	9	B-brand
DDI-DrugBank.d678.s4	inhibits	11	18	O
DDI-DrugBank.d678.s4	the	20	22	O
DDI-DrugBank.d678.s4	glucuronidation	24	38	O
DDI-DrugBank.d678.s4	of	40	41	O
DDI-DrugBank.d678.s4	acetaminophen	43	55	B-drug
DDI-DrugBank.d678.s4	and	57	59	O
DDI-DrugBank.d678.s4	could	61	65	O
DDI-DrugBank.d678.s4	possibly	67	74	O
DDI-DrugBank.d678.s4	potentiate	76	85	O
DDI-DrugBank.d678.s4	acetaminophen	87	99	B-drug
DDI-DrugBank.d678.s4	toxicity	101	108	O
DDI-DrugBank.d678.s4	.	109	109	O
DDI-DrugBank.d480.s0	The	0	2	O
DDI-DrugBank.d480.s0	risks	4	8	O
DDI-DrugBank.d480.s0	of	10	11	O
DDI-DrugBank.d480.s0	using	13	17	O
DDI-DrugBank.d480.s0	Clozapine	19	27	B-drug
DDI-DrugBank.d480.s0	in	25	26	I-drug
DDI-DrugBank.d480.s0	combination	32	42	O
DDI-DrugBank.d480.s0	with	44	47	O
DDI-DrugBank.d480.s0	other	49	53	O
DDI-DrugBank.d480.s0	drugs	55	59	O
DDI-DrugBank.d480.s0	have	61	64	O
DDI-DrugBank.d480.s0	not	66	68	O
DDI-DrugBank.d480.s0	been	70	73	O
DDI-DrugBank.d480.s0	systematically	75	88	O
DDI-DrugBank.d480.s0	evaluated	90	98	O
DDI-DrugBank.d480.s0	.	99	99	O
DDI-DrugBank.d480.s1	Pharmacodynamic-related	0	22	O
DDI-DrugBank.d480.s1	Interactions	24	35	O
DDI-DrugBank.d480.s1	:	36	36	O
DDI-DrugBank.d480.s1	The	38	40	O
DDI-DrugBank.d480.s1	mechanism	42	50	O
DDI-DrugBank.d480.s1	of	52	53	O
DDI-DrugBank.d480.s1	Clozapine	55	63	B-drug
DDI-DrugBank.d480.s1	induced	65	71	O
DDI-DrugBank.d480.s1	agranulocytosis	73	87	O
DDI-DrugBank.d480.s1	is	86	87	O
DDI-DrugBank.d480.s1	unknown	92	98	O
DDI-DrugBank.d480.s1	;	99	99	O
DDI-DrugBank.d480.s2	nonetheless	0	10	O
DDI-DrugBank.d480.s2	,	11	11	O
DDI-DrugBank.d480.s2	the	13	15	O
DDI-DrugBank.d480.s2	possibility	17	27	O
DDI-DrugBank.d480.s2	that	29	32	O
DDI-DrugBank.d480.s2	causative	34	42	O
DDI-DrugBank.d480.s2	factors	44	50	O
DDI-DrugBank.d480.s2	may	52	54	O
DDI-DrugBank.d480.s2	interact	56	63	O
DDI-DrugBank.d480.s2	synergistically	65	79	O
DDI-DrugBank.d480.s2	to	81	82	O
DDI-DrugBank.d480.s2	increase	84	91	O
DDI-DrugBank.d480.s2	the	93	95	O
DDI-DrugBank.d480.s2	risk	97	100	O
DDI-DrugBank.d480.s2	and/or	102	107	O
DDI-DrugBank.d480.s2	severity	109	116	O
DDI-DrugBank.d480.s2	of	118	119	O
DDI-DrugBank.d480.s2	bone	121	124	O
DDI-DrugBank.d480.s2	marrow	126	131	O
DDI-DrugBank.d480.s2	suppression	133	143	O
DDI-DrugBank.d480.s2	warrants	145	152	O
DDI-DrugBank.d480.s2	consideration	154	166	O
DDI-DrugBank.d480.s2	.	167	167	O
DDI-DrugBank.d480.s3	Therefore	0	8	O
DDI-DrugBank.d480.s3	,	9	9	O
DDI-DrugBank.d480.s3	Clozapine	11	19	B-drug
DDI-DrugBank.d480.s3	should	21	26	O
DDI-DrugBank.d480.s3	not	28	30	O
DDI-DrugBank.d480.s3	be	32	33	O
DDI-DrugBank.d480.s3	used	35	38	O
DDI-DrugBank.d480.s3	with	40	43	O
DDI-DrugBank.d480.s3	other	45	49	O
DDI-DrugBank.d480.s3	agents	51	56	O
DDI-DrugBank.d480.s3	having	58	63	O
DDI-DrugBank.d480.s3	a	59	59	O
DDI-DrugBank.d480.s3	well-known	67	76	O
DDI-DrugBank.d480.s3	potential	78	86	O
DDI-DrugBank.d480.s3	to	88	89	O
DDI-DrugBank.d480.s3	suppress	91	98	O
DDI-DrugBank.d480.s3	bone	100	103	O
DDI-DrugBank.d480.s3	marrow	105	110	O
DDI-DrugBank.d480.s3	function	112	119	O
DDI-DrugBank.d480.s3	.	120	120	O
DDI-DrugBank.d480.s4	Given	0	4	O
DDI-DrugBank.d480.s4	the	6	8	O
DDI-DrugBank.d480.s4	primary	10	16	O
DDI-DrugBank.d480.s4	CNS	18	20	O
DDI-DrugBank.d480.s4	effects	22	28	O
DDI-DrugBank.d480.s4	of	30	31	O
DDI-DrugBank.d480.s4	Clozapine	33	41	B-drug
DDI-DrugBank.d480.s4	,	42	42	O
DDI-DrugBank.d480.s4	caution	44	50	O
DDI-DrugBank.d480.s4	is	52	53	O
DDI-DrugBank.d480.s4	advised	55	61	O
DDI-DrugBank.d480.s4	in	63	64	O
DDI-DrugBank.d480.s4	using	66	70	O
DDI-DrugBank.d480.s4	it	72	73	O
DDI-DrugBank.d480.s4	concomitantly	75	87	O
DDI-DrugBank.d480.s4	with	89	92	O
DDI-DrugBank.d480.s4	other	94	98	O
DDI-DrugBank.d480.s4	CNS-active	100	109	O
DDI-DrugBank.d480.s4	drugs	111	115	O
DDI-DrugBank.d480.s4	or	117	118	O
DDI-DrugBank.d480.s4	alcohol	120	126	B-drug
DDI-DrugBank.d480.s4	.	127	127	O
DDI-DrugBank.d480.s5	Orthostatic	0	10	O
DDI-DrugBank.d480.s5	hypotension	12	22	O
DDI-DrugBank.d480.s5	in	24	25	O
DDI-DrugBank.d480.s5	patients	27	34	O
DDI-DrugBank.d480.s5	taking	36	41	O
DDI-DrugBank.d480.s5	clozapine	43	51	B-drug
DDI-DrugBank.d480.s5	can	53	55	O
DDI-DrugBank.d480.s5	,	56	56	O
DDI-DrugBank.d480.s5	in	58	59	O
DDI-DrugBank.d480.s5	rare	61	64	O
DDI-DrugBank.d480.s5	cases	66	70	O
DDI-DrugBank.d480.s5	(	72	72	O
DDI-DrugBank.d480.s5	approximately	73	85	O
DDI-DrugBank.d480.s5	1	87	87	O
DDI-DrugBank.d480.s5	case	89	92	O
DDI-DrugBank.d480.s5	per	94	96	O
DDI-DrugBank.d480.s5	3,000	98	102	O
DDI-DrugBank.d480.s5	patients	104	111	O
DDI-DrugBank.d480.s5	)	112	112	O
DDI-DrugBank.d480.s5	,	99	99	O
DDI-DrugBank.d480.s5	be	115	116	O
DDI-DrugBank.d480.s5	accompanied	118	128	O
DDI-DrugBank.d480.s5	by	130	131	O
DDI-DrugBank.d480.s5	profound	133	140	O
DDI-DrugBank.d480.s5	collapse	142	149	O
DDI-DrugBank.d480.s5	and	151	153	O
DDI-DrugBank.d480.s5	respiratory	155	165	O
DDI-DrugBank.d480.s5	and/or	167	172	O
DDI-DrugBank.d480.s5	cardiac	174	180	O
DDI-DrugBank.d480.s5	arrest	182	187	O
DDI-DrugBank.d480.s5	.	188	188	O
DDI-DrugBank.d480.s6	Some	0	3	O
DDI-DrugBank.d480.s6	of	5	6	O
DDI-DrugBank.d480.s6	the	8	10	O
DDI-DrugBank.d480.s6	cases	12	16	O
DDI-DrugBank.d480.s6	of	18	19	O
DDI-DrugBank.d480.s6	collapse/respiratory	21	40	O
DDI-DrugBank.d480.s6	arrest/cardiac	42	55	O
DDI-DrugBank.d480.s6	arrest	57	62	O
DDI-DrugBank.d480.s6	during	64	69	O
DDI-DrugBank.d480.s6	initial	71	77	O
DDI-DrugBank.d480.s6	treatment	79	87	O
DDI-DrugBank.d480.s6	occurred	89	96	O
DDI-DrugBank.d480.s6	in	98	99	O
DDI-DrugBank.d480.s6	patients	101	108	O
DDI-DrugBank.d480.s6	who	110	112	O
DDI-DrugBank.d480.s6	were	114	117	O
DDI-DrugBank.d480.s6	being	119	123	O
DDI-DrugBank.d480.s6	administered	125	136	O
DDI-DrugBank.d480.s6	benzodiazepines	138	152	B-group
DDI-DrugBank.d480.s6	;	153	153	O
DDI-DrugBank.d480.s7	similar	0	6	O
DDI-DrugBank.d480.s7	events	8	13	O
DDI-DrugBank.d480.s7	have	15	18	O
DDI-DrugBank.d480.s7	been	20	23	O
DDI-DrugBank.d480.s7	reported	25	32	O
DDI-DrugBank.d480.s7	in	34	35	O
DDI-DrugBank.d480.s7	patients	37	44	O
DDI-DrugBank.d480.s7	taking	46	51	O
DDI-DrugBank.d480.s7	other	53	57	O
DDI-DrugBank.d480.s7	psychotropic	59	70	B-group
DDI-DrugBank.d480.s7	drugs	72	76	I-group
DDI-DrugBank.d480.s7	or	78	79	O
DDI-DrugBank.d480.s7	even	81	84	O
DDI-DrugBank.d480.s7	Clozapine	86	94	B-drug
DDI-DrugBank.d480.s7	by	96	97	O
DDI-DrugBank.d480.s7	itself	99	104	O
DDI-DrugBank.d480.s7	.	105	105	O
DDI-DrugBank.d480.s8	Although	0	7	O
DDI-DrugBank.d480.s8	it	9	10	O
DDI-DrugBank.d480.s8	has	12	14	O
DDI-DrugBank.d480.s8	not	16	18	O
DDI-DrugBank.d480.s8	been	20	23	O
DDI-DrugBank.d480.s8	established	25	35	O
DDI-DrugBank.d480.s8	that	37	40	O
DDI-DrugBank.d480.s8	there	42	46	O
DDI-DrugBank.d480.s8	is	48	49	O
DDI-DrugBank.d480.s8	an	51	52	O
DDI-DrugBank.d480.s8	interaction	54	64	O
DDI-DrugBank.d480.s8	between	66	72	O
DDI-DrugBank.d480.s8	Clozapine	74	82	B-drug
DDI-DrugBank.d480.s8	and	84	86	O
DDI-DrugBank.d480.s8	benzodiazepines	88	102	B-group
DDI-DrugBank.d480.s8	or	104	105	O
DDI-DrugBank.d480.s8	other	107	111	O
DDI-DrugBank.d480.s8	psychotropics	113	125	B-group
DDI-DrugBank.d480.s8	,	126	126	O
DDI-DrugBank.d480.s8	caution	128	134	O
DDI-DrugBank.d480.s8	is	136	137	O
DDI-DrugBank.d480.s8	advised	139	145	O
DDI-DrugBank.d480.s8	when	147	150	O
DDI-DrugBank.d480.s8	clozapine	152	160	B-drug
DDI-DrugBank.d480.s8	is	142	143	O
DDI-DrugBank.d480.s8	initiated	165	173	O
DDI-DrugBank.d480.s8	in	158	159	I-drug
DDI-DrugBank.d480.s8	patients	178	185	O
DDI-DrugBank.d480.s8	taking	187	192	O
DDI-DrugBank.d480.s8	a	170	170	O
DDI-DrugBank.d480.s8	benzodiazepine	196	209	B-group
DDI-DrugBank.d480.s8	or	211	212	O
DDI-DrugBank.d480.s8	any	214	216	O
DDI-DrugBank.d480.s8	other	218	222	O
DDI-DrugBank.d480.s8	psychotropic	224	235	B-group
DDI-DrugBank.d480.s8	drug	237	240	I-group
DDI-DrugBank.d480.s8	.	241	241	O
DDI-DrugBank.d480.s9	Clozapine	0	8	B-drug
DDI-DrugBank.d480.s9	may	10	12	O
DDI-DrugBank.d480.s9	potentiate	14	23	O
DDI-DrugBank.d480.s9	the	25	27	O
DDI-DrugBank.d480.s9	hypotensive	29	39	O
DDI-DrugBank.d480.s9	effects	41	47	O
DDI-DrugBank.d480.s9	of	49	50	O
DDI-DrugBank.d480.s9	antihypertensive	52	67	B-group
DDI-DrugBank.d480.s9	drugs	69	73	I-group
DDI-DrugBank.d480.s9	and	75	77	O
DDI-DrugBank.d480.s9	the	79	81	O
DDI-DrugBank.d480.s9	anticholinergic	83	97	O
DDI-DrugBank.d480.s9	effects	99	105	O
DDI-DrugBank.d480.s9	of	107	108	O
DDI-DrugBank.d480.s9	atropine-type	110	122	O
DDI-DrugBank.d480.s9	drugs	124	128	O
DDI-DrugBank.d480.s9	.	129	129	O
DDI-DrugBank.d480.s10	The	0	2	O
DDI-DrugBank.d480.s10	administration	4	17	O
DDI-DrugBank.d480.s10	of	19	20	O
DDI-DrugBank.d480.s10	epinephrine	22	32	B-drug
DDI-DrugBank.d480.s10	should	34	39	O
DDI-DrugBank.d480.s10	be	41	42	O
DDI-DrugBank.d480.s10	avoided	44	50	O
DDI-DrugBank.d480.s10	in	52	53	O
DDI-DrugBank.d480.s10	the	55	57	O
DDI-DrugBank.d480.s10	treatment	59	67	O
DDI-DrugBank.d480.s10	of	69	70	O
DDI-DrugBank.d480.s10	drug	72	75	O
DDI-DrugBank.d480.s10	induced	77	83	O
DDI-DrugBank.d480.s10	hypotension	85	95	O
DDI-DrugBank.d480.s10	because	97	103	O
DDI-DrugBank.d480.s10	of	105	106	O
DDI-DrugBank.d480.s10	a	100	100	O
DDI-DrugBank.d480.s10	possible	110	117	O
DDI-DrugBank.d480.s10	reverse	119	125	O
DDI-DrugBank.d480.s10	epinephrine	127	137	B-drug
DDI-DrugBank.d480.s10	effect	139	144	O
DDI-DrugBank.d480.s10	.	145	145	O
DDI-DrugBank.d480.s11	Pharmacokinetic-related	0	22	O
DDI-DrugBank.d480.s11	Interactions	24	35	O
DDI-DrugBank.d480.s11	:	36	36	O
DDI-DrugBank.d480.s11	Clozapine	38	46	B-drug
DDI-DrugBank.d480.s11	is	48	49	O
DDI-DrugBank.d480.s11	a	51	51	O
DDI-DrugBank.d480.s11	substrate	53	61	O
DDI-DrugBank.d480.s11	for	63	65	O
DDI-DrugBank.d480.s11	many	67	70	O
DDI-DrugBank.d480.s11	CYP	72	74	O
DDI-DrugBank.d480.s11	450	76	78	O
DDI-DrugBank.d480.s11	isozymes	80	87	O
DDI-DrugBank.d480.s11	,	88	88	O
DDI-DrugBank.d480.s11	in	90	91	O
DDI-DrugBank.d480.s11	particular	93	102	O
DDI-DrugBank.d480.s11	1A2	104	106	O
DDI-DrugBank.d480.s11	,	107	107	O
DDI-DrugBank.d480.s11	2D6	109	111	O
DDI-DrugBank.d480.s11	,	107	107	O
DDI-DrugBank.d480.s11	and	114	116	O
DDI-DrugBank.d480.s11	3A4	118	120	O
DDI-DrugBank.d480.s11	.	121	121	O
DDI-DrugBank.d480.s12	The	0	2	O
DDI-DrugBank.d480.s12	risk	4	7	O
DDI-DrugBank.d480.s12	of	9	10	O
DDI-DrugBank.d480.s12	metabolic	12	20	O
DDI-DrugBank.d480.s12	interactions	22	33	O
DDI-DrugBank.d480.s12	caused	35	40	O
DDI-DrugBank.d480.s12	by	42	43	O
DDI-DrugBank.d480.s12	an	45	46	O
DDI-DrugBank.d480.s12	effect	48	53	O
DDI-DrugBank.d480.s12	on	55	56	O
DDI-DrugBank.d480.s12	an	58	59	O
DDI-DrugBank.d480.s12	individual	61	70	O
DDI-DrugBank.d480.s12	isoform	72	78	O
DDI-DrugBank.d480.s12	is	72	73	O
DDI-DrugBank.d480.s12	therefore	83	91	O
DDI-DrugBank.d480.s12	minimized	93	101	O
DDI-DrugBank.d480.s12	.	102	102	O
DDI-DrugBank.d480.s13	Nevertheless	0	11	O
DDI-DrugBank.d480.s13	,	12	12	O
DDI-DrugBank.d480.s13	caution	14	20	O
DDI-DrugBank.d480.s13	should	22	27	O
DDI-DrugBank.d480.s13	be	29	30	O
DDI-DrugBank.d480.s13	used	32	35	O
DDI-DrugBank.d480.s13	in	37	38	O
DDI-DrugBank.d480.s13	patients	40	47	O
DDI-DrugBank.d480.s13	receiving	49	57	O
DDI-DrugBank.d480.s13	concomitant	59	69	O
DDI-DrugBank.d480.s13	treatment	71	79	O
DDI-DrugBank.d480.s13	with	81	84	O
DDI-DrugBank.d480.s13	other	86	90	O
DDI-DrugBank.d480.s13	drugs	92	96	O
DDI-DrugBank.d480.s13	that	98	101	O
DDI-DrugBank.d480.s13	are	103	105	O
DDI-DrugBank.d480.s13	either	107	112	O
DDI-DrugBank.d480.s13	inhibitors	114	123	O
DDI-DrugBank.d480.s13	or	121	122	O
DDI-DrugBank.d480.s13	inducers	128	135	O
DDI-DrugBank.d480.s13	of	137	138	O
DDI-DrugBank.d480.s13	these	140	144	O
DDI-DrugBank.d480.s13	enzymes	146	152	O
DDI-DrugBank.d480.s13	.	153	153	O
DDI-DrugBank.d480.s14	Concomitant	0	10	O
DDI-DrugBank.d480.s14	administration	12	25	O
DDI-DrugBank.d480.s14	of	27	28	O
DDI-DrugBank.d480.s14	drugs	30	34	O
DDI-DrugBank.d480.s14	known	36	40	O
DDI-DrugBank.d480.s14	to	42	43	O
DDI-DrugBank.d480.s14	induce	45	50	O
DDI-DrugBank.d480.s14	cytochrome	52	61	O
DDI-DrugBank.d480.s14	P450	63	66	O
DDI-DrugBank.d480.s14	enzymes	68	74	O
DDI-DrugBank.d480.s14	may	76	78	O
DDI-DrugBank.d480.s14	decrease	80	87	O
DDI-DrugBank.d480.s14	the	89	91	O
DDI-DrugBank.d480.s14	plasma	93	98	O
DDI-DrugBank.d480.s14	levels	100	105	O
DDI-DrugBank.d480.s14	of	107	108	O
DDI-DrugBank.d480.s14	clozapine	110	118	B-drug
DDI-DrugBank.d480.s14	.	119	119	O
DDI-DrugBank.d480.s15	Phenytoin	0	8	B-drug
DDI-DrugBank.d480.s15	,	9	9	O
DDI-DrugBank.d480.s15	nicotine	11	18	B-drug
DDI-DrugBank.d480.s15	,	19	19	O
DDI-DrugBank.d480.s15	and	21	23	O
DDI-DrugBank.d480.s15	rifampin	25	32	B-drug
DDI-DrugBank.d480.s15	may	34	36	O
DDI-DrugBank.d480.s15	decrease	38	45	O
DDI-DrugBank.d480.s15	Clozapine	47	55	B-drug
DDI-DrugBank.d480.s15	plasma	57	62	O
DDI-DrugBank.d480.s15	levels	64	69	O
DDI-DrugBank.d480.s15	,	70	70	O
DDI-DrugBank.d480.s15	resulting	72	80	O
DDI-DrugBank.d480.s15	in	78	79	O
DDI-DrugBank.d480.s15	a	85	85	O
DDI-DrugBank.d480.s15	decrease	87	94	O
DDI-DrugBank.d480.s15	in	96	97	O
DDI-DrugBank.d480.s15	effectiveness	99	111	O
DDI-DrugBank.d480.s15	of	113	114	O
DDI-DrugBank.d480.s15	a	116	116	O
DDI-DrugBank.d480.s15	previously	118	127	O
DDI-DrugBank.d480.s15	effective	129	137	O
DDI-DrugBank.d480.s15	Clozapine	139	147	B-drug
DDI-DrugBank.d480.s15	dose	149	152	O
DDI-DrugBank.d480.s15	.	153	153	O
DDI-DrugBank.d480.s16	Concomitant	0	10	O
DDI-DrugBank.d480.s16	administration	12	25	O
DDI-DrugBank.d480.s16	of	27	28	O
DDI-DrugBank.d480.s16	drugs	30	34	O
DDI-DrugBank.d480.s16	known	36	40	O
DDI-DrugBank.d480.s16	to	42	43	O
DDI-DrugBank.d480.s16	inhibit	45	51	O
DDI-DrugBank.d480.s16	the	53	55	O
DDI-DrugBank.d480.s16	activity	57	64	O
DDI-DrugBank.d480.s16	of	66	67	O
DDI-DrugBank.d480.s16	cytochrome	69	78	O
DDI-DrugBank.d480.s16	P450	80	83	O
DDI-DrugBank.d480.s16	isozymes	85	92	O
DDI-DrugBank.d480.s16	may	94	96	O
DDI-DrugBank.d480.s16	increase	98	105	O
DDI-DrugBank.d480.s16	the	107	109	O
DDI-DrugBank.d480.s16	plasma	111	116	O
DDI-DrugBank.d480.s16	levels	118	123	O
DDI-DrugBank.d480.s16	of	125	126	O
DDI-DrugBank.d480.s16	clozapine	128	136	B-drug
DDI-DrugBank.d480.s16	.	137	137	O
DDI-DrugBank.d480.s17	Cimetidine	0	9	B-drug
DDI-DrugBank.d480.s17	,	10	10	O
DDI-DrugBank.d480.s17	caffeine	12	19	B-drug
DDI-DrugBank.d480.s17	,	20	20	O
DDI-DrugBank.d480.s17	and	22	24	O
DDI-DrugBank.d480.s17	erythromycin	26	37	B-drug
DDI-DrugBank.d480.s17	may	39	41	O
DDI-DrugBank.d480.s17	increase	43	50	O
DDI-DrugBank.d480.s17	plasma	52	57	O
DDI-DrugBank.d480.s17	levels	59	64	O
DDI-DrugBank.d480.s17	of	66	67	O
DDI-DrugBank.d480.s17	Clozapine	69	77	B-drug
DDI-DrugBank.d480.s17	,	78	78	O
DDI-DrugBank.d480.s17	potentially	80	90	O
DDI-DrugBank.d480.s17	resulting	92	100	O
DDI-DrugBank.d480.s17	in	98	99	O
DDI-DrugBank.d480.s17	adverse	105	111	O
DDI-DrugBank.d480.s17	effects	113	119	O
DDI-DrugBank.d480.s17	.	120	120	O
DDI-DrugBank.d480.s18	Although	0	7	O
DDI-DrugBank.d480.s18	concomitant	9	19	O
DDI-DrugBank.d480.s18	use	21	23	O
DDI-DrugBank.d480.s18	of	25	26	O
DDI-DrugBank.d480.s18	Clozapine	28	36	B-drug
DDI-DrugBank.d480.s18	and	38	40	O
DDI-DrugBank.d480.s18	carbamazepine	42	54	B-drug
DDI-DrugBank.d480.s18	is	56	57	O
DDI-DrugBank.d480.s18	not	59	61	O
DDI-DrugBank.d480.s18	recommended	63	73	O
DDI-DrugBank.d480.s18	,	74	74	O
DDI-DrugBank.d480.s18	it	76	77	O
DDI-DrugBank.d480.s18	should	79	84	O
DDI-DrugBank.d480.s18	be	86	87	O
DDI-DrugBank.d480.s18	noted	89	93	O
DDI-DrugBank.d480.s18	that	95	98	O
DDI-DrugBank.d480.s18	discontinuation	100	114	O
DDI-DrugBank.d480.s18	of	116	117	O
DDI-DrugBank.d480.s18	concomitant	119	129	O
DDI-DrugBank.d480.s18	carbamazepine	131	143	B-drug
DDI-DrugBank.d480.s18	administration	145	158	O
DDI-DrugBank.d480.s18	may	160	162	O
DDI-DrugBank.d480.s18	result	164	169	O
DDI-DrugBank.d480.s18	in	171	172	O
DDI-DrugBank.d480.s18	an	174	175	O
DDI-DrugBank.d480.s18	increase	177	184	O
DDI-DrugBank.d480.s18	in	171	172	O
DDI-DrugBank.d480.s18	Clozapine	189	197	B-drug
DDI-DrugBank.d480.s18	plasma	199	204	O
DDI-DrugBank.d480.s18	levels	206	211	O
DDI-DrugBank.d480.s18	.	212	212	O
DDI-DrugBank.d480.s19	In	0	1	O
DDI-DrugBank.d480.s19	a	3	3	O
DDI-DrugBank.d480.s19	study	5	9	O
DDI-DrugBank.d480.s19	of	11	12	O
DDI-DrugBank.d480.s19	schizophrenic	14	26	O
DDI-DrugBank.d480.s19	patients	28	35	O
DDI-DrugBank.d480.s19	who	37	39	O
DDI-DrugBank.d480.s19	received	41	48	O
DDI-DrugBank.d480.s19	clozapine	50	58	B-drug
DDI-DrugBank.d480.s19	under	60	64	O
DDI-DrugBank.d480.s19	steady	66	71	O
DDI-DrugBank.d480.s19	state	73	77	O
DDI-DrugBank.d480.s19	conditions	79	88	O
DDI-DrugBank.d480.s19	,	89	89	O
DDI-DrugBank.d480.s19	fluvoxamine	91	101	B-drug
DDI-DrugBank.d480.s19	or	103	104	O
DDI-DrugBank.d480.s19	paroxetine	106	115	B-drug
DDI-DrugBank.d480.s19	was	117	119	O
DDI-DrugBank.d480.s19	added	121	125	O
DDI-DrugBank.d480.s19	in	113	114	I-drug
DDI-DrugBank.d480.s19	16	130	131	O
DDI-DrugBank.d480.s19	and	133	135	O
DDI-DrugBank.d480.s19	14	137	138	O
DDI-DrugBank.d480.s19	patients	140	147	O
DDI-DrugBank.d480.s19	,	148	148	O
DDI-DrugBank.d480.s19	respectively	150	161	O
DDI-DrugBank.d480.s19	.	162	162	O
DDI-DrugBank.d480.s20	After	0	4	O
DDI-DrugBank.d480.s20	14	6	7	O
DDI-DrugBank.d480.s20	days	9	12	O
DDI-DrugBank.d480.s20	of	14	15	O
DDI-DrugBank.d480.s20	co-administration	17	33	O
DDI-DrugBank.d480.s20	,	34	34	O
DDI-DrugBank.d480.s20	mean	36	39	O
DDI-DrugBank.d480.s20	trough	41	46	O
DDI-DrugBank.d480.s20	concentrations	48	61	O
DDI-DrugBank.d480.s20	of	63	64	O
DDI-DrugBank.d480.s20	clozapine	66	74	B-drug
DDI-DrugBank.d480.s20	and	76	78	O
DDI-DrugBank.d480.s20	its	80	82	O
DDI-DrugBank.d480.s20	metabolites	84	94	O
DDI-DrugBank.d480.s20	,	95	95	O
DDI-DrugBank.d480.s20	N-desmethylclozapine	97	116	B-drug_n
DDI-DrugBank.d480.s20	and	118	120	O
DDI-DrugBank.d480.s20	clozapine	108	116	I-drug_n
DDI-DrugBank.d480.s20	N-oxide	132	138	I-drug_n
DDI-DrugBank.d480.s20	,	139	139	O
DDI-DrugBank.d480.s20	were	141	144	O
DDI-DrugBank.d480.s20	elevated	146	153	O
DDI-DrugBank.d480.s20	with	155	158	O
DDI-DrugBank.d480.s20	fluvoxamine	160	170	B-drug
DDI-DrugBank.d480.s20	by	172	173	O
DDI-DrugBank.d480.s20	about	175	179	O
DDI-DrugBank.d480.s20	three-fold	181	190	O
DDI-DrugBank.d480.s20	compared	192	199	O
DDI-DrugBank.d480.s20	to	201	202	O
DDI-DrugBank.d480.s20	baseline	204	211	O
DDI-DrugBank.d480.s20	concentrations	213	226	O
DDI-DrugBank.d480.s20	.	227	227	O
DDI-DrugBank.d480.s21	Paroxetine	0	9	B-drug
DDI-DrugBank.d480.s21	produced	11	18	O
DDI-DrugBank.d480.s21	only	20	23	O
DDI-DrugBank.d480.s21	minor	25	29	O
DDI-DrugBank.d480.s21	changes	31	37	O
DDI-DrugBank.d480.s21	in	39	40	O
DDI-DrugBank.d480.s21	the	42	44	O
DDI-DrugBank.d480.s21	levels	46	51	O
DDI-DrugBank.d480.s21	of	53	54	O
DDI-DrugBank.d480.s21	clozapine	56	64	B-drug
DDI-DrugBank.d480.s21	and	66	68	O
DDI-DrugBank.d480.s21	its	70	72	O
DDI-DrugBank.d480.s21	metabolites	74	84	O
DDI-DrugBank.d480.s21	.	85	85	O
DDI-DrugBank.d480.s22	However	0	6	O
DDI-DrugBank.d480.s22	,	7	7	O
DDI-DrugBank.d480.s22	other	9	13	O
DDI-DrugBank.d480.s22	published	15	23	O
DDI-DrugBank.d480.s22	reports	25	31	O
DDI-DrugBank.d480.s22	describe	33	40	O
DDI-DrugBank.d480.s22	modest	42	47	O
DDI-DrugBank.d480.s22	elevations	49	58	O
DDI-DrugBank.d480.s22	(	60	60	O
DDI-DrugBank.d480.s22	less	61	64	O
DDI-DrugBank.d480.s22	than	66	69	O
DDI-DrugBank.d480.s22	two-fold	71	78	O
DDI-DrugBank.d480.s22	)	79	79	O
DDI-DrugBank.d480.s22	of	81	82	O
DDI-DrugBank.d480.s22	clozapine	84	92	B-drug
DDI-DrugBank.d480.s22	and	94	96	O
DDI-DrugBank.d480.s22	metabolite	98	107	O
DDI-DrugBank.d480.s22	concentrations	109	122	O
DDI-DrugBank.d480.s22	when	124	127	O
DDI-DrugBank.d480.s22	clozapine	129	137	B-drug
DDI-DrugBank.d480.s22	was	139	141	O
DDI-DrugBank.d480.s22	taken	143	147	O
DDI-DrugBank.d480.s22	with	149	152	O
DDI-DrugBank.d480.s22	paroxetine	154	163	B-drug
DDI-DrugBank.d480.s22	,	164	164	O
DDI-DrugBank.d480.s22	fluoxetine	166	175	B-drug
DDI-DrugBank.d480.s22	,	164	164	O
DDI-DrugBank.d480.s22	and	178	180	O
DDI-DrugBank.d480.s22	sertraline	182	191	B-drug
DDI-DrugBank.d480.s22	.	192	192	O
DDI-DrugBank.d480.s23	Therefore	0	8	O
DDI-DrugBank.d480.s23	,	9	9	O
DDI-DrugBank.d480.s23	such	11	14	O
DDI-DrugBank.d480.s23	combined	16	23	O
DDI-DrugBank.d480.s23	treatment	25	33	O
DDI-DrugBank.d480.s23	should	35	40	O
DDI-DrugBank.d480.s23	be	42	43	O
DDI-DrugBank.d480.s23	approached	45	54	O
DDI-DrugBank.d480.s23	with	56	59	O
DDI-DrugBank.d480.s23	caution	61	67	O
DDI-DrugBank.d480.s23	and	69	71	O
DDI-DrugBank.d480.s23	patients	73	80	O
DDI-DrugBank.d480.s23	should	82	87	O
DDI-DrugBank.d480.s23	be	89	90	O
DDI-DrugBank.d480.s23	monitored	92	100	O
DDI-DrugBank.d480.s23	closely	102	108	O
DDI-DrugBank.d480.s23	when	110	113	O
DDI-DrugBank.d480.s23	Clozapine	115	123	B-drug
DDI-DrugBank.d480.s23	is	125	126	O
DDI-DrugBank.d480.s23	combined	128	135	O
DDI-DrugBank.d480.s23	with	137	140	O
DDI-DrugBank.d480.s23	these	142	146	O
DDI-DrugBank.d480.s23	drugs	148	152	O
DDI-DrugBank.d480.s23	,	153	153	O
DDI-DrugBank.d480.s23	particularly	155	166	O
DDI-DrugBank.d480.s23	with	168	171	O
DDI-DrugBank.d480.s23	fluvoxamine	173	183	B-drug
DDI-DrugBank.d480.s23	.	184	184	O
DDI-DrugBank.d480.s24	A	0	0	O
DDI-DrugBank.d480.s24	reduced	2	8	O
DDI-DrugBank.d480.s24	Clozapine	10	18	B-drug
DDI-DrugBank.d480.s24	dose	20	23	O
DDI-DrugBank.d480.s24	should	25	30	O
DDI-DrugBank.d480.s24	be	32	33	O
DDI-DrugBank.d480.s24	considered	35	44	O
DDI-DrugBank.d480.s24	.	45	45	O
DDI-DrugBank.d480.s25	A	0	0	O
DDI-DrugBank.d480.s25	subset	2	7	O
DDI-DrugBank.d480.s25	(	9	9	O
DDI-DrugBank.d480.s25	3	10	10	O
DDI-DrugBank.d480.s25	%	11	11	O
DDI-DrugBank.d480.s25	-10	12	14	O
DDI-DrugBank.d480.s25	%	15	15	O
DDI-DrugBank.d480.s25	)	16	16	O
DDI-DrugBank.d480.s25	of	18	19	O
DDI-DrugBank.d480.s25	the	21	23	O
DDI-DrugBank.d480.s25	population	25	34	O
DDI-DrugBank.d480.s25	has	36	38	O
DDI-DrugBank.d480.s25	reduced	40	46	O
DDI-DrugBank.d480.s25	activity	48	55	O
DDI-DrugBank.d480.s25	of	57	58	O
DDI-DrugBank.d480.s25	certain	60	66	O
DDI-DrugBank.d480.s25	drug	68	71	O
DDI-DrugBank.d480.s25	metabolizing	73	84	O
DDI-DrugBank.d480.s25	enzymes	86	92	O
DDI-DrugBank.d480.s25	such	94	97	O
DDI-DrugBank.d480.s25	as	99	100	O
DDI-DrugBank.d480.s25	the	102	104	O
DDI-DrugBank.d480.s25	cytochrome	106	115	O
DDI-DrugBank.d480.s25	P450	117	120	O
DDI-DrugBank.d480.s25	isozyme	122	128	O
DDI-DrugBank.d480.s25	P450	117	120	O
DDI-DrugBank.d480.s25	2D6	135	137	O
DDI-DrugBank.d480.s25	.	138	138	O
DDI-DrugBank.d480.s26	Such	0	3	O
DDI-DrugBank.d480.s26	individuals	5	15	O
DDI-DrugBank.d480.s26	are	17	19	O
DDI-DrugBank.d480.s26	referred	21	28	O
DDI-DrugBank.d480.s26	to	30	31	O
DDI-DrugBank.d480.s26	as	33	34	O
DDI-DrugBank.d480.s26	poor	36	39	O
DDI-DrugBank.d480.s26	metabolizers	41	52	O
DDI-DrugBank.d480.s26	of	54	55	O
DDI-DrugBank.d480.s26	drugs	57	61	O
DDI-DrugBank.d480.s26	such	63	66	O
DDI-DrugBank.d480.s26	as	68	69	O
DDI-DrugBank.d480.s26	debrisoquin	71	81	B-drug
DDI-DrugBank.d480.s26	,	82	82	O
DDI-DrugBank.d480.s26	dextromethorphan	84	99	B-drug
DDI-DrugBank.d480.s26	,	100	100	O
DDI-DrugBank.d480.s26	the	102	104	O
DDI-DrugBank.d480.s26	tricyclic	106	114	B-group
DDI-DrugBank.d480.s26	antidepressants	116	130	I-group
DDI-DrugBank.d480.s26	,	131	131	O
DDI-DrugBank.d480.s26	and	133	135	O
DDI-DrugBank.d480.s26	clozapine	137	145	B-drug
DDI-DrugBank.d480.s26	.	146	146	O
DDI-DrugBank.d480.s27	These	0	4	O
DDI-DrugBank.d480.s27	individuals	6	16	O
DDI-DrugBank.d480.s27	may	18	20	O
DDI-DrugBank.d480.s27	develop	22	28	O
DDI-DrugBank.d480.s27	higher	30	35	O
DDI-DrugBank.d480.s27	than	37	40	O
DDI-DrugBank.d480.s27	expected	42	49	O
DDI-DrugBank.d480.s27	plasma	51	56	O
DDI-DrugBank.d480.s27	concentrations	58	71	O
DDI-DrugBank.d480.s27	of	73	74	O
DDI-DrugBank.d480.s27	clozapine	76	84	B-drug
DDI-DrugBank.d480.s27	when	86	89	O
DDI-DrugBank.d480.s27	given	91	95	O
DDI-DrugBank.d480.s27	usual	97	101	O
DDI-DrugBank.d480.s27	doses	103	107	O
DDI-DrugBank.d480.s27	.	108	108	O
DDI-DrugBank.d480.s28	In	0	1	O
DDI-DrugBank.d480.s28	addition	3	10	O
DDI-DrugBank.d480.s28	,	11	11	O
DDI-DrugBank.d480.s28	certain	13	19	O
DDI-DrugBank.d480.s28	drugs	21	25	O
DDI-DrugBank.d480.s28	that	27	30	O
DDI-DrugBank.d480.s28	are	32	34	O
DDI-DrugBank.d480.s28	metabolized	36	46	O
DDI-DrugBank.d480.s28	by	48	49	O
DDI-DrugBank.d480.s28	this	51	54	O
DDI-DrugBank.d480.s28	isozyme	56	62	O
DDI-DrugBank.d480.s28	,	63	63	O
DDI-DrugBank.d480.s28	including	65	73	O
DDI-DrugBank.d480.s28	many	75	78	O
DDI-DrugBank.d480.s28	antidepressants	80	94	B-group
DDI-DrugBank.d480.s28	(	96	96	O
DDI-DrugBank.d480.s28	clozapine	97	105	B-drug
DDI-DrugBank.d480.s28	,	106	106	O
DDI-DrugBank.d480.s28	selective	108	116	B-group
DDI-DrugBank.d480.s28	serotonin	118	126	I-group
DDI-DrugBank.d480.s28	reuptake	128	135	I-group
DDI-DrugBank.d480.s28	inhibitors	137	146	I-group
DDI-DrugBank.d480.s28	,	147	147	O
DDI-DrugBank.d480.s28	and	149	151	O
DDI-DrugBank.d480.s28	others	153	158	O
DDI-DrugBank.d480.s28	)	159	159	O
DDI-DrugBank.d480.s28	,	147	147	O
DDI-DrugBank.d480.s28	may	162	164	O
DDI-DrugBank.d480.s28	inhibit	166	172	O
DDI-DrugBank.d480.s28	the	154	156	O
DDI-DrugBank.d480.s28	activity	178	185	O
DDI-DrugBank.d480.s28	of	187	188	O
DDI-DrugBank.d480.s28	this	190	193	O
DDI-DrugBank.d480.s28	isozyme	195	201	O
DDI-DrugBank.d480.s28	,	202	202	O
DDI-DrugBank.d480.s28	and	204	206	O
DDI-DrugBank.d480.s28	thus	208	211	O
DDI-DrugBank.d480.s28	may	213	215	O
DDI-DrugBank.d480.s28	make	217	220	O
DDI-DrugBank.d480.s28	normal	222	227	O
DDI-DrugBank.d480.s28	metabolizers	229	240	O
DDI-DrugBank.d480.s28	resemble	242	249	O
DDI-DrugBank.d480.s28	poor	251	254	O
DDI-DrugBank.d480.s28	metabolizers	229	240	O
DDI-DrugBank.d480.s28	with	269	272	O
DDI-DrugBank.d480.s28	regard	274	279	O
DDI-DrugBank.d480.s28	to	281	282	O
DDI-DrugBank.d480.s28	concomitant	284	294	O
DDI-DrugBank.d480.s28	therapy	296	302	O
DDI-DrugBank.d480.s28	with	269	272	O
DDI-DrugBank.d480.s28	other	309	313	O
DDI-DrugBank.d480.s28	drugs	315	319	O
DDI-DrugBank.d480.s28	metabolized	321	331	O
DDI-DrugBank.d480.s28	by	333	334	O
DDI-DrugBank.d480.s28	this	336	339	O
DDI-DrugBank.d480.s28	enzyme	341	346	O
DDI-DrugBank.d480.s28	system	348	353	O
DDI-DrugBank.d480.s28	,	354	354	O
DDI-DrugBank.d480.s28	leading	356	362	O
DDI-DrugBank.d480.s28	to	364	365	O
DDI-DrugBank.d480.s28	drug	367	370	O
DDI-DrugBank.d480.s28	interaction	372	382	O
DDI-DrugBank.d480.s28	.	383	383	O
DDI-DrugBank.d480.s29	Concomitant	0	10	O
DDI-DrugBank.d480.s29	use	12	14	O
DDI-DrugBank.d480.s29	of	16	17	O
DDI-DrugBank.d480.s29	clozapine	19	27	B-drug
DDI-DrugBank.d480.s29	with	29	32	O
DDI-DrugBank.d480.s29	other	34	38	O
DDI-DrugBank.d480.s29	drugs	40	44	O
DDI-DrugBank.d480.s29	metabolized	46	56	O
DDI-DrugBank.d480.s29	by	58	59	O
DDI-DrugBank.d480.s29	cytochrome	61	70	O
DDI-DrugBank.d480.s29	P450	72	75	O
DDI-DrugBank.d480.s29	2D6	77	79	O
DDI-DrugBank.d480.s29	may	81	83	O
DDI-DrugBank.d480.s29	require	85	91	O
DDI-DrugBank.d480.s29	lower	93	97	O
DDI-DrugBank.d480.s29	doses	99	103	O
DDI-DrugBank.d480.s29	than	105	108	O
DDI-DrugBank.d480.s29	usually	110	116	O
DDI-DrugBank.d480.s29	prescribed	118	127	O
DDI-DrugBank.d480.s29	for	129	131	O
DDI-DrugBank.d480.s29	either	133	138	O
DDI-DrugBank.d480.s29	clozapine	140	148	B-drug
DDI-DrugBank.d480.s29	or	130	131	O
DDI-DrugBank.d480.s29	the	135	137	O
DDI-DrugBank.d480.s29	other	157	161	O
DDI-DrugBank.d480.s29	drug	163	166	O
DDI-DrugBank.d480.s29	.	167	167	O
DDI-DrugBank.d480.s30	Therefore	0	8	O
DDI-DrugBank.d480.s30	,	9	9	O
DDI-DrugBank.d480.s30	co-administration	11	27	O
DDI-DrugBank.d480.s30	of	29	30	O
DDI-DrugBank.d480.s30	clozapine	32	40	B-drug
DDI-DrugBank.d480.s30	with	42	45	O
DDI-DrugBank.d480.s30	other	47	51	O
DDI-DrugBank.d480.s30	drugs	53	57	O
DDI-DrugBank.d480.s30	that	59	62	O
DDI-DrugBank.d480.s30	are	64	66	O
DDI-DrugBank.d480.s30	metabolized	68	78	O
DDI-DrugBank.d480.s30	by	80	81	O
DDI-DrugBank.d480.s30	this	83	86	O
DDI-DrugBank.d480.s30	isozyme	88	94	O
DDI-DrugBank.d480.s30	,	95	95	O
DDI-DrugBank.d480.s30	including	97	105	O
DDI-DrugBank.d480.s30	antidepressants	107	121	B-group
DDI-DrugBank.d480.s30	,	122	122	O
DDI-DrugBank.d480.s30	phenothiazines	124	137	B-group
DDI-DrugBank.d480.s30	,	138	138	O
DDI-DrugBank.d480.s30	carbamazepine	140	152	B-drug
DDI-DrugBank.d480.s30	,	138	138	O
DDI-DrugBank.d480.s30	and	155	157	O
DDI-DrugBank.d480.s30	Type	159	162	B-group
DDI-DrugBank.d480.s30	1C	164	165	I-group
DDI-DrugBank.d480.s30	antiarrhythmics	167	181	I-group
DDI-DrugBank.d480.s30	(	183	183	O
DDI-DrugBank.d480.s30	e.g.	184	187	O
DDI-DrugBank.d480.s30	,	188	188	O
DDI-DrugBank.d480.s30	propafenone	190	200	B-drug
DDI-DrugBank.d480.s30	,	188	188	O
DDI-DrugBank.d480.s30	flecainide	203	212	B-drug
DDI-DrugBank.d480.s30	and	214	216	O
DDI-DrugBank.d480.s30	encainide	218	226	B-drug
DDI-DrugBank.d480.s30	)	227	227	O
DDI-DrugBank.d480.s30	,	228	228	O
DDI-DrugBank.d480.s30	or	230	231	O
DDI-DrugBank.d480.s30	that	233	236	O
DDI-DrugBank.d480.s30	inhibit	238	244	O
DDI-DrugBank.d480.s30	this	246	249	O
DDI-DrugBank.d480.s30	enzyme	251	256	O
DDI-DrugBank.d480.s30	(	258	258	O
DDI-DrugBank.d480.s30	e.g.	259	262	O
DDI-DrugBank.d480.s30	,	263	263	O
DDI-DrugBank.d480.s30	quinidine	265	273	B-drug
DDI-DrugBank.d480.s30	)	274	274	O
DDI-DrugBank.d480.s30	,	263	263	O
DDI-DrugBank.d480.s30	should	277	282	O
DDI-DrugBank.d480.s30	be	284	285	O
DDI-DrugBank.d480.s30	approached	287	296	O
DDI-DrugBank.d480.s30	with	298	301	O
DDI-DrugBank.d480.s30	caution	303	309	O
DDI-DrugBank.d480.s30	.	310	310	O
DDI-DrugBank.d123.s0	Some	0	3	O
DDI-DrugBank.d123.s0	quinolones	5	14	B-group
DDI-DrugBank.d123.s0	,	15	15	O
DDI-DrugBank.d123.s0	including	17	25	O
DDI-DrugBank.d123.s0	ciprofloxacin	27	39	B-drug
DDI-DrugBank.d123.s0	,	40	40	O
DDI-DrugBank.d123.s0	have	42	45	O
DDI-DrugBank.d123.s0	also	47	50	O
DDI-DrugBank.d123.s0	been	52	55	O
DDI-DrugBank.d123.s0	shown	57	61	O
DDI-DrugBank.d123.s0	to	63	64	O
DDI-DrugBank.d123.s0	interfere	66	74	O
DDI-DrugBank.d123.s0	with	76	79	O
DDI-DrugBank.d123.s0	the	81	83	O
DDI-DrugBank.d123.s0	metabolism	85	94	O
DDI-DrugBank.d123.s0	of	96	97	O
DDI-DrugBank.d123.s0	caffeine	99	106	B-drug
DDI-DrugBank.d123.s0	.	107	107	O
DDI-DrugBank.d123.s1	This	0	3	O
DDI-DrugBank.d123.s1	may	5	7	O
DDI-DrugBank.d123.s1	lead	9	12	O
DDI-DrugBank.d123.s1	to	14	15	O
DDI-DrugBank.d123.s1	reduced	17	23	O
DDI-DrugBank.d123.s1	clearance	25	33	O
DDI-DrugBank.d123.s1	of	35	36	O
DDI-DrugBank.d123.s1	caffeine	38	45	B-drug
DDI-DrugBank.d123.s1	and	47	49	O
DDI-DrugBank.d123.s1	a	47	47	O
DDI-DrugBank.d123.s1	prolongation	53	64	O
DDI-DrugBank.d123.s1	of	66	67	O
DDI-DrugBank.d123.s1	its	69	71	O
DDI-DrugBank.d123.s1	serum	73	77	O
DDI-DrugBank.d123.s1	half-life	79	87	O
DDI-DrugBank.d123.s1	.	88	88	O
DDI-DrugBank.d123.s2	Some	0	3	O
DDI-DrugBank.d123.s2	quinolones	5	14	B-group
DDI-DrugBank.d123.s2	,	15	15	O
DDI-DrugBank.d123.s2	including	17	25	O
DDI-DrugBank.d123.s2	ciprofloxacin	27	39	B-drug
DDI-DrugBank.d123.s2	,	40	40	O
DDI-DrugBank.d123.s2	have	42	45	O
DDI-DrugBank.d123.s2	been	47	50	O
DDI-DrugBank.d123.s2	associated	52	61	O
DDI-DrugBank.d123.s2	with	63	66	O
DDI-DrugBank.d123.s2	transient	68	76	O
DDI-DrugBank.d123.s2	elevations	78	87	O
DDI-DrugBank.d123.s2	in	89	90	O
DDI-DrugBank.d123.s2	serum	92	96	O
DDI-DrugBank.d123.s2	creatinine	98	107	O
DDI-DrugBank.d123.s2	in	103	104	O
DDI-DrugBank.d123.s2	patients	112	119	O
DDI-DrugBank.d123.s2	receiving	121	129	O
DDI-DrugBank.d123.s2	cyclosporine	131	142	B-drug
DDI-DrugBank.d123.s2	concomitantly	144	156	O
DDI-DrugBank.d123.s2	.	157	157	O
DDI-DrugBank.d123.s3	Glyburide	0	8	B-drug
DDI-DrugBank.d123.s3	:	9	9	O
DDI-DrugBank.d123.s3	The	11	13	O
DDI-DrugBank.d123.s3	concomitant	15	25	O
DDI-DrugBank.d123.s3	administration	27	40	O
DDI-DrugBank.d123.s3	of	42	43	O
DDI-DrugBank.d123.s3	ciprofloxacin	45	57	B-drug
DDI-DrugBank.d123.s3	with	59	62	O
DDI-DrugBank.d123.s3	the	64	66	O
DDI-DrugBank.d123.s3	sulfonylurea	68	79	B-group
DDI-DrugBank.d123.s3	glyburide	81	89	B-drug
DDI-DrugBank.d123.s3	has	91	93	O
DDI-DrugBank.d123.s3	,	94	94	O
DDI-DrugBank.d123.s3	on	96	97	O
DDI-DrugBank.d123.s3	rare	99	102	O
DDI-DrugBank.d123.s3	occasions	104	112	O
DDI-DrugBank.d123.s3	,	113	113	O
DDI-DrugBank.d123.s3	resulted	115	122	O
DDI-DrugBank.d123.s3	in	124	125	O
DDI-DrugBank.d123.s3	severe	127	132	O
DDI-DrugBank.d123.s3	hypoglycemia	134	145	O
DDI-DrugBank.d123.s3	.	146	146	O
DDI-DrugBank.d123.s4	Histamine	0	8	B-group
DDI-DrugBank.d123.s4	H2-receptor	10	20	I-group
DDI-DrugBank.d123.s4	antagonists	22	32	I-group
DDI-DrugBank.d123.s4	:	33	33	O
DDI-DrugBank.d123.s4	Histamine	35	43	B-group
DDI-DrugBank.d123.s4	H2-receptor	45	55	I-group
DDI-DrugBank.d123.s4	antagonists	57	67	I-group
DDI-DrugBank.d123.s4	appear	69	74	O
DDI-DrugBank.d123.s4	to	76	77	O
DDI-DrugBank.d123.s4	have	79	82	O
DDI-DrugBank.d123.s4	no	84	85	O
DDI-DrugBank.d123.s4	significant	87	97	O
DDI-DrugBank.d123.s4	effect	99	104	O
DDI-DrugBank.d123.s4	on	106	107	O
DDI-DrugBank.d123.s4	the	109	111	O
DDI-DrugBank.d123.s4	bioavailability	113	127	O
DDI-DrugBank.d123.s4	of	129	130	O
DDI-DrugBank.d123.s4	ciprofloxacin	132	144	B-drug
DDI-DrugBank.d123.s4	.	145	145	O
DDI-DrugBank.d123.s5	Methotrexate	0	11	B-drug
DDI-DrugBank.d123.s5	Renal	13	17	O
DDI-DrugBank.d123.s5	tubular	19	25	O
DDI-DrugBank.d123.s5	transport	27	35	O
DDI-DrugBank.d123.s5	of	37	38	O
DDI-DrugBank.d123.s5	methotrexate	40	51	B-drug
DDI-DrugBank.d123.s5	may	53	55	O
DDI-DrugBank.d123.s5	be	57	58	O
DDI-DrugBank.d123.s5	inhibited	60	68	O
DDI-DrugBank.d123.s5	by	70	71	O
DDI-DrugBank.d123.s5	concomitant	73	83	O
DDI-DrugBank.d123.s5	administration	85	98	O
DDI-DrugBank.d123.s5	of	100	101	O
DDI-DrugBank.d123.s5	ciprofloxacin	103	115	B-drug
DDI-DrugBank.d123.s5	,	116	116	O
DDI-DrugBank.d123.s5	potentially	118	128	O
DDI-DrugBank.d123.s5	leading	130	136	O
DDI-DrugBank.d123.s5	to	138	139	O
DDI-DrugBank.d123.s5	increased	141	149	O
DDI-DrugBank.d123.s5	plasma	151	156	O
DDI-DrugBank.d123.s5	levels	158	163	O
DDI-DrugBank.d123.s5	of	165	166	O
DDI-DrugBank.d123.s5	methotrexate	168	179	B-drug
DDI-DrugBank.d123.s5	.	180	180	O
DDI-DrugBank.d123.s6	This	0	3	O
DDI-DrugBank.d123.s6	might	5	9	O
DDI-DrugBank.d123.s6	increase	11	18	O
DDI-DrugBank.d123.s6	the	20	22	O
DDI-DrugBank.d123.s6	risk	24	27	O
DDI-DrugBank.d123.s6	of	29	30	O
DDI-DrugBank.d123.s6	methotrexate	32	43	B-drug
DDI-DrugBank.d123.s6	toxic	45	49	O
DDI-DrugBank.d123.s6	reactions	51	59	O
DDI-DrugBank.d123.s6	.	60	60	O
DDI-DrugBank.d123.s7	Therefore	0	8	O
DDI-DrugBank.d123.s7	,	9	9	O
DDI-DrugBank.d123.s7	patients	11	18	O
DDI-DrugBank.d123.s7	under	20	24	O
DDI-DrugBank.d123.s7	methotrexate	26	37	B-drug
DDI-DrugBank.d123.s7	therapy	39	45	O
DDI-DrugBank.d123.s7	should	47	52	O
DDI-DrugBank.d123.s7	be	54	55	O
DDI-DrugBank.d123.s7	carefully	57	65	O
DDI-DrugBank.d123.s7	monitored	67	75	O
DDI-DrugBank.d123.s7	when	77	80	O
DDI-DrugBank.d123.s7	concomitant	82	92	O
DDI-DrugBank.d123.s7	ciprofloxacin	94	106	B-drug
DDI-DrugBank.d123.s7	therapy	108	114	O
DDI-DrugBank.d123.s7	is	116	117	O
DDI-DrugBank.d123.s7	indicated	119	127	O
DDI-DrugBank.d123.s7	.	128	128	O
DDI-DrugBank.d123.s8	Multivalent	0	10	O
DDI-DrugBank.d123.s8	Cation-Containing	12	28	O
DDI-DrugBank.d123.s8	Products	30	37	O
DDI-DrugBank.d123.s8	:	38	38	O
DDI-DrugBank.d123.s8	Concurrent	40	49	O
DDI-DrugBank.d123.s8	administration	51	64	O
DDI-DrugBank.d123.s8	of	66	67	O
DDI-DrugBank.d123.s8	a	69	69	O
DDI-DrugBank.d123.s8	quinolone	71	79	B-group
DDI-DrugBank.d123.s8	,	80	80	O
DDI-DrugBank.d123.s8	including	82	90	O
DDI-DrugBank.d123.s8	ciprofloxacin	92	104	B-drug
DDI-DrugBank.d123.s8	,	105	105	O
DDI-DrugBank.d123.s8	with	107	110	O
DDI-DrugBank.d123.s8	multivalent	112	122	O
DDI-DrugBank.d123.s8	cation-containing	124	140	O
DDI-DrugBank.d123.s8	products	142	149	O
DDI-DrugBank.d123.s8	such	151	154	O
DDI-DrugBank.d123.s8	as	156	157	O
DDI-DrugBank.d123.s8	magnesium	159	167	B-drug
DDI-DrugBank.d123.s8	or	169	170	O
DDI-DrugBank.d123.s8	aluminum	172	179	B-drug
DDI-DrugBank.d123.s8	antacids	181	188	B-group
DDI-DrugBank.d123.s8	,	189	189	O
DDI-DrugBank.d123.s8	sucralfate	191	200	B-drug
DDI-DrugBank.d123.s8	,	189	189	O
DDI-DrugBank.d123.s8	VIDEX	203	207	B-brand
DDI-DrugBank.d123.s8	chewable/buffered	209	225	O
DDI-DrugBank.d123.s8	tablets	227	233	O
DDI-DrugBank.d123.s8	or	235	236	O
DDI-DrugBank.d123.s8	pediatric	238	246	O
DDI-DrugBank.d123.s8	powder	248	253	O
DDI-DrugBank.d123.s8	,	254	254	O
DDI-DrugBank.d123.s8	or	235	236	O
DDI-DrugBank.d123.s8	products	259	266	O
DDI-DrugBank.d123.s8	containing	268	277	O
DDI-DrugBank.d123.s8	calcium	279	285	B-drug
DDI-DrugBank.d123.s8	,	286	286	O
DDI-DrugBank.d123.s8	iron	288	291	B-drug
DDI-DrugBank.d123.s8	,	286	286	O
DDI-DrugBank.d123.s8	or	294	295	O
DDI-DrugBank.d123.s8	zinc	297	300	B-drug
DDI-DrugBank.d123.s8	may	302	304	O
DDI-DrugBank.d123.s8	substantially	306	318	O
DDI-DrugBank.d123.s8	decrease	320	327	O
DDI-DrugBank.d123.s8	the	329	331	O
DDI-DrugBank.d123.s8	absorption	333	342	O
DDI-DrugBank.d123.s8	of	344	345	O
DDI-DrugBank.d123.s8	ciprofloxacin	347	359	B-drug
DDI-DrugBank.d123.s8	,	360	360	O
DDI-DrugBank.d123.s8	resulting	362	370	O
DDI-DrugBank.d123.s8	in	358	359	I-drug
DDI-DrugBank.d123.s8	serum	375	379	O
DDI-DrugBank.d123.s8	and	381	383	O
DDI-DrugBank.d123.s8	urine	385	389	O
DDI-DrugBank.d123.s8	levels	391	396	O
DDI-DrugBank.d123.s8	considerably	398	409	O
DDI-DrugBank.d123.s8	lower	411	415	O
DDI-DrugBank.d123.s8	than	417	420	O
DDI-DrugBank.d123.s8	desired	422	428	O
DDI-DrugBank.d123.s8	.	429	429	O
DDI-DrugBank.d123.s9	Proquin	0	6	B-brand
DDI-DrugBank.d123.s9	XR	8	9	I-brand
DDI-DrugBank.d123.s9	should	11	16	O
DDI-DrugBank.d123.s9	be	18	19	O
DDI-DrugBank.d123.s9	administered	21	32	O
DDI-DrugBank.d123.s9	at	34	35	O
DDI-DrugBank.d123.s9	least	37	41	O
DDI-DrugBank.d123.s9	4	43	43	O
DDI-DrugBank.d123.s9	hours	45	49	O
DDI-DrugBank.d123.s9	before	51	56	O
DDI-DrugBank.d123.s9	or	54	55	O
DDI-DrugBank.d123.s9	2	61	61	O
DDI-DrugBank.d123.s9	hours	63	67	O
DDI-DrugBank.d123.s9	after	69	73	O
DDI-DrugBank.d123.s9	these	75	79	O
DDI-DrugBank.d123.s9	products	81	88	O
DDI-DrugBank.d123.s9	.	89	89	O
DDI-DrugBank.d123.s10	This	0	3	O
DDI-DrugBank.d123.s10	time	5	8	O
DDI-DrugBank.d123.s10	window	10	15	O
DDI-DrugBank.d123.s10	is	17	18	O
DDI-DrugBank.d123.s10	different	20	28	O
DDI-DrugBank.d123.s10	than	30	33	O
DDI-DrugBank.d123.s10	for	35	37	O
DDI-DrugBank.d123.s10	other	39	43	O
DDI-DrugBank.d123.s10	oral	45	48	O
DDI-DrugBank.d123.s10	formulations	50	61	O
DDI-DrugBank.d123.s10	of	63	64	O
DDI-DrugBank.d123.s10	ciprofloxacin	66	78	B-drug
DDI-DrugBank.d123.s10	,	79	79	O
DDI-DrugBank.d123.s10	which	81	85	O
DDI-DrugBank.d123.s10	are	87	89	O
DDI-DrugBank.d123.s10	usually	91	97	O
DDI-DrugBank.d123.s10	administered	99	110	O
DDI-DrugBank.d123.s10	2	112	112	O
DDI-DrugBank.d123.s10	hours	114	118	O
DDI-DrugBank.d123.s10	before	120	125	O
DDI-DrugBank.d123.s10	or	123	124	O
DDI-DrugBank.d123.s10	6	130	130	O
DDI-DrugBank.d123.s10	hours	114	118	O
DDI-DrugBank.d123.s10	after	138	142	O
DDI-DrugBank.d123.s10	antacids	144	151	B-group
DDI-DrugBank.d123.s10	.	152	152	O
DDI-DrugBank.d123.s11	Non-steroidal	0	12	B-group
DDI-DrugBank.d123.s11	anti-inflammatory	14	30	I-group
DDI-DrugBank.d123.s11	drugs	32	36	I-group
DDI-DrugBank.d123.s11	(	38	38	O
DDI-DrugBank.d123.s11	but	39	41	O
DDI-DrugBank.d123.s11	not	43	45	O
DDI-DrugBank.d123.s11	aspirin	47	53	B-brand
DDI-DrugBank.d123.s11	)	54	54	O
DDI-DrugBank.d123.s11	:	55	55	O
DDI-DrugBank.d123.s11	These	57	61	O
DDI-DrugBank.d123.s11	drugs	63	67	O
DDI-DrugBank.d123.s11	in	69	70	O
DDI-DrugBank.d123.s11	combination	72	82	O
DDI-DrugBank.d123.s11	with	84	87	O
DDI-DrugBank.d123.s11	very	89	92	O
DDI-DrugBank.d123.s11	high	94	97	O
DDI-DrugBank.d123.s11	doses	99	103	O
DDI-DrugBank.d123.s11	of	105	106	O
DDI-DrugBank.d123.s11	quinolones	108	117	B-group
DDI-DrugBank.d123.s11	have	119	122	O
DDI-DrugBank.d123.s11	been	124	127	O
DDI-DrugBank.d123.s11	shown	129	133	O
DDI-DrugBank.d123.s11	to	135	136	O
DDI-DrugBank.d123.s11	provoke	138	144	O
DDI-DrugBank.d123.s11	convulsions	146	156	O
DDI-DrugBank.d123.s11	in	158	159	O
DDI-DrugBank.d123.s11	pre-clinical	161	172	O
DDI-DrugBank.d123.s11	studies	174	180	O
DDI-DrugBank.d123.s11	.	181	181	O
DDI-DrugBank.d123.s12	Omeprazole	0	9	B-drug
DDI-DrugBank.d123.s12	:	10	10	O
DDI-DrugBank.d123.s12	The	12	14	O
DDI-DrugBank.d123.s12	rate	16	19	O
DDI-DrugBank.d123.s12	and	21	23	O
DDI-DrugBank.d123.s12	extent	25	30	O
DDI-DrugBank.d123.s12	of	32	33	O
DDI-DrugBank.d123.s12	absorption	35	44	O
DDI-DrugBank.d123.s12	of	46	47	O
DDI-DrugBank.d123.s12	ciprofloxacin	49	61	B-drug
DDI-DrugBank.d123.s12	was	63	65	O
DDI-DrugBank.d123.s12	bioequivalent	67	79	O
DDI-DrugBank.d123.s12	when	81	84	O
DDI-DrugBank.d123.s12	Proquin	86	92	B-brand
DDI-DrugBank.d123.s12	XR	94	95	I-brand
DDI-DrugBank.d123.s12	was	97	99	O
DDI-DrugBank.d123.s12	given	101	105	O
DDI-DrugBank.d123.s12	alone	107	111	O
DDI-DrugBank.d123.s12	or	113	114	O
DDI-DrugBank.d123.s12	when	116	119	O
DDI-DrugBank.d123.s12	Proquin	121	127	B-brand
DDI-DrugBank.d123.s12	XR	129	130	I-brand
DDI-DrugBank.d123.s12	was	132	134	O
DDI-DrugBank.d123.s12	given	136	140	O
DDI-DrugBank.d123.s12	2	142	142	O
DDI-DrugBank.d123.s12	hours	144	148	O
DDI-DrugBank.d123.s12	after	150	154	O
DDI-DrugBank.d123.s12	omeprazole	156	165	B-drug
DDI-DrugBank.d123.s12	at	167	168	O
DDI-DrugBank.d123.s12	the	170	172	O
DDI-DrugBank.d123.s12	dose	174	177	O
DDI-DrugBank.d123.s12	that	179	182	O
DDI-DrugBank.d123.s12	maximally	184	192	O
DDI-DrugBank.d123.s12	suppresses	194	203	O
DDI-DrugBank.d123.s12	gastric	205	211	O
DDI-DrugBank.d123.s12	acid	213	216	O
DDI-DrugBank.d123.s12	secretion	218	226	O
DDI-DrugBank.d123.s12	.	227	227	O
DDI-DrugBank.d123.s13	Omeprazole	0	9	B-drug
DDI-DrugBank.d123.s13	should	11	16	O
DDI-DrugBank.d123.s13	be	18	19	O
DDI-DrugBank.d123.s13	taken	21	25	O
DDI-DrugBank.d123.s13	as	27	28	O
DDI-DrugBank.d123.s13	directed	30	37	O
DDI-DrugBank.d123.s13	and	39	41	O
DDI-DrugBank.d123.s13	Proquin	43	49	B-brand
DDI-DrugBank.d123.s13	XR	51	52	I-brand
DDI-DrugBank.d123.s13	should	54	59	O
DDI-DrugBank.d123.s13	be	61	62	O
DDI-DrugBank.d123.s13	taken	64	68	O
DDI-DrugBank.d123.s13	with	70	73	O
DDI-DrugBank.d123.s13	a	65	65	O
DDI-DrugBank.d123.s13	main	77	80	O
DDI-DrugBank.d123.s13	meal	82	85	O
DDI-DrugBank.d123.s13	of	87	88	O
DDI-DrugBank.d123.s13	the	90	92	O
DDI-DrugBank.d123.s13	day	94	96	O
DDI-DrugBank.d123.s13	,	97	97	O
DDI-DrugBank.d123.s13	preferably	99	108	O
DDI-DrugBank.d123.s13	the	90	92	O
DDI-DrugBank.d123.s13	evening	114	120	O
DDI-DrugBank.d123.s13	meal	122	125	O
DDI-DrugBank.d123.s13	..	126	127	O
DDI-DrugBank.d123.s14	Phenytoin	0	8	B-drug
DDI-DrugBank.d123.s14	:	9	9	O
DDI-DrugBank.d123.s14	Altered	11	17	O
DDI-DrugBank.d123.s14	serum	19	23	O
DDI-DrugBank.d123.s14	levels	25	30	O
DDI-DrugBank.d123.s14	of	32	33	O
DDI-DrugBank.d123.s14	phenytoin	35	43	B-drug
DDI-DrugBank.d123.s14	(	45	45	O
DDI-DrugBank.d123.s14	increased	46	54	O
DDI-DrugBank.d123.s14	and	56	58	O
DDI-DrugBank.d123.s14	decreased	60	68	O
DDI-DrugBank.d123.s14	)	69	69	O
DDI-DrugBank.d123.s14	have	71	74	O
DDI-DrugBank.d123.s14	been	76	79	O
DDI-DrugBank.d123.s14	reported	81	88	O
DDI-DrugBank.d123.s14	in	90	91	O
DDI-DrugBank.d123.s14	patients	93	100	O
DDI-DrugBank.d123.s14	receiving	102	110	O
DDI-DrugBank.d123.s14	concomitant	112	122	O
DDI-DrugBank.d123.s14	ciprofloxacin	124	136	B-drug
DDI-DrugBank.d123.s14	.	137	137	O
DDI-DrugBank.d123.s15	Probenecid	0	9	B-drug
DDI-DrugBank.d123.s15	:	10	10	O
DDI-DrugBank.d123.s15	Probenecid	12	21	B-drug
DDI-DrugBank.d123.s15	interferes	23	32	O
DDI-DrugBank.d123.s15	with	34	37	O
DDI-DrugBank.d123.s15	renal	39	43	O
DDI-DrugBank.d123.s15	tubular	45	51	O
DDI-DrugBank.d123.s15	secretion	53	61	O
DDI-DrugBank.d123.s15	of	63	64	O
DDI-DrugBank.d123.s15	ciprofloxacin	66	78	B-drug
DDI-DrugBank.d123.s15	and	80	82	O
DDI-DrugBank.d123.s15	produces	84	91	O
DDI-DrugBank.d123.s15	an	93	94	O
DDI-DrugBank.d123.s15	increase	96	103	O
DDI-DrugBank.d123.s15	in	96	97	O
DDI-DrugBank.d123.s15	the	108	110	O
DDI-DrugBank.d123.s15	level	112	116	O
DDI-DrugBank.d123.s15	of	118	119	O
DDI-DrugBank.d123.s15	ciprofloxacin	121	133	B-drug
DDI-DrugBank.d123.s15	in	132	133	I-drug
DDI-DrugBank.d123.s15	serum	138	142	O
DDI-DrugBank.d123.s15	.	143	143	O
DDI-DrugBank.d123.s16	Theophylline	0	11	B-drug
DDI-DrugBank.d123.s16	:	12	12	O
DDI-DrugBank.d123.s16	As	14	15	O
DDI-DrugBank.d123.s16	with	17	20	O
DDI-DrugBank.d123.s16	some	22	25	O
DDI-DrugBank.d123.s16	other	27	31	O
DDI-DrugBank.d123.s16	quinolones	33	42	B-group
DDI-DrugBank.d123.s16	,	43	43	O
DDI-DrugBank.d123.s16	concurrent	45	54	O
DDI-DrugBank.d123.s16	administration	56	69	O
DDI-DrugBank.d123.s16	of	71	72	O
DDI-DrugBank.d123.s16	ciprofloxacin	74	86	B-drug
DDI-DrugBank.d123.s16	with	88	91	O
DDI-DrugBank.d123.s16	theophylline	93	104	B-drug
DDI-DrugBank.d123.s16	may	106	108	O
DDI-DrugBank.d123.s16	lead	110	113	O
DDI-DrugBank.d123.s16	to	115	116	O
DDI-DrugBank.d123.s16	elevated	118	125	O
DDI-DrugBank.d123.s16	serum	127	131	O
DDI-DrugBank.d123.s16	concentrations	133	146	O
DDI-DrugBank.d123.s16	of	148	149	O
DDI-DrugBank.d123.s16	theophylline	151	162	B-drug
DDI-DrugBank.d123.s16	and	164	166	O
DDI-DrugBank.d123.s16	prolongation	168	179	O
DDI-DrugBank.d123.s16	of	181	182	O
DDI-DrugBank.d123.s16	its	184	186	O
DDI-DrugBank.d123.s16	elimination	188	198	O
DDI-DrugBank.d123.s16	half-life	200	208	O
DDI-DrugBank.d123.s16	.	209	209	O
DDI-DrugBank.d123.s17	This	0	3	O
DDI-DrugBank.d123.s17	may	5	7	O
DDI-DrugBank.d123.s17	result	9	14	O
DDI-DrugBank.d123.s17	in	16	17	O
DDI-DrugBank.d123.s17	increased	19	27	O
DDI-DrugBank.d123.s17	risk	29	32	O
DDI-DrugBank.d123.s17	of	34	35	O
DDI-DrugBank.d123.s17	theophylline-related	37	56	O
DDI-DrugBank.d123.s17	adverse	58	64	O
DDI-DrugBank.d123.s17	reactions	66	74	O
DDI-DrugBank.d123.s17	.	75	75	O
DDI-DrugBank.d123.s18	If	0	1	O
DDI-DrugBank.d123.s18	concomitant	3	13	O
DDI-DrugBank.d123.s18	use	15	17	O
DDI-DrugBank.d123.s18	can	19	21	O
DDI-DrugBank.d123.s18	not	22	24	O
DDI-DrugBank.d123.s18	be	26	27	O
DDI-DrugBank.d123.s18	avoided	29	35	O
DDI-DrugBank.d123.s18	,	36	36	O
DDI-DrugBank.d123.s18	serum	38	42	O
DDI-DrugBank.d123.s18	levels	44	49	O
DDI-DrugBank.d123.s18	of	51	52	O
DDI-DrugBank.d123.s18	theophylline	54	65	B-drug
DDI-DrugBank.d123.s18	should	67	72	O
DDI-DrugBank.d123.s18	be	74	75	O
DDI-DrugBank.d123.s18	monitored	77	85	O
DDI-DrugBank.d123.s18	and	87	89	O
DDI-DrugBank.d123.s18	dosage	91	96	O
DDI-DrugBank.d123.s18	adjustments	98	108	O
DDI-DrugBank.d123.s18	made	110	113	O
DDI-DrugBank.d123.s18	as	115	116	O
DDI-DrugBank.d123.s18	appropriate	118	128	O
DDI-DrugBank.d123.s18	.	129	129	O
DDI-DrugBank.d123.s19	Warfarin	0	7	B-drug
DDI-DrugBank.d123.s19	:	8	8	O
DDI-DrugBank.d123.s19	Quinolones	10	19	B-group
DDI-DrugBank.d123.s19	have	21	24	O
DDI-DrugBank.d123.s19	been	26	29	O
DDI-DrugBank.d123.s19	reported	31	38	O
DDI-DrugBank.d123.s19	to	40	41	O
DDI-DrugBank.d123.s19	enhance	43	49	O
DDI-DrugBank.d123.s19	the	51	53	O
DDI-DrugBank.d123.s19	effects	55	61	O
DDI-DrugBank.d123.s19	of	63	64	O
DDI-DrugBank.d123.s19	the	66	68	O
DDI-DrugBank.d123.s19	oral	70	73	O
DDI-DrugBank.d123.s19	anticoagulant	75	87	B-group
DDI-DrugBank.d123.s19	warfarin	89	96	B-drug
DDI-DrugBank.d123.s19	or	98	99	O
DDI-DrugBank.d123.s19	its	101	103	O
DDI-DrugBank.d123.s19	derivatives	105	115	O
DDI-DrugBank.d123.s19	.	116	116	O
DDI-DrugBank.d123.s20	When	0	3	O
DDI-DrugBank.d123.s20	these	5	9	O
DDI-DrugBank.d123.s20	products	11	18	O
DDI-DrugBank.d123.s20	are	20	22	O
DDI-DrugBank.d123.s20	administered	24	35	O
DDI-DrugBank.d123.s20	concomitantly	37	49	O
DDI-DrugBank.d123.s20	,	50	50	O
DDI-DrugBank.d123.s20	prothrombin	52	62	O
DDI-DrugBank.d123.s20	time	64	67	O
DDI-DrugBank.d123.s20	or	69	70	O
DDI-DrugBank.d123.s20	other	72	76	O
DDI-DrugBank.d123.s20	suitable	78	85	O
DDI-DrugBank.d123.s20	coagulation	87	97	O
DDI-DrugBank.d123.s20	tests	99	103	O
DDI-DrugBank.d123.s20	should	105	110	O
DDI-DrugBank.d123.s20	be	112	113	O
DDI-DrugBank.d123.s20	monitored	115	123	O
DDI-DrugBank.d123.s20	.	124	124	O
DDI-DrugBank.d323.s0	Co-administration	0	16	O
DDI-DrugBank.d323.s0	of	18	19	O
DDI-DrugBank.d323.s0	MYOBLOC	21	27	B-brand
DDI-DrugBank.d323.s0	and	29	31	O
DDI-DrugBank.d323.s0	aminoglycosides	33	47	B-group
DDI-DrugBank.d323.s0	or	49	50	O
DDI-DrugBank.d323.s0	other	52	56	O
DDI-DrugBank.d323.s0	agents	58	63	O
DDI-DrugBank.d323.s0	interfering	65	75	O
DDI-DrugBank.d323.s0	with	77	80	O
DDI-DrugBank.d323.s0	neuromuscular	82	94	O
DDI-DrugBank.d323.s0	transmission	96	107	O
DDI-DrugBank.d323.s0	(	109	109	O
DDI-DrugBank.d323.s0	e.g.	110	113	O
DDI-DrugBank.d323.s0	,	114	114	O
DDI-DrugBank.d323.s0	curare-like	116	126	B-group
DDI-DrugBank.d323.s0	compounds	128	136	I-group
DDI-DrugBank.d323.s0	)	137	137	O
DDI-DrugBank.d323.s0	should	139	144	O
DDI-DrugBank.d323.s0	only	146	149	O
DDI-DrugBank.d323.s0	be	151	152	O
DDI-DrugBank.d323.s0	performed	154	162	O
DDI-DrugBank.d323.s0	with	164	167	O
DDI-DrugBank.d323.s0	caution	169	175	O
DDI-DrugBank.d323.s0	as	177	178	O
DDI-DrugBank.d323.s0	the	180	182	O
DDI-DrugBank.d323.s0	effect	184	189	O
DDI-DrugBank.d323.s0	of	191	192	O
DDI-DrugBank.d323.s0	the	180	182	O
DDI-DrugBank.d323.s0	toxin	198	202	B-drug
DDI-DrugBank.d323.s0	may	204	206	O
DDI-DrugBank.d323.s0	be	208	209	O
DDI-DrugBank.d323.s0	potentiated	211	221	O
DDI-DrugBank.d323.s0	.	222	222	O
DDI-DrugBank.d323.s1	The	0	2	O
DDI-DrugBank.d323.s1	effect	4	9	O
DDI-DrugBank.d323.s1	of	11	12	O
DDI-DrugBank.d323.s1	administering	14	26	O
DDI-DrugBank.d323.s1	different	28	36	O
DDI-DrugBank.d323.s1	botulinum	38	46	B-group
DDI-DrugBank.d323.s1	neurotoxin	48	57	I-group
DDI-DrugBank.d323.s1	serotypes	59	67	O
DDI-DrugBank.d323.s1	at	69	70	O
DDI-DrugBank.d323.s1	the	72	74	O
DDI-DrugBank.d323.s1	same	76	79	O
DDI-DrugBank.d323.s1	time	81	84	O
DDI-DrugBank.d323.s1	or	86	87	O
DDI-DrugBank.d323.s1	within	89	94	O
DDI-DrugBank.d323.s1	less	96	99	O
DDI-DrugBank.d323.s1	than	101	104	O
DDI-DrugBank.d323.s1	4	106	106	O
DDI-DrugBank.d323.s1	months	108	113	O
DDI-DrugBank.d323.s1	of	115	116	O
DDI-DrugBank.d323.s1	each	118	121	O
DDI-DrugBank.d323.s1	other	123	127	O
DDI-DrugBank.d323.s1	is	129	130	O
DDI-DrugBank.d323.s1	unknown	132	138	O
DDI-DrugBank.d323.s1	.	139	139	O
DDI-DrugBank.d323.s2	However	0	6	O
DDI-DrugBank.d323.s2	,	7	7	O
DDI-DrugBank.d323.s2	neuromuscular	9	21	O
DDI-DrugBank.d323.s2	paralysis	23	31	O
DDI-DrugBank.d323.s2	may	33	35	O
DDI-DrugBank.d323.s2	be	37	38	O
DDI-DrugBank.d323.s2	potentiated	40	50	O
DDI-DrugBank.d323.s2	by	52	53	O
DDI-DrugBank.d323.s2	co-administration	55	71	O
DDI-DrugBank.d323.s2	or	73	74	O
DDI-DrugBank.d323.s2	overlapping	76	86	O
DDI-DrugBank.d323.s2	administration	88	101	O
DDI-DrugBank.d323.s2	of	103	104	O
DDI-DrugBank.d323.s2	different	106	114	O
DDI-DrugBank.d323.s2	botulinum	116	124	B-group
DDI-DrugBank.d323.s2	toxin	126	130	I-group
DDI-DrugBank.d323.s2	serotypes	132	140	O
DDI-DrugBank.d323.s2	.	141	141	O
DDI-DrugBank.d544.s0	No	0	1	O
DDI-DrugBank.d544.s0	dose	3	6	O
DDI-DrugBank.d544.s0	adjustment	8	17	O
DDI-DrugBank.d544.s0	is	19	20	O
DDI-DrugBank.d544.s0	necessary	22	30	O
DDI-DrugBank.d544.s0	when	32	35	O
DDI-DrugBank.d544.s0	Simulect	37	44	B-brand
DDI-DrugBank.d544.s0	is	46	47	O
DDI-DrugBank.d544.s0	added	49	53	O
DDI-DrugBank.d544.s0	to	55	56	O
DDI-DrugBank.d544.s0	triple-immunosuppression	58	81	O
DDI-DrugBank.d544.s0	regimens	83	90	O
DDI-DrugBank.d544.s0	including	92	100	O
DDI-DrugBank.d544.s0	cyclosporine	102	113	B-drug
DDI-DrugBank.d544.s0	,	114	114	O
DDI-DrugBank.d544.s0	corticosteroids	116	130	B-group
DDI-DrugBank.d544.s0	,	131	131	O
DDI-DrugBank.d544.s0	and	133	135	O
DDI-DrugBank.d544.s0	either	137	142	O
DDI-DrugBank.d544.s0	azathioprine	144	155	B-drug
DDI-DrugBank.d544.s0	or	157	158	O
DDI-DrugBank.d544.s0	mycophenolate	160	172	B-drug
DDI-DrugBank.d544.s0	mofetil	174	180	I-drug
DDI-DrugBank.d544.s0	.	181	181	O
DDI-DrugBank.d544.s1	Three	0	4	O
DDI-DrugBank.d544.s1	clinical	6	13	O
DDI-DrugBank.d544.s1	trials	15	20	O
DDI-DrugBank.d544.s1	have	22	25	O
DDI-DrugBank.d544.s1	investigated	27	38	O
DDI-DrugBank.d544.s1	Simulect	40	47	B-brand
DDI-DrugBank.d544.s1	use	49	51	O
DDI-DrugBank.d544.s1	in	53	54	O
DDI-DrugBank.d544.s1	combination	56	66	O
DDI-DrugBank.d544.s1	with	68	71	O
DDI-DrugBank.d544.s1	triple-therapy	73	86	O
DDI-DrugBank.d544.s1	regimens	88	95	O
DDI-DrugBank.d544.s1	.	96	96	O
DDI-DrugBank.d544.s2	Pharmacokinetics	0	15	O
DDI-DrugBank.d544.s2	were	17	20	O
DDI-DrugBank.d544.s2	assessed	22	29	O
DDI-DrugBank.d544.s2	in	31	32	O
DDI-DrugBank.d544.s2	two	34	36	O
DDI-DrugBank.d544.s2	of	38	39	O
DDI-DrugBank.d544.s2	these	41	45	O
DDI-DrugBank.d544.s2	trials	47	52	O
DDI-DrugBank.d544.s2	.	53	53	O
DDI-DrugBank.d544.s3	Total	0	4	O
DDI-DrugBank.d544.s3	body	6	9	O
DDI-DrugBank.d544.s3	clearance	11	19	O
DDI-DrugBank.d544.s3	of	21	22	O
DDI-DrugBank.d544.s3	Simulect	24	31	B-brand
DDI-DrugBank.d544.s3	was	33	35	O
DDI-DrugBank.d544.s3	reduced	37	43	O
DDI-DrugBank.d544.s3	by	45	46	O
DDI-DrugBank.d544.s3	an	48	49	O
DDI-DrugBank.d544.s3	average	51	57	O
DDI-DrugBank.d544.s3	22	59	60	O
DDI-DrugBank.d544.s3	%	61	61	O
DDI-DrugBank.d544.s3	and	63	65	O
DDI-DrugBank.d544.s3	51	67	68	O
DDI-DrugBank.d544.s3	%	61	61	O
DDI-DrugBank.d544.s3	when	71	74	O
DDI-DrugBank.d544.s3	azathioprine	76	87	B-drug
DDI-DrugBank.d544.s3	and	89	91	O
DDI-DrugBank.d544.s3	mycophenolate	93	105	B-drug
DDI-DrugBank.d544.s3	mofetil	107	113	I-drug
DDI-DrugBank.d544.s3	,	114	114	O
DDI-DrugBank.d544.s3	respectively	116	127	O
DDI-DrugBank.d544.s3	,	114	114	O
DDI-DrugBank.d544.s3	were	130	133	O
DDI-DrugBank.d544.s3	added	135	139	O
DDI-DrugBank.d544.s3	to	141	142	O
DDI-DrugBank.d544.s3	a	135	135	O
DDI-DrugBank.d544.s3	regimen	146	152	O
DDI-DrugBank.d544.s3	consisting	154	163	O
DDI-DrugBank.d544.s3	of	165	166	O
DDI-DrugBank.d544.s3	cyclosporine	168	179	B-drug
DDI-DrugBank.d544.s3	,	180	180	O
DDI-DrugBank.d544.s3	USP	182	184	O
DDI-DrugBank.d544.s3	(	186	186	O
DDI-DrugBank.d544.s3	MODIFIED	187	194	O
DDI-DrugBank.d544.s3	)	195	195	O
DDI-DrugBank.d544.s3	and	197	199	O
DDI-DrugBank.d544.s3	corticosteroids	201	215	B-group
DDI-DrugBank.d544.s3	.	216	216	O
DDI-DrugBank.d544.s4	Nonetheless	0	10	O
DDI-DrugBank.d544.s4	,	11	11	O
DDI-DrugBank.d544.s4	the	13	15	O
DDI-DrugBank.d544.s4	range	17	21	O
DDI-DrugBank.d544.s4	of	23	24	O
DDI-DrugBank.d544.s4	individual	26	35	O
DDI-DrugBank.d544.s4	Simulect	37	44	B-brand
DDI-DrugBank.d544.s4	clearance	46	54	O
DDI-DrugBank.d544.s4	values	56	61	O
DDI-DrugBank.d544.s4	in	63	64	O
DDI-DrugBank.d544.s4	the	66	68	O
DDI-DrugBank.d544.s4	presence	70	77	O
DDI-DrugBank.d544.s4	of	79	80	O
DDI-DrugBank.d544.s4	azathioprine	82	93	B-drug
DDI-DrugBank.d544.s4	(	95	95	O
DDI-DrugBank.d544.s4	12-57	96	100	O
DDI-DrugBank.d544.s4	mL/h	102	105	O
DDI-DrugBank.d544.s4	)	106	106	O
DDI-DrugBank.d544.s4	or	108	109	O
DDI-DrugBank.d544.s4	mycophenolate	111	123	B-drug
DDI-DrugBank.d544.s4	mofetil	125	131	I-drug
DDI-DrugBank.d544.s4	(	133	133	O
DDI-DrugBank.d544.s4	7-54	134	137	O
DDI-DrugBank.d544.s4	mL/h	139	142	O
DDI-DrugBank.d544.s4	)	143	143	O
DDI-DrugBank.d544.s4	did	145	147	O
DDI-DrugBank.d544.s4	not	149	151	O
DDI-DrugBank.d544.s4	extend	153	158	O
DDI-DrugBank.d544.s4	outside	160	166	O
DDI-DrugBank.d544.s4	the	168	170	O
DDI-DrugBank.d544.s4	range	172	176	O
DDI-DrugBank.d544.s4	observed	178	185	O
DDI-DrugBank.d544.s4	with	187	190	O
DDI-DrugBank.d544.s4	dual	192	195	O
DDI-DrugBank.d544.s4	therapy	197	203	O
DDI-DrugBank.d544.s4	(	205	205	O
DDI-DrugBank.d544.s4	10-78	206	210	O
DDI-DrugBank.d544.s4	mL/h	212	215	O
DDI-DrugBank.d544.s4	)	216	216	O
DDI-DrugBank.d544.s4	.	217	217	O
DDI-DrugBank.d544.s5	The	0	2	O
DDI-DrugBank.d544.s5	following	4	12	O
DDI-DrugBank.d544.s5	medications	14	24	O
DDI-DrugBank.d544.s5	have	26	29	O
DDI-DrugBank.d544.s5	been	31	34	O
DDI-DrugBank.d544.s5	administered	36	47	O
DDI-DrugBank.d544.s5	in	49	50	O
DDI-DrugBank.d544.s5	clinical	52	59	O
DDI-DrugBank.d544.s5	trials	61	66	O
DDI-DrugBank.d544.s5	with	68	71	O
DDI-DrugBank.d544.s5	Simulect	73	80	B-brand
DDI-DrugBank.d544.s5	with	82	85	O
DDI-DrugBank.d544.s5	no	87	88	O
DDI-DrugBank.d544.s5	increase	90	97	O
DDI-DrugBank.d544.s5	in	90	91	O
DDI-DrugBank.d544.s5	adverse	102	108	O
DDI-DrugBank.d544.s5	reactions	110	118	O
DDI-DrugBank.d544.s5	:	119	119	O
DDI-DrugBank.d544.s5	ATG/ALG	121	127	O
DDI-DrugBank.d544.s5	,	128	128	O
DDI-DrugBank.d544.s5	azathioprine	130	141	B-drug
DDI-DrugBank.d544.s5	,	128	128	O
DDI-DrugBank.d544.s5	corticosteroids	144	158	B-group
DDI-DrugBank.d544.s5	,	142	142	O
DDI-DrugBank.d544.s5	cyclosporine	161	172	B-drug
DDI-DrugBank.d544.s5	,	159	159	O
DDI-DrugBank.d544.s5	mycophenolate	175	187	B-drug
DDI-DrugBank.d544.s5	mofetil	189	195	I-drug
DDI-DrugBank.d544.s5	,	196	196	O
DDI-DrugBank.d544.s5	and	198	200	O
DDI-DrugBank.d544.s5	muromonab-CD3	202	214	B-drug
DDI-DrugBank.d544.s5	.	215	215	O
DDI-DrugBank.d557.s0	Drug/Laboratory	0	14	O
DDI-DrugBank.d557.s0	Test	16	19	O
DDI-DrugBank.d557.s0	Interactions	21	32	O
DDI-DrugBank.d557.s0	Positive	34	41	O
DDI-DrugBank.d557.s0	direct	43	48	O
DDI-DrugBank.d557.s0	Coombs	50	55	O
DDI-DrugBank.d557.s0	tests	58	62	O
DDI-DrugBank.d557.s0	have	64	67	O
DDI-DrugBank.d557.s0	been	69	72	O
DDI-DrugBank.d557.s0	reported	74	81	O
DDI-DrugBank.d557.s0	during	83	88	O
DDI-DrugBank.d557.s0	treatment	90	98	O
DDI-DrugBank.d557.s0	with	100	103	O
DDI-DrugBank.d557.s0	the	105	107	O
DDI-DrugBank.d557.s0	cephalosporin	109	121	B-group
DDI-DrugBank.d557.s0	antibiotics	123	133	I-group
DDI-DrugBank.d557.s0	.	134	134	O
DDI-DrugBank.d557.s1	In	0	1	O
DDI-DrugBank.d557.s1	hematologic	3	13	O
DDI-DrugBank.d557.s1	studies	15	21	O
DDI-DrugBank.d557.s1	or	23	24	O
DDI-DrugBank.d557.s1	in	26	27	O
DDI-DrugBank.d557.s1	transfusion	29	39	O
DDI-DrugBank.d557.s1	cross-matching	41	54	O
DDI-DrugBank.d557.s1	procedures	56	65	O
DDI-DrugBank.d557.s1	when	67	70	O
DDI-DrugBank.d557.s1	anti-globulin	72	84	O
DDI-DrugBank.d557.s1	tests	86	90	O
DDI-DrugBank.d557.s1	are	92	94	O
DDI-DrugBank.d557.s1	performed	96	104	O
DDI-DrugBank.d557.s1	on	106	107	O
DDI-DrugBank.d557.s1	the	109	111	O
DDI-DrugBank.d557.s1	minor	113	117	O
DDI-DrugBank.d557.s1	side	119	122	O
DDI-DrugBank.d557.s1	or	116	117	O
DDI-DrugBank.d557.s1	in	114	115	O
DDI-DrugBank.d557.s1	Coombs	130	135	O
DDI-DrugBank.d557.s1	testing	138	144	O
DDI-DrugBank.d557.s1	of	146	147	O
DDI-DrugBank.d557.s1	newborns	149	156	O
DDI-DrugBank.d557.s1	whose	158	162	O
DDI-DrugBank.d557.s1	mothers	164	170	O
DDI-DrugBank.d557.s1	have	172	175	O
DDI-DrugBank.d557.s1	received	177	184	O
DDI-DrugBank.d557.s1	cephalosporin	186	198	B-group
DDI-DrugBank.d557.s1	antibiotics	200	210	I-group
DDI-DrugBank.d557.s1	before	212	217	O
DDI-DrugBank.d557.s1	parturition	219	229	O
DDI-DrugBank.d557.s1	,	230	230	O
DDI-DrugBank.d557.s1	it	225	226	O
DDI-DrugBank.d557.s1	should	235	240	O
DDI-DrugBank.d557.s1	be	212	213	O
DDI-DrugBank.d557.s1	recognized	245	254	O
DDI-DrugBank.d557.s1	that	256	259	O
DDI-DrugBank.d557.s1	a	258	258	O
DDI-DrugBank.d557.s1	positive	263	270	O
DDI-DrugBank.d557.s1	Coombs	272	277	O
DDI-DrugBank.d557.s1	test	280	283	O
DDI-DrugBank.d557.s1	may	285	287	O
DDI-DrugBank.d557.s1	be	289	290	O
DDI-DrugBank.d557.s1	due	292	294	O
DDI-DrugBank.d557.s1	to	296	297	O
DDI-DrugBank.d557.s1	the	299	301	O
DDI-DrugBank.d557.s1	drug	303	306	O
DDI-DrugBank.d557.s1	.	307	307	O
DDI-DrugBank.d70.s0	Fulvestrant	0	10	B-drug
DDI-DrugBank.d70.s0	is	12	13	O
DDI-DrugBank.d70.s0	metabolized	15	25	O
DDI-DrugBank.d70.s0	by	27	28	O
DDI-DrugBank.d70.s0	CYP	30	32	O
DDI-DrugBank.d70.s0	3A4	34	36	O
DDI-DrugBank.d70.s0	in	38	39	O
DDI-DrugBank.d70.s0	vitro	41	45	O
DDI-DrugBank.d70.s0	.	46	46	O
DDI-DrugBank.d70.s1	Clinical	0	7	O
DDI-DrugBank.d70.s1	studies	9	15	O
DDI-DrugBank.d70.s1	of	17	18	O
DDI-DrugBank.d70.s1	the	20	22	O
DDI-DrugBank.d70.s1	effect	24	29	O
DDI-DrugBank.d70.s1	of	31	32	O
DDI-DrugBank.d70.s1	strong	34	39	O
DDI-DrugBank.d70.s1	CYP	41	43	O
DDI-DrugBank.d70.s1	3A4	45	47	O
DDI-DrugBank.d70.s1	inhibitors	49	58	O
DDI-DrugBank.d70.s1	on	60	61	O
DDI-DrugBank.d70.s1	the	63	65	O
DDI-DrugBank.d70.s1	pharmacokinetics	67	82	O
DDI-DrugBank.d70.s1	of	84	85	O
DDI-DrugBank.d70.s1	fulvestrant	87	97	B-drug
DDI-DrugBank.d70.s1	have	99	102	O
DDI-DrugBank.d70.s1	not	104	106	O
DDI-DrugBank.d70.s1	been	108	111	O
DDI-DrugBank.d70.s1	performed	113	121	O
DDI-DrugBank.d70.s1	.	122	122	O
DDI-DrugBank.d70.s2	Carcinogenesis	0	13	O
DDI-DrugBank.d70.s2	,	14	14	O
DDI-DrugBank.d70.s2	Mutagenesis	16	26	O
DDI-DrugBank.d70.s2	and	28	30	O
DDI-DrugBank.d70.s2	Impairment	32	41	O
DDI-DrugBank.d70.s2	of	43	44	O
DDI-DrugBank.d70.s2	Fertility	46	54	O
DDI-DrugBank.d70.s2	A	56	56	O
DDI-DrugBank.d70.s2	two-year	58	65	O
DDI-DrugBank.d70.s2	carcinogenesis	67	80	O
DDI-DrugBank.d70.s2	study	82	86	O
DDI-DrugBank.d70.s2	was	88	90	O
DDI-DrugBank.d70.s2	conducted	92	100	O
DDI-DrugBank.d70.s2	in	102	103	O
DDI-DrugBank.d70.s2	female	105	110	O
DDI-DrugBank.d70.s2	and	112	114	O
DDI-DrugBank.d70.s2	male	107	110	O
DDI-DrugBank.d70.s2	rats	121	124	O
DDI-DrugBank.d70.s2	,	125	125	O
DDI-DrugBank.d70.s2	at	122	123	O
DDI-DrugBank.d70.s2	intramuscular	130	142	O
DDI-DrugBank.d70.s2	doses	144	148	O
DDI-DrugBank.d70.s2	of	150	151	O
DDI-DrugBank.d70.s2	15	153	154	O
DDI-DrugBank.d70.s2	mg/kg/30	156	163	O
DDI-DrugBank.d70.s2	days	165	168	O
DDI-DrugBank.d70.s2	,	169	169	O
DDI-DrugBank.d70.s2	10	171	172	O
DDI-DrugBank.d70.s2	mg/rat/30	174	182	O
DDI-DrugBank.d70.s2	days	165	168	O
DDI-DrugBank.d70.s2	and	189	191	O
DDI-DrugBank.d70.s2	10	171	172	O
DDI-DrugBank.d70.s2	mg/rat/15	196	204	O
DDI-DrugBank.d70.s2	days	184	187	O
DDI-DrugBank.d70.s2	.	210	210	O
DDI-DrugBank.d70.s3	These	0	4	O
DDI-DrugBank.d70.s3	doses	6	10	O
DDI-DrugBank.d70.s3	correspond	12	21	O
DDI-DrugBank.d70.s3	to	23	24	O
DDI-DrugBank.d70.s3	approximately	26	38	O
DDI-DrugBank.d70.s3	1-	40	41	O
DDI-DrugBank.d70.s3	,	42	42	O
DDI-DrugBank.d70.s3	3-	44	45	O
DDI-DrugBank.d70.s3	,	42	42	O
DDI-DrugBank.d70.s3	and	48	50	O
DDI-DrugBank.d70.s3	5-fold	52	57	O
DDI-DrugBank.d70.s3	(	59	59	O
DDI-DrugBank.d70.s3	in	60	61	O
DDI-DrugBank.d70.s3	females	63	69	O
DDI-DrugBank.d70.s3	)	70	70	O
DDI-DrugBank.d70.s3	and	72	74	O
DDI-DrugBank.d70.s3	1.3-	76	79	O
DDI-DrugBank.d70.s3	,	80	80	O
DDI-DrugBank.d70.s3	1.3-	76	79	O
DDI-DrugBank.d70.s3	,	80	80	O
DDI-DrugBank.d70.s3	and	88	90	O
DDI-DrugBank.d70.s3	1.6-fold	92	99	O
DDI-DrugBank.d70.s3	(	101	101	O
DDI-DrugBank.d70.s3	in	102	103	O
DDI-DrugBank.d70.s3	males	105	109	O
DDI-DrugBank.d70.s3	)	110	110	O
DDI-DrugBank.d70.s3	the	112	114	O
DDI-DrugBank.d70.s3	systemic	116	123	O
DDI-DrugBank.d70.s3	exposure	125	132	O
DDI-DrugBank.d70.s3	[	134	134	O
DDI-DrugBank.d70.s3	AUC0-30	135	141	O
DDI-DrugBank.d70.s3	days	143	146	O
DDI-DrugBank.d70.s3	]	147	147	O
DDI-DrugBank.d70.s3	]	147	147	O
DDI-DrugBank.d70.s3	achieved	150	157	O
DDI-DrugBank.d70.s3	in	159	160	O
DDI-DrugBank.d70.s3	women	162	166	O
DDI-DrugBank.d70.s3	receiving	168	176	O
DDI-DrugBank.d70.s3	the	178	180	O
DDI-DrugBank.d70.s3	recommended	182	192	O
DDI-DrugBank.d70.s3	dose	194	197	O
DDI-DrugBank.d70.s3	of	199	200	O
DDI-DrugBank.d70.s3	250	202	204	O
DDI-DrugBank.d70.s3	mg/month	206	213	O
DDI-DrugBank.d70.s3	.	214	214	O
DDI-DrugBank.d70.s4	An	0	1	O
DDI-DrugBank.d70.s4	increased	3	11	O
DDI-DrugBank.d70.s4	incidence	13	21	O
DDI-DrugBank.d70.s4	of	23	24	O
DDI-DrugBank.d70.s4	benign	26	31	O
DDI-DrugBank.d70.s4	ovarian	33	39	O
DDI-DrugBank.d70.s4	granulosa	41	49	O
DDI-DrugBank.d70.s4	cell	51	54	O
DDI-DrugBank.d70.s4	tumors	56	61	O
DDI-DrugBank.d70.s4	and	63	65	O
DDI-DrugBank.d70.s4	testicular	67	76	O
DDI-DrugBank.d70.s4	Leydig	78	83	O
DDI-DrugBank.d70.s4	cell	85	88	O
DDI-DrugBank.d70.s4	tumors	90	95	O
DDI-DrugBank.d70.s4	was	97	99	O
DDI-DrugBank.d70.s4	evident	101	107	O
DDI-DrugBank.d70.s4	,	108	108	O
DDI-DrugBank.d70.s4	in	110	111	O
DDI-DrugBank.d70.s4	females	113	119	O
DDI-DrugBank.d70.s4	dosed	121	125	O
DDI-DrugBank.d70.s4	at	127	128	O
DDI-DrugBank.d70.s4	10	130	131	O
DDI-DrugBank.d70.s4	mg/rat/15	133	141	O
DDI-DrugBank.d70.s4	days	143	146	O
DDI-DrugBank.d70.s4	and	148	150	O
DDI-DrugBank.d70.s4	males	152	156	O
DDI-DrugBank.d70.s4	dosed	158	162	O
DDI-DrugBank.d70.s4	at	164	165	O
DDI-DrugBank.d70.s4	15	140	141	O
DDI-DrugBank.d70.s4	mg/rat/30	170	178	O
DDI-DrugBank.d70.s4	days	180	183	O
DDI-DrugBank.d70.s4	,	184	184	O
DDI-DrugBank.d70.s4	respectively	186	197	O
DDI-DrugBank.d70.s4	.	198	198	O
DDI-DrugBank.d70.s5	Induction	0	8	O
DDI-DrugBank.d70.s5	of	10	11	O
DDI-DrugBank.d70.s5	such	13	16	O
DDI-DrugBank.d70.s5	tumors	18	23	O
DDI-DrugBank.d70.s5	is	25	26	O
DDI-DrugBank.d70.s5	consistent	28	37	O
DDI-DrugBank.d70.s5	with	39	42	O
DDI-DrugBank.d70.s5	the	44	46	O
DDI-DrugBank.d70.s5	pharmacology-related	48	67	O
DDI-DrugBank.d70.s5	endocrine	69	77	O
DDI-DrugBank.d70.s5	feedback	79	86	O
DDI-DrugBank.d70.s5	alterations	88	98	O
DDI-DrugBank.d70.s5	in	100	101	O
DDI-DrugBank.d70.s5	gonadotropin	103	114	O
DDI-DrugBank.d70.s5	levels	116	121	O
DDI-DrugBank.d70.s5	caused	123	128	O
DDI-DrugBank.d70.s5	by	130	131	O
DDI-DrugBank.d70.s5	an	133	134	O
DDI-DrugBank.d70.s5	antiestrogen	136	147	B-group
DDI-DrugBank.d70.s5	.	148	148	O
DDI-DrugBank.d70.s6	Fulvestrant	0	10	B-drug
DDI-DrugBank.d70.s6	was	12	14	O
DDI-DrugBank.d70.s6	not	16	18	O
DDI-DrugBank.d70.s6	mutagenic	20	28	O
DDI-DrugBank.d70.s6	or	30	31	O
DDI-DrugBank.d70.s6	clastogenic	33	43	O
DDI-DrugBank.d70.s6	in	45	46	O
DDI-DrugBank.d70.s6	multiple	48	55	O
DDI-DrugBank.d70.s6	in	57	58	O
DDI-DrugBank.d70.s6	vitro	60	64	O
DDI-DrugBank.d70.s6	tests	66	70	O
DDI-DrugBank.d70.s6	with	72	75	O
DDI-DrugBank.d70.s6	and	77	79	O
DDI-DrugBank.d70.s6	without	81	87	O
DDI-DrugBank.d70.s6	the	89	91	O
DDI-DrugBank.d70.s6	addition	93	100	O
DDI-DrugBank.d70.s6	of	102	103	O
DDI-DrugBank.d70.s6	a	93	93	O
DDI-DrugBank.d70.s6	mammalian	107	115	O
DDI-DrugBank.d70.s6	liver	117	121	O
DDI-DrugBank.d70.s6	metabolic	123	131	O
DDI-DrugBank.d70.s6	activation	133	142	O
DDI-DrugBank.d70.s6	factor	144	149	O
DDI-DrugBank.d70.s6	(	151	151	O
DDI-DrugBank.d70.s6	bacterial	152	160	O
DDI-DrugBank.d70.s6	mutation	162	169	O
DDI-DrugBank.d70.s6	assay	171	175	O
DDI-DrugBank.d70.s6	in	177	178	O
DDI-DrugBank.d70.s6	strains	180	186	O
DDI-DrugBank.d70.s6	of	188	189	O
DDI-DrugBank.d70.s6	Salmonella	191	200	O
DDI-DrugBank.d70.s6	typhimurium	202	212	O
DDI-DrugBank.d70.s6	and	214	216	O
DDI-DrugBank.d70.s6	Escherichia	218	228	O
DDI-DrugBank.d70.s6	coli	230	233	O
DDI-DrugBank.d70.s6	,	234	234	O
DDI-DrugBank.d70.s6	in	236	237	O
DDI-DrugBank.d70.s6	vitro	239	243	O
DDI-DrugBank.d70.s6	cytogenetics	245	256	O
DDI-DrugBank.d70.s6	study	258	262	O
DDI-DrugBank.d70.s6	in	236	237	O
DDI-DrugBank.d70.s6	human	267	271	O
DDI-DrugBank.d70.s6	lymphocytes	273	283	O
DDI-DrugBank.d70.s6	,	284	284	O
DDI-DrugBank.d70.s6	mammalian	286	294	O
DDI-DrugBank.d70.s6	cell	296	299	O
DDI-DrugBank.d70.s6	mutation	301	308	O
DDI-DrugBank.d70.s6	assay	310	314	O
DDI-DrugBank.d70.s6	in	316	317	O
DDI-DrugBank.d70.s6	mouse	319	323	O
DDI-DrugBank.d70.s6	lymphoma	325	332	O
DDI-DrugBank.d70.s6	cells	334	338	O
DDI-DrugBank.d70.s6	and	340	342	O
DDI-DrugBank.d70.s6	in	316	317	O
DDI-DrugBank.d70.s6	vivo	347	350	O
DDI-DrugBank.d70.s6	micronucleus	352	363	O
DDI-DrugBank.d70.s6	test	365	368	O
DDI-DrugBank.d70.s6	in	316	317	O
DDI-DrugBank.d70.s6	rat	373	375	O
DDI-DrugBank.d70.s6	.	376	376	O
DDI-DrugBank.d70.s7	In	0	1	O
DDI-DrugBank.d70.s7	female	3	8	O
DDI-DrugBank.d70.s7	rats	10	13	O
DDI-DrugBank.d70.s7	,	14	14	O
DDI-DrugBank.d70.s7	fulvestrant	16	26	B-drug
DDI-DrugBank.d70.s7	administered	28	39	O
DDI-DrugBank.d70.s7	at	41	42	O
DDI-DrugBank.d70.s7	doses	44	48	O
DDI-DrugBank.d70.s7	0.01	52	55	O
DDI-DrugBank.d70.s7	mg/kg/day	57	65	O
DDI-DrugBank.d70.s7	(	67	67	O
DDI-DrugBank.d70.s7	approximately	68	80	O
DDI-DrugBank.d70.s7	one-hundredth	82	94	O
DDI-DrugBank.d70.s7	of	96	97	O
DDI-DrugBank.d70.s7	the	99	101	O
DDI-DrugBank.d70.s7	human	103	107	O
DDI-DrugBank.d70.s7	recommended	109	119	O
DDI-DrugBank.d70.s7	dose	121	124	O
DDI-DrugBank.d70.s7	based	126	130	O
DDI-DrugBank.d70.s7	on	132	133	O
DDI-DrugBank.d70.s7	body	135	138	O
DDI-DrugBank.d70.s7	surface	140	146	O
DDI-DrugBank.d70.s7	area	148	151	O
DDI-DrugBank.d70.s7	[	153	153	O
DDI-DrugBank.d70.s7	BSA	154	156	O
DDI-DrugBank.d70.s7	]	157	157	O
DDI-DrugBank.d70.s7	,	158	158	O
DDI-DrugBank.d70.s7	for	160	162	O
DDI-DrugBank.d70.s7	2	164	164	O
DDI-DrugBank.d70.s7	weeks	166	170	O
DDI-DrugBank.d70.s7	prior	172	176	O
DDI-DrugBank.d70.s7	to	178	179	O
DDI-DrugBank.d70.s7	and	181	183	O
DDI-DrugBank.d70.s7	for	160	162	O
DDI-DrugBank.d70.s7	1	189	189	O
DDI-DrugBank.d70.s7	week	166	169	O
DDI-DrugBank.d70.s7	following	196	204	O
DDI-DrugBank.d70.s7	mating	206	211	O
DDI-DrugBank.d70.s7	,	212	212	O
DDI-DrugBank.d70.s7	caused	214	219	O
DDI-DrugBank.d70.s7	a	207	207	O
DDI-DrugBank.d70.s7	reduction	223	231	O
DDI-DrugBank.d70.s7	in	202	203	O
DDI-DrugBank.d70.s7	fertility	236	244	O
DDI-DrugBank.d70.s7	and	246	248	O
DDI-DrugBank.d70.s7	embryonic	250	258	O
DDI-DrugBank.d70.s7	survival	260	267	O
DDI-DrugBank.d70.s7	.	268	268	O
DDI-DrugBank.d70.s8	No	0	1	O
DDI-DrugBank.d70.s8	adverse	3	9	O
DDI-DrugBank.d70.s8	effects	11	17	O
DDI-DrugBank.d70.s8	on	19	20	O
DDI-DrugBank.d70.s8	female	22	27	O
DDI-DrugBank.d70.s8	fertility	29	37	O
DDI-DrugBank.d70.s8	and	39	41	O
DDI-DrugBank.d70.s8	embryonic	43	51	O
DDI-DrugBank.d70.s8	survival	53	60	O
DDI-DrugBank.d70.s8	were	62	65	O
DDI-DrugBank.d70.s8	evident	67	73	O
DDI-DrugBank.d70.s8	in	75	76	O
DDI-DrugBank.d70.s8	female	78	83	O
DDI-DrugBank.d70.s8	animals	85	91	O
DDI-DrugBank.d70.s8	dosed	93	97	O
DDI-DrugBank.d70.s8	at	99	100	O
DDI-DrugBank.d70.s8	0.001	102	106	O
DDI-DrugBank.d70.s8	mg/kg/day	108	116	O
DDI-DrugBank.d70.s8	(	118	118	O
DDI-DrugBank.d70.s8	approximately	119	131	O
DDI-DrugBank.d70.s8	one-thousandth	133	146	O
DDI-DrugBank.d70.s8	of	148	149	O
DDI-DrugBank.d70.s8	the	151	153	O
DDI-DrugBank.d70.s8	human	155	159	O
DDI-DrugBank.d70.s8	dose	161	164	O
DDI-DrugBank.d70.s8	based	166	170	O
DDI-DrugBank.d70.s8	on	172	173	O
DDI-DrugBank.d70.s8	BSA	175	177	O
DDI-DrugBank.d70.s8	)	178	178	O
DDI-DrugBank.d70.s8	.	179	179	O
DDI-DrugBank.d70.s9	Restoration	0	10	O
DDI-DrugBank.d70.s9	of	12	13	O
DDI-DrugBank.d70.s9	female	15	20	O
DDI-DrugBank.d70.s9	fertility	22	30	O
DDI-DrugBank.d70.s9	to	32	33	O
DDI-DrugBank.d70.s9	values	35	40	O
DDI-DrugBank.d70.s9	similar	42	48	O
DDI-DrugBank.d70.s9	to	50	51	O
DDI-DrugBank.d70.s9	controls	53	60	O
DDI-DrugBank.d70.s9	was	62	64	O
DDI-DrugBank.d70.s9	evident	66	72	O
DDI-DrugBank.d70.s9	following	74	82	O
DDI-DrugBank.d70.s9	a	84	84	O
DDI-DrugBank.d70.s9	29-day	86	91	O
DDI-DrugBank.d70.s9	withdrawal	93	102	O
DDI-DrugBank.d70.s9	period	104	109	O
DDI-DrugBank.d70.s9	after	111	115	O
DDI-DrugBank.d70.s9	dosing	117	122	O
DDI-DrugBank.d70.s9	at	124	125	O
DDI-DrugBank.d70.s9	2	127	127	O
DDI-DrugBank.d70.s9	mg/kg/day	129	137	O
DDI-DrugBank.d70.s9	(	139	139	O
DDI-DrugBank.d70.s9	twice	140	144	O
DDI-DrugBank.d70.s9	the	146	148	O
DDI-DrugBank.d70.s9	human	150	154	O
DDI-DrugBank.d70.s9	dose	156	159	O
DDI-DrugBank.d70.s9	based	161	165	O
DDI-DrugBank.d70.s9	on	167	168	O
DDI-DrugBank.d70.s9	BSA	170	172	O
DDI-DrugBank.d70.s9	)	173	173	O
DDI-DrugBank.d70.s9	.	174	174	O
DDI-DrugBank.d70.s10	The	0	2	O
DDI-DrugBank.d70.s10	effects	4	10	O
DDI-DrugBank.d70.s10	of	12	13	O
DDI-DrugBank.d70.s10	fulvestrant	15	25	B-drug
DDI-DrugBank.d70.s10	on	27	28	O
DDI-DrugBank.d70.s10	the	30	32	O
DDI-DrugBank.d70.s10	fertility	34	42	O
DDI-DrugBank.d70.s10	of	44	45	O
DDI-DrugBank.d70.s10	female	47	52	O
DDI-DrugBank.d70.s10	rats	54	57	O
DDI-DrugBank.d70.s10	appear	59	64	O
DDI-DrugBank.d70.s10	to	66	67	O
DDI-DrugBank.d70.s10	be	69	70	O
DDI-DrugBank.d70.s10	consistent	72	81	O
DDI-DrugBank.d70.s10	with	83	86	O
DDI-DrugBank.d70.s10	its	88	90	O
DDI-DrugBank.d70.s10	anti-estrogenic	92	106	O
DDI-DrugBank.d70.s10	activity	108	115	O
DDI-DrugBank.d70.s10	.	116	116	O
DDI-DrugBank.d70.s11	The	0	2	O
DDI-DrugBank.d70.s11	potential	4	12	O
DDI-DrugBank.d70.s11	effects	14	20	O
DDI-DrugBank.d70.s11	of	22	23	O
DDI-DrugBank.d70.s11	fulvestrant	25	35	B-drug
DDI-DrugBank.d70.s11	on	37	38	O
DDI-DrugBank.d70.s11	the	40	42	O
DDI-DrugBank.d70.s11	fertility	44	52	O
DDI-DrugBank.d70.s11	of	54	55	O
DDI-DrugBank.d70.s11	male	57	60	O
DDI-DrugBank.d70.s11	animals	62	68	O
DDI-DrugBank.d70.s11	were	70	73	O
DDI-DrugBank.d70.s11	not	75	77	O
DDI-DrugBank.d70.s11	studied	79	85	O
DDI-DrugBank.d70.s11	but	87	89	O
DDI-DrugBank.d70.s11	in	91	92	O
DDI-DrugBank.d70.s11	a	94	94	O
DDI-DrugBank.d70.s11	6-month	96	102	O
DDI-DrugBank.d70.s11	toxicology	104	113	O
DDI-DrugBank.d70.s11	study	115	119	O
DDI-DrugBank.d70.s11	,	120	120	O
DDI-DrugBank.d70.s11	male	122	125	O
DDI-DrugBank.d70.s11	rats	127	130	O
DDI-DrugBank.d70.s11	treated	132	138	O
DDI-DrugBank.d70.s11	with	140	143	O
DDI-DrugBank.d70.s11	intramuscular	145	157	O
DDI-DrugBank.d70.s11	doses	159	163	O
DDI-DrugBank.d70.s11	of	165	166	O
DDI-DrugBank.d70.s11	15	168	169	O
DDI-DrugBank.d70.s11	mg/kg/30	171	178	O
DDI-DrugBank.d70.s11	days	180	183	O
DDI-DrugBank.d70.s11	,	184	184	O
DDI-DrugBank.d70.s11	10	186	187	O
DDI-DrugBank.d70.s11	mg/rat/30	189	197	O
DDI-DrugBank.d70.s11	days	180	183	O
DDI-DrugBank.d70.s11	,	184	184	O
DDI-DrugBank.d70.s11	or	205	206	O
DDI-DrugBank.d70.s11	10	186	187	O
DDI-DrugBank.d70.s11	mg/rat/15	211	219	O
DDI-DrugBank.d70.s11	days	199	202	O
DDI-DrugBank.d70.s11	fulvestrant	226	236	B-drug
DDI-DrugBank.d70.s11	showed	238	243	O
DDI-DrugBank.d70.s11	a	215	215	O
DDI-DrugBank.d70.s11	loss	247	250	O
DDI-DrugBank.d70.s11	of	252	253	O
DDI-DrugBank.d70.s11	spermatozoa	255	265	O
DDI-DrugBank.d70.s11	from	267	270	O
DDI-DrugBank.d70.s11	the	272	274	O
DDI-DrugBank.d70.s11	seminiferous	276	287	O
DDI-DrugBank.d70.s11	tubules	289	295	O
DDI-DrugBank.d70.s11	,	296	296	O
DDI-DrugBank.d70.s11	seminiferous	276	287	O
DDI-DrugBank.d70.s11	tubular	311	317	O
DDI-DrugBank.d70.s11	atrophy	319	325	O
DDI-DrugBank.d70.s11	,	296	296	O
DDI-DrugBank.d70.s11	and	328	330	O
DDI-DrugBank.d70.s11	degenerative	332	343	O
DDI-DrugBank.d70.s11	changes	345	351	O
DDI-DrugBank.d70.s11	in	301	302	O
DDI-DrugBank.d70.s11	the	356	358	O
DDI-DrugBank.d70.s11	epididymides	360	371	O
DDI-DrugBank.d70.s11	.	372	372	O
DDI-DrugBank.d70.s12	Changes	0	6	O
DDI-DrugBank.d70.s12	in	8	9	O
DDI-DrugBank.d70.s12	the	11	13	O
DDI-DrugBank.d70.s12	testes	15	20	O
DDI-DrugBank.d70.s12	and	22	24	O
DDI-DrugBank.d70.s12	epididymides	26	37	O
DDI-DrugBank.d70.s12	had	39	41	O
DDI-DrugBank.d70.s12	not	43	45	O
DDI-DrugBank.d70.s12	recovered	47	55	O
DDI-DrugBank.d70.s12	20	57	58	O
DDI-DrugBank.d70.s12	weeks	60	64	O
DDI-DrugBank.d70.s12	after	66	70	O
DDI-DrugBank.d70.s12	cessation	72	80	O
DDI-DrugBank.d70.s12	of	82	83	O
DDI-DrugBank.d70.s12	dosing	85	90	O
DDI-DrugBank.d70.s12	.	91	91	O
DDI-DrugBank.d70.s13	These	0	4	O
DDI-DrugBank.d70.s13	fulvestrant	6	16	B-drug
DDI-DrugBank.d70.s13	doses	18	22	O
DDI-DrugBank.d70.s13	correspond	24	33	O
DDI-DrugBank.d70.s13	to	35	36	O
DDI-DrugBank.d70.s13	approximately	38	50	O
DDI-DrugBank.d70.s13	2-	52	53	O
DDI-DrugBank.d70.s13	,	54	54	O
DDI-DrugBank.d70.s13	3-	56	57	O
DDI-DrugBank.d70.s13	,	54	54	O
DDI-DrugBank.d70.s13	and	60	62	O
DDI-DrugBank.d70.s13	3-fold	64	69	O
DDI-DrugBank.d70.s13	the	71	73	O
DDI-DrugBank.d70.s13	systemic	75	82	O
DDI-DrugBank.d70.s13	exposure	84	91	O
DDI-DrugBank.d70.s13	[	93	93	O
DDI-DrugBank.d70.s13	AUC0-30	94	100	O
DDI-DrugBank.d70.s13	days	102	105	O
DDI-DrugBank.d70.s13	]	106	106	O
DDI-DrugBank.d70.s13	achieved	108	115	O
DDI-DrugBank.d70.s13	in	117	118	O
DDI-DrugBank.d70.s13	women	120	124	O
DDI-DrugBank.d70.s13	.	125	125	O
DDI-DrugBank.d70.s14	Pregnancy	0	8	O
DDI-DrugBank.d70.s14	Pregnancy	10	18	O
DDI-DrugBank.d70.s14	Category	20	27	O
DDI-DrugBank.d70.s14	D	29	29	O
DDI-DrugBank.d70.s14	:	30	30	O
DDI-DrugBank.d70.s14	.	32	32	O
DDI-DrugBank.d70.s15	In	0	1	O
DDI-DrugBank.d70.s15	studies	3	9	O
DDI-DrugBank.d70.s15	in	11	12	O
DDI-DrugBank.d70.s15	female	14	19	O
DDI-DrugBank.d70.s15	rats	21	24	O
DDI-DrugBank.d70.s15	at	22	23	O
DDI-DrugBank.d70.s15	doses	29	33	O
DDI-DrugBank.d70.s15	0.01	37	40	O
DDI-DrugBank.d70.s15	mg/kg/day	42	50	O
DDI-DrugBank.d70.s15	(	52	52	O
DDI-DrugBank.d70.s15	IM	53	54	O
DDI-DrugBank.d70.s15	;	55	55	O
DDI-DrugBank.d70.s16	approximately	0	12	O
DDI-DrugBank.d70.s16	one-hundredth	14	26	O
DDI-DrugBank.d70.s16	of	28	29	O
DDI-DrugBank.d70.s16	the	31	33	O
DDI-DrugBank.d70.s16	human	35	39	O
DDI-DrugBank.d70.s16	recommended	41	51	O
DDI-DrugBank.d70.s16	dose	53	56	O
DDI-DrugBank.d70.s16	based	58	62	O
DDI-DrugBank.d70.s16	on	64	65	O
DDI-DrugBank.d70.s16	body	67	70	O
DDI-DrugBank.d70.s16	surface	72	78	O
DDI-DrugBank.d70.s16	area	80	83	O
DDI-DrugBank.d70.s16	[	85	85	O
DDI-DrugBank.d70.s16	BSA	86	88	O
DDI-DrugBank.d70.s16	]	89	89	O
DDI-DrugBank.d70.s16	)	90	90	O
DDI-DrugBank.d70.s16	,	91	91	O
DDI-DrugBank.d70.s16	fulvestrant	93	103	B-drug
DDI-DrugBank.d70.s16	caused	105	110	O
DDI-DrugBank.d70.s16	a	101	101	O
DDI-DrugBank.d70.s16	reversible	114	123	O
DDI-DrugBank.d70.s16	reduction	125	133	O
DDI-DrugBank.d70.s16	in	135	136	O
DDI-DrugBank.d70.s16	female	138	143	O
DDI-DrugBank.d70.s16	fertility	145	153	O
DDI-DrugBank.d70.s16	,	154	154	O
DDI-DrugBank.d70.s16	as	156	157	O
DDI-DrugBank.d70.s16	well	159	162	O
DDI-DrugBank.d70.s16	as	156	157	O
DDI-DrugBank.d70.s16	effects	167	173	O
DDI-DrugBank.d70.s16	on	175	176	O
DDI-DrugBank.d70.s16	embryo/fetal	178	189	O
DDI-DrugBank.d70.s16	development	191	201	O
DDI-DrugBank.d70.s16	consistent	203	212	O
DDI-DrugBank.d70.s16	with	214	217	O
DDI-DrugBank.d70.s16	its	219	221	O
DDI-DrugBank.d70.s16	anti-estrogenic	223	237	O
DDI-DrugBank.d70.s16	activity	239	246	O
DDI-DrugBank.d70.s16	.	247	247	O
DDI-DrugBank.d70.s17	Fulvestrant	0	10	B-drug
DDI-DrugBank.d70.s17	caused	12	17	O
DDI-DrugBank.d70.s17	an	19	20	O
DDI-DrugBank.d70.s17	increased	22	30	O
DDI-DrugBank.d70.s17	incidence	32	40	O
DDI-DrugBank.d70.s17	of	42	43	O
DDI-DrugBank.d70.s17	fetal	45	49	O
DDI-DrugBank.d70.s17	abnormalities	51	63	O
DDI-DrugBank.d70.s17	in	65	66	O
DDI-DrugBank.d70.s17	rats	68	71	O
DDI-DrugBank.d70.s17	(	73	73	O
DDI-DrugBank.d70.s17	tarsal	74	79	O
DDI-DrugBank.d70.s17	flexure	81	87	O
DDI-DrugBank.d70.s17	of	89	90	O
DDI-DrugBank.d70.s17	the	92	94	O
DDI-DrugBank.d70.s17	hind	96	99	O
DDI-DrugBank.d70.s17	paw	101	103	O
DDI-DrugBank.d70.s17	at	105	106	O
DDI-DrugBank.d70.s17	2	108	108	O
DDI-DrugBank.d70.s17	mg/kg/day	110	118	O
DDI-DrugBank.d70.s17	IM	120	121	O
DDI-DrugBank.d70.s17	;	122	122	O
DDI-DrugBank.d70.s18	twice	0	4	O
DDI-DrugBank.d70.s18	the	6	8	O
DDI-DrugBank.d70.s18	human	10	14	O
DDI-DrugBank.d70.s18	dose	16	19	O
DDI-DrugBank.d70.s18	on	21	22	O
DDI-DrugBank.d70.s18	BSA	24	26	O
DDI-DrugBank.d70.s18	)	27	27	O
DDI-DrugBank.d70.s18	and	29	31	O
DDI-DrugBank.d70.s18	non-ossification	33	48	O
DDI-DrugBank.d70.s18	of	50	51	O
DDI-DrugBank.d70.s18	the	53	55	O
DDI-DrugBank.d70.s18	odontoid	57	64	O
DDI-DrugBank.d70.s18	and	66	68	O
DDI-DrugBank.d70.s18	ventral	70	76	O
DDI-DrugBank.d70.s18	tubercle	78	85	O
DDI-DrugBank.d70.s18	of	87	88	O
DDI-DrugBank.d70.s18	the	90	92	O
DDI-DrugBank.d70.s18	first	94	98	O
DDI-DrugBank.d70.s18	cervical	100	107	O
DDI-DrugBank.d70.s18	vertebra	109	116	O
DDI-DrugBank.d70.s18	at	118	119	O
DDI-DrugBank.d70.s18	doses	121	125	O
DDI-DrugBank.d70.s18	0.1	129	131	O
DDI-DrugBank.d70.s18	mg/kg/day	133	141	O
DDI-DrugBank.d70.s18	IM	143	144	O
DDI-DrugBank.d70.s18	(	146	146	O
DDI-DrugBank.d70.s18	approximately	147	159	O
DDI-DrugBank.d70.s18	one-tenth	161	169	O
DDI-DrugBank.d70.s18	of	171	172	O
DDI-DrugBank.d70.s18	the	174	176	O
DDI-DrugBank.d70.s18	human	178	182	O
DDI-DrugBank.d70.s18	dose	184	187	O
DDI-DrugBank.d70.s18	on	161	162	O
DDI-DrugBank.d70.s18	BSA	192	194	O
DDI-DrugBank.d70.s18	)	195	195	O
DDI-DrugBank.d70.s18	when	197	200	O
DDI-DrugBank.d70.s18	administered	202	213	O
DDI-DrugBank.d70.s18	during	215	220	O
DDI-DrugBank.d70.s18	the	222	224	O
DDI-DrugBank.d70.s18	period	226	231	O
DDI-DrugBank.d70.s18	of	233	234	O
DDI-DrugBank.d70.s18	organogenesis	236	248	O
DDI-DrugBank.d70.s18	.	249	249	O
DDI-DrugBank.d70.s19	Rabbits	0	6	O
DDI-DrugBank.d70.s19	failed	8	13	O
DDI-DrugBank.d70.s19	to	15	16	O
DDI-DrugBank.d70.s19	maintain	18	25	O
DDI-DrugBank.d70.s19	pregnancy	27	35	O
DDI-DrugBank.d70.s19	when	37	40	O
DDI-DrugBank.d70.s19	dosed	42	46	O
DDI-DrugBank.d70.s19	with	48	51	O
DDI-DrugBank.d70.s19	1	53	53	O
DDI-DrugBank.d70.s19	mg/kg/day	55	63	O
DDI-DrugBank.d70.s19	fulvestrant	65	75	B-drug
DDI-DrugBank.d70.s19	IM	77	78	O
DDI-DrugBank.d70.s19	(	80	80	O
DDI-DrugBank.d70.s19	twice	81	85	O
DDI-DrugBank.d70.s19	the	87	89	O
DDI-DrugBank.d70.s19	human	91	95	O
DDI-DrugBank.d70.s19	dose	97	100	O
DDI-DrugBank.d70.s19	on	102	103	O
DDI-DrugBank.d70.s19	BSA	105	107	O
DDI-DrugBank.d70.s19	)	108	108	O
DDI-DrugBank.d70.s19	during	110	115	O
DDI-DrugBank.d70.s19	the	117	119	O
DDI-DrugBank.d70.s19	period	121	126	O
DDI-DrugBank.d70.s19	of	128	129	O
DDI-DrugBank.d70.s19	organogenesis	131	143	O
DDI-DrugBank.d70.s19	.	144	144	O
DDI-DrugBank.d70.s20	Further	0	6	O
DDI-DrugBank.d70.s20	,	7	7	O
DDI-DrugBank.d70.s20	in	9	10	O
DDI-DrugBank.d70.s20	rabbits	12	18	O
DDI-DrugBank.d70.s20	dosed	20	24	O
DDI-DrugBank.d70.s20	at	26	27	O
DDI-DrugBank.d70.s20	0.25	29	32	O
DDI-DrugBank.d70.s20	mg/kg/day	34	42	O
DDI-DrugBank.d70.s20	(	44	44	O
DDI-DrugBank.d70.s20	about	45	49	O
DDI-DrugBank.d70.s20	one-half	51	58	O
DDI-DrugBank.d70.s20	the	60	62	O
DDI-DrugBank.d70.s20	human	64	68	O
DDI-DrugBank.d70.s20	dose	70	73	O
DDI-DrugBank.d70.s20	on	75	76	O
DDI-DrugBank.d70.s20	BSA	78	80	O
DDI-DrugBank.d70.s20	)	81	81	O
DDI-DrugBank.d70.s20	,	82	82	O
DDI-DrugBank.d70.s20	increases	84	92	O
DDI-DrugBank.d70.s20	in	84	85	O
DDI-DrugBank.d70.s20	placental	97	105	O
DDI-DrugBank.d70.s20	weight	107	112	O
DDI-DrugBank.d70.s20	and	114	116	O
DDI-DrugBank.d70.s20	post-implantation	118	134	O
DDI-DrugBank.d70.s20	loss	136	139	O
DDI-DrugBank.d70.s20	were	141	144	O
DDI-DrugBank.d70.s20	observed	146	153	O
DDI-DrugBank.d70.s20	but	155	157	O
DDI-DrugBank.d70.s20	,	158	158	O
DDI-DrugBank.d70.s20	there	160	164	O
DDI-DrugBank.d70.s20	were	141	144	O
DDI-DrugBank.d70.s20	no	171	172	O
DDI-DrugBank.d70.s20	observed	174	181	O
DDI-DrugBank.d70.s20	effects	183	189	O
DDI-DrugBank.d70.s20	on	191	192	O
DDI-DrugBank.d70.s20	fetal	194	198	O
DDI-DrugBank.d70.s20	development	200	210	O
DDI-DrugBank.d70.s20	.	211	211	O
DDI-DrugBank.d70.s21	Fulvestrant	0	10	B-drug
DDI-DrugBank.d70.s21	was	12	14	O
DDI-DrugBank.d70.s21	associated	16	25	O
DDI-DrugBank.d70.s21	with	27	30	O
DDI-DrugBank.d70.s21	an	32	33	O
DDI-DrugBank.d70.s21	increased	35	43	O
DDI-DrugBank.d70.s21	incidence	45	53	O
DDI-DrugBank.d70.s21	of	55	56	O
DDI-DrugBank.d70.s21	fetal	58	62	O
DDI-DrugBank.d70.s21	variations	64	73	O
DDI-DrugBank.d70.s21	in	75	76	O
DDI-DrugBank.d70.s21	rabbits	78	84	O
DDI-DrugBank.d70.s21	(	86	86	O
DDI-DrugBank.d70.s21	backwards	87	95	O
DDI-DrugBank.d70.s21	displacement	97	108	O
DDI-DrugBank.d70.s21	of	110	111	O
DDI-DrugBank.d70.s21	the	113	115	O
DDI-DrugBank.d70.s21	pelvic	117	122	O
DDI-DrugBank.d70.s21	girdle	124	129	O
DDI-DrugBank.d70.s21	,	130	130	O
DDI-DrugBank.d70.s21	and	132	134	O
DDI-DrugBank.d70.s21	27	136	137	O
DDI-DrugBank.d70.s21	pre-sacral	139	148	O
DDI-DrugBank.d70.s21	vertebrae	150	158	O
DDI-DrugBank.d70.s21	at	160	161	O
DDI-DrugBank.d70.s21	0.25	163	166	O
DDI-DrugBank.d70.s21	mg/kg/day	168	176	O
DDI-DrugBank.d70.s21	IM	178	179	O
DDI-DrugBank.d70.s21	;	180	180	O
DDI-DrugBank.d70.s22	one-half	0	7	O
DDI-DrugBank.d70.s22	the	9	11	O
DDI-DrugBank.d70.s22	human	13	17	O
DDI-DrugBank.d70.s22	dose	19	22	O
DDI-DrugBank.d70.s22	on	24	25	O
DDI-DrugBank.d70.s22	BSA	27	29	O
DDI-DrugBank.d70.s22	)	30	30	O
DDI-DrugBank.d70.s22	when	32	35	O
DDI-DrugBank.d70.s22	administered	37	48	O
DDI-DrugBank.d70.s22	during	50	55	O
DDI-DrugBank.d70.s22	the	57	59	O
DDI-DrugBank.d70.s22	period	61	66	O
DDI-DrugBank.d70.s22	of	68	69	O
DDI-DrugBank.d70.s22	organogenesis	71	83	O
DDI-DrugBank.d70.s22	.	84	84	O
DDI-DrugBank.d70.s23	Because	0	6	O
DDI-DrugBank.d70.s23	pregnancy	8	16	O
DDI-DrugBank.d70.s23	could	18	22	O
DDI-DrugBank.d70.s23	not	24	26	O
DDI-DrugBank.d70.s23	be	28	29	O
DDI-DrugBank.d70.s23	maintained	31	40	O
DDI-DrugBank.d70.s23	in	37	38	O
DDI-DrugBank.d70.s23	the	45	47	O
DDI-DrugBank.d70.s23	rabbit	49	54	O
DDI-DrugBank.d70.s23	following	56	64	O
DDI-DrugBank.d70.s23	doses	66	70	O
DDI-DrugBank.d70.s23	of	72	73	O
DDI-DrugBank.d70.s23	fulvestrant	75	85	B-drug
DDI-DrugBank.d70.s23	of	87	88	O
DDI-DrugBank.d70.s23	1	90	90	O
DDI-DrugBank.d70.s23	mg/kg/day	92	100	O
DDI-DrugBank.d70.s23	and	102	104	O
DDI-DrugBank.d70.s23	above	106	110	O
DDI-DrugBank.d70.s23	,	111	111	O
DDI-DrugBank.d70.s23	this	113	116	O
DDI-DrugBank.d70.s23	study	118	122	O
DDI-DrugBank.d70.s23	was	124	126	O
DDI-DrugBank.d70.s23	inadequate	128	137	O
DDI-DrugBank.d70.s23	to	139	140	O
DDI-DrugBank.d70.s23	fully	142	146	O
DDI-DrugBank.d70.s23	define	148	153	O
DDI-DrugBank.d70.s23	the	155	157	O
DDI-DrugBank.d70.s23	possible	159	166	O
DDI-DrugBank.d70.s23	adverse	168	174	O
DDI-DrugBank.d70.s23	effects	176	182	O
DDI-DrugBank.d70.s23	on	184	185	O
DDI-DrugBank.d70.s23	fetal	187	191	O
DDI-DrugBank.d70.s23	development	193	203	O
DDI-DrugBank.d70.s23	at	205	206	O
DDI-DrugBank.d70.s23	clinically	208	217	O
DDI-DrugBank.d70.s23	relevant	219	226	O
DDI-DrugBank.d70.s23	exposures	228	236	O
DDI-DrugBank.d70.s23	.	237	237	O
DDI-DrugBank.d70.s24	Nursing	0	6	O
DDI-DrugBank.d70.s24	Mothers	8	14	O
DDI-DrugBank.d70.s24	Fulvestrant	16	26	B-drug
DDI-DrugBank.d70.s24	is	28	29	O
DDI-DrugBank.d70.s24	found	31	35	O
DDI-DrugBank.d70.s24	in	37	38	O
DDI-DrugBank.d70.s24	rat	40	42	O
DDI-DrugBank.d70.s24	milk	44	47	O
DDI-DrugBank.d70.s24	at	41	42	O
DDI-DrugBank.d70.s24	levels	52	57	O
DDI-DrugBank.d70.s24	significantly	59	71	O
DDI-DrugBank.d70.s24	higher	73	78	O
DDI-DrugBank.d70.s24	(	80	80	O
DDI-DrugBank.d70.s24	approximately	81	93	O
DDI-DrugBank.d70.s24	12-fold	95	101	O
DDI-DrugBank.d70.s24	)	102	102	O
DDI-DrugBank.d70.s24	than	104	107	O
DDI-DrugBank.d70.s24	plasma	109	114	O
DDI-DrugBank.d70.s24	after	116	120	O
DDI-DrugBank.d70.s24	administration	122	135	O
DDI-DrugBank.d70.s24	of	137	138	O
DDI-DrugBank.d70.s24	2	140	140	O
DDI-DrugBank.d70.s24	mg/kg	142	146	O
DDI-DrugBank.d70.s24	.	147	147	O
DDI-DrugBank.d70.s25	Drug	0	3	O
DDI-DrugBank.d70.s25	exposure	5	12	O
DDI-DrugBank.d70.s25	in	14	15	O
DDI-DrugBank.d70.s25	rodent	17	22	O
DDI-DrugBank.d70.s25	pups	24	27	O
DDI-DrugBank.d70.s25	from	29	32	O
DDI-DrugBank.d70.s25	fulvestrant-treated	34	52	O
DDI-DrugBank.d70.s25	lactating	54	62	O
DDI-DrugBank.d70.s25	dams	64	67	O
DDI-DrugBank.d70.s25	was	69	71	O
DDI-DrugBank.d70.s25	estimated	73	81	O
DDI-DrugBank.d70.s25	as	83	84	O
DDI-DrugBank.d70.s25	10	86	87	O
DDI-DrugBank.d70.s25	%	88	88	O
DDI-DrugBank.d70.s25	of	90	91	O
DDI-DrugBank.d70.s25	the	93	95	O
DDI-DrugBank.d70.s25	administered	97	108	O
DDI-DrugBank.d70.s25	dose	110	113	O
DDI-DrugBank.d70.s25	.	114	114	O
DDI-DrugBank.d70.s26	It	0	1	O
DDI-DrugBank.d70.s26	is	3	4	O
DDI-DrugBank.d70.s26	not	6	8	O
DDI-DrugBank.d70.s26	known	10	14	O
DDI-DrugBank.d70.s26	if	16	17	O
DDI-DrugBank.d70.s26	fulvestrant	19	29	B-drug
DDI-DrugBank.d70.s26	is	31	32	O
DDI-DrugBank.d70.s26	excreted	34	41	O
DDI-DrugBank.d70.s26	in	43	44	O
DDI-DrugBank.d70.s26	human	46	50	O
DDI-DrugBank.d70.s26	milk	52	55	O
DDI-DrugBank.d70.s26	.	56	56	O
DDI-DrugBank.d70.s27	Because	0	6	O
DDI-DrugBank.d70.s27	many	8	11	O
DDI-DrugBank.d70.s27	drugs	13	17	O
DDI-DrugBank.d70.s27	are	19	21	O
DDI-DrugBank.d70.s27	excreted	23	30	O
DDI-DrugBank.d70.s27	in	32	33	O
DDI-DrugBank.d70.s27	human	35	39	O
DDI-DrugBank.d70.s27	milk	41	44	O
DDI-DrugBank.d70.s27	,	45	45	O
DDI-DrugBank.d70.s27	and	47	49	O
DDI-DrugBank.d70.s27	because	51	57	O
DDI-DrugBank.d70.s27	of	59	60	O
DDI-DrugBank.d70.s27	the	62	64	O
DDI-DrugBank.d70.s27	potential	66	74	O
DDI-DrugBank.d70.s27	for	76	78	O
DDI-DrugBank.d70.s27	serious	80	86	O
DDI-DrugBank.d70.s27	adverse	88	94	O
DDI-DrugBank.d70.s27	reactions	96	104	O
DDI-DrugBank.d70.s27	from	106	109	O
DDI-DrugBank.d70.s27	FASLODEX	111	118	B-brand
DDI-DrugBank.d70.s27	in	120	121	O
DDI-DrugBank.d70.s27	nursing	123	129	O
DDI-DrugBank.d70.s27	infants	131	137	O
DDI-DrugBank.d70.s27	,	138	138	O
DDI-DrugBank.d70.s27	a	134	134	O
DDI-DrugBank.d70.s27	decision	142	149	O
DDI-DrugBank.d70.s27	should	151	156	O
DDI-DrugBank.d70.s27	be	158	159	O
DDI-DrugBank.d70.s27	made	161	164	O
DDI-DrugBank.d70.s27	whether	166	172	O
DDI-DrugBank.d70.s27	to	174	175	O
DDI-DrugBank.d70.s27	discontinue	177	187	O
DDI-DrugBank.d70.s27	nursing	189	195	O
DDI-DrugBank.d70.s27	or	197	198	O
DDI-DrugBank.d70.s27	to	174	175	O
DDI-DrugBank.d70.s27	discontinue	177	187	O
DDI-DrugBank.d70.s27	the	215	217	O
DDI-DrugBank.d70.s27	drug	219	222	O
DDI-DrugBank.d70.s27	taking	224	229	O
DDI-DrugBank.d70.s27	into	231	234	O
DDI-DrugBank.d70.s27	account	236	242	O
DDI-DrugBank.d70.s27	the	215	217	O
DDI-DrugBank.d70.s27	importance	248	257	O
DDI-DrugBank.d70.s27	of	259	260	O
DDI-DrugBank.d70.s27	the	244	246	O
DDI-DrugBank.d70.s27	drug	266	269	O
DDI-DrugBank.d70.s27	to	233	234	O
DDI-DrugBank.d70.s27	the	244	246	O
DDI-DrugBank.d70.s27	mother	278	283	O
DDI-DrugBank.d70.s27	.	284	284	O
DDI-DrugBank.d70.s28	Pediatric	0	8	O
DDI-DrugBank.d70.s28	Use	10	12	O
DDI-DrugBank.d70.s28	The	14	16	O
DDI-DrugBank.d70.s28	safety	18	23	O
DDI-DrugBank.d70.s28	and	25	27	O
DDI-DrugBank.d70.s28	efficacy	29	36	O
DDI-DrugBank.d70.s28	of	38	39	O
DDI-DrugBank.d70.s28	FASLODEX	41	48	B-brand
DDI-DrugBank.d70.s28	in	50	51	O
DDI-DrugBank.d70.s28	pediatric	53	61	O
DDI-DrugBank.d70.s28	patients	63	70	O
DDI-DrugBank.d70.s28	have	72	75	O
DDI-DrugBank.d70.s28	not	77	79	O
DDI-DrugBank.d70.s28	been	81	84	O
DDI-DrugBank.d70.s28	established	86	96	O
DDI-DrugBank.d70.s28	.	97	97	O
DDI-DrugBank.d70.s29	Geriatric	0	8	O
DDI-DrugBank.d70.s29	Use	10	12	O
DDI-DrugBank.d70.s29	When	14	17	O
DDI-DrugBank.d70.s29	tumor	19	23	O
DDI-DrugBank.d70.s29	response	25	32	O
DDI-DrugBank.d70.s29	was	34	36	O
DDI-DrugBank.d70.s29	considered	38	47	O
DDI-DrugBank.d70.s29	by	49	50	O
DDI-DrugBank.d70.s29	age	52	54	O
DDI-DrugBank.d70.s29	,	55	55	O
DDI-DrugBank.d70.s29	objective	57	65	O
DDI-DrugBank.d70.s29	responses	67	75	O
DDI-DrugBank.d70.s29	were	77	80	O
DDI-DrugBank.d70.s29	seen	82	85	O
DDI-DrugBank.d70.s29	in	87	88	O
DDI-DrugBank.d70.s29	24	90	91	O
DDI-DrugBank.d70.s29	%	92	92	O
DDI-DrugBank.d70.s29	and	94	96	O
DDI-DrugBank.d70.s29	22	98	99	O
DDI-DrugBank.d70.s29	%	92	92	O
DDI-DrugBank.d70.s29	of	102	103	O
DDI-DrugBank.d70.s29	patients	105	112	O
DDI-DrugBank.d70.s29	under	114	118	O
DDI-DrugBank.d70.s29	65	120	121	O
DDI-DrugBank.d70.s29	years	123	127	O
DDI-DrugBank.d70.s29	of	129	130	O
DDI-DrugBank.d70.s29	age	132	134	O
DDI-DrugBank.d70.s29	and	136	138	O
DDI-DrugBank.d70.s29	in	140	141	O
DDI-DrugBank.d70.s29	16	143	144	O
DDI-DrugBank.d70.s29	%	145	145	O
DDI-DrugBank.d70.s29	and	136	138	O
DDI-DrugBank.d70.s29	11	151	152	O
DDI-DrugBank.d70.s29	%	145	145	O
DDI-DrugBank.d70.s29	of	129	130	O
DDI-DrugBank.d70.s29	patients	158	165	O
DDI-DrugBank.d70.s29	65	167	168	O
DDI-DrugBank.d70.s29	years	170	174	O
DDI-DrugBank.d70.s29	of	155	156	O
DDI-DrugBank.d70.s29	age	179	181	O
DDI-DrugBank.d70.s29	and	183	185	O
DDI-DrugBank.d70.s29	older	187	191	O
DDI-DrugBank.d70.s29	,	192	192	O
DDI-DrugBank.d70.s29	who	194	196	O
DDI-DrugBank.d70.s29	were	198	201	O
DDI-DrugBank.d70.s29	treated	203	209	O
DDI-DrugBank.d70.s29	with	211	214	O
DDI-DrugBank.d70.s29	FASLODEX	216	223	B-brand
DDI-DrugBank.d70.s29	in	225	226	O
DDI-DrugBank.d70.s29	the	228	230	O
DDI-DrugBank.d70.s29	European	232	239	O
DDI-DrugBank.d70.s29	and	241	243	O
DDI-DrugBank.d70.s29	North	245	249	O
DDI-DrugBank.d70.s29	American	251	258	O
DDI-DrugBank.d70.s29	trials	260	265	O
DDI-DrugBank.d70.s29	,	266	266	O
DDI-DrugBank.d70.s29	respectively	268	279	O
DDI-DrugBank.d70.s29	.	280	280	O
DDI-MedLine.d195.s0	Influence	0	8	O
DDI-MedLine.d195.s0	of	10	11	O
DDI-MedLine.d195.s0	piperine	13	20	B-drug_n
DDI-MedLine.d195.s0	on	22	23	O
DDI-MedLine.d195.s0	ibuprofen	25	33	B-drug
DDI-MedLine.d195.s0	induced	35	41	O
DDI-MedLine.d195.s0	antinociception	43	57	O
DDI-MedLine.d195.s0	and	59	61	O
DDI-MedLine.d195.s0	its	63	65	O
DDI-MedLine.d195.s0	pharmacokinetics	67	82	O
DDI-MedLine.d195.s0	.	83	83	O
DDI-MedLine.d195.s1	Piperine	0	7	B-drug_n
DDI-MedLine.d195.s1	(	9	9	O
DDI-MedLine.d195.s1	CAS	10	12	O
DDI-MedLine.d195.s1	94-62-2	14	20	O
DDI-MedLine.d195.s1	)	21	21	O
DDI-MedLine.d195.s1	,	22	22	O
DDI-MedLine.d195.s1	an	24	25	O
DDI-MedLine.d195.s1	alkaloid	27	34	O
DDI-MedLine.d195.s1	obtained	36	43	O
DDI-MedLine.d195.s1	from	45	48	O
DDI-MedLine.d195.s1	Piper	50	54	O
DDI-MedLine.d195.s1	nigrum	56	61	O
DDI-MedLine.d195.s1	and	63	65	O
DDI-MedLine.d195.s1	P	67	67	O
DDI-MedLine.d195.s1	.	68	68	O
DDI-MedLine.d195.s2	longum	0	5	O
DDI-MedLine.d195.s2	,	6	6	O
DDI-MedLine.d195.s2	is	8	9	O
DDI-MedLine.d195.s2	a	11	11	O
DDI-MedLine.d195.s2	known	13	17	O
DDI-MedLine.d195.s2	inhibitor	19	27	O
DDI-MedLine.d195.s2	of	29	30	O
DDI-MedLine.d195.s2	various	32	38	O
DDI-MedLine.d195.s2	enzymes	40	46	O
DDI-MedLine.d195.s2	(	48	48	O
DDI-MedLine.d195.s2	CYP	49	51	O
DDI-MedLine.d195.s2	isozymes	53	60	O
DDI-MedLine.d195.s2	)	61	61	O
DDI-MedLine.d195.s2	responsible	63	73	O
DDI-MedLine.d195.s2	for	75	77	O
DDI-MedLine.d195.s2	biotransformation	79	95	O
DDI-MedLine.d195.s2	of	97	98	O
DDI-MedLine.d195.s2	drugs	100	104	O
DDI-MedLine.d195.s2	.	105	105	O
DDI-MedLine.d195.s3	By	0	1	O
DDI-MedLine.d195.s3	inhibiting	3	12	O
DDI-MedLine.d195.s3	the	14	16	O
DDI-MedLine.d195.s3	metabolism	18	27	O
DDI-MedLine.d195.s3	of	29	30	O
DDI-MedLine.d195.s3	drugs	32	36	O
DDI-MedLine.d195.s3	,	37	37	O
DDI-MedLine.d195.s3	piperine	39	46	B-drug_n
DDI-MedLine.d195.s3	improves	48	55	O
DDI-MedLine.d195.s3	the	57	59	O
DDI-MedLine.d195.s3	bioavailability	61	75	O
DDI-MedLine.d195.s3	of	77	78	O
DDI-MedLine.d195.s3	drugs	80	84	O
DDI-MedLine.d195.s3	.	85	85	O
DDI-MedLine.d195.s4	In	0	1	O
DDI-MedLine.d195.s4	the	3	5	O
DDI-MedLine.d195.s4	present	7	13	O
DDI-MedLine.d195.s4	study	15	19	O
DDI-MedLine.d195.s4	piperine	21	28	B-drug_n
DDI-MedLine.d195.s4	(	30	30	O
DDI-MedLine.d195.s4	10	31	32	O
DDI-MedLine.d195.s4	mg/kg	34	38	O
DDI-MedLine.d195.s4	)	39	39	O
DDI-MedLine.d195.s4	significantly	41	53	O
DDI-MedLine.d195.s4	increased	55	63	O
DDI-MedLine.d195.s4	the	65	67	O
DDI-MedLine.d195.s4	dose-dependent	69	82	O
DDI-MedLine.d195.s4	antinociceptive	84	98	O
DDI-MedLine.d195.s4	activity	100	107	O
DDI-MedLine.d195.s4	of	109	110	O
DDI-MedLine.d195.s4	ibuprofen	112	120	B-drug
DDI-MedLine.d195.s4	evaluated	122	130	O
DDI-MedLine.d195.s4	by	132	133	O
DDI-MedLine.d195.s4	both	135	138	O
DDI-MedLine.d195.s4	acetic	140	145	B-drug
DDI-MedLine.d195.s4	acid	147	150	I-drug
DDI-MedLine.d195.s4	writhing	152	159	O
DDI-MedLine.d195.s4	and	161	163	O
DDI-MedLine.d195.s4	formalin	165	172	O
DDI-MedLine.d195.s4	test	174	177	O
DDI-MedLine.d195.s4	,	178	178	O
DDI-MedLine.d195.s4	when	180	183	O
DDI-MedLine.d195.s4	it	185	186	O
DDI-MedLine.d195.s4	was	188	190	O
DDI-MedLine.d195.s4	administered	192	203	O
DDI-MedLine.d195.s4	with	205	208	O
DDI-MedLine.d195.s4	ibuprofen	210	218	B-drug
DDI-MedLine.d195.s4	.	219	219	O
DDI-MedLine.d195.s5	Ibuprofen	0	8	B-drug
DDI-MedLine.d195.s5	plasma	10	15	O
DDI-MedLine.d195.s5	concentration	17	29	O
DDI-MedLine.d195.s5	was	31	33	O
DDI-MedLine.d195.s5	also	35	38	O
DDI-MedLine.d195.s5	increased	40	48	O
DDI-MedLine.d195.s5	when	50	53	O
DDI-MedLine.d195.s5	it	55	56	O
DDI-MedLine.d195.s5	was	58	60	O
DDI-MedLine.d195.s5	administered	62	73	O
DDI-MedLine.d195.s5	with	75	78	O
DDI-MedLine.d195.s5	piperine	80	87	B-drug_n
DDI-MedLine.d195.s5	.	88	88	O
DDI-MedLine.d195.s6	The	0	2	O
DDI-MedLine.d195.s6	synergistic	4	14	O
DDI-MedLine.d195.s6	antinociception	16	30	O
DDI-MedLine.d195.s6	activity	32	39	O
DDI-MedLine.d195.s6	of	41	42	O
DDI-MedLine.d195.s6	ibuprofen	44	52	B-drug
DDI-MedLine.d195.s6	when	54	57	O
DDI-MedLine.d195.s6	administered	59	70	O
DDI-MedLine.d195.s6	with	72	75	O
DDI-MedLine.d195.s6	piperine	77	84	B-drug_n
DDI-MedLine.d195.s6	can	86	88	O
DDI-MedLine.d195.s6	be	90	91	O
DDI-MedLine.d195.s6	attributed	93	102	O
DDI-MedLine.d195.s6	to	104	105	O
DDI-MedLine.d195.s6	increased	107	115	O
DDI-MedLine.d195.s6	plasma	117	122	O
DDI-MedLine.d195.s6	concentration	124	136	O
DDI-MedLine.d195.s6	of	138	139	O
DDI-MedLine.d195.s6	ibuprofen	141	149	B-drug
DDI-MedLine.d195.s6	.	150	150	O
DDI-MedLine.d195.s7	From	0	3	O
DDI-MedLine.d195.s7	this	5	8	O
DDI-MedLine.d195.s7	study	10	14	O
DDI-MedLine.d195.s7	it	16	17	O
DDI-MedLine.d195.s7	can	19	21	O
DDI-MedLine.d195.s7	be	23	24	O
DDI-MedLine.d195.s7	concluded	26	34	O
DDI-MedLine.d195.s7	that	36	39	O
DDI-MedLine.d195.s7	piperine	41	48	B-drug_n
DDI-MedLine.d195.s7	can	50	52	O
DDI-MedLine.d195.s7	be	54	55	O
DDI-MedLine.d195.s7	used	57	60	O
DDI-MedLine.d195.s7	as	62	63	O
DDI-MedLine.d195.s7	a	62	62	O
DDI-MedLine.d195.s7	bioenhancer	67	77	O
DDI-MedLine.d195.s7	along	79	83	O
DDI-MedLine.d195.s7	with	85	88	O
DDI-MedLine.d195.s7	ibuprofen	90	98	B-drug
DDI-MedLine.d195.s7	.	99	99	O
DDI-DrugBank.d405.s0	Dicumarol	0	8	B-drug
DDI-DrugBank.d405.s0	and	10	12	O
DDI-DrugBank.d405.s0	warfarin	14	21	B-drug
DDI-DrugBank.d405.s0	may	23	25	O
DDI-DrugBank.d405.s0	decrease	27	34	O
DDI-DrugBank.d405.s0	hypoprothrombinemic	36	54	O
DDI-DrugBank.d405.s0	effect	56	61	O
DDI-DrugBank.d405.s0	.	62	62	O
DDI-DrugBank.d405.s1	Other	0	4	O
DDI-DrugBank.d405.s1	depressasnts	6	17	O
DDI-DrugBank.d405.s1	such	19	22	O
DDI-DrugBank.d405.s1	as	24	25	O
DDI-DrugBank.d405.s1	alcohol	27	33	B-drug
DDI-DrugBank.d405.s1	,	34	34	O
DDI-DrugBank.d405.s1	barbiturates	36	47	B-group
DDI-DrugBank.d405.s1	,	48	48	O
DDI-DrugBank.d405.s1	and	50	52	O
DDI-DrugBank.d405.s1	MAOIs	54	58	B-group
DDI-DrugBank.d405.s1	may	60	62	O
DDI-DrugBank.d405.s1	enhance	64	70	O
DDI-DrugBank.d405.s1	CNS	72	74	O
DDI-DrugBank.d405.s1	depression	76	85	O
DDI-DrugBank.d405.s1	when	87	90	O
DDI-DrugBank.d405.s1	administered	92	103	O
DDI-DrugBank.d405.s1	with	105	108	O
DDI-DrugBank.d405.s1	ethchlorvynol	110	122	B-drug
DDI-DrugBank.d405.s1	.	123	123	O
DDI-DrugBank.d758.s0	The	0	2	O
DDI-DrugBank.d758.s0	CNS	4	6	O
DDI-DrugBank.d758.s0	depressant	8	17	O
DDI-DrugBank.d758.s0	effects	19	25	O
DDI-DrugBank.d758.s0	of	27	28	O
DDI-DrugBank.d758.s0	oxycodone	30	38	B-drug
DDI-DrugBank.d758.s0	hydrochloride	40	52	I-drug
DDI-DrugBank.d758.s0	may	54	56	O
DDI-DrugBank.d758.s0	be	58	59	O
DDI-DrugBank.d758.s0	additive	61	68	O
DDI-DrugBank.d758.s0	with	70	73	O
DDI-DrugBank.d758.s0	that	75	78	O
DDI-DrugBank.d758.s0	of	80	81	O
DDI-DrugBank.d758.s0	other	83	87	O
DDI-DrugBank.d758.s0	CNS	89	91	B-group
DDI-DrugBank.d758.s0	depressants	93	103	I-group
DDI-DrugBank.d758.s0	..	104	105	O
DDI-DrugBank.d264.s0	No	0	1	O
DDI-DrugBank.d264.s0	Information	3	13	O
DDI-DrugBank.d264.s0	Provided	15	22	O
DDI-DrugBank.d164.s0	No	0	1	O
DDI-DrugBank.d164.s0	drug	3	6	O
DDI-DrugBank.d164.s0	interaction	8	18	O
DDI-DrugBank.d164.s0	studies	20	26	O
DDI-DrugBank.d164.s0	were	28	31	O
DDI-DrugBank.d164.s0	performed	33	41	O
DDI-DrugBank.d164.s0	.	42	42	O
DDI-DrugBank.d164.s1	No	0	1	O
DDI-DrugBank.d164.s1	in	3	4	O
DDI-DrugBank.d164.s1	vitro	6	10	O
DDI-DrugBank.d164.s1	metabolism	12	21	O
DDI-DrugBank.d164.s1	studies	23	29	O
DDI-DrugBank.d164.s1	were	31	34	O
DDI-DrugBank.d164.s1	performed	36	44	O
DDI-DrugBank.d164.s1	.	45	45	O
DDI-MedLine.d64.s0	Pharmacological	0	14	O
DDI-MedLine.d64.s0	treatment	16	24	O
DDI-MedLine.d64.s0	of	26	27	O
DDI-MedLine.d64.s0	depression	29	38	O
DDI-MedLine.d64.s0	:	39	39	O
DDI-MedLine.d64.s0	the	41	43	O
DDI-MedLine.d64.s0	role	45	48	O
DDI-MedLine.d64.s0	of	50	51	O
DDI-MedLine.d64.s0	paroxetine	53	62	B-drug
DDI-MedLine.d64.s0	.	63	63	O
DDI-MedLine.d64.s1	Depression	0	9	O
DDI-MedLine.d64.s1	is	11	12	O
DDI-MedLine.d64.s1	reaching	14	21	O
DDI-MedLine.d64.s1	epidemic	23	30	O
DDI-MedLine.d64.s1	proportions	32	42	O
DDI-MedLine.d64.s1	in	44	45	O
DDI-MedLine.d64.s1	the	47	49	O
DDI-MedLine.d64.s1	western	51	57	O
DDI-MedLine.d64.s1	world	59	63	O
DDI-MedLine.d64.s1	.	64	64	O
DDI-MedLine.d64.s2	With	0	3	O
DDI-MedLine.d64.s2	each	5	8	O
DDI-MedLine.d64.s2	successive	10	19	O
DDI-MedLine.d64.s2	generation	21	30	O
DDI-MedLine.d64.s2	more	32	35	O
DDI-MedLine.d64.s2	people	37	42	O
DDI-MedLine.d64.s2	are	44	46	O
DDI-MedLine.d64.s2	becoming	48	55	O
DDI-MedLine.d64.s2	more	57	60	O
DDI-MedLine.d64.s2	severely	62	69	O
DDI-MedLine.d64.s2	depressed	71	79	O
DDI-MedLine.d64.s2	at	81	82	O
DDI-MedLine.d64.s2	a	81	81	O
DDI-MedLine.d64.s2	younger	86	92	O
DDI-MedLine.d64.s2	age	94	96	O
DDI-MedLine.d64.s2	.	97	97	O
DDI-DrugBank.d392.s0	Patients	0	7	O
DDI-DrugBank.d392.s0	who	9	11	O
DDI-DrugBank.d392.s0	are	13	15	O
DDI-DrugBank.d392.s0	applying	17	24	O
DDI-DrugBank.d392.s0	Panretin	26	33	B-brand
DDI-DrugBank.d392.s0	gel	35	37	O
DDI-DrugBank.d392.s0	should	39	44	O
DDI-DrugBank.d392.s0	not	46	48	O
DDI-DrugBank.d392.s0	concurrently	50	61	O
DDI-DrugBank.d392.s0	use	63	65	O
DDI-DrugBank.d392.s0	products	67	74	O
DDI-DrugBank.d392.s0	that	76	79	O
DDI-DrugBank.d392.s0	contain	81	87	O
DDI-DrugBank.d392.s0	DEET	89	92	B-drug
DDI-DrugBank.d392.s0	(	94	94	O
DDI-DrugBank.d392.s0	N	95	95	O
DDI-DrugBank.d392.s0	,	96	96	O
DDI-DrugBank.d392.s0	N-diethyl-m-toluamide	98	118	B-drug
DDI-DrugBank.d392.s0	)	119	119	O
DDI-DrugBank.d392.s0	,	120	120	O
DDI-DrugBank.d392.s0	a	114	114	O
DDI-DrugBank.d392.s0	common	124	129	O
DDI-DrugBank.d392.s0	component	131	139	O
DDI-DrugBank.d392.s0	of	141	142	O
DDI-DrugBank.d392.s0	insect	144	149	O
DDI-DrugBank.d392.s0	repellent	151	159	O
DDI-DrugBank.d392.s0	products	161	168	O
DDI-DrugBank.d392.s0	.	169	169	O
DDI-DrugBank.d392.s1	Animal	0	5	O
DDI-DrugBank.d392.s1	toxicology	7	16	O
DDI-DrugBank.d392.s1	studies	18	24	O
DDI-DrugBank.d392.s1	showed	26	31	O
DDI-DrugBank.d392.s1	increased	33	41	O
DDI-DrugBank.d392.s1	DEET	43	46	B-drug
DDI-DrugBank.d392.s1	toxicity	48	55	O
DDI-DrugBank.d392.s1	when	57	60	O
DDI-DrugBank.d392.s1	DEET	62	65	B-drug
DDI-DrugBank.d392.s1	was	67	69	O
DDI-DrugBank.d392.s1	included	71	78	O
DDI-DrugBank.d392.s1	as	80	81	O
DDI-DrugBank.d392.s1	proof	83	87	O
DDI-DrugBank.d392.s1	of	86	87	O
DDI-DrugBank.d392.s1	the	92	94	O
DDI-DrugBank.d392.s1	formulation	96	106	O
DDI-DrugBank.d392.s1	.	107	107	O
DDI-DrugBank.d392.s2	Although	0	7	O
DDI-DrugBank.d392.s2	there	9	13	O
DDI-DrugBank.d392.s2	was	15	17	O
DDI-DrugBank.d392.s2	no	19	20	O
DDI-DrugBank.d392.s2	clinical	22	29	O
DDI-DrugBank.d392.s2	evidence	31	38	O
DDI-DrugBank.d392.s2	in	40	41	O
DDI-DrugBank.d392.s2	the	43	45	O
DDI-DrugBank.d392.s2	vehicle-controlled	47	64	O
DDI-DrugBank.d392.s2	studies	66	72	O
DDI-DrugBank.d392.s2	of	74	75	O
DDI-DrugBank.d392.s2	drug	77	80	O
DDI-DrugBank.d392.s2	interactions	82	93	O
DDI-DrugBank.d392.s2	with	95	98	O
DDI-DrugBank.d392.s2	systemic	100	107	O
DDI-DrugBank.d392.s2	antiretroviral	109	122	B-group
DDI-DrugBank.d392.s2	agents	124	129	I-group
DDI-DrugBank.d392.s2	,	130	130	O
DDI-DrugBank.d392.s2	including	132	140	O
DDI-DrugBank.d392.s2	protease	142	149	B-group
DDI-DrugBank.d392.s2	inhibitors	151	160	I-group
DDI-DrugBank.d392.s2	,	161	161	O
DDI-DrugBank.d392.s2	macrolide	163	171	B-group
DDI-DrugBank.d392.s2	antibiotics	173	183	I-group
DDI-DrugBank.d392.s2	,	184	184	O
DDI-DrugBank.d392.s2	and	186	188	O
DDI-DrugBank.d392.s2	azole	190	194	B-group
DDI-DrugBank.d392.s2	antifungals	196	206	I-group
DDI-DrugBank.d392.s2	,	184	184	O
DDI-DrugBank.d392.s2	the	209	211	O
DDI-DrugBank.d392.s2	effect	213	218	O
DDI-DrugBank.d392.s2	of	220	221	O
DDI-DrugBank.d392.s2	Panretin	223	230	B-brand
DDI-DrugBank.d392.s2	gel	232	234	O
DDI-DrugBank.d392.s2	on	236	237	O
DDI-DrugBank.d392.s2	the	209	211	O
DDI-DrugBank.d392.s2	steady-state	243	254	O
DDI-DrugBank.d392.s2	concentrations	256	269	O
DDI-DrugBank.d392.s2	of	271	272	O
DDI-DrugBank.d392.s2	these	274	278	O
DDI-DrugBank.d392.s2	drugs	280	284	O
DDI-DrugBank.d392.s2	is	286	287	O
DDI-DrugBank.d392.s2	not	289	291	O
DDI-DrugBank.d392.s2	known	293	297	O
DDI-DrugBank.d392.s2	.	298	298	O
DDI-DrugBank.d392.s3	No	0	1	O
DDI-DrugBank.d392.s3	drug	3	6	O
DDI-DrugBank.d392.s3	interaction	8	18	O
DDI-DrugBank.d392.s3	data	20	23	O
DDI-DrugBank.d392.s3	are	25	27	O
DDI-DrugBank.d392.s3	available	29	37	O
DDI-DrugBank.d392.s3	on	39	40	O
DDI-DrugBank.d392.s3	concomitant	42	52	O
DDI-DrugBank.d392.s3	administration	54	67	O
DDI-DrugBank.d392.s3	of	69	70	O
DDI-DrugBank.d392.s3	Panretin	72	79	B-brand
DDI-DrugBank.d392.s3	gel	81	83	O
DDI-DrugBank.d392.s3	and	85	87	O
DDI-DrugBank.d392.s3	systemic	89	96	O
DDI-DrugBank.d392.s3	anti-KS	98	104	O
DDI-DrugBank.d392.s3	agents	106	111	O
DDI-DrugBank.d392.s3	.	112	112	O
DDI-DrugBank.d361.s0	Combination	0	10	O
DDI-DrugBank.d361.s0	Therapy	12	18	O
DDI-DrugBank.d361.s0	:	19	19	O
DDI-DrugBank.d361.s0	Any	21	23	O
DDI-DrugBank.d361.s0	form	25	28	O
DDI-DrugBank.d361.s0	of	30	31	O
DDI-DrugBank.d361.s0	therapy	33	39	O
DDI-DrugBank.d361.s0	which	41	45	O
DDI-DrugBank.d361.s0	adds	47	50	O
DDI-DrugBank.d361.s0	to	52	53	O
DDI-DrugBank.d361.s0	the	55	57	O
DDI-DrugBank.d361.s0	stress	59	64	O
DDI-DrugBank.d361.s0	of	66	67	O
DDI-DrugBank.d361.s0	the	69	71	O
DDI-DrugBank.d361.s0	patient	73	79	O
DDI-DrugBank.d361.s0	,	80	80	O
DDI-DrugBank.d361.s0	interferes	82	91	O
DDI-DrugBank.d361.s0	with	93	96	O
DDI-DrugBank.d361.s0	nutrition	98	106	O
DDI-DrugBank.d361.s0	or	108	109	O
DDI-DrugBank.d361.s0	depresses	111	119	O
DDI-DrugBank.d361.s0	bone	121	124	O
DDI-DrugBank.d361.s0	marrow	126	131	O
DDI-DrugBank.d361.s0	function	133	140	O
DDI-DrugBank.d361.s0	will	142	145	O
DDI-DrugBank.d361.s0	increase	147	154	O
DDI-DrugBank.d361.s0	the	156	158	O
DDI-DrugBank.d361.s0	toxicity	160	167	O
DDI-DrugBank.d361.s0	of	169	170	O
DDI-DrugBank.d361.s0	Floxuridine	172	182	B-drug
DDI-DrugBank.d361.s0	.	183	183	O
DDI-DrugBank.d293.s0	May	0	2	O
DDI-DrugBank.d293.s0	interact	4	11	O
DDI-DrugBank.d293.s0	with	13	16	O
DDI-DrugBank.d293.s0	thyroid	18	24	O
DDI-DrugBank.d293.s0	medication	26	35	O
DDI-DrugBank.d293.s0	(	37	37	O
DDI-DrugBank.d293.s0	e.g.	38	41	O
DDI-DrugBank.d293.s0	,	42	42	O
DDI-DrugBank.d293.s0	levothyroxine	44	56	B-drug
DDI-DrugBank.d293.s0	)	57	57	O
DDI-DrugBank.d293.s0	,	58	58	O
DDI-DrugBank.d293.s0	iodine-containing	60	76	O
DDI-DrugBank.d293.s0	products	78	85	O
DDI-DrugBank.d293.s0	,	86	86	O
DDI-DrugBank.d293.s0	antacids	88	95	B-group
DDI-DrugBank.d293.s0	,	96	96	O
DDI-DrugBank.d293.s0	H2-antagonists	98	111	B-group
DDI-DrugBank.d293.s0	(	113	113	O
DDI-DrugBank.d293.s0	e.g.	114	117	O
DDI-DrugBank.d293.s0	,	118	118	O
DDI-DrugBank.d293.s0	famotidine	120	129	B-drug
DDI-DrugBank.d293.s0	,	118	118	O
DDI-DrugBank.d293.s0	ranitidine	132	141	B-drug
DDI-DrugBank.d293.s0	)	142	142	O
DDI-DrugBank.d293.s0	,	130	130	O
DDI-DrugBank.d293.s0	and	145	147	O
DDI-DrugBank.d293.s0	proton	149	154	B-group
DDI-DrugBank.d293.s0	pump	156	159	I-group
DDI-DrugBank.d293.s0	inhibitors	161	170	I-group
DDI-DrugBank.d293.s0	(	172	172	O
DDI-DrugBank.d293.s0	e.g.	173	176	O
DDI-DrugBank.d293.s0	,	177	177	O
DDI-DrugBank.d293.s0	lansoprazole	179	190	B-drug
DDI-DrugBank.d293.s0	,	177	177	O
DDI-DrugBank.d293.s0	omeprazole	193	202	B-drug
DDI-DrugBank.d293.s0	)	203	203	O
DDI-DrugBank.d293.s0	.	204	204	O
DDI-DrugBank.d293.s1	This	0	3	O
DDI-DrugBank.d293.s1	product	5	11	O
DDI-DrugBank.d293.s1	can	13	15	O
DDI-DrugBank.d293.s1	affect	17	22	O
DDI-DrugBank.d293.s1	the	24	26	O
DDI-DrugBank.d293.s1	results	28	34	O
DDI-DrugBank.d293.s1	of	36	37	O
DDI-DrugBank.d293.s1	certain	39	45	O
DDI-DrugBank.d293.s1	lab	47	49	O
DDI-DrugBank.d293.s1	tests	51	55	O
DDI-DrugBank.d293.s1	.	56	56	O
DDI-DrugBank.d356.s0	When	0	3	O
DDI-DrugBank.d356.s0	amiloride	5	13	B-drug
DDI-DrugBank.d356.s0	HCl	15	17	O
DDI-DrugBank.d356.s0	is	19	20	O
DDI-DrugBank.d356.s0	administered	22	33	O
DDI-DrugBank.d356.s0	concomitantly	35	47	O
DDI-DrugBank.d356.s0	with	49	52	O
DDI-DrugBank.d356.s0	an	54	55	O
DDI-DrugBank.d356.s0	angiotensin-converting	57	78	B-group
DDI-DrugBank.d356.s0	enzyme	80	85	I-group
DDI-DrugBank.d356.s0	inhibitor	87	95	I-group
DDI-DrugBank.d356.s0	,	96	96	O
DDI-DrugBank.d356.s0	the	98	100	O
DDI-DrugBank.d356.s0	risk	102	105	O
DDI-DrugBank.d356.s0	of	107	108	O
DDI-DrugBank.d356.s0	hyperkalemia	110	121	O
DDI-DrugBank.d356.s0	may	123	125	O
DDI-DrugBank.d356.s0	be	127	128	O
DDI-DrugBank.d356.s0	increased	130	138	O
DDI-DrugBank.d356.s0	.	139	139	O
DDI-DrugBank.d356.s1	Therefore	0	8	O
DDI-DrugBank.d356.s1	,	9	9	O
DDI-DrugBank.d356.s1	if	11	12	O
DDI-DrugBank.d356.s1	concomitant	14	24	O
DDI-DrugBank.d356.s1	use	26	28	O
DDI-DrugBank.d356.s1	of	30	31	O
DDI-DrugBank.d356.s1	these	33	37	O
DDI-DrugBank.d356.s1	agents	39	44	O
DDI-DrugBank.d356.s1	is	46	47	O
DDI-DrugBank.d356.s1	indicated	49	57	O
DDI-DrugBank.d356.s1	because	59	65	O
DDI-DrugBank.d356.s1	of	67	68	O
DDI-DrugBank.d356.s1	demonstrated	70	81	O
DDI-DrugBank.d356.s1	hypokalemia	83	93	O
DDI-DrugBank.d356.s1	,	94	94	O
DDI-DrugBank.d356.s1	they	96	99	O
DDI-DrugBank.d356.s1	should	101	106	O
DDI-DrugBank.d356.s1	be	108	109	O
DDI-DrugBank.d356.s1	used	111	114	O
DDI-DrugBank.d356.s1	with	116	119	O
DDI-DrugBank.d356.s1	caution	121	127	O
DDI-DrugBank.d356.s1	and	129	131	O
DDI-DrugBank.d356.s1	with	116	119	O
DDI-DrugBank.d356.s1	frequent	138	145	O
DDI-DrugBank.d356.s1	monitoring	147	156	O
DDI-DrugBank.d356.s1	of	158	159	O
DDI-DrugBank.d356.s1	serum	161	165	O
DDI-DrugBank.d356.s1	potassium	167	175	O
DDI-DrugBank.d356.s1	.	176	176	O
DDI-DrugBank.d356.s2	Lithium	0	6	B-drug
DDI-DrugBank.d356.s2	generally	8	16	O
DDI-DrugBank.d356.s2	should	18	23	O
DDI-DrugBank.d356.s2	not	25	27	O
DDI-DrugBank.d356.s2	be	29	30	O
DDI-DrugBank.d356.s2	given	32	36	O
DDI-DrugBank.d356.s2	with	38	41	O
DDI-DrugBank.d356.s2	diuretics	43	51	B-group
DDI-DrugBank.d356.s2	because	53	59	O
DDI-DrugBank.d356.s2	they	61	64	O
DDI-DrugBank.d356.s2	reduce	66	71	O
DDI-DrugBank.d356.s2	its	73	75	O
DDI-DrugBank.d356.s2	renal	77	81	O
DDI-DrugBank.d356.s2	clearance	83	91	O
DDI-DrugBank.d356.s2	and	93	95	O
DDI-DrugBank.d356.s2	add	97	99	O
DDI-DrugBank.d356.s2	a	86	86	O
DDI-DrugBank.d356.s2	high	103	106	O
DDI-DrugBank.d356.s2	risk	108	111	O
DDI-DrugBank.d356.s2	of	113	114	O
DDI-DrugBank.d356.s2	lithium	116	122	O
DDI-DrugBank.d356.s2	toxicity	124	131	O
DDI-DrugBank.d356.s2	.	132	132	O
DDI-DrugBank.d356.s3	Read	0	3	O
DDI-DrugBank.d356.s3	circulars	5	13	O
DDI-DrugBank.d356.s3	for	15	17	O
DDI-DrugBank.d356.s3	lithium	19	25	B-drug
DDI-DrugBank.d356.s3	preparations	27	38	O
DDI-DrugBank.d356.s3	before	40	45	O
DDI-DrugBank.d356.s3	use	47	49	O
DDI-DrugBank.d356.s3	of	51	52	O
DDI-DrugBank.d356.s3	such	54	57	O
DDI-DrugBank.d356.s3	concomitant	59	69	O
DDI-DrugBank.d356.s3	therapy	71	77	O
DDI-DrugBank.d356.s3	.	78	78	O
DDI-DrugBank.d356.s4	In	0	1	O
DDI-DrugBank.d356.s4	some	3	6	O
DDI-DrugBank.d356.s4	patients	8	15	O
DDI-DrugBank.d356.s4	,	16	16	O
DDI-DrugBank.d356.s4	the	18	20	O
DDI-DrugBank.d356.s4	administration	22	35	O
DDI-DrugBank.d356.s4	of	37	38	O
DDI-DrugBank.d356.s4	a	40	40	O
DDI-DrugBank.d356.s4	non-steroidal	42	54	B-group
DDI-DrugBank.d356.s4	anti-inflammatory	56	72	I-group
DDI-DrugBank.d356.s4	agent	74	78	I-group
DDI-DrugBank.d356.s4	can	80	82	O
DDI-DrugBank.d356.s4	reduce	84	89	O
DDI-DrugBank.d356.s4	the	91	93	O
DDI-DrugBank.d356.s4	diuretic	95	102	O
DDI-DrugBank.d356.s4	,	103	103	O
DDI-DrugBank.d356.s4	natriuretic	105	115	O
DDI-DrugBank.d356.s4	,	103	103	O
DDI-DrugBank.d356.s4	and	118	120	O
DDI-DrugBank.d356.s4	antihypertensive	122	137	O
DDI-DrugBank.d356.s4	effects	139	145	O
DDI-DrugBank.d356.s4	of	147	148	O
DDI-DrugBank.d356.s4	loop	150	153	B-group
DDI-DrugBank.d356.s4	,	154	154	O
DDI-DrugBank.d356.s4	potassium-sparing	156	172	B-group
DDI-DrugBank.d356.s4	and	174	176	O
DDI-DrugBank.d356.s4	thiazide	178	185	B-group
DDI-DrugBank.d356.s4	diuretics	187	195	I-group
DDI-DrugBank.d356.s4	.	196	196	O
DDI-DrugBank.d356.s5	Therefore	0	8	O
DDI-DrugBank.d356.s5	,	9	9	O
DDI-DrugBank.d356.s5	when	11	14	O
DDI-DrugBank.d356.s5	MIDAMOR	16	22	B-brand
DDI-DrugBank.d356.s5	and	24	26	O
DDI-DrugBank.d356.s5	non-steroidal	28	40	B-group
DDI-DrugBank.d356.s5	anti-inflammatory	42	58	I-group
DDI-DrugBank.d356.s5	agents	60	65	I-group
DDI-DrugBank.d356.s5	are	67	69	O
DDI-DrugBank.d356.s5	used	71	74	O
DDI-DrugBank.d356.s5	concomitantly	76	88	O
DDI-DrugBank.d356.s5	,	89	89	O
DDI-DrugBank.d356.s5	the	91	93	O
DDI-DrugBank.d356.s5	patient	95	101	O
DDI-DrugBank.d356.s5	should	103	108	O
DDI-DrugBank.d356.s5	be	110	111	O
DDI-DrugBank.d356.s5	observed	113	120	O
DDI-DrugBank.d356.s5	closely	122	128	O
DDI-DrugBank.d356.s5	to	130	131	O
DDI-DrugBank.d356.s5	determine	133	141	O
DDI-DrugBank.d356.s5	if	143	144	O
DDI-DrugBank.d356.s5	the	146	148	O
DDI-DrugBank.d356.s5	desired	150	156	O
DDI-DrugBank.d356.s5	effect	158	163	O
DDI-DrugBank.d356.s5	of	165	166	O
DDI-DrugBank.d356.s5	the	146	148	O
DDI-DrugBank.d356.s5	diuretic	172	179	B-group
DDI-DrugBank.d356.s5	is	181	182	O
DDI-DrugBank.d356.s5	obtained	184	191	O
DDI-DrugBank.d356.s5	.	192	192	O
DDI-DrugBank.d356.s6	Since	0	4	O
DDI-DrugBank.d356.s6	indomethacin	6	17	B-drug
DDI-DrugBank.d356.s6	and	19	21	O
DDI-DrugBank.d356.s6	potassium-sparing	23	39	B-group
DDI-DrugBank.d356.s6	diuretics	41	49	I-group
DDI-DrugBank.d356.s6	,	50	50	O
DDI-DrugBank.d356.s6	including	52	60	O
DDI-DrugBank.d356.s6	MIDAMOR	62	68	B-brand
DDI-DrugBank.d356.s6	,	69	69	O
DDI-DrugBank.d356.s6	may	71	73	O
DDI-DrugBank.d356.s6	each	75	78	O
DDI-DrugBank.d356.s6	be	80	81	O
DDI-DrugBank.d356.s6	associated	83	92	O
DDI-DrugBank.d356.s6	with	94	97	O
DDI-DrugBank.d356.s6	increased	99	107	O
DDI-DrugBank.d356.s6	serum	109	113	O
DDI-DrugBank.d356.s6	potassium	115	123	O
DDI-DrugBank.d356.s6	levels	125	130	O
DDI-DrugBank.d356.s6	,	131	131	O
DDI-DrugBank.d356.s6	the	133	135	O
DDI-DrugBank.d356.s6	potential	137	145	O
DDI-DrugBank.d356.s6	effects	147	153	O
DDI-DrugBank.d356.s6	on	155	156	O
DDI-DrugBank.d356.s6	potassium	158	166	O
DDI-DrugBank.d356.s6	kinetics	168	175	O
DDI-DrugBank.d356.s6	and	177	179	O
DDI-DrugBank.d356.s6	renal	181	185	O
DDI-DrugBank.d356.s6	function	187	194	O
DDI-DrugBank.d356.s6	should	196	201	O
DDI-DrugBank.d356.s6	be	203	204	O
DDI-DrugBank.d356.s6	considered	206	215	O
DDI-DrugBank.d356.s6	when	217	220	O
DDI-DrugBank.d356.s6	these	222	226	O
DDI-DrugBank.d356.s6	agents	228	233	O
DDI-DrugBank.d356.s6	are	235	237	O
DDI-DrugBank.d356.s6	administered	239	250	O
DDI-DrugBank.d356.s6	concurrently	252	263	O
DDI-DrugBank.d356.s6	.	264	264	O
DDI-MedLine.d79.s0	If	0	1	O
DDI-MedLine.d79.s0	taken	3	7	O
DDI-MedLine.d79.s0	1	9	9	O
DDI-MedLine.d79.s0	hour	11	14	O
DDI-MedLine.d79.s0	before	16	21	O
DDI-MedLine.d79.s0	indinavir	23	31	B-drug
DDI-MedLine.d79.s0	(	33	33	O
DDI-MedLine.d79.s0	IDV	34	36	B-drug
DDI-MedLine.d79.s0	)	37	37	O
DDI-MedLine.d79.s0	,	38	38	O
DDI-MedLine.d79.s0	didanosine	40	49	B-drug
DDI-MedLine.d79.s0	does	51	54	O
DDI-MedLine.d79.s0	not	56	58	O
DDI-MedLine.d79.s0	affect	60	65	O
DDI-MedLine.d79.s0	IDV	67	69	B-drug
DDI-MedLine.d79.s0	exposure	71	78	O
DDI-MedLine.d79.s0	,	79	79	O
DDI-MedLine.d79.s0	despite	81	87	O
DDI-MedLine.d79.s0	persistent	89	98	O
DDI-MedLine.d79.s0	buffering	100	108	O
DDI-MedLine.d79.s0	effects	110	116	O
DDI-MedLine.d79.s0	.	117	117	O
DDI-MedLine.d79.s1	Concurrent	0	9	O
DDI-MedLine.d79.s1	administration	11	24	O
DDI-MedLine.d79.s1	of	26	27	O
DDI-MedLine.d79.s1	indinavir	29	37	B-drug
DDI-MedLine.d79.s1	and	39	41	O
DDI-MedLine.d79.s1	didanosine	43	52	B-drug
DDI-MedLine.d79.s1	significantly	54	66	O
DDI-MedLine.d79.s1	reduces	68	74	O
DDI-MedLine.d79.s1	the	76	78	O
DDI-MedLine.d79.s1	level	80	84	O
DDI-MedLine.d79.s1	of	86	87	O
DDI-MedLine.d79.s1	exposure	89	96	O
DDI-MedLine.d79.s1	to	98	99	O
DDI-MedLine.d79.s1	indinavir	101	109	B-drug
DDI-MedLine.d79.s1	,	110	110	O
DDI-MedLine.d79.s1	but	112	114	O
DDI-MedLine.d79.s1	it	116	117	O
DDI-MedLine.d79.s1	is	119	120	O
DDI-MedLine.d79.s1	unclear	122	128	O
DDI-MedLine.d79.s1	how	130	132	O
DDI-MedLine.d79.s1	soon	134	137	O
DDI-MedLine.d79.s1	after	139	143	O
DDI-MedLine.d79.s1	didanosine	145	154	B-drug
DDI-MedLine.d79.s1	administration	156	169	O
DDI-MedLine.d79.s1	indinavir	171	179	B-drug
DDI-MedLine.d79.s1	may	181	183	O
DDI-MedLine.d79.s1	be	185	186	O
DDI-MedLine.d79.s1	given	188	192	O
DDI-MedLine.d79.s1	safely	194	199	O
DDI-MedLine.d79.s1	.	200	200	O
DDI-MedLine.d79.s2	We	0	1	O
DDI-MedLine.d79.s2	compared	3	10	O
DDI-MedLine.d79.s2	indinavir	12	20	B-drug
DDI-MedLine.d79.s2	pharmacokinetics	22	37	O
DDI-MedLine.d79.s2	and	39	41	O
DDI-MedLine.d79.s2	gastric	43	49	O
DDI-MedLine.d79.s2	pH	51	52	O
DDI-MedLine.d79.s2	in	54	55	O
DDI-MedLine.d79.s2	12	57	58	O
DDI-MedLine.d79.s2	human	60	64	O
DDI-MedLine.d79.s2	immunodeficiency	66	81	O
DDI-MedLine.d79.s2	virus-positive	83	96	O
DDI-MedLine.d79.s2	patients	98	105	O
DDI-MedLine.d79.s2	by	107	108	O
DDI-MedLine.d79.s2	use	110	112	O
DDI-MedLine.d79.s2	of	114	115	O
DDI-MedLine.d79.s2	800	117	119	O
DDI-MedLine.d79.s2	mg	121	122	O
DDI-MedLine.d79.s2	of	114	115	O
DDI-MedLine.d79.s2	indinavir	127	135	B-drug
DDI-MedLine.d79.s2	alone	137	141	O
DDI-MedLine.d79.s2	versus	143	148	O
DDI-MedLine.d79.s2	800	150	152	O
DDI-MedLine.d79.s2	mg	154	155	O
DDI-MedLine.d79.s2	of	157	158	O
DDI-MedLine.d79.s2	indinavir	160	168	B-drug
DDI-MedLine.d79.s2	administered	170	181	O
DDI-MedLine.d79.s2	1	183	183	O
DDI-MedLine.d79.s2	h	185	185	O
DDI-MedLine.d79.s2	after	187	191	O
DDI-MedLine.d79.s2	didanosine	193	202	B-drug
DDI-MedLine.d79.s2	administration	204	217	O
DDI-MedLine.d79.s2	.	218	218	O
DDI-MedLine.d79.s3	Median	0	5	O
DDI-MedLine.d79.s3	gastric	7	13	O
DDI-MedLine.d79.s3	pH	15	16	O
DDI-MedLine.d79.s3	was	18	20	O
DDI-MedLine.d79.s3	significantly	22	34	O
DDI-MedLine.d79.s3	higher	36	41	O
DDI-MedLine.d79.s3	when	43	46	O
DDI-MedLine.d79.s3	indinavir	48	56	B-drug
DDI-MedLine.d79.s3	was	58	60	O
DDI-MedLine.d79.s3	taken	62	66	O
DDI-MedLine.d79.s3	after	68	72	O
DDI-MedLine.d79.s3	didanosine	74	83	B-drug
DDI-MedLine.d79.s3	administration	85	98	O
DDI-MedLine.d79.s3	;	99	99	O
DDI-MedLine.d79.s4	however	0	6	O
DDI-MedLine.d79.s4	,	7	7	O
DDI-MedLine.d79.s4	no	9	10	O
DDI-MedLine.d79.s4	significant	12	22	O
DDI-MedLine.d79.s4	difference	24	33	O
DDI-MedLine.d79.s4	in	35	36	O
DDI-MedLine.d79.s4	the	38	40	O
DDI-MedLine.d79.s4	maximum	42	48	O
DDI-MedLine.d79.s4	concentration	50	62	O
DDI-MedLine.d79.s4	in	64	65	O
DDI-MedLine.d79.s4	plasma	67	72	O
DDI-MedLine.d79.s4	or	74	75	O
DDI-MedLine.d79.s4	the	77	79	O
DDI-MedLine.d79.s4	area	81	84	O
DDI-MedLine.d79.s4	under	86	90	O
DDI-MedLine.d79.s4	the	92	94	O
DDI-MedLine.d79.s4	concentration-time	96	113	O
DDI-MedLine.d79.s4	curve	115	119	O
DDI-MedLine.d79.s4	from	121	124	O
DDI-MedLine.d79.s4	time	110	113	O
DDI-MedLine.d79.s4	zero	131	134	O
DDI-MedLine.d79.s4	to	136	137	O
DDI-MedLine.d79.s4	8	139	139	O
DDI-MedLine.d79.s4	h	141	141	O
DDI-MedLine.d79.s4	was	143	145	O
DDI-MedLine.d79.s4	observed	147	154	O
DDI-MedLine.d79.s4	.	155	155	O
DDI-MedLine.d79.s5	Indinavir	0	8	B-drug
DDI-MedLine.d79.s5	may	10	12	O
DDI-MedLine.d79.s5	be	14	15	O
DDI-MedLine.d79.s5	taken	17	21	O
DDI-MedLine.d79.s5	with	23	26	O
DDI-MedLine.d79.s5	a	28	28	O
DDI-MedLine.d79.s5	light	30	34	O
DDI-MedLine.d79.s5	meal	36	39	O
DDI-MedLine.d79.s5	1	41	41	O
DDI-MedLine.d79.s5	h	43	43	O
DDI-MedLine.d79.s5	following	45	53	O
DDI-MedLine.d79.s5	the	55	57	O
DDI-MedLine.d79.s5	administration	59	72	O
DDI-MedLine.d79.s5	of	74	75	O
DDI-MedLine.d79.s5	400	77	79	O
DDI-MedLine.d79.s5	mg	81	82	O
DDI-MedLine.d79.s5	of	74	75	O
DDI-MedLine.d79.s5	didanosine	87	96	B-drug
DDI-MedLine.d79.s5	.	97	97	O
DDI-DrugBank.d703.s0	Interaction	0	10	O
DDI-DrugBank.d703.s0	with	12	15	O
DDI-DrugBank.d703.s0	Other	17	21	O
DDI-DrugBank.d703.s0	Central	23	29	B-group
DDI-DrugBank.d703.s0	Nervous	31	37	I-group
DDI-DrugBank.d703.s0	System	39	44	I-group
DDI-DrugBank.d703.s0	Depressants	46	56	I-group
DDI-DrugBank.d703.s0	:	57	57	O
DDI-DrugBank.d703.s0	MEPERIDINE	59	68	B-drug
DDI-DrugBank.d703.s0	SHOULD	70	75	O
DDI-DrugBank.d703.s0	BE	77	78	O
DDI-DrugBank.d703.s0	USED	80	83	O
DDI-DrugBank.d703.s0	WITH	85	88	O
DDI-DrugBank.d703.s0	GREAT	90	94	O
DDI-DrugBank.d703.s0	CAUTION	96	102	O
DDI-DrugBank.d703.s0	AND	104	106	O
DDI-DrugBank.d703.s0	IN	108	109	O
DDI-DrugBank.d703.s0	REDUCED	111	117	O
DDI-DrugBank.d703.s0	DOSAGE	119	124	O
DDI-DrugBank.d703.s0	IN	108	109	O
DDI-DrugBank.d703.s0	PATIENTS	129	136	O
DDI-DrugBank.d703.s0	WHO	138	140	O
DDI-DrugBank.d703.s0	ARE	142	144	O
DDI-DrugBank.d703.s0	CONCURRENTLY	146	157	O
DDI-DrugBank.d703.s0	RECEIVING	159	167	O
DDI-DrugBank.d703.s0	OTHER	169	173	O
DDI-DrugBank.d703.s0	NARCOTIC	175	182	B-group
DDI-DrugBank.d703.s0	ANALGESICS	184	193	I-group
DDI-DrugBank.d703.s0	,	194	194	O
DDI-DrugBank.d703.s0	GENERAL	196	202	O
DDI-DrugBank.d703.s0	ANESTHETICS	204	214	B-group
DDI-DrugBank.d703.s0	,	194	194	O
DDI-DrugBank.d703.s0	PHENOTHIAZINES	217	230	B-group
DDI-DrugBank.d703.s0	,	215	215	O
DDI-DrugBank.d703.s0	OTHER	233	237	O
DDI-DrugBank.d703.s0	TRANQUILIZERS	239	251	B-group
DDI-DrugBank.d703.s0	,	231	231	O
DDI-DrugBank.d703.s0	SEDATIVE-HYPNOTICS	254	271	B-group
DDI-DrugBank.d703.s0	(	273	273	O
DDI-DrugBank.d703.s0	INCLUDING	274	282	O
DDI-DrugBank.d703.s0	BARBITURATES	284	295	B-group
DDI-DrugBank.d703.s0	)	296	296	O
DDI-DrugBank.d703.s0	,	297	297	O
DDI-DrugBank.d703.s0	TRICYCLIC	299	307	B-group
DDI-DrugBank.d703.s0	ANTIDEPRESSANTS	309	323	I-group
DDI-DrugBank.d703.s0	AND	325	327	O
DDI-DrugBank.d703.s0	OTHER	329	333	O
DDI-DrugBank.d703.s0	CNS	335	337	B-group
DDI-DrugBank.d703.s0	DEPRESSANTS	313	323	I-group
DDI-DrugBank.d703.s0	(	351	351	O
DDI-DrugBank.d703.s0	INCLUDING	352	360	O
DDI-DrugBank.d703.s0	ALCOHOL	362	368	B-drug
DDI-DrugBank.d703.s0	)	369	369	O
DDI-DrugBank.d703.s0	.	370	370	O
DDI-DrugBank.d703.s1	RESPIRATORY	0	10	O
DDI-DrugBank.d703.s1	DEPRESSION	12	21	O
DDI-DrugBank.d703.s1	,	22	22	O
DDI-DrugBank.d703.s1	HYPOTENSION	24	34	O
DDI-DrugBank.d703.s1	,	35	35	O
DDI-DrugBank.d703.s1	AND	37	39	O
DDI-DrugBank.d703.s1	PROFOUND	41	48	O
DDI-DrugBank.d703.s1	SEDATION	50	57	O
DDI-DrugBank.d703.s1	OR	59	60	O
DDI-DrugBank.d703.s1	COMA	62	65	O
DDI-DrugBank.d703.s1	MAY	67	69	O
DDI-DrugBank.d703.s1	RESULT	71	76	O
DDI-DrugBank.d703.s1	.	77	77	O
DDI-DrugBank.d276.s0	Antacids	0	7	B-group
DDI-DrugBank.d276.s0	containing	9	18	O
DDI-DrugBank.d276.s0	magnesium	20	28	B-drug
DDI-DrugBank.d276.s0	trisilicate	30	40	I-drug
DDI-DrugBank.d276.s0	,	41	41	O
DDI-DrugBank.d276.s0	when	43	46	O
DDI-DrugBank.d276.s0	administered	48	59	O
DDI-DrugBank.d276.s0	concomitantly	61	73	O
DDI-DrugBank.d276.s0	with	75	78	O
DDI-DrugBank.d276.s0	nitrofurantoin	80	93	B-drug
DDI-DrugBank.d276.s0	,	94	94	O
DDI-DrugBank.d276.s0	reduce	96	101	O
DDI-DrugBank.d276.s0	both	103	106	O
DDI-DrugBank.d276.s0	the	108	110	O
DDI-DrugBank.d276.s0	rate	112	115	O
DDI-DrugBank.d276.s0	and	117	119	O
DDI-DrugBank.d276.s0	extent	121	126	O
DDI-DrugBank.d276.s0	of	128	129	O
DDI-DrugBank.d276.s0	absorption	131	140	O
DDI-DrugBank.d276.s0	.	141	141	O
DDI-DrugBank.d276.s1	The	0	2	O
DDI-DrugBank.d276.s1	mechanism	4	12	O
DDI-DrugBank.d276.s1	for	14	16	O
DDI-DrugBank.d276.s1	this	18	21	O
DDI-DrugBank.d276.s1	interaction	23	33	O
DDI-DrugBank.d276.s1	probably	35	42	O
DDI-DrugBank.d276.s1	is	44	45	O
DDI-DrugBank.d276.s1	adsorption	47	56	O
DDI-DrugBank.d276.s1	of	58	59	O
DDI-DrugBank.d276.s1	nitrofurantoin	61	74	B-drug
DDI-DrugBank.d276.s1	onto	76	79	O
DDI-DrugBank.d276.s1	the	81	83	O
DDI-DrugBank.d276.s1	surface	85	91	O
DDI-DrugBank.d276.s1	of	93	94	O
DDI-DrugBank.d276.s1	magnesium	96	104	B-drug
DDI-DrugBank.d276.s1	trisilicate	106	116	I-drug
DDI-DrugBank.d276.s1	.	117	117	O
DDI-DrugBank.d276.s2	Uricosuric	0	9	B-group
DDI-DrugBank.d276.s2	drugs	11	15	I-group
DDI-DrugBank.d276.s2	,	16	16	O
DDI-DrugBank.d276.s2	such	18	21	O
DDI-DrugBank.d276.s2	as	23	24	O
DDI-DrugBank.d276.s2	probenecid	26	35	B-drug
DDI-DrugBank.d276.s2	and	37	39	O
DDI-DrugBank.d276.s2	sulfinpyrazone	41	54	B-drug
DDI-DrugBank.d276.s2	,	55	55	O
DDI-DrugBank.d276.s2	can	57	59	O
DDI-DrugBank.d276.s2	inhibit	61	67	O
DDI-DrugBank.d276.s2	renal	69	73	O
DDI-DrugBank.d276.s2	tubular	75	81	O
DDI-DrugBank.d276.s2	secretion	83	91	O
DDI-DrugBank.d276.s2	of	93	94	O
DDI-DrugBank.d276.s2	nitrofurantoin	96	109	B-drug
DDI-DrugBank.d276.s2	.	110	110	O
DDI-DrugBank.d276.s3	The	0	2	O
DDI-DrugBank.d276.s3	resulting	4	12	O
DDI-DrugBank.d276.s3	increase	14	21	O
DDI-DrugBank.d276.s3	in	23	24	O
DDI-DrugBank.d276.s3	nitrofurantoin	26	39	B-drug
DDI-DrugBank.d276.s3	serum	41	45	O
DDI-DrugBank.d276.s3	levels	47	52	O
DDI-DrugBank.d276.s3	may	54	56	O
DDI-DrugBank.d276.s3	increase	58	65	O
DDI-DrugBank.d276.s3	toxicity	67	74	O
DDI-DrugBank.d276.s3	,	75	75	O
DDI-DrugBank.d276.s3	and	77	79	O
DDI-DrugBank.d276.s3	the	81	83	O
DDI-DrugBank.d276.s3	decreased	85	93	O
DDI-DrugBank.d276.s3	urinary	95	101	O
DDI-DrugBank.d276.s3	levels	103	108	O
DDI-DrugBank.d276.s3	could	110	114	O
DDI-DrugBank.d276.s3	lessen	116	121	O
DDI-DrugBank.d276.s3	its	123	125	O
DDI-DrugBank.d276.s3	efficacy	127	134	O
DDI-DrugBank.d276.s3	as	136	137	O
DDI-DrugBank.d276.s3	a	132	132	O
DDI-DrugBank.d276.s3	urinary	141	147	O
DDI-DrugBank.d276.s3	tract	149	153	O
DDI-DrugBank.d276.s3	antibacterial	155	167	B-group
DDI-DrugBank.d276.s3	.	168	168	O
DDI-DrugBank.d276.s4	Drug/Laboratory	0	14	O
DDI-DrugBank.d276.s4	Test	16	19	O
DDI-DrugBank.d276.s4	Interactions	21	32	O
DDI-DrugBank.d276.s4	As	34	35	O
DDI-DrugBank.d276.s4	a	37	37	O
DDI-DrugBank.d276.s4	result	39	44	O
DDI-DrugBank.d276.s4	of	46	47	O
DDI-DrugBank.d276.s4	the	49	51	O
DDI-DrugBank.d276.s4	presence	53	60	O
DDI-DrugBank.d276.s4	of	62	63	O
DDI-DrugBank.d276.s4	nitrofurantoin	65	78	B-drug
DDI-DrugBank.d276.s4	,	79	79	O
DDI-DrugBank.d276.s4	a	73	73	O
DDI-DrugBank.d276.s4	false-positive	83	96	O
DDI-DrugBank.d276.s4	reaction	98	105	O
DDI-DrugBank.d276.s4	for	107	109	O
DDI-DrugBank.d276.s4	glucose	111	117	O
DDI-DrugBank.d276.s4	in	119	120	O
DDI-DrugBank.d276.s4	the	122	124	O
DDI-DrugBank.d276.s4	urine	126	130	O
DDI-DrugBank.d276.s4	may	132	134	O
DDI-DrugBank.d276.s4	occur	136	140	O
DDI-DrugBank.d276.s4	.	141	141	O
DDI-DrugBank.d276.s5	This	0	3	O
DDI-DrugBank.d276.s5	has	5	7	O
DDI-DrugBank.d276.s5	been	9	12	O
DDI-DrugBank.d276.s5	observed	14	21	O
DDI-DrugBank.d276.s5	with	23	26	O
DDI-DrugBank.d276.s5	Benedict	28	35	O
DDI-DrugBank.d276.s5	s	37	37	O
DDI-DrugBank.d276.s5	and	39	41	O
DDI-DrugBank.d276.s5	Fehling	43	49	O
DDI-DrugBank.d276.s5	s	51	51	O
DDI-DrugBank.d276.s5	solutions	53	61	O
DDI-DrugBank.d276.s5	but	63	65	O
DDI-DrugBank.d276.s5	not	67	69	O
DDI-DrugBank.d276.s5	with	71	74	O
DDI-DrugBank.d276.s5	the	76	78	O
DDI-DrugBank.d276.s5	glucose	80	86	O
DDI-DrugBank.d276.s5	enzymatic	88	96	O
DDI-DrugBank.d276.s5	test	98	101	O
DDI-DrugBank.d276.s5	.	102	102	O
DDI-DrugBank.d487.s0	The	0	2	O
DDI-DrugBank.d487.s0	pharmacokinetic	4	18	O
DDI-DrugBank.d487.s0	interactions	20	31	O
DDI-DrugBank.d487.s0	listed	33	38	O
DDI-DrugBank.d487.s0	below	40	44	O
DDI-DrugBank.d487.s0	are	46	48	O
DDI-DrugBank.d487.s0	potentially	50	60	O
DDI-DrugBank.d487.s0	clinically	62	71	O
DDI-DrugBank.d487.s0	important	73	81	O
DDI-DrugBank.d487.s0	.	82	82	O
DDI-DrugBank.d487.s1	Drugs	0	4	O
DDI-DrugBank.d487.s1	that	6	9	O
DDI-DrugBank.d487.s1	induce	11	16	O
DDI-DrugBank.d487.s1	hepatic	18	24	O
DDI-DrugBank.d487.s1	enzymes	26	32	O
DDI-DrugBank.d487.s1	such	34	37	O
DDI-DrugBank.d487.s1	as	39	40	O
DDI-DrugBank.d487.s1	phenobarbital	42	54	B-drug
DDI-DrugBank.d487.s1	,	55	55	O
DDI-DrugBank.d487.s1	phenytoin	57	65	B-drug
DDI-DrugBank.d487.s1	and	67	69	O
DDI-DrugBank.d487.s1	rifampin	71	78	B-drug
DDI-DrugBank.d487.s1	may	80	82	O
DDI-DrugBank.d487.s1	increase	84	91	O
DDI-DrugBank.d487.s1	the	93	95	O
DDI-DrugBank.d487.s1	clearance	97	105	O
DDI-DrugBank.d487.s1	of	107	108	O
DDI-DrugBank.d487.s1	corticosteroids	110	124	B-group
DDI-DrugBank.d487.s1	and	126	128	O
DDI-DrugBank.d487.s1	may	130	132	O
DDI-DrugBank.d487.s1	require	134	140	O
DDI-DrugBank.d487.s1	increases	142	150	O
DDI-DrugBank.d487.s1	in	142	143	O
DDI-DrugBank.d487.s1	corticosteroid	155	168	B-group
DDI-DrugBank.d487.s1	dose	170	173	O
DDI-DrugBank.d487.s1	to	175	176	O
DDI-DrugBank.d487.s1	achieve	178	184	O
DDI-DrugBank.d487.s1	the	186	188	O
DDI-DrugBank.d487.s1	desired	190	196	O
DDI-DrugBank.d487.s1	response	198	205	O
DDI-DrugBank.d487.s1	.	206	206	O
DDI-DrugBank.d487.s2	Drugs	0	4	O
DDI-DrugBank.d487.s2	such	6	9	O
DDI-DrugBank.d487.s2	as	11	12	O
DDI-DrugBank.d487.s2	troleandomycin	14	27	B-drug
DDI-DrugBank.d487.s2	and	29	31	O
DDI-DrugBank.d487.s2	ketoconazole	33	44	B-drug
DDI-DrugBank.d487.s2	may	46	48	O
DDI-DrugBank.d487.s2	inhibit	50	56	O
DDI-DrugBank.d487.s2	the	58	60	O
DDI-DrugBank.d487.s2	metabolism	62	71	O
DDI-DrugBank.d487.s2	of	73	74	O
DDI-DrugBank.d487.s2	corticosteroids	76	90	B-group
DDI-DrugBank.d487.s2	and	92	94	O
DDI-DrugBank.d487.s2	thus	96	99	O
DDI-DrugBank.d487.s2	decrease	101	108	O
DDI-DrugBank.d487.s2	their	110	114	O
DDI-DrugBank.d487.s2	clearance	116	124	O
DDI-DrugBank.d487.s2	.	125	125	O
DDI-DrugBank.d487.s3	Therefore	0	8	O
DDI-DrugBank.d487.s3	,	9	9	O
DDI-DrugBank.d487.s3	the	11	13	O
DDI-DrugBank.d487.s3	dose	15	18	O
DDI-DrugBank.d487.s3	of	20	21	O
DDI-DrugBank.d487.s3	corticosteroid	23	36	B-group
DDI-DrugBank.d487.s3	should	38	43	O
DDI-DrugBank.d487.s3	be	45	46	O
DDI-DrugBank.d487.s3	titrated	48	55	O
DDI-DrugBank.d487.s3	to	57	58	O
DDI-DrugBank.d487.s3	avoid	60	64	O
DDI-DrugBank.d487.s3	steroid	66	72	O
DDI-DrugBank.d487.s3	toxicity	74	81	O
DDI-DrugBank.d487.s3	.	82	82	O
DDI-DrugBank.d487.s4	Corticosteroids	0	14	B-group
DDI-DrugBank.d487.s4	may	16	18	O
DDI-DrugBank.d487.s4	increase	20	27	O
DDI-DrugBank.d487.s4	the	29	31	O
DDI-DrugBank.d487.s4	clearance	33	41	O
DDI-DrugBank.d487.s4	of	43	44	O
DDI-DrugBank.d487.s4	chronic	46	52	O
DDI-DrugBank.d487.s4	high	54	57	O
DDI-DrugBank.d487.s4	dose	59	62	O
DDI-DrugBank.d487.s4	aspirin	64	70	B-brand
DDI-DrugBank.d487.s4	.	71	71	O
DDI-DrugBank.d487.s5	This	0	3	O
DDI-DrugBank.d487.s5	could	5	9	O
DDI-DrugBank.d487.s5	lead	11	14	O
DDI-DrugBank.d487.s5	to	16	17	O
DDI-DrugBank.d487.s5	decreased	19	27	O
DDI-DrugBank.d487.s5	salicylate	29	38	B-group
DDI-DrugBank.d487.s5	serum	40	44	O
DDI-DrugBank.d487.s5	levels	46	51	O
DDI-DrugBank.d487.s5	or	53	54	O
DDI-DrugBank.d487.s5	increase	56	63	O
DDI-DrugBank.d487.s5	the	65	67	O
DDI-DrugBank.d487.s5	risk	69	72	O
DDI-DrugBank.d487.s5	of	74	75	O
DDI-DrugBank.d487.s5	salicylate	77	86	B-group
DDI-DrugBank.d487.s5	toxicity	88	95	O
DDI-DrugBank.d487.s5	when	97	100	O
DDI-DrugBank.d487.s5	corticosteroid	102	115	B-drug
DDI-DrugBank.d487.s5	is	117	118	O
DDI-DrugBank.d487.s5	withdrawn	120	128	O
DDI-DrugBank.d487.s5	.	129	129	O
DDI-DrugBank.d487.s6	Aspirin	0	6	B-brand
DDI-DrugBank.d487.s6	should	8	13	O
DDI-DrugBank.d487.s6	be	15	16	O
DDI-DrugBank.d487.s6	used	18	21	O
DDI-DrugBank.d487.s6	cautiously	23	32	O
DDI-DrugBank.d487.s6	in	34	35	O
DDI-DrugBank.d487.s6	conjunction	37	47	O
DDI-DrugBank.d487.s6	with	49	52	O
DDI-DrugBank.d487.s6	cortico-steroids	54	69	B-group
DDI-DrugBank.d487.s6	in	71	72	O
DDI-DrugBank.d487.s6	patients	74	81	O
DDI-DrugBank.d487.s6	suffering	83	91	O
DDI-DrugBank.d487.s6	from	93	96	O
DDI-DrugBank.d487.s6	hypopro-thrombinemia	98	117	O
DDI-DrugBank.d487.s6	.	118	118	O
DDI-DrugBank.d487.s7	The	0	2	O
DDI-DrugBank.d487.s7	effect	4	9	O
DDI-DrugBank.d487.s7	of	11	12	O
DDI-DrugBank.d487.s7	corticosteroids	14	28	B-group
DDI-DrugBank.d487.s7	on	30	31	O
DDI-DrugBank.d487.s7	oral	33	36	O
DDI-DrugBank.d487.s7	anticoagulants	38	51	B-group
DDI-DrugBank.d487.s7	is	53	54	O
DDI-DrugBank.d487.s7	variable	56	63	O
DDI-DrugBank.d487.s7	.	64	64	O
DDI-DrugBank.d487.s8	There	0	4	O
DDI-DrugBank.d487.s8	are	6	8	O
DDI-DrugBank.d487.s8	reports	10	16	O
DDI-DrugBank.d487.s8	of	18	19	O
DDI-DrugBank.d487.s8	enhanced	21	28	O
DDI-DrugBank.d487.s8	as	30	31	O
DDI-DrugBank.d487.s8	well	33	36	O
DDI-DrugBank.d487.s8	as	38	39	O
DDI-DrugBank.d487.s8	diminished	41	50	O
DDI-DrugBank.d487.s8	effects	52	58	O
DDI-DrugBank.d487.s8	of	60	61	O
DDI-DrugBank.d487.s8	anticoagulants	63	76	B-group
DDI-DrugBank.d487.s8	when	78	81	O
DDI-DrugBank.d487.s8	given	83	87	O
DDI-DrugBank.d487.s8	concurrently	89	100	O
DDI-DrugBank.d487.s8	with	102	105	O
DDI-DrugBank.d487.s8	corticosteroids	107	121	B-group
DDI-DrugBank.d487.s8	.	122	122	O
DDI-DrugBank.d487.s9	Therefore	0	8	O
DDI-DrugBank.d487.s9	,	9	9	O
DDI-DrugBank.d487.s9	coagulation	11	21	O
DDI-DrugBank.d487.s9	indices	23	29	O
DDI-DrugBank.d487.s9	should	31	36	O
DDI-DrugBank.d487.s9	be	38	39	O
DDI-DrugBank.d487.s9	monitored	41	49	O
DDI-DrugBank.d487.s9	to	45	46	O
DDI-DrugBank.d487.s9	maintain	54	61	O
DDI-DrugBank.d487.s9	the	63	65	O
DDI-DrugBank.d487.s9	desired	67	73	O
DDI-DrugBank.d487.s9	anticoagulant	75	87	O
DDI-DrugBank.d487.s9	effect	89	94	O
DDI-DrugBank.d487.s9	.	95	95	O
DDI-DrugBank.d732.s0	CHEMET	0	5	B-brand
DDI-DrugBank.d732.s0	is	7	8	O
DDI-DrugBank.d732.s0	not	10	12	O
DDI-DrugBank.d732.s0	known	14	18	O
DDI-DrugBank.d732.s0	to	20	21	O
DDI-DrugBank.d732.s0	interact	23	30	O
DDI-DrugBank.d732.s0	with	32	35	O
DDI-DrugBank.d732.s0	other	37	41	O
DDI-DrugBank.d732.s0	drugs	43	47	O
DDI-DrugBank.d732.s0	including	49	57	O
DDI-DrugBank.d732.s0	iron	59	62	B-drug
DDI-DrugBank.d732.s0	supplements	64	74	O
DDI-DrugBank.d732.s0	;	75	75	O
DDI-DrugBank.d732.s1	interactions	0	11	O
DDI-DrugBank.d732.s1	have	13	16	O
DDI-DrugBank.d732.s1	not	18	20	O
DDI-DrugBank.d732.s1	been	22	25	O
DDI-DrugBank.d732.s1	systematically	27	40	O
DDI-DrugBank.d732.s1	studied	42	48	O
DDI-DrugBank.d732.s1	.	49	49	O
DDI-DrugBank.d732.s2	Concomitant	0	10	O
DDI-DrugBank.d732.s2	administration	12	25	O
DDI-DrugBank.d732.s2	of	27	28	O
DDI-DrugBank.d732.s2	CHEMET	30	35	B-brand
DDI-DrugBank.d732.s2	with	37	40	O
DDI-DrugBank.d732.s2	other	42	46	O
DDI-DrugBank.d732.s2	chelation	48	56	O
DDI-DrugBank.d732.s2	therapy	58	64	O
DDI-DrugBank.d732.s2	,	65	65	O
DDI-DrugBank.d732.s2	such	67	70	O
DDI-DrugBank.d732.s2	as	72	73	O
DDI-DrugBank.d732.s2	CaNa	75	78	B-drug
DDI-DrugBank.d732.s2	2	80	80	O
DDI-DrugBank.d732.s2	EDTA	82	85	I-drug
DDI-DrugBank.d732.s2	is	87	88	O
DDI-DrugBank.d732.s2	not	90	92	O
DDI-DrugBank.d732.s2	recommended	94	104	O
DDI-DrugBank.d732.s2	.	105	105	O
DDI-DrugBank.d732.s3	Drug/Laboratory	0	14	O
DDI-DrugBank.d732.s3	Tests	16	20	O
DDI-DrugBank.d732.s3	Interaction	22	32	O
DDI-DrugBank.d732.s3	:	33	33	O
DDI-DrugBank.d732.s3	Succimer	35	42	B-drug
DDI-DrugBank.d732.s3	may	44	46	O
DDI-DrugBank.d732.s3	interfere	48	56	O
DDI-DrugBank.d732.s3	with	58	61	O
DDI-DrugBank.d732.s3	serum	63	67	O
DDI-DrugBank.d732.s3	and	69	71	O
DDI-DrugBank.d732.s3	urinary	73	79	O
DDI-DrugBank.d732.s3	laboratory	81	90	O
DDI-DrugBank.d732.s3	tests	92	96	O
DDI-DrugBank.d732.s3	.	97	97	O
DDI-DrugBank.d732.s4	In	0	1	O
DDI-DrugBank.d732.s4	vitro	3	7	O
DDI-DrugBank.d732.s4	studies	9	15	O
DDI-DrugBank.d732.s4	have	17	20	O
DDI-DrugBank.d732.s4	shown	22	26	O
DDI-DrugBank.d732.s4	succimer	28	35	B-drug
DDI-DrugBank.d732.s4	to	37	38	O
DDI-DrugBank.d732.s4	cause	40	44	O
DDI-DrugBank.d732.s4	false	46	50	O
DDI-DrugBank.d732.s4	positive	52	59	O
DDI-DrugBank.d732.s4	results	61	67	O
DDI-DrugBank.d732.s4	for	69	71	O
DDI-DrugBank.d732.s4	ketones	73	79	O
DDI-DrugBank.d732.s4	in	81	82	O
DDI-DrugBank.d732.s4	urine	84	88	O
DDI-DrugBank.d732.s4	using	90	94	O
DDI-DrugBank.d732.s4	nitroprusside	96	108	O
DDI-DrugBank.d732.s4	reagents	110	117	O
DDI-DrugBank.d732.s4	such	119	122	O
DDI-DrugBank.d732.s4	as	124	125	O
DDI-DrugBank.d732.s4	Ketostix	127	134	O
DDI-DrugBank.d732.s4	and	139	141	O
DDI-DrugBank.d732.s4	falsely	143	149	O
DDI-DrugBank.d732.s4	decreased	151	159	O
DDI-DrugBank.d732.s4	measurements	161	172	O
DDI-DrugBank.d732.s4	of	174	175	O
DDI-DrugBank.d732.s4	serum	177	181	O
DDI-DrugBank.d732.s4	uric	183	186	O
DDI-DrugBank.d732.s4	acid	188	191	O
DDI-DrugBank.d732.s4	and	193	195	O
DDI-DrugBank.d732.s4	CPK	197	199	O
DDI-DrugBank.d732.s4	.	200	200	O
DDI-DrugBank.d473.s0	Although	0	7	O
DDI-DrugBank.d473.s0	no	9	10	O
DDI-DrugBank.d473.s0	clinical	12	19	O
DDI-DrugBank.d473.s0	drug-drug	21	29	O
DDI-DrugBank.d473.s0	interaction	31	41	O
DDI-DrugBank.d473.s0	studies	43	49	O
DDI-DrugBank.d473.s0	have	51	54	O
DDI-DrugBank.d473.s0	been	56	59	O
DDI-DrugBank.d473.s0	conducted	61	69	O
DDI-DrugBank.d473.s0	to	71	72	O
DDI-DrugBank.d473.s0	date	74	77	O
DDI-DrugBank.d473.s0	,	78	78	O
DDI-DrugBank.d473.s0	on	80	81	O
DDI-DrugBank.d473.s0	the	83	85	O
DDI-DrugBank.d473.s0	basis	87	91	O
DDI-DrugBank.d473.s0	of	93	94	O
DDI-DrugBank.d473.s0	the	83	85	O
DDI-DrugBank.d473.s0	in	100	101	O
DDI-DrugBank.d473.s0	vitro	103	107	O
DDI-DrugBank.d473.s0	studies	109	115	O
DDI-DrugBank.d473.s0	,	116	116	O
DDI-DrugBank.d473.s0	cytochrome	118	127	O
DDI-DrugBank.d473.s0	p450	129	132	O
DDI-DrugBank.d473.s0	inhibitors	134	143	O
DDI-DrugBank.d473.s0	and	145	147	O
DDI-DrugBank.d473.s0	inducers	149	156	O
DDI-DrugBank.d473.s0	are	158	160	O
DDI-DrugBank.d473.s0	unlikely	162	169	O
DDI-DrugBank.d473.s0	to	171	172	O
DDI-DrugBank.d473.s0	affect	174	179	O
DDI-DrugBank.d473.s0	the	181	183	O
DDI-DrugBank.d473.s0	metabolism	185	194	O
DDI-DrugBank.d473.s0	of	196	197	O
DDI-DrugBank.d473.s0	clofarabine	199	209	B-drug
DDI-DrugBank.d473.s0	.	210	210	O
DDI-DrugBank.d473.s1	The	0	2	O
DDI-DrugBank.d473.s1	effect	4	9	O
DDI-DrugBank.d473.s1	of	11	12	O
DDI-DrugBank.d473.s1	clofarabine	14	24	B-drug
DDI-DrugBank.d473.s1	on	26	27	O
DDI-DrugBank.d473.s1	the	29	31	O
DDI-DrugBank.d473.s1	metabolism	33	42	O
DDI-DrugBank.d473.s1	of	44	45	O
DDI-DrugBank.d473.s1	cytochrome	47	56	O
DDI-DrugBank.d473.s1	p450	58	61	O
DDI-DrugBank.d473.s1	substrates	63	72	O
DDI-DrugBank.d473.s1	has	74	76	O
DDI-DrugBank.d473.s1	not	78	80	O
DDI-DrugBank.d473.s1	been	82	85	O
DDI-DrugBank.d473.s1	studied	87	93	O
DDI-DrugBank.d473.s1	.	94	94	O
DDI-DrugBank.d473.s2	Drug/Laboratory	0	14	O
DDI-DrugBank.d473.s2	Tests	16	20	O
DDI-DrugBank.d473.s2	Interactions	22	33	O
DDI-DrugBank.d473.s2	There	35	39	O
DDI-DrugBank.d473.s2	are	41	43	O
DDI-DrugBank.d473.s2	no	45	46	O
DDI-DrugBank.d473.s2	known	48	52	O
DDI-DrugBank.d473.s2	clinically	54	63	O
DDI-DrugBank.d473.s2	significant	65	75	O
DDI-DrugBank.d473.s2	interactions	77	88	O
DDI-DrugBank.d473.s2	of	90	91	O
DDI-DrugBank.d473.s2	CLOLAR	93	98	B-brand
DDI-DrugBank.d473.s2	with	101	104	O
DDI-DrugBank.d473.s2	other	106	110	O
DDI-DrugBank.d473.s2	medications	112	122	O
DDI-DrugBank.d473.s2	or	124	125	O
DDI-DrugBank.d473.s2	laboratory	127	136	O
DDI-DrugBank.d473.s2	tests	138	142	O
DDI-DrugBank.d473.s2	.	143	143	O
DDI-DrugBank.d473.s3	No	0	1	O
DDI-DrugBank.d473.s3	formal	3	8	O
DDI-DrugBank.d473.s3	drug/laboratory	10	24	O
DDI-DrugBank.d473.s3	test	26	29	O
DDI-DrugBank.d473.s3	interaction	31	41	O
DDI-DrugBank.d473.s3	studies	43	49	O
DDI-DrugBank.d473.s3	have	51	54	O
DDI-DrugBank.d473.s3	been	56	59	O
DDI-DrugBank.d473.s3	conducted	61	69	O
DDI-DrugBank.d473.s3	with	71	74	O
DDI-DrugBank.d473.s3	CLOLAR	76	81	B-brand
DDI-DrugBank.d473.s3	.	84	84	O
DDI-DrugBank.d407.s0	Drug/Laboratory	0	14	O
DDI-DrugBank.d407.s0	Interactions	16	27	O
DDI-DrugBank.d407.s0	No	29	30	O
DDI-DrugBank.d407.s0	formal	32	37	O
DDI-DrugBank.d407.s0	drug	39	42	O
DDI-DrugBank.d407.s0	interaction	44	54	O
DDI-DrugBank.d407.s0	studies	56	62	O
DDI-DrugBank.d407.s0	have	64	67	O
DDI-DrugBank.d407.s0	been	69	72	O
DDI-DrugBank.d407.s0	performed	74	82	O
DDI-DrugBank.d407.s0	with	84	87	O
DDI-DrugBank.d407.s0	Campath	89	95	B-brand
DDI-DrugBank.d407.s0	.	96	96	O
DDI-DrugBank.d407.s1	An	0	1	O
DDI-DrugBank.d407.s1	immune	3	8	O
DDI-DrugBank.d407.s1	response	10	17	O
DDI-DrugBank.d407.s1	to	19	20	O
DDI-DrugBank.d407.s1	Campath	22	28	B-brand
DDI-DrugBank.d407.s1	may	30	32	O
DDI-DrugBank.d407.s1	interfere	34	42	O
DDI-DrugBank.d407.s1	with	44	47	O
DDI-DrugBank.d407.s1	subsequent	49	58	O
DDI-DrugBank.d407.s1	diagnostic	60	69	O
DDI-DrugBank.d407.s1	serum	71	75	O
DDI-DrugBank.d407.s1	tests	77	81	O
DDI-DrugBank.d407.s1	that	83	86	O
DDI-DrugBank.d407.s1	utilize	88	94	O
DDI-DrugBank.d407.s1	antibodies	96	105	B-group
DDI-DrugBank.d407.s2	.	0	0	O
DDI-MedLine.d201.s0	Antitumor	0	8	O
DDI-MedLine.d201.s0	effects	10	16	O
DDI-MedLine.d201.s0	of	18	19	O
DDI-MedLine.d201.s0	CRM197	21	26	B-drug_n
DDI-MedLine.d201.s0	,	27	27	O
DDI-MedLine.d201.s0	a	29	29	O
DDI-MedLine.d201.s0	specific	31	38	O
DDI-MedLine.d201.s0	inhibitor	40	48	O
DDI-MedLine.d201.s0	of	50	51	O
DDI-MedLine.d201.s0	HB-EGF	53	58	O
DDI-MedLine.d201.s0	,	59	59	O
DDI-MedLine.d201.s0	in	61	62	O
DDI-MedLine.d201.s0	T-cell	64	69	O
DDI-MedLine.d201.s0	acute	71	75	O
DDI-MedLine.d201.s0	lymphoblastic	77	89	O
DDI-MedLine.d201.s0	leukemia	91	98	O
DDI-MedLine.d201.s0	.	99	99	O
DDI-MedLine.d201.s1	The	0	2	O
DDI-MedLine.d201.s1	therapeutic	4	14	O
DDI-MedLine.d201.s1	outcome	16	22	O
DDI-MedLine.d201.s1	for	24	26	O
DDI-MedLine.d201.s1	T-cell	28	33	O
DDI-MedLine.d201.s1	acute	35	39	O
DDI-MedLine.d201.s1	lymphoblastic	41	53	O
DDI-MedLine.d201.s1	leukemia	55	62	O
DDI-MedLine.d201.s1	(	64	64	O
DDI-MedLine.d201.s1	T-ALL	65	69	O
DDI-MedLine.d201.s1	)	70	70	O
DDI-MedLine.d201.s1	remains	72	78	O
DDI-MedLine.d201.s1	poor	80	83	O
DDI-MedLine.d201.s1	;	84	84	O
DDI-MedLine.d201.s2	thus	0	3	O
DDI-MedLine.d201.s2	,	4	4	O
DDI-MedLine.d201.s2	novel	6	10	O
DDI-MedLine.d201.s2	,	11	11	O
DDI-MedLine.d201.s2	targeted	13	20	O
DDI-MedLine.d201.s2	therapies	22	30	O
DDI-MedLine.d201.s2	are	32	34	O
DDI-MedLine.d201.s2	urgently	36	43	O
DDI-MedLine.d201.s2	needed	45	50	O
DDI-MedLine.d201.s2	.	51	51	O
DDI-MedLine.d201.s3	Recently	0	7	O
DDI-MedLine.d201.s3	,	8	8	O
DDI-MedLine.d201.s3	we	10	11	O
DDI-MedLine.d201.s3	showed	13	18	O
DDI-MedLine.d201.s3	that	20	23	O
DDI-MedLine.d201.s3	heparin-binding	25	39	O
DDI-MedLine.d201.s3	epidermal	41	49	O
DDI-MedLine.d201.s3	growth	51	56	O
DDI-MedLine.d201.s3	factor-like	58	68	O
DDI-MedLine.d201.s3	growth	70	75	O
DDI-MedLine.d201.s3	factor	77	82	O
DDI-MedLine.d201.s3	(	84	84	O
DDI-MedLine.d201.s3	HB-EGF	85	90	O
DDI-MedLine.d201.s3	)	91	91	O
DDI-MedLine.d201.s3	,	92	92	O
DDI-MedLine.d201.s3	a	94	94	O
DDI-MedLine.d201.s3	member	96	101	O
DDI-MedLine.d201.s3	of	103	104	O
DDI-MedLine.d201.s3	the	106	108	O
DDI-MedLine.d201.s3	EGF	110	112	O
DDI-MedLine.d201.s3	family	114	119	O
DDI-MedLine.d201.s3	,	120	120	O
DDI-MedLine.d201.s3	is	122	123	O
DDI-MedLine.d201.s3	a	115	115	O
DDI-MedLine.d201.s3	promising	127	135	O
DDI-MedLine.d201.s3	target	137	142	O
DDI-MedLine.d201.s3	for	144	146	O
DDI-MedLine.d201.s3	the	148	150	O
DDI-MedLine.d201.s3	treatment	152	160	O
DDI-MedLine.d201.s3	of	162	163	O
DDI-MedLine.d201.s3	various	165	171	O
DDI-MedLine.d201.s3	types	173	177	O
DDI-MedLine.d201.s3	of	162	163	O
DDI-MedLine.d201.s3	cancer	182	187	O
DDI-MedLine.d201.s3	.	188	188	O
DDI-MedLine.d201.s4	The	0	2	O
DDI-MedLine.d201.s4	aim	4	6	O
DDI-MedLine.d201.s4	of	8	9	O
DDI-MedLine.d201.s4	the	11	13	O
DDI-MedLine.d201.s4	present	15	21	O
DDI-MedLine.d201.s4	study	23	27	O
DDI-MedLine.d201.s4	was	29	31	O
DDI-MedLine.d201.s4	to	33	34	O
DDI-MedLine.d201.s4	investigate	36	46	O
DDI-MedLine.d201.s4	whether	48	54	O
DDI-MedLine.d201.s4	HB-EGF	56	61	O
DDI-MedLine.d201.s4	is	63	64	O
DDI-MedLine.d201.s4	a	66	66	O
DDI-MedLine.d201.s4	therapeutic	68	78	O
DDI-MedLine.d201.s4	target	80	85	O
DDI-MedLine.d201.s4	for	87	89	O
DDI-MedLine.d201.s4	T-ALL	91	95	O
DDI-MedLine.d201.s4	,	96	96	O
DDI-MedLine.d201.s4	and	98	100	O
DDI-MedLine.d201.s4	to	102	103	O
DDI-MedLine.d201.s4	further	105	111	O
DDI-MedLine.d201.s4	elucidate	113	121	O
DDI-MedLine.d201.s4	the	108	110	O
DDI-MedLine.d201.s4	antitumor	127	135	O
DDI-MedLine.d201.s4	effects	137	143	O
DDI-MedLine.d201.s4	of	145	146	O
DDI-MedLine.d201.s4	a	127	127	O
DDI-MedLine.d201.s4	specific	150	157	O
DDI-MedLine.d201.s4	inhibitor	159	167	O
DDI-MedLine.d201.s4	of	145	146	O
DDI-MedLine.d201.s4	HB-EGF	172	177	O
DDI-MedLine.d201.s4	,	178	178	O
DDI-MedLine.d201.s4	cross-reacting	180	193	B-drug_n
DDI-MedLine.d201.s4	material	195	202	I-drug_n
DDI-MedLine.d201.s4	197	204	206	I-drug_n
DDI-MedLine.d201.s4	(	208	208	O
DDI-MedLine.d201.s4	CRM197	209	214	B-drug_n
DDI-MedLine.d201.s4	)	215	215	O
DDI-MedLine.d201.s4	.	216	216	O
DDI-MedLine.d201.s5	We	0	1	O
DDI-MedLine.d201.s5	elucidated	3	12	O
DDI-MedLine.d201.s5	the	14	16	O
DDI-MedLine.d201.s5	expression	18	27	O
DDI-MedLine.d201.s5	of	29	30	O
DDI-MedLine.d201.s5	HB-EGF	32	37	O
DDI-MedLine.d201.s5	in	39	40	O
DDI-MedLine.d201.s5	T-ALL	42	46	O
DDI-MedLine.d201.s5	cell	48	51	O
DDI-MedLine.d201.s5	lines	53	57	O
DDI-MedLine.d201.s5	,	58	58	O
DDI-MedLine.d201.s5	and	60	62	O
DDI-MedLine.d201.s5	evaluated	64	72	O
DDI-MedLine.d201.s5	the	74	76	O
DDI-MedLine.d201.s5	effect	78	83	O
DDI-MedLine.d201.s5	of	85	86	O
DDI-MedLine.d201.s5	CRM197	88	93	B-drug_n
DDI-MedLine.d201.s5	on	95	96	O
DDI-MedLine.d201.s5	these	98	102	O
DDI-MedLine.d201.s5	cells	104	108	O
DDI-MedLine.d201.s5	alone	110	114	O
DDI-MedLine.d201.s5	or	116	117	O
DDI-MedLine.d201.s5	in	119	120	O
DDI-MedLine.d201.s5	combination	122	132	O
DDI-MedLine.d201.s5	with	134	137	O
DDI-MedLine.d201.s5	anticancer	139	148	B-group
DDI-MedLine.d201.s5	agent	150	154	I-group
DDI-MedLine.d201.s5	.	155	155	O
DDI-MedLine.d201.s6	The	0	2	O
DDI-MedLine.d201.s6	expression	4	13	O
DDI-MedLine.d201.s6	of	15	16	O
DDI-MedLine.d201.s6	EGFR	18	21	O
DDI-MedLine.d201.s6	and	23	25	O
DDI-MedLine.d201.s6	EGFR	27	30	O
DDI-MedLine.d201.s6	ligands	32	38	O
DDI-MedLine.d201.s6	was	40	42	O
DDI-MedLine.d201.s6	determined	44	53	O
DDI-MedLine.d201.s6	by	55	56	O
DDI-MedLine.d201.s6	flow	58	61	O
DDI-MedLine.d201.s6	cytometry	63	71	O
DDI-MedLine.d201.s6	,	72	72	O
DDI-MedLine.d201.s6	RT-PCR	74	79	O
DDI-MedLine.d201.s6	and	81	83	O
DDI-MedLine.d201.s6	real-time	85	93	O
DDI-MedLine.d201.s6	quantitative	95	106	O
DDI-MedLine.d201.s6	PCR	108	110	O
DDI-MedLine.d201.s6	.	111	111	O
DDI-MedLine.d201.s7	Induction	0	8	O
DDI-MedLine.d201.s7	of	10	11	O
DDI-MedLine.d201.s7	apoptosis	13	21	O
DDI-MedLine.d201.s7	was	23	25	O
DDI-MedLine.d201.s7	assessed	27	34	O
DDI-MedLine.d201.s7	by	36	37	O
DDI-MedLine.d201.s7	TUNEL	39	43	O
DDI-MedLine.d201.s7	assay	45	49	O
DDI-MedLine.d201.s7	.	50	50	O
DDI-MedLine.d201.s8	HB-EGF	0	5	O
DDI-MedLine.d201.s8	was	7	9	O
DDI-MedLine.d201.s8	strongly	11	18	O
DDI-MedLine.d201.s8	expressed	20	28	O
DDI-MedLine.d201.s8	by	30	31	O
DDI-MedLine.d201.s8	T-ALL	33	37	O
DDI-MedLine.d201.s8	cell	39	42	O
DDI-MedLine.d201.s8	lines	44	48	O
DDI-MedLine.d201.s8	,	49	49	O
DDI-MedLine.d201.s8	and	51	53	O
DDI-MedLine.d201.s8	the	55	57	O
DDI-MedLine.d201.s8	expression	59	68	O
DDI-MedLine.d201.s8	of	70	71	O
DDI-MedLine.d201.s8	both	73	76	O
DDI-MedLine.d201.s8	HB-EGF	78	83	O
DDI-MedLine.d201.s8	and	85	87	O
DDI-MedLine.d201.s8	EGFR	89	92	O
DDI-MedLine.d201.s8	was	94	96	O
DDI-MedLine.d201.s8	enhanced	98	105	O
DDI-MedLine.d201.s8	by	107	108	O
DDI-MedLine.d201.s8	doxorubicin	110	120	B-drug
DDI-MedLine.d201.s8	.	121	121	O
DDI-MedLine.d201.s9	CRM197	0	5	B-drug_n
DDI-MedLine.d201.s9	induced	7	13	O
DDI-MedLine.d201.s9	apoptosis	15	23	O
DDI-MedLine.d201.s9	,	24	24	O
DDI-MedLine.d201.s9	and	26	28	O
DDI-MedLine.d201.s9	furthermore	30	40	O
DDI-MedLine.d201.s9	,	41	41	O
DDI-MedLine.d201.s9	the	43	45	O
DDI-MedLine.d201.s9	combination	47	57	O
DDI-MedLine.d201.s9	of	59	60	O
DDI-MedLine.d201.s9	CRM197	62	67	B-drug_n
DDI-MedLine.d201.s9	plus	69	72	O
DDI-MedLine.d201.s9	doxorubicin	74	84	B-drug
DDI-MedLine.d201.s9	enhanced	86	93	O
DDI-MedLine.d201.s9	cytotoxicity	95	106	O
DDI-MedLine.d201.s9	in	108	109	O
DDI-MedLine.d201.s9	a	111	111	O
DDI-MedLine.d201.s9	T-ALL	113	117	O
DDI-MedLine.d201.s9	cell	119	122	O
DDI-MedLine.d201.s9	line	124	127	O
DDI-MedLine.d201.s9	.	128	128	O
DDI-MedLine.d201.s10	These	0	4	O
DDI-MedLine.d201.s10	results	6	12	O
DDI-MedLine.d201.s10	suggest	14	20	O
DDI-MedLine.d201.s10	that	22	25	O
DDI-MedLine.d201.s10	HB-EGF	27	32	O
DDI-MedLine.d201.s10	is	34	35	O
DDI-MedLine.d201.s10	a	37	37	O
DDI-MedLine.d201.s10	promising	39	47	O
DDI-MedLine.d201.s10	therapeutic	49	59	O
DDI-MedLine.d201.s10	target	61	66	O
DDI-MedLine.d201.s10	for	68	70	O
DDI-MedLine.d201.s10	T-ALL	72	76	O
DDI-MedLine.d201.s10	.	77	77	O
DDI-DrugBank.d721.s0	The	0	2	O
DDI-DrugBank.d721.s0	bioavailability	4	18	O
DDI-DrugBank.d721.s0	of	20	21	O
DDI-DrugBank.d721.s0	SKELID	23	28	B-brand
DDI-DrugBank.d721.s0	is	30	31	O
DDI-DrugBank.d721.s0	decreased	33	41	O
DDI-DrugBank.d721.s0	80	43	44	O
DDI-DrugBank.d721.s0	%	45	45	O
DDI-DrugBank.d721.s0	by	47	48	O
DDI-DrugBank.d721.s0	calcium	50	56	B-drug
DDI-DrugBank.d721.s0	,	57	57	O
DDI-DrugBank.d721.s0	when	59	62	O
DDI-DrugBank.d721.s0	calcium	64	70	B-drug
DDI-DrugBank.d721.s0	and	72	74	O
DDI-DrugBank.d721.s0	SKELID	76	81	B-brand
DDI-DrugBank.d721.s0	are	83	85	O
DDI-DrugBank.d721.s0	administered	87	98	O
DDI-DrugBank.d721.s0	at	100	101	O
DDI-DrugBank.d721.s0	the	103	105	O
DDI-DrugBank.d721.s0	same	107	110	O
DDI-DrugBank.d721.s0	time	112	115	O
DDI-DrugBank.d721.s0	,	116	116	O
DDI-DrugBank.d721.s0	and	118	120	O
DDI-DrugBank.d721.s0	60	122	123	O
DDI-DrugBank.d721.s0	%	124	124	O
DDI-DrugBank.d721.s0	by	126	127	O
DDI-DrugBank.d721.s0	some	129	132	O
DDI-DrugBank.d721.s0	aluminum-	134	142	O
DDI-DrugBank.d721.s0	or	144	145	O
DDI-DrugBank.d721.s0	magnesium-containing	147	166	O
DDI-DrugBank.d721.s0	antacids	168	175	B-drug
DDI-DrugBank.d721.s0	,	176	176	O
DDI-DrugBank.d721.s0	when	178	181	O
DDI-DrugBank.d721.s0	administered	183	194	O
DDI-DrugBank.d721.s0	1	196	196	O
DDI-DrugBank.d721.s0	hour	198	201	O
DDI-DrugBank.d721.s0	before	203	208	O
DDI-DrugBank.d721.s0	SKELID	210	215	B-brand
DDI-DrugBank.d721.s0	.	216	216	O
DDI-DrugBank.d721.s1	Aspirin	0	6	B-brand
DDI-DrugBank.d721.s1	may	8	10	O
DDI-DrugBank.d721.s1	decrease	12	19	O
DDI-DrugBank.d721.s1	bioavailability	21	35	O
DDI-DrugBank.d721.s1	of	37	38	O
DDI-DrugBank.d721.s1	SKELID	40	45	B-brand
DDI-DrugBank.d721.s1	by	47	48	O
DDI-DrugBank.d721.s1	up	50	51	O
DDI-DrugBank.d721.s1	to	53	54	O
DDI-DrugBank.d721.s1	50	56	57	O
DDI-DrugBank.d721.s1	%	58	58	O
DDI-DrugBank.d721.s1	when	60	63	O
DDI-DrugBank.d721.s1	taken	65	69	O
DDI-DrugBank.d721.s1	2	71	71	O
DDI-DrugBank.d721.s1	hours	73	77	O
DDI-DrugBank.d721.s1	after	79	83	O
DDI-DrugBank.d721.s1	SKELID	85	90	B-brand
DDI-DrugBank.d721.s1	.	91	91	O
DDI-DrugBank.d721.s2	The	0	2	O
DDI-DrugBank.d721.s2	bioavailability	4	18	O
DDI-DrugBank.d721.s2	of	20	21	O
DDI-DrugBank.d721.s2	SKELID	23	28	B-brand
DDI-DrugBank.d721.s2	is	30	31	O
DDI-DrugBank.d721.s2	increased	33	41	O
DDI-DrugBank.d721.s2	2-4	43	45	O
DDI-DrugBank.d721.s2	fold	47	50	O
DDI-DrugBank.d721.s2	by	52	53	O
DDI-DrugBank.d721.s2	indomethacin	55	66	B-drug
DDI-DrugBank.d721.s2	but	68	70	O
DDI-DrugBank.d721.s2	is	72	73	O
DDI-DrugBank.d721.s2	not	75	77	O
DDI-DrugBank.d721.s2	significantly	79	91	O
DDI-DrugBank.d721.s2	altered	93	99	O
DDI-DrugBank.d721.s2	by	101	102	O
DDI-DrugBank.d721.s2	coadministration	104	119	O
DDI-DrugBank.d721.s2	of	121	122	O
DDI-DrugBank.d721.s2	diclofenac	124	133	B-drug
DDI-DrugBank.d721.s2	.	134	134	O
DDI-DrugBank.d721.s3	The	0	2	O
DDI-DrugBank.d721.s3	pharmacokinetic	4	18	O
DDI-DrugBank.d721.s3	parameters	20	29	O
DDI-DrugBank.d721.s3	of	31	32	O
DDI-DrugBank.d721.s3	digoxin	34	40	B-drug
DDI-DrugBank.d721.s3	are	42	44	O
DDI-DrugBank.d721.s3	not	46	48	O
DDI-DrugBank.d721.s3	significantly	50	62	O
DDI-DrugBank.d721.s3	modified	64	71	O
DDI-DrugBank.d721.s3	by	73	74	O
DDI-DrugBank.d721.s3	SKELID	76	81	B-brand
DDI-DrugBank.d721.s3	coadministration	83	98	O
DDI-DrugBank.d721.s3	.	99	99	O
DDI-DrugBank.d721.s4	In	0	1	O
DDI-DrugBank.d721.s4	vitro	3	7	O
DDI-DrugBank.d721.s4	studies	9	15	O
DDI-DrugBank.d721.s4	show	17	20	O
DDI-DrugBank.d721.s4	that	22	25	O
DDI-DrugBank.d721.s4	tiludronate	27	37	B-drug
DDI-DrugBank.d721.s4	does	39	42	O
DDI-DrugBank.d721.s4	not	44	46	O
DDI-DrugBank.d721.s4	displace	48	55	O
DDI-DrugBank.d721.s4	warfarin	57	64	B-drug
DDI-DrugBank.d721.s4	from	66	69	O
DDI-DrugBank.d721.s4	its	71	73	O
DDI-DrugBank.d721.s4	binding	75	81	O
DDI-DrugBank.d721.s4	site	83	86	O
DDI-DrugBank.d721.s4	on	88	89	O
DDI-DrugBank.d721.s4	protein	91	97	O
DDI-DrugBank.d721.s4	.	98	98	O
DDI-DrugBank.d55.s0	Isoproterenol	0	12	B-drug
DDI-DrugBank.d55.s0	hydrochloride	14	26	I-drug
DDI-DrugBank.d55.s0	injection	28	36	O
DDI-DrugBank.d55.s0	and	38	40	O
DDI-DrugBank.d55.s0	epinephrine	42	52	B-drug
DDI-DrugBank.d55.s0	should	54	59	O
DDI-DrugBank.d55.s0	not	61	63	O
DDI-DrugBank.d55.s0	be	65	66	O
DDI-DrugBank.d55.s0	administered	68	79	O
DDI-DrugBank.d55.s0	simultaneously	81	94	O
DDI-DrugBank.d55.s0	because	96	102	O
DDI-DrugBank.d55.s0	both	104	107	O
DDI-DrugBank.d55.s0	drugs	109	113	O
DDI-DrugBank.d55.s0	are	115	117	O
DDI-DrugBank.d55.s0	direct	119	124	O
DDI-DrugBank.d55.s0	cardiac	126	132	O
DDI-DrugBank.d55.s0	stimulants	134	143	O
DDI-DrugBank.d55.s0	and	145	147	O
DDI-DrugBank.d55.s0	their	149	153	O
DDI-DrugBank.d55.s0	combined	155	162	O
DDI-DrugBank.d55.s0	effects	164	170	O
DDI-DrugBank.d55.s0	may	172	174	O
DDI-DrugBank.d55.s0	induce	176	181	O
DDI-DrugBank.d55.s0	serious	183	189	O
DDI-DrugBank.d55.s0	arrhythmias	191	201	O
DDI-DrugBank.d55.s0	.	202	202	O
DDI-DrugBank.d55.s1	The	0	2	O
DDI-DrugBank.d55.s1	drugs	4	8	O
DDI-DrugBank.d55.s1	may	10	12	O
DDI-DrugBank.d55.s1	,	13	13	O
DDI-DrugBank.d55.s1	however	15	21	O
DDI-DrugBank.d55.s1	,	22	22	O
DDI-DrugBank.d55.s1	be	24	25	O
DDI-DrugBank.d55.s1	administered	27	38	O
DDI-DrugBank.d55.s1	alternately	40	50	O
DDI-DrugBank.d55.s1	provided	52	59	O
DDI-DrugBank.d55.s1	a	61	61	O
DDI-DrugBank.d55.s1	proper	63	68	O
DDI-DrugBank.d55.s1	interval	70	77	O
DDI-DrugBank.d55.s1	has	79	81	O
DDI-DrugBank.d55.s1	elapsed	83	89	O
DDI-DrugBank.d55.s1	between	91	97	O
DDI-DrugBank.d55.s1	doses	99	103	O
DDI-DrugBank.d55.s1	.	104	104	O
DDI-DrugBank.d55.s2	ISUPREL	0	6	B-brand
DDI-DrugBank.d55.s2	should	8	13	O
DDI-DrugBank.d55.s2	be	15	16	O
DDI-DrugBank.d55.s2	used	18	21	O
DDI-DrugBank.d55.s2	with	23	26	O
DDI-DrugBank.d55.s2	caution	28	34	O
DDI-DrugBank.d55.s2	,	35	35	O
DDI-DrugBank.d55.s2	if	37	38	O
DDI-DrugBank.d55.s2	at	40	41	O
DDI-DrugBank.d55.s2	all	43	45	O
DDI-DrugBank.d55.s2	,	46	46	O
DDI-DrugBank.d55.s2	when	48	51	O
DDI-DrugBank.d55.s2	potent	53	58	O
DDI-DrugBank.d55.s2	inhalational	60	71	O
DDI-DrugBank.d55.s2	anesthetics	73	83	B-group
DDI-DrugBank.d55.s2	such	85	88	O
DDI-DrugBank.d55.s2	as	90	91	O
DDI-DrugBank.d55.s2	halothane	93	101	B-drug
DDI-DrugBank.d55.s2	are	103	105	O
DDI-DrugBank.d55.s2	employed	107	114	O
DDI-DrugBank.d55.s2	because	116	122	O
DDI-DrugBank.d55.s2	of	124	125	O
DDI-DrugBank.d55.s2	potential	127	135	O
DDI-DrugBank.d55.s2	to	137	138	O
DDI-DrugBank.d55.s2	sensitize	140	148	O
DDI-DrugBank.d55.s2	the	150	152	O
DDI-DrugBank.d55.s2	myocardium	154	163	O
DDI-DrugBank.d55.s2	to	165	166	O
DDI-DrugBank.d55.s2	effects	168	174	O
DDI-DrugBank.d55.s2	of	176	177	O
DDI-DrugBank.d55.s2	sympathomimetic	179	193	B-group
DDI-DrugBank.d55.s2	amines	195	200	I-group
DDI-DrugBank.d55.s2	.	201	201	O
DDI-DrugBank.d337.s0	Warfarin	0	7	B-drug
DDI-DrugBank.d337.s0	:	8	8	O
DDI-DrugBank.d337.s0	Concomitant	10	20	O
DDI-DrugBank.d337.s0	administration	22	35	O
DDI-DrugBank.d337.s0	of	37	38	O
DDI-DrugBank.d337.s0	daptomycin	40	49	B-drug
DDI-DrugBank.d337.s0	(	51	51	O
DDI-DrugBank.d337.s0	6	52	52	O
DDI-DrugBank.d337.s0	mg/kg	54	58	O
DDI-DrugBank.d337.s0	once	60	63	O
DDI-DrugBank.d337.s0	every	65	69	O
DDI-DrugBank.d337.s0	24	71	72	O
DDI-DrugBank.d337.s0	hours	74	78	O
DDI-DrugBank.d337.s0	for	80	82	O
DDI-DrugBank.d337.s0	5	84	84	O
DDI-DrugBank.d337.s0	days	86	89	O
DDI-DrugBank.d337.s0	)	90	90	O
DDI-DrugBank.d337.s0	and	92	94	O
DDI-DrugBank.d337.s0	warfarin	96	103	B-drug
DDI-DrugBank.d337.s0	(	105	105	O
DDI-DrugBank.d337.s0	25	106	107	O
DDI-DrugBank.d337.s0	mg	109	110	O
DDI-DrugBank.d337.s0	single	112	117	O
DDI-DrugBank.d337.s0	oral	119	122	O
DDI-DrugBank.d337.s0	dose	124	127	O
DDI-DrugBank.d337.s0	)	128	128	O
DDI-DrugBank.d337.s0	had	130	132	O
DDI-DrugBank.d337.s0	no	134	135	O
DDI-DrugBank.d337.s0	significant	137	147	O
DDI-DrugBank.d337.s0	effect	149	154	O
DDI-DrugBank.d337.s0	on	156	157	O
DDI-DrugBank.d337.s0	the	159	161	O
DDI-DrugBank.d337.s0	pharmacokinetics	163	178	O
DDI-DrugBank.d337.s0	of	180	181	O
DDI-DrugBank.d337.s0	either	183	188	O
DDI-DrugBank.d337.s0	drug	190	193	O
DDI-DrugBank.d337.s0	,	194	194	O
DDI-DrugBank.d337.s0	and	196	198	O
DDI-DrugBank.d337.s0	the	185	187	O
DDI-DrugBank.d337.s0	INR	204	206	O
DDI-DrugBank.d337.s0	was	208	210	O
DDI-DrugBank.d337.s0	not	212	214	O
DDI-DrugBank.d337.s0	significantly	216	228	O
DDI-DrugBank.d337.s0	altered	230	236	O
DDI-DrugBank.d337.s0	.	237	237	O
DDI-DrugBank.d337.s1	HMG-CoA	0	6	B-group
DDI-DrugBank.d337.s1	Reductase	8	16	I-group
DDI-DrugBank.d337.s1	Inhibitors	18	27	I-group
DDI-DrugBank.d337.s1	:	28	28	O
DDI-DrugBank.d337.s1	Inhibitors	30	39	B-group
DDI-DrugBank.d337.s1	of	41	42	I-group
DDI-DrugBank.d337.s1	HMG-CoA	44	50	I-group
DDI-DrugBank.d337.s1	reductase	52	60	I-group
DDI-DrugBank.d337.s1	may	62	64	O
DDI-DrugBank.d337.s1	cause	66	70	O
DDI-DrugBank.d337.s1	myopathy	72	79	O
DDI-DrugBank.d337.s1	,	80	80	O
DDI-DrugBank.d337.s1	which	82	86	O
DDI-DrugBank.d337.s1	is	88	89	O
DDI-DrugBank.d337.s1	manifested	91	100	O
DDI-DrugBank.d337.s1	as	102	103	O
DDI-DrugBank.d337.s1	muscle	105	110	O
DDI-DrugBank.d337.s1	pain	112	115	O
DDI-DrugBank.d337.s1	or	117	118	O
DDI-DrugBank.d337.s1	weakness	120	127	O
DDI-DrugBank.d337.s1	associated	129	138	O
DDI-DrugBank.d337.s1	with	140	143	O
DDI-DrugBank.d337.s1	elevated	145	152	O
DDI-DrugBank.d337.s1	levels	154	159	O
DDI-DrugBank.d337.s1	of	161	162	O
DDI-DrugBank.d337.s1	CPK	164	166	O
DDI-DrugBank.d337.s1	.	167	167	O
DDI-DrugBank.d337.s2	There	0	4	O
DDI-DrugBank.d337.s2	were	6	9	O
DDI-DrugBank.d337.s2	no	11	12	O
DDI-DrugBank.d337.s2	reports	14	20	O
DDI-DrugBank.d337.s2	of	22	23	O
DDI-DrugBank.d337.s2	skeletal	25	32	O
DDI-DrugBank.d337.s2	myopathy	34	41	O
DDI-DrugBank.d337.s2	in	43	44	O
DDI-DrugBank.d337.s2	a	38	38	O
DDI-DrugBank.d337.s2	placebo-controlled	48	65	O
DDI-DrugBank.d337.s2	Phase	67	71	O
DDI-DrugBank.d337.s2	I	73	73	O
DDI-DrugBank.d337.s2	trial	75	79	O
DDI-DrugBank.d337.s2	in	81	82	O
DDI-DrugBank.d337.s2	which	84	88	O
DDI-DrugBank.d337.s2	10	90	91	O
DDI-DrugBank.d337.s2	healthy	93	99	O
DDI-DrugBank.d337.s2	subjects	101	108	O
DDI-DrugBank.d337.s2	on	110	111	O
DDI-DrugBank.d337.s2	stable	113	118	O
DDI-DrugBank.d337.s2	simvastatin	120	130	B-drug
DDI-DrugBank.d337.s2	therapy	132	138	O
DDI-DrugBank.d337.s2	were	140	143	O
DDI-DrugBank.d337.s2	treated	145	151	O
DDI-DrugBank.d337.s2	concurrently	153	164	O
DDI-DrugBank.d337.s2	with	166	169	O
DDI-DrugBank.d337.s2	daptomycin	171	180	B-drug
DDI-DrugBank.d337.s2	(	182	182	O
DDI-DrugBank.d337.s2	4	183	183	O
DDI-DrugBank.d337.s2	mg/kg	185	189	O
DDI-DrugBank.d337.s2	once	191	194	O
DDI-DrugBank.d337.s2	every	196	200	O
DDI-DrugBank.d337.s2	24	202	203	O
DDI-DrugBank.d337.s2	hours	205	209	O
DDI-DrugBank.d337.s2	)	210	210	O
DDI-DrugBank.d337.s2	for	212	214	O
DDI-DrugBank.d337.s2	14	216	217	O
DDI-DrugBank.d337.s2	days	219	222	O
DDI-DrugBank.d337.s2	.	223	223	O
DDI-DrugBank.d337.s3	Experience	0	9	O
DDI-DrugBank.d337.s3	with	11	14	O
DDI-DrugBank.d337.s3	co-administration	16	32	O
DDI-DrugBank.d337.s3	of	34	35	O
DDI-DrugBank.d337.s3	HMG-CoA	37	43	B-group
DDI-DrugBank.d337.s3	reductase	45	53	I-group
DDI-DrugBank.d337.s3	inhibitors	55	64	I-group
DDI-DrugBank.d337.s3	and	66	68	O
DDI-DrugBank.d337.s3	Fentanyl	70	77	B-drug
DDI-DrugBank.d337.s3	in	79	80	O
DDI-DrugBank.d337.s3	patients	82	89	O
DDI-DrugBank.d337.s3	is	91	92	O
DDI-DrugBank.d337.s3	limited	94	100	O
DDI-DrugBank.d337.s3	,	101	101	O
DDI-DrugBank.d337.s3	therefore	102	110	O
DDI-DrugBank.d337.s3	,	101	101	O
DDI-DrugBank.d337.s3	consideration	112	124	O
DDI-DrugBank.d337.s3	should	126	131	O
DDI-DrugBank.d337.s3	be	133	134	O
DDI-DrugBank.d337.s3	given	136	140	O
DDI-DrugBank.d337.s3	to	142	143	O
DDI-DrugBank.d337.s3	temporarily	145	155	O
DDI-DrugBank.d337.s3	suspending	157	166	O
DDI-DrugBank.d337.s3	use	168	170	O
DDI-DrugBank.d337.s3	of	172	173	O
DDI-DrugBank.d337.s3	HMG-CoA	175	181	B-group
DDI-DrugBank.d337.s3	reductase	183	191	I-group
DDI-DrugBank.d337.s3	inhibitors	193	202	I-group
DDI-DrugBank.d337.s3	in	193	194	I-group
DDI-DrugBank.d337.s3	patients	207	214	O
DDI-DrugBank.d337.s3	receiving	216	224	O
DDI-DrugBank.d337.s3	Fentanyl	226	233	B-drug
DDI-DrugBank.d337.s3	.	234	234	O
DDI-DrugBank.d337.s4	Drug-Laboratory	0	14	O
DDI-DrugBank.d337.s4	Test	16	19	O
DDI-DrugBank.d337.s4	Interactions	21	32	O
DDI-DrugBank.d337.s4	:	33	33	O
DDI-DrugBank.d337.s4	There	35	39	O
DDI-DrugBank.d337.s4	are	41	43	O
DDI-DrugBank.d337.s4	no	45	46	O
DDI-DrugBank.d337.s4	reported	48	55	O
DDI-DrugBank.d337.s4	drug-laboratory	57	71	O
DDI-DrugBank.d337.s4	test	73	76	O
DDI-DrugBank.d337.s4	interactions	78	89	O
DDI-DrugBank.d337.s4	.	90	90	O
DDI-DrugBank.d504.s0	There	0	4	O
DDI-DrugBank.d504.s0	have	6	9	O
DDI-DrugBank.d504.s0	been	11	14	O
DDI-DrugBank.d504.s0	rare	16	19	O
DDI-DrugBank.d504.s0	reports	21	27	O
DDI-DrugBank.d504.s0	of	29	30	O
DDI-DrugBank.d504.s0	significant	32	42	O
DDI-DrugBank.d504.s0	respiratory	44	54	O
DDI-DrugBank.d504.s0	depression	56	65	O
DDI-DrugBank.d504.s0	,	66	66	O
DDI-DrugBank.d504.s0	stupor	68	73	O
DDI-DrugBank.d504.s0	and/or	75	80	O
DDI-DrugBank.d504.s0	hypotension	82	92	O
DDI-DrugBank.d504.s0	with	94	97	O
DDI-DrugBank.d504.s0	the	99	101	O
DDI-DrugBank.d504.s0	concomitant	103	113	O
DDI-DrugBank.d504.s0	use	115	117	O
DDI-DrugBank.d504.s0	of	119	120	O
DDI-DrugBank.d504.s0	loxapine	122	129	B-drug
DDI-DrugBank.d504.s0	and	131	133	O
DDI-DrugBank.d504.s0	lorazepam	135	143	B-drug
DDI-DrugBank.d504.s0	.	144	144	O
DDI-DrugBank.d504.s1	The	0	2	O
DDI-DrugBank.d504.s1	risk	4	7	O
DDI-DrugBank.d504.s1	of	9	10	O
DDI-DrugBank.d504.s1	using	12	16	O
DDI-DrugBank.d504.s1	loxapine	18	25	B-drug
DDI-DrugBank.d504.s1	in	23	24	I-drug
DDI-DrugBank.d504.s1	combination	30	40	O
DDI-DrugBank.d504.s1	with	42	45	O
DDI-DrugBank.d504.s1	CNS-active	47	56	O
DDI-DrugBank.d504.s1	drugs	58	62	O
DDI-DrugBank.d504.s1	has	64	66	O
DDI-DrugBank.d504.s1	not	68	70	O
DDI-DrugBank.d504.s1	been	72	75	O
DDI-DrugBank.d504.s1	systematically	77	90	O
DDI-DrugBank.d504.s1	evaluated	92	100	O
DDI-DrugBank.d504.s1	.	101	101	O
DDI-DrugBank.d504.s2	Therefore	0	8	O
DDI-DrugBank.d504.s2	,	9	9	O
DDI-DrugBank.d504.s2	caution	11	17	O
DDI-DrugBank.d504.s2	is	19	20	O
DDI-DrugBank.d504.s2	advised	22	28	O
DDI-DrugBank.d504.s2	if	30	31	O
DDI-DrugBank.d504.s2	the	33	35	O
DDI-DrugBank.d504.s2	concomitant	37	47	O
DDI-DrugBank.d504.s2	administration	49	62	O
DDI-DrugBank.d504.s2	of	64	65	O
DDI-DrugBank.d504.s2	loxapine	67	74	B-drug
DDI-DrugBank.d504.s2	and	76	78	O
DDI-DrugBank.d504.s2	CNS-active	80	89	O
DDI-DrugBank.d504.s2	drugs	91	95	O
DDI-DrugBank.d504.s2	is	97	98	O
DDI-DrugBank.d504.s2	required	100	107	O
DDI-DrugBank.d504.s2	.	108	108	O
DDI-DrugBank.d747.s0	Tetracycline	0	11	B-group
DDI-DrugBank.d747.s0	,	12	12	O
DDI-DrugBank.d747.s0	a	14	14	O
DDI-DrugBank.d747.s0	bacteriostatic	16	29	O
DDI-DrugBank.d747.s0	antibiotic	31	40	B-group
DDI-DrugBank.d747.s0	,	41	41	O
DDI-DrugBank.d747.s0	may	43	45	O
DDI-DrugBank.d747.s0	antagonize	47	56	O
DDI-DrugBank.d747.s0	the	58	60	O
DDI-DrugBank.d747.s0	bactericidal	62	73	O
DDI-DrugBank.d747.s0	effect	75	80	O
DDI-DrugBank.d747.s0	of	82	83	O
DDI-DrugBank.d747.s0	penicillin	85	94	B-drug
DDI-DrugBank.d747.s0	and	96	98	O
DDI-DrugBank.d747.s0	concurrent	100	109	O
DDI-DrugBank.d747.s0	use	111	113	O
DDI-DrugBank.d747.s0	of	115	116	O
DDI-DrugBank.d747.s0	these	118	122	O
DDI-DrugBank.d747.s0	drugs	124	128	O
DDI-DrugBank.d747.s0	should	130	135	O
DDI-DrugBank.d747.s0	be	137	138	O
DDI-DrugBank.d747.s0	avoided	140	146	O
DDI-DrugBank.d747.s0	.	147	147	O
DDI-DrugBank.d511.s0	A	0	0	O
DDI-DrugBank.d511.s0	possible	2	9	O
DDI-DrugBank.d511.s0	drug	11	14	O
DDI-DrugBank.d511.s0	interaction	16	26	O
DDI-DrugBank.d511.s0	of	28	29	O
DDI-DrugBank.d511.s0	FOSCAVIR	31	38	B-brand
DDI-DrugBank.d511.s0	and	40	42	O
DDI-DrugBank.d511.s0	intravenous	44	54	O
DDI-DrugBank.d511.s0	pentamidine	56	66	B-drug
DDI-DrugBank.d511.s0	has	68	70	O
DDI-DrugBank.d511.s0	been	72	75	O
DDI-DrugBank.d511.s0	described	77	85	O
DDI-DrugBank.d511.s0	.	86	86	O
DDI-DrugBank.d511.s1	Concomitant	0	10	O
DDI-DrugBank.d511.s1	treatment	12	20	O
DDI-DrugBank.d511.s1	of	22	23	O
DDI-DrugBank.d511.s1	four	25	28	O
DDI-DrugBank.d511.s1	patients	30	37	O
DDI-DrugBank.d511.s1	in	39	40	O
DDI-DrugBank.d511.s1	the	42	44	O
DDI-DrugBank.d511.s1	United	46	51	O
DDI-DrugBank.d511.s1	Kingdom	53	59	O
DDI-DrugBank.d511.s1	with	61	64	O
DDI-DrugBank.d511.s1	FOSCAVIR	66	73	B-brand
DDI-DrugBank.d511.s1	and	75	77	O
DDI-DrugBank.d511.s1	intravenous	79	89	O
DDI-DrugBank.d511.s1	pentamidine	91	101	B-drug
DDI-DrugBank.d511.s1	may	103	105	O
DDI-DrugBank.d511.s1	have	107	110	O
DDI-DrugBank.d511.s1	caused	112	117	O
DDI-DrugBank.d511.s1	hypocalcemia	119	130	O
DDI-DrugBank.d511.s1	;	131	131	O
DDI-DrugBank.d511.s2	one	0	2	O
DDI-DrugBank.d511.s2	patient	4	10	O
DDI-DrugBank.d511.s2	died	12	15	O
DDI-DrugBank.d511.s2	with	17	20	O
DDI-DrugBank.d511.s2	severe	22	27	O
DDI-DrugBank.d511.s2	hypocalcemia	29	40	O
DDI-DrugBank.d511.s2	.	41	41	O
DDI-DrugBank.d511.s3	Toxicity	0	7	O
DDI-DrugBank.d511.s3	associated	9	18	O
DDI-DrugBank.d511.s3	with	20	23	O
DDI-DrugBank.d511.s3	concomitant	25	35	O
DDI-DrugBank.d511.s3	use	37	39	O
DDI-DrugBank.d511.s3	of	41	42	O
DDI-DrugBank.d511.s3	aerosolized	44	54	O
DDI-DrugBank.d511.s3	pentamidine	56	66	B-drug
DDI-DrugBank.d511.s3	has	68	70	O
DDI-DrugBank.d511.s3	not	72	74	O
DDI-DrugBank.d511.s3	been	76	79	O
DDI-DrugBank.d511.s3	reported	81	88	O
DDI-DrugBank.d511.s3	.	89	89	O
DDI-DrugBank.d511.s4	Because	0	6	O
DDI-DrugBank.d511.s4	of	8	9	O
DDI-DrugBank.d511.s4	foscarnets	11	20	O
DDI-DrugBank.d511.s4	tendency	22	29	O
DDI-DrugBank.d511.s4	to	31	32	O
DDI-DrugBank.d511.s4	cause	34	38	O
DDI-DrugBank.d511.s4	renal	40	44	O
DDI-DrugBank.d511.s4	impairment	46	55	O
DDI-DrugBank.d511.s4	,	56	56	O
DDI-DrugBank.d511.s4	the	58	60	O
DDI-DrugBank.d511.s4	use	62	64	O
DDI-DrugBank.d511.s4	of	66	67	O
DDI-DrugBank.d511.s4	FOSCAVIR	69	76	B-brand
DDI-DrugBank.d511.s4	should	78	83	O
DDI-DrugBank.d511.s4	be	85	86	O
DDI-DrugBank.d511.s4	avoided	88	94	O
DDI-DrugBank.d511.s4	in	96	97	O
DDI-DrugBank.d511.s4	combination	99	109	O
DDI-DrugBank.d511.s4	with	111	114	O
DDI-DrugBank.d511.s4	potentially	116	126	O
DDI-DrugBank.d511.s4	nephrotoxic	128	138	O
DDI-DrugBank.d511.s4	drugs	140	144	O
DDI-DrugBank.d511.s4	such	146	149	O
DDI-DrugBank.d511.s4	as	151	152	O
DDI-DrugBank.d511.s4	aminoglycosides	154	168	B-group
DDI-DrugBank.d511.s4	,	169	169	O
DDI-DrugBank.d511.s4	amphotericin	171	182	B-drug
DDI-DrugBank.d511.s4	B	184	184	O
DDI-DrugBank.d511.s4	and	186	188	O
DDI-DrugBank.d511.s4	intravenous	190	200	O
DDI-DrugBank.d511.s4	pentamidine	202	212	B-drug
DDI-DrugBank.d511.s4	unless	214	219	O
DDI-DrugBank.d511.s4	the	221	223	O
DDI-DrugBank.d511.s4	potential	225	233	O
DDI-DrugBank.d511.s4	benefits	235	242	O
DDI-DrugBank.d511.s4	outweigh	244	251	O
DDI-DrugBank.d511.s4	the	221	223	O
DDI-DrugBank.d511.s4	risks	257	261	O
DDI-DrugBank.d511.s4	to	263	264	O
DDI-DrugBank.d511.s4	the	253	255	O
DDI-DrugBank.d511.s4	patient	270	276	O
DDI-DrugBank.d511.s4	.	277	277	O
DDI-DrugBank.d511.s5	Since	0	4	O
DDI-DrugBank.d511.s5	FOSCAVIR	6	13	B-brand
DDI-DrugBank.d511.s5	decreases	15	23	O
DDI-DrugBank.d511.s5	serum	25	29	O
DDI-DrugBank.d511.s5	concentrations	31	44	O
DDI-DrugBank.d511.s5	of	46	47	O
DDI-DrugBank.d511.s5	ionized	49	55	O
DDI-DrugBank.d511.s5	calcium	57	63	O
DDI-DrugBank.d511.s5	,	64	64	O
DDI-DrugBank.d511.s5	concurrent	66	75	O
DDI-DrugBank.d511.s5	treatment	77	85	O
DDI-DrugBank.d511.s5	with	87	90	O
DDI-DrugBank.d511.s5	other	92	96	O
DDI-DrugBank.d511.s5	drugs	98	102	O
DDI-DrugBank.d511.s5	known	104	108	O
DDI-DrugBank.d511.s5	to	110	111	O
DDI-DrugBank.d511.s5	influence	113	121	O
DDI-DrugBank.d511.s5	serum	123	127	O
DDI-DrugBank.d511.s5	calcium	129	135	O
DDI-DrugBank.d511.s5	concentrations	137	150	O
DDI-DrugBank.d511.s5	should	152	157	O
DDI-DrugBank.d511.s5	be	159	160	O
DDI-DrugBank.d511.s5	used	162	165	O
DDI-DrugBank.d511.s5	with	167	170	O
DDI-DrugBank.d511.s5	particular	172	181	O
DDI-DrugBank.d511.s5	caution	183	189	O
DDI-DrugBank.d511.s5	.	190	190	O
DDI-DrugBank.d511.s6	Ganciclovir	0	10	B-drug
DDI-DrugBank.d511.s6	:	11	11	O
DDI-DrugBank.d511.s6	The	13	15	O
DDI-DrugBank.d511.s6	pharmacokinetics	17	32	O
DDI-DrugBank.d511.s6	of	34	35	O
DDI-DrugBank.d511.s6	foscarnet	37	45	B-drug
DDI-DrugBank.d511.s6	and	47	49	O
DDI-DrugBank.d511.s6	ganciclovir	51	61	B-drug
DDI-DrugBank.d511.s6	were	63	66	O
DDI-DrugBank.d511.s6	not	68	70	O
DDI-DrugBank.d511.s6	altered	72	78	O
DDI-DrugBank.d511.s6	in	80	81	O
DDI-DrugBank.d511.s6	13	83	84	O
DDI-DrugBank.d511.s6	patients	86	93	O
DDI-DrugBank.d511.s6	receiving	95	103	O
DDI-DrugBank.d511.s6	either	105	110	O
DDI-DrugBank.d511.s6	concomitant	112	122	O
DDI-DrugBank.d511.s6	therapy	124	130	O
DDI-DrugBank.d511.s6	or	132	133	O
DDI-DrugBank.d511.s6	daily	135	139	O
DDI-DrugBank.d511.s6	alternating	141	151	O
DDI-DrugBank.d511.s6	therapy	153	159	O
DDI-DrugBank.d511.s6	for	161	163	O
DDI-DrugBank.d511.s6	maintenance	165	175	O
DDI-DrugBank.d511.s6	of	177	178	O
DDI-DrugBank.d511.s6	CMV	180	182	O
DDI-DrugBank.d511.s6	disease	184	190	O
DDI-DrugBank.d511.s6	.	191	191	O
DDI-DrugBank.d628.s0	The	0	2	O
DDI-DrugBank.d628.s0	induction	4	12	O
DDI-DrugBank.d628.s0	dose	14	17	O
DDI-DrugBank.d628.s0	requirements	19	30	O
DDI-DrugBank.d628.s0	of	32	33	O
DDI-DrugBank.d628.s0	DIPRIVAN	35	42	B-brand
DDI-DrugBank.d628.s0	Injectable	44	53	O
DDI-DrugBank.d628.s0	Emulsion	55	62	O
DDI-DrugBank.d628.s0	may	64	66	O
DDI-DrugBank.d628.s0	be	68	69	O
DDI-DrugBank.d628.s0	reduced	71	77	O
DDI-DrugBank.d628.s0	in	79	80	O
DDI-DrugBank.d628.s0	patients	82	89	O
DDI-DrugBank.d628.s0	with	91	94	O
DDI-DrugBank.d628.s0	intramuscular	96	108	O
DDI-DrugBank.d628.s0	or	110	111	O
DDI-DrugBank.d628.s0	intravenous	113	123	O
DDI-DrugBank.d628.s0	premedication	125	137	O
DDI-DrugBank.d628.s0	,	138	138	O
DDI-DrugBank.d628.s0	particularly	140	151	O
DDI-DrugBank.d628.s0	with	153	156	O
DDI-DrugBank.d628.s0	narcotics	158	166	B-group
DDI-DrugBank.d628.s0	(	168	168	O
DDI-DrugBank.d628.s0	eg	169	170	O
DDI-DrugBank.d628.s0	,	171	171	O
DDI-DrugBank.d628.s0	morphine	173	180	B-drug
DDI-DrugBank.d628.s0	,	171	171	O
DDI-DrugBank.d628.s0	meperidine	183	192	B-drug
DDI-DrugBank.d628.s0	,	171	171	O
DDI-DrugBank.d628.s0	and	195	197	O
DDI-DrugBank.d628.s0	fentanyl	199	206	B-drug
DDI-DrugBank.d628.s0	,	193	193	O
DDI-DrugBank.d628.s0	etc	209	211	O
DDI-DrugBank.d628.s0	.	212	212	O
DDI-DrugBank.d628.s0	)	213	213	O
DDI-DrugBank.d628.s1	and	0	2	O
DDI-DrugBank.d628.s1	combinations	4	15	O
DDI-DrugBank.d628.s1	of	17	18	O
DDI-DrugBank.d628.s1	opioids	20	26	B-group
DDI-DrugBank.d628.s1	and	28	30	O
DDI-DrugBank.d628.s1	sedatives	32	40	B-group
DDI-DrugBank.d628.s1	(	42	42	O
DDI-DrugBank.d628.s1	eg	43	44	O
DDI-DrugBank.d628.s1	,	45	45	O
DDI-DrugBank.d628.s1	benzodiazepines	47	61	B-group
DDI-DrugBank.d628.s1	,	62	62	O
DDI-DrugBank.d628.s1	barbiturates	64	75	B-group
DDI-DrugBank.d628.s1	,	76	76	O
DDI-DrugBank.d628.s1	chloral	78	84	B-drug
DDI-DrugBank.d628.s1	hydrate	86	92	I-drug
DDI-DrugBank.d628.s1	,	93	93	O
DDI-DrugBank.d628.s1	droperidol	95	104	B-drug
DDI-DrugBank.d628.s1	,	105	105	O
DDI-DrugBank.d628.s1	etc	107	109	O
DDI-DrugBank.d628.s1	.	110	110	O
DDI-DrugBank.d628.s1	)	111	111	O
DDI-DrugBank.d628.s1	.	110	110	O
DDI-DrugBank.d628.s2	These	0	4	O
DDI-DrugBank.d628.s2	agents	6	11	O
DDI-DrugBank.d628.s2	may	13	15	O
DDI-DrugBank.d628.s2	increase	17	24	O
DDI-DrugBank.d628.s2	the	26	28	O
DDI-DrugBank.d628.s2	anesthetic	30	39	O
DDI-DrugBank.d628.s2	or	41	42	O
DDI-DrugBank.d628.s2	sedative	44	51	O
DDI-DrugBank.d628.s2	effects	53	59	O
DDI-DrugBank.d628.s2	of	61	62	O
DDI-DrugBank.d628.s2	DIPRIVAN	64	71	B-brand
DDI-DrugBank.d628.s2	Injectable	73	82	O
DDI-DrugBank.d628.s2	Emulsion	84	91	O
DDI-DrugBank.d628.s2	and	93	95	O
DDI-DrugBank.d628.s2	may	97	99	O
DDI-DrugBank.d628.s2	also	101	104	O
DDI-DrugBank.d628.s2	result	106	111	O
DDI-DrugBank.d628.s2	in	113	114	O
DDI-DrugBank.d628.s2	more	116	119	O
DDI-DrugBank.d628.s2	pronounced	121	130	O
DDI-DrugBank.d628.s2	decreases	132	140	O
DDI-DrugBank.d628.s2	in	142	143	O
DDI-DrugBank.d628.s2	systolic	145	152	O
DDI-DrugBank.d628.s2	,	153	153	O
DDI-DrugBank.d628.s2	diastolic	155	163	O
DDI-DrugBank.d628.s2	,	153	153	O
DDI-DrugBank.d628.s2	and	166	168	O
DDI-DrugBank.d628.s2	mean	170	173	O
DDI-DrugBank.d628.s2	arterial	175	182	O
DDI-DrugBank.d628.s2	pressures	184	192	O
DDI-DrugBank.d628.s2	and	166	168	O
DDI-DrugBank.d628.s2	cardiac	198	204	O
DDI-DrugBank.d628.s2	output	206	211	O
DDI-DrugBank.d628.s2	.	212	212	O
DDI-DrugBank.d628.s3	During	0	5	O
DDI-DrugBank.d628.s3	maintenance	7	17	O
DDI-DrugBank.d628.s3	of	19	20	O
DDI-DrugBank.d628.s3	anesthesia	22	31	O
DDI-DrugBank.d628.s3	or	33	34	O
DDI-DrugBank.d628.s3	sedation	36	43	O
DDI-DrugBank.d628.s3	,	44	44	O
DDI-DrugBank.d628.s3	the	46	48	O
DDI-DrugBank.d628.s3	rate	50	53	O
DDI-DrugBank.d628.s3	of	55	56	O
DDI-DrugBank.d628.s3	DIPRIVAN	58	65	B-brand
DDI-DrugBank.d628.s3	Injectable	67	76	O
DDI-DrugBank.d628.s3	Emulsion	78	85	O
DDI-DrugBank.d628.s3	administration	87	100	O
DDI-DrugBank.d628.s3	should	102	107	O
DDI-DrugBank.d628.s3	be	109	110	O
DDI-DrugBank.d628.s3	adjusted	112	119	O
DDI-DrugBank.d628.s3	according	121	129	O
DDI-DrugBank.d628.s3	to	131	132	O
DDI-DrugBank.d628.s3	the	134	136	O
DDI-DrugBank.d628.s3	desired	138	144	O
DDI-DrugBank.d628.s3	level	146	150	O
DDI-DrugBank.d628.s3	of	152	153	O
DDI-DrugBank.d628.s3	anesthesia	155	164	O
DDI-DrugBank.d628.s3	or	166	167	O
DDI-DrugBank.d628.s3	sedation	169	176	O
DDI-DrugBank.d628.s3	and	178	180	O
DDI-DrugBank.d628.s3	may	182	184	O
DDI-DrugBank.d628.s3	be	186	187	O
DDI-DrugBank.d628.s3	reduced	189	195	O
DDI-DrugBank.d628.s3	in	197	198	O
DDI-DrugBank.d628.s3	the	200	202	O
DDI-DrugBank.d628.s3	presence	204	211	O
DDI-DrugBank.d628.s3	of	213	214	O
DDI-DrugBank.d628.s3	supplemental	216	227	O
DDI-DrugBank.d628.s3	analgesic	229	237	B-group
DDI-DrugBank.d628.s3	agents	239	244	I-group
DDI-DrugBank.d628.s3	(	246	246	O
DDI-DrugBank.d628.s3	eg	247	248	O
DDI-DrugBank.d628.s3	,	249	249	O
DDI-DrugBank.d628.s3	nitrous	251	257	B-drug
DDI-DrugBank.d628.s3	oxide	259	263	I-drug
DDI-DrugBank.d628.s3	or	265	266	O
DDI-DrugBank.d628.s3	opioids	268	274	B-group
DDI-DrugBank.d628.s3	)	275	275	O
DDI-DrugBank.d628.s3	.	276	276	O
DDI-DrugBank.d628.s4	The	0	2	O
DDI-DrugBank.d628.s4	concurrent	4	13	O
DDI-DrugBank.d628.s4	administration	15	28	O
DDI-DrugBank.d628.s4	of	30	31	O
DDI-DrugBank.d628.s4	potent	33	38	O
DDI-DrugBank.d628.s4	inhalational	40	51	O
DDI-DrugBank.d628.s4	agents	53	58	O
DDI-DrugBank.d628.s4	(	60	60	O
DDI-DrugBank.d628.s4	eg	61	62	O
DDI-DrugBank.d628.s4	,	63	63	O
DDI-DrugBank.d628.s4	isoflurane	65	74	B-drug
DDI-DrugBank.d628.s4	,	75	75	O
DDI-DrugBank.d628.s4	enflurane	77	85	B-drug
DDI-DrugBank.d628.s4	,	86	86	O
DDI-DrugBank.d628.s4	and	88	90	O
DDI-DrugBank.d628.s4	halothane	92	100	B-drug
DDI-DrugBank.d628.s4	)	101	101	O
DDI-DrugBank.d628.s4	during	103	108	O
DDI-DrugBank.d628.s4	maintenance	110	120	O
DDI-DrugBank.d628.s4	with	122	125	O
DDI-DrugBank.d628.s4	DIPRIVAN	127	134	B-brand
DDI-DrugBank.d628.s4	Injectable	136	145	O
DDI-DrugBank.d628.s4	Emulsion	147	154	O
DDI-DrugBank.d628.s4	has	156	158	O
DDI-DrugBank.d628.s4	not	160	162	O
DDI-DrugBank.d628.s4	been	164	167	O
DDI-DrugBank.d628.s4	extensively	169	179	O
DDI-DrugBank.d628.s4	evaluated	181	189	O
DDI-DrugBank.d628.s4	.	190	190	O
DDI-DrugBank.d628.s5	These	0	4	O
DDI-DrugBank.d628.s5	inhalational	6	17	O
DDI-DrugBank.d628.s5	agents	19	24	O
DDI-DrugBank.d628.s5	can	26	28	O
DDI-DrugBank.d628.s5	also	30	33	O
DDI-DrugBank.d628.s5	be	35	36	O
DDI-DrugBank.d628.s5	expected	38	45	O
DDI-DrugBank.d628.s5	to	47	48	O
DDI-DrugBank.d628.s5	increase	50	57	O
DDI-DrugBank.d628.s5	the	59	61	O
DDI-DrugBank.d628.s5	anesthetic	63	72	O
DDI-DrugBank.d628.s5	or	74	75	O
DDI-DrugBank.d628.s5	sedative	77	84	O
DDI-DrugBank.d628.s5	and	86	88	O
DDI-DrugBank.d628.s5	cardiorespiratory	90	106	O
DDI-DrugBank.d628.s5	effects	108	114	O
DDI-DrugBank.d628.s5	of	116	117	O
DDI-DrugBank.d628.s5	DIPRIVAN	119	126	B-brand
DDI-DrugBank.d628.s5	Injectable	128	137	O
DDI-DrugBank.d628.s5	Emulsion	139	146	O
DDI-DrugBank.d628.s5	.	147	147	O
DDI-DrugBank.d628.s6	DIPRIVAN	0	7	B-brand
DDI-DrugBank.d628.s6	Injectable	9	18	O
DDI-DrugBank.d628.s6	Emulsion	20	27	O
DDI-DrugBank.d628.s6	does	29	32	O
DDI-DrugBank.d628.s6	not	34	36	O
DDI-DrugBank.d628.s6	cause	38	42	O
DDI-DrugBank.d628.s6	a	39	39	O
DDI-DrugBank.d628.s6	clinically	46	55	O
DDI-DrugBank.d628.s6	significant	57	67	O
DDI-DrugBank.d628.s6	change	69	74	O
DDI-DrugBank.d628.s6	in	76	77	O
DDI-DrugBank.d628.s6	onset	79	83	O
DDI-DrugBank.d628.s6	,	84	84	O
DDI-DrugBank.d628.s6	intensity	86	94	O
DDI-DrugBank.d628.s6	,	84	84	O
DDI-DrugBank.d628.s6	or	97	98	O
DDI-DrugBank.d628.s6	duration	100	107	O
DDI-DrugBank.d628.s6	of	109	110	O
DDI-DrugBank.d628.s6	action	112	117	O
DDI-DrugBank.d628.s6	of	109	110	O
DDI-DrugBank.d628.s6	the	122	124	O
DDI-DrugBank.d628.s6	commonly	126	133	O
DDI-DrugBank.d628.s6	used	135	138	O
DDI-DrugBank.d628.s6	neuromuscular	140	152	B-group
DDI-DrugBank.d628.s6	blocking	154	161	I-group
DDI-DrugBank.d628.s6	agents	163	168	I-group
DDI-DrugBank.d628.s6	(	170	170	O
DDI-DrugBank.d628.s6	eg	171	172	O
DDI-DrugBank.d628.s6	,	173	173	O
DDI-DrugBank.d628.s6	succinylcholine	175	189	B-drug
DDI-DrugBank.d628.s6	and	191	193	O
DDI-DrugBank.d628.s6	nondepolarizing	195	209	B-group
DDI-DrugBank.d628.s6	muscle	211	216	I-group
DDI-DrugBank.d628.s6	relaxants	218	226	I-group
DDI-DrugBank.d628.s6	)	227	227	O
DDI-DrugBank.d628.s6	.	228	228	O
DDI-DrugBank.d628.s7	No	0	1	O
DDI-DrugBank.d628.s7	significant	3	13	O
DDI-DrugBank.d628.s7	adverse	15	21	O
DDI-DrugBank.d628.s7	interactions	23	34	O
DDI-DrugBank.d628.s7	with	36	39	O
DDI-DrugBank.d628.s7	commonly	41	48	O
DDI-DrugBank.d628.s7	used	50	53	O
DDI-DrugBank.d628.s7	premedications	55	68	O
DDI-DrugBank.d628.s7	or	70	71	O
DDI-DrugBank.d628.s7	drugs	73	77	O
DDI-DrugBank.d628.s7	used	79	82	O
DDI-DrugBank.d628.s7	during	84	89	O
DDI-DrugBank.d628.s7	anesthesia	91	100	O
DDI-DrugBank.d628.s7	or	102	103	O
DDI-DrugBank.d628.s7	sedation	105	112	O
DDI-DrugBank.d628.s7	(	114	114	O
DDI-DrugBank.d628.s7	including	115	123	O
DDI-DrugBank.d628.s7	a	125	125	O
DDI-DrugBank.d628.s7	range	127	131	O
DDI-DrugBank.d628.s7	of	133	134	O
DDI-DrugBank.d628.s7	muscle	136	141	B-group
DDI-DrugBank.d628.s7	relaxants	143	151	I-group
DDI-DrugBank.d628.s7	,	152	152	O
DDI-DrugBank.d628.s7	inhalational	154	165	O
DDI-DrugBank.d628.s7	agents	167	172	O
DDI-DrugBank.d628.s7	,	152	152	O
DDI-DrugBank.d628.s7	analgesic	175	183	B-group
DDI-DrugBank.d628.s7	agents	167	172	O
DDI-DrugBank.d628.s7	,	173	173	O
DDI-DrugBank.d628.s7	and	193	195	O
DDI-DrugBank.d628.s7	local	197	201	O
DDI-DrugBank.d628.s7	anesthetic	203	212	B-group
DDI-DrugBank.d628.s7	agents	214	219	I-group
DDI-DrugBank.d628.s7	)	220	220	O
DDI-DrugBank.d628.s7	have	222	225	O
DDI-DrugBank.d628.s7	been	227	230	O
DDI-DrugBank.d628.s7	observed	232	239	O
DDI-DrugBank.d628.s7	.	240	240	O
DDI-DrugBank.d558.s0	Drug/Laboratory	0	14	O
DDI-DrugBank.d558.s0	Test	16	19	O
DDI-DrugBank.d558.s0	Interactions	21	32	O
DDI-DrugBank.d558.s0	None	34	37	O
DDI-DrugBank.d558.s0	known	39	43	O
DDI-DrugBank.d558.s0	.	44	44	O
DDI-DrugBank.d558.s1	Drug-Drug	0	8	O
DDI-DrugBank.d558.s1	Interactions	10	21	O
DDI-DrugBank.d558.s1	Cimetidine	23	32	B-drug
DDI-DrugBank.d558.s1	:	33	33	O
DDI-DrugBank.d558.s1	Concomitant	35	45	O
DDI-DrugBank.d558.s1	use	47	49	O
DDI-DrugBank.d558.s1	of	51	52	O
DDI-DrugBank.d558.s1	cimetidine	54	63	B-drug
DDI-DrugBank.d558.s1	is	65	66	O
DDI-DrugBank.d558.s1	contraindicated	68	82	O
DDI-DrugBank.d558.s1	.	83	83	O
DDI-DrugBank.d558.s2	Cimetidine	0	9	B-drug
DDI-DrugBank.d558.s2	at	11	12	O
DDI-DrugBank.d558.s2	400	14	16	O
DDI-DrugBank.d558.s2	mg	18	19	O
DDI-DrugBank.d558.s2	BID	21	23	O
DDI-DrugBank.d558.s2	(	25	25	O
DDI-DrugBank.d558.s2	the	26	28	O
DDI-DrugBank.d558.s2	usual	30	34	O
DDI-DrugBank.d558.s2	prescription	36	47	O
DDI-DrugBank.d558.s2	dose	49	52	O
DDI-DrugBank.d558.s2	)	53	53	O
DDI-DrugBank.d558.s2	co-administered	55	69	O
DDI-DrugBank.d558.s2	with	71	74	O
DDI-DrugBank.d558.s2	TIKOSYN	76	82	B-brand
DDI-DrugBank.d558.s2	(	84	84	O
DDI-DrugBank.d558.s2	500	85	87	O
DDI-DrugBank.d558.s2	mcg	89	91	O
DDI-DrugBank.d558.s2	BID	93	95	O
DDI-DrugBank.d558.s2	)	96	96	O
DDI-DrugBank.d558.s2	for	98	100	O
DDI-DrugBank.d558.s2	7	102	102	O
DDI-DrugBank.d558.s2	days	104	107	O
DDI-DrugBank.d558.s2	has	109	111	O
DDI-DrugBank.d558.s2	been	113	116	O
DDI-DrugBank.d558.s2	shown	118	122	O
DDI-DrugBank.d558.s2	to	124	125	O
DDI-DrugBank.d558.s2	increase	127	134	O
DDI-DrugBank.d558.s2	dofetilide	136	145	B-drug
DDI-DrugBank.d558.s2	plasma	147	152	O
DDI-DrugBank.d558.s2	levels	154	159	O
DDI-DrugBank.d558.s2	by	161	162	O
DDI-DrugBank.d558.s2	58	164	165	O
DDI-DrugBank.d558.s2	%	166	166	O
DDI-DrugBank.d558.s2	.	167	167	O
DDI-DrugBank.d558.s3	Cimetidine	0	9	B-drug
DDI-DrugBank.d558.s3	at	11	12	O
DDI-DrugBank.d558.s3	doses	14	18	O
DDI-DrugBank.d558.s3	of	20	21	O
DDI-DrugBank.d558.s3	100	23	25	O
DDI-DrugBank.d558.s3	mg	27	28	O
DDI-DrugBank.d558.s3	BID	30	32	O
DDI-DrugBank.d558.s3	(	34	34	O
DDI-DrugBank.d558.s3	OTC	35	37	O
DDI-DrugBank.d558.s3	dose	39	42	O
DDI-DrugBank.d558.s3	)	43	43	O
DDI-DrugBank.d558.s3	resulted	45	52	O
DDI-DrugBank.d558.s3	in	54	55	O
DDI-DrugBank.d558.s3	a	57	57	O
DDI-DrugBank.d558.s3	13	59	60	O
DDI-DrugBank.d558.s3	%	61	61	O
DDI-DrugBank.d558.s3	increase	63	70	O
DDI-DrugBank.d558.s3	in	63	64	O
DDI-DrugBank.d558.s3	dofetilide	75	84	B-drug
DDI-DrugBank.d558.s3	plasma	86	91	O
DDI-DrugBank.d558.s3	levels	93	98	O
DDI-DrugBank.d558.s3	(	100	100	O
DDI-DrugBank.d558.s3	500	101	103	O
DDI-DrugBank.d558.s3	mcg	105	107	O
DDI-DrugBank.d558.s3	single	109	114	O
DDI-DrugBank.d558.s3	dose	116	119	O
DDI-DrugBank.d558.s3	)	120	120	O
DDI-DrugBank.d558.s3	.	121	121	O
DDI-DrugBank.d558.s4	No	0	1	O
DDI-DrugBank.d558.s4	studies	3	9	O
DDI-DrugBank.d558.s4	have	11	14	O
DDI-DrugBank.d558.s4	been	16	19	O
DDI-DrugBank.d558.s4	conducted	21	29	O
DDI-DrugBank.d558.s4	at	31	32	O
DDI-DrugBank.d558.s4	intermediate	34	45	O
DDI-DrugBank.d558.s4	doses	47	51	O
DDI-DrugBank.d558.s4	of	53	54	O
DDI-DrugBank.d558.s4	cimetidine	56	65	B-drug
DDI-DrugBank.d558.s4	.	66	66	O
DDI-DrugBank.d558.s5	If	0	1	O
DDI-DrugBank.d558.s5	a	3	3	O
DDI-DrugBank.d558.s5	patient	5	11	O
DDI-DrugBank.d558.s5	requires	13	20	O
DDI-DrugBank.d558.s5	TIKOSYN	22	28	B-brand
DDI-DrugBank.d558.s5	and	30	32	O
DDI-DrugBank.d558.s5	anti-ulcer	34	43	B-group
DDI-DrugBank.d558.s5	therapy	45	51	O
DDI-DrugBank.d558.s5	,	52	52	O
DDI-DrugBank.d558.s5	it	54	55	O
DDI-DrugBank.d558.s5	is	57	58	O
DDI-DrugBank.d558.s5	suggested	60	68	O
DDI-DrugBank.d558.s5	that	70	73	O
DDI-DrugBank.d558.s5	omeprazole	75	84	B-drug
DDI-DrugBank.d558.s5	,	85	85	O
DDI-DrugBank.d558.s5	ranitidine	87	96	B-drug
DDI-DrugBank.d558.s5	,	85	85	O
DDI-DrugBank.d558.s5	or	99	100	O
DDI-DrugBank.d558.s5	antacids	102	109	B-group
DDI-DrugBank.d558.s5	(	111	111	O
DDI-DrugBank.d558.s5	aluminum	112	119	B-drug
DDI-DrugBank.d558.s5	and	121	123	O
DDI-DrugBank.d558.s5	magnesium	125	133	B-drug
DDI-DrugBank.d558.s5	hydroxides	135	144	O
DDI-DrugBank.d558.s5	)	145	145	O
DDI-DrugBank.d558.s5	be	147	148	O
DDI-DrugBank.d558.s5	used	150	153	O
DDI-DrugBank.d558.s5	as	155	156	O
DDI-DrugBank.d558.s5	alternatives	158	169	O
DDI-DrugBank.d558.s5	to	171	172	O
DDI-DrugBank.d558.s5	cimetidine	174	183	B-drug
DDI-DrugBank.d558.s5	,	184	184	O
DDI-DrugBank.d558.s5	as	186	187	O
DDI-DrugBank.d558.s5	these	189	193	O
DDI-DrugBank.d558.s5	agents	195	200	O
DDI-DrugBank.d558.s5	have	202	205	O
DDI-DrugBank.d558.s5	no	207	208	O
DDI-DrugBank.d558.s5	effect	210	215	O
DDI-DrugBank.d558.s5	on	217	218	O
DDI-DrugBank.d558.s5	the	189	191	O
DDI-DrugBank.d558.s5	pharmacokinetic	224	238	O
DDI-DrugBank.d558.s5	profile	240	246	O
DDI-DrugBank.d558.s5	of	242	243	O
DDI-DrugBank.d558.s5	TIKOSYN	251	257	B-brand
DDI-DrugBank.d558.s5	.	258	258	O
DDI-DrugBank.d558.s6	Verapamil	0	8	B-drug
DDI-DrugBank.d558.s6	:	9	9	O
DDI-DrugBank.d558.s6	Concomitant	11	21	O
DDI-DrugBank.d558.s6	use	23	25	O
DDI-DrugBank.d558.s6	of	27	28	O
DDI-DrugBank.d558.s6	verapamil	30	38	B-drug
DDI-DrugBank.d558.s6	is	40	41	O
DDI-DrugBank.d558.s6	contraindicated	43	57	O
DDI-DrugBank.d558.s6	.	58	58	O
DDI-DrugBank.d558.s7	Co-administration	0	16	O
DDI-DrugBank.d558.s7	of	18	19	O
DDI-DrugBank.d558.s7	TIKOSYN	21	27	B-brand
DDI-DrugBank.d558.s7	with	29	32	O
DDI-DrugBank.d558.s7	verapamil	34	42	B-drug
DDI-DrugBank.d558.s7	resulted	44	51	O
DDI-DrugBank.d558.s7	in	53	54	O
DDI-DrugBank.d558.s7	increases	56	64	O
DDI-DrugBank.d558.s7	in	66	67	O
DDI-DrugBank.d558.s7	dofetilide	69	78	B-drug
DDI-DrugBank.d558.s7	peak	80	83	O
DDI-DrugBank.d558.s7	plasma	85	90	O
DDI-DrugBank.d558.s7	levels	92	97	O
DDI-DrugBank.d558.s7	of	99	100	O
DDI-DrugBank.d558.s7	42	102	103	O
DDI-DrugBank.d558.s7	%	104	104	O
DDI-DrugBank.d558.s7	,	105	105	O
DDI-DrugBank.d558.s7	although	107	114	O
DDI-DrugBank.d558.s7	overall	116	122	O
DDI-DrugBank.d558.s7	exposure	124	131	O
DDI-DrugBank.d558.s7	to	133	134	O
DDI-DrugBank.d558.s7	dofetilide	136	145	B-drug
DDI-DrugBank.d558.s7	was	147	149	O
DDI-DrugBank.d558.s7	not	151	153	O
DDI-DrugBank.d558.s7	significantly	155	167	O
DDI-DrugBank.d558.s7	increased	169	177	O
DDI-DrugBank.d558.s7	.	178	178	O
DDI-DrugBank.d558.s8	In	0	1	O
DDI-DrugBank.d558.s8	an	3	4	O
DDI-DrugBank.d558.s8	analysis	6	13	O
DDI-DrugBank.d558.s8	of	15	16	O
DDI-DrugBank.d558.s8	the	18	20	O
DDI-DrugBank.d558.s8	supraventricular	22	37	O
DDI-DrugBank.d558.s8	arrhythmia	39	48	O
DDI-DrugBank.d558.s8	and	50	52	O
DDI-DrugBank.d558.s8	DIAMOND	54	60	O
DDI-DrugBank.d558.s8	patient	62	68	O
DDI-DrugBank.d558.s8	populations	70	80	O
DDI-DrugBank.d558.s8	,	81	81	O
DDI-DrugBank.d558.s8	the	83	85	O
DDI-DrugBank.d558.s8	concomitant	87	97	O
DDI-DrugBank.d558.s8	administration	99	112	O
DDI-DrugBank.d558.s8	of	114	115	O
DDI-DrugBank.d558.s8	verapamil	117	125	B-drug
DDI-DrugBank.d558.s8	with	127	130	O
DDI-DrugBank.d558.s8	dofetilide	132	141	B-drug
DDI-DrugBank.d558.s8	was	143	145	O
DDI-DrugBank.d558.s8	associated	147	156	O
DDI-DrugBank.d558.s8	with	158	161	O
DDI-DrugBank.d558.s8	a	144	144	O
DDI-DrugBank.d558.s8	higher	165	170	O
DDI-DrugBank.d558.s8	occurrence	172	181	O
DDI-DrugBank.d558.s8	of	183	184	O
DDI-DrugBank.d558.s8	torsade	186	192	O
DDI-DrugBank.d558.s8	de	191	192	O
DDI-DrugBank.d558.s8	pointes	197	203	O
DDI-DrugBank.d558.s8	.	204	204	O
DDI-DrugBank.d558.s9	Ketoconazole	0	11	B-drug
DDI-DrugBank.d558.s9	:	12	12	O
DDI-DrugBank.d558.s9	Concomitant	14	24	O
DDI-DrugBank.d558.s9	use	26	28	O
DDI-DrugBank.d558.s9	of	30	31	O
DDI-DrugBank.d558.s9	ketoconazole	33	44	B-drug
DDI-DrugBank.d558.s9	is	46	47	O
DDI-DrugBank.d558.s9	contraindicated	49	63	O
DDI-DrugBank.d558.s9	.	64	64	O
DDI-DrugBank.d558.s10	Ketoconazole	0	11	B-drug
DDI-DrugBank.d558.s10	at	13	14	O
DDI-DrugBank.d558.s10	400	16	18	O
DDI-DrugBank.d558.s10	mg	20	21	O
DDI-DrugBank.d558.s10	daily	23	27	O
DDI-DrugBank.d558.s10	(	29	29	O
DDI-DrugBank.d558.s10	the	30	32	O
DDI-DrugBank.d558.s10	maximum	34	40	O
DDI-DrugBank.d558.s10	approved	42	49	O
DDI-DrugBank.d558.s10	prescription	51	62	O
DDI-DrugBank.d558.s10	dose	64	67	O
DDI-DrugBank.d558.s10	)	68	68	O
DDI-DrugBank.d558.s10	co-administered	70	84	O
DDI-DrugBank.d558.s10	with	86	89	O
DDI-DrugBank.d558.s10	TIKOSYN	91	97	B-brand
DDI-DrugBank.d558.s10	(	99	99	O
DDI-DrugBank.d558.s10	500	100	102	O
DDI-DrugBank.d558.s10	mcg	104	106	O
DDI-DrugBank.d558.s10	BID	108	110	O
DDI-DrugBank.d558.s10	)	111	111	O
DDI-DrugBank.d558.s10	for	113	115	O
DDI-DrugBank.d558.s10	7	117	117	O
DDI-DrugBank.d558.s10	days	119	122	O
DDI-DrugBank.d558.s10	has	124	126	O
DDI-DrugBank.d558.s10	been	128	131	O
DDI-DrugBank.d558.s10	shown	133	137	O
DDI-DrugBank.d558.s10	to	139	140	O
DDI-DrugBank.d558.s10	increase	142	149	O
DDI-DrugBank.d558.s10	dofetilide	151	160	B-drug
DDI-DrugBank.d558.s10	Cmax	162	165	O
DDI-DrugBank.d558.s10	by	167	168	O
DDI-DrugBank.d558.s10	53	170	171	O
DDI-DrugBank.d558.s10	%	172	172	O
DDI-DrugBank.d558.s10	in	174	175	O
DDI-DrugBank.d558.s10	males	177	181	O
DDI-DrugBank.d558.s10	and	183	185	O
DDI-DrugBank.d558.s10	97	187	188	O
DDI-DrugBank.d558.s10	%	172	172	O
DDI-DrugBank.d558.s10	in	174	175	O
DDI-DrugBank.d558.s10	females	194	200	O
DDI-DrugBank.d558.s10	,	201	201	O
DDI-DrugBank.d558.s10	and	183	185	O
DDI-DrugBank.d558.s10	AUC	207	209	O
DDI-DrugBank.d558.s10	by	211	212	O
DDI-DrugBank.d558.s10	41	214	215	O
DDI-DrugBank.d558.s10	%	189	189	O
DDI-DrugBank.d558.s10	in	191	192	O
DDI-DrugBank.d558.s10	males	196	200	O
DDI-DrugBank.d558.s10	and	203	205	O
DDI-DrugBank.d558.s10	69	231	232	O
DDI-DrugBank.d558.s10	%	216	216	O
DDI-DrugBank.d558.s10	in	218	219	O
DDI-DrugBank.d558.s10	females	238	244	O
DDI-DrugBank.d558.s10	.	245	245	O
DDI-DrugBank.d558.s11	Trimethoprim	0	11	B-drug
DDI-DrugBank.d558.s11	Alone	13	17	O
DDI-DrugBank.d558.s11	or	19	20	O
DDI-DrugBank.d558.s11	in	22	23	O
DDI-DrugBank.d558.s11	Combination	25	35	O
DDI-DrugBank.d558.s11	with	37	40	O
DDI-DrugBank.d558.s11	Sulfamethoxazole	42	57	B-drug
DDI-DrugBank.d558.s11	:	58	58	O
DDI-DrugBank.d558.s11	Concomitant	60	70	O
DDI-DrugBank.d558.s11	use	72	74	O
DDI-DrugBank.d558.s11	of	76	77	O
DDI-DrugBank.d558.s11	trimethoprim	79	90	B-drug
DDI-DrugBank.d558.s11	alone	92	96	O
DDI-DrugBank.d558.s11	or	98	99	O
DDI-DrugBank.d558.s11	in	101	102	O
DDI-DrugBank.d558.s11	combination	104	114	O
DDI-DrugBank.d558.s11	with	116	119	O
DDI-DrugBank.d558.s11	sulfamethoxazole	121	136	B-drug
DDI-DrugBank.d558.s11	is	138	139	O
DDI-DrugBank.d558.s11	contraindicated	141	155	O
DDI-DrugBank.d558.s11	.	156	156	O
DDI-DrugBank.d558.s12	Hydrochlorothiazide	0	18	B-drug
DDI-DrugBank.d558.s12	(	20	20	O
DDI-DrugBank.d558.s12	HCTZ	21	24	B-drug
DDI-DrugBank.d558.s12	)	25	25	O
DDI-DrugBank.d558.s12	Alone	27	31	O
DDI-DrugBank.d558.s12	or	33	34	O
DDI-DrugBank.d558.s12	in	36	37	O
DDI-DrugBank.d558.s12	Combination	39	49	O
DDI-DrugBank.d558.s12	with	51	54	O
DDI-DrugBank.d558.s12	Triamterene	56	66	B-drug
DDI-DrugBank.d558.s12	:	67	67	O
DDI-DrugBank.d558.s12	Concomitant	69	79	O
DDI-DrugBank.d558.s12	use	81	83	O
DDI-DrugBank.d558.s12	of	85	86	O
DDI-DrugBank.d558.s12	HCTZ	88	91	B-drug
DDI-DrugBank.d558.s12	alone	93	97	O
DDI-DrugBank.d558.s12	or	99	100	O
DDI-DrugBank.d558.s12	in	102	103	O
DDI-DrugBank.d558.s12	combination	105	115	O
DDI-DrugBank.d558.s12	with	117	120	O
DDI-DrugBank.d558.s12	triamterene	122	132	B-drug
DDI-DrugBank.d558.s12	is	134	135	O
DDI-DrugBank.d558.s12	contraindicated	137	151	O
DDI-DrugBank.d558.s12	.	152	152	O
DDI-DrugBank.d558.s13	HCTZ	0	3	B-drug
DDI-DrugBank.d558.s13	50	5	6	O
DDI-DrugBank.d558.s13	mg	8	9	O
DDI-DrugBank.d558.s13	QD	11	12	O
DDI-DrugBank.d558.s13	or	14	15	O
DDI-DrugBank.d558.s13	HCTZ/triamterene	17	32	O
DDI-DrugBank.d558.s13	50/100	34	39	O
DDI-DrugBank.d558.s13	mg	41	42	O
DDI-DrugBank.d558.s13	QD	44	45	O
DDI-DrugBank.d558.s13	was	47	49	O
DDI-DrugBank.d558.s13	co-administered	51	65	O
DDI-DrugBank.d558.s13	with	67	70	O
DDI-DrugBank.d558.s13	TIKOSYN	72	78	B-brand
DDI-DrugBank.d558.s13	(	80	80	O
DDI-DrugBank.d558.s13	500	81	83	O
DDI-DrugBank.d558.s13	mcg	85	87	O
DDI-DrugBank.d558.s13	BID	89	91	O
DDI-DrugBank.d558.s13	)	92	92	O
DDI-DrugBank.d558.s13	for	94	96	O
DDI-DrugBank.d558.s13	5	81	81	O
DDI-DrugBank.d558.s13	days	100	103	O
DDI-DrugBank.d558.s13	(	105	105	O
DDI-DrugBank.d558.s13	following	106	114	O
DDI-DrugBank.d558.s13	2	116	116	O
DDI-DrugBank.d558.s13	days	100	103	O
DDI-DrugBank.d558.s13	of	123	124	O
DDI-DrugBank.d558.s13	diuretic	126	133	B-group
DDI-DrugBank.d558.s13	use	135	137	O
DDI-DrugBank.d558.s13	at	139	140	O
DDI-DrugBank.d558.s13	half	142	145	O
DDI-DrugBank.d558.s13	dose	147	150	O
DDI-DrugBank.d558.s13	)	151	151	O
DDI-DrugBank.d558.s13	.	152	152	O
DDI-DrugBank.d558.s14	In	0	1	O
DDI-DrugBank.d558.s14	patients	3	10	O
DDI-DrugBank.d558.s14	receiving	12	20	O
DDI-DrugBank.d558.s14	HCTZ	22	25	B-drug
DDI-DrugBank.d558.s14	alone	27	31	O
DDI-DrugBank.d558.s14	,	32	32	O
DDI-DrugBank.d558.s14	dofetilide	34	43	B-drug
DDI-DrugBank.d558.s14	AUC	45	47	O
DDI-DrugBank.d558.s14	increased	49	57	O
DDI-DrugBank.d558.s14	by	59	60	O
DDI-DrugBank.d558.s14	27	62	63	O
DDI-DrugBank.d558.s14	%	64	64	O
DDI-DrugBank.d558.s14	and	66	68	O
DDI-DrugBank.d558.s14	Cmax	70	73	O
DDI-DrugBank.d558.s14	by	75	76	O
DDI-DrugBank.d558.s14	21	78	79	O
DDI-DrugBank.d558.s14	%	80	80	O
DDI-DrugBank.d558.s14	.	81	81	O
DDI-DrugBank.d558.s15	However	0	6	O
DDI-DrugBank.d558.s15	,	7	7	O
DDI-DrugBank.d558.s15	the	9	11	O
DDI-DrugBank.d558.s15	pharmacodynamic	13	27	O
DDI-DrugBank.d558.s15	effect	29	34	O
DDI-DrugBank.d558.s15	increased	36	44	O
DDI-DrugBank.d558.s15	by	46	47	O
DDI-DrugBank.d558.s15	197	49	51	O
DDI-DrugBank.d558.s15	%	52	52	O
DDI-DrugBank.d558.s15	(	54	54	O
DDI-DrugBank.d558.s15	QTc	55	57	O
DDI-DrugBank.d558.s15	increase	59	66	O
DDI-DrugBank.d558.s15	over	68	71	O
DDI-DrugBank.d558.s15	time	73	76	O
DDI-DrugBank.d558.s15	)	77	77	O
DDI-DrugBank.d558.s15	and	79	81	O
DDI-DrugBank.d558.s15	by	83	84	O
DDI-DrugBank.d558.s15	95	86	87	O
DDI-DrugBank.d558.s15	%	88	88	O
DDI-DrugBank.d558.s15	(	90	90	O
DDI-DrugBank.d558.s15	maximum	91	97	O
DDI-DrugBank.d558.s15	QTc	99	101	O
DDI-DrugBank.d558.s15	increase	103	110	O
DDI-DrugBank.d558.s15	)	111	111	O
DDI-DrugBank.d558.s15	.	112	112	O
DDI-DrugBank.d558.s16	However	0	6	O
DDI-DrugBank.d558.s16	,	7	7	O
DDI-DrugBank.d558.s16	the	9	11	O
DDI-DrugBank.d558.s16	pharmacodynamic	13	27	O
DDI-DrugBank.d558.s16	effect	29	34	O
DDI-DrugBank.d558.s16	increased	36	44	O
DDI-DrugBank.d558.s16	by	46	47	O
DDI-DrugBank.d558.s16	190	49	51	O
DDI-DrugBank.d558.s16	%	52	52	O
DDI-DrugBank.d558.s16	(	54	54	O
DDI-DrugBank.d558.s16	QTc	55	57	O
DDI-DrugBank.d558.s16	increase	59	66	O
DDI-DrugBank.d558.s16	over	68	71	O
DDI-DrugBank.d558.s16	time	73	76	O
DDI-DrugBank.d558.s16	)	77	77	O
DDI-DrugBank.d558.s16	and	79	81	O
DDI-DrugBank.d558.s16	by	83	84	O
DDI-DrugBank.d558.s16	84	86	87	O
DDI-DrugBank.d558.s16	%	88	88	O
DDI-DrugBank.d558.s16	(	90	90	O
DDI-DrugBank.d558.s16	Maximum	91	97	O
DDI-DrugBank.d558.s16	QTc	99	101	O
DDI-DrugBank.d558.s16	increase	103	110	O
DDI-DrugBank.d558.s16	)	111	111	O
DDI-DrugBank.d558.s16	.	112	112	O
DDI-DrugBank.d558.s17	The	0	2	O
DDI-DrugBank.d558.s17	pharmacodynamic	4	18	O
DDI-DrugBank.d558.s17	effects	20	26	O
DDI-DrugBank.d558.s17	can	28	30	O
DDI-DrugBank.d558.s17	be	32	33	O
DDI-DrugBank.d558.s17	explained	35	43	O
DDI-DrugBank.d558.s17	by	45	46	O
DDI-DrugBank.d558.s17	a	48	48	O
DDI-DrugBank.d558.s17	combination	50	60	O
DDI-DrugBank.d558.s17	of	62	63	O
DDI-DrugBank.d558.s17	the	65	67	O
DDI-DrugBank.d558.s17	increase	69	76	O
DDI-DrugBank.d558.s17	in	69	70	O
DDI-DrugBank.d558.s17	dofetilide	81	90	B-drug
DDI-DrugBank.d558.s17	exposure	92	99	O
DDI-DrugBank.d558.s17	and	101	103	O
DDI-DrugBank.d558.s17	the	105	107	O
DDI-DrugBank.d558.s17	reductions	109	118	O
DDI-DrugBank.d558.s17	in	120	121	O
DDI-DrugBank.d558.s17	serum	123	127	O
DDI-DrugBank.d558.s17	potassium	129	137	O
DDI-DrugBank.d558.s17	.	138	138	O
DDI-DrugBank.d558.s18	In	0	1	O
DDI-DrugBank.d558.s18	the	3	5	O
DDI-DrugBank.d558.s18	DIAMOND	7	13	O
DDI-DrugBank.d558.s18	trials	15	20	O
DDI-DrugBank.d558.s18	,	21	21	O
DDI-DrugBank.d558.s18	1252	23	26	O
DDI-DrugBank.d558.s18	patients	28	35	O
DDI-DrugBank.d558.s18	were	37	40	O
DDI-DrugBank.d558.s18	treated	42	48	O
DDI-DrugBank.d558.s18	with	50	53	O
DDI-DrugBank.d558.s18	TIKOSYN	55	61	B-brand
DDI-DrugBank.d558.s18	and	63	65	O
DDI-DrugBank.d558.s18	diuretics	67	75	B-group
DDI-DrugBank.d558.s18	concomitantly	77	89	O
DDI-DrugBank.d558.s18	of	91	92	O
DDI-DrugBank.d558.s18	whom	94	97	O
DDI-DrugBank.d558.s18	493	99	101	O
DDI-DrugBank.d558.s18	died	103	106	O
DDI-DrugBank.d558.s18	compared	108	115	O
DDI-DrugBank.d558.s18	to	117	118	O
DDI-DrugBank.d558.s18	508	120	122	O
DDI-DrugBank.d558.s18	deaths	124	129	O
DDI-DrugBank.d558.s18	among	131	135	O
DDI-DrugBank.d558.s18	the	137	139	O
DDI-DrugBank.d558.s18	1248	141	144	O
DDI-DrugBank.d558.s18	patients	146	153	O
DDI-DrugBank.d558.s18	receiving	155	163	O
DDI-DrugBank.d558.s18	placebo	165	171	O
DDI-DrugBank.d558.s18	and	173	175	O
DDI-DrugBank.d558.s18	diuretics	177	185	B-group
DDI-DrugBank.d558.s18	.	186	186	O
DDI-DrugBank.d558.s19	Of	0	1	O
DDI-DrugBank.d558.s19	the	3	5	O
DDI-DrugBank.d558.s19	229	7	9	O
DDI-DrugBank.d558.s19	patients	11	18	O
DDI-DrugBank.d558.s19	who	20	22	O
DDI-DrugBank.d558.s19	had	24	26	O
DDI-DrugBank.d558.s19	potassium	28	36	B-group
DDI-DrugBank.d558.s19	depleting	38	46	I-group
DDI-DrugBank.d558.s19	diuretics	48	56	I-group
DDI-DrugBank.d558.s19	added	58	62	O
DDI-DrugBank.d558.s19	to	64	65	O
DDI-DrugBank.d558.s19	their	67	71	O
DDI-DrugBank.d558.s19	concomitant	73	83	O
DDI-DrugBank.d558.s19	medications	85	95	O
DDI-DrugBank.d558.s19	in	97	98	O
DDI-DrugBank.d558.s19	the	100	102	O
DDI-DrugBank.d558.s19	DIAMOND	104	110	O
DDI-DrugBank.d558.s19	trials	112	117	O
DDI-DrugBank.d558.s19	,	118	118	O
DDI-DrugBank.d558.s19	the	120	122	O
DDI-DrugBank.d558.s19	patients	124	131	O
DDI-DrugBank.d558.s19	on	133	134	O
DDI-DrugBank.d558.s19	TIKOSYN	136	142	B-brand
DDI-DrugBank.d558.s19	had	144	146	O
DDI-DrugBank.d558.s19	a	125	125	O
DDI-DrugBank.d558.s19	non-significantly	150	166	O
DDI-DrugBank.d558.s19	reduced	168	174	O
DDI-DrugBank.d558.s19	relative	176	183	O
DDI-DrugBank.d558.s19	risk	185	188	O
DDI-DrugBank.d558.s19	for	190	192	O
DDI-DrugBank.d558.s19	death	194	198	O
DDI-DrugBank.d558.s19	of	200	201	O
DDI-DrugBank.d558.s19	0.68	203	206	O
DDI-DrugBank.d558.s19	(	208	208	O
DDI-DrugBank.d558.s19	95	209	210	O
DDI-DrugBank.d558.s19	%	211	211	O
DDI-DrugBank.d558.s19	CI	213	214	O
DDI-DrugBank.d558.s19	0.376	216	220	O
DDI-DrugBank.d558.s19	,	221	221	O
DDI-DrugBank.d558.s19	1.230	223	227	O
DDI-DrugBank.d558.s19	)	228	228	O
DDI-DrugBank.d558.s19	.	204	204	O
DDI-DrugBank.d558.s20	Potential	0	8	O
DDI-DrugBank.d558.s20	Drug	10	13	O
DDI-DrugBank.d558.s20	Interactions	15	26	O
DDI-DrugBank.d558.s20	Dofetilide	28	37	B-drug
DDI-DrugBank.d558.s20	is	39	40	O
DDI-DrugBank.d558.s20	eliminated	42	51	O
DDI-DrugBank.d558.s20	in	53	54	O
DDI-DrugBank.d558.s20	the	56	58	O
DDI-DrugBank.d558.s20	kidney	60	65	O
DDI-DrugBank.d558.s20	by	67	68	O
DDI-DrugBank.d558.s20	cationic	70	77	O
DDI-DrugBank.d558.s20	secretion	79	87	O
DDI-DrugBank.d558.s20	.	88	88	O
DDI-DrugBank.d558.s21	Inhibitors	0	9	O
DDI-DrugBank.d558.s21	of	11	12	O
DDI-DrugBank.d558.s21	renal	14	18	O
DDI-DrugBank.d558.s21	cationic	20	27	O
DDI-DrugBank.d558.s21	secretion	29	37	O
DDI-DrugBank.d558.s21	are	39	41	O
DDI-DrugBank.d558.s21	contraindicated	43	57	O
DDI-DrugBank.d558.s21	with	59	62	O
DDI-DrugBank.d558.s21	TIKOSYN	64	70	B-brand
DDI-DrugBank.d558.s21	.	71	71	O
DDI-DrugBank.d558.s22	In	0	1	O
DDI-DrugBank.d558.s22	addition	3	10	O
DDI-DrugBank.d558.s22	,	11	11	O
DDI-DrugBank.d558.s22	drugs	13	17	O
DDI-DrugBank.d558.s22	that	19	22	O
DDI-DrugBank.d558.s22	are	24	26	O
DDI-DrugBank.d558.s22	actively	28	35	O
DDI-DrugBank.d558.s22	secreted	37	44	O
DDI-DrugBank.d558.s22	via	46	48	O
DDI-DrugBank.d558.s22	this	50	53	O
DDI-DrugBank.d558.s22	route	55	59	O
DDI-DrugBank.d558.s22	(	61	61	O
DDI-DrugBank.d558.s22	e.g.	62	65	O
DDI-DrugBank.d558.s22	,	66	66	O
DDI-DrugBank.d558.s22	triamterene	68	78	B-drug
DDI-DrugBank.d558.s22	,	79	79	O
DDI-DrugBank.d558.s22	metformin	81	89	B-drug
DDI-DrugBank.d558.s22	and	91	93	O
DDI-DrugBank.d558.s22	amiloride	95	103	B-drug
DDI-DrugBank.d558.s22	)	104	104	O
DDI-DrugBank.d558.s22	should	106	111	O
DDI-DrugBank.d558.s22	be	113	114	O
DDI-DrugBank.d558.s22	co-administered	116	130	O
DDI-DrugBank.d558.s22	with	132	135	O
DDI-DrugBank.d558.s22	care	137	140	O
DDI-DrugBank.d558.s22	as	142	143	O
DDI-DrugBank.d558.s22	they	145	148	O
DDI-DrugBank.d558.s22	might	150	154	O
DDI-DrugBank.d558.s22	increase	156	163	O
DDI-DrugBank.d558.s22	dofetilide	165	174	B-drug
DDI-DrugBank.d558.s22	levels	176	181	O
DDI-DrugBank.d558.s22	.	182	182	O
DDI-DrugBank.d558.s23	Dofetilide	0	9	B-drug
DDI-DrugBank.d558.s23	is	11	12	O
DDI-DrugBank.d558.s23	metabolized	14	24	O
DDI-DrugBank.d558.s23	to	26	27	O
DDI-DrugBank.d558.s23	a	29	29	O
DDI-DrugBank.d558.s23	small	31	35	O
DDI-DrugBank.d558.s23	extent	37	42	O
DDI-DrugBank.d558.s23	by	44	45	O
DDI-DrugBank.d558.s23	the	47	49	O
DDI-DrugBank.d558.s23	CYP3A4	51	56	O
DDI-DrugBank.d558.s23	isoenzyme	58	66	O
DDI-DrugBank.d558.s23	of	68	69	O
DDI-DrugBank.d558.s23	the	71	73	O
DDI-DrugBank.d558.s23	cytochrome	75	84	O
DDI-DrugBank.d558.s23	P450	86	89	O
DDI-DrugBank.d558.s23	system	91	96	O
DDI-DrugBank.d558.s23	.	97	97	O
DDI-DrugBank.d558.s24	Inhibitors	0	9	O
DDI-DrugBank.d558.s24	of	11	12	O
DDI-DrugBank.d558.s24	the	14	16	O
DDI-DrugBank.d558.s24	CYP3A4	18	23	O
DDI-DrugBank.d558.s24	isoenzyme	25	33	O
DDI-DrugBank.d558.s24	could	35	39	O
DDI-DrugBank.d558.s24	increase	41	48	O
DDI-DrugBank.d558.s24	systemic	50	57	O
DDI-DrugBank.d558.s24	dofetilide	59	68	B-drug
DDI-DrugBank.d558.s24	exposure	70	77	O
DDI-DrugBank.d558.s24	.	78	78	O
DDI-DrugBank.d558.s25	Inhibitors	0	9	O
DDI-DrugBank.d558.s25	of	11	12	O
DDI-DrugBank.d558.s25	this	14	17	O
DDI-DrugBank.d558.s25	isoenzyme	19	27	O
DDI-DrugBank.d558.s25	(	29	29	O
DDI-DrugBank.d558.s25	e.g.	30	33	O
DDI-DrugBank.d558.s25	,	34	34	O
DDI-DrugBank.d558.s25	macrolide	36	44	B-group
DDI-DrugBank.d558.s25	antibiotics	46	56	I-group
DDI-DrugBank.d558.s25	,	57	57	O
DDI-DrugBank.d558.s25	azole	59	63	B-group
DDI-DrugBank.d558.s25	antifungal	65	74	I-group
DDI-DrugBank.d558.s25	agents	76	81	I-group
DDI-DrugBank.d558.s25	,	82	82	O
DDI-DrugBank.d558.s25	protease	84	91	B-group
DDI-DrugBank.d558.s25	inhibitors	93	102	I-group
DDI-DrugBank.d558.s25	,	103	103	O
DDI-DrugBank.d558.s25	serotonin	105	113	B-group
DDI-DrugBank.d558.s25	reuptake	115	122	I-group
DDI-DrugBank.d558.s25	inhibitors	124	133	I-group
DDI-DrugBank.d558.s25	,	134	134	O
DDI-DrugBank.d558.s25	amiodarone	136	145	B-drug
DDI-DrugBank.d558.s25	,	134	134	O
DDI-DrugBank.d558.s25	cannabinoids	148	159	B-group
DDI-DrugBank.d558.s25	,	146	146	O
DDI-DrugBank.d558.s25	diltiazem	162	170	B-drug
DDI-DrugBank.d558.s25	,	160	160	O
DDI-DrugBank.d558.s25	grapefruit	173	182	O
DDI-DrugBank.d558.s25	juice	184	188	O
DDI-DrugBank.d558.s25	,	171	171	O
DDI-DrugBank.d558.s25	nefazadone	191	200	B-drug
DDI-DrugBank.d558.s25	,	189	189	O
DDI-DrugBank.d558.s25	norfloxacin	203	213	B-drug
DDI-DrugBank.d558.s25	,	201	201	O
DDI-DrugBank.d558.s25	quinine	216	222	B-drug
DDI-DrugBank.d558.s25	,	201	201	O
DDI-DrugBank.d558.s25	zafirlukast	225	235	B-drug
DDI-DrugBank.d558.s25	)	236	236	O
DDI-DrugBank.d558.s25	should	238	243	O
DDI-DrugBank.d558.s25	be	245	246	O
DDI-DrugBank.d558.s25	cautiously	248	257	O
DDI-DrugBank.d558.s25	coadministered	259	272	O
DDI-DrugBank.d558.s25	with	274	277	O
DDI-DrugBank.d558.s25	TIKOSYN	279	285	B-brand
DDI-DrugBank.d558.s25	as	287	288	O
DDI-DrugBank.d558.s25	they	290	293	O
DDI-DrugBank.d558.s25	can	295	297	O
DDI-DrugBank.d558.s25	potentially	299	309	O
DDI-DrugBank.d558.s25	increase	311	318	O
DDI-DrugBank.d558.s25	dofetilide	320	329	B-drug
DDI-DrugBank.d558.s25	levels	331	336	O
DDI-DrugBank.d558.s25	.	337	337	O
DDI-DrugBank.d558.s26	Dofetilide	0	9	B-drug
DDI-DrugBank.d558.s26	is	11	12	O
DDI-DrugBank.d558.s26	not	14	16	O
DDI-DrugBank.d558.s26	an	18	19	O
DDI-DrugBank.d558.s26	inhibitor	21	29	O
DDI-DrugBank.d558.s26	of	31	32	O
DDI-DrugBank.d558.s26	CYP3A4	34	39	O
DDI-DrugBank.d558.s26	nor	41	43	O
DDI-DrugBank.d558.s26	of	45	46	O
DDI-DrugBank.d558.s26	other	48	52	O
DDI-DrugBank.d558.s26	cytochrome	54	63	O
DDI-DrugBank.d558.s26	P450	65	68	O
DDI-DrugBank.d558.s26	isoenzymes	70	79	O
DDI-DrugBank.d558.s26	(	81	81	O
DDI-DrugBank.d558.s26	e.g.	82	85	O
DDI-DrugBank.d558.s26	,	86	86	O
DDI-DrugBank.d558.s26	CYP2C9	88	93	O
DDI-DrugBank.d558.s26	,	86	86	O
DDI-DrugBank.d558.s26	CYP2D6	96	101	O
DDI-DrugBank.d558.s26	)	102	102	O
DDI-DrugBank.d558.s26	and	104	106	O
DDI-DrugBank.d558.s26	is	108	109	O
DDI-DrugBank.d558.s26	not	111	113	O
DDI-DrugBank.d558.s26	expected	115	122	O
DDI-DrugBank.d558.s26	to	124	125	O
DDI-DrugBank.d558.s26	increase	127	134	O
DDI-DrugBank.d558.s26	levels	136	141	O
DDI-DrugBank.d558.s26	of	143	144	O
DDI-DrugBank.d558.s26	drugs	146	150	O
DDI-DrugBank.d558.s26	metabolized	152	162	O
DDI-DrugBank.d558.s26	by	164	165	O
DDI-DrugBank.d558.s26	CYP3A4	167	172	O
DDI-DrugBank.d558.s26	.	173	173	O
DDI-DrugBank.d558.s27	Other	0	4	O
DDI-DrugBank.d558.s27	Drug	6	9	O
DDI-DrugBank.d558.s27	Interaction	11	21	O
DDI-DrugBank.d558.s27	Information	23	33	O
DDI-DrugBank.d558.s27	Digoxin	35	41	B-drug
DDI-DrugBank.d558.s27	:	42	42	O
DDI-DrugBank.d558.s27	Studies	44	50	O
DDI-DrugBank.d558.s27	in	52	53	O
DDI-DrugBank.d558.s27	healthy	55	61	O
DDI-DrugBank.d558.s27	volunteers	63	72	O
DDI-DrugBank.d558.s27	have	74	77	O
DDI-DrugBank.d558.s27	shown	79	83	O
DDI-DrugBank.d558.s27	that	85	88	O
DDI-DrugBank.d558.s27	TIKOSYN	90	96	B-brand
DDI-DrugBank.d558.s27	does	98	101	O
DDI-DrugBank.d558.s27	not	103	105	O
DDI-DrugBank.d558.s27	affect	107	112	O
DDI-DrugBank.d558.s27	the	114	116	O
DDI-DrugBank.d558.s27	pharmacokinetics	118	133	O
DDI-DrugBank.d558.s27	of	135	136	O
DDI-DrugBank.d558.s27	digoxin	138	144	B-drug
DDI-DrugBank.d558.s27	.	145	145	O
DDI-DrugBank.d558.s28	In	0	1	O
DDI-DrugBank.d558.s28	patients	3	10	O
DDI-DrugBank.d558.s28	,	11	11	O
DDI-DrugBank.d558.s28	the	13	15	O
DDI-DrugBank.d558.s28	concomitant	17	27	O
DDI-DrugBank.d558.s28	administration	29	42	O
DDI-DrugBank.d558.s28	of	44	45	O
DDI-DrugBank.d558.s28	digoxin	47	53	B-drug
DDI-DrugBank.d558.s28	with	55	58	O
DDI-DrugBank.d558.s28	dofetilide	60	69	B-drug
DDI-DrugBank.d558.s28	was	71	73	O
DDI-DrugBank.d558.s28	associated	75	84	O
DDI-DrugBank.d558.s28	with	86	89	O
DDI-DrugBank.d558.s28	a	81	81	O
DDI-DrugBank.d558.s28	higher	93	98	O
DDI-DrugBank.d558.s28	occurrence	100	109	O
DDI-DrugBank.d558.s28	of	111	112	O
DDI-DrugBank.d558.s28	torsade	114	120	O
DDI-DrugBank.d558.s28	de	119	120	O
DDI-DrugBank.d558.s28	pointes	125	131	O
DDI-DrugBank.d558.s28	.	132	132	O
DDI-DrugBank.d558.s29	It	0	1	O
DDI-DrugBank.d558.s29	is	3	4	O
DDI-DrugBank.d558.s29	not	6	8	O
DDI-DrugBank.d558.s29	clear	10	14	O
DDI-DrugBank.d558.s29	whether	16	22	O
DDI-DrugBank.d558.s29	this	24	27	O
DDI-DrugBank.d558.s29	represents	29	38	O
DDI-DrugBank.d558.s29	an	40	41	O
DDI-DrugBank.d558.s29	interaction	43	53	O
DDI-DrugBank.d558.s29	with	55	58	O
DDI-DrugBank.d558.s29	TIKOSYN	60	66	B-brand
DDI-DrugBank.d558.s29	or	68	69	O
DDI-DrugBank.d558.s29	the	71	73	O
DDI-DrugBank.d558.s29	presence	75	82	O
DDI-DrugBank.d558.s29	of	84	85	O
DDI-DrugBank.d558.s29	more	87	90	O
DDI-DrugBank.d558.s29	severe	92	97	O
DDI-DrugBank.d558.s29	structural	99	108	O
DDI-DrugBank.d558.s29	heart	110	114	O
DDI-DrugBank.d558.s29	disease	116	122	O
DDI-DrugBank.d558.s29	in	124	125	O
DDI-DrugBank.d558.s29	patients	127	134	O
DDI-DrugBank.d558.s29	on	136	137	O
DDI-DrugBank.d558.s29	digoxin	139	145	B-drug
DDI-DrugBank.d558.s29	;	146	146	O
DDI-DrugBank.d558.s30	structural	0	9	O
DDI-DrugBank.d558.s30	heart	11	15	O
DDI-DrugBank.d558.s30	disease	17	23	O
DDI-DrugBank.d558.s30	is	25	26	O
DDI-DrugBank.d558.s30	a	28	28	O
DDI-DrugBank.d558.s30	known	30	34	O
DDI-DrugBank.d558.s30	risk	36	39	O
DDI-DrugBank.d558.s30	factor	41	46	O
DDI-DrugBank.d558.s30	for	48	50	O
DDI-DrugBank.d558.s30	arrhythmia	52	61	O
DDI-DrugBank.d558.s30	.	62	62	O
DDI-DrugBank.d558.s31	No	0	1	O
DDI-DrugBank.d558.s31	increase	3	10	O
DDI-DrugBank.d558.s31	in	12	13	O
DDI-DrugBank.d558.s31	mortality	15	23	O
DDI-DrugBank.d558.s31	was	25	27	O
DDI-DrugBank.d558.s31	observed	29	36	O
DDI-DrugBank.d558.s31	in	38	39	O
DDI-DrugBank.d558.s31	patients	41	48	O
DDI-DrugBank.d558.s31	taking	50	55	O
DDI-DrugBank.d558.s31	digoxin	57	63	B-drug
DDI-DrugBank.d558.s31	as	65	66	O
DDI-DrugBank.d558.s31	concomitant	68	78	O
DDI-DrugBank.d558.s31	medication	80	89	O
DDI-DrugBank.d558.s31	.	90	90	O
DDI-DrugBank.d558.s32	Other	0	4	O
DDI-DrugBank.d558.s32	Drugs	6	10	O
DDI-DrugBank.d558.s32	:	11	11	O
DDI-DrugBank.d558.s32	In	13	14	O
DDI-DrugBank.d558.s32	healthy	16	22	O
DDI-DrugBank.d558.s32	volunteers	24	33	O
DDI-DrugBank.d558.s32	,	34	34	O
DDI-DrugBank.d558.s32	amlodipine	36	45	B-drug
DDI-DrugBank.d558.s32	,	46	46	O
DDI-DrugBank.d558.s32	phenytoin	48	56	B-drug
DDI-DrugBank.d558.s32	,	57	57	O
DDI-DrugBank.d558.s32	glyburide	59	67	B-drug
DDI-DrugBank.d558.s32	,	68	68	O
DDI-DrugBank.d558.s32	ranitidine	70	79	B-drug
DDI-DrugBank.d558.s32	,	80	80	O
DDI-DrugBank.d558.s32	omeprazole	82	91	B-drug
DDI-DrugBank.d558.s32	,	92	92	O
DDI-DrugBank.d558.s32	hormone	94	100	O
DDI-DrugBank.d558.s32	replacement	102	112	O
DDI-DrugBank.d558.s32	therapy	114	120	O
DDI-DrugBank.d558.s32	(	122	122	O
DDI-DrugBank.d558.s32	a	118	118	O
DDI-DrugBank.d558.s32	combination	125	135	O
DDI-DrugBank.d558.s32	of	137	138	O
DDI-DrugBank.d558.s32	conjugated	140	149	O
DDI-DrugBank.d558.s32	estrogens	151	159	B-group
DDI-DrugBank.d558.s32	and	161	163	O
DDI-DrugBank.d558.s32	medroxyprogesterone	165	183	B-drug
DDI-DrugBank.d558.s32	)	184	184	O
DDI-DrugBank.d558.s32	,	185	185	O
DDI-DrugBank.d558.s32	antacid	187	193	B-group
DDI-DrugBank.d558.s32	(	195	195	O
DDI-DrugBank.d558.s32	aluminum	196	203	B-drug
DDI-DrugBank.d558.s32	and	205	207	O
DDI-DrugBank.d558.s32	magnesium	209	217	B-drug
DDI-DrugBank.d558.s32	hydroxides	219	228	O
DDI-DrugBank.d558.s32	)	229	229	O
DDI-DrugBank.d558.s32	and	231	233	O
DDI-DrugBank.d558.s32	theophylline	235	246	B-drug
DDI-DrugBank.d558.s32	did	248	250	O
DDI-DrugBank.d558.s32	not	252	254	O
DDI-DrugBank.d558.s32	affect	256	261	O
DDI-DrugBank.d558.s32	the	235	237	B-drug
DDI-DrugBank.d558.s32	pharmacokinetics	267	282	O
DDI-DrugBank.d558.s32	of	284	285	O
DDI-DrugBank.d558.s32	TIKOSYN	287	293	B-brand
DDI-DrugBank.d558.s32	.	294	294	O
DDI-DrugBank.d558.s33	In	0	1	O
DDI-DrugBank.d558.s33	addition	3	10	O
DDI-DrugBank.d558.s33	,	11	11	O
DDI-DrugBank.d558.s33	studies	13	19	O
DDI-DrugBank.d558.s33	in	21	22	O
DDI-DrugBank.d558.s33	healthy	24	30	O
DDI-DrugBank.d558.s33	volunteers	32	41	O
DDI-DrugBank.d558.s33	have	43	46	O
DDI-DrugBank.d558.s33	shown	48	52	O
DDI-DrugBank.d558.s33	that	54	57	O
DDI-DrugBank.d558.s33	TIKOSYN	59	65	B-brand
DDI-DrugBank.d558.s33	does	67	70	O
DDI-DrugBank.d558.s33	not	72	74	O
DDI-DrugBank.d558.s33	affect	76	81	O
DDI-DrugBank.d558.s33	the	83	85	O
DDI-DrugBank.d558.s33	pharmacokinetics	87	102	O
DDI-DrugBank.d558.s33	or	104	105	O
DDI-DrugBank.d558.s33	pharmacodynamics	107	122	O
DDI-DrugBank.d558.s33	of	124	125	O
DDI-DrugBank.d558.s33	warfarin	127	134	B-drug
DDI-DrugBank.d558.s33	,	135	135	O
DDI-DrugBank.d558.s33	or	137	138	O
DDI-DrugBank.d558.s33	the	140	142	O
DDI-DrugBank.d558.s33	pharmacokinetics	144	159	O
DDI-DrugBank.d558.s33	of	161	162	O
DDI-DrugBank.d558.s33	propranolol	164	174	B-drug
DDI-DrugBank.d558.s33	(	176	176	O
DDI-DrugBank.d558.s33	40	177	178	O
DDI-DrugBank.d558.s33	mg	180	181	O
DDI-DrugBank.d558.s33	twice	183	187	O
DDI-DrugBank.d558.s33	daily	189	193	O
DDI-DrugBank.d558.s33	)	194	194	O
DDI-DrugBank.d558.s33	,	195	195	O
DDI-DrugBank.d558.s33	phenytoin	197	205	B-drug
DDI-DrugBank.d558.s33	,	195	195	O
DDI-DrugBank.d558.s33	theophylline	208	219	B-drug
DDI-DrugBank.d558.s33	,	195	195	O
DDI-DrugBank.d558.s33	or	222	223	O
DDI-DrugBank.d558.s33	oral	225	228	O
DDI-DrugBank.d558.s33	contraceptives	230	243	B-group
DDI-DrugBank.d558.s33	.	244	244	O
DDI-DrugBank.d558.s34	Population	0	9	O
DDI-DrugBank.d558.s34	pharmacokinetic	11	25	O
DDI-DrugBank.d558.s34	analyses	27	34	O
DDI-DrugBank.d558.s34	were	36	39	O
DDI-DrugBank.d558.s34	conducted	41	49	O
DDI-DrugBank.d558.s34	on	51	52	O
DDI-DrugBank.d558.s34	plasma	54	59	O
DDI-DrugBank.d558.s34	concentration	61	73	O
DDI-DrugBank.d558.s34	data	75	78	O
DDI-DrugBank.d558.s34	from	80	83	O
DDI-DrugBank.d558.s34	1445	85	88	O
DDI-DrugBank.d558.s34	patients	90	97	O
DDI-DrugBank.d558.s34	in	99	100	O
DDI-DrugBank.d558.s34	clinical	102	109	O
DDI-DrugBank.d558.s34	trials	111	116	O
DDI-DrugBank.d558.s34	to	118	119	O
DDI-DrugBank.d558.s34	examine	121	127	O
DDI-DrugBank.d558.s34	the	129	131	O
DDI-DrugBank.d558.s34	effects	133	139	O
DDI-DrugBank.d558.s34	of	141	142	O
DDI-DrugBank.d558.s34	concomitant	144	154	O
DDI-DrugBank.d558.s34	medications	156	166	O
DDI-DrugBank.d558.s34	on	164	165	O
DDI-DrugBank.d558.s34	clearance	171	179	O
DDI-DrugBank.d558.s34	or	181	182	O
DDI-DrugBank.d558.s34	volume	184	189	O
DDI-DrugBank.d558.s34	of	191	192	O
DDI-DrugBank.d558.s34	distribution	194	205	O
DDI-DrugBank.d558.s34	of	191	192	O
DDI-DrugBank.d558.s34	dofetilide	210	219	B-drug
DDI-DrugBank.d558.s34	.	220	220	O
DDI-DrugBank.d558.s35	Concomitant	0	10	O
DDI-DrugBank.d558.s35	medications	12	22	O
DDI-DrugBank.d558.s35	were	24	27	O
DDI-DrugBank.d558.s35	grouped	29	35	O
DDI-DrugBank.d558.s35	as	37	38	O
DDI-DrugBank.d558.s35	ACE	40	42	B-group
DDI-DrugBank.d558.s35	inhibitors	44	53	I-group
DDI-DrugBank.d558.s35	,	54	54	O
DDI-DrugBank.d558.s35	oral	56	59	O
DDI-DrugBank.d558.s35	anticoagulants	61	74	B-group
DDI-DrugBank.d558.s35	,	75	75	O
DDI-DrugBank.d558.s35	calcium	77	83	B-group
DDI-DrugBank.d558.s35	channel	85	91	I-group
DDI-DrugBank.d558.s35	blockers	93	100	I-group
DDI-DrugBank.d558.s35	,	101	101	O
DDI-DrugBank.d558.s35	beta	103	106	B-group
DDI-DrugBank.d558.s35	blockers	108	115	I-group
DDI-DrugBank.d558.s35	,	116	116	O
DDI-DrugBank.d558.s35	cardiac	118	124	B-group
DDI-DrugBank.d558.s35	glycosides	126	135	I-group
DDI-DrugBank.d558.s35	,	136	136	O
DDI-DrugBank.d558.s35	inducers	138	145	O
DDI-DrugBank.d558.s35	of	147	148	O
DDI-DrugBank.d558.s35	CYP3A4	150	155	O
DDI-DrugBank.d558.s35	,	156	156	O
DDI-DrugBank.d558.s35	substrates	158	167	O
DDI-DrugBank.d558.s35	and	169	171	O
DDI-DrugBank.d558.s35	inhibitors	173	182	O
DDI-DrugBank.d558.s35	of	184	185	O
DDI-DrugBank.d558.s35	CYP3A4	187	192	O
DDI-DrugBank.d558.s35	,	193	193	O
DDI-DrugBank.d558.s35	substrates	195	204	O
DDI-DrugBank.d558.s35	and	206	208	O
DDI-DrugBank.d558.s35	inhibitors	210	219	O
DDI-DrugBank.d558.s35	of	221	222	O
DDI-DrugBank.d558.s35	P-glycoprotein	224	237	O
DDI-DrugBank.d558.s35	,	238	238	O
DDI-DrugBank.d558.s35	nitrates	240	247	B-group
DDI-DrugBank.d558.s35	,	238	238	O
DDI-DrugBank.d558.s35	sulphonylureas	250	263	B-group
DDI-DrugBank.d558.s35	,	238	238	O
DDI-DrugBank.d558.s35	loop	266	269	B-group
DDI-DrugBank.d558.s35	diuretics	271	279	I-group
DDI-DrugBank.d558.s35	,	248	248	O
DDI-DrugBank.d558.s35	potassium	282	290	B-group
DDI-DrugBank.d558.s35	sparing	292	298	I-group
DDI-DrugBank.d558.s35	diuretics	271	279	I-group
DDI-DrugBank.d558.s35	,	280	280	O
DDI-DrugBank.d558.s35	thiazide	311	318	B-group
DDI-DrugBank.d558.s35	diuretics	300	308	I-group
DDI-DrugBank.d558.s35	,	309	309	O
DDI-DrugBank.d558.s35	substrates	331	340	O
DDI-DrugBank.d558.s35	and	342	344	O
DDI-DrugBank.d558.s35	inhibitors	346	355	O
DDI-DrugBank.d558.s35	of	357	358	O
DDI-DrugBank.d558.s35	tubular	360	366	O
DDI-DrugBank.d558.s35	organic	368	374	O
DDI-DrugBank.d558.s35	cation	376	381	O
DDI-DrugBank.d558.s35	transport	383	391	O
DDI-DrugBank.d558.s35	,	392	392	O
DDI-DrugBank.d558.s35	and	394	396	O
DDI-DrugBank.d558.s35	QTc-prolonging	398	411	O
DDI-DrugBank.d558.s35	drugs	413	417	O
DDI-DrugBank.d558.s35	.	418	418	O
DDI-DrugBank.d558.s36	Differences	0	10	O
DDI-DrugBank.d558.s36	in	12	13	O
DDI-DrugBank.d558.s36	clearance	15	23	O
DDI-DrugBank.d558.s36	between	25	31	O
DDI-DrugBank.d558.s36	patients	33	40	O
DDI-DrugBank.d558.s36	on	42	43	O
DDI-DrugBank.d558.s36	these	45	49	O
DDI-DrugBank.d558.s36	medications	51	61	O
DDI-DrugBank.d558.s36	(	63	63	O
DDI-DrugBank.d558.s36	at	56	57	O
DDI-DrugBank.d558.s36	any	67	69	O
DDI-DrugBank.d558.s36	occasion	71	78	O
DDI-DrugBank.d558.s36	in	80	81	O
DDI-DrugBank.d558.s36	the	83	85	O
DDI-DrugBank.d558.s36	study	87	91	O
DDI-DrugBank.d558.s36	)	92	92	O
DDI-DrugBank.d558.s36	and	94	96	O
DDI-DrugBank.d558.s36	those	98	102	O
DDI-DrugBank.d558.s36	off	104	106	O
DDI-DrugBank.d558.s36	medications	108	118	O
DDI-DrugBank.d558.s36	varied	120	125	O
DDI-DrugBank.d558.s36	between	127	133	O
DDI-DrugBank.d558.s36	-16	135	137	O
DDI-DrugBank.d558.s36	%	138	138	O
DDI-DrugBank.d558.s36	and	140	142	O
DDI-DrugBank.d558.s36	+3	144	145	O
DDI-DrugBank.d558.s36	%	138	138	O
DDI-DrugBank.d558.s36	.	147	147	O
DDI-DrugBank.d558.s37	The	0	2	O
DDI-DrugBank.d558.s37	mean	4	7	O
DDI-DrugBank.d558.s37	clearances	9	18	O
DDI-DrugBank.d558.s37	of	20	21	O
DDI-DrugBank.d558.s37	dofetilide	23	32	B-drug
DDI-DrugBank.d558.s37	were	34	37	O
DDI-DrugBank.d558.s37	16	39	40	O
DDI-DrugBank.d558.s37	%	41	41	O
DDI-DrugBank.d558.s37	and	43	45	O
DDI-DrugBank.d558.s37	15	47	48	O
DDI-DrugBank.d558.s37	%	41	41	O
DDI-DrugBank.d558.s37	lower	51	55	O
DDI-DrugBank.d558.s37	in	57	58	O
DDI-DrugBank.d558.s37	patients	60	67	O
DDI-DrugBank.d558.s37	on	69	70	O
DDI-DrugBank.d558.s37	thiazide	72	79	B-group
DDI-DrugBank.d558.s37	diuretics	81	89	I-group
DDI-DrugBank.d558.s37	and	91	93	O
DDI-DrugBank.d558.s37	inhibitors	95	104	O
DDI-DrugBank.d558.s37	of	106	107	O
DDI-DrugBank.d558.s37	tubular	109	115	O
DDI-DrugBank.d558.s37	organic	117	123	O
DDI-DrugBank.d558.s37	cation	125	130	O
DDI-DrugBank.d558.s37	transport	132	140	O
DDI-DrugBank.d558.s37	,	141	141	O
DDI-DrugBank.d558.s37	respectively	143	154	O
DDI-DrugBank.d558.s37	.	155	155	O
DDI-DrugBank.d172.s0	General	0	6	O
DDI-DrugBank.d172.s0	:	7	7	O
DDI-DrugBank.d172.s0	Significant	9	19	O
DDI-DrugBank.d172.s0	interactions	21	32	O
DDI-DrugBank.d172.s0	may	34	36	O
DDI-DrugBank.d172.s0	occur	38	42	O
DDI-DrugBank.d172.s0	when	44	47	O
DDI-DrugBank.d172.s0	celecoxib	49	57	B-drug
DDI-DrugBank.d172.s0	is	59	60	O
DDI-DrugBank.d172.s0	administered	62	73	O
DDI-DrugBank.d172.s0	together	75	82	O
DDI-DrugBank.d172.s0	with	84	87	O
DDI-DrugBank.d172.s0	drugs	89	93	O
DDI-DrugBank.d172.s0	that	95	98	O
DDI-DrugBank.d172.s0	inhibit	100	106	O
DDI-DrugBank.d172.s0	P450	108	111	O
DDI-DrugBank.d172.s0	2C9	113	115	O
DDI-DrugBank.d172.s0	.	116	116	O
DDI-DrugBank.d172.s1	Celecoxib	0	8	B-drug
DDI-DrugBank.d172.s1	metabolism	10	19	O
DDI-DrugBank.d172.s1	is	21	22	O
DDI-DrugBank.d172.s1	predominantly	24	36	O
DDI-DrugBank.d172.s1	mediated	38	45	O
DDI-DrugBank.d172.s1	via	47	49	O
DDI-DrugBank.d172.s1	cytochrome	51	60	O
DDI-DrugBank.d172.s1	P450	62	65	O
DDI-DrugBank.d172.s1	2C9	67	69	O
DDI-DrugBank.d172.s1	in	71	72	O
DDI-DrugBank.d172.s1	the	74	76	O
DDI-DrugBank.d172.s1	liver	78	82	O
DDI-DrugBank.d172.s1	.	83	83	O
DDI-DrugBank.d172.s2	Co-administration	0	16	O
DDI-DrugBank.d172.s2	of	18	19	O
DDI-DrugBank.d172.s2	celecoxib	21	29	B-drug
DDI-DrugBank.d172.s2	with	31	34	O
DDI-DrugBank.d172.s2	drugs	36	40	O
DDI-DrugBank.d172.s2	that	42	45	O
DDI-DrugBank.d172.s2	are	47	49	O
DDI-DrugBank.d172.s2	known	51	55	O
DDI-DrugBank.d172.s2	to	57	58	O
DDI-DrugBank.d172.s2	inhibit	60	66	O
DDI-DrugBank.d172.s2	2C9	68	70	O
DDI-DrugBank.d172.s2	should	72	77	O
DDI-DrugBank.d172.s2	be	79	80	O
DDI-DrugBank.d172.s2	done	82	85	O
DDI-DrugBank.d172.s2	with	87	90	O
DDI-DrugBank.d172.s2	caution	92	98	O
DDI-DrugBank.d172.s2	.	99	99	O
DDI-DrugBank.d172.s3	In	0	1	O
DDI-DrugBank.d172.s3	vitro	3	7	O
DDI-DrugBank.d172.s3	studies	9	15	O
DDI-DrugBank.d172.s3	indicate	17	24	O
DDI-DrugBank.d172.s3	that	26	29	O
DDI-DrugBank.d172.s3	celecoxib	31	39	B-drug
DDI-DrugBank.d172.s3	is	41	42	O
DDI-DrugBank.d172.s3	not	44	46	O
DDI-DrugBank.d172.s3	an	48	49	O
DDI-DrugBank.d172.s3	inhibitor	51	59	O
DDI-DrugBank.d172.s3	of	61	62	O
DDI-DrugBank.d172.s3	cytochrome	64	73	O
DDI-DrugBank.d172.s3	P450	75	78	O
DDI-DrugBank.d172.s3	2C9	80	82	O
DDI-DrugBank.d172.s3	,	83	83	O
DDI-DrugBank.d172.s3	2C19	85	88	O
DDI-DrugBank.d172.s3	or	90	91	O
DDI-DrugBank.d172.s3	3A4	93	95	O
DDI-DrugBank.d172.s3	.	96	96	O
DDI-DrugBank.d172.s4	In	0	1	O
DDI-DrugBank.d172.s4	vitro	3	7	O
DDI-DrugBank.d172.s4	studies	9	15	O
DDI-DrugBank.d172.s4	also	17	20	O
DDI-DrugBank.d172.s4	indicate	22	29	O
DDI-DrugBank.d172.s4	that	31	34	O
DDI-DrugBank.d172.s4	celecoxib	36	44	B-drug
DDI-DrugBank.d172.s4	,	45	45	O
DDI-DrugBank.d172.s4	although	47	54	O
DDI-DrugBank.d172.s4	not	56	58	O
DDI-DrugBank.d172.s4	a	60	60	O
DDI-DrugBank.d172.s4	substrate	62	70	O
DDI-DrugBank.d172.s4	,	71	71	O
DDI-DrugBank.d172.s4	is	73	74	O
DDI-DrugBank.d172.s4	an	76	77	O
DDI-DrugBank.d172.s4	inhibitor	79	87	O
DDI-DrugBank.d172.s4	of	89	90	O
DDI-DrugBank.d172.s4	cytochrome	92	101	O
DDI-DrugBank.d172.s4	P450	103	106	O
DDI-DrugBank.d172.s4	2D6	108	110	O
DDI-DrugBank.d172.s4	.	111	111	O
DDI-DrugBank.d172.s5	Therefore	0	8	O
DDI-DrugBank.d172.s5	,	9	9	O
DDI-DrugBank.d172.s5	there	11	15	O
DDI-DrugBank.d172.s5	is	17	18	O
DDI-DrugBank.d172.s5	a	20	20	O
DDI-DrugBank.d172.s5	potential	22	30	O
DDI-DrugBank.d172.s5	for	32	34	O
DDI-DrugBank.d172.s5	an	36	37	O
DDI-DrugBank.d172.s5	in	39	40	O
DDI-DrugBank.d172.s5	vivo	42	45	O
DDI-DrugBank.d172.s5	drug	47	50	O
DDI-DrugBank.d172.s5	interaction	52	62	O
DDI-DrugBank.d172.s5	with	64	67	O
DDI-DrugBank.d172.s5	drugs	69	73	O
DDI-DrugBank.d172.s5	that	75	78	O
DDI-DrugBank.d172.s5	are	80	82	O
DDI-DrugBank.d172.s5	metabolized	84	94	O
DDI-DrugBank.d172.s5	by	96	97	O
DDI-DrugBank.d172.s5	P450	99	102	O
DDI-DrugBank.d172.s5	2D6	104	106	O
DDI-DrugBank.d172.s5	.	107	107	O
DDI-DrugBank.d172.s6	Clinical	0	7	O
DDI-DrugBank.d172.s6	studies	9	15	O
DDI-DrugBank.d172.s6	with	17	20	O
DDI-DrugBank.d172.s6	celecoxib	22	30	B-drug
DDI-DrugBank.d172.s6	have	32	35	O
DDI-DrugBank.d172.s6	identified	37	46	O
DDI-DrugBank.d172.s6	potentially	48	58	O
DDI-DrugBank.d172.s6	significant	60	70	O
DDI-DrugBank.d172.s6	interactions	72	83	O
DDI-DrugBank.d172.s6	with	85	88	O
DDI-DrugBank.d172.s6	fluconazole	90	100	B-drug
DDI-DrugBank.d172.s6	and	102	104	O
DDI-DrugBank.d172.s6	lithium	106	112	B-drug
DDI-DrugBank.d172.s6	.	113	113	O
DDI-DrugBank.d172.s7	Experience	0	9	O
DDI-DrugBank.d172.s7	with	11	14	O
DDI-DrugBank.d172.s7	nonsteroidal	16	27	B-group
DDI-DrugBank.d172.s7	anti-inflammatory	29	45	I-group
DDI-DrugBank.d172.s7	drugs	47	51	I-group
DDI-DrugBank.d172.s7	(	53	53	O
DDI-DrugBank.d172.s7	NSAIDs	54	59	B-group
DDI-DrugBank.d172.s7	)	60	60	O
DDI-DrugBank.d172.s7	suggests	62	69	O
DDI-DrugBank.d172.s7	the	71	73	O
DDI-DrugBank.d172.s7	potential	75	83	O
DDI-DrugBank.d172.s7	for	85	87	O
DDI-DrugBank.d172.s7	interactions	89	100	O
DDI-DrugBank.d172.s7	with	102	105	O
DDI-DrugBank.d172.s7	furosemide	107	116	B-drug
DDI-DrugBank.d172.s7	and	118	120	O
DDI-DrugBank.d172.s7	ACE	122	124	B-group
DDI-DrugBank.d172.s7	inhibitors	126	135	I-group
DDI-DrugBank.d172.s7	.	136	136	O
DDI-DrugBank.d172.s8	The	0	2	O
DDI-DrugBank.d172.s8	effects	4	10	O
DDI-DrugBank.d172.s8	celecoxib	12	20	B-drug
DDI-DrugBank.d172.s8	on	22	23	O
DDI-DrugBank.d172.s8	the	25	27	O
DDI-DrugBank.d172.s8	pharmacokinetics	29	44	O
DDI-DrugBank.d172.s8	and/or	46	51	O
DDI-DrugBank.d172.s8	pharmacodynamics	53	68	O
DDI-DrugBank.d172.s8	of	70	71	O
DDI-DrugBank.d172.s8	glyburide	73	81	B-drug
DDI-DrugBank.d172.s8	,	82	82	O
DDI-DrugBank.d172.s8	ketoconazole	84	95	B-drug
DDI-DrugBank.d172.s8	,	96	96	O
DDI-DrugBank.d172.s8	methotrexate	98	109	B-drug
DDI-DrugBank.d172.s8	,	110	110	O
DDI-DrugBank.d172.s8	phenytoin	112	120	B-drug
DDI-DrugBank.d172.s8	,	110	110	O
DDI-DrugBank.d172.s8	tolbutamide	123	133	B-drug
DDI-DrugBank.d172.s8	,	121	121	O
DDI-DrugBank.d172.s8	and	136	138	O
DDI-DrugBank.d172.s8	warfarin	140	147	B-drug
DDI-DrugBank.d172.s8	have	149	152	O
DDI-DrugBank.d172.s8	been	154	157	O
DDI-DrugBank.d172.s8	studied	159	165	O
DDI-DrugBank.d172.s8	in	167	168	O
DDI-DrugBank.d172.s8	vivo	170	173	O
DDI-DrugBank.d172.s8	and	175	177	O
DDI-DrugBank.d172.s8	clinically	179	188	O
DDI-DrugBank.d172.s8	important	190	198	O
DDI-DrugBank.d172.s8	interactions	200	211	O
DDI-DrugBank.d172.s8	have	213	216	O
DDI-DrugBank.d172.s8	not	218	220	O
DDI-DrugBank.d172.s8	been	222	225	O
DDI-DrugBank.d172.s8	found	227	231	O
DDI-DrugBank.d172.s8	.	232	232	O
DDI-DrugBank.d172.s9	ACE	0	2	B-group
DDI-DrugBank.d172.s9	inhibitors	4	13	I-group
DDI-DrugBank.d172.s9	:	14	14	O
DDI-DrugBank.d172.s9	Reports	16	22	O
DDI-DrugBank.d172.s9	suggest	24	30	O
DDI-DrugBank.d172.s9	that	32	35	O
DDI-DrugBank.d172.s9	NSAIDs	37	42	B-group
DDI-DrugBank.d172.s9	may	44	46	O
DDI-DrugBank.d172.s9	diminish	48	55	O
DDI-DrugBank.d172.s9	the	57	59	O
DDI-DrugBank.d172.s9	antihypertensive	61	76	O
DDI-DrugBank.d172.s9	effect	78	83	O
DDI-DrugBank.d172.s9	of	85	86	O
DDI-DrugBank.d172.s9	Angiotensin	88	98	B-group
DDI-DrugBank.d172.s9	Converting	100	109	I-group
DDI-DrugBank.d172.s9	Enzyme	111	116	I-group
DDI-DrugBank.d172.s9	(	118	118	O
DDI-DrugBank.d172.s9	ACE	119	121	I-group
DDI-DrugBank.d172.s9	)	122	122	O
DDI-DrugBank.d172.s9	inhibitors	124	133	I-group
DDI-DrugBank.d172.s9	.	134	134	O
DDI-DrugBank.d172.s10	This	0	3	O
DDI-DrugBank.d172.s10	interaction	5	15	O
DDI-DrugBank.d172.s10	should	17	22	O
DDI-DrugBank.d172.s10	be	24	25	O
DDI-DrugBank.d172.s10	given	27	31	O
DDI-DrugBank.d172.s10	consideration	33	45	O
DDI-DrugBank.d172.s10	in	47	48	O
DDI-DrugBank.d172.s10	patients	50	57	O
DDI-DrugBank.d172.s10	taking	59	64	O
DDI-DrugBank.d172.s10	CELEBREX	66	73	B-brand
DDI-DrugBank.d172.s10	concomitantly	75	87	O
DDI-DrugBank.d172.s10	with	89	92	O
DDI-DrugBank.d172.s10	ACE-inhibitors	94	107	B-group
DDI-DrugBank.d172.s10	.	108	108	O
DDI-DrugBank.d172.s11	Furosemide	0	9	B-drug
DDI-DrugBank.d172.s11	:	10	10	O
DDI-DrugBank.d172.s11	Clinical	12	19	O
DDI-DrugBank.d172.s11	studies	21	27	O
DDI-DrugBank.d172.s11	,	28	28	O
DDI-DrugBank.d172.s11	as	30	31	O
DDI-DrugBank.d172.s11	well	33	36	O
DDI-DrugBank.d172.s11	as	38	39	O
DDI-DrugBank.d172.s11	post	41	44	O
DDI-DrugBank.d172.s11	marketing	46	54	O
DDI-DrugBank.d172.s11	observations	56	67	O
DDI-DrugBank.d172.s11	,	68	68	O
DDI-DrugBank.d172.s11	have	70	73	O
DDI-DrugBank.d172.s11	shown	75	79	O
DDI-DrugBank.d172.s11	that	81	84	O
DDI-DrugBank.d172.s11	NSAIDs	86	91	B-group
DDI-DrugBank.d172.s11	can	93	95	O
DDI-DrugBank.d172.s11	reduce	97	102	O
DDI-DrugBank.d172.s11	the	104	106	O
DDI-DrugBank.d172.s11	natriuretic	108	118	O
DDI-DrugBank.d172.s11	effect	120	125	O
DDI-DrugBank.d172.s11	of	127	128	O
DDI-DrugBank.d172.s11	furosemide	130	139	B-drug
DDI-DrugBank.d172.s11	and	141	143	O
DDI-DrugBank.d172.s11	thiazides	145	153	B-group
DDI-DrugBank.d172.s11	in	155	156	O
DDI-DrugBank.d172.s11	some	158	161	O
DDI-DrugBank.d172.s11	patients	163	170	O
DDI-DrugBank.d172.s11	.	171	171	O
DDI-DrugBank.d172.s12	This	0	3	O
DDI-DrugBank.d172.s12	response	5	12	O
DDI-DrugBank.d172.s12	has	14	16	O
DDI-DrugBank.d172.s12	been	18	21	O
DDI-DrugBank.d172.s12	attributed	23	32	O
DDI-DrugBank.d172.s12	to	34	35	O
DDI-DrugBank.d172.s12	inhibition	37	46	O
DDI-DrugBank.d172.s12	of	48	49	O
DDI-DrugBank.d172.s12	renal	51	55	O
DDI-DrugBank.d172.s12	prostaglandin	57	69	O
DDI-DrugBank.d172.s12	synthesis	71	79	O
DDI-DrugBank.d172.s12	.	80	80	O
DDI-DrugBank.d172.s13	Aspirin	0	6	B-brand
DDI-DrugBank.d172.s13	:	7	7	O
DDI-DrugBank.d172.s13	CELEBREX	9	16	B-brand
DDI-DrugBank.d172.s13	can	18	20	O
DDI-DrugBank.d172.s13	be	22	23	O
DDI-DrugBank.d172.s13	used	25	28	O
DDI-DrugBank.d172.s13	with	30	33	O
DDI-DrugBank.d172.s13	low	35	37	O
DDI-DrugBank.d172.s13	dose	39	42	O
DDI-DrugBank.d172.s13	aspirin	44	50	B-brand
DDI-DrugBank.d172.s13	.	51	51	O
DDI-DrugBank.d172.s14	However	0	6	O
DDI-DrugBank.d172.s14	,	7	7	O
DDI-DrugBank.d172.s14	concomitant	9	19	O
DDI-DrugBank.d172.s14	administration	21	34	O
DDI-DrugBank.d172.s14	of	36	37	O
DDI-DrugBank.d172.s14	aspirin	39	45	B-brand
DDI-DrugBank.d172.s14	with	47	50	O
DDI-DrugBank.d172.s14	CELEBREX	52	59	B-brand
DDI-DrugBank.d172.s14	may	61	63	O
DDI-DrugBank.d172.s14	result	65	70	O
DDI-DrugBank.d172.s14	in	72	73	O
DDI-DrugBank.d172.s14	an	75	76	O
DDI-DrugBank.d172.s14	increased	78	86	O
DDI-DrugBank.d172.s14	rate	88	91	O
DDI-DrugBank.d172.s14	of	93	94	O
DDI-DrugBank.d172.s14	GI	96	97	O
DDI-DrugBank.d172.s14	ulceration	99	108	O
DDI-DrugBank.d172.s14	or	110	111	O
DDI-DrugBank.d172.s14	other	113	117	O
DDI-DrugBank.d172.s14	complications	119	131	O
DDI-DrugBank.d172.s14	,	132	132	O
DDI-DrugBank.d172.s14	compared	134	141	O
DDI-DrugBank.d172.s14	to	143	144	O
DDI-DrugBank.d172.s14	use	146	148	O
DDI-DrugBank.d172.s14	of	150	151	O
DDI-DrugBank.d172.s14	CELEBREX	153	160	B-brand
DDI-DrugBank.d172.s14	alone	162	166	O
DDI-DrugBank.d172.s14	.	167	167	O
DDI-DrugBank.d172.s15	Because	0	6	O
DDI-DrugBank.d172.s15	of	8	9	O
DDI-DrugBank.d172.s15	its	11	13	O
DDI-DrugBank.d172.s15	lack	15	18	O
DDI-DrugBank.d172.s15	of	20	21	O
DDI-DrugBank.d172.s15	platelet	23	30	O
DDI-DrugBank.d172.s15	effects	32	38	O
DDI-DrugBank.d172.s15	,	39	39	O
DDI-DrugBank.d172.s15	CELEBREX	41	48	B-brand
DDI-DrugBank.d172.s15	is	50	51	O
DDI-DrugBank.d172.s15	not	53	55	O
DDI-DrugBank.d172.s15	a	57	57	O
DDI-DrugBank.d172.s15	substitute	59	68	O
DDI-DrugBank.d172.s15	for	70	72	O
DDI-DrugBank.d172.s15	aspirin	74	80	B-brand
DDI-DrugBank.d172.s15	for	70	72	O
DDI-DrugBank.d172.s15	cardiovascular	86	99	O
DDI-DrugBank.d172.s15	prophylaxis	101	111	O
DDI-DrugBank.d172.s15	.	112	112	O
DDI-DrugBank.d172.s16	Fluconazole	0	10	B-drug
DDI-DrugBank.d172.s16	:	11	11	O
DDI-DrugBank.d172.s16	Concomitant	13	23	O
DDI-DrugBank.d172.s16	administration	25	38	O
DDI-DrugBank.d172.s16	of	40	41	O
DDI-DrugBank.d172.s16	fluconazole	43	53	B-drug
DDI-DrugBank.d172.s16	at	55	56	O
DDI-DrugBank.d172.s16	200	58	60	O
DDI-DrugBank.d172.s16	mg	62	63	O
DDI-DrugBank.d172.s16	QD	65	66	O
DDI-DrugBank.d172.s16	resulted	68	75	O
DDI-DrugBank.d172.s16	in	77	78	O
DDI-DrugBank.d172.s16	a	80	80	O
DDI-DrugBank.d172.s16	two-fold	82	89	O
DDI-DrugBank.d172.s16	increase	91	98	O
DDI-DrugBank.d172.s16	in	91	92	O
DDI-DrugBank.d172.s16	celecoxib	103	111	B-drug
DDI-DrugBank.d172.s16	plasma	113	118	O
DDI-DrugBank.d172.s16	concentration	120	132	O
DDI-DrugBank.d172.s16	.	133	133	O
DDI-DrugBank.d172.s17	This	0	3	O
DDI-DrugBank.d172.s17	increase	5	12	O
DDI-DrugBank.d172.s17	is	14	15	O
DDI-DrugBank.d172.s17	due	17	19	O
DDI-DrugBank.d172.s17	to	21	22	O
DDI-DrugBank.d172.s17	the	24	26	O
DDI-DrugBank.d172.s17	inhibition	28	37	O
DDI-DrugBank.d172.s17	of	39	40	O
DDI-DrugBank.d172.s17	celecoxib	42	50	B-drug
DDI-DrugBank.d172.s17	metabolism	52	61	O
DDI-DrugBank.d172.s17	via	63	65	O
DDI-DrugBank.d172.s17	P450	67	70	O
DDI-DrugBank.d172.s17	2C9	72	74	O
DDI-DrugBank.d172.s17	by	76	77	O
DDI-DrugBank.d172.s17	fluconazole	79	89	B-drug
DDI-DrugBank.d172.s17	(	91	91	O
DDI-DrugBank.d172.s17	see	92	94	O
DDI-DrugBank.d172.s17	CLINICAL	96	103	O
DDI-DrugBank.d172.s17	PHARMACOLOGY	105	116	O
DDI-DrugBank.d172.s17	-	118	118	O
DDI-DrugBank.d172.s17	Pharmacokinetics	120	135	O
DDI-DrugBank.d172.s17	:	136	136	O
DDI-DrugBank.d172.s17	Metabolism	138	147	O
DDI-DrugBank.d172.s17	)	148	148	O
DDI-DrugBank.d172.s17	.	149	149	O
DDI-DrugBank.d172.s18	CELEBREX	0	7	B-brand
DDI-DrugBank.d172.s18	should	9	14	O
DDI-DrugBank.d172.s18	be	16	17	O
DDI-DrugBank.d172.s18	introduced	19	28	O
DDI-DrugBank.d172.s18	at	30	31	O
DDI-DrugBank.d172.s18	the	33	35	O
DDI-DrugBank.d172.s18	lowest	37	42	O
DDI-DrugBank.d172.s18	recommended	44	54	O
DDI-DrugBank.d172.s18	dose	56	59	O
DDI-DrugBank.d172.s18	in	61	62	O
DDI-DrugBank.d172.s18	patients	64	71	O
DDI-DrugBank.d172.s18	receiving	73	81	O
DDI-DrugBank.d172.s18	fluconazole	83	93	B-drug
DDI-DrugBank.d172.s18	.	94	94	O
DDI-DrugBank.d172.s19	Lithium	0	6	B-drug
DDI-DrugBank.d172.s19	:	7	7	O
DDI-DrugBank.d172.s19	In	9	10	O
DDI-DrugBank.d172.s19	a	12	12	O
DDI-DrugBank.d172.s19	study	14	18	O
DDI-DrugBank.d172.s19	conducted	20	28	O
DDI-DrugBank.d172.s19	in	30	31	O
DDI-DrugBank.d172.s19	healthy	33	39	O
DDI-DrugBank.d172.s19	subjects	41	48	O
DDI-DrugBank.d172.s19	,	49	49	O
DDI-DrugBank.d172.s19	mean	51	54	O
DDI-DrugBank.d172.s19	steady-state	56	67	O
DDI-DrugBank.d172.s19	lithium	69	75	B-drug
DDI-DrugBank.d172.s19	plasma	77	82	O
DDI-DrugBank.d172.s19	levels	84	89	O
DDI-DrugBank.d172.s19	increased	91	99	O
DDI-DrugBank.d172.s19	approximately	101	113	O
DDI-DrugBank.d172.s19	17	115	116	O
DDI-DrugBank.d172.s19	%	117	117	O
DDI-DrugBank.d172.s19	in	119	120	O
DDI-DrugBank.d172.s19	subjects	122	129	O
DDI-DrugBank.d172.s19	receiving	131	139	O
DDI-DrugBank.d172.s19	lithium	141	147	B-drug
DDI-DrugBank.d172.s19	450	149	151	O
DDI-DrugBank.d172.s19	mg	153	154	O
DDI-DrugBank.d172.s19	BID	156	158	O
DDI-DrugBank.d172.s19	with	160	163	O
DDI-DrugBank.d172.s19	CELEBREX	165	172	B-brand
DDI-DrugBank.d172.s19	200	174	176	O
DDI-DrugBank.d172.s19	mg	153	154	O
DDI-DrugBank.d172.s19	BID	156	158	O
DDI-DrugBank.d172.s19	as	185	186	O
DDI-DrugBank.d172.s19	compared	188	195	O
DDI-DrugBank.d172.s19	to	197	198	O
DDI-DrugBank.d172.s19	subjects	200	207	O
DDI-DrugBank.d172.s19	receiving	209	217	O
DDI-DrugBank.d172.s19	lithium	219	225	B-drug
DDI-DrugBank.d172.s19	alone	227	231	O
DDI-DrugBank.d172.s19	.	232	232	O
DDI-DrugBank.d172.s20	Patients	0	7	O
DDI-DrugBank.d172.s20	on	9	10	O
DDI-DrugBank.d172.s20	lithium	12	18	B-drug
DDI-DrugBank.d172.s20	treatment	20	28	O
DDI-DrugBank.d172.s20	should	30	35	O
DDI-DrugBank.d172.s20	be	37	38	O
DDI-DrugBank.d172.s20	closely	40	46	O
DDI-DrugBank.d172.s20	monitored	48	56	O
DDI-DrugBank.d172.s20	when	58	61	O
DDI-DrugBank.d172.s20	CELEBREX	63	70	B-brand
DDI-DrugBank.d172.s20	is	72	73	O
DDI-DrugBank.d172.s20	introduced	75	84	O
DDI-DrugBank.d172.s20	or	86	87	O
DDI-DrugBank.d172.s20	withdrawn	89	97	O
DDI-DrugBank.d172.s20	.	98	98	O
DDI-DrugBank.d172.s21	Methotrexate	0	11	B-drug
DDI-DrugBank.d172.s21	:	12	12	O
DDI-DrugBank.d172.s21	In	14	15	O
DDI-DrugBank.d172.s21	an	17	18	O
DDI-DrugBank.d172.s21	interaction	20	30	O
DDI-DrugBank.d172.s21	study	32	36	O
DDI-DrugBank.d172.s21	of	38	39	O
DDI-DrugBank.d172.s21	rheumatoid	41	50	O
DDI-DrugBank.d172.s21	arthritis	52	60	O
DDI-DrugBank.d172.s21	patients	62	69	O
DDI-DrugBank.d172.s21	taking	71	76	O
DDI-DrugBank.d172.s21	methotrexate	78	89	B-drug
DDI-DrugBank.d172.s21	,	90	90	O
DDI-DrugBank.d172.s21	CELEBREX	92	99	B-brand
DDI-DrugBank.d172.s21	did	101	103	O
DDI-DrugBank.d172.s21	not	105	107	O
DDI-DrugBank.d172.s21	have	109	112	O
DDI-DrugBank.d172.s21	a	110	110	O
DDI-DrugBank.d172.s21	significant	116	126	O
DDI-DrugBank.d172.s21	effect	128	133	O
DDI-DrugBank.d172.s21	on	135	136	O
DDI-DrugBank.d172.s21	the	138	140	O
DDI-DrugBank.d172.s21	pharmacokinetics	142	157	O
DDI-DrugBank.d172.s21	of	159	160	O
DDI-DrugBank.d172.s21	methotrexate	162	173	B-drug
DDI-DrugBank.d172.s21	.	174	174	O
DDI-DrugBank.d172.s22	Warfarin	0	7	B-drug
DDI-DrugBank.d172.s22	:	8	8	O
DDI-DrugBank.d172.s22	The	10	12	O
DDI-DrugBank.d172.s22	effect	14	19	O
DDI-DrugBank.d172.s22	of	21	22	O
DDI-DrugBank.d172.s22	celecoxib	24	32	B-drug
DDI-DrugBank.d172.s22	on	34	35	O
DDI-DrugBank.d172.s22	the	37	39	O
DDI-DrugBank.d172.s22	anti-coagulant	41	54	O
DDI-DrugBank.d172.s22	effect	56	61	O
DDI-DrugBank.d172.s22	of	63	64	O
DDI-DrugBank.d172.s22	warfarin	66	73	B-drug
DDI-DrugBank.d172.s22	was	75	77	O
DDI-DrugBank.d172.s22	studied	79	85	O
DDI-DrugBank.d172.s22	in	87	88	O
DDI-DrugBank.d172.s22	a	76	76	O
DDI-DrugBank.d172.s22	group	92	96	O
DDI-DrugBank.d172.s22	of	98	99	O
DDI-DrugBank.d172.s22	healthy	101	107	O
DDI-DrugBank.d172.s22	subjects	109	116	O
DDI-DrugBank.d172.s22	receiving	118	126	O
DDI-DrugBank.d172.s22	daily	128	132	O
DDI-DrugBank.d172.s22	doses	134	138	O
DDI-DrugBank.d172.s22	of	140	141	O
DDI-DrugBank.d172.s22	2-5	143	145	O
DDI-DrugBank.d172.s22	mg	147	148	O
DDI-DrugBank.d172.s22	of	140	141	O
DDI-DrugBank.d172.s22	warfarin	153	160	B-drug
DDI-DrugBank.d172.s22	.	161	161	O
DDI-DrugBank.d172.s23	In	0	1	O
DDI-DrugBank.d172.s23	these	3	7	O
DDI-DrugBank.d172.s23	subjects	9	16	O
DDI-DrugBank.d172.s23	,	17	17	O
DDI-DrugBank.d172.s23	celecoxib	19	27	B-drug
DDI-DrugBank.d172.s23	did	29	31	O
DDI-DrugBank.d172.s23	not	33	35	O
DDI-DrugBank.d172.s23	alter	37	41	O
DDI-DrugBank.d172.s23	the	43	45	O
DDI-DrugBank.d172.s23	anticoagulant	47	59	O
DDI-DrugBank.d172.s23	effect	61	66	O
DDI-DrugBank.d172.s23	of	68	69	O
DDI-DrugBank.d172.s23	warfarin	71	78	B-drug
DDI-DrugBank.d172.s23	as	80	81	O
DDI-DrugBank.d172.s23	determined	83	92	O
DDI-DrugBank.d172.s23	by	94	95	O
DDI-DrugBank.d172.s23	prothrombin	97	107	O
DDI-DrugBank.d172.s23	time	109	112	O
DDI-DrugBank.d172.s23	.	113	113	O
DDI-DrugBank.d172.s24	However	0	6	O
DDI-DrugBank.d172.s24	,	7	7	O
DDI-DrugBank.d172.s24	caution	9	15	O
DDI-DrugBank.d172.s24	should	17	22	O
DDI-DrugBank.d172.s24	be	24	25	O
DDI-DrugBank.d172.s24	used	27	30	O
DDI-DrugBank.d172.s24	when	32	35	O
DDI-DrugBank.d172.s24	administering	37	49	O
DDI-DrugBank.d172.s24	CELEBREX	51	58	B-brand
DDI-DrugBank.d172.s24	with	60	63	O
DDI-DrugBank.d172.s24	warfarin	65	72	B-drug
DDI-DrugBank.d172.s24	since	74	78	O
DDI-DrugBank.d172.s24	these	80	84	O
DDI-DrugBank.d172.s24	patients	86	93	O
DDI-DrugBank.d172.s24	are	95	97	O
DDI-DrugBank.d172.s24	at	87	88	O
DDI-DrugBank.d172.s24	increased	102	110	O
DDI-DrugBank.d172.s24	risk	112	115	O
DDI-DrugBank.d172.s24	of	117	118	O
DDI-DrugBank.d172.s24	bleeding	120	127	O
DDI-DrugBank.d172.s24	complications	129	141	O
DDI-DrugBank.d172.s24	.	142	142	O
DDI-DrugBank.d553.s0	Drug	0	3	O
DDI-DrugBank.d553.s0	Laboratory	5	14	O
DDI-DrugBank.d553.s0	Test	16	19	O
DDI-DrugBank.d553.s0	Interactions	21	32	O
DDI-DrugBank.d553.s0	:	33	33	O
DDI-DrugBank.d553.s0	Prolongation	35	46	O
DDI-DrugBank.d553.s0	of	48	49	O
DDI-DrugBank.d553.s0	the	51	53	O
DDI-DrugBank.d553.s0	template	55	62	O
DDI-DrugBank.d553.s0	bleeding	64	71	O
DDI-DrugBank.d553.s0	time	73	76	O
DDI-DrugBank.d553.s0	has	78	80	O
DDI-DrugBank.d553.s0	been	82	85	O
DDI-DrugBank.d553.s0	reported	87	94	O
DDI-DrugBank.d553.s0	during	96	101	O
DDI-DrugBank.d553.s0	continuous	103	112	O
DDI-DrugBank.d553.s0	intravenous	114	124	O
DDI-DrugBank.d553.s0	infusion	126	133	O
DDI-DrugBank.d553.s0	of	135	136	O
DDI-DrugBank.d553.s0	AMICAR	138	143	B-brand
DDI-DrugBank.d553.s0	at	145	146	O
DDI-DrugBank.d553.s0	dosages	148	154	O
DDI-DrugBank.d553.s0	exceeding	156	164	O
DDI-DrugBank.d553.s0	24	166	167	O
DDI-DrugBank.d553.s0	g/day	169	173	O
DDI-DrugBank.d553.s0	.	174	174	O
DDI-DrugBank.d553.s1	Platelet	0	7	O
DDI-DrugBank.d553.s1	function	9	16	O
DDI-DrugBank.d553.s1	studies	18	24	O
DDI-DrugBank.d553.s1	in	26	27	O
DDI-DrugBank.d553.s1	these	29	33	O
DDI-DrugBank.d553.s1	patients	35	42	O
DDI-DrugBank.d553.s1	have	44	47	O
DDI-DrugBank.d553.s1	not	49	51	O
DDI-DrugBank.d553.s1	demonstrated	53	64	O
DDI-DrugBank.d553.s1	any	66	68	O
DDI-DrugBank.d553.s1	significant	70	80	O
DDI-DrugBank.d553.s1	platelet	82	89	O
DDI-DrugBank.d553.s1	dysfunction	91	101	O
DDI-DrugBank.d553.s1	.	102	102	O
DDI-DrugBank.d553.s2	However	0	6	O
DDI-DrugBank.d553.s2	,	7	7	O
DDI-DrugBank.d553.s2	in	9	10	O
DDI-DrugBank.d553.s2	vitro	12	16	O
DDI-DrugBank.d553.s2	studies	18	24	O
DDI-DrugBank.d553.s2	have	26	29	O
DDI-DrugBank.d553.s2	shown	31	35	O
DDI-DrugBank.d553.s2	that	37	40	O
DDI-DrugBank.d553.s2	at	39	40	O
DDI-DrugBank.d553.s2	high	45	48	O
DDI-DrugBank.d553.s2	concentrations	50	63	O
DDI-DrugBank.d553.s2	(	65	65	O
DDI-DrugBank.d553.s2	7.4	66	68	O
DDI-DrugBank.d553.s2	mMol/L	70	75	O
DDI-DrugBank.d553.s2	or	77	78	O
DDI-DrugBank.d553.s2	0.97	80	83	O
DDI-DrugBank.d553.s2	mg/mL	85	89	O
DDI-DrugBank.d553.s2	and	91	93	O
DDI-DrugBank.d553.s2	greater	95	101	O
DDI-DrugBank.d553.s2	)	102	102	O
DDI-DrugBank.d553.s2	EACA	104	107	B-drug
DDI-DrugBank.d553.s2	inhibits	109	116	O
DDI-DrugBank.d553.s2	ADP	118	120	O
DDI-DrugBank.d553.s2	and	122	124	O
DDI-DrugBank.d553.s2	collagen-induced	126	141	O
DDI-DrugBank.d553.s2	platelet	143	150	O
DDI-DrugBank.d553.s2	aggregation	152	162	O
DDI-DrugBank.d553.s2	,	163	163	O
DDI-DrugBank.d553.s2	the	165	167	O
DDI-DrugBank.d553.s2	release	169	175	O
DDI-DrugBank.d553.s2	of	177	178	O
DDI-DrugBank.d553.s2	ATP	180	182	O
DDI-DrugBank.d553.s2	and	184	186	O
DDI-DrugBank.d553.s2	serotonin	188	196	O
DDI-DrugBank.d553.s2	,	197	197	O
DDI-DrugBank.d553.s2	and	184	186	O
DDI-DrugBank.d553.s2	the	203	205	O
DDI-DrugBank.d553.s2	binding	207	213	O
DDI-DrugBank.d553.s2	of	215	216	O
DDI-DrugBank.d553.s2	fibrinogen	218	227	O
DDI-DrugBank.d553.s2	to	229	230	O
DDI-DrugBank.d553.s2	the	203	205	O
DDI-DrugBank.d553.s2	platelets	236	244	O
DDI-DrugBank.d553.s2	in	208	209	O
DDI-DrugBank.d553.s2	a	238	238	O
DDI-DrugBank.d553.s2	concentration-response	251	272	O
DDI-DrugBank.d553.s2	manner	274	279	O
DDI-DrugBank.d553.s2	.	280	280	O
DDI-DrugBank.d553.s3	Following	0	8	O
DDI-DrugBank.d553.s3	a	10	10	O
DDI-DrugBank.d553.s3	10	12	13	O
DDI-DrugBank.d553.s3	g	15	15	O
DDI-DrugBank.d553.s3	bolus	17	21	O
DDI-DrugBank.d553.s3	of	23	24	O
DDI-DrugBank.d553.s3	AMICAR	26	31	B-brand
DDI-DrugBank.d553.s3	,	32	32	O
DDI-DrugBank.d553.s3	transient	34	42	O
DDI-DrugBank.d553.s3	peak	44	47	O
DDI-DrugBank.d553.s3	plasma	49	54	O
DDI-DrugBank.d553.s3	concentrations	56	69	O
DDI-DrugBank.d553.s3	of	71	72	O
DDI-DrugBank.d553.s3	4.6	74	76	O
DDI-DrugBank.d553.s3	mMol/L	78	83	O
DDI-DrugBank.d553.s3	or	85	86	O
DDI-DrugBank.d553.s3	0.60	88	91	O
DDI-DrugBank.d553.s3	mg/mL	93	97	O
DDI-DrugBank.d553.s3	have	99	102	O
DDI-DrugBank.d553.s3	been	104	107	O
DDI-DrugBank.d553.s3	obtained	109	116	O
DDI-DrugBank.d553.s3	.	117	117	O
DDI-DrugBank.d553.s4	The	0	2	O
DDI-DrugBank.d553.s4	concentration	4	16	O
DDI-DrugBank.d553.s4	of	18	19	O
DDI-DrugBank.d553.s4	AMICAR	21	26	B-brand
DDI-DrugBank.d553.s4	necessary	28	36	O
DDI-DrugBank.d553.s4	to	38	39	O
DDI-DrugBank.d553.s4	maintain	41	48	O
DDI-DrugBank.d553.s4	inhibition	50	59	O
DDI-DrugBank.d553.s4	of	61	62	O
DDI-DrugBank.d553.s4	fibrinolysis	64	75	O
DDI-DrugBank.d553.s4	is	74	75	O
DDI-DrugBank.d553.s4	0.99	80	83	O
DDI-DrugBank.d553.s4	mMol/L	85	90	O
DDI-DrugBank.d553.s4	or	92	93	O
DDI-DrugBank.d553.s4	0.13	95	98	O
DDI-DrugBank.d553.s4	mg/mL	100	104	O
DDI-DrugBank.d553.s4	.	96	96	O
DDI-DrugBank.d553.s5	Administration	0	13	O
DDI-DrugBank.d553.s5	of	15	16	O
DDI-DrugBank.d553.s5	a	18	18	O
DDI-DrugBank.d553.s5	5	20	20	O
DDI-DrugBank.d553.s5	g	22	22	O
DDI-DrugBank.d553.s5	bolus	24	28	O
DDI-DrugBank.d553.s5	followed	30	37	O
DDI-DrugBank.d553.s5	by	39	40	O
DDI-DrugBank.d553.s5	1	42	42	O
DDI-DrugBank.d553.s5	to	44	45	O
DDI-DrugBank.d553.s5	1.25	47	50	O
DDI-DrugBank.d553.s5	g/hr	52	55	O
DDI-DrugBank.d553.s5	should	57	62	O
DDI-DrugBank.d553.s5	achieve	64	70	O
DDI-DrugBank.d553.s5	and	72	74	O
DDI-DrugBank.d553.s5	sustain	76	82	O
DDI-DrugBank.d553.s5	plasma	84	89	O
DDI-DrugBank.d553.s5	levels	91	96	O
DDI-DrugBank.d553.s5	of	98	99	O
DDI-DrugBank.d553.s5	0.13	101	104	O
DDI-DrugBank.d553.s5	mg/mL	106	110	O
DDI-DrugBank.d553.s5	.	102	102	O
DDI-DrugBank.d553.s6	Thus	0	3	O
DDI-DrugBank.d553.s6	,	4	4	O
DDI-DrugBank.d553.s6	concentrations	6	19	O
DDI-DrugBank.d553.s6	which	21	25	O
DDI-DrugBank.d553.s6	have	27	30	O
DDI-DrugBank.d553.s6	been	32	35	O
DDI-DrugBank.d553.s6	obtained	37	44	O
DDI-DrugBank.d553.s6	in	41	42	O
DDI-DrugBank.d553.s6	vivo	49	52	O
DDI-DrugBank.d553.s6	clinically	54	63	O
DDI-DrugBank.d553.s6	in	56	57	O
DDI-DrugBank.d553.s6	patients	68	75	O
DDI-DrugBank.d553.s6	with	77	80	O
DDI-DrugBank.d553.s6	normal	82	87	O
DDI-DrugBank.d553.s6	renal	89	93	O
DDI-DrugBank.d553.s6	function	95	102	O
DDI-DrugBank.d553.s6	are	104	106	O
DDI-DrugBank.d553.s6	considerably	108	119	O
DDI-DrugBank.d553.s6	lower	121	125	O
DDI-DrugBank.d553.s6	than	127	130	O
DDI-DrugBank.d553.s6	the	132	134	O
DDI-DrugBank.d553.s6	in	136	137	O
DDI-DrugBank.d553.s6	vitro	139	143	O
DDI-DrugBank.d553.s6	concentrations	145	158	O
DDI-DrugBank.d553.s6	found	160	164	O
DDI-DrugBank.d553.s6	to	166	167	O
DDI-DrugBank.d553.s6	induce	169	174	O
DDI-DrugBank.d553.s6	abnormalities	176	188	O
DDI-DrugBank.d553.s6	in	169	170	O
DDI-DrugBank.d553.s6	platelet	193	200	O
DDI-DrugBank.d553.s6	function	202	209	O
DDI-DrugBank.d553.s6	tests	211	215	O
DDI-DrugBank.d553.s6	.	216	216	O
DDI-DrugBank.d553.s7	However	0	6	O
DDI-DrugBank.d553.s7	,	7	7	O
DDI-DrugBank.d553.s7	higher	9	14	O
DDI-DrugBank.d553.s7	plasma	16	21	O
DDI-DrugBank.d553.s7	concentrations	23	36	O
DDI-DrugBank.d553.s7	of	38	39	O
DDI-DrugBank.d553.s7	AMICAR	41	46	B-brand
DDI-DrugBank.d553.s7	may	48	50	O
DDI-DrugBank.d553.s7	occur	52	56	O
DDI-DrugBank.d553.s7	in	58	59	O
DDI-DrugBank.d553.s7	patients	61	68	O
DDI-DrugBank.d553.s7	with	70	73	O
DDI-DrugBank.d553.s7	severe	75	80	O
DDI-DrugBank.d553.s7	renal	82	86	O
DDI-DrugBank.d553.s7	failure	88	94	O
DDI-DrugBank.d553.s7	.	95	95	O
DDI-DrugBank.d665.s0	Concurrent	0	9	O
DDI-DrugBank.d665.s0	administration	11	24	O
DDI-DrugBank.d665.s0	of	26	27	O
DDI-DrugBank.d665.s0	bacteriostatic	29	42	B-group
DDI-DrugBank.d665.s0	antibiotics	44	54	I-group
DDI-DrugBank.d665.s0	(	56	56	O
DDI-DrugBank.d665.s0	e.g.	57	60	O
DDI-DrugBank.d665.s0	,	61	61	O
DDI-DrugBank.d665.s0	erythromycin	63	74	B-drug
DDI-DrugBank.d665.s0	,	75	75	O
DDI-DrugBank.d665.s0	tetracycline	77	88	B-drug
DDI-DrugBank.d665.s0	)	89	89	O
DDI-DrugBank.d665.s0	may	91	93	O
DDI-DrugBank.d665.s0	diminish	95	102	O
DDI-DrugBank.d665.s0	the	104	106	O
DDI-DrugBank.d665.s0	bactericidal	108	119	O
DDI-DrugBank.d665.s0	effects	121	127	O
DDI-DrugBank.d665.s0	of	129	130	O
DDI-DrugBank.d665.s0	penicillins	132	142	B-group
DDI-DrugBank.d665.s0	by	144	145	O
DDI-DrugBank.d665.s0	slowing	147	153	O
DDI-DrugBank.d665.s0	the	155	157	O
DDI-DrugBank.d665.s0	rate	159	162	O
DDI-DrugBank.d665.s0	of	164	165	O
DDI-DrugBank.d665.s0	bacterial	167	175	O
DDI-DrugBank.d665.s0	growth	177	182	O
DDI-DrugBank.d665.s0	.	183	183	O
DDI-DrugBank.d665.s1	Bactericidal	0	11	O
DDI-DrugBank.d665.s1	agents	13	18	O
DDI-DrugBank.d665.s1	work	20	23	O
DDI-DrugBank.d665.s1	most	25	28	O
DDI-DrugBank.d665.s1	effectively	30	40	O
DDI-DrugBank.d665.s1	against	42	48	O
DDI-DrugBank.d665.s1	the	50	52	O
DDI-DrugBank.d665.s1	immature	54	61	O
DDI-DrugBank.d665.s1	cell	63	66	O
DDI-DrugBank.d665.s1	wall	68	71	O
DDI-DrugBank.d665.s1	of	73	74	O
DDI-DrugBank.d665.s1	rapidly	76	82	O
DDI-DrugBank.d665.s1	proliferating	84	96	O
DDI-DrugBank.d665.s1	microorganisms	98	111	O
DDI-DrugBank.d665.s1	.	112	112	O
DDI-DrugBank.d665.s2	This	0	3	O
DDI-DrugBank.d665.s2	has	5	7	O
DDI-DrugBank.d665.s2	been	9	12	O
DDI-DrugBank.d665.s2	demonstrated	14	25	O
DDI-DrugBank.d665.s2	in	27	28	O
DDI-DrugBank.d665.s2	vitro	30	34	O
DDI-DrugBank.d665.s2	;	35	35	O
DDI-DrugBank.d665.s3	however	0	6	O
DDI-DrugBank.d665.s3	,	7	7	O
DDI-DrugBank.d665.s3	the	9	11	O
DDI-DrugBank.d665.s3	clinical	13	20	O
DDI-DrugBank.d665.s3	significance	22	33	O
DDI-DrugBank.d665.s3	of	35	36	O
DDI-DrugBank.d665.s3	this	38	41	O
DDI-DrugBank.d665.s3	interaction	43	53	O
DDI-DrugBank.d665.s3	is	55	56	O
DDI-DrugBank.d665.s3	not	58	60	O
DDI-DrugBank.d665.s3	well	62	65	O
DDI-DrugBank.d665.s3	documented	67	76	O
DDI-DrugBank.d665.s3	.	77	77	O
DDI-DrugBank.d665.s4	There	0	4	O
DDI-DrugBank.d665.s4	are	6	8	O
DDI-DrugBank.d665.s4	few	10	12	O
DDI-DrugBank.d665.s4	clinical	14	21	O
DDI-DrugBank.d665.s4	situations	23	32	O
DDI-DrugBank.d665.s4	in	34	35	O
DDI-DrugBank.d665.s4	which	37	41	O
DDI-DrugBank.d665.s4	the	43	45	O
DDI-DrugBank.d665.s4	concurrent	47	56	O
DDI-DrugBank.d665.s4	use	58	60	O
DDI-DrugBank.d665.s4	of	62	63	O
DDI-DrugBank.d665.s4	``	-1	0	O
DDI-DrugBank.d665.s4	static	67	72	O
DDI-DrugBank.d665.s4	''	65	66	O
DDI-DrugBank.d665.s4	and	76	78	O
DDI-DrugBank.d665.s4	``	-1	0	O
DDI-DrugBank.d665.s4	cidal	82	86	O
DDI-DrugBank.d665.s4	``	-1	0	O
DDI-DrugBank.d665.s4	antibiotics	91	101	B-group
DDI-DrugBank.d665.s4	are	103	105	O
DDI-DrugBank.d665.s4	indicated	107	115	O
DDI-DrugBank.d665.s4	.	116	116	O
DDI-DrugBank.d665.s5	However	0	6	O
DDI-DrugBank.d665.s5	,	7	7	O
DDI-DrugBank.d665.s5	in	9	10	O
DDI-DrugBank.d665.s5	selected	12	19	O
DDI-DrugBank.d665.s5	circumstances	21	33	O
DDI-DrugBank.d665.s5	in	35	36	O
DDI-DrugBank.d665.s5	which	38	42	O
DDI-DrugBank.d665.s5	such	44	47	O
DDI-DrugBank.d665.s5	therapy	49	55	O
DDI-DrugBank.d665.s5	is	57	58	O
DDI-DrugBank.d665.s5	appropriate	60	70	O
DDI-DrugBank.d665.s5	,	71	71	O
DDI-DrugBank.d665.s5	using	73	77	O
DDI-DrugBank.d665.s5	adequate	79	86	O
DDI-DrugBank.d665.s5	doses	88	92	O
DDI-DrugBank.d665.s5	of	94	95	O
DDI-DrugBank.d665.s5	antibacterial	97	109	B-group
DDI-DrugBank.d665.s5	agents	111	116	O
DDI-DrugBank.d665.s5	and	118	120	O
DDI-DrugBank.d665.s5	beginning	122	130	O
DDI-DrugBank.d665.s5	penicillin	132	141	O
DDI-DrugBank.d665.s5	therapy	143	149	O
DDI-DrugBank.d665.s5	first	151	155	O
DDI-DrugBank.d665.s5	,	156	156	O
DDI-DrugBank.d665.s5	should	158	163	O
DDI-DrugBank.d665.s5	minimize	165	172	O
DDI-DrugBank.d665.s5	the	174	176	O
DDI-DrugBank.d665.s5	potential	178	186	O
DDI-DrugBank.d665.s5	for	188	190	O
DDI-DrugBank.d665.s5	interaction	192	202	O
DDI-DrugBank.d665.s5	.	203	203	O
DDI-DrugBank.d665.s6	Penicillin	0	9	B-group
DDI-DrugBank.d665.s6	blood	11	15	O
DDI-DrugBank.d665.s6	levels	17	22	O
DDI-DrugBank.d665.s6	may	24	26	O
DDI-DrugBank.d665.s6	be	28	29	O
DDI-DrugBank.d665.s6	prolonged	31	39	O
DDI-DrugBank.d665.s6	by	41	42	O
DDI-DrugBank.d665.s6	concurrent	44	53	O
DDI-DrugBank.d665.s6	administration	55	68	O
DDI-DrugBank.d665.s6	of	70	71	O
DDI-DrugBank.d665.s6	probenecid	73	82	B-drug
DDI-DrugBank.d665.s6	which	84	88	O
DDI-DrugBank.d665.s6	blocks	90	95	O
DDI-DrugBank.d665.s6	the	97	99	O
DDI-DrugBank.d665.s6	renal	101	105	O
DDI-DrugBank.d665.s6	tubular	107	113	O
DDI-DrugBank.d665.s6	secretion	115	123	O
DDI-DrugBank.d665.s6	of	125	126	O
DDI-DrugBank.d665.s6	penicillins	128	138	B-group
DDI-DrugBank.d665.s6	.	139	139	O
DDI-DrugBank.d665.s7	Displacement	0	11	O
DDI-DrugBank.d665.s7	of	13	14	O
DDI-DrugBank.d665.s7	penicillin	16	25	B-group
DDI-DrugBank.d665.s7	from	27	30	O
DDI-DrugBank.d665.s7	plasma	32	37	O
DDI-DrugBank.d665.s7	protein	39	45	O
DDI-DrugBank.d665.s7	binding	47	53	O
DDI-DrugBank.d665.s7	sites	55	59	O
DDI-DrugBank.d665.s7	will	61	64	O
DDI-DrugBank.d665.s7	elevate	66	72	O
DDI-DrugBank.d665.s7	the	74	76	O
DDI-DrugBank.d665.s7	level	78	82	O
DDI-DrugBank.d665.s7	of	84	85	O
DDI-DrugBank.d665.s7	free	87	90	O
DDI-DrugBank.d665.s7	penicillin	92	101	B-group
DDI-DrugBank.d665.s7	in	100	101	I-group
DDI-DrugBank.d665.s7	the	106	108	O
DDI-DrugBank.d665.s7	serum	110	114	O
DDI-DrugBank.d665.s7	.	115	115	O
DDI-MedLine.d49.s0	Interaction	0	10	O
DDI-MedLine.d49.s0	of	12	13	O
DDI-MedLine.d49.s0	clindamycin	15	25	B-drug
DDI-MedLine.d49.s0	and	27	29	O
DDI-MedLine.d49.s0	gentamicin	31	40	B-drug
DDI-MedLine.d49.s0	in	39	40	I-drug
DDI-MedLine.d49.s0	vitro	45	49	O
DDI-MedLine.d49.s0	.	50	50	O
DDI-MedLine.d49.s1	The	0	2	O
DDI-MedLine.d49.s1	minimal	4	10	O
DDI-MedLine.d49.s1	inhibitory	12	21	O
DDI-MedLine.d49.s1	concentrations	23	36	O
DDI-MedLine.d49.s1	of	38	39	O
DDI-MedLine.d49.s1	clindamycin	41	51	B-drug
DDI-MedLine.d49.s1	and	53	55	O
DDI-MedLine.d49.s1	gentamicin	57	66	B-drug
DDI-MedLine.d49.s1	alone	68	72	O
DDI-MedLine.d49.s1	and	74	76	O
DDI-MedLine.d49.s1	in	78	79	O
DDI-MedLine.d49.s1	combinations	81	92	O
DDI-MedLine.d49.s1	were	94	97	O
DDI-MedLine.d49.s1	determined	99	108	O
DDI-MedLine.d49.s1	by	110	111	O
DDI-MedLine.d49.s1	a	113	113	O
DDI-MedLine.d49.s1	microdilution	115	127	O
DDI-MedLine.d49.s1	method	129	134	O
DDI-MedLine.d49.s1	for	136	138	O
DDI-MedLine.d49.s1	163	140	142	O
DDI-MedLine.d49.s1	aerobic	144	150	O
DDI-MedLine.d49.s1	,	151	151	O
DDI-MedLine.d49.s1	facultative	153	163	O
DDI-MedLine.d49.s1	,	151	151	O
DDI-MedLine.d49.s1	and	166	168	O
DDI-MedLine.d49.s1	anaerobic	170	178	O
DDI-MedLine.d49.s1	clinical	180	187	O
DDI-MedLine.d49.s1	isolates	189	196	O
DDI-MedLine.d49.s1	.	197	197	O
DDI-MedLine.d49.s2	All	0	2	O
DDI-MedLine.d49.s2	77	4	5	O
DDI-MedLine.d49.s2	strains	7	13	O
DDI-MedLine.d49.s2	of	15	16	O
DDI-MedLine.d49.s2	Staphylococcus	18	31	O
DDI-MedLine.d49.s2	aureus	33	38	O
DDI-MedLine.d49.s2	,	39	39	O
DDI-MedLine.d49.s2	Diplococcus	41	51	O
DDI-MedLine.d49.s2	pneumoniae	53	62	O
DDI-MedLine.d49.s2	,	63	63	O
DDI-MedLine.d49.s2	Streptococcus	65	77	O
DDI-MedLine.d49.s2	pyogenes	79	86	O
DDI-MedLine.d49.s2	,	87	87	O
DDI-MedLine.d49.s2	and	89	91	O
DDI-MedLine.d49.s2	anaerobic	93	101	O
DDI-MedLine.d49.s2	bacteria	103	110	O
DDI-MedLine.d49.s2	(	112	112	O
DDI-MedLine.d49.s2	except	113	118	O
DDI-MedLine.d49.s2	for	120	122	O
DDI-MedLine.d49.s2	three	124	128	O
DDI-MedLine.d49.s2	strains	130	136	O
DDI-MedLine.d49.s2	of	138	139	O
DDI-MedLine.d49.s2	Clostridium	141	151	O
DDI-MedLine.d49.s2	)	152	152	O
DDI-MedLine.d49.s2	were	154	157	O
DDI-MedLine.d49.s2	inhibited	159	167	O
DDI-MedLine.d49.s2	by	169	170	O
DDI-MedLine.d49.s2	1.6	172	174	O
DDI-MedLine.d49.s2	mug	176	178	O
DDI-MedLine.d49.s2	or	180	181	O
DDI-MedLine.d49.s2	less	183	186	O
DDI-MedLine.d49.s2	of	188	189	O
DDI-MedLine.d49.s2	clindamycin	191	201	B-drug
DDI-MedLine.d49.s2	per	203	205	O
DDI-MedLine.d49.s2	ml	207	208	O
DDI-MedLine.d49.s2	.	209	209	O
DDI-MedLine.d49.s3	Gentamicin	0	9	B-drug
DDI-MedLine.d49.s3	did	11	13	O
DDI-MedLine.d49.s3	not	15	17	O
DDI-MedLine.d49.s3	interfere	19	27	O
DDI-MedLine.d49.s3	with	29	32	O
DDI-MedLine.d49.s3	the	34	36	O
DDI-MedLine.d49.s3	activity	38	45	O
DDI-MedLine.d49.s3	of	47	48	O
DDI-MedLine.d49.s3	clindamycin	50	60	B-drug
DDI-MedLine.d49.s3	within	62	67	O
DDI-MedLine.d49.s3	the	69	71	O
DDI-MedLine.d49.s3	range	73	77	O
DDI-MedLine.d49.s3	of	79	80	O
DDI-MedLine.d49.s3	concentrations	82	95	O
DDI-MedLine.d49.s3	tested	97	102	O
DDI-MedLine.d49.s3	(	104	104	O
DDI-MedLine.d49.s3	0.1	105	107	O
DDI-MedLine.d49.s3	to	109	110	O
DDI-MedLine.d49.s3	100	112	114	O
DDI-MedLine.d49.s3	mug/ml	116	121	O
DDI-MedLine.d49.s3	)	122	122	O
DDI-MedLine.d49.s3	;	123	123	O
DDI-MedLine.d49.s4	for	0	2	O
DDI-MedLine.d49.s4	some	4	7	O
DDI-MedLine.d49.s4	strains	9	15	O
DDI-MedLine.d49.s4	combinations	17	28	O
DDI-MedLine.d49.s4	were	30	33	O
DDI-MedLine.d49.s4	synergistic	35	45	O
DDI-MedLine.d49.s4	.	46	46	O
DDI-MedLine.d49.s5	Sixty-two	0	8	O
DDI-MedLine.d49.s5	(	10	10	O
DDI-MedLine.d49.s5	94	11	12	O
DDI-MedLine.d49.s5	%	13	13	O
DDI-MedLine.d49.s5	)	14	14	O
DDI-MedLine.d49.s5	of	16	17	O
DDI-MedLine.d49.s5	66	19	20	O
DDI-MedLine.d49.s5	strains	22	28	O
DDI-MedLine.d49.s5	of	30	31	O
DDI-MedLine.d49.s5	Enterobacteriaceae	33	50	O
DDI-MedLine.d49.s5	and	52	54	O
DDI-MedLine.d49.s5	Pseudomonas	56	66	O
DDI-MedLine.d49.s5	aeruginosa	68	77	O
DDI-MedLine.d49.s5	were	79	82	O
DDI-MedLine.d49.s5	inhibited	84	92	O
DDI-MedLine.d49.s5	by	94	95	O
DDI-MedLine.d49.s5	6.2	97	99	O
DDI-MedLine.d49.s5	mug	101	103	O
DDI-MedLine.d49.s5	or	105	106	O
DDI-MedLine.d49.s5	less	108	111	O
DDI-MedLine.d49.s5	of	113	114	O
DDI-MedLine.d49.s5	gentamicin	116	125	B-drug
DDI-MedLine.d49.s5	per	127	129	O
DDI-MedLine.d49.s5	ml	131	132	O
DDI-MedLine.d49.s5	.	133	133	O
DDI-MedLine.d49.s6	Combinations	0	11	O
DDI-MedLine.d49.s6	of	13	14	O
DDI-MedLine.d49.s6	clindamycin	16	26	B-drug
DDI-MedLine.d49.s6	and	28	30	O
DDI-MedLine.d49.s6	gentamicin	32	41	B-drug
DDI-MedLine.d49.s6	were	43	46	O
DDI-MedLine.d49.s6	indifferent	48	58	O
DDI-MedLine.d49.s6	for	60	62	O
DDI-MedLine.d49.s6	29	64	65	O
DDI-MedLine.d49.s6	strains	67	73	O
DDI-MedLine.d49.s6	and	75	77	O
DDI-MedLine.d49.s6	synergistic	79	89	O
DDI-MedLine.d49.s6	for	91	93	O
DDI-MedLine.d49.s6	33	95	96	O
DDI-MedLine.d49.s6	strains	98	104	O
DDI-MedLine.d49.s6	.	105	105	O
DDI-MedLine.d49.s7	All	0	2	O
DDI-MedLine.d49.s7	20	4	5	O
DDI-MedLine.d49.s7	strains	7	13	O
DDI-MedLine.d49.s7	of	15	16	O
DDI-MedLine.d49.s7	enterococcus	18	29	O
DDI-MedLine.d49.s7	,	30	30	O
DDI-MedLine.d49.s7	three	32	36	O
DDI-MedLine.d49.s7	strains	38	44	O
DDI-MedLine.d49.s7	of	46	47	O
DDI-MedLine.d49.s7	Clostridium	49	59	O
DDI-MedLine.d49.s7	,	60	60	O
DDI-MedLine.d49.s7	three	62	66	O
DDI-MedLine.d49.s7	strains	68	74	O
DDI-MedLine.d49.s7	of	76	77	O
DDI-MedLine.d49.s7	Escherichia	79	89	O
DDI-MedLine.d49.s7	coli	91	94	O
DDI-MedLine.d49.s7	,	95	95	O
DDI-MedLine.d49.s7	and	97	99	O
DDI-MedLine.d49.s7	one	101	103	O
DDI-MedLine.d49.s7	strain	105	110	O
DDI-MedLine.d49.s7	of	112	113	O
DDI-MedLine.d49.s7	Proteus	115	121	O
DDI-MedLine.d49.s7	rettgeri	123	130	O
DDI-MedLine.d49.s7	were	132	135	O
DDI-MedLine.d49.s7	resistant	137	145	O
DDI-MedLine.d49.s7	to	147	148	O
DDI-MedLine.d49.s7	both	150	153	O
DDI-MedLine.d49.s7	clindamycin	155	165	B-drug
DDI-MedLine.d49.s7	(	167	167	O
DDI-MedLine.d49.s7	minimal	168	174	O
DDI-MedLine.d49.s7	inhibitory	176	185	O
DDI-MedLine.d49.s7	concentration	187	199	O
DDI-MedLine.d49.s7	greater	201	207	O
DDI-MedLine.d49.s7	than	209	212	O
DDI-MedLine.d49.s7	3.1	214	216	O
DDI-MedLine.d49.s7	mug/ml	218	223	O
DDI-MedLine.d49.s7	)	224	224	O
DDI-MedLine.d49.s7	and	226	228	O
DDI-MedLine.d49.s7	gentamicin	230	239	B-drug
DDI-MedLine.d49.s7	(	241	241	O
DDI-MedLine.d49.s7	minimal	242	248	O
DDI-MedLine.d49.s7	inhibitory	250	259	O
DDI-MedLine.d49.s7	concentration	261	273	O
DDI-MedLine.d49.s7	greater	275	281	O
DDI-MedLine.d49.s7	than	283	286	O
DDI-MedLine.d49.s7	6.2	288	290	O
DDI-MedLine.d49.s7	mug/ml	292	297	O
DDI-MedLine.d49.s7	)	298	298	O
DDI-MedLine.d49.s7	.	289	289	O
DDI-MedLine.d49.s8	Combinations	0	11	O
DDI-MedLine.d49.s8	of	13	14	O
DDI-MedLine.d49.s8	clindamycin	16	26	B-drug
DDI-MedLine.d49.s8	and	28	30	O
DDI-MedLine.d49.s8	gentamicin	32	41	B-drug
DDI-MedLine.d49.s8	were	43	46	O
DDI-MedLine.d49.s8	indifferent	48	58	O
DDI-MedLine.d49.s8	for	60	62	O
DDI-MedLine.d49.s8	16	64	65	O
DDI-MedLine.d49.s8	and	67	69	O
DDI-MedLine.d49.s8	synergistic	71	81	O
DDI-MedLine.d49.s8	for	83	85	O
DDI-MedLine.d49.s8	11	87	88	O
DDI-MedLine.d49.s8	of	90	91	O
DDI-MedLine.d49.s8	the	93	95	O
DDI-MedLine.d49.s8	resistant	97	105	O
DDI-MedLine.d49.s8	strains	107	113	O
DDI-MedLine.d49.s8	.	114	114	O
DDI-MedLine.d49.s9	Except	0	5	O
DDI-MedLine.d49.s9	for	7	9	O
DDI-MedLine.d49.s9	clindamycin-sensitive	11	31	O
DDI-MedLine.d49.s9	isolates	33	40	O
DDI-MedLine.d49.s9	,	41	41	O
DDI-MedLine.d49.s9	synergy	43	49	O
DDI-MedLine.d49.s9	was	51	53	O
DDI-MedLine.d49.s9	usually	55	61	O
DDI-MedLine.d49.s9	observed	63	70	O
DDI-MedLine.d49.s9	only	72	75	O
DDI-MedLine.d49.s9	at	77	78	O
DDI-MedLine.d49.s9	concentrations	80	93	O
DDI-MedLine.d49.s9	of	95	96	O
DDI-MedLine.d49.s9	one	98	100	O
DDI-MedLine.d49.s9	or	102	103	O
DDI-MedLine.d49.s9	both	105	108	O
DDI-MedLine.d49.s9	drugs	110	114	O
DDI-MedLine.d49.s9	which	116	120	O
DDI-MedLine.d49.s9	are	122	124	O
DDI-MedLine.d49.s9	not	126	128	O
DDI-MedLine.d49.s9	readily	130	136	O
DDI-MedLine.d49.s9	obtainable	138	147	O
DDI-MedLine.d49.s9	in	142	143	O
DDI-MedLine.d49.s9	vivo	152	155	O
DDI-MedLine.d49.s9	.	156	156	O
DDI-MedLine.d49.s10	Antagonism	0	9	O
DDI-MedLine.d49.s10	was	11	13	O
DDI-MedLine.d49.s10	never	15	19	O
DDI-MedLine.d49.s10	observed	21	28	O
DDI-MedLine.d49.s10	.	29	29	O
DDI-DrugBank.d443.s0	Uricosuric	0	9	B-group
DDI-DrugBank.d443.s0	Agents	11	16	I-group
DDI-DrugBank.d443.s0	:	17	17	O
DDI-DrugBank.d443.s0	Aspirin	19	25	B-brand
DDI-DrugBank.d443.s0	may	27	29	O
DDI-DrugBank.d443.s0	decrease	31	38	O
DDI-DrugBank.d443.s0	the	40	42	O
DDI-DrugBank.d443.s0	effects	44	50	O
DDI-DrugBank.d443.s0	of	52	53	O
DDI-DrugBank.d443.s0	probenecid	55	64	B-drug
DDI-DrugBank.d443.s0	,	65	65	O
DDI-DrugBank.d443.s0	sulfinpyrazone	67	80	B-drug
DDI-DrugBank.d443.s0	,	81	81	O
DDI-DrugBank.d443.s0	and	83	85	O
DDI-DrugBank.d443.s0	phenylbutazone	87	100	B-drug
DDI-DrugBank.d443.s0	.	101	101	O
DDI-DrugBank.d443.s1	Alcohol	0	6	B-drug
DDI-DrugBank.d443.s1	:	7	7	O
DDI-DrugBank.d443.s1	Has	9	11	O
DDI-DrugBank.d443.s1	a	13	13	O
DDI-DrugBank.d443.s1	synergistic	15	25	O
DDI-DrugBank.d443.s1	effect	27	32	O
DDI-DrugBank.d443.s1	with	34	37	O
DDI-DrugBank.d443.s1	aspirin	39	45	B-brand
DDI-DrugBank.d443.s1	in	44	45	I-brand
DDI-DrugBank.d443.s1	causing	50	56	O
DDI-DrugBank.d443.s1	gastrointestinal	58	73	O
DDI-DrugBank.d443.s1	bleeding	75	82	O
DDI-DrugBank.d443.s1	.	83	83	O
DDI-DrugBank.d443.s2	Corticosteroids	0	14	B-group
DDI-DrugBank.d443.s2	:	15	15	O
DDI-DrugBank.d443.s2	Concomitant	17	27	O
DDI-DrugBank.d443.s2	administration	29	42	O
DDI-DrugBank.d443.s2	with	44	47	O
DDI-DrugBank.d443.s2	aspirin	49	55	B-brand
DDI-DrugBank.d443.s2	may	57	59	O
DDI-DrugBank.d443.s2	increase	61	68	O
DDI-DrugBank.d443.s2	the	70	72	O
DDI-DrugBank.d443.s2	risk	74	77	O
DDI-DrugBank.d443.s2	of	79	80	O
DDI-DrugBank.d443.s2	gastrointestinal	82	97	O
DDI-DrugBank.d443.s2	ulceration	99	108	O
DDI-DrugBank.d443.s2	and	110	112	O
DDI-DrugBank.d443.s2	may	114	116	O
DDI-DrugBank.d443.s2	reduce	118	123	O
DDI-DrugBank.d443.s2	serum	125	129	O
DDI-DrugBank.d443.s2	salicylate	131	140	O
DDI-DrugBank.d443.s2	levels	142	147	O
DDI-DrugBank.d443.s2	.	148	148	O
DDI-DrugBank.d443.s3	Pyrazolone	0	9	B-group
DDI-DrugBank.d443.s3	Derivatives	11	21	I-group
DDI-DrugBank.d443.s3	(	23	23	O
DDI-DrugBank.d443.s3	phenylbutazone	24	37	B-drug
DDI-DrugBank.d443.s3	,	38	38	O
DDI-DrugBank.d443.s3	oxyphenbutazone	40	54	B-drug
DDI-DrugBank.d443.s3	,	55	55	O
DDI-DrugBank.d443.s3	and	57	59	O
DDI-DrugBank.d443.s3	possibly	61	68	O
DDI-DrugBank.d443.s3	dipyrone	70	77	B-drug
DDI-DrugBank.d443.s3	)	78	78	O
DDI-DrugBank.d443.s3	:	79	79	O
DDI-DrugBank.d443.s3	Concomitant	81	91	O
DDI-DrugBank.d443.s3	administration	93	106	O
DDI-DrugBank.d443.s3	with	108	111	O
DDI-DrugBank.d443.s3	aspirin	113	119	B-drug
DDI-DrugBank.d443.s3	may	121	123	O
DDI-DrugBank.d443.s3	increase	125	132	O
DDI-DrugBank.d443.s3	the	134	136	O
DDI-DrugBank.d443.s3	risk	138	141	O
DDI-DrugBank.d443.s3	of	143	144	O
DDI-DrugBank.d443.s3	gastrointestinal	146	161	O
DDI-DrugBank.d443.s3	ulceration	163	172	O
DDI-DrugBank.d443.s3	.	173	173	O
DDI-DrugBank.d443.s4	Nonsteroidal	0	11	B-drug
DDI-DrugBank.d443.s4	Antiinflammatory	13	28	I-drug
DDI-DrugBank.d443.s4	Agents	30	35	O
DDI-DrugBank.d443.s4	:	36	36	O
DDI-DrugBank.d443.s4	Aspirin	38	44	B-drug
DDI-DrugBank.d443.s4	is	46	47	O
DDI-DrugBank.d443.s4	contraindicated	49	63	O
DDI-DrugBank.d443.s4	in	65	66	O
DDI-DrugBank.d443.s4	patients	68	75	O
DDI-DrugBank.d443.s4	who	77	79	O
DDI-DrugBank.d443.s4	are	81	83	O
DDI-DrugBank.d443.s4	hypersensitive	85	98	O
DDI-DrugBank.d443.s4	to	100	101	O
DDI-DrugBank.d443.s4	nonsteroidal	103	114	B-drug
DDI-DrugBank.d443.s4	anti-inflammatory	116	132	I-drug
DDI-DrugBank.d443.s4	agents	134	139	O
DDI-DrugBank.d443.s4	.	140	140	O
DDI-DrugBank.d443.s5	Urinary	0	6	O
DDI-DrugBank.d443.s5	Alkalinizers	8	19	O
DDI-DrugBank.d443.s5	:	20	20	O
DDI-DrugBank.d443.s5	Decrease	22	29	O
DDI-DrugBank.d443.s5	aspirin	31	37	B-brand
DDI-DrugBank.d443.s5	effectiveness	39	51	O
DDI-DrugBank.d443.s5	by	53	54	O
DDI-DrugBank.d443.s5	increasing	56	65	O
DDI-DrugBank.d443.s5	the	67	69	O
DDI-DrugBank.d443.s5	rate	71	74	O
DDI-DrugBank.d443.s5	of	76	77	O
DDI-DrugBank.d443.s5	salicylate	79	88	B-group
DDI-DrugBank.d443.s5	renal	90	94	O
DDI-DrugBank.d443.s5	excretion	96	104	O
DDI-DrugBank.d443.s5	.	105	105	O
DDI-DrugBank.d443.s6	Phenobarbital	0	12	B-drug
DDI-DrugBank.d443.s6	:	13	13	O
DDI-DrugBank.d443.s6	Decreases	15	23	O
DDI-DrugBank.d443.s6	aspirin	25	31	B-brand
DDI-DrugBank.d443.s6	effectiveness	33	45	O
DDI-DrugBank.d443.s6	by	47	48	O
DDI-DrugBank.d443.s6	enzyme	50	55	O
DDI-DrugBank.d443.s6	induction	57	65	O
DDI-DrugBank.d443.s6	.	66	66	O
DDI-DrugBank.d443.s7	Phenytoin	0	8	B-drug
DDI-DrugBank.d443.s7	:	9	9	O
DDI-DrugBank.d443.s7	Serum	11	15	O
DDI-DrugBank.d443.s7	phenytoin	17	25	B-drug
DDI-DrugBank.d443.s7	levels	27	32	O
DDI-DrugBank.d443.s7	may	34	36	O
DDI-DrugBank.d443.s7	be	38	39	O
DDI-DrugBank.d443.s7	increased	41	49	O
DDI-DrugBank.d443.s7	by	51	52	O
DDI-DrugBank.d443.s7	aspirin	54	60	B-brand
DDI-DrugBank.d443.s7	.	61	61	O
DDI-DrugBank.d443.s8	Propranolol	0	10	B-drug
DDI-DrugBank.d443.s8	:	11	11	O
DDI-DrugBank.d443.s8	May	13	15	O
DDI-DrugBank.d443.s8	decrease	17	24	O
DDI-DrugBank.d443.s8	aspirins	26	33	B-brand
DDI-DrugBank.d443.s8	anti-inflammatory	35	51	O
DDI-DrugBank.d443.s8	action	53	58	O
DDI-DrugBank.d443.s8	by	60	61	O
DDI-DrugBank.d443.s8	competing	63	71	O
DDI-DrugBank.d443.s8	for	73	75	O
DDI-DrugBank.d443.s8	the	77	79	O
DDI-DrugBank.d443.s8	same	81	84	O
DDI-DrugBank.d443.s8	receptors	86	94	O
DDI-DrugBank.d443.s8	.	95	95	O
DDI-DrugBank.d443.s9	Antacids	0	7	B-group
DDI-DrugBank.d443.s9	:	8	8	O
DDI-DrugBank.d443.s9	Enteric	10	16	O
DDI-DrugBank.d443.s9	Coated	18	23	O
DDI-DrugBank.d443.s9	Aspirin	25	31	B-brand
DDI-DrugBank.d443.s9	should	33	38	O
DDI-DrugBank.d443.s9	not	40	42	O
DDI-DrugBank.d443.s9	be	44	45	O
DDI-DrugBank.d443.s9	given	47	51	O
DDI-DrugBank.d443.s9	concurrently	53	64	O
DDI-DrugBank.d443.s9	with	66	69	O
DDI-DrugBank.d443.s9	antacids	71	78	B-group
DDI-DrugBank.d443.s9	,	79	79	O
DDI-DrugBank.d443.s9	since	81	85	O
DDI-DrugBank.d443.s9	an	87	88	O
DDI-DrugBank.d443.s9	increase	90	97	O
DDI-DrugBank.d443.s9	in	90	91	O
DDI-DrugBank.d443.s9	the	102	104	O
DDI-DrugBank.d443.s9	pH	106	107	O
DDI-DrugBank.d443.s9	of	109	110	O
DDI-DrugBank.d443.s9	the	102	104	O
DDI-DrugBank.d443.s9	stomach	116	122	O
DDI-DrugBank.d443.s9	may	124	126	O
DDI-DrugBank.d443.s9	effect	128	133	O
DDI-DrugBank.d443.s9	the	135	137	O
DDI-DrugBank.d443.s9	enteric	139	145	O
DDI-DrugBank.d443.s9	coating	147	153	O
DDI-DrugBank.d443.s9	of	155	156	O
DDI-DrugBank.d443.s9	the	135	137	O
DDI-DrugBank.d443.s9	tablets	162	168	O
DDI-DrugBank.d443.s9	.	169	169	O
DDI-DrugBank.d352.s0	Antidiabetic	0	11	B-group
DDI-DrugBank.d352.s0	drug	13	16	I-group
DDI-DrugBank.d352.s0	requirements	18	29	O
DDI-DrugBank.d352.s0	(	31	31	O
DDI-DrugBank.d352.s0	i.e.	32	35	O
DDI-DrugBank.d352.s0	,	36	36	O
DDI-DrugBank.d352.s0	insulin	38	44	B-drug
DDI-DrugBank.d352.s0	)	45	45	O
DDI-DrugBank.d352.s0	may	47	49	O
DDI-DrugBank.d352.s0	be	51	52	O
DDI-DrugBank.d352.s0	altered	54	60	O
DDI-DrugBank.d352.s0	.	61	61	O
DDI-DrugBank.d352.s1	Concurrent	0	9	O
DDI-DrugBank.d352.s1	use	11	13	O
DDI-DrugBank.d352.s1	with	15	18	O
DDI-DrugBank.d352.s1	general	20	26	O
DDI-DrugBank.d352.s1	anesthetics	28	38	B-group
DDI-DrugBank.d352.s1	may	40	42	O
DDI-DrugBank.d352.s1	result	44	49	O
DDI-DrugBank.d352.s1	in	51	52	O
DDI-DrugBank.d352.s1	arrhythmias	54	64	O
DDI-DrugBank.d352.s1	.	65	65	O
DDI-DrugBank.d352.s2	The	0	2	O
DDI-DrugBank.d352.s2	pressor	4	10	O
DDI-DrugBank.d352.s2	effects	12	18	O
DDI-DrugBank.d352.s2	of	20	21	O
DDI-DrugBank.d352.s2	diethylpropion	23	36	B-drug
DDI-DrugBank.d352.s2	and	38	40	O
DDI-DrugBank.d352.s2	those	42	46	O
DDI-DrugBank.d352.s2	of	48	49	O
DDI-DrugBank.d352.s2	other	51	55	O
DDI-DrugBank.d352.s2	drugs	57	61	O
DDI-DrugBank.d352.s2	may	63	65	O
DDI-DrugBank.d352.s2	be	67	68	O
DDI-DrugBank.d352.s2	additive	70	77	O
DDI-DrugBank.d352.s2	when	79	82	O
DDI-DrugBank.d352.s2	the	84	86	O
DDI-DrugBank.d352.s2	drugs	88	92	O
DDI-DrugBank.d352.s2	are	94	96	O
DDI-DrugBank.d352.s2	used	98	101	O
DDI-DrugBank.d352.s2	concomitantly	103	115	O
DDI-DrugBank.d352.s2	;	116	116	O
DDI-DrugBank.d352.s3	conversely	0	9	O
DDI-DrugBank.d352.s3	,	10	10	O
DDI-DrugBank.d352.s3	diethylpropion	12	25	B-drug
DDI-DrugBank.d352.s3	may	27	29	O
DDI-DrugBank.d352.s3	interfere	31	39	O
DDI-DrugBank.d352.s3	with	41	44	O
DDI-DrugBank.d352.s3	antihypertensive	46	61	B-group
DDI-DrugBank.d352.s3	drugs	63	67	I-group
DDI-DrugBank.d352.s3	(	69	69	O
DDI-DrugBank.d352.s3	i.e.	70	73	O
DDI-DrugBank.d352.s3	,	74	74	O
DDI-DrugBank.d352.s3	guanethidine	76	87	B-drug
DDI-DrugBank.d352.s3	,	88	88	O
DDI-DrugBank.d352.s3	a-methyldopa	90	101	B-drug
DDI-DrugBank.d352.s3	)	102	102	O
DDI-DrugBank.d352.s3	.	103	103	O
DDI-DrugBank.d352.s4	Concurrent	0	9	O
DDI-DrugBank.d352.s4	use	11	13	O
DDI-DrugBank.d352.s4	of	15	16	O
DDI-DrugBank.d352.s4	phenothiazines	18	31	B-group
DDI-DrugBank.d352.s4	may	33	35	O
DDI-DrugBank.d352.s4	antagonize	37	46	O
DDI-DrugBank.d352.s4	the	48	50	O
DDI-DrugBank.d352.s4	anorectic	52	60	O
DDI-DrugBank.d352.s4	effect	62	67	O
DDI-DrugBank.d352.s4	of	69	70	O
DDI-DrugBank.d352.s4	diethylpropion	72	85	B-drug
DDI-DrugBank.d352.s4	.	86	86	O
DDI-MedLine.d102.s0	Influence	0	8	O
DDI-MedLine.d102.s0	of	10	11	O
DDI-MedLine.d102.s0	estradiol	13	21	B-drug
DDI-MedLine.d102.s0	and	23	25	O
DDI-MedLine.d102.s0	progesterone	27	38	B-drug
DDI-MedLine.d102.s0	on	36	37	I-drug
DDI-MedLine.d102.s0	the	43	45	O
DDI-MedLine.d102.s0	sensitivity	47	57	O
DDI-MedLine.d102.s0	of	59	60	O
DDI-MedLine.d102.s0	rat	62	64	O
DDI-MedLine.d102.s0	thoracic	66	73	O
DDI-MedLine.d102.s0	aorta	75	79	O
DDI-MedLine.d102.s0	to	81	82	O
DDI-MedLine.d102.s0	noradrenaline	84	96	B-drug
DDI-MedLine.d102.s0	.	97	97	O
DDI-MedLine.d102.s1	The	0	2	O
DDI-MedLine.d102.s1	aim	4	6	O
DDI-MedLine.d102.s1	of	8	9	O
DDI-MedLine.d102.s1	this	11	14	O
DDI-MedLine.d102.s1	study	16	20	O
DDI-MedLine.d102.s1	was	22	24	O
DDI-MedLine.d102.s1	to	26	27	O
DDI-MedLine.d102.s1	investigate	29	39	O
DDI-MedLine.d102.s1	the	41	43	O
DDI-MedLine.d102.s1	effects	45	51	O
DDI-MedLine.d102.s1	of	53	54	O
DDI-MedLine.d102.s1	low	56	58	O
DDI-MedLine.d102.s1	and	60	62	O
DDI-MedLine.d102.s1	high	64	67	O
DDI-MedLine.d102.s1	doses	69	73	O
DDI-MedLine.d102.s1	of	75	76	O
DDI-MedLine.d102.s1	estradiol	78	86	B-drug
DDI-MedLine.d102.s1	,	87	87	O
DDI-MedLine.d102.s1	and	89	91	O
DDI-MedLine.d102.s1	of	75	76	O
DDI-MedLine.d102.s1	progesterone	96	107	B-drug
DDI-MedLine.d102.s1	on	105	106	I-drug
DDI-MedLine.d102.s1	the	112	114	O
DDI-MedLine.d102.s1	response	116	123	O
DDI-MedLine.d102.s1	to	125	126	O
DDI-MedLine.d102.s1	noradrenaline	128	140	B-drug
DDI-MedLine.d102.s1	in	138	139	I-drug
DDI-MedLine.d102.s1	rat	145	147	O
DDI-MedLine.d102.s1	thoracic	149	156	O
DDI-MedLine.d102.s1	aorta	158	162	O
DDI-MedLine.d102.s1	.	163	163	O
DDI-MedLine.d102.s2	Two	0	2	O
DDI-MedLine.d102.s2	weeks	4	8	O
DDI-MedLine.d102.s2	after	10	14	O
DDI-MedLine.d102.s2	bilateral	16	24	O
DDI-MedLine.d102.s2	ovariectomy	26	36	O
DDI-MedLine.d102.s2	,	37	37	O
DDI-MedLine.d102.s2	female	39	44	O
DDI-MedLine.d102.s2	rats	46	49	O
DDI-MedLine.d102.s2	received	51	58	O
DDI-MedLine.d102.s2	a	60	60	O
DDI-MedLine.d102.s2	s.c	62	64	O
DDI-MedLine.d102.s2	.	63	63	O
DDI-MedLine.d102.s3	injection	0	8	O
DDI-MedLine.d102.s3	of	10	11	O
DDI-MedLine.d102.s3	vehicle	13	19	O
DDI-MedLine.d102.s3	(	21	21	O
DDI-MedLine.d102.s3	corn	22	25	O
DDI-MedLine.d102.s3	oil	27	29	O
DDI-MedLine.d102.s3	,	30	30	O
DDI-MedLine.d102.s3	0.1	32	34	O
DDI-MedLine.d102.s3	mL/day	36	41	O
DDI-MedLine.d102.s3	)	42	42	O
DDI-MedLine.d102.s3	,	43	43	O
DDI-MedLine.d102.s3	estradiol	45	53	B-drug
DDI-MedLine.d102.s3	(	55	55	O
DDI-MedLine.d102.s3	10	56	57	O
DDI-MedLine.d102.s3	microg/kg/day	59	71	O
DDI-MedLine.d102.s3	or	73	74	O
DDI-MedLine.d102.s3	4	76	76	O
DDI-MedLine.d102.s3	mg/kg/day	78	86	O
DDI-MedLine.d102.s3	)	87	87	O
DDI-MedLine.d102.s3	and/or	89	94	O
DDI-MedLine.d102.s3	progesterone	96	107	B-drug
DDI-MedLine.d102.s3	(	109	109	O
DDI-MedLine.d102.s3	20	110	111	O
DDI-MedLine.d102.s3	mg/kg/day	113	121	O
DDI-MedLine.d102.s3	)	122	122	O
DDI-MedLine.d102.s3	,	123	123	O
DDI-MedLine.d102.s3	for	125	127	O
DDI-MedLine.d102.s3	eight	129	133	O
DDI-MedLine.d102.s3	days	135	138	O
DDI-MedLine.d102.s3	.	139	139	O
DDI-MedLine.d102.s4	On	0	1	O
DDI-MedLine.d102.s4	the	3	5	O
DDI-MedLine.d102.s4	ninth	7	11	O
DDI-MedLine.d102.s4	day	13	15	O
DDI-MedLine.d102.s4	,	16	16	O
DDI-MedLine.d102.s4	the	18	20	O
DDI-MedLine.d102.s4	rats	22	25	O
DDI-MedLine.d102.s4	were	27	30	O
DDI-MedLine.d102.s4	sacrificed	32	41	O
DDI-MedLine.d102.s4	and	43	45	O
DDI-MedLine.d102.s4	aortic	47	52	O
DDI-MedLine.d102.s4	rings	54	58	O
DDI-MedLine.d102.s4	,	59	59	O
DDI-MedLine.d102.s4	with	61	64	O
DDI-MedLine.d102.s4	or	66	67	O
DDI-MedLine.d102.s4	without	69	75	O
DDI-MedLine.d102.s4	endothelium	77	87	O
DDI-MedLine.d102.s4	,	88	88	O
DDI-MedLine.d102.s4	were	90	93	O
DDI-MedLine.d102.s4	used	95	98	O
DDI-MedLine.d102.s4	to	100	101	O
DDI-MedLine.d102.s4	generate	103	110	O
DDI-MedLine.d102.s4	concentration-response	112	133	O
DDI-MedLine.d102.s4	curves	135	140	O
DDI-MedLine.d102.s4	to	142	143	O
DDI-MedLine.d102.s4	noradrenaline	145	157	B-drug
DDI-MedLine.d102.s4	.	158	158	O
DDI-MedLine.d102.s5	Aortic	0	5	O
DDI-MedLine.d102.s5	rings	7	11	O
DDI-MedLine.d102.s5	with	13	16	O
DDI-MedLine.d102.s5	intact	18	23	O
DDI-MedLine.d102.s5	endothelium	25	35	O
DDI-MedLine.d102.s5	from	37	40	O
DDI-MedLine.d102.s5	the	42	44	O
DDI-MedLine.d102.s5	high-dose	46	54	O
DDI-MedLine.d102.s5	(	56	56	O
DDI-MedLine.d102.s5	4	57	57	O
DDI-MedLine.d102.s5	mg/kg/day	59	67	O
DDI-MedLine.d102.s5	)	68	68	O
DDI-MedLine.d102.s5	estradiol	70	78	B-drug
DDI-MedLine.d102.s5	group	80	84	O
DDI-MedLine.d102.s5	were	86	89	O
DDI-MedLine.d102.s5	supersensitive	91	104	O
DDI-MedLine.d102.s5	to	106	107	O
DDI-MedLine.d102.s5	noradrenaline	109	121	B-drug
DDI-MedLine.d102.s5	compared	123	130	O
DDI-MedLine.d102.s5	to	132	133	O
DDI-MedLine.d102.s5	the	135	137	O
DDI-MedLine.d102.s5	vehicle	139	145	O
DDI-MedLine.d102.s5	or	147	148	O
DDI-MedLine.d102.s5	low-dose	150	157	O
DDI-MedLine.d102.s5	(	159	159	O
DDI-MedLine.d102.s5	10	160	161	O
DDI-MedLine.d102.s5	microg/kg/day	163	175	O
DDI-MedLine.d102.s5	)	176	176	O
DDI-MedLine.d102.s5	estradiol	178	186	O
DDI-MedLine.d102.s5	groups	188	193	O
DDI-MedLine.d102.s5	(	195	195	O
DDI-MedLine.d102.s5	pD2	196	198	O
DDI-MedLine.d102.s5	values	200	205	O
DDI-MedLine.d102.s5	=	207	207	O
DDI-MedLine.d102.s5	7.86+/-0.09	209	219	O
DDI-MedLine.d102.s5	,	220	220	O
DDI-MedLine.d102.s5	7.30+/-0.11	222	232	O
DDI-MedLine.d102.s5	and	234	236	O
DDI-MedLine.d102.s5	7.35+/-0.04	238	248	O
DDI-MedLine.d102.s5	,	220	220	O
DDI-MedLine.d102.s5	respectively	251	262	O
DDI-MedLine.d102.s5	)	263	263	O
DDI-MedLine.d102.s5	.	239	239	O
DDI-MedLine.d102.s6	Endothelium-intact	0	17	O
DDI-MedLine.d102.s6	aortic	19	24	O
DDI-MedLine.d102.s6	rings	26	30	O
DDI-MedLine.d102.s6	from	32	35	O
DDI-MedLine.d102.s6	high-estradiol	37	50	O
DDI-MedLine.d102.s6	rats	52	55	O
DDI-MedLine.d102.s6	were	57	60	O
DDI-MedLine.d102.s6	supersensitive	62	75	O
DDI-MedLine.d102.s6	to	77	78	O
DDI-MedLine.d102.s6	noradrenaline	80	92	B-drug
DDI-MedLine.d102.s6	when	94	97	O
DDI-MedLine.d102.s6	compared	99	106	O
DDI-MedLine.d102.s6	to	108	109	O
DDI-MedLine.d102.s6	vehicle-	111	118	O
DDI-MedLine.d102.s6	,	119	119	O
DDI-MedLine.d102.s6	progesterone-	121	133	O
DDI-MedLine.d102.s6	and	135	137	O
DDI-MedLine.d102.s6	progesterone	139	150	B-drug
DDI-MedLine.d102.s6	+	152	152	O
DDI-MedLine.d102.s6	high-estradiol-treated	154	175	O
DDI-MedLine.d102.s6	rats	177	180	O
DDI-MedLine.d102.s6	(	182	182	O
DDI-MedLine.d102.s6	pD2	183	185	O
DDI-MedLine.d102.s6	values	187	192	O
DDI-MedLine.d102.s6	=	194	194	O
DDI-MedLine.d102.s6	7.77+/-0.12	196	206	O
DDI-MedLine.d102.s6	,	207	207	O
DDI-MedLine.d102.s6	7.21+/-0.13	209	219	O
DDI-MedLine.d102.s6	,	207	207	O
DDI-MedLine.d102.s6	6.93+/-0.04	222	232	O
DDI-MedLine.d102.s6	and	234	236	O
DDI-MedLine.d102.s6	7.22+/-0.18	238	248	O
DDI-MedLine.d102.s6	,	249	249	O
DDI-MedLine.d102.s6	respectively	251	262	O
DDI-MedLine.d102.s6	)	263	263	O
DDI-MedLine.d102.s6	.	239	239	O
DDI-MedLine.d102.s7	There	0	4	O
DDI-MedLine.d102.s7	were	6	9	O
DDI-MedLine.d102.s7	no	11	12	O
DDI-MedLine.d102.s7	significant	14	24	O
DDI-MedLine.d102.s7	differences	26	36	O
DDI-MedLine.d102.s7	among	38	42	O
DDI-MedLine.d102.s7	the	44	46	O
DDI-MedLine.d102.s7	pD2	48	50	O
DDI-MedLine.d102.s7	values	52	57	O
DDI-MedLine.d102.s7	for	59	61	O
DDI-MedLine.d102.s7	noradrenaline	63	75	B-drug
DDI-MedLine.d102.s7	in	73	74	I-drug
DDI-MedLine.d102.s7	aortic	80	85	O
DDI-MedLine.d102.s7	rings	87	91	O
DDI-MedLine.d102.s7	without	93	99	O
DDI-MedLine.d102.s7	endothelium	101	111	O
DDI-MedLine.d102.s7	.	112	112	O
DDI-MedLine.d102.s8	Both	0	3	O
DDI-MedLine.d102.s8	of	5	6	O
DDI-MedLine.d102.s8	these	8	12	O
DDI-MedLine.d102.s8	effects	14	20	O
DDI-MedLine.d102.s8	were	22	25	O
DDI-MedLine.d102.s8	endothelium-dependent	27	47	O
DDI-MedLine.d102.s8	.	48	48	O
DDI-DrugBank.d46.s0	When	0	3	O
DDI-DrugBank.d46.s0	given	5	9	O
DDI-DrugBank.d46.s0	concurrently	11	22	O
DDI-DrugBank.d46.s0	the	24	26	O
DDI-DrugBank.d46.s0	following	28	36	O
DDI-DrugBank.d46.s0	drugs	38	42	O
DDI-DrugBank.d46.s0	may	44	46	O
DDI-DrugBank.d46.s0	interact	48	55	O
DDI-DrugBank.d46.s0	with	57	60	O
DDI-DrugBank.d46.s0	thiazide	62	69	B-group
DDI-DrugBank.d46.s0	diuretics	71	79	I-group
DDI-DrugBank.d46.s0	.	80	80	O
DDI-DrugBank.d46.s1	-	0	0	O
DDI-DrugBank.d46.s1	Alcohol	2	8	B-drug
DDI-DrugBank.d46.s1	,	9	9	O
DDI-DrugBank.d46.s1	barbiturates	11	22	B-group
DDI-DrugBank.d46.s1	,	23	23	O
DDI-DrugBank.d46.s1	or	25	26	O
DDI-DrugBank.d46.s1	narcotics	28	36	B-group
DDI-DrugBank.d46.s1	:	37	37	O
DDI-DrugBank.d46.s1	Potentiation	39	50	O
DDI-DrugBank.d46.s1	of	52	53	O
DDI-DrugBank.d46.s1	otthostatic	55	65	O
DDI-DrugBank.d46.s1	hypotension	67	77	O
DDI-DrugBank.d46.s1	may	79	81	O
DDI-DrugBank.d46.s1	occur	83	87	O
DDI-DrugBank.d46.s2	.	0	0	O
DDI-DrugBank.d46.s3	-	0	0	O
DDI-DrugBank.d46.s3	Antidiabetic	2	13	B-group
DDI-DrugBank.d46.s3	drugs	15	19	I-group
DDI-DrugBank.d46.s3	:	20	20	O
DDI-DrugBank.d46.s3	(	22	22	O
DDI-DrugBank.d46.s3	Oral	23	26	O
DDI-DrugBank.d46.s3	agents	28	33	O
DDI-DrugBank.d46.s3	and	35	37	O
DDI-DrugBank.d46.s3	insulin	39	45	B-drug
DDI-DrugBank.d46.s3	)	46	46	O
DDI-DrugBank.d46.s3	Dosage	48	53	O
DDI-DrugBank.d46.s3	adjustment	55	64	O
DDI-DrugBank.d46.s3	of	66	67	O
DDI-DrugBank.d46.s3	the	69	71	O
DDI-DrugBank.d46.s3	antidiabetic	73	84	B-group
DDI-DrugBank.d46.s3	drug	86	89	I-group
DDI-DrugBank.d46.s3	may	91	93	O
DDI-DrugBank.d46.s3	be	95	96	O
DDI-DrugBank.d46.s3	required	98	105	O
DDI-DrugBank.d46.s4	.	0	0	O
DDI-DrugBank.d46.s5	-	0	0	O
DDI-DrugBank.d46.s5	Other	2	6	O
DDI-DrugBank.d46.s5	antihypertensive	8	23	B-group
DDI-DrugBank.d46.s5	drugs	25	29	I-group
DDI-DrugBank.d46.s5	:	30	30	O
DDI-DrugBank.d46.s5	Additive	32	39	O
DDI-DrugBank.d46.s5	effect	41	46	O
DDI-DrugBank.d46.s5	or	48	49	O
DDI-DrugBank.d46.s5	potentiation	51	62	O
DDI-DrugBank.d46.s6	.	0	0	O
DDI-DrugBank.d46.s7	-	0	0	O
DDI-DrugBank.d46.s7	Cholestyramine	2	15	B-drug
DDI-DrugBank.d46.s7	and	17	19	O
DDI-DrugBank.d46.s7	colestipol	21	30	B-drug
DDI-DrugBank.d46.s7	resins	32	37	B-group
DDI-DrugBank.d46.s7	:	38	38	O
DDI-DrugBank.d46.s7	Cholestytamine	40	53	B-drug
DDI-DrugBank.d46.s7	and	55	57	O
DDI-DrugBank.d46.s7	colestipol	59	68	B-drug
DDI-DrugBank.d46.s7	resins	70	75	B-group
DDI-DrugBank.d46.s7	have	77	80	O
DDI-DrugBank.d46.s7	the	82	84	O
DDI-DrugBank.d46.s7	potential	86	94	O
DDI-DrugBank.d46.s7	of	96	97	O
DDI-DrugBank.d46.s7	binding	99	105	O
DDI-DrugBank.d46.s7	thiazide	107	114	B-group
DDI-DrugBank.d46.s7	diuretics	116	124	I-group
DDI-DrugBank.d46.s7	and	126	128	O
DDI-DrugBank.d46.s7	reducing	130	137	O
DDI-DrugBank.d46.s7	diuretic	139	146	B-group
DDI-DrugBank.d46.s7	absorption	148	157	O
DDI-DrugBank.d46.s7	from	159	162	O
DDI-DrugBank.d46.s7	the	164	166	O
DDI-DrugBank.d46.s7	gastrointestinal	168	183	O
DDI-DrugBank.d46.s7	tract	185	189	O
DDI-DrugBank.d46.s8	.	0	0	O
DDI-DrugBank.d46.s9	-	0	0	O
DDI-DrugBank.d46.s9	Corticosteroids	2	16	B-group
DDI-DrugBank.d46.s9	,	17	17	O
DDI-DrugBank.d46.s9	ACTH	19	22	B-drug
DDI-DrugBank.d46.s9	:	23	23	O
DDI-DrugBank.d46.s9	Intensified	25	35	O
DDI-DrugBank.d46.s9	electrolyte	37	47	O
DDI-DrugBank.d46.s9	depletion	49	57	O
DDI-DrugBank.d46.s9	,	58	58	O
DDI-DrugBank.d46.s9	particularly	60	71	O
DDI-DrugBank.d46.s9	hypokalemia	73	83	O
DDI-DrugBank.d46.s10	.	0	0	O
DDI-DrugBank.d46.s11	-	0	0	O
DDI-DrugBank.d46.s11	Pressor	2	8	O
DDI-DrugBank.d46.s11	amines	10	15	O
DDI-DrugBank.d46.s11	(	17	17	O
DDI-DrugBank.d46.s11	e.g.	18	21	O
DDI-DrugBank.d46.s11	,	22	22	O
DDI-DrugBank.d46.s11	norepinephrine	24	37	B-drug
DDI-DrugBank.d46.s11	)	38	38	O
DDI-DrugBank.d46.s11	:	39	39	O
DDI-DrugBank.d46.s11	Possible	41	48	O
DDI-DrugBank.d46.s11	decreased	50	58	O
DDI-DrugBank.d46.s11	response	60	67	O
DDI-DrugBank.d46.s11	to	69	70	O
DDI-DrugBank.d46.s11	pressor	72	78	O
DDI-DrugBank.d46.s11	amines	80	85	O
DDI-DrugBank.d46.s11	but	87	89	O
DDI-DrugBank.d46.s11	not	91	93	O
DDI-DrugBank.d46.s11	sufficient	95	104	O
DDI-DrugBank.d46.s11	to	106	107	O
DDI-DrugBank.d46.s11	preclude	109	116	O
DDI-DrugBank.d46.s11	their	118	122	O
DDI-DrugBank.d46.s11	use	124	126	O
DDI-DrugBank.d46.s12	.	0	0	O
DDI-DrugBank.d46.s13	-	0	0	O
DDI-DrugBank.d46.s13	Skeletal	2	9	B-group
DDI-DrugBank.d46.s13	muscle	11	16	I-group
DDI-DrugBank.d46.s13	relaxants	18	26	I-group
DDI-DrugBank.d46.s13	,	27	27	O
DDI-DrugBank.d46.s13	nondepolarizing	29	43	O
DDI-DrugBank.d46.s13	(	45	45	O
DDI-DrugBank.d46.s13	e.g.	46	49	O
DDI-DrugBank.d46.s13	,	50	50	O
DDI-DrugBank.d46.s13	tubocurarine	52	63	B-drug
DDI-DrugBank.d46.s13	)	64	64	O
DDI-DrugBank.d46.s13	:	65	65	O
DDI-DrugBank.d46.s13	Possible	67	74	O
DDI-DrugBank.d46.s13	increased	76	84	O
DDI-DrugBank.d46.s13	responsiveness	86	99	O
DDI-DrugBank.d46.s13	to	101	102	O
DDI-DrugBank.d46.s13	the	104	106	O
DDI-DrugBank.d46.s13	muscle	108	113	B-group
DDI-DrugBank.d46.s13	relaxant	115	122	I-group
DDI-DrugBank.d46.s14	.	0	0	O
DDI-DrugBank.d46.s15	-	0	0	O
DDI-DrugBank.d46.s15	Lithium	2	8	B-drug
DDI-DrugBank.d46.s15	:	9	9	O
DDI-DrugBank.d46.s15	Generally	11	19	O
DDI-DrugBank.d46.s15	should	21	26	O
DDI-DrugBank.d46.s15	not	28	30	O
DDI-DrugBank.d46.s15	be	32	33	O
DDI-DrugBank.d46.s15	given	35	39	O
DDI-DrugBank.d46.s15	with	41	44	O
DDI-DrugBank.d46.s15	diuretics	46	54	B-group
DDI-DrugBank.d46.s15	.	55	55	O
DDI-DrugBank.d46.s16	Diuretic	0	7	B-group
DDI-DrugBank.d46.s16	agents	9	14	I-group
DDI-DrugBank.d46.s16	reduce	16	21	O
DDI-DrugBank.d46.s16	the	23	25	O
DDI-DrugBank.d46.s16	renal	27	31	O
DDI-DrugBank.d46.s16	clearance	33	41	O
DDI-DrugBank.d46.s16	of	43	44	O
DDI-DrugBank.d46.s16	lithium	46	52	B-drug
DDI-DrugBank.d46.s16	and	54	56	O
DDI-DrugBank.d46.s16	add	58	60	O
DDI-DrugBank.d46.s16	a	54	54	O
DDI-DrugBank.d46.s16	high	64	67	O
DDI-DrugBank.d46.s16	risk	69	72	O
DDI-DrugBank.d46.s16	of	74	75	O
DDI-DrugBank.d46.s16	lithium	77	83	B-drug
DDI-DrugBank.d46.s16	toxicity	85	92	O
DDI-DrugBank.d46.s16	.	93	93	O
DDI-DrugBank.d46.s17	Refer	0	4	O
DDI-DrugBank.d46.s17	to	6	7	O
DDI-DrugBank.d46.s17	the	9	11	O
DDI-DrugBank.d46.s17	package	13	19	O
DDI-DrugBank.d46.s17	insert	21	26	O
DDI-DrugBank.d46.s17	for	28	30	O
DDI-DrugBank.d46.s17	lithium	32	38	B-drug
DDI-DrugBank.d46.s17	preparations	40	51	O
DDI-DrugBank.d46.s17	before	53	58	O
DDI-DrugBank.d46.s17	use	60	62	O
DDI-DrugBank.d46.s17	of	64	65	O
DDI-DrugBank.d46.s17	such	67	70	O
DDI-DrugBank.d46.s17	preparations	72	83	O
DDI-DrugBank.d46.s17	with	85	88	O
DDI-DrugBank.d46.s17	chlorothiazide	90	103	B-drug
DDI-DrugBank.d46.s18	.	0	0	O
DDI-DrugBank.d46.s19	-	0	0	O
DDI-DrugBank.d46.s19	Non-steroidal	2	14	B-group
DDI-DrugBank.d46.s19	Anti-inflammatory	16	32	I-group
DDI-DrugBank.d46.s19	Drugs	34	38	I-group
DDI-DrugBank.d46.s19	:	39	39	O
DDI-DrugBank.d46.s19	In	41	42	O
DDI-DrugBank.d46.s19	some	44	47	O
DDI-DrugBank.d46.s19	patients	49	56	O
DDI-DrugBank.d46.s19	,	57	57	O
DDI-DrugBank.d46.s19	the	59	61	O
DDI-DrugBank.d46.s19	administration	63	76	O
DDI-DrugBank.d46.s19	of	78	79	O
DDI-DrugBank.d46.s19	a	72	72	O
DDI-DrugBank.d46.s19	non-steroidal	83	95	B-group
DDI-DrugBank.d46.s19	anti-inflammatory	97	113	I-group
DDI-DrugBank.d46.s19	agent	115	119	I-group
DDI-DrugBank.d46.s19	can	121	123	O
DDI-DrugBank.d46.s19	reduce	125	130	O
DDI-DrugBank.d46.s19	the	132	134	O
DDI-DrugBank.d46.s19	diuretic	136	143	O
DDI-DrugBank.d46.s19	,	144	144	O
DDI-DrugBank.d46.s19	natriuretic	146	156	O
DDI-DrugBank.d46.s19	,	144	144	O
DDI-DrugBank.d46.s19	and	159	161	O
DDI-DrugBank.d46.s19	antihypertensive	163	178	O
DDI-DrugBank.d46.s19	effects	180	186	O
DDI-DrugBank.d46.s19	of	188	189	O
DDI-DrugBank.d46.s19	loop	191	194	B-group
DDI-DrugBank.d46.s19	,	195	195	O
DDI-DrugBank.d46.s19	potassium-sparing	197	213	B-group
DDI-DrugBank.d46.s19	and	215	217	O
DDI-DrugBank.d46.s19	thiazide	219	226	B-drug
DDI-DrugBank.d46.s19	diuretics	228	236	I-drug
DDI-DrugBank.d46.s19	.	237	237	O
DDI-DrugBank.d46.s20	Therefore	0	8	O
DDI-DrugBank.d46.s20	,	9	9	O
DDI-DrugBank.d46.s20	when	11	14	O
DDI-DrugBank.d46.s20	chlorothiazide	16	29	B-drug
DDI-DrugBank.d46.s20	and	31	33	O
DDI-DrugBank.d46.s20	non-steroidal	35	47	B-group
DDI-DrugBank.d46.s20	anti-inflammatory	49	65	I-group
DDI-DrugBank.d46.s20	agents	67	72	I-group
DDI-DrugBank.d46.s20	are	74	76	O
DDI-DrugBank.d46.s20	used	78	81	O
DDI-DrugBank.d46.s20	concomitantly	83	95	O
DDI-DrugBank.d46.s20	,	96	96	O
DDI-DrugBank.d46.s20	the	98	100	O
DDI-DrugBank.d46.s20	patient	102	108	O
DDI-DrugBank.d46.s20	should	110	115	O
DDI-DrugBank.d46.s20	be	117	118	O
DDI-DrugBank.d46.s20	observed	120	127	O
DDI-DrugBank.d46.s20	closely	129	135	O
DDI-DrugBank.d46.s20	to	137	138	O
DDI-DrugBank.d46.s20	determine	140	148	O
DDI-DrugBank.d46.s20	if	150	151	O
DDI-DrugBank.d46.s20	the	153	155	O
DDI-DrugBank.d46.s20	desired	157	163	O
DDI-DrugBank.d46.s20	effect	165	170	O
DDI-DrugBank.d46.s20	of	172	173	O
DDI-DrugBank.d46.s20	the	153	155	O
DDI-DrugBank.d46.s20	diuretic	179	186	B-group
DDI-DrugBank.d46.s20	is	188	189	O
DDI-DrugBank.d46.s20	obtained	191	198	O
DDI-DrugBank.d46.s21	.	0	0	O
DDI-DrugBank.d46.s22	-	0	0	O
DDI-DrugBank.d46.s22	Drug/Laboratory	2	16	O
DDI-DrugBank.d46.s22	Test	18	21	O
DDI-DrugBank.d46.s22	Interactions	23	34	O
DDI-DrugBank.d46.s22	:	35	35	O
DDI-DrugBank.d46.s22	Thiazides	37	45	B-group
DDI-DrugBank.d46.s22	should	47	52	O
DDI-DrugBank.d46.s22	be	54	55	O
DDI-DrugBank.d46.s22	discontinued	57	68	O
DDI-DrugBank.d46.s22	before	70	75	O
DDI-DrugBank.d46.s22	carrying	77	84	O
DDI-DrugBank.d46.s22	out	86	88	O
DDI-DrugBank.d46.s22	tests	90	94	O
DDI-DrugBank.d46.s22	for	96	98	O
DDI-DrugBank.d46.s22	parathyroid	100	110	O
DDI-DrugBank.d46.s22	function	112	119	O
DDI-DrugBank.d46.s22	.	120	120	O
DDI-DrugBank.d485.s0	Ethinyl	0	6	B-drug
DDI-DrugBank.d485.s0	estradiol	8	16	I-drug
DDI-DrugBank.d485.s0	:	17	17	O
DDI-DrugBank.d485.s0	Substrate	19	27	O
DDI-DrugBank.d485.s0	of	29	30	O
DDI-DrugBank.d485.s0	CYP3A4	32	37	O
DDI-DrugBank.d485.s0	(	39	39	O
DDI-DrugBank.d485.s0	major	40	44	O
DDI-DrugBank.d485.s0	)	45	45	O
DDI-DrugBank.d485.s0	,	46	46	O
DDI-DrugBank.d485.s0	3A5-7	48	52	O
DDI-DrugBank.d485.s0	(	54	54	O
DDI-DrugBank.d485.s0	minor	55	59	O
DDI-DrugBank.d485.s0	)	60	60	O
DDI-DrugBank.d485.s0	;	61	61	O
DDI-DrugBank.d485.s1	Inhibits	0	7	O
DDI-DrugBank.d485.s1	CYP1A2	9	14	O
DDI-DrugBank.d485.s1	(	16	16	O
DDI-DrugBank.d485.s1	weak	17	20	O
DDI-DrugBank.d485.s1	)	21	21	O
DDI-DrugBank.d485.s1	,	22	22	O
DDI-DrugBank.d485.s1	2B6	24	26	O
DDI-DrugBank.d485.s1	(	28	28	O
DDI-DrugBank.d485.s1	weak	29	32	O
DDI-DrugBank.d485.s1	)	33	33	O
DDI-DrugBank.d485.s1	,	34	34	O
DDI-DrugBank.d485.s1	2C19	36	39	O
DDI-DrugBank.d485.s1	(	41	41	O
DDI-DrugBank.d485.s1	weak	42	45	O
DDI-DrugBank.d485.s1	)	46	46	O
DDI-DrugBank.d485.s1	,	47	47	O
DDI-DrugBank.d485.s1	3A4	49	51	O
DDI-DrugBank.d485.s1	(	53	53	O
DDI-DrugBank.d485.s1	weak	54	57	O
DDI-DrugBank.d485.s1	)	58	58	O
DDI-DrugBank.d485.s1	.	59	59	O
DDI-DrugBank.d485.s2	Acetaminophen	0	12	B-drug
DDI-DrugBank.d485.s2	:	13	13	O
DDI-DrugBank.d485.s2	May	15	17	O
DDI-DrugBank.d485.s2	increase	19	26	O
DDI-DrugBank.d485.s2	plasma	28	33	O
DDI-DrugBank.d485.s2	concentration	35	47	O
DDI-DrugBank.d485.s2	of	49	50	O
DDI-DrugBank.d485.s2	synthetic	52	60	B-group
DDI-DrugBank.d485.s2	estrogens	62	70	I-group
DDI-DrugBank.d485.s2	,	71	71	O
DDI-DrugBank.d485.s2	possibly	73	80	O
DDI-DrugBank.d485.s2	by	82	83	O
DDI-DrugBank.d485.s2	inhibiting	85	94	O
DDI-DrugBank.d485.s2	conjugation	96	106	O
DDI-DrugBank.d485.s2	.	107	107	O
DDI-DrugBank.d485.s3	Combination	0	10	O
DDI-DrugBank.d485.s3	hormonal	12	19	B-group
DDI-DrugBank.d485.s3	contraceptives	21	34	I-group
DDI-DrugBank.d485.s3	may	36	38	O
DDI-DrugBank.d485.s3	also	40	43	O
DDI-DrugBank.d485.s3	decrease	45	52	O
DDI-DrugBank.d485.s3	the	54	56	O
DDI-DrugBank.d485.s3	plasma	58	63	O
DDI-DrugBank.d485.s3	concentration	65	77	O
DDI-DrugBank.d485.s3	of	79	80	O
DDI-DrugBank.d485.s3	acetaminophen	82	94	B-drug
DDI-DrugBank.d485.s3	.	95	95	O
DDI-DrugBank.d485.s4	Acitretin	0	8	B-drug
DDI-DrugBank.d485.s4	:	9	9	O
DDI-DrugBank.d485.s4	Interferes	11	20	O
DDI-DrugBank.d485.s4	with	22	25	O
DDI-DrugBank.d485.s4	the	27	29	O
DDI-DrugBank.d485.s4	contraceptive	31	43	O
DDI-DrugBank.d485.s4	effect	45	50	O
DDI-DrugBank.d485.s4	of	52	53	O
DDI-DrugBank.d485.s4	microdosed	55	64	O
DDI-DrugBank.d485.s4	progestin-containing	66	85	O
DDI-DrugBank.d485.s4	minipill	87	94	O
DDI-DrugBank.d485.s4	preparations	96	107	O
DDI-DrugBank.d485.s4	.	108	108	O
DDI-DrugBank.d485.s5	The	0	2	O
DDI-DrugBank.d485.s5	effect	4	9	O
DDI-DrugBank.d485.s5	on	11	12	O
DDI-DrugBank.d485.s5	other	14	18	O
DDI-DrugBank.d485.s5	progestational	20	33	B-group
DDI-DrugBank.d485.s5	contraceptives	35	48	I-group
DDI-DrugBank.d485.s5	(	50	50	O
DDI-DrugBank.d485.s5	eg	51	52	O
DDI-DrugBank.d485.s5	,	53	53	O
DDI-DrugBank.d485.s5	implants	55	62	O
DDI-DrugBank.d485.s5	,	63	63	O
DDI-DrugBank.d485.s5	injectables	65	75	O
DDI-DrugBank.d485.s5	)	76	76	O
DDI-DrugBank.d485.s5	is	78	79	O
DDI-DrugBank.d485.s5	unknown	81	87	O
DDI-DrugBank.d485.s5	.	88	88	O
DDI-DrugBank.d485.s6	Aminoglutethimide	0	16	B-drug
DDI-DrugBank.d485.s6	:	17	17	O
DDI-DrugBank.d485.s6	May	19	21	O
DDI-DrugBank.d485.s6	increase	23	30	O
DDI-DrugBank.d485.s6	CYP	32	34	O
DDI-DrugBank.d485.s6	metabolism	36	45	O
DDI-DrugBank.d485.s6	of	47	48	O
DDI-DrugBank.d485.s6	progestins	50	59	B-group
DDI-DrugBank.d485.s6	leading	61	67	O
DDI-DrugBank.d485.s6	to	69	70	O
DDI-DrugBank.d485.s6	possible	72	79	O
DDI-DrugBank.d485.s6	decrease	81	88	O
DDI-DrugBank.d485.s6	in	90	91	O
DDI-DrugBank.d485.s6	contraceptive	93	105	O
DDI-DrugBank.d485.s6	effectiveness	107	119	O
DDI-DrugBank.d485.s6	.	120	120	O
DDI-DrugBank.d485.s7	Use	0	2	O
DDI-DrugBank.d485.s7	of	4	5	O
DDI-DrugBank.d485.s7	a	7	7	O
DDI-DrugBank.d485.s7	nonhormonal	9	19	B-group
DDI-DrugBank.d485.s7	contraceptive	21	33	I-group
DDI-DrugBank.d485.s7	product	35	41	I-group
DDI-DrugBank.d485.s7	is	43	44	O
DDI-DrugBank.d485.s7	recommended	46	56	O
DDI-DrugBank.d485.s7	.	57	57	O
DDI-DrugBank.d485.s8	Antibiotics	0	10	B-group
DDI-DrugBank.d485.s8	(	12	12	O
DDI-DrugBank.d485.s8	ampicillin	13	22	B-drug
DDI-DrugBank.d485.s8	,	23	23	O
DDI-DrugBank.d485.s8	tetracycline	25	36	B-drug
DDI-DrugBank.d485.s8	)	37	37	O
DDI-DrugBank.d485.s8	:	38	38	O
DDI-DrugBank.d485.s8	Pregnancy	40	48	O
DDI-DrugBank.d485.s8	has	50	52	O
DDI-DrugBank.d485.s8	been	54	57	O
DDI-DrugBank.d485.s8	reported	59	66	O
DDI-DrugBank.d485.s8	following	68	76	O
DDI-DrugBank.d485.s8	concomitant	78	88	O
DDI-DrugBank.d485.s8	use	90	92	O
DDI-DrugBank.d485.s8	,	93	93	O
DDI-DrugBank.d485.s8	however	95	101	O
DDI-DrugBank.d485.s8	,	93	93	O
DDI-DrugBank.d485.s8	pharmacokinetic	104	118	O
DDI-DrugBank.d485.s8	studies	120	126	O
DDI-DrugBank.d485.s8	have	128	131	O
DDI-DrugBank.d485.s8	not	133	135	O
DDI-DrugBank.d485.s8	shown	137	141	O
DDI-DrugBank.d485.s8	consistent	143	152	O
DDI-DrugBank.d485.s8	effects	154	160	O
DDI-DrugBank.d485.s8	with	162	165	O
DDI-DrugBank.d485.s8	these	167	171	O
DDI-DrugBank.d485.s8	antibiotics	173	183	B-group
DDI-DrugBank.d485.s8	on	185	186	O
DDI-DrugBank.d485.s8	plasma	188	193	O
DDI-DrugBank.d485.s8	concentrations	195	208	O
DDI-DrugBank.d485.s8	of	210	211	O
DDI-DrugBank.d485.s8	synthetic	213	221	B-group
DDI-DrugBank.d485.s8	steroids	223	230	I-group
DDI-DrugBank.d485.s8	.	231	231	O
DDI-DrugBank.d485.s9	Use	0	2	O
DDI-DrugBank.d485.s9	of	4	5	O
DDI-DrugBank.d485.s9	a	7	7	O
DDI-DrugBank.d485.s9	nonhormonal	9	19	B-group
DDI-DrugBank.d485.s9	contraceptive	21	33	I-group
DDI-DrugBank.d485.s9	product	35	41	I-group
DDI-DrugBank.d485.s9	is	43	44	O
DDI-DrugBank.d485.s9	recommended	46	56	O
DDI-DrugBank.d485.s9	.	57	57	O
DDI-DrugBank.d485.s10	Anticoagulants	0	13	B-group
DDI-DrugBank.d485.s10	:	14	14	O
DDI-DrugBank.d485.s10	Combination	16	26	O
DDI-DrugBank.d485.s10	hormonal	28	35	B-group
DDI-DrugBank.d485.s10	contraceptives	37	50	I-group
DDI-DrugBank.d485.s10	may	52	54	O
DDI-DrugBank.d485.s10	increase	56	63	O
DDI-DrugBank.d485.s10	or	65	66	O
DDI-DrugBank.d485.s10	decrease	68	75	O
DDI-DrugBank.d485.s10	the	77	79	O
DDI-DrugBank.d485.s10	effects	81	87	O
DDI-DrugBank.d485.s10	of	89	90	O
DDI-DrugBank.d485.s10	coumarin	92	99	B-group
DDI-DrugBank.d485.s10	derivatives	101	111	I-group
DDI-DrugBank.d485.s10	.	112	112	O
DDI-DrugBank.d485.s11	Combination	0	10	O
DDI-DrugBank.d485.s11	hormonal	12	19	B-group
DDI-DrugBank.d485.s11	contraceptives	21	34	I-group
DDI-DrugBank.d485.s11	may	36	38	O
DDI-DrugBank.d485.s11	also	40	43	O
DDI-DrugBank.d485.s11	increase	45	52	O
DDI-DrugBank.d485.s11	risk	54	57	O
DDI-DrugBank.d485.s11	of	59	60	O
DDI-DrugBank.d485.s11	thromboembolic	62	75	O
DDI-DrugBank.d485.s11	disorders	77	85	O
DDI-DrugBank.d485.s11	.	86	86	O
DDI-DrugBank.d485.s12	Anticonvulsants	0	14	B-group
DDI-DrugBank.d485.s12	(	16	16	O
DDI-DrugBank.d485.s12	carbamazepine	17	29	B-drug
DDI-DrugBank.d485.s12	,	30	30	O
DDI-DrugBank.d485.s12	felbamate	32	40	B-drug
DDI-DrugBank.d485.s12	,	41	41	O
DDI-DrugBank.d485.s12	phenobarbital	43	55	B-drug
DDI-DrugBank.d485.s12	,	56	56	O
DDI-DrugBank.d485.s12	phenytoin	58	66	B-drug
DDI-DrugBank.d485.s12	,	67	67	O
DDI-DrugBank.d485.s12	topiramate	69	78	B-drug
DDI-DrugBank.d485.s12	)	79	79	O
DDI-DrugBank.d485.s12	:	80	80	O
DDI-DrugBank.d485.s12	Increase	82	89	O
DDI-DrugBank.d485.s12	the	91	93	O
DDI-DrugBank.d485.s12	metabolism	95	104	O
DDI-DrugBank.d485.s12	of	106	107	O
DDI-DrugBank.d485.s12	ethinyl	109	115	B-drug
DDI-DrugBank.d485.s12	estradiol	117	125	I-drug
DDI-DrugBank.d485.s12	and/or	127	132	O
DDI-DrugBank.d485.s12	some	134	137	O
DDI-DrugBank.d485.s12	progestins	139	148	B-group
DDI-DrugBank.d485.s12	,	149	149	O
DDI-DrugBank.d485.s12	leading	151	157	O
DDI-DrugBank.d485.s12	to	159	160	O
DDI-DrugBank.d485.s12	possible	162	169	O
DDI-DrugBank.d485.s12	decrease	171	178	O
DDI-DrugBank.d485.s12	in	180	181	O
DDI-DrugBank.d485.s12	contraceptive	183	195	O
DDI-DrugBank.d485.s12	effectiveness	197	209	O
DDI-DrugBank.d485.s12	.	210	210	O
DDI-DrugBank.d485.s13	Use	0	2	O
DDI-DrugBank.d485.s13	of	4	5	O
DDI-DrugBank.d485.s13	a	7	7	O
DDI-DrugBank.d485.s13	nonhormonal	9	19	B-group
DDI-DrugBank.d485.s13	contraceptive	21	33	I-group
DDI-DrugBank.d485.s13	product	35	41	I-group
DDI-DrugBank.d485.s13	is	43	44	O
DDI-DrugBank.d485.s13	recommended	46	56	O
DDI-DrugBank.d485.s13	.	57	57	O
DDI-DrugBank.d485.s14	Ascorbic	0	7	B-drug
DDI-DrugBank.d485.s14	acid	9	12	I-drug
DDI-DrugBank.d485.s14	:	13	13	O
DDI-DrugBank.d485.s14	Doses	15	19	O
DDI-DrugBank.d485.s14	of	21	22	O
DDI-DrugBank.d485.s14	ascorbic	24	31	B-drug
DDI-DrugBank.d485.s14	acid	33	36	I-drug
DDI-DrugBank.d485.s14	(	38	38	O
DDI-DrugBank.d485.s14	vitamin	39	45	B-drug
DDI-DrugBank.d485.s14	C	47	47	O
DDI-DrugBank.d485.s14	)	48	48	O
DDI-DrugBank.d485.s14	1	50	50	O
DDI-DrugBank.d485.s14	g/day	52	56	O
DDI-DrugBank.d485.s14	have	58	61	O
DDI-DrugBank.d485.s14	been	63	66	O
DDI-DrugBank.d485.s14	reported	68	75	O
DDI-DrugBank.d485.s14	to	77	78	O
DDI-DrugBank.d485.s14	increase	80	87	O
DDI-DrugBank.d485.s14	plasma	89	94	O
DDI-DrugBank.d485.s14	concentration	96	108	O
DDI-DrugBank.d485.s14	of	110	111	O
DDI-DrugBank.d485.s14	synthetic	113	121	B-group
DDI-DrugBank.d485.s14	estrogens	123	131	I-group
DDI-DrugBank.d485.s14	by	133	134	O
DDI-DrugBank.d485.s14	~47	136	138	O
DDI-DrugBank.d485.s14	%	139	139	O
DDI-DrugBank.d485.s14	,	140	140	O
DDI-DrugBank.d485.s14	possibly	142	149	O
DDI-DrugBank.d485.s14	by	133	134	O
DDI-DrugBank.d485.s14	inhibiting	154	163	O
DDI-DrugBank.d485.s14	conjugation	165	175	O
DDI-DrugBank.d485.s14	;	176	176	O
DDI-DrugBank.d485.s15	clinical	0	7	O
DDI-DrugBank.d485.s15	implications	9	20	O
DDI-DrugBank.d485.s15	are	22	24	O
DDI-DrugBank.d485.s15	unclear	26	32	O
DDI-DrugBank.d485.s15	.	33	33	O
DDI-DrugBank.d485.s16	Atorvastatin	0	11	B-drug
DDI-DrugBank.d485.s16	:	12	12	O
DDI-DrugBank.d485.s16	Atorvastatin	14	25	B-drug
DDI-DrugBank.d485.s16	increases	27	35	O
DDI-DrugBank.d485.s16	the	37	39	O
DDI-DrugBank.d485.s16	AUC	41	43	O
DDI-DrugBank.d485.s16	for	45	47	O
DDI-DrugBank.d485.s16	norethindrone	49	61	B-drug
DDI-DrugBank.d485.s16	and	63	65	O
DDI-DrugBank.d485.s16	ethinyl	67	73	B-drug
DDI-DrugBank.d485.s16	estradiol	75	83	I-drug
DDI-DrugBank.d485.s16	.	84	84	O
DDI-DrugBank.d485.s17	Benzodiazepines	0	14	B-group
DDI-DrugBank.d485.s17	:	15	15	O
DDI-DrugBank.d485.s17	Combination	17	27	O
DDI-DrugBank.d485.s17	hormonal	29	36	B-group
DDI-DrugBank.d485.s17	contraceptives	38	51	I-group
DDI-DrugBank.d485.s17	may	53	55	O
DDI-DrugBank.d485.s17	decrease	57	64	O
DDI-DrugBank.d485.s17	the	66	68	O
DDI-DrugBank.d485.s17	clearance	70	78	O
DDI-DrugBank.d485.s17	of	80	81	O
DDI-DrugBank.d485.s17	some	83	86	O
DDI-DrugBank.d485.s17	benzodiazepines	88	102	B-group
DDI-DrugBank.d485.s17	(	104	104	O
DDI-DrugBank.d485.s17	alprazolam	105	114	B-drug
DDI-DrugBank.d485.s17	,	115	115	O
DDI-DrugBank.d485.s17	chlordiazepoxide	117	132	B-drug
DDI-DrugBank.d485.s17	,	133	133	O
DDI-DrugBank.d485.s17	diazepam	135	142	B-drug
DDI-DrugBank.d485.s17	)	143	143	O
DDI-DrugBank.d485.s17	and	145	147	O
DDI-DrugBank.d485.s17	increase	149	156	O
DDI-DrugBank.d485.s17	the	158	160	O
DDI-DrugBank.d485.s17	clearance	162	170	O
DDI-DrugBank.d485.s17	of	172	173	O
DDI-DrugBank.d485.s17	others	175	180	O
DDI-DrugBank.d485.s17	(	182	182	O
DDI-DrugBank.d485.s17	lorazepam	183	191	B-drug
DDI-DrugBank.d485.s17	,	192	192	O
DDI-DrugBank.d485.s17	oxazepam	194	201	B-drug
DDI-DrugBank.d485.s17	,	192	192	O
DDI-DrugBank.d485.s17	temazepam	204	212	B-drug
DDI-DrugBank.d485.s17	)	213	213	O
DDI-DrugBank.d485.s17	.	214	214	O
DDI-DrugBank.d485.s18	Clofibric	0	8	B-drug_n
DDI-DrugBank.d485.s18	acid	10	13	I-drug_n
DDI-DrugBank.d485.s18	:	14	14	O
DDI-DrugBank.d485.s18	Combination	16	26	O
DDI-DrugBank.d485.s18	hormonal	28	35	B-group
DDI-DrugBank.d485.s18	contraceptives	37	50	I-group
DDI-DrugBank.d485.s18	may	52	54	O
DDI-DrugBank.d485.s18	increase	56	63	O
DDI-DrugBank.d485.s18	the	65	67	O
DDI-DrugBank.d485.s18	clearance	69	77	O
DDI-DrugBank.d485.s18	of	79	80	O
DDI-DrugBank.d485.s18	clofibric	82	90	B-drug_n
DDI-DrugBank.d485.s18	acid	92	95	I-drug_n
DDI-DrugBank.d485.s18	.	96	96	O
DDI-DrugBank.d485.s19	Cyclosporine	0	11	B-drug
DDI-DrugBank.d485.s19	:	12	12	O
DDI-DrugBank.d485.s19	Combination	14	24	O
DDI-DrugBank.d485.s19	hormonal	26	33	B-group
DDI-DrugBank.d485.s19	contraceptives	35	48	I-group
DDI-DrugBank.d485.s19	may	50	52	O
DDI-DrugBank.d485.s19	inhibit	54	60	O
DDI-DrugBank.d485.s19	the	62	64	O
DDI-DrugBank.d485.s19	metabolism	66	75	O
DDI-DrugBank.d485.s19	of	77	78	O
DDI-DrugBank.d485.s19	cyclosporine	80	91	B-drug
DDI-DrugBank.d485.s19	,	92	92	O
DDI-DrugBank.d485.s19	leading	94	100	O
DDI-DrugBank.d485.s19	to	102	103	O
DDI-DrugBank.d485.s19	increased	105	113	O
DDI-DrugBank.d485.s19	plasma	115	120	O
DDI-DrugBank.d485.s19	concentrations	122	135	O
DDI-DrugBank.d485.s19	;	136	136	O
DDI-DrugBank.d485.s20	monitor	0	6	O
DDI-DrugBank.d485.s20	cyclosporine	8	19	B-drug
DDI-DrugBank.d485.s20	levels	21	26	O
DDI-DrugBank.d485.s20	.	27	27	O
DDI-DrugBank.d485.s21	CYP3A4	0	5	O
DDI-DrugBank.d485.s21	inducers	7	14	O
DDI-DrugBank.d485.s21	:	15	15	O
DDI-DrugBank.d485.s21	CYP3A4	17	22	O
DDI-DrugBank.d485.s21	inducers	24	31	O
DDI-DrugBank.d485.s21	may	33	35	O
DDI-DrugBank.d485.s21	decrease	37	44	O
DDI-DrugBank.d485.s21	the	46	48	O
DDI-DrugBank.d485.s21	levels/effects	50	63	O
DDI-DrugBank.d485.s21	of	65	66	O
DDI-DrugBank.d485.s21	ethinyl	68	74	B-drug
DDI-DrugBank.d485.s21	estradiol	76	84	I-drug
DDI-DrugBank.d485.s21	.	85	85	O
DDI-DrugBank.d485.s22	Example	0	6	O
DDI-DrugBank.d485.s22	inducers	8	15	O
DDI-DrugBank.d485.s22	include	17	23	O
DDI-DrugBank.d485.s22	aminoglutethimide	25	41	B-drug
DDI-DrugBank.d485.s22	,	42	42	O
DDI-DrugBank.d485.s22	carbamazepine	44	56	B-drug
DDI-DrugBank.d485.s22	,	57	57	O
DDI-DrugBank.d485.s22	nafcillin	59	67	B-drug
DDI-DrugBank.d485.s22	,	68	68	O
DDI-DrugBank.d485.s22	nevirapine	70	79	B-drug
DDI-DrugBank.d485.s22	,	80	80	O
DDI-DrugBank.d485.s22	phenobarbital	82	94	B-drug
DDI-DrugBank.d485.s22	,	95	95	O
DDI-DrugBank.d485.s22	phenytoin	97	105	B-drug
DDI-DrugBank.d485.s22	,	106	106	O
DDI-DrugBank.d485.s22	and	108	110	O
DDI-DrugBank.d485.s22	rifamycins	112	121	B-group
DDI-DrugBank.d485.s22	.	122	122	O
DDI-DrugBank.d485.s23	Griseofulvin	0	11	B-drug
DDI-DrugBank.d485.s23	:	12	12	O
DDI-DrugBank.d485.s23	Griseofulvin	14	25	B-drug
DDI-DrugBank.d485.s23	may	27	29	O
DDI-DrugBank.d485.s23	induce	31	36	O
DDI-DrugBank.d485.s23	the	38	40	O
DDI-DrugBank.d485.s23	metabolism	42	51	O
DDI-DrugBank.d485.s23	of	53	54	O
DDI-DrugBank.d485.s23	combination	56	66	B-group
DDI-DrugBank.d485.s23	hormonal	68	75	I-group
DDI-DrugBank.d485.s23	contraceptives	77	90	I-group
DDI-DrugBank.d485.s23	causing	92	98	O
DDI-DrugBank.d485.s23	menstrual	100	108	O
DDI-DrugBank.d485.s23	changes	110	116	O
DDI-DrugBank.d485.s23	;	117	117	O
DDI-DrugBank.d485.s24	pregnancies	0	10	O
DDI-DrugBank.d485.s24	have	12	15	O
DDI-DrugBank.d485.s24	been	17	20	O
DDI-DrugBank.d485.s24	reported	22	29	O
DDI-DrugBank.d485.s24	.	30	30	O
DDI-DrugBank.d485.s25	Use	0	2	O
DDI-DrugBank.d485.s25	of	4	5	O
DDI-DrugBank.d485.s25	barrier	7	13	O
DDI-DrugBank.d485.s25	form	15	18	O
DDI-DrugBank.d485.s25	of	20	21	O
DDI-DrugBank.d485.s25	contraception	23	35	O
DDI-DrugBank.d485.s25	is	37	38	O
DDI-DrugBank.d485.s25	suggested	40	48	O
DDI-DrugBank.d485.s25	while	50	54	O
DDI-DrugBank.d485.s25	on	56	57	O
DDI-DrugBank.d485.s25	griseofulvin	59	70	B-drug
DDI-DrugBank.d485.s25	therapy	72	78	O
DDI-DrugBank.d485.s25	.	79	79	O
DDI-DrugBank.d485.s26	Morphine	0	7	B-drug
DDI-DrugBank.d485.s26	:	8	8	O
DDI-DrugBank.d485.s26	Combination	10	20	O
DDI-DrugBank.d485.s26	hormonal	22	29	B-group
DDI-DrugBank.d485.s26	contraceptives	31	44	I-group
DDI-DrugBank.d485.s26	may	46	48	O
DDI-DrugBank.d485.s26	increase	50	57	O
DDI-DrugBank.d485.s26	the	59	61	O
DDI-DrugBank.d485.s26	clearance	63	71	O
DDI-DrugBank.d485.s26	of	73	74	O
DDI-DrugBank.d485.s26	morphine	76	83	B-drug
DDI-DrugBank.d485.s26	.	84	84	O
DDI-DrugBank.d485.s27	Non-nucleoside	0	13	B-group
DDI-DrugBank.d485.s27	reverse	15	21	I-group
DDI-DrugBank.d485.s27	transcriptase	23	35	I-group
DDI-DrugBank.d485.s27	inhibitors	37	46	I-group
DDI-DrugBank.d485.s27	(	48	48	O
DDI-DrugBank.d485.s27	NNRTIs	49	54	B-group
DDI-DrugBank.d485.s27	)	55	55	O
DDI-DrugBank.d485.s27	:	56	56	O
DDI-DrugBank.d485.s27	Nevirapine	58	67	B-drug
DDI-DrugBank.d485.s27	may	69	71	O
DDI-DrugBank.d485.s27	decrease	73	80	O
DDI-DrugBank.d485.s27	plasma	82	87	O
DDI-DrugBank.d485.s27	levels	89	94	O
DDI-DrugBank.d485.s27	of	96	97	O
DDI-DrugBank.d485.s27	combination	99	109	B-group
DDI-DrugBank.d485.s27	hormonal	111	118	I-group
DDI-DrugBank.d485.s27	contraceptives	120	133	I-group
DDI-DrugBank.d485.s27	;	134	134	O
DDI-DrugBank.d485.s28	use	0	2	O
DDI-DrugBank.d485.s28	of	4	5	O
DDI-DrugBank.d485.s28	a	7	7	O
DDI-DrugBank.d485.s28	nonhormonal	9	19	B-group
DDI-DrugBank.d485.s28	contraceptive	21	33	I-group
DDI-DrugBank.d485.s28	product	35	41	I-group
DDI-DrugBank.d485.s28	is	43	44	O
DDI-DrugBank.d485.s28	recommended	46	56	O
DDI-DrugBank.d485.s28	.	57	57	O
DDI-DrugBank.d485.s29	No	0	1	O
DDI-DrugBank.d485.s29	data	3	6	O
DDI-DrugBank.d485.s29	for	8	10	O
DDI-DrugBank.d485.s29	delavirdine	12	22	B-drug
DDI-DrugBank.d485.s29	;	23	23	O
DDI-DrugBank.d485.s30	incomplete	0	9	O
DDI-DrugBank.d485.s30	data	11	14	O
DDI-DrugBank.d485.s30	for	16	18	O
DDI-DrugBank.d485.s30	efavirenz	20	28	B-drug
DDI-DrugBank.d485.s30	.	29	29	O
DDI-DrugBank.d485.s31	Prednisolone	0	11	B-drug
DDI-DrugBank.d485.s31	:	12	12	O
DDI-DrugBank.d485.s31	Ethinyl	14	20	B-drug
DDI-DrugBank.d485.s31	estradiol	22	30	I-drug
DDI-DrugBank.d485.s31	may	32	34	O
DDI-DrugBank.d485.s31	inhibit	36	42	O
DDI-DrugBank.d485.s31	the	44	46	O
DDI-DrugBank.d485.s31	metabolism	48	57	O
DDI-DrugBank.d485.s31	of	59	60	O
DDI-DrugBank.d485.s31	prednisolone	62	73	B-drug
DDI-DrugBank.d485.s31	,	74	74	O
DDI-DrugBank.d485.s31	leading	76	82	O
DDI-DrugBank.d485.s31	to	84	85	O
DDI-DrugBank.d485.s31	increased	87	95	O
DDI-DrugBank.d485.s31	plasma	97	102	O
DDI-DrugBank.d485.s31	concentrations	104	117	O
DDI-DrugBank.d485.s31	.	118	118	O
DDI-DrugBank.d485.s32	Protease	0	7	B-group
DDI-DrugBank.d485.s32	inhibitors	9	18	I-group
DDI-DrugBank.d485.s32	:	19	19	O
DDI-DrugBank.d485.s32	Amprenavir	21	30	B-drug
DDI-DrugBank.d485.s32	,	31	31	O
DDI-DrugBank.d485.s32	lopinavir	33	41	B-drug
DDI-DrugBank.d485.s32	,	42	42	O
DDI-DrugBank.d485.s32	nelfinavir	44	53	B-drug
DDI-DrugBank.d485.s32	,	54	54	O
DDI-DrugBank.d485.s32	and	56	58	O
DDI-DrugBank.d485.s32	ritonavir	60	68	B-drug
DDI-DrugBank.d485.s32	have	70	73	O
DDI-DrugBank.d485.s32	been	75	78	O
DDI-DrugBank.d485.s32	shown	80	84	O
DDI-DrugBank.d485.s32	to	86	87	O
DDI-DrugBank.d485.s32	decrease	89	96	O
DDI-DrugBank.d485.s32	plasma	98	103	O
DDI-DrugBank.d485.s32	levels	105	110	O
DDI-DrugBank.d485.s32	of	112	113	O
DDI-DrugBank.d485.s32	combination	115	125	B-group
DDI-DrugBank.d485.s32	hormonal	127	134	I-group
DDI-DrugBank.d485.s32	contraceptives	136	149	I-group
DDI-DrugBank.d485.s32	;	150	150	O
DDI-DrugBank.d485.s33	use	0	2	O
DDI-DrugBank.d485.s33	of	4	5	O
DDI-DrugBank.d485.s33	a	7	7	O
DDI-DrugBank.d485.s33	nonhormonal	9	19	B-group
DDI-DrugBank.d485.s33	contraceptive	21	33	I-group
DDI-DrugBank.d485.s33	product	35	41	I-group
DDI-DrugBank.d485.s33	is	43	44	O
DDI-DrugBank.d485.s33	recommended	46	56	O
DDI-DrugBank.d485.s33	.	57	57	O
DDI-DrugBank.d485.s34	Indinavir	0	8	B-drug
DDI-DrugBank.d485.s34	has	10	12	O
DDI-DrugBank.d485.s34	been	14	17	O
DDI-DrugBank.d485.s34	shown	19	23	O
DDI-DrugBank.d485.s34	to	25	26	O
DDI-DrugBank.d485.s34	increase	28	35	O
DDI-DrugBank.d485.s34	plasma	37	42	O
DDI-DrugBank.d485.s34	levels	44	49	O
DDI-DrugBank.d485.s34	of	51	52	O
DDI-DrugBank.d485.s34	combination	54	64	B-group
DDI-DrugBank.d485.s34	hormonal	66	73	I-group
DDI-DrugBank.d485.s34	contraceptives	75	88	I-group
DDI-DrugBank.d485.s34	.	89	89	O
DDI-DrugBank.d485.s35	No	0	1	O
DDI-DrugBank.d485.s35	data	3	6	O
DDI-DrugBank.d485.s35	for	8	10	O
DDI-DrugBank.d485.s35	saquinavir	12	21	B-drug
DDI-DrugBank.d485.s35	.	22	22	O
DDI-DrugBank.d485.s36	Rifampin	0	7	B-drug
DDI-DrugBank.d485.s36	:	8	8	O
DDI-DrugBank.d485.s36	Rifampin	10	17	B-drug
DDI-DrugBank.d485.s36	increases	19	27	O
DDI-DrugBank.d485.s36	the	29	31	O
DDI-DrugBank.d485.s36	metabolism	33	42	O
DDI-DrugBank.d485.s36	of	44	45	O
DDI-DrugBank.d485.s36	ethinyl	47	53	B-drug
DDI-DrugBank.d485.s36	estradiol	55	63	I-drug
DDI-DrugBank.d485.s36	and	65	67	O
DDI-DrugBank.d485.s36	some	69	72	O
DDI-DrugBank.d485.s36	progestins	74	83	B-group
DDI-DrugBank.d485.s36	(	85	85	O
DDI-DrugBank.d485.s36	norethindrone	86	98	B-drug
DDI-DrugBank.d485.s36	)	99	99	O
DDI-DrugBank.d485.s36	resulting	101	109	O
DDI-DrugBank.d485.s36	in	107	108	O
DDI-DrugBank.d485.s36	decreased	114	122	O
DDI-DrugBank.d485.s36	contraceptive	124	136	O
DDI-DrugBank.d485.s36	effectiveness	138	150	O
DDI-DrugBank.d485.s36	and	152	154	O
DDI-DrugBank.d485.s36	increased	156	164	O
DDI-DrugBank.d485.s36	menstrual	166	174	O
DDI-DrugBank.d485.s36	irregularities	176	189	O
DDI-DrugBank.d485.s36	.	190	190	O
DDI-DrugBank.d485.s37	Use	0	2	O
DDI-DrugBank.d485.s37	of	4	5	O
DDI-DrugBank.d485.s37	a	7	7	O
DDI-DrugBank.d485.s37	nonhormonal	9	19	B-group
DDI-DrugBank.d485.s37	contraceptive	21	33	I-group
DDI-DrugBank.d485.s37	product	35	41	I-group
DDI-DrugBank.d485.s37	is	43	44	O
DDI-DrugBank.d485.s37	recommended	46	56	O
DDI-DrugBank.d485.s37	.	57	57	O
DDI-DrugBank.d485.s38	Salicylic	0	8	B-drug
DDI-DrugBank.d485.s38	acid	10	13	I-drug
DDI-DrugBank.d485.s38	:	14	14	O
DDI-DrugBank.d485.s38	Combination	16	26	O
DDI-DrugBank.d485.s38	hormonal	28	35	B-group
DDI-DrugBank.d485.s38	contraceptives	37	50	I-group
DDI-DrugBank.d485.s38	may	52	54	O
DDI-DrugBank.d485.s38	increase	56	63	O
DDI-DrugBank.d485.s38	the	65	67	O
DDI-DrugBank.d485.s38	clearance	69	77	O
DDI-DrugBank.d485.s38	of	79	80	O
DDI-DrugBank.d485.s38	salicylic	82	90	B-drug
DDI-DrugBank.d485.s38	acid	92	95	I-drug
DDI-DrugBank.d485.s38	.	96	96	O
DDI-DrugBank.d485.s39	Selegiline	0	9	B-drug
DDI-DrugBank.d485.s39	:	10	10	O
DDI-DrugBank.d485.s39	Combination	12	22	B-group
DDI-DrugBank.d485.s39	hormonal	24	31	I-group
DDI-DrugBank.d485.s39	contraceptives	33	46	I-group
DDI-DrugBank.d485.s39	may	48	50	O
DDI-DrugBank.d485.s39	increase	52	59	O
DDI-DrugBank.d485.s39	the	61	63	O
DDI-DrugBank.d485.s39	serum	65	69	O
DDI-DrugBank.d485.s39	concentration	71	83	O
DDI-DrugBank.d485.s39	of	85	86	O
DDI-DrugBank.d485.s39	selegiline	88	97	B-drug
DDI-DrugBank.d485.s39	.	98	98	O
DDI-DrugBank.d485.s40	Theophylline	0	11	B-drug
DDI-DrugBank.d485.s40	:	12	12	O
DDI-DrugBank.d485.s40	Ethinyl	14	20	B-drug
DDI-DrugBank.d485.s40	estradiol	22	30	I-drug
DDI-DrugBank.d485.s40	may	32	34	O
DDI-DrugBank.d485.s40	inhibit	36	42	O
DDI-DrugBank.d485.s40	the	44	46	O
DDI-DrugBank.d485.s40	metabolism	48	57	O
DDI-DrugBank.d485.s40	of	59	60	O
DDI-DrugBank.d485.s40	theophylline	62	73	B-drug
DDI-DrugBank.d485.s40	,	74	74	O
DDI-DrugBank.d485.s40	leading	76	82	O
DDI-DrugBank.d485.s40	to	84	85	O
DDI-DrugBank.d485.s40	increased	87	95	O
DDI-DrugBank.d485.s40	plasma	97	102	O
DDI-DrugBank.d485.s40	concentrations	104	117	O
DDI-DrugBank.d485.s40	.	118	118	O
DDI-DrugBank.d485.s41	Tricyclic	0	8	B-group
DDI-DrugBank.d485.s41	antidepressants	10	24	I-group
DDI-DrugBank.d485.s41	(	26	26	O
DDI-DrugBank.d485.s41	amitriptyline	27	39	B-drug
DDI-DrugBank.d485.s41	,	40	40	O
DDI-DrugBank.d485.s41	imipramine	42	51	B-drug
DDI-DrugBank.d485.s41	,	52	52	O
DDI-DrugBank.d485.s41	nortriptyline	54	66	B-drug
DDI-DrugBank.d485.s41	)	67	67	O
DDI-DrugBank.d485.s41	:	68	68	O
DDI-DrugBank.d485.s41	Metabolism	70	79	O
DDI-DrugBank.d485.s41	may	81	83	O
DDI-DrugBank.d485.s41	be	85	86	O
DDI-DrugBank.d485.s41	inhibited	88	96	O
DDI-DrugBank.d485.s41	by	98	99	O
DDI-DrugBank.d485.s41	combination	101	111	B-group
DDI-DrugBank.d485.s41	hormonal	113	120	I-group
DDI-DrugBank.d485.s41	contraceptives	122	135	I-group
DDI-DrugBank.d485.s41	,	136	136	O
DDI-DrugBank.d485.s41	increasing	138	147	O
DDI-DrugBank.d485.s41	plasma	149	154	O
DDI-DrugBank.d485.s41	levels	156	161	O
DDI-DrugBank.d485.s41	of	163	164	O
DDI-DrugBank.d485.s41	antidepressant	166	179	B-group
DDI-DrugBank.d485.s41	;	180	180	O
DDI-DrugBank.d485.s42	use	0	2	O
DDI-DrugBank.d485.s42	caution	4	10	O
DDI-DrugBank.d485.s42	.	11	11	O
DDI-DrugBank.d485.s43	ETHANOL	0	6	B-drug
DDI-DrugBank.d485.s43	/	8	8	O
DDI-DrugBank.d485.s43	NUTRITION	10	18	O
DDI-DrugBank.d485.s43	/	20	20	O
DDI-DrugBank.d485.s43	HERB	22	25	O
DDI-DrugBank.d485.s43	INTERACTIONS	27	38	O
DDI-DrugBank.d485.s43	:	39	39	O
DDI-DrugBank.d485.s43	Food	41	44	O
DDI-DrugBank.d485.s43	:	39	39	O
DDI-DrugBank.d485.s43	CNS	47	49	O
DDI-DrugBank.d485.s43	effects	51	57	O
DDI-DrugBank.d485.s43	of	59	60	O
DDI-DrugBank.d485.s43	caffeine	62	69	B-drug
DDI-DrugBank.d485.s43	may	71	73	O
DDI-DrugBank.d485.s43	be	75	76	O
DDI-DrugBank.d485.s43	enhanced	78	85	O
DDI-DrugBank.d485.s43	if	87	88	O
DDI-DrugBank.d485.s43	combination	90	100	B-group
DDI-DrugBank.d485.s43	hormonal	102	109	I-group
DDI-DrugBank.d485.s43	contraceptives	111	124	I-group
DDI-DrugBank.d485.s43	are	126	128	O
DDI-DrugBank.d485.s43	used	130	133	O
DDI-DrugBank.d485.s43	concurrently	135	146	O
DDI-DrugBank.d485.s43	with	148	151	O
DDI-DrugBank.d485.s43	caffeine	153	160	B-drug
DDI-DrugBank.d485.s43	.	161	161	O
DDI-DrugBank.d485.s44	Grapefruit	0	9	O
DDI-DrugBank.d485.s44	juice	11	15	O
DDI-DrugBank.d485.s44	increases	17	25	O
DDI-DrugBank.d485.s44	ethinyl	27	33	B-drug
DDI-DrugBank.d485.s44	estradiol	35	43	I-drug
DDI-DrugBank.d485.s44	concentrations	45	58	O
DDI-DrugBank.d485.s44	and	60	62	O
DDI-DrugBank.d485.s44	would	64	68	O
DDI-DrugBank.d485.s44	be	70	71	O
DDI-DrugBank.d485.s44	expected	73	80	O
DDI-DrugBank.d485.s44	to	82	83	O
DDI-DrugBank.d485.s44	increase	85	92	O
DDI-DrugBank.d485.s44	progesterone	94	105	B-drug
DDI-DrugBank.d485.s44	serum	107	111	O
DDI-DrugBank.d485.s44	levels	113	118	O
DDI-DrugBank.d485.s44	as	120	121	O
DDI-DrugBank.d485.s44	well	123	126	O
DDI-DrugBank.d485.s44	;	127	127	O
DDI-DrugBank.d485.s45	clinical	0	7	O
DDI-DrugBank.d485.s45	implications	9	20	O
DDI-DrugBank.d485.s45	are	22	24	O
DDI-DrugBank.d485.s45	unclear	26	32	O
DDI-DrugBank.d485.s45	.	33	33	O
DDI-DrugBank.d485.s46	Herb/Nutraceutical	0	17	O
DDI-DrugBank.d485.s46	:	18	18	O
DDI-DrugBank.d485.s46	St	20	21	O
DDI-DrugBank.d485.s46	Johns	23	27	O
DDI-DrugBank.d485.s46	wort	29	32	O
DDI-DrugBank.d485.s46	may	34	36	O
DDI-DrugBank.d485.s46	decrease	38	45	O
DDI-DrugBank.d485.s46	the	47	49	O
DDI-DrugBank.d485.s46	effectiveness	51	63	O
DDI-DrugBank.d485.s46	of	65	66	O
DDI-DrugBank.d485.s46	combination	68	78	B-group
DDI-DrugBank.d485.s46	hormonal	80	87	I-group
DDI-DrugBank.d485.s46	contraceptives	89	102	I-group
DDI-DrugBank.d485.s46	by	104	105	O
DDI-DrugBank.d485.s46	inducing	107	114	O
DDI-DrugBank.d485.s46	hepatic	116	122	O
DDI-DrugBank.d485.s46	enzymes	124	130	O
DDI-DrugBank.d485.s46	.	131	131	O
DDI-DrugBank.d485.s47	Avoid	0	4	O
DDI-DrugBank.d485.s47	dong	6	9	O
DDI-DrugBank.d485.s47	quai	11	14	O
DDI-DrugBank.d485.s47	and	16	18	O
DDI-DrugBank.d485.s47	black	20	24	O
DDI-DrugBank.d485.s47	cohosh	26	31	O
DDI-DrugBank.d485.s47	(	33	33	O
DDI-DrugBank.d485.s47	have	34	37	O
DDI-DrugBank.d485.s47	estrogen	39	46	O
DDI-DrugBank.d485.s47	activity	48	55	O
DDI-DrugBank.d485.s47	)	56	56	O
DDI-DrugBank.d485.s47	.	57	57	O
DDI-DrugBank.d485.s48	Avoid	0	4	O
DDI-DrugBank.d485.s48	saw	6	8	O
DDI-DrugBank.d485.s48	palmetto	10	17	O
DDI-DrugBank.d485.s48	,	18	18	O
DDI-DrugBank.d485.s48	red	20	22	O
DDI-DrugBank.d485.s48	clover	24	29	O
DDI-DrugBank.d485.s48	,	30	30	O
DDI-DrugBank.d485.s48	ginseng	32	38	O
DDI-DrugBank.d485.s48	.	39	39	O
DDI-DrugBank.d89.s0	Cytochrome	0	9	O
DDI-DrugBank.d89.s0	P450	11	14	O
DDI-DrugBank.d89.s0	1A2	16	18	O
DDI-DrugBank.d89.s0	(	20	20	O
DDI-DrugBank.d89.s0	CYP1A2	21	26	O
DDI-DrugBank.d89.s0	)	27	27	O
DDI-DrugBank.d89.s0	is	29	30	O
DDI-DrugBank.d89.s0	known	32	36	O
DDI-DrugBank.d89.s0	to	38	39	O
DDI-DrugBank.d89.s0	be	41	42	O
DDI-DrugBank.d89.s0	the	44	46	O
DDI-DrugBank.d89.s0	major	48	52	O
DDI-DrugBank.d89.s0	enzyme	54	59	O
DDI-DrugBank.d89.s0	involved	61	68	O
DDI-DrugBank.d89.s0	in	61	62	O
DDI-DrugBank.d89.s0	the	73	75	O
DDI-DrugBank.d89.s0	metabolism	77	86	O
DDI-DrugBank.d89.s0	of	88	89	O
DDI-DrugBank.d89.s0	caffeine	91	98	B-drug
DDI-DrugBank.d89.s0	.	99	99	O
DDI-DrugBank.d89.s1	Therefore	0	8	O
DDI-DrugBank.d89.s1	,	9	9	O
DDI-DrugBank.d89.s1	caffeine	11	18	B-drug
DDI-DrugBank.d89.s1	has	20	22	O
DDI-DrugBank.d89.s1	the	24	26	O
DDI-DrugBank.d89.s1	potential	28	36	O
DDI-DrugBank.d89.s1	to	38	39	O
DDI-DrugBank.d89.s1	interact	41	48	O
DDI-DrugBank.d89.s1	with	50	53	O
DDI-DrugBank.d89.s1	drugs	55	59	O
DDI-DrugBank.d89.s1	that	61	64	O
DDI-DrugBank.d89.s1	are	66	68	O
DDI-DrugBank.d89.s1	substrates	70	79	O
DDI-DrugBank.d89.s1	for	81	83	O
DDI-DrugBank.d89.s1	CYP1A2	85	90	O
DDI-DrugBank.d89.s1	,	91	91	O
DDI-DrugBank.d89.s1	inhibit	93	99	O
DDI-DrugBank.d89.s1	CYP1A2	101	106	O
DDI-DrugBank.d89.s1	,	107	107	O
DDI-DrugBank.d89.s1	or	109	110	O
DDI-DrugBank.d89.s1	induce	112	117	O
DDI-DrugBank.d89.s1	CYP1A2	101	106	O
DDI-DrugBank.d89.s1	.	125	125	O
DDI-DrugBank.d89.s2	Few	0	2	O
DDI-DrugBank.d89.s2	data	4	7	O
DDI-DrugBank.d89.s2	exist	9	13	O
DDI-DrugBank.d89.s2	on	15	16	O
DDI-DrugBank.d89.s2	drug	18	21	O
DDI-DrugBank.d89.s2	interactions	23	34	O
DDI-DrugBank.d89.s2	with	36	39	O
DDI-DrugBank.d89.s2	caffeine	41	48	B-drug
DDI-DrugBank.d89.s2	in	46	47	I-drug
DDI-DrugBank.d89.s2	preterm	53	59	O
DDI-DrugBank.d89.s2	neonates	61	68	O
DDI-DrugBank.d89.s2	.	69	69	O
DDI-DrugBank.d89.s3	Based	0	4	O
DDI-DrugBank.d89.s3	on	6	7	O
DDI-DrugBank.d89.s3	adult	9	13	O
DDI-DrugBank.d89.s3	data	15	18	O
DDI-DrugBank.d89.s3	,	19	19	O
DDI-DrugBank.d89.s3	lower	21	25	O
DDI-DrugBank.d89.s3	doses	27	31	O
DDI-DrugBank.d89.s3	of	33	34	O
DDI-DrugBank.d89.s3	caffeine	36	43	B-drug
DDI-DrugBank.d89.s3	may	45	47	O
DDI-DrugBank.d89.s3	be	49	50	O
DDI-DrugBank.d89.s3	needed	52	57	O
DDI-DrugBank.d89.s3	following	59	67	O
DDI-DrugBank.d89.s3	coadministration	69	84	O
DDI-DrugBank.d89.s3	of	86	87	O
DDI-DrugBank.d89.s3	drugs	89	93	O
DDI-DrugBank.d89.s3	which	95	99	O
DDI-DrugBank.d89.s3	are	101	103	O
DDI-DrugBank.d89.s3	reported	105	112	O
DDI-DrugBank.d89.s3	to	114	115	O
DDI-DrugBank.d89.s3	decrease	117	124	O
DDI-DrugBank.d89.s3	caffeine	126	133	B-drug
DDI-DrugBank.d89.s3	elimination	135	145	O
DDI-DrugBank.d89.s3	(	147	147	O
DDI-DrugBank.d89.s3	e.g.	148	151	O
DDI-DrugBank.d89.s3	,	152	152	O
DDI-DrugBank.d89.s3	cimetidine	154	163	B-drug
DDI-DrugBank.d89.s3	and	165	167	O
DDI-DrugBank.d89.s3	ketoconazole	169	180	B-drug
DDI-DrugBank.d89.s3	)	181	181	O
DDI-DrugBank.d89.s3	and	165	167	O
DDI-DrugBank.d89.s3	higher	187	192	O
DDI-DrugBank.d89.s3	caffeine	194	201	B-drug
DDI-DrugBank.d89.s3	doses	203	207	O
DDI-DrugBank.d89.s3	may	209	211	O
DDI-DrugBank.d89.s3	be	213	214	O
DDI-DrugBank.d89.s3	needed	216	221	O
DDI-DrugBank.d89.s3	following	223	231	O
DDI-DrugBank.d89.s3	coadministration	233	248	O
DDI-DrugBank.d89.s3	of	250	251	O
DDI-DrugBank.d89.s3	drugs	253	257	O
DDI-DrugBank.d89.s3	that	259	262	O
DDI-DrugBank.d89.s3	increase	264	271	O
DDI-DrugBank.d89.s3	caffeine	273	280	B-drug
DDI-DrugBank.d89.s3	elimination	282	292	O
DDI-DrugBank.d89.s3	(	294	294	O
DDI-DrugBank.d89.s3	e.g.	295	298	O
DDI-DrugBank.d89.s3	,	299	299	O
DDI-DrugBank.d89.s3	phenobarbital	301	313	B-drug
DDI-DrugBank.d89.s3	and	315	317	O
DDI-DrugBank.d89.s3	phenytoin	319	327	B-drug
DDI-DrugBank.d89.s3	)	328	328	O
DDI-DrugBank.d89.s3	.	296	296	O
DDI-DrugBank.d89.s4	Caffeine	0	7	B-drug
DDI-DrugBank.d89.s4	administered	9	20	O
DDI-DrugBank.d89.s4	concurrently	22	33	O
DDI-DrugBank.d89.s4	with	35	38	O
DDI-DrugBank.d89.s4	ketoprofen	40	49	B-drug
DDI-DrugBank.d89.s4	reduced	51	57	O
DDI-DrugBank.d89.s4	the	59	61	O
DDI-DrugBank.d89.s4	urine	63	67	O
DDI-DrugBank.d89.s4	volume	69	74	O
DDI-DrugBank.d89.s4	in	76	77	O
DDI-DrugBank.d89.s4	4	79	79	O
DDI-DrugBank.d89.s4	healthy	81	87	O
DDI-DrugBank.d89.s4	volunteers	89	98	O
DDI-DrugBank.d89.s4	.	99	99	O
DDI-DrugBank.d89.s5	The	0	2	O
DDI-DrugBank.d89.s5	clinical	4	11	O
DDI-DrugBank.d89.s5	significance	13	24	O
DDI-DrugBank.d89.s5	of	26	27	O
DDI-DrugBank.d89.s5	this	29	32	O
DDI-DrugBank.d89.s5	interaction	34	44	O
DDI-DrugBank.d89.s5	in	46	47	O
DDI-DrugBank.d89.s5	preterm	49	55	O
DDI-DrugBank.d89.s5	neonates	57	64	O
DDI-DrugBank.d89.s5	is	66	67	O
DDI-DrugBank.d89.s5	not	69	71	O
DDI-DrugBank.d89.s5	known	73	77	O
DDI-DrugBank.d89.s5	.	78	78	O
DDI-DrugBank.d89.s6	Interconversion	0	14	O
DDI-DrugBank.d89.s6	between	16	22	O
DDI-DrugBank.d89.s6	caffeine	24	31	B-drug
DDI-DrugBank.d89.s6	and	33	35	O
DDI-DrugBank.d89.s6	theophylline	37	48	B-drug
DDI-DrugBank.d89.s6	has	50	52	O
DDI-DrugBank.d89.s6	been	54	57	O
DDI-DrugBank.d89.s6	reported	59	66	O
DDI-DrugBank.d89.s6	in	68	69	O
DDI-DrugBank.d89.s6	preterm	71	77	O
DDI-DrugBank.d89.s6	neonates	79	86	O
DDI-DrugBank.d89.s6	.	87	87	O
DDI-DrugBank.d89.s7	The	0	2	O
DDI-DrugBank.d89.s7	concurrent	4	13	O
DDI-DrugBank.d89.s7	use	15	17	O
DDI-DrugBank.d89.s7	of	19	20	O
DDI-DrugBank.d89.s7	these	22	26	O
DDI-DrugBank.d89.s7	drugs	28	32	O
DDI-DrugBank.d89.s7	is	34	35	O
DDI-DrugBank.d89.s7	not	37	39	O
DDI-DrugBank.d89.s7	recommended	41	51	O
DDI-DrugBank.d89.s7	.	52	52	O
DDI-MedLine.d103.s0	Magnesium	0	8	B-drug
DDI-MedLine.d103.s0	and	10	12	O
DDI-MedLine.d103.s0	therapeutics	14	25	O
DDI-MedLine.d103.s0	.	26	26	O
DDI-MedLine.d103.s1	Two	0	2	O
DDI-MedLine.d103.s1	different	4	12	O
DDI-MedLine.d103.s1	types	14	18	O
DDI-MedLine.d103.s1	of	20	21	O
DDI-MedLine.d103.s1	therapy	23	29	O
DDI-MedLine.d103.s1	with	31	34	O
DDI-MedLine.d103.s1	magnesium	36	44	B-drug
DDI-MedLine.d103.s1	are	46	48	O
DDI-MedLine.d103.s1	used	50	53	O
DDI-MedLine.d103.s1	:	54	54	O
DDI-MedLine.d103.s1	physiological	56	68	O
DDI-MedLine.d103.s1	oral	70	73	O
DDI-MedLine.d103.s1	magnesium	75	83	B-drug
DDI-MedLine.d103.s1	supplementation	85	99	O
DDI-MedLine.d103.s1	which	101	105	O
DDI-MedLine.d103.s1	is	107	108	O
DDI-MedLine.d103.s1	totally	110	116	O
DDI-MedLine.d103.s1	atoxic	118	123	O
DDI-MedLine.d103.s1	since	125	129	O
DDI-MedLine.d103.s1	it	131	132	O
DDI-MedLine.d103.s1	palliates	134	142	O
DDI-MedLine.d103.s1	magnesium	144	152	B-drug
DDI-MedLine.d103.s1	deficiencies	154	165	O
DDI-MedLine.d103.s1	by	167	168	O
DDI-MedLine.d103.s1	simply	170	175	O
DDI-MedLine.d103.s1	normalizing	177	187	O
DDI-MedLine.d103.s1	the	189	191	O
DDI-MedLine.d103.s1	magnesium	193	201	B-drug
DDI-MedLine.d103.s1	intake	203	208	O
DDI-MedLine.d103.s1	and	210	212	O
DDI-MedLine.d103.s1	pharmacological	214	228	O
DDI-MedLine.d103.s1	magnesium	230	238	B-drug
DDI-MedLine.d103.s1	therapy	240	246	O
DDI-MedLine.d103.s1	which	248	252	O
DDI-MedLine.d103.s1	may	254	256	O
DDI-MedLine.d103.s1	induce	258	263	O
DDI-MedLine.d103.s1	toxicity	265	272	O
DDI-MedLine.d103.s1	since	274	278	O
DDI-MedLine.d103.s1	it	270	271	O
DDI-MedLine.d103.s1	creates	283	289	O
DDI-MedLine.d103.s1	iatrogenic	291	300	O
DDI-MedLine.d103.s1	magnesium	302	310	B-drug
DDI-MedLine.d103.s1	overload	312	319	O
DDI-MedLine.d103.s1	.	320	320	O
DDI-MedLine.d103.s2	Primary	0	6	O
DDI-MedLine.d103.s2	and	8	10	O
DDI-MedLine.d103.s2	secondary	12	20	O
DDI-MedLine.d103.s2	magnesium	22	30	B-drug
DDI-MedLine.d103.s2	deficiencies	32	43	O
DDI-MedLine.d103.s2	constitute	45	54	O
DDI-MedLine.d103.s2	the	56	58	O
DDI-MedLine.d103.s2	sole	60	63	O
DDI-MedLine.d103.s2	indication	65	74	O
DDI-MedLine.d103.s2	of	76	77	O
DDI-MedLine.d103.s2	physiological	79	91	O
DDI-MedLine.d103.s2	oral	93	96	O
DDI-MedLine.d103.s2	magnesium	98	106	B-drug
DDI-MedLine.d103.s2	therapy	108	114	O
DDI-MedLine.d103.s2	.	115	115	O
DDI-MedLine.d103.s3	It	0	1	O
DDI-MedLine.d103.s3	is	3	4	O
DDI-MedLine.d103.s3	therefore	6	14	O
DDI-MedLine.d103.s3	necessary	16	24	O
DDI-MedLine.d103.s3	to	26	27	O
DDI-MedLine.d103.s3	be	29	30	O
DDI-MedLine.d103.s3	well	32	35	O
DDI-MedLine.d103.s3	acquainted	37	46	O
DDI-MedLine.d103.s3	with	48	51	O
DDI-MedLine.d103.s3	the	53	55	O
DDI-MedLine.d103.s3	clinical	57	64	O
DDI-MedLine.d103.s3	and	66	68	O
DDI-MedLine.d103.s3	paraclinical	70	81	O
DDI-MedLine.d103.s3	pattern	83	89	O
DDI-MedLine.d103.s3	of	91	92	O
DDI-MedLine.d103.s3	magnesium	94	102	B-drug
DDI-MedLine.d103.s3	deficit	104	110	O
DDI-MedLine.d103.s3	and	112	114	O
DDI-MedLine.d103.s3	to	116	117	O
DDI-MedLine.d103.s3	discriminate	119	130	O
DDI-MedLine.d103.s3	between	132	138	O
DDI-MedLine.d103.s3	magnesium	140	148	B-drug
DDI-MedLine.d103.s3	deficiency	150	159	O
DDI-MedLine.d103.s3	due	161	163	O
DDI-MedLine.d103.s3	to	165	166	O
DDI-MedLine.d103.s3	an	168	169	O
DDI-MedLine.d103.s3	insufficient	171	182	O
DDI-MedLine.d103.s3	magnesium	184	192	B-drug
DDI-MedLine.d103.s3	intake	194	199	O
DDI-MedLine.d103.s3	which	201	205	O
DDI-MedLine.d103.s3	only	207	210	O
DDI-MedLine.d103.s3	requires	212	219	O
DDI-MedLine.d103.s3	oral	221	224	O
DDI-MedLine.d103.s3	physiological	226	238	O
DDI-MedLine.d103.s3	supplementation	240	254	O
DDI-MedLine.d103.s3	and	256	258	O
DDI-MedLine.d103.s3	magnesium	260	268	B-drug
DDI-MedLine.d103.s3	depletion	270	278	O
DDI-MedLine.d103.s3	related	280	286	O
DDI-MedLine.d103.s3	to	288	289	O
DDI-MedLine.d103.s3	a	256	256	O
DDI-MedLine.d103.s3	dysregulation	293	305	O
DDI-MedLine.d103.s3	of	307	308	O
DDI-MedLine.d103.s3	the	310	312	O
DDI-MedLine.d103.s3	control	314	320	O
DDI-MedLine.d103.s3	mechanisms	322	331	O
DDI-MedLine.d103.s3	of	307	308	O
DDI-MedLine.d103.s3	magnesium	336	344	B-drug
DDI-MedLine.d103.s3	status	346	351	O
DDI-MedLine.d103.s3	which	353	357	O
DDI-MedLine.d103.s3	requires	359	366	O
DDI-MedLine.d103.s3	more	368	371	O
DDI-MedLine.d103.s3	or	369	370	O
DDI-MedLine.d103.s3	less	376	379	O
DDI-MedLine.d103.s3	specific	381	388	O
DDI-MedLine.d103.s3	regulation	390	399	O
DDI-MedLine.d103.s3	of	401	402	O
DDI-MedLine.d103.s3	its	404	406	O
DDI-MedLine.d103.s3	causal	408	413	O
DDI-MedLine.d103.s3	dysregulation	415	427	O
DDI-MedLine.d103.s3	.	428	428	O
DDI-MedLine.d103.s4	Physiological	0	12	O
DDI-MedLine.d103.s4	oral	14	17	O
DDI-MedLine.d103.s4	magnesium	19	27	B-drug
DDI-MedLine.d103.s4	load	29	32	O
DDI-MedLine.d103.s4	constitutes	34	44	O
DDI-MedLine.d103.s4	the	46	48	O
DDI-MedLine.d103.s4	best	50	53	O
DDI-MedLine.d103.s4	tool	55	58	O
DDI-MedLine.d103.s4	for	60	62	O
DDI-MedLine.d103.s4	diagnosis	64	72	O
DDI-MedLine.d103.s4	of	74	75	O
DDI-MedLine.d103.s4	magnesium	77	85	B-drug
DDI-MedLine.d103.s4	deficiency	87	96	O
DDI-MedLine.d103.s4	and	98	100	O
DDI-MedLine.d103.s4	the	102	104	O
DDI-MedLine.d103.s4	first	106	110	O
DDI-MedLine.d103.s4	step	112	115	O
DDI-MedLine.d103.s4	of	117	118	O
DDI-MedLine.d103.s4	its	120	122	O
DDI-MedLine.d103.s4	treatment	124	132	O
DDI-MedLine.d103.s4	.	133	133	O
DDI-MedLine.d103.s5	Physiological	0	12	O
DDI-MedLine.d103.s5	oral	14	17	O
DDI-MedLine.d103.s5	magnesium	19	27	B-drug
DDI-MedLine.d103.s5	supplementation	29	43	O
DDI-MedLine.d103.s5	(	45	45	O
DDI-MedLine.d103.s5	5	46	46	O
DDI-MedLine.d103.s5	mg/kg/day	48	56	O
DDI-MedLine.d103.s5	)	57	57	O
DDI-MedLine.d103.s5	is	59	60	O
DDI-MedLine.d103.s5	easy	62	65	O
DDI-MedLine.d103.s5	and	67	69	O
DDI-MedLine.d103.s5	can	71	73	O
DDI-MedLine.d103.s5	be	75	76	O
DDI-MedLine.d103.s5	carried	78	84	O
DDI-MedLine.d103.s5	out	86	88	O
DDI-MedLine.d103.s5	in	90	91	O
DDI-MedLine.d103.s5	the	93	95	O
DDI-MedLine.d103.s5	diet	97	100	O
DDI-MedLine.d103.s5	or	102	103	O
DDI-MedLine.d103.s5	with	105	108	O
DDI-MedLine.d103.s5	magnesium	110	118	B-drug
DDI-MedLine.d103.s5	salts	120	124	O
DDI-MedLine.d103.s5	,	125	125	O
DDI-MedLine.d103.s5	with	127	130	O
DDI-MedLine.d103.s5	practically	132	142	O
DDI-MedLine.d103.s5	only	144	147	O
DDI-MedLine.d103.s5	one	149	151	O
DDI-MedLine.d103.s5	contra-indication	153	169	O
DDI-MedLine.d103.s5	:	170	170	O
DDI-MedLine.d103.s5	overt	172	176	O
DDI-MedLine.d103.s5	renal	178	182	O
DDI-MedLine.d103.s5	failure	184	190	O
DDI-MedLine.d103.s5	.	191	191	O
DDI-MedLine.d103.s6	Specific	0	7	O
DDI-MedLine.d103.s6	and	9	11	O
DDI-MedLine.d103.s6	aspecific	13	21	O
DDI-MedLine.d103.s6	treatments	23	32	O
DDI-MedLine.d103.s6	of	34	35	O
DDI-MedLine.d103.s6	magnesium	37	45	B-drug
DDI-MedLine.d103.s6	depletion	47	55	O
DDI-MedLine.d103.s6	are	57	59	O
DDI-MedLine.d103.s6	tricky	61	66	O
DDI-MedLine.d103.s6	using	68	72	O
DDI-MedLine.d103.s6	for	74	76	O
DDI-MedLine.d103.s6	example	78	84	O
DDI-MedLine.d103.s6	magnesium	86	94	B-group
DDI-MedLine.d103.s6	sparing	96	102	I-group
DDI-MedLine.d103.s6	diuretics	104	112	I-group
DDI-MedLine.d103.s6	,	113	113	O
DDI-MedLine.d103.s6	pharmacological	115	129	O
DDI-MedLine.d103.s6	doses	131	135	O
DDI-MedLine.d103.s6	of	137	138	O
DDI-MedLine.d103.s6	vitamin	140	146	B-drug
DDI-MedLine.d103.s6	B6	148	149	I-drug
DDI-MedLine.d103.s6	,	150	150	O
DDI-MedLine.d103.s6	physiological	152	164	O
DDI-MedLine.d103.s6	doses	166	170	O
DDI-MedLine.d103.s6	of	172	173	O
DDI-MedLine.d103.s6	vitamin	175	181	B-group
DDI-MedLine.d103.s6	D	183	183	O
DDI-MedLine.d103.s6	and	185	187	O
DDI-MedLine.d103.s6	of	172	173	O
DDI-MedLine.d103.s6	selenium	192	199	B-drug
DDI-MedLine.d103.s6	.	200	200	O
DDI-MedLine.d103.s7	In	0	1	O
DDI-MedLine.d103.s7	order	3	7	O
DDI-MedLine.d103.s7	to	9	10	O
DDI-MedLine.d103.s7	use	12	14	O
DDI-MedLine.d103.s7	the	16	18	O
DDI-MedLine.d103.s7	pharmacological	20	34	O
DDI-MedLine.d103.s7	properties	36	45	O
DDI-MedLine.d103.s7	of	47	48	O
DDI-MedLine.d103.s7	induced	50	56	O
DDI-MedLine.d103.s7	therapeutic	58	68	O
DDI-MedLine.d103.s7	hypermagnesaemia	70	85	O
DDI-MedLine.d103.s7	,	86	86	O
DDI-MedLine.d103.s7	high	88	91	O
DDI-MedLine.d103.s7	oral	93	96	O
DDI-MedLine.d103.s7	doses	98	102	O
DDI-MedLine.d103.s7	of	104	105	O
DDI-MedLine.d103.s7	magnesium	107	115	B-drug
DDI-MedLine.d103.s7	(	117	117	O
DDI-MedLine.d103.s7	>	118	118	O
DDI-MedLine.d103.s7	10	120	121	O
DDI-MedLine.d103.s7	mg/kg/day	123	131	O
DDI-MedLine.d103.s7	)	132	132	O
DDI-MedLine.d103.s7	are	134	136	O
DDI-MedLine.d103.s7	advisable	138	146	O
DDI-MedLine.d103.s7	for	148	150	O
DDI-MedLine.d103.s7	chronic	152	158	O
DDI-MedLine.d103.s7	indications	160	170	O
DDI-MedLine.d103.s7	and	172	174	O
DDI-MedLine.d103.s7	the	176	178	O
DDI-MedLine.d103.s7	parenteral	180	189	O
DDI-MedLine.d103.s7	route	191	195	O
DDI-MedLine.d103.s7	is	197	198	O
DDI-MedLine.d103.s7	suitable	200	207	O
DDI-MedLine.d103.s7	for	209	211	O
DDI-MedLine.d103.s7	acute	213	217	O
DDI-MedLine.d103.s7	indications	219	229	O
DDI-MedLine.d103.s7	.	230	230	O
DDI-MedLine.d103.s8	There	0	4	O
DDI-MedLine.d103.s8	are	6	8	O
DDI-MedLine.d103.s8	3	10	10	O
DDI-MedLine.d103.s8	types	12	16	O
DDI-MedLine.d103.s8	of	18	19	O
DDI-MedLine.d103.s8	indications	21	31	O
DDI-MedLine.d103.s8	:	32	32	O
DDI-MedLine.d103.s8	specific	34	41	O
DDI-MedLine.d103.s8	(	43	43	O
DDI-MedLine.d103.s8	for	44	46	O
DDI-MedLine.d103.s8	the	48	50	O
DDI-MedLine.d103.s8	treatment	52	60	O
DDI-MedLine.d103.s8	of	62	63	O
DDI-MedLine.d103.s8	some	65	68	O
DDI-MedLine.d103.s8	forms	70	74	O
DDI-MedLine.d103.s8	of	76	77	O
DDI-MedLine.d103.s8	magnesium	79	87	B-drug
DDI-MedLine.d103.s8	deficit	89	95	O
DDI-MedLine.d103.s8	i.e	97	99	O
DDI-MedLine.d103.s8	.	98	98	O
DDI-MedLine.d103.s8	acute	102	106	O
DDI-MedLine.d103.s8	)	107	107	O
DDI-MedLine.d103.s8	,	108	108	O
DDI-MedLine.d103.s8	pharmacological	110	124	O
DDI-MedLine.d103.s8	(	126	126	O
DDI-MedLine.d103.s8	i.e	127	129	O
DDI-MedLine.d103.s8	.	128	128	O
DDI-MedLine.d103.s8	without	132	138	O
DDI-MedLine.d103.s8	alterations	140	150	O
DDI-MedLine.d103.s8	of	152	153	O
DDI-MedLine.d103.s8	magnesium	155	163	B-drug
DDI-MedLine.d103.s8	status	165	170	O
DDI-MedLine.d103.s8	)	171	171	O
DDI-MedLine.d103.s8	and	173	175	O
DDI-MedLine.d103.s8	mixed	177	181	O
DDI-MedLine.d103.s8	--	182	183	O
DDI-MedLine.d103.s8	pharmacological	184	198	O
DDI-MedLine.d103.s8	and	173	175	O
DDI-MedLine.d103.s8	aetiopathogenic	204	218	O
DDI-MedLine.d103.s8	--	219	220	O
DDI-MedLine.d103.s8	(	221	221	O
DDI-MedLine.d103.s8	for	222	224	O
DDI-MedLine.d103.s8	example	226	232	O
DDI-MedLine.d103.s8	complications	234	246	O
DDI-MedLine.d103.s8	of	248	249	O
DDI-MedLine.d103.s8	chronic	251	257	O
DDI-MedLine.d103.s8	alcoholism	259	268	O
DDI-MedLine.d103.s8	)	269	269	O
DDI-MedLine.d103.s8	.	270	270	O
DDI-MedLine.d103.s9	Today	0	4	O
DDI-MedLine.d103.s9	pharmacological	6	20	O
DDI-MedLine.d103.s9	magnesium	22	30	B-drug
DDI-MedLine.d103.s9	therapy	32	38	O
DDI-MedLine.d103.s9	mainly	40	45	O
DDI-MedLine.d103.s9	concerns	47	54	O
DDI-MedLine.d103.s9	the	56	58	O
DDI-MedLine.d103.s9	obstetrical	60	70	O
DDI-MedLine.d103.s9	,	71	71	O
DDI-MedLine.d103.s9	cardiological	73	85	O
DDI-MedLine.d103.s9	and	87	89	O
DDI-MedLine.d103.s9	anaesthesiological	91	108	O
DDI-MedLine.d103.s9	fields	110	115	O
DDI-MedLine.d103.s9	.	116	116	O
DDI-MedLine.d103.s10	The	0	2	O
DDI-MedLine.d103.s10	main	4	7	O
DDI-MedLine.d103.s10	indications	9	19	O
DDI-MedLine.d103.s10	are	21	23	O
DDI-MedLine.d103.s10	eclampsia	25	33	O
DDI-MedLine.d103.s10	,	34	34	O
DDI-MedLine.d103.s10	some	36	39	O
DDI-MedLine.d103.s10	dysrhythmias	41	52	O
DDI-MedLine.d103.s10	(	54	54	O
DDI-MedLine.d103.s10	torsades	55	62	O
DDI-MedLine.d103.s10	de	60	61	O
DDI-MedLine.d103.s10	pointe	67	72	O
DDI-MedLine.d103.s10	particularly	74	85	O
DDI-MedLine.d103.s10	)	86	86	O
DDI-MedLine.d103.s10	and	88	90	O
DDI-MedLine.d103.s10	myocardial	92	101	O
DDI-MedLine.d103.s10	ischaemias	103	112	O
DDI-MedLine.d103.s10	.	113	113	O
DDI-MedLine.d103.s11	But	0	2	O
DDI-MedLine.d103.s11	it	4	5	O
DDI-MedLine.d103.s11	is	7	8	O
DDI-MedLine.d103.s11	now	10	12	O
DDI-MedLine.d103.s11	difficult	14	22	O
DDI-MedLine.d103.s11	to	24	25	O
DDI-MedLine.d103.s11	situate	27	33	O
DDI-MedLine.d103.s11	the	35	37	O
DDI-MedLine.d103.s11	exact	39	43	O
DDI-MedLine.d103.s11	place	45	49	O
DDI-MedLine.d103.s11	of	51	52	O
DDI-MedLine.d103.s11	the	54	56	O
DDI-MedLine.d103.s11	pharmacological	58	72	O
DDI-MedLine.d103.s11	indications	74	84	O
DDI-MedLine.d103.s11	of	86	87	O
DDI-MedLine.d103.s11	magnesium	89	97	B-drug
DDI-MedLine.d103.s11	.	98	98	O
DDI-MedLine.d103.s12	Magnesium	0	8	B-drug
DDI-MedLine.d103.s12	infusions	10	18	O
DDI-MedLine.d103.s12	can	20	22	O
DDI-MedLine.d103.s12	only	24	27	O
DDI-MedLine.d103.s12	be	29	30	O
DDI-MedLine.d103.s12	envisaged	32	40	O
DDI-MedLine.d103.s12	in	42	43	O
DDI-MedLine.d103.s12	intensive	45	53	O
DDI-MedLine.d103.s12	care	55	58	O
DDI-MedLine.d103.s12	units	60	64	O
DDI-MedLine.d103.s12	with	66	69	O
DDI-MedLine.d103.s12	careful	71	77	O
DDI-MedLine.d103.s12	monitoring	79	88	O
DDI-MedLine.d103.s12	of	90	91	O
DDI-MedLine.d103.s12	pulse	93	97	O
DDI-MedLine.d103.s12	,	98	98	O
DDI-MedLine.d103.s12	arterial	100	107	O
DDI-MedLine.d103.s12	pressure	109	116	O
DDI-MedLine.d103.s12	,	117	117	O
DDI-MedLine.d103.s12	deep	119	122	O
DDI-MedLine.d103.s12	tendon	124	129	O
DDI-MedLine.d103.s12	reflexes	131	138	O
DDI-MedLine.d103.s12	,	139	139	O
DDI-MedLine.d103.s12	hourly	141	146	O
DDI-MedLine.d103.s12	diuresis	148	155	O
DDI-MedLine.d103.s12	,	139	139	O
DDI-MedLine.d103.s12	electrocardiogram	158	174	O
DDI-MedLine.d103.s12	and	176	178	O
DDI-MedLine.d103.s12	respiratory	180	190	O
DDI-MedLine.d103.s12	recordings	192	201	O
DDI-MedLine.d103.s12	.	202	202	O
DDI-MedLine.d103.s13	High	0	3	O
DDI-MedLine.d103.s13	oral	5	8	O
DDI-MedLine.d103.s13	magnesium	10	18	B-drug
DDI-MedLine.d103.s13	doses	20	24	O
DDI-MedLine.d103.s13	besides	26	32	O
DDI-MedLine.d103.s13	their	34	38	O
DDI-MedLine.d103.s13	laxative	40	47	O
DDI-MedLine.d103.s13	action	49	54	O
DDI-MedLine.d103.s13	may	56	58	O
DDI-MedLine.d103.s13	bring	60	64	O
DDI-MedLine.d103.s13	latent	66	71	O
DDI-MedLine.d103.s13	complications	73	85	O
DDI-MedLine.d103.s13	which	87	91	O
DDI-MedLine.d103.s13	may	93	95	O
DDI-MedLine.d103.s13	reduce	97	102	O
DDI-MedLine.d103.s13	lifespan	104	111	O
DDI-MedLine.d103.s13	.	112	112	O
DDI-MedLine.d103.s14	There	0	4	O
DDI-MedLine.d103.s14	may	6	8	O
DDI-MedLine.d103.s14	remain	10	15	O
DDI-MedLine.d103.s14	some	17	20	O
DDI-MedLine.d103.s14	indications	22	32	O
DDI-MedLine.d103.s14	of	34	35	O
DDI-MedLine.d103.s14	the	37	39	O
DDI-MedLine.d103.s14	laxative	41	48	O
DDI-MedLine.d103.s14	and	50	52	O
DDI-MedLine.d103.s14	antacid	54	60	O
DDI-MedLine.d103.s14	properties	62	71	O
DDI-MedLine.d103.s14	of	73	74	O
DDI-MedLine.d103.s14	non	76	78	O
DDI-MedLine.d103.s14	soluble	80	86	O
DDI-MedLine.d103.s14	magnesium	88	96	B-drug
DDI-MedLine.d103.s14	,	97	97	O
DDI-MedLine.d103.s14	particularly	99	110	O
DDI-MedLine.d103.s14	during	112	117	O
DDI-MedLine.d103.s14	intermittent	119	130	O
DDI-MedLine.d103.s14	haemodialysis	132	144	O
DDI-MedLine.d103.s14	.	145	145	O
DDI-MedLine.d103.s15	Lastly	0	5	O
DDI-MedLine.d103.s15	local	7	11	O
DDI-MedLine.d103.s15	use	13	15	O
DDI-MedLine.d103.s15	of	17	18	O
DDI-MedLine.d103.s15	the	20	22	O
DDI-MedLine.d103.s15	mucocutaneous	24	36	O
DDI-MedLine.d103.s15	and	38	40	O
DDI-MedLine.d103.s15	cytoprotective	42	55	O
DDI-MedLine.d103.s15	properties	57	66	O
DDI-MedLine.d103.s15	of	68	69	O
DDI-MedLine.d103.s15	magnesium	71	79	B-drug
DDI-MedLine.d103.s15	is	81	82	O
DDI-MedLine.d103.s15	still	84	88	O
DDI-MedLine.d103.s15	valid	90	94	O
DDI-MedLine.d103.s15	,	95	95	O
DDI-MedLine.d103.s15	in	97	98	O
DDI-MedLine.d103.s15	cardioplegic	100	111	B-drug
DDI-MedLine.d103.s15	solutions	113	121	I-drug
DDI-MedLine.d103.s15	and	123	125	O
DDI-MedLine.d103.s15	for	127	129	O
DDI-MedLine.d103.s15	preservation	131	142	O
DDI-MedLine.d103.s15	of	144	145	O
DDI-MedLine.d103.s15	transplants	147	157	O
DDI-MedLine.d103.s15	particularly	159	170	O
DDI-MedLine.d103.s15	.	171	171	O
DDI-DrugBank.d415.s0	Coumarin-Type	0	12	B-group
DDI-DrugBank.d415.s0	Anticoagulants	14	27	I-group
DDI-DrugBank.d415.s0	:	28	28	O
DDI-DrugBank.d415.s0	Several	30	36	O
DDI-DrugBank.d415.s0	short-term	38	47	O
DDI-DrugBank.d415.s0	controlled	49	58	O
DDI-DrugBank.d415.s0	studies	60	66	O
DDI-DrugBank.d415.s0	failed	68	73	O
DDI-DrugBank.d415.s0	to	75	76	O
DDI-DrugBank.d415.s0	wshow	78	82	O
DDI-DrugBank.d415.s0	that	84	87	O
DDI-DrugBank.d415.s0	ibuprofen	89	97	B-drug
DDI-DrugBank.d415.s0	significantly	99	111	O
DDI-DrugBank.d415.s0	affected	113	120	O
DDI-DrugBank.d415.s0	prothrombin	122	132	O
DDI-DrugBank.d415.s0	times	134	138	O
DDI-DrugBank.d415.s0	or	140	141	O
DDI-DrugBank.d415.s0	a	143	143	O
DDI-DrugBank.d415.s0	variety	145	151	O
DDI-DrugBank.d415.s0	of	153	154	O
DDI-DrugBank.d415.s0	other	156	160	O
DDI-DrugBank.d415.s0	clotting	162	169	O
DDI-DrugBank.d415.s0	factors	171	177	O
DDI-DrugBank.d415.s0	when	179	182	O
DDI-DrugBank.d415.s0	administered	184	195	O
DDI-DrugBank.d415.s0	to	174	175	O
DDI-DrugBank.d415.s0	individuals	200	210	O
DDI-DrugBank.d415.s0	on	212	213	O
DDI-DrugBank.d415.s0	coumarin-type	215	227	B-group
DDI-DrugBank.d415.s0	anticoagulants	229	242	I-group
DDI-DrugBank.d415.s0	.	243	243	O
DDI-DrugBank.d415.s1	However	0	6	O
DDI-DrugBank.d415.s1	,	7	7	O
DDI-DrugBank.d415.s1	because	9	15	O
DDI-DrugBank.d415.s1	bleeding	17	24	O
DDI-DrugBank.d415.s1	has	26	28	O
DDI-DrugBank.d415.s1	been	30	33	O
DDI-DrugBank.d415.s1	reported	35	42	O
DDI-DrugBank.d415.s1	when	44	47	O
DDI-DrugBank.d415.s1	ibuprofen	49	57	B-drug
DDI-DrugBank.d415.s1	and	59	61	O
DDI-DrugBank.d415.s1	other	63	67	O
DDI-DrugBank.d415.s1	nonsteroidal	69	80	B-group
DDI-DrugBank.d415.s1	anti-inflammatory	82	98	I-group
DDI-DrugBank.d415.s1	agents	100	105	I-group
DDI-DrugBank.d415.s1	have	107	110	O
DDI-DrugBank.d415.s1	been	112	115	O
DDI-DrugBank.d415.s1	administered	117	128	O
DDI-DrugBank.d415.s1	to	130	131	O
DDI-DrugBank.d415.s1	patients	133	140	O
DDI-DrugBank.d415.s1	on	142	143	O
DDI-DrugBank.d415.s1	coumarin-type	145	157	B-group
DDI-DrugBank.d415.s1	anticoagulants	159	172	I-group
DDI-DrugBank.d415.s1	,	173	173	O
DDI-DrugBank.d415.s1	the	175	177	O
DDI-DrugBank.d415.s1	physician	179	187	O
DDI-DrugBank.d415.s1	should	189	194	O
DDI-DrugBank.d415.s1	be	196	197	O
DDI-DrugBank.d415.s1	cautious	199	206	O
DDI-DrugBank.d415.s1	when	208	211	O
DDI-DrugBank.d415.s1	administering	213	225	O
DDI-DrugBank.d415.s1	ibuprofen	227	235	B-drug
DDI-DrugBank.d415.s1	to	237	238	O
DDI-DrugBank.d415.s1	patients	240	247	O
DDI-DrugBank.d415.s1	on	249	250	O
DDI-DrugBank.d415.s1	anticoagulants	252	265	B-group
DDI-DrugBank.d415.s1	.	266	266	O
DDI-DrugBank.d415.s2	Aspirin	0	6	B-brand
DDI-DrugBank.d415.s2	:	7	7	O
DDI-DrugBank.d415.s2	Animal	9	14	O
DDI-DrugBank.d415.s2	studies	16	22	O
DDI-DrugBank.d415.s2	wshow	24	28	O
DDI-DrugBank.d415.s2	that	30	33	O
DDI-DrugBank.d415.s2	aspirin	35	41	B-brand
DDI-DrugBank.d415.s2	given	43	47	O
DDI-DrugBank.d415.s2	with	49	52	O
DDI-DrugBank.d415.s2	nonsteroidal	54	65	B-group
DDI-DrugBank.d415.s2	anti-inflammatory	67	83	I-group
DDI-DrugBank.d415.s2	agents	85	90	I-group
DDI-DrugBank.d415.s2	,	91	91	O
DDI-DrugBank.d415.s2	including	93	101	O
DDI-DrugBank.d415.s2	ibuprofen	103	111	B-drug
DDI-DrugBank.d415.s2	,	112	112	O
DDI-DrugBank.d415.s2	yields	114	119	O
DDI-DrugBank.d415.s2	a	121	121	O
DDI-DrugBank.d415.s2	net	123	125	O
DDI-DrugBank.d415.s2	decrease	127	134	O
DDI-DrugBank.d415.s2	in	136	137	O
DDI-DrugBank.d415.s2	anti-inflammatory	139	155	O
DDI-DrugBank.d415.s2	activity	157	164	O
DDI-DrugBank.d415.s2	with	166	169	O
DDI-DrugBank.d415.s2	lowered	171	177	O
DDI-DrugBank.d415.s2	blood	179	183	O
DDI-DrugBank.d415.s2	levels	185	190	O
DDI-DrugBank.d415.s2	of	192	193	O
DDI-DrugBank.d415.s2	the	195	197	O
DDI-DrugBank.d415.s2	non-aspirin	199	209	O
DDI-DrugBank.d415.s2	drug	211	214	O
DDI-DrugBank.d415.s2	.	215	215	O
DDI-DrugBank.d415.s3	Single	0	5	O
DDI-DrugBank.d415.s3	dose	7	10	O
DDI-DrugBank.d415.s3	bioavailability	12	26	O
DDI-DrugBank.d415.s3	studies	28	34	O
DDI-DrugBank.d415.s3	in	36	37	O
DDI-DrugBank.d415.s3	normal	39	44	O
DDI-DrugBank.d415.s3	volunteers	46	55	O
DDI-DrugBank.d415.s3	have	57	60	O
DDI-DrugBank.d415.s3	failed	62	67	O
DDI-DrugBank.d415.s3	to	69	70	O
DDI-DrugBank.d415.s3	wshow	72	76	O
DDI-DrugBank.d415.s3	an	78	79	O
DDI-DrugBank.d415.s3	effect	81	86	O
DDI-DrugBank.d415.s3	of	88	89	O
DDI-DrugBank.d415.s3	aspirin	91	97	B-brand
DDI-DrugBank.d415.s3	on	99	100	O
DDI-DrugBank.d415.s3	ibuprofen	102	110	B-drug
DDI-DrugBank.d415.s3	blood	112	116	O
DDI-DrugBank.d415.s3	levels	118	123	O
DDI-DrugBank.d415.s3	.	124	124	O
DDI-DrugBank.d415.s4	Correlative	0	10	O
DDI-DrugBank.d415.s4	clinical	12	19	O
DDI-DrugBank.d415.s4	studies	21	27	O
DDI-DrugBank.d415.s4	have	29	32	O
DDI-DrugBank.d415.s4	not	34	36	O
DDI-DrugBank.d415.s4	been	38	41	O
DDI-DrugBank.d415.s4	performed	43	51	O
DDI-DrugBank.d415.s4	.	52	52	O
DDI-DrugBank.d415.s5	Methotrexate	0	11	B-drug
DDI-DrugBank.d415.s5	:	12	12	O
DDI-DrugBank.d415.s5	Ibuprofen	14	22	B-drug
DDI-DrugBank.d415.s5	,	23	23	O
DDI-DrugBank.d415.s5	as	25	26	O
DDI-DrugBank.d415.s5	well	28	31	O
DDI-DrugBank.d415.s5	as	33	34	O
DDI-DrugBank.d415.s5	other	36	40	O
DDI-DrugBank.d415.s5	nonsteroidal	42	53	B-group
DDI-DrugBank.d415.s5	anti-inflammatory	55	71	I-group
DDI-DrugBank.d415.s5	drugs	73	77	I-group
DDI-DrugBank.d415.s5	,	78	78	O
DDI-DrugBank.d415.s5	probably	80	87	O
DDI-DrugBank.d415.s5	reduces	89	95	O
DDI-DrugBank.d415.s5	the	97	99	O
DDI-DrugBank.d415.s5	tubular	101	107	O
DDI-DrugBank.d415.s5	secretion	109	117	O
DDI-DrugBank.d415.s5	of	119	120	O
DDI-DrugBank.d415.s5	methotrexate	122	133	B-drug
DDI-DrugBank.d415.s5	based	135	139	O
DDI-DrugBank.d415.s5	on	141	142	O
DDI-DrugBank.d415.s5	in	144	145	O
DDI-DrugBank.d415.s5	vitro	147	151	O
DDI-DrugBank.d415.s5	studies	153	159	O
DDI-DrugBank.d415.s5	in	144	145	O
DDI-DrugBank.d415.s5	rabbit	164	169	O
DDI-DrugBank.d415.s5	kidney	171	176	O
DDI-DrugBank.d415.s5	slices	178	183	O
DDI-DrugBank.d415.s5	.	184	184	O
DDI-DrugBank.d415.s6	This	0	3	O
DDI-DrugBank.d415.s6	may	5	7	O
DDI-DrugBank.d415.s6	indicate	9	16	O
DDI-DrugBank.d415.s6	that	18	21	O
DDI-DrugBank.d415.s6	ibuprofen	23	31	B-drug
DDI-DrugBank.d415.s6	could	33	37	O
DDI-DrugBank.d415.s6	enhance	39	45	O
DDI-DrugBank.d415.s6	the	47	49	O
DDI-DrugBank.d415.s6	toxicity	51	58	O
DDI-DrugBank.d415.s6	of	60	61	O
DDI-DrugBank.d415.s6	methotrexate	63	74	B-drug
DDI-DrugBank.d415.s6	.	75	75	O
DDI-DrugBank.d415.s7	Caution	0	6	O
DDI-DrugBank.d415.s7	should	8	13	O
DDI-DrugBank.d415.s7	be	15	16	O
DDI-DrugBank.d415.s7	used	18	21	O
DDI-DrugBank.d415.s7	if	23	24	O
DDI-DrugBank.d415.s7	ibuprofen	26	34	B-drug
DDI-DrugBank.d415.s7	is	36	37	O
DDI-DrugBank.d415.s7	administered	39	50	O
DDI-DrugBank.d415.s7	concomitantly	52	64	O
DDI-DrugBank.d415.s7	with	66	69	O
DDI-DrugBank.d415.s7	methotrexate	71	82	B-drug
DDI-DrugBank.d415.s7	.	83	83	O
DDI-DrugBank.d415.s8	H-2	0	2	O
DDI-DrugBank.d415.s8	Antagonists	4	14	O
DDI-DrugBank.d415.s8	:	15	15	O
DDI-DrugBank.d415.s8	In	17	18	O
DDI-DrugBank.d415.s8	studies	20	26	O
DDI-DrugBank.d415.s8	with	28	31	O
DDI-DrugBank.d415.s8	human	33	37	O
DDI-DrugBank.d415.s8	volunteers	39	48	O
DDI-DrugBank.d415.s8	,	49	49	O
DDI-DrugBank.d415.s8	co-administration	51	67	O
DDI-DrugBank.d415.s8	of	69	70	O
DDI-DrugBank.d415.s8	cimetidine	72	81	B-drug
DDI-DrugBank.d415.s8	or	83	84	O
DDI-DrugBank.d415.s8	ranitidine	86	95	B-drug
DDI-DrugBank.d415.s8	with	97	100	O
DDI-DrugBank.d415.s8	ibuprofen	102	110	B-drug
DDI-DrugBank.d415.s8	had	112	114	O
DDI-DrugBank.d415.s8	no	116	117	O
DDI-DrugBank.d415.s8	substantive	119	129	O
DDI-DrugBank.d415.s8	effect	131	136	O
DDI-DrugBank.d415.s8	on	138	139	O
DDI-DrugBank.d415.s8	ibuprofen	141	149	B-drug
DDI-DrugBank.d415.s8	serum	151	155	O
DDI-DrugBank.d415.s8	concentrations	157	170	O
DDI-DrugBank.d415.s8	.	171	171	O
DDI-DrugBank.d415.s9	Furosemide	0	9	B-drug
DDI-DrugBank.d415.s9	:	10	10	O
DDI-DrugBank.d415.s9	Clinical	12	19	O
DDI-DrugBank.d415.s9	studies	21	27	O
DDI-DrugBank.d415.s9	,	28	28	O
DDI-DrugBank.d415.s9	as	30	31	O
DDI-DrugBank.d415.s9	well	33	36	O
DDI-DrugBank.d415.s9	as	38	39	O
DDI-DrugBank.d415.s9	random	41	46	O
DDI-DrugBank.d415.s9	observations	48	59	O
DDI-DrugBank.d415.s9	,	60	60	O
DDI-DrugBank.d415.s9	have	62	65	O
DDI-DrugBank.d415.s9	shown	67	71	O
DDI-DrugBank.d415.s9	that	73	76	O
DDI-DrugBank.d415.s9	ibuprofen	78	86	B-drug
DDI-DrugBank.d415.s9	can	88	90	O
DDI-DrugBank.d415.s9	reduce	92	97	O
DDI-DrugBank.d415.s9	the	99	101	O
DDI-DrugBank.d415.s9	natriuretic	103	113	O
DDI-DrugBank.d415.s9	effect	115	120	O
DDI-DrugBank.d415.s9	of	122	123	O
DDI-DrugBank.d415.s9	furosemide	125	134	B-drug
DDI-DrugBank.d415.s9	and	136	138	O
DDI-DrugBank.d415.s9	thiazides	140	148	B-group
DDI-DrugBank.d415.s9	in	150	151	O
DDI-DrugBank.d415.s9	some	153	156	O
DDI-DrugBank.d415.s9	patients	158	165	O
DDI-DrugBank.d415.s9	.	166	166	O
DDI-DrugBank.d415.s10	This	0	3	O
DDI-DrugBank.d415.s10	response	5	12	O
DDI-DrugBank.d415.s10	has	14	16	O
DDI-DrugBank.d415.s10	been	18	21	O
DDI-DrugBank.d415.s10	attributed	23	32	O
DDI-DrugBank.d415.s10	to	34	35	O
DDI-DrugBank.d415.s10	inhibition	37	46	O
DDI-DrugBank.d415.s10	of	48	49	O
DDI-DrugBank.d415.s10	renal	51	55	O
DDI-DrugBank.d415.s10	prostaglandin	57	69	O
DDI-DrugBank.d415.s10	synthesis	71	79	O
DDI-DrugBank.d415.s10	.	80	80	O
DDI-DrugBank.d415.s11	During	0	5	O
DDI-DrugBank.d415.s11	concomitant	7	17	O
DDI-DrugBank.d415.s11	therapy	19	25	O
DDI-DrugBank.d415.s11	with	27	30	O
DDI-DrugBank.d415.s11	ibuprofen	32	40	B-drug
DDI-DrugBank.d415.s11	,	41	41	O
DDI-DrugBank.d415.s11	the	43	45	O
DDI-DrugBank.d415.s11	patient	47	53	O
DDI-DrugBank.d415.s11	should	55	60	O
DDI-DrugBank.d415.s11	be	62	63	O
DDI-DrugBank.d415.s11	observed	65	72	O
DDI-DrugBank.d415.s11	closely	74	80	O
DDI-DrugBank.d415.s11	for	82	84	O
DDI-DrugBank.d415.s11	signs	86	90	O
DDI-DrugBank.d415.s11	of	92	93	O
DDI-DrugBank.d415.s11	renal	95	99	O
DDI-DrugBank.d415.s11	failure	101	107	O
DDI-DrugBank.d415.s11	,	108	108	O
DDI-DrugBank.d415.s11	as	110	111	O
DDI-DrugBank.d415.s11	well	113	116	O
DDI-DrugBank.d415.s11	as	110	111	O
DDI-DrugBank.d415.s11	to	121	122	O
DDI-DrugBank.d415.s11	assure	124	129	O
DDI-DrugBank.d415.s11	diuretic	131	138	B-group
DDI-DrugBank.d415.s11	efficacy	140	147	O
DDI-DrugBank.d415.s11	.	148	148	O
DDI-DrugBank.d415.s12	Lithium	0	6	B-drug
DDI-DrugBank.d415.s12	:	7	7	O
DDI-DrugBank.d415.s12	Ibuprofen	9	17	B-drug
DDI-DrugBank.d415.s12	produced	19	26	O
DDI-DrugBank.d415.s12	an	28	29	O
DDI-DrugBank.d415.s12	elevation	31	39	O
DDI-DrugBank.d415.s12	of	41	42	O
DDI-DrugBank.d415.s12	plasma	44	49	O
DDI-DrugBank.d415.s12	lithium	51	57	B-drug
DDI-DrugBank.d415.s12	levels	59	64	O
DDI-DrugBank.d415.s12	and	66	68	O
DDI-DrugBank.d415.s12	a	66	66	O
DDI-DrugBank.d415.s12	reduction	72	80	O
DDI-DrugBank.d415.s12	in	82	83	O
DDI-DrugBank.d415.s12	renal	85	89	O
DDI-DrugBank.d415.s12	lithium	91	97	B-drug
DDI-DrugBank.d415.s12	clearance	99	107	O
DDI-DrugBank.d415.s12	in	109	110	O
DDI-DrugBank.d415.s12	a	102	102	O
DDI-DrugBank.d415.s12	study	114	118	O
DDI-DrugBank.d415.s12	of	120	121	O
DDI-DrugBank.d415.s12	eleven	123	128	O
DDI-DrugBank.d415.s12	normal	130	135	O
DDI-DrugBank.d415.s12	volunteers	137	146	O
DDI-DrugBank.d415.s12	.	147	147	O
DDI-DrugBank.d415.s13	The	0	2	O
DDI-DrugBank.d415.s13	mean	4	7	O
DDI-DrugBank.d415.s13	minimum	9	15	O
DDI-DrugBank.d415.s13	lithium	17	23	B-drug
DDI-DrugBank.d415.s13	concentration	25	37	O
DDI-DrugBank.d415.s13	increased	39	47	O
DDI-DrugBank.d415.s13	15	49	50	O
DDI-DrugBank.d415.s13	%	51	51	O
DDI-DrugBank.d415.s13	and	53	55	O
DDI-DrugBank.d415.s13	the	57	59	O
DDI-DrugBank.d415.s13	renal	61	65	O
DDI-DrugBank.d415.s13	clearance	67	75	O
DDI-DrugBank.d415.s13	of	77	78	O
DDI-DrugBank.d415.s13	lithium	80	86	B-drug
DDI-DrugBank.d415.s13	was	88	90	O
DDI-DrugBank.d415.s13	decreased	92	100	O
DDI-DrugBank.d415.s13	by	102	103	O
DDI-DrugBank.d415.s13	19	105	106	O
DDI-DrugBank.d415.s13	%	107	107	O
DDI-DrugBank.d415.s13	during	109	114	O
DDI-DrugBank.d415.s13	this	116	119	O
DDI-DrugBank.d415.s13	period	121	126	O
DDI-DrugBank.d415.s13	of	128	129	O
DDI-DrugBank.d415.s13	concomitant	131	141	O
DDI-DrugBank.d415.s13	drug	143	146	O
DDI-DrugBank.d415.s13	administration	148	161	O
DDI-DrugBank.d415.s13	.	162	162	O
DDI-DrugBank.d415.s14	This	0	3	O
DDI-DrugBank.d415.s14	effect	5	10	O
DDI-DrugBank.d415.s14	has	12	14	O
DDI-DrugBank.d415.s14	been	16	19	O
DDI-DrugBank.d415.s14	attributed	21	30	O
DDI-DrugBank.d415.s14	to	32	33	O
DDI-DrugBank.d415.s14	inhibition	35	44	O
DDI-DrugBank.d415.s14	of	46	47	O
DDI-DrugBank.d415.s14	renal	49	53	O
DDI-DrugBank.d415.s14	prostaglandin	55	67	O
DDI-DrugBank.d415.s14	synthesis	69	77	O
DDI-DrugBank.d415.s14	by	79	80	O
DDI-DrugBank.d415.s14	ibuprofen	82	90	B-drug
DDI-DrugBank.d415.s14	.	91	91	O
DDI-DrugBank.d415.s15	Thus	0	3	O
DDI-DrugBank.d415.s15	,	4	4	O
DDI-DrugBank.d415.s15	when	6	9	O
DDI-DrugBank.d415.s15	ibuprofen	11	19	B-drug
DDI-DrugBank.d415.s15	and	21	23	O
DDI-DrugBank.d415.s15	lithium	25	31	B-drug
DDI-DrugBank.d415.s15	are	33	35	O
DDI-DrugBank.d415.s15	administered	37	48	O
DDI-DrugBank.d415.s15	concurrently	50	61	O
DDI-DrugBank.d415.s15	,	62	62	O
DDI-DrugBank.d415.s15	subjects	64	71	O
DDI-DrugBank.d415.s15	should	73	78	O
DDI-DrugBank.d415.s15	be	80	81	O
DDI-DrugBank.d415.s15	observed	83	90	O
DDI-DrugBank.d415.s15	carefully	92	100	O
DDI-DrugBank.d415.s15	for	102	104	O
DDI-DrugBank.d415.s15	signs	106	110	O
DDI-DrugBank.d415.s15	of	112	113	O
DDI-DrugBank.d415.s15	lithium	115	121	B-drug
DDI-DrugBank.d415.s15	toxicity	123	130	O
DDI-DrugBank.d415.s15	.	131	131	O
DDI-DrugBank.d415.s16	(	0	0	O
DDI-DrugBank.d415.s16	Read	1	4	O
DDI-DrugBank.d415.s16	circulars	6	14	O
DDI-DrugBank.d415.s16	for	16	18	O
DDI-DrugBank.d415.s16	lithium	20	26	B-drug
DDI-DrugBank.d415.s16	preparation	28	38	O
DDI-DrugBank.d415.s16	before	40	45	O
DDI-DrugBank.d415.s16	use	47	49	O
DDI-DrugBank.d415.s16	of	51	52	O
DDI-DrugBank.d415.s16	such	54	57	O
DDI-DrugBank.d415.s16	concurrent	59	68	O
DDI-DrugBank.d415.s16	therapy	70	76	O
DDI-DrugBank.d415.s16	)	77	77	O
DDI-DrugBank.d415.s16	.	78	78	O
DDI-DrugBank.d29.s0	Esomeprazole	0	11	B-drug
DDI-DrugBank.d29.s0	is	13	14	O
DDI-DrugBank.d29.s0	extensively	16	26	O
DDI-DrugBank.d29.s0	metabolized	28	38	O
DDI-DrugBank.d29.s0	in	40	41	O
DDI-DrugBank.d29.s0	the	43	45	O
DDI-DrugBank.d29.s0	liver	47	51	O
DDI-DrugBank.d29.s0	by	53	54	O
DDI-DrugBank.d29.s0	CYP2C19	56	62	O
DDI-DrugBank.d29.s0	and	64	66	O
DDI-DrugBank.d29.s0	CYP3A4	68	73	O
DDI-DrugBank.d29.s0	.	74	74	O
DDI-DrugBank.d29.s1	In	0	1	O
DDI-DrugBank.d29.s1	vitro	3	7	O
DDI-DrugBank.d29.s1	and	9	11	O
DDI-DrugBank.d29.s1	in	13	14	O
DDI-DrugBank.d29.s1	vivo	16	19	O
DDI-DrugBank.d29.s1	studies	21	27	O
DDI-DrugBank.d29.s1	have	29	32	O
DDI-DrugBank.d29.s1	shown	34	38	O
DDI-DrugBank.d29.s1	that	40	43	O
DDI-DrugBank.d29.s1	esomeprazole	45	56	B-drug
DDI-DrugBank.d29.s1	is	58	59	O
DDI-DrugBank.d29.s1	not	61	63	O
DDI-DrugBank.d29.s1	likely	65	70	O
DDI-DrugBank.d29.s1	to	72	73	O
DDI-DrugBank.d29.s1	inhibit	75	81	O
DDI-DrugBank.d29.s1	CYPs	83	86	O
DDI-DrugBank.d29.s1	1A2	88	90	O
DDI-DrugBank.d29.s1	,	91	91	O
DDI-DrugBank.d29.s1	2A6	93	95	O
DDI-DrugBank.d29.s1	,	91	91	O
DDI-DrugBank.d29.s1	2C9	98	100	O
DDI-DrugBank.d29.s1	,	91	91	O
DDI-DrugBank.d29.s1	2D6	103	105	O
DDI-DrugBank.d29.s1	,	91	91	O
DDI-DrugBank.d29.s1	2E1	108	110	O
DDI-DrugBank.d29.s1	and	112	114	O
DDI-DrugBank.d29.s1	3A4	116	118	O
DDI-DrugBank.d29.s1	.	119	119	O
DDI-DrugBank.d29.s2	No	0	1	O
DDI-DrugBank.d29.s2	clinically	3	12	O
DDI-DrugBank.d29.s2	relevant	14	21	O
DDI-DrugBank.d29.s2	interactions	23	34	O
DDI-DrugBank.d29.s2	with	36	39	O
DDI-DrugBank.d29.s2	drugs	41	45	O
DDI-DrugBank.d29.s2	metabolized	47	57	O
DDI-DrugBank.d29.s2	by	59	60	O
DDI-DrugBank.d29.s2	these	62	66	O
DDI-DrugBank.d29.s2	CYP	68	70	O
DDI-DrugBank.d29.s2	enzymes	72	78	O
DDI-DrugBank.d29.s2	would	80	84	O
DDI-DrugBank.d29.s2	be	86	87	O
DDI-DrugBank.d29.s2	expected	89	96	O
DDI-DrugBank.d29.s2	.	97	97	O
DDI-DrugBank.d29.s3	Drug	0	3	O
DDI-DrugBank.d29.s3	interaction	5	15	O
DDI-DrugBank.d29.s3	studies	17	23	O
DDI-DrugBank.d29.s3	have	25	28	O
DDI-DrugBank.d29.s3	shown	30	34	O
DDI-DrugBank.d29.s3	that	36	39	O
DDI-DrugBank.d29.s3	esomeprazole	41	52	B-drug
DDI-DrugBank.d29.s3	does	54	57	O
DDI-DrugBank.d29.s3	not	59	61	O
DDI-DrugBank.d29.s3	have	63	66	O
DDI-DrugBank.d29.s3	any	68	70	O
DDI-DrugBank.d29.s3	clinically	72	81	O
DDI-DrugBank.d29.s3	significant	83	93	O
DDI-DrugBank.d29.s3	interactions	95	106	O
DDI-DrugBank.d29.s3	with	108	111	O
DDI-DrugBank.d29.s3	phenytoin	113	121	B-drug
DDI-DrugBank.d29.s3	,	122	122	O
DDI-DrugBank.d29.s3	warfarin	124	131	B-drug
DDI-DrugBank.d29.s3	,	122	122	O
DDI-DrugBank.d29.s3	quinidine	134	142	B-drug
DDI-DrugBank.d29.s3	,	132	132	O
DDI-DrugBank.d29.s3	clarithromycin	145	158	B-drug
DDI-DrugBank.d29.s3	or	160	161	O
DDI-DrugBank.d29.s3	amoxicillin	163	173	B-drug
DDI-DrugBank.d29.s3	.	174	174	O
DDI-DrugBank.d29.s4	Post-marketing	0	13	O
DDI-DrugBank.d29.s4	reports	15	21	O
DDI-DrugBank.d29.s4	of	23	24	O
DDI-DrugBank.d29.s4	changes	26	32	O
DDI-DrugBank.d29.s4	in	34	35	O
DDI-DrugBank.d29.s4	prothrombin	37	47	O
DDI-DrugBank.d29.s4	measures	49	56	O
DDI-DrugBank.d29.s4	have	58	61	O
DDI-DrugBank.d29.s4	been	63	66	O
DDI-DrugBank.d29.s4	received	68	75	O
DDI-DrugBank.d29.s4	among	77	81	O
DDI-DrugBank.d29.s4	patients	83	90	O
DDI-DrugBank.d29.s4	on	92	93	O
DDI-DrugBank.d29.s4	concomitant	95	105	O
DDI-DrugBank.d29.s4	warfarin	107	114	B-drug
DDI-DrugBank.d29.s4	and	116	118	O
DDI-DrugBank.d29.s4	esomeprazole	120	131	B-drug
DDI-DrugBank.d29.s4	therapy	133	139	O
DDI-DrugBank.d29.s4	.	140	140	O
DDI-DrugBank.d29.s5	Increases	0	8	O
DDI-DrugBank.d29.s5	in	10	11	O
DDI-DrugBank.d29.s5	INR	13	15	O
DDI-DrugBank.d29.s5	and	17	19	O
DDI-DrugBank.d29.s5	prothrombin	21	31	O
DDI-DrugBank.d29.s5	time	33	36	O
DDI-DrugBank.d29.s5	may	38	40	O
DDI-DrugBank.d29.s5	lead	42	45	O
DDI-DrugBank.d29.s5	to	47	48	O
DDI-DrugBank.d29.s5	abnormal	50	57	O
DDI-DrugBank.d29.s5	bleeding	59	66	O
DDI-DrugBank.d29.s5	and	68	70	O
DDI-DrugBank.d29.s5	even	72	75	O
DDI-DrugBank.d29.s5	death	77	81	O
DDI-DrugBank.d29.s5	.	82	82	O
DDI-DrugBank.d29.s6	Patients	0	7	O
DDI-DrugBank.d29.s6	treated	9	15	O
DDI-DrugBank.d29.s6	with	17	20	O
DDI-DrugBank.d29.s6	proton	22	27	B-group
DDI-DrugBank.d29.s6	pump	29	32	I-group
DDI-DrugBank.d29.s6	inhibitors	34	43	I-group
DDI-DrugBank.d29.s6	and	45	47	O
DDI-DrugBank.d29.s6	warfarin	49	56	B-drug
DDI-DrugBank.d29.s6	concomitantly	58	70	O
DDI-DrugBank.d29.s6	may	72	74	O
DDI-DrugBank.d29.s6	need	76	79	O
DDI-DrugBank.d29.s6	to	81	82	O
DDI-DrugBank.d29.s6	be	84	85	O
DDI-DrugBank.d29.s6	monitored	87	95	O
DDI-DrugBank.d29.s6	for	97	99	O
DDI-DrugBank.d29.s6	increases	101	109	O
DDI-DrugBank.d29.s6	in	101	102	O
DDI-DrugBank.d29.s6	INR	114	116	O
DDI-DrugBank.d29.s6	and	118	120	O
DDI-DrugBank.d29.s6	prothrombin	122	132	O
DDI-DrugBank.d29.s6	time	134	137	O
DDI-DrugBank.d29.s6	.	138	138	O
DDI-DrugBank.d29.s7	Esomeprazole	0	11	B-drug
DDI-DrugBank.d29.s7	may	13	15	O
DDI-DrugBank.d29.s7	potentially	17	27	O
DDI-DrugBank.d29.s7	interfere	29	37	O
DDI-DrugBank.d29.s7	with	39	42	O
DDI-DrugBank.d29.s7	CYP2C19	44	50	O
DDI-DrugBank.d29.s7	,	51	51	O
DDI-DrugBank.d29.s7	the	53	55	O
DDI-DrugBank.d29.s7	major	57	61	O
DDI-DrugBank.d29.s7	esomeprazole	63	74	B-drug
DDI-DrugBank.d29.s7	metabolizing	76	87	O
DDI-DrugBank.d29.s7	enzyme	89	94	O
DDI-DrugBank.d29.s7	.	95	95	O
DDI-DrugBank.d29.s8	Coadministration	0	15	O
DDI-DrugBank.d29.s8	of	17	18	O
DDI-DrugBank.d29.s8	esomeprazole	20	31	B-drug
DDI-DrugBank.d29.s8	30	33	34	O
DDI-DrugBank.d29.s8	mg	36	37	O
DDI-DrugBank.d29.s8	and	39	41	O
DDI-DrugBank.d29.s8	diazepam	43	50	B-drug
DDI-DrugBank.d29.s8	,	51	51	O
DDI-DrugBank.d29.s8	a	49	49	O
DDI-DrugBank.d29.s8	CYP2C19	55	61	O
DDI-DrugBank.d29.s8	substrate	63	71	O
DDI-DrugBank.d29.s8	,	72	72	O
DDI-DrugBank.d29.s8	resulted	74	81	O
DDI-DrugBank.d29.s8	in	83	84	O
DDI-DrugBank.d29.s8	a	86	86	O
DDI-DrugBank.d29.s8	45	88	89	O
DDI-DrugBank.d29.s8	%	90	90	O
DDI-DrugBank.d29.s8	decrease	92	99	O
DDI-DrugBank.d29.s8	in	101	102	O
DDI-DrugBank.d29.s8	clearance	104	112	O
DDI-DrugBank.d29.s8	of	114	115	O
DDI-DrugBank.d29.s8	diazepam	117	124	B-drug
DDI-DrugBank.d29.s8	.	125	125	O
DDI-DrugBank.d29.s9	Increased	0	8	O
DDI-DrugBank.d29.s9	plasma	10	15	O
DDI-DrugBank.d29.s9	levels	17	22	O
DDI-DrugBank.d29.s9	of	24	25	O
DDI-DrugBank.d29.s9	diazepam	27	34	B-drug
DDI-DrugBank.d29.s9	were	36	39	O
DDI-DrugBank.d29.s9	observed	41	48	O
DDI-DrugBank.d29.s9	12	50	51	O
DDI-DrugBank.d29.s9	hours	53	57	O
DDI-DrugBank.d29.s9	after	59	63	O
DDI-DrugBank.d29.s9	dosing	65	70	O
DDI-DrugBank.d29.s9	and	72	74	O
DDI-DrugBank.d29.s9	onwards	76	82	O
DDI-DrugBank.d29.s9	.	83	83	O
DDI-DrugBank.d29.s10	However	0	6	O
DDI-DrugBank.d29.s10	,	7	7	O
DDI-DrugBank.d29.s10	at	9	10	O
DDI-DrugBank.d29.s10	that	12	15	O
DDI-DrugBank.d29.s10	time	17	20	O
DDI-DrugBank.d29.s10	,	21	21	O
DDI-DrugBank.d29.s10	the	23	25	O
DDI-DrugBank.d29.s10	plasma	27	32	O
DDI-DrugBank.d29.s10	levels	34	39	O
DDI-DrugBank.d29.s10	of	41	42	O
DDI-DrugBank.d29.s10	diazepam	44	51	B-drug
DDI-DrugBank.d29.s10	were	53	56	O
DDI-DrugBank.d29.s10	below	58	62	O
DDI-DrugBank.d29.s10	the	64	66	O
DDI-DrugBank.d29.s10	therapeutic	68	78	O
DDI-DrugBank.d29.s10	interval	80	87	O
DDI-DrugBank.d29.s10	,	88	88	O
DDI-DrugBank.d29.s10	and	90	92	O
DDI-DrugBank.d29.s10	thus	94	97	O
DDI-DrugBank.d29.s10	this	99	102	O
DDI-DrugBank.d29.s10	interaction	104	114	O
DDI-DrugBank.d29.s10	is	101	102	O
DDI-DrugBank.d29.s10	unlikely	119	126	O
DDI-DrugBank.d29.s10	to	128	129	O
DDI-DrugBank.d29.s10	be	131	132	O
DDI-DrugBank.d29.s10	of	134	135	O
DDI-DrugBank.d29.s10	clinical	137	144	O
DDI-DrugBank.d29.s10	relevance	146	154	O
DDI-DrugBank.d29.s10	.	155	155	O
DDI-DrugBank.d29.s11	Esomeprazole	0	11	B-drug
DDI-DrugBank.d29.s11	inhibits	13	20	O
DDI-DrugBank.d29.s11	gastric	22	28	O
DDI-DrugBank.d29.s11	acid	30	33	O
DDI-DrugBank.d29.s11	secretion	35	43	O
DDI-DrugBank.d29.s11	.	44	44	O
DDI-DrugBank.d29.s12	Therefore	0	8	O
DDI-DrugBank.d29.s12	,	9	9	O
DDI-DrugBank.d29.s12	esomeprazole	11	22	B-drug
DDI-DrugBank.d29.s12	may	24	26	O
DDI-DrugBank.d29.s12	interfere	28	36	O
DDI-DrugBank.d29.s12	with	38	41	O
DDI-DrugBank.d29.s12	the	43	45	O
DDI-DrugBank.d29.s12	absorption	47	56	O
DDI-DrugBank.d29.s12	of	58	59	O
DDI-DrugBank.d29.s12	drugs	61	65	O
DDI-DrugBank.d29.s12	where	67	71	O
DDI-DrugBank.d29.s12	gastric	73	79	O
DDI-DrugBank.d29.s12	pH	81	82	O
DDI-DrugBank.d29.s12	is	84	85	O
DDI-DrugBank.d29.s12	an	87	88	O
DDI-DrugBank.d29.s12	important	90	98	O
DDI-DrugBank.d29.s12	determinant	100	110	O
DDI-DrugBank.d29.s12	of	112	113	O
DDI-DrugBank.d29.s12	bioavailability	115	129	O
DDI-DrugBank.d29.s12	(	131	131	O
DDI-DrugBank.d29.s12	eg	132	133	O
DDI-DrugBank.d29.s12	,	134	134	O
DDI-DrugBank.d29.s12	ketoconazole	136	147	B-drug
DDI-DrugBank.d29.s12	,	134	134	O
DDI-DrugBank.d29.s12	iron	150	153	B-drug
DDI-DrugBank.d29.s12	salts	155	159	O
DDI-DrugBank.d29.s12	and	161	163	O
DDI-DrugBank.d29.s12	digoxin	165	171	B-drug
DDI-DrugBank.d29.s12	)	172	172	O
DDI-DrugBank.d29.s12	.	173	173	O
DDI-DrugBank.d29.s13	Coadministration	0	15	O
DDI-DrugBank.d29.s13	of	17	18	O
DDI-DrugBank.d29.s13	oral	20	23	O
DDI-DrugBank.d29.s13	contraceptives	25	38	B-group
DDI-DrugBank.d29.s13	,	39	39	O
DDI-DrugBank.d29.s13	diazepam	41	48	B-drug
DDI-DrugBank.d29.s13	,	49	49	O
DDI-DrugBank.d29.s13	phenytoin	51	59	B-drug
DDI-DrugBank.d29.s13	,	60	60	O
DDI-DrugBank.d29.s13	or	62	63	O
DDI-DrugBank.d29.s13	quinidine	65	73	B-drug
DDI-DrugBank.d29.s13	did	75	77	O
DDI-DrugBank.d29.s13	not	79	81	O
DDI-DrugBank.d29.s13	seem	83	86	O
DDI-DrugBank.d29.s13	to	88	89	O
DDI-DrugBank.d29.s13	change	91	96	O
DDI-DrugBank.d29.s13	the	98	100	O
DDI-DrugBank.d29.s13	pharmacokinetic	102	116	O
DDI-DrugBank.d29.s13	profile	118	124	O
DDI-DrugBank.d29.s13	of	120	121	O
DDI-DrugBank.d29.s13	esomeprazole	129	140	B-drug
DDI-DrugBank.d29.s13	.	141	141	O
DDI-DrugBank.d29.s14	Concomitant	0	10	O
DDI-DrugBank.d29.s14	administration	12	25	O
DDI-DrugBank.d29.s14	of	27	28	O
DDI-DrugBank.d29.s14	clarithromycin	30	43	B-drug
DDI-DrugBank.d29.s14	with	45	48	O
DDI-DrugBank.d29.s14	pimozide	50	57	B-drug
DDI-DrugBank.d29.s14	is	59	60	O
DDI-DrugBank.d29.s14	contraindicated	62	76	O
DDI-DrugBank.d29.s14	.	77	77	O
DDI-DrugBank.d378.s0	Renal	0	4	O
DDI-DrugBank.d378.s0	function	6	13	O
DDI-DrugBank.d378.s0	should	15	20	O
DDI-DrugBank.d378.s0	be	22	23	O
DDI-DrugBank.d378.s0	monitored	25	33	O
DDI-DrugBank.d378.s0	carefully	35	43	O
DDI-DrugBank.d378.s0	if	45	46	O
DDI-DrugBank.d378.s0	high	48	51	O
DDI-DrugBank.d378.s0	doses	53	57	O
DDI-DrugBank.d378.s0	of	59	60	O
DDI-DrugBank.d378.s0	aminoglycosides	62	76	B-group
DDI-DrugBank.d378.s0	are	78	80	O
DDI-DrugBank.d378.s0	to	82	83	O
DDI-DrugBank.d378.s0	be	85	86	O
DDI-DrugBank.d378.s0	administered	88	99	O
DDI-DrugBank.d378.s0	with	101	104	O
DDI-DrugBank.d378.s0	MAXIPIME	106	113	B-brand
DDI-DrugBank.d378.s0	because	115	121	O
DDI-DrugBank.d378.s0	of	123	124	O
DDI-DrugBank.d378.s0	the	126	128	O
DDI-DrugBank.d378.s0	increased	130	138	O
DDI-DrugBank.d378.s0	potential	140	148	O
DDI-DrugBank.d378.s0	of	150	151	O
DDI-DrugBank.d378.s0	nephrotoxicity	153	166	O
DDI-DrugBank.d378.s0	and	168	170	O
DDI-DrugBank.d378.s0	ototoxicity	172	182	O
DDI-DrugBank.d378.s0	of	184	185	O
DDI-DrugBank.d378.s0	aminoglycoside	187	200	B-group
DDI-DrugBank.d378.s0	antibiotics	202	212	I-group
DDI-DrugBank.d378.s0	.	213	213	O
DDI-DrugBank.d378.s1	Nephrotoxicity	0	13	O
DDI-DrugBank.d378.s1	has	15	17	O
DDI-DrugBank.d378.s1	been	19	22	O
DDI-DrugBank.d378.s1	reported	24	31	O
DDI-DrugBank.d378.s1	following	33	41	O
DDI-DrugBank.d378.s1	concomitant	43	53	O
DDI-DrugBank.d378.s1	administration	55	68	O
DDI-DrugBank.d378.s1	of	70	71	O
DDI-DrugBank.d378.s1	other	73	77	O
DDI-DrugBank.d378.s1	cephalosporins	79	92	B-group
DDI-DrugBank.d378.s1	with	94	97	O
DDI-DrugBank.d378.s1	potent	99	104	O
DDI-DrugBank.d378.s1	diuretics	106	114	B-group
DDI-DrugBank.d378.s1	such	116	119	O
DDI-DrugBank.d378.s1	as	121	122	O
DDI-DrugBank.d378.s1	furosemide	124	133	B-drug
DDI-DrugBank.d378.s1	.	134	134	O
DDI-DrugBank.d378.s2	Drug/Laboratory	0	14	O
DDI-DrugBank.d378.s2	Test	16	19	O
DDI-DrugBank.d378.s2	Interactions	21	32	O
DDI-DrugBank.d378.s2	The	34	36	O
DDI-DrugBank.d378.s2	administration	38	51	O
DDI-DrugBank.d378.s2	of	53	54	O
DDI-DrugBank.d378.s2	cefepime	56	63	B-drug
DDI-DrugBank.d378.s2	may	65	67	O
DDI-DrugBank.d378.s2	result	69	74	O
DDI-DrugBank.d378.s2	in	76	77	O
DDI-DrugBank.d378.s2	a	79	79	O
DDI-DrugBank.d378.s2	false-positive	81	94	O
DDI-DrugBank.d378.s2	reaction	96	103	O
DDI-DrugBank.d378.s2	for	105	107	O
DDI-DrugBank.d378.s2	glucose	109	115	O
DDI-DrugBank.d378.s2	in	117	118	O
DDI-DrugBank.d378.s2	the	120	122	O
DDI-DrugBank.d378.s2	urine	124	128	O
DDI-DrugBank.d378.s2	when	130	133	O
DDI-DrugBank.d378.s2	using	135	139	O
DDI-DrugBank.d378.s2	Clinitest	141	149	O
DDI-DrugBank.d378.s2	tablets	152	158	O
DDI-DrugBank.d378.s2	.	159	159	O
DDI-DrugBank.d378.s3	It	0	1	O
DDI-DrugBank.d378.s3	is	3	4	O
DDI-DrugBank.d378.s3	recommended	6	16	O
DDI-DrugBank.d378.s3	that	18	21	O
DDI-DrugBank.d378.s3	glucose	23	29	O
DDI-DrugBank.d378.s3	tests	31	35	O
DDI-DrugBank.d378.s3	based	37	41	O
DDI-DrugBank.d378.s3	on	43	44	O
DDI-DrugBank.d378.s3	enzymatic	46	54	O
DDI-DrugBank.d378.s3	glucose	56	62	O
DDI-DrugBank.d378.s3	oxidase	64	70	O
DDI-DrugBank.d378.s3	reactions	72	80	O
DDI-DrugBank.d378.s3	(	82	82	O
DDI-DrugBank.d378.s3	such	83	86	O
DDI-DrugBank.d378.s3	as	88	89	O
DDI-DrugBank.d378.s3	Clinistix	91	99	O
DDI-DrugBank.d378.s3	or	102	103	O
DDI-DrugBank.d378.s3	Tes-Tape	105	112	O
DDI-DrugBank.d378.s3	)	115	115	O
DDI-DrugBank.d378.s3	be	117	118	O
DDI-DrugBank.d378.s3	used	120	123	O
DDI-DrugBank.d378.s3	.	124	124	O
DDI-DrugBank.d450.s0	Potassium-depleting	0	18	B-group
DDI-DrugBank.d450.s0	diuretics	20	28	I-group
DDI-DrugBank.d450.s0	are	30	32	O
DDI-DrugBank.d450.s0	a	34	34	O
DDI-DrugBank.d450.s0	major	36	40	O
DDI-DrugBank.d450.s0	contributing	42	53	O
DDI-DrugBank.d450.s0	factor	55	60	O
DDI-DrugBank.d450.s0	to	58	59	O
DDI-DrugBank.d450.s0	digitalis	65	73	B-group
DDI-DrugBank.d450.s0	toxicity	75	82	O
DDI-DrugBank.d450.s0	.	83	83	O
DDI-DrugBank.d450.s1	Calcium	0	6	B-drug
DDI-DrugBank.d450.s1	,	7	7	O
DDI-DrugBank.d450.s1	particularly	9	20	O
DDI-DrugBank.d450.s1	if	22	23	O
DDI-DrugBank.d450.s1	administered	25	36	O
DDI-DrugBank.d450.s1	rapidly	38	44	O
DDI-DrugBank.d450.s1	by	46	47	O
DDI-DrugBank.d450.s1	the	49	51	O
DDI-DrugBank.d450.s1	intravenous	53	63	O
DDI-DrugBank.d450.s1	route	65	69	O
DDI-DrugBank.d450.s1	,	70	70	O
DDI-DrugBank.d450.s1	may	72	74	O
DDI-DrugBank.d450.s1	produce	76	82	O
DDI-DrugBank.d450.s1	serious	84	90	O
DDI-DrugBank.d450.s1	arrhythmias	92	102	O
DDI-DrugBank.d450.s1	in	104	105	O
DDI-DrugBank.d450.s1	digitalized	107	117	O
DDI-DrugBank.d450.s1	patients	119	126	O
DDI-DrugBank.d450.s1	.	127	127	O
DDI-DrugBank.d450.s2	Quinidine	0	8	B-drug
DDI-DrugBank.d450.s2	,	9	9	O
DDI-DrugBank.d450.s2	verapamil	11	19	B-drug
DDI-DrugBank.d450.s2	,	20	20	O
DDI-DrugBank.d450.s2	amiodarone	22	31	B-drug
DDI-DrugBank.d450.s2	,	32	32	O
DDI-DrugBank.d450.s2	propafenone	34	44	B-drug
DDI-DrugBank.d450.s2	,	45	45	O
DDI-DrugBank.d450.s2	indomethacin	47	58	B-drug
DDI-DrugBank.d450.s2	,	59	59	O
DDI-DrugBank.d450.s2	itraconazole	61	72	B-drug
DDI-DrugBank.d450.s2	,	73	73	O
DDI-DrugBank.d450.s2	alprazolam	75	84	B-drug
DDI-DrugBank.d450.s2	,	85	85	O
DDI-DrugBank.d450.s2	and	87	89	O
DDI-DrugBank.d450.s2	spironolactone	91	104	B-drug
DDI-DrugBank.d450.s2	raise	106	110	O
DDI-DrugBank.d450.s2	the	112	114	O
DDI-DrugBank.d450.s2	serum	116	120	O
DDI-DrugBank.d450.s2	digoxin	122	128	B-drug
DDI-DrugBank.d450.s2	concentration	130	142	O
DDI-DrugBank.d450.s2	due	144	146	O
DDI-DrugBank.d450.s2	to	148	149	O
DDI-DrugBank.d450.s2	a	138	138	O
DDI-DrugBank.d450.s2	reduction	153	161	O
DDI-DrugBank.d450.s2	in	163	164	O
DDI-DrugBank.d450.s2	clearance	166	174	O
DDI-DrugBank.d450.s2	and/or	176	181	O
DDI-DrugBank.d450.s2	in	163	164	O
DDI-DrugBank.d450.s2	volume	186	191	O
DDI-DrugBank.d450.s2	of	193	194	O
DDI-DrugBank.d450.s2	distribution	196	207	O
DDI-DrugBank.d450.s2	of	193	194	O
DDI-DrugBank.d450.s2	the	212	214	O
DDI-DrugBank.d450.s2	drug	216	219	O
DDI-DrugBank.d450.s2	,	220	220	O
DDI-DrugBank.d450.s2	with	222	225	O
DDI-DrugBank.d450.s2	the	212	214	O
DDI-DrugBank.d450.s2	implication	231	241	O
DDI-DrugBank.d450.s2	that	243	246	O
DDI-DrugBank.d450.s2	digitalis	248	256	B-group
DDI-DrugBank.d450.s2	intoxication	258	269	O
DDI-DrugBank.d450.s2	may	271	273	O
DDI-DrugBank.d450.s2	result	275	280	O
DDI-DrugBank.d450.s2	.	281	281	O
DDI-DrugBank.d450.s3	Erythromycin	0	11	B-drug
DDI-DrugBank.d450.s3	and	13	15	O
DDI-DrugBank.d450.s3	clarithromycin	17	30	B-drug
DDI-DrugBank.d450.s3	(	32	32	O
DDI-DrugBank.d450.s3	and	33	35	O
DDI-DrugBank.d450.s3	possibly	37	44	O
DDI-DrugBank.d450.s3	other	46	50	O
DDI-DrugBank.d450.s3	macrolide	52	60	B-group
DDI-DrugBank.d450.s3	antibiotics	62	72	I-group
DDI-DrugBank.d450.s3	)	73	73	O
DDI-DrugBank.d450.s3	and	75	77	O
DDI-DrugBank.d450.s3	tetracycline	79	90	B-drug
DDI-DrugBank.d450.s3	may	92	94	O
DDI-DrugBank.d450.s3	increase	96	103	O
DDI-DrugBank.d450.s3	digoxin	105	111	B-drug
DDI-DrugBank.d450.s3	absorption	113	122	O
DDI-DrugBank.d450.s3	in	110	111	I-drug
DDI-DrugBank.d450.s3	patients	127	134	O
DDI-DrugBank.d450.s3	who	136	138	O
DDI-DrugBank.d450.s3	inactivate	140	149	O
DDI-DrugBank.d450.s3	digoxin	151	157	B-drug
DDI-DrugBank.d450.s3	by	159	160	O
DDI-DrugBank.d450.s3	bacterial	162	170	O
DDI-DrugBank.d450.s3	metabolism	172	181	O
DDI-DrugBank.d450.s3	in	183	184	O
DDI-DrugBank.d450.s3	the	186	188	O
DDI-DrugBank.d450.s3	lower	190	194	O
DDI-DrugBank.d450.s3	intestine	196	204	O
DDI-DrugBank.d450.s3	,	205	205	O
DDI-DrugBank.d450.s3	so	207	208	O
DDI-DrugBank.d450.s3	that	210	213	O
DDI-DrugBank.d450.s3	digitalis	215	223	B-group
DDI-DrugBank.d450.s3	intoxication	225	236	O
DDI-DrugBank.d450.s3	may	238	240	O
DDI-DrugBank.d450.s3	result	242	247	O
DDI-DrugBank.d450.s3	.	248	248	O
DDI-DrugBank.d450.s4	The	0	2	O
DDI-DrugBank.d450.s4	risk	4	7	O
DDI-DrugBank.d450.s4	of	9	10	O
DDI-DrugBank.d450.s4	this	12	15	O
DDI-DrugBank.d450.s4	interaction	17	27	O
DDI-DrugBank.d450.s4	may	29	31	O
DDI-DrugBank.d450.s4	be	33	34	O
DDI-DrugBank.d450.s4	reduced	36	42	O
DDI-DrugBank.d450.s4	if	44	45	O
DDI-DrugBank.d450.s4	digoxin	47	53	B-drug
DDI-DrugBank.d450.s4	is	55	56	O
DDI-DrugBank.d450.s4	given	58	62	O
DDI-DrugBank.d450.s4	as	64	65	O
DDI-DrugBank.d450.s4	capsules	67	74	O
DDI-DrugBank.d450.s4	.	75	75	O
DDI-DrugBank.d450.s5	Propantheline	0	12	B-drug
DDI-DrugBank.d450.s5	and	14	16	O
DDI-DrugBank.d450.s5	diphenoxylate	18	30	B-drug
DDI-DrugBank.d450.s5	,	31	31	O
DDI-DrugBank.d450.s5	by	33	34	O
DDI-DrugBank.d450.s5	decreasing	36	45	O
DDI-DrugBank.d450.s5	gut	47	49	O
DDI-DrugBank.d450.s5	motility	51	58	O
DDI-DrugBank.d450.s5	,	59	59	O
DDI-DrugBank.d450.s5	may	61	63	O
DDI-DrugBank.d450.s5	increase	65	72	O
DDI-DrugBank.d450.s5	digoxin	74	80	B-drug
DDI-DrugBank.d450.s5	absorption	82	91	O
DDI-DrugBank.d450.s5	.	92	92	O
DDI-DrugBank.d450.s6	Antacids	0	7	B-group
DDI-DrugBank.d450.s6	,	8	8	O
DDI-DrugBank.d450.s6	kaolin-pectin	10	22	O
DDI-DrugBank.d450.s6	,	23	23	O
DDI-DrugBank.d450.s6	sulfasalazine	25	37	B-drug
DDI-DrugBank.d450.s6	,	38	38	O
DDI-DrugBank.d450.s6	neomycin	40	47	B-drug
DDI-DrugBank.d450.s6	,	48	48	O
DDI-DrugBank.d450.s6	cholestyramine	50	63	B-drug
DDI-DrugBank.d450.s6	,	64	64	O
DDI-DrugBank.d450.s6	certain	66	72	O
DDI-DrugBank.d450.s6	anticancer	74	83	O
DDI-DrugBank.d450.s6	drugs	85	89	O
DDI-DrugBank.d450.s6	,	90	90	O
DDI-DrugBank.d450.s6	and	92	94	O
DDI-DrugBank.d450.s6	metoclopramide	96	109	B-drug
DDI-DrugBank.d450.s6	may	111	113	O
DDI-DrugBank.d450.s6	interfere	115	123	O
DDI-DrugBank.d450.s6	with	125	128	O
DDI-DrugBank.d450.s6	intestinal	130	139	O
DDI-DrugBank.d450.s6	digoxin	141	147	B-drug
DDI-DrugBank.d450.s6	absorption	149	158	O
DDI-DrugBank.d450.s6	,	159	159	O
DDI-DrugBank.d450.s6	resulting	161	169	O
DDI-DrugBank.d450.s6	in	167	168	O
DDI-DrugBank.d450.s6	unexpectedly	174	185	O
DDI-DrugBank.d450.s6	low	187	189	O
DDI-DrugBank.d450.s6	serum	191	195	O
DDI-DrugBank.d450.s6	concentrations	197	210	O
DDI-DrugBank.d450.s6	.	211	211	O
DDI-DrugBank.d450.s7	Rifampin	0	7	B-drug
DDI-DrugBank.d450.s7	may	9	11	O
DDI-DrugBank.d450.s7	decrease	13	20	O
DDI-DrugBank.d450.s7	serum	22	26	O
DDI-DrugBank.d450.s7	digoxin	28	34	B-drug
DDI-DrugBank.d450.s7	concentration	36	48	O
DDI-DrugBank.d450.s7	,	49	49	O
DDI-DrugBank.d450.s7	especially	51	60	O
DDI-DrugBank.d450.s7	in	62	63	O
DDI-DrugBank.d450.s7	patients	65	72	O
DDI-DrugBank.d450.s7	with	74	77	O
DDI-DrugBank.d450.s7	renal	79	83	O
DDI-DrugBank.d450.s7	dysfunction	85	95	O
DDI-DrugBank.d450.s7	,	96	96	O
DDI-DrugBank.d450.s7	by	98	99	O
DDI-DrugBank.d450.s7	increasing	101	110	O
DDI-DrugBank.d450.s7	the	112	114	O
DDI-DrugBank.d450.s7	non-renal	116	124	O
DDI-DrugBank.d450.s7	clearance	126	134	O
DDI-DrugBank.d450.s7	of	136	137	O
DDI-DrugBank.d450.s7	digoxin	139	145	B-drug
DDI-DrugBank.d450.s7	.	146	146	O
DDI-DrugBank.d450.s8	There	0	4	O
DDI-DrugBank.d450.s8	have	6	9	O
DDI-DrugBank.d450.s8	been	11	14	O
DDI-DrugBank.d450.s8	inconsistent	16	27	O
DDI-DrugBank.d450.s8	reports	29	35	O
DDI-DrugBank.d450.s8	regarding	37	45	O
DDI-DrugBank.d450.s8	the	47	49	O
DDI-DrugBank.d450.s8	effects	51	57	O
DDI-DrugBank.d450.s8	of	59	60	O
DDI-DrugBank.d450.s8	other	62	66	O
DDI-DrugBank.d450.s8	drugs	68	72	O
DDI-DrugBank.d450.s8	(	74	74	O
DDI-DrugBank.d450.s8	e.g.	75	78	O
DDI-DrugBank.d450.s8	,	79	79	O
DDI-DrugBank.d450.s8	quinine	81	87	B-drug
DDI-DrugBank.d450.s8	,	79	79	O
DDI-DrugBank.d450.s8	penicillamine	90	102	B-drug
DDI-DrugBank.d450.s8	)	103	103	O
DDI-DrugBank.d450.s8	on	105	106	O
DDI-DrugBank.d450.s8	serum	108	112	O
DDI-DrugBank.d450.s8	digoxin	114	120	B-drug
DDI-DrugBank.d450.s8	concentration	122	134	O
DDI-DrugBank.d450.s8	.	135	135	O
DDI-DrugBank.d450.s9	Thyroid	0	6	B-group
DDI-DrugBank.d450.s9	administration	8	21	O
DDI-DrugBank.d450.s9	to	23	24	O
DDI-DrugBank.d450.s9	a	26	26	O
DDI-DrugBank.d450.s9	digitalized	28	38	O
DDI-DrugBank.d450.s9	,	39	39	O
DDI-DrugBank.d450.s9	hypothyroid	41	51	O
DDI-DrugBank.d450.s9	patient	53	59	O
DDI-DrugBank.d450.s9	may	61	63	O
DDI-DrugBank.d450.s9	increase	65	72	O
DDI-DrugBank.d450.s9	the	74	76	O
DDI-DrugBank.d450.s9	dose	78	81	O
DDI-DrugBank.d450.s9	requirement	83	93	O
DDI-DrugBank.d450.s9	of	95	96	O
DDI-DrugBank.d450.s9	digoxin	98	104	B-drug
DDI-DrugBank.d450.s9	.	105	105	O
DDI-DrugBank.d450.s10	Concomitant	0	10	O
DDI-DrugBank.d450.s10	use	12	14	O
DDI-DrugBank.d450.s10	of	16	17	O
DDI-DrugBank.d450.s10	digoxin	19	25	B-drug
DDI-DrugBank.d450.s10	and	27	29	O
DDI-DrugBank.d450.s10	sympathomimetics	31	46	B-group
DDI-DrugBank.d450.s10	increases	48	56	O
DDI-DrugBank.d450.s10	the	58	60	O
DDI-DrugBank.d450.s10	risk	62	65	O
DDI-DrugBank.d450.s10	of	67	68	O
DDI-DrugBank.d450.s10	cardiac	70	76	O
DDI-DrugBank.d450.s10	arrhythmias	78	88	O
DDI-DrugBank.d450.s10	.	89	89	O
DDI-DrugBank.d450.s11	Succinylcholine	0	14	B-drug
DDI-DrugBank.d450.s11	may	16	18	O
DDI-DrugBank.d450.s11	cause	20	24	O
DDI-DrugBank.d450.s11	a	26	26	O
DDI-DrugBank.d450.s11	sudden	28	33	O
DDI-DrugBank.d450.s11	extrusion	35	43	O
DDI-DrugBank.d450.s11	of	45	46	O
DDI-DrugBank.d450.s11	potassium	48	56	O
DDI-DrugBank.d450.s11	from	58	61	O
DDI-DrugBank.d450.s11	muscle	63	68	O
DDI-DrugBank.d450.s11	cells	70	74	O
DDI-DrugBank.d450.s11	,	75	75	O
DDI-DrugBank.d450.s11	and	77	79	O
DDI-DrugBank.d450.s11	may	81	83	O
DDI-DrugBank.d450.s11	thereby	85	91	O
DDI-DrugBank.d450.s11	cause	93	97	O
DDI-DrugBank.d450.s11	arrhythmias	99	109	O
DDI-DrugBank.d450.s11	in	111	112	O
DDI-DrugBank.d450.s11	digitalized	114	124	O
DDI-DrugBank.d450.s11	patients	126	133	O
DDI-DrugBank.d450.s11	.	134	134	O
DDI-DrugBank.d450.s12	Although	0	7	O
DDI-DrugBank.d450.s12	beta-adrenergic	9	23	B-group
DDI-DrugBank.d450.s12	blockers	25	32	I-group
DDI-DrugBank.d450.s12	or	34	35	O
DDI-DrugBank.d450.s12	calcium	37	43	B-group
DDI-DrugBank.d450.s12	channel	45	51	I-group
DDI-DrugBank.d450.s12	blockers	53	60	I-group
DDI-DrugBank.d450.s12	and	62	64	O
DDI-DrugBank.d450.s12	digoxin	66	72	B-drug
DDI-DrugBank.d450.s12	may	74	76	O
DDI-DrugBank.d450.s12	be	78	79	O
DDI-DrugBank.d450.s12	useful	81	86	O
DDI-DrugBank.d450.s12	in	88	89	O
DDI-DrugBank.d450.s12	combination	91	101	O
DDI-DrugBank.d450.s12	to	103	104	O
DDI-DrugBank.d450.s12	control	106	112	O
DDI-DrugBank.d450.s12	atrial	114	119	O
DDI-DrugBank.d450.s12	fibrillation	121	132	O
DDI-DrugBank.d450.s12	,	133	133	O
DDI-DrugBank.d450.s12	their	135	139	O
DDI-DrugBank.d450.s12	additive	141	148	O
DDI-DrugBank.d450.s12	effects	150	156	O
DDI-DrugBank.d450.s12	on	158	159	O
DDI-DrugBank.d450.s12	AV	161	162	O
DDI-DrugBank.d450.s12	node	164	167	O
DDI-DrugBank.d450.s12	conduction	169	178	O
DDI-DrugBank.d450.s12	can	180	182	O
DDI-DrugBank.d450.s12	result	184	189	O
DDI-DrugBank.d450.s12	in	191	192	O
DDI-DrugBank.d450.s12	advanced	194	201	O
DDI-DrugBank.d450.s12	or	203	204	O
DDI-DrugBank.d450.s12	complete	206	213	O
DDI-DrugBank.d450.s12	heart	215	219	O
DDI-DrugBank.d450.s12	block	221	225	O
DDI-DrugBank.d450.s12	.	226	226	O
DDI-DrugBank.d450.s13	Due	0	2	O
DDI-DrugBank.d450.s13	to	4	5	O
DDI-DrugBank.d450.s13	the	7	9	O
DDI-DrugBank.d450.s13	considerable	11	22	O
DDI-DrugBank.d450.s13	variability	24	34	O
DDI-DrugBank.d450.s13	of	36	37	O
DDI-DrugBank.d450.s13	these	39	43	O
DDI-DrugBank.d450.s13	interactions	45	56	O
DDI-DrugBank.d450.s13	,	57	57	O
DDI-DrugBank.d450.s13	the	59	61	O
DDI-DrugBank.d450.s13	dosage	63	68	O
DDI-DrugBank.d450.s13	of	70	71	O
DDI-DrugBank.d450.s13	digoxin	73	79	B-drug
DDI-DrugBank.d450.s13	should	81	86	O
DDI-DrugBank.d450.s13	be	88	89	O
DDI-DrugBank.d450.s13	individualized	91	104	O
DDI-DrugBank.d450.s13	when	106	109	O
DDI-DrugBank.d450.s13	patients	111	118	O
DDI-DrugBank.d450.s13	receive	120	126	O
DDI-DrugBank.d450.s13	these	128	132	O
DDI-DrugBank.d450.s13	medications	134	144	O
DDI-DrugBank.d450.s13	concurrently	146	157	O
DDI-DrugBank.d450.s13	.	158	158	O
DDI-DrugBank.d450.s14	Furthermore	0	10	O
DDI-DrugBank.d450.s14	,	11	11	O
DDI-DrugBank.d450.s14	caution	13	19	O
DDI-DrugBank.d450.s14	should	21	26	O
DDI-DrugBank.d450.s14	be	28	29	O
DDI-DrugBank.d450.s14	exercised	31	39	O
DDI-DrugBank.d450.s14	when	41	44	O
DDI-DrugBank.d450.s14	combining	46	54	O
DDI-DrugBank.d450.s14	digoxin	56	62	B-drug
DDI-DrugBank.d450.s14	with	64	67	O
DDI-DrugBank.d450.s14	any	69	71	O
DDI-DrugBank.d450.s14	drug	73	76	O
DDI-DrugBank.d450.s14	that	78	81	O
DDI-DrugBank.d450.s14	may	83	85	O
DDI-DrugBank.d450.s14	cause	87	91	O
DDI-DrugBank.d450.s14	a	80	80	O
DDI-DrugBank.d450.s14	significant	95	105	O
DDI-DrugBank.d450.s14	deterioration	107	119	O
DDI-DrugBank.d450.s14	in	121	122	O
DDI-DrugBank.d450.s14	renal	124	128	O
DDI-DrugBank.d450.s14	function	130	137	O
DDI-DrugBank.d450.s14	,	138	138	O
DDI-DrugBank.d450.s14	since	140	144	O
DDI-DrugBank.d450.s14	a	127	127	O
DDI-DrugBank.d450.s14	decline	148	154	O
DDI-DrugBank.d450.s14	in	141	142	O
DDI-DrugBank.d450.s14	glomerular	159	168	O
DDI-DrugBank.d450.s14	filtration	170	179	O
DDI-DrugBank.d450.s14	or	181	182	O
DDI-DrugBank.d450.s14	tubular	184	190	O
DDI-DrugBank.d450.s14	secretion	192	200	O
DDI-DrugBank.d450.s14	may	202	204	O
DDI-DrugBank.d450.s14	impair	206	211	O
DDI-DrugBank.d450.s14	the	213	215	O
DDI-DrugBank.d450.s14	excretion	217	225	O
DDI-DrugBank.d450.s14	of	227	228	O
DDI-DrugBank.d450.s14	digoxin	230	236	B-drug
DDI-DrugBank.d450.s14	.	237	237	O
DDI-DrugBank.d12.s0	Caution	0	6	O
DDI-DrugBank.d12.s0	should	8	13	O
DDI-DrugBank.d12.s0	be	15	16	O
DDI-DrugBank.d12.s0	exercised	18	26	O
DDI-DrugBank.d12.s0	when	28	31	O
DDI-DrugBank.d12.s0	anticoagulants	33	46	B-group
DDI-DrugBank.d12.s0	are	48	50	O
DDI-DrugBank.d12.s0	given	52	56	O
DDI-DrugBank.d12.s0	in	58	59	O
DDI-DrugBank.d12.s0	conjunction	61	71	O
DDI-DrugBank.d12.s0	with	73	76	O
DDI-DrugBank.d12.s0	Atromid-S	78	86	B-brand
DDI-DrugBank.d12.s0	.	87	87	O
DDI-DrugBank.d12.s1	Usually	0	6	O
DDI-DrugBank.d12.s1	,	7	7	O
DDI-DrugBank.d12.s1	the	9	11	O
DDI-DrugBank.d12.s1	dosage	13	18	O
DDI-DrugBank.d12.s1	of	20	21	O
DDI-DrugBank.d12.s1	the	23	25	O
DDI-DrugBank.d12.s1	anticoagulant	27	39	B-group
DDI-DrugBank.d12.s1	should	41	46	O
DDI-DrugBank.d12.s1	be	48	49	O
DDI-DrugBank.d12.s1	reduced	51	57	O
DDI-DrugBank.d12.s1	by	59	60	O
DDI-DrugBank.d12.s1	one-half	62	69	O
DDI-DrugBank.d12.s1	(	71	71	O
DDI-DrugBank.d12.s1	depending	72	80	O
DDI-DrugBank.d12.s1	on	82	83	O
DDI-DrugBank.d12.s1	the	85	87	O
DDI-DrugBank.d12.s1	individual	89	98	O
DDI-DrugBank.d12.s1	case	100	103	O
DDI-DrugBank.d12.s1	)	104	104	O
DDI-DrugBank.d12.s1	to	106	107	O
DDI-DrugBank.d12.s1	maintain	109	116	O
DDI-DrugBank.d12.s1	the	118	120	O
DDI-DrugBank.d12.s1	prothrombin	122	132	O
DDI-DrugBank.d12.s1	time	134	137	O
DDI-DrugBank.d12.s1	at	139	140	O
DDI-DrugBank.d12.s1	the	142	144	O
DDI-DrugBank.d12.s1	desired	146	152	O
DDI-DrugBank.d12.s1	level	154	158	O
DDI-DrugBank.d12.s1	to	160	161	O
DDI-DrugBank.d12.s1	prevent	163	169	O
DDI-DrugBank.d12.s1	bleeding	171	178	O
DDI-DrugBank.d12.s1	complications	180	192	O
DDI-DrugBank.d12.s1	.	193	193	O
DDI-DrugBank.d12.s2	Frequent	0	7	O
DDI-DrugBank.d12.s2	prothrombin	9	19	O
DDI-DrugBank.d12.s2	determinations	21	34	O
DDI-DrugBank.d12.s2	are	36	38	O
DDI-DrugBank.d12.s2	advisable	40	48	O
DDI-DrugBank.d12.s2	until	50	54	O
DDI-DrugBank.d12.s2	it	56	57	O
DDI-DrugBank.d12.s2	has	59	61	O
DDI-DrugBank.d12.s2	been	63	66	O
DDI-DrugBank.d12.s2	determined	68	77	O
DDI-DrugBank.d12.s2	definitely	79	88	O
DDI-DrugBank.d12.s2	that	90	93	O
DDI-DrugBank.d12.s2	the	95	97	O
DDI-DrugBank.d12.s2	prothrombin	99	109	O
DDI-DrugBank.d12.s2	level	111	115	O
DDI-DrugBank.d12.s2	has	117	119	O
DDI-DrugBank.d12.s2	been	121	124	O
DDI-DrugBank.d12.s2	stabilized	126	135	O
DDI-DrugBank.d12.s2	.	136	136	O
DDI-DrugBank.d12.s3	Atromid-S	0	8	B-brand
DDI-DrugBank.d12.s3	may	10	12	O
DDI-DrugBank.d12.s3	displace	14	21	O
DDI-DrugBank.d12.s3	acidic	23	28	O
DDI-DrugBank.d12.s3	drugs	30	34	O
DDI-DrugBank.d12.s3	such	36	39	O
DDI-DrugBank.d12.s3	as	41	42	O
DDI-DrugBank.d12.s3	phenytoin	44	52	B-drug
DDI-DrugBank.d12.s3	or	54	55	O
DDI-DrugBank.d12.s3	tolbutamide	57	67	B-drug
DDI-DrugBank.d12.s3	from	69	72	O
DDI-DrugBank.d12.s3	their	74	78	O
DDI-DrugBank.d12.s3	binding	80	86	O
DDI-DrugBank.d12.s3	sites	88	92	O
DDI-DrugBank.d12.s3	.	93	93	O
DDI-DrugBank.d12.s4	Caution	0	6	O
DDI-DrugBank.d12.s4	should	8	13	O
DDI-DrugBank.d12.s4	be	15	16	O
DDI-DrugBank.d12.s4	exercised	18	26	O
DDI-DrugBank.d12.s4	when	28	31	O
DDI-DrugBank.d12.s4	treating	33	40	O
DDI-DrugBank.d12.s4	patients	42	49	O
DDI-DrugBank.d12.s4	with	51	54	O
DDI-DrugBank.d12.s4	either	56	61	O
DDI-DrugBank.d12.s4	of	63	64	O
DDI-DrugBank.d12.s4	these	66	70	O
DDI-DrugBank.d12.s4	drugs	72	76	O
DDI-DrugBank.d12.s4	or	78	79	O
DDI-DrugBank.d12.s4	other	81	85	O
DDI-DrugBank.d12.s4	highly	87	92	O
DDI-DrugBank.d12.s4	protein-bound	94	106	O
DDI-DrugBank.d12.s4	drugs	108	112	O
DDI-DrugBank.d12.s4	and	114	116	O
DDI-DrugBank.d12.s4	Atromid-S	118	126	B-brand
DDI-DrugBank.d12.s4	.	127	127	O
DDI-DrugBank.d12.s5	The	0	2	O
DDI-DrugBank.d12.s5	hypoglycemic	4	15	O
DDI-DrugBank.d12.s5	effect	17	22	O
DDI-DrugBank.d12.s5	of	24	25	O
DDI-DrugBank.d12.s5	tolbutamide	27	37	B-drug
DDI-DrugBank.d12.s5	has	39	41	O
DDI-DrugBank.d12.s5	been	43	46	O
DDI-DrugBank.d12.s5	reported	48	55	O
DDI-DrugBank.d12.s5	to	57	58	O
DDI-DrugBank.d12.s5	increase	60	67	O
DDI-DrugBank.d12.s5	when	69	72	O
DDI-DrugBank.d12.s5	Atromid-S	74	82	B-brand
DDI-DrugBank.d12.s5	is	84	85	O
DDI-DrugBank.d12.s5	given	87	91	O
DDI-DrugBank.d12.s5	concurrently	93	104	O
DDI-DrugBank.d12.s5	.	105	105	O
DDI-DrugBank.d12.s6	Fulminant	0	8	O
DDI-DrugBank.d12.s6	rhabdomyolysis	10	23	O
DDI-DrugBank.d12.s6	has	25	27	O
DDI-DrugBank.d12.s6	been	29	32	O
DDI-DrugBank.d12.s6	seen	34	37	O
DDI-DrugBank.d12.s6	as	39	40	O
DDI-DrugBank.d12.s6	early	42	46	O
DDI-DrugBank.d12.s6	as	48	49	O
DDI-DrugBank.d12.s6	three	51	55	O
DDI-DrugBank.d12.s6	weeks	57	61	O
DDI-DrugBank.d12.s6	after	63	67	O
DDI-DrugBank.d12.s6	initiation	69	78	O
DDI-DrugBank.d12.s6	of	80	81	O
DDI-DrugBank.d12.s6	combined	83	90	O
DDI-DrugBank.d12.s6	therapy	92	98	O
DDI-DrugBank.d12.s6	with	100	103	O
DDI-DrugBank.d12.s6	another	105	111	O
DDI-DrugBank.d12.s6	fibrate	113	119	B-group
DDI-DrugBank.d12.s6	and	121	123	O
DDI-DrugBank.d12.s6	lovastatin	125	134	B-drug
DDI-DrugBank.d12.s6	but	136	138	O
DDI-DrugBank.d12.s6	may	140	142	O
DDI-DrugBank.d12.s6	be	144	145	O
DDI-DrugBank.d12.s6	seen	147	150	O
DDI-DrugBank.d12.s6	after	152	156	O
DDI-DrugBank.d12.s6	several	158	164	O
DDI-DrugBank.d12.s6	months	166	171	O
DDI-DrugBank.d12.s6	.	172	172	O
DDI-DrugBank.d12.s7	For	0	2	O
DDI-DrugBank.d12.s7	these	4	8	O
DDI-DrugBank.d12.s7	reasons	10	16	O
DDI-DrugBank.d12.s7	,	17	17	O
DDI-DrugBank.d12.s7	it	19	20	O
DDI-DrugBank.d12.s7	is	22	23	O
DDI-DrugBank.d12.s7	felt	25	28	O
DDI-DrugBank.d12.s7	that	30	33	O
DDI-DrugBank.d12.s7	,	34	34	O
DDI-DrugBank.d12.s7	in	36	37	O
DDI-DrugBank.d12.s7	most	39	42	O
DDI-DrugBank.d12.s7	subjects	44	51	O
DDI-DrugBank.d12.s7	who	53	55	O
DDI-DrugBank.d12.s7	have	57	60	O
DDI-DrugBank.d12.s7	had	62	64	O
DDI-DrugBank.d12.s7	an	66	67	O
DDI-DrugBank.d12.s7	unsatisfactory	69	82	O
DDI-DrugBank.d12.s7	lipid	84	88	O
DDI-DrugBank.d12.s7	response	90	97	O
DDI-DrugBank.d12.s7	to	99	100	O
DDI-DrugBank.d12.s7	either	102	107	O
DDI-DrugBank.d12.s7	drug	109	112	O
DDI-DrugBank.d12.s7	alone	114	118	O
DDI-DrugBank.d12.s7	,	119	119	O
DDI-DrugBank.d12.s7	the	104	106	O
DDI-DrugBank.d12.s7	possible	125	132	O
DDI-DrugBank.d12.s7	benefits	134	141	O
DDI-DrugBank.d12.s7	of	143	144	O
DDI-DrugBank.d12.s7	combined	146	153	O
DDI-DrugBank.d12.s7	therapy	155	161	O
DDI-DrugBank.d12.s7	with	163	166	O
DDI-DrugBank.d12.s7	lovastatin	168	177	B-drug
DDI-DrugBank.d12.s7	and	179	181	O
DDI-DrugBank.d12.s7	a	159	159	O
DDI-DrugBank.d12.s7	fibrate	185	191	B-group
DDI-DrugBank.d12.s7	do	193	194	O
DDI-DrugBank.d12.s7	not	196	198	O
DDI-DrugBank.d12.s7	outweigh	200	207	O
DDI-DrugBank.d12.s7	the	209	211	O
DDI-DrugBank.d12.s7	risks	213	217	O
DDI-DrugBank.d12.s7	of	219	220	O
DDI-DrugBank.d12.s7	severe	222	227	O
DDI-DrugBank.d12.s7	myopathy	229	236	O
DDI-DrugBank.d12.s7	,	237	237	O
DDI-DrugBank.d12.s7	rhabdomyolysis	239	252	O
DDI-DrugBank.d12.s7	,	237	237	O
DDI-DrugBank.d12.s7	and	255	257	O
DDI-DrugBank.d12.s7	acute	259	263	O
DDI-DrugBank.d12.s7	renal	265	269	O
DDI-DrugBank.d12.s7	failure	271	277	O
DDI-DrugBank.d12.s7	.	278	278	O
DDI-DrugBank.d12.s8	While	0	4	O
DDI-DrugBank.d12.s8	it	6	7	O
DDI-DrugBank.d12.s8	is	9	10	O
DDI-DrugBank.d12.s8	not	12	14	O
DDI-DrugBank.d12.s8	known	16	20	O
DDI-DrugBank.d12.s8	whether	22	28	O
DDI-DrugBank.d12.s8	this	30	33	O
DDI-DrugBank.d12.s8	interaction	35	45	O
DDI-DrugBank.d12.s8	occurs	47	52	O
DDI-DrugBank.d12.s8	with	54	57	O
DDI-DrugBank.d12.s8	fibrates	59	66	B-group
DDI-DrugBank.d12.s8	other	68	72	O
DDI-DrugBank.d12.s8	than	74	77	O
DDI-DrugBank.d12.s8	gemfibrozil	79	89	B-drug
DDI-DrugBank.d12.s8	,	90	90	O
DDI-DrugBank.d12.s8	myopathy	92	99	O
DDI-DrugBank.d12.s8	and	101	103	O
DDI-DrugBank.d12.s8	rhabdomyolysis	105	118	O
DDI-DrugBank.d12.s8	have	120	123	O
DDI-DrugBank.d12.s8	occasionally	125	136	O
DDI-DrugBank.d12.s8	been	138	141	O
DDI-DrugBank.d12.s8	associated	143	152	O
DDI-DrugBank.d12.s8	with	154	157	O
DDI-DrugBank.d12.s8	the	159	161	O
DDI-DrugBank.d12.s8	use	163	165	O
DDI-DrugBank.d12.s8	of	167	168	O
DDI-DrugBank.d12.s8	fibrates	170	177	B-group
DDI-DrugBank.d12.s8	alone	179	183	O
DDI-DrugBank.d12.s8	,	184	184	O
DDI-DrugBank.d12.s8	including	186	194	O
DDI-DrugBank.d12.s8	clofibrate	196	205	B-drug
DDI-DrugBank.d12.s8	.	206	206	O
DDI-DrugBank.d12.s9	Therefore	0	8	O
DDI-DrugBank.d12.s9	,	9	9	O
DDI-DrugBank.d12.s9	the	11	13	O
DDI-DrugBank.d12.s9	combined	15	22	O
DDI-DrugBank.d12.s9	use	24	26	O
DDI-DrugBank.d12.s9	of	28	29	O
DDI-DrugBank.d12.s9	lovastatin	31	40	B-drug
DDI-DrugBank.d12.s9	with	42	45	O
DDI-DrugBank.d12.s9	fibrates	47	54	B-group
DDI-DrugBank.d12.s9	should	56	61	O
DDI-DrugBank.d12.s9	generally	63	71	O
DDI-DrugBank.d12.s9	be	73	74	O
DDI-DrugBank.d12.s9	avoided	76	82	O
DDI-DrugBank.d12.s9	.	83	83	O
DDI-DrugBank.d279.s0	The	0	2	O
DDI-DrugBank.d279.s0	adverse	4	10	O
DDI-DrugBank.d279.s0	effects	12	18	O
DDI-DrugBank.d279.s0	of	20	21	O
DDI-DrugBank.d279.s0	CAMPTOSAR	23	31	B-brand
DDI-DrugBank.d279.s0	,	32	32	O
DDI-DrugBank.d279.s0	such	34	37	O
DDI-DrugBank.d279.s0	as	39	40	O
DDI-DrugBank.d279.s0	myelosuppression	42	57	O
DDI-DrugBank.d279.s0	and	59	61	O
DDI-DrugBank.d279.s0	diarrhea	63	70	O
DDI-DrugBank.d279.s0	,	71	71	O
DDI-DrugBank.d279.s0	would	73	77	O
DDI-DrugBank.d279.s0	be	79	80	O
DDI-DrugBank.d279.s0	expected	82	89	O
DDI-DrugBank.d279.s0	to	91	92	O
DDI-DrugBank.d279.s0	be	94	95	O
DDI-DrugBank.d279.s0	exacerbated	97	107	O
DDI-DrugBank.d279.s0	by	109	110	O
DDI-DrugBank.d279.s0	other	112	116	O
DDI-DrugBank.d279.s0	antineoplastic	118	131	B-group
DDI-DrugBank.d279.s0	agents	133	138	I-group
DDI-DrugBank.d279.s0	having	140	145	O
DDI-DrugBank.d279.s0	similar	147	153	O
DDI-DrugBank.d279.s0	adverse	155	161	O
DDI-DrugBank.d279.s0	effects	163	169	O
DDI-DrugBank.d279.s0	.	170	170	O
DDI-DrugBank.d279.s1	Patients	0	7	O
DDI-DrugBank.d279.s1	who	9	11	O
DDI-DrugBank.d279.s1	have	13	16	O
DDI-DrugBank.d279.s1	previously	18	27	O
DDI-DrugBank.d279.s1	received	29	36	O
DDI-DrugBank.d279.s1	pelvic/	38	44	O
DDI-DrugBank.d279.s1	abdominal	46	54	O
DDI-DrugBank.d279.s1	irradiation	56	66	O
DDI-DrugBank.d279.s1	are	68	70	O
DDI-DrugBank.d279.s1	at	72	73	O
DDI-DrugBank.d279.s1	increased	75	83	O
DDI-DrugBank.d279.s1	risk	85	88	O
DDI-DrugBank.d279.s1	of	90	91	O
DDI-DrugBank.d279.s1	severe	93	98	O
DDI-DrugBank.d279.s1	myelosuppression	100	115	O
DDI-DrugBank.d279.s1	following	117	125	O
DDI-DrugBank.d279.s1	the	127	129	O
DDI-DrugBank.d279.s1	administration	131	144	O
DDI-DrugBank.d279.s1	of	146	147	O
DDI-DrugBank.d279.s1	CAMPTOSAR	149	157	B-brand
DDI-DrugBank.d279.s1	.	158	158	O
DDI-DrugBank.d279.s2	The	0	2	O
DDI-DrugBank.d279.s2	concurrent	4	13	O
DDI-DrugBank.d279.s2	administration	15	28	O
DDI-DrugBank.d279.s2	of	30	31	O
DDI-DrugBank.d279.s2	CAMPTOSAR	33	41	B-brand
DDI-DrugBank.d279.s2	with	43	46	O
DDI-DrugBank.d279.s2	irradiation	48	58	O
DDI-DrugBank.d279.s2	has	60	62	O
DDI-DrugBank.d279.s2	not	64	66	O
DDI-DrugBank.d279.s2	been	68	71	O
DDI-DrugBank.d279.s2	adequately	73	82	O
DDI-DrugBank.d279.s2	studied	84	90	O
DDI-DrugBank.d279.s2	and	92	94	O
DDI-DrugBank.d279.s2	is	96	97	O
DDI-DrugBank.d279.s2	not	99	101	O
DDI-DrugBank.d279.s2	recommended	103	113	O
DDI-DrugBank.d279.s2	.	114	114	O
DDI-DrugBank.d279.s3	Lymphocytopenia	0	14	O
DDI-DrugBank.d279.s3	has	16	18	O
DDI-DrugBank.d279.s3	been	20	23	O
DDI-DrugBank.d279.s3	reported	25	32	O
DDI-DrugBank.d279.s3	in	34	35	O
DDI-DrugBank.d279.s3	patients	37	44	O
DDI-DrugBank.d279.s3	receiving	46	54	O
DDI-DrugBank.d279.s3	CAMPTOSAR	56	64	B-brand
DDI-DrugBank.d279.s3	,	65	65	O
DDI-DrugBank.d279.s3	and	67	69	O
DDI-DrugBank.d279.s3	it	71	72	O
DDI-DrugBank.d279.s3	is	74	75	O
DDI-DrugBank.d279.s3	possible	77	84	O
DDI-DrugBank.d279.s3	that	86	89	O
DDI-DrugBank.d279.s3	the	91	93	O
DDI-DrugBank.d279.s3	administration	95	108	O
DDI-DrugBank.d279.s3	of	110	111	O
DDI-DrugBank.d279.s3	dexamethasone	113	125	B-drug
DDI-DrugBank.d279.s3	as	121	122	I-drug
DDI-DrugBank.d279.s3	antiemetic	130	139	O
DDI-DrugBank.d279.s3	prophylaxis	141	151	O
DDI-DrugBank.d279.s3	may	153	155	O
DDI-DrugBank.d279.s3	have	157	160	O
DDI-DrugBank.d279.s3	enhanced	162	169	O
DDI-DrugBank.d279.s3	the	171	173	O
DDI-DrugBank.d279.s3	likelihood	175	184	O
DDI-DrugBank.d279.s3	of	186	187	O
DDI-DrugBank.d279.s3	this	189	192	O
DDI-DrugBank.d279.s3	effect	194	199	O
DDI-DrugBank.d279.s3	.	200	200	O
DDI-DrugBank.d279.s4	However	0	6	O
DDI-DrugBank.d279.s4	,	7	7	O
DDI-DrugBank.d279.s4	serious	9	15	O
DDI-DrugBank.d279.s4	opportunistic	17	29	O
DDI-DrugBank.d279.s4	infections	31	40	O
DDI-DrugBank.d279.s4	have	42	45	O
DDI-DrugBank.d279.s4	not	47	49	O
DDI-DrugBank.d279.s4	been	51	54	O
DDI-DrugBank.d279.s4	observed	56	63	O
DDI-DrugBank.d279.s4	,	64	64	O
DDI-DrugBank.d279.s4	and	66	68	O
DDI-DrugBank.d279.s4	no	70	71	O
DDI-DrugBank.d279.s4	complications	73	85	O
DDI-DrugBank.d279.s4	have	87	90	O
DDI-DrugBank.d279.s4	specifically	92	103	O
DDI-DrugBank.d279.s4	been	105	108	O
DDI-DrugBank.d279.s4	attributed	110	119	O
DDI-DrugBank.d279.s4	to	121	122	O
DDI-DrugBank.d279.s4	lymphocytopenia	124	138	O
DDI-DrugBank.d279.s4	.	139	139	O
DDI-DrugBank.d279.s5	Hyperglycemia	0	12	O
DDI-DrugBank.d279.s5	has	14	16	O
DDI-DrugBank.d279.s5	also	18	21	O
DDI-DrugBank.d279.s5	been	23	26	O
DDI-DrugBank.d279.s5	reported	28	35	O
DDI-DrugBank.d279.s5	in	37	38	O
DDI-DrugBank.d279.s5	patients	40	47	O
DDI-DrugBank.d279.s5	receiving	49	57	O
DDI-DrugBank.d279.s5	CAMPTOSAR	59	67	B-brand
DDI-DrugBank.d279.s5	.	68	68	O
DDI-DrugBank.d279.s6	Usually	0	6	O
DDI-DrugBank.d279.s6	,	7	7	O
DDI-DrugBank.d279.s6	this	9	12	O
DDI-DrugBank.d279.s6	has	14	16	O
DDI-DrugBank.d279.s6	been	18	21	O
DDI-DrugBank.d279.s6	observed	23	30	O
DDI-DrugBank.d279.s6	in	32	33	O
DDI-DrugBank.d279.s6	patients	35	42	O
DDI-DrugBank.d279.s6	with	44	47	O
DDI-DrugBank.d279.s6	a	49	49	O
DDI-DrugBank.d279.s6	history	51	57	O
DDI-DrugBank.d279.s6	of	59	60	O
DDI-DrugBank.d279.s6	diabetes	62	69	O
DDI-DrugBank.d279.s6	mellitus	71	78	O
DDI-DrugBank.d279.s6	or	80	81	O
DDI-DrugBank.d279.s6	evidence	83	90	O
DDI-DrugBank.d279.s6	of	92	93	O
DDI-DrugBank.d279.s6	glucose	95	101	O
DDI-DrugBank.d279.s6	intolerance	103	113	O
DDI-DrugBank.d279.s6	prior	115	119	O
DDI-DrugBank.d279.s6	to	105	106	O
DDI-DrugBank.d279.s6	administration	124	137	O
DDI-DrugBank.d279.s6	of	139	140	O
DDI-DrugBank.d279.s6	CAMPTOSAR	142	150	B-brand
DDI-DrugBank.d279.s6	.	151	151	O
DDI-DrugBank.d279.s7	It	0	1	O
DDI-DrugBank.d279.s7	is	3	4	O
DDI-DrugBank.d279.s7	probable	6	13	O
DDI-DrugBank.d279.s7	that	15	18	O
DDI-DrugBank.d279.s7	dexamethasone	20	32	B-drug
DDI-DrugBank.d279.s7	,	33	33	O
DDI-DrugBank.d279.s7	given	35	39	O
DDI-DrugBank.d279.s7	as	41	42	O
DDI-DrugBank.d279.s7	antiemetic	44	53	O
DDI-DrugBank.d279.s7	prophylaxis	55	65	O
DDI-DrugBank.d279.s7	,	66	66	O
DDI-DrugBank.d279.s7	contributed	68	78	O
DDI-DrugBank.d279.s7	to	80	81	O
DDI-DrugBank.d279.s7	hyperglycemia	83	95	O
DDI-DrugBank.d279.s7	in	97	98	O
DDI-DrugBank.d279.s7	some	100	103	O
DDI-DrugBank.d279.s7	patients	105	112	O
DDI-DrugBank.d279.s7	.	113	113	O
DDI-DrugBank.d279.s8	The	0	2	O
DDI-DrugBank.d279.s8	incidence	4	12	O
DDI-DrugBank.d279.s8	of	14	15	O
DDI-DrugBank.d279.s8	akathisia	17	25	O
DDI-DrugBank.d279.s8	in	27	28	O
DDI-DrugBank.d279.s8	clinical	30	37	O
DDI-DrugBank.d279.s8	trials	39	44	O
DDI-DrugBank.d279.s8	of	46	47	O
DDI-DrugBank.d279.s8	the	49	51	O
DDI-DrugBank.d279.s8	weekly	53	58	O
DDI-DrugBank.d279.s8	dosage	60	65	O
DDI-DrugBank.d279.s8	schedule	67	74	O
DDI-DrugBank.d279.s8	was	76	78	O
DDI-DrugBank.d279.s8	greater	80	86	O
DDI-DrugBank.d279.s8	(	88	88	O
DDI-DrugBank.d279.s8	8.5	89	91	O
DDI-DrugBank.d279.s8	%	92	92	O
DDI-DrugBank.d279.s8	,	93	93	O
DDI-DrugBank.d279.s8	4/47	95	98	O
DDI-DrugBank.d279.s8	patients	100	107	O
DDI-DrugBank.d279.s8	)	108	108	O
DDI-DrugBank.d279.s8	when	110	113	O
DDI-DrugBank.d279.s8	prochlorperazine	115	130	B-drug
DDI-DrugBank.d279.s8	was	132	134	O
DDI-DrugBank.d279.s8	administered	136	147	O
DDI-DrugBank.d279.s8	on	149	150	O
DDI-DrugBank.d279.s8	the	152	154	O
DDI-DrugBank.d279.s8	same	156	159	O
DDI-DrugBank.d279.s8	day	161	163	O
DDI-DrugBank.d279.s8	as	165	166	O
DDI-DrugBank.d279.s8	CAMPTOSAR	168	176	B-brand
DDI-DrugBank.d279.s8	than	178	181	O
DDI-DrugBank.d279.s8	when	183	186	O
DDI-DrugBank.d279.s8	these	188	192	O
DDI-DrugBank.d279.s8	drugs	194	198	O
DDI-DrugBank.d279.s8	were	200	203	O
DDI-DrugBank.d279.s8	given	205	209	O
DDI-DrugBank.d279.s8	on	211	212	O
DDI-DrugBank.d279.s8	separate	214	221	O
DDI-DrugBank.d279.s8	days	223	226	O
DDI-DrugBank.d279.s8	(	228	228	O
DDI-DrugBank.d279.s8	1.3	229	231	O
DDI-DrugBank.d279.s8	%	232	232	O
DDI-DrugBank.d279.s8	,	233	233	O
DDI-DrugBank.d279.s8	1/80	235	238	O
DDI-DrugBank.d279.s8	patients	240	247	O
DDI-DrugBank.d279.s8	)	248	248	O
DDI-DrugBank.d279.s8	.	230	230	O
DDI-DrugBank.d279.s9	The	0	2	O
DDI-DrugBank.d279.s9	8.5	4	6	O
DDI-DrugBank.d279.s9	%	7	7	O
DDI-DrugBank.d279.s9	incidence	9	17	O
DDI-DrugBank.d279.s9	of	19	20	O
DDI-DrugBank.d279.s9	akathisia	22	30	O
DDI-DrugBank.d279.s9	,	31	31	O
DDI-DrugBank.d279.s9	however	33	39	O
DDI-DrugBank.d279.s9	,	40	40	O
DDI-DrugBank.d279.s9	is	42	43	O
DDI-DrugBank.d279.s9	within	45	50	O
DDI-DrugBank.d279.s9	the	52	54	O
DDI-DrugBank.d279.s9	range	56	60	O
DDI-DrugBank.d279.s9	reported	62	69	O
DDI-DrugBank.d279.s9	for	71	73	O
DDI-DrugBank.d279.s9	use	75	77	O
DDI-DrugBank.d279.s9	of	79	80	O
DDI-DrugBank.d279.s9	prochlorperazine	82	97	B-drug
DDI-DrugBank.d279.s9	when	99	102	O
DDI-DrugBank.d279.s9	given	104	108	O
DDI-DrugBank.d279.s9	as	110	111	O
DDI-DrugBank.d279.s9	a	110	110	O
DDI-DrugBank.d279.s9	premedication	115	127	O
DDI-DrugBank.d279.s9	for	129	131	O
DDI-DrugBank.d279.s9	other	133	137	O
DDI-DrugBank.d279.s9	chemotherapies	139	152	O
DDI-DrugBank.d279.s9	.	153	153	O
DDI-DrugBank.d279.s10	It	0	1	O
DDI-DrugBank.d279.s10	would	3	7	O
DDI-DrugBank.d279.s10	be	9	10	O
DDI-DrugBank.d279.s10	expected	12	19	O
DDI-DrugBank.d279.s10	that	21	24	O
DDI-DrugBank.d279.s10	laxative	26	33	B-group
DDI-DrugBank.d279.s10	use	35	37	O
DDI-DrugBank.d279.s10	during	39	44	O
DDI-DrugBank.d279.s10	therapy	46	52	O
DDI-DrugBank.d279.s10	with	54	57	O
DDI-DrugBank.d279.s10	CAMPTOSAR	59	67	B-brand
DDI-DrugBank.d279.s10	would	69	73	O
DDI-DrugBank.d279.s10	worsen	75	80	O
DDI-DrugBank.d279.s10	the	82	84	O
DDI-DrugBank.d279.s10	incidence	86	94	O
DDI-DrugBank.d279.s10	or	96	97	O
DDI-DrugBank.d279.s10	severity	99	106	O
DDI-DrugBank.d279.s10	of	108	109	O
DDI-DrugBank.d279.s10	diarrhea	111	118	O
DDI-DrugBank.d279.s10	,	119	119	O
DDI-DrugBank.d279.s10	but	121	123	O
DDI-DrugBank.d279.s10	this	125	128	O
DDI-DrugBank.d279.s10	has	130	132	O
DDI-DrugBank.d279.s10	not	134	136	O
DDI-DrugBank.d279.s10	been	138	141	O
DDI-DrugBank.d279.s10	studied	143	149	O
DDI-DrugBank.d279.s10	.	150	150	O
DDI-DrugBank.d279.s11	In	0	1	O
DDI-DrugBank.d279.s11	view	3	6	O
DDI-DrugBank.d279.s11	of	8	9	O
DDI-DrugBank.d279.s11	the	11	13	O
DDI-DrugBank.d279.s11	potential	15	23	O
DDI-DrugBank.d279.s11	risk	25	28	O
DDI-DrugBank.d279.s11	of	30	31	O
DDI-DrugBank.d279.s11	dehydration	33	43	O
DDI-DrugBank.d279.s11	secondary	45	53	O
DDI-DrugBank.d279.s11	to	55	56	O
DDI-DrugBank.d279.s11	vomiting	58	65	O
DDI-DrugBank.d279.s11	and/or	67	72	O
DDI-DrugBank.d279.s11	diarrhea	74	81	O
DDI-DrugBank.d279.s11	induced	83	89	O
DDI-DrugBank.d279.s11	by	91	92	O
DDI-DrugBank.d279.s11	CAMPTOSAR	94	102	B-brand
DDI-DrugBank.d279.s11	,	103	103	O
DDI-DrugBank.d279.s11	the	105	107	O
DDI-DrugBank.d279.s11	physician	109	117	O
DDI-DrugBank.d279.s11	may	119	121	O
DDI-DrugBank.d279.s11	wish	123	126	O
DDI-DrugBank.d279.s11	to	128	129	O
DDI-DrugBank.d279.s11	withhold	131	138	O
DDI-DrugBank.d279.s11	diuretics	140	148	B-group
DDI-DrugBank.d279.s11	during	150	155	O
DDI-DrugBank.d279.s11	dosing	157	162	O
DDI-DrugBank.d279.s11	with	164	167	O
DDI-DrugBank.d279.s11	CAMPTOSAR	169	177	B-brand
DDI-DrugBank.d279.s11	and	179	181	O
DDI-DrugBank.d279.s11	,	182	182	O
DDI-DrugBank.d279.s11	certainly	184	192	O
DDI-DrugBank.d279.s11	,	182	182	O
DDI-DrugBank.d279.s11	during	195	200	O
DDI-DrugBank.d279.s11	periods	202	208	O
DDI-DrugBank.d279.s11	of	210	211	O
DDI-DrugBank.d279.s11	active	213	218	O
DDI-DrugBank.d279.s11	vomiting	220	227	O
DDI-DrugBank.d279.s11	or	229	230	O
DDI-DrugBank.d279.s11	diarrhea	232	239	O
DDI-DrugBank.d279.s11	.	240	240	O
DDI-DrugBank.d279.s12	Drug-Laboratory	0	14	O
DDI-DrugBank.d279.s12	Test	16	19	O
DDI-DrugBank.d279.s12	Interactions	21	32	O
DDI-DrugBank.d279.s12	There	34	38	O
DDI-DrugBank.d279.s12	are	40	42	O
DDI-DrugBank.d279.s12	no	44	45	O
DDI-DrugBank.d279.s12	known	47	51	O
DDI-DrugBank.d279.s12	interactions	53	64	O
DDI-DrugBank.d279.s12	between	66	72	O
DDI-DrugBank.d279.s12	CAMPTOSAR	74	82	B-brand
DDI-DrugBank.d279.s12	and	84	86	O
DDI-DrugBank.d279.s12	laboratory	88	97	O
DDI-DrugBank.d279.s12	tests	99	103	O
DDI-DrugBank.d279.s12	.	104	104	O
DDI-DrugBank.d34.s0	Although	0	7	O
DDI-DrugBank.d34.s0	acid-base	9	17	O
DDI-DrugBank.d34.s0	and	19	21	O
DDI-DrugBank.d34.s0	electrolyte	23	33	O
DDI-DrugBank.d34.s0	disturbances	35	46	O
DDI-DrugBank.d34.s0	were	48	51	O
DDI-DrugBank.d34.s0	not	53	55	O
DDI-DrugBank.d34.s0	reported	57	64	O
DDI-DrugBank.d34.s0	in	66	67	O
DDI-DrugBank.d34.s0	the	69	71	O
DDI-DrugBank.d34.s0	clinical	73	80	O
DDI-DrugBank.d34.s0	trials	82	87	O
DDI-DrugBank.d34.s0	with	89	92	O
DDI-DrugBank.d34.s0	dorzolamide	94	104	B-drug
DDI-DrugBank.d34.s0	,	105	105	O
DDI-DrugBank.d34.s0	these	107	111	O
DDI-DrugBank.d34.s0	disturbances	113	124	O
DDI-DrugBank.d34.s0	have	126	129	O
DDI-DrugBank.d34.s0	been	131	134	O
DDI-DrugBank.d34.s0	reported	136	143	O
DDI-DrugBank.d34.s0	with	145	148	O
DDI-DrugBank.d34.s0	oral	150	153	O
DDI-DrugBank.d34.s0	carbonic	155	162	B-group
DDI-DrugBank.d34.s0	anhydrase	164	172	I-group
DDI-DrugBank.d34.s0	inhibitors	174	183	I-group
DDI-DrugBank.d34.s0	and	185	187	O
DDI-DrugBank.d34.s0	have	189	192	O
DDI-DrugBank.d34.s0	,	193	193	O
DDI-DrugBank.d34.s0	in	174	175	I-group
DDI-DrugBank.d34.s0	some	198	201	O
DDI-DrugBank.d34.s0	instances	203	211	O
DDI-DrugBank.d34.s0	,	193	193	O
DDI-DrugBank.d34.s0	resulted	214	221	O
DDI-DrugBank.d34.s0	in	195	196	O
DDI-DrugBank.d34.s0	drug	226	229	O
DDI-DrugBank.d34.s0	interactions	231	242	O
DDI-DrugBank.d34.s0	(	244	244	O
DDI-DrugBank.d34.s0	e.g.	245	248	O
DDI-DrugBank.d34.s0	,	249	249	O
DDI-DrugBank.d34.s0	toxicity	251	258	O
DDI-DrugBank.d34.s0	associated	260	269	O
DDI-DrugBank.d34.s0	with	271	274	O
DDI-DrugBank.d34.s0	high-dose	276	284	O
DDI-DrugBank.d34.s0	salicylate	286	295	B-group
DDI-DrugBank.d34.s0	therapy	297	303	O
DDI-DrugBank.d34.s0	)	304	304	O
DDI-DrugBank.d34.s0	.	305	305	O
DDI-DrugBank.d34.s1	Therefore	0	8	O
DDI-DrugBank.d34.s1	,	9	9	O
DDI-DrugBank.d34.s1	the	11	13	O
DDI-DrugBank.d34.s1	potential	15	23	O
DDI-DrugBank.d34.s1	for	25	27	O
DDI-DrugBank.d34.s1	such	29	32	O
DDI-DrugBank.d34.s1	drug	34	37	O
DDI-DrugBank.d34.s1	interactions	39	50	O
DDI-DrugBank.d34.s1	should	52	57	O
DDI-DrugBank.d34.s1	be	59	60	O
DDI-DrugBank.d34.s1	considered	62	71	O
DDI-DrugBank.d34.s1	in	73	74	O
DDI-DrugBank.d34.s1	patients	76	83	O
DDI-DrugBank.d34.s1	receiving	85	93	O
DDI-DrugBank.d34.s1	dorzolamide	95	105	B-drug
DDI-DrugBank.d34.s1	.	106	106	O
DDI-DrugBank.d11.s0	Drug-Drug	0	8	O
DDI-DrugBank.d11.s0	Interactions	10	21	O
DDI-DrugBank.d11.s0	Albuterol	23	31	B-drug
DDI-DrugBank.d11.s0	-	33	33	O
DDI-DrugBank.d11.s0	STRATTERA	35	43	B-brand
DDI-DrugBank.d11.s0	should	45	50	O
DDI-DrugBank.d11.s0	be	52	53	O
DDI-DrugBank.d11.s0	administered	55	66	O
DDI-DrugBank.d11.s0	with	68	71	O
DDI-DrugBank.d11.s0	caution	73	79	O
DDI-DrugBank.d11.s0	to	81	82	O
DDI-DrugBank.d11.s0	patients	84	91	O
DDI-DrugBank.d11.s0	being	93	97	O
DDI-DrugBank.d11.s0	treated	99	105	O
DDI-DrugBank.d11.s0	with	107	110	O
DDI-DrugBank.d11.s0	systemically-administered	112	136	O
DDI-DrugBank.d11.s0	(	138	138	O
DDI-DrugBank.d11.s0	oral	139	142	O
DDI-DrugBank.d11.s0	or	139	140	O
DDI-DrugBank.d11.s0	intravenous	147	157	O
DDI-DrugBank.d11.s0	)	158	158	O
DDI-DrugBank.d11.s0	albuterol	160	168	B-drug
DDI-DrugBank.d11.s0	(	170	170	O
DDI-DrugBank.d11.s0	or	171	172	O
DDI-DrugBank.d11.s0	other	174	178	O
DDI-DrugBank.d11.s0	beta2	180	184	B-group
DDI-DrugBank.d11.s0	agonists	186	193	I-group
DDI-DrugBank.d11.s0	)	194	194	O
DDI-DrugBank.d11.s0	because	196	202	O
DDI-DrugBank.d11.s0	the	204	206	O
DDI-DrugBank.d11.s0	action	208	213	O
DDI-DrugBank.d11.s0	of	215	216	O
DDI-DrugBank.d11.s0	albuterol	218	226	B-drug
DDI-DrugBank.d11.s0	on	212	213	O
DDI-DrugBank.d11.s0	the	204	206	O
DDI-DrugBank.d11.s0	cardiovascular	235	248	O
DDI-DrugBank.d11.s0	system	250	255	O
DDI-DrugBank.d11.s0	can	257	259	O
DDI-DrugBank.d11.s0	be	261	262	O
DDI-DrugBank.d11.s0	potentiated	264	274	O
DDI-DrugBank.d11.s0	resulting	276	284	O
DDI-DrugBank.d11.s0	in	282	283	O
DDI-DrugBank.d11.s0	increases	289	297	O
DDI-DrugBank.d11.s0	in	282	283	O
DDI-DrugBank.d11.s0	heart	302	306	O
DDI-DrugBank.d11.s0	rate	308	311	O
DDI-DrugBank.d11.s0	and	313	315	O
DDI-DrugBank.d11.s0	blood	317	321	O
DDI-DrugBank.d11.s0	pressure	323	330	O
DDI-DrugBank.d11.s0	.	331	331	O
DDI-DrugBank.d11.s1	CYP2D6	0	5	O
DDI-DrugBank.d11.s1	inhibitors	7	16	O
DDI-DrugBank.d11.s1	-	18	18	O
DDI-DrugBank.d11.s1	Atomoxetine	20	30	B-drug
DDI-DrugBank.d11.s1	is	32	33	O
DDI-DrugBank.d11.s1	primarily	35	43	O
DDI-DrugBank.d11.s1	metabolized	45	55	O
DDI-DrugBank.d11.s1	by	57	58	O
DDI-DrugBank.d11.s1	the	60	62	O
DDI-DrugBank.d11.s1	CYP2D6	64	69	O
DDI-DrugBank.d11.s1	pathway	71	77	O
DDI-DrugBank.d11.s1	to	79	80	O
DDI-DrugBank.d11.s1	4-hydroxyatomoxetine	82	101	B-drug_n
DDI-DrugBank.d11.s1	.	102	102	O
DDI-DrugBank.d11.s2	In	0	1	O
DDI-DrugBank.d11.s2	EMs	3	5	O
DDI-DrugBank.d11.s2	,	6	6	O
DDI-DrugBank.d11.s2	selective	8	16	O
DDI-DrugBank.d11.s2	inhibitors	18	27	O
DDI-DrugBank.d11.s2	of	29	30	O
DDI-DrugBank.d11.s2	CYP2D6	32	37	O
DDI-DrugBank.d11.s2	increase	39	46	O
DDI-DrugBank.d11.s2	atomoxetine	48	58	B-drug
DDI-DrugBank.d11.s2	steady-state	60	71	O
DDI-DrugBank.d11.s2	plasma	73	78	O
DDI-DrugBank.d11.s2	concentrations	80	93	O
DDI-DrugBank.d11.s2	to	95	96	O
DDI-DrugBank.d11.s2	exposures	98	106	O
DDI-DrugBank.d11.s2	similar	108	114	O
DDI-DrugBank.d11.s2	to	116	117	O
DDI-DrugBank.d11.s2	those	119	123	O
DDI-DrugBank.d11.s2	observed	125	132	O
DDI-DrugBank.d11.s2	in	134	135	O
DDI-DrugBank.d11.s2	PMs	137	139	O
DDI-DrugBank.d11.s2	.	140	140	O
DDI-DrugBank.d11.s3	Dosage	0	5	O
DDI-DrugBank.d11.s3	adjustment	7	16	O
DDI-DrugBank.d11.s3	of	18	19	O
DDI-DrugBank.d11.s3	STRATTERA	21	29	B-brand
DDI-DrugBank.d11.s3	may	31	33	O
DDI-DrugBank.d11.s3	be	35	36	O
DDI-DrugBank.d11.s3	necessary	38	46	O
DDI-DrugBank.d11.s3	when	48	51	O
DDI-DrugBank.d11.s3	coadministered	53	66	O
DDI-DrugBank.d11.s3	with	68	71	O
DDI-DrugBank.d11.s3	CYP2D6	73	78	O
DDI-DrugBank.d11.s3	inhibitors	80	89	O
DDI-DrugBank.d11.s3	,	90	90	O
DDI-DrugBank.d11.s3	e.g.	92	95	O
DDI-DrugBank.d11.s3	,	90	90	O
DDI-DrugBank.d11.s3	paroxetine	98	107	B-drug
DDI-DrugBank.d11.s3	,	96	96	O
DDI-DrugBank.d11.s3	fluoxetine	110	119	B-drug
DDI-DrugBank.d11.s3	,	108	108	O
DDI-DrugBank.d11.s3	and	122	124	O
DDI-DrugBank.d11.s3	quinidine	126	134	B-drug
DDI-DrugBank.d11.s3	.	135	135	O
DDI-DrugBank.d11.s4	In	0	1	O
DDI-DrugBank.d11.s4	EM	3	4	O
DDI-DrugBank.d11.s4	individuals	6	16	O
DDI-DrugBank.d11.s4	treated	18	24	O
DDI-DrugBank.d11.s4	with	26	29	O
DDI-DrugBank.d11.s4	paroxetine	31	40	B-drug
DDI-DrugBank.d11.s4	or	42	43	O
DDI-DrugBank.d11.s4	fluoxetine	45	54	B-drug
DDI-DrugBank.d11.s4	,	55	55	O
DDI-DrugBank.d11.s4	the	57	59	O
DDI-DrugBank.d11.s4	AUC	61	63	O
DDI-DrugBank.d11.s4	of	65	66	O
DDI-DrugBank.d11.s4	atomoxetine	68	78	B-drug
DDI-DrugBank.d11.s4	is	80	81	O
DDI-DrugBank.d11.s4	approximately	83	95	O
DDI-DrugBank.d11.s4	6-	97	98	O
DDI-DrugBank.d11.s4	to	100	101	O
DDI-DrugBank.d11.s4	8-fold	103	108	O
DDI-DrugBank.d11.s4	and	110	112	O
DDI-DrugBank.d11.s4	Css	114	116	O
DDI-DrugBank.d11.s4	,	117	117	O
DDI-DrugBank.d11.s4	max	118	120	O
DDI-DrugBank.d11.s4	is	122	123	O
DDI-DrugBank.d11.s4	about	125	129	O
DDI-DrugBank.d11.s4	3-	131	132	O
DDI-DrugBank.d11.s4	to	134	135	O
DDI-DrugBank.d11.s4	4-fold	137	142	O
DDI-DrugBank.d11.s4	greater	144	150	O
DDI-DrugBank.d11.s4	than	152	155	O
DDI-DrugBank.d11.s4	atomoxetine	157	167	B-drug
DDI-DrugBank.d11.s4	alone	169	173	O
DDI-DrugBank.d11.s4	.	174	174	O
DDI-DrugBank.d11.s5	In	0	1	O
DDI-DrugBank.d11.s5	vitro	3	7	O
DDI-DrugBank.d11.s5	studies	9	15	O
DDI-DrugBank.d11.s5	suggest	17	23	O
DDI-DrugBank.d11.s5	that	25	28	O
DDI-DrugBank.d11.s5	coadministration	30	45	O
DDI-DrugBank.d11.s5	of	47	48	O
DDI-DrugBank.d11.s5	cytochrome	50	59	O
DDI-DrugBank.d11.s5	P450	61	64	O
DDI-DrugBank.d11.s5	inhibitors	66	75	O
DDI-DrugBank.d11.s5	to	72	73	O
DDI-DrugBank.d11.s5	PMs	80	82	O
DDI-DrugBank.d11.s5	will	84	87	O
DDI-DrugBank.d11.s5	not	89	91	O
DDI-DrugBank.d11.s5	increase	93	100	O
DDI-DrugBank.d11.s5	the	102	104	O
DDI-DrugBank.d11.s5	plasma	106	111	O
DDI-DrugBank.d11.s5	concentrations	113	126	O
DDI-DrugBank.d11.s5	of	128	129	O
DDI-DrugBank.d11.s5	atomoxetine	131	141	B-drug
DDI-DrugBank.d11.s5	.	142	142	O
DDI-DrugBank.d11.s6	Pressor	0	6	O
DDI-DrugBank.d11.s6	agents	8	13	O
DDI-DrugBank.d11.s6	-	15	15	O
DDI-DrugBank.d11.s6	Because	17	23	O
DDI-DrugBank.d11.s6	of	25	26	O
DDI-DrugBank.d11.s6	possible	28	35	O
DDI-DrugBank.d11.s6	effects	37	43	O
DDI-DrugBank.d11.s6	on	45	46	O
DDI-DrugBank.d11.s6	blood	48	52	O
DDI-DrugBank.d11.s6	pressure	54	61	O
DDI-DrugBank.d11.s6	,	62	62	O
DDI-DrugBank.d11.s6	STRATTERA	64	72	B-brand
DDI-DrugBank.d11.s6	should	74	79	O
DDI-DrugBank.d11.s6	be	81	82	O
DDI-DrugBank.d11.s6	used	84	87	O
DDI-DrugBank.d11.s6	cautiously	89	98	O
DDI-DrugBank.d11.s6	with	100	103	O
DDI-DrugBank.d11.s6	pressor	105	111	O
DDI-DrugBank.d11.s6	agents	113	118	O
DDI-DrugBank.d11.s6	.	119	119	O
DDI-DrugBank.d597.s0	ACE	0	2	B-group
DDI-DrugBank.d597.s0	inhibitors	4	13	I-group
DDI-DrugBank.d597.s0	Reports	15	21	O
DDI-DrugBank.d597.s0	suggest	23	29	O
DDI-DrugBank.d597.s0	that	31	34	O
DDI-DrugBank.d597.s0	NSAIDs	36	41	B-group
DDI-DrugBank.d597.s0	may	43	45	O
DDI-DrugBank.d597.s0	diminish	47	54	O
DDI-DrugBank.d597.s0	the	56	58	O
DDI-DrugBank.d597.s0	antihypertensive	60	75	O
DDI-DrugBank.d597.s0	effect	77	82	O
DDI-DrugBank.d597.s0	of	84	85	O
DDI-DrugBank.d597.s0	angiotensin-converting	87	108	B-group
DDI-DrugBank.d597.s0	enzyme	110	115	I-group
DDI-DrugBank.d597.s0	(	117	117	O
DDI-DrugBank.d597.s0	ACE	118	120	I-group
DDI-DrugBank.d597.s0	)	121	121	O
DDI-DrugBank.d597.s0	inhibitors	123	132	I-group
DDI-DrugBank.d597.s0	.	133	133	O
DDI-DrugBank.d597.s1	This	0	3	O
DDI-DrugBank.d597.s1	interaction	5	15	O
DDI-DrugBank.d597.s1	should	17	22	O
DDI-DrugBank.d597.s1	be	24	25	O
DDI-DrugBank.d597.s1	given	27	31	O
DDI-DrugBank.d597.s1	consideration	33	45	O
DDI-DrugBank.d597.s1	in	47	48	O
DDI-DrugBank.d597.s1	patients	50	57	O
DDI-DrugBank.d597.s1	taking	59	64	O
DDI-DrugBank.d597.s1	NSAIDs	66	71	B-group
DDI-DrugBank.d597.s1	concomitantly	73	85	O
DDI-DrugBank.d597.s1	with	87	90	O
DDI-DrugBank.d597.s1	ACE	92	94	B-group
DDI-DrugBank.d597.s1	inhibitors	96	105	I-group
DDI-DrugBank.d597.s1	.	106	106	O
DDI-DrugBank.d597.s2	Aspirin	0	6	B-brand
DDI-DrugBank.d597.s2	:	7	7	O
DDI-DrugBank.d597.s2	Concomitant	9	19	O
DDI-DrugBank.d597.s2	administration	21	34	O
DDI-DrugBank.d597.s2	of	36	37	O
DDI-DrugBank.d597.s2	aspirin	39	45	B-brand
DDI-DrugBank.d597.s2	(	47	47	O
DDI-DrugBank.d597.s2	1000	48	51	O
DDI-DrugBank.d597.s2	mg	53	54	O
DDI-DrugBank.d597.s2	TID	56	58	O
DDI-DrugBank.d597.s2	)	59	59	O
DDI-DrugBank.d597.s2	to	61	62	O
DDI-DrugBank.d597.s2	healthy	64	70	O
DDI-DrugBank.d597.s2	volunteers	72	81	O
DDI-DrugBank.d597.s2	tended	83	88	O
DDI-DrugBank.d597.s2	to	90	91	O
DDI-DrugBank.d597.s2	increase	93	100	O
DDI-DrugBank.d597.s2	the	102	104	O
DDI-DrugBank.d597.s2	AUC	106	108	O
DDI-DrugBank.d597.s2	(	110	110	O
DDI-DrugBank.d597.s2	10	111	112	O
DDI-DrugBank.d597.s2	%	113	113	O
DDI-DrugBank.d597.s2	)	114	114	O
DDI-DrugBank.d597.s2	and	116	118	O
DDI-DrugBank.d597.s2	Cmax	120	123	O
DDI-DrugBank.d597.s2	(	110	110	O
DDI-DrugBank.d597.s2	24	126	127	O
DDI-DrugBank.d597.s2	%	113	113	O
DDI-DrugBank.d597.s2	)	114	114	O
DDI-DrugBank.d597.s2	of	131	132	O
DDI-DrugBank.d597.s2	meloxicam	134	142	B-drug
DDI-DrugBank.d597.s2	.	143	143	O
DDI-DrugBank.d597.s3	The	0	2	O
DDI-DrugBank.d597.s3	clinical	4	11	O
DDI-DrugBank.d597.s3	significance	13	24	O
DDI-DrugBank.d597.s3	of	26	27	O
DDI-DrugBank.d597.s3	this	29	32	O
DDI-DrugBank.d597.s3	interaction	34	44	O
DDI-DrugBank.d597.s3	is	46	47	O
DDI-DrugBank.d597.s3	not	49	51	O
DDI-DrugBank.d597.s3	known	53	57	O
DDI-DrugBank.d597.s3	;	58	58	O
DDI-DrugBank.d597.s4	however	0	6	O
DDI-DrugBank.d597.s4	,	7	7	O
DDI-DrugBank.d597.s4	as	9	10	O
DDI-DrugBank.d597.s4	with	12	15	O
DDI-DrugBank.d597.s4	other	17	21	O
DDI-DrugBank.d597.s4	NSAIDs	23	28	B-group
DDI-DrugBank.d597.s4	,	29	29	O
DDI-DrugBank.d597.s4	concomitant	31	41	O
DDI-DrugBank.d597.s4	administration	43	56	O
DDI-DrugBank.d597.s4	of	58	59	O
DDI-DrugBank.d597.s4	meloxicam	61	69	B-drug
DDI-DrugBank.d597.s4	and	71	73	O
DDI-DrugBank.d597.s4	aspirin	75	81	B-brand
DDI-DrugBank.d597.s4	is	83	84	O
DDI-DrugBank.d597.s4	not	86	88	O
DDI-DrugBank.d597.s4	generally	90	98	O
DDI-DrugBank.d597.s4	recommended	100	110	O
DDI-DrugBank.d597.s4	because	112	118	O
DDI-DrugBank.d597.s4	of	120	121	O
DDI-DrugBank.d597.s4	the	123	125	O
DDI-DrugBank.d597.s4	potential	127	135	O
DDI-DrugBank.d597.s4	for	137	139	O
DDI-DrugBank.d597.s4	increased	141	149	O
DDI-DrugBank.d597.s4	adverse	151	157	O
DDI-DrugBank.d597.s4	effects	159	165	O
DDI-DrugBank.d597.s4	.	166	166	O
DDI-DrugBank.d597.s5	Concomitant	0	10	O
DDI-DrugBank.d597.s5	administration	12	25	O
DDI-DrugBank.d597.s5	of	27	28	O
DDI-DrugBank.d597.s5	low-dose	30	37	O
DDI-DrugBank.d597.s5	aspirin	39	45	B-brand
DDI-DrugBank.d597.s5	with	47	50	O
DDI-DrugBank.d597.s5	MOBIC	52	56	B-brand
DDI-DrugBank.d597.s5	may	58	60	O
DDI-DrugBank.d597.s5	result	62	67	O
DDI-DrugBank.d597.s5	in	69	70	O
DDI-DrugBank.d597.s5	an	72	73	O
DDI-DrugBank.d597.s5	increased	75	83	O
DDI-DrugBank.d597.s5	rate	85	88	O
DDI-DrugBank.d597.s5	of	90	91	O
DDI-DrugBank.d597.s5	GI	93	94	O
DDI-DrugBank.d597.s5	ulceration	96	105	O
DDI-DrugBank.d597.s5	or	107	108	O
DDI-DrugBank.d597.s5	other	110	114	O
DDI-DrugBank.d597.s5	complications	116	128	O
DDI-DrugBank.d597.s5	,	129	129	O
DDI-DrugBank.d597.s5	compared	131	138	O
DDI-DrugBank.d597.s5	to	140	141	O
DDI-DrugBank.d597.s5	use	143	145	O
DDI-DrugBank.d597.s5	of	147	148	O
DDI-DrugBank.d597.s5	MOBIC	150	154	B-brand
DDI-DrugBank.d597.s5	alone	156	160	O
DDI-DrugBank.d597.s5	.	161	161	O
DDI-DrugBank.d597.s6	MOBIC	0	4	B-brand
DDI-DrugBank.d597.s6	is	6	7	O
DDI-DrugBank.d597.s6	not	9	11	O
DDI-DrugBank.d597.s6	a	13	13	O
DDI-DrugBank.d597.s6	substitute	15	24	O
DDI-DrugBank.d597.s6	for	26	28	O
DDI-DrugBank.d597.s6	aspirin	30	36	B-brand
DDI-DrugBank.d597.s6	for	38	40	O
DDI-DrugBank.d597.s6	cardiovascular	42	55	O
DDI-DrugBank.d597.s6	prophylaxis	57	67	O
DDI-DrugBank.d597.s6	.	68	68	O
DDI-DrugBank.d597.s7	Cholestyramine	0	13	B-drug
DDI-DrugBank.d597.s7	:	14	14	O
DDI-DrugBank.d597.s7	Pretreatment	16	27	O
DDI-DrugBank.d597.s7	for	29	31	O
DDI-DrugBank.d597.s7	four	33	36	O
DDI-DrugBank.d597.s7	days	38	41	O
DDI-DrugBank.d597.s7	with	43	46	O
DDI-DrugBank.d597.s7	cholestyramine	48	61	B-drug
DDI-DrugBank.d597.s7	significantly	63	75	O
DDI-DrugBank.d597.s7	increased	77	85	O
DDI-DrugBank.d597.s7	the	87	89	O
DDI-DrugBank.d597.s7	clearance	91	99	O
DDI-DrugBank.d597.s7	of	101	102	O
DDI-DrugBank.d597.s7	meloxicam	104	112	B-drug
DDI-DrugBank.d597.s7	by	114	115	O
DDI-DrugBank.d597.s7	50	117	118	O
DDI-DrugBank.d597.s7	%	119	119	O
DDI-DrugBank.d597.s7	.	120	120	O
DDI-DrugBank.d597.s8	This	0	3	O
DDI-DrugBank.d597.s8	resulted	5	12	O
DDI-DrugBank.d597.s8	in	14	15	O
DDI-DrugBank.d597.s8	a	17	17	O
DDI-DrugBank.d597.s8	decrease	19	26	O
DDI-DrugBank.d597.s8	in	28	29	O
DDI-DrugBank.d597.s8	t1/2	31	34	O
DDI-DrugBank.d597.s8	,	35	35	O
DDI-DrugBank.d597.s8	from	37	40	O
DDI-DrugBank.d597.s8	19.2	42	45	O
DDI-DrugBank.d597.s8	hours	47	51	O
DDI-DrugBank.d597.s8	to	53	54	O
DDI-DrugBank.d597.s8	12.5	56	59	O
DDI-DrugBank.d597.s8	hours	61	65	O
DDI-DrugBank.d597.s8	,	66	66	O
DDI-DrugBank.d597.s8	and	68	70	O
DDI-DrugBank.d597.s8	a	68	68	O
DDI-DrugBank.d597.s8	35	74	75	O
DDI-DrugBank.d597.s8	%	76	76	O
DDI-DrugBank.d597.s8	reduction	78	86	O
DDI-DrugBank.d597.s8	in	88	89	O
DDI-DrugBank.d597.s8	AUC	91	93	O
DDI-DrugBank.d597.s8	.	94	94	O
DDI-DrugBank.d597.s9	This	0	3	O
DDI-DrugBank.d597.s9	suggests	5	12	O
DDI-DrugBank.d597.s9	the	14	16	O
DDI-DrugBank.d597.s9	existence	18	26	O
DDI-DrugBank.d597.s9	of	28	29	O
DDI-DrugBank.d597.s9	a	31	31	O
DDI-DrugBank.d597.s9	recirculation	33	45	O
DDI-DrugBank.d597.s9	pathway	47	53	O
DDI-DrugBank.d597.s9	for	55	57	O
DDI-DrugBank.d597.s9	meloxicam	59	67	B-drug
DDI-DrugBank.d597.s9	in	69	70	O
DDI-DrugBank.d597.s9	the	72	74	O
DDI-DrugBank.d597.s9	gastrointestinal	76	91	O
DDI-DrugBank.d597.s9	tract	93	97	O
DDI-DrugBank.d597.s9	.	98	98	O
DDI-DrugBank.d597.s10	The	0	2	O
DDI-DrugBank.d597.s10	clinical	4	11	O
DDI-DrugBank.d597.s10	relevance	13	21	O
DDI-DrugBank.d597.s10	of	23	24	O
DDI-DrugBank.d597.s10	this	26	29	O
DDI-DrugBank.d597.s10	interaction	31	41	O
DDI-DrugBank.d597.s10	has	43	45	O
DDI-DrugBank.d597.s10	not	47	49	O
DDI-DrugBank.d597.s10	been	51	54	O
DDI-DrugBank.d597.s10	established	56	66	O
DDI-DrugBank.d597.s10	.	67	67	O
DDI-DrugBank.d597.s11	Cimetidine	0	9	B-drug
DDI-DrugBank.d597.s11	:	10	10	O
DDI-DrugBank.d597.s11	Concomitant	12	22	O
DDI-DrugBank.d597.s11	administration	24	37	O
DDI-DrugBank.d597.s11	of	39	40	O
DDI-DrugBank.d597.s11	200	42	44	O
DDI-DrugBank.d597.s11	mg	46	47	O
DDI-DrugBank.d597.s11	cimetidine	49	58	B-drug
DDI-DrugBank.d597.s11	QID	60	62	O
DDI-DrugBank.d597.s11	did	64	66	O
DDI-DrugBank.d597.s11	not	68	70	O
DDI-DrugBank.d597.s11	alter	72	76	O
DDI-DrugBank.d597.s11	the	78	80	O
DDI-DrugBank.d597.s11	single-dose	82	92	O
DDI-DrugBank.d597.s11	pharmacokinetics	94	109	O
DDI-DrugBank.d597.s11	of	111	112	O
DDI-DrugBank.d597.s11	30	114	115	O
DDI-DrugBank.d597.s11	mg	117	118	O
DDI-DrugBank.d597.s11	meloxicam	120	128	B-drug
DDI-DrugBank.d597.s11	.	129	129	O
DDI-DrugBank.d597.s12	Digoxin	0	6	B-drug
DDI-DrugBank.d597.s12	:	7	7	O
DDI-DrugBank.d597.s12	Meloxicam	9	17	B-drug
DDI-DrugBank.d597.s12	15	19	20	O
DDI-DrugBank.d597.s12	mg	22	23	O
DDI-DrugBank.d597.s12	once	25	28	O
DDI-DrugBank.d597.s12	daily	30	34	O
DDI-DrugBank.d597.s12	for	36	38	O
DDI-DrugBank.d597.s12	7	40	40	O
DDI-DrugBank.d597.s12	days	42	45	O
DDI-DrugBank.d597.s12	did	47	49	O
DDI-DrugBank.d597.s12	not	51	53	O
DDI-DrugBank.d597.s12	alter	55	59	O
DDI-DrugBank.d597.s12	the	61	63	O
DDI-DrugBank.d597.s12	plasma	65	70	O
DDI-DrugBank.d597.s12	concentration	72	84	O
DDI-DrugBank.d597.s12	profile	86	92	O
DDI-DrugBank.d597.s12	of	88	89	O
DDI-DrugBank.d597.s12	digoxin	97	103	B-drug
DDI-DrugBank.d597.s12	after	105	109	O
DDI-DrugBank.d597.s12	b-acetyldigoxin	111	125	O
DDI-DrugBank.d597.s12	administration	127	140	O
DDI-DrugBank.d597.s12	for	142	144	O
DDI-DrugBank.d597.s12	7	146	146	O
DDI-DrugBank.d597.s12	days	148	151	O
DDI-DrugBank.d597.s12	at	136	137	O
DDI-DrugBank.d597.s12	clinical	156	163	O
DDI-DrugBank.d597.s12	doses	165	169	O
DDI-DrugBank.d597.s12	.	170	170	O
DDI-DrugBank.d597.s13	In	0	1	O
DDI-DrugBank.d597.s13	vitro	3	7	O
DDI-DrugBank.d597.s13	testing	9	15	O
DDI-DrugBank.d597.s13	found	17	21	O
DDI-DrugBank.d597.s13	no	23	24	O
DDI-DrugBank.d597.s13	protein	26	32	O
DDI-DrugBank.d597.s13	binding	34	40	O
DDI-DrugBank.d597.s13	drug	42	45	O
DDI-DrugBank.d597.s13	interaction	47	57	O
DDI-DrugBank.d597.s13	between	59	65	O
DDI-DrugBank.d597.s13	digoxin	67	73	B-drug
DDI-DrugBank.d597.s13	and	75	77	O
DDI-DrugBank.d597.s13	meloxicam	79	87	B-drug
DDI-DrugBank.d597.s13	.	88	88	O
DDI-DrugBank.d597.s14	Furosemide	0	9	B-drug
DDI-DrugBank.d597.s14	:	10	10	O
DDI-DrugBank.d597.s14	Clinical	12	19	O
DDI-DrugBank.d597.s14	studies	21	27	O
DDI-DrugBank.d597.s14	,	28	28	O
DDI-DrugBank.d597.s14	as	30	31	O
DDI-DrugBank.d597.s14	well	33	36	O
DDI-DrugBank.d597.s14	as	38	39	O
DDI-DrugBank.d597.s14	post-marketing	41	54	O
DDI-DrugBank.d597.s14	observations	56	67	O
DDI-DrugBank.d597.s14	,	68	68	O
DDI-DrugBank.d597.s14	have	70	73	O
DDI-DrugBank.d597.s14	shown	75	79	O
DDI-DrugBank.d597.s14	that	81	84	O
DDI-DrugBank.d597.s14	NSAIDs	86	91	B-group
DDI-DrugBank.d597.s14	can	93	95	O
DDI-DrugBank.d597.s14	reduce	97	102	O
DDI-DrugBank.d597.s14	the	104	106	O
DDI-DrugBank.d597.s14	natriuretic	108	118	O
DDI-DrugBank.d597.s14	effect	120	125	O
DDI-DrugBank.d597.s14	of	127	128	O
DDI-DrugBank.d597.s14	furosemide	130	139	B-drug
DDI-DrugBank.d597.s14	and	141	143	O
DDI-DrugBank.d597.s14	thiazide	145	152	B-group
DDI-DrugBank.d597.s14	diuretics	154	162	I-group
DDI-DrugBank.d597.s14	in	164	165	O
DDI-DrugBank.d597.s14	some	167	170	O
DDI-DrugBank.d597.s14	patients	172	179	O
DDI-DrugBank.d597.s14	.	180	180	O
DDI-DrugBank.d597.s15	This	0	3	O
DDI-DrugBank.d597.s15	effect	5	10	O
DDI-DrugBank.d597.s15	has	12	14	O
DDI-DrugBank.d597.s15	been	16	19	O
DDI-DrugBank.d597.s15	attributed	21	30	O
DDI-DrugBank.d597.s15	to	32	33	O
DDI-DrugBank.d597.s15	inhibition	35	44	O
DDI-DrugBank.d597.s15	of	46	47	O
DDI-DrugBank.d597.s15	renal	49	53	O
DDI-DrugBank.d597.s15	prostaglandin	55	67	O
DDI-DrugBank.d597.s15	synthesis	69	77	O
DDI-DrugBank.d597.s15	.	78	78	O
DDI-DrugBank.d597.s16	Studies	0	6	O
DDI-DrugBank.d597.s16	with	8	11	O
DDI-DrugBank.d597.s16	furosemide	13	22	B-drug
DDI-DrugBank.d597.s16	agents	24	29	O
DDI-DrugBank.d597.s16	and	31	33	O
DDI-DrugBank.d597.s16	meloxicam	35	43	B-drug
DDI-DrugBank.d597.s16	have	45	48	O
DDI-DrugBank.d597.s16	not	50	52	O
DDI-DrugBank.d597.s16	demonstrated	54	65	O
DDI-DrugBank.d597.s16	a	62	62	O
DDI-DrugBank.d597.s16	reduction	69	77	O
DDI-DrugBank.d597.s16	in	79	80	O
DDI-DrugBank.d597.s16	natriuretic	82	92	O
DDI-DrugBank.d597.s16	effect	94	99	O
DDI-DrugBank.d597.s16	.	100	100	O
DDI-DrugBank.d597.s17	Furosemide	0	9	B-drug
DDI-DrugBank.d597.s17	:	10	10	O
DDI-DrugBank.d597.s17	single	12	17	O
DDI-DrugBank.d597.s17	and	19	21	O
DDI-DrugBank.d597.s17	multiple	23	30	O
DDI-DrugBank.d597.s17	dose	32	35	O
DDI-DrugBank.d597.s17	pharmacodynamics	37	52	O
DDI-DrugBank.d597.s17	and	54	56	O
DDI-DrugBank.d597.s17	pharmacokinetics	58	73	O
DDI-DrugBank.d597.s17	are	75	77	O
DDI-DrugBank.d597.s17	not	79	81	O
DDI-DrugBank.d597.s17	affected	83	90	O
DDI-DrugBank.d597.s17	by	92	93	O
DDI-DrugBank.d597.s17	multiple	95	102	O
DDI-DrugBank.d597.s17	doses	104	108	O
DDI-DrugBank.d597.s17	of	110	111	O
DDI-DrugBank.d597.s17	meloxicam	113	121	B-drug
DDI-DrugBank.d597.s17	.	122	122	O
DDI-DrugBank.d597.s18	Nevertheless	0	11	O
DDI-DrugBank.d597.s18	,	12	12	O
DDI-DrugBank.d597.s18	during	14	19	O
DDI-DrugBank.d597.s18	concomitant	21	31	O
DDI-DrugBank.d597.s18	therapy	33	39	O
DDI-DrugBank.d597.s18	with	41	44	O
DDI-DrugBank.d597.s18	furosemide	46	55	B-drug
DDI-DrugBank.d597.s18	and	57	59	O
DDI-DrugBank.d597.s18	MOBIC	61	65	B-brand
DDI-DrugBank.d597.s18	,	66	66	O
DDI-DrugBank.d597.s18	patients	68	75	O
DDI-DrugBank.d597.s18	should	77	82	O
DDI-DrugBank.d597.s18	be	84	85	O
DDI-DrugBank.d597.s18	observed	87	94	O
DDI-DrugBank.d597.s18	closely	96	102	O
DDI-DrugBank.d597.s18	for	104	106	O
DDI-DrugBank.d597.s18	signs	108	112	O
DDI-DrugBank.d597.s18	of	114	115	O
DDI-DrugBank.d597.s18	declining	117	125	O
DDI-DrugBank.d597.s18	renal	127	131	O
DDI-DrugBank.d597.s18	function	133	140	O
DDI-DrugBank.d597.s18	,	141	141	O
DDI-DrugBank.d597.s18	as	143	144	O
DDI-DrugBank.d597.s18	well	146	149	O
DDI-DrugBank.d597.s18	as	143	144	O
DDI-DrugBank.d597.s18	to	154	155	O
DDI-DrugBank.d597.s18	assure	157	162	O
DDI-DrugBank.d597.s18	diuretic	164	171	O
DDI-DrugBank.d597.s18	efficacy	173	180	O
DDI-DrugBank.d597.s18	.	181	181	O
DDI-DrugBank.d597.s19	Lithium	0	6	B-drug
DDI-DrugBank.d597.s19	:	7	7	O
DDI-DrugBank.d597.s19	In	9	10	O
DDI-DrugBank.d597.s19	clinical	12	19	O
DDI-DrugBank.d597.s19	trials	21	26	O
DDI-DrugBank.d597.s19	,	27	27	O
DDI-DrugBank.d597.s19	NSAIDs	29	34	B-group
DDI-DrugBank.d597.s19	have	36	39	O
DDI-DrugBank.d597.s19	produced	41	48	O
DDI-DrugBank.d597.s19	an	50	51	O
DDI-DrugBank.d597.s19	elevation	53	61	O
DDI-DrugBank.d597.s19	of	63	64	O
DDI-DrugBank.d597.s19	plasma	66	71	O
DDI-DrugBank.d597.s19	lithium	73	79	B-drug
DDI-DrugBank.d597.s19	levels	81	86	O
DDI-DrugBank.d597.s19	and	88	90	O
DDI-DrugBank.d597.s19	a	88	88	O
DDI-DrugBank.d597.s19	reduction	94	102	O
DDI-DrugBank.d597.s19	in	104	105	O
DDI-DrugBank.d597.s19	renal	107	111	O
DDI-DrugBank.d597.s19	lithium	113	119	B-drug
DDI-DrugBank.d597.s19	clearance	121	129	O
DDI-DrugBank.d597.s19	.	130	130	O
DDI-DrugBank.d597.s20	In	0	1	O
DDI-DrugBank.d597.s20	a	3	3	O
DDI-DrugBank.d597.s20	study	5	9	O
DDI-DrugBank.d597.s20	conducted	11	19	O
DDI-DrugBank.d597.s20	in	21	22	O
DDI-DrugBank.d597.s20	healthy	24	30	O
DDI-DrugBank.d597.s20	subjects	32	39	O
DDI-DrugBank.d597.s20	,	40	40	O
DDI-DrugBank.d597.s20	mean	42	45	O
DDI-DrugBank.d597.s20	pre-dose	47	54	O
DDI-DrugBank.d597.s20	lithium	56	62	B-drug
DDI-DrugBank.d597.s20	concentration	64	76	O
DDI-DrugBank.d597.s20	and	78	80	O
DDI-DrugBank.d597.s20	AUC	82	84	O
DDI-DrugBank.d597.s20	were	86	89	O
DDI-DrugBank.d597.s20	increased	91	99	O
DDI-DrugBank.d597.s20	by	101	102	O
DDI-DrugBank.d597.s20	21	104	105	O
DDI-DrugBank.d597.s20	%	106	106	O
DDI-DrugBank.d597.s20	in	91	92	O
DDI-DrugBank.d597.s20	subjects	111	118	O
DDI-DrugBank.d597.s20	receiving	120	128	O
DDI-DrugBank.d597.s20	lithium	130	136	B-drug
DDI-DrugBank.d597.s20	doses	138	142	O
DDI-DrugBank.d597.s20	ranging	144	150	O
DDI-DrugBank.d597.s20	from	152	155	O
DDI-DrugBank.d597.s20	804	157	159	O
DDI-DrugBank.d597.s20	to	161	162	O
DDI-DrugBank.d597.s20	1072	164	167	O
DDI-DrugBank.d597.s20	mg	169	170	O
DDI-DrugBank.d597.s20	BID	172	174	O
DDI-DrugBank.d597.s20	with	176	179	O
DDI-DrugBank.d597.s20	meloxicam	181	189	B-drug
DDI-DrugBank.d597.s20	15	191	192	O
DDI-DrugBank.d597.s20	mg	169	170	O
DDI-DrugBank.d597.s20	QD	197	198	O
DDI-DrugBank.d597.s20	as	200	201	O
DDI-DrugBank.d597.s20	compared	203	210	O
DDI-DrugBank.d597.s20	to	212	213	O
DDI-DrugBank.d597.s20	subjects	215	222	O
DDI-DrugBank.d597.s20	receiving	224	232	O
DDI-DrugBank.d597.s20	lithium	234	240	B-drug
DDI-DrugBank.d597.s20	alone	242	246	O
DDI-DrugBank.d597.s20	.	247	247	O
DDI-DrugBank.d597.s21	These	0	4	O
DDI-DrugBank.d597.s21	effects	6	12	O
DDI-DrugBank.d597.s21	have	14	17	O
DDI-DrugBank.d597.s21	been	19	22	O
DDI-DrugBank.d597.s21	attributed	24	33	O
DDI-DrugBank.d597.s21	to	35	36	O
DDI-DrugBank.d597.s21	inhibition	38	47	O
DDI-DrugBank.d597.s21	of	49	50	O
DDI-DrugBank.d597.s21	renal	52	56	O
DDI-DrugBank.d597.s21	prostaglandin	58	70	O
DDI-DrugBank.d597.s21	synthesis	72	80	O
DDI-DrugBank.d597.s21	by	82	83	O
DDI-DrugBank.d597.s21	MOBIC	85	89	B-brand
DDI-DrugBank.d597.s21	.	90	90	O
DDI-DrugBank.d597.s22	Patients	0	7	O
DDI-DrugBank.d597.s22	on	9	10	O
DDI-DrugBank.d597.s22	lithium	12	18	B-drug
DDI-DrugBank.d597.s22	treatment	20	28	O
DDI-DrugBank.d597.s22	should	30	35	O
DDI-DrugBank.d597.s22	be	37	38	O
DDI-DrugBank.d597.s22	closely	40	46	O
DDI-DrugBank.d597.s22	monitored	48	56	O
DDI-DrugBank.d597.s22	when	58	61	O
DDI-DrugBank.d597.s22	MOBIC	63	67	B-brand
DDI-DrugBank.d597.s22	is	69	70	O
DDI-DrugBank.d597.s22	introduced	72	81	O
DDI-DrugBank.d597.s22	or	83	84	O
DDI-DrugBank.d597.s22	withdrawn	86	94	O
DDI-DrugBank.d597.s22	.	95	95	O
DDI-DrugBank.d597.s23	Methotrexate	0	11	B-drug
DDI-DrugBank.d597.s23	:	12	12	O
DDI-DrugBank.d597.s23	A	14	14	O
DDI-DrugBank.d597.s23	study	16	20	O
DDI-DrugBank.d597.s23	in	22	23	O
DDI-DrugBank.d597.s23	13	25	26	O
DDI-DrugBank.d597.s23	rheumatoid	28	37	O
DDI-DrugBank.d597.s23	arthritis	39	47	O
DDI-DrugBank.d597.s23	(	49	49	O
DDI-DrugBank.d597.s23	RA	50	51	O
DDI-DrugBank.d597.s23	)	52	52	O
DDI-DrugBank.d597.s23	patients	54	61	O
DDI-DrugBank.d597.s23	evaluated	63	71	O
DDI-DrugBank.d597.s23	the	73	75	O
DDI-DrugBank.d597.s23	effects	77	83	O
DDI-DrugBank.d597.s23	of	85	86	O
DDI-DrugBank.d597.s23	multiple	88	95	O
DDI-DrugBank.d597.s23	doses	97	101	O
DDI-DrugBank.d597.s23	of	103	104	O
DDI-DrugBank.d597.s23	meloxicam	106	114	B-drug
DDI-DrugBank.d597.s23	on	116	117	O
DDI-DrugBank.d597.s23	the	119	121	O
DDI-DrugBank.d597.s23	pharmacokinetics	123	138	O
DDI-DrugBank.d597.s23	of	140	141	O
DDI-DrugBank.d597.s23	methotrexate	143	154	B-drug
DDI-DrugBank.d597.s23	taken	156	160	O
DDI-DrugBank.d597.s23	once	162	165	O
DDI-DrugBank.d597.s23	weekly	167	172	O
DDI-DrugBank.d597.s23	.	173	173	O
DDI-DrugBank.d597.s24	Meloxicam	0	8	B-drug
DDI-DrugBank.d597.s24	did	10	12	O
DDI-DrugBank.d597.s24	not	14	16	O
DDI-DrugBank.d597.s24	have	18	21	O
DDI-DrugBank.d597.s24	a	19	19	O
DDI-DrugBank.d597.s24	significant	25	35	O
DDI-DrugBank.d597.s24	effect	37	42	O
DDI-DrugBank.d597.s24	on	44	45	O
DDI-DrugBank.d597.s24	the	47	49	O
DDI-DrugBank.d597.s24	pharmacokinetics	51	66	O
DDI-DrugBank.d597.s24	of	68	69	O
DDI-DrugBank.d597.s24	single	71	76	O
DDI-DrugBank.d597.s24	doses	78	82	O
DDI-DrugBank.d597.s24	of	84	85	O
DDI-DrugBank.d597.s24	methotrexate	87	98	B-drug
DDI-DrugBank.d597.s24	.	99	99	O
DDI-DrugBank.d597.s25	In	0	1	O
DDI-DrugBank.d597.s25	vitro	3	7	O
DDI-DrugBank.d597.s25	,	8	8	O
DDI-DrugBank.d597.s25	methotrexate	10	21	B-drug
DDI-DrugBank.d597.s25	did	23	25	O
DDI-DrugBank.d597.s25	not	27	29	O
DDI-DrugBank.d597.s25	displace	31	38	O
DDI-DrugBank.d597.s25	meloxicam	40	48	B-drug
DDI-DrugBank.d597.s25	from	50	53	O
DDI-DrugBank.d597.s25	its	55	57	O
DDI-DrugBank.d597.s25	human	59	63	O
DDI-DrugBank.d597.s25	serum	65	69	O
DDI-DrugBank.d597.s25	binding	71	77	O
DDI-DrugBank.d597.s25	sites	79	83	O
DDI-DrugBank.d597.s25	.	84	84	O
DDI-DrugBank.d597.s26	Warfarin	0	7	B-drug
DDI-DrugBank.d597.s26	:	8	8	O
DDI-DrugBank.d597.s26	Anticoagulant	10	22	O
DDI-DrugBank.d597.s26	activity	24	31	O
DDI-DrugBank.d597.s26	should	33	38	O
DDI-DrugBank.d597.s26	be	40	41	O
DDI-DrugBank.d597.s26	monitored	43	51	O
DDI-DrugBank.d597.s26	,	52	52	O
DDI-DrugBank.d597.s26	particularly	54	65	O
DDI-DrugBank.d597.s26	in	67	68	O
DDI-DrugBank.d597.s26	the	70	72	O
DDI-DrugBank.d597.s26	first	74	78	O
DDI-DrugBank.d597.s26	few	80	82	O
DDI-DrugBank.d597.s26	days	84	87	O
DDI-DrugBank.d597.s26	after	89	93	O
DDI-DrugBank.d597.s26	initiating	95	104	O
DDI-DrugBank.d597.s26	or	106	107	O
DDI-DrugBank.d597.s26	changing	109	116	O
DDI-DrugBank.d597.s26	MOBIC	118	122	B-brand
DDI-DrugBank.d597.s26	therapy	124	130	O
DDI-DrugBank.d597.s26	in	114	115	O
DDI-DrugBank.d597.s26	patients	135	142	O
DDI-DrugBank.d597.s26	receiving	144	152	O
DDI-DrugBank.d597.s26	warfarin	154	161	B-drug
DDI-DrugBank.d597.s26	or	163	164	O
DDI-DrugBank.d597.s26	similar	166	172	O
DDI-DrugBank.d597.s26	agents	174	179	O
DDI-DrugBank.d597.s26	,	180	180	O
DDI-DrugBank.d597.s26	since	182	186	O
DDI-DrugBank.d597.s26	these	188	192	O
DDI-DrugBank.d597.s26	patients	194	201	O
DDI-DrugBank.d597.s26	are	203	205	O
DDI-DrugBank.d597.s26	at	195	196	O
DDI-DrugBank.d597.s26	an	210	211	O
DDI-DrugBank.d597.s26	increased	213	221	O
DDI-DrugBank.d597.s26	risk	223	226	O
DDI-DrugBank.d597.s26	of	228	229	O
DDI-DrugBank.d597.s26	bleeding	231	238	O
DDI-DrugBank.d597.s26	.	239	239	O
DDI-DrugBank.d597.s27	The	0	2	O
DDI-DrugBank.d597.s27	effect	4	9	O
DDI-DrugBank.d597.s27	of	11	12	O
DDI-DrugBank.d597.s27	meloxicam	14	22	B-drug
DDI-DrugBank.d597.s27	on	24	25	O
DDI-DrugBank.d597.s27	the	27	29	O
DDI-DrugBank.d597.s27	anticoagulant	31	43	O
DDI-DrugBank.d597.s27	effect	45	50	O
DDI-DrugBank.d597.s27	of	52	53	O
DDI-DrugBank.d597.s27	warfarin	55	62	B-drug
DDI-DrugBank.d597.s27	was	64	66	O
DDI-DrugBank.d597.s27	studied	68	74	O
DDI-DrugBank.d597.s27	in	76	77	O
DDI-DrugBank.d597.s27	a	79	79	O
DDI-DrugBank.d597.s27	group	81	85	O
DDI-DrugBank.d597.s27	of	87	88	O
DDI-DrugBank.d597.s27	healthy	90	96	O
DDI-DrugBank.d597.s27	subjects	98	105	O
DDI-DrugBank.d597.s27	receiving	107	115	O
DDI-DrugBank.d597.s27	daily	117	121	O
DDI-DrugBank.d597.s27	doses	123	127	O
DDI-DrugBank.d597.s27	of	129	130	O
DDI-DrugBank.d597.s27	warfarin	132	139	B-drug
DDI-DrugBank.d597.s27	that	141	144	O
DDI-DrugBank.d597.s27	produced	146	153	O
DDI-DrugBank.d597.s27	an	155	156	O
DDI-DrugBank.d597.s27	INR	158	160	O
DDI-DrugBank.d597.s27	(	162	162	O
DDI-DrugBank.d597.s27	International	163	175	O
DDI-DrugBank.d597.s27	Normalized	177	186	O
DDI-DrugBank.d597.s27	Ratio	188	192	O
DDI-DrugBank.d597.s27	)	193	193	O
DDI-DrugBank.d597.s27	between	195	201	O
DDI-DrugBank.d597.s27	1.2	203	205	O
DDI-DrugBank.d597.s27	and	207	209	O
DDI-DrugBank.d597.s27	1.8	211	213	O
DDI-DrugBank.d597.s27	.	204	204	O
DDI-DrugBank.d597.s28	In	0	1	O
DDI-DrugBank.d597.s28	these	3	7	O
DDI-DrugBank.d597.s28	subjects	9	16	O
DDI-DrugBank.d597.s28	,	17	17	O
DDI-DrugBank.d597.s28	meloxicam	19	27	B-drug
DDI-DrugBank.d597.s28	did	29	31	O
DDI-DrugBank.d597.s28	not	33	35	O
DDI-DrugBank.d597.s28	alter	37	41	O
DDI-DrugBank.d597.s28	warfarin	43	50	B-drug
DDI-DrugBank.d597.s28	pharmacokinetics	52	67	O
DDI-DrugBank.d597.s28	and	69	71	O
DDI-DrugBank.d597.s28	the	73	75	O
DDI-DrugBank.d597.s28	average	77	83	O
DDI-DrugBank.d597.s28	anticoagulant	85	97	O
DDI-DrugBank.d597.s28	effect	99	104	O
DDI-DrugBank.d597.s28	of	106	107	O
DDI-DrugBank.d597.s28	warfarin	109	116	B-drug
DDI-DrugBank.d597.s28	as	118	119	O
DDI-DrugBank.d597.s28	determined	121	130	O
DDI-DrugBank.d597.s28	by	132	133	O
DDI-DrugBank.d597.s28	prothrombin	135	145	O
DDI-DrugBank.d597.s28	time	147	150	O
DDI-DrugBank.d597.s28	.	151	151	O
DDI-DrugBank.d597.s29	However	0	6	O
DDI-DrugBank.d597.s29	,	7	7	O
DDI-DrugBank.d597.s29	one	9	11	O
DDI-DrugBank.d597.s29	subject	13	19	O
DDI-DrugBank.d597.s29	showed	21	26	O
DDI-DrugBank.d597.s29	an	28	29	O
DDI-DrugBank.d597.s29	increase	31	38	O
DDI-DrugBank.d597.s29	in	40	41	O
DDI-DrugBank.d597.s29	INR	43	45	O
DDI-DrugBank.d597.s29	from	47	50	O
DDI-DrugBank.d597.s29	1.5	52	54	O
DDI-DrugBank.d597.s29	to	56	57	O
DDI-DrugBank.d597.s29	2.1	59	61	O
DDI-DrugBank.d597.s29	.	53	53	O
DDI-DrugBank.d597.s30	Caution	0	6	O
DDI-DrugBank.d597.s30	should	8	13	O
DDI-DrugBank.d597.s30	be	15	16	O
DDI-DrugBank.d597.s30	used	18	21	O
DDI-DrugBank.d597.s30	when	23	26	O
DDI-DrugBank.d597.s30	administering	28	40	O
DDI-DrugBank.d597.s30	MOBIC	42	46	B-brand
DDI-DrugBank.d597.s30	with	48	51	O
DDI-DrugBank.d597.s30	warfarin	53	60	B-drug
DDI-DrugBank.d597.s30	since	62	66	O
DDI-DrugBank.d597.s30	patients	68	75	O
DDI-DrugBank.d597.s30	on	77	78	O
DDI-DrugBank.d597.s30	warfarin	80	87	B-drug
DDI-DrugBank.d597.s30	may	89	91	O
DDI-DrugBank.d597.s30	experience	93	102	O
DDI-DrugBank.d597.s30	changes	104	110	O
DDI-DrugBank.d597.s30	in	112	113	O
DDI-DrugBank.d597.s30	INR	115	117	O
DDI-DrugBank.d597.s30	and	119	121	O
DDI-DrugBank.d597.s30	an	106	107	O
DDI-DrugBank.d597.s30	increased	126	134	O
DDI-DrugBank.d597.s30	risk	136	139	O
DDI-DrugBank.d597.s30	of	141	142	O
DDI-DrugBank.d597.s30	bleeding	144	151	O
DDI-DrugBank.d597.s30	complications	153	165	O
DDI-DrugBank.d597.s30	when	167	170	O
DDI-DrugBank.d597.s30	a	160	160	O
DDI-DrugBank.d597.s30	new	174	176	O
DDI-DrugBank.d597.s30	medication	178	187	O
DDI-DrugBank.d597.s30	is	189	190	O
DDI-DrugBank.d597.s30	introduced	192	201	O
DDI-DrugBank.d597.s30	.	202	202	O
DDI-DrugBank.d167.s0	Potentially	0	10	O
DDI-DrugBank.d167.s0	fatal	12	16	O
DDI-DrugBank.d167.s0	drug	18	21	O
DDI-DrugBank.d167.s0	interactions	23	34	O
DDI-DrugBank.d167.s0	may	36	38	O
DDI-DrugBank.d167.s0	occur	40	44	O
DDI-DrugBank.d167.s0	when	46	49	O
DDI-DrugBank.d167.s0	coadministered	51	64	O
DDI-DrugBank.d167.s0	with	66	69	O
DDI-DrugBank.d167.s0	digoxin	71	77	B-drug
DDI-DrugBank.d167.s0	,	78	78	O
DDI-DrugBank.d167.s0	as	80	81	O
DDI-DrugBank.d167.s0	this	83	86	O
DDI-DrugBank.d167.s0	may	88	90	O
DDI-DrugBank.d167.s0	enhance	92	98	O
DDI-DrugBank.d167.s0	cardiovascular	100	113	O
DDI-DrugBank.d167.s0	depression	115	124	O
DDI-DrugBank.d167.s0	and	126	128	O
DDI-DrugBank.d167.s0	bradyarrhythmias	130	145	O
DDI-DrugBank.d167.s0	may	147	149	O
DDI-DrugBank.d167.s0	occur	151	155	O
DDI-DrugBank.d167.s0	.	156	156	O
DDI-DrugBank.d167.s1	Anticholinesterases	0	18	B-group
DDI-DrugBank.d167.s1	(	20	20	O
DDI-DrugBank.d167.s1	neostgmine	21	30	O
DDI-DrugBank.d167.s1	,	31	31	O
DDI-DrugBank.d167.s1	physostigmine	33	45	B-drug
DDI-DrugBank.d167.s1	)	46	46	O
DDI-DrugBank.d167.s1	,	47	47	O
DDI-DrugBank.d167.s1	lignocaine	49	58	B-drug
DDI-DrugBank.d167.s1	,	59	59	O
DDI-DrugBank.d167.s1	quinine	61	67	B-drug
DDI-DrugBank.d167.s1	,	68	68	O
DDI-DrugBank.d167.s1	procainamide	70	81	B-drug
DDI-DrugBank.d167.s1	can	83	85	O
DDI-DrugBank.d167.s1	enhance	87	93	O
DDI-DrugBank.d167.s1	toxicity	95	102	O
DDI-DrugBank.d167.s1	and	104	106	O
DDI-DrugBank.d167.s1	cause	108	112	O
DDI-DrugBank.d167.s1	cardio	114	119	O
DDI-DrugBank.d167.s1	respiratory	121	131	O
DDI-DrugBank.d167.s1	depression	133	142	O
DDI-DrugBank.d167.s1	.	143	143	O
DDI-DrugBank.d167.s2	In	0	1	O
DDI-DrugBank.d167.s2	addition	3	10	O
DDI-DrugBank.d167.s2	,	11	11	O
DDI-DrugBank.d167.s2	neuromuscular	13	25	O
DDI-DrugBank.d167.s2	blocking	27	34	O
DDI-DrugBank.d167.s2	action	36	41	O
DDI-DrugBank.d167.s2	is	43	44	O
DDI-DrugBank.d167.s2	enhanced	46	53	O
DDI-DrugBank.d167.s2	by	55	56	O
DDI-DrugBank.d167.s2	general	58	64	O
DDI-DrugBank.d167.s2	anesthetics	66	76	B-group
DDI-DrugBank.d167.s2	,	77	77	O
DDI-DrugBank.d167.s2	local	79	83	O
DDI-DrugBank.d167.s2	anesthetics	85	95	B-group
DDI-DrugBank.d167.s2	like	97	100	O
DDI-DrugBank.d167.s2	lidocaine	102	110	B-drug
DDI-DrugBank.d167.s2	,	111	111	O
DDI-DrugBank.d167.s2	procaine	113	120	B-drug
DDI-DrugBank.d167.s2	,	111	111	O
DDI-DrugBank.d167.s2	beta-blockers	123	135	B-group
DDI-DrugBank.d167.s2	,	121	121	O
DDI-DrugBank.d167.s2	metaclopramide	138	151	B-drug
DDI-DrugBank.d167.s2	,	136	136	O
DDI-DrugBank.d167.s2	lithium	154	160	B-drug
DDI-DrugBank.d167.s2	carbonate	162	170	I-drug
DDI-DrugBank.d167.s2	,	171	171	O
DDI-DrugBank.d167.s2	and	173	175	O
DDI-DrugBank.d167.s2	terbutaline	177	187	B-drug
DDI-DrugBank.d167.s2	.	188	188	O
DDI-DrugBank.d603.s0	When	0	3	O
DDI-DrugBank.d603.s0	administered	5	16	O
DDI-DrugBank.d603.s0	concomitantly	18	30	O
DDI-DrugBank.d603.s0	with	32	35	O
DDI-DrugBank.d603.s0	ProAmatine	37	46	B-brand
DDI-DrugBank.d603.s0	,	50	50	O
DDI-DrugBank.d603.s0	cardiac	52	58	B-group
DDI-DrugBank.d603.s0	glycosides	60	69	I-group
DDI-DrugBank.d603.s0	may	71	73	O
DDI-DrugBank.d603.s0	enhance	75	81	O
DDI-DrugBank.d603.s0	or	83	84	O
DDI-DrugBank.d603.s0	precipitate	86	96	O
DDI-DrugBank.d603.s0	bradycardia	98	108	O
DDI-DrugBank.d603.s0	,	109	109	O
DDI-DrugBank.d603.s0	A.V	111	113	O
DDI-DrugBank.d603.s0	.	112	112	O
DDI-DrugBank.d603.s1	block	0	4	O
DDI-DrugBank.d603.s1	or	6	7	O
DDI-DrugBank.d603.s1	arrhythmia	9	18	O
DDI-DrugBank.d603.s1	.	19	19	O
DDI-DrugBank.d603.s2	The	0	2	O
DDI-DrugBank.d603.s2	use	4	6	O
DDI-DrugBank.d603.s2	of	8	9	O
DDI-DrugBank.d603.s2	drugs	11	15	O
DDI-DrugBank.d603.s2	that	17	20	O
DDI-DrugBank.d603.s2	stimulate	22	30	O
DDI-DrugBank.d603.s2	alpha-adrenergic	32	47	O
DDI-DrugBank.d603.s2	receptors	49	57	O
DDI-DrugBank.d603.s2	(	59	59	O
DDI-DrugBank.d603.s2	e.g.	60	63	O
DDI-DrugBank.d603.s2	,	64	64	O
DDI-DrugBank.d603.s2	phenylephrine	66	78	B-drug
DDI-DrugBank.d603.s2	,	79	79	O
DDI-DrugBank.d603.s2	pseudoephedrine	81	95	B-drug
DDI-DrugBank.d603.s2	,	96	96	O
DDI-DrugBank.d603.s2	ephedrine	87	95	I-drug
DDI-DrugBank.d603.s2	,	96	96	O
DDI-DrugBank.d603.s2	phenylpropanolamine	109	127	B-drug
DDI-DrugBank.d603.s2	or	129	130	O
DDI-DrugBank.d603.s2	dihydroergotamine	132	148	B-drug
DDI-DrugBank.d603.s2	)	149	149	O
DDI-DrugBank.d603.s2	may	151	153	O
DDI-DrugBank.d603.s2	enhance	155	161	O
DDI-DrugBank.d603.s2	or	163	164	O
DDI-DrugBank.d603.s2	potentiate	166	175	O
DDI-DrugBank.d603.s2	the	177	179	O
DDI-DrugBank.d603.s2	pressor	181	187	O
DDI-DrugBank.d603.s2	effects	189	195	O
DDI-DrugBank.d603.s2	of	197	198	O
DDI-DrugBank.d603.s2	ProAmatine	200	209	B-brand
DDI-DrugBank.d603.s2	.	213	213	O
DDI-DrugBank.d603.s2	Therefore	215	223	O
DDI-DrugBank.d603.s2	,	224	224	O
DDI-DrugBank.d603.s2	caution	226	232	O
DDI-DrugBank.d603.s2	should	234	239	O
DDI-DrugBank.d603.s2	be	241	242	O
DDI-DrugBank.d603.s2	used	244	247	O
DDI-DrugBank.d603.s2	when	249	252	O
DDI-DrugBank.d603.s2	ProAmatine	254	263	B-brand
DDI-DrugBank.d603.s2	is	268	269	O
DDI-DrugBank.d603.s2	administered	271	282	O
DDI-DrugBank.d603.s2	concomitantly	284	296	O
DDI-DrugBank.d603.s2	with	298	301	O
DDI-DrugBank.d603.s2	agents	303	308	O
DDI-DrugBank.d603.s2	that	310	313	O
DDI-DrugBank.d603.s2	cause	315	319	O
DDI-DrugBank.d603.s2	vasoconstriction	321	336	O
DDI-DrugBank.d603.s2	.	337	337	O
DDI-DrugBank.d603.s3	ProAmatine	0	9	B-brand
DDI-DrugBank.d603.s3	has	14	16	O
DDI-DrugBank.d603.s3	been	18	21	O
DDI-DrugBank.d603.s3	used	23	26	O
DDI-DrugBank.d603.s3	in	28	29	O
DDI-DrugBank.d603.s3	patients	31	38	O
DDI-DrugBank.d603.s3	concomitantly	40	52	O
DDI-DrugBank.d603.s3	treated	54	60	O
DDI-DrugBank.d603.s3	with	62	65	O
DDI-DrugBank.d603.s3	salt-retaining	67	80	O
DDI-DrugBank.d603.s3	steroid	82	88	O
DDI-DrugBank.d603.s3	therapy	90	96	O
DDI-DrugBank.d603.s3	(	98	98	O
DDI-DrugBank.d603.s3	i.e.	99	102	O
DDI-DrugBank.d603.s3	,	103	103	O
DDI-DrugBank.d603.s3	fludrocortisone	105	119	B-drug
DDI-DrugBank.d603.s3	acetate	121	127	I-drug
DDI-DrugBank.d603.s3	)	128	128	O
DDI-DrugBank.d603.s3	,	129	129	O
DDI-DrugBank.d603.s3	with	131	134	O
DDI-DrugBank.d603.s3	or	136	137	O
DDI-DrugBank.d603.s3	without	139	145	O
DDI-DrugBank.d603.s3	salt	147	150	O
DDI-DrugBank.d603.s3	supplementation	152	166	O
DDI-DrugBank.d603.s3	.	167	167	O
DDI-DrugBank.d603.s4	The	0	2	O
DDI-DrugBank.d603.s4	potential	4	12	O
DDI-DrugBank.d603.s4	for	14	16	O
DDI-DrugBank.d603.s4	supine	18	23	O
DDI-DrugBank.d603.s4	hypertension	25	36	O
DDI-DrugBank.d603.s4	should	38	43	O
DDI-DrugBank.d603.s4	be	45	46	O
DDI-DrugBank.d603.s4	carefully	48	56	O
DDI-DrugBank.d603.s4	monitored	58	66	O
DDI-DrugBank.d603.s4	in	68	69	O
DDI-DrugBank.d603.s4	these	71	75	O
DDI-DrugBank.d603.s4	patients	77	84	O
DDI-DrugBank.d603.s4	and	86	88	O
DDI-DrugBank.d603.s4	may	90	92	O
DDI-DrugBank.d603.s4	be	94	95	O
DDI-DrugBank.d603.s4	minimized	97	105	O
DDI-DrugBank.d603.s4	by	107	108	O
DDI-DrugBank.d603.s4	either	110	115	O
DDI-DrugBank.d603.s4	reducing	117	124	O
DDI-DrugBank.d603.s4	the	112	114	O
DDI-DrugBank.d603.s4	dose	130	133	O
DDI-DrugBank.d603.s4	of	135	136	O
DDI-DrugBank.d603.s4	fludrocortisone	138	152	B-drug
DDI-DrugBank.d603.s4	acetate	154	160	I-drug
DDI-DrugBank.d603.s4	or	145	146	I-drug
DDI-DrugBank.d603.s4	decreasing	165	174	O
DDI-DrugBank.d603.s4	the	176	178	O
DDI-DrugBank.d603.s4	salt	180	183	O
DDI-DrugBank.d603.s4	intake	185	190	O
DDI-DrugBank.d603.s4	prior	192	196	O
DDI-DrugBank.d603.s4	to	198	199	O
DDI-DrugBank.d603.s4	initiation	201	210	O
DDI-DrugBank.d603.s4	of	212	213	O
DDI-DrugBank.d603.s4	treatment	215	223	O
DDI-DrugBank.d603.s4	with	225	228	O
DDI-DrugBank.d603.s4	.	229	229	O
DDI-DrugBank.d603.s5	ProAmatine	0	9	B-brand
DDI-DrugBank.d603.s5	.	10	10	O
DDI-DrugBank.d603.s5	Alpha-adrenergic	12	27	B-group
DDI-DrugBank.d603.s5	blocking	29	36	I-group
DDI-DrugBank.d603.s5	agents	38	43	I-group
DDI-DrugBank.d603.s5	,	44	44	O
DDI-DrugBank.d603.s5	such	46	49	O
DDI-DrugBank.d603.s5	as	51	52	O
DDI-DrugBank.d603.s5	prazosin	54	61	B-drug
DDI-DrugBank.d603.s5	,	62	62	O
DDI-DrugBank.d603.s5	terazosin	64	72	B-drug
DDI-DrugBank.d603.s5	,	73	73	O
DDI-DrugBank.d603.s5	and	75	77	O
DDI-DrugBank.d603.s5	doxazosin	79	87	B-drug
DDI-DrugBank.d603.s5	,	88	88	O
DDI-DrugBank.d603.s5	can	90	92	O
DDI-DrugBank.d603.s5	antagonize	94	103	O
DDI-DrugBank.d603.s5	the	105	107	O
DDI-DrugBank.d603.s5	effects	109	115	O
DDI-DrugBank.d603.s5	of	117	118	O
DDI-DrugBank.d603.s5	ProAmatine	120	129	B-brand
DDI-DrugBank.d603.s5	.	130	130	O
DDI-DrugBank.d603.s5	Potential	132	140	O
DDI-DrugBank.d603.s5	for	142	144	O
DDI-DrugBank.d603.s5	Drug	146	149	O
DDI-DrugBank.d603.s5	Interactions	151	162	O
DDI-DrugBank.d603.s5	:	163	163	O
DDI-DrugBank.d603.s5	It	165	166	O
DDI-DrugBank.d603.s5	appears	168	174	O
DDI-DrugBank.d603.s5	possible	176	183	O
DDI-DrugBank.d603.s5	,	184	184	O
DDI-DrugBank.d603.s5	although	186	193	O
DDI-DrugBank.d603.s5	there	195	199	O
DDI-DrugBank.d603.s5	is	201	202	O
DDI-DrugBank.d603.s5	no	204	205	O
DDI-DrugBank.d603.s5	supporting	207	216	O
DDI-DrugBank.d603.s5	experimental	218	229	O
DDI-DrugBank.d603.s5	evidence	231	238	O
DDI-DrugBank.d603.s5	,	239	239	O
DDI-DrugBank.d603.s5	that	241	244	O
DDI-DrugBank.d603.s5	the	246	248	O
DDI-DrugBank.d603.s5	high	250	253	O
DDI-DrugBank.d603.s5	renal	255	259	O
DDI-DrugBank.d603.s5	clearance	261	269	O
DDI-DrugBank.d603.s5	of	271	272	O
DDI-DrugBank.d603.s5	desglymidodrine	274	288	B-drug_n
DDI-DrugBank.d603.s5	(	290	290	O
DDI-DrugBank.d603.s5	a	258	258	O
DDI-DrugBank.d603.s5	base	293	296	O
DDI-DrugBank.d603.s5	)	297	297	O
DDI-DrugBank.d603.s5	is	299	300	O
DDI-DrugBank.d603.s5	due	302	304	O
DDI-DrugBank.d603.s5	to	306	307	O
DDI-DrugBank.d603.s5	active	309	314	O
DDI-DrugBank.d603.s5	tubular	316	322	O
DDI-DrugBank.d603.s5	secretion	324	332	O
DDI-DrugBank.d603.s5	by	334	335	O
DDI-DrugBank.d603.s5	the	337	339	O
DDI-DrugBank.d603.s5	base-secreting	341	354	O
DDI-DrugBank.d603.s5	system	356	361	O
DDI-DrugBank.d603.s5	also	363	366	O
DDI-DrugBank.d603.s5	responsible	368	378	O
DDI-DrugBank.d603.s5	for	380	382	O
DDI-DrugBank.d603.s5	the	337	339	O
DDI-DrugBank.d603.s5	secretion	388	396	O
DDI-DrugBank.d603.s5	of	398	399	O
DDI-DrugBank.d603.s5	such	401	404	O
DDI-DrugBank.d603.s5	drugs	406	410	O
DDI-DrugBank.d603.s5	as	412	413	O
DDI-DrugBank.d603.s5	metformin	415	423	B-drug
DDI-DrugBank.d603.s5	,	424	424	O
DDI-DrugBank.d603.s5	cimetidine	426	435	B-drug
DDI-DrugBank.d603.s5	,	424	424	O
DDI-DrugBank.d603.s5	ranitidine	438	447	B-drug
DDI-DrugBank.d603.s5	,	424	424	O
DDI-DrugBank.d603.s5	procainamide	450	461	B-drug
DDI-DrugBank.d603.s5	,	424	424	O
DDI-DrugBank.d603.s5	triamterene	464	474	B-drug
DDI-DrugBank.d603.s5	,	424	424	O
DDI-DrugBank.d603.s5	flecainide	477	486	B-drug
DDI-DrugBank.d603.s5	,	424	424	O
DDI-DrugBank.d603.s5	and	489	491	O
DDI-DrugBank.d603.s5	quinidine	493	501	B-drug
DDI-DrugBank.d603.s5	.	502	502	O
DDI-DrugBank.d603.s6	Thus	0	3	O
DDI-DrugBank.d603.s6	there	5	9	O
DDI-DrugBank.d603.s6	may	11	13	O
DDI-DrugBank.d603.s6	be	15	16	O
DDI-DrugBank.d603.s6	a	18	18	O
DDI-DrugBank.d603.s6	potential	20	28	O
DDI-DrugBank.d603.s6	for	30	32	O
DDI-DrugBank.d603.s6	drug-drug	34	42	O
DDI-DrugBank.d603.s6	interactions	44	55	O
DDI-DrugBank.d603.s6	with	57	60	O
DDI-DrugBank.d603.s6	these	62	66	O
DDI-DrugBank.d603.s6	drugs	68	72	O
DDI-DrugBank.d603.s6	.	73	73	O
DDI-DrugBank.d411.s0	The	0	2	O
DDI-DrugBank.d411.s0	magnitude	4	12	O
DDI-DrugBank.d411.s0	and	14	16	O
DDI-DrugBank.d411.s0	relative	18	25	O
DDI-DrugBank.d411.s0	importance	27	36	O
DDI-DrugBank.d411.s0	of	38	39	O
DDI-DrugBank.d411.s0	the	41	43	O
DDI-DrugBank.d411.s0	effects	45	51	O
DDI-DrugBank.d411.s0	noted	53	57	O
DDI-DrugBank.d411.s0	below	59	63	O
DDI-DrugBank.d411.s0	are	65	67	O
DDI-DrugBank.d411.s0	likely	69	74	O
DDI-DrugBank.d411.s0	to	76	77	O
DDI-DrugBank.d411.s0	be	79	80	O
DDI-DrugBank.d411.s0	patient	82	88	O
DDI-DrugBank.d411.s0	specific	90	97	O
DDI-DrugBank.d411.s0	and	99	101	O
DDI-DrugBank.d411.s0	may	103	105	O
DDI-DrugBank.d411.s0	vary	107	110	O
DDI-DrugBank.d411.s0	by	112	113	O
DDI-DrugBank.d411.s0	such	115	118	O
DDI-DrugBank.d411.s0	factors	120	126	O
DDI-DrugBank.d411.s0	as	128	129	O
DDI-DrugBank.d411.s0	age	131	133	O
DDI-DrugBank.d411.s0	,	134	134	O
DDI-DrugBank.d411.s0	gender	136	141	O
DDI-DrugBank.d411.s0	,	134	134	O
DDI-DrugBank.d411.s0	race	144	147	O
DDI-DrugBank.d411.s0	,	134	134	O
DDI-DrugBank.d411.s0	intercurrent	150	161	O
DDI-DrugBank.d411.s0	illnesses	163	171	O
DDI-DrugBank.d411.s0	,	148	148	O
DDI-DrugBank.d411.s0	dose	174	177	O
DDI-DrugBank.d411.s0	of	179	180	O
DDI-DrugBank.d411.s0	either	182	187	O
DDI-DrugBank.d411.s0	agent	189	193	O
DDI-DrugBank.d411.s0	,	172	172	O
DDI-DrugBank.d411.s0	additional	196	205	O
DDI-DrugBank.d411.s0	concomitant	207	217	O
DDI-DrugBank.d411.s0	medications	219	229	O
DDI-DrugBank.d411.s0	,	230	230	O
DDI-DrugBank.d411.s0	and	232	234	O
DDI-DrugBank.d411.s0	timing	236	241	O
DDI-DrugBank.d411.s0	of	243	244	O
DDI-DrugBank.d411.s0	drug	246	249	O
DDI-DrugBank.d411.s0	administration	251	264	O
DDI-DrugBank.d411.s0	.	265	265	O
DDI-DrugBank.d411.s1	Any	0	2	O
DDI-DrugBank.d411.s1	agent	4	8	O
DDI-DrugBank.d411.s1	that	10	13	O
DDI-DrugBank.d411.s1	alters	15	20	O
DDI-DrugBank.d411.s1	thyroid	22	28	O
DDI-DrugBank.d411.s1	hormone	30	36	O
DDI-DrugBank.d411.s1	synthesis	38	46	O
DDI-DrugBank.d411.s1	,	47	47	O
DDI-DrugBank.d411.s1	secretion	49	57	O
DDI-DrugBank.d411.s1	,	58	58	O
DDI-DrugBank.d411.s1	distribution	60	71	O
DDI-DrugBank.d411.s1	,	72	72	O
DDI-DrugBank.d411.s1	effect	74	79	O
DDI-DrugBank.d411.s1	on	81	82	O
DDI-DrugBank.d411.s1	target	84	89	O
DDI-DrugBank.d411.s1	tissues	91	97	O
DDI-DrugBank.d411.s1	,	98	98	O
DDI-DrugBank.d411.s1	metabolism	100	109	O
DDI-DrugBank.d411.s1	,	98	98	O
DDI-DrugBank.d411.s1	or	112	113	O
DDI-DrugBank.d411.s1	elimination	115	125	O
DDI-DrugBank.d411.s1	may	127	129	O
DDI-DrugBank.d411.s1	alter	131	135	O
DDI-DrugBank.d411.s1	the	137	139	O
DDI-DrugBank.d411.s1	optimal	141	147	O
DDI-DrugBank.d411.s1	therapeutic	149	159	O
DDI-DrugBank.d411.s1	dose	161	164	O
DDI-DrugBank.d411.s1	of	166	167	O
DDI-DrugBank.d411.s1	levothyroxine	169	181	B-drug
DDI-DrugBank.d411.s1	sodium	183	188	O
DDI-DrugBank.d411.s1	.	189	189	O
DDI-DrugBank.d411.s2	Levothyroxine	0	12	B-drug
DDI-DrugBank.d411.s2	Sodium	14	19	I-drug
DDI-DrugBank.d411.s2	Absorption	21	30	O
DDI-DrugBank.d411.s2	:	31	31	O
DDI-DrugBank.d411.s2	The	33	35	O
DDI-DrugBank.d411.s2	following	37	45	O
DDI-DrugBank.d411.s2	agents	47	52	O
DDI-DrugBank.d411.s2	may	54	56	O
DDI-DrugBank.d411.s2	bind	58	61	O
DDI-DrugBank.d411.s2	and	63	65	O
DDI-DrugBank.d411.s2	decrease	67	74	O
DDI-DrugBank.d411.s2	absorption	76	85	O
DDI-DrugBank.d411.s2	of	87	88	O
DDI-DrugBank.d411.s2	levothyroxine	90	102	B-drug
DDI-DrugBank.d411.s2	sodium	104	109	I-drug
DDI-DrugBank.d411.s2	from	111	114	O
DDI-DrugBank.d411.s2	the	116	118	O
DDI-DrugBank.d411.s2	gastrointestinal	120	135	O
DDI-DrugBank.d411.s2	tract	137	141	O
DDI-DrugBank.d411.s2	:	142	142	O
DDI-DrugBank.d411.s2	aluminum	144	151	B-drug
DDI-DrugBank.d411.s2	hydoxide	153	160	I-drug
DDI-DrugBank.d411.s2	,	161	161	O
DDI-DrugBank.d411.s2	cholestyramine	163	176	B-drug
DDI-DrugBank.d411.s2	resin	178	182	O
DDI-DrugBank.d411.s2	,	183	183	O
DDI-DrugBank.d411.s2	colestipol	185	194	B-drug
DDI-DrugBank.d411.s2	hydrochloride	196	208	I-drug
DDI-DrugBank.d411.s2	,	209	209	O
DDI-DrugBank.d411.s2	ferrous	211	217	B-drug
DDI-DrugBank.d411.s2	sulfate	219	225	I-drug
DDI-DrugBank.d411.s2	,	209	209	O
DDI-DrugBank.d411.s2	sodium	228	233	B-drug
DDI-DrugBank.d411.s2	polystyrene	235	245	I-drug
DDI-DrugBank.d411.s2	sulfonate	247	255	I-drug
DDI-DrugBank.d411.s2	,	256	256	O
DDI-DrugBank.d411.s2	soybean	258	264	O
DDI-DrugBank.d411.s2	flour	266	270	O
DDI-DrugBank.d411.s2	(	272	272	O
DDI-DrugBank.d411.s2	e.g.	273	276	O
DDI-DrugBank.d411.s2	,	256	256	O
DDI-DrugBank.d411.s2	infant	279	284	O
DDI-DrugBank.d411.s2	formula	286	292	O
DDI-DrugBank.d411.s2	)	293	293	O
DDI-DrugBank.d411.s2	,	277	277	O
DDI-DrugBank.d411.s2	sucralfate	296	305	B-drug
DDI-DrugBank.d411.s2	.	274	274	O
DDI-DrugBank.d411.s3	Binding	0	6	O
DDI-DrugBank.d411.s3	to	8	9	O
DDI-DrugBank.d411.s3	Serum	11	15	O
DDI-DrugBank.d411.s3	Proteins	17	24	O
DDI-DrugBank.d411.s3	:	25	25	O
DDI-DrugBank.d411.s3	The	27	29	O
DDI-DrugBank.d411.s3	following	31	39	O
DDI-DrugBank.d411.s3	agents	41	46	O
DDI-DrugBank.d411.s3	may	48	50	O
DDI-DrugBank.d411.s3	either	52	57	O
DDI-DrugBank.d411.s3	inhibit	59	65	O
DDI-DrugBank.d411.s3	levothyroxine	67	79	B-drug
DDI-DrugBank.d411.s3	sodium	81	86	I-drug
DDI-DrugBank.d411.s3	binding	88	94	O
DDI-DrugBank.d411.s3	to	96	97	O
DDI-DrugBank.d411.s3	serum	99	103	O
DDI-DrugBank.d411.s3	proteins	105	112	O
DDI-DrugBank.d411.s3	or	114	115	O
DDI-DrugBank.d411.s3	alter	117	121	O
DDI-DrugBank.d411.s3	the	123	125	O
DDI-DrugBank.d411.s3	concentrations	127	140	O
DDI-DrugBank.d411.s3	of	142	143	O
DDI-DrugBank.d411.s3	serum	145	149	O
DDI-DrugBank.d411.s3	binding	151	157	O
DDI-DrugBank.d411.s3	proteins	159	166	O
DDI-DrugBank.d411.s3	:	167	167	O
DDI-DrugBank.d411.s3	androgens	169	177	B-group
DDI-DrugBank.d411.s3	and	169	171	B-group
DDI-DrugBank.d411.s3	related	183	189	O
DDI-DrugBank.d411.s3	anabolic	191	198	B-group
DDI-DrugBank.d411.s3	hormones	200	207	I-group
DDI-DrugBank.d411.s3	,	208	208	O
DDI-DrugBank.d411.s3	asparaginase	210	221	B-drug
DDI-DrugBank.d411.s3	,	208	208	O
DDI-DrugBank.d411.s3	clofibrate	224	233	B-drug
DDI-DrugBank.d411.s3	,	208	208	O
DDI-DrugBank.d411.s3	estrogens	236	244	B-group
DDI-DrugBank.d411.s3	and	246	248	O
DDI-DrugBank.d411.s3	estrogen-containing	250	268	B-group
DDI-DrugBank.d411.s3	compounds	270	278	I-group
DDI-DrugBank.d411.s3	,	279	279	O
DDI-DrugBank.d411.s3	5-fluorouracil	281	294	B-drug
DDI-DrugBank.d411.s3	,	279	279	O
DDI-DrugBank.d411.s3	furosemide	297	306	B-drug
DDI-DrugBank.d411.s3	,	279	279	O
DDI-DrugBank.d411.s3	glucocorticoids	309	323	B-group
DDI-DrugBank.d411.s3	,	295	295	O
DDI-DrugBank.d411.s3	meclofenamic	326	337	B-drug
DDI-DrugBank.d411.s3	acid	339	342	I-drug
DDI-DrugBank.d411.s3	,	307	307	O
DDI-DrugBank.d411.s3	mefenamic	345	353	B-drug
DDI-DrugBank.d411.s3	acid	339	342	I-drug
DDI-DrugBank.d411.s3	,	324	324	O
DDI-DrugBank.d411.s3	methadone	361	369	B-drug
DDI-DrugBank.d411.s3	,	343	343	O
DDI-DrugBank.d411.s3	perphenazine	372	383	B-drug
DDI-DrugBank.d411.s3	,	343	343	O
DDI-DrugBank.d411.s3	phenylbutazone	386	399	B-drug
DDI-DrugBank.d411.s3	,	359	359	O
DDI-DrugBank.d411.s3	phenytoin	402	410	B-drug
DDI-DrugBank.d411.s3	,	370	370	O
DDI-DrugBank.d411.s3	salicylates	413	423	B-group
DDI-DrugBank.d411.s3	,	384	384	O
DDI-DrugBank.d411.s3	tamoxifen	426	434	B-drug
DDI-DrugBank.d411.s3	.	435	435	O
DDI-DrugBank.d411.s4	Thyroid	0	6	O
DDI-DrugBank.d411.s4	Physiology	8	17	O
DDI-DrugBank.d411.s4	:	18	18	O
DDI-DrugBank.d411.s4	The	20	22	O
DDI-DrugBank.d411.s4	following	24	32	O
DDI-DrugBank.d411.s4	agents	34	39	O
DDI-DrugBank.d411.s4	may	41	43	O
DDI-DrugBank.d411.s4	alter	45	49	O
DDI-DrugBank.d411.s4	thyroid	51	57	O
DDI-DrugBank.d411.s4	hormone	59	65	O
DDI-DrugBank.d411.s4	or	60	61	O
DDI-DrugBank.d411.s4	TSH	70	72	O
DDI-DrugBank.d411.s4	levels	74	79	O
DDI-DrugBank.d411.s4	,	80	80	O
DDI-DrugBank.d411.s4	generally	82	90	O
DDI-DrugBank.d411.s4	by	92	93	O
DDI-DrugBank.d411.s4	effects	95	101	O
DDI-DrugBank.d411.s4	on	103	104	O
DDI-DrugBank.d411.s4	thyroid	106	112	O
DDI-DrugBank.d411.s4	hormone	114	120	O
DDI-DrugBank.d411.s4	synthesis	122	130	O
DDI-DrugBank.d411.s4	,	131	131	O
DDI-DrugBank.d411.s4	secretion	133	141	O
DDI-DrugBank.d411.s4	,	131	131	O
DDI-DrugBank.d411.s4	distribution	144	155	O
DDI-DrugBank.d411.s4	,	142	142	O
DDI-DrugBank.d411.s4	metabolism	158	167	O
DDI-DrugBank.d411.s4	,	156	156	O
DDI-DrugBank.d411.s4	hormone	170	176	O
DDI-DrugBank.d411.s4	action	178	183	O
DDI-DrugBank.d411.s4	,	168	168	O
DDI-DrugBank.d411.s4	or	171	172	O
DDI-DrugBank.d411.s4	elimination	189	199	O
DDI-DrugBank.d411.s4	,	184	184	O
DDI-DrugBank.d411.s4	or	186	187	O
DDI-DrugBank.d411.s4	altered	205	211	O
DDI-DrugBank.d411.s4	TSH	213	215	O
DDI-DrugBank.d411.s4	secretion	217	225	O
DDI-DrugBank.d411.s4	:	226	226	O
DDI-DrugBank.d411.s4	aminoglutethimide	228	244	B-drug
DDI-DrugBank.d411.s4	,	245	245	O
DDI-DrugBank.d411.s4	p-aminosalicylic	247	262	B-drug
DDI-DrugBank.d411.s4	acid	264	267	I-drug
DDI-DrugBank.d411.s4	,	245	245	O
DDI-DrugBank.d411.s4	amiodarone	270	279	B-drug
DDI-DrugBank.d411.s4	,	268	268	O
DDI-DrugBank.d411.s4	androgens	282	290	B-group
DDI-DrugBank.d411.s4	and	282	284	B-group
DDI-DrugBank.d411.s4	related	296	302	O
DDI-DrugBank.d411.s4	anabolic	304	311	O
DDI-DrugBank.d411.s4	hormones	313	320	O
DDI-DrugBank.d411.s4	,	321	321	O
DDI-DrugBank.d411.s4	complex	323	329	O
DDI-DrugBank.d411.s4	anions	331	336	O
DDI-DrugBank.d411.s4	(	338	338	O
DDI-DrugBank.d411.s4	thiocyanate	339	349	B-drug
DDI-DrugBank.d411.s4	,	321	321	O
DDI-DrugBank.d411.s4	perchlorate	352	362	B-drug
DDI-DrugBank.d411.s4	,	321	321	O
DDI-DrugBank.d411.s4	pertechnetate	365	377	B-drug
DDI-DrugBank.d411.s4	)	378	378	O
DDI-DrugBank.d411.s4	,	350	350	O
DDI-DrugBank.d411.s4	antithyroid	381	391	B-group
DDI-DrugBank.d411.s4	drugs	393	397	I-group
DDI-DrugBank.d411.s4	,	363	363	O
DDI-DrugBank.d411.s4	b-adrenergic	400	411	B-group
DDI-DrugBank.d411.s4	blocking	413	420	I-group
DDI-DrugBank.d411.s4	agents	422	427	I-group
DDI-DrugBank.d411.s4	,	398	398	O
DDI-DrugBank.d411.s4	carbamazepine	430	442	B-drug
DDI-DrugBank.d411.s4	,	398	398	O
DDI-DrugBank.d411.s4	chloral	445	451	B-drug
DDI-DrugBank.d411.s4	hydrate	453	459	I-drug
DDI-DrugBank.d411.s4	,	428	428	O
DDI-DrugBank.d411.s4	diazepam	462	469	B-drug
DDI-DrugBank.d411.s4	,	428	428	O
DDI-DrugBank.d411.s4	dopamine	472	479	B-drug
DDI-DrugBank.d411.s4	and	481	483	O
DDI-DrugBank.d411.s4	dopamine	472	479	B-drug
DDI-DrugBank.d411.s4	agonists	494	501	I-group
DDI-DrugBank.d411.s4	,	460	460	O
DDI-DrugBank.d411.s4	ethionamide	504	514	B-drug
DDI-DrugBank.d411.s4	,	460	460	O
DDI-DrugBank.d411.s4	glucocorticoids	517	531	B-group
DDI-DrugBank.d411.s4	,	502	502	O
DDI-DrugBank.d411.s4	heparin	534	540	B-drug
DDI-DrugBank.d411.s4	,	502	502	O
DDI-DrugBank.d411.s4	hepatic	543	549	O
DDI-DrugBank.d411.s4	enzyme	551	556	O
DDI-DrugBank.d411.s4	inducers	558	565	O
DDI-DrugBank.d411.s4	,	515	515	O
DDI-DrugBank.d411.s4	insulin	568	574	B-drug
DDI-DrugBank.d411.s4	,	515	515	O
DDI-DrugBank.d411.s4	iodinated	577	585	O
DDI-DrugBank.d411.s4	cholestographic	587	601	O
DDI-DrugBank.d411.s4	agents	603	608	O
DDI-DrugBank.d411.s4	,	566	566	O
DDI-DrugBank.d411.s4	iodine-containing	611	627	B-group
DDI-DrugBank.d411.s4	compounds	629	637	I-group
DDI-DrugBank.d411.s4	,	575	575	O
DDI-DrugBank.d411.s4	levodopa	640	647	B-drug
DDI-DrugBank.d411.s4	,	609	609	O
DDI-DrugBank.d411.s4	lovastatin	650	659	B-drug
DDI-DrugBank.d411.s4	,	609	609	O
DDI-DrugBank.d411.s4	lithium	662	668	B-drug
DDI-DrugBank.d411.s4	,	609	609	O
DDI-DrugBank.d411.s4	6-mercaptopurine	671	686	B-drug
DDI-DrugBank.d411.s4	,	638	638	O
DDI-DrugBank.d411.s4	metoclopramide	689	702	B-drug
DDI-DrugBank.d411.s4	,	638	638	O
DDI-DrugBank.d411.s4	mitotane	705	712	B-drug
DDI-DrugBank.d411.s4	,	648	648	O
DDI-DrugBank.d411.s4	nitroprusside	715	727	B-drug
DDI-DrugBank.d411.s4	,	660	660	O
DDI-DrugBank.d411.s4	phenobarbital	730	742	B-drug
DDI-DrugBank.d411.s4	,	669	669	O
DDI-DrugBank.d411.s4	phenytoin	745	753	B-drug
DDI-DrugBank.d411.s4	,	687	687	O
DDI-DrugBank.d411.s4	resorcinol	756	765	B-drug
DDI-DrugBank.d411.s4	,	703	703	O
DDI-DrugBank.d411.s4	rifampin	768	775	B-drug
DDI-DrugBank.d411.s4	,	703	703	O
DDI-DrugBank.d411.s4	somatostatin	778	789	B-group
DDI-DrugBank.d411.s4	analogs	791	797	I-group
DDI-DrugBank.d411.s4	,	728	728	O
DDI-DrugBank.d411.s4	sulfonamides	800	811	B-group
DDI-DrugBank.d411.s4	,	743	743	O
DDI-DrugBank.d411.s4	sulfonylureas	814	826	B-group
DDI-DrugBank.d411.s4	,	754	754	O
DDI-DrugBank.d411.s4	thiazide	829	836	B-group
DDI-DrugBank.d411.s4	diuretics	838	846	I-group
DDI-DrugBank.d411.s4	.	847	847	O
DDI-DrugBank.d411.s5	Adrenocorticoids	0	15	O
DDI-DrugBank.d411.s5	:	16	16	O
DDI-DrugBank.d411.s5	Metabolic	18	26	O
DDI-DrugBank.d411.s5	clearance	28	36	O
DDI-DrugBank.d411.s5	of	38	39	O
DDI-DrugBank.d411.s5	adrenocorticoids	41	56	O
DDI-DrugBank.d411.s5	is	58	59	O
DDI-DrugBank.d411.s5	decreased	61	69	O
DDI-DrugBank.d411.s5	in	71	72	O
DDI-DrugBank.d411.s5	hypothyroid	74	84	O
DDI-DrugBank.d411.s5	patients	86	93	O
DDI-DrugBank.d411.s5	and	95	97	O
DDI-DrugBank.d411.s5	increased	99	107	O
DDI-DrugBank.d411.s5	in	99	100	O
DDI-DrugBank.d411.s5	hyperthyroid	112	123	O
DDI-DrugBank.d411.s5	patients	125	132	O
DDI-DrugBank.d411.s5	,	133	133	O
DDI-DrugBank.d411.s5	and	135	137	O
DDI-DrugBank.d411.s5	may	139	141	O
DDI-DrugBank.d411.s5	therefore	143	151	O
DDI-DrugBank.d411.s5	change	153	158	O
DDI-DrugBank.d411.s5	with	160	163	O
DDI-DrugBank.d411.s5	changing	165	172	O
DDI-DrugBank.d411.s5	thyroid	174	180	O
DDI-DrugBank.d411.s5	status	182	187	O
DDI-DrugBank.d411.s5	.	188	188	O
DDI-DrugBank.d411.s6	Amiodarone	0	9	B-drug
DDI-DrugBank.d411.s6	:	10	10	O
DDI-DrugBank.d411.s6	Amiodarone	12	21	B-drug
DDI-DrugBank.d411.s6	therapy	23	29	O
DDI-DrugBank.d411.s6	alone	31	35	O
DDI-DrugBank.d411.s6	can	37	39	O
DDI-DrugBank.d411.s6	cause	41	45	O
DDI-DrugBank.d411.s6	hypothyroidism	47	60	O
DDI-DrugBank.d411.s6	or	62	63	O
DDI-DrugBank.d411.s6	hyperthyroidism	65	79	O
DDI-DrugBank.d411.s6	.	80	80	O
DDI-DrugBank.d411.s7	Anticoagulants	0	13	B-group
DDI-DrugBank.d411.s7	(	15	15	O
DDI-DrugBank.d411.s7	Oral	16	19	O
DDI-DrugBank.d411.s7	)	20	20	O
DDI-DrugBank.d411.s7	:	21	21	O
DDI-DrugBank.d411.s7	The	23	25	O
DDI-DrugBank.d411.s7	hypoprothrombinemic	27	45	O
DDI-DrugBank.d411.s7	effect	47	52	O
DDI-DrugBank.d411.s7	of	54	55	O
DDI-DrugBank.d411.s7	anticoagulants	57	70	B-group
DDI-DrugBank.d411.s7	may	72	74	O
DDI-DrugBank.d411.s7	be	76	77	O
DDI-DrugBank.d411.s7	potentiated	79	89	O
DDI-DrugBank.d411.s7	,	90	90	O
DDI-DrugBank.d411.s7	apparently	92	101	O
DDI-DrugBank.d411.s7	by	103	104	O
DDI-DrugBank.d411.s7	increased	106	114	O
DDI-DrugBank.d411.s7	catabloism	116	125	O
DDI-DrugBank.d411.s7	of	127	128	O
DDI-DrugBank.d411.s7	vitamin	130	136	O
DDI-DrugBank.d411.s7	K-dependent	138	148	O
DDI-DrugBank.d411.s7	clotting	150	157	O
DDI-DrugBank.d411.s7	factors	159	165	O
DDI-DrugBank.d411.s7	.	166	166	O
DDI-DrugBank.d411.s8	Antidiabetic	0	11	B-group
DDI-DrugBank.d411.s8	Agents	13	18	I-group
DDI-DrugBank.d411.s8	(	20	20	O
DDI-DrugBank.d411.s8	Insulin	21	27	B-drug
DDI-DrugBank.d411.s8	,	28	28	O
DDI-DrugBank.d411.s8	Sulfonylureas	30	42	B-group
DDI-DrugBank.d411.s8	)	43	43	O
DDI-DrugBank.d411.s8	:	44	44	O
DDI-DrugBank.d411.s8	Requirements	46	57	O
DDI-DrugBank.d411.s8	for	59	61	O
DDI-DrugBank.d411.s8	insulin	63	69	B-drug
DDI-DrugBank.d411.s8	or	71	72	O
DDI-DrugBank.d411.s8	oral	74	77	O
DDI-DrugBank.d411.s8	antidiabetic	79	90	B-group
DDI-DrugBank.d411.s8	agents	92	97	I-group
DDI-DrugBank.d411.s8	may	99	101	O
DDI-DrugBank.d411.s8	be	103	104	O
DDI-DrugBank.d411.s8	reduced	106	112	O
DDI-DrugBank.d411.s8	in	114	115	O
DDI-DrugBank.d411.s8	hypothyroid	117	127	O
DDI-DrugBank.d411.s8	patients	129	136	O
DDI-DrugBank.d411.s8	with	138	141	O
DDI-DrugBank.d411.s8	diabetes	143	150	O
DDI-DrugBank.d411.s8	mellitus	152	159	O
DDI-DrugBank.d411.s8	and	161	163	O
DDI-DrugBank.d411.s8	may	165	167	O
DDI-DrugBank.d411.s8	subsequently	169	180	O
DDI-DrugBank.d411.s8	increase	182	189	O
DDI-DrugBank.d411.s8	with	191	194	O
DDI-DrugBank.d411.s8	the	196	198	O
DDI-DrugBank.d411.s8	initiation	200	209	O
DDI-DrugBank.d411.s8	of	211	212	O
DDI-DrugBank.d411.s8	thyroid	214	220	O
DDI-DrugBank.d411.s8	hormone	222	228	O
DDI-DrugBank.d411.s8	replacement	230	240	O
DDI-DrugBank.d411.s8	therapy	242	248	O
DDI-DrugBank.d411.s8	.	249	249	O
DDI-DrugBank.d411.s9	b-Adrenergic	0	11	B-group
DDI-DrugBank.d411.s9	Blocking	13	20	I-group
DDI-DrugBank.d411.s9	Agents	22	27	I-group
DDI-DrugBank.d411.s9	:	28	28	O
DDI-DrugBank.d411.s9	Actions	30	36	O
DDI-DrugBank.d411.s9	of	38	39	O
DDI-DrugBank.d411.s9	some	41	44	O
DDI-DrugBank.d411.s9	of	46	47	O
DDI-DrugBank.d411.s9	beta-blocking	49	61	B-group
DDI-DrugBank.d411.s9	agents	63	68	I-group
DDI-DrugBank.d411.s9	may	70	72	O
DDI-DrugBank.d411.s9	be	74	75	O
DDI-DrugBank.d411.s9	impaired	77	84	O
DDI-DrugBank.d411.s9	when	86	89	O
DDI-DrugBank.d411.s9	hypothyroid	91	101	O
DDI-DrugBank.d411.s9	patients	103	110	O
DDI-DrugBank.d411.s9	become	112	117	O
DDI-DrugBank.d411.s9	euthyroid	119	127	O
DDI-DrugBank.d411.s9	.	128	128	O
DDI-DrugBank.d411.s10	Cytokines	0	8	B-group
DDI-DrugBank.d411.s10	(	10	10	O
DDI-DrugBank.d411.s10	interferon	11	20	B-group
DDI-DrugBank.d411.s10	,	21	21	O
DDI-DrugBank.d411.s10	interleukin	23	33	B-group
DDI-DrugBank.d411.s10	)	34	34	O
DDI-DrugBank.d411.s10	:	35	35	O
DDI-DrugBank.d411.s10	Cytokines	37	45	B-group
DDI-DrugBank.d411.s10	have	47	50	O
DDI-DrugBank.d411.s10	been	52	55	O
DDI-DrugBank.d411.s10	reported	57	64	O
DDI-DrugBank.d411.s10	to	66	67	O
DDI-DrugBank.d411.s10	induce	69	74	O
DDI-DrugBank.d411.s10	both	76	79	O
DDI-DrugBank.d411.s10	hyperthyroidism	81	95	O
DDI-DrugBank.d411.s10	and	97	99	O
DDI-DrugBank.d411.s10	hypothyroidism	101	114	O
DDI-DrugBank.d411.s10	.	115	115	O
DDI-DrugBank.d411.s11	Digitalis	0	8	B-group
DDI-DrugBank.d411.s11	Glycosides	10	19	I-group
DDI-DrugBank.d411.s11	:	20	20	O
DDI-DrugBank.d411.s11	Therapeutic	22	32	O
DDI-DrugBank.d411.s11	effects	34	40	O
DDI-DrugBank.d411.s11	of	42	43	O
DDI-DrugBank.d411.s11	digitalis	45	53	B-group
DDI-DrugBank.d411.s11	glycosides	55	64	I-group
DDI-DrugBank.d411.s11	may	66	68	O
DDI-DrugBank.d411.s11	be	70	71	O
DDI-DrugBank.d411.s11	reduced	73	79	O
DDI-DrugBank.d411.s11	.	80	80	O
DDI-DrugBank.d411.s12	Serum	0	4	O
DDI-DrugBank.d411.s12	digitalis	6	14	B-group
DDI-DrugBank.d411.s12	levels	16	21	O
DDI-DrugBank.d411.s12	may	23	25	O
DDI-DrugBank.d411.s12	be	27	28	O
DDI-DrugBank.d411.s12	decreased	30	38	O
DDI-DrugBank.d411.s12	in	40	41	O
DDI-DrugBank.d411.s12	hyperthyroidism	43	57	O
DDI-DrugBank.d411.s12	or	59	60	O
DDI-DrugBank.d411.s12	when	62	65	O
DDI-DrugBank.d411.s12	a	67	67	O
DDI-DrugBank.d411.s12	hypothyroid	69	79	O
DDI-DrugBank.d411.s12	patient	81	87	O
DDI-DrugBank.d411.s12	becomes	89	95	O
DDI-DrugBank.d411.s12	euthyroid	97	105	O
DDI-DrugBank.d411.s12	.	106	106	O
DDI-DrugBank.d411.s13	Ketamine	0	7	B-drug
DDI-DrugBank.d411.s13	:	8	8	O
DDI-DrugBank.d411.s13	Marked	10	15	O
DDI-DrugBank.d411.s13	hypertension	17	28	O
DDI-DrugBank.d411.s13	and	30	32	O
DDI-DrugBank.d411.s13	tachycardia	34	44	O
DDI-DrugBank.d411.s13	have	46	49	O
DDI-DrugBank.d411.s13	been	51	54	O
DDI-DrugBank.d411.s13	reported	56	63	O
DDI-DrugBank.d411.s13	in	65	66	O
DDI-DrugBank.d411.s13	association	68	78	O
DDI-DrugBank.d411.s13	with	80	83	O
DDI-DrugBank.d411.s13	concomitant	85	95	O
DDI-DrugBank.d411.s13	administration	97	110	O
DDI-DrugBank.d411.s13	of	112	113	O
DDI-DrugBank.d411.s13	levothyroxine	115	127	B-drug
DDI-DrugBank.d411.s13	sodium	129	134	I-drug
DDI-DrugBank.d411.s13	and	136	138	O
DDI-DrugBank.d411.s13	ketamine	140	147	B-drug
DDI-DrugBank.d411.s13	.	148	148	O
DDI-DrugBank.d411.s14	Maprotiline	0	10	B-drug
DDI-DrugBank.d411.s14	:	11	11	O
DDI-DrugBank.d411.s14	Risk	13	16	O
DDI-DrugBank.d411.s14	of	18	19	O
DDI-DrugBank.d411.s14	cardiac	21	27	O
DDI-DrugBank.d411.s14	arrhythmias	29	39	O
DDI-DrugBank.d411.s14	may	41	43	O
DDI-DrugBank.d411.s14	increase	45	52	O
DDI-DrugBank.d411.s14	.	53	53	O
DDI-DrugBank.d411.s15	Sodium	0	5	B-drug
DDI-DrugBank.d411.s15	Iodide	7	12	I-drug
DDI-DrugBank.d411.s15	(	14	14	O
DDI-DrugBank.d411.s15	123I	15	18	O
DDI-DrugBank.d411.s15	and	20	22	O
DDI-DrugBank.d411.s15	131I	24	27	O
DDI-DrugBank.d411.s15	)	28	28	O
DDI-DrugBank.d411.s15	,	29	29	O
DDI-DrugBank.d411.s15	Sodium	31	36	B-drug
DDI-DrugBank.d411.s15	Pertechnetate	38	50	I-drug
DDI-DrugBank.d411.s15	Tc99m	52	56	I-drug
DDI-DrugBank.d411.s15	:	57	57	O
DDI-DrugBank.d411.s15	Uptake	59	64	O
DDI-DrugBank.d411.s15	of	66	67	O
DDI-DrugBank.d411.s15	radiolabeled	69	80	O
DDI-DrugBank.d411.s15	ions	82	85	O
DDI-DrugBank.d411.s15	may	87	89	O
DDI-DrugBank.d411.s15	be	91	92	O
DDI-DrugBank.d411.s15	decreased	94	102	O
DDI-DrugBank.d411.s15	.	103	103	O
DDI-DrugBank.d411.s16	Somatrem/Somatropin	0	18	O
DDI-DrugBank.d411.s16	:	19	19	O
DDI-DrugBank.d411.s16	Excessive	21	29	O
DDI-DrugBank.d411.s16	concurrent	31	40	O
DDI-DrugBank.d411.s16	use	42	44	O
DDI-DrugBank.d411.s16	of	46	47	O
DDI-DrugBank.d411.s16	thyroid	49	55	B-group
DDI-DrugBank.d411.s16	hormone	57	63	I-group
DDI-DrugBank.d411.s16	may	65	67	O
DDI-DrugBank.d411.s16	accelerate	69	78	O
DDI-DrugBank.d411.s16	epiphyseal	80	89	O
DDI-DrugBank.d411.s16	closure	91	97	O
DDI-DrugBank.d411.s16	.	98	98	O
DDI-DrugBank.d411.s17	Untreated	0	8	O
DDI-DrugBank.d411.s17	hypothyroidism	10	23	O
DDI-DrugBank.d411.s17	may	25	27	O
DDI-DrugBank.d411.s17	interfere	29	37	O
DDI-DrugBank.d411.s17	with	39	42	O
DDI-DrugBank.d411.s17	the	44	46	O
DDI-DrugBank.d411.s17	growth	48	53	O
DDI-DrugBank.d411.s17	response	55	62	O
DDI-DrugBank.d411.s17	to	64	65	O
DDI-DrugBank.d411.s17	somatrem	67	74	B-drug
DDI-DrugBank.d411.s17	or	76	77	O
DDI-DrugBank.d411.s17	somatropin	79	88	B-drug
DDI-DrugBank.d411.s17	.	89	89	O
DDI-DrugBank.d411.s18	Theophylline	0	11	B-drug
DDI-DrugBank.d411.s18	:	12	12	O
DDI-DrugBank.d411.s18	Theophylline	14	25	B-drug
DDI-DrugBank.d411.s18	clearance	27	35	O
DDI-DrugBank.d411.s18	may	37	39	O
DDI-DrugBank.d411.s18	decrease	41	48	O
DDI-DrugBank.d411.s18	in	50	51	O
DDI-DrugBank.d411.s18	hypothyroid	53	63	O
DDI-DrugBank.d411.s18	patients	65	72	O
DDI-DrugBank.d411.s18	and	74	76	O
DDI-DrugBank.d411.s18	return	78	83	O
DDI-DrugBank.d411.s18	toward	85	90	O
DDI-DrugBank.d411.s18	normal	92	97	O
DDI-DrugBank.d411.s18	when	99	102	O
DDI-DrugBank.d411.s18	a	96	96	O
DDI-DrugBank.d411.s18	euthyroid	106	114	O
DDI-DrugBank.d411.s18	state	116	120	O
DDI-DrugBank.d411.s18	is	122	123	O
DDI-DrugBank.d411.s18	achieved	125	132	O
DDI-DrugBank.d411.s18	.	133	133	O
DDI-DrugBank.d411.s19	Tricyclic	0	8	B-group
DDI-DrugBank.d411.s19	Antidepressants	10	24	I-group
DDI-DrugBank.d411.s19	:	25	25	O
DDI-DrugBank.d411.s19	Concurrent	27	36	O
DDI-DrugBank.d411.s19	use	38	40	O
DDI-DrugBank.d411.s19	may	42	44	O
DDI-DrugBank.d411.s19	increase	46	53	O
DDI-DrugBank.d411.s19	the	55	57	O
DDI-DrugBank.d411.s19	therapeutic	59	69	O
DDI-DrugBank.d411.s19	and	71	73	O
DDI-DrugBank.d411.s19	toxic	75	79	O
DDI-DrugBank.d411.s19	effects	81	87	O
DDI-DrugBank.d411.s19	of	89	90	O
DDI-DrugBank.d411.s19	both	92	95	O
DDI-DrugBank.d411.s19	drugs	97	101	O
DDI-DrugBank.d411.s19	,	102	102	O
DDI-DrugBank.d411.s19	possibly	104	111	O
DDI-DrugBank.d411.s19	due	113	115	O
DDI-DrugBank.d411.s19	to	117	118	O
DDI-DrugBank.d411.s19	increased	120	128	O
DDI-DrugBank.d411.s19	catecholamine	130	142	O
DDI-DrugBank.d411.s19	sensitivity	144	154	O
DDI-DrugBank.d411.s19	.	155	155	O
DDI-DrugBank.d411.s20	Onset	0	4	O
DDI-DrugBank.d411.s20	of	6	7	O
DDI-DrugBank.d411.s20	action	9	14	O
DDI-DrugBank.d411.s20	of	16	17	O
DDI-DrugBank.d411.s20	tricyclics	19	28	B-group
DDI-DrugBank.d411.s20	may	30	32	O
DDI-DrugBank.d411.s20	be	34	35	O
DDI-DrugBank.d411.s20	accelerated	37	47	O
DDI-DrugBank.d411.s20	.	48	48	O
DDI-DrugBank.d411.s21	Sympathomimetic	0	14	B-group
DDI-DrugBank.d411.s21	Agents	16	21	I-group
DDI-DrugBank.d411.s21	:	22	22	O
DDI-DrugBank.d411.s21	Possible	24	31	O
DDI-DrugBank.d411.s21	increased	33	41	O
DDI-DrugBank.d411.s21	risk	43	46	O
DDI-DrugBank.d411.s21	of	48	49	O
DDI-DrugBank.d411.s21	coronary	51	58	O
DDI-DrugBank.d411.s21	insufficiency	60	72	O
DDI-DrugBank.d411.s21	in	74	75	O
DDI-DrugBank.d411.s21	patients	77	84	O
DDI-DrugBank.d411.s21	with	86	89	O
DDI-DrugBank.d411.s21	coronary	91	98	O
DDI-DrugBank.d411.s21	artery	100	105	O
DDI-DrugBank.d411.s21	disease	107	113	O
DDI-DrugBank.d411.s21	.	114	114	O
DDI-DrugBank.d693.s0	Reduced	0	6	O
DDI-DrugBank.d693.s0	absorption	8	17	O
DDI-DrugBank.d693.s0	of	19	20	O
DDI-DrugBank.d693.s0	folic	22	26	B-drug
DDI-DrugBank.d693.s0	acid	28	31	I-drug
DDI-DrugBank.d693.s0	and	33	35	O
DDI-DrugBank.d693.s0	digoxin	37	43	B-drug
DDI-DrugBank.d693.s0	have	45	48	O
DDI-DrugBank.d693.s0	been	50	53	O
DDI-DrugBank.d693.s0	reported	55	62	O
DDI-DrugBank.d693.s0	when	64	67	O
DDI-DrugBank.d693.s0	those	69	73	O
DDI-DrugBank.d693.s0	agents	75	80	O
DDI-DrugBank.d693.s0	were	82	85	O
DDI-DrugBank.d693.s0	administered	87	98	O
DDI-DrugBank.d693.s0	concomitantly	100	112	O
DDI-DrugBank.d693.s0	with	114	117	O
DDI-DrugBank.d693.s0	sulfasalazine	119	131	B-drug
DDI-DrugBank.d693.s0	.	132	132	O
DDI-DrugBank.d693.s1	When	0	3	O
DDI-DrugBank.d693.s1	daily	5	9	O
DDI-DrugBank.d693.s1	doses	11	15	O
DDI-DrugBank.d693.s1	of	17	18	O
DDI-DrugBank.d693.s1	sulfasalazine	20	32	B-drug
DDI-DrugBank.d693.s1	2	34	34	O
DDI-DrugBank.d693.s1	g	36	36	O
DDI-DrugBank.d693.s1	and	38	40	O
DDI-DrugBank.d693.s1	weekly	42	47	O
DDI-DrugBank.d693.s1	doses	49	53	O
DDI-DrugBank.d693.s1	of	55	56	O
DDI-DrugBank.d693.s1	methotrexate	58	69	B-drug
DDI-DrugBank.d693.s1	7.5	71	73	O
DDI-DrugBank.d693.s1	mg	75	76	O
DDI-DrugBank.d693.s1	were	78	81	O
DDI-DrugBank.d693.s1	coadministered	83	96	O
DDI-DrugBank.d693.s1	to	98	99	O
DDI-DrugBank.d693.s1	15	101	102	O
DDI-DrugBank.d693.s1	rheumatoid	104	113	O
DDI-DrugBank.d693.s1	arthritis	115	123	O
DDI-DrugBank.d693.s1	patients	125	132	O
DDI-DrugBank.d693.s1	in	134	135	O
DDI-DrugBank.d693.s1	a	115	115	O
DDI-DrugBank.d693.s1	drug-drug	139	147	O
DDI-DrugBank.d693.s1	interaction	149	159	O
DDI-DrugBank.d693.s1	study	161	165	O
DDI-DrugBank.d693.s1	,	166	166	O
DDI-DrugBank.d693.s1	the	168	170	O
DDI-DrugBank.d693.s1	pharmacokinetic	172	186	O
DDI-DrugBank.d693.s1	disposition	188	198	O
DDI-DrugBank.d693.s1	of	200	201	O
DDI-DrugBank.d693.s1	the	203	205	O
DDI-DrugBank.d693.s1	drugs	207	211	O
DDI-DrugBank.d693.s1	was	213	215	O
DDI-DrugBank.d693.s1	not	217	219	O
DDI-DrugBank.d693.s1	altered	221	227	O
DDI-DrugBank.d693.s1	.	228	228	O
DDI-DrugBank.d693.s2	Daily	0	4	O
DDI-DrugBank.d693.s2	doses	6	10	O
DDI-DrugBank.d693.s2	of	12	13	O
DDI-DrugBank.d693.s2	sulfasalazine	15	27	B-drug
DDI-DrugBank.d693.s2	2	29	29	O
DDI-DrugBank.d693.s2	g	31	31	O
DDI-DrugBank.d693.s2	(	33	33	O
DDI-DrugBank.d693.s2	maximum	34	40	O
DDI-DrugBank.d693.s2	3	42	42	O
DDI-DrugBank.d693.s2	g	44	44	O
DDI-DrugBank.d693.s2	)	45	45	O
DDI-DrugBank.d693.s2	and	47	49	O
DDI-DrugBank.d693.s2	weekly	51	56	O
DDI-DrugBank.d693.s2	doses	58	62	O
DDI-DrugBank.d693.s2	of	64	65	O
DDI-DrugBank.d693.s2	methotrexate	67	78	B-drug
DDI-DrugBank.d693.s2	7.5	80	82	O
DDI-DrugBank.d693.s2	mg	84	85	O
DDI-DrugBank.d693.s2	(	87	87	O
DDI-DrugBank.d693.s2	maximum	88	94	O
DDI-DrugBank.d693.s2	15	96	97	O
DDI-DrugBank.d693.s2	mg	84	85	O
DDI-DrugBank.d693.s2	)	101	101	O
DDI-DrugBank.d693.s2	were	103	106	O
DDI-DrugBank.d693.s2	administered	108	119	O
DDI-DrugBank.d693.s2	alone	121	125	O
DDI-DrugBank.d693.s2	or	127	128	O
DDI-DrugBank.d693.s2	in	111	112	O
DDI-DrugBank.d693.s2	combination	133	143	O
DDI-DrugBank.d693.s2	to	145	146	O
DDI-DrugBank.d693.s2	310	148	150	O
DDI-DrugBank.d693.s2	rheumatoid	152	161	O
DDI-DrugBank.d693.s2	arthritis	163	171	O
DDI-DrugBank.d693.s2	patients	173	180	O
DDI-DrugBank.d693.s2	in	182	183	O
DDI-DrugBank.d693.s2	two	185	187	O
DDI-DrugBank.d693.s2	controlled	189	198	O
DDI-DrugBank.d693.s2	52-week	200	206	O
DDI-DrugBank.d693.s2	clinical	208	215	O
DDI-DrugBank.d693.s2	studies	217	223	O
DDI-DrugBank.d693.s2	.	224	224	O
DDI-DrugBank.d693.s3	The	0	2	O
DDI-DrugBank.d693.s3	overall	4	10	O
DDI-DrugBank.d693.s3	toxicity	12	19	O
DDI-DrugBank.d693.s3	profile	21	27	O
DDI-DrugBank.d693.s3	of	29	30	O
DDI-DrugBank.d693.s3	the	32	34	O
DDI-DrugBank.d693.s3	combination	36	46	O
DDI-DrugBank.d693.s3	revealed	48	55	O
DDI-DrugBank.d693.s3	an	57	58	O
DDI-DrugBank.d693.s3	increased	60	68	O
DDI-DrugBank.d693.s3	incidence	70	78	O
DDI-DrugBank.d693.s3	of	80	81	O
DDI-DrugBank.d693.s3	gastrointestinal	83	98	O
DDI-DrugBank.d693.s3	adverse	100	106	O
DDI-DrugBank.d693.s3	events	108	113	O
DDI-DrugBank.d693.s3	,	114	114	O
DDI-DrugBank.d693.s3	especially	116	125	O
DDI-DrugBank.d693.s3	nausea	127	132	O
DDI-DrugBank.d693.s3	,	133	133	O
DDI-DrugBank.d693.s3	when	135	138	O
DDI-DrugBank.d693.s3	compared	140	147	O
DDI-DrugBank.d693.s3	to	149	150	O
DDI-DrugBank.d693.s3	the	152	154	O
DDI-DrugBank.d693.s3	incidence	156	164	O
DDI-DrugBank.d693.s3	associated	166	175	O
DDI-DrugBank.d693.s3	with	177	180	O
DDI-DrugBank.d693.s3	either	182	187	O
DDI-DrugBank.d693.s3	drug	189	192	O
DDI-DrugBank.d693.s3	administered	194	205	O
DDI-DrugBank.d693.s3	alone	207	211	O
DDI-DrugBank.d693.s3	.	212	212	O
DDI-DrugBank.d693.s4	Drug/Laboratory	0	14	O
DDI-DrugBank.d693.s4	Test	16	19	O
DDI-DrugBank.d693.s4	Interactions	21	32	O
DDI-DrugBank.d693.s4	:	33	33	O
DDI-DrugBank.d693.s4	The	35	37	O
DDI-DrugBank.d693.s4	presence	39	46	O
DDI-DrugBank.d693.s4	of	48	49	O
DDI-DrugBank.d693.s4	sulfasalazine	51	63	B-drug
DDI-DrugBank.d693.s4	or	65	66	O
DDI-DrugBank.d693.s4	its	68	70	O
DDI-DrugBank.d693.s4	metabolites	72	82	O
DDI-DrugBank.d693.s4	in	84	85	O
DDI-DrugBank.d693.s4	body	87	90	O
DDI-DrugBank.d693.s4	fluids	92	97	O
DDI-DrugBank.d693.s4	has	99	101	O
DDI-DrugBank.d693.s4	not	103	105	O
DDI-DrugBank.d693.s4	been	107	110	O
DDI-DrugBank.d693.s4	reported	112	119	O
DDI-DrugBank.d693.s4	to	121	122	O
DDI-DrugBank.d693.s4	interfere	124	132	O
DDI-DrugBank.d693.s4	with	134	137	O
DDI-DrugBank.d693.s4	laboratory	139	148	O
DDI-DrugBank.d693.s4	test	150	153	O
DDI-DrugBank.d693.s4	procedures	155	164	O
DDI-DrugBank.d693.s4	.	165	165	O
DDI-DrugBank.d693.s5	REFERENCES	0	9	O
DDI-DrugBank.d693.s5	7.Farr	11	16	O
DDI-DrugBank.d693.s5	M	18	18	O
DDI-DrugBank.d693.s5	,	19	19	O
DDI-DrugBank.d693.s5	et	21	22	O
DDI-DrugBank.d693.s5	al	24	25	O
DDI-DrugBank.d693.s5	.	26	26	O
DDI-DrugBank.d693.s6	Immunodeficiencies	0	17	O
DDI-DrugBank.d693.s6	associated	19	28	O
DDI-DrugBank.d693.s6	with	30	33	O
DDI-DrugBank.d693.s6	sulphasalazine	35	48	B-drug
DDI-DrugBank.d693.s6	therapy	50	56	O
DDI-DrugBank.d693.s6	in	58	59	O
DDI-DrugBank.d693.s6	inflammatory	61	72	O
DDI-DrugBank.d693.s6	arthritis	74	82	O
DDI-DrugBank.d693.s6	.	83	83	O
DDI-DrugBank.d693.s7	British	0	6	O
DDI-DrugBank.d693.s7	Jnl	8	10	O
DDI-DrugBank.d693.s7	Rheum	12	16	O
DDI-DrugBank.d693.s7	1991	18	21	O
DDI-DrugBank.d693.s7	;	22	22	O
DDI-DrugBank.d693.s7	30:413-417	23	32	O
DDI-DrugBank.d693.s7	.	33	33	O
DDI-DrugBank.d700.s0	Antacids	0	7	B-group
DDI-DrugBank.d700.s0	:	8	8	O
DDI-DrugBank.d700.s0	Absorption	10	19	O
DDI-DrugBank.d700.s0	of	21	22	O
DDI-DrugBank.d700.s0	a	24	24	O
DDI-DrugBank.d700.s0	single	26	31	O
DDI-DrugBank.d700.s0	dose	33	36	O
DDI-DrugBank.d700.s0	of	38	39	O
DDI-DrugBank.d700.s0	Myfortic	41	48	B-brand
DDI-DrugBank.d700.s0	was	50	52	O
DDI-DrugBank.d700.s0	decreased	54	62	O
DDI-DrugBank.d700.s0	when	64	67	O
DDI-DrugBank.d700.s0	administered	69	80	O
DDI-DrugBank.d700.s0	to	82	83	O
DDI-DrugBank.d700.s0	12	85	86	O
DDI-DrugBank.d700.s0	stable	88	93	O
DDI-DrugBank.d700.s0	renal	95	99	O
DDI-DrugBank.d700.s0	transplant	101	110	O
DDI-DrugBank.d700.s0	patients	112	119	O
DDI-DrugBank.d700.s0	also	121	124	O
DDI-DrugBank.d700.s0	taking	126	131	O
DDI-DrugBank.d700.s0	magnesium-aluminum	133	150	O
DDI-DrugBank.d700.s0	containing	152	161	O
DDI-DrugBank.d700.s0	antacids	163	170	B-group
DDI-DrugBank.d700.s0	(	172	172	O
DDI-DrugBank.d700.s0	30	173	174	O
DDI-DrugBank.d700.s0	mL	176	177	O
DDI-DrugBank.d700.s0	)	178	178	O
DDI-DrugBank.d700.s0	:	179	179	O
DDI-DrugBank.d700.s0	the	181	183	O
DDI-DrugBank.d700.s0	mean	185	188	O
DDI-DrugBank.d700.s0	Cmax	190	193	O
DDI-DrugBank.d700.s0	and	195	197	O
DDI-DrugBank.d700.s0	AUC	199	201	O
DDI-DrugBank.d700.s0	(	202	202	O
DDI-DrugBank.d700.s0	0-t	203	205	O
DDI-DrugBank.d700.s0	)	178	178	O
DDI-DrugBank.d700.s0	values	208	213	O
DDI-DrugBank.d700.s0	for	215	217	O
DDI-DrugBank.d700.s0	MPA	219	221	O
DDI-DrugBank.d700.s0	were	223	226	O
DDI-DrugBank.d700.s0	25	228	229	O
DDI-DrugBank.d700.s0	%	230	230	O
DDI-DrugBank.d700.s0	and	232	234	O
DDI-DrugBank.d700.s0	37	236	237	O
DDI-DrugBank.d700.s0	%	230	230	O
DDI-DrugBank.d700.s0	lower	240	244	O
DDI-DrugBank.d700.s0	,	245	245	O
DDI-DrugBank.d700.s0	respectively	247	258	O
DDI-DrugBank.d700.s0	,	245	245	O
DDI-DrugBank.d700.s0	than	261	264	O
DDI-DrugBank.d700.s0	when	266	269	O
DDI-DrugBank.d700.s0	Myfortic	271	278	B-brand
DDI-DrugBank.d700.s0	was	280	282	O
DDI-DrugBank.d700.s0	administered	284	295	O
DDI-DrugBank.d700.s0	alone	297	301	O
DDI-DrugBank.d700.s0	under	303	307	O
DDI-DrugBank.d700.s0	fasting	309	315	O
DDI-DrugBank.d700.s0	conditions	317	326	O
DDI-DrugBank.d700.s0	.	327	327	O
DDI-DrugBank.d700.s1	It	0	1	O
DDI-DrugBank.d700.s1	is	3	4	O
DDI-DrugBank.d700.s1	recommended	6	16	O
DDI-DrugBank.d700.s1	that	18	21	O
DDI-DrugBank.d700.s1	Myfortic	23	30	B-drug
DDI-DrugBank.d700.s1	and	32	34	O
DDI-DrugBank.d700.s1	antacids	36	43	B-group
DDI-DrugBank.d700.s1	not	45	47	O
DDI-DrugBank.d700.s1	be	49	50	O
DDI-DrugBank.d700.s1	administered	52	63	O
DDI-DrugBank.d700.s1	simultaneously	65	78	O
DDI-DrugBank.d700.s1	.	79	79	O
DDI-DrugBank.d700.s2	Cyclosporine	0	11	B-drug
DDI-DrugBank.d700.s2	:	12	12	O
DDI-DrugBank.d700.s2	When	14	17	O
DDI-DrugBank.d700.s2	studied	19	25	O
DDI-DrugBank.d700.s2	in	27	28	O
DDI-DrugBank.d700.s2	stable	30	35	O
DDI-DrugBank.d700.s2	renal	37	41	O
DDI-DrugBank.d700.s2	transplant	43	52	O
DDI-DrugBank.d700.s2	patients	54	61	O
DDI-DrugBank.d700.s2	,	62	62	O
DDI-DrugBank.d700.s2	cyclosporine	64	75	B-drug
DDI-DrugBank.d700.s2	,	76	76	O
DDI-DrugBank.d700.s2	USP	78	80	O
DDI-DrugBank.d700.s2	(	82	82	O
DDI-DrugBank.d700.s2	MODIFIED	83	90	O
DDI-DrugBank.d700.s2	)	91	91	O
DDI-DrugBank.d700.s2	pharmacokinetics	93	108	O
DDI-DrugBank.d700.s2	were	110	113	O
DDI-DrugBank.d700.s2	unaffected	115	124	O
DDI-DrugBank.d700.s2	by	126	127	O
DDI-DrugBank.d700.s2	steady	129	134	O
DDI-DrugBank.d700.s2	state	136	140	O
DDI-DrugBank.d700.s2	dosing	142	147	O
DDI-DrugBank.d700.s2	of	149	150	O
DDI-DrugBank.d700.s2	Myfortic	152	159	B-brand
DDI-DrugBank.d700.s2	.	160	160	O
DDI-DrugBank.d700.s3	Acyclovir/Ganciclovir	0	20	O
DDI-DrugBank.d700.s3	:	21	21	O
DDI-DrugBank.d700.s3	may	23	25	O
DDI-DrugBank.d700.s3	be	27	28	O
DDI-DrugBank.d700.s3	taken	30	34	O
DDI-DrugBank.d700.s3	with	36	39	O
DDI-DrugBank.d700.s3	Myfortic	41	48	B-brand
DDI-DrugBank.d700.s3	;	49	49	O
DDI-DrugBank.d700.s4	however	0	6	O
DDI-DrugBank.d700.s4	,	7	7	O
DDI-DrugBank.d700.s4	during	9	14	O
DDI-DrugBank.d700.s4	the	16	18	O
DDI-DrugBank.d700.s4	period	20	25	O
DDI-DrugBank.d700.s4	of	27	28	O
DDI-DrugBank.d700.s4	treatment	30	38	O
DDI-DrugBank.d700.s4	,	39	39	O
DDI-DrugBank.d700.s4	physicians	41	50	O
DDI-DrugBank.d700.s4	should	52	57	O
DDI-DrugBank.d700.s4	monitor	59	65	O
DDI-DrugBank.d700.s4	blood	67	71	O
DDI-DrugBank.d700.s4	cell	73	76	O
DDI-DrugBank.d700.s4	counts	78	83	O
DDI-DrugBank.d700.s4	.	84	84	O
DDI-DrugBank.d700.s5	Both	0	3	O
DDI-DrugBank.d700.s5	acyclovir/ganciclovir	5	25	O
DDI-DrugBank.d700.s5	and	27	29	O
DDI-DrugBank.d700.s5	MPAG	31	34	B-drug_n
DDI-DrugBank.d700.s5	concentrations	36	49	O
DDI-DrugBank.d700.s5	are	51	53	O
DDI-DrugBank.d700.s5	increased	55	63	O
DDI-DrugBank.d700.s5	in	65	66	O
DDI-DrugBank.d700.s5	the	68	70	O
DDI-DrugBank.d700.s5	presence	72	79	O
DDI-DrugBank.d700.s5	of	81	82	O
DDI-DrugBank.d700.s5	renal	84	88	O
DDI-DrugBank.d700.s5	impairment	90	99	O
DDI-DrugBank.d700.s5	,	100	100	O
DDI-DrugBank.d700.s5	their	102	106	O
DDI-DrugBank.d700.s5	coexistence	108	118	O
DDI-DrugBank.d700.s5	may	120	122	O
DDI-DrugBank.d700.s5	compete	124	130	O
DDI-DrugBank.d700.s5	for	132	134	O
DDI-DrugBank.d700.s5	tubular	136	142	O
DDI-DrugBank.d700.s5	secretion	144	152	O
DDI-DrugBank.d700.s5	and	154	156	O
DDI-DrugBank.d700.s5	further	158	164	O
DDI-DrugBank.d700.s5	increase	166	173	O
DDI-DrugBank.d700.s5	in	166	167	O
DDI-DrugBank.d700.s5	the	161	163	O
DDI-DrugBank.d700.s5	concentrations	182	195	O
DDI-DrugBank.d700.s5	of	197	198	O
DDI-DrugBank.d700.s5	the	178	180	O
DDI-DrugBank.d700.s5	two	204	206	O
DDI-DrugBank.d700.s5	.	207	207	O
DDI-DrugBank.d700.s6	Azathioprine/Mycophenolate	0	25	O
DDI-DrugBank.d700.s6	Mofetil	27	33	I-drug
DDI-DrugBank.d700.s6	:	34	34	O
DDI-DrugBank.d700.s6	Given	36	40	O
DDI-DrugBank.d700.s6	that	42	45	O
DDI-DrugBank.d700.s6	azathioprine	47	58	B-drug
DDI-DrugBank.d700.s6	and	60	62	O
DDI-DrugBank.d700.s6	mycophenolate	64	76	B-drug
DDI-DrugBank.d700.s6	mofetil	78	84	I-drug
DDI-DrugBank.d700.s6	inhibit	86	92	O
DDI-DrugBank.d700.s6	purine	94	99	O
DDI-DrugBank.d700.s6	metabolism	101	110	O
DDI-DrugBank.d700.s6	,	111	111	O
DDI-DrugBank.d700.s6	it	113	114	O
DDI-DrugBank.d700.s6	is	108	109	O
DDI-DrugBank.d700.s6	recommended	119	129	O
DDI-DrugBank.d700.s6	that	131	134	O
DDI-DrugBank.d700.s6	Myfortic	136	143	B-brand
DDI-DrugBank.d700.s6	not	145	147	O
DDI-DrugBank.d700.s6	be	149	150	O
DDI-DrugBank.d700.s6	administered	152	163	O
DDI-DrugBank.d700.s6	concomitantly	165	177	O
DDI-DrugBank.d700.s6	with	179	182	O
DDI-DrugBank.d700.s6	azathioprine	184	195	B-drug
DDI-DrugBank.d700.s6	or	197	198	O
DDI-DrugBank.d700.s6	mycophenolate	200	212	B-drug
DDI-DrugBank.d700.s6	mofetil	214	220	I-drug
DDI-DrugBank.d700.s6	.	221	221	O
DDI-DrugBank.d700.s7	Cholestyramine	0	13	B-drug
DDI-DrugBank.d700.s7	and	15	17	O
DDI-DrugBank.d700.s7	Drugs	19	23	O
DDI-DrugBank.d700.s7	that	25	28	O
DDI-DrugBank.d700.s7	Bind	30	33	O
DDI-DrugBank.d700.s7	Bile	35	38	O
DDI-DrugBank.d700.s7	Acids	40	44	O
DDI-DrugBank.d700.s7	:	45	45	O
DDI-DrugBank.d700.s7	These	47	51	O
DDI-DrugBank.d700.s7	drugs	53	57	O
DDI-DrugBank.d700.s7	interrupt	59	67	O
DDI-DrugBank.d700.s7	enterohepatic	69	81	O
DDI-DrugBank.d700.s7	recirculation	83	95	O
DDI-DrugBank.d700.s7	and	97	99	O
DDI-DrugBank.d700.s7	reduce	101	106	O
DDI-DrugBank.d700.s7	MPA	108	110	B-drug_n
DDI-DrugBank.d700.s7	exposure	112	119	O
DDI-DrugBank.d700.s7	when	121	124	O
DDI-DrugBank.d700.s7	coadministered	126	139	O
DDI-DrugBank.d700.s7	with	141	144	O
DDI-DrugBank.d700.s7	mycophenolate	146	158	B-drug
DDI-DrugBank.d700.s7	mofetil	160	166	I-drug
DDI-DrugBank.d700.s7	.	167	167	O
DDI-DrugBank.d700.s8	Therefore	0	8	O
DDI-DrugBank.d700.s8	,	9	9	O
DDI-DrugBank.d700.s8	do	11	12	O
DDI-DrugBank.d700.s8	not	14	16	O
DDI-DrugBank.d700.s8	administer	18	27	O
DDI-DrugBank.d700.s8	Myfortic	29	36	B-drug
DDI-DrugBank.d700.s8	with	38	41	O
DDI-DrugBank.d700.s8	cholestyramine	43	56	B-drug
DDI-DrugBank.d700.s8	or	58	59	O
DDI-DrugBank.d700.s8	other	61	65	O
DDI-DrugBank.d700.s8	agents	67	72	O
DDI-DrugBank.d700.s8	that	74	77	O
DDI-DrugBank.d700.s8	may	79	81	O
DDI-DrugBank.d700.s8	interfere	83	91	O
DDI-DrugBank.d700.s8	with	93	96	O
DDI-DrugBank.d700.s8	enterohepatic	98	110	O
DDI-DrugBank.d700.s8	recirculation	112	124	O
DDI-DrugBank.d700.s8	or	126	127	O
DDI-DrugBank.d700.s8	drugs	129	133	O
DDI-DrugBank.d700.s8	that	135	138	O
DDI-DrugBank.d700.s8	may	140	142	O
DDI-DrugBank.d700.s8	bind	144	147	O
DDI-DrugBank.d700.s8	bile	149	152	O
DDI-DrugBank.d700.s8	acids	154	158	O
DDI-DrugBank.d700.s8	,	159	159	O
DDI-DrugBank.d700.s8	for	161	163	O
DDI-DrugBank.d700.s8	example	165	171	O
DDI-DrugBank.d700.s8	bile	149	152	O
DDI-DrugBank.d700.s8	acid	154	157	O
DDI-DrugBank.d700.s8	sequestrates	183	194	O
DDI-DrugBank.d700.s8	or	196	197	O
DDI-DrugBank.d700.s8	oral	199	202	O
DDI-DrugBank.d700.s8	activated	204	212	B-drug
DDI-DrugBank.d700.s8	charcoal	214	221	I-drug
DDI-DrugBank.d700.s8	,	222	222	O
DDI-DrugBank.d700.s8	because	224	230	O
DDI-DrugBank.d700.s8	of	232	233	O
DDI-DrugBank.d700.s8	the	235	237	O
DDI-DrugBank.d700.s8	potential	239	247	O
DDI-DrugBank.d700.s8	to	249	250	O
DDI-DrugBank.d700.s8	reduce	252	257	O
DDI-DrugBank.d700.s8	the	235	237	O
DDI-DrugBank.d700.s8	efficacy	263	270	O
DDI-DrugBank.d700.s8	of	232	233	O
DDI-DrugBank.d700.s8	Myfortic	275	282	B-brand
DDI-DrugBank.d700.s8	.	283	283	O
DDI-DrugBank.d700.s9	Oral	0	3	O
DDI-DrugBank.d700.s9	Contraceptives	5	18	B-group
DDI-DrugBank.d700.s9	:	19	19	O
DDI-DrugBank.d700.s9	Given	21	25	O
DDI-DrugBank.d700.s9	the	27	29	O
DDI-DrugBank.d700.s9	different	31	39	O
DDI-DrugBank.d700.s9	metabolism	41	50	O
DDI-DrugBank.d700.s9	of	52	53	O
DDI-DrugBank.d700.s9	Myfortic	55	62	B-brand
DDI-DrugBank.d700.s9	and	64	66	O
DDI-DrugBank.d700.s9	oral	68	71	O
DDI-DrugBank.d700.s9	contraceptives	73	86	B-group
DDI-DrugBank.d700.s9	,	87	87	O
DDI-DrugBank.d700.s9	no	89	90	O
DDI-DrugBank.d700.s9	drug	92	95	O
DDI-DrugBank.d700.s9	interaction	97	107	O
DDI-DrugBank.d700.s9	between	109	115	O
DDI-DrugBank.d700.s9	these	117	121	O
DDI-DrugBank.d700.s9	two	123	125	O
DDI-DrugBank.d700.s9	classes	127	133	O
DDI-DrugBank.d700.s9	of	135	136	O
DDI-DrugBank.d700.s9	drug	138	141	O
DDI-DrugBank.d700.s9	is	143	144	O
DDI-DrugBank.d700.s9	expected	146	153	O
DDI-DrugBank.d700.s9	.	154	154	O
DDI-DrugBank.d700.s10	However	0	6	O
DDI-DrugBank.d700.s10	,	7	7	O
DDI-DrugBank.d700.s10	in	9	10	O
DDI-DrugBank.d700.s10	a	12	12	O
DDI-DrugBank.d700.s10	drug-drug	14	22	O
DDI-DrugBank.d700.s10	interaction	24	34	O
DDI-DrugBank.d700.s10	study	36	40	O
DDI-DrugBank.d700.s10	,	41	41	O
DDI-DrugBank.d700.s10	mean	43	46	O
DDI-DrugBank.d700.s10	levonorgesterol	48	62	B-drug
DDI-DrugBank.d700.s10	AUC	64	66	O
DDI-DrugBank.d700.s10	was	68	70	O
DDI-DrugBank.d700.s10	decreased	72	80	O
DDI-DrugBank.d700.s10	by	82	83	O
DDI-DrugBank.d700.s10	15	85	86	O
DDI-DrugBank.d700.s10	%	87	87	O
DDI-DrugBank.d700.s10	when	89	92	O
DDI-DrugBank.d700.s10	coadministered	94	107	O
DDI-DrugBank.d700.s10	with	109	112	O
DDI-DrugBank.d700.s10	mycophenolate	114	126	B-drug
DDI-DrugBank.d700.s10	mofetil	128	134	I-drug
DDI-DrugBank.d700.s10	.	135	135	O
DDI-DrugBank.d700.s11	Therefore	0	8	O
DDI-DrugBank.d700.s11	,	9	9	O
DDI-DrugBank.d700.s11	it	11	12	O
DDI-DrugBank.d700.s11	is	14	15	O
DDI-DrugBank.d700.s11	recommended	17	27	O
DDI-DrugBank.d700.s11	that	29	32	O
DDI-DrugBank.d700.s11	oral	34	37	O
DDI-DrugBank.d700.s11	contraceptives	39	52	B-group
DDI-DrugBank.d700.s11	are	54	56	O
DDI-DrugBank.d700.s11	co-	58	60	O
DDI-DrugBank.d700.s11	administered	62	73	O
DDI-DrugBank.d700.s11	with	75	78	O
DDI-DrugBank.d700.s11	Myfortic	80	87	B-brand
DDI-DrugBank.d700.s11	with	89	92	O
DDI-DrugBank.d700.s11	caution	94	100	O
DDI-DrugBank.d700.s11	and	102	104	O
DDI-DrugBank.d700.s11	additional	106	115	O
DDI-DrugBank.d700.s11	birth	117	121	O
DDI-DrugBank.d700.s11	control	123	129	O
DDI-DrugBank.d700.s11	methods	131	137	O
DDI-DrugBank.d700.s11	be	139	140	O
DDI-DrugBank.d700.s11	considered	142	151	O
DDI-DrugBank.d700.s11	.	152	152	O
DDI-DrugBank.d700.s12	Live	0	3	B-group
DDI-DrugBank.d700.s12	Vaccines	5	12	I-group
DDI-DrugBank.d700.s12	:	13	13	O
DDI-DrugBank.d700.s12	During	15	20	O
DDI-DrugBank.d700.s12	treatment	22	30	O
DDI-DrugBank.d700.s12	with	32	35	O
DDI-DrugBank.d700.s12	Myfortic	37	44	B-drug
DDI-DrugBank.d700.s12	,	45	45	O
DDI-DrugBank.d700.s12	the	47	49	O
DDI-DrugBank.d700.s12	use	51	53	O
DDI-DrugBank.d700.s12	of	55	56	O
DDI-DrugBank.d700.s12	live	58	61	B-group
DDI-DrugBank.d700.s12	attenuated	63	72	I-group
DDI-DrugBank.d700.s12	vaccines	74	81	I-group
DDI-DrugBank.d700.s12	should	83	88	O
DDI-DrugBank.d700.s12	be	90	91	O
DDI-DrugBank.d700.s12	avoided	93	99	O
DDI-DrugBank.d700.s12	and	101	103	O
DDI-DrugBank.d700.s12	patients	105	112	O
DDI-DrugBank.d700.s12	should	114	119	O
DDI-DrugBank.d700.s12	be	121	122	O
DDI-DrugBank.d700.s12	advised	124	130	O
DDI-DrugBank.d700.s12	that	132	135	O
DDI-DrugBank.d700.s12	vaccinations	137	148	O
DDI-DrugBank.d700.s12	may	150	152	O
DDI-DrugBank.d700.s12	be	154	155	O
DDI-DrugBank.d700.s12	less	157	160	O
DDI-DrugBank.d700.s12	effective	162	170	O
DDI-DrugBank.d700.s12	.	171	171	O
DDI-DrugBank.d700.s13	Influenza	0	8	O
DDI-DrugBank.d700.s13	vaccination	10	20	O
DDI-DrugBank.d700.s13	may	22	24	O
DDI-DrugBank.d700.s13	be	26	27	O
DDI-DrugBank.d700.s13	of	29	30	O
DDI-DrugBank.d700.s13	value	32	36	O
DDI-DrugBank.d700.s13	.	37	37	O
DDI-DrugBank.d700.s14	Prescribers	0	10	O
DDI-DrugBank.d700.s14	should	12	17	O
DDI-DrugBank.d700.s14	refer	19	23	O
DDI-DrugBank.d700.s14	to	25	26	O
DDI-DrugBank.d700.s14	national	28	35	O
DDI-DrugBank.d700.s14	guidelines	37	46	O
DDI-DrugBank.d700.s14	for	48	50	O
DDI-DrugBank.d700.s14	influenza	52	60	O
DDI-DrugBank.d700.s14	vaccination	62	72	O
DDI-DrugBank.d700.s14	.	73	73	O
DDI-DrugBank.d700.s15	Drugs	0	4	O
DDI-DrugBank.d700.s15	that	6	9	O
DDI-DrugBank.d700.s15	alter	11	15	O
DDI-DrugBank.d700.s15	the	17	19	O
DDI-DrugBank.d700.s15	gastrointestinal	21	36	O
DDI-DrugBank.d700.s15	flora	38	42	O
DDI-DrugBank.d700.s15	may	44	46	O
DDI-DrugBank.d700.s15	interact	48	55	O
DDI-DrugBank.d700.s15	with	57	60	O
DDI-DrugBank.d700.s15	Myfortic	62	69	B-brand
DDI-DrugBank.d700.s15	by	71	72	O
DDI-DrugBank.d700.s15	disrupting	74	83	O
DDI-DrugBank.d700.s15	enterohepatic	85	97	O
DDI-DrugBank.d700.s15	recirculation	99	111	O
DDI-DrugBank.d700.s15	.	112	112	O
DDI-DrugBank.d700.s16	Interference	0	11	O
DDI-DrugBank.d700.s16	of	13	14	O
DDI-DrugBank.d700.s16	MPAG	16	19	B-drug_n
DDI-DrugBank.d700.s16	hydrolysis	21	30	O
DDI-DrugBank.d700.s16	may	32	34	O
DDI-DrugBank.d700.s16	lead	36	39	O
DDI-DrugBank.d700.s16	to	41	42	O
DDI-DrugBank.d700.s16	less	44	47	O
DDI-DrugBank.d700.s16	MPA	49	51	B-drug_n
DDI-DrugBank.d700.s16	available	53	61	O
DDI-DrugBank.d700.s16	for	63	65	O
DDI-DrugBank.d700.s16	absorption	67	76	O
DDI-DrugBank.d700.s16	.	77	77	O
DDI-DrugBank.d330.s0	Caution	0	6	O
DDI-DrugBank.d330.s0	should	8	13	O
DDI-DrugBank.d330.s0	be	15	16	O
DDI-DrugBank.d330.s0	taken	18	22	O
DDI-DrugBank.d330.s0	in	24	25	O
DDI-DrugBank.d330.s0	concurrent	27	36	O
DDI-DrugBank.d330.s0	or	38	39	O
DDI-DrugBank.d330.s0	serial	41	46	O
DDI-DrugBank.d330.s0	use	48	50	O
DDI-DrugBank.d330.s0	of	52	53	O
DDI-DrugBank.d330.s0	other	55	59	O
DDI-DrugBank.d330.s0	neurotoxic	61	70	O
DDI-DrugBank.d330.s0	and/	72	75	O
DDI-DrugBank.d330.s0	or	77	78	O
DDI-DrugBank.d330.s0	nephrotoxic	80	90	O
DDI-DrugBank.d330.s0	drugs	92	96	O
DDI-DrugBank.d330.s0	because	98	104	O
DDI-DrugBank.d330.s0	of	106	107	O
DDI-DrugBank.d330.s0	possible	109	116	O
DDI-DrugBank.d330.s0	enhancement	118	128	O
DDI-DrugBank.d330.s0	of	130	131	O
DDI-DrugBank.d330.s0	the	133	135	O
DDI-DrugBank.d330.s0	nephrotoxicity	137	150	O
DDI-DrugBank.d330.s0	and/or	152	157	O
DDI-DrugBank.d330.s0	ototoxicity	159	169	O
DDI-DrugBank.d330.s0	of	171	172	O
DDI-DrugBank.d330.s0	neomycin	174	181	B-drug
DDI-DrugBank.d330.s0	.	182	182	O
DDI-DrugBank.d330.s1	Caution	0	6	O
DDI-DrugBank.d330.s1	should	8	13	O
DDI-DrugBank.d330.s1	also	15	18	O
DDI-DrugBank.d330.s1	be	20	21	O
DDI-DrugBank.d330.s1	taken	23	27	O
DDI-DrugBank.d330.s1	in	29	30	O
DDI-DrugBank.d330.s1	concurrent	32	41	O
DDI-DrugBank.d330.s1	or	43	44	O
DDI-DrugBank.d330.s1	serial	46	51	O
DDI-DrugBank.d330.s1	use	53	55	O
DDI-DrugBank.d330.s1	of	57	58	O
DDI-DrugBank.d330.s1	other	60	64	O
DDI-DrugBank.d330.s1	aminoglycosides	66	80	B-group
DDI-DrugBank.d330.s1	and	82	84	O
DDI-DrugBank.d330.s1	polymyxins	86	95	B-group
DDI-DrugBank.d330.s1	because	97	103	O
DDI-DrugBank.d330.s1	they	105	108	O
DDI-DrugBank.d330.s1	may	110	112	O
DDI-DrugBank.d330.s1	enhance	114	120	O
DDI-DrugBank.d330.s1	neomycin	122	129	O
DDI-DrugBank.d330.s1	s	131	131	O
DDI-DrugBank.d330.s1	nephrotoxicity	133	146	O
DDI-DrugBank.d330.s1	and/or	148	153	O
DDI-DrugBank.d330.s1	ototoxicity	155	165	O
DDI-DrugBank.d330.s1	and	148	150	O
DDI-DrugBank.d330.s1	potentiate	171	180	O
DDI-DrugBank.d330.s1	neomycin	182	189	B-drug
DDI-DrugBank.d330.s1	sulfate	191	197	I-drug
DDI-DrugBank.d330.s1	neuromuscular	199	211	O
DDI-DrugBank.d330.s1	blocking	213	220	O
DDI-DrugBank.d330.s1	effects	222	228	O
DDI-DrugBank.d330.s1	.	229	229	O
DDI-DrugBank.d330.s2	Oral	0	3	O
DDI-DrugBank.d330.s2	neomycin	5	12	B-drug
DDI-DrugBank.d330.s2	inhibits	14	21	O
DDI-DrugBank.d330.s2	the	23	25	O
DDI-DrugBank.d330.s2	gastrointestinal	27	42	O
DDI-DrugBank.d330.s2	absorption	44	53	O
DDI-DrugBank.d330.s2	of	55	56	O
DDI-DrugBank.d330.s2	penicillin	58	67	B-drug
DDI-DrugBank.d330.s2	V	69	69	O
DDI-DrugBank.d330.s2	,	70	70	O
DDI-DrugBank.d330.s2	oral	72	75	O
DDI-DrugBank.d330.s2	vitamin	77	83	B-drug
DDI-DrugBank.d330.s2	B-12	85	88	I-drug
DDI-DrugBank.d330.s2	,	89	89	O
DDI-DrugBank.d330.s2	methotrexate	91	102	B-drug
DDI-DrugBank.d330.s2	and	104	106	O
DDI-DrugBank.d330.s2	5-fluorouracil	108	121	B-drug
DDI-DrugBank.d330.s2	.	122	122	O
DDI-DrugBank.d330.s3	The	0	2	O
DDI-DrugBank.d330.s3	gastrointestinal	4	19	O
DDI-DrugBank.d330.s3	absorption	21	30	O
DDI-DrugBank.d330.s3	of	32	33	O
DDI-DrugBank.d330.s3	digoxin	35	41	B-drug
DDI-DrugBank.d330.s3	also	43	46	O
DDI-DrugBank.d330.s3	appears	48	54	O
DDI-DrugBank.d330.s3	to	56	57	O
DDI-DrugBank.d330.s3	be	59	60	O
DDI-DrugBank.d330.s3	inhibited	62	70	O
DDI-DrugBank.d330.s3	.	71	71	O
DDI-DrugBank.d330.s4	Therefore	0	8	O
DDI-DrugBank.d330.s4	,	9	9	O
DDI-DrugBank.d330.s4	digoxin	11	17	B-drug
DDI-DrugBank.d330.s4	serum	19	23	O
DDI-DrugBank.d330.s4	levels	25	30	O
DDI-DrugBank.d330.s4	should	32	37	O
DDI-DrugBank.d330.s4	be	39	40	O
DDI-DrugBank.d330.s4	monitored	42	50	O
DDI-DrugBank.d330.s4	.	51	51	O
DDI-DrugBank.d330.s5	Oral	0	3	O
DDI-DrugBank.d330.s5	neomycin	5	12	B-drug
DDI-DrugBank.d330.s5	sulfate	14	20	I-drug
DDI-DrugBank.d330.s5	may	22	24	O
DDI-DrugBank.d330.s5	enhance	26	32	O
DDI-DrugBank.d330.s5	the	34	36	O
DDI-DrugBank.d330.s5	effect	38	43	O
DDI-DrugBank.d330.s5	of	45	46	O
DDI-DrugBank.d330.s5	coumarin	48	55	B-group
DDI-DrugBank.d330.s5	in	54	55	I-group
DDI-DrugBank.d330.s5	anticoagulants	60	73	B-group
DDI-DrugBank.d330.s5	by	75	76	O
DDI-DrugBank.d330.s5	decreasing	78	87	O
DDI-DrugBank.d330.s5	vitamin	89	95	O
DDI-DrugBank.d330.s5	K	97	97	O
DDI-DrugBank.d330.s5	availability	99	110	O
DDI-DrugBank.d330.s5	.	111	111	O
DDI-DrugBank.d136.s0	Alcohol	0	6	B-drug
DDI-DrugBank.d136.s0	(	8	8	O
DDI-DrugBank.d136.s0	increases	9	17	O
DDI-DrugBank.d136.s0	bioavailability	19	33	O
DDI-DrugBank.d136.s0	by	35	36	O
DDI-DrugBank.d136.s0	50	38	39	O
DDI-DrugBank.d136.s0	%	40	40	O
DDI-DrugBank.d136.s0	)	41	41	O
DDI-DrugBank.d136.s0	,	42	42	O
DDI-DrugBank.d136.s0	cimetidine	44	53	B-drug
DDI-DrugBank.d136.s0	,	54	54	O
DDI-DrugBank.d136.s0	and	56	58	O
DDI-DrugBank.d136.s0	valproates	60	69	O
DDI-DrugBank.d136.s0	.	70	70	O
DDI-MedLine.d14.s0	[	0	0	O
DDI-MedLine.d14.s0	A	1	1	O
DDI-MedLine.d14.s0	pharmacological	3	17	O
DDI-MedLine.d14.s0	analysis	19	26	O
DDI-MedLine.d14.s0	of	28	29	O
DDI-MedLine.d14.s0	the	31	33	O
DDI-MedLine.d14.s0	effect	35	40	O
DDI-MedLine.d14.s0	of	42	43	O
DDI-MedLine.d14.s0	angiotensin	45	55	B-drug_n
DDI-MedLine.d14.s0	on	57	58	O
DDI-MedLine.d14.s0	stimulated	60	69	O
DDI-MedLine.d14.s0	gastric	71	77	O
DDI-MedLine.d14.s0	secretion	79	87	O
DDI-MedLine.d14.s0	]	88	88	O
DDI-MedLine.d14.s0	Chronic	91	97	O
DDI-MedLine.d14.s0	experiments	99	109	O
DDI-MedLine.d14.s0	on	111	112	O
DDI-MedLine.d14.s0	dogs	114	117	O
DDI-MedLine.d14.s0	with	119	122	O
DDI-MedLine.d14.s0	gastric	124	130	O
DDI-MedLine.d14.s0	fistulas	132	139	O
DDI-MedLine.d14.s0	were	141	144	O
DDI-MedLine.d14.s0	carried	146	152	O
DDI-MedLine.d14.s0	out	154	156	O
DDI-MedLine.d14.s0	to	158	159	O
DDI-MedLine.d14.s0	study	161	165	O
DDI-MedLine.d14.s0	the	167	169	O
DDI-MedLine.d14.s0	influence	171	179	O
DDI-MedLine.d14.s0	of	181	182	O
DDI-MedLine.d14.s0	angiotensin	184	194	B-drug_n
DDI-MedLine.d14.s0	1	196	196	O
DDI-MedLine.d14.s0	and	198	200	O
DDI-MedLine.d14.s0	angiotensin	184	194	B-drug_n
DDI-MedLine.d14.s0	2	214	214	O
DDI-MedLine.d14.s0	on	216	217	O
DDI-MedLine.d14.s0	pentagastrin-	219	231	O
DDI-MedLine.d14.s0	and	198	200	O
DDI-MedLine.d14.s0	histamine-induced	237	253	O
DDI-MedLine.d14.s0	gastric	255	261	O
DDI-MedLine.d14.s0	acid	263	266	O
DDI-MedLine.d14.s0	secretion	268	276	O
DDI-MedLine.d14.s0	.	277	277	O
DDI-MedLine.d14.s1	It	0	1	O
DDI-MedLine.d14.s1	was	3	5	O
DDI-MedLine.d14.s1	established	7	17	O
DDI-MedLine.d14.s1	that	19	22	O
DDI-MedLine.d14.s1	both	24	27	O
DDI-MedLine.d14.s1	angiotensins	29	40	O
DDI-MedLine.d14.s1	inhibited	42	50	O
DDI-MedLine.d14.s1	gastric	52	58	O
DDI-MedLine.d14.s1	acid	60	63	O
DDI-MedLine.d14.s1	secretion	65	73	O
DDI-MedLine.d14.s1	stimulated	75	84	O
DDI-MedLine.d14.s1	by	86	87	O
DDI-MedLine.d14.s1	pentagastrin	89	100	B-drug
DDI-MedLine.d14.s1	but	102	104	O
DDI-MedLine.d14.s1	not	106	108	O
DDI-MedLine.d14.s1	by	110	111	O
DDI-MedLine.d14.s1	histamine	113	121	B-drug
DDI-MedLine.d14.s1	.	122	122	O
DDI-MedLine.d14.s2	Comparative	0	10	O
DDI-MedLine.d14.s2	analysis	12	19	O
DDI-MedLine.d14.s2	of	21	22	O
DDI-MedLine.d14.s2	the	24	26	O
DDI-MedLine.d14.s2	effects	28	34	O
DDI-MedLine.d14.s2	of	36	37	O
DDI-MedLine.d14.s2	stimulation	39	49	O
DDI-MedLine.d14.s2	and	51	53	O
DDI-MedLine.d14.s2	inhibition	55	64	O
DDI-MedLine.d14.s2	of	66	67	O
DDI-MedLine.d14.s2	cholino-	69	76	O
DDI-MedLine.d14.s2	and	78	80	O
DDI-MedLine.d14.s2	adrenoreceptors	82	96	O
DDI-MedLine.d14.s2	on	98	99	O
DDI-MedLine.d14.s2	this	101	104	O
DDI-MedLine.d14.s2	inhibitory	106	115	O
DDI-MedLine.d14.s2	action	117	122	O
DDI-MedLine.d14.s2	of	124	125	O
DDI-MedLine.d14.s2	angiotensins	127	138	B-drug_n
DDI-MedLine.d14.s2	suggested	140	148	O
DDI-MedLine.d14.s2	the	150	152	O
DDI-MedLine.d14.s2	mediation	154	162	O
DDI-MedLine.d14.s2	of	164	165	O
DDI-MedLine.d14.s2	angiotensin	167	177	B-drug_n
DDI-MedLine.d14.s2	influence	179	187	O
DDI-MedLine.d14.s2	through	189	195	O
DDI-MedLine.d14.s2	the	197	199	O
DDI-MedLine.d14.s2	modulation	201	210	O
DDI-MedLine.d14.s2	of	212	213	O
DDI-MedLine.d14.s2	cholinergic	215	225	O
DDI-MedLine.d14.s2	reactions	227	235	O
DDI-MedLine.d14.s2	of	212	213	O
DDI-MedLine.d14.s2	parietal	240	247	O
DDI-MedLine.d14.s2	cells	249	253	O
DDI-MedLine.d14.s2	in	255	256	O
DDI-MedLine.d14.s2	the	258	260	O
DDI-MedLine.d14.s2	stomach	262	268	O
DDI-MedLine.d14.s2	.	269	269	O
DDI-MedLine.d189.s0	Effects	0	6	O
DDI-MedLine.d189.s0	of	8	9	O
DDI-MedLine.d189.s0	CYP	11	13	O
DDI-MedLine.d189.s0	inhibitors	15	24	O
DDI-MedLine.d189.s0	on	26	27	O
DDI-MedLine.d189.s0	precocene	29	37	B-drug_n
DDI-MedLine.d189.s0	I	39	39	O
DDI-MedLine.d189.s0	metabolism	41	50	O
DDI-MedLine.d189.s0	and	52	54	O
DDI-MedLine.d189.s0	toxicity	56	63	O
DDI-MedLine.d189.s0	in	65	66	O
DDI-MedLine.d189.s0	rat	68	70	O
DDI-MedLine.d189.s0	liver	72	76	O
DDI-MedLine.d189.s0	slices	78	83	O
DDI-MedLine.d189.s0	.	84	84	O
DDI-MedLine.d189.s1	We	0	1	O
DDI-MedLine.d189.s1	present	3	9	O
DDI-MedLine.d189.s1	a	11	11	O
DDI-MedLine.d189.s1	comprehensive	13	25	O
DDI-MedLine.d189.s1	in	27	28	O
DDI-MedLine.d189.s1	vitro	30	34	O
DDI-MedLine.d189.s1	approach	36	43	O
DDI-MedLine.d189.s1	to	45	46	O
DDI-MedLine.d189.s1	assessing	48	56	O
DDI-MedLine.d189.s1	metabolism-mediated	58	76	O
DDI-MedLine.d189.s1	hepatotoxicity	78	91	O
DDI-MedLine.d189.s1	using	93	97	O
DDI-MedLine.d189.s1	male	99	102	O
DDI-MedLine.d189.s1	Sprague-Dawley	104	117	O
DDI-MedLine.d189.s1	rat	119	121	O
DDI-MedLine.d189.s1	liver	123	127	O
DDI-MedLine.d189.s1	slices	129	134	O
DDI-MedLine.d189.s1	incubated	136	144	O
DDI-MedLine.d189.s1	with	146	149	O
DDI-MedLine.d189.s1	the	151	153	O
DDI-MedLine.d189.s1	well	155	158	O
DDI-MedLine.d189.s1	characterized	160	172	O
DDI-MedLine.d189.s1	hepatotoxicant	174	187	O
DDI-MedLine.d189.s1	,	188	188	O
DDI-MedLine.d189.s1	precocene	190	198	B-drug_n
DDI-MedLine.d189.s1	I	200	200	O
DDI-MedLine.d189.s1	,	188	188	O
DDI-MedLine.d189.s1	and	203	205	O
DDI-MedLine.d189.s1	inhibitors	207	216	O
DDI-MedLine.d189.s1	of	218	219	O
DDI-MedLine.d189.s1	cytochrome	221	230	O
DDI-MedLine.d189.s1	P450	232	235	O
DDI-MedLine.d189.s1	(	237	237	O
DDI-MedLine.d189.s1	CYP	238	240	O
DDI-MedLine.d189.s1	)	241	241	O
DDI-MedLine.d189.s1	enzymes	243	249	O
DDI-MedLine.d189.s1	.	250	250	O
DDI-MedLine.d189.s2	This	0	3	O
DDI-MedLine.d189.s2	approach	5	12	O
DDI-MedLine.d189.s2	combines	14	21	O
DDI-MedLine.d189.s2	liquid	23	28	O
DDI-MedLine.d189.s2	chromatography	30	43	O
DDI-MedLine.d189.s2	mass	45	48	O
DDI-MedLine.d189.s2	spectrometry	50	61	O
DDI-MedLine.d189.s2	(	63	63	O
DDI-MedLine.d189.s2	LC	64	65	O
DDI-MedLine.d189.s2	MS	67	68	O
DDI-MedLine.d189.s2	)	69	69	O
DDI-MedLine.d189.s2	detection	71	79	O
DDI-MedLine.d189.s2	methods	81	87	O
DDI-MedLine.d189.s2	with	89	92	O
DDI-MedLine.d189.s2	multiple	94	101	O
DDI-MedLine.d189.s2	toxicity	103	110	O
DDI-MedLine.d189.s2	endpoints	112	120	O
DDI-MedLine.d189.s2	to	122	123	O
DDI-MedLine.d189.s2	enable	125	130	O
DDI-MedLine.d189.s2	identification	132	145	O
DDI-MedLine.d189.s2	of	147	148	O
DDI-MedLine.d189.s2	critical	150	157	O
DDI-MedLine.d189.s2	metabolic	159	167	O
DDI-MedLine.d189.s2	pathways	169	176	O
DDI-MedLine.d189.s2	for	178	180	O
DDI-MedLine.d189.s2	hepatotoxicity	182	195	O
DDI-MedLine.d189.s2	.	196	196	O
DDI-MedLine.d189.s3	The	0	2	O
DDI-MedLine.d189.s3	incubations	4	14	O
DDI-MedLine.d189.s3	were	16	19	O
DDI-MedLine.d189.s3	performed	21	29	O
DDI-MedLine.d189.s3	in	31	32	O
DDI-MedLine.d189.s3	the	34	36	O
DDI-MedLine.d189.s3	absence	38	44	O
DDI-MedLine.d189.s3	and	46	48	O
DDI-MedLine.d189.s3	presence	50	57	O
DDI-MedLine.d189.s3	of	59	60	O
DDI-MedLine.d189.s3	the	62	64	O
DDI-MedLine.d189.s3	non-specific	66	77	O
DDI-MedLine.d189.s3	CYP	79	81	O
DDI-MedLine.d189.s3	inhibitor	83	91	O
DDI-MedLine.d189.s3	,	92	92	O
DDI-MedLine.d189.s3	1-aminobenzotriazole	94	113	B-drug_n
DDI-MedLine.d189.s3	(	115	115	O
DDI-MedLine.d189.s3	ABT	116	118	B-drug_n
DDI-MedLine.d189.s3	)	119	119	O
DDI-MedLine.d189.s3	and	121	123	O
DDI-MedLine.d189.s3	isoform-specific	125	140	O
DDI-MedLine.d189.s3	inhibitors	142	151	O
DDI-MedLine.d189.s3	.	152	152	O
DDI-MedLine.d189.s4	The	0	2	O
DDI-MedLine.d189.s4	metabolite	4	13	O
DDI-MedLine.d189.s4	profile	15	21	O
DDI-MedLine.d189.s4	of	23	24	O
DDI-MedLine.d189.s4	precocene	26	34	B-drug_n
DDI-MedLine.d189.s4	I	36	36	O
DDI-MedLine.d189.s4	in	38	39	O
DDI-MedLine.d189.s4	rat	41	43	O
DDI-MedLine.d189.s4	liver	45	49	O
DDI-MedLine.d189.s4	slices	51	56	O
DDI-MedLine.d189.s4	shares	58	63	O
DDI-MedLine.d189.s4	some	65	68	O
DDI-MedLine.d189.s4	features	70	77	O
DDI-MedLine.d189.s4	of	79	80	O
DDI-MedLine.d189.s4	the	82	84	O
DDI-MedLine.d189.s4	in	86	87	O
DDI-MedLine.d189.s4	vivo	89	92	O
DDI-MedLine.d189.s4	profile	94	100	O
DDI-MedLine.d189.s4	,	101	101	O
DDI-MedLine.d189.s4	but	103	105	O
DDI-MedLine.d189.s4	also	107	110	O
DDI-MedLine.d189.s4	had	112	114	O
DDI-MedLine.d189.s4	a	107	107	O
DDI-MedLine.d189.s4	major	118	122	O
DDI-MedLine.d189.s4	difference	124	133	O
DDI-MedLine.d189.s4	in	135	136	O
DDI-MedLine.d189.s4	that	138	141	O
DDI-MedLine.d189.s4	epoxide	143	149	O
DDI-MedLine.d189.s4	dihydrodiol	151	161	O
DDI-MedLine.d189.s4	hydrolysis	163	172	O
DDI-MedLine.d189.s4	products	174	181	O
DDI-MedLine.d189.s4	were	183	186	O
DDI-MedLine.d189.s4	not	188	190	O
DDI-MedLine.d189.s4	observed	192	199	O
DDI-MedLine.d189.s4	to	201	202	O
DDI-MedLine.d189.s4	a	204	204	O
DDI-MedLine.d189.s4	measurable	206	215	O
DDI-MedLine.d189.s4	extent	217	222	O
DDI-MedLine.d189.s4	.	223	223	O
DDI-MedLine.d189.s5	As	0	1	O
DDI-MedLine.d189.s5	examples	3	10	O
DDI-MedLine.d189.s5	of	12	13	O
DDI-MedLine.d189.s5	our	15	17	O
DDI-MedLine.d189.s5	liver	19	23	O
DDI-MedLine.d189.s5	slice	25	29	O
DDI-MedLine.d189.s5	metabolite	31	40	O
DDI-MedLine.d189.s5	identification	42	55	O
DDI-MedLine.d189.s5	procedure	57	65	O
DDI-MedLine.d189.s5	,	66	66	O
DDI-MedLine.d189.s5	a	68	68	O
DDI-MedLine.d189.s5	minor	70	74	O
DDI-MedLine.d189.s5	glutathione	76	86	O
DDI-MedLine.d189.s5	adduct	88	93	O
DDI-MedLine.d189.s5	and	95	97	O
DDI-MedLine.d189.s5	previously	99	108	O
DDI-MedLine.d189.s5	unreported	110	119	O
DDI-MedLine.d189.s5	7-O-desmethyl	121	133	O
DDI-MedLine.d189.s5	and	135	137	O
DDI-MedLine.d189.s5	glucuronidated	139	152	O
DDI-MedLine.d189.s5	metabolites	154	164	O
DDI-MedLine.d189.s5	of	166	167	O
DDI-MedLine.d189.s5	precocene	169	177	B-drug_n
DDI-MedLine.d189.s5	I	179	179	O
DDI-MedLine.d189.s5	are	181	183	O
DDI-MedLine.d189.s5	reported	185	192	O
DDI-MedLine.d189.s5	.	193	193	O
DDI-MedLine.d189.s6	Precocene	0	8	B-drug_n
DDI-MedLine.d189.s6	I	10	10	O
DDI-MedLine.d189.s6	induced	12	18	O
DDI-MedLine.d189.s6	hepatocellular	20	33	O
DDI-MedLine.d189.s6	necrosis	35	42	O
DDI-MedLine.d189.s6	in	44	45	O
DDI-MedLine.d189.s6	a	47	47	O
DDI-MedLine.d189.s6	dose-	49	53	O
DDI-MedLine.d189.s6	and	55	57	O
DDI-MedLine.d189.s6	time-dependent	59	72	O
DDI-MedLine.d189.s6	manner	74	79	O
DDI-MedLine.d189.s6	.	80	80	O
DDI-MedLine.d189.s7	ABT	0	2	B-drug_n
DDI-MedLine.d189.s7	decreased	4	12	O
DDI-MedLine.d189.s7	the	14	16	O
DDI-MedLine.d189.s7	toxicity	18	25	O
DDI-MedLine.d189.s7	of	27	28	O
DDI-MedLine.d189.s7	precocene	30	38	B-drug_n
DDI-MedLine.d189.s7	I	40	40	O
DDI-MedLine.d189.s7	,	41	41	O
DDI-MedLine.d189.s7	increased	43	51	O
DDI-MedLine.d189.s7	exposure	53	60	O
DDI-MedLine.d189.s7	to	62	63	O
DDI-MedLine.d189.s7	parent	65	70	O
DDI-MedLine.d189.s7	compound	72	79	O
DDI-MedLine.d189.s7	,	80	80	O
DDI-MedLine.d189.s7	and	82	84	O
DDI-MedLine.d189.s7	decreased	86	94	O
DDI-MedLine.d189.s7	metabolite	96	105	O
DDI-MedLine.d189.s7	levels	107	112	O
DDI-MedLine.d189.s7	in	114	115	O
DDI-MedLine.d189.s7	a	117	117	O
DDI-MedLine.d189.s7	dose-dependent	119	132	O
DDI-MedLine.d189.s7	manner	134	139	O
DDI-MedLine.d189.s7	.	140	140	O
DDI-MedLine.d189.s8	Of	0	1	O
DDI-MedLine.d189.s8	the	3	5	O
DDI-MedLine.d189.s8	isoform-specific	7	22	O
DDI-MedLine.d189.s8	CYP	24	26	O
DDI-MedLine.d189.s8	inhibitors	28	37	O
DDI-MedLine.d189.s8	tested	39	44	O
DDI-MedLine.d189.s8	for	46	48	O
DDI-MedLine.d189.s8	an	50	51	O
DDI-MedLine.d189.s8	effect	53	58	O
DDI-MedLine.d189.s8	on	60	61	O
DDI-MedLine.d189.s8	the	63	65	O
DDI-MedLine.d189.s8	precocene	67	75	B-drug_n
DDI-MedLine.d189.s8	I	77	77	O
DDI-MedLine.d189.s8	metabolite	79	88	O
DDI-MedLine.d189.s8	profile	90	96	O
DDI-MedLine.d189.s8	,	97	97	O
DDI-MedLine.d189.s8	only	99	102	O
DDI-MedLine.d189.s8	tranylcypromine	104	118	B-drug
DDI-MedLine.d189.s8	was	120	122	O
DDI-MedLine.d189.s8	noticeably	124	133	O
DDI-MedLine.d189.s8	effective	135	143	O
DDI-MedLine.d189.s8	,	144	144	O
DDI-MedLine.d189.s8	indicating	146	155	O
DDI-MedLine.d189.s8	a	151	151	O
DDI-MedLine.d189.s8	role	159	162	O
DDI-MedLine.d189.s8	of	164	165	O
DDI-MedLine.d189.s8	CYPs	167	170	O
DDI-MedLine.d189.s8	2A6	172	174	O
DDI-MedLine.d189.s8	,	175	175	O
DDI-MedLine.d189.s8	2C9	177	179	O
DDI-MedLine.d189.s8	,	175	175	O
DDI-MedLine.d189.s8	2Cl9	182	185	O
DDI-MedLine.d189.s8	,	175	175	O
DDI-MedLine.d189.s8	and	188	190	O
DDI-MedLine.d189.s8	2E1	192	194	O
DDI-MedLine.d189.s8	.	195	195	O
DDI-MedLine.d189.s9	With	0	3	O
DDI-MedLine.d189.s9	respect	5	11	O
DDI-MedLine.d189.s9	to	13	14	O
DDI-MedLine.d189.s9	toxicity	16	23	O
DDI-MedLine.d189.s9	,	24	24	O
DDI-MedLine.d189.s9	the	26	28	O
DDI-MedLine.d189.s9	order	30	34	O
DDI-MedLine.d189.s9	of	36	37	O
DDI-MedLine.d189.s9	CYP	39	41	O
DDI-MedLine.d189.s9	inhibitor	43	51	O
DDI-MedLine.d189.s9	effectiveness	53	65	O
DDI-MedLine.d189.s9	was	67	69	O
DDI-MedLine.d189.s9	ABT	71	73	B-drug_n
DDI-MedLine.d189.s9	>	74	74	O
DDI-MedLine.d189.s9	diethyldithiocarbamate~tranylcypromine	75	112	O
DDI-MedLine.d189.s9	>	113	113	O
DDI-MedLine.d189.s9	ketoconazole	114	125	B-drug
DDI-MedLine.d189.s9	.	126	126	O
DDI-MedLine.d189.s10	Furafylline	0	10	B-drug_n
DDI-MedLine.d189.s10	and	12	14	O
DDI-MedLine.d189.s10	sulfaphenazole	16	29	B-drug_n
DDI-MedLine.d189.s10	had	31	33	O
DDI-MedLine.d189.s10	no	35	36	O
DDI-MedLine.d189.s10	effect	38	43	O
DDI-MedLine.d189.s10	,	44	44	O
DDI-MedLine.d189.s10	while	46	50	O
DDI-MedLine.d189.s10	quinidine	52	60	B-drug
DDI-MedLine.d189.s10	appeared	62	69	O
DDI-MedLine.d189.s10	to	71	72	O
DDI-MedLine.d189.s10	augment	74	80	O
DDI-MedLine.d189.s10	precocene	82	90	B-drug_n
DDI-MedLine.d189.s10	I	92	92	O
DDI-MedLine.d189.s10	toxicity	94	101	O
DDI-MedLine.d189.s10	.	102	102	O
DDI-MedLine.d189.s11	These	0	4	O
DDI-MedLine.d189.s11	results	6	12	O
DDI-MedLine.d189.s11	suggest	14	20	O
DDI-MedLine.d189.s11	that	22	25	O
DDI-MedLine.d189.s11	rat	27	29	O
DDI-MedLine.d189.s11	liver	31	35	O
DDI-MedLine.d189.s11	slices	37	42	O
DDI-MedLine.d189.s11	do	44	45	O
DDI-MedLine.d189.s11	not	47	49	O
DDI-MedLine.d189.s11	reproduce	51	59	O
DDI-MedLine.d189.s11	the	61	63	O
DDI-MedLine.d189.s11	reported	65	72	O
DDI-MedLine.d189.s11	in	74	75	O
DDI-MedLine.d189.s11	vivo	77	80	O
DDI-MedLine.d189.s11	biotransformation	82	98	O
DDI-MedLine.d189.s11	of	100	101	O
DDI-MedLine.d189.s11	precocene	103	111	B-drug_n
DDI-MedLine.d189.s11	I	113	113	O
DDI-MedLine.d189.s11	and	115	117	O
DDI-MedLine.d189.s11	therefore	119	127	O
DDI-MedLine.d189.s11	may	129	131	O
DDI-MedLine.d189.s11	not	133	135	O
DDI-MedLine.d189.s11	be	137	138	O
DDI-MedLine.d189.s11	an	140	141	O
DDI-MedLine.d189.s11	appropriate	143	153	O
DDI-MedLine.d189.s11	model	155	159	O
DDI-MedLine.d189.s11	for	161	163	O
DDI-MedLine.d189.s11	precocene	165	173	B-drug_n
DDI-MedLine.d189.s11	I	175	175	O
DDI-MedLine.d189.s11	metabolism	177	186	O
DDI-MedLine.d189.s11	.	187	187	O
DDI-MedLine.d189.s12	However	0	6	O
DDI-MedLine.d189.s12	,	7	7	O
DDI-MedLine.d189.s12	these	9	13	O
DDI-MedLine.d189.s12	results	15	21	O
DDI-MedLine.d189.s12	provide	23	29	O
DDI-MedLine.d189.s12	an	31	32	O
DDI-MedLine.d189.s12	example	34	40	O
DDI-MedLine.d189.s12	of	42	43	O
DDI-MedLine.d189.s12	how	45	47	O
DDI-MedLine.d189.s12	small	49	53	O
DDI-MedLine.d189.s12	molecule	55	62	O
DDI-MedLine.d189.s12	manipulation	64	75	O
DDI-MedLine.d189.s12	of	77	78	O
DDI-MedLine.d189.s12	CYP	80	82	O
DDI-MedLine.d189.s12	activity	84	91	O
DDI-MedLine.d189.s12	in	93	94	O
DDI-MedLine.d189.s12	an	96	97	O
DDI-MedLine.d189.s12	in	93	94	O
DDI-MedLine.d189.s12	vitro	102	106	O
DDI-MedLine.d189.s12	model	108	112	O
DDI-MedLine.d189.s12	can	114	116	O
DDI-MedLine.d189.s12	be	118	119	O
DDI-MedLine.d189.s12	used	121	124	O
DDI-MedLine.d189.s12	to	126	127	O
DDI-MedLine.d189.s12	confirm	129	135	O
DDI-MedLine.d189.s12	metabolism-mediated	137	155	O
DDI-MedLine.d189.s12	toxicity	157	164	O
DDI-MedLine.d189.s12	.	165	165	O
DDI-DrugBank.d217.s0	Elevated	0	7	O
DDI-DrugBank.d217.s0	plasma	9	14	O
DDI-DrugBank.d217.s0	levels	16	21	O
DDI-DrugBank.d217.s0	of	23	24	O
DDI-DrugBank.d217.s0	theophylline	26	37	B-drug
DDI-DrugBank.d217.s0	have	39	42	O
DDI-DrugBank.d217.s0	been	44	47	O
DDI-DrugBank.d217.s0	reported	49	56	O
DDI-DrugBank.d217.s0	with	58	61	O
DDI-DrugBank.d217.s0	concomitant	63	73	O
DDI-DrugBank.d217.s0	quinolone	75	83	B-group
DDI-DrugBank.d217.s0	use	85	87	O
DDI-DrugBank.d217.s0	.	88	88	O
DDI-DrugBank.d217.s1	There	0	4	O
DDI-DrugBank.d217.s1	have	6	9	O
DDI-DrugBank.d217.s1	been	11	14	O
DDI-DrugBank.d217.s1	reports	16	22	O
DDI-DrugBank.d217.s1	of	24	25	O
DDI-DrugBank.d217.s1	theophylline-related	27	46	O
DDI-DrugBank.d217.s1	side	48	51	O
DDI-DrugBank.d217.s1	effects	53	59	O
DDI-DrugBank.d217.s1	in	61	62	O
DDI-DrugBank.d217.s1	patients	64	71	O
DDI-DrugBank.d217.s1	on	73	74	O
DDI-DrugBank.d217.s1	concomitant	76	86	O
DDI-DrugBank.d217.s1	therapy	88	94	O
DDI-DrugBank.d217.s1	with	96	99	O
DDI-DrugBank.d217.s1	norfloxacin	101	111	B-drug
DDI-DrugBank.d217.s1	and	113	115	O
DDI-DrugBank.d217.s1	theophylline	117	128	B-drug
DDI-DrugBank.d217.s1	.	129	129	O
DDI-DrugBank.d217.s2	Therefore	0	8	O
DDI-DrugBank.d217.s2	,	9	9	O
DDI-DrugBank.d217.s2	monitoring	11	20	O
DDI-DrugBank.d217.s2	of	22	23	O
DDI-DrugBank.d217.s2	theophylline	25	36	B-drug
DDI-DrugBank.d217.s2	plasma	38	43	O
DDI-DrugBank.d217.s2	levels	45	50	O
DDI-DrugBank.d217.s2	should	52	57	O
DDI-DrugBank.d217.s2	be	59	60	O
DDI-DrugBank.d217.s2	considered	62	71	O
DDI-DrugBank.d217.s2	and	73	75	O
DDI-DrugBank.d217.s2	dosage	77	82	O
DDI-DrugBank.d217.s2	of	84	85	O
DDI-DrugBank.d217.s2	theophylline	87	98	B-drug
DDI-DrugBank.d217.s2	adjusted	100	107	O
DDI-DrugBank.d217.s2	as	109	110	O
DDI-DrugBank.d217.s2	required	112	119	O
DDI-DrugBank.d217.s2	.	120	120	O
DDI-DrugBank.d217.s3	Elevated	0	7	O
DDI-DrugBank.d217.s3	serum	9	13	O
DDI-DrugBank.d217.s3	levels	15	20	O
DDI-DrugBank.d217.s3	of	22	23	O
DDI-DrugBank.d217.s3	cyclosporine	25	36	B-drug
DDI-DrugBank.d217.s3	have	38	41	O
DDI-DrugBank.d217.s3	been	43	46	O
DDI-DrugBank.d217.s3	reported	48	55	O
DDI-DrugBank.d217.s3	with	57	60	O
DDI-DrugBank.d217.s3	concomitant	62	72	O
DDI-DrugBank.d217.s3	use	74	76	O
DDI-DrugBank.d217.s3	of	78	79	O
DDI-DrugBank.d217.s3	cyclosporine	81	92	B-drug
DDI-DrugBank.d217.s3	with	94	97	O
DDI-DrugBank.d217.s3	norfloxacin	99	109	B-drug
DDI-DrugBank.d217.s3	.	110	110	O
DDI-DrugBank.d217.s4	Therefore	0	8	O
DDI-DrugBank.d217.s4	,	9	9	O
DDI-DrugBank.d217.s4	cyclosporine	11	22	B-drug
DDI-DrugBank.d217.s4	serum	24	28	O
DDI-DrugBank.d217.s4	levels	30	35	O
DDI-DrugBank.d217.s4	should	37	42	O
DDI-DrugBank.d217.s4	be	44	45	O
DDI-DrugBank.d217.s4	monitored	47	55	O
DDI-DrugBank.d217.s4	and	57	59	O
DDI-DrugBank.d217.s4	appropriate	61	71	O
DDI-DrugBank.d217.s4	cyclosporine	73	84	B-drug
DDI-DrugBank.d217.s4	dosage	86	91	O
DDI-DrugBank.d217.s4	adjustments	93	103	O
DDI-DrugBank.d217.s4	made	105	108	O
DDI-DrugBank.d217.s4	when	110	113	O
DDI-DrugBank.d217.s4	these	115	119	O
DDI-DrugBank.d217.s4	drugs	121	125	O
DDI-DrugBank.d217.s4	are	127	129	O
DDI-DrugBank.d217.s4	used	131	134	O
DDI-DrugBank.d217.s4	concomitantly	136	148	O
DDI-DrugBank.d217.s4	.	149	149	O
DDI-DrugBank.d217.s5	Quinolones	0	9	B-group
DDI-DrugBank.d217.s5	,	10	10	O
DDI-DrugBank.d217.s5	including	12	20	O
DDI-DrugBank.d217.s5	norfloxacin	22	32	B-drug
DDI-DrugBank.d217.s5	,	33	33	O
DDI-DrugBank.d217.s5	may	35	37	O
DDI-DrugBank.d217.s5	enhance	39	45	O
DDI-DrugBank.d217.s5	the	47	49	O
DDI-DrugBank.d217.s5	effects	51	57	O
DDI-DrugBank.d217.s5	of	59	60	O
DDI-DrugBank.d217.s5	oral	62	65	O
DDI-DrugBank.d217.s5	anticoagulants	67	80	B-group
DDI-DrugBank.d217.s5	,	81	81	O
DDI-DrugBank.d217.s5	including	83	91	O
DDI-DrugBank.d217.s5	warfarin	93	100	B-drug
DDI-DrugBank.d217.s5	or	102	103	O
DDI-DrugBank.d217.s5	its	105	107	O
DDI-DrugBank.d217.s5	derivatives	109	119	O
DDI-DrugBank.d217.s5	or	121	122	O
DDI-DrugBank.d217.s5	similar	124	130	O
DDI-DrugBank.d217.s5	agents	132	137	O
DDI-DrugBank.d217.s5	.	138	138	O
DDI-DrugBank.d217.s6	When	0	3	O
DDI-DrugBank.d217.s6	these	5	9	O
DDI-DrugBank.d217.s6	products	11	18	O
DDI-DrugBank.d217.s6	are	20	22	O
DDI-DrugBank.d217.s6	administered	24	35	O
DDI-DrugBank.d217.s6	concomitantly	37	49	O
DDI-DrugBank.d217.s6	,	50	50	O
DDI-DrugBank.d217.s6	prothrombin	52	62	O
DDI-DrugBank.d217.s6	time	64	67	O
DDI-DrugBank.d217.s6	or	69	70	O
DDI-DrugBank.d217.s6	other	72	76	O
DDI-DrugBank.d217.s6	suitable	78	85	O
DDI-DrugBank.d217.s6	coagulation	87	97	O
DDI-DrugBank.d217.s6	tests	99	103	O
DDI-DrugBank.d217.s6	should	105	110	O
DDI-DrugBank.d217.s6	be	112	113	O
DDI-DrugBank.d217.s6	closely	115	121	O
DDI-DrugBank.d217.s6	monitored	123	131	O
DDI-DrugBank.d217.s6	.	132	132	O
DDI-DrugBank.d217.s7	The	0	2	O
DDI-DrugBank.d217.s7	concomitant	4	14	O
DDI-DrugBank.d217.s7	administration	16	29	O
DDI-DrugBank.d217.s7	of	31	32	O
DDI-DrugBank.d217.s7	quinolones	34	43	B-group
DDI-DrugBank.d217.s7	including	45	53	O
DDI-DrugBank.d217.s7	norfloxacin	55	65	B-drug
DDI-DrugBank.d217.s7	with	67	70	O
DDI-DrugBank.d217.s7	glyburide	72	80	B-drug
DDI-DrugBank.d217.s7	(	82	82	O
DDI-DrugBank.d217.s7	a	83	83	O
DDI-DrugBank.d217.s7	sulfonylurea	85	96	B-group
DDI-DrugBank.d217.s7	agent	98	102	I-group
DDI-DrugBank.d217.s7	)	103	103	O
DDI-DrugBank.d217.s7	has	105	107	O
DDI-DrugBank.d217.s7	,	108	108	O
DDI-DrugBank.d217.s7	on	110	111	O
DDI-DrugBank.d217.s7	rare	113	116	O
DDI-DrugBank.d217.s7	occasions	118	126	O
DDI-DrugBank.d217.s7	,	127	127	O
DDI-DrugBank.d217.s7	resulted	129	136	O
DDI-DrugBank.d217.s7	in	138	139	O
DDI-DrugBank.d217.s7	severe	141	146	O
DDI-DrugBank.d217.s7	hypoglycemia	148	159	O
DDI-DrugBank.d217.s7	.	160	160	O
DDI-DrugBank.d217.s8	Therefore	0	8	O
DDI-DrugBank.d217.s8	,	9	9	O
DDI-DrugBank.d217.s8	monitoring	11	20	O
DDI-DrugBank.d217.s8	of	22	23	O
DDI-DrugBank.d217.s8	blood	25	29	O
DDI-DrugBank.d217.s8	glucose	31	37	O
DDI-DrugBank.d217.s8	is	39	40	O
DDI-DrugBank.d217.s8	recommended	42	52	O
DDI-DrugBank.d217.s8	when	54	57	O
DDI-DrugBank.d217.s8	these	59	63	O
DDI-DrugBank.d217.s8	agents	65	70	O
DDI-DrugBank.d217.s8	are	72	74	O
DDI-DrugBank.d217.s8	co-administered	76	90	O
DDI-DrugBank.d217.s8	.	91	91	O
DDI-DrugBank.d217.s9	Diminished	0	9	O
DDI-DrugBank.d217.s9	urinary	11	17	O
DDI-DrugBank.d217.s9	excretion	19	27	O
DDI-DrugBank.d217.s9	of	29	30	O
DDI-DrugBank.d217.s9	norfloxacin	32	42	B-drug
DDI-DrugBank.d217.s9	has	44	46	O
DDI-DrugBank.d217.s9	been	48	51	O
DDI-DrugBank.d217.s9	reported	53	60	O
DDI-DrugBank.d217.s9	during	62	67	O
DDI-DrugBank.d217.s9	the	69	71	O
DDI-DrugBank.d217.s9	concomitant	73	83	O
DDI-DrugBank.d217.s9	administration	85	98	O
DDI-DrugBank.d217.s9	of	100	101	O
DDI-DrugBank.d217.s9	probenecid	103	112	B-drug
DDI-DrugBank.d217.s9	and	114	116	O
DDI-DrugBank.d217.s9	norfloxacin	118	128	B-drug
DDI-DrugBank.d217.s9	.	129	129	O
DDI-DrugBank.d217.s10	The	0	2	O
DDI-DrugBank.d217.s10	concomitant	4	14	O
DDI-DrugBank.d217.s10	use	16	18	O
DDI-DrugBank.d217.s10	of	20	21	O
DDI-DrugBank.d217.s10	nitrofurantoin	23	36	B-drug
DDI-DrugBank.d217.s10	is	38	39	O
DDI-DrugBank.d217.s10	not	41	43	O
DDI-DrugBank.d217.s10	recommended	45	55	O
DDI-DrugBank.d217.s10	since	57	61	O
DDI-DrugBank.d217.s10	nitrofurantoin	63	76	B-drug
DDI-DrugBank.d217.s10	may	78	80	O
DDI-DrugBank.d217.s10	antagonize	82	91	O
DDI-DrugBank.d217.s10	the	93	95	O
DDI-DrugBank.d217.s10	antibacterial	97	109	O
DDI-DrugBank.d217.s10	effect	111	116	O
DDI-DrugBank.d217.s10	of	118	119	O
DDI-DrugBank.d217.s10	Norfloxacin	121	131	B-drug
DDI-DrugBank.d217.s10	in	130	131	I-drug
DDI-DrugBank.d217.s10	the	136	138	O
DDI-DrugBank.d217.s10	urinary	140	146	O
DDI-DrugBank.d217.s10	tract	148	152	O
DDI-DrugBank.d217.s10	.	153	153	O
DDI-DrugBank.d217.s11	Multivitamins	0	12	B-group
DDI-DrugBank.d217.s11	,	13	13	O
DDI-DrugBank.d217.s11	or	15	16	O
DDI-DrugBank.d217.s11	other	18	22	O
DDI-DrugBank.d217.s11	products	24	31	O
DDI-DrugBank.d217.s11	containing	33	42	O
DDI-DrugBank.d217.s11	iron	44	47	B-drug
DDI-DrugBank.d217.s11	or	49	50	O
DDI-DrugBank.d217.s11	zinc	52	55	B-drug
DDI-DrugBank.d217.s11	,	56	56	O
DDI-DrugBank.d217.s11	antacids	58	65	B-group
DDI-DrugBank.d217.s11	or	67	68	O
DDI-DrugBank.d217.s11	sucralfate	70	79	B-drug
DDI-DrugBank.d217.s11	should	81	86	O
DDI-DrugBank.d217.s11	not	88	90	O
DDI-DrugBank.d217.s11	be	92	93	O
DDI-DrugBank.d217.s11	administered	95	106	O
DDI-DrugBank.d217.s11	concomitantly	108	120	O
DDI-DrugBank.d217.s11	with	122	125	O
DDI-DrugBank.d217.s11	,	126	126	O
DDI-DrugBank.d217.s11	or	128	129	O
DDI-DrugBank.d217.s11	within	131	136	O
DDI-DrugBank.d217.s11	2	138	138	O
DDI-DrugBank.d217.s11	hours	140	144	O
DDI-DrugBank.d217.s11	of	146	147	O
DDI-DrugBank.d217.s11	,	148	148	O
DDI-DrugBank.d217.s11	the	150	152	O
DDI-DrugBank.d217.s11	administration	154	167	O
DDI-DrugBank.d217.s11	of	146	147	O
DDI-DrugBank.d217.s11	norfloxacin	172	182	B-drug
DDI-DrugBank.d217.s11	,	183	183	O
DDI-DrugBank.d217.s11	because	185	191	O
DDI-DrugBank.d217.s11	they	193	196	O
DDI-DrugBank.d217.s11	may	198	200	O
DDI-DrugBank.d217.s11	interfere	202	210	O
DDI-DrugBank.d217.s11	with	212	215	O
DDI-DrugBank.d217.s11	absorption	217	226	O
DDI-DrugBank.d217.s11	resulting	228	236	O
DDI-DrugBank.d217.s11	in	234	235	O
DDI-DrugBank.d217.s11	lower	241	245	O
DDI-DrugBank.d217.s11	serum	247	251	O
DDI-DrugBank.d217.s11	and	253	255	O
DDI-DrugBank.d217.s11	urine	257	261	O
DDI-DrugBank.d217.s11	levels	263	268	O
DDI-DrugBank.d217.s11	of	270	271	O
DDI-DrugBank.d217.s11	norfloxacin	273	283	B-drug
DDI-DrugBank.d217.s11	.	284	284	O
DDI-DrugBank.d217.s12	Videx	0	4	B-brand
DDI-DrugBank.d217.s12	(	6	6	O
DDI-DrugBank.d217.s12	Didanosine	7	16	B-drug
DDI-DrugBank.d217.s12	)	17	17	O
DDI-DrugBank.d217.s12	chewable/buffered	19	35	O
DDI-DrugBank.d217.s12	tablets	37	43	O
DDI-DrugBank.d217.s12	or	45	46	O
DDI-DrugBank.d217.s12	the	48	50	O
DDI-DrugBank.d217.s12	pediatric	52	60	O
DDI-DrugBank.d217.s12	powder	62	67	O
DDI-DrugBank.d217.s12	for	69	71	O
DDI-DrugBank.d217.s12	oral	73	76	O
DDI-DrugBank.d217.s12	solution	78	85	O
DDI-DrugBank.d217.s12	should	87	92	O
DDI-DrugBank.d217.s12	not	94	96	O
DDI-DrugBank.d217.s12	be	98	99	O
DDI-DrugBank.d217.s12	administered	101	112	O
DDI-DrugBank.d217.s12	concomitantly	114	126	O
DDI-DrugBank.d217.s12	with	128	131	O
DDI-DrugBank.d217.s12	,	132	132	O
DDI-DrugBank.d217.s12	or	134	135	O
DDI-DrugBank.d217.s12	within	137	142	O
DDI-DrugBank.d217.s12	2	144	144	O
DDI-DrugBank.d217.s12	hours	146	150	O
DDI-DrugBank.d217.s12	of	152	153	O
DDI-DrugBank.d217.s12	,	154	154	O
DDI-DrugBank.d217.s12	the	156	158	O
DDI-DrugBank.d217.s12	administration	160	173	O
DDI-DrugBank.d217.s12	of	152	153	O
DDI-DrugBank.d217.s12	norfloxacin	178	188	B-drug
DDI-DrugBank.d217.s12	,	189	189	O
DDI-DrugBank.d217.s12	because	191	197	O
DDI-DrugBank.d217.s12	these	199	203	O
DDI-DrugBank.d217.s12	products	205	212	O
DDI-DrugBank.d217.s12	may	214	216	O
DDI-DrugBank.d217.s12	interfere	218	226	O
DDI-DrugBank.d217.s12	with	228	231	O
DDI-DrugBank.d217.s12	absorption	233	242	O
DDI-DrugBank.d217.s12	resulting	244	252	O
DDI-DrugBank.d217.s12	in	250	251	O
DDI-DrugBank.d217.s12	lower	257	261	O
DDI-DrugBank.d217.s12	serum	263	267	O
DDI-DrugBank.d217.s12	and	269	271	O
DDI-DrugBank.d217.s12	urine	273	277	O
DDI-DrugBank.d217.s12	levels	279	284	O
DDI-DrugBank.d217.s12	of	286	287	O
DDI-DrugBank.d217.s12	norfloxacin	289	299	B-drug
DDI-DrugBank.d217.s12	.	300	300	O
DDI-DrugBank.d217.s13	Some	0	3	O
DDI-DrugBank.d217.s13	quinolones	5	14	B-group
DDI-DrugBank.d217.s13	have	16	19	O
DDI-DrugBank.d217.s13	also	21	24	O
DDI-DrugBank.d217.s13	been	26	29	O
DDI-DrugBank.d217.s13	shown	31	35	O
DDI-DrugBank.d217.s13	to	37	38	O
DDI-DrugBank.d217.s13	interfere	40	48	O
DDI-DrugBank.d217.s13	with	50	53	O
DDI-DrugBank.d217.s13	the	55	57	O
DDI-DrugBank.d217.s13	metabolism	59	68	O
DDI-DrugBank.d217.s13	of	70	71	O
DDI-DrugBank.d217.s13	caffeine	73	80	B-drug
DDI-DrugBank.d217.s13	.	81	81	O
DDI-DrugBank.d217.s14	This	0	3	O
DDI-DrugBank.d217.s14	may	5	7	O
DDI-DrugBank.d217.s14	lead	9	12	O
DDI-DrugBank.d217.s14	to	14	15	O
DDI-DrugBank.d217.s14	reduced	17	23	O
DDI-DrugBank.d217.s14	clearance	25	33	O
DDI-DrugBank.d217.s14	of	35	36	O
DDI-DrugBank.d217.s14	caffeine	38	45	B-drug
DDI-DrugBank.d217.s14	and	47	49	O
DDI-DrugBank.d217.s14	a	47	47	O
DDI-DrugBank.d217.s14	prolongation	53	64	O
DDI-DrugBank.d217.s14	of	66	67	O
DDI-DrugBank.d217.s14	its	69	71	O
DDI-DrugBank.d217.s14	plasma	73	78	O
DDI-DrugBank.d217.s14	half-life	80	88	O
DDI-DrugBank.d217.s14	.	89	89	O
